<SEC-DOCUMENT>0001193125-23-077859.txt : 20230323
<SEC-HEADER>0001193125-23-077859.hdr.sgml : 20230323
<ACCEPTANCE-DATETIME>20230323160632
ACCESSION NUMBER:		0001193125-23-077859
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230323
DATE AS OF CHANGE:		20230323

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CymaBay Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001042074
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943103561
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36500
		FILM NUMBER:		23756240

	BUSINESS ADDRESS:	
		STREET 1:		7575 GATEWAY BOULEVARD
		STREET 2:		SUITE 110
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560
		BUSINESS PHONE:		510-293-8800

	MAIL ADDRESS:	
		STREET 1:		7575 GATEWAY BOULEVARD
		STREET 2:		SUITE 110
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METABOLEX, INC.
		DATE OF NAME CHANGE:	20090721

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METABOLEX INC
		DATE OF NAME CHANGE:	19970710
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d446975d10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:cbay="http://www.cymabay.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>10-K</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="">
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2022To12_31_2022">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2022To12_31_2022">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2022To12_31_2022">0001042074</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden71088888" contextRef="P01_01_2022To12_31_2022">CA</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cbay-20221231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="cbay-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="cbay-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="cbay-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="cbay-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P01_01_2022To12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_15_2023" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-15</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_15_2021To01_15_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-15</xbrli:startDate> <xbrli:endDate>2021-01-15</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_12_2021To03_12_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-12</xbrli:startDate> <xbrli:endDate>2021-03-12</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_31_2021To08_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-31</xbrli:startDate> <xbrli:endDate>2021-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2022To08_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-08-01</xbrli:startDate> <xbrli:endDate>2022-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OfficeAndComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >cbay:OfficeAndComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:MaketableSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_SupranationalDebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >cbay:SupranationalDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_UsAgencySecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >cbay:UsAgencySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:DebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_OrphanDrugMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >cbay:OrphanDrugMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashEquivalentsMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashEquivalentsMemberusgaapInvestmentTypeAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CashEquivalentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashEquivalentsMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CashEquivalentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CashEquivalentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_SupranationalDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:SupranationalDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_SupranationalDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:SupranationalDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_UsAgencySecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:UsAgencySecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_UsAgencySecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:UsAgencySecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EquityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:EquityIncentivePlanTwoThousandAndTwentyPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_JanssenPharmaceuticalNVMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >cbay:JanssenPharmaceuticalNVMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_IncentiveStockAwardsMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:IncentiveStockAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >cbay:PrefundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_OptionsAndIncentiveAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >cbay:OptionsAndIncentiveAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CbayequityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:CbayequityIncentivePlanTwoThousandAndTwentyPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CbayequityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:CbayequityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_LeaseFacilityMemberusgaapLeaseContractualTermAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis" >cbay:LeaseFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_FederalAndStateTaxAuthorityMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >cbay:FederalAndStateTaxAuthorityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OfficeAndComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >cbay:OfficeAndComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:MaketableSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_NoncurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >cbay:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:DebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashEquivalentsMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashEquivalentsMemberusgaapInvestmentTypeAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CashEquivalentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashEquivalentsMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CashEquivalentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CashEquivalentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:CashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommercialPaperMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_JanssenPharmaceuticalNVMembersrtCounterpartyNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >cbay:JanssenPharmaceuticalNVMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_IncentiveStockAwardsMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:IncentiveStockAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AbwCyclopsSpvLpMembersrtCounterpartyNameAxis_FinancingAgreementTerminationEventConditionOneMemberCBAYFinancingAgreementTerminationEventConditionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="cbay:FinancingAgreementTerminationEventConditionAxis" >cbay:FinancingAgreementTerminationEventConditionOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AbwCyclopsSpvLpMembersrtCounterpartyNameAxis_FinancingAgreementTerminationEventConditionTwoMemberCBAYFinancingAgreementTerminationEventConditionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="cbay:FinancingAgreementTerminationEventConditionAxis" >cbay:FinancingAgreementTerminationEventConditionTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AbwCyclopsSpvLpMembersrtCounterpartyNameAxis_FinancingAgreementTerminationEventConditionThreeMemberCBAYFinancingAgreementTerminationEventConditionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="cbay:FinancingAgreementTerminationEventConditionAxis" >cbay:FinancingAgreementTerminationEventConditionThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >cbay:PrefundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_OptionsAndIncentiveAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >cbay:OptionsAndIncentiveAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CbayequityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:CbayequityIncentivePlanTwoThousandAndTwentyPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CbayequityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:CbayequityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PendingLitigationMemberusgaapLitigationStatusAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis" >us-gaap:PendingLitigationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_EmployeeOrNonEmployeeStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >cbay:EmployeeOrNonEmployeeStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_IncentiveStockAwardsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >cbay:IncentiveStockAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:DebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FederalMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >cbay:FederalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FederalMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MinimumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >cbay:FederalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:OperatingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_LeaseFacilityMemberusgaapLeaseContractualTermAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis" >cbay:LeaseFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_FederalAndStateTaxAuthorityMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >cbay:FederalAndStateTaxAuthorityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EmployeeOrNonEmployeeStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >cbay:EmployeeOrNonEmployeeStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_IncentiveStockAwardsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" >cbay:IncentiveStockAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DebtSecuritiesMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >us-gaap:DebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:DomesticCountryMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:OperatingExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_22_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >cbay:PrefundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-22</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2006To06_30_2006_JanssenPharmaceuticalNVMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis" >cbay:JanssenPharmaceuticalNVMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2006-06-01</xbrli:startDate> <xbrli:endDate>2006-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_30_2021_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P08_31_2021To08_31_2021_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis_InstallmentFundingNumberOneMemberCBAYNumberOfInstallmentFundingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="cbay:NumberOfInstallmentFundingAxis" >cbay:InstallmentFundingNumberOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-31</xbrli:startDate> <xbrli:endDate>2021-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_31_2021To08_31_2021_FixedSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="cbay:SuccessPaymentTypeAxis" >cbay:FixedSuccessPaymentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-31</xbrli:startDate> <xbrli:endDate>2021-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_31_2021To08_31_2021_VariableSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="cbay:SuccessPaymentTypeAxis" >cbay:VariableSuccessPaymentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-08-31</xbrli:startDate> <xbrli:endDate>2021-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_30_2021To11_30_2021_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis_InstallmentFundingNumberTwoMemberCBAYNumberOfInstallmentFundingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="cbay:NumberOfInstallmentFundingAxis" >cbay:InstallmentFundingNumberTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-11-30</xbrli:startDate> <xbrli:endDate>2021-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_31_2022To01_31_2022_InstallmentFundingNumberThreeMemberCBAYNumberOfInstallmentFundingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="cbay:NumberOfInstallmentFundingAxis" >cbay:InstallmentFundingNumberThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-31</xbrli:startDate> <xbrli:endDate>2022-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_31_2022To01_31_2022_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis_FinancingAgreementFundingInstallmentsTwoMemberCBAYCbayfinancingAgreementFundingInstallmentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="cbay:CbayfinancingAgreementFundingInstallmentsAxis" >cbay:FinancingAgreementFundingInstallmentsTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-31</xbrli:startDate> <xbrli:endDate>2022-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_31_2022To01_31_2022_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-31</xbrli:startDate> <xbrli:endDate>2022-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:EquityIncentivePlanTwoThousandAndTwentyPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-09-01</xbrli:startDate> <xbrli:endDate>2013-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-09-01</xbrli:startDate> <xbrli:endDate>2013-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_NonQualifiedStockOptionsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >cbay:NonQualifiedStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-09-01</xbrli:startDate> <xbrli:endDate>2013-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_IncentiveStockOptionsForEmployeesAndDirectorsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >cbay:IncentiveStockOptionsForEmployeesAndDirectorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2013-09-01</xbrli:startDate> <xbrli:endDate>2013-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2013-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2017To12_31_2017_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_StockOptionsToTenPercentShareholdersMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >cbay:StockOptionsToTenPercentShareholdersMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-01-01</xbrli:startDate> <xbrli:endDate>2017-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_EquityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:EquityIncentivePlanTwoThousandAndTwentyPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2022_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2014_IncentiveStockAwardsMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:IncentiveStockAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2014-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2014_IncentiveStockAwardsMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >cbay:IncentiveStockAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2014-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2017_FederalMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >cbay:FederalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018_FederalMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" >cbay:FederalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_23_2023To01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-23</xbrli:startDate> <xbrli:endDate>2023-01-23</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >cbay:PrefundedWarrantsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-23</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_06_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="cbay:AgreementAxis" >cbay:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-06</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_KakenPharmaceuticalCo.LtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="cbay:AgreementAxis" >cbay:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >cbay:KakenPharmaceuticalCo.LtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="cbay:AgreementAxis" >cbay:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_KakenPharmaceuticalCo.LtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="cbay:AgreementAxis" >cbay:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >cbay:KakenPharmaceuticalCo.LtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="cbay:AgreementAxis" >cbay:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis" >cbay:PrefundedWarrantsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2022_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis" >cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="cbay:AgreementAxis" >cbay:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001042074</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_sqft" > <xbrli:measure>utr:sqft</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_JPY" > <xbrli:measure>iso4217:JPY</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_segment" > <xbrli:measure>cbay:segment</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_INSTALLMENTS" > <xbrli:measure>cbay:INSTALLMENTS</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Facility" > <xbrli:measure>cbay:Facility</xbrli:measure> </xbrli:unit></ix:resources></ix:header></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 4pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">UNITED STATES </div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 11pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 3pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">FORM </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2022To12_31_2022">10-K</ix:nonNumeric></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentAnnualReport" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="P01_01_2022To12_31_2022" format="ixt:date-monthname-day-year-en"><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="P01_01_2022To12_31_2022" format="ixt:date-monthname-day-en">December 31</ix:nonNumeric>, <ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2022To12_31_2022">2022</ix:nonNumeric></ix:nonNumeric> </div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 3pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">OR </div></div></div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div></div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Commission file number: </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="P01_01_2022To12_31_2022">001-36500</ix:nonNumeric></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></div><div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g446975g00g01.jpg" style="width: 94px; height: 32px;"/><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 22pt; margin-top: 3pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 22pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2022To12_31_2022">CYMABAY THERAPEUTICS, INC.</ix:nonNumeric> </div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">(Exact name of registrant as specified in its charter) </div></div></div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 48%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2022To12_31_2022">94-3103561</ix:nonNumeric></div></div></div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">(State or other jurisdiction of</div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">incorporation or organization)</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">(I.R.S. Employer</div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Identification No.)</div></div></div></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2022To12_31_2022">7575 Gateway Blvd</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="P01_01_2022To12_31_2022">Suite 110</ix:nonNumeric></div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2022To12_31_2022">Newark</ix:nonNumeric>,&#160;CA</div></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2022To12_31_2022">94560</ix:nonNumeric></div></div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">(Address of principal executive offices)</div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">(Zip Code)</div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2022To12_31_2022">510</ix:nonNumeric>) </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2022To12_31_2022">293-8800</ix:nonNumeric></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">(Registrant&#8217;s telephone number, including area code) </div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(b) of the Act: </div></div></div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 32%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 32%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Title of each class</div></div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Trading</div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">symbol(s)</div></div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Name of each exchange</div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">on which registered</div></div></div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="P01_01_2022To12_31_2022">Common stock, $0.0001 par value per share</ix:nonNumeric></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="P01_01_2022To12_31_2022">CBAY</ix:nonNumeric></div></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></div></div></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Securities registered pursuant to Section&#160;12(g) of the Act: </div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">None </div></div></div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="text-align: center;;text-indent: 0px;"><div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="P01_01_2022To12_31_2022">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="P01_01_2022To12_31_2022">No</ix:nonNumeric>&#160;&#160;&#9746; </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="P01_01_2022To12_31_2022">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">S-T</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="P01_01_2022To12_31_2022">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744; </div></div></div><div style="font-size: 3pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 3pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 15%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 61%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 19%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 2%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Large&#160;accelerated&#160;filer</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Accelerated&#160;filer</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#9744;</div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 3pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 3pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 3pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#9746;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Smaller&#160;reporting&#160;company</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></div></div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 3pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 3pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 3pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td colspan="2" style="height: 3pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Emerging&#160;Growth&#160;Company</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div></div></td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744; </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;<ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">If securities are registered pursuant to Section&#160;12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;&#160;&#9744; </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#167;240.10D-1(b).&#160;&#160;&#9744;</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Indicate by check mark whether the registrant is a shell company (as defined in Rule </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric name="dei:EntityShellCompany" contextRef="P01_01_2022To12_31_2022" format="ixt:fixed-false">&#9746;</ix:nonNumeric> </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">The aggregate market value of the voting and </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> common equity held by </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"> of the registrant based upon the closing price of its Common Stock on the Nasdaq Global Select Market on June&#160;30, 2022, was <div style="letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="dei:EntityPublicFloat" contextRef="PAsOn06_30_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">218,053,044</ix:nonFraction></div>. This excludes 330,617 shares of the registrant&#8217;s Common Stock held by executive officers, directors and stockholders affiliated with directors outstanding at June&#160;30, 2022. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">The number of shares of common stock outstanding as of </div></div></div> <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 12px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 4%; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">March&#160;15, 2023</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">, was <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="PAsOn03_15_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">97,293,397</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">DOCUMENTS INCORPORATED BY REFERENCE </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Portions of the registrant&#8217;s Proxy Statement for its 2023 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days after the registrant&#8217;s fiscal year ended December&#160;31, 2022, are incorporated by reference in Part III, Items <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-14</div> of this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">C<small>YMABAY</small> T<small>HERAPEUTICS</small>, I<small>NC</small>. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ANNUAL REPORT ON FORM <span style="white-space:nowrap">10-K</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">For the Year Ended December&#160;31, 2022 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:95%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold"><a href="#txa446975_1">PART I</a></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_2">Item&#160;1. Business</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_3">Item&#160;1A. Risk Factors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">29</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_4">Item&#160;1B. Unresolved Staff Comments</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_5">Item&#160;2. Properties</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_6">Item&#160;3. Legal Proceedings</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_7">Item&#160;4. Mine Safety Disclosures</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold"><a href="#txa446975_8">PART II</a></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_9">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_10">Item&#160;6. [Reserved]</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_11">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">56</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_12">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_13">Item&#160;8. Financial Statements and Supplementary Data</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_14">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_15">Item&#160;9A. Controls and Procedures</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_16">Item&#160;9B. Other Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_17">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold"><a href="#txa446975_18">PART III</a></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_19">Item&#160;10. Directors, Executive Officers and Corporate Governance</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_20">Item&#160;11. Executive Compensation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_21">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_22">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_23">Item&#160;14. Principal Accountant Fees and Services</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" align="center"><span style="font-weight:bold"><a href="#txa446975_24">PART IV</a></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_25">Item&#160;15. Exhibits and Financial Statement Schedules</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_26">Item&#160;16. Form <span style="white-space:nowrap">10-K</span> Summary</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txa446975_27">Signatures</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CAUTIONARY LANGUAGE REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This Annual Report on Form <span style="white-space:nowrap">10-K</span> contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, that are subject to the &#8220;safe harbor&#8221; created by those sections. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;projected,&#8221; &#8220;potential,&#8221; &#8220;seek,&#8221; &#8220;target,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements. We discuss many of these risks, uncertainties and other factors in this Annual Report on Form <span style="white-space:nowrap">10-K</span> in greater detail under the heading &#8220;Risk Factors.&#8221; Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this filing. You should read this Annual Report on Form <span style="white-space:nowrap">10-K</span> completely and with the understanding that our actual future results may be materially different from what we expect. We hereby qualify our forward-looking statements by our cautionary statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">In addition, statements that &#8220;we believe&#8221; or &#8220;we expect&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this report. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and readers are cautioned not to unduly rely on these statements. </span></p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">RISK FACTOR SUMMARY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to a number of risks that if realized could materially harm our business, prospects, operating results, and financial condition. Some of the more significant risks and uncertainties we face include those summarized below. The summary below is not exhaustive and is qualified by reference to the full set of risk factors set forth in Item 1A of this Form <span style="white-space:nowrap">10-K</span> &#8220;Risk Factors.&#8221; Please carefully consider all the information in this Form <span style="white-space:nowrap">10-K,</span> including the full set of risks set forth in the &#8220;Risk Factors&#8221; section, and in our other filings with the SEC before making an investment decision regarding CymaBay. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Financial Condition and Capital Requirements </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have incurred significant net losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future. We may need to raise additional equity and/or debt capital to fund our continued operations, including clinical trials and other product development. In the event we do not successfully raise sufficient funds to finance our product development activities, we will curtail our product development and other activities commensurate with the magnitude of the shortfall or our product development activities may cease altogether. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Failure to remain in compliance with our obligations under the development financing agreement with Abingworth could lead to acceleration of potentially significant payments to Abingworth. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our ability to generate future revenues from product sales is uncertain and depends upon our ability to successfully develop, obtain regulatory approval for, and commercialize product candidates, including most importantly, seladelpar. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Clinical Development and Regulatory Approval </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Drug development and obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Serious complications or side effects in connection with the use or development of our product candidates could lead to delay or discontinuation of development of our product candidates. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to <span style="white-space:nowrap">COVID-19</span> </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our business may be adversely affected by the effects of <span style="white-space:nowrap">the&#160;COVID-19&#160;situation,</span> including those impacting our ability to enroll and conduct critical clinical trials, as well as impacts to our other development efforts, administrative personnel and third-party service providers. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Reliance on Third Parties </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our manufacturing partners and other service providers, including CROs managing our clinical trials, may fail to perform adequately in their efforts to support the development, manufacture, and commercialization of our drug candidates and future products. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Commercialization of Our Product Candidates </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have never successfully commercialized a product. If any of our product candidates receive marketing approval, they may nonetheless be unable to gain sufficient market acceptance by physicians, patients, health care payors and others in the medical community. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our products, we may be unable to generate any revenue. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The commercial success of our products is subject to significant competition from products that may be superior to, or more cost effective than, our products. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risks Related to Our Intellectual Property </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We may not be able to protect the confidentiality of our trade secrets, and our patents or other means of defending our intellectual property may be insufficient to protect our proprietary rights. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Patents or proprietary rights of others may restrict our development, manufacturing, and/or commercialization efforts and subject us to litigation and other proceedings that could find us liable for damages. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other Risks Factors &#8211; Risks Related to Employees, Information Technology, and Owning Our Common Stock </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our business is dependent on our key personnel and will be harmed if we cannot recruit and retain leaders in our development, administrative, and commercial organizations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Significant disruptions of information technology systems or breaches of data security could adversely affect our business. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Changes in and failures to comply with United States and foreign privacy and data protection laws, regulations and standards may adversely affect our business, operations and consolidated financial performance. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="txa446975_1">PART I </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="txa446975_2">Item&#160;1. Business </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span>), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. We are focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We reported net losses of approximately $106.0&#160;million and $90.0&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. As of December&#160;31, 2022, we had cash, cash equivalents and marketable securities totaling $135.5&#160;million. We believe those funds, along with the upfront payment of $34.2&#160;million received from Kaken Pharmaceutical Co., Ltd. pursuant to the Collaboration and License Agreement and $92.4&#160;million obtained in connection with a public equity offering, as discussed in <span style="font-style:italic">Note 13&#8212;Subsequent Events</span>, are sufficient to fund our current operating plan through the third quarter of 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to become a leading biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Key elements of our strategy are to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Advance clinical development of seladelpar for patients with PBC, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Obtain regulatory approval and commercialize seladelpar for patients with PBC, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Strengthen our patent portfolio and other means of protecting exclusivity, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Acquire or develop other products or product candidates. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Phase 3 Trials </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We completed enrollment of 193 patients in a global, Phase 3 registration study (RESPONSE) to evaluate seladelpar in patients with PBC in July 2022 and anticipate releasing top line data for RESPONSE in the third quarter of 2023. We are also continuing the enrollment of a global long-term extension study (ASSURE) to evaluate seladelpar in patients with PBC that is intended to collect additional long-term safety and efficacy data to support registration. We have enrolled over 200 patients in ASSURE and expect to ultimately enroll over 300 patients. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">CymaBay Pipeline Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our pipeline includes two clinical stage product candidates: seladelpar (a PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> agonist) and <span style="white-space:nowrap">MBX-2982</span> (a GPR119 agonist). </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:37%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:8%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:34%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Product</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Candidates</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Disease/condition</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Status</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Seladelpar<br /> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">(PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> agonist)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Primary Biliary Cholangitis (PBC)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Phase&#160;3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Ongoing&#160;52-week&#160;Phase&#160;3&#160;study</span> to evaluate seladelpar in PBC patients with inadequate response or intolerance to ursodeoxycholic acid (UDCA) (RESPONSE)</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Ongoing open-label, long-term extension study evaluating seladelpar in PBC patients (ASSURE)</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="white-space:nowrap">MBX-2982</span><br /> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">(GPR119&#160;agonist)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Hypoglycemia in Type 1 Diabetics</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Phase&#160;2a</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Ongoing <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-pharmacology</span></span> Phase 2a study*</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Being conducted and funded by third parties (see <span style="white-space:nowrap">MBX-2982</span> section below) </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Seladelpar <span style="white-space:nowrap">(MBX-8025)</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Summary </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seladelpar is a selective agonist for the peroxisome proliferator-activated receptor delta (PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span>). The PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> receptor is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells. Seladelpar has the potential to treat certain diseases of the liver and a variety of disorders of lipid metabolism. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Seladelpar was initially developed for treatment of mixed dyslipidemia, which is characterized by elevated <span style="white-space:nowrap">low-density</span> lipoprotein <span style="white-space:nowrap">(LDL-C)</span> and triglycerides (TGs). Results from our Phase 2 clinical study of seladelpar in patients with mixed dyslipidemia established effects that we believe have the potential to benefit patients affected with PBC and other conditions. These benefits include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reductions in <span style="white-space:nowrap">LDL-C</span> and total cholesterol, and increases in high-density-lipoprotein <span style="white-space:nowrap">(HDL-C),</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reductions in triglycerides and free fatty acids, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reductions in high-sensitivity <span style="white-space:nowrap">C-reactive</span> protein <span style="white-space:nowrap">(hs-CRP),</span> a marker of inflammation, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reductions in alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT). </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, the United States Food and Drug Administration (FDA) granted seladelpar Breakthrough Therapy Designation for the treatment of early stage PBC, and in October 2016, seladelpar received the European Medicines Agency (EMA) PRIority Medicines (PRIME) designation for the treatment of PBC. In November 2016, the FDA granted orphan drug designation to seladelpar for the treatment of PBC. In September 2017, EMA&#8217;s Committee for Orphan Medicinal Products (COMP) granted orphan drug designation to seladelpar for the treatment of PBC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have completed <span style="white-space:nowrap">six-month</span> and twelve-month toxicity studies of seladelpar in rats and monkeys, respectively, as well as <span style="white-space:nowrap">two-year</span> carcinogenicity studies in mice and rats. In addition, we have completed multiple Phase 1 clinical studies, three Phase 2 and one Phase 3 clinical study (ENHANCE) of seladelpar in PBC. In addition, we are in the process of conducting a second Phase 3 study (RESPONSE) with seladelpar in PBC and a Phase 3 long-term extension study (ASSURE) of seladelpar in PBC patients. We believe that the data from the Phase 2 studies and the ENHANCE Phase 3 study established seladelpar&#8217;s anti-cholestatic and anti-inflammatory effects and identified a dose (10 mg/day) that has the potential to offer patients improved efficacy </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and better tolerability over the only approved second-line treatment available today. Those studies showed reductions in markers of cholestasis including ALP and GGT, and showed improved inflammatory and metabolic markers with patients experiencing decreases in levels of transaminases, <span style="white-space:nowrap">hs-CRP,</span> and <span style="white-space:nowrap">LDL-C.</span> Many PBC patients suffer from pruritus, or itching, which can significantly impact their quality of life. Based on data from our completed Phase 2 and Phase 3 studies, and unlike the only approved second-line treatment currently available, we believe that seladelpar may reduce the incidence and severity of pruritus in PBC patients. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Target Indications for Seladelpar </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are actively pursuing PBC as our initial launch indication for seladelpar. We may look to develop seladelpar in other indications in the future. Following is a review of our development progress for seladelpar in PBC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Primary Biliary Cholangitis (PBC) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Summary </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PBC is a rare, chronic, progressive, autoimmune liver disease that predominantly affects middle-aged women. A <span style="white-space:nowrap">T-cell</span> mediated immune response is thought to damage, and ultimately destroy, the interlobular and septal bile ducts. The loss of bile duct function leads to decreased bile secretion and retention of toxic substances, including bile acids, within the liver parenchyma. This retention may ultimately cause liver cirrhosis and liver failure in PBC patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PBC primarily affects an estimated one in 1,000 women over the age of 40. Due to its low prevalence, PBC has been recognized as an orphan disease in the U.S. and E.U., meeting their respective FDA and EMA orphan designation criteria. Diagnosis of PBC is confirmed by elevated serum ALP presence and/or the magnitude of antimitochondrial antibody (AMA presence) and liver biopsies, although biopsies are not required for diagnosis in most patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most common clinical symptoms of PBC include fatigue and pruritus (or itching (up to 70% occurrence)), which adversely affects many patients&#8217; quality of life. PBC patients are also frequently affected by conditions including jaundice, hyperlipidemia (notably hypercholesterolemia), hypothyroidism, osteopenia and osteoporosis, and coexisting autoimmune diseases. Late complications of PBC include portal hypertension, malabsorption, deficiencies of <span style="white-space:nowrap">fat-soluble</span> vitamins, and steatorrhea (excess fat in feces). Left untreated, or without sufficient treatment, PBC disease progression can lead to the need for liver transplantation and liver-related mortality. Despite being a rare disease, PBC is one of the top six indications for liver transplantation in the U.S. and E.U. Recurrence of PBC following liver transplantation is reported in <span style="white-space:nowrap">11-46%</span> of transplantations, with an estimated prevalence of 30% at 10 years following transplantation, further demonstrating a need for effective therapies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Retrospective analyses of PBC clinical outcomes data have shown that elevated levels of ALP and bilirubin are associated with worsened clinical outcomes including liver transplantation and death associated with PBC. These analyses supported the use of ALP and bilirubin as elements of a clinical surrogate reasonably likely to predict outcomes that was used for the approval of obeticholic acid as a second line therapy for PBC. The current first line therapy for PBC is ursodeoxycholic acid (UDCA), a secondary bile acid. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Studies of Seladelpar in PBC </span></p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">RESPONSE (Phase 3) </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2022, we completed enrollment of our global, Phase 3 registration study (RESPONSE) to evaluate seladelpar in patients with PBC. The Phase 3 study is a <span style="white-space:nowrap">52-week,</span> double blind, placebo-controlled, randomized, global, registration study evaluating the safety and efficacy of seladelpar in patients with PBC. The study has </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enrolled 193 patients who have an inadequate response to, or intolerance to, UDCA, in a 2:1 randomization to oral, once daily seladelpar 10 mg or placebo. The primary outcome measure will be the composite biochemical responder rate at 52 weeks. A responder is defined as a patient who achieves an ALP level less than 1.67 times the upper limit of normal with at least a 15% decrease from baseline and has a normal level of total bilirubin. Additional key outcomes of efficacy will compare the rate of normalization of ALP at 52&#160;weeks and the change from baseline in level of pruritus at six months for patients with moderate to severe pruritus at baseline assessed by a numerical rating scale (NRS) recorded with an electronic diary. We expect to release top line data for RESPONSE in the third quarter of 2023. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ASSURE (Phase 3) </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2021, we commenced a long-term open-label safety study (ASSURE) of seladelpar for patients with PBC. The study is open to patients from our prior Phase 2 open label study and our Phase 3 ENHANCE study, as well as patients completing treatment in RESPONSE and certain Phase 1 studies. The ASSURE trial is ongoing and has enrolled over 200 patients, with additional patients expected to enroll. We expect to ultimately enroll over 300 patients in ASSURE. ASSURE will provide us with additional efficacy and safety data to supplement our RESPONSE and ENHANCE trials as we continue to build a rich efficacy and safety database to support our NDA submission for seladelpar in PBC, including seladelpar treatment of over 400 unique PBC patients. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">ENHANCE (Phase 3) </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2018 we commenced a global, Phase 3 registration study (ENHANCE) to evaluate seladelpar in patients with PBC. ENHANCE was a double-blind, randomized, placebo-controlled <span style="white-space:nowrap">52-week</span> study evaluating the safety and efficacy of 5 mg and 10 mg of seladelpar versus placebo in patients with PBC who had an inadequate response to, or were intolerant to, first-line treatment with UDCA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approximately 265 patients were randomized to receive placebo, 5 mg of seladelpar, or 10 mg of seladelpar. Patients on 5 mg could potentially increase their dose, in a double-blinded manner, to 10 mg after 6 months if they had not yet met the composite biochemical response criteria. The primary endpoint was a composite response, defined as a patient achieving an ALP level below 1.67 times the upper limit of normal, with at least a 15% reduction from baseline, and a normal total bilirubin at 52 weeks. Key secondary endpoints were the ALP normalization rate and changes from baseline in pruritus, as measured by NRS in patients with <span style="white-space:nowrap"><span style="white-space:nowrap">moderate-to-severe</span></span> pruritus at baseline. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019 we terminated ENHANCE early, based on initial histological observations obtained in our Phase 2b study of seladelpar in nonalcoholic steatohepatitis (NASH). In May 2020, we announced completion of an independent expert panel review into the NASH findings that concluded the data, in aggregate, did not support liver injury related to seladelpar. In June 2020, we discussed the data, the panel&#8217;s conclusions, and other matters with the FDA. In July 2020, the FDA lifted the clinical hold on the program and we reinstated clinical development of seladelpar in PBC. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020 we announced positive results from ENHANCE, which we believe support seladelpar as a safe, well-tolerated, and efficacious treatment for patients with PBC. Although the study was terminated prior to the completion of <span style="white-space:nowrap">the&#160;52-week&#160;treatment</span> period, the statistical analysis plan was amended while the study remained blinded to adjust for evaluation of the primary and two key secondary endpoints at Week 12 rather than Week 52. Topline data for patients through 12 and to 26 weeks showed what we believe to be robust anti-cholestatic, anti-inflammatory and anti-pruritic activity of seladelpar. Specifically, 78.2% of patients on 10 mg of seladelpar compared with 12.5% on placebo achieved the primary composite outcome after 3 months (p&lt;0.0001), and 27.3% of patients on 10 mg of seladelpar compared with 0% on placebo normalized ALP by 3 months (p&lt;0.0001). In addition, the study revealed statistically significant improvement in change from baseline in pruritus at 3 months (p&lt;0.05) for patients <span style="white-space:nowrap"><span style="white-space:nowrap">with&#160;moderate-to-severe&#160;itch</span></span> treated with seladelpar 10 mg versus placebo. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Safety Studies </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the decision to terminate in December 2019, we were conducting a long-term safety study of seladelpar, which was open to patients who had participated in other company-sponsored PBC studies. Patients completing the Phase 2 open label study discussed immediately below, as well as those from ENHANCE, were able to transfer into the long-term safety study. As of the time of termination, 106 patients had received seladelpar for at least 12 months and 51 patients had received seladelpar for at least 24 months. The safety study was discontinued due to the histological observations in the Phase 2b NASH study. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the reinstatement of the clinical development of seladelpar in 2020, we commenced a long-term safety study (ASSURE), which is open to patients who were eligible for the prior long-term extension study, including those from our Phase 2 open label study and our Phase 3 ENHANCE study, as well as patients completing treatment in RESPONSE and certain Phase 1 studies. The ASSURE trial is ongoing and has enrolled over 200 patients, with additional patients expected to enroll from other seladelpar PBC trials, including RESPONSE. We expect to ultimately enroll over 300 patients in ASSURE. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Phase 2 Open Label Study </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2016, we initiated a Phase 2 study of seladelpar in patients with PBC. The study was an open label, randomized, dose-ranging study evaluating 2 mg, 5 mg and 10mg doses of seladelpar and the primary efficacy endpoint was percent change in ALP from baseline. The study had an initial twelve-week period in which starting doses were maintained, but after which doses could be increased to as high as 10 mg for those patients in which a greater biochemical response was deemed appropriate, these being described as titration groups. Secondary outcomes included the evaluation of other markers of cholestasis, inflammation, and lipid parameters, as well as clinical symptoms such as pruritus and quality of life. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2018 we announced data from the study that we believe showed that seladelpar treatment led to sustained anti-cholestatic and anti-inflammatory effects with no worsening of pruritus through 52 weeks. Specifically, at 52&#160;weeks the mean decreases in ALP were <span style="white-space:nowrap">-47%</span> and <span style="white-space:nowrap">-46%</span> in the 5/10 titration and 10 mg groups, respectively. A key secondary outcome was the composite response measured at week 52 where a responder was defined as a patient with ALP &lt;1.67 x ULN, &#8805;15% decrease in ALP, and total bilirubin &#8804;ULN. At 52 weeks 59% and 71% of patients met the composite endpoint in the 5/10 titration and 10 mg groups, respectively. The anti-cholestatic effect of seladelpar was further substantiated with ALP normalization at 52 weeks in 24% and 29% of patients in the 5/10 titration and 10 mg groups, respectively. Treatment with seladelpar also demonstrated a robust anti-inflammatory activity with median transaminase decreases of <span style="white-space:nowrap">-31%</span> and <span style="white-space:nowrap">-33%</span> in the 5/10 titration and 10 mg groups, respectively. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We subsequently reported on a <span style="white-space:nowrap">52-week</span> analysis from the study on the effect of seladelpar on pruritus, or itching, which is a common clinical symptom of PBC that adversely effects a patient&#8217;s quality of life. Patient self-reported experiences were collected using the pruritus visual analogue scale (VAS) in 101 PBC patients in the 5/10 titration or 10 mg groups. In patients with moderate to severe pruritus (VAS &#8805; 40), substantial improvement in pruritus (VAS &#8805; <span style="white-space:nowrap">20-point</span> decrease) was seen in 58% and 93% of patients in the 5/10 titration and 10 mg groups, respectively. These data suggest that seladelpar is not associated with drug-induced pruritus and supported further evaluation of seladelpar&#8217;s potential benefit on pruritus. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">MBX-2982</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">MBX-2982</span> targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Preclinical data indicate that <span style="white-space:nowrap">MBX-2982</span> is a potent selective orally-active GPR119 agonist that functions through a unique dual mechanism of action that acts directly on the beta cell to increase insulin secretion and stimulates release of the incretin <span style="white-space:nowrap">GLP-1</span> from the gut. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
We have previously conducted clinical studies for <span style="white-space:nowrap">MBX-2982</span> as a potential treatment for diabetes, demonstrating <span style="white-space:nowrap">MBX-2982</span> was, we believe, safe and well tolerated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe <span style="white-space:nowrap">MBX-2982</span> may also have utility in various diseases impacting the gut, liver or <span style="white-space:nowrap">gut-liver</span> axis and are currently exploring potential opportunities to advance development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2020, we announced a study to evaluate the potential for <span style="white-space:nowrap">MBX-2982</span> to stimulate the release of the hormone glucagon in response to hypoglycemia in patients with type 1 diabetes (T1D). Glucagon is a regulatory hormone that elevates blood sugar levels in response to below normal glucose levels (hypoglycemia). Insulin-induced hypoglycemia in diabetes is a significant limiting factor in achieving the desired glucose control and is the cause of significant morbidity. In recent preclinical studies, GPR119 agonists were shown to enhance glucagon secretion in response to low glucose levels and were able to prevent hypoglycemia in animal models. The Phase 2a <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-pharmacology</span></span> study will assess whether <span style="white-space:nowrap">MBX-2982</span> can enhance glucagon secretion during insulin-induced hypoglycemia in subjects with T1D. If successful, studies to evaluate <span style="white-space:nowrap">MBX-2982</span> as a potential preventive therapy for hypoglycemia in patients with T1D may be warranted. The study is being led by the AdventHealth Translational Research Institute in Orlando, Florida and is fully funded by The Leona M. and Harry B. Helmsley Charitable Trust. CymaBay retains full commercial rights to <span style="white-space:nowrap">MBX-2982.</span> The study is ongoing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">COVID-19</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through the date of filing of this Annual Report, the biggest impact of the <span style="white-space:nowrap">COVID-19</span> outbreak on our operations, financial condition and liquidity has been the hybrid-remote operation of our operations personnel and what we believe to be slower enrollment timelines for our RESPONSE trial. As a result of the continuing <span style="white-space:nowrap">COVID-19&#160;situation,</span> we may experience future disruptions that could impact these and additional aspects of our business, including our progress towards the completion of our clinical studies and other associated development activities. Possible disruptions are currently difficult to foresee. We continue to monitor areas of potential risk, which include but are not limited to the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Remote workforce operations</span>. During the pandemic to date, our workforce has adapted to remotely working to maintain operations. Our operations are currently in a hybrid model with most employees working from our office for a portion of the week and working remotely for the rest of the week. Our reliance on personnel working from home could potentially negatively impact future productivity, or disrupt, delay, or otherwise adversely impact our business. In addition, remote operations could increase our cyber-security and data privacy risks, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations, or delay necessary interactions with regulators, contract manufacturers, contract research organizations, clinical trial sites, and other important agencies and contractors, which may result in increased costs to us. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Clinical trial and drug manufacturing operations</span>. In collaboration with our clinical research organization partners, we sponsor clinical trials that take place at investigator sites in the U.S. and internationally. We also partner with contract manufacturing organizations to develop, manufacture, and distribute our product candidate drug supplies. To date, these collective research and development personnel and vendors have adapted to <span style="white-space:nowrap">COVID-19&#160;related</span> restrictions and reduced access to work facilities through the use of remote working technologies and other measures as we continue to progress toward completion of our clinical trials. However, in the future, as we look to complete the clinical development of seladelpar and initiate other programs, our research and development personnel and vendors may not be able to sufficiently access their applicable work facilities as a result of facility closure orders and the possibility of other governmental action. Furthermore, patients in our clinical trials may also be impacted by any ongoing travel and facility access restrictions. Although we and our vendors continue to plan for and develop <span style="white-space:nowrap"><span style="white-space:nowrap">COVID-19-related</span></span> risk mitigation strategies, it is uncertain whether these plans will be sufficient to fully offset the impact that travel and facility access </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
restrictions (or other unanticipated impediments) may have on our ability to execute our development activities in a timely and cost-effective manner. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Drug regulator interactions</span>. The FDA, comparable foreign regulatory agencies, and ethics boards may experience operational interruptions or delays, which could impact timelines for regulatory meetings, submissions, trial initiations, and regulatory approvals. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-style:italic">Financial reporting and compliance</span>. To date, there has been no adverse impact on our ability to maintain our established financial reporting functions and internal controls over financial reporting. However, our ability to prepare our financial results timely and accurately is partially dependent upon the availability of third-party information systems and other cloud-based services. Any degradation in the quality or timeliness of critical third-party information or cloud-based services could adversely impact our financial reporting capabilities. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Overall, we cannot at this time predict the specific extent, duration, or full impact that the continuing <span style="white-space:nowrap">COVID-19</span> situation will have on our financial condition and operations. The impact of the <span style="white-space:nowrap">COVID-19</span> situation on our company will depend on future developments, including the duration and spread of the outbreak and related governmental advisories and restrictions. These developments and the impact of <span style="white-space:nowrap">COVID-19</span> on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, this may negatively impact our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">License Agreements and Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">General </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We actively seek to obtain, where appropriate, patent protection and regulatory exclusivity for the proprietary technology that we consider important to our business, including compounds, compositions and formulations, their methods of use and processes for their manufacture both in the United States and other countries. We also rely on trade secrets, <span style="white-space:nowrap">know-how,</span> continuing technological innovation and <span style="white-space:nowrap">in-licensing</span> to develop and maintain our proprietary position. Our success depends in part on our ability to obtain, maintain and enforce proprietary protection for our product candidates, technology and <span style="white-space:nowrap">know-how,</span> to operate without infringing the proprietary rights of others, and to exclude others from infringing our proprietary rights. However, patent protection may not afford us complete protection against competitors who seek to circumvent our patents. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also depend upon the skills, knowledge, experience and <span style="white-space:nowrap">know-how</span> of our management, research and development personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary <span style="white-space:nowrap">know-how,</span> which is not patentable, and for inventions for which patents may be difficult to enforce, we currently rely, and will in the future rely, on trade secret protection and confidentiality agreements to protect our interests. To this end, we require all our employees, consultants, advisors and other contractors to enter into confidentiality agreements that prohibit the disclosure of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Finance and Licensing Agreements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current significant finance and licensing arrangements are summarized below: </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Kaken Pharmaceutical:</span> In January&#160;2023, we entered into a Collaboration and License Agreement (the License Agreement) with Kaken Pharmaceutical Co., Ltd. (Kaken). Pursuant to the License Agreement, we granted Kaken an exclusive license to commercialize seladelpar (the&#160;Licensed Product) for the prevention or treatment of PBC in Japan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the License Agreement, Kaken will bear the cost of, and be responsible for, among other things, conducting the clinical studies and other developmental activities for the Licensed Product in PBC </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in Japan as well as preparing and filing applications for regulatory approval in Japan and commercializing the Licensed Product in Japan. Kaken is obligated to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize, the Licensed Product in Japan, including obtaining pricing approval for the Licensed Product in Japan. We are obligated to supply to Kaken, its requirements of Licensed Product for clinical and commercial use in Japan, which obligation may be terminated upon specified circumstances and technology transfer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the license and other rights granted by us, Kaken made an upfront cash payment to us of $34.2&#160;million and is obligated to pay potential milestone payments to us totaling up to &#165;17.0&#160;billion (approximately $128.0&#160;million at contract inception date) for the achievement of certain regulatory and sales milestones. In addition, during the Royalty Term (as defined below), while we supply Licensed Product to Kaken, Kaken will make payments to us for each unit of Licensed Product that we supply at a percentage of the Japanese National Health Insurance price of the Licensed Product that equates to 20+% royalties. If we are not supplying product to Kaken during the Royalty Term, a lower royalty payment will be payable to us by Kaken based on Kaken net sales of Licensed Product in Japan. After the Royalty Term, if we are supplying Licensed Product to Kaken, we will receive payments for each unit of Licensed Product based on a percentage of the Japanese National Health Insurance price of the Licensed Product that is lower than during the Royalty Term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Royalty Term means the period ending on the latest to occur of (a)&#160;the expiration of the last valid claim of the royalty patents covering such Licensed Product in Japan, (b)&#160;the expiration of regulatory exclusivity for such Licensed Product in Japan, and (c) 10 years after the first commercial sale of such Licensed Product in Japan. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The License Agreement is effective until the date upon which (a)&#160;the Royalty Term has expired in Japan for the final Licensed Product, or (b)&#160;the License Agreement is earlier terminated (the Initial Term). After the Initial Term (except in the case of early termination), the License Agreement will be automatically renewed <span style="white-space:nowrap">for&#160;2-year&#160;periods,</span> unless either party has given the other party a written notice not to renew the License Agreement no later than 12 months prior to the expiration of the Initial Term or any subsequent renewal term, in which case the License Agreement shall expire (and thus terminate) at the end of the then-existing term or, if applicable, shall earlier terminate upon an early termination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The License Agreement may be early terminated by either party for material breach, upon a party&#8217;s insolvency or bankruptcy or upon a challenge by one party of any patents of the other party, and Kaken may terminate in specified situations, including for a safety concern, clinical failure or termination of an <span style="white-space:nowrap">underlying&#160;in-license&#160;to</span> us from Janssen Pharmaceutica NV (see below), or at its convenience with specified prior notice. Upon an intentional or willful material breach of the License Agreement by us, Kaken also has an alternative remedy for material breach of the License Agreement that results in a reduction in the payments otherwise payable to us under the License Agreement. Upon early termination, (i)&#160;license rights granted under the License Agreement terminate, (ii)&#160;to the extent permitted by applicable law, Kaken is obligated to transfer to us copies of, and its entire right, title and interest in, all regulatory materials in Japan (subject to a royalty if such termination is by Kaken for our uncured material breach) and (iii)&#160;Kaken will automatically grant to us, with immediate effect, <span style="white-space:nowrap">a&#160;non-exclusive,&#160;fully</span> paid, royalty-free license under the Kaken program intellectual property solely for the exploitation of Licensed Products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the License Agreement, we and Kaken agreed to establish a joint steering committee to provide strategic oversight of both our and Kaken&#8217;s activities under the License Agreement. The License Agreement also contains customary representations, warranties and covenants by both us and Kaken, as well as customary provisions relating to indemnification, confidentiality, intellectual property and other matters. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Johnson</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;&amp; Johnson:</span> In June 2006, we entered into a license agreement with Janssen Pharmaceutica&#160;NV (Janssen NV), an affiliate of Johnson&#160;&amp; Johnson, in which we received an exclusive worldwide, royalty-bearing license to seladelpar and certain other PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> compounds (the PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> Products) with the right to grant </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sublicenses to third parties to make, use and sell such PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> Products. Under the terms of the agreement, we have full control and responsibility over the research, development and registration of any PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> Products and are required to use diligent efforts to conduct all such activities. Janssen NV has the sole responsibility for the preparation, filing, prosecution, maintenance of, and defense of certain patents related to the PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> Products. Under the terms of the agreement Janssen NV is entitled to receive up to an 8% royalty on net sales of PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> Products. Under the terms of the agreement, if we do not expend more than a de minimis amount of effort and resources on the research and/or development of at least one PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> Product, such action would constitute a default under the agreement. In addition, if we fail to use diligent efforts to promote, market and sell any PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> Product under the agreement, such action would constitute a default under the agreement. In the event of such default, or upon our termination of the agreement, we are obligated to grant Janssen NV a worldwide, exclusive, irrevocable license under the agreement in all information that is controlled, developed or acquired by us that relates to a PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> compound or PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> Product and in all patents that are filed during the term of the agreement with a priority date after the effective date of the agreement and relate to a PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> compound or PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> Product. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2010, we entered into two development and license agreements with Janssen Pharmaceuticals, Inc. (Janssen), an affiliate of Johnson&#160;&amp; Johnson, under which Janssen obtained the right to further develop undisclosed metabolic disease target agonists for the treatment of Type 2 diabetes and other disorders, and we received a <span style="white-space:nowrap">one-time</span> nonrefundable technology access fee related to the agreements. These development and licensing agreements were terminated as of April 2015. In December 2015, we exercised an option pursuant to the terms of one of the original agreements to continue work to research, develop and commercialize compounds with activity against an undisclosed metabolic disease target. Janssen granted us an exclusive, worldwide license (with rights to sublicense) under the Janssen <span style="white-space:nowrap">know-how</span> and patents to research, develop, make, have made, import, use, offer for sale and sell such compounds. We have full control and responsibility over the research, development and registration of any products developed and/or discovered from the metabolic disease target and are required to use diligent efforts to conduct all such activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Abingworth:</span> In July 2021, we entered into a Development Financing Agreement (the Financing Agreement) with ABW Cyclops SPV LP, an affiliate of Abingworth LLP (Abingworth), pursuant to which Abingworth provided us with $75&#160;million of funding to support our development of seladelpar for the treatment of PBC. In return, we will pay to Abingworth (1)&#160;contingent upon the first to occur of regulatory approval of seladelpar for the treatment of PBC in the U.S., U.K., Germany, Spain, Italy or France (Regulatory Approval), fixed success payments equal to 2.0x of the funding provided, consisting of $10&#160;million payable within 90 days after Regulatory Approval and thereafter payments due on the first six anniversaries of the Regulatory Approval in the amounts of $15&#160;million, $22.5&#160;million, $22.5&#160;million, $25.0&#160;million, $27.5&#160;million and $27.5&#160;million, respectively and (2)&#160;variable success payments equal to 1.1x of the funding provided, consisting of sales milestone payments of (x) $17.5&#160;million and $27.5&#160;million, respectively upon first reaching certain cumulative U.S. product sales thresholds, and (y)&#160;$37.5&#160;million upon first reaching a specified U.S. product sales run rate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had an option to receive an additional $25.0&#160;million (the Optional Funding) within approximately two months of enrollment completion of our Phase 3 RESPONSE clinical trial. We did not exercise the Optional Funding and the option has expired. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Promptly following receipt of Regulatory Approval, we are required to execute and deliver a promissory note to Abingworth to convert the fixed and variable success payments into a note payable. At the time that Abingworth receives, collectively, an aggregate of 3.1x of the funding provided (approximately $232.5&#160;million), our payment obligations under the Financing Agreement will be fully satisfied. We have the option to satisfy our payment obligations to Abingworth upon Regulatory Approval, or a change of control of us, by paying an amount equal to the remaining payments payable to Abingworth subject to <span style="white-space:nowrap">a&#160;mid-single-digit&#160;discount</span> rate. Upon a change of control of us, an acceleration payment of 1.35x of the funding provided is payable, net of payments already made to Abingworth and creditable against future payments to Abingworth. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Financing Agreement, we are required to use commercially reasonable efforts to develop seladelpar and complete our development program in accordance with the Financing Agreement and an agreed </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
timeline. In addition, an executive review committee was established between Abingworth and us to discuss our development of seladelpar. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Financing Agreement, we granted Abingworth a security interest in all of our assets (other than intellectual property not related to seladelpar), provided that we are permitted to incur certain indebtedness. The security interest will terminate when we have paid Abingworth 2.0x of the funding provided or upon certain terminations of the Financing Agreement. The Financing Agreement also provides for negative, affirmative and additional covenants, with which we have agreed to comply. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Financing Agreement terminates upon the payment of all payments owing to Abingworth, unless earlier terminated. The Financing Agreement may be earlier terminated by Abingworth if (i)&#160;we fail to use commercially reasonable efforts to develop seladelpar as set forth in the Financing Agreement or fail to make required payments (Fundamental Breach), (ii) we suffer a material adverse event, (iii)&#160;there is a material adverse patent impact on our intellectual property covering seladelpar, (iv)&#160;there are certain irresolvable disagreements within the executive review committee, (v)&#160;the security interests of Abingworth are invalidated or terminated other than as set forth in the Financing Agreement or (vi)&#160;the RESPONSE clinical trial is completed or terminated and (1)&#160;the primary endpoint is not met or (2)&#160;Abingworth reasonably determines that the results of the RESPONSE clinical trial do not support regulatory approval. The Financing Agreement may be earlier terminated by us if (i)&#160;Abingworth fails to fund as provided in the Financing Agreement, (ii)&#160;Abingworth fails to release its security interests as provided in the Financing Agreement or (iii)&#160;the RESPONSE clinical trial is completed or terminated and the primary endpoint is not met. The Financing Agreement may be terminated by either party (i)&#160;if the other party materially breaches the Financing Agreement (Material Breach), (ii) if seladelpar fails to receive regulatory approval in the U.S., U.K. or E.U., (iii) upon the bankruptcy of the other party, (iv)&#160;if a serious safety concern arises in a seladelpar clinical trial or (v)&#160;upon a change of control of us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In certain instances, upon the termination of the Financing Agreement, we will be obligated to pay Abingworth a multiple of the amounts paid to us under the Financing Agreement, including specifically, </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(i) 310% of such amounts in the event that Abingworth terminates the Financing Agreement due to (x)&#160;a Fundamental Breach, (y)&#160;our bankruptcy, or (z)&#160;a safety concern resulting from gross negligence on our part or due to a safety concern that was material on the effective date of the Financing Agreement and the material data showing such safety concern was not publicly known, disclosed to Abingworth, or in the diligence room made available to Abingworth, </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(ii) 200% of such amounts in the event the Financing Agreement is terminated due to (x)&#160;our Material Breach or (y)&#160;the security interests of Abingworth being invalidated or terminated other than as set forth in the Financing Agreement, and </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(iii) 100% of such amounts in the event of certain irresolvable disagreements within the executive review committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if, following certain terminations, we continue to develop&#160;seladelpar for the treatment of PBC and obtain Regulatory Approval, we will make the payments to Abingworth as if the Financing Agreement had not been terminated, less any payments made upon termination. We are not obligated to make any payments to Abingworth under certain instances of technical or regulatory failure of the development program. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Research and Development </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently own or operate research and development facilities. We rely on contract service providers (CSPs), including clinical research organizations, clinical trial sites, central laboratories and other service providers to ensure the proper and timely conduct of our clinical trials. While we have agreements governing their activities, we have limited influence over their actual performance. We have relied and plan to continue to rely upon CSPs to monitor and manage data for our ongoing clinical programs for our product </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates, as well as the execution of nonclinical studies. We control only certain aspects of our CSPs&#8217; activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CSPs does not relieve us of our regulatory responsibilities. We also rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us, which could also adversely affect the progress of our research, development and commercialization objectives. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own approximately 30 United States patents and 270 foreign patents, as well as a number of United States patent applications and foreign and Patent Cooperation Treaty applications that are counterparts to certain United States patents and patent applications. In addition, we license from third parties 11 United States patents and 1 United States patent application and approximately 200 foreign patents and 6 foreign and Patent Cooperation Treaty applications that are counterparts to certain United States patents and patent applications. These patents and patent applications include claims covering various aspects of our product pipeline and research and development strategies, including certain PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> agonists (including seladelpar), their compositions and uses both alone and in combination with other drugs as well as certain GPR119 agonist compositions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The seladelpar portfolio consists of approximately 460 issued patents and 30 pending patent applications related to composition and method of use that expire between 2025 and 2038, before accounting for any potential patent term extension or orphan disease exclusivity. Patent and trade secret protection is critical to our business. Our success will depend in large part on our ability to obtain, maintain, defend and enforce patents and other intellectual property, to extend the life of patents covering our product candidates, to preserve trade secrets and proprietary <span style="white-space:nowrap">know-how,</span> and to operate without infringing the patents and proprietary rights of third parties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Manufacturing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently own or operate manufacturing facilities for the production or testing of seladelpar or other product candidates that we develop, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We presently depend on third party contract manufacturers to obtain all our required raw materials, active pharmaceutical ingredients (APIs) and finished products for our clinical studies for seladelpar. We also expect to use third party contract manufacturers to obtain our commercial supplies of seladelpar. We have executed manufacturing agreements for our API and clinical supplies of seladelpar with established manufacturing firms that are responsible for sourcing and obtaining the raw materials necessary for, as well as manufacturing, the API, finished drug product and packaged product. The raw materials necessary to manufacture the API for seladelpar are available from more than one source. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical industry is highly competitive and subject to rapid and significant innovation. Although we believe that our development expertise and scientific knowledge provide us with advantages over our competitors, particularly in the therapeutic areas in which we are focused, other biopharmaceutical companies in the industry may be able to develop therapeutics that are able to achieve better results. Our competitors include pharmaceutical companies, biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, technical and human resources than we have. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have been developing seladelpar for the treatment of patients with PBC and a description of the competition in this indication is below. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">PBC Competition </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, the only <span style="white-space:nowrap">FDA-approved</span> treatments for PBC are ursodeoxycholic acid (UCDA), also known as ursodiol, an isomer of chenodeoxycholic acid and the synthetic bile acid analog obeticholic acid (Ocaliva<sup style="font-size:75%; vertical-align:top">&#174;</sup>, Intercept Pharmaceuticals, Inc.). Ursodiol decreases serum levels of ALP, bilirubin, alanine aminotransferase, aspartate aminotransferase, cholesterol, and immunoglobulin M, all of which are elevated in patients with PBC and can serve as biochemical markers of the disease. In a study that combined data from three controlled trials with a total of 548 patients, ursodiol significantly reduced the likelihood of liver transplantation or death after four years. Ursodiol also delayed the progression of hepatic fibrosis in early-stage PBC, but was not effective in advanced disease. It has been reported that up to 50% of PBC patients fail to respond adequately to ursodiol therapy. Ursodiol is available as a generic, is approved for other indications, and is priced at a discount to typical branded therapies used in rare populations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ocaliva was approved by the FDA and European Medicines Agency in 2016 for the treatment of PBC in combination with UDCA in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. Ocaliva also received orphan designations in the U.S. and the E.U. A Phase 3 study was completed with a primary composite endpoint defined as a responder rate comprised of the percentage of patients with ALP &lt; 1.67 times upper limit of normal with a decrease in ALP of at least 15% and total bilirubin less than or equal to upper limit of normal. This study met its goals and Ocaliva was granted accelerated approval based on meeting this primary composite endpoint. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although not approved for use in PBC, <span style="white-space:nowrap">off-label</span> use of fibrate drugs has been reported, though many fibrates are specifically contraindicated for use in PBC due to potential concerns over acute and long-term safety in this patient population. Nevertheless, <span style="white-space:nowrap">off-label</span> use of fibrates is mentioned in several published treatment guidelines. Other therapies, such as colchicine, methotrexate, prednisone and multiple immunosuppressive regimens have been attempted. However, their efficacy is limited or unproven, and they are associated with multiple side-effects impacting tolerance and safety. Liver transplantation improves survival in patients with PBC, and it is the only effective treatment for those with liver failure. Liver transplantation however is problematic because of its costs, the limited availability of donor organs, and by the fact that the disease may recur after an initially successful transplantation. As a result, despite the previously mentioned therapeutic interventions, it is recognized that PBC continues to progress in many patients and additional medical treatment is needed to address this disease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Elafibranor (Genfit S.A./Ipsen, S.A.) is a mixed PPAR&#945;/<span style="FONT-FAMILY:SYMBOL">&#100;</span> agonist in development for patients with PBC. In April 2019, Genfit announced elafibranor had been granted Breakthrough Therapy Designation by the FDA for the treatment of PBC. In December 2018, Genfit announced positive Phase 2 results from a Phase 2 study evaluating the efficacy and safety of elafibranor (80 mg and 120 mg once-daily) in adult patients with PBC who had an inadequate response to UDCA. In September 2020, Genfit announced the commencement of a Phase 3 study of elafibranor in patients with PBC who had an inadequate response or intolerance to UDCA. In December 2021 Genfit announced that it had entered into an exclusive licensing agreement with Ipsen for the development and commercialization of elafibranor. Another potential therapy in clinical development for PBC is the dual PPAR&#945;/<span style="FONT-FAMILY:SYMBOL">&#103;</span> agonist saroglitazar (Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited). In November 2020, Phase 2 results were presented at the Liver Meeting hosted by the American Association for the Study of Liver Disease. In December 2020, Zydus announced saroglitizar had been granted Fast Track Designation for PBC and in January 2021 it received Orphan Drug Designation for PBC by the FDA. In December 2021, Zydus announced it had initiated a Phase 2(b)/3 study of saroglitazar in patients with PBC. Calliditas Therapeutics AB&#8217;s selective NOX inhibitor setanaxib has also reported Phase 2 study data for PBC and in August 2021, Calliditas announced setanaxib had been granted Fast Track Designation for PBC by the FDA and that setanaxib has previously been granted orphan drug designation for PBC in the U.S. and Europe. In February 2022, Calliditas announced it had initiated a Phase 2b/3 study in PBC. In cholestatic pruritus, GSK2330672 (GSK plc) is an inhibitor of the Intestinal Bile Acid Transporter (IBAT), which is undergoing evaluation for decreasing symptoms of pruritus, including in PBC. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government Regulation and Product Approval </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those we are developing. The pharmaceutical drug product candidates that we develop must be approved by the Food and Drug Administration (FDA) before they may be legally marketed in the United States. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">United States Pharmaceutical Product Development Process </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates pharmaceutical products under the Federal Food, Drug and Cosmetic Act, and implements regulations. Pharmaceutical products are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a pharmaceutical product may be marketed in the United States generally involves the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices (GLP) or other applicable regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Submission to the FDA of an Investigational New Drug (IND) application, which must become effective before human clinical studies may begin; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Performance of adequate and well-controlled human clinical studies according to the FDA&#8217;s current Good Clinical Practices (GCP), to establish the safety and efficacy of the proposed pharmaceutical product for its intended use; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Submission to the FDA of a New Drug Application (NDA) for a new pharmaceutical product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the pharmaceutical product is produced to assess compliance with the FDA&#8217;s current Good Manufacturing Practice standards (cGMP), to assure that the facilities, methods and controls are adequate to preserve the pharmaceutical product&#8217;s identity, strength, quality and purity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Potential FDA audit of selected preclinical and clinical study sites that generated the data in support of the NDA; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA review and approval of the NDA. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require the expenditure of substantial resources and approvals are inherently uncertain. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before testing any compounds with potential therapeutic value in humans, the pharmaceutical product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the pharmaceutical product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements including GLP. The sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. The IND automatically becomes effective 30 days after receipt by the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FDA, unless the FDA has concerns and notifies the sponsor by way of a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical study can begin. The FDA may also impose clinical holds on a pharmaceutical product candidate at any time before or during clinical studies due to safety concerns or <span style="white-space:nowrap">non-compliance.</span> Submission of an IND may not result in the FDA allowing clinical studies to begin and, once begun, issues may arise that lead to suspension or termination of such clinical study. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical studies involve the administration of the drug candidate to healthy volunteers or patients under the supervision of qualified investigators, who are generally physicians not employed by or under the clinical study sponsor&#8217;s control. Clinical studies are conducted under protocols detailing, among other things, the objectives of the clinical study, dosing procedures, subject selection and exclusion criteria, how the results will be analyzed and presented and the parameters to be used to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND. Clinical studies must be conducted in accordance with GCP. Further, each clinical study must be reviewed and approved by an independent Institutional Review Board (IRB) at, or servicing, each institution at which the clinical study will be conducted. An IRB is charged with protecting the welfare and rights of study participants and considers such items as whether the risks to individuals participating in the clinical studies are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical study subject or his or her legal representative and must monitor the clinical study until completed. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human clinical studies are typically conducted in three sequential phases that may overlap or be combined: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 1. The pharmaceutical product is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 2. The pharmaceutical product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases, to determine dosage tolerance, optimal dosage and dosing schedule and to identify patient populations with specific characteristics where the pharmaceutical product may be more effective. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase 3. Clinical studies are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical study sites. These clinical studies are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. The studies must be well-controlled and usually include a control arm for comparison. One or two Phase 3 studies are required by the FDA for an NDA approval, depending on the disease severity and other available treatment options. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Post-approval studies, or Phase 4 clinical studies, may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical studies must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events or any finding from tests in laboratory animals that suggests a significant risk for human subjects. Phase 1, Phase 2 and Phase 3 clinical studies may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical study at any time on various grounds, including, but not limited to, a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical study at its institution if the clinical study is not being conducted in accordance with the IRB&#8217;s requirements or if the drug candidate has been associated with unexpected serious harm to patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with clinical studies, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final pharmaceutical product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">United States Review and Approval Processes </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Pre-Approval</span> Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of product development, preclinical studies and clinical studies, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the pharmaceutical product, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Pediatric Research Equity Act (PREA), an NDA or supplement to an NDA must contain data to assess the safety and effectiveness of the pharmaceutical product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise required by regulation, PREA does not apply to any pharmaceutical product for an indication for which orphan designation has been granted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews all NDAs submitted before it accepts them for filing and may request additional information rather than accepting an NDA for filing. Once the submission is accepted for filing, the FDA begins an <span style="white-space:nowrap">in-depth</span> review of the NDA. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act (PDUFA), the FDA has 10 months from filing in which to complete its initial review of a standard NDA and respond to the applicant, and six months from filing for a priority NDA. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs. The review process and the PDUFA goal date may be extended by three months if the FDA requests or if the NDA sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the NDA submission is accepted for filing, the FDA reviews the NDA application to determine, among other things, whether the proposed product is safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, strength, quality and purity. The FDA may refer applications for novel pharmaceutical products or pharmaceutical products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the pharmaceutical product approval process, the FDA also will determine whether a risk evaluation and mitigation strategy (REMS) is necessary to assure the safe use of the pharmaceutical product. If the FDA concludes that a REMS is needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without a REMS, if required. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. In addition, the FDA will require the review and approval of product labeling. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The NDA review and approval process is lengthy and difficult and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical data or other data and information. Even if such data and information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical studies are not always conclusive and the FDA may interpret data differently than we interpret the same data. The FDA will issue a complete response letter if the agency decides not to approve the NDA. The complete response letter describes the specific deficiencies in the NDA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical studies. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. In addition, the FDA may require Phase 4 testing which involves clinical studies designed to further assess pharmaceutical product safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Expedited Development and Review Programs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA offers a number of expedited development and review programs for qualifying product candidates. A product intended to treat a serious or life-threatening disease or condition may be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation provides opportunities for frequent interactions with the review team during product development and, once an NDA is submitted, the product may be eligible for priority review. The NDA may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Orphan Drug Designation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA application fee. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective. A comparable orphan drug program is provided under EU law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Post-Approval Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any pharmaceutical products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, complying with certain electronic records and signature requirements and complying with FDA promotion and advertising requirements, which include, among others, standards for <span style="white-space:nowrap"><span style="white-space:nowrap">direct-to-consumer</span></span> advertising, prohibitions on promoting pharmaceutical products for uses or in patient populations that are not described in the pharmaceutical product&#8217;s approved labeling (known as <span style="white-space:nowrap">&#8220;off-label</span> use&#8221;), industry-sponsored scientific and educational activities and promotional activities involving the internet. Failure to comply with FDA requirements can have negative consequences, including adverse publicity, enforcement letters from the FDA, actions by the United States Department of Justice and/or United States Department of Health and Human Services (HHS) Office of Inspector General, mandated corrective advertising or communications with doctors, and civil or criminal penalties. Although physicians may prescribe legally available pharmaceutical products for <span style="white-space:nowrap">off-label</span> uses, manufacturers may not directly or indirectly market or promote such <span style="white-space:nowrap">off-label</span> uses. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers of our products are required to comply with applicable FDA manufacturing requirements contained in the FDA&#8217;s cGMP regulations. cGMP regulations require, among other things, quality control and quality assurance, as well as the corresponding maintenance of records and documentation. Pharmaceutical product manufacturers and other entities involved in the manufacture and distribution of approved pharmaceutical products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA, including withdrawal of the product from the market. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA also may require post-marketing testing, known as Phase 4 testing, risk minimization action plans and surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">U.S. Foreign Corrupt Practices Act </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. Foreign Corrupt Practices Act, or FCPA, prohibits certain individuals and entities, including us, from promising, paying, offering to pay, or authorizing the payment of anything of value to any foreign government official, directly or indirectly, to obtain or retain business or an improper advantage. The U.S. Department of Justice and the U.S. Securities and Exchange Commission, or SEC, have increased their enforcement efforts with respect to the FCPA. Violations of the FCPA may result in large civil and criminal penalties and could result in an adverse effect on a company&#8217;s reputation, operations, and financial condition. A company may also face collateral consequences such as debarment and the loss of export privileges. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Federal and State HealthCare Laws </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal healthcare laws have been applied to restrict certain business practices in the biopharmaceutical industry in recent years. These laws include anti-kickback statutes, false claims statutes, data privacy and security laws, as </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
well as transparency laws regarding payments or other items of value provided to healthcare providers. The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or in return for purchasing, leasing, ordering, or arranging for the purchase, lease, or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federally financed healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payment, ownership interests and providing anything at less than its fair market value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and our practices may not in all cases meet all of the criteria for statutory exemptions or safe harbor protection. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. The intent standard of the Anti-Kickback Statute was also broadened by the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the PPACA, so that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the PPACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act (discussed below). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal False Claims Act prohibits any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus <span style="white-space:nowrap">non-reimbursable,</span> uses. Additionally, the civil monetary penalties statute imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payers and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Physician Payments Sunshine Act, created under the PPACA, and its implementing regulations, require certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually information related to certain payments or other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals, and applicable manufacturers and group purchasing organizations to report annually certain ownership and investment interests held by physicians and their immediate family members. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes certain requirements on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective business associates that create, receive, maintain or transmit individually identifiable health </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information for or on behalf of a covered entity as well as their covered subcontractors relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates&#8221;. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of states also have statutes or regulations similar to the aforementioned federal fraud and abuse laws, some of which are broader in scope and apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Further, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments or other transfers of value provided to physicians and other health care providers and entities, marketing expenditures, and drug pricing. Certain state and local laws also require the registration of pharmaceutical sales representatives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These federal and state laws may impact, among other things, our proposed sales, marketing and education programs. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, criminal and civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare programs, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate its business and our results of operations. To the extent that any of our product candidates are ultimately sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent Term Restoration and Marketing Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of the FDA approval of the use of our pharmaceutical product candidates, some of our patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally <span style="white-space:nowrap">one-half</span> the time between the effective date of an IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an approved pharmaceutical product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The United States Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending upon the expected length of the clinical studies and other factors involved in the filing of the relevant NDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions under the U.S. Food, Drug, and Cosmetic Act can also delay the submission or the approval of certain applications of other companies seeking to reference another company&#8217;s NDA. Currently seven years of reference product exclusivity are available to pharmaceutical products designated as orphan drugs, during which the FDA may not approve generic products relying upon the reference product&#8217;s data. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This <span style="white-space:nowrap">six-month</span> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric clinical study in accordance with an <span style="white-space:nowrap">FDA-issued</span> &#8220;Written Request&#8221; for such a clinical study. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Pharmaceutical Coverage, Pricing and Reimbursement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical product candidates for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part upon the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government payors such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. While commercial payors often follow Medicare coverage policy and payment limitations, coverage and reimbursement for products can differ significantly from payor to payor. The process for determining whether a payor will provide coverage for a pharmaceutical product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the pharmaceutical product. Third-party payors may limit coverage to specific pharmaceutical products on an approved list, or formulary, which might not include all of the <span style="white-space:nowrap">FDA-approved</span> pharmaceutical products for a particular indication. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of its products, in addition to the costs required to obtain the FDA approvals. Our pharmaceutical product candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a pharmaceutical product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. In addition, in the United States there is a growing emphasis on comparative effectiveness research, both by private payors and by government agencies. To the extent other drugs or therapies are found to be more effective than our products, payors may elect to cover such therapies in lieu of our products and/or reimburse our products at a lower rate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Different pricing and reimbursement schemes exist in other countries. The downward pressure on health care costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from <span style="white-space:nowrap">low-priced</span> markets exert a commercial pressure on pricing within a country. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The marketability of any pharmaceutical product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect this will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs. For example, in March 2010 the PPACA was enacted, which includes measures to significantly </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
change the way healthcare is financed by both governmental and private insurers. Among the provisions of the PPACA of importance to the pharmaceutical and biotechnology industry are the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an increase in the rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for branded and generic drugs, respectively; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% <span style="white-space:nowrap"><span style="white-space:nowrap">point-of-sale</span></span> discounts to negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the Federal Poverty Level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">new transparency reporting requirements under the federal Physician Payments Sunshine Act, created under Section&#160;6002 of the PPACA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a requirement to annually report drug samples that manufacturers and distributors provide to physicians; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expansion of health care fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a licensure framework for <span style="white-space:nowrap">follow-on</span> biologic products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishment of a Center for Medicare&#160;&amp; Medicaid Innovation at the Centers for Medicare&#160;&amp; Medicaid Services (CMS) to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment there have been executive, judicial and Congressional challenges to certain aspects of the PPACA. For example, President Trump signed several Executive Orders and other directives designed to delay the implementation of certain provisions of the PPACA or otherwise circumvent some of the requirements for health insurance mandated by the PPACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the PPACA. On June&#160;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, on August&#160;16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in PPACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum <span style="white-space:nowrap"><span style="white-space:nowrap">out-of-pocket</span></span> cost and creating a new manufacturer discount program. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges, and the healthcare reform measures of the Biden administration will impact the PPACA and our business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction, or joint committee, to recommend proposals in spending reductions to Congress. The joint committee did not achieve its targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering automatic reductions to several government programs. These reductions include aggregate reductions to Medicare payments to providers of up to 2%&#160;per fiscal year, starting in 2013 and, due to subsequent legislative amendments, will remain in effect until 2031 unless additional congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. Additionally, on March&#160;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&#160;1, 2024. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there have been several congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. At the federal level, for example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September&#160;9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. Further, the IRA, among other things (i)&#160;directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii)&#160;imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. Additionally, the Biden administration released an additional executive order on October&#160;14, 2022, directing HHS to report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">International Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, there are a variety of foreign regulations governing clinical studies and commercial sales and distribution of our future product candidates. Whether or not FDA approval is obtained for a product, approval of a product must be obtained by the comparable regulatory authorities of foreign countries before clinical studies or marketing of the product can commence in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical studies, product licensing, pricing and reimbursement vary greatly from country to country. In addition, certain regulatory authorities in select countries may require us to repeat previously conducted preclinical and/or clinical studies under specific criteria for approval in their respective country which may delay and/or greatly increase the cost of approval in certain markets targeted for approval by us. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Environment, Health and Safety </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Various laws and regulations have been implemented or are under consideration to mitigate the effects of climate change caused by greenhouse gas emissions. For example, the California Air Resources Board is in the process of drafting regulations to meet state emissions targets. Based on current information and subject to the finalization of the proposed regulations, we believe that our primary risk related to climate change is the risk of increased energy costs. However, because we are not an energy-intensive business, we do not anticipate being subject to a cap and trade system or any other mitigation measures that would likely be material to our capital expenditures, results of operations or competitive position. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to other federal, state and local regulations regarding workplace safety and protection of the environment. We use hazardous materials, chemicals, and various compounds in our research and development activities and cannot eliminate the risk of accidental contamination or injury from these materials. Certain misuse or accidents involving these materials could lead to significant litigation, fines and penalties. We have implemented proactive programs to reduce and minimize the risk of hazardous materials incidents. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CymaBay Therapeutics, Inc., formerly Metabolex, Inc., was incorporated under the laws of the State of Delaware on October&#160;5, 1988, originally under the name Transtech Corporation. Our executive offices are located at 7575 Gateway Blvd., Suite 110, Newark, CA 94560. The telephone number at our executive office is <span style="white-space:nowrap">(510)&#160;293-8800.</span> Our corporate website address is www.cymabay.com. We do not incorporate the information contained on, or accessible through, our website into this Annual Report on Form <span style="white-space:nowrap">10-K,</span> and you should not consider it part of this Annual Report. We make available free of charge on or through our website our annual report on Form <span style="white-space:nowrap">10-K,</span> quarterly reports on Form <span style="white-space:nowrap">10-Q,</span> current reports on Form <span style="white-space:nowrap">8-K,</span> and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act of 1934, as amended, or the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employees </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, and February&#160;28, 2023, we had 60 and 63 full-time employees, respectively. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Information about our Executive Officers </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of February&#160;28, 2023, our executive officers were as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:42%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:54%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position Held With CymaBay</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sujal Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">49</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">President&#160;&amp; Chief Executive Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles A. McWherter, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">68</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">President of Research and Development and Chief Scientific Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dennis Kim, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">53</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Medical Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lewis Stuart</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">63</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Commercial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Klara Dickinson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">56</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Regulatory and Quality Assurance Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul T. Quinlan</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">60</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">General Counsel and Chief Compliance Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Menold</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">53</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Vice President, Finance</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Biographical Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Sujal Shah</span> has served as our President and Chief Executive Officer since November 2017. Prior to that he served as our Interim President and Chief Executive Officer from March 2017 to November 2017. From December 2013 to March 2017, Mr.&#160;Shah served as Chief Financial Officer. Prior to that he served as a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consultant and acting Chief Financial Officer for us from June 2012 to December 2013. From 2010 to 2012, Mr.&#160;Shah served as Director, Health Care Investment Banking for Citigroup Inc., where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010 Mr.&#160;Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. Mr.&#160;Shah currently serves on the Board of Directors of Tvardi Therapeutics, Inc.. Mr.&#160;Shah received an M.B.A. from Carnegie Mellon University&#8212;Tepper School of Business and M.S. and B.S. degrees in Biomedical Engineering from Northwestern University. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Charles A. McWherter, Ph.D.</span> has served as our President of Research and Development and Chief Scientific Officer since November 2022. Previously, he served as Chief Scientific Officer since 2013. From 2007 to 2013, he served as our Senior Vice President, Research and Preclinical Development. From 2003 to 2007, he served as Vice President and head of the cardiovascular therapeutics areas of Pfizer Inc., a biopharmaceutical company. From 2001 to 2003, Dr.&#160;McWherter served as Vice President of Drug Discovery at Sugen, Inc., a biopharmaceutical company acquired by Pfizer Inc. in 2003. Dr.&#160;McWherter obtained his Ph.D. from Cornell University. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Dennis Kim, M.D.</span>&#160;has served as our Chief Medical Officer since May 2021 and his employment with us will terminate on May&#160;17, 2023. From November 2020 to March 2021 he served as Chief Medical Officer of Afyx Therapeutics, a topical drug delivery company, where he led clinical, medical and regulatory development for Rivelin, a novel mucoadhesive patch to deliver treatment for diseases such as oral lichen planus. Prior to this, from March 2019 to November 2020 he served as Chief Medical Officer of Emerald Health Sciences, a biotechnology company, where he was responsible for the general supervision of the company&#8217;s clinical and medical affairs, and from September 2011 to February 2019 was Chief Medical Officer at Zafgen, Inc., a biotechnology company, where he was responsible for the general supervision of the company&#8217;s clinical and medical affairs. Prior to this Dr.&#160;Kim served in senior leadership roles at Orexigen, EnteroMedics and Amylin Pharmaceutical. He received his medical degree from The Chicago School of Medicine, completed his internal medicine residency at Rush University Medical College, and specialty fellowship training in endocrinology/metabolism at University of California, San Diego&#160;(UCSD) Medical Center. He also holds a M.B.A. with emphasis in biotechnology structure and strategy from UCSD Rady School of Business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Lewis Stuart</span>&#160;has served as our Chief Commercial Officer since May 2021. From December 2019 to May 2021, Mr.&#160;Stuart served as Vice President and Prostate Cancer Franchise Leader for Myovant Sciences, a biopharmaceutical company. In this role he led the company&#8217;s Prostate Cancer Launch Readiness cross functional team of commercial, medical, legal, and manufacturing functions. From 2013 to 2017, Mr.&#160;Stuart served as Vice President, US Oncology Franchise at Genomic Health, a healthcare company, in which role he was responsible for various commercial aspects of the company&#8217;s oncology business. Prior to Genomic Health, Mr.&#160;Stuart held senior leadership roles at several leading biopharmaceutical companies including Genomic Health and CV&#160;Therapeutics. He received a B.A. in Communications and Marketing Management from Virginia Polytechnic&#160;&amp; State University, with graduate studies at Northeastern University. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Klara Dickinson </span>has served as our Chief Regulatory and Quality Assurance Officer since October 2020. Prior to that she was our Chief Regulatory and Compliance Officer since January 2019, and our Senior Vice President, Regulatory Affairs and Compliance since June 2017. Previously, she served as Senior Vice President, Chief Regulatory Officer of Anthera Pharmaceuticals, Inc., a biopharmaceutical company. From 2007 to 2014, she was Senior Vice President of Regulatory Affairs and Compliance at Hyperion Therapeutics&#160;Inc, where she was responsible for the general supervision of the company&#8217;s regulatory affairs and quality assurance. Ms.&#160;Dickinson also spent three years at CoTherix,&#160;Inc. as Vice President, Regulatory Affairs and Healthcare Compliance Officer, and held various positions at biopharmaceutical companies such as Scios,&#160;Inc. and DEY Laboratories (a subsidiary of Mylan,&#160;Inc.). Ms.&#160;Dickinson holds a B.S. in Biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Paul T. Quinlan</span>&#160;has served as our General Counsel, Chief Compliance Officer and Corporate Secretary since October 2020. He was also our General Counsel and Corporate Secretary from December 2017 to February </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2020. Previously, Mr.&#160;Quinlan served as General Counsel and Secretary at TerraVia Holdings, Inc. (formerly Solazyme, Inc.), a biotechnology company, from 2010 until January 2018, where he was responsible for the general supervision of the company&#8217;s legal affairs. From 2005 to 2010, Mr.&#160;Quinlan was General Counsel and Secretary at Metabolex, Inc., a biopharmaceutical company, and from 2000 to 2005, Mr.&#160;Quinlan held various positions in the legal department at Maxygen, Inc., a biopharmaceutical company, most recently that of Chief Corporate Securities Counsel. Prior to joining Maxygen, Mr.&#160;Quinlan was an associate at Cooley LLP and Cravath, Swaine&#160;&amp; Moore LLP. Mr.&#160;Quinlan obtained a law degree from Columbia University Law School and a M.Sc. in Medical Biophysics from the University of Toronto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Daniel Menold</span> has served as our Vice President, Finance since April&#160;2017, and previously served as our Corporate Controller since January&#160;2014. Prior to joining this, Mr.&#160;Menold served as Corporate Controller for technology firm Zoosk,&#160;Inc., from 2011 to 2013, where he was responsible for the accounting and financial reporting functions and as Controller and Director of Accounting at Affymetrix, Inc. from 2005 to 2010. Prior to 2005, he also held accounting and finance positions of increasing responsibility at public and private life sciences and high technology companies in the Silicon Valley. Earlier in his career, Mr.&#160;Menold was at Ernst&#160;&amp; Young LLP where he was an audit manager and served on audits of life sciences and high technology companies. Mr.&#160;Menold received a M.S. in accounting and B.S. in finance from The University of Virginia McIntire School of Commerce. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="txa446975_3">Item&#160;1A. Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">In addition to the factors discussed elsewhere in this report, the following are important factors that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business could be harmed. </span></p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Risks Related to Our Financial Condition and Capital Requirements </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need additional capital in the future to sufficiently fund our operations and research. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred significant net losses since our inception. We anticipate that we will continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability. As of December&#160;31, 2022, we had cash, cash equivalents and marketable securities totaling $135.5&#160;million. To date, we have raised capital primarily through equity financings, licensing transactions and a structured finance arrangement. For example, in January 2023, we entered into a Collaboration and License Agreement with Kaken Pharmaceutical Co., Ltd. (Kaken), granting Kaken an exclusive license to commercialize and market seladelpar for the prevention or treatment of primary biliary cholangitis (PBC) in Japan in consideration for an upfront payment to the Company of $34.2&#160;million that was paid in January 2023, potential milestone payments to the Company totaling up to &#165;17.0&#160;billion (approximately $128.0&#160;million at contract inception date) for the achievement of certain regulatory and sales milestones in Japan and additional payments to the Company for the supply of seladelpar to Kaken. In January 2023, we sold 11,821,428&#160;shares of common stock at $7.00 per share and a <span style="white-space:nowrap">pre-funded</span> warrant to purchase 2,142,857 shares of common stock at $6.9999 per share in a public equity offering for total gross offering proceeds of $97.7&#160;million. In July&#160;2021, we entered into a Development Financing Agreement with an affiliate of Abingworth LLP pursuant to which Abingworth provided $75&#160;million in funding to the Company. We may need to raise additional equity and/or debt capital or enter into strategic transactions to fund our continued operations, including clinical trials, other product development and <span style="white-space:nowrap">pre-commercialization</span> activities. Our monthly spending levels vary based on new and ongoing development and corporate activities. Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a time-consuming, expensive and uncertain process that takes years to complete. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event we do not successfully raise sufficient funds to finance our product development activities, we will curtail our product development activities and other activities commensurate with the magnitude of the shortfall and our product development activities may cease altogether. To the extent that the costs of ongoing development exceed our current estimates and we are unable to raise sufficient additional capital to cover such additional costs, we will need to reduce operating expenses, sell assets, enter into strategic transactions, or effect a combination of the above. No assurance can be given that we will be able to enter into any of such transactions on acceptable terms, if at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future funding requirements and sources will depend on many factors, including but not limited to the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the rate of progress and cost of our clinical studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the need for additional or expanded clinical studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the rate of progress and cost of our Chemistry, Manufacturing and Control development, registration, validation and commercial programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing, economic and other terms of any licensing, collaboration or other similar arrangement into which we may enter; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs and timing of seeking and obtaining FDA and other regulatory approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent of our other development activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of our <span style="white-space:nowrap">pre-commercialization</span> activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effect of competing products and market developments. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing development and commercialization efforts, which would have a material adverse effect on our business, operating results, prospects, and on our ability to develop our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Failure to remain in compliance with our obligations under the Development Financing Agreement (the Financing Agreement) with Abingworth could lead to the acceleration of potentially significant payments to Abingworth. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July&#160;2021, we entered into a Development Financing Agreement (the Financing Agreement) with Abingworth, pursuant to which Abingworth has provided $75&#160;million in funding to us to support our development of seladelpar for the treatment of PBC. Pursuant to the Financing Agreement, we are required to use commercially reasonable efforts to develop seladelpar and complete our development program in accordance with the Financing Agreement and an agreed timeline. In return, we are obligated to pay to Abingworth (1)&#160;upon the first to occur of regulatory approval of seladelpar for the treatment of PBC in the U.S., U.K., Germany, Spain, Italy or France (Regulatory Approval), fixed success payments equal to 2.0x of the funding provided and (2)&#160;variable success payments equal to 1.1x of the funding provided upon first reaching certain U.S. product sales milestones. At the time that Abingworth receives, collectively, an aggregate of 3.1x of the funding provided, our payment obligations under the Financing Agreement will be fully satisfied. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Financing Agreement terminates upon the payment of all payments owing to Abingworth, unless earlier terminated. The Agreement may be earlier terminated in a number of circumstances including (i)&#160;by Abingworth if&#160;we fail to use commercially reasonable efforts to develop seladelpar as set forth in the Financing Agreement or if we fail to make required payments (Fundamental Breach) or (ii)&#160;by either party&#160;if the other party materially breaches the Agreement (Material Breach). In certain instances, upon the termination of the Financing </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Agreement, we will be obligated to pay Abingworth a multiple of the amounts paid to us under the Agreement, including specifically, </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(i)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">310% of such amounts in the event that Abingworth terminates the agreement due to (x)&#160;a Fundamental Breach, (y)&#160;our bankruptcy, or (z)&#160;a safety concern resulting from gross negligence on our part or due to a safety concern that was material on the Effective Date and the material data showing such safety concern was not publicly known, disclosed to Abingworth, or in the diligence room made available to Abingworth, </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(ii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">200% of such amounts in the event the Agreement is terminated due to (x)&#160;our Material Breach or (y)&#160;the security interests of Abingworth being invalidated or terminated other than as set forth in the Financing Agreement, and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(iii)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">100% of such amounts in the event of certain irresolvable disagreements within the executive review committee overseeing our development of seladelpar. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if, following certain terminations, we continue to develop&#160;seladelpar for the treatment of PBC and obtain Regulatory Approval, we will make the payments to Abingworth as if the Financing Agreement had not been terminated, less any payments made upon termination. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The payments required under the Financing Agreement are significant. Failure to raise sufficient capital or generate sufficient revenue to make such payments if and as they become due, or failure to otherwise finance such payments would have a material adverse effect on our business. In addition, if we are unable to comply with our obligations under the Financing Agreement and/or one of the termination events described above occurs our payments obligations thereunder may be accelerated. The acceleration of payments under the Financing Agreement would have a material impact on our business and we may not be able to make such payments at such time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to generate future revenues from product sales is uncertain and depends upon our ability to successfully develop, obtain regulatory approval for, and commercialize product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to generate revenue and achieve profitability depends on our ability, alone or with collaborators, to successfully complete the development of, obtain the necessary regulatory approvals for, and commercialize, product candidates. We do not anticipate generating revenues from sales of our product candidates in the near future, if ever. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting preclinical testing and clinical trials is a time-consuming, expensive, and uncertain process that takes years to complete, and we may never generate the necessary data required to obtain regulatory approval and achieve product sales. Our anticipated development costs would likely increase if we do not obtain favorable results or if development of our product candidates is delayed. In particular, we would likely incur higher costs than we currently anticipate if development of our product candidates is delayed because we are required by a regulatory authority such as the FDA to perform studies or trials in addition to those that we currently anticipate. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or amount of any increase in our anticipated development costs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if at all. Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs in connection with commercialization. As a result, we cannot assure you that we will be able to generate revenues from sales of any approved products, or that we will achieve or maintain profitability even if we do generate sales. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. We do not have any committed external source of funds. If appropriate opportunities become available, we may seek to raise additional equity and/or debt capital to fund our continued operations, including clinical trials and other product development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To raise additional funds to support our operations, we may sell additional equity or debt securities, enter into collaborations, strategic alliances, or licensing arrangements or other marketing or distribution arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, ownership interests of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, and declaring dividends, and may impose limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations, strategic alliances, licensing arrangements or other marketing or distribution arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to expand our operations or otherwise capitalize on our business opportunities, our business, financial condition and results of operations could be materially adversely affected. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts, or grant others rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions could adversely affect our current financial condition and projected business operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March&#160;10, 2023, Silicon Valley Bank (SVB), where we hold a small portion of our cash and cash equivalents, was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (FDIC), as receiver. On March&#160;12, 2023, the Department of the Treasury, the Federal Reserve and the FDIC jointly released a statement that depositors at SVB would have access to their funds, even those funds in excess of FDIC insurance limits, under a systemic risk exception. As of March&#160;13, 2023, we had access to our cash and cash equivalents at SVB; however, there is uncertainty in the markets regarding the stability of regional banks and the safety of deposits in excess of the FDIC insured deposit limits. The ultimate outcome of these events cannot be predicted, but these events could have a material adverse effect on our business operations if our ability to access funds at SVB or any other banks we use is compromised. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Risks Related to Clinical Development and Regulatory Approval </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We depend on the success of our product candidates and we may not obtain regulatory approval or successfully commercialize our product candidates. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not marketed, distributed or sold any products. The success of our business depends upon our ability to develop and commercialize our product candidates. The success of any product candidate will depend on many factors, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successful enrollment and completion of clinical trials, including, in the case of RESPONSE, sufficient subjects that receive liver biopsies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the successful and timely collection and analysis of trial data; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">receipt of marketing approvals from the FDA and regulatory authorities outside the United States for the product candidate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing commercial manufacturing capabilities by making arrangements with third-party manufacturers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">launching commercial sales of the product, whether alone or in collaboration with others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acceptance of the product by patients, the medical community and third-party payors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">effectively competing with other therapies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a continued acceptable safety profile of the product following marketing approval; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining, maintaining, enforcing and defending intellectual property rights and claims. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidate, which would materially harm our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We depend on the successful completion of clinical trials for our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approval for the sale of our product candidates, we must complete our current clinical trials as well as potentially additional clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more of our clinical trials can occur at any stage of testing. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for their products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience a number of unforeseen events during clinical trials for our product candidates, including seladelpar, that could delay or prevent the commencement and/or completion of our clinical trials, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the clinical study protocol may require one or more amendments delaying study completion; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of subjects required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, we may have to compete with other clinical trials to enroll eligible subjects, or subjects may drop out of these clinical trials at a higher rate than we anticipate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of patients in our RESPONSE clinical trial that receive biopsies may be insufficient to satisfy regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical investigators or study subjects may fail to comply with clinical study protocols; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trial conduct and data analysis issues may occur, including, but not limited to, failure to collect and analyze data in a timely manner, data entry and/or labeling errors or data analysis errors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we might have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the subjects are being exposed to unacceptable health risks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">geo-political</span> turmoil between Russia and Ukraine and/or continuing military actions in Ukraine may interfere with our wind down of clinical trials of seladelpar in Russia and analysis of relevant data; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of clinical trials of our product candidates may be greater than we anticipate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the supply or quality of our clinical trial materials or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators to suspend or terminate the trials. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because successful development of product candidates is uncertain, we are unable to estimate the actual funds required to complete research and development and commercialize our products under development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Negative or inconclusive results of our future clinical trials of product candidates could cause the FDA or other regulatory authorities to require that we repeat or conduct additional clinical studies. If later stage clinical trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates may be adversely impacted. For example, we expect to release top line data for RESPONSE in the third quarter of 2023, and if positive, to submit an NDA seeking approval from the FDA for seladelpar for the second line treatment of PBC. The combined data from our trials may be inconclusive or may not be sufficient to gain approval from the FDA. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Geo-political</span> turmoil between Russia and Ukraine and continuing military actions in Ukraine have caused us to suspend clinical trial activity in Ukraine and wind down clinical trial activity in Russia. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a small number of clinical sites in Russia in our RESPONSE clinical trial and in our ASSURE clinical trial. Because of continuing military action in Ukraine we suspended all clinical trial activity in Ukraine. Ongoing <span style="white-space:nowrap">geo-political</span> turmoil and continuing military action in the region, together with widening sanctions imposed on Russia, have also caused us to begin to wind down clinical trial activity in Russia. We expect clinical trial activity in Russia to terminate by the end of the third quarter of 2023. The ongoing military action and sanctions may still affect our RESPONSE and ASSURE clinical trials in Russia prior to completion of our wind down. Shipments of seladelpar to Russia may become difficult, delayed or impossible. Shipments of clinical samples from Russia may also become difficult, delayed or impossible. In addition, sites, site personnel and patients may not be able to continue in the trials and we may need to suspend or terminate the trials in Russia prior to the end of our expected wind down. While we have only a small number of clinical sites and enrolled patients in Russia, these disruptions and potential suspensions could complicate the analysis of data from subjects in Russia. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to outcome. We may experience delays in clinical trials at any stage of development and testing of our product candidates and any delay could result in increased costs to us. Any clinical trials we undertake may not begin on time, have an effective design, enroll a sufficient number of subjects, or be completed on schedule, if at all. The impact of the ongoing <span style="white-space:nowrap">COVID-19</span> situation is also uncertain, and may create additional delays in completing our clinical trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Events that may result in delays or unsuccessful completion of clinical trials include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reluctance of patients to enroll in our clinical trials due to <span style="white-space:nowrap">COVID-19;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">personnel shortages at clinical sites due to the <span style="white-space:nowrap">COVID-19</span> situation that impacts our timeline or operations at clinical trial sites participating in our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">competition for eligible patients from competing clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in obtaining regulatory approval to commence a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching agreement with the FDA or other regulatory authorities on final trial design; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">imposition of a clinical hold following a reported safety event; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an inspection of our clinical trial operations or trial sites by the FDA or other regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in obtaining required institutional review board (IRB) approval at each site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in recruiting suitable patients to participate in a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in having subjects complete participation in a trial or return for post-treatment <span style="white-space:nowrap">follow-up;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays caused by subjects dropping out of a trial due to side effects or otherwise; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes to treatment guidelines or the introduction of a new standard of care; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays caused by clinical sites dropping out of a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">time required to add new clinical sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in importing clinical trial materials into foreign countries where our clinical trials are being conducted. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If initiation or completion of any clinical trials we may undertake for our product candidates is delayed for any of the above reasons, our development costs may increase, the approval process could be delayed, any periods during which we may have the exclusive right to commercialize our product candidates may be reduced and our competitors may bring products to market before us. Any of these events could impair our ability to generate revenues from product sales, which would have a material adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval or limit the scope of any approved label or market acceptance. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2016, we announced results of a High Dose Phase 2 clinical study of seladelpar in patients with PBC. During the course of this trial three cases of asymptomatic, reversible transaminase elevations occurred, and we made the decision to discontinue the study early after review of safety and efficacy data demonstrated a need for further dose reduction to optimize clinical safety and efficacy. The emergence of adverse events (AEs) and histological observations in subsequent seladelpar clinical trials could prevent us from further developing seladelpar or could result in the denial of regulatory approval. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, if any of our approved products cause serious or unexpected side effects after receiving market approval, a number of potentially significant negative consequences could result, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in a form of a risk evaluation and mitigation strategy (REMS) plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may require the addition of labeling statements, such as black box or other warnings or contraindications that could diminish the usage of the product or otherwise limit the commercial success of the affected product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be required to change the way the product is administered or to conduct additional clinical studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may choose to discontinue sale of the product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we could be sued and held liable for harm caused to patients; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our reputation may suffer. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Potential conflicts of interest arising from relationships with principal investigators for our clinical studies and any related compensation with respect to clinical studies could adversely affect the drug approval process. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Principal investigators for our clinical studies may serve as scientific advisors or consultants to us or may be affiliated with our other service providers, including clinical research organizations or site management organizations, and from time to time receive cash compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical study site or in the applicable study may be questioned or jeopardized. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to costly claims related to our clinical studies and may not be able to obtain adequate insurance. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we conduct clinical studies in humans, we face the risk that the use of seladelpar or other product candidates will result in adverse side effects. We cannot predict the possible harms or side effects that may result from our clinical studies. Although we have clinical study liability insurance, our insurance may be insufficient to cover any such events. There is also a risk that we may not be able to continue to obtain clinical study coverage on acceptable terms. In addition, we may not have sufficient resources to pay for any liabilities resulting from a claim excluded from, or beyond the limit of, our insurance coverage. There is also a risk that third parties that we have agreed to indemnify could incur liability. Any litigation arising from our clinical studies, even if we are ultimately successful, would consume substantial amounts of our financial and managerial resources and may create adverse publicity. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">After the completion of our clinical trials, we cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates and we cannot, therefore, predict the timing of any future revenue from our product candidates. Regulatory approval of a product candidate is not guaranteed, and the approval process is expensive, uncertain and lengthy. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot commercialize our product candidates until the appropriate regulatory authorities, such as the FDA, have reviewed and approved the product candidate. The regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval for our product candidates. Additional delays may result if a product candidate is brought before an FDA advisory committee, which could recommend restrictions on approval or recommend <span style="white-space:nowrap">non-approval</span> of the product candidate. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
administrative action, or changes in regulatory agency policy during the period of product development, clinical studies and the review process. As a result, we cannot predict when, if at all, we will receive any future revenue from commercialization of any of our product candidates. The FDA and foreign regulatory authorities have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be unable to demonstrate to the satisfaction of regulatory authorities that a product candidate is safe and effective for any indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may not find the data from nonclinical studies and clinical studies sufficient or may differ in the interpretation of the data; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may require additional nonclinical or clinical studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities might not approve our third-party manufacturers&#8217; processes or facilities for clinical or commercial product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may change their approval policies or adopt new regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may disagree with the design or implementation of our clinical studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory authorities may not accept clinical data from studies that are conducted in countries where the standard of care is potentially different from the jurisdiction of that regulatory authority; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the results of clinical studies may not meet the level of statistical significance required by regulatory authorities for approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the data collection from clinical studies of our product candidates may not be sufficient to support the submission of a new drug application (NDA), marketing authorization or other equivalent submission, or to obtain regulatory approval in the United States or elsewhere. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased caution by the FDA and other regulatory authorities in reviewing new pharmaceuticals based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we obtain regulatory approval for our product candidates, we will still face extensive regulatory requirements and our products may face future development and regulatory difficulties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approval in the United States, the FDA may still impose significant restrictions on the indicated uses or marketing of our products or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. Our products would be subject to additional ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record-keeping and reporting of safety and other post-market information. The holder of an approved NDA is obligated to monitor and report AEs and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. Furthermore, promotional materials must be approved by the FDA prior to use for any drug receiving accelerated approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, manufacturers of drug products and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current Good Manufacturing Practices (cGMP), and adherence to commitments made in the NDA. If we, or a regulatory agency, discover previously unknown problems with a product, such as quality issues or AEs of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requesting recall or withdrawal of the product from the market or suspension of manufacturing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we, or our third-party contractors, fail to comply with applicable regulatory requirements following approval of our product candidate, a regulatory agency may: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issue an untitled or warning letter asserting violation of the law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">seek an injunction or impose civil or criminal penalties up to and including imprisonment or monetary fines; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspend or withdraw regulatory approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspend any ongoing clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refuse to approve a pending NDA or supplements to an NDA; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">request recall and/or seize product. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our products and inhibit our ability to generate revenues. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products. If we are found to have improperly promoted our products for <span style="white-space:nowrap">off-label</span> uses, we may become subject to significant fines and other liability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for our product candidates, physicians may nevertheless prescribe such products to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such <span style="white-space:nowrap">off-label</span> uses, we may become subject to significant government fines and other related liability. For example, the federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in <span style="white-space:nowrap">off-label</span> promotion. The FDA also has requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we obtain FDA approval for our product candidates in the United States, we may never obtain approval for or commercialize our product candidates outside of the United States, which would limit our ability to realize their full market potential. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements on a <span style="white-space:nowrap"><span style="white-space:nowrap">country-by-country</span></span> basis regarding safety and efficacy. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional preclinical studies or clinical trials that could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be unrealized. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Coverage and adequate reimbursement may not be available for our future products, which could make it difficult for us to sell profitably, if approved. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market acceptance and sales of any products that we commercialize will depend in part on the extent to which coverage and adequate reimbursement will be available from third-party payers, including government health administration authorities, managed care organizations and private health insurers. Third-party payers decide which therapies they will pay for and establish reimbursement levels. Third-party payers in the United States often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any products that we develop will be made on a <span style="white-space:nowrap"><span style="white-space:nowrap">payer-by-payer</span></span> basis. One payer&#8217;s determination to provide coverage for a drug does not assure that other payers will also provide coverage and adequate reimbursement for the drug. Additionally, a third-party payer&#8217;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Third-party payers are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our relationships with health care professionals, customers and payors may be subject to applicable anti-kickback, fraud and abuse and other health care laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Health care professionals and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, third-party payors and customers may expose us to broadly applicable fraud and abuse and other health care laws and regulations that may constrain the business or financial arrangements and relationships through which we research, as well as market, sell and distribute our products. Restrictions under applicable federal and state health care laws and regulations, include the federal Anti-Kickback Statute, the federal False Claims Act, Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, the federal false statements statute, the federal transparency requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or PPACA, commonly referred to as the Physician Payments Sunshine Act, and analogous state laws and regulations, such as state anti-kickback and false claims laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our business arrangements with third parties will comply with applicable health care laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, exclusion from government funded health care programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded health care programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Current laws and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the health care system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any products for which we obtain marketing approval. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, the PPACA was enacted to broaden access to health insurance, reduce or constrain the growth of health care spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. Since its enactment there have been judicial and Congressional challenges to certain aspects of the PPACA as well as efforts to repeal or replace certain aspects of the PPACA. For example, Congress considered legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the PPACA. It is unclear how litigation, and the healthcare reform measures of the Biden administration will impact the PPACA and our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. In addition, there have been several recent congressional inquiries, proposed bills and other proposals designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products including instituting reference pricing. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. However, it is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. Further, it is possible that additional governmental action is taken in response to the <span style="white-space:nowrap">COVID-19</span> situation. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Risks Related to <span style="white-space:nowrap">COVID-19</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business may be adversely affected by the ongoing <span style="white-space:nowrap">COVID-19</span> situation. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the <span style="white-space:nowrap">COVID-19</span> pandemic did not materially adversely affect our business operations in the year ended December&#160;31, 2022, economic and health conditions in the United States and across most of the globe have continued to change. As a result of the <span style="white-space:nowrap">COVID-19</span> pandemic, we have experienced and may continue to experience disruptions that could impact aspects of our business, including our progress towards the completion of our clinical studies and other drug development activities. Possible future disruptions are currently difficult to foresee and include, but are not limited to, potential risk areas as noted below: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are currently managing clinical trials and expect to begin clinical trials in geographies that are affected by <span style="white-space:nowrap">COVID-19.</span> While we have not experienced material impacts to our clinical activities through December&#160;31, 2022, we are observing impacts due to <span style="white-space:nowrap">COVID-19,</span> including reluctance of subjects to enroll in clinical studies, restrictions impacting study personnel and trial participants, personnel shortages at clinical sites and operations and facility restrictions impacting trial operations. We believe that <span style="white-space:nowrap">COVID-19</span> will have a continuing impact on various aspects of our clinical activities in the future. For example, pandemic-related reluctance or restrictions, including curtailment of activities, could reduce or slow the rate of patient enrollment in our clinical trials, and impair the ability to efficiently treat patients at investigator sites. Additionally, our employees, representatives from our clinical research organization partners, and study investigators may be required to delay, or alter, their approach to complete work on our trials. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have moved to a hybrid model of operations, with most employees working from our office for a portion of the week and working remotely for the rest of the week. The safety, health and well-being of our workforce is of primary concern and we may need to enact further precautionary measures to help minimize the risk of our employees being exposed to the coronavirus. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our continuing reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. In addition, this could increase our cyber-security and data privacy risks, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations, or delay necessary interactions with regulators, contract manufacturers, contract research organizations, clinical trial sites, and other important agencies and contractors, which could result in increased costs to us. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The United States Food and Drug Administration (FDA), comparable foreign regulatory agencies, and ethics boards may experience operational interruptions or delays, which could impact timelines for regulatory meetings, submissions, trial initiations, and regulatory approvals. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">COVID-19</span> situation continues to evolve. The emergence of additional <span style="white-space:nowrap">COVID-19</span> variants may also continue to affect the impact of the situation. The extent to which <span style="white-space:nowrap">COVID-19</span> may impact our business, including our preclinical, clinical and associated drug development activities, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of <span style="white-space:nowrap">COVID-19</span> and variants to <span style="white-space:nowrap">COVID-19</span> that continue to arise and their relative transmissibility and virulence,&#160;as well as business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Risks Related to Our Reliance on Third Parties </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on third-party manufacturers to produce our preclinical and clinical drug supplies, and we intend to rely on third parties to produce commercial supplies of any approved products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate, and we do not expect to own or operate, facilities for product manufacturing, storage and distribution, or testing. We currently rely on third-party manufacturers for supply of our preclinical and clinical drug supplies. We expect that in the future we will continue to rely on such manufacturers for drug supplies that will be used in clinical trials of our product candidates, and for commercialization of any of our product candidates that receive regulatory approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The facilities used by our contract manufacturers to manufacture the approved product must be approved by the FDA pursuant to inspections that will be conducted only after we submit an NDA to the FDA, if at all. A representative from the European Medicines Agency (EMA) or another regulatory authority may also require inspection and approval of such contract manufacturing facilities. We are completely dependent on our contract manufacturing partners for compliance with the FDA&#8217;s requirements for manufacture of finished pharmaceutical products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA&#8217;s strict regulatory requirements of safety, purity and potency, we will not be able to secure and/or maintain FDA approval for our product candidates. In addition, we have no direct control over the ability of the contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If our contract manufacturers cannot meet FDA standards, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our products. No assurance can be given that our manufacturers can continue to make clinical and commercial supplies of product candidates, at an appropriate scale and cost to make it commercially feasible. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we do not have the capability to package and distribute finished products to pharmacies and other customers. If we receive marketing approval from the FDA, we intend to sell pharmaceutical product packaged and distributed by one or more pharmaceutical product packagers/distributors. Although we have </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entered into agreements with our current contract manufacturers and packager/distributor for clinical trial material, we will need to enter into commercial agreements with contract manufacturers and with one or more pharmaceutical product packagers/distributors to ensure proper supply chain management once we are authorized to make commercial sales of our product candidates. However, we may be unable to maintain agreements or negotiate commercial supply agreements on commercially reasonable terms with contract manufacturers and pharmaceutical product packagers/distributors, which could delay our ability to launch commercial sales and/or have a material adverse impact upon our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on limited sources of supply for our product candidates, and any disruption in the chain of supply may cause delay in developing and commercializing for each product candidate. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If supply from an approved vendor is interrupted, there could be a significant disruption in commercial supply of our products. An alternative vendor would need to be qualified through a supplemental registration, which would be expensive, time consuming and could result in further delay. The FDA or other regulatory agencies outside of the United States may also require additional studies if a new drug substance or drug product supplier is relied upon for commercial production. These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our products, and cause us to incur additional costs. Furthermore, if our suppliers fail to deliver the required commercial quantities of active pharmaceutical ingredient on a timely basis and at commercially reasonable prices, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, the supply chain for our products may be delayed, which could inhibit our ability to generate revenues. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization of our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the manufacturing processes are scaled up they may reveal manufacturing challenges or previously unknown impurities that could require resolution in order to proceed with our planned clinical trials and obtain regulatory approval for the commercial marketing of our products. In the future, we may identify manufacturing issues or impurities that could result in delays in the clinical program and regulatory approval for our products, increases in our operating expenses, or failure to obtain or maintain approval for our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on third-party manufacturers entails risks, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to meet our product specifications, including product formulation, and quality requirements consistently; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a delay or inability to procure or expand sufficient manufacturing capacity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manufacturing and product quality issues, including those related to <span style="white-space:nowrap">scale-up</span> of manufacturing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs and validation of new equipment and facilities required for <span style="white-space:nowrap">scale-up;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a failure to comply with cGMP and similar quality standards; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the reliance on a limited number of sources, and in some cases, single sources for key materials, such that if we are unable to secure a sufficient supply of these key materials, we will be unable to manufacture and sell our products in a timely fashion, in sufficient quantities or under acceptable terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the lack of qualified backup suppliers for those materials that are currently purchased from a sole or single source supplier; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disruption of the distribution of chemical supplies between the U.K. and E.U. due to Brexit; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">carrier disruptions or increased costs that are beyond our control; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the failure to deliver our products under specified storage conditions and in a timely manner. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could lead to delays in any clinical study we may undertake, failure to obtain regulatory approval or impact our ability to successfully commercialize our products. Some of these events could be the basis for FDA or other regulatory authorities&#8217; action, including injunction, recall, seizure, or total or partial suspension of production. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely on third parties to conduct, supervise and monitor our clinical studies, and if those third parties perform in an unsatisfactory manner, it may harm our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on contract service providers (CSPs), including clinical research organizations, clinical trial sites, central laboratories and other service providers to ensure the proper and timely conduct of our clinical trials. While we have agreements governing their activities, we have limited influence over their actual performance. We have relied and plan to continue to rely upon CSPs to monitor and manage data for clinical programs for our product candidates, as well as the execution of nonclinical studies. We control only certain aspects of our CSPs&#8217; activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CSPs does not relieve us of our regulatory responsibilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our CSPs are required to comply with the FDA&#8217;s guidance, which follows the International Council for Harmonization Good Clinical Practice (ICH GCP), which are regulations and guidelines enforced by the FDA for all of our product candidates in clinical development. The FDA enforces the ICH GCP through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CSPs fail to comply with the ICH GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our marketing applications. Our CSPs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and nonclinical programs. These CSPs may also have relationships with other entities, including our competitors, for whom they may also be conducting clinical studies, or other drug development activities that could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our confidential information, including our intellectual property, by CSPs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology, among other things. If our CSPs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates that we develop would be harmed, our costs could increase, and our ability to generate revenues could be delayed. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Risks Related to Commercialization of Our Product Candidates </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The commercial success of any product will depend upon the acceptance of these products by the medical community, including physicians, patients and health care payors. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates receive marketing approval, they may nonetheless be unable to gain sufficient market acceptance by physicians, patients, health care payors and others in the medical community. If </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
these products do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of any of our products will depend on a number of factors, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">demonstration of clinical safety and efficacy in our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk/benefit profile of our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the relative convenience, ease of administration and acceptance by physicians, patients and health care payors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prevalence and severity of any side effects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the safety of products seen in a broader patient group, including its use outside the approved indications; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">limitations or warnings contained in the FDA and other regulatory authorities approved label for the relevant product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">acceptance of the product by physicians, other health care providers and patients as a safe and effective treatment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential and perceived advantages of products over alternative treatments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of market introduction of competitive products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">pricing and cost-effectiveness; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effectiveness of our or any future collaborators&#8217; sales and marketing strategies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain formulary approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to obtain and maintain sufficient third-party coverage or reimbursement, which may vary from country to country; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the effectiveness of our or any future collaborators&#8217; sales, marketing and distribution efforts. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates is approved but does not achieve an adequate level of acceptance by physicians, patients and health care payors, we may not generate sufficient revenue and we may not become or remain profitable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product, we may be unable to generate any revenue. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently do not have an organization for the sales, marketing and distribution of pharmaceutical products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved we must build our sales, marketing, managerial and other <span style="white-space:nowrap">non-technical</span> capabilities or make arrangements with third parties to perform these services. We may enter into strategic partnerships with third parties to commercialize our products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to successfully manage <span style="white-space:nowrap">pre-commercialization</span> activities, including but not limited to building our own sales force (or negotiate one or more strategic partnership(s) for the commercialization of our products) or establish marketing and distribution channels, we may be forced to delay the potential commercialization of the product, or reduce the scope of our sales or marketing activities. If we elect to increase our expenditures to fund commercialization activities ourselves, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we will not be able to bring the product to market or generate product revenue. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate sufficient product revenue and may not become profitable. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
We will be competing with companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform sales and marketing functions, we may be unable to compete successfully against these more established companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, there are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we obtain approval to commercialize any products outside of the United States, a variety of risks associated with international operations could materially adversely affect our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our product candidates are approved for commercialization outside the United States, we expect that we will be subject to additional risks related to international operations, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">different regulatory requirements for drug approvals in foreign countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">reduced protection for intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unexpected changes in tariffs, trade barriers and regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">differing payor reimbursement regimes, governmental payors or patient <span style="white-space:nowrap">self-pay</span> systems and price controls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">economic weakness, including inflation, or political instability in particular foreign economies and markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">foreign taxes, including withholding of payroll taxes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">workforce uncertainty in countries where labor unrest is more common than in the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">business interruptions resulting from geopolitical actions, including war and terrorism, pandemics, or natural disasters including earthquakes, typhoons, volcanic eruptions, floods and fires. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by both the European Union and many of the individual countries in Europe with which we would need to comply. Many U.S.-based biopharmaceutical companies have found the process of marketing their own products in Europe to be very challenging. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our competitors develop and market products that are more effective, safer or less expensive than our own, our commercial opportunities will be negatively impacted. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The life sciences industry is highly competitive, and we face significant competition from other pharmaceutical, biopharmaceutical and biotechnology companies and possibly from academic institutions, government agencies and private and public research institutions that are researching, developing and marketing products designed to address diseases that we are seeking to treat. Our competitors generally have significantly </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
greater financial, manufacturing, marketing and drug development resources. Large pharmaceutical companies, in particular, have extensive experience in the clinical testing of, obtaining regulatory approvals for, and marketing of, drugs. New developments, including the development of other pharmaceutical technologies and methods of treating disease, occur in the pharmaceutical and life sciences industries at a rapid pace. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These developments may render our product candidates obsolete or noncompetitive. Compared to us, potential competitors may have substantially greater: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">research and development resources, including personnel and technology; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory experience; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience in pharmaceutical development and commercialization; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ability to negotiate competitive pricing and reimbursement with third-party payors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">experience and expertise in the exploitation of intellectual property rights; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">capital resources. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of these factors, our competitors may obtain regulatory approval of their products more rapidly than we do or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. The competitors may also develop products that are more effective, better tolerated, more useful and less costly than our products and they may also be more successful in manufacturing and marketing their products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical studies, and will face an even greater risk if we sell our products commercially. An individual or a group of individuals may bring a liability claim against us if one of our product candidates causes, or merely appears to have caused, an injury. If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">decreased demand for our products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">impairment to our business reputation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">withdrawal of clinical study participants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">distraction of management&#8217;s attention from our primary business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">substantial monetary awards to patients or other claimants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to commercialize our products; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of revenues. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We carry product liability insurance for our clinical studies. Further, we intend to expand our insurance coverage to include the sale of commercial products if marketing approval is obtained for any of our product candidates. However, we may be unable to obtain this product liability insurance on commercially reasonable terms and with insurance coverage that will be adequate to satisfy any liability that may arise. On occasion, large judgments have been awarded in class action or individual lawsuits relating to marketed pharmaceuticals. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of our business depends primarily upon our ability to identify, develop and commercialize product candidates. Because we have limited financial and managerial resources, we focus on specific product candidates for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or other indications that later prove to have greater commercial potential. We may focus our efforts and resources on product candidates that ultimately prove to be unsuccessful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to retain sole development and commercialization rights. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Risks Related to Our Intellectual Property </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to obtain or protect intellectual property rights related to our products and product candidates, we may not be able to compete effectively in our market. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our products and product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own, <span style="white-space:nowrap">co-own</span> or <span style="white-space:nowrap">in-license</span> may fail to result in issued patents with claims that cover the products in the United States or in other countries. If this were to occur, early generic competition could be expected against our products. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which if it exists could be used to invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, third parties may challenge their validity, enforceability, scope or ownership, which may result in such patents, or our rights to such patents, being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. If the patent applications we hold or license with respect to our product candidates fail to issue or if their breadth or strength of protection is threatened, it could dissuade companies from collaborating with us and threaten our ability to commercialize our products. We cannot offer any assurances about which, if any, patents will issue or whether any issued patents will be found invalid or unenforceable, will be challenged by third parties or will adequately protect our products. Further, if we encounter delays in development or regulatory approvals, the period of time during which we could market our products under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates. Furthermore, if third parties have filed such patent applications, an interference proceeding in the United States can be started by a third party or instituted by us to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license it from the prevailing party, which may not be available on commercially reasonable terms or at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary <span style="white-space:nowrap">know-how</span> that is not patentable, processes for which patents are difficult to enforce and other elements of our drug discovery and development processes that involve proprietary <span style="white-space:nowrap">know-how,</span> information or technology that is not covered by patents. Although we expect all of our employees to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary <span style="white-space:nowrap">know-how,</span> information or technology to enter into confidentiality agreements, we cannot provide any </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assurances that all such agreements have been duly executed, that such agreements provide adequate protection and will not be breached, that our trade secrets and other confidential proprietary information will not otherwise be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. If we are unable to prevent material disclosure of the <span style="white-space:nowrap">non-patented</span> intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the laws of some foreign countries do not protect patents and other proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property abroad. We may also fail to pursue or obtain patents and other intellectual property protection relating to our products and product candidates in all foreign countries. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts or otherwise affect our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our avoiding infringement and other violations of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter party <span style="white-space:nowrap">re-examination</span> proceedings before the United States Patent and Trademark Office (U.S. PTO) and its foreign counterparts. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting <span style="white-space:nowrap">know-how</span> and inventions. We have been involved in the past in legal proceedings alleging the misappropriation of trade secrets. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist that might be enforced against our products or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We license certain key intellectual property from third parties, and the loss of our license rights could have a materially adverse effect on our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to a number of technology licenses that are important to our business and may enter into additional licenses in the future. For example, we rely on an exclusive license to certain patents and <span style="white-space:nowrap">know-how</span> from Janssen Pharmaceutical&#160;NV (Janssen NV), which include seladelpar and certain other PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> compounds (the PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> Products). Under the exclusive license with Janssen NV we have full control and responsibility over the research, development and registration of any PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> Products and are required to use diligent efforts to conduct all such activities. If we fail to comply with our obligations under our agreement with Janssen NV, including our obligations to expend more than a de minimis amount of effort and resources on the research and/or development of at least one PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> Product, to make any payment called for under the agreement, not to disclose any <span style="white-space:nowrap">non-exempt</span> confidential information related to the agreement, or to use diligent efforts to promote, market and sell any PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span> Product under the agreement, such action would constitute a default under the agreement and Janssen NV may have the right to terminate the license, in which event we would not be able to develop or market products covered by the license, including in the case of the Janssen NV license, seladelpar, which would have a materially adverse effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is invalid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter-claims against us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in a litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <span style="white-space:nowrap">non-compliance</span> with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees on any issued patent are due to be paid to the U.S. PTO and foreign patent agencies in several stages over the lifetime of the patent. The U.S. PTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <span style="white-space:nowrap">Non-compliance</span> events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <span style="white-space:nowrap">non-payment</span> of fees and failure to properly legalize and submit formal documents. If we or our licensors that control the prosecution and maintenance of our licensed patents fail to maintain the patents and patent applications covering our product candidates, we may lose our rights and our competitors might be able to enter the market, which would have a material adverse effect on our business. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Risks Related to Our Business Operations and Industry </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our business could be negatively affected as a result of the actions of activist or hostile stockholders. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business could be negatively affected as a result of stockholder activism, which could cause us to incur significant expense, hinder execution of our business strategy, and impact the trading value of our securities. For example, in April&#160;2020, a stockholder filed a preliminary proxy statement containing proposed opposition to our preliminarily filed proxy statement, including a proposal to elect three new directors to our Board of Directors and a proposal not to increase to the number of shares of common stock authorized for issuance. While this proxy contest was subsequently suspended, stockholder activism could recur and requires significant time and attention by management and the Board of Directors, potentially interfering with our ability to execute our strategic plan. Stockholder activism could give rise to perceived uncertainties as to our future direction, adversely affect our relationships with key executives and business partners, and make it more difficult to attract and retain qualified personnel. Also, we may be required to incur significant legal fees and other expenses related to activist stockholder matters. Any of these impacts could materially and adversely affect our business and operating results. Further, the market price of our common stock could be subject to significant fluctuation or otherwise be adversely affected by stockholder activism. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are dependent on principal members of our executive team. While we have entered into employment offer letters with each of our executive officers, any of them could leave our employment at any time, as all of our employees are &#8220;at will&#8221; employees. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. Recruiting and retaining other qualified employees for our business, including clinical, scientific, technical and sales and marketing personnel, will also be critical to our success. There is currently a shortage of skilled executives in our industry, which is likely to continue. We also experience competition from universities, competitors and research institutions for the hiring of scientific and clinical personnel. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. In addition, failure of any of our clinical studies may make it more challenging to recruit and retain qualified personnel. If we are unable to successfully recruit key employees or replace key executives or key employees, it may adversely affect the progress of our research, development and commercialization objectives. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategies. Our consultants and advisors may be engaged by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us, which could also adversely affect the progress of our research, development and commercialization objectives. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">As we continue to build our clinical and drug development operations, we will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we continue to build our clinical and drug development programs, we are expanding our employee base to increase our managerial, clinical, scientific, sales and marketing and other operational teams. Such growth imposes additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, our management may need to divert a greater amount of attention away from <span style="white-space:nowrap"><span style="white-space:nowrap">our&#160;day-to-day&#160;activities</span></span> and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among current employees. Our expected growth could require greater capital expenditures and may divert financial resources from other projects, such as the development of product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to create value and/or generate revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to develop and commercialize seladelpar and other potential product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Significant disruptions of information technology systems or breaches of data security could materially adversely affect our business, results of operations and financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business, particularly in view of our current remote work schedule. In the ordinary course of our business, we collect, store and transmit confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools, and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. Our internal information technology systems and infrastructure, and those of our current and any future collaborators, contractors and consultants and other third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. The costs to us to mitigate network security problems and security vulnerabilities could be significant, and our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. If such an event is to occur and cause interruptions in our operations or our vendors, it may result in a material disruption of our product development </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
programs and our reputation could be materially damaged. We could also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in and failures to comply with United States and foreign privacy and data protection laws, regulations and standards may adversely affect our business, operations and consolidated financial performance. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, retention, and security of personal data, such as information that we collect about patients and healthcare providers in connection with clinical trials in the United States and abroad. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in our business, affect our or our vendors&#8217; ability to operate in certain jurisdictions or to collect, store, transfer, use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others. In many jurisdictions, enforcement actions and consequences for noncompliance are rising. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, HIPAA imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In the event that we are subject to HIPAA or other United States privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. Our operations abroad may also be subject to increased scrutiny or attention from data protection authorities. Many countries in these regions have established or are in the process of establishing privacy and data security legal frameworks with which we, our customers, or our vendors must comply. For example, the EU has adopted the General Data Protection Regulation (EU) 2016/679, or GDPR, which went into effect in May 2018 and includes strict requirements for processing the personal information of EU subjects, including clinical trial data. The GDPR has increased compliance burdens on us, including by mandating potentially burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose, retain and process information about them. The processing of sensitive personal data, such as physical health condition, has imposed heightened compliance burdens under the GDPR and is a topic of active interest among foreign regulators. In addition, the GDPR provides for robust regulatory enforcement and fines for a noncompliant company. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Risks Relating to Owning Our Common Stock </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">An active trading market for our common stock may not continue and the market price for our common stock may decline in value. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock was formerly listed on the Nasdaq Capital Market and since the second quarter of 2018 it has been trading on the Nasdaq Global Select Market under the symbol &#8220;CBAY&#8221;. The historical trading prices of our common stock on the Nasdaq Capital Market and the Nasdaq Global Select Market may not be indicative of the price levels at which our common stock will trade in the future, and we cannot predict the extent to which investor interest in us will continue to support an active public trading market for our common stock or how liquid will be that public market. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our stock price is volatile, and our stockholders&#8217; investment in our stock could decline in value. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The historical trading price of our common stock has been volatile. Our stock price may continue to be subject to wide fluctuations in response to a variety of factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in completing the RESPONSE clinical trial and our other clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse, delayed or inconclusive results in our clinical trials, particularly our RESPONSE clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse or inconclusive results or delays in preclinical testing; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to obtain additional funding; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any delay in filing an Investigational New Drug (IND) application or NDA for any of our future product candidates and any adverse development or perceived adverse development with respect to the FDA&#8217;s review of an IND or NDA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to enter into new collaborations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure by us or our licensors to prosecute, maintain or enforce our intellectual property rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to successfully develop and commercialize our future product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in laws or regulations applicable to future products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the structure of health care payment systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adverse regulatory decisions; </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">introduction of new products, services or technologies by our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to meet or exceed financial projections we may provide to the public; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to meet or exceed the estimates and projections of the investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of significant or potential equity or debt sales by us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcements of clinical trial plans or results by us or our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additions or departures of key scientific or management personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">significant lawsuits, including patent or stockholder litigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the market valuations of similar companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of our common stock by us or our stockholders in the future; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">trading volume of our common stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies trading in the stock market in general have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant additional capital may be needed in the future to continue our product development efforts in current and future clinical trials and operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If in the future we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. These sales may also result in new investors gaining rights superior to our existing stockholders. Pursuant to our equity incentive plans, we are authorized to grant stock options and other equity-based awards to our employees, directors and consultants. The number of shares available for future grant under our equity incentive plans as of December&#160;31, 2022 was 2,680,621 shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our certificate of incorporation and our bylaws may delay or prevent an acquisition of us. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management team. In addition, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits, with some exceptions, stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Finally, our charter documents establish advance notice requirements for nominations for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings. Although we believe these provisions together provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">General Risks </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We do not anticipate paying cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not anticipate paying cash dividends in the future. As a result, only appreciation of the price of our common stock, which may never occur, will provide a return to stockholders. Investors seeking cash dividends should not invest in our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to securities litigation, which is expensive and could divert management attention. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our share price is volatile, and in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="txa446975_4">Item&#160;1B. Unresolved Staff Comments </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="txa446975_5">Item&#160;2. Properties </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate office is located in Newark, California. Our office lease for that facility terminates on January&#160;15, 2024 and has an option to extend the lease for an additional five years. We believe that our current facilities are sufficient for our needs for the foreseeable future. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="txa446975_6">Item&#160;3. Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Genfit Litigation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;15, 2021, Genfit S.A. (Genfit) filed a complaint against us in the U.S. District Court for the Northern District of California, alleging misappropriation of trade secrets and related causes of action based on our receipt of a Genfit protocol synopsis for Genfit&#8217;s Phase 3 clinical trial of its drug candidate elafibranor in patients with primary biliary cholangitis. An Amended Complaint was filed on April&#160;16, 2021 with substantially the same allegations. Genfit was seeking damages in an unspecified amount as well as injunctive relief. We have stated in pleadings that we did not request or take any steps to obtain Genfit&#8217;s protocol synopsis, have taken diligent steps to remove and quarantine it, and are not using any Genfit trade secrets in our clinical trials. On March&#160;12, 2021, the court granted a Temporary Restraining Order (later converted to a Preliminary Injunction), prohibiting us from accessing or disseminating the protocol synopsis, using any Genfit trade secrets contained therein or destroying any evidence related thereto. We filed a Motion to Dismiss the Amended Complaint that was granted on September&#160;9, 2021, with leave to amend. Genfit filed a Second Amended Complaint on October&#160;15, 2021 with substantially the same allegations and claims for relief as in the original complaint. We filed a Motion to Dismiss the Second Amended Complaint that was granted on January&#160;21, 2022, without further leave to amend. What remained in the complaint was an alleged misappropriation of the protocol synopsis as a whole. We filed our Answer to what remained of the Second Amended Complaint on February&#160;4, 2022. On February&#160;21, 2023, the parties entered into a Settlement Agreement and the action was dismissed with prejudice. We did not admit to any liability and the litigation has been resolved completely. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="txa446975_7">Item&#160;4. Mine Safety Disclosures </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="txa446975_8">PART II </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="txa446975_9">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Market for Common Equity </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;CBAY&#8221;. As of February&#160;28, 2023, there were approximately 213 holders of record of our common stock, although there are a substantially greater number of &#8220;beneficial holders,&#8221; whose shares are held of record by banks, brokers and other financial institutions in &#8220;street name.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dividend Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends to our stockholders. Our board of directors will make any future decisions regarding dividends. We currently intend to retain and use any future earnings, if any, for the development and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Under our Development Financing Agreement with Abingworth we are not permitted to pay dividends without the consent of Abingworth. Except for the restrictions under our agreement with Abingworth, our board of directors has complete discretion on whether to pay dividends. Even if our board of directors is able to and decides to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that the board of directors may deem relevant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="txa446975_10">Item&#160;6. [Reserved] </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="txa446975_11"><span style="font-weight:bold">Item&#160;7</span><span style="font-weight:bold"><span style="font-style:italic">. Management</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">&#8217;</span></span><span style="font-weight:bold"></span><span style="font-weight:bold"><span style="font-style:italic">s Discussion and Analysis of Financial Condition and Results of Operations </span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward-Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Some of the statements under in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; are forward-looking statements. See &#8220;Cautionary Language Regarding Forward Looking Statements&#8221; at the beginning of this Annual Report for cautionary information regarding forward-looking statements. These statements appear throughout this Annual Report on <span style="white-space:nowrap">Form&#160;10-K</span> and are statements regarding our current expectation, belief, or intent, primarily with respect to our operations and related industry developments. Examples of these statements include, but are not limited to, statements regarding our expectations with respect to the following: our business and scientific strategies; the progress of our product development programs, and the timing of results; regulatory submissions and approvals;&#160;the impact of <span style="white-space:nowrap">COVID-19</span> on our company and operations; our drug discovery technologies; our research and development expenses; protection of our intellectual property; sufficiency of our cash and capital resources and the need for additional capital; and our operations and legal risks. You should not place undue reliance on these forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements for many reasons. Factors that might cause such a difference include those discussed under the caption &#8220;Risk&#160;Factors&#8221; and elsewhere in this Annual Report on Form <span style="white-space:nowrap">10-K.</span> These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this Annual Report. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPAR<span style="FONT-FAMILY:SYMBOL">&#100;</span>), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation, and fibrosis. We have been focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Seladelpar&#8212;Primary Biliary Cholangitis (PBC) </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2022, we completed enrollment of 193 patients in RESPONSE, a <span style="white-space:nowrap">52-week,</span> double blind, placebo-controlled, randomized, global, Phase 3 registration study evaluating the safety and efficacy of seladelpar in PBC. The study enrolled patients who have an inadequate response to, or intolerance to, ursodeoxycholic acid (UDCA), in a 2:1 randomization to oral, once daily seladelpar 10 mg or placebo. The primary outcome measure will be the composite biochemical responder rate at 52 weeks. A responder is defined as a patient who achieves an alkaline phosphatase (ALP) level less than 1.67 times the upper limit of normal with at least a 15% decrease from baseline and has a normal level of total bilirubin. Additional key outcomes of efficacy will compare the rate of normalization of ALP at 52&#160;weeks and the change from baseline in level of pruritus at six months for patients with moderate to severe pruritus at baseline assessed by a numerical rating scale (NRS) recorded with an electronic diary. We expect to release top line data for RESPONSE in the third quarter of 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to RESPONSE, we are also actively recruiting and enrolling eligible patients for our ASSURE trial, an open-label, long-term study intended to collect additional long-term safety and efficacy data to support registration. ASSURE is open to patients who were eligible for our previous long-term extension study that was terminated early in late 2019, including those patients from our previously completed Phase 2 open label study and our Phase 3 ENHANCE study, as well as patients who complete treatment in RESPONSE and certain Phase&#160;1 studies. The ASSURE trial currently has over 200 subjects enrolled and is expected to ultimately enroll in excess of 300 patients. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">MBX-2982</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">MBX-2982</span> targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. In November 2020, we announced a Phase 2a <span style="white-space:nowrap"><span style="white-space:nowrap">proof-of-pharmacology</span></span> study to assess whether <span style="white-space:nowrap">MBX-2982</span> can enhance glucagon secretion during insulin-induced hypoglycemia in subjects with T1D. The study is actively enrolling patients. If successful, studies to evaluate <span style="white-space:nowrap">MBX-2982</span> as a potential preventive therapy for hypoglycemia in patients with T1D may be warranted. The study is being led by the AdventHealth Translational Research Institute in Orlando, Florida and is fully funded by The Leona M. and Harry B. Helmsley Charitable Trust. CymaBay retains full commercial rights to <span style="white-space:nowrap">MBX-2982.</span> We believe <span style="white-space:nowrap">MBX-2982</span> may also have utility in various inflammatory diseases and we are currently exploring potential opportunities to advance development. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">COVID-19</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the <span style="white-space:nowrap">COVID-19</span> situation, we may experience future disruptions that could impact aspects of our business, including our progress towards the initiation and completion of certain clinical trials, and other associated drug development activities. <span style="white-space:nowrap">COVID-19</span> has disrupted, and may continue to disrupt, aspects of our business, in particular in regard to the initiation and operation of clinical trial sites in portions of the United States, in the U.K and in Europe. Possible future disruptions are currently difficult to foresee. We continue to monitor areas of potential risk which include, but are not limited to, the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Clinical trial and drug manufacturing operations&#8212;In collaboration with our clinical research organization partners, we sponsor clinical trials that take place at investigator sites in the U.S. and internationally. We also partner with contract manufacturing organizations to develop, manufacture, and distribute our product candidate drug supplies. To date, these collective research and development personnel and vendors have adapted to <span style="white-space:nowrap">COVID-19</span> restrictions and reduced access to work facilities through the use of remote working technologies and other measures as they continue to progress toward completion of our clinical trials. Although we and our vendors continue to plan for and develop COVID-related risk mitigation strategies, it is uncertain whether these plans will continue to be sufficient to fully offset the potential impact <span style="white-space:nowrap">COVID-19</span> may have on our ability to execute our development activities in a timely and cost-effective manner. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Drug regulator interactions&#8212;The FDA and comparable foreign regulatory agencies may experience operational interruptions or delays, which could impact timelines for regulatory meetings, submissions, trial initiations, and regulatory approvals. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Financial reporting and compliance&#8212;To date, there has been no adverse impact on our ability to maintain our established financial reporting functions and internal controls over financial reporting. However, our ability to prepare our financial results timely and accurately is partially dependent upon the availability of third-party information systems and other cloud-based services. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Remote workforce operations&#8212;To date, our workforce has adapted to remotely working to maintain operations. Our operations are currently in a hybrid model with most employees working from our office for a portion of the week and working remotely for the rest of the week. Our continued use of partially remote operations, however, could increase our cyber-security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations, or delay necessary interactions with regulators, contract manufacturers, contract research organizations, clinical trial sites, and other important agencies and contractors, which may result in increased costs to us. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Overall, we cannot at this time predict the specific extent, duration, or full impact that the continuing <span style="white-space:nowrap">COVID-19</span> situation will have on our future consolidated financial condition and operations. The impact of <span style="white-space:nowrap">COVID-19</span> on our consolidated financial performance will depend on future developments, including emergence of additional <span style="white-space:nowrap">COVID-19</span> variants, the duration and spread of the virus and related governmental advisories and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restrictions, which could result in unexpected costs to us. These developments and the impact of <span style="white-space:nowrap">COVID-19</span> on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, our results may be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Policies and Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements, as well as the reported revenues and expenses during the reporting periods. We base our estimates on historical experience and on various other factors that we believe to be materially reasonable under the circumstances, the results of which form our basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources and evaluate our estimates on an ongoing basis. Actual results may materially differ from those estimates under different assumptions or conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we describe our significant accounting policies in more detail in <span style="font-style:italic">Note 2&#8212;Summary of Significant Accounting Policies</span> of our consolidated financial statements included in this Annual Report, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation and understanding of our consolidated financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research and Development Expenses and Related Prepayments and Accruals </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of costs incurred in identifying, developing, and testing product candidates. These expenses consist primarily of costs for research and development personnel, including related stock-based compensation; contract research organizations (CRO) and other third parties that assist in managing, monitoring, and analyzing clinical trials; investigator and site fees; laboratory services; consultants; contract manufacturing services; <span style="white-space:nowrap">non-clinical</span> studies, including materials; and allocated expenses, such as depreciation of assets, and facilities and information technology that support research and development activities. Research and development costs are expensed as incurred unless there is an alternative future use in other research and development projects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our consolidated financial statements, we are required to estimate certain research and development expenses. This process involves reviewing contracts, reviewing the terms of our license agreements, communicating with our vendors and applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service either when we have prepaid or when we have not yet been invoiced or otherwise notified of actual cost. Although certain of our vendors require us to prepay in advance of services rendered, the majority of our service providers invoice us monthly in arrears for services performed. We make estimates of prepayments to consume or expenses to be accrued as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. Such payments are evaluated for current or noncurrent classification based on when they will be realized. Additionally, if expectations change such that we do not expect goods to be delivered or services to be rendered, such prepayments are charged to expense to the extent they are refundable. Examples of research and development expenses include fees to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">contract research organizations and other service providers in connection with clinical studies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">contract manufacturers in connection with the production of clinical trial materials; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">vendors in connection with preclinical development activities. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We base our expenses related to clinical studies on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conduct and manage clinical studies on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows and expense recognition. Payments under some of these contracts depend on factors such as the successful screening and enrollment of patients and the completion of clinical trial milestones. In expensing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the related prepayment or accrual accordingly. Our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in our reporting changes in estimates in any particular period. Adjustments to prior period estimates have not been material for the years ended December&#160;31, 2022 and 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Development Financing Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We account for our Development Financing Agreement with Abingworth (the Financing Agreement) as a debt instrument. Accordingly, we have recorded payments received under the Financing Agreement as part of a development financing liability in our consolidated balance sheet. The liability is recorded at amortized cost and accreted to the contractual success fee amounts based on the estimated timing of regulatory approval and attainment of certain sales milestones using an imputed interest rate. Certain transaction fees incurred specifically to complete the Financing Agreement were capitalized and recorded as a reduction to the carrying amount of the development financing liability and are being amortized to interest expense using the effective interest rate method. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are several factors that could affect the estimated timing of regulatory approval and attainment of sales milestones, some of which are not entirely within our control. Therefore, we periodically reassess the estimated timing of regulatory approval and attainment of sales milestones, and the expected contractual success fee payments due therefrom. If the timing and/or amount of such expected payments is materially different than original estimates, we will prospectively adjust the accretion of the development financing liability and the imputed interest rate. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We identified certain contingent repayment features in the Financing Agreement that are required to be bifurcated from the debt host instrument as embedded derivative liabilities; however, we determined the fair value of these features, both individually and in aggregate, were immaterial at inception and as of December&#160;31, 2022 and 2021. The fair value of these features will be assessed at each subsequent reporting date and will be marked to market, if material. To determine the amount to record for the embedded derivative liability, we must assess the probability of occurrence of various potential future events that could affect the timing and/or amount of future cash flows related to the Financing Agreement.<span style="font-weight:bold"><span style="font-style:italic"> </span></span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Stock-Based Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We measure stock-based compensation cost at the grant date, based on the estimated fair-value of the awards, and we recognize the portion that we ultimately expect to vest as an expense over the related vesting periods, net of actual forfeitures as they occur. We estimate the grant-date fair value based of stock options using the Black-Scholes option pricing model and recognize compensation expense over the service period and forfeitures are accounted for as they occur. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Black-Scholes option-pricing model requires the input of certain assumptions. These variables include, but are not limited to, our stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors. We determine our stock price volatility based on the sufficiency of our historical stock price data. Due to insufficient historical data of exercise behavior, we have used the &#8220;simplified method&#8221; to determine the expected life of stock options granted with a service condition. Management continually assesses the assumptions and methodologies used to calculate the estimated fair value of stock-based compensation and evaluates the need to make changes when and if necessary. Any such changes to our valuation assumptions and methodologies could materially impact our fair value determination and the resulting stock-based compensation expense. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">General </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not generated any income from operations. As of December&#160;31, 2022, we have an accumulated deficit of $872.9&#160;million, primarily as a result of expenditures for research and development, general and administrative expenses and net interest expenses from inception to that date. Currently, our lead product candidate is at a later stage of development and will require additional work and regulatory approval before it can be fully licensed or commercialized. Accordingly, we expect to continue to incur substantial losses from operations for the foreseeable future and there can be no assurance that we will ever generate sufficient revenue to achieve and sustain profitability. Until we can generate sufficient product revenue, which we may never do, we will need to finance future cash needs through potential collaborative, partnering or other strategic arrangements, as well as through equity offerings, debt financings or a combination of the foregoing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating Results </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our results of operations for the years ended December&#160;31, 2022 and 2021 are presented below (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:60%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">Year Ended</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022&#160;vs&#160;2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">($ in thousands)</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 67,995</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 64,542</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 3,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25,116</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">23,040</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,076</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">93,111</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">87,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,529</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(93,111</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(87,582</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(5,529</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,017</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">167</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,850</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(14,907</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,583</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,324</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total interest expense, net</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(12,890</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,416</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(10,474</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(106,001</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(89,998</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(16,003</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Research&#160;&amp; Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting research and development is central to our business model. Research and development expenses increased $3.5&#160;million to $68.0&#160;million from $64.5&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. We expect that our research and development expenses will increase in the future primarily due to costs associated with our ongoing late-stage development of seladelpar in PBC. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses are detailed further in the table below (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:62%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">Year Ended</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="2" align="center"><span style="font-weight:bold">Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022&#160;vs.&#160;2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Project costs:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Seladelpar PBC clinical studies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,143</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(864</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Seladelpar drug manufacturing&#160;&amp; development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,585</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,531</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,054</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Seladelpar and <span style="white-space:nowrap">non-seladelpar</span> other studies</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">907</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,289</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total project costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,635</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43,734</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(2,099</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Internal research and development costs</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,808</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,552</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">67,995</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">64,542</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,453</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our project costs consist primarily of: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct our clinical trials and a substantial portion of our preclinical activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of acquiring materials and manufacturing drug products for use in clinical trial and other research activities; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other costs associated with development activities, including additional studies. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Internal research and development costs consist primarily of salaries and related fringe benefits costs for our employees (such as workers&#8217; compensation and health insurance premiums), stock-based compensation charges, travel costs, and overhead expenses. Internal costs generally benefit multiple projects and are not separately tracked per project. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total project costs decreased by $2.1&#160;million to $41.6&#160;million from $43.7&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. Project costs for the year ended December&#160;31, 2022 primarily consisted of clinical trial expenses related to the development of seladelpar for the treatment of patients with PBC. These cost decreases were driven primarily by the completion of enrollment of our RESPONSE trial and lower spending in other Phase 1 <span style="white-space:nowrap">NDA-enabling</span> clinical studies for PBC during the year ended December&#160;31, 2022. Additionally, <span style="white-space:nowrap">non-seladelpar</span> other studies were lower due to the termination of clinical development in this area. Internal research and development costs increased by $5.6&#160;million to $26.4&#160;million from $20.8&#160;million for the years ended December&#160;31, 2022 and 2021, respectively, primarily due to an increase in headcount in research and development personnel to support our clinical studies. As we continue to progress late-stage development of seladelpar in PBC, we expect research and development expenses to increase in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist principally of personnel-related costs, professional fees for legal, consulting, and accounting services, rent, and other general operating expenses not otherwise included in research and development. General and administrative expenses increased by $2.1&#160;million to $25.1&#160;million from $23.0&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. The increase was driven primarily by an increase in headcount in general and administrative personnel as we continue to add administrative personnel and expand our infrastructure in support of our drug development activities. We expect these types of general and administrative expenses to continue to increase in the future as we further expand support for our ongoing drug development activities and as we begin to conduct initiatives to plan and prepare for potential commercialization of seladelpar in PBC. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interest Expense, Net </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense, net includes interest expense related to the accretion of the development financing liability recorded in connection with the July 2021 Abingworth Development Financing Agreement (the Financing Agreement) using the effective interest method, net of interest income earned on our marketable securities portfolio. Interest expense, net, increased $10.5&#160;million to $12.9&#160;million from $2.4&#160;million for the years ended December&#160;31, 2022 and 2021, respectively primarily due to an increase in interest expense of $12.3&#160;million that was driven by additional proceeds received under the Financing Agreement in January 2022 and because interest was accrued for the full year in 2022 as compared to six months in 2021. This increase in interest expense was partially offset by $1.9&#160;million of additional interest income earned on our investment portfolio, which benefited in 2022 from higher prevailing interest rates that enhanced the portfolio&#8217;s overall yield compared to 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Income Taxes </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, we had federal net operating loss carryforwards of $346.0&#160;million and state net operating loss carryforwards of $214.9&#160;million to offset future taxable income, if any. In addition, we had federal research and development tax credit carryforwards of $4.1&#160;million, federal orphan drug tax credit carryforwards of $28.1&#160;million, and state research and development tax credit carryforwards of $9.2&#160;million. If not utilized, the federal net operating losses for the years beginning before January&#160;1, 2018 of $79.1&#160;million will expire beginning in 2024 through 2037, and the federal net operating losses for the tax years beginning after January&#160;1, 2018 of $266.9&#160;million will be carried forward indefinitely (subject to certain utilization limitations). The state net operating loss carryforwards will expire beginning in 2028 through 2040. The federal research and development and federal orphan drug tax credit carryforwards expire 2033 through 2042, and the state tax credit will carry forward indefinitely. Current federal and state tax laws include substantial restrictions on the utilization of net operating losses and tax credits in the event of an ownership change. During 2022, we completed a study and determined historical ownership changes occurred through December&#160;31, 2022 and accordingly, we have reduced our carryforwards to incorporate the effects of these federal and state restrictions. Carryforwards that remain available may be subject to annual limitations, lack of future taxable income, or future ownership changes that could result in the expiration of the carryforwards before they are utilized. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&#160;31, 2022, we recorded a full valuation allowance against our deferred tax assets of approximately $144.7&#160;million, as our management believes it is more likely than not that they will not be fully realized. Interest and penalties for the years ended December&#160;31, 2022 and 2021 were not material. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have financed our operations primarily through the sale of equity securities, licensing fees, issuance of debt and collaborations with third parties. As of December&#160;31, 2022, cash, cash equivalents and marketable securities totaled $135.5&#160;million, compared to $194.6&#160;million at December&#160;31, 2021. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Development Financing Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&#160;30, 2021, we entered into a Development Financing Agreement (the Financing Agreement) with Abingworth to obtain funding to support our development of seladelpar for the treatment of PBC. The Financing Agreement provided us up to $100.0&#160;million in funding, of which $25.0&#160;million was received in August 2021, $25.0&#160;million was received in November 2021 and $25.0&#160;million was subsequently received in January 2022. We had an option to receive an additional $25.0&#160;million within approximately two months following enrollment completion of our Phase 3 RESPONSE clinical trial; however, we did not exercise the option to receive this additional funding. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Collaboration and License Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;6, 2023, we entered into a Collaboration and License Agreement with Kaken Pharmaceutical Co., Ltd. Pursuant to the agreement, we granted Kaken an exclusive license to commercialize seladelpar for the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
treatment of PBC in Japan. In exchange for the license and other rights granted by us, Kaken paid us &#165;4.5&#160;billion ($34.2 million) in January 2023 and they are also obligated to make aggregate potential future milestone payments to us totaling up to &#165;17.0&#160;billion ($128.0&#160;million at exchange rates in effect at contract inception date) upon Kaken&#8217; achievement of certain regulatory and sales milestones. We are obligated to manufacture and supply seladelpar to Kaken for use in the territory in exchange for payments from Kaken as defined in the agreement. For further details, refer to <span style="font-style:italic">Note 13&#8212;Subsequent Events</span> of our consolidated financial statements included in this Annual Report. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sale of Common Stock and <span style="white-space:nowrap">Pre-funded</span> Warrant </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;23, 2023, we sold 11,821,428 shares of common stock at $7.00 per share and a <span style="white-space:nowrap">pre-funded</span> warrant to purchase 2,142,857 shares of common stock at $6.9999 per share in a public equity offering (the January 2023 public equity offering), for total gross offering proceeds of approximately $97.7&#160;million. The net proceeds from this offering were $92.4&#160;million after deducting underwriting and other offering expenses. We anticipate using the offering proceeds to fund ongoing development of seladelpar and for working capital and general corporate purposes. For further details, refer to <span style="font-style:italic">Note 13&#8212;Subsequent Events </span>of our consolidated financial statements included in this Annual Report. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap"><span style="white-space:nowrap">At-the-Market</span></span> (ATM) Facility </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In July 2020, we filed a $200.0&#160;million registration statement on Form <span style="white-space:nowrap">S-3</span> with the SEC and entered into an <span style="white-space:nowrap"><span style="white-space:nowrap">at-the-market</span></span> facility (ATM) to sell up to $75.0&#160;million of common stock under the registration statement pursuant to the Controlled Equity Offering<sup style="font-size:75%; vertical-align:top">SM</sup> Sales Agreement with Cantor Fitzgerald&#160;&amp; Co. (Cantor), dated July&#160;2, 2020 (the Sales Agreement). To date, we have not sold any shares of common stock under the ATM. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of the net cash flow activity for each of the periods indicated below (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:71%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="6" align="center"><span style="font-weight:bold">Year Ended</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(84,080</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(69,431</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(45,985</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">48,589</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24,550</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">118,455</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">(105,515</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">97,613</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Flows from Operating Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities for the year ended December&#160;31, 2022 increased by $14.6&#160;million to $84.1&#160;million compared to $69.4&#160;million in the prior year. The increase in cash used was primarily due to a $16.0&#160;million increase in our net loss to $106.0&#160;million from $90.0&#160;million in the prior year period as a result of&#160;the expansion of late-stage clinical trial activities related to the seladelpar development program. In addition, cash was used to fund changes in our working capital. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Flows from Investing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities was $46.0&#160;million for the year ended December&#160;31, 2022 compared to $48.6&#160;million provided by investing activities in the prior year, primarily due to the timing of our purchases of investments and maturities of marketable securities and portfolio risk management. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Flows from Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $24.6&#160;million for the year ended December&#160;31, 2022 compared to $118.5&#160;million in the prior year. In 2022, we received $25&#160;million in proceeds pursuant to our Financing Agreement with Abingworth. Financing proceeds in 2021 were comparatively higher and included $70.5&#160;million in net proceeds received from our November 2021 public equity offering and $47.7&#160;million in net proceeds received from our Financing Agreement with Abingworth. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Capital Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred operating losses since inception and had an accumulated deficit of $872.9&#160;million at December&#160;31, 2022. As of December&#160;31, 2022, we had cash, cash equivalents and marketable securities of approximately $135.5&#160;million. We believe these existing funds, together with the $34.2&#160;million upfront payment received from Kaken in January 2023 pursuant to the Collaboration and License Agreement and the $92.4&#160;million of net proceeds received in connection with our January 2023 public equity offering, are sufficient to fund our current operating plan through the third quarter of 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur substantial expenses related to our development activities for the foreseeable future as we continue product development for seladelpar and begin to prepare for its potential commercialization in PBC. Since product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later stage clinical trials, we expect that our research and development expenses will increase in the future. We will therefore continue to require additional financing to develop our products and fund future operating losses and will seek funds through equity financings, debt, collaborative or other arrangements with corporate sources, or through other sources of financing. It is unclear if or when any such financing transactions will occur, on satisfactory terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If adequate funds are not available to us, it could have a material adverse effect on our business, results of operations, and financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Contractual Obligations and Other Cash Requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our long-term contractual obligations as of December&#160;31, 2022 include monthly rental payments for our corporate office lease, which are payable through January 2024, the lease termination date. We are also obligated to reimburse the lessor for a prorated portion of monthly facility operating expenses during the lease term. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our <span style="white-space:nowrap">non-cancellable</span> contractual obligations as of December&#160;31, 2022, which relate to our operating lease, are presented in the table below (amounts in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:89%"></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ending December&#160;31,</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">707</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total undiscounted future minimum lease payments</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">737</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we rely on contract research organizations and other research support providers to perform clinical and preclinical studies for us and we contract with firms to supply our drug compounds for use in our development activities. Under the terms of our agreements with these organizations, we are obligated to make&#160;future payments as services are provided. However, these agreements are terminable by us upon written notice and we are generally only liable for actual effort expended or cost incurred by the organizations through the termination notice period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the normal course of business, we also enter into various firm purchase commitments and other contractual obligations with other vendors, which are generally cancelable within ninety days or less. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have significant potential payment obligations under the Financing Agreement that are contingently payable by us to Abingworth upon regulatory approval of seladelpar in PBC and achievement of certain sales for seladelpar. Specifically, we will pay to Abingworth fixed and variable success payments, including (1)&#160;contingent upon the first to occur of regulatory approval of seladelpar for the treatment of PBC in the U.S., U.K., Germany, Spain, Italy or France (Regulatory Approval), fixed success payments equal to 2.0x of the funding provided, consisting of $10&#160;million payable within 90 days after Regulatory Approval and thereafter payments due on the first six anniversaries of the Regulatory Approval in the amounts of $15&#160;million, $22.5&#160;million, $22.5&#160;million, $25.0&#160;million, $27.5&#160;million and $27.5&#160;million, respectively and (2)&#160;variable success payments equal to 1.1x of the funding provided, consisting of sales milestone payments of (x) $17.5&#160;million and $27.5&#160;million, respectively upon first reaching certain cumulative U.S. product sales thresholds, and (y)&#160;$37.5&#160;million upon first reaching a specified U.S. product sales run rate. See <span style="font-style:italic">Note 6&#8212;Development Financing Agreement</span> of our consolidated financial statements in this Annual Report for a more complete description of our financial obligations under the Financing Agreement. We were in compliance with all terms and covenants related to the Financing Agreement as of December&#160;31, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="txa446975_12">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="txa446975_13">Item&#160;8. Financial Statements and Supplementary Data </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The disclosure required in this Item is included in Item&#160;15, which information is incorporated by reference here. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="txa446975_14"><span style="font-weight:bold">Item&#160;9.</span><span style="font-weight:bold"><span style="font-style:italic"> Changes in and Disagreements with Accountants on Accounting and Financial Disclosure </span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="txa446975_15"><span style="font-weight:bold">Item&#160;9A.</span><span style="font-weight:bold"><span style="font-style:italic"> Controls and Procedures </span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Evaluation of Disclosure Controls and Procedures </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act, and the rules&#160;and regulations thereunder, is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms and that such information is accumulated and communicated to our management, including our chief executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure.&#160;In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the evaluation of our disclosure controls and procedures (as defined in Rules <span style="white-space:nowrap">13a-15(e)</span> and <span style="white-space:nowrap">15d-15(e)</span> under the Exchange Act), our chief executive officer and principal financial officer have concluded that, as of the end of the period covered by this report, the design and operation of our disclosure controls and procedures were effective at the reasonable assurance level. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Management&#8217;s Annual Report on Internal Control Over Financial Reporting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed by, or under the supervision of, our President and Chief Executive Officer and our Vice President, Finance to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in accordance with generally accepted accounting principles and includes those policies and procedures that (1)&#160;pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the supervision and with the participation of our management, including our President and Chief Executive Officer and Vice President, Finance, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on criteria established in &#8220;Internal Control&#8212;Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of December&#160;31, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a <span style="white-space:nowrap">non-accelerated</span> filer, we are not required to obtain an opinion of our independent auditors with respect to our internal controls over financial reporting for the period ended December&#160;31, 2022. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Limitations on the Effectiveness of Controls </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the controls are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Changes in Internal Controls </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no changes in our internal control over financial reporting that occurred during the quarter ended December&#160;31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="txa446975_16"><span style="font-weight:bold">Item&#160;9B.</span><span style="font-weight:bold"><span style="font-style:italic"> Other Information </span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="txa446975_17"><span style="font-weight:bold">Item&#160;9C. </span><span style="font-weight:bold"><span style="font-style:italic">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="txa446975_18">PART III </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="txa446975_19"><span style="font-weight:bold">Item&#160;10.</span><span style="font-weight:bold"><span style="font-style:italic"> Directors, Executive Officers and Corporate Governance </span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item with respect to our executive officers is incorporated herein by reference to the information set forth under the caption &#8220;Information about our Executive Officers&#8221; in Part I of this Annual Report. The information required by this item with respect to our directors is incorporated herein by reference to the information set forth under the caption &#8220;Proposal 1&#8211;Election of Directors&#8221; in our proxy statement for our 2023 annual meeting of stockholders, or the 2023 Proxy Statement. The information required by this item with respect to late Section&#160;16 filings, if any, is incorporated by reference to the information set forth under the caption &#8220;Section&#160;16(a) Beneficial Ownership Reporting Compliance&#8221; in the 2023 Proxy Statement. The </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information required by this item with respect to the committees of our board of directors is incorporated by reference to the information set forth under the caption &#8220;Information Regarding the Board of Directors and Corporate Governance&#8211;Information Regarding Committees of the Board&#8221; in the 2023 Proxy Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the&#160;2023 Proxy Statement is not filed within 120&#160;days after the end of the fiscal year covered by this Annual Report on <span style="white-space:nowrap">Form&#160;10-K,</span> the omitted information will be included in an amendment to this Annual Report on <span style="white-space:nowrap">Form&#160;10-K</span> filed not later than the end of such <span style="white-space:nowrap">120-day</span> period. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Code of Business Conduct </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Code of Business Conduct and Ethics applies to all officers, directors and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of our Code of Business Conduct and Ethics can be found on our website, http://ir.cymabay.com/governance-docs. The contents of our website are not a part of this Annual Report on Form <span style="white-space:nowrap">10-K.</span> We intend to satisfy the disclosure requirement under Item&#160;5.05 of Form <span style="white-space:nowrap">8-K</span> regarding an amendment to, or waiver from, a provision of this Code of Business Conduct and Ethics by posting such information on our website, at the address and location specified above. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="txa446975_20"><span style="font-weight:bold">Item&#160;11.</span><span style="font-weight:bold"><span style="font-style:italic"> Executive Compensation </span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to the information to be included under the headings &#8220;Executive Compensation&#8221; and &#8220;Director Compensation&#8221; in our 2023 Proxy Statement, which information is hereby incorporated by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="txa446975_21"><span style="font-weight:bold">Item&#160;12. </span><span style="font-weight:bold"><span style="font-style:italic">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item with respect to security ownership of certain beneficial owners and management will be set forth in our 2023 Proxy Statement under the caption &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Equity Compensation Plan Information </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information concerning our equity compensation plans will be set forth in our 2023 Proxy Statement under the caption &#8220;Securities Authorized for Issuance under Equity Compensation Plans&#8212;Equity Compensation Plan Information&#8221; and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="txa446975_22"><span style="font-weight:bold">Item&#160;13.</span><span style="font-weight:bold"><span style="font-style:italic"> Certain Relationships and Related Transactions, and Director Independence </span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item will be set forth in our 2023 Proxy Statement under the captions &#8220;Transactions with Related Persons&#8221; and &#8220;Information Regarding the Board of Directors and Corporate Governance&#8212;Independence of the Board of Directors&#8221; and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="txa446975_23"><span style="font-weight:bold">Item&#160;14.</span><span style="font-weight:bold"><span style="font-style:italic"> Principal Accountant Fees and Services </span></span><span style="font-weight:bold"> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information required by this item will be set forth in our 2023 Proxy Statement under the caption &#8220;Principal Accountant Fees and Services&#8221; in the proposal under the caption &#8220;Ratification of Selection of Independent Registered Public Accounting Firm&#8221; and is incorporated herein by reference. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="txa446975_24">PART IV </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" id="txa446975_25"><span style="font-weight:bold">Item&#160;15.</span><span style="font-weight:bold"><span style="font-style:italic"> Exhibits and Financial Statement Schedules </span></span><span style="font-weight:bold"> </span></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(a)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Documents filed as part of this report </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">1. Financial Statements </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:95%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txb446975_1">Report of Independent Registered Public Accounting Firm (PCAOB&#160;ID: 42)</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">72</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txb446975_2">Consolidated Balance Sheets as of December&#160;31, 2022 and 2021</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txb446975_3">Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2022 and 2021</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txb446975_4">Consolidated Statements of Stockholders&#8217; Equity for the years ended December&#160;31, 2022 and 2021</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">75</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txb446975_5">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2022 and 2021</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">76</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#txb446975_6">Notes to Consolidated Financial Statements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">2. Financial Statement Schedules </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial statement schedules have been omitted in this report because they are not applicable, not required under the instructions, or the information requested is set forth in the consolidated financial statements or related notes thereto. </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) List of Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:8%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:53%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:6%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:11%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:6%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:11%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Incorporation By Reference</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit<br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">SEC&#160;File&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Filing Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#160;&#160;3.1</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312513401450/d569374dex31.htm">Amended and Restated Certificate of Incorporation.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">000-55021</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10/17/2013</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#160;&#160;3.2</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312520180903/d938886dex31.htm">Certificate of Amendment of the Amended and Restated Certificate of Incorporation. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">6/26/2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#160;&#160;3.3</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312513401450/d569374dex32.htm">Amended and Restated <span style="white-space:nowrap">By-Laws.</span></a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">000-55021</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10/17/2013</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#160;&#160;4.1</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Reference is made to Exhibits <a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312513401450/d569374dex31.htm">3.1</a>, <a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312513401450/d569374dex31.htm">3.2</a> and <a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312513401450/d569374dex32.htm">3.3</a>.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#160;&#160;4.2</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312521094424/d41924dex42.htm">Description of Common Stock.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">4.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">3/25/2021</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#160;&#160;4.3</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312521333983/d166338dex41.htm">Form of Warrant to Purchase Shares of Common Stock. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">11/18/2021</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&#160;&#160;4.4</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312523014677/d448337dex41.htm">Form of Warrant to Purchase Shares of Common Stock. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">1/25/2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.1*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312513331146/d569374dex101.htm">2003 Equity Incentive Plan.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">000-55021</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">8/12/2013</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.2*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312513331146/d569374dex102.htm">Form of 2003 Equity Incentive Plan Stock Option Agreement.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">000-55021</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">8/12/2013</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.3*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312513331146/d569374dex103.htm">Form of 2003 Equity Incentive Plan Early Exercise Stock Option Agreement.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">000-55021</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">8/12/2013</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.4*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312518186789/d594001dex101.htm">2013 Equity Incentive Plan.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">6/7/2018</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.5*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312513401450/d569374dex1026.htm">Form of Option Grant Notice and Option Agreement under the 2013 Equity Incentive Plan.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10/A</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">000-55021</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.26</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10/17/2013</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.6*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312514124127/d662100dex1022.htm">Form of Incentive Award Grant Notice under the 2013 Equity Incentive Plan.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">000-55021</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.22</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">3/31/2014</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.7*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312521094424/d41924dex107.htm">2020 New Hire Plan.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">3/25/2021</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.8*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312521094424/d41924dex108.htm">Form of Stock Option Grant Notice and Option Agreement under the 2020 New Hire Plan.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.8</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">3/25/2021</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.9</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000156459018005831/cbay-ex107_169.htm">Form of CymaBay Indemnity Agreement.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.7</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">3/15/2018</td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:8%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:53%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:6%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:11%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:6%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:11%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Incorporation By Reference</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit<br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">SEC&#160;File&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Filing Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.10#</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312518010030/d521281dex101.htm"><span style="white-space:nowrap">PPAR-d</span> License Agreement, dated June&#160;20, 2006, by and between Metabolex, Inc. and Janssen Pharmaceutical NV.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-Q</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">11/14/2022</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.11#</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312521325946/d219235dex101.htm">Development Financing Agreement, dated July&#160;30, 2021, by and between CymaBay Therapeutics, Inc. and ABW Cyclops SPV LP.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-Q</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">11/10/2021</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.12#+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d446975dex1012.htm">Collaboration and License Agreement, dated January&#160;6, 2023, between CymaBay Therapeutics, Inc. and Kaken Pharmaceutical Co., Ltd. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.13</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312513453184/d608283dex1027.htm">Lease, dated November<span style="text-decoration:underline"></span>&#160;8, 2013, between CymaBay Therapeutics, Inc. and <span style="white-space:nowrap">BMR-Pacific</span> Research Center, L.P.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-Q</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">000-55021</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.27</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">11/25/2013</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.14</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000156459018011853/cbay-ex101_90.htm">First Amendment to Lease, dated April<span style="text-decoration:underline"></span>&#160;16, 2018, between CymaBay Therapeutics, Inc. and <span style="white-space:nowrap">BMR-Pacific</span> Research Center, LP.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-Q</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">5/8/2018</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.15*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312514124127/d662100dex1024.htm">Offer Letter, dated December<span style="text-decoration:underline"></span>&#160;6, 2013, between CymaBay Therapeutics, Inc. and Sujal Shah.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">000-55021</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.24</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">3/31/2014</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.16*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312514124127/d662100dex1026.htm">Offer Letter, dated November<span style="text-decoration:underline"></span>&#160;21, 2013, between CymaBay Therapeutics, Inc. and Charles A. McWherter.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">000-55021</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.26</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">3/31/2014</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.17*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312517254432/d404099dex104.htm">Offer Letter, dated August<span style="text-decoration:underline"></span>&#160;2, 2017, between CymaBay Therapeutics, Inc. and Daniel Menold.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-Q</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.4</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">8/10/2017</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.18*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000156459019005435/cbay-ex1016_257.htm">Offer Letter, dated September<span style="text-decoration:underline"></span>&#160;4, 2018, between CymaBay Therapeutics, Inc. and Klara Dickinson.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.16</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">2/28/2019</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.19*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312521094424/d41924dex1018.htm">Offer Letter, dated August<span style="text-decoration:underline"></span>&#160;27, 2020, between CymaBay Therapeutics, Inc. and Paul Quinlan.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.18</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">3/25/2021</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.20*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312521244646/d156733dex101.htm">Offer Letter, dated March<span style="text-decoration:underline"></span>&#160;24, 2021, between CymaBay Therapeutics, Inc. and Lewis Stuart.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-Q</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">8/12/2021</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.21*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312521244646/d156733dex102.htm">Offer Letter, dated April<span style="text-decoration:underline"></span>&#160;30, 2021, between CymaBay Therapeutics, Inc. and Dennis D. Kim.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-Q</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">8/12/2021</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.22*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312523046728/d468912dex101.htm">Notice of Resignation and Transition, effective February&#160;20, 2023, between CymaBay Therapeutics, Inc. and Dennis Kim. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">8-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-35600</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">2/23/2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.23*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000156459019005435/cbay-ex1017_256.htm"><span style="white-space:nowrap">Non-Employee</span> Director Compensation Program.</a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">10-K</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">001-36500</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">10.17</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">2/28/2019</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10.24</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1042074/000119312520186924/d934315dex12.htm">Controlled Equity Offering<sup style="font-size:75%; vertical-align:top">SM</sup> Sales Agreement, dated July&#160;2, 2020, between CymaBay Therapeutics, Inc. and Cantor Fitzgerald&#160;&amp; Co. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">S-3</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center"><span style="white-space:nowrap">333-239670</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">1.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">7/2/2020</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">21.1+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d446975dex211.htm">List of subsidiaries of the Registrant. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">23.1+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d446975dex231.htm">Consent of Independent Registered Public Accounting Firm. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:8%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:53%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:6%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:11%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:6%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:11%"></td></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="7" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Incorporation By Reference</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit<br />Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit Description</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Form</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">SEC&#160;File&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Filing Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">24.1+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="#sig">Power of Attorney. (Incorporated by reference to the signature page of this Annual Report on <span style="white-space:nowrap">Form&#160;10-K.)</span> </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">31.1+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d446975dex311.htm">Certification of President and Chief Executive Officer (Principal Executive Officer) pursuant to Rule <span style="white-space:nowrap"><span style="white-space:nowrap">13-a-14(a)</span></span> or Rule <span style="white-space:nowrap">15(d)-14(a)</span> of the Exchange Act. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">31.2+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d446975dex312.htm">Certification of Vice President, Finance (Principal Financial Officer) pursuant to Rule <span style="white-space:nowrap">13a-14(a)</span> or Rule <span style="white-space:nowrap">15d-14(a)</span> of the Exchange Act. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">32.1++</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d446975dex321.htm">Certification of President and Chief Executive Officer (Principal Executive Officer) and Vice President, Finance (Principal Financial Officer) pursuant to 18&#160;U.S.C. Section&#160;1350 as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002. </a></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.INS+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.SCH+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.CAL+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.DEF+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.LAB+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Label Linkbase Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">101.PRE+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Document</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">104</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as inline XBRL and contained in exhibit 101)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">+</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Filed herewith. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">++</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Furnished herewith. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates management contract or compensatory plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">#</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Certain portions of this exhibit have been omitted because the omitted portions are both not material and is the type of information that CymaBay treats as private or confidential. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following exhibits are included herein or incorporated herein by reference: </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>
<div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="hidden71088836" contextRef="PAsOn12_31_2022">http://fasb.org/us-gaap/2022#OtherAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="hidden71088837" contextRef="PAsOn12_31_2021">http://fasb.org/us-gaap/2022#OtherAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="hidden71088416" contextRef="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis">P3Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cbay-20221231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="cbay-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="cbay-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="cbay-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="cbay-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references></ix:header></div><div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CymaBay Therapeutics, Inc. </div></div></div></div> <div id="index" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Index to Consolidated Financial Statements </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 95%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#txb446975_1">Report of Independent Registered Public Accounting Firm (PCAOB ID:&#160;<ix:nonNumeric name="dei:AuditorFirmId" contextRef="P01_01_2022To12_31_2022">42</ix:nonNumeric>)</a></div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">72</div><br/></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 95%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#txb446975_2">Consolidated Balance Sheets as of December&#160;31, 2022 and 2021</a></div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">73</div><br/></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 95%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#txb446975_3">Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2022 and 2021</a></div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">74</div><br/></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 95%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#txb446975_4">Consolidated Statements of Stockholders&#8217; Equity for the years ended December&#160;31, 2022 and 2021</a></div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">75</div><br/></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 95%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#txb446975_5">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2022 and 2021</a></div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">76</div><br/></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt; width: 95%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#txb446975_6">Notes to Consolidated Financial Statements</a></div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="display:inline;">77</div><br/></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">71</div><br/></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div id="txb446975_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Stockholders and the Board of Directors of CymaBay Therapeutics, Inc. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of CymaBay Therapeutics, Inc. (the Company) as of December&#160;31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the years then ended, in conformity with U.S. generally accepted accounting principles. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical Audit Matters </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1)&#160;relate to accounts or disclosures that are material to the financial statements and (2)&#160;involved our especially challenging, subjective or complex judgments. We determined that there are no critical audit matters. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ </div></div><ix:nonNumeric name="dei:AuditorName" contextRef="P01_01_2022To12_31_2022">Ernst &amp; Young LLP</ix:nonNumeric> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 1994. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:AuditorLocation" contextRef="P01_01_2022To12_31_2022">San Mateo, California</ix:nonNumeric> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">23</div>, 2023 </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">72</div><br/></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"></div> </div> </div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CymaBay Therapeutics, Inc. </div></div></div></div> <div id="txb446975_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheets </div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(In thousands, except share amounts and par value)</div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,291</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">125,806</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Marketable securities</div> </td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,194</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">60,729</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Prepaid expenses and other current assets</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,588</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,564</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">138,073</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">191,099</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">701</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,178</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> marketable securities</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,067</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">169</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">254</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,909</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,720</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total assets</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">141,852</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">202,318</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Liabilities and stockholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current liabilities:</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,096</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,728</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued research and development expenses</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="cbay:AccruedResearchAndDevelopmentExpenses" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,530</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="cbay:AccruedResearchAndDevelopmentExpenses" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,752</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other accrued liabilities</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,815</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,886</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,441</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,366</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Development financing liability</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="cbay:DevelopmentFinancingLiabilityNonCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">90,227</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="cbay:DevelopmentFinancingLiabilityNonCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,320</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term portion of operating lease liability</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">695</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">105,698</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">69,381</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commitments and contingencies</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders&#8217; equity:</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">84,681,063</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">84,677,939</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2022 and December&#160;31, 2021, respectively</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">909,329</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">899,798</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated other comprehensive loss</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">326</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">872,857</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">766,856</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stockholders&#8217; equity</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,154</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">132,937</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total liabilities and stockholders&#8217; equity</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">141,852</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">202,318</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to the consolidated financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">73</div><br/></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"></div> </div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CymaBay Therapeutics, Inc.</div></div></div> <div id="txb446975_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Operations and Comprehensive Loss </div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(In thousands, except share and per share information) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">67,995</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">64,542</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,116</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,040</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">93,111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss from operations</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">93,111</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">87,582</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Interest expense, net:</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,017</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">167</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest expense</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,907</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,583</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">Total interest expense</div>, net</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,890</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,416</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">106,001</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">89,998</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other comprehensive loss:</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Unrealized loss on marketable securities, net of tax</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">313</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other comprehensive loss</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">313</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Comprehensive loss</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">106,314</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">90,019</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 77%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted net loss per common share</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">1.21</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">1.27</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 77%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average common shares outstanding used to calculate basic and diluted net loss per common share</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">87,804,063</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">71,055,331</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr> </table> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to the consolidated financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">74</div><br/></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CymaBay Therapeutics, Inc. </div></div></div></div> <div id="txb446975_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Stockholders&#8217; Equity </div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(In thousands, except share and per share information) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 43%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: top; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: top; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: top; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="4" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" rowspan="4" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Comprehensive</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Income (Loss)</div></div></div></td>
<td rowspan="4" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="4" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="4" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></div></td>
<td rowspan="4" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="4" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="4" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity</div></div></div></td>
<td rowspan="4" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balances as of December&#160;31, 2020</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">68,946,092</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">819,549</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">676,858</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">142,706</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of common stock upon exercise of stock options</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">106,847</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">219</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">219</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,996</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,996</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; white-space: nowrap; width: 43%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: 11pt; white-space: nowrap;"><div style="font-size: 10pt; line-height: 11pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px; line-height: 11pt;;display:inline;">pre-funded</div> warrants, net of <br/>$</div><div style="font-size: 10pt; line-height: 11pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,965</ix:nonFraction></div><div style="font-size: 10pt; line-height: 11pt; white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"> issuance costs</div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="cbay:IssuanceOfCommonStockAndPrefundedWarrantsShares" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">15,625,000</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="cbay:IssuanceOfCommonStockAndPrefundedWarrants" contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="cbay:IssuanceOfCommonStockAndPrefundedWarrants" contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">70,034</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="cbay:IssuanceOfCommonStockAndPrefundedWarrants" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">70,035</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">89,998</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">89,998</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net unrealized loss on marketable securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balances as of December&#160;31, 2021</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">84,677,939</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">899,798</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">766,856</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">132,937</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of common stock upon exercise of stock options</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,124</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Issuance costs related to issuance of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants</div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="cbay:IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="cbay:IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,517</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,517</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">106,001</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">106,001</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net unrealized loss on marketable securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">313</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">313</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 43%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balances as of December&#160;31, 2022</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">84,681,063</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">909,329</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">326</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">872,857</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 2%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,154</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 43%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; text-indent: 0px;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to the consolidated financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">75</div><br/></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"></div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CymaBay Therapeutics, Inc. </div></div></div></div> <div id="txb446975_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Cash Flows </div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(In thousands) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 81%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating activities</div></div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">106,001</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">89,998</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">710</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">688</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,517</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,996</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Write-off</div> of deferred financing costs</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">312</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accretion of development financing liability</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="cbay:AccretionOfDevelopmentFinancingLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,907</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="cbay:AccretionOfDevelopmentFinancingLiability" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,583</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net accretion and amortization of investments in marketable securities</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">874</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">637</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Changes in assets and liabilities:</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets</div><br/></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,976</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">386</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,189</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,513</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,444</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,309</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued research and development expenses</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="cbay:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="cbay:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,054</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other accrued liabilities</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,540</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net <div style="letter-spacing: 0px; top: 0px;;display:inline;">cash (used in) operating</div>&#160;activities</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,080</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">69,431</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Investing activities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;and equipment</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">148</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">87</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of marketable securities</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">174,977</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">78,084</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from maturities of marketable securities</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">129,140</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">126,760</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash (used in) provided by investing activities</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">45,985</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,589</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Financing activities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of common stock pursuant to equity award plans</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">219</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants, net of issuance costs</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="cbay:ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">459</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="white-space:nowrap;vertical-align:bottom">)</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="cbay:ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">70,499</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from development financing, net of transaction costs</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="cbay:ProceedsFromDevelopmentFinancingNetOFtransactionCosts" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="cbay:ProceedsFromDevelopmentFinancingNetOFtransactionCosts" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,737</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net cash provided by financing activities</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,550</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">118,455</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 81%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net (decrease) increase in cash and cash equivalents</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">105,515</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">97,613</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents at beginning of period</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">125,806</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,193</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 81%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents at end of period</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,291</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">125,806</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 81%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental disclosure</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">686</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">666</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Supplemental <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> investing and financing activities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 81%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unpaid financing costs</div> </td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 2%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAssumed1" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">464</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear: both; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to the consolidated financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">76</div><br/></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"></div> </div> </div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div id="txb446975_6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088096"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Organization and Description of Business </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-weight:bold;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">CymaBay Therapeutics, Inc. (the Company or CymaBay) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. The Company&#8217;s lead clinical development candidate is seladelpar. Seladelpar has been primarily under development for the treatment primary biliary cholangitis (PBC), a rare liver disease. The Company was incorporated in Delaware in October 1988 as Transtech Corporation. The Company&#8217;s headquarters and operations are located in Newark, California and it operates<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in </div><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_segment" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> segment.</div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Liquidity </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred net operating losses and negative cash flows from operations since its inception. During the year ended December&#160;31, 2022, the Company incurred a net loss of $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">106.0</ix:nonFraction>&#160;million and used $<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">84.1</ix:nonFraction>&#160;million of cash in operations. At December&#160;31, 2022, the Company had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">872.9</ix:nonFraction>&#160;million. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, the Company has incurred substantial research and development expenses in the course of studying its product candidates in clinical trials. To date, none of the Company&#8217;s product candidates have been approved for marketing and sale, and the Company has not recorded any revenue from product sales. Generally, the Company&#8217;s ability to achieve profitability is dependent on its ability to successfully develop, acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> additional product candidates, conduct clinical trials for those product candidates, obtain regulatory approvals, and support commercialization activities for those product candidates. Any products developed will require approval of the U.S. Food and Drug Administration (FDA) or a foreign regulatory authority prior to commercial sale. The regulatory approval process is expensive, time-consuming, and uncertain, and any denial or delay of approval could have a material adverse effect on the Company. Even if approved, the Company&#8217;s products may not achieve market acceptance and will face competition from both generic and branded pharmaceutical products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During and subsequent to the year ended December&#160;31, 2022, the Company completed certain transactions as follows: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In January 2022, the Company received the third installment of&#160;</div>$<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P01_31_2022To01_31_2022_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis_FinancingAgreementFundingInstallmentsTwoMemberCBAYCbayfinancingAgreementFundingInstallmentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million of the Company&#8217;s Development Financing Agreement (the Financing Agreement) with ABW Cyclops SPV LP, an affiliate of Abingworth LLP (Abingworth), pursuant to which Abingworth committed to provide&#160;</div>$<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P01_31_2022To01_31_2022_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">75.0</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million in funding in&#160;</div><ix:nonFraction name="cbay:NumberOfFundingInstallments" contextRef="PAsOn01_31_2022_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis" unitRef="Unit_INSTALLMENTS" decimals="0" scale="0" format="ixt-sec:numwordsen">three </ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">equal quarterly installments. For further details, refer to<div style="font-style:italic;display:inline;"> Note 6&#8212;Development Financing Agreement.&#160;</div></div> </div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On January 6, 2023, the Company entered into a Collaboration and License Agreement with Kaken Pharmaceutical Co., Ltd (Kaken). Pursuant to the agreement, the Company granted Kaken an exclusive license to commercialize seladelpar for the treatment of PBC in Japan and received an upfront cash payment of&#160;</div>$<ix:nonFraction name="cbay:UpfrontCashPayment" contextRef="PAsOn01_06_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">34.2</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million. For further details, refer to <div style="font-style:italic;display:inline;">Note 13&#8212;Subsequent Events.&#160;</div></div> </div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;;text-indent: 0px;">On January&#160;23, 2023, the Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_23_2023To01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">11,821,428</ix:nonFraction> shares of common stock at $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">7.00</ix:nonFraction> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">per share and a pre-funded warrant to purchas</div>e <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,142,857</ix:nonFraction> shares of common stock at $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">6.9999</ix:nonFraction> <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">per share in a public equity offering, for total net proceeds of</div>&#160;</div>$<ix:nonFraction name="cbay:GrossProceedsFromPublicOffering" contextRef="P01_23_2023To01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">92.4</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million, after deducting underwriting and other offering expenses. For further details, refer to <div style="font-style:italic;display:inline;">Note 13&#8212;Subsequent Events.&#160;</div></div> </div></td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022, the Company had cash, cash equivalents and marketable securities totaling<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">135.5</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million. As the Company continues to advance its clinical studies of seladelpar, the Company believes its existing funds, together with the </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="cbay:UpfrontCashPayment" contextRef="PAsOn01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_KakenPharmaceuticalCo.LtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">34.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million upfront payment received from Kaken in January 2023 pursuant to the Collaboration and License Agreement and the </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_KakenPharmaceuticalCo.LtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">92.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million in net proceeds raised in connection with the January 2023 public equity offering, are sufficient to fund the Company&#8217;s current operating plan for at least twelve months from the issuance date of its financial </div></div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">statements. </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><ix:exclude> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">77</div></div> </ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_71088096" continuedAt="TextSelectionAppend_71088096_1"><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088096_1" continuedAt="TextSelectionAppend_71088096_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088096_2" continuedAt="TextSelectionAppend_71088096_3"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_71088096_3"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">The Company has <div style="display:inline;">historically </div>obtained, and expects to obtain in the future, additional <div style="display:inline;">financing </div>to fund its business strategy through: future equity offerings; debt financing; one or more possible licenses, collaborations or other similar arrangements with respect to development and/or commercialization rights of the Company&#8217;s product candidates; or a combination of the above. It is unclear if or when any such transactions will occur, on satisfactory terms or at all. The Company&#8217;s failure to raise capital as and when needed could have a negative impact on its financial condition and its ability to pursue its business strategies. If adequate funds are not available to the Company, it could have a material adverse effect on the Company&#8217;s business, results of operations, and financial condition. Market volatility could also adversely impact the Company&#8217;s ability to access capital when and as needed. Failure to raise sufficient capital when needed could require the Company to significantly delay, scale back or discontinue its product development programs or commercialization efforts or other aspects of its business plans, and its operating results and financial condition would be adversely </div></div></div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">affected. </div></div></div><br/></div></ix:continuation> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088094"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of Significant Accounting <div style="letter-spacing: 0px; top: 0px;;display:inline;">Policies</div> </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Basis of Presentation and Use of Estimates </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements are comprised of the accounts of CymaBay and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company has no unconsolidated subsidiaries or investments accounted for under the equity method. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These consolidated statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), which requires management to make informed estimates and assumptions that impact the amounts and disclosures reported in the consolidated financial statements and accompanying notes. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting estimates and assumptions are inherently uncertain. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ materially from those estimates and assumptions. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each reporting period and updated to reflect current information. </div></div></div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088070"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial instruments during the periods reported consist of cash, cash equivalents, marketable securities, accounts payable, certain accrued liabilities, and the development financing liability. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs and is as follows: </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2&#8212;Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3&#8212;Inputs that are significant to the fair value measurement and are unobservable (i.e. supported by little market activity), which requires the reporting entity to develop its own valuation techniques and </div></div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assumptions. </div></div></div> <ix:exclude> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">78</div><br/></div> </ix:exclude> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></ix:nonNumeric></div></div> <ix:continuation id="TextSelection_71088070" continuedAt="TextSelectionAppend_71088070_1"><ix:continuation id="TextSelection_71088094" continuedAt="TextSelectionAppend_71088094_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088094_1" continuedAt="TextSelectionAppend_71088094_2"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a><br/></div> </ix:exclude></ix:continuation></ix:continuation></div></div> <div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088094_2" continuedAt="TextSelectionAppend_71088094_3"><ix:continuation id="TextSelectionAppend_71088070_1"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of cash equivalents approximate their related fair value due to the short-term nature of these instruments. Cash equivalents are classified as level 1 under the fair value hierarchy. </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> following tables present the Company&#8217;s financial assets that are measured at fair value on a recurring basis using the above input categories (in thousands): </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents:</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CashEquivalentsMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,770</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CashEquivalentsMemberusgaapInvestmentTypeAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,770</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CashEquivalentsMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,770</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CashEquivalentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,770</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities:</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign commercial paper</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,121</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,121</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign corporate debt securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,807</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,807</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supranational debt securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_SupranationalDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,890</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_SupranationalDebtSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,890</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. agency securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_UsAgencySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,759</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_UsAgencySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,759</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasury securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,617</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,617</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total marketable securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,194</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,194</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,770</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,194</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">124,964</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CashEquivalentsMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,638</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CashEquivalentsMemberusgaapInvestmentTypeAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,638</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CashEquivalentsMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,638</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CashEquivalentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,638</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities:</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign commercial paper</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,760</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,760</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign corporate debt securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,535</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,535</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,522</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,522</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasury securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,979</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,979</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total marketable securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">68,796</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">68,796</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,638</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">68,796</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">154,434</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="padding: 0px;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="clear:both;max-height:0pt;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div> <div style="display: inline; background-color: white;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"> <div style="display: inline;"> <div style="top: 0px; letter-spacing: 0px; font-family: 'Times New Roman'; font-size: 10pt; display: inline;"> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> </div> </div> </div> </div> </div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="margin-top: 1em; margin-bottom: 1em"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimates the fair value of its money market funds, corporate debt, asset-backed securities, commercial paper, U.S. treasury and agency securities, and supranational debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s development financing liability is $<ix:nonFraction name="us-gaap:FinancialLiabilitiesFairValueDisclosure" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">79.5</ix:nonFraction>&#160;million. The development financing liability is classified as level 3 under the fair value hierarchy as its valuation is based on a discounted cash flow model that uses unobservable inputs such as the estimated timing of regulatory approval, attainment of certain sales milestones and the discount </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">rate. </div></div></div> </ix:continuation><ix:exclude> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">79 </div></div></div> </ix:exclude> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_71088094_3" continuedAt="TextSelectionAppend_71088094_4"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088094_4" continuedAt="TextSelectionAppend_71088094_5"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088094_5" continuedAt="TextSelectionAppend_71088094_6"><ix:nonNumeric name="cbay:CashEquivalentsAndInvestmentsPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, Cash Equivalents, and Marketable Securities </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with an original maturity of <ix:nonNumeric name="cbay:CashEquivalentMaturityDescription" contextRef="P01_01_2022To12_31_2022">90 days or less</ix:nonNumeric> at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking, interest-bearing, and money market funds. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company invests excess cash in marketable securities with high credit ratings. These securities consist primarily of corporate debt, commercial paper, asset-backed securities, U.S. treasury, U.S. agency securities and supranational debt securities and are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;available-for-sale.&#8221;</div></div> The Company considers marketable securities as short-term investments if the maturity date </div>is less than or equal to <ix:nonNumeric name="cbay:ShortTermInvestmentContractualMaturity" contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen">one year</ix:nonNumeric> from the balance sheet date. The Company considers marketable securities as long-term investments if the maturity date is in excess of <ix:nonNumeric name="cbay:ShortTermInvestmentContractualMaturity" contextRef="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis" format="ixt-sec:durwordsen">one year</ix:nonNumeric> from the balance sheet date.<br/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Realized </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">gains</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;and losses from the sale of marketable securities, if any, are calculated using the specific-identification method. Realized gains and losses and declines in value judged to be other-than-temporary are included in interest income or expense in the consolidated statements of operations and comprehensive loss. Unrealized holding gains and losses are reported in accumulated other comprehensive loss in the consolidated balance sheets. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. In determining whether a decline in market value is other-than-temporary, various factors are considered, including the cause, duration of time and severity of the impairment, any adverse changes in the investees&#8217; financial condition, and the Company&#8217;s intent and ability to hold the security for a period of time sufficient to allow for an anticipated recovery in market value.</div></div> </ix:nonNumeric></ix:continuation></div> </div> </div> </div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088094_6" continuedAt="TextSelectionAppend_71088094_7"><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Concentration of Risk </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, <div style="letter-spacing: 0px; top: 0px;;display:inline;">and market</div>able securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded on the balance sheet. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the consolidated balance sheets. <div style="background-color:rgba(255, 255, 255, .0);;display:inline;">The Company maintains deposits in excess of FDIC insured deposit limits with its financial institutions. </div></div> <div style="background-color:rgba(255, 255, 255, .0);;display:inline;"> </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an NDA filed with the FDA for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.&#160;</div></div> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property </div></div>and equipment are recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method, and the costs are amortized over the estimated useful lives of the respective assets, which are generally <span style="-sec-ix-hidden:hidden71088416">three</span> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen">seven years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the useful lives or the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> term of the related lease. Maintenance and repair costs are charged as expense in the consolidated statements of operations and comprehensive loss as incurred. </div> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088153"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Lived Assets </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company reviews the carrying value long-lived assets, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> operating lease assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assets </div></div></div> <ix:exclude> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">80 </div></div></div> </ix:exclude> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;;text-indent: 0px;"></div></ix:exclude> </ix:nonNumeric></ix:continuation></div> </div> <ix:continuation id="TextSelection_71088153" continuedAt="TextSelectionAppend_71088153_1"><ix:continuation id="TextSelectionAppend_71088094_7" continuedAt="TextSelectionAppend_71088094_8"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088094_8" continuedAt="TextSelectionAppend_71088094_9"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088153_1" continuedAt="TextSelectionAppend_71088153_2"><ix:continuation id="TextSelectionAppend_71088094_9" continuedAt="TextSelectionAppend_71088094_10"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></ix:continuation></ix:continuation></div> </div> </div> </div> </div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088094_10" continuedAt="TextSelectionAppend_71088094_11"><ix:continuation id="TextSelectionAppend_71088153_2"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> may not be fully recoverable. If a change in circumstance occurs, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. If cash flows cannot be separately and independently identified for a single asset, the Company will determine whether impairment has occurred for the group of assets for which the Company can identify the projected cash flows. If the carrying values are in excess of undiscounted expected future cash flows, the Company measures any impairment by comparing the fair value of the asset or asset group to its carrying value. There were no indicators of impairment of long-lived assets for any periods <div style="display:inline;">presented</div>.</div></div></div></ix:continuation> <ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The Company has one lease, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> operating lease agreement for its corporate office. The Company recognizes a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. The Company determines whether an arrangement is or contains a lease at contract inception. Operating leases are included in operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, other accrued liabilities, and long-term portion of operating lease liabilities in the Company&#8217;s consolidated balance sheets at December&#160;31, 2022 and 2021. Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date. The incremental borrowing rate represents the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company considers a lease term to be the noncancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets also include any lease payments made and exclude lease incentives. Lease expense is recognized on a straight-line basis over the expected lease term. The Company has elected to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for its leased assets and accounts for all lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components of its agreements as a single lease component. The Company does not record leases on its consolidated balance sheets when a lease has a term of one year or less. </div></div> </ix:nonNumeric><div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"></div> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088048"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Expenses</div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses consist of costs incurred in identifying, developing, and testing product candidates. These expenses consist primarily of costs for research and development personnel, including related stock-based compensation; contract research organizations (CRO) and other third parties that assist in managing, monitoring, and analyzing clinical trials; investigator and site fees; laboratory services; consultants; contract manufacturing services; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies, including materials; and allocated expenses, such as depreciation of assets, and facilities and information technology that support research and development activities. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are recorded as prepaid assets until the goods are received or services are rendered. Such payments are evaluated for current or long-term classification based on when they will be realized. Additionally, if expectations change such that the Company does not expect goods to be delivered or services to be rendered, such prepayments are charged to expense to the extent they are nonrefundable. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records expenses related to clinical studies and manufacturing development activities based on its estimates of the services received and efforts expended pursuant to contracts with multiple CROs and manufacturing vendors that conduct and manage these activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical trial milestones. In expensing service fees, the Company estimates the time period over which services will be performed, enrollment of subjects, number of </div></div></div> <ix:exclude> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">81 </div></div></div> </ix:exclude> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_71088048" continuedAt="TextSelectionAppend_71088048_1"><ix:continuation id="TextSelectionAppend_71088094_11" continuedAt="TextSelectionAppend_71088094_12"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088094_12" continuedAt="TextSelectionAppend_71088094_13"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088094_13" continuedAt="TextSelectionAppend_71088094_14"><ix:continuation id="TextSelectionAppend_71088048_1" continuedAt="TextSelectionAppend_71088048_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company&#8217;s estimate, the Company will adjust the accrued or prepaid expense balance accordingly. In 2022 and 2021, there have been no material differences from the Company&#8217;s estimates to the amounts actually incurred. </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> </ix:continuation><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><ix:continuation id="TextSelectionAppend_71088048_2"></ix:continuation> </div> <ix:nonNumeric name="cbay:DevelopmentFinancingAgreementPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Development Financing Agreement </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for the Development Financing Agreement with Abingworth as a debt instrument. Accordingly, the Company has recorded payments received under the Financing Agreement as part of a development financing liability in the Company&#8217;s consolidated balance sheet. The liability is recorded at amortized cost and accreted to the contractual success fee amounts based on the estimated timing of regulatory approval and attainment of certain sales milestones using an imputed interest rate. Certain transaction fees incurred specifically to complete the Financing Agreement were capitalized and recorded as a reduction to the carrying amount of the development financing liability and are being amortized to interest expense using the effective interest rate method. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are several factors that could affect the estimated timing of regulatory approval and attainment of sales milestones, some of which are not entirely within the Company&#8217;s control. Therefore, the Company periodically reassesses the estimated timing of regulatory approval and attainment of sales milestones, and the expected contractual success fee payments due therefrom. If the timing and/or amount of such expected payments is materially different than original estimates, the Company will prospectively adjust the accretion of the development financing liability and the imputed interest rate. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company identified certain contingent repayment features in the Financing Agreement that are required to be bifurcated from the debt host instrument as embedded derivative liabilities; however, the Company determined the fair value of these features, both individually and in the aggregate, was immaterial at inception and as of December&#160;31, 2022. The fair value of these features will be assessed at each reporting date and will be marked to market, if material. To determine the amount to record for the embedded derivative liabilities, the Company must assess the probability of occurrence of various potential <div style="letter-spacing: 0px; top: 0px;;display:inline;">future </div>events that could affect the timing and/or amount of future cash flows related to the Financing Agreement. </div></div></div> </ix:nonNumeric> <ix:nonNumeric name="cbay:PrefundedWarrantsPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded</div> Warrants </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Company&#8217;s public equity offering co<div style="letter-spacing: 0px; top: 0px;;display:inline;">mpleted in </div>November 2021, the Company issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn11_22_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,125,000</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn11_22_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">3.9999</ix:nonFraction> per share. These <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants have an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn11_22_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>per share, were fully exercisable upon issuance, and have no expiration date. The Company determined that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants should be equity classified because they are freestanding financial instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. In addition, such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants do not provide any guarantee of value or return. Accordingly, the proceeds from the issuance of the warrants were recorded as additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital on the Company&#8217;s consolidated balance sheet as of December&#160;31, 2022. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 9&#8212;Stockholders&#8217; Equity</div></div> for additional </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">information. </div></div></div> </ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088156"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-Based Compensation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation is measured at fair value on the grant date of the award. Compensation cost is recognized as expense on a straight-line basis over the vesting period for options with service conditions and forfeitures are accounted for as they occur. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock option awards. The determination of fair value for stock-based awards using an option-pricing model requires management to make certain assumptions regarding subjective input variables such as expected term, dividends, volatility and risk-free rate. If actual results are not consistent with the </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:exclude> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;">82</div><br/></div> </ix:exclude> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></ix:continuation></div></div> <ix:continuation id="TextSelection_71088156" continuedAt="TextSelectionAppend_71088156_1"><ix:continuation id="TextSelectionAppend_71088094_14" continuedAt="TextSelectionAppend_71088094_15"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088094_15" continuedAt="TextSelectionAppend_71088094_16"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088094_16" continuedAt="TextSelectionAppend_71088094_17"><ix:continuation id="TextSelectionAppend_71088156_1"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company&#8217;s assumptions used in making these estimates, the Company may be required to increase or decrease compensation expense, which could be material to the Company&#8217;s results of operations.</div></div></div> </ix:continuation><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <div style="display:inline;">Company </div>utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and the tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when it is more likely than not that all or part of a deferred tax asset will not be realized. When the Company establishes or reduces the valuation allowance related to the deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination based on the technical merits of the position. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to file federal and state income tax returns in the United States. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect that could affect the amount of tax paid to these jurisdictions. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records interest related to income tax reserves, if any, as interest expense, and any penalties would be recorded as other expense in the consolidated statements of operations and comprehensive loss. </div> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Comprehensive Loss </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss includes net loss and net unrealized gains and losses on marketable securities, which are presented in a single continuous statement. Other comprehensive (loss) gain is also disclosed in the consolidated balance sheets and statements of stockholders&#8217; equity in accumulated other comprehensive income (loss), and is stated net of related tax effects, if any. <br/></div> </ix:nonNumeric> </ix:continuation></div></div> </div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088094_17" continuedAt="TextSelectionAppend_71088094_18"><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088144"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss Per Common Share </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per share of common stock is based on the weighted average number of shares of common stock and common stock equivalents outstanding during the period. The weighted-average common shares outstanding as of December 31, 2022 and 2021 includes pre-funded warrants to purchase up to&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn12_31_2022_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,125,000</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">shares of common stock that were issued in connection with the November 2021 public offering, as </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">discussed in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note&#160;9&#8212;Stockholders&#8217; Equity</div></div>. Diluted </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> net loss per share of common stock is calculated as the weighted average number of shares of common stock outstanding adjusted to include the assumed exercises of stock options, if dilutive. In all periods presented, the Company&#8217;s outstanding stock options and incentive awards were excluded from the calculation of net loss per share because the effect would be antidilutive. </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>83</ix:exclude></div><br/></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_71088144" continuedAt="TextSelectionAppend_71088144_1"><ix:continuation id="TextSelectionAppend_71088094_18" continuedAt="TextSelectionAppend_71088094_19"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088094_19" continuedAt="TextSelectionAppend_71088094_20"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </ix:exclude></ix:continuation> </ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088094_20"><ix:continuation id="TextSelectionAppend_71088144_1"><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share amounts): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div></div></td>
<td style="vertical-align: bottom; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">106,001</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">89,998</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of:</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock shares outstanding</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="cbay:WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">84,679,063</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="cbay:WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">70,712,865</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded warrants outstanding</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="cbay:WeightedAverageNumberOfPreFundedWarrantsOutstanding" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,125,000</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="cbay:WeightedAverageNumberOfPreFundedWarrantsOutstanding" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">342,466</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 63%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">87,804,063</ix:nonFraction></ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">71,055,331</ix:nonFraction></ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">1.21</ix:nonFraction></ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">1.27</ix:nonFraction></ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088132"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock options</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_EmployeeOrNonEmployeeStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,930</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_EmployeeOrNonEmployeeStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,791</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Incentive awards</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022_IncentiveStockAwardsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021_IncentiveStockAwardsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Total</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,031</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,892</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> </ix:nonNumeric></ix:continuation> <ix:continuation id="TextSelection_71088132"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> </ix:continuation> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Issued Accounting Pronouncements </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> Financial Instruments&#8212;Credit Losses (Topic 326): <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Measurement of Credit Losses on Financial Instruments</div></div>, an amendment which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. Accordingly, these financial assets will be presented at the net amount expected to be collected. The amendment also requires that credit losses related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. In November 2019, FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2019-10,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842)</div></div>, which deferred the adoption deadline for smaller reporting companies to fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years. Early adoption is permitted, and entities are required to use a modified retrospective approach, with certain exceptions. The Company intends to adopt this ASU on January&#160;1, 2023 and does not expect a material impact to its consolidated financial statements and related disclosures. </div></div></ix:nonNumeric></ix:continuation> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">84 </div></div></div> </div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <ix:nonNumeric name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088091"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Marketable <div style="letter-spacing: 0px; top: 0px;;display:inline;">Securities</div> </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div> <ix:nonNumeric name="us-gaap:MarketableSecuritiesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">Marketable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities consist of the following (in&#160;thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/>Cost</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Gains</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Losses</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/>Fair Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Money market funds</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,770</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,770</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,770</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,770</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Current marketable securities:</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">U.S. and foreign commercial paper</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,121</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,121</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">U.S. and foreign corporate debt securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,964</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">157</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,807</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Supranational debt securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_SupranationalDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,946</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_SupranationalDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">56</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_SupranationalDebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,890</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">U.S. agency securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_UsAgencySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,782</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_UsAgencySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_UsAgencySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_UsAgencySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,759</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">U.S. treasury securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,707</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">92</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">23,617</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Total current marketable securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,520</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">344</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,194</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2022_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">125,290</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2022_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2022_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">344</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">124,964</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/>Cost</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/>Unrealized<br/>Gains</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/>Unrealized<br/>Losses</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/>Fair Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"></div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,638</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,638</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash equivalents</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,638</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,638</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current marketable securities:</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign commercial paper</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,760</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,760</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign corporate debt securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,476</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,468</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,524</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,522</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasury securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,982</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,979</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current marketable securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">60,742</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">60,729</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> marketable securities:</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. corporate debt securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,067</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_NoncurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_NoncurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_NoncurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,068</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total marketable securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="PAsOn12_31_2021_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">154,447</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="PAsOn12_31_2021_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="PAsOn12_31_2021_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2021_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">154,435</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-align: center;;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> </ix:nonNumeric> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s commercial paper and corporate debt securities consist of U.S. and foreign securities from issuers in various sectors, including finance and industry and have similar credit quality and risk characteristics. The Company&#8217;s asset-backed securities are collateralized by credit card receivables and have investment-grade ratings. The Company&#8217;s government securities are issued by the U.S. treasury and certain U.S. government-backed agencies. Supranational debt securities consist of securities issued with funding from various national governments. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were <ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="P01_01_2021To12_31_2021_DebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="P01_01_2022To12_31_2022_DebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> realized gains and losses for the years ended December&#160;31, 2022 and 2021. <ix:nonFraction name="cbay:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments" contextRef="PAsOn12_31_2021_DebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="cbay:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments" contextRef="PAsOn12_31_2022_DebtSecuritiesMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">None</ix:nonFraction></ix:nonFraction><div style="display:inline;">&#160;of our investments have been in a continuous unrealized loss position for more than 12 months as of December 31, 2022 and 2021. The Company may sell certain of its marketable securities prior to their stated maturities for reasons including, but not limited to, managing liquidity, credit risk, duration and asset allocation.&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>85</ix:exclude></div></div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div></div> <ix:continuation id="TextSelection_71088091" continuedAt="TextSelectionAppend_71088091_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation> <ix:continuation id="TextSelectionAppend_71088091_1" continuedAt="TextSelectionAppend_71088091_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_71088091_2" continuedAt="TextSelectionAppend_71088091_3"><div style="display:inline;"></div></ix:continuation></div></div> </div></div> <div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088091_3"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:nonNumeric name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088928"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table shows the fair value of the Company&#8217;s marketable securities, by contractual maturity, as of December&#160;31, 2022 (in thousands): </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="vertical-align: bottom; width: 7%;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 83%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due less than 1 year</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractualObligationDueInNextTwelveMonths" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,194</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 83%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due between 1 and 2 years</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ContractualObligationDueInSecondYear" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 83%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total fair value</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,194</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> </ix:nonNumeric></ix:continuation> <ix:continuation id="TextSelection_71088928"><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> </ix:continuation> <ix:nonNumeric name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Certain Balance Sheet Items </div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are recorded at cost and consist of the following (in thousands):</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,429</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,429</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Office and computer equipment</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_OfficeAndComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">290</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_OfficeAndComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">290</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Purchased software</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">44</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">44</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Furniture and fixtures</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">687</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">539</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt; width: 66%;"><div style="margin-top: 0px; margin-bottom: 0px; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt; width: 11%;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt; width: 11%;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,450</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,302</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Less: Accumulated depreciation and amortization</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,749</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,124</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">701</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,178</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense for the years ended December&#160;31, 2022 and 2021 was approximately $<ix:nonFraction name="us-gaap:DepreciationExpenseOnReclassifiedAssets" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DepreciationExpenseOnReclassifiedAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million, respectively, and was recorded straight-line in both research and development expense and general and administrative expense in the consolidated statements of operations and comprehensive loss. All the Company&#8217;s property and equipment is located in the U.S. </div> <ix:nonNumeric name="cbay:ScheduleOfOtherAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued liabilities consist of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued compensation</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,779</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,986</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional fees and other</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="cbay:AccruedProfessionalFeesAndOtherCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,372</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="cbay:AccruedProfessionalFeesAndOtherCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,333</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of operating lease liability</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">664</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">567</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other accrued liabilities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="cbay:AccruedLiabilitiesForPurchaseOfProductiveAssets" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,815</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="cbay:AccruedLiabilitiesForPurchaseOfProductiveAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,886</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-License</div> Agreement </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Janssen Pharmaceutica NV </div></div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In June&#160;2006, the Company entered into an exclusive worldwide, royalty-bearing license to seladelpar and certain other PPAR<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">d</div> compounds (the PPAR<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">d</div> Products) with Janssen Pharmaceutica NV (Janssen NV), with the right to grant sublicenses to third parties to make, use and sell such PPAR<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">d</div> Products. Under the terms of the agreement, the Company has full control and responsibility over the research, development and registration of any PPAR<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">d</div> Products and is required to use diligent efforts to conduct all such activities. Janssen NV has the sole responsibility for the preparation, filing, prosecution, maintenance of, and defense of the patents with respect to, the PPAR<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">d</div> Products. Under the terms of the agreement Janssen NV is entitled to receive up to an </div><ix:nonFraction name="cbay:RoyaltyPercentageBasedOnNetSales" contextRef="P06_01_2006To06_30_2006_JanssenPharmaceuticalNVMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.0</ix:nonFraction>% royalty on net sales of PPAR<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">d</div> Products. <ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2021_JanssenPharmaceuticalNVMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2022_JanssenPharmaceuticalNVMembersrtCounterpartyNameAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction> amounts were incurred or accrued for this agreement as of and for the years ended <div style="letter-spacing: 0px; top: 0px;;display:inline;">December&#160;</div>31, 2022 and <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </ix:nonNumeric> <div style="letter-spacing: 0px; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="cbay:DisclosureOfDevelopmentFinancingTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088890"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Development Financing Agreement </div></div></div></div> <div style="letter-spacing: 0px; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;30, 2021 (the Effective Date), the Company entered into a Development Financing Agreement (the Financing Agreement) with Abingworth to provide funding to the Company to support its development of seladelpar for the treatment of primary biliary cholangitis (PBC). The Financing Agreement provided the Company up to </div></div>$<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn07_30_2021_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">75.0</ix:nonFraction>&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million in base funding</div>, of which $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P08_31_2021To08_31_2021_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis_InstallmentFundingNumberOneMemberCBAYNumberOfInstallmentFundingAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction>&#160;million was provided in August 2021, $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P11_30_2021To11_30_2021_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis_InstallmentFundingNumberTwoMemberCBAYNumberOfInstallmentFundingAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction>&#160;million was provided in November 2021, and $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P01_31_2022To01_31_2022_InstallmentFundingNumberThreeMemberCBAYNumberOfInstallmentFundingAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction>&#160;million was provided in <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">January 2022. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The use of proceeds from the funding is limited to PBC &#8220;Development Program&#8221; costs incurred or paid as defined in the Financing Agreement. In return, the Company will pay to Abingworth:</div></div> </ix:nonNumeric></div></div> </div></div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelection_71088890" continuedAt="TextSelectionAppend_71088890_1"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) contingent upon the first to occur of regulatory approval of seladelpar for the treatment of PBC in the U.S., U.K., Germany, Spain, Italy or France (Regulatory Approval), fixed success payments equal to <ix:nonNumeric name="cbay:DescriptionOfPercentageFixedSuccessPayments" contextRef="P08_31_2021To08_31_2021">2.0</ix:nonNumeric>x of the funding provided, consisting of $<ix:nonFraction name="us-gaap:RepaymentsOfLinesOfCredit" contextRef="P08_31_2021To08_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction>&#160;million payable in 90 days after the Regulatory Approval and thereafter, payments due on the first six anniversaries of the Regulatory Approval in the amounts of $<ix:nonFraction name="cbay:AnniversaryPaymentsDueYearOne" contextRef="P08_31_2021To08_31_2021_FixedSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction>&#160;million, $<ix:nonFraction name="cbay:AnniversaryPaymentsDueYearTwo" contextRef="P08_31_2021To08_31_2021_FixedSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">22.5</ix:nonFraction>&#160;million, $<ix:nonFraction name="cbay:AnniversaryPaymentsDueYearThree" contextRef="P08_31_2021To08_31_2021_FixedSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">22.5</ix:nonFraction>&#160;million, $<ix:nonFraction name="cbay:Anniversarypaymentsdueyearfour" contextRef="P08_31_2021To08_31_2021_FixedSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction>&#160;million, $<ix:nonFraction name="cbay:AnniversaryPaymentsDueYearFive" contextRef="P08_31_2021To08_31_2021_FixedSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">27.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="cbay:AnniversaryPaymentsDueYearSix" contextRef="P08_31_2021To08_31_2021_FixedSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">27.5</ix:nonFraction>&#160;million, respectively and </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) variable success payments equal to <ix:nonNumeric name="cbay:DescriptionOfPercentageVariableSuccessPayments" contextRef="P08_31_2021To08_31_2021">1.1</ix:nonNumeric>x of the funding provided, consisting of sales milestone payments of (x) $<ix:nonFraction name="cbay:PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne" contextRef="P08_31_2021To08_31_2021_VariableSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">17.5</ix:nonFraction>&#160;million and $<ix:nonFraction name="cbay:PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo" contextRef="P08_31_2021To08_31_2021_VariableSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">27.5</ix:nonFraction>&#160;million, respectively upon first reaching certain cumulative U.S. product sales thresholds, and (y) $<ix:nonFraction name="cbay:PaymentsUponReachingProductSalesRunRate" contextRef="P08_31_2021To08_31_2021_VariableSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">37.5</ix:nonFraction>&#160;million upon first reaching a specified U.S. product sales run rate. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Promptly following receipt of Regulatory Approval, the Company is required to execute a note agreement and deliver a promissory note to Abingworth within two business days to convert the fixed and variable success payments into a note payable. At the time that Abingworth receives, collectively, an aggregate of <ix:nonNumeric name="cbay:DescriptionOfAggregateReturnFromTheFundsProvided" contextRef="P08_31_2021To08_31_2021">3.1</ix:nonNumeric>x of the funding provided (approximately $<ix:nonFraction name="cbay:AggregateReturnPercentageFromTheFundsProvided" contextRef="P08_31_2021To08_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">232.5</ix:nonFraction>&#160;million), the Company&#8217;s payment obligations under the Financing Agreement will be fully satisfied. The Company has the option to satisfy its payment obligations to Abingworth upon Regulatory Approval, or a change of control of the Company, by paying an amount equal to the remaining payments payable to Abingworth subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single-digit</div> discount rate. Upon a change of control of the Company, an acceleration payment of <ix:nonNumeric name="cbay:PercentageOfAcceleratePaymentPayableOnFundsProvided" contextRef="P08_31_2021To08_31_2021">1.35</ix:nonNumeric>x of the funding provided is payable, net of payments already made to Abingworth and creditable against future payments to Abingworth. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Financing Agreement, the Company granted Abingworth a security interest in all its assets (other than intellectual property not related to seladelpar), provided that the Company is permitted to incur certain indebtedness. The security interest will terminate when the Company has paid Abingworth <ix:nonNumeric name="cbay:DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement" contextRef="P08_31_2021To08_31_2021">2.0</ix:nonNumeric>x<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>of the funding provided or upon termination of the Financing Agreement. </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Financing Agreement provides for negative, affirmative and additional covenants, which the Company must comply with for the duration of the Financing Agreement term. As of December&#160;31, 2022, the Company was in compliance with all covenants stipulated in the Financing Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In certain instances, upon the termination of the Financing Agreement, the Company will be obligated to pay Abingworth a multiple of the amounts paid to the Company under the Financing Agreement, including specifically: </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <ix:nonFraction name="cbay:PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement" contextRef="PAsOn12_31_2021_AbwCyclopsSpvLpMembersrtCounterpartyNameAxis_FinancingAgreementTerminationEventConditionOneMemberCBAYFinancingAgreementTerminationEventConditionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">310</ix:nonFraction>% of such amounts in the event that Abingworth terminates the Financing Agreement due to (x)&#160;a Fundamental Breach, as defined in the Financing Agreement, (y)&#160;the bankruptcy of the Company, or (z)&#160;a safety concern resulting from gross negligence on the part of the Company or due to a safety concern that was material on the Effective Date and the material data showing such safety concern was not publicly known, disclosed to Abingworth, or in the diligence room made available to <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Abingworth, </div></div></div><ix:exclude> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">87 </div></div></div> </ix:exclude> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:continuation></div></div><ix:continuation id="TextSelectionAppend_71088890_1" continuedAt="TextSelectionAppend_71088890_2"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088890_2" continuedAt="TextSelectionAppend_71088890_3"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088890_3" continuedAt="TextSelectionAppend_71088890_4"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">(ii) <ix:nonFraction name="cbay:PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement" contextRef="PAsOn12_31_2021_AbwCyclopsSpvLpMembersrtCounterpartyNameAxis_FinancingAgreementTerminationEventConditionTwoMemberCBAYFinancingAgreementTerminationEventConditionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">200</ix:nonFraction>% of such amounts in the event the Financing Agreement is terminated due to (x)&#160;Material Breach, as defined in the Financing Agreement, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by the Company or (y)&#160;the security interests of Abingworth being invalidated or terminated other than as set forth in the Financing Agreement, and </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iii)</div></div>&#160;<ix:nonFraction name="cbay:PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement" contextRef="PAsOn12_31_2021_AbwCyclopsSpvLpMembersrtCounterpartyNameAxis_FinancingAgreementTerminationEventConditionThreeMemberCBAYFinancingAgreementTerminationEventConditionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of such amounts in the event of certain irresolvable disagreements within the executive review committee overseeing the Company&#8217;s development of seladelpar. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if, following certain terminations, the Company continues to develop seladelpar for the treatment of PBC and obtains regulatory approval, it will make the payments to Abingworth as if the Financing Agreement had not been terminated, less any payments made upon termination. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall not be obligated to make any payments to Abingworth under certain instances of technical or regulatory failure of the PBC development program as defined in the Financing Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the arrangement, an executive review committee was established between the Company and Abingworth to discuss the Company&#8217;s development of seladelpar.<br/></div><div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><br/></div></ix:continuation></div></div> </div></div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088890_4" continuedAt="TextSelectionAppend_71088890_5"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated the Financing Agreement and determined it to be a research and development funding arrangement with the characteristics of a debt instrument as the transfer of financial risk to Abingworth was not considered substantive and genuine. Accordingly, the Company has recorded payments received under the Financing Agreement as part of a development financing liability in its consolidated balance sheets. The Company accounts for the overall development financing liability at amortized cost based on the estimated timing of regulatory approval and attainment of certain sales milestones and the contractual success fee payments expected to be due therefrom, as discounted using an imputed interest rate. The development financing liability is being accreted as interest expense to its expected future repayment amount over the expected life of the agreement using the effective interest rate method. Certain legal and financial advisory fees incurred specifically to complete the Financing Agreement were capitalized and recorded as a reduction to the carrying amount of the development financing liability and are also being amortized to interest expense using the effective interest method. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are several factors that could affect the estimated timing of regulatory approval and attainment of sales milestones, some of which are not entirely within the Company&#8217;s control. Therefore, the Company periodically reassesses the estimated timing of regulatory approval and attainment of sales milestones, and the expected contractual success fee payments due therefrom. If the timing and/or amount of such expected payments is materially different than original estimates, the Company will prospectively adjust the accretion of the development financing liability and the imputed interest rate. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company identified certain contingent repayment features in the agreement that are required to be bifurcated from the debt host instrument as embedded derivative liabilities; however, the fair value of these features was immaterial at the Effective Date and as of December&#160;31, 2022 and 2021. The fair value of the embedded derivative liabilities will be assessed at subsequent reporting dates if material. </div></div></div><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of the changes in the carrying value of the Company&#8217;s development financing liability (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 88%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 0px;">
<td style="width: 85%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 0px;">
<td style="width: 85%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 0px;">
<td style="width: 85%;"></td>
<td style="vertical-align: bottom; width: 6%;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Balance at December 31, 2021</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,320</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Cash received</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Accretion of development financing liability</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="cbay:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,907</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 85%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Balance at December 31, 2022</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">90,227</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 85%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> </ix:nonNumeric> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the development financing liability was classified as a long-term liability as the Company expects the related repayments to take place between 2024 and 2030 for purposes of the <div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">model used to </div></div></div> <ix:exclude> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">88 </div></div></div> </ix:exclude> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:continuation></div></div><ix:continuation id="TextSelectionAppend_71088890_5" continuedAt="TextSelectionAppend_71088890_6"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088890_6" continuedAt="TextSelectionAppend_71088890_7"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088890_7"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin-left: 0in;"></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin-left: 0in;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">calc</div></div>ulate its carrying value. The imputed interest rate on the unamortized portion <div style="letter-spacing: 0px; top: 0px;;display:inline;">of </div>the development financing liability was approximately <ix:nonFraction name="cbay:PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">19.2</ix:nonFraction>% as of December&#160;31, 2022.</div></ix:continuation><div style="margin-top: 1em; margin-bottom: 1em"></div><div style="margin-top: 1em; margin-bottom: 1em"></div><ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Leases </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has <ix:nonFraction name="cbay:NumberOfLeasedFacilitiesOperatingLeases" contextRef="PAsOn12_31_2022_LeaseFacilityMemberusgaapLeaseContractualTermAxis" unitRef="Unit_Facility" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> operating lease pertaining to <ix:nonFraction name="cbay:AreaOfOfficeSpace" contextRef="P01_01_2022To12_31_2022_LeaseFacilityMemberusgaapLeaseContractualTermAxis" unitRef="Unit_sqft" decimals="0" scale="0" format="ixt:num-dot-decimal">17,698</ix:nonFraction> square feet of corporate office space in Newark, California pursuant to a lease agreement that commenced <ix:nonNumeric name="cbay:LeaseStartDate" contextRef="P01_01_2022To12_31_2022_LeaseFacilityMemberusgaapLeaseContractualTermAxis" format="ixt:date-monthname-day-year-en">January 16, 2014</ix:nonNumeric> and was amended on April&#160;16, 2018. At December&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s lease portfolio had a weighted average remaining term of <ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2022" format="ixt-sec:duryear">1.1</ix:nonNumeric> years, and <ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2021" format="ixt-sec:duryear">2.1</ix:nonNumeric> years, respectively, with an <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="P01_01_2022To12_31_2022">option to extend for an additional 5 years</ix:nonNumeric>. The lease requires monthly lease payments that are subject to annual increases throughout the lease term. The optional period has not been considered in the determination of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets or lease liabilities associated with this lease as the Company did not consider it reasonably certain it would exercise the option. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company cannot determine the implicit rate in its lease, and therefore the Company uses its incremental borrowing rate of <ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">12.6</ix:nonFraction>% as the <span style="-sec-ix-hidden:hidden71088836">discount</span> <span style="-sec-ix-hidden:hidden71088837">rate</span> when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a particular currency environment. The Company used an incremental borrowing rate as of the date of adoption for leases that commenced prior to January&#160;1, 2019. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&#160;31, 2022 and 2021, the Company incurred $<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2021To12_31_2021_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction>&#160;million, respectively,&#160;of lease costs included in operating expenses in the consolidated statements of operations and comprehensive loss in relation to its operating lease, a portion of which was variable rent expense and not included within the measurement of the Company&#8217;s operating ROU assets and lease liabilities. The variable rent expense consists primarily of the Company&#8217;s proportionate share of operating expenses, property taxes, and insurance and is classified as lease expense due to the Company&#8217;s election to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. Short-term lease costs were not material. At December&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset totaled $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>&#160;million, respectively, and the operating lease liability totaled $<ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.3</ix:nonFraction>&#160;million, respectively. As of December&#160;31, 2022, the short-term portion of the operating lease liability was <ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2022To12_31_2022_OperatingExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million and is contained within other accrued liabilities on the balance sheet, with an immaterial amount reported on the balance sheet as the long-term portion of operating lease liability. <br/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><br/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 92%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 0px;">
<td style="width: 89%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Year ending December&#160;31,</div></td>
<td style="vertical-align: bottom; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">2023</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">707</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">2024</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 89%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 89%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total undiscounted future minimum lease payments</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">737</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 89%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 89%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 89%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease liability</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">694</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 89%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current portion of operating lease liability</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">664</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 89%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 89%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term portion of lease liability</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 89%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric></ix:nonNumeric> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088087"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Commitments and Contingencies </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Indemnification </div></div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification, including indemnification associated </div></div></div> <ix:exclude> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">89 </div></div></div> </ix:exclude> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div></div> <ix:continuation id="TextSelection_71088087" continuedAt="TextSelectionAppend_71088087_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088087_1" continuedAt="TextSelectionAppend_71088087_2"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088087_2"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">with product liability or infringement of intellectual property rights. The Company&#8217;s exposure under these agreements is unknown because it involves future claims that may be made against the Company that may be, but have not yet been, made. To date, the Company has not paid any claims or been required to defend any action related to these indemnification obligations, and no amounts have been accrued in the accompanying consolidated balance sheets related to these indemnification obligations. </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has agreed to indemnify its officers and directors for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments the Company could be required to make under this indemnification is unlimited; however, the Company maintains insurance policies that may limit its exposure and may enable it to recover a portion of any future amounts paid. Assuming <div style="letter-spacing: 0px; top: 0px;;display:inline;">the</div> applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits, and other policy provisions, the Company believes the fair value of these indemnification obligations is not material. Accordingly, the Company has <ix:nonFraction name="cbay:IndemnificationLiability" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="cbay:IndemnificationLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t recognized any liabilities relating to these obligations as of December&#160;31, 2022 and 2021. No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case the Company may incur substantial liabilities as a result of these indemnification obligations. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Genfit Litigation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On <ix:nonNumeric name="us-gaap:LossContingencyLawsuitFilingDate" contextRef="P01_15_2021To01_15_2021">January 15, 2021</ix:nonNumeric>, <ix:nonNumeric name="us-gaap:LossContingencyNameOfPlaintiff" contextRef="P01_15_2021To01_15_2021">Genfit S.A</ix:nonNumeric>. (Genfit) filed a complaint against the Company in the U.S. District Court for the Northern District of California, <ix:nonNumeric name="us-gaap:LossContingencyAllegations" contextRef="P01_15_2021To01_15_2021">alleging misappropriation of trade secrets and related causes of action based on the Company&#8217;s receipt of a Genfit protocol synopsis for Genfit&#8217;s Phase 3 clinical trial of its drug candidate elafibranor in patients with primary biliary cholangitis</ix:nonNumeric>. An Amended Complaint was filed on <ix:nonNumeric name="us-gaap:LossContingencyLawsuitFilingDate" contextRef="P01_01_2022To12_31_2022_PendingLitigationMemberusgaapLitigationStatusAxis">April 16, 2021</ix:nonNumeric> with substantially the same allegations. Genfit <div style="letter-spacing: 0px; top: 0px;;display:inline;">was </div>seek<div style="letter-spacing: 0px; top: 0px;;display:inline;">ing</div> damages in an unspecified amount as well as injunctive relief. <ix:nonNumeric name="us-gaap:LossContingencyActionsTakenByCourtArbitratorOrMediator" contextRef="P03_12_2021To03_12_2021">On March 12, 2021, the Court granted a Temporary Restraining Order (later converted to a Preliminary Injunction), prohibiting the Company from accessing or disseminating the protocol synopsis, using any Genfit trade secrets contained therein or destroying any evidence related thereto.</ix:nonNumeric> The Company filed a Motion to Dismiss the Amended Complaint that was granted on September&#160;9, 2021, with leave to amend. Genfit filed a Second Amended Complaint on October&#160;15, 2021 with substantially the same allegations and claims for relief as in the original complaint. The Company filed a Motion to Dismiss most of the Second Amended Complaint that was granted on January&#160;21, 2022, without further leave to amend. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">What remained in the complaint was an alleged misappropriation of the protocol synopsis as a whole. The Company filed its Answer to what remained of the Second Amended Complaint on February&#160;4, 2022</div></div>.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><ix:nonNumeric name="us-gaap:LossContingencyActionsTakenByDefendant" contextRef="P01_15_2021To01_15_2021">On February 21, 2023, the parties entered into a Settlement Agreement and the action was dismissed with prejudice. The Company did not admit to any liability and the litigation has been resolved completely.</ix:nonNumeric></div> </ix:continuation> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088150"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>. Stockholders&#8217; Equity </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preferred and Common Stock Authorized </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock as of December&#160;31, 2022 and 2021, and <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">200,000,000</ix:nonFraction></ix:nonFraction> shares of common stock as of December&#160;31, 2022 and 2021.</div> <ix:exclude> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">90</div><br/></div> </ix:exclude> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div></div> <ix:continuation id="TextSelection_71088150" continuedAt="TextSelectionAppend_71088150_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088150_1" continuedAt="TextSelectionAppend_71088150_2"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088150_2" continuedAt="TextSelectionAppend_71088150_3"></ix:continuation></div></div> </div></div> <div> <div style="background-color:white;display: inline;"> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088150_3"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Common Stock Reserved for Future Issuance </div></div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:nonNumeric name="cbay:ReservedSharesOfCommonStockForIssuanceTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022 and 2021, the Company had reserved shares of common stock for future issuances as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded</div> warrants to purchase common stock</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,125,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,125,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Equity award plans:</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options and incentive awards outstanding, all equity plans</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022_OptionsAndIncentiveAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">14,031,377</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2021_OptionsAndIncentiveAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,892,613</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Equity awards available for future grant - 2013 Plan</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022_CbayequityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,680,621</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2021_CbayequityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,588,613</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Equity awards available for future grant - 2020 Plan</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022_CbayequityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2021_CbayequityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total shares of common stock reserved for future issuance</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">19,836,998</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">15,606,226</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sale of Common Stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded</div> Warrants &#160;&#160;&#160;&#160; </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">In November 2021, pursuant to a shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3,</div> the Company completed the sale of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants pursuant to an underwritten public equity offering. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchas</div>e <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn11_30_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,125,000</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">shares of common stock were issued at a price of </div></div>$<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn11_30_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">3.9999</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">per share, have an exercise price of </div></div>$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn11_30_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;">per share, were fully exercisable upon issuance, and have no expiration date. The Company determined that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants should be equity classified because they are freestanding financial instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. In addition, such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants do not provide any guarantee of value or return. Accordingly, the proceeds from the issuance of the warrants were recorded as additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital on the Company&#8217;s consolidated balance sheet as of December&#160;31, 2022. None of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants have been exercised, and therefore they remain outstanding as of December&#160;31, 2022. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;23, 2023, the Company issue</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">d <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_23_2023To01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">11,821,428</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">shares of its common stock at </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">7.00</ix:nonFraction> </div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">per share in an underwritten public offering. The Company also issued a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrant to purchase up to an aggregate o</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">f <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,142,857</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">shares of common stock at a purchase price o</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">f $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">6.9999</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per share and has an exercise price of </div>$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;per share. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 13&#8212;Subsequent Events</div></div> for further information. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></ix:continuation> <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088080"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Stock Plans and Stock-Based Compensation </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Plans </div></div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2013, the Company&#8217;s stockholders approved the 2013 Equity Incentive Plan (the 2013 Plan), under which shares of common stock are reserved for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other stock awards by the Company. These awards may be granted to employees, members of the Board of Directors, and consultants. The 2013 Plan has a term of ten years and <div style="letter-spacing: 0px; top: 0px;;display:inline;">replaced </div>the 2003 Equity Incentive Plan, which had similar terms. The 2013 Plan permits the Company to (i)&#160;grant incentive stock options to directors and employees at not less than <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_IncentiveStockOptionsForEmployeesAndDirectorsMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the fair value of common stock on the date of grant; (ii)&#160;grant nonqualified options to employees, directors, and consultants at not less than <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_NonQualifiedStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">85</ix:nonFraction>% of fair value; (iii)&#160;award stock bonuses; and (iv)&#160;grant rights to acquire restricted stock at not less than <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">85</ix:nonFraction>% of fair value. Options generally vest over a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> period and have a term of ten years. Options granted to <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10% </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>&#160;</ix:exclude></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>91</ix:exclude></div></div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:nonNumeric></div> </div> <ix:continuation id="TextSelection_71088080" continuedAt="TextSelectionAppend_71088080_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088080_1" continuedAt="TextSelectionAppend_71088080_2"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088080_2" continuedAt="TextSelectionAppend_71088080_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;">stockholders have a maximum term of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2017To12_31_2017_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_StockOptionsToTenPercentShareholdersMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">five years</ix:nonNumeric> and require an exercise price equal to at least <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P01_01_2017To12_31_2017_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_StockOptionsToTenPercentShareholdersMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">110</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the fair value on the date of grant. The exercise price of all options granted to date has been at least equal to the fair value of common stock on the date of grant. Stock option exercises are settled with shares reserved under the 2013 Plan. The share reserve under the 2013 Plan will automatically increase on </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">January&#160;1<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">st</div> o</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">f each year, for a period of not more </div></div>than <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>, in an amount equal to <ix:nonFraction name="cbay:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" contextRef="PAsOn09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the total number of shares of capital stock outstanding on December&#160;31<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">st</div> of the preceding calendar year, unless the Board determines otherwise prior to December&#160;31<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">st</div> of such calendar year. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2020, the Company&#8217;s board of directors approved the 2020 New Hire Plan (the 2020 Plan), under which shares of common stock are reserved for the granting of nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other stock awards by the Company as an inducement to prospective new hire employees of the Company. The 2020 Plan has a term of ten years. The 2020 Plan permits the Company to (i)&#160;grant nonqualified options to new hire employees at not less than <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="P01_01_2020To12_31_2020_EquityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">85</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of fair value; (ii)&#160;award stock bonuses; and (iii)&#160;grant rights to acquire restricted stock at not less than 85% of fair value. Options generally vest over a four-year period and have a term of ten years. The share reserve under the 2020 Plan may be increased at the discretion of and approval by the board of directors.</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Plan Activity </div></div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn12_31_2022_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,680,621</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn12_31_2022_EquityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares available for grant under the 2013 and 2020 Plans, respectively. On January&#160;1, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>, in accordance with the annual share increase provision in the 2013 Plan, the Company added <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn01_01_2022_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">4,234,053</ix:nonFraction> shares to the 2013 Plan share reserve. </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes activity in the Company&#8217;s stock option grants: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">&#160;</div></div></div><div style="background-color:#ffffff;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/>Subject to<br/>Outstanding<br/>Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Exercise<br/>Price of<br/>Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value (in<br/>thousands)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December 31, 2021</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,791,431</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">6.01</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 51%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options granted</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,692,868</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.94</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercised</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,124</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.94</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options forfeited</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">403,210</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.08</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options expired</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">147,770</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">5.24</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December 31, 2022</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">13,930,195</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">5.26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear">6.96</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,089</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested and expected to vest as of December&#160;31, 2022</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">13,930,195</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">5.26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear">6.96</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,089</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable as of December&#160;31, 2022</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">9,004,373</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">6.00</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear">6.08</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,858</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> </ix:nonNumeric> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total </div></div>intrinsic value of options exercised was immaterial and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction>&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total fair value of options vested was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, unamortized stock-based compensation expense of $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">14.7</ix:nonFraction>&#160;million is expected to be recognized over a weighted average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear">2.4</ix:nonNumeric> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">years. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>&#160;</ix:exclude></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>92</ix:exclude></div></div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:continuation></div> </div> <ix:continuation id="TextSelectionAppend_71088080_3" continuedAt="TextSelectionAppend_71088080_4"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088080_4" continuedAt="TextSelectionAppend_71088080_5"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088080_5" continuedAt="TextSelectionAppend_71088080_6"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Incentive Awards </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2013,&#160;January 2014, and April 2014, as permitted by the 2013 Plan, the Company issued certain incentive awards to directors, employees and a consultant which are subject to <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn04_30_2014_IncentiveStockAwardsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">252,752</ix:nonFraction> shares of the Company&#8217;s common stock and are exercisable at a weighted average price of $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="PAsOn01_31_2014_IncentiveStockAwardsMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">5.21</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per share when vested. The Company may determine at its option whether to settle exercised awards in shares of common stock or in cash. The incentive awards were fully vested as of December&#160;31, 2022 and 2021 and have a term of 10 years.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Incentive awards outstanding totaled <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2022_IncentiveStockAwardsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2021_IncentiveStockAwardsMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">101,182</ix:nonFraction></ix:nonFraction> as of December&#160;31, 2022 and 2021. </div></div><br/></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><br/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> </ix:continuation></div> </div> </div> </div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088080_6" continuedAt="TextSelectionAppend_71088080_7"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation Expense </div></div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense is included in the consolidated statements of operations and comprehensive loss and is as follows (in </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">thousands): </div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,274</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,470</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,243</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,526</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,517</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,996</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div></ix:nonNumeric> <div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Valuation Assumptions </div></div></div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the weighted-average assumptions the Company used in the Black-Scholes option-pricing model to derive the grant date fair values of stock options granted in each of the years <div style="display:inline;">presented </div>along with the resulting estimated weighted-average grant date fair values per share: </div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 85%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (years)</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To12_31_2022" format="ixt-sec:duryear">6.0</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">6.1</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.8</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="0" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Weighted-average grant date fair value per share</div></td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">2.33</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">3.91</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></ix:nonNumeric><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Term </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company does not believe it can currently place reliance on its historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term due to the lack of sufficient prior exercise data available. Therefore, for stock option grants made during the years ended December&#160;31, 2022 and 2021, the Company has elected to use the simplified method for estimating the expected term, which is an</div></div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">average of the contractual term of the options and its ordinary vesting period. The Company will reevaluate this methodology at a point in time when sufficient exercise data becomes available. The expected term represents the period of time that options are expected to be outstanding.</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Volatility </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimates expected volatility by measuring the historical volatility of its common stock price over a historical period commensurate with the expected term of the related award. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>&#160;</ix:exclude></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>93</ix:exclude></div></div></div><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_71088080_7" continuedAt="TextSelectionAppend_71088080_8"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088080_8" continuedAt="TextSelectionAppend_71088080_9"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088080_9"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;">Risk-Free Interest Rate</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk-free interest rate assumption was based on U.S. treasury instruments with constant maturities whose term was consistent with the expected term of stock options granted by the Company. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Dividend Yield </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The Company has never declared or paid cash dividends and does not plan to pay cash dividends <div style="letter-spacing: 0px; top: 0px;;display:inline;">in </div>the foreseeable future. Consequently, the Company uses an expected dividend yield of zero.</div></div></div></ix:continuation> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"></div><ix:nonNumeric name="us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11. 401(k) Plan </div></div></div></div><div style="null;text-indent: 0px;;font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company provides a qualified 401(k) savings plan for its employees. All employees are eligible to participate, provided they meet the requirements of the plan. As is permitted under the plan, the Company has elected to match employee contributions up to $<ix:nonFraction name="cbay:EmployerMatchingContributionToQualifiedSavingsPlan" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="cbay:EmployerMatchingContributionToQualifiedSavingsPlan" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt:num-dot-decimal">750</ix:nonFraction></ix:nonFraction> and accordingly matching contributions totaling an insignificant amount were made in the years ended December&#160;31, 2022 and 2021.</div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088151"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. Income Taxes&#160;</div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonFraction name="cbay:ProvisionForStateAndLocalIncomeTaxes" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="cbay:ProvisionForStateAndLocalIncomeTaxes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction> provision for U.S. income taxes exists due to tax losses incurred in all periods presented. All losses incurred were U.S. based. <ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088217"><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 32.6667px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">Significant</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">components of the Company&#8217;s <div style="display:inline;">deferred </div>tax assets are as follows (in thousands): </div></div></ix:nonNumeric></div><ix:continuation id="TextSelection_71088217"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Federal and state net operating loss carryforwards</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">87,681</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">129,898</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap; width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">State and federal research and development tax credit carryforwards</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,016</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,951</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Intangibles and capitalized research and development</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="cbay:DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,912</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="cbay:DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,670</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Stock-based compensation</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,624</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,329</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Other</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,574</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,222</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Total deferred tax assets</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">144,807</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">174,070</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Deferred tax liabilities:</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Depreciation and amortization</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">79</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">158</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Other</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">36</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">53</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Total deferred tax liabilities</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">211</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Valuation allowance</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">144,692</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">173,859</ix:nonFraction></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Net deferred tax assets</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 69%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="clear:both;max-height:0pt;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></ix:continuation><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Realization of the net deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which is uncertain. Based on the weight of available positive and negative objective evidence, management believes it more likely than not that the Company&#8217;s deferred tax assets are not realizable. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance decreased by $</div></div><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">29.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million primarily due primarily to a $</div></div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><ix:nonFraction name="cbay:WriteOffOfTaxAttributeDueToLimitation" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">38.4</ix:nonFraction></div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million write-off of tax attributes pursuant to certain Section 382 limitations and to a lesser extent the utilization of net operating losses during the year ended December 31, 2022, These valuation allowance reductions were offset in part by valuation allowance increases to cover additions to the Company&#8217;s capitalized research and development and other deferred tax assets during the year ended December 31, 2022. The valuation allowance increased by $</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">14.7</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;million primarily due to an increase in the Company&#8217;s taxable loss during the year ended </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2021. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>&#160;</ix:exclude></div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>94</ix:exclude></div></div></div><ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude></ix:nonNumeric></div></div><ix:continuation id="TextSelection_71088151" continuedAt="TextSelectionAppend_71088151_1"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088151_1" continuedAt="TextSelectionAppend_71088151_2"><ix:exclude><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width: 8.5in; text-align: left; margin-left: auto; margin-right: auto; font-size: 10pt;"><ix:continuation id="TextSelectionAppend_71088151_2" continuedAt="TextSelectionAppend_71088151_3"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div></ix:continuation></div></div></div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088151_3" continuedAt="TextSelectionAppend_71088151_4"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a reconciliation of the expected statutory federal income tax provision to the actual income tax provision (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Income tax benefit at federal statutory tax rate</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">22,260</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">18,900</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Change in valuation allowance</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29,165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,739</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Impairment of tax attributes</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,398</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Research credits</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,640</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,802</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Cancelled options</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="cbay:IncomeTaxReconciliationTaxCancelledOptions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">49</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="cbay:IncomeTaxReconciliationTaxCancelledOptions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">141</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Development financing liability</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="cbay:IncomeTaxReconciliationDevelopmentFinancingLiability" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,301</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="cbay:IncomeTaxReconciliationDevelopmentFinancingLiability" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,654</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Permanent differences</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="cbay:IncomeTaxReconciliationPermanentDifferences" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">511</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="cbay:IncomeTaxReconciliationPermanentDifferences" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">429</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">State income taxes, net of federal benefit</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,806</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">267</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Other, net</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Income tax (benefit) expense</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-block: 0em;">&#160;</div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Internal Revenue Code (IRC) Sections&#160;382 and 383 and similar state laws, use of the Company&#8217;s U.S. federal and state net operating loss and research and credit carryforwards may be limited in the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">event</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of a cumulative change in ownership of more than&#160;<ix:nonFraction name="cbay:CumulativePercentageChangeInOwnershipPercentagePerimissible" contextRef="PAsOn12_31_2022_FederalAndStateTaxAuthorityMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% within a&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><ix:nonNumeric name="cbay:PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage" contextRef="P01_01_2022To12_31_2022_FederalAndStateTaxAuthorityMemberusgaapIncomeTaxAuthorityAxis" format="ixt-sec:durwordsen"><div style="letter-spacing: 0px; top: 0px;;display:inline;">three</div>-year</ix:nonNumeric></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;period. In 2022, the Company completed an ownership change analysis and determined that its net operating losses and research and development credits were subject to limitations due to historical changes in ownership that occurred through December&#160;31, 2022. Accordingly, the net operating loss carryforwards reflected in the deferred tax assets at December&#160;31, 2022 have been reduced to reflect Section&#160;382 limitations resulting from these changes. As the Company is expected to incur additional losses in the future, any future ownership changes that might occur could further restrict the Company&#8217;s ability to utilize its net operating loss and research and development carryforwards. </div></div></div> <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;31, 2022, the Company had federal net operating loss carryforwards of $</div><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">346.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and state net operating loss carryforwards of $</div><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">214.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to offset future taxable income, if any. In addition, the Company had federal research and development tax credit carryforwards of $</div><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_OrphanDrugMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, federal orphan drug tax credit carryforwards of $</div><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">28.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and state research and development tax credit carryforwards of $</div><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.2</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. If not utilized, the federal net operating losses for the years beginning before January&#160;1, 2018 of $</div><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2017_FederalMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">79.1</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million will expire beginning in </div><ix:nonNumeric name="cbay:NetOperatingLossCarryforwardExpirationYear" contextRef="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_MinimumMembersrtRangeAxis">2024</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through </div><ix:nonNumeric name="cbay:NetOperatingLossCarryforwardExpirationYear" contextRef="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_MaximumMembersrtRangeAxis">2037</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and the federal net operating losses for the tax years beginning after January&#160;1, 2018 of $</div><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2018_FederalMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">266.9</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million will be carried forward indefinitely (subject to certain utilization limitations).</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" contextRef="P01_01_2022To12_31_2022">The state net operating loss carryforwards will expire beginning in <ix:nonNumeric name="cbay:NetOperatingLossCarryforwardExpirationYear" contextRef="P01_01_2022To12_31_2022_FederalMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MinimumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2028</ix:nonNumeric> through <ix:nonNumeric name="cbay:NetOperatingLossCarryforwardExpirationYear" contextRef="P01_01_2022To12_31_2022_FederalMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2040</ix:nonNumeric>. The <ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" contextRef="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">federal research and development and federal orphan drug tax credit carryforwards expire 2033 through 2042</ix:nonNumeric>, and the state tax credit will carry forward indefinitely.</ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_71088225">The following table summarizes activity related to the Company&#8217;s gross unrecognized tax benefits (in&#160;thousands):</ix:nonNumeric></div> <ix:continuation id="TextSelection_71088225"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 89%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 0px;">
<td style="width: 86%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Balances as of December 31, 2020</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,205</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Increases related to prior year tax positions</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Increases related to 2021 tax positions</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">783</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Balances as of December 31, 2021</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,997</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Decreases related to prior year tax positions</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,223</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Increases related to 2022 tax positions</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">730</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Balances as of December 31, 2022</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,504</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> </ix:continuation> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The unrecognized tax benefits, if recognized, would not have an impact on the Company&#8217;s effective tax rate assuming the Company continues to maintain a full valuation allowance position. Based on prior year&#8217;s operations and experience, the Company does&#160;</div><ix:nonFraction name="us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction>t<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;expect a significant change to its </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unrecognized tax benefits </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>&#160;</ix:exclude></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:exclude>95</ix:exclude></div></div></div> <ix:exclude><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div></ix:exclude> </ix:continuation></div></div><ix:continuation id="TextSelectionAppend_71088151_4" continuedAt="TextSelectionAppend_71088151_5"><ix:exclude><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_71088151_5" continuedAt="TextSelectionAppend_71088151_6"><ix:exclude> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </ix:exclude></ix:continuation> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_71088151_6" continuedAt="TextSelectionAppend_71088151_7"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">over the next twelve months. The unrecognized tax benefits may increase or change in the future for unexpected or unusual items for items that may arise in the ordinary course of business.&#160;</div> </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The Company&#8217;s major income tax filing jurisdictions are the U.S. federal&#160;and California state and is not currently under examination by federal, state, or local taxing authorities for any open tax years. Due to net operating loss carryforwards</div></div>, <ix:nonNumeric name="us-gaap:IncomeTaxExaminationDescription" contextRef="P01_01_2022To12_31_2022">the tax years <ix:nonNumeric name="us-gaap:OpenTaxYear" contextRef="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis">2004</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:OpenTaxYear" contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis">2022</ix:nonNumeric> remain open for income tax examination by tax authorities</ix:nonNumeric> in the U.S. and states in which the Company files tax <div style="letter-spacing: 0px; top: 0px;;display:inline;">returns. Interest and penalties for the years ended December 31, 2022 and 2021 were not material.&#160;</div></div></ix:continuation></div></div> </div></div> <div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_71088151_7"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">In August 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law. The IRA provides several tax incentives, including the expanded Internal Revenue Code (IRC) Section&#160;179D deduction, increased ability to leverage the R&amp;D credit to offset payroll taxes for eligible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">start-up</div> businesses, and <ix:nonFraction name="cbay:AlternateMinimumTaxRate" contextRef="P08_01_2022To08_31_2022" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">15</ix:nonFraction>% alternative minimum tax (AMT) for corporations with average income of more than $<ix:nonFraction name="us-gaap:Revenues" contextRef="P08_01_2022To08_31_2022" unitRef="Unit_USD" decimals="-9" scale="9" format="ixt:num-dot-decimal">1</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;billion for the past three tax periods. The IRA did not have a material impact on the Company&#8217;s consolidated financial statements; however, the Company continues to examine the impacts the above-mentioned tax legislations may have on its business, results of operations, financial condition and liquidity.&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"></div></div> </ix:continuation><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13. Subsequent Events </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaboration and License Agreement with Kaken Pharmaceutical Co., Ltd. </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January&#160;2023, the Company entered into a Collaboration and License Agreement (the License Agreement) with Kaken Pharmaceutical Co., Ltd. (Kaken). Pursuant to the License Agreement, the Company granted Kaken an exclusive license to commercialize seladelpar (the&#160;Licensed Product) for the treatment of PBC in Japan. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kaken will bear the cost of, and be responsible for, conducting clinical studies and other developmental activities, preparing and filing applications for regulatory approval and commercializing seladelpar in Japan. The Company is generally obligated to supply seladelpar to Kaken for use in Japan, at a supply price per unit as defined in the agreement. </div></div><br/></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">In consideration of the license and other rights granted by the Company, Kaken made an upfront cash payment to the Company of $</div></div></div><ix:nonFraction name="cbay:UpfrontCashPayment" contextRef="PAsOn01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">34.2</ix:nonFraction><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in January 2023 and is obligated to make potential milestone payments to the Company totaling up to &#165;</div><ix:nonFraction name="cbay:PotentialMilestonePayments" contextRef="P01_01_2023To01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_JPY" decimals="-8" scale="9" format="ixt:num-dot-decimal">17.0</ix:nonFraction><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;billion (approximately $</div><ix:nonFraction name="cbay:PotentialMilestonePayments" contextRef="P01_01_2023To01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">128.0</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;million using exchange rates in effect at the contract inception date) contingent upon Kaken&#8217;s achievement of certain regulatory and sales milestones as defined in the agreement.&#160;</div><div style="letter-spacing: 0px; top: 0px; text-indent: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sale of Common Stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded</div> Warrant </div></div></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;23, 2023, pursuant to a shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">S-3,</div> the Company <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">sold</div> <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_23_2023To01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">11,821,428</ix:nonFraction>&#160;of its common <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">shares</div> at $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">7.00</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">per share in an underwritten public<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">equity&#160;</div>offering&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">and a</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrant to purchase&#160;</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">2,142,857</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">shares of common stock at a purchase price of </div></div>$<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">6.9999</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per share, which represents the per share public offering price for the common stock less the </div></div>$<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">per share exercise price of the pre-funded warrant. The Company received net proceeds</div></div>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">of</div> $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_01_2023To12_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal">92.4</ix:nonFraction>&#160;<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million from this public equity offering after deducting underwriting and other offering expenses. </div></div></div> </ix:nonNumeric> <div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold" id="txa446975_26">Item&#160;16. Form <div style="white-space:nowrap;display:inline;">10-K</div> Summary </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="display:inline;">96</div></div> </div></div></div> </div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
<h5><a href="#toc">Table of Contents</a></h5>


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="txa446975_27">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:46%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:5%"></td>

<td style="vertical-align:bottom"></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:46%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">CymaBay&#160;Therapeutics,&#160;Inc.</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Registrant</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">March&#160;23, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sujal Shah</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sujal Shah</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</p></td></tr>
</table> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="sig">POWER OF ATTORNEY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Sujal Shah and Daniel Menold, as his or her true and lawful <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> and agent, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form <span style="white-space:nowrap">10-K,</span> and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said <span style="white-space:nowrap"><span style="white-space:nowrap">attorney-in-fact</span></span> and agent, and any of them or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1934, this report has been signed by the following persons on behalf of the Registrant in the capacities indicated on the date set forth below: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:31%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and Signature</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:middle"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sujal Shah</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Sujal Shah</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">President, Chief Executive Officer&#160;and&#160;Director</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">(Principal Executive Officer)</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">March&#160;23, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel Menold</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Daniel Menold</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">Vice President, Finance</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">(Principal&#160;Financial&#160;and Accounting Officer)</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">March&#160;23, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert J. Wills</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Robert J. Wills</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">March&#160;23, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kurt von Emster</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Kurt von Emster</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">March&#160;23, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Caroline Loewy</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Caroline Loewy</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">March&#160;23, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas G. Wiggans</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Thomas G. Wiggans</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">March&#160;23, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Janet Dorling</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Janet Dorling</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">March&#160;23, 2023</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ &#201;ric Lefebvre</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">&#201;ric Lefebvre</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" align="center">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">March&#160;23, 2023</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>2
<FILENAME>d446975dex1012.htm
<DESCRIPTION>EX-10.12
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.12</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.12 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I)&nbsp;NOT MATERIAL AND (II)&nbsp;IS THE TYPE OF
INFORMATION THAT CYMABAY TREATS AS PRIVATE OR CONFIDENTIAL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>E<SMALL>XECUTION</SMALL> C<SMALL>OPY</SMALL> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COLLABORATION AND LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This COLLABORATION AND LICENSE AGREEMENT (this &#147;<B>Agreement</B>&#148;), dated as of January&nbsp;6, 2023 (the &#147;<B>Effective
Date</B>&#148;), is entered into by and between <B>CymaBay Therapeutics, Inc.</B>, a Delaware corporation (&#147;<B>CymaBay</B>&#148;), and <B>Kaken Pharmaceutical Co., Ltd.</B>, a company organized under the laws of Japan
(&#147;<B>Kaken</B>&#148;). CymaBay and Kaken may be referred to in this Agreement individually as a &#147;<B>Party</B>&#148; and collectively as the &#147;<B>Parties</B>&#148;. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, CymaBay is a clinical-stage biopharmaceutical company involved in the research, development and commercialization of
pharmaceutical therapies for liver and other chronic diseases with high unmet need; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Kaken is involved in and possesses
expertise and experience in developing, manufacturing, marketing and selling pharmaceutical products worldwide; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
CymaBay and Kaken desire to enter into an agreement under which they shall collaborate to develop and commercialize CymaBay&#146;s Seladelpar product for use in particular indications solely in Japan, as more fully described in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the foregoing premises and the mutual covenants herein contained, the Parties hereby agree as
follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless specifically set
forth to the contrary herein, the following capitalized terms, whether used in the singular or plural, will have the respective meanings set forth below: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> &#147;<B>Abbreviated New Drug Application</B>&#148; or &#147;<B>ANDA</B>&#148; has the meaning set forth in the FD&amp;C Act 21
U.S.C. &#167; 355(b)(2), 21 U.S.C. &#167; 355(j) and 21 C.F.R. &#167; 314.3 as amended, or such analogous provisions of Applicable Law outside the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> &#147;<B>Accounting Standards</B>&#148; means: (a)&nbsp;with respect to CymaBay, generally accepted accounting principles as
practiced in the United States, and (b)&nbsp;with respect to Kaken and its Related Parties, generally accepted accounting principles as practiced in Japan or IFRS, as applicable, in each of case (a)&nbsp;and (b) as generally and consistently applied
throughout the Party&#146;s organization. Each Party will promptly notify the other in the event that it changes the Accounting Standards pursuant to which its records are
maintained;<I><U>&nbsp;provided</U></I><I>,</I><I></I><I><U>&nbsp;however</U></I>, that each Party may only use internationally recognized accounting principles (e.g. IFRS, GAAP, etc.). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.3</B> &#147;<B>Acquirer</B>&#148; has the meaning ascribed to such term, with respect to a particular Change of Control, as set forth in
<U>Section</U><U></U><U>&nbsp;1.18</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.4</B> &#147;<B>Additional Indication</B>&#148; means a human disease or pathological
condition intended to be treatable by a therapeutic product other than the Initial Indication. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.5</B> &#147;<B>Additional Indication Japan License</B>&#148; has the meaning set forth
in <U>Section</U><U></U><U>&nbsp;10.6</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.6</B> &#147;<B>Additional Indication Notice</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;10.6</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.7</B> &#147;<B>Affiliate</B>&#148; means, with respect to a Person, any other Person that
controls, is controlled by, or is under common control with, such Person, at the applicable time during the Term of this Agreement. For purposes of this definition, &#147;control&#148; means (with corresponding meanings for the terms
&#147;controlled by&#148; and &#147;under common control with&#148;) that the applicable Person owns or controls, directly or indirectly, more than fifty percent (50%) of the equity securities of the applicable other Person entitled to vote in the
election of directors (or, in the case that such other Person is not a corporation, for the election of the corresponding managing authority), or otherwise has the power to direct the management and policies of such other Person. The Parties
acknowledge that in the case of certain entities organized under the laws of certain countries outside the United States, the maximum percentage ownership permitted by Applicable Law for a foreign investor may be less than fifty percent (50%), and
that in such case such lower percentage will be substituted in the preceding sentence,<I><U>&nbsp;provided</U></I>&nbsp;that such foreign investor has the power to direct the management and policies of such entity. For clarity, a Person may be or
become an Affiliate of another Person and may cease to be an Affiliate of such Person, in each case, during the Term of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.8</B> &#147;<B>Agreement</B>&#148; has the meaning set forth in the preamble. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.9</B> &#147;<B>Alliance Manager</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;2.1</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.10</B> &#147;<B>Anti-Corruption Laws</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;10.2.17</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.11</B> &#147;<B>Applicable Law</B>&#148; means all laws, statutes, rules, regulations, orders, judgments, injunctions, ordinances or other
pronouncements having the binding effect of law of any Governmental Authority, in each case to the extent applicable to the particular circumstance or obligation under this Agreement, and including if either Party is or becomes subject to a legal
obligation to a Regulatory Authority or other Governmental Authority (such as a corporate integrity agreement or settlement agreement with a Governmental Authority). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.12</B> &#147;<B>Auditor</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.7</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.13</B> &#147;<B>Bankrupt Party</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;7.5</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.14</B> &#147;<B>Bankruptcy Code</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;13.6</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.15</B> &#147;<B>Brief</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;14.3.4.2(b)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.16</B> &#147;<B>Business Day</B>&#148; means a day other than a Saturday, Sunday or a bank or other public holiday in New York, United
States or in Tokyo, Japan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.17</B> &#147;<B>CDISC</B>&#148; means the Clinical Data Interchange Standards Consortium, which is an
interdisciplinary nonprofit organization that establishes international standards for data collection, interchange, application, and storage for the purpose of promoting interoperation of clinical research data. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.18</B> &#147;<B>Change of Control</B>&#148; means, with respect to a Party, (a)&nbsp;a merger or consolidation of such Party with a Third
Party that results in the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to represent at least fifty percent (50%) of the combined
voting power of the surviving entity or the parent of the surviving entity immediately after such merger or consolidation, (b)&nbsp;a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the
direct or indirect beneficial owner of more than fifty percent (50%) of the combined voting power of the outstanding securities of such Party, or (c)&nbsp;the sale or other transfer to a Third Party of all or substantially all of such Party&#146;s
and its controlled Affiliates&#146; assets. With respect to any such Change of Control of a particular Party, the Third Party referenced in subclause (a), (b) or (c) (as applicable to such Change of Control), and including all of such Third
Party&#146;s Affiliates, shall be referred to herein as the &#147;Acquirer&#148; of such Party in such Change of Control. Notwithstanding the foregoing, any transaction or series of transactions effected for the primary purpose of financing the
operations of the applicable Party or changing the form or jurisdiction of organization of such Party will not be deemed a &#147;Change of Control&#148; for purposes of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.19</B> &#147;<B>Claims</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;11.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.20</B> &#147;<B>Clinical Failure</B>&#148; means, as determined by Kaken acting reasonably,
that either (a) [***] or (b) [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.21</B> &#147;<B>Clinical Study</B>&#148; means, with respect to any product, a Phase 1 Study,
Phase 2 Study, Phase 3 Study, Post-Marketing Study, Supplemental Study or other study (including a <FONT STYLE="white-space:nowrap">non-interventional</FONT> study) in humans to obtain information regarding such product, including information
relating to the safety, tolerability, pharmacological activity, pharmacokinetics, dose ranging and/or efficacy of such product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.22</B> &#147;<B>Clinical Supply Agreement</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.2.1</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.23</B> &#147;<B>Clinical Transfer Price</B>&#148; means the supply price calculated as set forth in the Clinical Supply Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.24</B> &#147;<B>CMC</B>&#148; means chemistry, manufacturing and controls with respect to a product, which includes (a)&nbsp;Manufacturing
process development records for such product, (b)&nbsp;all chemistry, Manufacturing and control procedures necessary for the Manufacture of such product, and (c)&nbsp;sourcing and testing of all raw materials and components used in the Manufacture
of such product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.25</B> &#147;<B>CMC Activities</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.6</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.26</B> &#147;<B>CMC Work Plan</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.4.3</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.27</B> &#147;<B>Collaboration</B>&#148; means the collaboration of the Parties under this Agreement for the Development, Manufacture and
Commercialization of Licensed Products in the Field of Use in the Kaken Territory. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.28</B> &#147;<B>Combination Product</B>&#148;
means a pharmaceutical product containing (a)&nbsp;Licensed Compound and (b)&nbsp;one or more additional active pharmaceutical ingredients (other than Licensed Compound) having a meaningful pharmaceutical therapeutic effect (whether <FONT
STYLE="white-space:nowrap">co-formulated</FONT> or <FONT STYLE="white-space:nowrap">co-packaged</FONT> with any of the compounds of clause (a)). For the avoidance of doubt, (i)&nbsp;equipment, devices or packaging used to administer or deliver any
of the foregoing, and (ii)&nbsp;formulation substances or materials (including substances intended to increase or modify bioavailability), will not be deemed an &#147;additional active pharmaceutical ingredient&#148; for the purposes of the
definition of &#147;Combination Product.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.29</B> &#147;<B>Commercial Supply Agreement</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;6.2.3</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.30</B> &#147;<B>Commercialization</B>&#148; or &#147;<B>Commercialize</B>&#148; means, with
respect to any product, any and all activities directed to marketing, promoting, distributing, importing, exporting, using, offering to sell, selling or otherwise commercializing such product, and any and all activities directed to obtaining any
Pricing Approvals for such product, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.31</B> &#147;<B>Commercially Reasonable Efforts</B>&#148; means, with respect to
the efforts and resources to be expended by a Party with respect to any objective, obligation or task under this Agreement, [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.32</B> &#147;<B>Committee</B>&#148; means the Joint Steering Committee or any joint subcommittee of the JSC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.33</B> &#147;<B>Competing Product</B>&#148; means, other than any Licensed Product, any pharmaceutical product [***], excluding (a) [***]
and (b) [***]; for clarity, a pharmaceutical product that [***]. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.34</B> &#147;<B>Competitive Infringement</B>&#148; means the circumstance where the
making, using, selling, offering for sale, or importing, by any Third Party (other than any Sublicensee or authorized purchaser or other authorized transferee of Licensed Product by either Party), of any pharmaceutical product is Covered by a Valid
Claim of any CymaBay Licensed Patent or a Kaken Controlled Patent. For clarity, the filing of an Abbreviated New Drug Application with any applicable Regulatory Authority with respect to a Licensed Product as the reference product by any such Third
Party will be deemed to be Competitive Infringement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.35</B> &#147;<B>Competitive (CymaBay) Infringement</B>&#148; means any
Competitive Infringement occurring in the CymaBay Territory, but for clarity does not include any Competitive (Kaken) Infringement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.36</B> &#147;<B>Competitive (Kaken) Infringement</B>&#148; means any Competitive Infringement occurring in the Kaken Territory, but for
clarity does not include any Competitive (CymaBay) Infringement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.37</B> &#147;<B>Confidential Information</B>&#148; means, with
respect to a Party, any and all confidential or proprietary information and data and all other scientific, <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical, regulatory, Manufacturing, marketing, financial and commercial information or
data, whether communicated in writing or orally or by any other method, that is or has been provided by one Party or any of its Affiliates to the other Party or any of its Affiliates in connection with this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.38</B> &#147;<B>Contract</B>&#148; means any contract, agreement, lease, sublease, license, sales order, purchase order, loan, credit
agreement, bond, debenture, note, mortgage, indenture, guarantee, undertaking, instrument, arrangement, understanding or other commitment, whether written or oral, that is or was binding on any Person or any part of its property under Applicable
Law, whether in effect or if expired or terminated solely with respect to any provisions surviving such expiration or termination as of the Effective Date, including all amendments related to any of the foregoing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.39</B> &#147;<B>Control</B>&#148; means, with respect to any particular Patents or <FONT STYLE="white-space:nowrap">Know-How,</FONT> that
the applicable Party owns or has a license (or sublicense) or other rights (other than by a license, sublicense or other right granted (but not assignment) pursuant to this Agreement) to such Patents or
<FONT STYLE="white-space:nowrap">Know-How</FONT> and has the ability and right to assign or grant to the other Party the licenses, sublicenses or rights to access and use such Patent(s) or <FONT STYLE="white-space:nowrap">Know-How</FONT> as provided
for in this Agreement, without (a)&nbsp;violating the terms or conditions of any agreement or other arrangement with any Third Party in existence as of the time such Party would be required hereunder to grant such license, sublicense, or rights of
access and use, and (b)&nbsp;paying, or owing an obligation to pay, any consideration to any Third Party, except for that which a Party <FONT STYLE="white-space:nowrap">in-licenses</FONT> and under which the other Party elects to take a sublicense
and agrees to make the associated payments pursuant to this Agreement, which will be considered under the Control of such Party. Notwithstanding anything in this Agreement to the contrary, if a Party undergoes a Change of Control, such Party will be
deemed not to Control any Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> that are owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> (other than from such Party) by the Acquirer in such Change of Control, except that such
Party shall be deemed to Control any particular Patents or <FONT STYLE="white-space:nowrap">Know-How</FONT> of Acquirer: (a)&nbsp;arising from active participation by employees or consultants of the Acquirer in the Collaboration after such Change of
Control, (b)&nbsp;that are included in or used in furtherance of the Collaboration by the Acquirer after such Change of Control, or (c)&nbsp;that (i) constitute improvements (or direct improvements to such improvements) to the CymaBay Licensed
Technology or Program IP (as applicable) in existence prior to such Change of Control and (ii)&nbsp;are developed or conceived by any employees or consultants of the Acquirer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.40</B> &#147;<B>Controlling Party</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;12.6.4</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.41</B> &#147;<B>Cover</B>&#148;, &#147;<B>Covering</B>&#148; or &#147;<B>Covered</B>&#148; means, with respect to a particular claim in a
Patent, and to a particular Licensed Product under this Agreement or product of a Third Party, that the manufacture, use, sale, offer for sale or importation of such Licensed Product or such product, as applicable, in the Field of Use in the
relevant Territory by an unauthorized Person (<I>i.e.,</I> the Person does not possess a valid license or sublicense under such claim) would infringe such claim, or with respect to a claim in a pending patent application, would infringe such if
issued in a patent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.42</B> &#147;<B>CymaBay</B>&#148; has the meaning set forth in the preamble. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.43</B> &#147;<B>CymaBay Indemnitees</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;11.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.44</B> &#147;<B>CymaBay Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148;
means any and all <FONT STYLE="white-space:nowrap">Know-How</FONT> (including applicable New CymaBay IP or CymaBay&#146;s interest in the Joint Program IP) that is Controlled by CymaBay or its Affiliates (solely or jointly with a Third Party) and
(a)&nbsp;is in existence as of the Effective Date, or arises during the Term, and (b)&nbsp;is necessary or reasonably useful for the Exploitation of Licensed Products in the Field of Use. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.45</B> &#147;<B>CymaBay Licensed Patents</B>&#148; means any and all Patents (including applicable Patents within New CymaBay IP) in the
Kaken Territory that are Controlled by CymaBay or its Affiliates (solely or jointly with a Third Party) and (a)&nbsp;are in existence as of the Effective Date, or arise during the Term, and (b)&nbsp;are necessary or reasonably useful for the
Exploitation of any Licensed Products in the Field of Use. To the Knowledge of CymaBay, the CymaBay Licensed Patents existing as of the Effective Date are set forth on <U>Schedule</U><U></U><U>&nbsp;1.45</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.46</B> &#147;<B>CymaBay Licensed Technology</B>&#148; means, collectively, the CymaBay Licensed
<FONT STYLE="white-space:nowrap">Know-How</FONT> and the CymaBay Licensed Patents. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.47</B> &#147;<B>CymaBay Supply
Termination</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.3</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.48</B> &#147;<B>CymaBay Supply Termination
Notice</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;6.3</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.49</B> &#147;<B>CymaBay Territory</B>&#148;
means all countries, territories and possessions of the world, except Japan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.50</B> &#147;<B>Develop</B>&#148; and
&#147;<B>Development</B>&#148; means, with respect to any Licensed Product, any and all nonclinical, preclinical and clinical drug development activities conducted before or after obtaining Regulatory Approval for such product that are reasonably
related to or leading to the development, preparation, or submission of data and information to a Regulatory Authority for the purpose of obtaining, supporting or expanding Regulatory Approval of such product, together with all activities related to
pharmacokinetic profiling, design and conduct of Nonclinical Studies and Clinical Studies (including Post-Marketing Studies) of such product, and regulatory affairs, statistical analysis, report writing, and regulatory filing creation and submission
related to the foregoing (including the services of outside advisors and consultants in connection therewith). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.51</B>
&#147;<B>Development Costs</B>&#148; means, with respect to a Licensed Product, those costs and expenses directly incurred in connection with the performance of any Development activities, including as set forth under the Initial Indication
Development Plan, for such Licensed Product, including costs for scientific or technical persons, fees charged by Third Party service providers, and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT>
Costs, any and all costs and expenses incurred in connection with the performance of any Clinical Study for such Licensed Product, including the cost to manufacture the supply of drug product for such Licensed Product for any Clinical Studies, and
costs related to preparing and filing applications for Regulatory Approval or submissions to Regulatory Authorities (including associated filing fees, translation expenses and legal and other professional service fees). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.52</B> &#147;<B>Dispute</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;14.3.1</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.53</B> &#147;<B>Dollars</B>&#148; or &#147;$&#148; means the legal tender of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.54</B> &#147;<B>Effective Date</B>&#148; has the meaning set forth in the preamble. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.55</B> &#147;<B>Efficacy Concern</B>&#148; means that [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.56</B> &#147;<B>Executive Officer</B>&#148; means: (a)&nbsp;for CymaBay, its Chief Executive Officer or another senior executive designee
with responsibilities and seniority comparable thereto, and (b)&nbsp;for Kaken, its president or another senior executive officer designee with responsibilities and seniority comparable thereto, including, in the case of Kaken, a <I>shikko
yakuin</I>; provided that any of the foregoing individuals may designate the Chief </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Financial Officer or, in the case of Kaken, its officer in charge of the accounting department, as his/her designee for financial related matters. In the event that the position of any of the
Executive Officers identified in this <U>Section</U><U></U><U>&nbsp;1.56</U>&nbsp;no longer exists due to a Change of Control, corporate reorganization, corporate restructuring or the like that results in the elimination of the identified position,
the applicable Executive Officer will be replaced with another executive officer with responsibilities and seniority comparable to the eliminated Executive Officer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.57</B> &#147;<B>Existing <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Agreements</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;7.3.1.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.58</B> &#147;<B>Expedited Arbitration</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;14.3.4.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.59</B> &#147;<B>Expedited Dispute</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;14.3.4.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.60</B> &#147;<B>Exploit</B>&#148; or &#147;<B>Exploitation</B>&#148; means, collectively,
research, Develop, Manufacture, Commercialize, register or otherwise exploit the applicable pharmaceutical product. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.61</B>
&#147;<B>FDA</B>&#148; means the United States Food and Drug Administration or any successor agency thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.62</B> &#147;<B>FD&amp;C
Act</B>&#148; means the United States Federal Food, Drug and Cosmetic Act, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.63</B> &#147;<B>Field of Use</B>&#148; means
the prevention or treatment of the Initial Indication in human patients. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.64</B> &#147;<B>First Commercial Sale</B>&#148; means the
first commercial sale in an arms&#146; length transaction of a particular Licensed Product to a Third Party by Kaken or any of its Related Parties in the Kaken Territory following receipt of applicable Regulatory Approval of such Licensed Product in
the Kaken Territory. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.65</B> &#147;<B>GCP</B>&#148; means the then current standards for clinical trials for pharmaceuticals, as set
forth in the FD&amp;C Act and applicable regulations promulgated thereunder, as amended from time to time, and such standards of good clinical practice as are required by Regulatory Authorities in the Kaken Territory. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.66</B> &#147;<B>Generic Competition Percentage</B>&#148; means, with respect to a particular Licensed Product and as assessed on a Kaken
Fiscal <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Quarter-by-Kaken</FONT></FONT> Fiscal Quarter basis, a fraction (expressed as a percentage), the numerator of which is the aggregate number of units of specific Generic
Products (for such Licensed Product) sold in the Kaken Territory during the applicable Kaken Fiscal Quarter, and the denominator of which is the aggregate number of units of such specific Generic Products (for such Licensed Product) sold in the
Kaken Territory during such Kaken Fiscal Quarter plus the aggregate number of units of such Licensed Product sold in the Kaken Territory during such Kaken Fiscal Quarter, based on [***] obtained by Kaken for such Generic Product, or if such data is
not available, such other reliable data source as is reasonably determined by Kaken. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.67</B> &#147;<B>Generic Product</B>&#148; means
a Third Party product containing an active pharmaceutical ingredient that is the same or substantially the same chemical structure as that contained in a Licensed Product (whether approved under an ANDA, or other applicable abbreviated or expedited
approval process), and where bioequivalence of such Third Party product to such Licensed Product has been asserted in the application for approval to a Regulatory Authority, and where such Third Party product is approved by the applicable Regulatory
Authority based upon or in reliance upon safety and efficacy data generated by CymaBay, Kaken (or any of their respective Affiliates) or any Related Party for such Licensed Product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.68</B> [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.69</B>
&#147;<B>Global Development Plan</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.4.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.70</B>
&#147;<B>GLP</B>&#148; means the then current standards for laboratory activities for pharmaceuticals, as set forth in the FD&amp;C Act and applicable regulations promulgated thereunder, as amended from time to time, and such standards of good
laboratory practice as are required by Regulatory Authorities in the Kaken Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.71</B> &#147;<B>GMP</B>&#148; means the then current standards for Manufacturing for
pharmaceuticals, as set forth in the FD&amp;C Act and applicable regulations promulgated thereunder, as amended from time to time, and such standards of good manufacturing practice as are required by Regulatory Authorities in the Kaken Territory.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.72</B> &#147;<B>Governmental Authority</B>&#148; means any applicable government authority, court, tribunal, arbitrator, agency,
department, legislative body, commission or other instrumentality of (a)&nbsp;any government of any country or territory, (b)&nbsp;any nation, state, province, county, city or other political subdivision thereof, or (c)&nbsp;any supranational body.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.73</B> &#147;<B>Harmonization Principle</B>&#148; means the principle that the Development and Commercialization of the Licensed
Products in the Kaken Territory, including such activities as clinical indication selection, clinical study design (including dosing), Regulatory Approval strategy (including labelling), CMC, and marketing and commercialization strategy,
(a)&nbsp;will be conducted so as to harmonize with the Development and Commercialization of the Licensed Products by or on behalf of CymaBay (and any CymaBay licensee of Licensed Product) in the CymaBay Territory, and (b)&nbsp;in no event will be
conducted in a manner that&nbsp;would materially adversely affect the Development or Commercialization of&nbsp;the Licensed Products by or on behalf of CymaBay (or any CymaBay licensee of Licensed Product) anywhere in the CymaBay Territory. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.74</B> &#147;<B>ICC</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;14.3.3</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.75</B> &#147;<B>IFRS</B>&#148; means International Financial Reporting Standards, as consistently applied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.76</B> &#147;<B>IND</B>&#148; means any Investigational New Drug Application, as defined in 21 C.F.R. &#167; 312, or any corresponding
application in any country or jurisdiction other than the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.77</B> &#147;<B>Indemnified Party</B>&#148; has the meaning
set forth in <U>Section</U><U></U><U>&nbsp;11.3</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.78</B> &#147;<B>Indemnifying Party</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;11.3</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.79</B> &#147;<B>Infringement Claim</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;12.12.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.80</B> &#147;<B>Initial Indication</B>&#148; means primary biliary cholangitis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.81</B> &#147;<B>Initial Indication Development Plan</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;3.4.2</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.82</B> &#147;<B>Initial Term</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;13.1</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.83</B> &#147;<B>Intellectual Property</B>&#148; means, in any and all jurisdictions throughout the world, all (a)&nbsp;Patents, (b)
trademarks, service marks, trade dress, slogans, logos, symbols, trade names, brand names or other identifiers of source or goodwill recognized by any Governmental Authority, including registrations and applications for registration thereof and
including the goodwill symbolized thereby or associated therewith, (c)&nbsp;Internet domain names and associated uniform resource locators and social media addresses and accounts, (d)&nbsp;copyrights, whether in published and unpublished works of
authorship, registrations, applications, renewals and extensions therefor, mask works, and any and all similar rights recognized in a work of authorship by a Governmental Authority, (e)&nbsp;any trade secret rights in any inventions, discoveries,
improvements, trade secrets and all other confidential or proprietary information (including <FONT STYLE="white-space:nowrap">know-how,</FONT> data (including data), formulas, processes and procedures, research records, records of inventions, test
information, and market surveys), and all rights to limit the use or disclosure thereof, (f)&nbsp;registered and unregistered design rights, (g)&nbsp;rights of privacy and publicity and (h)&nbsp;any and all other intellectual property rights
recognized by any Governmental Authority under the Applicable Law of any country throughout the world. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.84</B>
&#147;<B>Janssen</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.6.3</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.85</B> &#147;<B>Janssen License
Agreement</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.6.3</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.86</B> &#147;<B>Japanese Trademark</B>&#148; has the meaning set forth
in<U>&nbsp;Section 12.11.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.87</B> &#147;<B>Joint Program IP</B>&#148;&nbsp;has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;12.2.3</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.88</B> &#147;<B>Joint Program IP Patents</B>&#148; means all Patents within the Joint
Program IP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.89</B> &#147;<B>Joint Steering Committee</B>&#148; or &#147;<B>JSC</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;2.2.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.90</B> &#147;<B>JRA Exception</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;12.1.2</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.91</B> &#147;<B>Kaken</B>&#148; has the meaning set forth in the preamble. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.92</B> &#147;<B>Kaken Background Technology</B>&#148; means any Patents and <FONT STYLE="white-space:nowrap">Know-How</FONT> Controlled by
Kaken or its Affiliates (solely or jointly with a Third Party)&nbsp;(a) in existence as of the Effective Date or (b)&nbsp;arising during the Term but independently from this Agreement, that, in each case of (a)&nbsp;and (b), are necessary or
reasonably useful for the Development, Manufacture or Commercialization of any Licensed Products in the Field of Use, and are used or practiced by Kaken or any of its Affiliates in connection with the Development, Manufacture or Commercialization of
Licensed Products in the Field of Use in the Kaken Territory, and, for clarity, excluding the Kaken Program IP and Kaken&#146;s interest in the Joint Program IP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.93</B> &#147;<B>Kaken Controlled Patents</B>&#148;&nbsp;has the meaning set forth in <U>Section</U><U></U><U>&nbsp;12.5.1.1</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.94</B> <B>&#147;Kaken Fiscal Quarter</B>&#148; means one of the respective periods of three (3)&nbsp;consecutive calendar months ending on
June&nbsp;30, September&nbsp;30, December&nbsp;31 or March&nbsp;31 of a particular Kaken Fiscal Year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.95</B> &#147;<B>Kaken Fiscal
Year</B>&#148; means each successive period of twelve (12)&nbsp;months commencing on April&nbsp;1 of any year and ending on March&nbsp;31 of the succeeding year. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.96</B> &#147;<B>Kaken Indemnitees</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;11.2</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.97</B> &#147;<B>Kaken Licensed Technology</B>&#148; means, collectively the Kaken Program IP and Kaken&#146;s interest in the Joint
Program IP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.98</B> &#147;<B>Kaken Program IP</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;12.2.2</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.99</B> &#147;<B>Kaken Program IP Patents</B>&#148; means all Patents within the Kaken Program IP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.100</B> &#147;<B>Kaken Territory</B>&#148; means Japan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.101</B> &#147;<B>Kaken Territory Commercialization Plan</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.2</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.102</B> &#147;<B><FONT STYLE="white-space:nowrap">Know-How</FONT></B>&#148; means all commercial, technical, scientific and other <FONT
STYLE="white-space:nowrap">know-how</FONT> and information, trade secrets, knowledge, technology, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings,
assembly procedures, computer programs, specifications, data and results (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, preclinical, clinical, safety, Manufacturing and quality control data
and <FONT STYLE="white-space:nowrap">know-how,</FONT> including regulatory data, study designs and protocols), and Materials, in all cases, whether or not confidential, proprietary, patented or patentable, in written, electronic or any other form
now known or hereafter developed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.103</B> &#147;<B>Knowledge of CymaBay</B>&#148; means, with respect to a particular fact or item of
information that such term is applied to under this Agreement, that based on their actual knowledge (after reasonable inquiry) as of the Effective Date, [***] are aware that such fact or item of information is not true. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.104</B> &#147;<B>Licensed Compound</B>&#148; means Seladelpar, including any deuterated
form, hydrate, solvate, salt, polymorph, prodrug, metabolite, isomer, stereoisomer, diastereomer, enantiomer and racemate of Seladelpar. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.105</B> &#147;<B>Licensed Product</B>&#148; means any pharmaceutical product containing Licensed Compound as an active pharmaceutical
ingredient, in any strengths, forms, formulations, and modes of administration and delivery. For clarity, a Combination Product is a Licensed Product, but is a different Licensed Product from a Licensed Product that contains Licensed Compound as the
sole active pharmaceutical ingredient. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.106</B> &#147;<B>Lien</B>&#148; means any lien, pledge, hypothecation, charge, mortgage,
security interest, encumbrance, adverse claim, option, right of first refusal, preemptive right, community property interest or other restriction of any nature (including any restriction on the voting of any security, any restriction on the transfer
of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any
asset). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.107</B> &#147;<B>Losses</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;11.1</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.108</B> &#147;<B>Manufacturing</B>&#148; or &#147;<B>Manufacture</B>&#148; means, with respect to a particular product, all activities
related to the manufacture of such product, including manufacturing active pharmaceutical ingredient and drug product for Development or Commercialization, packaging, <FONT STYLE="white-space:nowrap">in-process</FONT> and finished product testing,
release of such product or any component or ingredient thereof, quality assurance and quality control activities related to manufacturing and release of such product, ongoing stability tests, storage, shipment, and regulatory activities related to
any of the foregoing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.109</B> &#147;<B>Manufacturing Price</B>&#148; means the Cost of Manufacturing (as such term is defined in the
Commercial Supply Agreement). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.110</B> &#147;<B>Material Communications</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;5.1.2</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.111</B> &#147;<B>Materials</B>&#148; means all tangible compositions of matter, devices,
articles of manufacture, assays, biological, chemical or physical materials and other similar materials. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.112</B>
&#147;<B>MHLW</B>&#148; means the Japanese Ministry of Health, Labour and Welfare or any successor agency thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.113</B>
&#147;<B>NDA</B>&#148; means any New Drug Application as described in 21 C.F.R. &#167; 314, or any corresponding application for Regulatory Approval in any country or jurisdiction other than the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.114</B> &#147;<B>Negotiation Period</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;10.6</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.115</B> &#147;<B>Net Recovery</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;12.6.7</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.116</B> &#147;<B>Net Sales</B>&#148; means, with respect to a Licensed Product, the gross amounts invoiced or otherwise charged by or on
behalf of Kaken or any of its Related Parties for any Licensed Product sold to Third Parties (other than Sublicensees, but including wholesalers and distributors) in bona fide, arms-length transactions, as determined in accordance with Accounting
Standards consistently applied, less the following permitted deductions to the extent actually taken or allowed with respect to such sales: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">In the case of any sale
or other disposal of a Licensed Product between or among Kaken and any of its Related Parties for resale, Net Sales will be calculated only on the value charged or invoiced on the first <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> sale
thereafter to a Third Party (other than a Sublicensee, but including wholesalers and distributors). In the case of any sale or other disposal for value, such as barter or countertrade, of any Licensed
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Product, or part thereof, other than in an arm&#146;s length transaction exclusively for money, Net Sales will be calculated on the value of the <FONT STYLE="white-space:nowrap">non-cash</FONT>
consideration received or the fair market price (if higher) of such Licensed Product(s) in the country of sale or disposal. In addition, in the case of any sale to a distributor or other Third Party other than in an arm&#146;s length transaction or
in a transaction under which Kaken or any of its Related Parties receives cash consideration other than or in addition to that metered on units of Licensed Product, then for purposes of the calculation of Net Sales associated with such transaction,
all amounts paid and other value provided by the distributor or other Third Party to Kaken or such Related Party will be equitably apportioned between the purchased units of Licensed Product and any other products or services provided by Kaken or
such Related Party to the distributor or other Third Party and the amount apportioned to units of Licensed Product will be included in the calculation of Net Sales. Kaken will promptly deliver to CymaBay a written report setting forth such
apportionment. If CymaBay disagrees with such apportionment, CymaBay will so notify Kaken, and the Parties will meet to discuss and resolve such disagreement in good faith. If the Parties are unable to agree in good faith on such apportionment
within thirty (30)&nbsp;days, the matter will be submitted to Expedited Arbitration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the following will
not be included in Net Sales: (i)&nbsp;samples of Licensed Product used to promote additional Net Sales, in amounts consistent with normal business practices of the selling party; and (ii)&nbsp;disposal or use of Licensed Products in Clinical
Studies or under compassionate use, patient assistance, named patient use, or <FONT STYLE="white-space:nowrap">non-registrational</FONT> studies or other similar programs or studies where the Licensed Product is supplied without charge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If Kaken desires to sell a Licensed Product as part of a Combination Product, and the Parties agree (pursuant to
<U>Section</U><U></U><U>&nbsp;7.1.5</U>) that Kaken may do so, then the Supply Transfer Price and Net Sales for purposes of calculating amounts owed hereunder for such Combination Product will be calculated in the manner as agreed to by the Parties
pursuant to <U>Section</U><U></U><U>&nbsp;7.1.5</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.117</B> &#147;<B><FONT STYLE="white-space:nowrap">New-Controlling</FONT>
Party</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;12.6.5.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.118</B> &#147;<B>New CymaBay IP</B>&#148;
has the meaning set forth in <U>Section</U><U></U><U>&nbsp;12.2.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.119</B> &#147;<B>NHI</B>&#148; means the National Health
Insurance in Japan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.120</B> &#147;<B>NHI Price</B>&#148; means the NHI drug price in Japan (<I>yakka</I>) for Licensed Product, as
established by the Central Social Insurance Medical Council (Chuikyo) of the MHLW (or successor agency). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.121</B> &#147;<B><FONT
STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;7.5</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.122</B> &#147;<B>Nonclinical Studies</B>&#148; means all <FONT STYLE="white-space:nowrap">non-human</FONT> studies, including preclinical
studies and toxicology studies, of Licensed Products. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.123</B> &#147;<B><FONT STYLE="white-space:nowrap">Non-Controlling</FONT>
Party</B>&#148; has the meaning set forth in<U>&nbsp;Section 12.6.4</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.124</B> &#147;<B><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs</B>&#148; means, with respect to certain activities hereunder, direct expenses paid or payable by either Party or its Affiliate to Third Parties and specifically identifiable and incurred
to conduct such activities for a Licensed Product, including payments to contract personnel (including contractors, consultants and subcontractors). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.125</B> &#147;<B>Parties</B>&#148; has the meaning set forth in the preamble. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.126</B> &#147;<B>Party</B>&#148; has the meaning set forth in the preamble. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.127</B> &#147;<B>Patent</B>&#148; means all patents and patent applications and all substitutions, divisions, continuations, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> any patent issued with respect to any such patent applications, any reissue, reexamination, utility models or designs, renewal or extension (including
any supplementary protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, and all counterparts and equivalents of any of the foregoing in any country or
jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.128</B> &#147;<B>Patent Challenge</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;13.7</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.129</B> &#147;<B>Patent Costs</B>&#148; means the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Out-of-Pocket</FONT></FONT> Costs and expenses paid to outside legal counsel and other Third Parties (including to any licensor pursuant to any <FONT STYLE="white-space:nowrap">in-license),</FONT> and filing and
maintenance expenses, incurred in Prosecuting and Maintaining Patents and enforcing and defending them. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.130</B>
&#147;<B>Person</B>&#148; means any natural person, corporation, unincorporated organization, partnership, association, sole proprietorship, joint stock company, joint venture, limited liability company, trust or government, or Governmental
Authority, or any other similar entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.131</B> &#147;<B>Phase 1 Study</B>&#148; means a clinical study of an investigational product
in healthy volunteers and patients with the primary objective of characterizing its safety, tolerability, and pharmacokinetics and identifying a recommended dose and regimen for future studies as described in 21 C.F.R. &#167; 312.21(a), or a
comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.132</B>
&#147;<B>Phase 2 Study</B>&#148; means a clinical study of an investigational product in patients with the primary objective of characterizing its activity in a specific disease state as well as generating more detailed safety, tolerability, and
pharmacokinetics information as described in 21 C.F.R. &#167; 312.21(b), or a comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States including a human clinical trial that is also designed
to satisfy the requirements of 21 C.F.R. &#167; 312.21(a) or corresponding foreign regulations and is subsequently optimized or expanded to satisfy the requirements of 21 C.F.R. &#167; 312.21(b) (or corresponding foreign regulations) or otherwise to
enable a Phase 3 Study (e.g., a phase 1/2 trial). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.133</B> &#147;<B>Phase 3 Study</B>&#148; means a clinical study of an
investigational product in patients that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to obtain Regulatory Approval in any country as described in 21 C.F.R. &#167; 312.21(c), or a
comparable clinical study prescribed by the relevant Regulatory Authority in a country other than the United States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.134</B>
&#147;<B>PMDA</B>&#148; means Japan&#146;s Pharmaceuticals and Medical Devices Agency or any successor agency thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.135</B>
&#147;<B>Post-Marketing Study</B>&#148; means a <FONT STYLE="white-space:nowrap">non-human</FONT> or human clinical study of a Licensed Product initiated after receipt of Regulatory Approval for such Licensed Product in a country or territory, that
is required by the Regulatory Authority in such country or territory to maintain the Regulatory Approval for such Licensed Product in such country or territory but excluding any Supplemental Study. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.136</B> &#147;<B>Pricing Approval</B>&#148; means such governmental approval, agreement, determination, or decision establishing prices
for a Licensed Product that can be charged or reimbursed in regulatory jurisdictions where the applicable Governmental Authorities approve or determine the price or reimbursement of pharmaceutical products. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.137</B> &#147;<B>Pricing Matters</B>&#148; means all issues and decisions regarding (a)&nbsp;price, price terms and other contract terms
with respect to Licensed Product sales, including discounts, rebates, other price concessions and service fees to payors and purchasers and (b)&nbsp;reimbursement programs applicable to a Licensed Product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.138</B> &#147;<B>Proceeding</B>&#148; means an action, suit or other similar proceeding before a governmental tribunal. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.139</B> &#147;<B>Promotional Materials</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;4.4</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.140</B> &#147;<B>Prosecution and Maintenance</B>&#148; means, with respect to a
particular Patent, the preparation, filing, prosecution and maintenance of such Patent, as well as <FONT STYLE="white-space:nowrap">re-examinations,</FONT> reissues and the like with respect to that Patent, together with the conduct of
interferences, the defense of oppositions and other similar proceedings with respect to that Patent (and the foreign equivalents of any of the foregoing). &#147;Prosecute and Maintain&#148; and &#147;Prosecuting and Maintaining&#148; have
corresponding meanings. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.141</B> &#147;<B>Regulatory Approval</B>&#148; means all approvals issued by Regulatory Authorities necessary
for the manufacture, marketing, importation and sale of a product for one or more indications in a country or regulatory jurisdiction, which may include satisfaction of all applicable regulatory and notification requirements, but not including any
Pricing Approvals. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.142</B> &#147;<B>Regulatory Authority</B>&#148; means any Governmental Authority involved in granting approvals
for the Development, Manufacturing, Commercialization, Pricing Approval of pharmaceutical products, including the FDA, the European Medicines Agency, the European Commission, the MHLW and the PMDA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.143</B> &#147;<B>Regulatory Exclusivity</B>&#148; means, with respect to any product, any exclusive marketing rights or data exclusivity
rights with respect to such product (other than provided by Patents Covering such product) conferred for the Kaken Territory by any Regulatory Authority or Applicable Law of the Kaken Territory. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.144</B> &#147;<B>Regulatory Filing</B>&#148; means any submission to a Regulatory Authority, including all applications, registrations,
licenses, authorizations and approvals (including Regulatory Approvals), together with any related correspondence and documentation submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any
communications with any Regulatory Authority) and all supporting documents and all clinical studies and tests, relating to a product and all data contained in any of the foregoing, including all INDs, NDAs, regulatory drug lists, advertising and
promotion documents, clinical data, adverse event files and complaint files, and includes any submission to a regulatory advisory board, marketing authorization application, and any supplement or amendment to any of the foregoing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.145</B> &#147;<B>Regulatory Materials</B>&#148; means any regulatory notification, communication, correspondence, Regulatory Filings,
Regulatory Approvals and other filings made to, received from or otherwise conducted with a Regulatory Authority related to Developing, Manufacturing, obtaining marketing authorization, marketing, selling or otherwise Commercializing a
pharmaceutical product in a particular country or jurisdiction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.146</B> &#147;<B>Regulatory Milestone Event</B>&#148; has the meaning
set forth in <U>Section</U><U></U><U>&nbsp;8.2.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.147</B> &#147;<B>Regulatory Milestone Payment</B>&#148; has the meaning set
forth in <U>Section</U><U></U><U>&nbsp;8.2.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.148</B> &#147;<B>Related Party(ies)</B>&#148; means (a)&nbsp;with respect to Kaken,
Kaken&#146;s Affiliates and Sublicensees, and (b)&nbsp;with respect to CymaBay, CymaBay&#146;s Affiliates and Sublicensees. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.149</B>
&#147;<B>Representatives</B>&#148; means, with respect to a Party, the Affiliates of such Party, and each of such Party&#146;s and its Affiliates&#146; respective officers, directors, managers, employees, consultants, and contractors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.150</B> &#147;<B>Royalty Patents</B>&#148; means [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.151</B> &#147;<B>Royalty Term</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.4.3</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.152</B> &#147;<B>Safety Concern</B>&#148; means, with respect to any Licensed Product, (a) [***], or (b) [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.153</B> &#147;<B>Sales Milestone Event</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.3.1</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.154</B> &#147;<B>Sales Milestone Payment</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;8.3.1</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.155</B> &#147;<B>SDEA</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;5.5</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.156</B> &#147;<B>Securitization Transaction</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;14.1.2</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.157</B> &#147;<B>Seladelpar</B>&#148; means the molecule known as seladelpar and described on <U>Schedule</U><U></U><U>&nbsp;1.157</U>.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.158</B> &#147;<B>Serious Adverse Event</B>&#148; means an adverse drug experience or
circumstance that results in any of the following outcomes: (a)&nbsp;death, (b) life-threatening condition, (c)&nbsp;inpatient hospitalization or a significant prolongation of existing hospitalization, (d)&nbsp;persistent or significant disability
or incapacity or substantial disruption of the ability to conduct normal life functions, (e)&nbsp;congenital anomaly/birth defect, or (f)&nbsp;significant intervention required to prevent permanent impairment or damage. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.159</B> &#147;<B>Sublicensee</B>&#148; means a Third Party to which a Party or its Affiliate has granted or grants rights, as permitted
under this Agreement, to Develop, Manufacture or Commercialize Licensed Product, or any further sublicensee of such rights (regardless of the number of tiers, layers or levels of sublicenses of such rights). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.160</B> &#147;<B>Supplemental Study</B>&#148; means any Clinical Study (other than any Post-Marketing Study) for a Licensed Product beyond
what is contemplated in the Initial Indication Development Plan. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.161</B> &#147;<B>Supply Agreements</B>&#148; means the Clinical
Supply Agreement and the Commercial Supply Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.162</B> &#147;<B>Supply Transfer Price</B>&#148; means, with respect to
Licensed Product delivered [***] by (or on behalf of) CymaBay to Kaken (or its Related Party) pursuant to the Commercial Supply Agreement, [***] of the amount that equals [***] NHI Price for the Licensed Product [***]. For example, if NHI Price is
[***], the Supply Transfer Price shall be [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.163</B> &#147;<B>Technology Transfer Plan</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;3.9.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.164</B> &#147;<B>Term</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;13.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.165</B> &#147;<B>Territory</B>&#148; means (a)&nbsp;with respect to CymaBay, the CymaBay
Territory and (b)&nbsp;with respect to Kaken, the Kaken Territory. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.166</B> &#147;<B>Third Party</B>&#148; means any Person other than
Kaken, CymaBay or their respective Affiliates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.167</B> &#147;<B>Third Party Action</B>&#148; has the meaning set forth in
<U>Section</U><U></U><U>&nbsp;12.6.3</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.168</B> &#147;<B>Trademark</B>&#148; means any trademark, trade name, service mark, service
name, brand, domain name, trade dress, logo, slogan or other indicia of origin or ownership, including the goodwill and activities associated with each of the foregoing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.169</B> &#147;<B>United States</B>&#148; or &#147;<B>U.S.</B>&#148; means the United States of America and its territories, possessions
and commonwealths. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.170</B> &#147;<B>Valid Claim</B>&#148; means a claim of a Patent that (a)&nbsp;has not been rejected, revoked or
held to be invalid or unenforceable by a court or other authority of competent jurisdiction, from which decision no appeal can be further taken, or (b)&nbsp;has not been finally abandoned, disclaimed or admitted to be invalid or unenforceable
through reissue or disclaimer. In order to be a Valid Claim, any claim being prosecuted in a pending patent application must be prosecuted in good faith and not have been pending for more than [***] from the filing date of the first utility patent
application (or equivalent concept in any such country) in the patent application family of such patent application in the country in question, in which case it will cease to be considered a Valid Claim until the patent issues and recites said
claim. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.171</B> &#147;<B>Withdrawing Party</B>&#148; has the meaning set forth in <U>Section</U><U></U><U>&nbsp;12.6.5.1</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.172</B> &#147;<B>Yen</B>&#148; or &#147;<B>JPY</B>&#148; means the legal tender of Japan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GOVERNANCE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.1</B>
<B><U>Alliance Managers</U></B>. Promptly following the Effective Date, each Party will designate an individual to facilitate communication and coordination of the Parties&#146; activities under this Agreement relating to Licensed Products for
Commercialization in the Kaken Territory (each, an &#147;<B>Alliance Manager</B>&#148;). Each Alliance Manager may also serve as a representative of its respective Party on one or more Committees. For clarity, unless an Alliance Manager is a
representative of its respective Party on a particular Committee, each Alliance Manager will have no voting right on any Committee unless otherwise agreed to in writing by the Parties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B><U>Joint Steering Committee</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2.1</B> <I>Formation; Composition; Dissolution</I>. Within thirty (30)&nbsp;days after the Effective Date, the Parties will establish a
committee to provide strategic oversight of the Parties&#146; activities under the Collaboration (the &#147;<B>Joint Steering Committee</B>&#148; or &#147;<B>JSC</B>&#148;). Each Party will initially appoint three (3)&nbsp;representatives to the
JSC. Each representative on the JSC shall have knowledge and expertise in the Development and Commercialization of molecules and products similar to the Licensed Products and having sufficient seniority within the applicable Party to provide
meaningful input and make decisions arising within the scope of the JSC&#146;s responsibility. The JSC may change its size from time to time by mutual consent of the Parties,<I><U>&nbsp;provided</U></I>&nbsp;that the JSC will consist at all times of
an equal number of representatives of each of CymaBay and Kaken. Each Party may replace one or more of its JSC representatives at any time upon written notice to the other Party. The JSC may invite <FONT STYLE="white-space:nowrap">non-members</FONT>
to participate in the discussions and meetings of the JSC,<I><U>&nbsp;provided</U></I>&nbsp;that such participants are bound under written obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> no less protective of the
Parties&#146; Confidential Information than those set forth in this Agreement. For clarity, such <FONT STYLE="white-space:nowrap">non-member</FONT> participants shall have no voting rights or authority at the JSC. The JSC will be chaired on a Kaken
Fiscal Year basis by a chairperson alternately designated by CymaBay or Kaken. The initial chairperson of the JSC for the period commencing on the Effective Date and ending on March&nbsp;31, 2024 will be a CymaBay designated chairperson, who will
then be replaced by a Kaken designated chairperson on April&nbsp;1, 2024, and so forth. The JSC chairperson&#146;s responsibilities will include conducting meetings of the JSC, including, when feasible, ensuring that objectives for each meeting are
set and achieved. The JSC will exist for so long as there is Licensed Product being Developed or Commercialized under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2.2</B> <I>Specific Responsibilities of the JSC</I>. The JSC will have the following responsibilities in connection with the
Collaboration: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2.2.1</B> reviewing, discussing and approving the Initial Indication Development Plan and any amendments to the
Initial Indication Development Plan; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2.2.2</B> reviewing, discussing and approving the initial CMC Work Plan and any updates or
amendments thereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2.2.3</B> reviewing, discussing and approving any proposed Post-Marketing Studies for any Licensed Product in
the Kaken Territory; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2.2.4</B> approving the commercial positioning with respect to target patients of the Licensed Products in the
Kaken Territory and approving any proposed material changes thereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2.2.5</B> approving the key promotional message with respect to
the Licensed Products in the Kaken Territory and approving any proposed material changes thereto; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2.2.6</B> approving the Kaken
Territory Commercialization Plan for each Licensed Product, including, in each case, any amendments thereto; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2.2.7</B> reviewing, discussing and providing input on the strategy with respect to
Pricing Matters, including the price negotiation strategy with Regulatory Authorities for the Licensed Products in the Kaken Territory and other communications with Regulatory Authorities, and approving such strategy with respect to Pricing Matters
(including the price bands for purposes of such strategy) for the Licensed Products in the Kaken Territory; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2.2.8</B> providing a
forum for CymaBay to raise for discussion and resolution of any decision or action regarding the Development or Commercialization of the Licensed Products in the Kaken Territory perceived by CymaBay to be deviating from the Harmonization Principle;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2.2.9</B> coordinating the filing of Joint Program IP Patent applications; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2.2.10</B> discussing and, if appropriate, approving any Kaken request to conduct Development of Licensed Product outside the Kaken
Territory; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2.2.11</B> determining and overseeing a reasonable and expeditious process to identify, and under which CymaBay will
provide to Kaken, any submissions, filings or other material communications with a Regulatory Authority with respect to a Licensed Product in the CymaBay Territory to which Kaken needs access to support obtaining or maintaining a Regulatory Approval
for a Licensed Product in the Kaken Territory; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2.2.12</B> facilitating the flow of information between the Parties with respect to
the Commercialization of Licensed Products in the Kaken Territory, including information as to pricing for the Licensed Products; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2.2.13</B> reviewing Promotional Materials pursuant to the provisions of <U>Section</U><U></U><U>&nbsp;4.4</U>; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2.2.14</B> discussing strategies for abating a Competitive Infringement of any Licensed Product within either Party&#146;s respective
Territory as contemplated by <U>Section</U><U></U><U>&nbsp;12.6.1</U>; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2.2.15</B> establishing such additional joint subcommittees
of the JSC as it deems necessary to oversee activities relating to the Licensed Products in the Kaken Territory to achieve the objectives and intent of the Collaboration; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2.2.16</B> resolving any issues escalated by, or disputes within, any joint subcommittee of the JSC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2.3</B> <I>Meetings</I>. The JSC will meet (a)&nbsp;at least [***] prior to March&nbsp;31, 2024, (b) at least [***] per Kaken Fiscal Year
after March&nbsp;31, 2024 and prior to obtaining Regulatory Approval for the Initial Indication in the Kaken Territory and (c)&nbsp;at least [***] per Kaken Fiscal Year after obtaining such Regulatory Approval, unless the Parties mutually agree in
writing to not meet or to meet at a different frequency. The JSC may meet in person, by videoconference, or by teleconference. The first JSC meeting shall be held within [***]. Meetings of the JSC will be effective only if at least one
(1)&nbsp;representative of each Party is present or participating in such meeting. Each Party will bear the expense of its respective JSC members&#146; participation in JSC meetings, with any fees for interpretation being borne fifty percent (50%)
by each Party. No later than five (5)&nbsp;Business Days prior to any meeting of the JSC (or such shorter time period as the Parties may agree), the Alliance Managers together will prepare and circulate an agenda for such
meeting;<I><U>&nbsp;provided</U></I><I>,</I><I></I><I><U>&nbsp;however</U></I>, that either Party will be free to propose additional topics to be included on such agenda, either prior to or in the course of such meeting, and any Party that will be
presenting to the JSC at any meeting as part of such agenda will prepare and provide detailed materials to the JSC representatives to support discussion. Either Party may also call a special meeting of the JSC (by videoconference, teleconference or
in person) by providing at least ten (10)&nbsp;Business Days prior written notice to the other Party if such Party reasonably believes that a significant matter must be addressed prior to the next scheduled meeting, in which event such Party will
work with the Alliance Managers to provide the members of the JSC no later than three (3)&nbsp;Business Days prior to the special meeting with an agenda for the meeting and materials reasonably adequate to enable an informed decision, with the
reasonable fees for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interpretation at such a special meeting being borne entirely by the Party requesting the special meeting. The JSC chairperson will be responsible for preparing reasonably detailed written
minutes of JSC meetings that reflect all decisions made and action items identified at such meetings. The JSC chairperson will send meeting minutes to each member of the JSC for review and approval within ten (10)&nbsp;Business Days after each JSC
meeting. Minutes will be deemed approved unless one or more members of the JSC objects to the accuracy of such minutes within ten (10)&nbsp;Business Days of receipt. Any material changes proposed to any meeting minutes by either Party&#146;s members
of the JSC will be promptly circulated by the JSC chairperson to each member of the JSC for review and approval within ten (10)&nbsp;Business Days of receipt, with such process repeating until the meeting minutes are approved by all JSC members.
Minutes will be officially endorsed by the JSC at the next JSC meeting and will be signed by one (1)&nbsp;JSC representative of each Party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.2.4</B> <I>Decision-Making</I>. The representatives from each Party will have, collectively, one (1)&nbsp;vote on behalf of that Party.
Approvals of the JSC will require unanimous agreement; <I>provided</I>, <I>however</I>, that if CymaBay has ceased its participation in the JSC pursuant to <U>Section</U><U></U><U>&nbsp;2.4</U> or <U>13.8.3</U>, approvals of the JSC will require
only the vote of the representative appointed by Kaken. If the JSC cannot reach unanimous agreement on an issue that comes before the JSC within fifteen (15)&nbsp;days of the meeting where such issue was raised and over which the JSC has oversight,
the Parties will refer such issue for resolution in accordance with <U>Section</U><U></U><U>&nbsp;2.3</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.3 <U>Resolution of
Committee Disputes.</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.3.1</B> <I>Referral to Executive Officers and Executive Management</I>. The JSC may refer any matter as
to which the JSC cannot reach a consensus decision to the Executive Officers for resolution. If the JSC does so, the JSC will submit in writing the respective positions of the Parties to their respective Executive Officers. Such Executive Officers
will use good faith efforts, in compliance with this <U>Section</U><U></U><U>&nbsp;2.3.1</U>, to resolve promptly such matter, which good faith efforts will include at least [***] between such Executive Officers within [***] Business Days after the
JSC&#146;s submission of such matter to them. If the Executive Officers are unable to reach unanimous agreement on any such matter within [***] days of the matter being presented to them, then: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> if the matter escalated by the JSC relates to the Exploitation of the Licensed Products in the Field of Use in the Kaken Territory
(including Pricing Matters, the Initial Indication Development Plan, the CMC Work Plan and the Kaken Territory Commercialization Plan), Kaken will have final decision-making authority over such matter (other than with respect to the matters covered
by (c));<I><U>&nbsp;provided</U></I>,<I><U>&nbsp;however</U></I>, that Kaken shall not have final decision-making authority over matters relating to (i)&nbsp;the Manufacture of the Licensed Products in the Field of Use in the Kaken Territory unless
and until Kaken takes over the Manufacture of the Licensed Products and (ii)&nbsp;the Global Development Plan; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> if the matter
escalated by the JSC relates to the Global Development Plan, to the extent not covered by clause (a) (other than with respect to the matters covered by (c)), CymaBay will have final decision-making authority over such matter; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> if the matter escalated by the JSC relates to (i)&nbsp;whether a decision, strategy or implementation of a strategy is consistent
with the Harmonization Principle, or (ii)&nbsp;if the matter otherwise does not fall within those specified in either clause (a)&nbsp;or clause (b), the Executive Officers will submit their respective positions on such matter to be resolved by
Expedited Arbitration. Notwithstanding anything herein to the contrary, no exercise of a Party&#146;s decision-making authority on any matters may, without the other Party&#146;s prior written consent, (i)&nbsp;result in a material increase in the
other Party&#146;s or its Related Parties&#146; obligations, costs or expenses, including expenditure of such Party&#146;s resources, under this Agreement, the Initial Indication Development Plan, the CMC Work Plan or the Kaken Territory
Commercialization Plan, (ii)&nbsp;unilaterally modify, amend or waive its own compliance with the terms or conditions of this Agreement, or (iii)&nbsp;otherwise conflict with this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.3.2</B> <I>Good Faith</I>. In conducting themselves on Committees, and in exercising their rights under this<U>&nbsp;Section 2.3</U>, all
representatives of both Parties will consider diligently, reasonably and in good faith all input received from the other Party and will use reasonable efforts to reach unanimous agreement on all matters before them. In exercising any decision-making
authority granted to it under this<U>&nbsp;Section 2.3</U>, each Party will act based on its good faith business judgment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.4</B> <B><U>General Committee Authority</U></B>. Each Committee has solely the powers
expressly assigned to it in this <U>ARTICLE 2</U>. No Committee will have any power to amend, modify, or waive the terms or conditions of this Agreement or compliance with the terms and conditions of this Agreement. CymaBay may elect, in writing to
Kaken, at any time to cease its participation in a particular Committee. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEVELOPMENT </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.1</B>
<B><U>Kaken Responsibility; Costs</U></B>. Subject to the responsibilities of the JSC and the other terms and conditions of this <U>ARTICLE 3</U>&nbsp;and this Agreement, Kaken will be responsible for conducting or having conducted, in accordance
with the Initial Indication Development Plan and the Harmonization Principle, the additional Development of the Licensed Products in the Initial Indication in the Kaken Territory as are needed, in addition to the Nonclinical Study data, CMC data and
Clinical Study data provided by CymaBay hereunder, for purposes of obtaining and maintaining Regulatory Approval of Licensed Products in the Initial Indication in the Kaken Territory and in support of Commercializing such Licensed Products in the
Initial Indication in the Kaken Territory, including conducting Clinical Studies pursuant to the Initial Indication Development Plan and the preparation of electronic data with respect to such Clinical Studies that meets CDISC compliance in the
Kaken Territory. Subject to&nbsp;the rest of this <U>Section</U><U></U><U>&nbsp;3.1</U>, Kaken will bear one hundred percent (100%) of the Development Costs incurred in connection with the foregoing Development activities, including the Development
Costs that are related to preparing and filing applications for Regulatory Approval or submissions to Regulatory Authorities (including associated filing fees, translation expenses for translation into Japanese and legal and other professional
service fees) in the Initial Indication in the Kaken Territory based upon data from Clinical Studies conducted by Kaken pursuant to the Initial Indication Development Plan for purposes of obtaining and maintaining Regulatory Approval of Licensed
Products in the Initial Indication in the Kaken Territory and post-Regulatory Approval clinical research in support of Commercializing such Licensed Products in the Initial Indication in the Kaken Territory. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B><U>CymaBay Retained Rights</U></B>. CymaBay retains the exclusive rights to conduct (or have conducted), and will have sole
discretion and control over, the Development of the Licensed Products for purposes of obtaining and maintaining Regulatory Approval for Commercialization of such Licensed Products anywhere in the world, <I>other than</I> for use in the Initial
Indication in the Kaken Territory. CymaBay will bear one hundred percent (100%) of the Development Costs incurred in connection with the foregoing Development activities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B><U>CymaBay Cooperation. </U></B>Upon Kaken&#146;s reasonable request, CymaBay shall provide reasonable cooperation and assistance
to Kaken in connection with Kaken&#146;s Development activities in the Initial Indication in the Kaken Territory [***] subject to the reasonable availability of CymaBay&#146;s relevant resources. Such cooperation will include, but is not limited to
[***], Third Party manufacturer compliance with [***], and referrals to relevant [***] as reasonably requested by Kaken. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.4</B>
<B><U>Development Plans</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.4.1</B> <I>Global Development Plan</I>. CymaBay&#146;s worldwide plan for the Development of the
Licensed Products is attached hereto as <U>Schedule</U><U></U><U>&nbsp;3.4.1</U> (as may be updated by CymaBay from time to time so long as such update (i)&nbsp;does not materially adversely impact the rights or increase the obligations of Kaken and
(ii)&nbsp;is reported to the JSC at the next JSC meeting) (the &#147;<B>Global Development Plan</B>&#148;). CymaBay will keep Kaken reasonably informed of the status, progress and results of major Development activities for Licensed Products
conducted by or on behalf of CymaBay. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.4.2</B> <I>Initial Indication Development Plan</I>. No later than [***] following the
Effective Date, Kaken will prepare and deliver to the JSC for its review and input and approval a reasonable written plan (the &#147;<B>Initial Indication Development Plan</B>&#148;) that summarizes in reasonable detail Development activities that
are necessary to be undertaken for the Licensed Product to support obtaining Regulatory Approval for the Initial Indication in the Kaken Territory as soon as reasonably practicable, including the anticipated timeline of such development. Such plan
will include Development activities for the Licensed Products in the Field of Use in the Kaken Territory and will be consistent with the Harmonization Principle and the above timing goals.&nbsp;The JSC will review, discuss and approve the Initial
Indication Development Plan and any amendments thereto in accordance with <U>Section</U><U></U><U>&nbsp;2.2.2.1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.4.3</B> <I>CMC
Work Plan</I>. As soon as practicable after the Effective Date, the Parties will work together to prepare and deliver to the JSC for its review, input and approval in accordance with <U>Section</U><U></U><U>&nbsp;2.2.2.2</U>, a reasonable written
plan that summarizes the CMC Activities that are necessary to be undertaken for the Licensed Product to support obtaining Regulatory Approval for the Initial Indication in the Kaken Territory and subsequent Commercialization thereof in the Initial
Indication in the Kaken Territory, which plan will include the applicable timetable and be consistent with the Harmonization Principle (the &#147;<B>CMC Work Plan</B>&#148;).&nbsp;The CMC Work Plan will be updated as appropriate from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> and include all CMC activities related to all phases of Manufacturing the Licensed Product through and including the packaging of Licensed Product in the format
determined by the JSC to be preferable for the Japanese market [***]. The JSC will also review from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> updates and amendments to the CMC Work Plan submitted to
it in accordance with<U>&nbsp;Section </U><U>2.2.2.2</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.4.4</B> <I>CymaBay Phase 3 Study.</I> If CymaBay (itself or through an
Affiliate) desires to conduct a Phase 3 Study of a Licensed Product in an Additional Indication, then CymaBay will notify Kaken thereof in writing. If Kaken desires to participate in any such Phase 3 Study, CymaBay and Kaken will, through the JSC,
discuss such participation, including applicable activities, terms and conditions of such participation. If CymaBay approves Kaken&#146;s participation in such Phase 3 Study, such approval not to be unreasonably withheld, conditioned, or delayed,
then the Parties shall promptly prepare a development plan that reflects such participation, and Kaken may so participate in such Phase 3 Study in accordance with such agreed development plan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.5</B> <B><U>Diligence; Standards of Conduct</U></B><B>.</B> Kaken will use Commercially Reasonable Efforts to perform and complete all the
Development activities specified in the Initial Indication Development Plan on the timeline specified in such Plan, as it may be adjusted from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> by the JSC
consistent with the terms of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.6</B> <B><U>CMC Development</U></B>. All Development relating to CMC required to&nbsp;be
conducted to support obtaining and maintaining Regulatory Approval in the Kaken Territory for any Licensed Product in the Initial Indication that is the subject of the&nbsp;Initial Indication Development Plan, including all CMC activities related to
all phases of Manufacturing the Licensed Product through and including the packaging of Licensed Product in the format determined by the JSC to be preferable for the Japanese market [***] for Commercialization in the Kaken Territory&nbsp;(the
&#147;<B>CMC Activities</B>&#148;), will be conducted by CymaBay [***] in accordance with the Harmonization Principle and the CMC Work Plan. Any and all costs and expenses incurred in connection with the CMC Activities [***] that are specific to the
Japan regulatory activities or Japan market will be&nbsp;borne solely by Kaken (and reimbursed to CymaBay by Kaken based on invoices submitted); <I>provided, however</I>, that [***]. With respect to any such costs and expenses borne by Kaken, if any
of the data and related CMC information, that are generated by the CMC Activities paid for by Kaken, are later utilized by CymaBay or any of its licensees in the CymaBay Territory or outside the Field of Use in the Kaken Territory, then CymaBay will
promptly notify Kaken of such utilization [***]. Costs and expenses payable to CymaBay by Kaken under this <U>Section</U><U></U><U>&nbsp;3.6</U> shall be paid in Dollars pursuant to invoices provided to Kaken by CymaBay after the end of each Kaken
Fiscal Quarter, due and payable by Kaken to CymaBay within [***] of Kaken&#146;s receipt of such invoice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.7</B> <B><U>Third
Parties</U></B><I>.</I> Subject to<U>&nbsp;Section </U><U>7.1.4</U> and the rest of this<U>&nbsp;Section </U><U>3.7</U>, a Party will be entitled to subcontract to Third Parties, and to utilize the services of Third Parties to perform, its
Development activities, if any, under this<U>&nbsp;ARTICLE 3</U>,<I><U>&nbsp;provided</U></I>&nbsp;that (a)&nbsp;such Party requires under any such agreement executed on or after the Effective Date that such Third Party operate in a manner
consistent with this Agreement and reasonably acceptable to the other Party, (b)&nbsp;such Party remains at all times fully liable to the other Party for its Development responsibilities under this Agreement, and (c)&nbsp;such Party provides
reasonable updates to the other Party (through JSC meetings) of the activities of such subcontractors and results of such activities. Such Party will be solely responsible for direction of and communications with such Third-Party service provider.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.8</B> <B><U>Scientific Records</U></B>. Each Party will maintain scientific records, in
sufficient detail and in sound scientific manner appropriate for Patent and regulatory purposes and in compliance with GLP, GCP and GMP, as applicable, with respect to all Development activities, and the results of such activities, intended to
support or be submitted in regulatory filings covering Licensed Product, which records will fully and accurately reflect and document all work done and results achieved in the performance of the Development activities, Clinical Studies, and
Supplemental Studies with respect to Licensed Products by such Party under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.9</B> <B><U>Technology Transfer</U></B>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.9.1</B> As soon as practicable after the Effective Date, the Parties will negotiate in good faith and enter into a technology
transfer plan to effect the transfer by CymaBay to Kaken [***] (as such period may be extended by mutual written agreement of the Parties) of all CymaBay Licensed Technology to be disclosed pursuant to this<U>&nbsp;Section </U><U>3.9</U>. Under such
transfer plan, CymaBay will complete a transfer to Kaken of the CymaBay Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> in existence as of the date of such transfer that is reasonably useful for the Exploitation of Licensed Products in the
Field of Use in the Kaken Territory (but excluding <FONT STYLE="white-space:nowrap">Know-How</FONT> solely related to Manufacturing of Licensed Product), which transfer will include [***], all solely to the extent Controlled by CymaBay and relating
to the Licensed Products in the Initial Indication. Such technology transfer plan will set forth the CymaBay Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> to be transferred in a format that meets [***] applicable in the U.S. and the
Kaken Territory and the timing of such transfer to be completed (the &#147;<B>Technology Transfer Plan</B>&#148;). CymaBay will disclose to Kaken all of the CymaBay Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> that is required to be
disclosed pursuant to this<U>&nbsp;Section </U><U>3.9.1</U> in accordance with the disclosure timing set forth in such transfer plan. For clarity, the transfer of any CymaBay Licensed <FONT STYLE="white-space:nowrap">Know-How</FONT> relating solely
to the Manufacturing of Licensed Product shall be conducted in accordance with <U>Section</U><U></U><U>&nbsp;3.9.3</U>, in order to facilitate Kaken&#146;s conditional Manufacturing rights as set forth in<U>&nbsp;Section </U><U>7.1.3</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.9.2</B> Without limiting the terms of the technology transfers contemplated in <U>Section</U><U></U><U>&nbsp;3.9.1</U>, CymaBay will
promptly provide to Kaken the following on an ongoing basis during the Term: (a)&nbsp;all applicable data from CymaBay&#146;s [***] as needed to seek Regulatory Approval for the Licensed Products in the Initial Indication, (b)&nbsp;all <FONT
STYLE="white-space:nowrap">Know-How</FONT> that is Controlled by CymaBay and has been generated for Exploitation and pricing activities related to the Licensed Products worldwide, to the extent such <FONT STYLE="white-space:nowrap">Know-How</FONT>
is reasonably useful for such Exploitation or Pricing Matters in the Kaken Territory and is available and accessible to CymaBay, and (c) [***] a complete copy of any dossier for the Licensed Products, and minutes of meetings with Regulatory
Authorities, all to the extent such information is Controlled by CymaBay and is reasonably necessary for Kaken to seek Regulatory Approval in the Kaken Territory. Further, CymaBay will use reasonable efforts to provide such other assistance
reasonably requested by Kaken to enable Kaken to carry out its obligations under this Agreement. Any and all internal and third-party costs and expenses incurred in connection with providing such requested assistance, unless the terms of this
Agreement allocate the particular costs to be borne by CymaBay, will be borne solely by Kaken (and reimbursed to CymaBay by Kaken based on invoices submitted); [***]. Notwithstanding the foregoing, CymaBay shall have no obligations under
this<U>&nbsp;Section </U><U>3.9.2</U> to the extent that providing the applicable information, data or assistance would violate Third Party rights or Applicable Law or would breach contract obligations of CymaBay to a Third Party, unless the
requested information, data or assistance is required by Regulatory Authorities for Kaken to obtain Regulatory Approval in the Kaken Territory. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.9.3</B> In the event CymaBay provides a CymaBay Supply Termination Notice, or in the event that the Parties otherwise agree that Kaken
will Manufacture Licensed Products, then immediately after such notice or agreement, the Parties shall meet and discuss reasonably and enter into a manufacturing technology transfer plan to effect the transfer by CymaBay to Kaken of all needed
CymaBay <FONT STYLE="white-space:nowrap">Know-How</FONT> relating to the Manufacture of Licensed Product, including then-current Manufacturing process, manufacturing data and any other related information within such CymaBay <FONT
STYLE="white-space:nowrap">Know-How</FONT> as is necessary or reasonably useful for Manufacturing Licensed Products for use in the Field of Use. [***].</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMERCIALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B><U>Responsibility, Costs</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.1.1</B> <I>Kaken.</I>&nbsp;Subject to the oversight of the JSC and to the other terms and conditions of this<U>&nbsp;Section 4.1</U> and
of this Agreement, Kaken will be responsible for all Commercialization activities relating to the Licensed Products in the Field of Use in the Kaken Territory, at its sole cost and expense, in accordance with the Kaken Territory Commercialization
Plan and the Harmonization Principle. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.1.2</B> <I>CymaBay.</I>&nbsp;CymaBay, at its sole cost and expense, will have sole
responsibility and control of all Commercialization activities relating to the Licensed Product, <I>other than </I>in the Field of Use in the Kaken Territory. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> <B><U>Kaken Territory Commercialization Plan</U></B><I>. </I>No later than [***], Kaken will prepare and deliver to the JSC for its
review, input and approval a reasonable written plan that summarizes the Commercialization activities (including any <FONT STYLE="white-space:nowrap">pre-Regulatory</FONT> Approval activities in preparation for commercial launch) to be undertaken
with respect to the Licensed Products in the Field of Use in the Kaken Territory, where such plan will include details of anticipated timing and all marketing and promotional activities for the Licensed Products in the Field of Use in the Kaken
Territory aligned with the commercial positioning and the key message approved by the JSC and consistent with the Harmonization Principle, and of the resources to be allocated to such Commercialization efforts (the &#147;<B>Kaken Territory
Commercialization Plan</B>&#148;). Updates and modifications of the Kaken Territory Commercialization Plan shall be proposed by Kaken for approval by the JSC, from time to time and no less frequently than once per Kaken Fiscal Year, based upon,
among other things, Kaken&#146;s Commercialization activities and plans for activities with respect to the Licensed Products in the Field of Use in the Kaken Territory. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> <B><U>Diligence; Standards of Conduct</U></B><I>.</I> Kaken will use Commercially Reasonable Efforts to (a)&nbsp;Commercialize
Licensed Products in the Kaken Territory for use in the Field of Use with the intent of maximizing sales, including performing the Commercialization activities specified in the Kaken Territory Commercialization Plan, (b)&nbsp;subject to the
provisions of<U>&nbsp;Section </U><U>5.2</U>, obtain Pricing Approval for a Licensed Product in the Kaken Territory within a reasonable time after having received approval from the MHLW to Commercialize such Licensed Product in the Initial
Indication, and (c)&nbsp;begin to Commercialize such Licensed Product in the Initial Indication in the Kaken Territory [***] of having obtained Pricing Approval for such Licensed Product in the Kaken Territory. Notwithstanding the foregoing, if
CymaBay breaches any terms of this Agreement and such breach materially impedes Kaken&#146;s ability to perform its obligations under<U>&nbsp;Section </U><U>3.1</U>, this<U>&nbsp;Section </U><U>4.3</U> or<U>&nbsp;Section </U><U>5.2</U>, then Kaken
shall be relieved of performing such obligations to the extent that such breach impedes such performance, but only for so long as such breach continues (and will not be precluded from seeking legal and equitable remedies to such breach by CymaBay,
but only for so long as such breach continues). [***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.4</B> <B><U>Advertising and Promotional Materials</U></B>. Kaken will be
responsible for the creation, preparation, production, reproduction, and distribution of all relevant or needed written sales, promotion and advertising materials relating to each Licensed Product (&#147;<B>Promotional Materials</B>&#148;) for use
in the Field of Use in the Kaken Territory. All such Promotional Materials will be compliant with Applicable Law, consistent in all material respects with the Kaken Territory Commercialization Plan, and with the Harmonization Principle. CymaBay and
Kaken will submit representative samples of its respective Promotional Materials developed by it for use in the CymaBay Territory and the Kaken Territory, respectively, to the JSC at least annually thereafter. Kaken will consider in good faith any
timely comments CymaBay may have with respect to any such Promotional Materials, but will have final decision-making authority in the Kaken Territory with respect to such Promotional Materials. Notwithstanding the foregoing, Kaken will incorporate
any changes to Promotional Materials requested by CymaBay in a timely fashion in cases where CymaBay indicates that it believes in good faith that such change is necessary to enable CymaBay to comply with any Applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.5</B> <B><U>Reporting Obligations</U></B><I>.</I> Kaken will report to the JSC in
writing, on an annual basis in the first Kaken Calendar Quarter of each Kaken Fiscal Year, beginning with the Kaken Fiscal Year following the first Regulatory Approval of a Licensed Product in the Field of Use in the Kaken Territory (for the period
ending March&nbsp;31 of the prior Kaken Fiscal Year), summarizing in reasonable detail Kaken&#146;s Commercialization activities for such Licensed Product performed to date and the results of such activities (or updating such report for activities
performed since the last such report was given hereunder, as applicable). In addition, Kaken will provide CymaBay with written notice of the First Commercial Sale of each Licensed Product in the Field of Use in the Kaken Territory as soon as
reasonably practicable after such event;<I><U>&nbsp;provided</U></I>,<I><U>&nbsp;however</U></I><I>,</I>&nbsp;that, Kaken will inform CymaBay of such event prior to public disclosure of such event by Kaken. Kaken will provide such other information
to the JSC as CymaBay may reasonably request with respect to Commercialization of Licensed Products in the Field of Use in the Kaken Territory and will keep the JSC reasonably informed of Kaken&#146;s Commercialization activities with respect to
Licensed Products. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.6</B> <B><U>Booking of Sales and Handling of Returns</U></B><I>.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.6.1</B> Kaken will be responsible for booking sales of the Licensed Products sold in the Field of Use in the Kaken Territory. CymaBay will
be responsible for booking sales of the Licensed Products sold in the CymaBay Territory. Each Party may warehouse Licensed Products both inside and outside of such Party&#146;s Territory,<I><U>&nbsp;provided</U></I>&nbsp;that any sales with respect
to such Licensed Products occur and are booked in such Party&#146;s Territory. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.6.2</B> Kaken will be solely responsible for
conducting and handling all aspects of Licensed Product order processing, invoicing and collection, distribution, inventory and receivables of Licensed Products sold in the Kaken Territory in the Field of Use. Kaken will be solely responsible for
conducting and handling all rejections, returns, withdrawals and recalls of any Licensed Product sold in the Kaken Territory for the Field of Use. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.7</B> <B><U>Recalls, Market Withdrawals or Corrective Actions</U></B><I>.</I> In the event that any Regulatory Authority issues or
requests a recall or withdrawal, or takes a similar action in connection with, a Licensed Product in a Territory, or in the event either Party determines that an event, incident or circumstance has occurred that may result in the need for a recall
or market withdrawal of a Licensed Product in its Territory, the Party notified of such recall or similar action, or the Party that desires such recall or similar action, will as promptly as possible, notify the other Party&#146;s Alliance Manager,
JSC representatives and applicable quality assurance representatives thereof by telephone or <FONT STYLE="white-space:nowrap">e-mail,</FONT> and will discuss with the other Party the reasons for the recall, market withdrawal or similar action. Each
Party will decide whether to conduct a recall or withdrawal of a Licensed Product in its own Territory and the manner in which any such recall will be conducted (except in the case of a government mandated recall, when such Party may act without
such advance notice, but will notify the other Party as soon as possible thereafter). Except as may otherwise be agreed to by the Parties, each Party will bear the expense of any such recall or withdrawal in its own Territory. Each Party will make
available all of its pertinent records that may be reasonably requested by the other Party in order for a Party to effect a recall of a Licensed Product in its Territory. The Parties&#146; rights and obligations under this<U>&nbsp;Section
</U><U>4.7</U> will be subject to the terms and conditions of any supply agreement(s), including any SDEA or quality related agreements entered into between the Parties. In the event of a conflict between the provisions of any such supply agreement,
SDEA or quality related agreements and this<U>&nbsp;Section </U><U>4.7</U>, the provisions of such supply agreement, SDEA or quality related agreements will govern with respect to the conflicting provision. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.8 <U><FONT STYLE="white-space:nowrap">Ex-Territory</FONT> Sales; Export Monitoring</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.8.1</B> <I><FONT STYLE="white-space:nowrap">Ex-Territory</FONT> Sales</I><I>.</I>&nbsp;Subject to Applicable Law, neither Party will
engage in any advertising or promotional activities relating to any Licensed Product directed primarily to customers or other buyers or users of such Licensed Product located outside of its Territory or accept orders for Licensed Products from or
sell Licensed Products into such other Party&#146;s Territory for its own account (except for those rights retained by CymaBay outside the Field of Use in the Kaken Territory), and, if a Party (or one of its Related Parties) receives, or becomes
aware of, any order for any Licensed Product in the other Party&#146;s Territory, it will refer such orders to the other Party, to the extent it is not prohibited from doing so under Applicable Law. For clarity, but subject to Kaken&#146;s rights
under<U>&nbsp;Section 10.6</U>, nothing in this<U>&nbsp;Section 4.8.1</U>&nbsp;will prevent CymaBay and its Related Parties from undertaking, or having undertaken, any of the foregoing activities with respect to any Licensed Product outside of the
Field of Use in the Kaken Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.8.2</B> <I>Export Monitoring.</I>&nbsp;Each Party will use [***] to monitor and prevent
exports of Licensed Products from its own Territory for Commercialization in the other Party&#146;s Territory using methods permitted under Applicable Law that are consistent with its past practice and commonly used in the industry in the relevant
Party&#146;s Territory for such purpose (if any), and will promptly inform the other Party of any such exports of Licensed Products from its Territory, and any actions taken to prevent such exports, <I>provided that</I>, for clarity, the foregoing
does not restrict CymaBay in performing its obligations under the Supply Agreements, or in exercising any of its retained rights outside the Field of Use. Each Party agrees to take reasonable actions requested in writing by the other Party that are
consistent with Applicable Law and commonly used in the industry in the relevant Party&#146;s Territory for such purpose to prevent exports of Licensed Products from its Territory for Commercialization in the other Party&#146;s Territory. For
clarity, but subject to Kaken&#146;s rights under<U>&nbsp;Section </U><U>10.6</U>, nothing in this<U>&nbsp;Section </U><U>4.8.2</U>&nbsp;will prevent CymaBay and its Related Parties from exporting Licensed Products from the CymaBay Territory for
Commercialization of such Licensed Products outside of the Field of Use in the Kaken Territory. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 5 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGULATORY </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B>
<B><U>Regulatory Filings and Interactions</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.1.1</B> <I>Regulatory Responsibilities</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>5.1.1.1</B> <I>Kaken</I>. Kaken, at its sole cost and expense, will be solely responsible for all regulatory matters relating to Licensed
Product for use in the Field of Use in the Kaken Territory. Kaken shall use Commercially Reasonable Efforts to obtain all Regulatory Approvals needed to Commercialize a Licensed Product in the Field of Use in the Kaken Territory as soon as
reasonably practicable, and to obtain [***] for Licensed Product in the Kaken Territory. Kaken will solely and exclusively own all Regulatory Materials with respect to such Licensed Product for use in the Field of Use in the Kaken Territory,
including [***] by Kaken solely with respect thereto. Kaken, at its sole cost and expense, will have the sole and exclusive right to (a)&nbsp;oversee, monitor and coordinate all regulatory actions, communications and filings with, and submissions
to, each Regulatory Authority in the Kaken Territory with respect to each Licensed Product for use in the Field of Use, (b)&nbsp;interface, correspond and meet with each Regulatory Authority in the Kaken Territory with respect to Licensed Product
for use in the Field of Use, and (c)&nbsp;seek and maintain all Regulatory Filings in the Kaken Territory with respect to each Licensed Product for use in the Field of Use. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>5.1.1.2</B> <I>CymaBay</I>. CymaBay, at its sole cost and expense, will be solely responsible for all regulatory matters relating to a
Licensed Product, other than as relates to use in the Field of Use in the Kaken Territory, and will solely and exclusively own all Regulatory Materials with respect thereto, including [***] by or on behalf of CymaBay, but excluding, for clarity, any
Regulatory Materials specifically with respect to Licensed Product for use in the Field of Use in the Kaken Territory. CymaBay, at its sole cost and expense, will have the sole and exclusive right to (a)&nbsp;oversee, monitor and coordinate all
regulatory actions, communications and filings with, and submissions to, each Regulatory Authority with respect to each Licensed Product, (b)&nbsp;interface, correspond and meet with each Regulatory Authority with respect to each Licensed Product,
and (c)&nbsp;seek and maintain all Regulatory Filings with respect to each Licensed Product, in each case of (a), (b) and (c), <I>other than</I> Licensed Products for use in the Field of Use in the Kaken Territory. As provided in
<U>Section</U><U></U><U>&nbsp;3.9.1</U>, CymaBay will provide to Kaken all Nonclinical Study data, CMC data and Clinical Study data in its possession and Control that is reasonably required by Kaken to apply for Regulatory Approval for Licensed
Product for use in the Field of Use in the Kaken Territory. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.1.2</B> <I>Communications with Regulatory Authorities.</I> Kaken will notify the JSC,
including a brief description in English, of the principal issues raised in each Material Communication with Regulatory Authorities with respect to each Licensed Product for the Initial Indication in the Kaken Territory within [***] days after
receipt thereof. Upon CymaBay&#146;s request, Kaken will provide to CymaBay, at CymaBay&#146;s expense: (a)&nbsp;a summary translation of such Material Communications in English, (b)&nbsp;complete copies of the original correspondence with such
Regulatory Authorities in their native language, or (c)&nbsp;a complete translation of such Material Communications in English, in each case of (a)&nbsp;through (c) within a reasonable period of time following such request. For the purposes of
this<U>&nbsp;Section 5.1.2</U>, &#147;<B>Material Communications</B>&#148; with Regulatory Authorities include meetings with Regulatory Authorities, and Regulatory Authority questions or concerns, with respect to significant issues regarding
Licensed Product, including issues as to any of the following: [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.1.3</B> <I>Regulatory Meetings. </I>Kaken will provide CymaBay
with reasonable advance notice of all substantive meetings with the Governmental Authorities in the Kaken Territory pertaining to Licensed Product for use in the Field of Use, with as much advance notice as practicable under the circumstances. Kaken
will use Commercially Reasonable Efforts, to the extent reasonably practicable, to permit CymaBay to have, at CymaBay&#146;s expense, mutually acceptable representatives of CymaBay attend, solely as a
<FONT STYLE="white-space:nowrap">non-participating</FONT> observer, material, substantive meetings with any Governmental Authorities within the Kaken Territory pertaining to such Licensed Product for use in the Field of
Use;<I><U>&nbsp;provided</U></I>,<I><U>&nbsp;however</U></I>, that (a)&nbsp;if required by the Governmental Authority, attendance by CymaBay will be permitted, (b)&nbsp;attendance by the representatives of CymaBay will not prevent participation of a
representative of Kaken due to restrictions imposed by Regulatory Authorities on the number of attendees; and (c)&nbsp;Kaken will not be obligated to change the schedule of such meeting in order to accommodate the schedule of CymaBay&#146;s
representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.1.4</B> <I>Submissions.</I> Kaken will provide CymaBay with written notice of each of the following events with
regard to each Licensed Product for the Initial Indication in the Kaken Territory, within a reasonable period of time following the occurrence thereof, (a)&nbsp;the submission of any filings or applications for Regulatory Approval of such Licensed
Product for the Initial Indication in the Kaken Territory to any Regulatory Authority, and (b)&nbsp;receipt or denial of Regulatory Approval for such Licensed Product for the Initial Indication in the Kaken
Territory,<I><U>&nbsp;provided</U></I>,<I><U>&nbsp;however</U></I>, that Kaken will inform CymaBay such event under (a)&nbsp;or (b) prior to public disclosure of such event by Kaken. Kaken, within a reasonable period of time following CymaBay&#146;s
written request, will provide to CymaBay, at CymaBay&#146;s cost and expense, a complete copy of any of the filings or applications of clause (a). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.1.5</B> <I>Coordination</I>. The activities of Kaken and its Related Parties under this<U>&nbsp;Section 5.1</U>&nbsp;will be subject to
the coordination and other responsibilities of the JSC and the Harmonization Principle. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B> <B><U>Diligence; Standards of
Conduct</U></B>. Kaken and its Related Parties will use Commercially Reasonable Efforts to conduct all such Development (including regulatory) activities needed to obtain Regulatory Approval for at least one Licensed Product in the Initial
Indication in the Kaken Territory [***]; <I><U>provided, however,</U></I> that [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B> <B><U>Costs of Regulatory
Affairs</U></B>. Except as otherwise indicated in this Agreement, each Party will be responsible for all costs and expenses incurred in connection with its efforts to apply for, obtain and maintain Regulatory Approval with respect to Licensed
Products in its Territory, and its related regulatory affairs activities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4</B> <B><U>Right of Reference</U></B><I>.</I>&nbsp;Each
Party, on behalf of itself and its Related Parties, hereby grants to the other Party, and at the request of the other Party will grant to the other Party&#146;s Related Parties, a &#147;Right of Reference,&#148; as that term is defined in 21 C.F.R.
&#167; 314.3(b) (or any successor rule or analogous law recognized outside of the United States), to, and a right to copy, access, and otherwise use, all information and data (including [***]) included in or used in support of any regulatory filing,
Regulatory Approval, [***] or other Regulatory Materials maintained on behalf of such Party (or its Related Parties) that relates to Licensed Product, in each case to the extent necessary for, and solely for use in support of, the applicable Party
to obtain Regulatory Approval of Licensed Product in the Kaken Territory or the CymaBay Territory, as applicable. Such other Party will provide a signed statement to this effect, if requested by the Party granted such rights of reference, in
accordance with 21 C.F.R. &#167; 314.50(g)(3) (or any successor or analogous Applicable Law outside of the United States). In addition, upon the reasonable request of either Party (on behalf of itself or any of its Related Parties), the other Party
will, and will cause its Related Parties to, obtain and provide to the requesting Party certificates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or other formal or official attestations concerning the regulatory status of the Licensed Products in the Kaken Territory or the CymaBay Territory, as applicable (<I>e.g.</I>, Certificates of
Free Sale, Certificates for Export, Certificates to Foreign Governments), at the requesting Party&#146;s request and cost, and provided further that such attestations are reasonably necessary for the requesting Party to exercise its rights under
this Agreement. For clarity, Kaken&#146;s rights under this<U>&nbsp;Section 5.4</U> may be exercised solely as is necessary to support filing for, obtaining and maintaining Regulatory Approval for a Licensed Product for use in the Field of Use in
the Kaken Territory. Notwithstanding anything to the contrary in this Agreement other than for Safety Concerns, neither Party nor any of its Related Parties will withdraw or inactivate any Regulatory Filing that the other Party or the other
Party&#146;s Related Parties references or otherwise uses pursuant to the rights of reference granted in this <U>Section</U><U></U><U>&nbsp;5.4</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5</B> <B><U>Pharmacovigilance</U></B>. The Parties will cooperate with regard to the reporting and handling of safety information
involving the Licensed Products in accordance with all Applicable Law concerning pharmacovigilance and clinical safety, with CymaBay being responsible, at its cost, for maintaining a global safety database, and Kaken being responsible, at its cost,
for pharmacovigilance and safety reporting in the Kaken Territory. No later than [***] prior to the enrollment of the first patient in a [***] for the Licensed Product in the Kaken Territory (as such period may be extended by mutual written
agreement of the Parties, but within such time to ensure that all regulatory requirements are met), the Parties will negotiate in good faith and enter into a Safety Data Exchange Agreement (&#147;<B>SDEA</B>&#148;), which will define the
pharmacovigilance responsibilities of the Parties and include safety data exchange procedures to enable each Party (and their respective related Third Parties, if any) to comply with all of its legal and regulatory obligations related to the
Licensed Products. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MANUFACTURE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.1</B>
<B><U>Overview of Manufacturing and Supply Obligations</U></B>. The Parties agree that, except as otherwise provided below, CymaBay shall manufacture (or have manufactured) and supply to Kaken its and its Related Parties&#146; [***] and commercial
requirements of finished drug product for the Licensed Products for use and sale in the Kaken Territory in the Field of Use. Such supply shall be pursuant to the Supply Agreements and <U>Section</U><U></U><U>&nbsp;6.2</U>, and the commercial supply
obligation shall be subject to termination by CymaBay after the applicable time, as provided in <U>Section</U><U></U><U>&nbsp;6.3</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.2</B> <B><U>Supply Agreements and Quality Agreement</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.2.1</B> <I>Clinical Supply Agreement</I>. As soon as practicable following the execution of this Agreement, the Parties will enter into a
clinical supply agreement (the &#147;<B>Clinical</B> <B>Supply Agreement</B>&#148;), substantially in the form attached as <U>Schedule</U><U></U><U>&nbsp;6.2.1</U> of this Agreement (with such changes as the Parties may mutually agree to), pursuant
to which CymaBay will supply Kaken&#146;s and its Related Parties&#146; clinical requirements of [***] for the Licensed Products for the Kaken Territory for the Field of Use at the Clinical Transfer Price [***] and at [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.2.2</B> <I>Non-Clinical Supply</I>. CymaBay will supply Kaken&#146;s and its Related Parties&#146; requirements of [***] included in the
Licensed Product to be used in connection with Kaken&#146;s Nonclinical Studies and CMC Activities. The price for such [***] shall be at [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.2.3</B> <I>Commercial Supply Agreement</I>. [***], the Parties will negotiate reasonably and in good faith and enter into a commercial
supply agreement (the &#147;<B>Commercial</B> <B>Supply Agreement</B>&#148;) pursuant to which CymaBay will supply Kaken&#146;s and its Related Parties&#146; commercial requirements of finished drug product for the Licensed Products for the Kaken
Territory for the Field of Use, such Commercial Supply Agreement to be commercially reasonable and typical for the pharmaceutical industry, which will include customary commercial terms such as, by way of
<FONT STYLE="white-space:nowrap">non-limiting</FONT> examples, the right to receive a fair allocation of supply relative to CymaBay and its Affiliates and other licensees, sublicensees and distributors in the event of supply shortfall, and the right
to require a second or alternative source of supply. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.2.4</B> <I>Quality Agreement</I>. Simultaneously with the Clinical Supply Agreement and
Commercial Supply Agreement, the Parties will negotiate reasonably and in good faith and enter into a quality agreement for <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical use as well as commercial use, respectively, governing all
manufacturing and quality control and quality assurance aspects for the supply of Licensed Product to meet the requirements of Applicable Law and local market standards in the Kaken Territory and that will be commercially reasonable and typical for
the pharmaceutical industry. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.3</B> <B><U>Supply Agreement Termination</U></B>. No earlier than [***] after the date of First
Commercial Sale of the first Licensed Product in the Kaken Territory, CymaBay may give notice (a &#147;<B>CymaBay Supply Termination Notice</B>&#148;) to Kaken that CymaBay is terminating its supply obligations under the Supply Agreements and
transferring to Kaken the manufacturing and supply rights regarding Licensed Compound and/or Licensed Product for sale in the Kaken Territory. The termination of such supply obligations under any such CymaBay Supply Termination Notice (the
&#147;<B>CymaBay Supply Termination</B>&#148;) shall become effective on the date that is the later of: (a) [***] after the date of such notice, or (b)&nbsp;the date on which either (i)&nbsp;Kaken or its designee obtains Manufacturing accreditation
from the applicable Regulatory Authority for Manufacturing Licensed Products for use in the Field of Use for the Kaken Territory, or (ii)&nbsp;Kaken or its Affiliate or Sublicensee obtains the contract rights to purchase, from qualified Third Party
manufacturers, its requirements for Licensed Product for sale in the Kaken Territory, <I>provided that</I> the CymaBay Supply Termination will in any event occur no later than [***] after such notice; <I>provided further, </I>that if Kaken (or its
designee, if applicable) does not obtain such Manufacturing accreditation after good faith reasonable efforts to do so within such [***] period, and Kaken cannot obtain supply from CymaBay&#146;s Third Party manufacturer, the Parties shall discuss a
further extension of the CymaBay Supply Termination in good faith. After receipt of a CymaBay Supply Termination Notice, Kaken (and its designee, if applicable) shall use good faith reasonable efforts to obtain as soon as possible Manufacturing
accreditation from the applicable Regulatory Authority for Manufacturing Licensed Products for use in the Field of Use for the Kaken Territory, or the contractual rights to purchase Licensed Product for sale in the Kaken Territory. On and after the
delivery of the CymaBay Supply Termination Notice, CymaBay shall conduct (and shall cause any of its applicable subcontractors to conduct) a technology transfer to Kaken of the Manufacturing technology as needed to manufacture Licensed Compound
and/or the Licensed Product. Such transfer would be conducted as provided in <U>Section</U><U></U><U>&nbsp;3.9.3</U> and is intended to ensure that Kaken has either (i)&nbsp;arrangements in place with CymaBay&#146;s Third Party manufacturers for
supply of Licensed Compound and Licensed Product or (ii)&nbsp;the CymaBay manufacturing information needed to manufacture Licensed Product, in each case for sale to Kaken for use in the Kaken Territory in the Field of Use commencing a reasonable
amount of time prior to the date of the CymaBay Supply Termination, [***]. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.1</B>
<B><U>License Grants to Kaken</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.1.1</B> <I>Development License</I>. Subject to the terms and conditions of this Agreement,
CymaBay hereby grants Kaken a <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except as provided in<U>&nbsp;Section </U><U>14.1</U>), sublicensable through multiple tiers (subject to<U>&nbsp;Sections </U><U>3.7</U> and<U>&nbsp;7.1.4</U>)
license under the CymaBay Licensed Technology to Develop Licensed Products in the Field of Use;<I><U>&nbsp;provided</U></I>, that such license grant for Development is limited in each case solely for use as and to the extent permitted under this
Agreement, and in each case, solely for purposes of obtaining Regulatory Approval of Licensed Products in the Field of Use in the Kaken Territory and Commercializing Licensed Products in the Field of Use in the Kaken Territory. Such Development
license to Kaken is exclusive (even as to CymaBay and its Affiliates) to Kaken in the Kaken Territory, and may be exercised outside the Kaken Territory solely to the extent approved in writing by the JSC. Notwithstanding the foregoing license grant,
CymaBay retains for clarity the right under the CymaBay Licensed Technology, with the right to grant licenses through multiple tiers in accordance with<U>&nbsp;Section </U><U>7.2.4</U>, which will apply<I>&nbsp;mutatis mutandis</I>, (a)&nbsp;(i) to
Develop Licensed Products anywhere in the world for obtaining Regulatory Approval of Licensed Products in any indications in the CymaBay Territory and Commercializing Licensed Products in any indications in the CymaBay Territory, and (ii)&nbsp;to
Develop Licensed Products anywhere in the world for obtaining Regulatory Approval of Licensed Products outside of the Field of Use in the Kaken Territory and Commercializing Licensed Products outside of the Field of Use in the Kaken Territory, but
subject to Kaken&#146;s rights under<U>&nbsp;Section 10.6</U>, and (b)&nbsp;to perform, and have performed, its obligations under the Initial Indication Development Plan, including the CMC Work Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.1.2</B> <I>Commercialization License in the Kaken Territory</I>. Subject to the terms
and conditions of this Agreement, CymaBay hereby grants Kaken a <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except as provided in<U>&nbsp;Section </U><U>14.1</U>), sublicensable through multiple tiers (subject to<U>&nbsp;Section
</U><U>7.1.4</U>), exclusive (even as to CymaBay and its Affiliates) license under the CymaBay Licensed Technology to Commercialize Licensed Products solely in the Field of Use in the Kaken Territory. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.1.3</B> <I>Conditional Manufacturing License</I>. Subject to the terms and conditions of this Agreement, and exercisable only following
delivery of a CymaBay Supply Termination Notice or as otherwise provided in the terms of the Supply Agreements, CymaBay hereby grants Kaken a <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except as provided in<U>&nbsp;Section
</U><U>14.1</U>), sublicensable through multiple tiers (subject to<U>&nbsp;Section </U><U>7.1.4</U>), <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under the CymaBay Licensed Technology to Manufacture and have Manufactured Licensed
Products anywhere in the world solely for (a)&nbsp;Development solely for purposes of obtaining Regulatory Approval of Licensed Products in the Field of Use in the Kaken Territory; and (b)&nbsp;Commercialization of Licensed Products in the Field of
Use in the Kaken Territory. In no event, whether pursuant to rights under this Agreement or the Supply Agreements, will Kaken or any of its Related Parties have the right to Manufacture Licensed Products for Development (except as otherwise approved
by the JSC) or Commercialization in the CymaBay Territory or for Development or Commercialization outside of the Field of Use in the Kaken Territory, but subject to Kaken&#146;s rights under<U>&nbsp;Section </U><U>10.6</U>. For clarity,
notwithstanding the foregoing conditional license grant, CymaBay retains the right under the CymaBay Licensed Technology, with the right to grant licenses through multiple tiers in accordance with<U>&nbsp;Section </U><U>7.2.4</U>, to Manufacture and
have Manufactured Licensed Products anywhere in the world: (i)&nbsp;(A) for Development of Licensed Products and Commercialization of Licensed Products in any indications in the CymaBay Territory, (B)&nbsp;for Development of Licensed Products and
Commercialization of Licensed Products outside of the Field of Use in the Kaken Territory, but subject to Kaken&#146;s rights under<U>&nbsp;Section </U><U>10.6</U>, and (C)&nbsp;for Development of Licensed Products in the Field of Use in the Kaken
Territory, and (ii)&nbsp;to supply (or have supplied) Licensed Products to Kaken pursuant to the Supply Agreements (or any other supply agreement covering Licensed Product that may be agreed to between the Parties). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.1.4</B> <I>Kaken Sublicensing Terms</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> In addition to its subcontracting rights pursuant to<U>&nbsp;Section 3.7</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> Kaken will have the right to sublicense any of its rights under<U>&nbsp;Sections </U><U>7.1.1</U>,<U>&nbsp;7.1.2</U>
and<U>&nbsp;7.1.3</U>, to any of its Affiliates without the prior consent of CymaBay, but subject to the requirements of this<U>&nbsp;Section </U><U>7.1.4</U>; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(ii)</B> Kaken will have the right to sublicense any of its rights under<U>&nbsp;Sections 7.1.1</U>,<U>&nbsp;7.1.2</U>
and<U>&nbsp;7.1.3</U> to any Third Party with CymaBay&#146;s prior written consent (such consent not to be unreasonably withheld, conditioned or delayed), subject to the requirements of this<U>&nbsp;Section
7.1.4</U>;<I>&nbsp;provided</I>,<I>&nbsp;however</I>, that, for clarity, Kaken&#146;s appointment of a Third Party distributor will not constitute a sublicense of Kaken&#146;s rights under <U>Section</U><U></U><U>&nbsp;7.1.2</U> requiring
CymaBay&#146;s prior written consent, but any other sublicensing of Commercialization activities relating to Licensed Products in the Kaken Territory will be a sublicense requiring such CymaBay&#146;s prior written consent in accordance with the
foregoing sentence. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Without limiting<U>&nbsp;Section 7.1.4(a)(i)</U>, each sublicense granted by Kaken pursuant to
this<U>&nbsp;Section 7.1.4</U>, and sublicense or subcontracting agreement entered into by Kaken pursuant to<U>&nbsp;Section 3.7</U>, will be subject and subordinate to this Agreement and will contain provisions consistent with the terms and
conditions of this Agreement. As soon as reasonably practicable after entry into any such sublicense or subcontracting agreement, Kaken will provide CymaBay with a copy of any such executed agreement that includes a material sublicense granted
hereunder (which copy may be redacted to remove financial provisions and other provisions that are not necessary to monitor compliance with this<U>&nbsp;Section 7.1.4</U>). Each such sublicense agreement will contain the following provisions:
(i)&nbsp;a requirement that the Sublicensee comply with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> provisions of<U>&nbsp;Section 9.1</U> with respect to CymaBay&#146;s Confidential Information, (ii)&nbsp;if such sublicense
agreement contains a sublicense of rights granted under<U>&nbsp;Section 7.1.2</U>, such sublicense agreement will also contain the following provisions: (A)&nbsp;a requirement that the Sublicensee submit applicable sales or other reports to Kaken to
the extent necessary or relevant to the reports required to be made or records required to be maintained under this Agreement, and (B)&nbsp;the audit requirement set forth in<U>&nbsp;Section 8.7</U>, (iii) a requirement that the Sublicensee comply
with the applicable provisions under any <FONT STYLE="white-space:nowrap">in-license</FONT> agreement, (iv)&nbsp;provisions whereby such sublicensee undertakes to indemnify and defend CymaBay for all matters covered by
<U>Section</U><U></U><U>&nbsp;11.1</U> for which sublicensee may be responsible, and (v)&nbsp;provisions whereby Kaken obtains ownership of, or a fully sublicensable <FONT STYLE="white-space:nowrap">non-exclusive</FONT> (or exclusive) license (or an
option to obtain such license) under and to, any <FONT STYLE="white-space:nowrap">Know-How</FONT> and Patents that are developed by the Sublicensee in the performance of such agreement and are reasonably necessary or useful to the Development,
Manufacture or Commercialization of Licensed Products in the Field of Use;<I><U>&nbsp;provided</U></I>&nbsp;that the foregoing requirement to obtain ownership of, or a fully sublicensable <FONT STYLE="white-space:nowrap">non-exclusive</FONT> (or
exclusive) license (or an option to obtain such license) will not apply to any improvements unless such improvements are reasonably necessary to the Development, Manufacture or Commercialization of those Licensed Products in the Field of Use. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Notwithstanding any sublicense granted pursuant to this<U>&nbsp;Section 7.1.4</U>, Kaken will (i)&nbsp;remain primarily liable to
CymaBay for the performance of all of Kaken&#146;s obligations under, and Kaken&#146;s compliance with all provisions of, this Agreement and (ii)&nbsp;be liable for any act or omission of any such Sublicensee that is a breach of any of Kaken&#146;s
obligations under this Agreement as though the same were a breach by Kaken, and CymaBay shall have the right to proceed directly against Kaken without any obligation to first proceed against such Sublicensee for any such breach or liability. Each
(sub)license by Kaken and its Affiliates will be subject to the applicable terms and conditions of this Agreement. For clarity, Kaken grants no rights hereunder to permit CymaBay to proceed directly against a Sublicensee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.1.5</B> <I>Rights Regarding Combination Products</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> While the license rights granted by CymaBay to Kaken in <U>Sections 7.1.1</U>, <U>7.1.2</U>, and <U>7.1.3</U> include the exclusive
license rights with respect to Combination Products solely in the Kaken Territory in the Field of Use, the Parties agree that Kaken and its Related Parties shall not, and Kaken covenants that it and its Related Parties shall not, Develop or
Commercialize any Combination Product, unless and until the Parties agree as to the financial and related terms for such activities, as provided in <U>Section</U><U></U><U>&nbsp;7.1.5(b)</U>. Kaken hereby covenants that it and its Related Parties
shall not Develop or Commercialize any Combination Product except as provided pursuant to such agreement of the Parties pursuant to <U>Section</U><U></U><U>&nbsp;7.1.5(b)</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> If Kaken desires to Develop and Commercialize in the Kaken Territory a particular Combination Product, Kaken shall notify CymaBay
of such desire, which notice shall provide all the material details of the proposed Combination Product, and the proposed financial structure for compensating CymaBay for such Combination Product (which structure shall, as much as practicable,
provide to CymaBay compensation equivalent to what it would receive for supply and sale of Licensed Product hereunder). If such a notice is given by Kaken, then the Parties shall meet thereafter and discuss Kaken&#146;s request and proposal, and
shall negotiate reasonably and in good faith with the goal of reaching agreement and entering into an amendment to this Agreement that provides for the financial terms, and any other needed terms, for Kaken to have the right to Develop and
Commercialize such Combination Product in Field of Use in the Kaken Territory. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.1.6</B> <I>Limited Covenant Not To Sue.</I> CymaBay
hereby covenants that, with respect to any Development work conducted hereunder by Kaken (or its Affiliate) outside the Kaken Territory on Licensed Product for use in the Field of Use that has been approved in writing by the JSC, CymaBay and its
Affiliates shall not assert in a legal action against Kaken (or its Affiliate) any of its Intellectual Property rights relating to Licensed Product with respect to such Development work, to the extent such work is intended solely for use in the
Kaken Territory in the Field of Use. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.2 <U>License Grants to CymaBay</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.2.1</B> <I>Development Licenses</I>. Subject to the terms and conditions of this Agreement, Kaken hereby grants CymaBay a <FONT
STYLE="white-space:nowrap">non-transferable</FONT> (except as provided in<U>&nbsp;Section </U><U>14.1</U>), sublicensable through multiple tiers (subject to<U>&nbsp;Section </U><U>7.2.4</U>), terminable (pursuant to the provisions of<U>&nbsp;ARTICLE
13</U>), nonexclusive, royalty-free and fully paid license under the Kaken Program IP (a)&nbsp;to Develop Licensed Products anywhere in the world solely for obtaining Regulatory Approval of Licensed Products in any indications in the CymaBay
Territory and Commercializing Licensed Products in any indications in the CymaBay Territory, and (b)&nbsp;to Develop Licensed Products anywhere in the world solely for obtaining Regulatory Approval of Licensed Products outside of the Field of Use in
the Kaken Territory and Commercializing Licensed Products outside of the Field of Use in the Kaken Territory, but subject to Kaken&#146;s rights under<U>&nbsp;Section </U><U>10.6</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.2.2</B> <I>Commercialization Licenses in the CymaBay Territory</I>. Subject to the terms and conditions of this Agreement, Kaken hereby
grants CymaBay a <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except as provided in<U>&nbsp;Section </U><U>14.1</U>), sublicensable through multiple tiers (subject to<U>&nbsp;Section </U><U>7.2.4</U>), terminable (pursuant to the
provisions of <U>ARTICLE 13</U>), nonexclusive, royalty-free and fully paid license under the Kaken Program IP (a)&nbsp;to Commercialize Licensed Products in any indications in the CymaBay Territory, and (b)&nbsp;to Commercialize Licensed Products
outside of the Field of Use in the Kaken Territory, but subject to Kaken&#146;s rights under<U>&nbsp;Section </U><U>10.6</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.2.3</B>
<I>Manufacturing Licenses</I>. Subject to the terms and conditions of this Agreement and the Supply Agreements (or any other applicable supply agreement between the Parties), Kaken hereby grants CymaBay a
<FONT STYLE="white-space:nowrap">non-transferable</FONT> (except as provided in<U>&nbsp;Section </U><U>14.1</U>), sublicensable through multiple tiers (subject to<U>&nbsp;Section </U><U>7.2.4</U>), terminable (pursuant to the provisions
of<U>&nbsp;ARTICLE 13</U>), nonexclusive, royalty-free and fully paid license under the Kaken Program IP to Manufacture and have Manufactured Licensed Products anywhere in the world solely (a)&nbsp;for Development of Licensed Products and
Commercialization of Licensed Products in any indications in the CymaBay Territory, and (b)&nbsp;for Development of Licensed Products and Commercialization of Licensed Products outside of the Field of Use in the Kaken Territory, but subject to
Kaken&#146;s rights under<U>&nbsp;Section </U><U>10.6</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.2.4</B> <I>Sublicensing Terms</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> CymaBay will have the right to sublicense any of its rights under<U>&nbsp;Sections </U><U>7.2.1</U>, <U>7.2.2</U>, and <U>7.2.3</U>
to any of its Affiliates or to any Third Party (which sublicensed rights may be further sublicensable through multiple tiers) without the prior consent of Kaken, subject to the requirements of this<U>&nbsp;Section </U><U>7.2.4</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Each sublicense granted by CymaBay pursuant to this<U>&nbsp;Section </U><U>7.2.4</U> will be subject and subordinate to this
Agreement and will contain provisions consistent with the terms and conditions of this Agreement. Each such sublicense agreement will contain the following provisions: (i)&nbsp;a requirement that the Sublicensee comply with the confidentiality and <FONT
STYLE="white-space:nowrap">non-use</FONT> provisions of<U>&nbsp;Section </U><U>9.1</U> with respect to Kaken&#146;s Confidential Information, and (ii)&nbsp;a requirement that the Sublicensee comply with the applicable provisions under any <FONT
STYLE="white-space:nowrap">in-license</FONT> agreement of Kaken under which CymaBay elects to take a sublicense pursuant to<U>&nbsp;Section </U><U>7.3.2</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> Notwithstanding any sublicense granted pursuant to this<U>&nbsp;Section 7.2.4</U>, CymaBay will (i)&nbsp;remain primarily liable to
Kaken for the performance of all of CymaBay&#146;s obligations under, and CymaBay&#146;s compliance with all provisions of, this Agreement and (ii)&nbsp;be liable for any act or omission of any such Sublicensee that is a breach of any of
CymaBay&#146;s obligations under this Agreement as though the same were a breach by CymaBay, and Kaken shall have the right to proceed directly against CymaBay without any obligation to first proceed against such Sublicensee with respect to such
breach or liability. For clarity, CymaBay grants no rights hereunder to permit Kaken to proceed directly against a Sublicensee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.3</B> <B><U>Third Party <FONT STYLE="white-space:nowrap">In-Licenses;</FONT>
Payments</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.3.1</B> <I>Existing <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Agreements</I>.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>7.3.1.1</B> CymaBay will be responsible for all payments owed by CymaBay that are associated with any agreements to which CymaBay is a
party related to the CymaBay Licensed Technology that exist as of the Effective Date (&#147;<B>Existing <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Agreeme</B><B>nts</B>&#148;), except as otherwise agreed by Kaken in writing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.3.2</B> <I>Needed
Additional <FONT STYLE="white-space:nowrap">In-Licensing</FONT> Agreements.</I>&nbsp;If Kaken reasonably determines that it is necessary during the Term to enter into an agreement with a Third Party to
<FONT STYLE="white-space:nowrap">in-license</FONT> any Intellectual Property rights controlled by such Third Party that are necessary for the Exploitation by Kaken of the Licensed Product in the Field of Use in the Kaken Territory where such
Intellectual Property rights, but for such <FONT STYLE="white-space:nowrap">in-license,</FONT> would be infringed, misappropriated or otherwise violated by the use, offer for sale or sale of the Licensed Product in the Kaken Territory in the Field
of Use, as such Licensed Product existed on the Effective Date and was disclosed by CymaBay to Kaken in accordance with the technology transfer pursuant to the terms of<U>&nbsp;Section </U><U>3.9</U>, then Kaken may enter into a license agreement
with such Third Party to <FONT STYLE="white-space:nowrap">in-license</FONT> such Intellectual Property rights for use in the Exploitation of the Licensed Product in the Kaken Territory in the Field of Use (and also, to manufacture such Licensed
Product, if applicable). If Kaken executes and enters into such an <FONT STYLE="white-space:nowrap">in-license</FONT> agreement, Kaken shall be responsible for any payments owed under such <FONT STYLE="white-space:nowrap">in-license</FONT>
agreement, and Kaken may credit (subject to the below limitation), against amounts owed to CymaBay hereunder, [***] of the royalty payments made by Kaken to the Third Party licensor under such agreement to the extent such royalty payments are
payable based on the sales of Licensed Product in Japan by Kaken or its Related Party, <I>provided that </I>any such credit shall not reduce any amount owed to CymaBay hereunder by more than [***] of the amount otherwise owed. [***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.4</B> <B><U>Combinations</U></B>. Notwithstanding any other provision of this Agreement, for purposes of the license grants
under<U>&nbsp;Section 7.1</U> with respect to any Licensed Product that is a Combination Product, any such license grant covers only the grant of license rights with respect to the Seladelpar component of such Combination Product. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.5</B> <B><U>Bankruptcy</U></B>. All rights and licenses granted under or pursuant to this Agreement by a Party to the other are and will
otherwise be deemed to be, for purposes of Section&nbsp;365(n) of the Bankruptcy Code, a license of a right to &#147;intellectual property&#148; as defined under Section&nbsp;101 of the Bankruptcy Code. The Parties acknowledge and agree that the
Parties and their respective Sublicensees, as Sublicensees of such rights under this Agreement, will retain and may fully exercise all of their rights and elections under the Bankruptcy Code and any foreign counterpart thereto. The Parties further
agree that upon commencement of a bankruptcy proceeding by or against a Party (the &#147;<B>Bankrupt Party</B>&#148;) under the Bankruptcy Code, the other Party (the &#147;<B><FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party</B>&#148;) will
be entitled to a complete duplicate of, or complete access to (as the <FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party deems appropriate), all such intellectual property and all embodiments of such intellectual property. Such intellectual
property and all embodiments of such intellectual property will be promptly delivered to the <FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party (a)&nbsp;upon any such commencement of a bankruptcy proceeding and upon written request by the <FONT
STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party, unless the Bankrupt Party elects to continue to perform all of its obligations under this Agreement, or (b)&nbsp;if not delivered under (a)&nbsp;above, upon the rejection of this Agreement by or
on behalf of the Bankrupt Party and upon written request by the <FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party. The Bankrupt Party (in any capacity, including
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">debtor-in-possession)</FONT></FONT> and its successors and assigns (including any trustee) agree not to interfere with the exercise by the
<FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party or its Related Parties of its rights and licenses to such intellectual property and such embodiments of intellectual property in accordance with this Agreement, and agrees to assist the <FONT
STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party and its Related Parties in obtaining such intellectual property and such embodiments of intellectual property in the possession or control of Third Parties as are reasonably necessary or desirable
for the <FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party to exercise such rights and licenses in accordance with this Agreement. The foregoing provisions are without prejudice to any rights the
<FONT STYLE="white-space:nowrap">Non-Bankrupt</FONT> Party may have arising under the Bankruptcy Code or other Applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.6</B> <B><U>Kaken Background Technology</U></B><B>.</B> In the event that Kaken (or its
Affiliate) uses, develops or acquires rights (including by <FONT STYLE="white-space:nowrap">in-license)</FONT> to any Kaken Background Technology, Kaken shall give CymaBay written notice of such Kaken Background Technology, including a detailed
description thereof. CymaBay shall have the option to obtain a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide license to such Kaken Background Technology, solely (a)&nbsp;to Develop and Commercialize Licensed Products in any
indications in the CymaBay Territory, and (b)&nbsp;to Develop and Commercialize Licensed Products outside of the Field of Use in the Kaken Territory, but subject to Kaken&#146;s rights under<U>&nbsp;Section 10.6</U>. CymaBay shall have the right to
exercise such option to a license by providing Kaken written notice of its election. Upon such exercise, Kaken is deemed to grant the above license, <I><U>provided that</U></I><I> </I>CymaBay shall pay to Kaken any amounts that Kaken would owe to a
Third Party licensor of the applicable Kaken Background Technology, for CymaBay&#146;s (or its Affiliate&#146;s or sublicensee&#146;s) practice of such Kaken Background Technology under the above license. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.7</B> <B><U>No Other Rights</U></B>. Except as otherwise expressly provided in this Agreement, under no circumstances will a Party or any
of its Affiliates, as a result of this Agreement, obtain any ownership interest, license or other right (whether by implication, estoppel or otherwise) in or to any <FONT STYLE="white-space:nowrap">Know-How,</FONT> Patents or other Intellectual
Property rights of the other Party or any of such other Party&#146;s Affiliates, including tangible or intangible items owned, controlled or developed by the other Party or any of such other Party&#146;s Affiliates, or provided by the other Party or
any of its Affiliates to the receiving Party or any of its Affiliates at any time, pursuant to this Agreement. Neither Party nor any of its Affiliates will use or practice any <FONT STYLE="white-space:nowrap">Know-How</FONT> or Patents licensed or
provided to such Party or any of its Affiliates outside the scope of or otherwise not in compliance with the rights and licenses granted to such Party and its Affiliates under this Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 8 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PAYMENTS
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.1</B> <B><U>Upfront Fee</U></B>. Within [***] of receipt by Kaken of an invoice therefor, Kaken will pay to CymaBay a <FONT
STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> payment of Four Billion Five Hundred Million Japanese Yen (4,500,000,000 JPY). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.2</B> <B><U>Regulatory Milestone Payments</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.2.1</B> <I>Regulatory Milestones</I>. Kaken will make, pursuant to <U>Section</U><U></U><U>&nbsp;8.2.2</U>,
<FONT STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> milestone payments to CymaBay (each, a &#147;<B>Regulatory Milestone Payment</B>&#148;)
upon the first achievement of each of the regulatory events as set forth in the below table&nbsp;with respect to Licensed Product (each, a &#147;<B>Regulatory Milestone Event</B>&#148;) by Kaken or its Related Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.2.2</B> <I>Payment Terms for Regulatory Milestone Payments</I>. Kaken will notify CymaBay within five (5)&nbsp;Business Days after the
achievement of a Regulatory Milestone Event by Kaken or its Related Parties. CymaBay will invoice Kaken after receipt of such notice for the applicable Regulatory Milestone Payment amount set forth in the above table of<U>&nbsp;Section
</U><U>8.2.1</U>, and Kaken shall pay to CymaBay such amount within [***] after receipt of such invoice. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.3</B> <B><U>Sales Milestone
Payments</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.3.1</B> <I>Sales Milestones</I>. Kaken will make, pursuant to <U>Section</U><U></U><U>&nbsp;8.3.2</U>, <FONT
STYLE="white-space:nowrap">one-time,</FONT> <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> milestone payments to CymaBay (each, a &#147;<B>Sales Milestone Payment</B>&#148;) when
aggregate Net Sales of Licensed Products in the Kaken Territory in a given Kaken Fiscal Year first reach the JPY threshold values indicated in the table below (each, a &#147;<B>Sales Milestone Event</B>&#148;) during the Term: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For clarity, the Sales Milestone
Payments will each be paid only once, such that, the maximum total amount payable by Kaken to CymaBay under this<U>&nbsp;Section 8.3</U>&nbsp;is [***] JPY (it being understood that the Sales Milestone Payments will be additive). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.3.2</B> <I>Payment Terms for Sales Milestone Payments</I>. Within [***] after the end
of each Kaken Fiscal Quarter, Kaken will notify CymaBay of the achievement of a Sales Milestone Event(s) during such Kaken Fiscal Quarter. CymaBay will thereafter invoice Kaken for the applicable Sales Milestone Payment amount set forth in the above
table of<U>&nbsp;Section </U><U>8.3.1</U>, and Kaken shall pay to CymaBay such amount within [***] after receipt of such invoice; [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.4</B> <B><U>Supply Transfer Price; <FONT STYLE="white-space:nowrap">Back-Up</FONT> Royalties</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.4.1</B> <I>Supply Transfer Price During Royalty Term</I>. With respect to Licensed Product supplied by CymaBay to Kaken during the
applicable Royalty Term for Licensed Product, and subject to<U>&nbsp;Sections </U><U>8.4.3</U>&nbsp;and<U>&nbsp;8.6.2</U>, Kaken will make <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT>
payments to CymaBay, on a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis, in an amount, payable in JPY at the time of such supply, equal to the Supply Transfer Price then in
effect for such Licensed Product (other than with respect to a Combination Product, [***] for which shall be calculated as provided in the agreement between the Parties under <U>Section</U><U></U><U>&nbsp;7.1.5(b)</U> for such Combination Product),
for each unit of such Licensed Product that CymaBay supplies to Kaken under the Commercial Supply Agreement (or under any other commercial supply agreement between the Parties other than the Clinical Supply Agreement). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.4.2</B> <I>Supply Transfer Price Post-Royalty Term</I>. On a Licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis, after the Royalty Term expires for such Licensed Product and for so long as CymaBay continues to supply such Licensed Product pursuant
to the Commercial Supply Agreement, Kaken will make <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> payments to CymaBay, on a Licensed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis, in an amount, payable in JPY at the time of such supply, equal to [***] (other than with respect to a Combination Product, the [***] for which shall be calculated as
provided in the agreement between the Parties under <U>Section</U><U></U><U>&nbsp;7.1.5(b)</U> for such Combination Product), for each unit of such Licensed Product that CymaBay supplies to Kaken under the Commercial Supply Agreement (or under any
other agreement between the Parties). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.4.3</B> <I><FONT STYLE="white-space:nowrap">Back-Up</FONT> Royalties.</I><I></I>&nbsp;If, at
any time during the applicable Royalty Term for a Licensed Product, the Commercial Supply Agreement is terminated or is otherwise no longer in effect, including if there is a CymaBay Supply Termination, then, with respect to the sales or other
commercial transfer of such Licensed Product in the Kaken Territory, Kaken will make <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">non-creditable</FONT> royalty payments in JPY to CymaBay at a royalty rate
equal to [***] of Net Sales of such Licensed Product. On a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis, the royalties due under this
<U>Section</U><U></U><U>&nbsp;8.4.3</U> will be payable until the latest to occur of (a)&nbsp;the expiration of the last Valid Claim of the Royalty Patents Covering such Licensed Product in the Kaken Territory, (b)&nbsp;the expiration of Regulatory
Exclusivity for such Licensed Product in the Kaken Territory, and (c)&nbsp;ten (10) years after the First Commercial Sale of such Licensed Product in the Kaken Territory (the &#147;<B>Royalty Term</B>&#148;, as to the applicable Licensed Product).
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.5</B> <B><U>Additional Supply Transfer Price and <FONT STYLE="white-space:nowrap">Back-Up</FONT> Royalty Terms</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.5.1</B> <I>Only One Royalty</I>. In the event<U>&nbsp;Section 8.4.3</U>&nbsp;applies as to sale of a Licensed Product, only one royalty
will be due thereunder with respect to the sale of the same unit of Licensed Product, even if the manufacture, use, sale, offer for sale or importation of such Licensed Product is Covered by more than one claim of the Royalty Patents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.5.2</B> <I>Reduction for Loss of Patent Protection</I>. On a Licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis, upon the expiration of the last Valid Claim of the Royalty Patents Covering such Licensed Product in the Kaken Territory then:
(i)&nbsp;the amount owed by Kaken under <U>Section</U><U></U><U>&nbsp;8.4.1</U> for supply by CymaBay of such Licensed Product after such occurrence shall be [***], and (ii)&nbsp;if applicable, the royalties payable to CymaBay under<U>&nbsp;Section
</U><U>8.4.3</U>&nbsp;will be [***];<I><U>&nbsp;provided</U></I>, that no such reduction shall apply under this<U>&nbsp;Section </U><U>8.5.2</U>&nbsp;if any reduction under<U>&nbsp;Section </U><U>8.5.3</U>&nbsp;applies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.5.3</B> <I>Royalty Reduction for Generic Competition</I>. With respect to a particular
Licensed Product being sold in the Kaken Territory, on a Licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Product-by-Licensed</FONT></FONT> Product basis and a Kaken Fiscal <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Quarter-by-Kaken</FONT></FONT> Fiscal Quarter basis, if the Generic Competition Percentage in the Kaken Territory with respect to such Licensed Product for all sales in such Kaken Fiscal Quarter equals or exceeds [***],
then beginning from the immediately following Kaken Fiscal Quarter: (i)&nbsp;the amount owed by Kaken under <U>Section</U><U></U><U>&nbsp;8.4.1</U> for supply of such Licensed Product during such Kaken Fiscal Quarter shall be [***] (with applicable
adjustments for amounts already paid by Kaken for such supply, if needed), or (ii)&nbsp;if applicable, the royalties on Net Sales payable to CymaBay under<U>&nbsp;Section </U><U>8.4.3</U>&nbsp;shall be [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.5.4</B> <I>Minimum Floor</I>. In no event will the Supply Transfer Price or, if applicable, the royalties payable to CymaBay
under<U>&nbsp;Section 8.4.3</U>,&nbsp;be reduced for any particular amount owed by more than [***] of the amount that otherwise would have been due and payable to CymaBay but for the reductions set forth in<U>&nbsp;Sections 8.5.2</U>
and<U>&nbsp;8.5.3</U>, and further, in no event will the Supply Transfer Price (whether during or after the Royalty Term) be reduced to the amount that is less than [***]. Kaken may not carry forward any reductions or credits that are not applied
against the amounts payable to CymaBay hereunder as a result of the foregoing floor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.5.5</B> <I>Transfer Price Revisions</I>. In the
event that at any time [***] for a Licensed Product is less than [***], the Parties will negotiate reasonably and in good faith to agree on a new Supply Transfer Price that is fair and reasonable to both Parties;<I><U>&nbsp;provided</U></I>, that,
in such circumstance, until the Parties mutually agree on a new Supply Transfer Price, then: (a)&nbsp;the existing Supply Transfer Price will continue to apply, and (b)&nbsp;the Parties will submit the determination of such a new Supply Transfer
Price to Expedited Arbitration under <U>Section</U><U></U><U>&nbsp;14.3.4</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.5.6</B> <I>Other Amounts Payable</I>. With respect to
any amounts owed under this Agreement by one Party to the other for which no other invoicing and payment procedure is specified herein, within [***] after the end of each Kaken Fiscal Quarter, each Party will provide an invoice, together with
reasonable supporting documentation, to the other Party for such amounts owed in respect of such Kaken Fiscal Quarter. The owing Party will pay any undisputed amounts within [***] of receipt of the invoice, and any disputed amounts owed by a Party
will be paid within [***] of resolution of the dispute. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.6</B> <B><U>Payment Terms</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.6.1</B> <I>Manner of Payment</I>. All payments to be made by Kaken hereunder will be made in Dollars or Yen, as the same has been
specified in the applicable provision of this Agreement, by wire transfer to such bank account as CymaBay may designate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.6.2</B>
<I>Reports and <FONT STYLE="white-space:nowrap">Back-Up</FONT> Royalty Payments</I>. All amounts payable to CymaBay pursuant to<U>&nbsp;Section </U><U>8.4.3</U>, if applicable, will be paid in JPY within [***] after the end of each Kaken Fiscal
Quarter. Each such payment of royalties due to CymaBay will be accompanied by a written report showing in JPY the amount of Net Sales of Licensed Products and the royalty due for such Kaken Fiscal Quarter. The report will include, at a minimum, the
following information for the applicable Kaken Fiscal Quarter, each listed by Licensed Product: (a)&nbsp;the number of units of each Licensed Product on which royalties are owed to CymaBay hereunder sold either by Kaken or its Related Parties,
(b)&nbsp;the gross amount received for such sales, (c)&nbsp;Net Sales (including all permitted deductions taken or applied), and (d)&nbsp;the royalties owed to CymaBay. All such reports will be treated as Confidential Information of Kaken. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.6.3</B> <I>Reports for CymaBay Royalty Payments</I>. Kaken acknowledges that CymaBay has a royalty obligation payable to Janssen
Pharmaceutica NV (&#147;<B>Janssen</B>&#148;) pursuant to an <FONT STYLE="white-space:nowrap">in-license</FONT> agreement dated as of June&nbsp;6, 2006 (the &#147;<B>Janssen License Agreement</B>&#148;). To facilitate CymaBay&#146;s calculation of
such royalty obligation for sales of Licensed Product by or on behalf of Kaken in the corresponding period, Kaken will provide CymaBay with a written report within [***] of the end of each Kaken Fiscal Quarter in which sales of Licensed Product have
been made by or on behalf of Kaken. The report will include the following information (in JPY) for the applicable Kaken Fiscal Quarter: (a)&nbsp;the gross amount invoiced by Kaken and its Related Parties (including any distributors) to Third Party
purchasers from the sale or distribution to Third Parties of Licensed Product, [***]. All such reports will be treated as Confidential Information of Kaken but CymaBay will be allowed to share such reports with Janssen in connection with
CymaBay&#146;s payment of royalties pursuant to the Janssen License Agreement, including subject to its duties to maintain the confidentiality of such information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.7</B> <B><U>Records and Audits</U></B><B>.</B> Kaken will keep, and will cause its
Related Parties to keep, complete, true and accurate books and records in accordance with the applicable Accounting Standards in relation to this Agreement, including in relation to Net Sales and royalties and other amounts owed hereunder. Kaken
will keep, and will cause its Related Parties to keep, such books and records for at least three (3)&nbsp;years following the Kaken Fiscal Year to which they pertain. CymaBay may, upon written request, cause an internationally recognized independent
accounting firm (the &#147;<B>Auditor</B>&#148;), which is reasonably acceptable to Kaken, to inspect the relevant records of Kaken and its Affiliates to verify the payments made by Kaken and the related reports, statements and books of accounts, as
applicable. Before beginning its audit, the Auditor will execute an undertaking reasonably acceptable to Kaken by which the Auditor agrees to keep confidential all information reviewed during the audit. The Auditor will have the right to disclose to
CymaBay only its conclusions regarding any payments owed under this Agreement and the basis for such conclusions (if material to CymaBay). Kaken and its Affiliates will make their records available for inspection by the Auditor during regular
business hours at such place or places where such records are customarily kept, upon receipt of reasonable advance notice from CymaBay. The records will be reviewed solely to verify the accuracy of Kaken&#146;s royalties and other payment
obligations and compliance with the financial and reporting terms of this Agreement. Such inspection right will not be exercised more than once in any Kaken Fiscal Year and not more frequently than once with respect to records covering any specific
period of time. In addition, CymaBay will only be entitled to audit the books and records of Kaken for the three (3)&nbsp;Kaken Fiscal Years prior to the Kaken Fiscal Year in which the audit request is made. CymaBay agrees to hold in strict
confidence all information received and all information learned in the course of any audit or inspection, except to the extent necessary to enforce its rights under this Agreement or to the extent required to comply with any Applicable Law or
judicial order. The Auditor will provide its audit report and basis for any determination to Kaken at the time such report is provided to CymaBay before it is considered final. If the final result of the inspection reveals an underpayment or
overpayment by Kaken, the underpaid or overpaid amount will be settled promptly, with Kaken paying to CymaBay any such underpayment within [***] of the report, and any overpayment being credited against any subsequent payment owed by Kaken. CymaBay
will pay for such inspections, as well as its expenses associated with enforcing its rights with respect to any payments hereunder, except, if an underpayment of more than [***] of the total payments due hereunder for the applicable year is
discovered, then the fees and expenses charged by the Auditor will be paid by Kaken. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.8 <U>Taxes</U>. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.8.1</B> Kaken may withhold from payments due to CymaBay amounts for payment of any withholding tax that is required by Applicable Law to
be paid to any taxing authority on behalf of CymaBay with respect to such payments. Kaken will provide CymaBay all relevant documents and correspondence, and will also provide to CymaBay any other cooperation or assistance on a reasonable basis as
may be necessary to enable CymaBay to claim exemption from such withholding taxes and/or to receive a refund of such withholding tax or claim a foreign tax credit. Kaken will give proper evidence from time to time as to the payment of any such tax.
The Parties will cooperate with each other in seeking deductions under any double taxation or other similar treaty or agreement from time to time in force. Such cooperation may include (a)&nbsp;Kaken making payments from a single source in the U.S.,
where possible and necessary for enabling CymaBay to claim deductions, (b)&nbsp;CymaBay confirming that it is entitled to exemption from withholding tax on the royalties under this Agreement under the U.S.-Japan income tax convention, (c)&nbsp;if it
is entitled to that exemption, CymaBay preparing and submitting to Kaken the applicable application form for the above income tax convention and any other attachment thereto so that Kaken for the benefit of CymaBay will file them with the relevant
taxation office in Japan prior to the payment from Kaken to CymaBay pursuant to this Agreement, (d)&nbsp;Kaken making such filing in a timely manner, and (e)&nbsp;if such withholding tax is payable, Kaken filing the application for certification of
tax payment that is duly prepared and submitted to Kaken by CymaBay with the relevant taxation office in Japan in a timely manner. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.8.2</B> Apart from any taxes withheld by Kaken pursuant to the provisions of<U>&nbsp;Section 8.8.1</U>&nbsp;and those deductions expressly
included in the definition of Net Sales, the amounts payable hereunder will not be reduced on account of any taxes, charges, duties or other levies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.9</B> <B><U>Blocked Payments</U></B><B>.</B> In the event that, by reason of Applicable
Law in the Kaken Territory, it becomes impossible or illegal for Kaken to transfer, or have transferred on its behalf, payments owed to CymaBay hereunder, Kaken will promptly notify CymaBay of the conditions preventing such transfer and such
payments will be deposited in local currency in the Kaken Territory to the credit of CymaBay in a recognized banking institution designated by CymaBay or, if none is designated by CymaBay within a period of [***], in a recognized banking institution
selected by Kaken, as the case may be, and identified in a written notice given to CymaBay pursuant to<U>&nbsp;Section </U><U>14.10</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.10</B> <B><U>Interest on Late Payments</U></B><B>.</B> If a Party does not receive payment of any sum due to it on or before the due date
therefor, interest shall thereafter accrue on the sum due to such Party from the due date until the date of payment at a rate of [***] (recalculated and compounding as of the end of each Kaken Fiscal Quarter), or the maximum rate allowable by
Applicable Law, whichever is less, and any such accrued interest shall be paid to such Party by the owing Party at the time the related payment is made; <I>provided</I>, <I>however</I>, that [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.11</B> <B><U>Mutual Convenience</U></B>. The royalty and other payment obligations set forth hereunder have been agreed to by the Parties
for the purpose of reflecting and advancing their mutual convenience, including the ease of calculating and paying royalties and other amounts owed to CymaBay. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 9 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONFIDENTIALITY AND PUBLICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1</B> <B><U>Nondisclosure and <FONT STYLE="white-space:nowrap">Non-Use</FONT> Obligations</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.1.1</B> During the Term and for a period of five (5)&nbsp;years thereafter, all Confidential Information disclosed by one Party to the
other Party under this Agreement will be maintained in confidence by the receiving Party (and its Affiliates) and will not be disclosed to a Third Party or used for any purpose except pursuant to the licenses granted under this Agreement as
otherwise set forth herein, without the prior written consent of the disclosing Party, except that the foregoing obligations shall not apply to particular Confidential Information that the receiving Party can demonstrate: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the disclosing Party, as
documented by the receiving Party&#146;s business records; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> is known to the public before its receipt from the disclosing
Party, or thereafter becomes generally known to the public through no breach of this Agreement by the receiving Party; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> is
subsequently disclosed to the receiving Party by a Third Party who is not known by the receiving Party to be under an obligation of confidentiality to the disclosing Party; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> is developed by the receiving Party independently of and without use of or access to any Confidential Information received from the
disclosing Party, as documented by the receiving Party&#146;s business records. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">For clarity, all information and data relating to the
inventions claimed by Patents within the New CymaBay IP and the CymaBay Licensed Technology and the <FONT STYLE="white-space:nowrap">Know-How</FONT> specific thereto, will be Confidential Information of CymaBay, and all information and data relating
to the inventions claimed by Patents within the Kaken Licensed Technology and the <FONT STYLE="white-space:nowrap">Know-How</FONT> specific thereto, will be Confidential Information of Kaken. Specific aspects or details of Confidential Information
will not be deemed to be within the public domain or in the possession of the receiving Party merely because the Confidential Information is encompassed by more general information in the public domain or in the possession of the receiving Party.
Further, any combination of Confidential Information will not be considered in the public domain or in the possession of the receiving Party merely because individual elements of such Confidential Information are in the public domain or in the
possession of the receiving Party unless the combination and its principles are in the public domain or in the possession of the receiving Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">The existence and terms and conditions of this Agreement are hereby deemed to be the
Confidential Information of each Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.1.2</B> Notwithstanding the obligations of confidentiality and
<FONT STYLE="white-space:nowrap">non-use</FONT> set forth above in <U>Section</U><U></U><U>&nbsp;9.1.1</U>, a receiving Party may provide Confidential Information of the other Party, and may disclose the existence and particular terms and conditions
of this Agreement, in each case, as may be reasonably required in order to perform its obligations or to exercise its rights under this Agreement, with the foregoing disclosures specifically limited to: (a)&nbsp;Related Parties, and their employees,
directors, agents, consultants, or advisors to the extent reasonably needed for the performance of its obligations or exercise of its rights under this Agreement, in each case who are under an obligation of confidentiality with respect to such
information that is no less stringent than the terms of this<U>&nbsp;ARTICLE 9</U>; (b) Governmental Authorities or Regulatory Authorities in order to obtain Patents or perform its obligations or exercise its rights under this
Agreement,<I><U>&nbsp;provided</U></I>&nbsp;that such Confidential Information will be disclosed only to the extent reasonably necessary to do so, and where permitted, subject to confidential treatment; (c)&nbsp;those entitled to receive such
information, pursuant to a disclosure that is required by Applicable Law, including by the rules or regulations of the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States or of any
stock exchange or listing entity; (d)&nbsp;with respect to the terms and conditions of this Agreement only, any bona fide actual or prospective acquirers, merger partners, underwriters, investors, lenders or other financing sources and any bona fide
actual or prospective collaborators, licensors, Sublicensees, licensees or strategic partners and to employees, directors, agents, consultants or advisers of such Third Party, in each case who are under obligations of confidentiality and <FONT
STYLE="white-space:nowrap">non-use</FONT> with respect to such information that are no less stringent than the terms of this<U>&nbsp;ARTICLE 9</U>&nbsp;(but of duration customary in confidentiality agreements entered into for a similar purpose), or,
with respect to recipients who are lawyers or certified accountants, are subject to professional obligations that impose such confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> requirement; and (e)&nbsp;to any Third Party licensor
of rights hereunder to the extent a Party is required to do so pursuant to the terms and conditions of an <FONT STYLE="white-space:nowrap">in-license</FONT> agreement with such Third Party relating to the intellectual property rights sublicensed by
such Party hereunder. If a Party is required by Applicable Law to disclose Confidential Information of the other Party that is subject to the confidentiality or <FONT STYLE="white-space:nowrap">non-disclosure</FONT> provisions of
this<U>&nbsp;ARTICLE 9</U>, such Party will promptly inform the other Party of the disclosure that is being sought to provide the other Party an opportunity to challenge, limit, and/or seek a protective or similar order regarding the disclosure.
Notwithstanding<U>&nbsp;Section </U><U>9.1</U>, Confidential Information that is permitted or required to be disclosed hereunder will remain otherwise subject to the confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> provisions of
this<U>&nbsp;ARTICLE 9</U>. If either Party concludes that a copy of this Agreement must be filed with the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States, such Party will, a
reasonable time prior to any such filing, provide the other Party with a copy of such agreement showing any provisions hereof as to which the Party proposes to request confidential treatment, will provide the other Party with an opportunity to
comment on any such proposed redactions and to suggest additional redactions, and will take such Party&#146;s reasonable comments into consideration before filing such agreement and use reasonable efforts to have terms identified by such other Party
afforded confidential treatment by the applicable regulatory agency. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2</B> <B><U>Publication and Publicity</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.2.1</B> <I>Publication</I>. Except for disclosures permitted pursuant to<U>&nbsp;Sections </U><U>9.1</U>&nbsp;and<U>&nbsp;9.3.3</U>, if a
Party wishes to make a publication or public presentation that (x)&nbsp;contains the Confidential Information of the other Party, or (y)&nbsp;discloses or discusses any results of Development activities under this Agreement in the Kaken Territory,
or (z)&nbsp;mentions Kaken or CymaBay with regards to this Agreement or any activities in connection with this Agreement in the Kaken Territory, such Party will deliver to the other Party a copy of the proposed written publication or presentation at
least [***] prior to submission for publication or presentation. The other Party will have the right (a)&nbsp;to propose modifications to the publication or presentation for patent reasons or trade secret reasons or to remove Confidential
Information of the other Party, and such Party will remove all Confidential Information of the other Party if so requested by the other Party and otherwise will incorporate the other Party&#146;s reasonable comments, or (b)&nbsp;to request a
reasonable delay in publication or presentation in order to protect patentable information. If the other Party requests a delay, such Party will delay submission or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
presentation for a period of [***] (or such shorter period as may be mutually agreed by the Parties) to enable the other Party to file patent applications protecting the other Party&#146;s rights
in such information. With respect to any proposed publications or disclosures by investigators or academic or <FONT STYLE="white-space:nowrap">non-profit</FONT> collaborators, such materials will be subject to review under this<U>&nbsp;Section
9.2.1</U>&nbsp;to the extent that such Party has the right and ability (after using Commercially Reasonable Efforts to obtain such right and ability) to do so. Such Party will not submit or publish any article or other publication to or with any
scientific journal or other publisher that requires, as a condition of publication, that such Party agrees to make available to the publisher or Third Parties any Materials that are the subject of the publication. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.2.2</B> <I>Publicity</I>. Except as permitted in<U>&nbsp;Section </U><U>9.1</U>,<U>&nbsp;9.2.1</U>&nbsp;or<U>&nbsp;9.3</U>, the terms and
conditions of this Agreement may not be disclosed by either Party, and neither Party will use the name or any other Trademarks of the other Party or the name of its employees in any publicity, news release or other disclosure relating to this
Agreement, its subject matter, or the activities of the Parties under the Collaboration without the prior express written permission of the other Party, except (a)&nbsp;as may be required by Applicable Law, including by the rules or regulations of
the United States Securities and Exchange Commission or similar regulatory agency in any country other than the United States or of any stock exchange or listing entity,<I><U>&nbsp;provided</U></I><I><U></U></I>&nbsp;that the Party making such
disclosure or use of the name or other Trademarks of the other Party or the name of its employees, gives the other Party reasonable prior notice and otherwise complies with<U>&nbsp;Section </U><U>9.1.2</U>, or (b)&nbsp;as expressly permitted by the
terms and conditions of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3</B> <B><U>Press Release</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.3.1</B> The Parties will issue the press releases in <U>Schedule</U><U></U><U>&nbsp;9.3.1</U> on January&nbsp;9, 2023, or such other
mutually agreed date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.3.2</B> Except as provided in <U>Section</U><U></U><U>&nbsp;9.2.2</U> or this
<U>Section</U><U></U><U>&nbsp;9.3</U>, neither Party will issue a press release or public announcement relating to this Agreement without the prior written approval of the other Party (such approval not to be unreasonably withheld, conditioned or
delayed), except that a Party may (a)&nbsp;once a press release or other public statement is approved in writing by both Parties, make subsequent public disclosure of the information contained in such press release or other written statement without
the further approval of the other Party, and (b)&nbsp;issue a press release or public announcement as required by Applicable Law, including by the rules or regulations of the United States Securities and Exchange Commission or similar regulatory
agency in a country other than the United States or of any stock exchange or listing entity, <I><U>provided</U></I> that the Party issuing such press release gives reasonable prior notice to the other Party of and the opportunity to comment on the
press release or public announcement, and otherwise complies with this <U>ARTICLE 9</U>. In addition, CymaBay may with Kaken&#146;s prior written approval, such approval not to be unreasonably withheld, conditioned or delayed, issue a press release
regarding the payment or receipt of any milestone payments under this Agreement with respect to any Licensed Products, <I><U>provided</U></I>, that such press release complies with this <U>Section</U><U></U><U>&nbsp;9.3</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.3.3</B> Notwithstanding anything in this <U>Section</U><U></U><U>&nbsp;9.3</U> to the contrary, either Party may issue a press release or
make a public disclosure relating to such Party&#146;s Development, Manufacturing or Commercialization activities under this Agreement with respect to Licensed Products in such Party&#146;s Territory, <I><U>provided</U></I> that such press release
or public disclosure does not disclose Confidential Information of the other Party. Prior to making any such disclosure under this <U>Section</U><U></U><U>&nbsp;9.3.3</U> however, the disclosing Party will provide the other Party with a draft of
such proposed disclosure within a reasonable time (but at least five (5)&nbsp;Business Days) prior to disclosure for the other Party&#146;s review and comment, and the disclosing Party will consider in good faith any timely comments provided by the
other Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 10 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REPRESENTATIONS, WARRANTIES AND COVENANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.1</B> <B><U>Mutual Representations and Warranties</U></B>. Each Party represents and warrants to the other Party that, as of the
Effective Date: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.1.1</B> such Party is a corporation duly organized, validly existing and in good standing under the laws of its
jurisdiction of incorporation or formation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.1.2</B> such Party has all requisite corporate power and corporate authority to enter
into this Agreement and to carry out its obligations under this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.1.3</B> all requisite corporate action on the part of
such Party, its directors and stockholders required by Applicable Law for the authorization, execution and delivery by such Party of this Agreement, and the performance of all obligations of such Party under this Agreement, has been taken; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.1.4</B> the execution, delivery and performance of this Agreement, and compliance with the provisions of this Agreement, by such Party do
not and will not: (a)&nbsp;violate any provision of Applicable Law or any ruling, writ, injunction, order, permit, judgment or decree of any Governmental Authority, (b)&nbsp;constitute a breach of, or default under (or an event which, with notice or
lapse of time or both, would become a default under) or conflict with, or give rise to any right of termination, cancellation or acceleration of, or adversely affect any rights under, any agreement, arrangement or instrument, whether written or
oral, by which such Party or any of its assets are bound (including, in the case of CymaBay, the CymaBay Licensed Technology and the Licensed Products), or (c)&nbsp;violate or conflict with any of the provisions of such Party&#146;s organizational
documents (including any articles or memoranda of organization or association, charter, bylaws or similar documents); and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.1.5</B> no
consent, approval, authorization or other order of, or filing with, or notice to, any Governmental Authority or other Third Party is required to be obtained or made by such Party in connection with the authorization, execution and delivery by such
Party of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.1.6</B> this Agreement constitutes a legal, valid and binding obligation of such Party, enforceable against
such Party in accordance with its terms, except as enforceability may be limited by applicable equitable principles or bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&#146; rights generally. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.2</B> <B><U>Additional Representations and Warranties of CymaBay</U></B>. CymaBay represents and warrants to Kaken that, as of the
Effective Date in the Kaken Territory, except as set forth on<U>&nbsp;Schedule</U><U></U><U>&nbsp;10.2</U>: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.1</B> CymaBay or one
of its Affiliates is the sole and exclusive owner, or has exclusive rights to, the CymaBay Licensed Technology existing as of the Effective Date. All of the CymaBay Licensed Technology is free and clear of any Liens. No Person has alleged in writing
to CymaBay or any of its Representatives that any Third Party owns, in whole or in part, any of the CymaBay Licensed Technology, and to the Knowledge of CymaBay, there is no reasonable basis for any such allegation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.2</B> None of the issued CymaBay Licensed Patents existing as of the Effective Date has been adjudged invalid, unenforceable or
unpatentable by any Governmental Authority of competent jurisdiction, and, to the Knowledge of CymaBay, there is no prior art or other facts regarding the issued CymaBay Licensed Patents existing as of the Effective Date that would cause such
CymaBay Licensed Patents to be invalid or unenforceable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.3</B> To the Knowledge of CymaBay, (a)&nbsp;the Exploitation of Licensed
Products as contemplated in this Agreement and based upon the CymaBay Licensed Technology as it exists on the Effective Date does not infringe any issued Patent or any pending and published Patent application (were its claims to issue in their form
as of the Effective Date) of any Person, and (b)&nbsp;Kaken&#146;s use of the CymaBay Licensed Technology as contemplated in this Agreement, and exercise of its rights under the CymaBay Licensed Technology to Exploit Licensed Products as
contemplated hereunder, does not infringe, misappropriate or otherwise violate the trade secret rights or copyrights of any other Person. No written claim or demand of any Third Party has been made, or to the Knowledge of CymaBay, is threatened,
against CymaBay or any of its Affiliates, and to the Knowledge of CymaBay there is no Proceeding, or action, claim (including regarding infringement of Intellectual Property), complaint, demand, suit, proceeding, or arbitration brought by a Third
Party, pending, or, to the Knowledge of CymaBay, threatened, as of the Effective Date, against CymaBay or any of its Affiliates, in each case that (x) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
involves any of the CymaBay Licensed Technology or Licensed Products existing as of the Effective Date or the Exploitation of the foregoing and (y)&nbsp;(i) challenges any rights of CymaBay or
any of its Affiliates in any such CymaBay Licensed Technology or Licensed Products, (ii)&nbsp;alleges that any issued Patent within such CymaBay Licensed Technology is invalid or unenforceable, (iii)&nbsp;alleges that the use of any CymaBay Licensed
Technology existing as of the Effective Date infringes any issued Patent of a Third Party or infringes, misappropriates or otherwise violates the Intellectual Property rights of any Person, (iv)&nbsp;challenges the transactions contemplated by this
Agreement or (v)&nbsp;asserts that the manufacture, use, sale, offer for sale or importation of Licensed Products or the processes used to make Licensed Products is or was infringing or otherwise violates or violated any Intellectual Property of any
Person;<I><U>&nbsp;provided</U></I>,<I><U>&nbsp;however</U></I>, that, &#147;Proceeding&#148; for purposes of the representations and warranties of this<U>&nbsp;Section 10.2.3</U>&nbsp;includes any notice of
<FONT STYLE="white-space:nowrap">non-compliance,</FONT> summons, subpoena, inquiry or investigation by a Governmental Authority, of any nature, whether civil, criminal, regulatory, or otherwise, in law or in equity, but excludes office actions or
similar communications issued by any patent office or comparable registration authority in the ordinary course of prosecution of any patent application within the CymaBay Licensed Patents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.4</B> To the Knowledge of CymaBay, each of CymaBay and its Affiliates is and has been in compliance in all material respects with all
Applicable Law applicable to and in connection with the Exploitation of the CymaBay Licensed Technology and the Licensed Products, except to the extent any <FONT STYLE="white-space:nowrap">non-compliance</FONT> would not reasonably be expected to
have a material adverse effect on the ability of Kaken to Exploit the Licensed Products in the Field of Use in the Kaken Territory in compliance with all Applicable Law. There are no, and there have not been any, issued judicial orders, writs,
injunctions, decrees, judgments or stipulations in force against CymaBay or its Affiliates with respect to the CymaBay Licensed Technology or Licensed Products that would reasonably be expected to have a material adverse effect on the ability of
Kaken to Exploit the Licensed Products in the Field of Use in the Kaken Territory in compliance with all Applicable Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.5</B> To
the Knowledge of CymaBay, no Third Party has infringed, misappropriated or otherwise violated any CymaBay Licensed Technology. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.6</B> The CymaBay Licensed Patents owned by CymaBay are both Controlled by and prosecuted by CymaBay and, to the Knowledge of CymaBay,
the CymaBay Licensed Patents Controlled but not prosecuted by CymaBay have been filed and diligently Prosecuted and Maintained in accordance with all Applicable Law, including disclosure of all prior art to the relevant patent authority to the
extent required by Applicable Law, and with all applicable fees due with respect thereto having been paid. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.7</B> To the Knowledge
of CymaBay, the scientific, technical and other information relating to the CymaBay Licensed Technology and Licensed Products disclosed or made available by CymaBay or any of its Representatives to Kaken in writing in the electronic data room has
been true and correct in all respects. Any experimental data therein that purports to be the result of work conducted by or on behalf of CymaBay or its Affiliates is based upon actual experimentation conducted by or on behalf of CymaBay or its
Affiliates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.8</B> Except as set forth on<U>&nbsp;Schedule</U><U></U><U>&nbsp;10.2.8</U>, no IND has been filed by CymaBay with any
Regulatory Authority in the Kaken Territory with respect to the Licensed Products. CymaBay is not currently assisting any Third Party in preparation for or in connection with filing an IND with respect to the Licensed Products in the Kaken
Territory. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.9</B> CymaBay has the unrestricted right to grant to Kaken the license rights under the CymaBay Licensed Technology in
the Kaken Territory that are being granted to Kaken under this Agreement upon the terms set forth herein. Neither CymaBay nor any of its Affiliates has granted any license or sublicense to any rights in the CymaBay Licensed Technology in the Kaken
Territory to any Third Party that are in conflict with the rights granted to Kaken in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.10</B> To the Knowledge of
CymaBay, <U>Schedule</U><U></U><U>&nbsp;1.45</U>&nbsp;sets forth, with the countries, application numbers and application dates indicated, as applicable, all CymaBay Licensed Patents that have issued or that have been applied for and are pending
issuance with any Governmental Authority. If it is subsequently discovered that there exists a Patent in CymaBay&#146;s Control that is a CymaBay Licensed Patent and is not listed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
on <U>Schedule</U><U></U><U>&nbsp;1.45</U>, then as the sole remedy for such situation, the Parties shall amend <U>Schedule</U><U></U><U>&nbsp;1.45</U> to add such CymaBay Licensed Patent to such
Schedule. To the Knowledge of CymaBay, there is no information that, in CymaBay&#146;s reasonable judgment, would likely render any of the granted CymaBay Licensed Patents invalid or unenforceable and that is not part of the publicly available file
history, except to the extent such invalidity or unenforceability would not reasonably be expected to have a material adverse effect on the ability of Kaken to Exploit the Licensed Products in the Field of Use in the Kaken Territory in compliance
with all Applicable Law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.11</B> CymaBay and its Affiliates have taken reasonable and customary measures to maintain and protect,
as applicable, the confidentiality of its or their owned Confidential Information within the CymaBay Licensed Technology. Notwithstanding the foregoing, it is acknowledged and agreed by Kaken that CymaBay and its Affiliates have disclosed
Confidential Information to (a)&nbsp;Third Parties under an obligation of confidentiality with respect to such information, (b)&nbsp;Governmental Authorities or Regulatory Authorities in order to obtain Patents or develop or submit Regulatory
Filings for products, and (c)&nbsp;the extent required by Applicable Law, including by the rules or regulations of the United States Securities and Exchange Commission or similar regulatory agency in a country other than the United States or of any
stock exchange or listing entity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.12</B> All employees, consultants, contractors and other persons who have contributed to the
design, creation, conception, reduction to practice or invention of any Intellectual Property in the applicable CymaBay Licensed Technology or CymaBay Licensed Patents owned by CymaBay have entered into written agreements with CymaBay assigning to
CymaBay all rights relating to such design, conception, reduction to practice, or invention of the applicable CymaBay Licensed Technology. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.13</B> <U>Schedule</U><U></U><U>&nbsp;10.2.13</U> sets forth a true and complete list of all material Contracts to which CymaBay or any
of its Affiliates is a party and under which CymaBay or its Affiliates have <FONT STYLE="white-space:nowrap">in-licensed</FONT> Intellectual Property of a Third Party that comprises CymaBay Licensed Technology or is otherwise material to the
Exploitation of the Licensed Products in the Field of Use in the Kaken Territory. Except as described in <U>Schedule</U><U></U><U>&nbsp;10.2.13</U>, none of such Contracts set forth on<U>&nbsp;Schedule</U><U></U><U>&nbsp;10.2.13</U>&nbsp;prevent
CymaBay from licensing or sublicensing rights to Kaken or require royalties to be paid in connection with a sublicense. True and correct copies of the Contracts set forth on<U>&nbsp;Schedule</U><U></U><U>&nbsp;10.2.13</U>&nbsp;have been provided to
Kaken, and such Contracts are in full force and effect and have not been modified or amended. Neither CymaBay or its Affiliates nor, to the Knowledge of CymaBay, the other party to such Contracts is in default with respect to a material obligation
under, and none of such parties has claimed or, to the Knowledge of CymaBay with respect to such counterparty&#146;s claims against CymaBay or any of its Affiliates, has grounds upon which to claim that the other party is in default with respect to
a material obligation under, such Contracts. None of CymaBay and its Affiliates has received any written notice of breach under any of the Contracts listed in<U>&nbsp;Schedule </U><U>10.2.13</U>. None of CymaBay and its Affiliates has waived or
allowed to lapse any of its material rights under any Contracts listed in <U>Schedule </U><U>10.2.13</U> with respect to Licensed Products, and no such rights have lapsed or otherwise expired or been terminated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.14</B> To the Knowledge of CymaBay, there are no Safety Concerns, adverse events or Efficacy Concerns in relation to Clinical Studies
of the Licensed Products or issues with any Governmental Authorities in relation to the Regulatory Approval of the Licensed Products for the Initial Indication, other than as has previously been made available as of the Effective Date to Kaken in
writing in the electronic data room, that would reasonably be expected to have a material adverse effect on the ability of Kaken or CymaBay to Exploit the Licensed Products in the Field of Use in the Kaken Territory in compliance with all Applicable
Law. Without limiting the foregoing, to the Knowledge of CymaBay, CymaBay has made available to Kaken prior to the Effective Date in writing in the electronic data room all material adverse information in its possession with respect to the Safety
Concerns, adverse events or Efficacy Concerns in relation to the Development of the Licensed Products or issues with any Governmental Authorities in relation to the Regulatory Approval of the Licensed Products for the Initial Indication. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.15</B> To the Knowledge of CymaBay, all Clinical Studies and Nonclinical Studies sponsored by CymaBay relating to Licensed Products
have been and are being conducted in material compliance with Applicable Law, including GCP requirements, and federal, national, state and local laws, rules, regulations and guidance restricting the use and disclosure of individually identifiable
health information. CymaBay has not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
received any written notices or other written correspondence from the FDA or any other Governmental Authority performing functions similar to those performed by the FDA with respect to any
ongoing Clinical Studies and Nonclinical Studies relating to the Licensed Products requiring the termination, suspension or material modification of such Clinical Studies and Nonclinical Studies. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.16</B> The inventions Covered by the owned CymaBay Licensed Patents: (1)&nbsp;were not conceived, discovered, developed or otherwise
made, in whole or in part, using funds provided by the federal government of the U.S. or any agency thereof or any other Governmental Authority; (2)&nbsp;are not a &#147;subject invention&#148; as that term is described in 35 U.S.C.
Section&nbsp;201(e); and (3)&nbsp;are not otherwise subject to the provisions of the Bayh-Dole Act (35 U.S.C. &#167;&#167; <FONT STYLE="white-space:nowrap">200-212,</FONT> as well as any regulations promulgated pursuant thereto, including 37 C.F.R.
Part 401). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.17</B> In connection with the Exploitation of the Licensed Products conducted by CymaBay, CymaBay has maintained as of
the Effective Date internal procedures and policies that comply in all material respects with the U.S. Foreign Corrupt Practices Act (15 U.S.C. <FONT STYLE="white-space:nowrap">&#167;&#167;78dd-1,</FONT> et seq.) and any other applicable
anti-bribery or anti-corruption laws (collectively &#147;<B>Anti-Corruption Laws</B>&#148;) and the Physicians&#146; Payment Sunshine Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.18</B> To the Knowledge of CymaBay, CymaBay has not (a)&nbsp;made an untrue statement of a material fact or fraudulent statement to the
FDA or any Governmental Authority with respect to Licensed Products, (b)&nbsp;failed to disclose a material fact required to be disclosed to the FDA or any Governmental Authority with respect to Licensed Products, or (c)&nbsp;committed any other
act, made any statement or failed to make any statement, that (in any such case) establishes a reasonable basis for the FDA to invoke its Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities Policy or for any other state or
foreign Governmental Authority to invoke any similar policy with respect to Licensed Products. CymaBay is not the subject of any pending or, to the Knowledge of CymaBay, any threatened investigation by the FDA pursuant to its Fraud, Untrue
Statements of Material Facts, Bribery, and Illegal Gratuities Final Policy. Neither CymaBay, nor any of its Affiliates has been convicted of any crime or engaged in any conduct which has resulted in or, to the Knowledge of CymaBay, is reasonably
likely to result in debarment, exclusion or disqualification by the FDA or any other Governmental Authority. To the Knowledge of CymaBay, none of its collaborators, agents or subcontractors it has used in the Development of the Licensed Products has
been convicted of any crime or engaged in any conduct which has resulted in debarment, exclusion or disqualification by the FDA or any other Governmental Authority. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.2.19</B> With respect to the Janssen License Agreement, Janssen has provided to CymaBay the technology transfer contemplated by
<U>Section</U><U></U><U>&nbsp;3.4</U> thereof requested by CymaBay and the transfer of the Materials (as defined therein) contemplated by <U>Section</U><U></U><U>&nbsp;3.5</U> thereof, in each case in accordance with the terms of the Janssen License
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.3</B> <B><U>Warranty Disclaimer</U></B>. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, NEITHER PARTY MAKES
ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, TO THE OTHER PARTY WITH RESPECT TO ANY PATENTS, <FONT STYLE="white-space:nowrap">KNOW-HOW,</FONT> MATERIALS, LICENSED PRODUCT, SERVICES, RIGHTS OR OTHER SUBJECT
MATTER OF THIS AGREEMENT, AND EACH PARTY HEREBY DISCLAIMS ALL SUCH OTHER WARRANTIES AND ALL IMPLIED WARRANTIES OF MERCHANTABILITY, NONINFRINGEMENT, AND FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO ANY AND ALL OF THE FOREGOING. EACH PARTY HEREBY
DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF ANY LICENSED PRODUCT PURSUANT TO THIS AGREEMENT WILL BE SUCCESSFUL. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.4</B> <B><U>Certain Covenants</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.4.1</B> <I>Compliance</I>. Each Party and its Related Parties will conduct the Collaboration and the Development and Commercialization of
the Licensed Products in accordance with all Applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.4.2</B> <I>No Debarment</I>. Each Party will use reasonable efforts to not use, in any
capacity in connection with the Collaboration or the performance of its obligations under this Agreement, any Person that has been debarred pursuant to Section&nbsp;306 of the FD&amp;C Act, as amended, or that is the subject of a conviction
described in such section, or, in the case of Kaken, such equivalent Applicable Law in the Kaken Territory. Each Party agrees to inform the other Party in writing immediately if it or any Person that is performing activities in the Collaboration or
under this Agreement, is debarred or is subject to debarment or is the subject of a conviction described in Section&nbsp;306 of the FD&amp;C Act or, in the case of Kaken, such equivalent Applicable Law in the Kaken Territory, or if any action, suit,
claim, investigation or legal or administrative proceeding is pending or, to the notifying Party&#146;s knowledge, is threatened, relating to the debarment or conviction of the notifying Party or any Person or entity used in any capacity by such
Party or any of its Affiliates in connection with the Collaboration or the performance of its other obligations under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.4.3</B> <I>Conflicting Transactions</I>. During the Term, CymaBay will not, and will cause its Affiliates not to, enter into any
agreement granting a license or other right or interest under the CymaBay Licensed Technology that is inconsistent with this Agreement or that would impair the licenses to Kaken as purported to be granted pursuant to this Agreement. During the Term,
Kaken will not, and will cause its Affiliates not to, enter into any agreement granting a license or other right under the Kaken Licensed Technology that is inconsistent with this Agreement or that would impair the licenses or other rights granted
to CymaBay by Kaken as purported to be granted pursuant to this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.4.4</B> <I>Internal Procedures and Policies</I>. CymaBay
will maintain and enforce in all material respects throughout the Term appropriate internal procedures and policies that comply with the Anti-Corruption Laws and the Physicians&#146; Payment Sunshine Act (and any equivalent Applicable Law in any
other country or jurisdiction outside the United States), including: (A)&nbsp;an applicable code of conduct and (B)&nbsp;provisions for monitoring, training and obtaining certifications of compliance from all Third Parties involved with the
Exploitation of the Licensed Products. CymaBay shall provide such reasonable assistance and documentation as may be reasonably necessary for Kaken and its Affiliates to comply with the Anti-Corruption Laws, the Physicians&#146; Payment Sunshine Act
(and any equivalent Applicable Law in any other country or jurisdiction outside the United States). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.5</B> <B><U>Exclusivity</U></B>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.5.1</B> Subject to<U>&nbsp;Section </U><U>10.5.3</U>, [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.5.2</B> Subject to<U>&nbsp;Section </U><U>10.5.3</U>, [***]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.5.3</B> Notwithstanding the terms of <U>Section</U><U></U><U>&nbsp;10.5.1</U> and <U>Section</U><U></U><U>&nbsp;10.5.2</U>, it is agreed
that, if Kaken undergoes a Change of Control with an Acquirer that was (either directly or through an Affiliate) Developing, Manufacturing or Commercializing a Competing Product prior to the closing of such Change of Control transaction, and Kaken
thereby becomes an Affiliate of such Acquirer, then such Acquirer [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.6</B> <B>Kaken Right of First Negotiation for Additional
Indications in the Kaken Territory</B>. CymaBay hereby grants to Kaken a right of first negotiation during the Term of this Agreement to obtain a license (an &#147;<B>Additional Indication Japan License</B>&#148;) under the CymaBay Licensed
Technology to Develop, Manufacture and Commercialize Licensed Products for use in any particular Additional Indication (or set of Additional Indications) in the Kaken Territory in the event that CymaBay intends to grant an Additional Indication
Japan License to any Third Party with respect to one or more particular Additional Indications. Such right is as follows: If CymaBay intends to grant an Additional Indication Japan License to any Third Party with respect to one or more particular
Additional Indications, then CymaBay will provide Kaken written notice of such intent (an &#147;<B>Additional Indication Notice</B>&#148;), [***]. Kaken will have [***] from its receipt of such a Notice to notify CymaBay in writing either of its
desire to commence negotiations or its rejection of such proposal. If Kaken notifies CymaBay of its rejection of such proposal, or if Kaken fails to respond to CymaBay in writing during such [***] period, CymaBay will have no further obligations to
Kaken under this <U>Section</U><U></U><U>&nbsp;10.6</U>&nbsp;with respect to the Additional Indication Japan License that was the subject of the applicable Additional Indication Notice. If Kaken notifies CymaBay of its desire to commerce
negotiations during such [***] period, then: (a) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Kaken will have a right of first negotiation to obtain an Additional Indication Japan License consistent with such Additional Indication Notice, such right continuing for a period of [***] after
Kaken&#146;s receipt of such Additional Indication Notice from CymaBay (the &#147;<B>Negotiation Period</B>&#148;), and (b)&nbsp;the Parties will promptly commence such negotiations and shall reasonably negotiate the terms of the proposed Additional
Indication Japan License during such Negotiation Period, and (c)&nbsp;CymaBay will not, and will ensure that its Affiliates will not, during the Negotiation Period engage in negotiations with any Third Party other than Kaken (and Kaken&#146;s
designee(s) for such negotiations) with respect to the Additional Indication Japan License that is the subject of such Additional Indication Notice from CymaBay. During the Negotiation Period, each Party will negotiate with the other in good faith
towards executing a license agreement for such Additional Indication Japan License [***] during the Negotiation Period. It is understood that such license agreement can instead be a written amendment to this Agreement if so mutually agreed by the
Parties during the Negotiation Period. Upon the expiration of the Negotiation Period, unless Kaken and CymaBay have executed a license agreement (or an amendment to this Agreement) covering such Additional Indication Japan License, CymaBay will be
free to enter into negotiations with any Third Party for such Additional Indication Japan License and enter into any agreement for the same; [***]. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 11 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION; LIMITATION OF LIABILITY; INSURANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.1</B> <B><U>General Indemnification by Kaken</U></B>. Kaken will indemnify, hold harmless and defend CymaBay, its Related Parties, and
their respective directors, officers, employees and agents (&#147;<B>CymaBay Indemnitees</B>&#148;) from and against any and all liabilities, damages, costs, fees and expenses (including reasonable attorneys&#146; fees and litigation expenses)
(collectively, &#147;<B>Losses</B>&#148;) incurred in connection with Third Party claims, suits or other legal proceedings (&#147;<B>Claims</B>&#148;) against any CymaBay Indemnitee to the extent arising out of or resulting from: (a)&nbsp;any breach
of, or inaccuracy in, any representation or warranty made by Kaken in this Agreement, or any breach or violation of any covenant or agreement of Kaken in, or in the performance of, this Agreement, (b)&nbsp;the [***] by or of Kaken or any of its
Related Parties, or any of their respective directors, officers, employees or agents in the performance of Kaken&#146;s obligations or exercise of its rights under this Agreement, or (c)&nbsp;the Development or Commercialization or other
Exploitation of Licensed Products by or on behalf of Kaken or any of its Related Parties. Kaken will have no obligation to indemnify the CymaBay Indemnitees to the extent that the Losses arise out of or result from any matters for which CymaBay is
obligated to indemnify Kaken under <U>Section</U><U></U><U>&nbsp;11.2</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.2</B> <B><U>General Indemnification by CymaBay</U></B>.
CymaBay will indemnify, hold harmless, and defend Kaken, its Related Parties and their respective directors, officers, employees and agents (&#147;<B>Kaken Indemnitees</B>&#148;) from and against any and all Losses incurred in connection with Third
Party Claims against a Kaken Indemnitee to the extent arising out of or resulting from: (a)&nbsp;any breach of, or inaccuracy in, any representation or warranty made by CymaBay in this Agreement, or any breach or violation by CymaBay of any CymaBay
covenant or agreement in this Agreement, (b)&nbsp;the [***] by or of CymaBay or any of its Related Parties, or any of their respective directors, officers, employees or agents in the performance of CymaBay&#146;s obligations under this Agreement, or
(c)&nbsp;the Development or Commercialization or other Exploitation of Licensed Products by or on behalf of CymaBay or any of its Related Parties. CymaBay will have no obligation to indemnify the Kaken Indemnitees to the extent that the Losses or
Claims arise out of or result from any matters for which Kaken is obligated to indemnify CymaBay under <U>Section</U><U></U><U>&nbsp;11.1</U>. For clarity, any such Third Party Claims against a Kaken Indemnity, and all Losses from such Claims, that
arise out of or result from alleged manufacturing defects in License Product due to the Manufacture by CymaBay of Licensed Product supplied to Kaken are excluded from the obligations of CymaBay under this <U>Section</U><U></U><U>&nbsp;11.2</U>, as
the indemnification for such Claims and Losses is addressed in the indemnification provisions of the Supply Agreements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.3</B>
<B><U>Indemnification Procedure</U></B>. The Party entitled to indemnification under this <U>ARTICLE 11</U> (an &#147;<B>Indemnified Party</B>&#148;) will notify the Party potentially responsible for such indemnification (the &#147;<B>Indemnifying
Party</B>&#148;) in writing promptly upon being notified of or having actual knowledge of any claim or claims asserted or threatened against the Indemnified Party which could give rise to a right of indemnification under this Agreement;
<I><U>provided</U></I>, that the failure to give such notice will not relieve the Indemnifying Party of its indemnity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obligation hereunder except to the extent that such failure materially prejudices the Indemnifying Party. If the Indemnifying Party has acknowledged in writing to the Indemnified Party the
Indemnifying Party&#146;s responsibility for defending a claim, the Indemnifying Party will have the right to defend, at its sole cost and expense, such claim by all appropriate proceedings;<I><U>&nbsp;provided</U></I>, that the Indemnifying Party
may not enter into any compromise or settlement unless (a)&nbsp;such compromise or settlement imposes only a monetary obligation on the Indemnifying Party and includes as an unconditional term thereof, the giving by each claimant or plaintiff to the
Indemnified Party of a release from all liability in respect of such claim; or (b)&nbsp;the Indemnified Party consents to such compromise or settlement, which consent will not be unreasonably withheld, conditioned or delayed unless such compromise
or settlement involves (i)&nbsp;any admission of legal wrongdoing by the Indemnified Party, (ii)&nbsp;any payment by the Indemnified Party that is not indemnified under this Agreement, or (iii)&nbsp;the imposition of any equitable relief against the
Indemnified Party. The Indemnified Party will cooperate with the Indemnifying Party and may participate in, but not control, any defense or settlement of any claim controlled by the Indemnifying Party pursuant to this<U>&nbsp;Section
11.3</U>&nbsp;and will bear its own costs and expenses with respect to such participation;<I><U>&nbsp;provided</U></I>&nbsp;that the Indemnifying Party will bear such costs and expenses if counsel for the Indemnifying Party will have reasonably
determined that such counsel may not properly represent both the Indemnifying Party and the Indemnified Party. If the Indemnifying Party does not elect to assume control of the defense of a claim or if a good faith and diligent defense, in the
Indemnified Party&#146;s reasonable opinion, is not being or ceases to be materially conducted by the Indemnifying Party, the Indemnified Party will have the right, at the expense of the Indemnifying Party, upon at least ten (10)&nbsp;Business
Days&#146; prior written notice to the Indemnifying Party of its intent to do so, to undertake the defense of such claim for the account of the Indemnifying Party (with counsel reasonably selected by the Indemnified Party and approved by the
Indemnifying Party, such approval not to be unreasonably withheld, conditioned or delayed);<I><U>&nbsp;provided</U></I>&nbsp;that the Indemnified Party will keep the Indemnifying Party apprised of all material developments with respect to such
claim. The Indemnified Party may not enter into any compromise or settlement without the prior written consent of the Indemnifying Party, such consent not to be unreasonably withheld, conditioned or delayed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.4</B> <B><U>Limitation of Liability</U></B>. NEITHER PARTY WILL BE LIABLE TO THE OTHER FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE
DAMAGES ARISING OUT OF THIS AGREEMENT, OR THE EXERCISE OF ITS RIGHTS OR THE PERFORMANCE OF ITS OBLIGATIONS HEREUNDER, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES, EXCEPT AS A RESULT OF A BREACH OF <U>ARTICLE 9</U>. NOTHING IN THIS<U>&nbsp;SECTION
</U><U>11.4</U>&nbsp;IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER THIS<U>&nbsp;ARTICLE 11</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.5</B> <B><U>Insurance</U></B>. Each Party will obtain and maintain insurance during the Term and for a period of at least two
(2)&nbsp;years after the last commercial sale of any Licensed Product for which it is responsible, with a reputable, solvent insurer in an amount appropriate for its business and products of the type that are the subject of this Agreement, and for
its obligations under this Agreement. Specifically, each Party will maintain (i)&nbsp;product liability insurance and (ii)&nbsp;clinical trial liability insurance with limits of at least [***] and [***], respectively. Upon request, each Party will
provide the other Party with evidence of the existence and maintenance of such insurance coverage. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 12 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INTELLECTUAL PROPERTY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.1</B> <B><U>Inventorship</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.1.1</B> <I>Determination of Inventorship</I>. Inventorship for inventions and discoveries (including
<FONT STYLE="white-space:nowrap">Know-How)</FONT> first made during the course of the performance of activities pursuant to the Collaboration will be determined in accordance with United States patent laws for determining inventorship. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.1.2</B> <I>JRA Exception</I>. Notwithstanding anything to the contrary in this Agreement, each Party will have the right to invoke the
America Invents Act Joint Research Agreement exception codified at 35 U.S.C. &#167; 102(c) (the &#147;<B>JRA Exception</B>&#148;) when exercising its rights under this Agreement, but only with prior written consent of the other Party in its sole
discretion. If a Party intends to invoke the JRA Exception, once agreed to by the other Party if required by the preceding sentence, it will notify the other Party and the other Party will cooperate and coordinate its activities with such Party with
respect to any filings or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a &#147;joint research agreement&#148; as defined 35 U.S.C. &#167; 100(h). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.2</B> <B><U>Ownership</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.2.1</B> <I>CymaBay</I>. As between the Parties, CymaBay will own the entire right, title and interest in and to all <FONT
STYLE="white-space:nowrap">Know-How</FONT> (and Patents claiming inventions therein and all other Intellectual Property therein) first developed or conceived solely by CymaBay in the performance of the Collaboration (&#147;<B>New CymaBay
IP</B>&#148;); for clarity, all Kaken Program IP and the Joint Program IP are not included in New CymaBay IP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.2.2</B> <I>Kaken.</I>
As between the Parties, Kaken will own the entire right, title and interest in and to [***], (collectively, the &#147;<B>Kaken Program IP</B>&#148;); for clarity, all New CymaBay IP and all Joint Program IP, and all PPAR<FONT
STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>-related <FONT STYLE="white-space:nowrap">Know-How</FONT> (and Patents claiming inventions therein and all other Intellectual Property therein) developed or conceived by Kaken independent of the Collaboration,
are not included in Kaken Program IP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.2.3</B> <I>Joint Ownership</I>. The Parties will jointly own all <FONT
STYLE="white-space:nowrap">Know-How</FONT> (and Patents claiming inventions therein and all other Intellectual Property therein) developed or conceived in the performance of the Collaboration that is first developed or conceived jointly by
(i)&nbsp;Kaken or any of its Related Parties and (ii)&nbsp;CymaBay or any of its Related Parties (the &#147;<B>Joint Program IP</B>&#148;); for clarity, New CymaBay IP and Kaken Program IP are not included in Joint Program IP. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.3</B> <B><U>Covenants in Support of IP Ownership Allocation</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.3.1</B> Each Party will have an equal and undivided joint ownership interest in and to the Joint Program IP. Each Party will have the
right to exercise its ownership in and to such Joint Program IP, including: (a)&nbsp;the right to license and sublicense, and (b)&nbsp;otherwise to exploit, transfer or encumber its ownership interest, in each case without any accounting or
obligation to, or consent required from, the other Party, but subject to the licenses under this Agreement and the other terms and conditions of this Agreement. A Party will give reasonable written notice to the other Party of any such license or
other exploitation or transfer that is material. At the reasonable written request of a Party, the other Party will in writing grant such consents and confirm that no such accounting is required to effect the foregoing regarding Joint Program IP.
Each Party, for itself and on behalf of its Affiliates, licensees and sublicensees, and employees, subcontractors, consultants and agents of any of the foregoing, hereby assigns (and to the extent such assignment can only be made in the future
hereby agrees to assign), to the other Party an equal and undivided joint ownership interest in and to all Joint Program IP. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.3.2</B>
Each Party will provide the other Party (at such other Party&#146;s cost and expense) with such additional reasonable cooperation as needed to give effect to the allocation of ownership, as between the Parties, of the New CymaBay IP, Kaken Program
IP and Joint Program IP (including with respect to rights of priority), in each case, as contemplated by<U>&nbsp;Section 12.2</U>, including executing and delivering needed further assignments, consents, releases and other commercially reasonable
documentation, and providing good faith testimony by affidavit, declaration, deposition, in person or other proper means and otherwise assisting such other Party in support of its efforts to establish, perfect, defend, or enforce its rights in its
respective intellectual property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.4</B> <B><U>Disclosure of Inventions and IP</U></B>. The Parties will promptly disclose to each
other any New CymaBay IP, Kaken Program IP or Joint Program IP developed or conceived during the Term, but no later than [***] after the applicable Party&#146;s intellectual property department receives notice of such development or conception. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.5</B> <B><U>Prosecution and Maintenance of Patents</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.5.1</B> <I>Kaken</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>12.5.1.1</B> <I>General.</I><I></I>&nbsp;Subject to the remainder of
this<U>&nbsp;Section </U><U>12.5.1</U>, as between the Parties, Kaken will have sole control of and responsibility for the Prosecution and Maintenance of (and all applicable Patent Costs therefor), in Kaken&#146;s name, all Joint Program IP Patents
within the Kaken Territory and Kaken Program IP Patents (collectively, the &#147;<B>Kaken Controlled Patents</B>&#148;). Kaken will furnish to CymaBay, via electronic mail or such other method as mutually agreed by the Parties, copies of proposed
filings and material documents sent to or received from patent counsel in the course of Prosecuting and Maintaining the Kaken Controlled Patents in the CymaBay Territory, and copies of material documents filed with or received from the relevant
national patent offices or other Governmental Authorities with respect to the Kaken Controlled Patents in the CymaBay Territory, and such other material documents related to the Prosecution and Maintenance of the Kaken Controlled Patents in the
CymaBay Territory, in sufficient time prior to filing such document or making any payment due thereunder to allow for review and comment by CymaBay. Kaken will consider in good faith timely comments and recommendations made by CymaBay in connection
with such review. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>12.5.1.2</B> <I>Kaken Controlled Patents Abandonment</I>. In the event that Kaken elects not to Prosecute and
Maintain (or continue to Prosecute and Maintain, including filing a Patent claiming priority to a Patent prior to its issuance), any Kaken Controlled Patent, Kaken will notify CymaBay at least [***] before any such Kaken Controlled Patent would
become abandoned, no longer available or otherwise forfeited, whereupon, at the written request of CymaBay, the Parties will meet to discuss any such decision by Kaken. Subject to, if applicable, the provisions of any
<FONT STYLE="white-space:nowrap">in-license</FONT> agreement of Kaken applicable to such Kaken Controlled Patent, CymaBay will have the right (but not the obligation), at its sole discretion, to assume the Prosecution and Maintenance (and all
applicable Patent Costs therefor) of such Kaken Controlled Patent in the name of Kaken (which right will include the right to file additional Patents claiming priority to such Patent). CymaBay will consult reasonably with Kaken on its strategy for
the Prosecution and Maintenance of all such assumed Kaken Controlled Patents. CymaBay will furnish to Kaken, via electronic mail or such other method as mutually agreed by the Parties, copies of proposed filings and material documents sent to or
received from patent counsel in the course of Prosecuting and Maintaining such assumed Kaken Controlled Patents, and copies of material documents filed with or received from the relevant national patent offices or other Governmental Authorities with
respect to such assumed Kaken Controlled Patents, and such other material documents related to the Prosecution and Maintenance of such assumed Kaken Controlled Patents, in sufficient time prior to filing such document or making any payment due
thereunder to allow for review and comment by Kaken. CymaBay will consider in good faith timely comments and recommendations made by Kaken in connection with such review. Kaken will sign, or will use Commercially Reasonable Efforts to have signed,
all legal documents as are reasonably necessary for CymaBay to assume the Prosecution and Maintenance of such assumed Kaken Controlled Patent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.5.2</B> <I>CymaBay</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>12.5.2.1</B> <I>General.</I><I></I>&nbsp;Subject to remainder of this<U>&nbsp;Section 12.5.2</U>, as between the Parties, CymaBay will have
sole control of and responsibility for the Prosecution and Maintenance [***], in CymaBay&#146;s name, of all Patents within the New CymaBay IP, all Joint Program IP Patents in the CymaBay Territory, and all other CymaBay Licensed Patents. CymaBay
will furnish to Kaken, via electronic mail or such other method as mutually agreed by the Parties, copies of proposed filings and material documents sent to or received from patent counsel in the course of Prosecuting and Maintaining the CymaBay
Licensed Patents, and copies of material documents filed with or received from the relevant national patent offices or other Governmental Authorities with respect to such foregoing Patents in the Kaken Territory, and such other material documents
related to the Prosecution and Maintenance of such foregoing Patents in the Kaken Territory, in sufficient time prior to filing such document or making any payment due thereunder to allow for review and comment by Kaken. CymaBay will consider in
good faith timely comments and recommendations made by Kaken in connection with such review. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>12.5.2.2</B> <I>CymaBay Licensed Patents
Abandonment</I>. In the event that CymaBay elects not to Prosecute and Maintain (or continue to Prosecute and Maintain, including filing a Patent claiming priority to a Patent prior to its issuance), any CymaBay Licensed Patent, CymaBay will notify
Kaken at least [***] before any such CymaBay Licensed Patent would become abandoned, no longer available or otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
forfeited, whereupon, at the written request of Kaken, the Parties will meet to discuss any such decision by CymaBay. Subject to, if applicable, the provisions of any <FONT
STYLE="white-space:nowrap">in-license</FONT> agreement of CymaBay applicable to such CymaBay Licensed Patent, Kaken will have the right (but not the obligation), at Kaken&#146;s sole discretion, to assume the Prosecution and Maintenance (and all
applicable Patent Costs therefor) of such foregoing Patent in the name of CymaBay (which right will include the right to file additional Patents claiming priority to such Patent). Kaken will consult with CymaBay on its strategy for the Prosecution
and Maintenance of all such assumed foregoing Patents. Kaken will furnish to CymaBay, via electronic mail or such other method as mutually agreed by the Parties, copies of proposed filings and material documents sent to or received from patent
counsel in the course of Prosecuting and Maintaining such assumed foregoing Patents, and copies of material documents filed with or received from the relevant national patent offices or other Governmental Authorities with respect to such assumed
foregoing Patents, and such other material documents related to the Prosecution and Maintenance of such assumed foregoing Patents, in sufficient time prior to filing such document or making any payment due thereunder to allow for review and comment
by CymaBay. Kaken will consider in good faith timely comments and recommendations made by CymaBay in connection with such review. CymaBay will sign, or will use reasonable efforts to have signed, all legal documents as are reasonably necessary for
Kaken to assume the Prosecution and Maintenance of such assumed foregoing Patents. If Kaken, in its sole discretion, elects to assume the Prosecution and Maintenance of such CymaBay Licensed Patent that CymaBay has notified Kaken of its intention to
abandon the Prosecution and Maintenance of, such CymaBay Licensed Patent shall remain a CymaBay Licensed Patent, but shall not be Royalty Patent. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>12.5.2.3</B> <I>Notice of CymaBay Licensed Patent Abandonment after Expiration</I>. In the event that CymaBay elects not to Prosecute and
Maintain (or continue to Prosecute and Maintain, including filing a Patent claiming priority to a Patent prior to its issuance), any CymaBay Licensed Patent after expiration of this Agreement under <U>Section</U><U></U><U>&nbsp;13.1</U>, CymaBay
will notify Kaken at least [***] before any such CymaBay Licensed Patent would become abandoned, no longer available or otherwise forfeited, whereupon, at the written request of Kaken, the Parties will meet to discuss any such decision by CymaBay
and the Parties will negotiate in good faith to agree upon any appropriate action in regard to such CymaBay Licensed Patent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.5.3</B>
<I>Patent Miscellaneous</I>. Each Party hereby agrees: (a)&nbsp;to use Commercially Reasonable Efforts to make its employees, agents and consultants reasonably available to the other Party (or to the other Party&#146;s authorized attorneys, agents
or representatives), to the extent reasonably necessary to enable such Party to undertake any Prosecution and Maintenance described in this<U>&nbsp;Section 12.5</U>; and (b)&nbsp;to reasonably cooperate in any such Prosecution and Maintenance by the
other Party to the extent requested. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.6</B> <B><U>Third Party Infringement and Defense</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.6.1</B> <I>Notices</I>. Each Party will promptly report in writing to the other Party any Competitive Infringement of which such Party
(or any of its Affiliates or Sublicensees) becomes aware, and will provide the other Party with all available material evidence of such Competitive Infringement in such Party&#146;s control; <I><U>provided</U></I>, <I><U>however</U></I>, that
(a)&nbsp;for cases of Competitive Infringement under<U>&nbsp;Section </U><U>12.6.2.3</U>, such written notice will be given within [***], and (b)&nbsp;for cases of infringement as described in<U>&nbsp;Section </U><U>12.6.2.4</U>, such written notice
will be given as specified in<U>&nbsp;Section </U><U>12.6.2.4</U>. Without limiting the last sentence of the definition of &#147;Competitive Infringement,&#148; a notice under 21 U.S.C. &#167; 355(b)(2)(A)(iv) or 355(j)(2)(A)(vii)(IV) (however those
sections may be amended) or any equivalent provision under Applicable Law outside of the United States with respect to any Patents that are the subject of this Agreement will be deemed to describe an act of Competitive Infringement, regardless of
its content. Subject to the rest of this<U>&nbsp;Section </U><U>12.6</U>, the JSC will discuss in good faith strategies for abating such Competitive Infringement of any Licensed Product within each of the Party&#146;s respective Territory. For
clarity, it is agreed that any discussion between the Parties (including the JSC) under this <U>Section</U><U></U><U>&nbsp;12.6</U> shall not require either Party to disclose any information if such disclosure would likely act as a waiver of the
attorney-client privilege, protections under the work product doctrine, or any similar privilege. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.6.2</B> <I>Rights to Enforce</I>.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>12.6.2.1</B> <I>Competitive (Kaken) Infringement</I>. As between the Parties, Kaken will
have the first right (but not the obligation), at Kaken&#146;s sole discretion, through counsel of its choosing reasonably acceptable to CymaBay (solely if Kaken is enforcing a CymaBay Licensed Patent), to seek to abate any Competitive (Kaken)
Infringement by enforcing any CymaBay Licensed Patents or any Kaken Controlled Patents, in each case, solely in the Kaken Territory. Kaken will pay all Patent Costs incurred by Kaken for such enforcement. If Kaken does not take steps to abate such
Competitive (Kaken) Infringement, within [***] of becoming aware, or receiving written notice from CymaBay, of such Competitive (Kaken) Infringement (or such shorter period of time as is required to comply with Applicable Law to not waive any
statutory rights), Kaken will provide CymaBay with written notice of such decision, and CymaBay will have the rights set forth in<U>&nbsp;Section </U><U>12.6.5.1</U>&nbsp;with respect to enforcing the CymaBay Licensed Patents and the Kaken
Controlled Patents in the Kaken Territory to abate such Competitive (Kaken) Infringement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>12.6.2.2</B> <I>Competitive (CymaBay)
Infringement</I>. As between the Parties, CymaBay will have the first right (but not the obligation), at CymaBay&#146;s sole discretion, through counsel of its choosing reasonably acceptable to Kaken (solely if CymaBay is enforcing a Kaken
Controlled Patent), to seek to abate any Competitive (CymaBay) Infringement by, as applicable, (a)&nbsp;enforcing any Patents within the New CymaBay IP that are not also CymaBay Licensed Patents anywhere in the world and (b)&nbsp;enforcing any Kaken
Controlled Patent or any CymaBay Licensed Patents solely in the CymaBay Territory. CymaBay will pay all Patent Costs incurred by CymaBay for such enforcement. If CymaBay does not take steps to abate such Competitive (CymaBay) Infringement, within
[***] of becoming aware, or receiving written notice from Kaken, of such Competitive (CymaBay) Infringement (or such shorter period of time as is required to comply with Applicable Law to not waive any statutory rights), CymaBay will provide Kaken
with written notice of such decision, and Kaken will have the rights set forth in<U>&nbsp;Section </U><U>12.6.5.1</U>&nbsp;with respect to enforcing the Kaken Controlled Patents in the CymaBay Territory (but not, for clarity, the right to enforce
any CymaBay Licensed Patents) to abate such Competitive (CymaBay) Infringement in the CymaBay Territory. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>12.6.2.3</B> <I>35 U.S.C.
</I><I>&#167;</I><I> 271(e)(2) Infringement</I>. Notwithstanding anything to the contrary in this<U>&nbsp;Section </U><U>12.6.2</U>, for a Competitive Infringement under 35 U.S.C. &#167; 271(e)(2), the time period set forth in<U>&nbsp;Section
</U><U>12.6.2.1</U>&nbsp;or<U>&nbsp;12.6.2.2</U>, as applicable, during which a Party will have the initial right to bring a Proceeding will be shortened to [***], so that, to the extent the other Party has the right, pursuant to
such<U>&nbsp;Section </U><U>12.6.2.1</U>&nbsp;or<U>&nbsp;12.6.2.2</U>, as applicable, to initiate a Proceeding, if the first Party does not initiate a Proceeding, then such other Party will have such right if the first Party does not initiate a
Proceeding within such twenty-five (25)&nbsp;days after such first Party&#146;s receipt of written notice of such Competitive Infringement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>12.6.2.4</B> <I>Notification of Patent Certification</I>.&nbsp;If either Party becomes aware of any allegations of alleged patent
invalidity, unenforceability or <FONT STYLE="white-space:nowrap">non-infringement</FONT> of any Patent licensed under this Agreement Covering a Licensed Product (including methods of use thereof) pursuant to a Paragraph IV Patent Certification by a
Third Party filing an Abbreviated New Drug Application, or other similar patent certification by a Third Party, and any foreign equivalent thereof, for a Generic Product, such Party will notify and provide the other Party with copies of such
allegations. Such notification and copies will be provided to such other Party as soon as practicable and at least within [***] after such Party receives such certification, and will be sent by overnight courier to the address set forth
in<U>&nbsp;Section </U><U>14.10</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.6.3</B> <I>Defense of Patent Challenges</I>. As between the Parties, the Party controlling the
Prosecution and Maintenance of any Patent under<U>&nbsp;Section </U><U>12.5</U> will have the right (but not the obligation), at its sole discretion, to defend against a declaratory judgment action or other action (such as a revocation proceeding or
an opposition) challenging any such Patent (a &#147;<B>Third Party Action</B>&#148;), other than with respect to (a)&nbsp;any counter-claims in any enforcement action brought by the other Party pursuant to<U>&nbsp;Section </U><U>12.6.2</U>&nbsp;or
(b)&nbsp;any action by a Third Party in response to an enforcement action brought by the other Party, which in both cases ((a) and (b)) will be controlled by such other Party. If the Party controlling such Prosecution and Maintenance of Patents
under <U>Section</U><U></U><U>&nbsp;12.5</U> does not provide notice to the other Party of such Party&#146;s intent to defend such Patent under this <U>Section</U><U></U><U>&nbsp;12.6.3</U> within [***] (or such shorter period of time as is required
to not waive any statutory rights), or elects not to initiate or continue any such defense (in which case it will promptly provide notice thereof to the other Party), then (i)&nbsp;in the case of any of the foregoing done by CymaBay with respect to
any Patent under this Agreement for which CymaBay is responsible for the Prosecution and Maintenance thereof at such time in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Kaken Territory, Kaken will have the right (but not the obligation), at its sole discretion, to defend any CymaBay Licensed Patent against any such Third Party Action in the Kaken Territory,
and (ii)&nbsp;in the case of any of the foregoing done by Kaken with respect to any Patent under this Agreement for which Kaken is responsible for the Prosecution and Maintenance thereof at such time in the CymaBay Territory, CymaBay will have the
right (but not the obligation), at its sole discretion, to defend any Kaken Controlled Patent against any such Third Party Action in the CymaBay Territory, in each case of (i)&nbsp;and (ii), as further set forth in
<U>Section</U><U></U><U>&nbsp;12.6.5</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.6.4</B> <I>Cooperation Regarding Enforcement or Defense</I>. With respect to any
Competitive Infringement action brought by a Party under <U>Section</U><U></U><U>&nbsp;12.6.2</U> or defense of any Third Party Action identified above in<U>&nbsp;Section </U><U>12.6.3</U>,&nbsp;and subject to the terms and conditions of
this<U>&nbsp;Section </U><U>12.6.4</U>, the Party controlling any such Competitive Infringement action or Third Party Action (the &#147;<B>Controlling Party</B>&#148;) will keep the other Party (the
&#147;<B><FONT STYLE="white-space:nowrap">Non-Controlling</FONT> Party</B>&#148;) reasonably informed of the status and progress of such enforcement or defense efforts, and will reasonably consider the
<FONT STYLE="white-space:nowrap">Non-Controlling</FONT> Party&#146;s comments on any such efforts, and will reasonably seek to achieve both the interests of such Party and those of the other Party in any such efforts. The <FONT
STYLE="white-space:nowrap">Non-Controlling</FONT> Party will provide the Controlling Party with all reasonable assistance in the enforcement or defense of the applicable Patents, as the Controlling Party may request, at such Controlling Party&#146;s
expense, including by signing or executing any necessary documents and consenting to it being named a party to any applicable Proceedings. Where the <FONT STYLE="white-space:nowrap">Non-Controlling</FONT> Party is named a party or joins any
applicable Proceeding, the <FONT STYLE="white-space:nowrap">Non-Controlling</FONT> Party will have the right to be represented by counsel of its choice at the <FONT STYLE="white-space:nowrap">Non-Controlling</FONT> Party&#146;s expense. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.6.5</B> <I>Withdrawal, Cooperation and Participation</I>. With respect to any Competitive Infringement action or Third-Party Action
identified above in<U>&nbsp;Sections </U><U>12.6.2</U>&nbsp;and<U>&nbsp;12.6.3</U>&nbsp;and subject to the terms and conditions of this<U>&nbsp;Section </U><U>12.6.5</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>12.6.5.1</B> If the Controlling Party does not pursue or ceases to pursue or withdraws from such action (the &#147;<B>Withdrawing
Party</B>&#148;), it will promptly notify the other Party (in sufficient time to enable such other Party to meet any deadlines by which any action must be taken to preserve any rights in such infringement or defensive action) and (a)&nbsp;if CymaBay
is the Withdrawing Party, then Kaken will have the right (but not the obligation) to substitute itself for CymaBay in any Competitive Infringement action or Third Party Action identified above in<U>&nbsp;Section
</U><U>12.6.2.2</U>&nbsp;or<U>&nbsp;12.6.3</U>&nbsp;solely to the extent involving the Kaken Controlled Patents in the CymaBay Territory and proceed under the terms and conditions of this<U>&nbsp;Section </U><U>12.6.5</U>, and (b)&nbsp;if Kaken is
the Withdrawing Party, then CymaBay will have the right (but not the obligation) to substitute itself for Kaken in any Competitive Infringement action identified above in<U>&nbsp;Section </U><U>12.6.2.1</U>&nbsp;or<U>&nbsp;12.6.3</U> solely to the
extent involving or relating to the CymaBay Licensed Patents or the Program IP Patents in the Kaken Territory, and proceed under the terms and conditions of this<U>&nbsp;Section </U><U>12.6.5</U>&nbsp;(Kaken or CymaBay, as applicable, under
(a)&nbsp;or (b), the &#147;<B><FONT STYLE="white-space:nowrap">New-Controlling</FONT> Party</B>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>12.6.5.2</B> The Withdrawing
Party will cooperate with the <FONT STYLE="white-space:nowrap">New-Controlling</FONT> Party controlling any such action (as may be reasonably requested by the <FONT STYLE="white-space:nowrap">New-Controlling</FONT> Party), including, at the <FONT
STYLE="white-space:nowrap">New-Controlling</FONT> Party&#146;s sole cost and expense, (a)&nbsp;providing access to relevant documents and other evidence, (b)&nbsp;using reasonable efforts to make its Affiliates and its and its Affiliates&#146;
licensees and Sublicensees and all of their respective employees, subcontractors, consultants and agents available at reasonable business hours and for reasonable periods of time, but only to the extent relevant to such action, and (c)&nbsp;if
reasonably necessary, by being joined as a party, subject to, for this clause (c), the <FONT STYLE="white-space:nowrap">New-Controlling</FONT> Party agreeing to indemnify such Withdrawing Party for its involvement as a named party in such action and
paying those Patent Costs incurred by such Withdrawing Party in connection with such joinder. The <FONT STYLE="white-space:nowrap">New-Controlling</FONT> Party controlling any such action will keep the Withdrawing Party reasonably updated with
respect to any such action, including providing copies of all materials documents received or filed in connection with any such action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>12.6.5.3</B> The Withdrawing Party will have the right to consult with the <FONT STYLE="white-space:nowrap">New-Controlling</FONT> Party
regarding any such action controlled by such <FONT STYLE="white-space:nowrap">New-Controlling</FONT> Party, in each case at such Withdrawing Party&#146;s sole cost and expense. If the Withdrawing Party elects to so be involved, the <FONT
STYLE="white-space:nowrap">New-Controlling</FONT> Party will provide such Withdrawing Party and its counsel with an opportunity to consult with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<FONT STYLE="white-space:nowrap">New-Controlling</FONT> Party and its counsel regarding the prosecution of such action (including reviewing the contents of any material correspondence, legal
papers or other documents related thereto), and the <FONT STYLE="white-space:nowrap">New-Controlling</FONT> Party will take into account reasonable and timely requests and comments of the Withdrawing Party regarding such enforcement or defense.
However, nothing in this<U>&nbsp;Section 12.6.5.3</U>&nbsp;will limit the <FONT STYLE="white-space:nowrap">New-Controlling</FONT> Party&#146;s ability to prosecute any such action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.6.6</B> <I>Settlement</I>. With respect to any Competitive Infringement or Third Party Action identified above in this<U>&nbsp;Section
12.6</U>, the Controlling Party of such action will have the right to settle or otherwise dispose of such action on such terms and conditions as such Party will determine in its sole discretion, including by granting a license or sublicense (such
sublicense must comply with the terms of <U>Section</U><U></U><U>&nbsp;7.1.4</U>, as applicable) to a Third Party under the rights granted to such Party in<U>&nbsp;ARTICLE 7</U>;<I><U>&nbsp;provided</U></I>&nbsp;that, notwithstanding the foregoing,
no such settlement or other disposition will (a)&nbsp;impose any monetary restriction or obligation on or admit fault of the other Party, or (b)&nbsp;adversely affect the other Party&#146;s rights under this Agreement to any such Patent then being
enforced or defended, in each case ((a) and (b)) without the prior written consent of the other Party, not to be unreasonably withheld, conditioned or delayed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.6.7</B> <I>Allocation of Recovery</I>. Unless otherwise agreed by the Parties, all monies and amounts recovered upon the final judgment
or settlement of any action described in this<U>&nbsp;Section </U><U>12.6</U>&nbsp;will be used first to reimburse the Controlling Party for its Patent Costs incurred in conducting the action, with the balance of any such recovery (the &#147;<B>Net
Recovery</B>&#148;) to be retained or divided as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">[***] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.7</B> <B><U>Patent Extensions</U></B>. With respect to any election for patent term restoration or extension, supplemental protection
certificate or any of their equivalents, (a)&nbsp;Kaken will have the sole and exclusive right to make any such decision relating to any Kaken Controlled Patents that are not Joint Program IP Patents, (b)&nbsp;CymaBay will have the sole and
exclusive right to make any such decision relating to any Patents within the CymaBay Licensed Technology that are not Joint Program IP Patents, and (c)&nbsp;Kaken and CymaBay together will make such decision relating to any Joint Program IP Patents,
in each case of (a), (b) and (c)&nbsp;with respect to any Licensed Product,<I><U>&nbsp;provided</U></I>&nbsp;that notwithstanding the foregoing clauses (a)&nbsp;and (b), each Party will use reasonable efforts to obtain any such patent term
restoration or extension, supplemental protection certificate or any of their equivalents available for the Patents subject to the enforcement rights specified in<U>&nbsp;Section </U><U>12.6.2</U>&nbsp;with respect to any Licensed Product; and
further<I><U>&nbsp;provided, however</U></I>, that no Party will be required to use any such reasonable efforts in a manner inconsistent with any term or condition of this<U>&nbsp;Section </U><U>12.7</U>&nbsp;if any such item could impair the
applicable Patent (including its enforcement potential) or the ability to obtain any such patent term restoration or extension, supplemental protection certificate or any of their equivalents for any other pharmaceutical product. Upon the written
request by a Party, the other Party will reasonably cooperate with the implementation of such requesting Party&#146;s decisions made in a manner consistent with this<U>&nbsp;Section </U><U>12.7</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.8</B> <B><U>Patent Listings</U></B>. With respect to any filings of Patents made with Regulatory Authorities for any Licensed Product,
including as required or allowed in connection with, in the United States, the FDA&#146;s Orange Book, or, outside of the United States, other international equivalents, but subject to<U>&nbsp;Section </U><U>12.6.2.3</U>, (a) each of the Parties
will list any such Patents as may be required by Applicable Law with respect to any such filings for Licensed Products made with Regulatory Authorities in their respective Territory, and (b)&nbsp;otherwise (i) Kaken will have the sole and exclusive
right to make any such decision whether to list any Kaken Program IP Patents and Joint Program IP Patents with respect to any Licensed Product in filings made with Regulatory Authorities in the Kaken Territory, and (ii)&nbsp;CymaBay will have the
sole and exclusive right to make any such decision whether to list any Joint Program IP Patents and any CymaBay Licensed Patents that are not Joint Program IP Patents with respect to any Licensed Product in filings made with Regulatory Authorities
in the CymaBay Territory,<I><U>&nbsp;provided</U></I><I><U></U></I>&nbsp;that notwithstanding the foregoing clauses (b)(i) and (ii), each Party will use Commercially Reasonable Efforts to make any such listing if available for the Patents subject to
the enforcement rights specified in<U>&nbsp;Section </U><U>12.6.2</U>&nbsp;with respect to any Licensed Product; and further<I><U>&nbsp;provided</U></I>,<I><U>&nbsp;however</U></I>, that no Party will be required to use any such Commercially
Reasonable Efforts in a manner inconsistent with any term or condition of this<U>&nbsp;Section </U><U>12.8</U>&nbsp;if any such item could impair the applicable Patent (including its enforcement potential) or the ability to list such Patent for any
other pharmaceutical product. Upon the request by a Party, such other Party will reasonably cooperate in the implementation of such requesting Party&#146;s decisions made in a manner consistent with this<U>&nbsp;Section 12.8</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.9</B> <B><U>Third Party Rights</U></B>. Notwithstanding the foregoing provisions of
this<U> ARTICLE 12</U>, each Party&#146;s rights and obligations with respect to any Patent under this<U> ARTICLE 12</U> will be subject to any Third-Party rights and obligations that such Party is subject to (including under any <FONT
STYLE="white-space:nowrap">in-license</FONT> of a Party applicable to such Party&#146;s licensed intellectual property rights hereunder). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.10</B> <B><U>Common Interest</U></B>. All information exchanged between the Parties regarding the Prosecution and Maintenance, and
enforcement and defense, of Patents under this <U>ARTICLE 12</U> will be deemed Confidential Information of the disclosing Party. In addition, the Parties acknowledge and agree that, with regard to such Prosecution and Maintenance, and enforcement
and defense, the interests of the Parties as collaborators and licensor and licensee are to obtain the strongest patent protection possible, and as such, are aligned and are legal in nature. The Parties agree and acknowledge that they have not
waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning the Patents under this<U>&nbsp;ARTICLE 12</U>, including privilege under the common interest doctrine and similar or related doctrines. Notwithstanding
anything to the contrary contained herein, to the extent a Party has a good faith belief that any information required to be disclosed by such Party to the other Party under this <U>ARTICLE 12</U> is protected by attorney-client privilege or any
other applicable legal privilege or immunity, such Party will not be required to disclose such information, and the Parties will in good faith cooperate to agree upon a procedure (including entering into a specific common interest agreement,
disclosing such information on a &#147;for counsel eyes only&#148; basis or similar procedure) under which such information may be disclosed without waiving or breaching such privilege or immunity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.11</B> <B><U>Trademarks</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.11.1</B> <I>Licensed Products Trademarks</I>. Kaken will have the right to determine the branding for the Licensed Product in the Field
of Use in the Kaken Territory using those trademarks, logos, and trade names that it determines appropriate for such Licensed Product. In consultation with the JSC, Kaken shall determine the Trademark for the Commercialization of the Licensed
Products in the Field of Use in the Kaken Territory (the &#147;<B>Japanese Trademark</B>&#148;). The Japanese Trademark may not include other Trademarks Controlled by CymaBay. As between the Parties, Kaken will own all right, title, and interest
(including all applications for registration and registrations) in and to the Japanese Trademark. Kaken shall be responsible for the registration, maintenance and defense of the Japanese Trademark for use in connection with the sale or marketing of
Licensed Products in the Field of Use in the Kaken Territory, and the fees and expenses incurred in connection therewith for the Japanese Trademark applicable to Licensed Products in the Kaken Territory shall be the responsibility of Kaken. Kaken
will own also all rights to any Internet domain names incorporating the Japanese Trademark or any variation or part thereof used as its URL address or any part of such address. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.11.2</B> <I>Trademark Infringement</I>. In the event either Party becomes aware of any infringement of the Japanese Trademark, by a Third
Party, such Party will promptly notify the other Party, and the Parties will consult with each other and discuss the best way to prevent such infringement, including by the institution of legal proceedings against such Third Party. Notwithstanding
the foregoing, Kaken retains the sole and exclusive right (but not obligation) to seek to abate any such infringement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.11.3</B>
<I>No Other Trademark Rights</I>. For the avoidance of doubt, except as expressly permitted by this Agreement or as otherwise agreed in writing by the Parties, neither Party will have any right to use the other Party&#146;s or the other Party&#146;s
Affiliates&#146; Trademarks, corporate names or logos in connection with Development, Manufacturing, or Commercialization of Licensed Products. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.12</B> <B><U>Third Party Claims of Infringement</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.12.1</B> <I>Notice</I>. In the event that a Party receives any claim by a Third Party alleging infringement and/or misappropriation of
Patent or any other Intellectual Property owned or controlled by such Third Party (each, an &#147;<B>Infringement Claim</B>&#148;) that is provided in <U>Section</U><U></U><U>&nbsp;12.12.2</U> or <U>12.12.3</U>, such Party shall promptly, but in any
event no later than [***] after receipt thereof, notify the other Party in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.12.2</B> <I></I><I>Claims Based on Exploitation in Kaken Territory</I>. If a Third
Party brings any Infringement Claim in the Kaken Territory against Kaken, or its Related Party, or CymaBay or its Affiliate, based upon any activities by Kaken or its Related Party in Exploiting Licensed Product in the Kaken Territory, then Kaken
shall have the sole right and responsibility (except as otherwise provided below), at its expense, to conduct and control the defense of such claim or action. Kaken shall keep CymaBay fully informed of such defense, and will provide CymaBay and its
counsel with an opportunity to consult with Kaken and its counsel regarding the defense of such claim or action (including reviewing the contents of any material correspondence, legal papers or other documents related thereto), and Kaken will take
into account reasonable and timely requests and comments of CymaBay regarding such defense. However, if CymaBay (or its Affiliate) is a defendant in any such Third-Party claim or action, CymaBay shall retain the right to conduct its own defense of
its interests as affected by such action or claim, notwithstanding anything else in this Section. If Kaken pays to such Third Party that brought the Infringement Claim any damages or royalty payments as a result of the final judgment or settlement
of any such Infringement Claim under this <U>Section</U><U></U><U>&nbsp;12.12.2</U>, [***]. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.12.3</B> <I>Claims Based on CymaBay
Manufacturing</I>. If a Third Party brings any Infringement Claim (a)&nbsp;against CymaBay or its Affiliate, or against Kaken or its Related Party, and (b)&nbsp;such claim or action is based primarily upon any activities by CymaBay or its contract
manufacturer in the manufacture of Licensed Compound and/or the Licensed Product by or on behalf of CymaBay for supply to Kaken for use and sale in the Kaken Territory, then CymaBay shall have the sole right and responsibility (except as otherwise
provided below), at its expense, to conduct and control the defense of such claim or action. CymaBay shall keep Kaken reasonably informed of such defense, and will provide Kaken and its counsel with an opportunity to consult with CymaBay and its
counsel regarding the defense of such claim or action to the extent relevant to Kaken or its rights hereunder (including reviewing the contents of any material and relevant correspondence, legal papers or other documents related thereto), and
CymaBay will take into account reasonable and timely requests and comments of Kaken regarding such defense. If Kaken (or its Affiliate) is a defendant in any such Third-Party claim or action, Kaken shall retain the right to conduct its own defense
of its interests as affected by such action or claim. If CymaBay concludes an <FONT STYLE="white-space:nowrap">in-license</FONT> agreement under any Intellectual Properties owned or controlled by Third Party to resolve an Infringement Claim under
this <U>Section</U><U></U><U>&nbsp;12.12.3</U>, then CymaBay shall use Commercially Reasonable Efforts to secure the right to grant a sublicense under such Intellectual Properties to Kaken to manufacture the Licensed Compound and Licensed Products
for supply, use and Commercialization in the Field of Use in the Kaken Territory, and any payments under such <FONT STYLE="white-space:nowrap">in-license</FONT> agreement shall be CymaBay&#146;s responsibility.
<U>Section</U><U></U><U>&nbsp;7.3.1.2</U> shall apply <I>mutatis mutandis</I> to <FONT STYLE="white-space:nowrap">in-license</FONT> agreements that CymaBay concludes with a Third Party under this <U>Section</U><U></U><U>&nbsp;12.12.3</U>. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 13 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TERM AND
TERMINATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.1</B> <B><U>Term</U></B>. This Agreement will be effective as of the Effective Date and will continue until the
date upon which (a)&nbsp;the Royalty Term has expired in the Kaken Territory for the final Licensed Product, in which case the Agreement will expire if not renewed, or (b)&nbsp;the Agreement is earlier terminated (the &#147;<B>Initial
Term</B>&#148;). After the Initial Term (except in the case of early termination), this Agreement will be automatically renewed for two (2)&nbsp;year periods, unless either Party has given the other Party a written notice not to renew the Agreement
no later than twelve (12)&nbsp;months prior to the expiration of the Initial Term or any subsequent renewal term, in which case the Agreement shall expire (and thus terminate) at the end of the then-existing term or, if applicable, shall earlier
terminate upon an early termination (with the time period from the Effective Date to (i)&nbsp;the end of the later of (x)&nbsp;the Initial Term and (y)&nbsp;any subsequent renewal term, or (ii)&nbsp;if applicable, the date of an earlier termination
of the Agreement, being the &#147;<B>Term</B>&#148;). Upon expiration of the Royalty Term for a Licensed Product in the Kaken Territory or upon expiration of this Agreement, all licenses granted from one Party to the other Party in<U>&nbsp;ARTICLE
7</U>&nbsp;with respect to such Licensed Product will become fully paid (subject to any continuing Kaken payment obligations as set forth in the Agreement or the Commercial Supply Agreement, including Kaken&#146;s continuing obligation to pay for
the supply of Licensed Product to Kaken as provided in <U>Section</U><U></U><U>&nbsp;8.4</U>), irrevocable and perpetual. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.2</B> <B><U>Termination by Kaken for Convenience</U></B>. Kaken may terminate this
Agreement upon prior written notice to CymaBay, provided such notice is given at least [***] prior to the date of termination if the date of termination is prior to achieving the first Regulatory Approval of the first Licensed Product in the Kaken
Territory, and [***] prior to the date of termination if the date of termination is after achieving the first Regulatory Approval of the first Licensed Product in the Kaken Territory. Such termination may be for any reason or no reason. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.3</B> <B><U>Termination by Kaken due to Termination of Janssen License Agreement</U></B>. Kaken may terminate this Agreement immediately
upon termination of the Janssen License Agreement by providing written notice thereof to CymaBay. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.4</B> <B><U>Termination by Kaken
for Safety Concern or Clinical Failure</U></B>. At any time, Kaken will have the right to terminate this Agreement in its entirety in the event of (a)&nbsp;a Safety Concern or (b)&nbsp;a Clinical Failure, in each case of (a)&nbsp;or (b), upon [***]
prior written notice to CymaBay,<I><U>&nbsp;provided</U></I>&nbsp;that, during such [***] period, Kaken will consult with CymaBay in respect of measures to overcome the Safety Concern or Clinical Failure, as applicable, and avoid termination of this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.5</B> <B><U>Termination for Material Breach</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.5.1</B> <I>Material Breach</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>13.5.1.1</B> Subject to<U>&nbsp;Section </U><U>13.5.2</U>, CymaBay will have the right to terminate this Agreement in its entirety upon
delivery of written notice to Kaken in the event of any material breach by Kaken of this Agreement,<I><U>&nbsp;provided</U></I>&nbsp;that such termination will not be effective if such breach has been cured within thirty (30)&nbsp;days after written
notice thereof is given by CymaBay to Kaken specifying the nature of the alleged breach (or, if such default cannot be cured within such thirty (30)&nbsp;day period, within ninety (90)&nbsp;days after such notice if Kaken commences actions to cure
such default within such thirty (30)&nbsp;day period and thereafter diligently continues such actions, but fails to cure the default by the end of such ninety (90)&nbsp;days);<I><U>&nbsp;provided</U></I><I>,</I><I></I><I><U>&nbsp;however</U></I>,
that if such material breach involves the failure to make a payment when due, such breach must be cured within [***] after written notice thereof is given by CymaBay to Kaken. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>13.5.1.2</B> Subject to<U>&nbsp;Section </U><U>13.5.2</U>, and to Kaken&#146;s election of the alternative remedy under
<U>Section</U><U></U><U>&nbsp;13.8</U>, Kaken will have the right to terminate this Agreement in its entirety upon delivery of written notice to CymaBay in the event of any material breach by CymaBay of this
Agreement,<I><U>&nbsp;provided</U></I>&nbsp;that such termination will not be effective if such breach has been cured within thirty (30)&nbsp;days after written notice thereof is given by Kaken to CymaBay specifying the nature of the alleged breach
(or, if such default cannot be cured within such thirty (30)&nbsp;day period, within ninety (90)&nbsp;days after such notice if CymaBay commences actions to cure such default within such thirty (30)&nbsp;day period and thereafter diligently
continues such actions, but fails to cure the default by the end of such ninety (90)&nbsp;days);<I><U>&nbsp;provided</U></I><I>,</I><I></I><I><U>&nbsp;however</U></I>, that to the extent such material breach involves the failure to make a payment
when due, such breach must be cured within [***] after written notice thereof is given by Kaken to CymaBay. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.5.2</B> <I>Disputed
Breach</I>. If the alleged breaching Party disputes in good faith (a)&nbsp;the existence or materiality of a breach specified in a notice provided by the other Party in accordance with<U>&nbsp;Section </U><U>13.5.1</U>, or (b)&nbsp;the lack of cure
of such breach, and such alleged breaching Party provides the other Party notice of such dispute prior to the end of the applicable cure period above, then the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party will not have the right to
terminate this Agreement under<U>&nbsp;Section </U><U>13.5.1</U>&nbsp;unless and until the dispute resolution process set forth in<U>&nbsp;Section </U><U>14.3</U>&nbsp;has been completed (including the tolling and cure periods set forth therein) and
such completed resolution process has determined that the asserted material breach did occur and has not been cured. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.6</B> <B><U>Termination for Bankruptcy</U></B>. If, at any time during the Term
(a)&nbsp;a case is commenced by or against either Party under Title 11, United States Code, as amended, or analogous provisions of Applicable Law outside the United States (the &#147;<B>Bankruptcy Code</B>&#148;) and, in the event of an involuntary
case under the Bankruptcy Code, such case is not dismissed within sixty (60)&nbsp;days after the commencement thereof, (b)&nbsp;either Party files for or is subject to the institution of bankruptcy, liquidation or receivership proceedings (other
than a case under the Bankruptcy Code), (c) either Party assigns all or a substantial portion of its assets for the benefit of creditors, (d)&nbsp;a receiver or custodian is appointed for either Party&#146;s business, or (e)&nbsp;a substantial
portion of either Party&#146;s business is subject to attachment or similar process; then, in any such case ((a), (b), (c), (d) or (e)), the other Party may terminate this Agreement upon written notice to the extent permitted under Applicable Law.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.7</B> <B><U>Patent Challenge</U></B>. A Party has the right to terminate this Agreement upon written notice to the other Party in
the event that the other Party or any of its Affiliates or Sublicensees directly or indirectly challenges in a legal or administrative proceeding the patentability, enforceability or validity of any Patents within the CymaBay Licensed Technology
(with respect to a challenge brought by Kaken), any Patents within the Kaken Licensed Technology (with respect to a challenge brought by CymaBay), or any Joint Program IP Patents (with respect to a challenge brought by either Party), as the case may
be (each, a &#147;<B>Patent Challenge</B>&#148;); <I><U>provided</U></I> that (a)&nbsp;with respect to any Third Party that becomes an Affiliate of a Party during the Term as a result of a Change of Control of such Party or acquisition by such
Party, this<U>&nbsp;Section </U><U>13.7</U>&nbsp;will not apply to any Patent Challenge involving such Third Party if such proceeding was initiated before the signing of the definitive document(s) whereby such Third Party becomes such an Affiliate,
and (b)&nbsp;with respect to any <FONT STYLE="white-space:nowrap">non-Affiliate</FONT> Sublicensee, a Party will not have the right to terminate this Agreement under this<U>&nbsp;Section </U><U>13.7</U>&nbsp;if the other Party (i)&nbsp;causes such
Patent Challenge to be terminated or dismissed (or in the case of<I><FONT STYLE="white-space:nowrap">&nbsp;ex-parte</FONT></I>&nbsp;proceedings, multi-party proceedings, or other Patent Challenges in which the challenging party does not have the
power to unilaterally cause the Patent Challenge to be withdrawn, causes such Sublicensee to withdraw as a party from such Patent Challenge and to cease actively assisting any other party to such Patent Challenge), or (ii)&nbsp;terminates such
Sublicensee&#146;s sublicense to the Patents being challenged by the Sublicensee, in each case, [***] of the terminating Party&#146;s notice to the other Party under this<U>&nbsp;Section </U><U>13.7</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.8</B> <B><U>Kaken Alternative Remedy for Intentional or Willful CymaBay Breach or Janssen Agreement Termination</U></B><B>.</B> If
(a)&nbsp;CymaBay materially breaches this Agreement and such breach is intentional or willful, and CymaBay does not cure such breach in accordance with <U>Section</U><U></U><U>&nbsp;13.5.2</U>, or (b)&nbsp;the Janssen License Agreement is
terminated, [***]: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.8.1</B> Upon such election, this Agreement will remain in full force and effect, including each Party retaining
all of its licenses and other rights granted under this Agreement, subject to all of its payment and other obligations hereunder; [***]; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.8.2</B> [***]; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.8.3</B> Kaken may (if it so elects) terminate CymaBay&#146;s participation in the JSC, <I>provided that </I>after any such termination,
Kaken would provide to CymaBay written reporting, every six (6)&nbsp;months, summarizing the progress and results of its and its Related Parties&#146; Development and Commercialization activities for Licensed Product in the Kaken Territory, such
reporting in reasonable detail. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Kaken exercises its alternative remedy under this <U>Section</U><U></U><U>&nbsp;13.8</U>, then the above alternate
remedy will be the sole monetary remedy available to Kaken for the uncured material breach by CymaBay, but Kaken will retain the right to seek any applicable equitable remedies for such breach. For the avoidance of doubt, if Kaken exercises the
alternative remedy set forth above in this <U>Section</U><U></U><U>&nbsp;13.8</U>, then all rights and obligations of both Parties under this Agreement will continue unaffected, <I>except </I>as otherwise set forth in this
<U>Section</U><U></U><U>&nbsp;13.8</U>, and unless and until this Agreement is subsequently terminated by either Party pursuant to this <U>ARTICLE 13</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.9</B> <B><U>General Consequences of Termination or Expiration</U></B>. Upon expiration
or early termination of this Agreement, the following shall apply (in addition to any other applicable rights and obligations under this<U>&nbsp;ARTICLE 13</U>&nbsp;or otherwise under this Agreement with respect to such termination or expiration):
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.9.1</B> <I>Winding Down of Activities</I>. If there are any <FONT STYLE="white-space:nowrap">on-going</FONT> Development or
Commercialization activities at termination or expiration of this Agreement, the Parties shall negotiate in good faith and adopt a plan to wind-down such activities in an orderly fashion or, at the continuing Party&#146;s election, promptly
transition such activities from the <FONT STYLE="white-space:nowrap">non-continuing</FONT> Party to the continuing Party or its designee, with due regard for patient safety and the rights of any subjects that are participants in any Clinical Studies
of the Licensed Products, and take any actions it deems reasonably necessary or appropriate to avoid any human health or safety problems and in compliance with all Applicable Law. Further, unless this Agreement is terminated pursuant to
<U>Section</U><U></U><U>&nbsp;13.3</U>, Kaken will conduct all reasonable actions, as reasonably requested by CymaBay, to ensure the smooth and prompt transition to CymaBay of the entire Licensed Product program in Japan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.9.2</B> <I>Return of Confidential Information</I>. Except to the extent that the applicable Party retains a license or other rights to
use the applicable information under the surviving terms of this Agreement, each Party will promptly return all records and materials in its possession or control containing or comprising the other Party&#146;s Confidential Information. Each Party
shall have the right to maintain one copy of such records in its files for archive purposes;&nbsp;any such copy shall be maintained by the retaining Party in accordance with the surviving confidentiality and
<FONT STYLE="white-space:nowrap">non-use</FONT> obligations of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.9.3</B> <I>Dissolution of Committees</I>. All
Committees will be dissolved as of the effective date of such termination or expiration, provided that, for any surviving terms or conditions of the Agreement that would require action or decision by any of the Committees or an Executive Officer,
each Party will appoint representatives to act as its Committee members or Executive Officer, as applicable, solely to effect such required action or decision. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.9.4</B> <I>Right of Reference. </I>Any Right of Reference granted by one Party to the other Party in
<U>Section</U><U></U><U>&nbsp;5.4</U> will terminate, except to the extent such other Party has a reasonable need for such Right of Reference to exercise its rights under the surviving terms of this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.9.5</B> <I>Termination of Rights and Obligations</I>. Except as otherwise set forth in this<U>&nbsp;Section 13.9</U> or
in<U>&nbsp;Sections 13.10</U> or <U>13.12</U>, all rights and obligations of the Parties under this Agreement will terminate as of the effective date of such termination or expiration. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.10</B> <B><U>Rights Arising on Early Termination</U></B><B>.</B> In the event this Agreement is early terminated by either Party pursuant
to <U>Sections </U><U>13.2</U>, <U>13.3</U>, <U>13.4</U>, <U>13.5</U>, <U>13.6</U> or <U>13.7</U>, then: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.10.1</B>
<I>Termination/Survival of License Rights.</I> Except for license rights that expressly survive the expiration or termination (pursuant to applicable survival provisions hereunder), any and all license rights granted by one Party to the other Party
under this Agreement will terminate, provided that such licenses will continue solely as necessary for the Parties to complete the orderly wind-down of their activities under this Agreement in accordance with Applicable Law and as otherwise required
in accordance this Agreement; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.10.2</B> <I>Kaken Regulatory Materials. </I>To the extent permitted by Applicable Law, Kaken shall
transfer to CymaBay copies of and its entire right, title and interest in all Regulatory Materials in the Kaken Territory, but subject to <U>Section</U><U></U><U>&nbsp;13.11</U> if such termination is by Kaken under
<U>Section</U><U></U><U>&nbsp;13.5</U> for CymaBay&#146;s uncured material breach; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.10.3</B> <I>Japanese Trademark.</I> If CymaBay so
requests, Kaken shall assign to CymaBay all right title and interest in and to any Japanese Trademark and any other trademarks used exclusively with Licensed Products in the Kaken Territory (excluding any such trademarks that include, in whole or in
part, any corporate name or logo of Kaken or its Affiliates or Sublicensees), but subject to <U>Section</U><U></U><U>&nbsp;13.11</U> if such termination is by Kaken under <U>Section</U><U></U><U>&nbsp;13.5</U> for CymaBay&#146;s uncured material
breach; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.10.4</B> <I>Third Party Agreements. </I>If CymaBay so requests, and to the extent permitted under Kaken&#146;s or such
Affiliate&#146;s obligations to such Third-Party counterparties, Kaken will transfer and assign to CymaBay any Third-Party agreements relating to the Development, Manufacture or Commercialization of the Licensed Products to which Kaken or any of its
Affiliates is a party, subject to any required consents of such Third Party (if such consent is required, Kaken shall use good faith, reasonable efforts to obtain such needed consents); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.10.5</B> <I>Product Inventory. </I>If CymaBay so requests, Kaken will transfer to
CymaBay any inventory of the Licensed Products owned by Kaken or its Affiliates as of the effective date of termination at the actual price paid by Kaken for such supply; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.10.6</B> <I>Grant Back License. </I>Kaken will grant, and is deemed automatically to grant upon such termination, to CymaBay, with
immediate effect from the effective date of the termination, a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> fully paid up, royalty-free sublicensable (through multiple tiers) license under the Kaken Program IP solely for the Exploitation
of Licensed Compounds and Licensed Products worldwide. At CymaBay&#146;s written request promptly after such termination, Kaken will use reasonable efforts to disclose to CymaBay promptly thereafter all applicable Kaken Program IP (reports, data,
documents, etc.) that are included in the reversion license grant under this Section. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.11</B> <B><U>Certain Compensation for Rights
After Termination by Kaken for Breach</U></B><B>.</B> In the event this Agreement is early terminated by Kaken pursuant to <U>Section</U><U></U><U>&nbsp;13.5</U> for uncured material breach by CymaBay, then in consideration of the rights granted or
documents transferred by Kaken pursuant to <U>Sections </U><U>13.10.2</U> or <U>13.10.3</U>, CymaBay shall pay to Kaken [***], but solely to the extent that CymaBay or its Affiliate or licensee actually used or practiced the rights or documents
granted or transferred by Kaken under such Sections in connection with Developing or Commercializing such Licensed Product in Japan. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.12</B> <B><U>Remedies Survive Termination</U></B>.&nbsp;Termination or expiration of this Agreement for any reason shall not release
either Party from any liability or obligation that already has accrued prior to such expiration or termination, nor affect the survival of any provision hereof to the extent it is expressly stated to survive such termination. Termination or
expiration of this Agreement for any reason shall not constitute a waiver or release of, or otherwise be deemed to prejudice or adversely affect, any rights, remedies or claims, whether for damages or otherwise, that a Party may have hereunder based
on the other Party&#146;s performance under this Agreement prior to such termination or expiration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.13</B> <B><U>Effect of
Expiration or Termination; Survival</U></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.13.1</B> Expiration or termination of this Agreement for any reason will not preclude
either Party from pursuing all rights and remedies it may have hereunder or at law or in equity, with respect to any breach of this Agreement occurring prior to such expiration or termination. For the avoidance of doubt, termination of this
Agreement will not affect any SDEA, which will continue to survive so long as any Licensed Products thereunder are being Commercialized. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.13.2</B> Subject to the expiration and termination consequences set forth in <U>Sections 13.1</U>, <U>13.9</U> and <U>13.10</U> (and any
Sections or Articles referenced therein), the following provisions will survive expiration or termination of this Agreement for any reason: <U>ARTICLE 1</U> (to the extent the applicable defined terms therein are used in the Articles or Sections
that survive hereunder), <U>ARTICLE 9</U>, <U>ARTICLE 11</U> and <U>ARTICLE 14</U>, and <U>Sections 4.7</U>, <U>5.4</U> (to the extent the applicable Party retains the applicable right of reference under the surviving terms of this Agreement),
<U>5.5</U> (as applicable with respect to Licensed Product sold or otherwise commercially transferred during the Term), <U>7.1.3</U> (solely after expiration of the Term), <U>7.3.1.2</U> (solely after expiration of the Term), <U>7.7</U>,
<U>8.4.2</U>, <U>8.5.4</U> (as to supply after the Term), <U>8.6</U> through <U>8.10</U> (with respect to all payment obligations that accrue during the Term, and payment obligations that accrue pursuant to <U>Section</U><U></U><U>&nbsp;8.4.2</U>
after the Term, [***], <U>10.3</U>, <U>12.1</U>, <U>12.2</U>, <U>12.3</U>, <U>12.4</U>, <U>12.5.2.3</U>, <U>12.9</U>, <U>12.10</U>, <U>12.12</U> (to the extent the applicable Infringement Claims arise from actions during the Term), <U>13.1</U>,
<U>13.9</U>, <U>13.10</U>, <U>13.11</U>, <U>13.12</U> and <U>13.13</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 14 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.1</B> <B><U>Assignment</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>14.1.1</B> <I>General</I>. Except as provided in this<U>&nbsp;Section </U><U>14.1.1</U> or <U>Section</U><U></U><U>&nbsp;14.1.2</U>, this
Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the prior written consent of the other Party, such consent not to be unreasonably withheld,
conditioned or delayed. Notwithstanding anything in this<U>&nbsp;Section 14.1.1</U>&nbsp;to the contrary, each Party may, without the other Party&#146;s prior written consent, assign this Agreement and its rights and obligations hereunder in whole
or in part to an Affiliate or to a party that acquires, by or otherwise in connection with, a merger, sale of assets, reorganization or other similar transaction, all or substantially all of the assets of the Party relating to its pharmaceutical
business. Any permitted successor or assignee of any rights or obligation under this Agreement must expressly assume the performance thereof in a writing delivered to the <FONT STYLE="white-space:nowrap">non-assigning</FONT> Party; provided that the
assigning Party shall provide notice of such permitted assignment to the <FONT STYLE="white-space:nowrap">non-assigning</FONT> Party promptly following the occurrence thereof. Notwithstanding any permitted assignment, the assigning Party, in the
case of an assignment to the Party&#146;s Affiliate, will remain responsible for the performance by such Affiliate assignee of any obligation hereunder so assigned. Any purported assignment in violation of this<U>&nbsp;Section 14.1.1</U>&nbsp;will
be void. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>14.1.2</B> <I>Securitization</I>.&nbsp;Notwithstanding anything to the contrary in<U>&nbsp;Section </U><U>14.1.1</U> or
elsewhere in this Agreement, CymaBay may assign to a Third Party its right to receive any of the milestone payments or royalty payments owed to CymaBay under<U>&nbsp;ARTICLE 8</U>&nbsp;(such assignment, a &#147;<B>Securitization
Transaction</B>&#148;) without the prior written consent of Kaken. Further, in connection with a contemplated Securitization Transaction, CymaBay may disclose to such Third Party the Confidential Information of Kaken (including the royalty reports
contemplated under<U>&nbsp;Section </U><U>8.6.2</U>), without the prior written consent of Kaken, to the extent reasonably necessary to enable such Third Party to evaluate the Securitization Transaction opportunity
(<I><U>provided</U></I><I><U></U></I>&nbsp;that such Third Party is under obligations of confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> with respect to such Confidential Information that are no less stringent than the terms
of<U>&nbsp;Section </U><U>9.1</U>), and to allow such Third Party to exercise its rights under this<U>&nbsp;Section </U><U>14.1.2</U>. As part of any consummated Securitization Transaction, CymaBay may assign, without the prior written consent of
Kaken, its right to receive the royalty reports and to conduct audits under<U>&nbsp;Section </U><U>8.7</U>&nbsp;to the counterparty in such Securitization Transaction, and to allow such counterparty to exercise its rights under such Sections. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.2</B> <B><U>Governing Law</U></B>. The Agreement will be construed, and the respective rights of the Parties determined, in accordance
with the substantive laws of the State of New York, United States, notwithstanding any provisions of New York law or any other Applicable Law governing conflicts of laws to the contrary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.3</B> <B><U>Dispute Resolution; Arbitration</U></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>14.3.1</B> <I>Disputes</I>. Except as otherwise expressly set forth in this Agreement, including <U>Section</U><U></U><U>&nbsp;2.3.1</U>,
any dispute of any nature between the Parties arising under, relating to, or in connection with this Agreement (a &#147;<B>Dispute</B>&#148;) will be resolved pursuant to this<U>&nbsp;Section </U><U>14.3</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>14.3.2</B> <I>Dispute Escalation</I>. In the event of a Dispute, the Parties will first attempt to resolve such Dispute by negotiation and
consultation between themselves. In the event that such Dispute is not resolved on an informal basis within [***] from receipt by a Party of written notice of such Dispute from the other Party, any Party may, by written notice to the other, have
such Dispute referred to the Executive Officers (or their designee, which designee is required to have decision-making authority on behalf of such Party), who will attempt to resolve such Dispute by good faith, reasonable negotiation and
consultation for a [***] period following receipt of such written notice of referral. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>14.3.3</B> <I>Full Arbitration</I>. Except as
otherwise expressly set forth in this Agreement, in the event the Parties have not resolved such Dispute within [***] of receipt of the written notice referring such Dispute to the Executive Officers, either Party may at any time after the end of
such [***] period submit such Dispute to be finally settled by arbitration administered in accordance with the procedural rules of the International Chamber of Commerce (the &#147;<B>ICC</B>&#148;) in effect at the time of submission, as such rules
are modified by this<U>&nbsp;Section </U><U>14.3</U>. The arbitration will be governed by the laws of the State of New York. The arbitration will be heard and determined by three (3)&nbsp;arbitrators who are retired judges or attorneys, each of whom
will be impartial and independent of each Party and its Affiliates. Each Party will appoint one (1)&nbsp;arbitrator and the third (3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP>) arbitrator will be selected by the two
(2)&nbsp;Party-appointed arbitrators, or, failing agreement within [***] following appointment of the second (2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP>) arbitrator, by the ICC; each such appointed arbitrator must meet
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the criteria set forth above for arbitrators. Such arbitration will take place in Honolulu, HI, United States. The arbitration award so given will, absent manifest error, be a final and binding
determination of the Dispute, will be fully enforceable in any court of competent jurisdiction, and will not include any damages expressly prohibited by<U>&nbsp;Section 11.4</U>. Fees, costs and expenses of arbitration are to be divided by the
Parties in the following manner: Kaken will pay for the arbitrator it chooses, CymaBay will pay for the arbitrator it chooses, and the Parties will share payment for the third (3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP>) arbitrator.
Except in a proceeding to enforce the results of the arbitration or as otherwise required by Applicable Law, neither Party nor any arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written
consent of both Parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>14.3.4</B> <I>Expedited Arbitration</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>14.3.4.1</B> If, as to a Dispute that is subject to ICC arbitration under the terms of <U>Section</U><U></U><U>&nbsp;14.3.3</U>, a Party
exercises its right under this Agreement to refer such dispute to arbitration and in such referral such Party elects expedited arbitration (an &#147;<B>Expedited Dispute</B>&#148;), then the Parties will follow the expedited dispute resolution
process in this <U>Section</U><U></U><U>&nbsp;14.3.4</U> (and not the dispute resolution process in <U>Section</U><U></U><U>&nbsp;14.3.3</U> of this Agreement) (&#147;<B>Expedited Arbitration</B>&#148;). The Parties agree and acknowledge that any
good faith dispute under Expedited Arbitration will not be deemed to be a material breach of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>14.3.4.2</B> The
Expedited Dispute will be submitted to fast-track, binding arbitration in accordance with the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(a)</B> Arbitration will be
conducted in Honolulu, HI, United States, under the rules of the ICC for the resolution of commercial disputes in the most expedited manner permitted by such rules. The Parties will appoint a single arbitrator to be selected by mutual agreement. If
the Parties are unable to agree on an arbitrator, the Parties will request that the ICC select the arbitrator. The arbitrator will be a professional in business or licensing experienced in the valuation of biopharmaceutical products with at least
ten (10)&nbsp;years of experience in the pharmaceutical and life sciences industries, including the conduct of development and commercialization collaborations. The cost of the arbitration will be borne equally by the Parties. Except in a proceeding
to enforce the results of the arbitration or as otherwise required by Applicable Law, neither Kaken nor CymaBay nor any arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written agreement of
Kaken and CymaBay. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(b)</B> Within thirty (30)&nbsp;days after such matter is referred to arbitration, each Party will provide the
arbitrator with a proposal and written memorandum in support of its position regarding the Expedited Dispute, as well as any documentary evidence it wishes to provide in support thereof (each a &#147;<B>Brief</B>&#148;) and the arbitrator will
provide each Party&#146;s Brief to the other Party after it receives it from both Parties. The Parties agree and acknowledge that the Harmonization Principle will serve as a guiding principle for each Party&#146;s Brief and for the arbitrator&#146;s
determination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(c)</B> [***] after a Party submits its Brief, the other Party will have the right to respond thereto. The response and
any material in support thereof will be provided to the arbitrator and the other Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>(d)</B> The arbitrator will have the right to
meet with the Parties as necessary to inform the arbitrator&#146;s determination and to perform independent research and analysis. Within thirty (30)&nbsp;days of the receipt by the arbitrator of both Parties&#146; responses (or expiration of the
thirty (30)&nbsp;day period if any Party fails to submit a response), the arbitrator will deliver his/her decision regarding the Expedited Dispute in writing;<I><U>&nbsp;provided</U></I>&nbsp;that the arbitrator will select one of the resolutions
proposed by the Parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>14.3.5</B> <I>Injunctive Relief</I>. Notwithstanding the dispute resolution procedures set forth in
this<U>&nbsp;Section </U><U>14.3</U>, in the event of an actual or threatened breach of this Agreement, the aggrieved Party may seek provisional equitable relief (including restraining orders, specific performance or other injunctive relief),
without first submitting to any dispute resolution procedures under this <U>ARTICLE 14</U>. Any claim for such equitable relief shall be submitted to the United States District Court for the Southern District of New York or any New York State court
sitting in New York City so long as one of such courts has subject matter jurisdiction </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
over such claim, and each Party hereby irrevocably consents to the exclusive jurisdiction of such courts (and of the appropriate appellate courts therefrom) in any proceeding with respect to any
such equitable claim and irrevocably waives, to the fullest extent permitted by Applicable Law, any objection that it may now or hereafter have to the laying of the venue of any such proceeding in any such court or that any such proceeding brought
in any such court has been brought in an inconvenient forum. Process in any such proceeding may be served on either Party anywhere in the world, whether within or without the jurisdiction of any such court. Without limiting the foregoing, each Party
agrees that service of process on such Party in accordance with <U>Section</U><U></U><U>&nbsp;14.10</U> shall be deemed effective service of process on such Party with respect to any such equitable claim and proceeding under this
<U>Section</U><U></U><U>&nbsp;14.3.5</U>. Each of the Parties hereby irrevocably waives any and all right to trial by jury in any such equitable proceeding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>14.3.6</B> <I>Tolling</I>. The Parties agree that, with respect to any particular Dispute, all applicable statutes of limitation and
time-based defenses (such as estoppel and laches), as well as all time periods in which a Party must exercise rights with hereunder with respect to such Dispute, will be tolled once the dispute resolution procedures set forth in this<U>&nbsp;Section
14.3</U>&nbsp;have been initiated as to such Dispute and for so long as they are pending, and the Parties will cooperate in taking all actions reasonably necessary to achieve such results. In addition, during the pendency of any such dispute
resolution procedures for a Dispute under this Agreement initiated before the end of any applicable cure period, including under<U>&nbsp;Section 13.5</U>, (a) this Agreement will remain in full force and effect, (b)&nbsp;the provisions of this
Agreement relating to termination for material breach with respect to such Dispute will not be effective, (c)&nbsp;the time periods for cure under<U>&nbsp;Section 13.5</U> as to any termination notice given prior to the initiation of arbitration
will be tolled, (d)&nbsp;any time periods to exercise rights or perform obligations will be tolled, and (e)&nbsp;neither Party will issue a notice of termination pursuant to this Agreement based on the subject matter of the arbitration, until in
each case the arbitral tribunal has confirmed that the alleged material breach did occur, based on the existence of the facts claimed by a Party to be the basis for the asserted material breach, and was not cured;<I><U>&nbsp;provided</U></I>, that
if such breach can be cured (i)&nbsp;by the payment of money, the defaulting Party will have an additional ten (10)&nbsp;days within its receipt of the arbitral tribunal&#146;s decision to pay such amount, or (ii)&nbsp;by the taking of specific
remedial actions, the defaulting Party will have a reasonably necessary period to diligently undertake and complete such remedial actions within such period (not in any event to exceed ninety (90)&nbsp;days after the date of the decision), such
period as established by such arbitral tribunal&#146;s decision, before any such notice of termination can be issued. Further, with respect to any time periods that have run during the pendency of the dispute, the applicable Party will have a
reasonable period of time or any specific timeframe established by such arbitral tribunal&#146;s decision to exercise any rights or perform any obligations affected by the running of such time periods. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.4</B> <B><U>Entire Agreement; Amendments</U></B>. This Agreement, together with any applicable supply agreement (and related quality
agreements) between the Parties, and SDEA, contains the entire understanding of the Parties with respect to the subject matter hereof, and supersedes all previous arrangements with respect to the subject matter hereof, whether written or oral,
including, effective as of the Effective Date, the Mutual <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement between CymaBay and Kaken, dated as of February&nbsp;24, 2022 (provided that all information disclosed or exchanged under such
agreement will be treated as Confidential Information disclosed by the applicable Party hereunder). This Agreement (including all its Schedules) may be amended, or any term or condition hereof modified, only by a written instrument duly executed by
authorized representatives of both Parties. Any term or condition of this Agreement may be waived if, but only if, such waiver is in writing and signed by an authorized representative of the Party against whom the waiver is to be effective. The
Schedules attached hereto are part of the Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.5</B> <B><U>Severability</U></B>. If any provision hereof should be held
invalid, illegal or unenforceable in any respect in any jurisdiction, the Parties will substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable provisions, which valid provisions in their economic effect are
sufficiently similar to the invalid, illegal or unenforceable provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such valid provisions. In case such valid provisions cannot be agreed upon, the
invalid, illegal or unenforceable nature of one or several provisions of this Agreement will not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provisions are of such essential importance to this
Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.6</B> <B><U>Headings</U></B>. The captions to the Articles and Sections hereof are not
a part of this Agreement but are merely for convenience to assist in locating and reading the several Articles and Sections hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.7</B> <B><U>Waiver of Rule of Construction</U></B>. Each Party has had the opportunity to consult with counsel in connection with the
review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement will be construed against the drafting Party will not apply. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.8</B> <B><U>Interpretation</U></B>. Except where the context expressly requires otherwise, (a)&nbsp;the use of any gender herein will be
deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa); (b) the words &#147;include&#148;, &#147;includes&#148; and &#147;including&#148; will be deemed to be
followed by the phrase &#147;without limitation&#148; and will not be interpreted to limit the provision to which it relates; (c)&nbsp;the word &#147;shall&#148; will be construed to have the same meaning and effect as the word &#147;will&#148;; (d)
any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any
restrictions on such amendments, supplements or modifications set forth herein); (e) any reference herein to any Person will be construed to include the Person&#146;s successors and assigns; (f)&nbsp;the words &#147;herein&#148;, &#147;hereof&#148;
and &#147;hereunder&#148;, and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof; (g)&nbsp;all references herein to Articles, Sections or Schedules will be construed to
refer to Articles, Sections or Schedules of this Agreement, and references to this Agreement include all Schedules hereto and any capitalized terms used but not defined in any Schedules shall have their respective meanings as defined in this
Agreement; (h)&nbsp;the word &#147;notice&#148; means notice in writing (whether or not specifically stated) and will include notices, consents, approvals and other written communications contemplated under this Agreement; (i)&nbsp;provisions that
require that a Party, the Parties or any committee hereunder &#147;agree,&#148; &#147;consent&#148; or &#147;approve&#148; or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement,
letter, approved minutes or otherwise (but excluding <FONT STYLE="white-space:nowrap">e-mail</FONT> and instant messaging); (j) references to any specific law or article, section or other division thereof, will be deemed to include the then-current
amendments thereto or any replacement or successor law thereof; and (k)&nbsp;the term &#147;or&#148; will be interpreted in the inclusive sense commonly associated with the term &#147;and/or&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.9</B> <B><U>No Implied Waivers; Rights Cumulative</U></B>. No failure on the part of CymaBay or Kaken to exercise, and no delay in
exercising, any right, power, remedy or privilege under this Agreement, or provided by statute or at law or in equity or otherwise, will impair, prejudice or constitute a waiver of any such right, power, remedy or privilege or be construed as a
waiver of any breach of this Agreement or as an acquiescence therein, nor will any single or partial exercise of any such right, power, remedy or privilege preclude any other or further exercise thereof or the exercise of any other right, power,
remedy or privilege. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.10</B> <B><U>Notices</U></B>. All notices that are required or permitted hereunder will be in writing and
sufficient if delivered personally, sent by nationally recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to CymaBay, to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CymaBay Therapeutics, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7575 Gateway Blvd.,
Suite 110</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Newark, CA 94560, USA</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: General
Counsel</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">With a copy to (which will not constitute notice):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooley LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3175 Hanover St.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Palo Alto, CA 94304, USA</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Barclay James
Kamb</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">If to Kaken, to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kaken Pharmaceutical Co., Ltd.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20th Floor,
Bunkyo Green Court</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">28-8,</FONT> Honkomagome <FONT STYLE="white-space:nowrap">2-chome,</FONT> <FONT
STYLE="white-space:nowrap">Bunkyo-ku</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tokyo <FONT STYLE="white-space:nowrap">113-8650,</FONT> Japan</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Head of Business Development</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">With a copy to (which will not constitute notice):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jones Day</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Okura Prestige Tower</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-10-4</FONT></FONT> Toranomon, <FONT STYLE="white-space:nowrap">Minato-ku</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tokyo <FONT STYLE="white-space:nowrap">105-0001,</FONT> Japan</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Benjamin Lang</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. Any such notice will be deemed to have been given: (a)&nbsp;when delivered if personally delivered on a Business Day (or if delivered or sent on a <FONT STYLE="white-space:nowrap">non-Business</FONT> Day, then on the next
Business Day); (b) on the Business Day of receipt if sent by overnight courier; or (c)&nbsp;on the Business Day of receipt if sent by mail. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.11</B> <B><U>Compliance with Export Regulations</U></B>. Neither Party will export any technology licensed to it by the other Party under
this Agreement except in compliance with U.S. export laws and regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.12</B> <B><U>Force Majeure</U></B><I>.</I>&nbsp;Neither
Party will be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any particular obligation under this Agreement to the extent that such failure or delay is caused by or
results from causes beyond the reasonable control of the affected Party, potentially including embargoes, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire,
earthquakes, floods, or other acts of God, <I>provided that </I>such affected Party (a)&nbsp;provides written notice to the other Party of such force majeure circumstances as soon as reasonably practical, and (b)&nbsp;promptly undertakes all
reasonable efforts necessary to cure or avoid the effects of such force majeure circumstances, resumes performance of the applicable obligations hereunder as soon as practicable after such force majeure effects cease or can be avoided, and continues
in full its performance of all its other obligations hereunder. If such a force majeure event occurs and causes failure or delay in performance by a Party of a material obligation of such Party under this Agreement, then the other Party may
terminate this Agreement on written notice if such obligation is not performed within one hundred eighty (180)&nbsp;days of the start of such event, except as otherwise agreed by the Parties in writing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.13</B> <B><U>Independent Parties</U></B>. It is expressly agreed that CymaBay and Kaken will be independent contractors and that the
relationship between CymaBay and Kaken will not constitute a partnership, joint venture or agency. CymaBay will not have the authority to make any statements, representations or commitments of any kind, or to take any action, that will be binding on
Kaken, without the prior written consent of Kaken, and Kaken will not have the authority to make any statements, representations or commitments of any kind, or to take any action, that will be binding on CymaBay, without the prior written consent of
CymaBay. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.14</B> <B><U>Expenses</U></B>. Except as otherwise provided herein, all fees, costs and expenses (including any legal,
accounting and banking fees) incurred in connection with the preparation, negotiation, execution and delivery of this Agreement and to consummate the transactions contemplated hereby will be paid by the Party incurring such fees, costs and expenses.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.15</B> <B><U>Counterparts/Execution</U></B>. The Agreement may be executed in two or more counterparts, including by facsimile or
PDF signature pages, each of which will be deemed an original, but all of which together will constitute one and the same instrument. This Agreement may also be executed using any electronic signature complying with the U.S. federal ESIGN Act of
2000 (such as DocuSign), the Uniform Electronic Transactions Act or other Applicable Law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.16</B> <B><U>Binding Effect; No Third-Party Beneficiaries</U></B>. As of the Effective
Date, this Agreement will be binding upon and inure to the benefit of the Parties and their respective permitted successors and permitted assigns. Except as expressly set forth in this Agreement, no Person other than the Parties and their respective
Affiliates and permitted assignees hereunder will be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.17</B> <B><U>Further Assurances</U></B>. The Parties agree to reasonably cooperate with each other in connection with any actions
required to be taken in furtherance of their respective obligations under this Agreement, including (a)&nbsp;furnishing to each other such further information; (b)&nbsp;executing and delivering to each other such other documents; and (c)&nbsp;doing
such other acts and things (including working collaboratively to correct any clerical, typographical, or other similar errors in this Agreement), all as the other Party may reasonably request for the purpose of carrying out the intent of this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[THE REMAINDER OF THIS PAGE HAS BEEN LEFT INTENTIONALLY BLANK] </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>CymaBay Therapeutics, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Kaken Pharmaceutical Co., Ltd.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>By</B>:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sujal Shah</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>By</B>:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Hiroyuki Horiuchi</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Name: </B>Sujal Shah</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Name: </B>Hiroyuki Horiuchi</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Title: </B>CEO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>Title: </B>President and Representative Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to the Collaboration and License Agreement] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>List of Schedules </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 1.33</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Kaken&#146;s Existing Pharmaceutical Products</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 1.45</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">CymaBay&#146;s Licensed Patents</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 1.157</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Seladelpar</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 3.4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Global Development Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 6.2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Clinical Supply Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 9.3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Disclosure Schedule</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 10.2.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">INDs filed in Japan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Schedule 10.2.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Material Contracts</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>d446975dex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 21.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>List of Subsidiaries </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Name of Subsidiary</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">State or Jurisdiction in</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Which&nbsp;Incorporated&nbsp;or</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Organized</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CymaBay UK, Ltd.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United&nbsp;Kingdom</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CymaBay Ireland, Limited</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ireland</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">CymaBay Canada, Ltd.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Canada</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d446975dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the incorporation by reference in the following Registration Statements: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration Statement (Form <FONT STYLE="white-space:nowrap">S-3</FONT>
<FONT STYLE="white-space:nowrap">No.&nbsp;333-239670)</FONT> of CymaBay Therapeutics, Inc., and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Registration Statements (Form <FONT STYLE="white-space:nowrap">S-8</FONT> Nos.
<FONT STYLE="white-space:nowrap">333-195211,</FONT> <FONT STYLE="white-space:nowrap">333-198289,</FONT> <FONT STYLE="white-space:nowrap">333-202941,</FONT> <FONT STYLE="white-space:nowrap">333-210453,</FONT>
<FONT STYLE="white-space:nowrap">333-216905,</FONT> <FONT STYLE="white-space:nowrap">333-223687,</FONT> <FONT STYLE="white-space:nowrap">333-226741,</FONT> <FONT STYLE="white-space:nowrap">333-229953,</FONT>
<FONT STYLE="white-space:nowrap">333-254697</FONT> and <FONT STYLE="white-space:nowrap">333-263644)</FONT> pertaining to the Metabolex, Inc. 2003 Equity Incentive Plan, the CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan, and the CymaBay
Therapeutics, Inc. 2020 New Hire Plan; </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of our report dated March&nbsp;23, 2023, with respect to the consolidated financial statements
of CymaBay Therapeutics, Inc. included in this Annual Report (Form <FONT STYLE="white-space:nowrap">10-K)</FONT> of CymaBay Therapeutics, Inc. for the year ended December&nbsp;31, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Mateo, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;23, 2023 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>d446975dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Sujal Shah, certify
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this Form <FONT STYLE="white-space:nowrap">10-K</FONT> of CymaBay Therapeutics, Inc.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;23, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sujal Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sujal Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Principal Executive Officer)</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>d446975dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Daniel Menold, certify
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">I have reviewed this Form <FONT STYLE="white-space:nowrap">10-K</FONT> of CymaBay Therapeutics, Inc.;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(e))</FONT> and internal control over financial reporting (as defined in Exchange Act
Rules <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> and <FONT STYLE="white-space:nowrap">15d-15(f))</FONT> for the registrant and have: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is
being prepared; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this
report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that
occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal
control over financial reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of
internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any fraud, whether or not material, that involves management or other employees who have a significant role in
the registrant&#146;s internal control over financial reporting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: March&nbsp;23, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel Menold</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Daniel Menold</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vice President, Finance</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Principal Financial and Accounting Officer)</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>d446975dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the
requirement set forth in Rule <FONT STYLE="white-space:nowrap">13a-14(b)</FONT> of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), and Section&nbsp;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C.
&#167;1350), Sujal Shah., President and Chief Executive Officer and Daniel Menold, Vice President, Finance of CymaBay Therapeutics, Inc. (the &#147;Company&#148;), hereby certifies that, to the best of his knowledge: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the period ended
December&nbsp;31, 2022, to which this Certification is attached as Exhibit 32.1 (the &#147;Annual Report&#148;) fully complies with the requirements of Section&nbsp;13(a) or Section&nbsp;15(d) of the Exchange Act, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The information contained in the Annual Report fairly presents, in all material respects, the financial
condition and results of operations of the Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In <B>Witness Whereof</B>, the undersigned have set their hands hereto as of the 23<SUP
STYLE="font-size:75%; vertical-align:top">rd</SUP> day of March, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Sujal Shah</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sujal Shah</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Principal Executive Officer)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Daniel Menold</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Daniel Menold</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Vice President, Finance</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(Principal Financial and Accounting Officer)</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This certification accompanies the Form <FONT STYLE="white-space:nowrap">10-K</FONT> to which it relates, is not deemed
filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of CymaBay Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made
before or after the date of the Form <FONT STYLE="white-space:nowrap">10-K),</FONT> irrespective of any general incorporation language contained in such filing. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>cbay-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 23-March-2023 [11:30:25] {PM}-->
<schema targetNamespace="http://www.cymabay.com/20221231" elementFormDefault="qualified" xmlns:cbay="http://www.cymabay.com/20221231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.cymabay.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<link:definition>1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
<link:definition>1005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" id="ConsolidatedStatementOfStockholdersEquityParenthetical">
<link:definition>1006 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/OrganizationAndDescriptionOfBusiness" id="OrganizationAndDescriptionOfBusiness">
<link:definition>1008 - Disclosure - Organization and Description of Business</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/MarketableSecurities" id="MarketableSecurities">
<link:definition>1010 - Disclosure - Marketable Securities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/CertainBalanceSheetItems" id="CertainBalanceSheetItems">
<link:definition>1011 - Disclosure - Certain Balance Sheet Items</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/InLicenseAgreement" id="InLicenseAgreement">
<link:definition>1012 - Disclosure - In-License Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/DevelopmentFinancingAgreement" id="DevelopmentFinancingAgreement">
<link:definition>1013 - Disclosure - Development Financing Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/Leases" id="Leases">
<link:definition>1014 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1015 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>1016 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensation" id="StockPlansAndStockBasedCompensation">
<link:definition>1017 - Disclosure - Stock Plans and Stock-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/KPlan" id="KPlan">
<link:definition>1018 - Disclosure - 401(k) Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1019 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1020 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1021 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1022 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/MarketableSecuritiesTables" id="MarketableSecuritiesTables">
<link:definition>1023 - Disclosure - Marketable Securities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/CertainBalanceSheetItemsTables" id="CertainBalanceSheetItemsTables">
<link:definition>1024 - Disclosure - Certain Balance Sheet Items (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/DevelopmentFinancingAgreementTables" id="DevelopmentFinancingAgreementTables">
<link:definition>1025 - Disclosure - Development Financing Agreement (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/LeasesTables" id="LeasesTables">
<link:definition>1026 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
<link:definition>1027 - Disclosure - Stockholders' Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationTables" id="StockPlansAndStockBasedCompensationTables">
<link:definition>1028 - Disclosure - Stock Plans and Stock-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1029 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" id="OrganizationAndDescriptionOfBusinessAdditionalInformationDetail">
<link:definition>1030 - Disclosure - Organization and Description of Business - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail" id="SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail">
<link:definition>1031 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Assets Measured on Recurring Basis (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1032 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail" id="SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail">
<link:definition>1033 - Disclosure - Summary of Significant Accounting Policies - Computation of Basic and Diluted Net Loss per Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail" id="SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail">
<link:definition>1034 - Disclosure - Summary of Significant Accounting Policies - Anti-Dilutive Securities Excluded from the Computation of Diluted Net Loss per Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail" id="MarketableSecuritiesAdditionalInformationDetail">
<link:definition>1035 - Disclosure - Marketable Securities - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail" id="MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail">
<link:definition>1036 - Disclosure - Marketable Securities - Marketable Available-for-Sale Securities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/MarketableSecuritiesScheduleOfFairValueOfTheCompanyMarketableSecuritiesByContractualMaturityDetail" id="MarketableSecuritiesScheduleOfFairValueOfTheCompanyMarketableSecuritiesByContractualMaturityDetail">
<link:definition>1037 - Disclosure - Marketable Securities - Schedule Of Fair Value Of The Company  Marketable Securities By Contractual Maturity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail" id="CertainBalanceSheetItemsPropertyAndEquipmentDetail">
<link:definition>1038 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/CertainBalanceSheetItemsAdditionalInformationDetail" id="CertainBalanceSheetItemsAdditionalInformationDetail">
<link:definition>1039 - Disclosure - Certain Balance Sheet Items - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail" id="CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail">
<link:definition>1040 - Disclosure - Certain Balance Sheet Items - Other Accrued Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail" id="InLicenseAgreementAdditionalInformationDetail">
<link:definition>1041 - Disclosure - In-License Agreement - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail" id="DevelopmentFinancingAgreementAdditionalInformationDetail">
<link:definition>1042 - Disclosure - Development Financing Agreement - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/DevelopmentFinancingAgreementScheduleOfChangesInFairValueOfLiabilitiesDetail" id="DevelopmentFinancingAgreementScheduleOfChangesInFairValueOfLiabilitiesDetail">
<link:definition>1043 - Disclosure - Development Financing Agreement - Schedule of Changes in Fair Value of Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" id="LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail">
<link:definition>1044 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/LeasesAdditionalInformationDetail" id="LeasesAdditionalInformationDetail">
<link:definition>1045 - Disclosure - Leases - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
<link:definition>1046 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail" id="StockholdersEquityAdditionalInformationDetail">
<link:definition>1047 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail" id="StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail">
<link:definition>1048 - Disclosure - Stockholder's Equity - Summary of Reserved Shares of Common Stock for Future Issuances (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail" id="StockPlansAndStockBasedCompensationAdditionalInformationDetail">
<link:definition>1049 - Disclosure - Stock Plans and Stock-Based Compensation - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail" id="StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail">
<link:definition>1050 - Disclosure - Stock Plans and Stock-Based Compensation - Summary of Stock Option Grants, Including Performance Options (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail" id="StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail">
<link:definition>1051 - Disclosure - Stock Plans and Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail" id="StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail">
<link:definition>1052 - Disclosure - Stock Plans and Stock-Based Compensation - Estimated Weighted-Average Grant Date Fair Value (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/KPlanAdditionalInformationDetail" id="KPlanAdditionalInformationDetail">
<link:definition>1053 - Disclosure - 401(k) Plan - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1054 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail" id="IncomeTaxesComponentsOfDeferredTaxAssetsDetail">
<link:definition>1055 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail" id="IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail">
<link:definition>1056 - Disclosure - Income Taxes - Summary of Reconciliation of Expected Statutory Federal Income Tax Provision to Actual Income Tax Provision (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/IncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetail" id="IncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetail">
<link:definition>1057 - Disclosure - Income Taxes - Summary of Gross Unrecognized Tax Benefits (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail" id="SubsequentEventsAdditionalInformationDetail">
<link:definition>1058 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="cbay-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="cbay-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="cbay-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="cbay-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
<import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
<import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
<import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
<import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
<import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
<element name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="cbay_AccruedResearchAndDevelopmentExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DevelopmentFinancingLiabilityNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="cbay_DevelopmentFinancingLiabilityNonCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfCommonStockAndPrefundedWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_IssuanceOfCommonStockAndPrefundedWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfCommonStockAndPrefundedWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares" substitutionGroup="xbrli:item" />
<element name="IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromDevelopmentFinancingNetOFtransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccretionOfDevelopmentFinancingLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_AccretionOfDevelopmentFinancingLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisclosureOfDevelopmentFinancingTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_DisclosureOfDevelopmentFinancingTextBlock" substitutionGroup="xbrli:item" />
<element name="CashEquivalentsAndInvestmentsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_CashEquivalentsAndInvestmentsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DevelopmentFinancingAgreementPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_DevelopmentFinancingAgreementPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="PrefundedWarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_PrefundedWarrantsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfOtherAccruedLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_ScheduleOfOtherAccruedLiabilitiesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ReservedSharesOfCommonStockForIssuanceTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_ReservedSharesOfCommonStockForIssuanceTableTextBlock" substitutionGroup="xbrli:item" />
<element name="AbwCyclopsSpvLpMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_AbwCyclopsSpvLpMember" substitutionGroup="xbrli:item" />
<element name="NumberOfFundingInstallments" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="cbay_NumberOfFundingInstallments" substitutionGroup="xbrli:item" />
<element name="GrossProceedsFromPublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_GrossProceedsFromPublicOffering" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UpfrontCashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="cbay_UpfrontCashPayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CbayfinancingAgreementFundingInstallmentsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_CbayfinancingAgreementFundingInstallmentsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="CbayfinancingAgreementFundingInstallmentsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_CbayfinancingAgreementFundingInstallmentsDomain" substitutionGroup="xbrli:item" />
<element name="FinancingAgreementFundingInstallmentsTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_FinancingAgreementFundingInstallmentsTwoMember" substitutionGroup="xbrli:item" />
<element name="PrefundedWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_PrefundedWarrantsMember" substitutionGroup="xbrli:item" />
<element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_AgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_AgreementDomain" substitutionGroup="xbrli:item" />
<element name="CollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_CollaborationAndLicenseAgreementMember" substitutionGroup="xbrli:item" />
<element name="KakenPharmaceuticalCo.LtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_KakenPharmaceuticalCo.LtdMember" substitutionGroup="xbrli:item" />
<element name="UsAgencySecuritiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_UsAgencySecuritiesMember" substitutionGroup="xbrli:item" />
<element name="SupranationalDebtSecuritiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_SupranationalDebtSecuritiesMember" substitutionGroup="xbrli:item" />
<element name="ShortTermInvestmentContractualMaturity" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_ShortTermInvestmentContractualMaturity" substitutionGroup="xbrli:item" />
<element name="CashEquivalentMaturityDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_CashEquivalentMaturityDescription" substitutionGroup="xbrli:item" />
<element name="CashCashEquivalentsAndMarketableSecuritiesAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_CashCashEquivalentsAndMarketableSecuritiesAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="CashCashEquivalentsAndMarketableSecuritiesDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_CashCashEquivalentsAndMarketableSecuritiesDomain" substitutionGroup="xbrli:item" />
<element name="WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted" substitutionGroup="xbrli:item" />
<element name="WeightedAverageNumberOfPreFundedWarrantsOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding" substitutionGroup="xbrli:item" />
<element name="IncentiveStockAwardsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_IncentiveStockAwardsMember" substitutionGroup="xbrli:item" />
<element name="EmployeeOrNonEmployeeStockOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_EmployeeOrNonEmployeeStockOptionsMember" substitutionGroup="xbrli:item" />
<element name="AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CurrentMarketableSecuritiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_CurrentMarketableSecuritiesMember" substitutionGroup="xbrli:item" />
<element name="MaketableSecuritiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_MaketableSecuritiesMember" substitutionGroup="xbrli:item" />
<element name="NoncurrentMarketableSecuritiesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_NoncurrentMarketableSecuritiesMember" substitutionGroup="xbrli:item" />
<element name="ContractualObligationFiscalYearMaturityScheduleTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_ContractualObligationFiscalYearMaturityScheduleTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ContractualObligationFiscalYearMaturityScheduleLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_ContractualObligationFiscalYearMaturityScheduleLineItems" substitutionGroup="xbrli:item" />
<element name="OfficeAndComputerEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_OfficeAndComputerEquipmentMember" substitutionGroup="xbrli:item" />
<element name="AccruedLiabilitiesForPurchaseOfProductiveAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedProfessionalFeesAndOtherCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="cbay_AccruedProfessionalFeesAndOtherCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RoyaltyPercentageBasedOnNetSales" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_RoyaltyPercentageBasedOnNetSales" substitutionGroup="xbrli:item" />
<element name="JanssenPharmaceuticalNVMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_JanssenPharmaceuticalNVMember" substitutionGroup="xbrli:item" />
<element name="FinancingAgreementTerminationEventConditionAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_FinancingAgreementTerminationEventConditionAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="FinancingAgreementTerminationEventConditionDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_FinancingAgreementTerminationEventConditionDomain" substitutionGroup="xbrli:item" />
<element name="FinancingAgreementTerminationEventConditionOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_FinancingAgreementTerminationEventConditionOneMember" substitutionGroup="xbrli:item" />
<element name="FinancingAgreementTerminationEventConditionTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_FinancingAgreementTerminationEventConditionTwoMember" substitutionGroup="xbrli:item" />
<element name="FinancingAgreementTerminationEventConditionThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_FinancingAgreementTerminationEventConditionThreeMember" substitutionGroup="xbrli:item" />
<element name="SuccessPaymentTypeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_SuccessPaymentTypeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="SuccessPaymentTypeDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_SuccessPaymentTypeDomain" substitutionGroup="xbrli:item" />
<element name="VariableSuccessPaymentsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_VariableSuccessPaymentsMember" substitutionGroup="xbrli:item" />
<element name="FixedSuccessPaymentsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_FixedSuccessPaymentsMember" substitutionGroup="xbrli:item" />
<element name="AnniversaryPaymentsDueYearFive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_AnniversaryPaymentsDueYearFive" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AnniversaryPaymentsDueYearSix" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_AnniversaryPaymentsDueYearSix" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AnniversaryPaymentsDueYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_AnniversaryPaymentsDueYearTwo" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AnniversaryPaymentsDueYearThree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_AnniversaryPaymentsDueYearThree" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Anniversarypaymentsdueyearfour" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_Anniversarypaymentsdueyearfour" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AggregateReturnPercentageFromTheFundsProvided" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_AggregateReturnPercentageFromTheFundsProvided" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DescriptionOfPercentageFixedSuccessPayments" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_DescriptionOfPercentageFixedSuccessPayments" substitutionGroup="xbrli:item" />
<element name="AnniversaryPaymentsDueYearOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_AnniversaryPaymentsDueYearOne" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement" substitutionGroup="xbrli:item" />
<element name="PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability" substitutionGroup="xbrli:item" />
<element name="DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement" substitutionGroup="xbrli:item" />
<element name="PercentageOfAcceleratePaymentPayableOnFundsProvided" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided" substitutionGroup="xbrli:item" />
<element name="DescriptionOfAggregateReturnFromTheFundsProvided" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_DescriptionOfAggregateReturnFromTheFundsProvided" substitutionGroup="xbrli:item" />
<element name="PaymentsUponReachingProductSalesRunRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_PaymentsUponReachingProductSalesRunRate" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DescriptionOfPercentageVariableSuccessPayments" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_DescriptionOfPercentageVariableSuccessPayments" substitutionGroup="xbrli:item" />
<element name="NumberOfInstallmentFundingAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_NumberOfInstallmentFundingAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="NumberOfInstallmentFundingDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_NumberOfInstallmentFundingDomain" substitutionGroup="xbrli:item" />
<element name="InstallmentFundingNumberOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_InstallmentFundingNumberOneMember" substitutionGroup="xbrli:item" />
<element name="InstallmentFundingNumberTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_InstallmentFundingNumberTwoMember" substitutionGroup="xbrli:item" />
<element name="InstallmentFundingNumberThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_InstallmentFundingNumberThreeMember" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AreaOfOfficeSpace" type="dtr-types:areaItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_AreaOfOfficeSpace" substitutionGroup="xbrli:item" />
<element name="NumberOfLeasedFacilitiesOperatingLeases" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="cbay_NumberOfLeasedFacilitiesOperatingLeases" substitutionGroup="xbrli:item" />
<element name="LeaseStartDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_LeaseStartDate" substitutionGroup="xbrli:item" />
<element name="LeaseFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_LeaseFacilityMember" substitutionGroup="xbrli:item" />
<element name="IndemnificationLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="cbay_IndemnificationLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OptionsAndIncentiveAwardsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_OptionsAndIncentiveAwardsMember" substitutionGroup="xbrli:item" />
<element name="CbayequityIncentivePlanTwoThousandAndTwentyPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember" substitutionGroup="xbrli:item" />
<element name="CbayequityIncentivePlanTwoThousandAndThirteenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember" substitutionGroup="xbrli:item" />
<element name="EquityIncentivePlanTwoThousandAndThirteenMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_EquityIncentivePlanTwoThousandAndThirteenMember" substitutionGroup="xbrli:item" />
<element name="EquityIncentivePlanTwoThousandAndTwentyPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" substitutionGroup="xbrli:item" />
<element name="NonQualifiedStockOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_NonQualifiedStockOptionsMember" substitutionGroup="xbrli:item" />
<element name="IncentiveStockOptionsForEmployeesAndDirectorsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember" substitutionGroup="xbrli:item" />
<element name="StockOptionsToTenPercentShareholdersMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_StockOptionsToTenPercentShareholdersMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" substitutionGroup="xbrli:item" />
<element name="EmployerMatchingContributionToQualifiedSavingsPlan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_EmployerMatchingContributionToQualifiedSavingsPlan" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomeTaxTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_IncomeTaxTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="FederalAndStateTaxAuthorityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_FederalAndStateTaxAuthorityMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_IncomeTaxLineItems" substitutionGroup="xbrli:item" />
<element name="ProvisionForStateAndLocalIncomeTaxes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_ProvisionForStateAndLocalIncomeTaxes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NetOperatingLossCarryforwardExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_NetOperatingLossCarryforwardExpirationYear" substitutionGroup="xbrli:item" />
<element name="AlternateMinimumTaxRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_AlternateMinimumTaxRate" substitutionGroup="xbrli:item" />
<element name="WriteOffOfTaxAttributeDueToLimitation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_WriteOffOfTaxAttributeDueToLimitation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CumulativePercentageChangeInOwnershipPercentagePerimissible" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible" substitutionGroup="xbrli:item" />
<element name="PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage" substitutionGroup="xbrli:item" />
<element name="FederalMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_FederalMember" substitutionGroup="xbrli:item" />
<element name="OrphanDrugMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cbay_OrphanDrugMember" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="cbay_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomeTaxReconciliationTaxCancelledOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_IncomeTaxReconciliationTaxCancelledOptions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomeTaxReconciliationDevelopmentFinancingLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_IncomeTaxReconciliationDevelopmentFinancingLiability" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncomeTaxReconciliationPermanentDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_IncomeTaxReconciliationPermanentDifferences" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PotentialMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="cbay_PotentialMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>cbay-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 23-March-2023 [11:30:25] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.cymabay.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail" roleURI="http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CertainBalanceSheetItemsPropertyAndEquipmentDetail" roleURI="http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail" roleURI="http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" roleURI="http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#IncomeTaxesComponentsOfDeferredTaxAssetsDetail" roleURI="http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail" roleURI="http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail" />
<calculationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" use="optional" order="10" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AccretionOfDevelopmentFinancingLiability" xlink:label="loc_CBAY_AccretionOfDevelopmentFinancingLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CBAY_AccretionOfDevelopmentFinancingLiability" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="loc_CBAY_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CBAY_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="12" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants" xlink:label="loc_CBAY_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CBAY_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts" xlink:label="loc_CBAY_ProceedsFromDevelopmentFinancingNetOFtransactionCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CBAY_ProceedsFromDevelopmentFinancingNetOFtransactionCosts" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="18" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AccruedResearchAndDevelopmentExpenses" xlink:label="loc_CBAY_AccruedResearchAndDevelopmentExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_CBAY_AccruedResearchAndDevelopmentExpenses" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DevelopmentFinancingLiabilityNonCurrent" xlink:label="loc_CBAY_DevelopmentFinancingLiabilityNonCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_CBAY_DevelopmentFinancingLiabilityNonCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="13" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="21" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets" xlink:label="loc_CBAY_AccruedLiabilitiesForPurchaseOfProductiveAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CBAY_AccruedLiabilitiesForPurchaseOfProductiveAssets" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AccruedProfessionalFeesAndOtherCurrent" xlink:label="loc_CBAY_AccruedProfessionalFeesAndOtherCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CBAY_AccruedLiabilitiesForPurchaseOfProductiveAssets" xlink:to="loc_CBAY_AccruedProfessionalFeesAndOtherCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CBAY_AccruedLiabilitiesForPurchaseOfProductiveAssets" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="1" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxLiabilities" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment" xlink:label="loc_CBAY_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_CBAY_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment" use="optional" order="10" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncomeTaxReconciliationTaxCancelledOptions" xlink:label="loc_CBAY_IncomeTaxReconciliationTaxCancelledOptions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_CBAY_IncomeTaxReconciliationTaxCancelledOptions" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncomeTaxReconciliationDevelopmentFinancingLiability" xlink:label="loc_CBAY_IncomeTaxReconciliationDevelopmentFinancingLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_CBAY_IncomeTaxReconciliationDevelopmentFinancingLiability" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncomeTaxReconciliationPermanentDifferences" xlink:label="loc_CBAY_IncomeTaxReconciliationPermanentDifferences" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_CBAY_IncomeTaxReconciliationPermanentDifferences" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" use="optional" order="9" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cbay-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 23-March-2023 [11:30:25] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CoverPage" roleURI="http://www.cymabay.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail" roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail" roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail" roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#MarketableSecuritiesAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail" roleURI="http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#MarketableSecuritiesScheduleOfFairValueOfTheCompanyMarketableSecuritiesByContractualMaturityDetail" roleURI="http://www.cymabay.com/role/MarketableSecuritiesScheduleOfFairValueOfTheCompanyMarketableSecuritiesByContractualMaturityDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CertainBalanceSheetItemsPropertyAndEquipmentDetail" roleURI="http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail" roleURI="http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#InLicenseAgreementAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#DevelopmentFinancingAgreementAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail" roleURI="http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockPlansAndStockBasedCompensationAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail" roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail" roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.cymabay.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail" roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#Leases" roleURI="http://www.cymabay.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#LeasesTables" roleURI="http://www.cymabay.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" roleURI="http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#IncomeTaxesComponentsOfDeferredTaxAssetsDetail" roleURI="http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail" roleURI="http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CertainBalanceSheetItemsAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/CertainBalanceSheetItemsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#IncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetail" roleURI="http://www.cymabay.com/role/IncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#ConsolidatedStatementOfStockholdersEquityParenthetical" roleURI="http://www.cymabay.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#IncomeTaxesTables" roleURI="http://www.cymabay.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#KPlanAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/KPlanAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cymabay.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#OrganizationAndDescriptionOfBusiness" roleURI="http://www.cymabay.com/role/OrganizationAndDescriptionOfBusiness" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#MarketableSecurities" roleURI="http://www.cymabay.com/role/MarketableSecurities" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CertainBalanceSheetItems" roleURI="http://www.cymabay.com/role/CertainBalanceSheetItems" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#InLicenseAgreement" roleURI="http://www.cymabay.com/role/InLicenseAgreement" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CommitmentsAndContingencies" roleURI="http://www.cymabay.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockholdersEquity" roleURI="http://www.cymabay.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockPlansAndStockBasedCompensation" roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#KPlan" roleURI="http://www.cymabay.com/role/KPlan" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#IncomeTaxes" roleURI="http://www.cymabay.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#MarketableSecuritiesTables" roleURI="http://www.cymabay.com/role/MarketableSecuritiesTables" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CertainBalanceSheetItemsTables" roleURI="http://www.cymabay.com/role/CertainBalanceSheetItemsTables" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockholdersEquityTables" roleURI="http://www.cymabay.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockPlansAndStockBasedCompensationTables" roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#DevelopmentFinancingAgreement" roleURI="http://www.cymabay.com/role/DevelopmentFinancingAgreement" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#DevelopmentFinancingAgreementTables" roleURI="http://www.cymabay.com/role/DevelopmentFinancingAgreementTables" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#DevelopmentFinancingAgreementScheduleOfChangesInFairValueOfLiabilitiesDetail" roleURI="http://www.cymabay.com/role/DevelopmentFinancingAgreementScheduleOfChangesInFairValueOfLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SubsequentEvents" roleURI="http://www.cymabay.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_622308" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_622305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_DocumentInformationTable_622305" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_622306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_622305" xlink:to="loc_us-gaap_StatementClassOfStockAxis_622306" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_622307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_622306" xlink:to="loc_us-gaap_ClassOfStockDomain_622307" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_622307_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_622306" xlink:to="loc_us-gaap_ClassOfStockDomain_622307_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_622309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_DocumentType_622309" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_622311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_AmendmentFlag_622311" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_622314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_DocumentPeriodEndDate_622314" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_622315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_DocumentFiscalYearFocus_622315" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_622316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_DocumentFiscalPeriodFocus_622316" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_622317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_TradingSymbol_622317" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_622319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityRegistrantName_622319" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_622320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityCentralIndexKey_622320" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_622321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_CurrentFiscalYearEndDate_622321" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_622322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityFilerCategory_622322" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_622324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityCurrentReportingStatus_622324" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_622325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntitySmallBusiness_622325" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_622327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityEmergingGrowthCompany_622327" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_622328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_622328" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_622329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityShellCompany_622329" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_622330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityFileNumber_622330" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_622331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityTaxIdentificationNumber_622331" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_622334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityAddressAddressLine1_622334" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_622335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityAddressAddressLine2_622335" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_622336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityAddressCityOrTown_622336" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_622338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityAddressStateOrProvince_622338" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_622339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityAddressPostalZipCode_622339" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_622345" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_CityAreaCode_622345" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_622346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_LocalPhoneNumber_622346" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_622348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityInteractiveDataCurrent_622348" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_622349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_Security12bTitle_622349" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_622350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_SecurityExchangeName_622350" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_622351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityIncorporationStateCountryCode_622351" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_622353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_DocumentAnnualReport_622353" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_622354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_DocumentTransitionReport_622354" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_622397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_622397" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_622399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityVoluntaryFilers_622399" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_626111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityPublicFloat_626111" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_863789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_IcfrAuditorAttestationFlag_863789" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_1311458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_AuditorName_1311458" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_1311459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_AuditorFirmId_1311459" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_1311460" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_AuditorLocation_1311460" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_93" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_99" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_SharesOutstanding_99" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_98" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_StockholdersEquity_98" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_105" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_104" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_NetIncomeLoss_109" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_106" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IssuanceOfCommonStockAndPrefundedWarrants" xlink:label="loc_cbay_IssuanceOfCommonStockAndPrefundedWarrants_1311634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_cbay_IssuanceOfCommonStockAndPrefundedWarrants_1311634" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares" xlink:label="loc_cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares_1311637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares_1311637" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_110" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_90" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_StatementTable_90" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_91" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_90" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_91" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_92" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_91" xlink:to="loc_us-gaap_EquityComponentDomain_92" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_92_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_91" xlink:to="loc_us-gaap_EquityComponentDomain_92_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_97" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_92" xlink:to="loc_us-gaap_RetainedEarningsMember_97" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_96" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_92" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_96" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_95" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_92" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_95" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_94" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_92" xlink:to="loc_us-gaap_CommonStockMember_94" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants" xlink:label="loc_cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants_1341906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants_1341906" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_622501" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622501" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_152" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622501" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_153" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_622515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622501" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_622515" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_622515" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_143" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_622515" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_144" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_622515" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_145" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_622515" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_142" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_622520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622501" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_622520" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_622520" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_147" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_622520" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_151" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants" xlink:label="loc_cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants_1310155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_622520" xlink:to="loc_cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants_1310155" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts" xlink:label="loc_cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts_1310178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_622520" xlink:to="loc_cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts_1310178" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_622521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622501" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_622521" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_622541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_622521" xlink:to="loc_us-gaap_OperatingLeasePayments_622541" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_622522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622501" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_622522" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_1310157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_622522" xlink:to="loc_us-gaap_LiabilitiesAssumed1_1310157" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_622503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622501" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_622503" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_622503" xlink:to="loc_us-gaap_ProfitLoss_125" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_622505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_622503" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_622505" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_622505" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_128" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_622505" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_126" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_622505" xlink:to="loc_us-gaap_ShareBasedCompensation_127" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_622507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_622505" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_622507" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_622507" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_137" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="loc_cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_1311664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_622507" xlink:to="loc_cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_1311664" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1311665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_622507" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1311665" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_622507" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_138" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1329035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_622507" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1329035" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AccretionOfDevelopmentFinancingLiability" xlink:label="loc_cbay_AccretionOfDevelopmentFinancingLiability_1310152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_622505" xlink:to="loc_cbay_AccretionOfDevelopmentFinancingLiability_1310152" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_1310160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_622505" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_1310160" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_622503" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_141" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_622498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_622501" xlink:to="loc_us-gaap_StatementTable_622498" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_622531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_622498" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_622531" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_622532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_622531" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_622532" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_622532_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_622531" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_622532_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_622499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_622498" xlink:to="loc_us-gaap_StatementClassOfStockAxis_622499" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_622500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_622499" xlink:to="loc_us-gaap_ClassOfStockDomain_622500" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_622500_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_622499" xlink:to="loc_us-gaap_ClassOfStockDomain_622500_default" use="optional" order="38" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_862967" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_258" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_257" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_256" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_NetIncomeLoss_255" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NumberOfFundingInstallments" xlink:label="loc_cbay_NumberOfFundingInstallments_1311721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_cbay_NumberOfFundingInstallments_1311721" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_NumberOfOperatingSegments_254" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_862962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_862962" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_1311677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_862962" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_1311677" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_1311678" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_1311677" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_1311678" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_1311678_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_1311677" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_1311678_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AbwCyclopsSpvLpMember" xlink:label="loc_cbay_AbwCyclopsSpvLpMember_1311684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_1311678" xlink:to="loc_cbay_AbwCyclopsSpvLpMember_1311684" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_862963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_862962" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_862963" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_862964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_862963" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_862964" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_862964_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_862963" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_862964_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1341921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_862964" xlink:to="loc_us-gaap_IPOMember_1341921" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CbayfinancingAgreementFundingInstallmentsAxis" xlink:label="loc_cbay_CbayfinancingAgreementFundingInstallmentsAxis_1311693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_862962" xlink:to="loc_cbay_CbayfinancingAgreementFundingInstallmentsAxis_1311693" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CbayfinancingAgreementFundingInstallmentsDomain" xlink:label="loc_cbay_CbayfinancingAgreementFundingInstallmentsDomain_1311696" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cbay_CbayfinancingAgreementFundingInstallmentsAxis_1311693" xlink:to="loc_cbay_CbayfinancingAgreementFundingInstallmentsDomain_1311696" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CbayfinancingAgreementFundingInstallmentsDomain" xlink:label="loc_cbay_CbayfinancingAgreementFundingInstallmentsDomain_1311696_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cbay_CbayfinancingAgreementFundingInstallmentsAxis_1311693" xlink:to="loc_cbay_CbayfinancingAgreementFundingInstallmentsDomain_1311696_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementFundingInstallmentsTwoMember" xlink:label="loc_cbay_FinancingAgreementFundingInstallmentsTwoMember_1311701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_CbayfinancingAgreementFundingInstallmentsDomain_1311696" xlink:to="loc_cbay_FinancingAgreementFundingInstallmentsTwoMember_1311701" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1311705" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_862962" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1311705" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1311706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1311705" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1311706" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1311706_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1311705" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1311706_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1311708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1311706" xlink:to="loc_us-gaap_SubsequentEventMember_1311708" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1311751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_862962" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1311751" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1311752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1311751" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1311752" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1311752_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1311751" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1311752_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PrefundedWarrantsMember" xlink:label="loc_cbay_PrefundedWarrantsMember_1311753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1311752" xlink:to="loc_cbay_PrefundedWarrantsMember_1311753" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AgreementAxis" xlink:label="loc_cbay_AgreementAxis_1341913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_862962" xlink:to="loc_cbay_AgreementAxis_1341913" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AgreementDomain" xlink:label="loc_cbay_AgreementDomain_1341914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cbay_AgreementAxis_1341913" xlink:to="loc_cbay_AgreementDomain_1341914" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AgreementDomain" xlink:label="loc_cbay_AgreementDomain_1341914_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cbay_AgreementAxis_1341913" xlink:to="loc_cbay_AgreementDomain_1341914_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CollaborationAndLicenseAgreementMember" xlink:label="loc_cbay_CollaborationAndLicenseAgreementMember_1341915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_AgreementDomain_1341914" xlink:to="loc_cbay_CollaborationAndLicenseAgreementMember_1341915" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1341917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_862962" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1341917" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1341918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1341917" xlink:to="loc_us-gaap_RelatedPartyDomain_1341918" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1341918_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1341917" xlink:to="loc_us-gaap_RelatedPartyDomain_1341918_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_KakenPharmaceuticalCo.LtdMember" xlink:label="loc_cbay_KakenPharmaceuticalCo.LtdMember_1341919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1341918" xlink:to="loc_cbay_KakenPharmaceuticalCo.LtdMember_1341919" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_1311669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_1311669" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1311739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1311739" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1311740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1311740" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1311741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1311741" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_GrossProceedsFromPublicOffering" xlink:label="loc_cbay_GrossProceedsFromPublicOffering_1312197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_cbay_GrossProceedsFromPublicOffering_1312197" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_UpfrontCashPayment" xlink:label="loc_cbay_UpfrontCashPayment_1341912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_cbay_UpfrontCashPayment_1341912" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1341916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1341916" use="optional" order="42" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_270" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_270" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_282" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_270" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_261" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_261" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_268" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_268" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_269" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_269_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_268" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_269_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_261" xlink:to="loc_us-gaap_InvestmentTypeAxis_264" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_264" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_265" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_265_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_264" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_265_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_265" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_275" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_265" xlink:to="loc_us-gaap_CashEquivalentsMember_274" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_266" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_261" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_266" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_266" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_266" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_UsAgencySecuritiesMember" xlink:label="loc_cbay_UsAgencySecuritiesMember_862947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" xlink:to="loc_cbay_UsAgencySecuritiesMember_862947" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_SupranationalDebtSecuritiesMember" xlink:label="loc_cbay_SupranationalDebtSecuritiesMember_873482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" xlink:to="loc_cbay_SupranationalDebtSecuritiesMember_873482" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_280" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_279" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_278" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" xlink:to="loc_us-gaap_CommercialPaperMember_277" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" xlink:to="loc_us-gaap_MoneyMarketFundsMember_276" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_261" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_262" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_262" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_262" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_272" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_271" use="optional" order="25" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems_293" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_293" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_302" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ShortTermInvestmentContractualMaturity" xlink:label="loc_cbay_ShortTermInvestmentContractualMaturity_300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_293" xlink:to="loc_cbay_ShortTermInvestmentContractualMaturity_300" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_293" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_286" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_286" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_291" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_291" xlink:to="loc_us-gaap_TypeOfAdoptionMember_292" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_292_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_291" xlink:to="loc_us-gaap_TypeOfAdoptionMember_292_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_286" xlink:to="loc_srt_RangeAxis_287" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_287" xlink:to="loc_srt_RangeMember_288" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_288_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_287" xlink:to="loc_srt_RangeMember_288_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_288" xlink:to="loc_srt_MinimumMember_295" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_288" xlink:to="loc_srt_MaximumMember_294" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_1311779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_286" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_1311779" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_1311780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_1311779" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_1311780" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_1311780_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_1311779" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_1311780_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_286" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_289" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_289" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_290" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_290_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_289" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_290_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CashCashEquivalentsAndMarketableSecuritiesAxis" xlink:label="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesAxis_1310199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_286" xlink:to="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesAxis_1310199" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CashCashEquivalentsAndMarketableSecuritiesDomain" xlink:label="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesDomain_1310202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesAxis_1310199" xlink:to="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesDomain_1310202" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CashCashEquivalentsAndMarketableSecuritiesDomain" xlink:label="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesDomain_1310202_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesAxis_1310199" xlink:to="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesDomain_1310202_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1311649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_286" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1311649" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1311650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1311649" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1311650" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1311650_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1311649" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1311650_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PrefundedWarrantsMember" xlink:label="loc_cbay_PrefundedWarrantsMember_1311652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1311650" xlink:to="loc_cbay_PrefundedWarrantsMember_1311652" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CashEquivalentMaturityDescription" xlink:label="loc_cbay_CashEquivalentMaturityDescription_299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_293" xlink:to="loc_cbay_CashEquivalentMaturityDescription_299" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1311640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_293" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1311640" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1311641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_293" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1311641" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1311642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_293" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1311642" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_1341993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_293" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_1341993" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1341985" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1341985" xlink:to="loc_us-gaap_EarningsPerShareDiluted_333" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1341985" xlink:to="loc_us-gaap_NetIncomeLossAbstract_323" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_862918" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_323" xlink:to="loc_us-gaap_NetIncomeLoss_862918" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1341985" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_324" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_324" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_329" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted" xlink:label="loc_cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted_1341976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_324" xlink:to="loc_cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted_1341976" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding" xlink:label="loc_cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding_1341977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_324" xlink:to="loc_cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding_1341977" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1341978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_324" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1341978" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1341985" xlink:to="loc_us-gaap_EarningsPerShareBasic_332" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1341979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1341985" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1341979" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1341981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1341979" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1341981" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1341982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1341981" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1341982" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1341982_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1341981" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1341982_default" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_339" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_339" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_336" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_336" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_337" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_338" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_337" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_338" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_338_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_337" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_338_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncentiveStockAwardsMember" xlink:label="loc_cbay_IncentiveStockAwardsMember_342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_338" xlink:to="loc_cbay_IncentiveStockAwardsMember_342" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_EmployeeOrNonEmployeeStockOptionsMember" xlink:label="loc_cbay_EmployeeOrNonEmployeeStockOptionsMember_341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_338" xlink:to="loc_cbay_EmployeeOrNonEmployeeStockOptionsMember_341" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_339" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_343" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_367" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_367" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_360" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_360" xlink:to="loc_srt_RangeAxis_365" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_365" xlink:to="loc_srt_RangeMember_366" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_366_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_365" xlink:to="loc_srt_RangeMember_366_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_363" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_360" xlink:to="loc_us-gaap_InvestmentTypeAxis_363" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_363" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_364" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_364_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_363" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_364_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_360" xlink:to="loc_us-gaap_FinancialInstrumentAxis_361" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_362" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_361" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_362" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_362_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_361" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_362_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_362" xlink:to="loc_us-gaap_DebtSecuritiesMember_371" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments" xlink:label="loc_cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments_377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_367" xlink:to="loc_cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments_377" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_367" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_376" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_349" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_349" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_354" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_349" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_356" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_349" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_355" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_349" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_346" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_636551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_346" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_636551" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_636552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_636551" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_636552" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_636552_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_636551" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_636552_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_636553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_636552" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_636553" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CurrentMarketableSecuritiesMember" xlink:label="loc_cbay_CurrentMarketableSecuritiesMember_636555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_636552" xlink:to="loc_cbay_CurrentMarketableSecuritiesMember_636555" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_MaketableSecuritiesMember" xlink:label="loc_cbay_MaketableSecuritiesMember_637025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_636552" xlink:to="loc_cbay_MaketableSecuritiesMember_637025" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NoncurrentMarketableSecuritiesMember" xlink:label="loc_cbay_NoncurrentMarketableSecuritiesMember_1310173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_636552" xlink:to="loc_cbay_NoncurrentMarketableSecuritiesMember_1310173" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_346" xlink:to="loc_us-gaap_FinancialInstrumentAxis_347" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_347" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_347" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_636557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" xlink:to="loc_us-gaap_MoneyMarketFundsMember_636557" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_352" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_353" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_350" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_350" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_351" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_UsAgencySecuritiesMember" xlink:label="loc_cbay_UsAgencySecuritiesMember_873410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" xlink:to="loc_cbay_UsAgencySecuritiesMember_873410" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_SupranationalDebtSecuritiesMember" xlink:label="loc_cbay_SupranationalDebtSecuritiesMember_873403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" xlink:to="loc_cbay_SupranationalDebtSecuritiesMember_873403" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_349" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_357" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/MarketableSecuritiesScheduleOfFairValueOfTheCompanyMarketableSecuritiesByContractualMaturityDetail">
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:label="loc_cbay_ContractualObligationFiscalYearMaturityScheduleLineItems_1311885" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1310210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_ContractualObligationFiscalYearMaturityScheduleLineItems_1311885" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1310210" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_1310208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_ContractualObligationFiscalYearMaturityScheduleLineItems_1311885" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_1310208" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_1310207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_ContractualObligationFiscalYearMaturityScheduleLineItems_1311885" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_1310207" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ContractualObligationFiscalYearMaturityScheduleTable" xlink:label="loc_cbay_ContractualObligationFiscalYearMaturityScheduleTable_1310206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cbay_ContractualObligationFiscalYearMaturityScheduleLineItems_1311885" xlink:to="loc_cbay_ContractualObligationFiscalYearMaturityScheduleTable_1310206" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_383" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_380" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_383" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_380" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_380" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_381" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_381" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_382" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_382_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_381" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_382_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_382" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_384" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_OfficeAndComputerEquipmentMember" xlink:label="loc_cbay_OfficeAndComputerEquipmentMember_385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_382" xlink:to="loc_cbay_OfficeAndComputerEquipmentMember_385" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_382" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_386" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_382" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_387" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_383" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_390" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_383" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_389" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_383" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_388" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_622841" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622841" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_393" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets" xlink:label="loc_cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets_396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622841" xlink:to="loc_cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets_396" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AccruedProfessionalFeesAndOtherCurrent" xlink:label="loc_cbay_AccruedProfessionalFeesAndOtherCurrent_394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622841" xlink:to="loc_cbay_AccruedProfessionalFeesAndOtherCurrent_394" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_622834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_622841" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_622834" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_622838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_622841" xlink:to="loc_us-gaap_StatementTable_622838" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_622844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_622838" xlink:to="loc_us-gaap_FinancialInstrumentAxis_622844" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_622847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_622844" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_622847" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_622847_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_622844" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_622847_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_622839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_622838" xlink:to="loc_us-gaap_StatementClassOfStockAxis_622839" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_622840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_622839" xlink:to="loc_us-gaap_ClassOfStockDomain_622840" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_622840_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_622839" xlink:to="loc_us-gaap_ClassOfStockDomain_622840_default" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_410" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_RoyaltyPercentageBasedOnNetSales" xlink:label="loc_cbay_RoyaltyPercentageBasedOnNetSales_429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_410" xlink:to="loc_cbay_RoyaltyPercentageBasedOnNetSales_429" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_410" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_431" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_410" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_399" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_399" xlink:to="loc_srt_RangeAxis_404" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_404" xlink:to="loc_srt_RangeMember_405" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_405_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_404" xlink:to="loc_srt_RangeMember_405_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_415" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_405" xlink:to="loc_srt_MaximumMember_415" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_399" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_408" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_408" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_409" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_409_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_408" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_409_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_399" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_402" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_403" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_402" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_403" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_403_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_402" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_403_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_400" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_399" xlink:to="loc_srt_CounterpartyNameAxis_400" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_400" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_401" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_401_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_400" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_401_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_JanssenPharmaceuticalNVMember" xlink:label="loc_cbay_JanssenPharmaceuticalNVMember_421" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_401" xlink:to="loc_cbay_JanssenPharmaceuticalNVMember_421" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_399" xlink:to="loc_srt_ProductOrServiceAxis_406" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_406" xlink:to="loc_srt_ProductsAndServicesDomain_407" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_407_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_406" xlink:to="loc_srt_ProductsAndServicesDomain_407_default" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1310262" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1310267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1310267" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AnniversaryPaymentsDueYearFive" xlink:label="loc_cbay_AnniversaryPaymentsDueYearFive_1310279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_AnniversaryPaymentsDueYearFive_1310279" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AnniversaryPaymentsDueYearSix" xlink:label="loc_cbay_AnniversaryPaymentsDueYearSix_1310281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_AnniversaryPaymentsDueYearSix_1310281" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AnniversaryPaymentsDueYearTwo" xlink:label="loc_cbay_AnniversaryPaymentsDueYearTwo_1310274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_AnniversaryPaymentsDueYearTwo_1310274" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AnniversaryPaymentsDueYearThree" xlink:label="loc_cbay_AnniversaryPaymentsDueYearThree_1310275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_AnniversaryPaymentsDueYearThree_1310275" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_Anniversarypaymentsdueyearfour" xlink:label="loc_cbay_Anniversarypaymentsdueyearfour_1310277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_Anniversarypaymentsdueyearfour_1310277" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AggregateReturnPercentageFromTheFundsProvided" xlink:label="loc_cbay_AggregateReturnPercentageFromTheFundsProvided_1310305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_AggregateReturnPercentageFromTheFundsProvided_1310305" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1310226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_us-gaap_DebtInstrumentTable_1310226" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementTerminationEventConditionAxis" xlink:label="loc_cbay_FinancingAgreementTerminationEventConditionAxis_1310231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1310226" xlink:to="loc_cbay_FinancingAgreementTerminationEventConditionAxis_1310231" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementTerminationEventConditionDomain" xlink:label="loc_cbay_FinancingAgreementTerminationEventConditionDomain_1310233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cbay_FinancingAgreementTerminationEventConditionAxis_1310231" xlink:to="loc_cbay_FinancingAgreementTerminationEventConditionDomain_1310233" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementTerminationEventConditionDomain" xlink:label="loc_cbay_FinancingAgreementTerminationEventConditionDomain_1310233_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cbay_FinancingAgreementTerminationEventConditionAxis_1310231" xlink:to="loc_cbay_FinancingAgreementTerminationEventConditionDomain_1310233_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementTerminationEventConditionOneMember" xlink:label="loc_cbay_FinancingAgreementTerminationEventConditionOneMember_1310236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_FinancingAgreementTerminationEventConditionDomain_1310233" xlink:to="loc_cbay_FinancingAgreementTerminationEventConditionOneMember_1310236" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementTerminationEventConditionTwoMember" xlink:label="loc_cbay_FinancingAgreementTerminationEventConditionTwoMember_1310240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_FinancingAgreementTerminationEventConditionDomain_1310233" xlink:to="loc_cbay_FinancingAgreementTerminationEventConditionTwoMember_1310240" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementTerminationEventConditionThreeMember" xlink:label="loc_cbay_FinancingAgreementTerminationEventConditionThreeMember_1310242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_FinancingAgreementTerminationEventConditionDomain_1310233" xlink:to="loc_cbay_FinancingAgreementTerminationEventConditionThreeMember_1310242" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_1310253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1310226" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_1310253" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_1310255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_1310253" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_1310255" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_1310255_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_1310253" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_1310255_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AbwCyclopsSpvLpMember" xlink:label="loc_cbay_AbwCyclopsSpvLpMember_1310250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1310249" xlink:to="loc_cbay_AbwCyclopsSpvLpMember_1310250" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AbwCyclopsSpvLpMember" xlink:label="loc_cbay_AbwCyclopsSpvLpMember_1310256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_1310255" xlink:to="loc_cbay_AbwCyclopsSpvLpMember_1310256" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_SuccessPaymentTypeAxis" xlink:label="loc_cbay_SuccessPaymentTypeAxis_1310257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1310226" xlink:to="loc_cbay_SuccessPaymentTypeAxis_1310257" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_SuccessPaymentTypeDomain" xlink:label="loc_cbay_SuccessPaymentTypeDomain_1310258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cbay_SuccessPaymentTypeAxis_1310257" xlink:to="loc_cbay_SuccessPaymentTypeDomain_1310258" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_SuccessPaymentTypeDomain" xlink:label="loc_cbay_SuccessPaymentTypeDomain_1310258_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cbay_SuccessPaymentTypeAxis_1310257" xlink:to="loc_cbay_SuccessPaymentTypeDomain_1310258_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_VariableSuccessPaymentsMember" xlink:label="loc_cbay_VariableSuccessPaymentsMember_1310260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_SuccessPaymentTypeDomain_1310258" xlink:to="loc_cbay_VariableSuccessPaymentsMember_1310260" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FixedSuccessPaymentsMember" xlink:label="loc_cbay_FixedSuccessPaymentsMember_1310259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_SuccessPaymentTypeDomain_1310258" xlink:to="loc_cbay_FixedSuccessPaymentsMember_1310259" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_1310248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1310226" xlink:to="loc_srt_CounterpartyNameAxis_1310248" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1310249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1310248" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1310249" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1310249_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1310248" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1310249_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NumberOfInstallmentFundingAxis" xlink:label="loc_cbay_NumberOfInstallmentFundingAxis_1310318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1310226" xlink:to="loc_cbay_NumberOfInstallmentFundingAxis_1310318" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NumberOfInstallmentFundingDomain" xlink:label="loc_cbay_NumberOfInstallmentFundingDomain_1310319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cbay_NumberOfInstallmentFundingAxis_1310318" xlink:to="loc_cbay_NumberOfInstallmentFundingDomain_1310319" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NumberOfInstallmentFundingDomain" xlink:label="loc_cbay_NumberOfInstallmentFundingDomain_1310319_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cbay_NumberOfInstallmentFundingAxis_1310318" xlink:to="loc_cbay_NumberOfInstallmentFundingDomain_1310319_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_InstallmentFundingNumberOneMember" xlink:label="loc_cbay_InstallmentFundingNumberOneMember_1310322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_NumberOfInstallmentFundingDomain_1310319" xlink:to="loc_cbay_InstallmentFundingNumberOneMember_1310322" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_InstallmentFundingNumberTwoMember" xlink:label="loc_cbay_InstallmentFundingNumberTwoMember_1310327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_NumberOfInstallmentFundingDomain_1310319" xlink:to="loc_cbay_InstallmentFundingNumberTwoMember_1310327" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_InstallmentFundingNumberThreeMember" xlink:label="loc_cbay_InstallmentFundingNumberThreeMember_1310329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_NumberOfInstallmentFundingDomain_1310319" xlink:to="loc_cbay_InstallmentFundingNumberThreeMember_1310329" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1310334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1310226" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1310334" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1310335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1310334" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1310335" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1310335_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1310334" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1310335_default" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_1310270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_1310270" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DescriptionOfPercentageFixedSuccessPayments" xlink:label="loc_cbay_DescriptionOfPercentageFixedSuccessPayments_1310271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_DescriptionOfPercentageFixedSuccessPayments_1310271" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_1310272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_1310272" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AnniversaryPaymentsDueYearOne" xlink:label="loc_cbay_AnniversaryPaymentsDueYearOne_1310273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_AnniversaryPaymentsDueYearOne_1310273" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement" xlink:label="loc_cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement_1310365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement_1310365" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability" xlink:label="loc_cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability_1310376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability_1310376" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement" xlink:label="loc_cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement_1310358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement_1310358" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided" xlink:label="loc_cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided_1310355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided_1310355" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DescriptionOfAggregateReturnFromTheFundsProvided" xlink:label="loc_cbay_DescriptionOfAggregateReturnFromTheFundsProvided_1310302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_DescriptionOfAggregateReturnFromTheFundsProvided_1310302" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PaymentsUponReachingProductSalesRunRate" xlink:label="loc_cbay_PaymentsUponReachingProductSalesRunRate_1310298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_PaymentsUponReachingProductSalesRunRate_1310298" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo" xlink:label="loc_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo_1310295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo_1310295" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne" xlink:label="loc_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne_1310289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne_1310289" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DescriptionOfPercentageVariableSuccessPayments" xlink:label="loc_cbay_DescriptionOfPercentageVariableSuccessPayments_1310284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_DescriptionOfPercentageVariableSuccessPayments_1310284" use="optional" order="49" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AreaOfOfficeSpace" xlink:label="loc_cbay_AreaOfOfficeSpace_623126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_cbay_AreaOfOfficeSpace_623126" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_623113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_623113" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_623114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_623114" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_623115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_623115" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_623116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_OperatingLeaseLiability_623116" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_623117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_623117" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_623124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_OperatingLeaseCost_623124" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NumberOfLeasedFacilitiesOperatingLeases" xlink:label="loc_cbay_NumberOfLeasedFacilitiesOperatingLeases_623125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_cbay_NumberOfLeasedFacilitiesOperatingLeases_623125" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_LeaseStartDate" xlink:label="loc_cbay_LeaseStartDate_623127" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_cbay_LeaseStartDate_623127" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_623111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_623111" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_623090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_StatementTable_623090" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_623098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_623090" xlink:to="loc_us-gaap_LeaseContractualTermAxis_623098" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_623099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_623098" xlink:to="loc_us-gaap_LeaseContractualTermDomain_623099" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_623099_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_623098" xlink:to="loc_us-gaap_LeaseContractualTermDomain_623099_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_LeaseFacilityMember" xlink:label="loc_cbay_LeaseFacilityMember_623100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_623099" xlink:to="loc_cbay_LeaseFacilityMember_623100" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_623094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_623090" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_623094" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_623095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_623094" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_623095" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_623095_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_623094" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_623095_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_623096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_623095" xlink:to="loc_us-gaap_OperatingExpenseMember_623096" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1312172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1312172" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_492" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_492" xlink:to="loc_us-gaap_LossContingenciesTable_489" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_489" xlink:to="loc_us-gaap_LeaseContractualTermAxis_490" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_490" xlink:to="loc_us-gaap_LeaseContractualTermDomain_491" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_491_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_490" xlink:to="loc_us-gaap_LeaseContractualTermDomain_491_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_1310169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_489" xlink:to="loc_us-gaap_LitigationStatusAxis_1310169" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_1310171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_1310169" xlink:to="loc_us-gaap_LitigationStatusDomain_1310171" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_1310171_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_1310169" xlink:to="loc_us-gaap_LitigationStatusDomain_1310171_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_1310172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_1310171" xlink:to="loc_us-gaap_PendingLitigationMember_1310172" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_862874" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_489" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_862874" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_862875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_862874" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_862875" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_862875_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_862874" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_862875_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyLawsuitFilingDate" xlink:label="loc_us-gaap_LossContingencyLawsuitFilingDate_862877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_492" xlink:to="loc_us-gaap_LossContingencyLawsuitFilingDate_862877" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:label="loc_us-gaap_LossContingencyNameOfPlaintiff_862879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_492" xlink:to="loc_us-gaap_LossContingencyNameOfPlaintiff_862879" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IndemnificationLiability" xlink:label="loc_cbay_IndemnificationLiability_501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_492" xlink:to="loc_cbay_IndemnificationLiability_501" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAllegations" xlink:label="loc_us-gaap_LossContingencyAllegations_862880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_492" xlink:to="loc_us-gaap_LossContingencyAllegations_862880" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyActionsTakenByDefendant" xlink:label="loc_us-gaap_LossContingencyActionsTakenByDefendant_862881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_492" xlink:to="loc_us-gaap_LossContingencyActionsTakenByDefendant_862881" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyActionsTakenByCourtArbitratorOrMediator" xlink:label="loc_us-gaap_LossContingencyActionsTakenByCourtArbitratorOrMediator_1310167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_492" xlink:to="loc_us-gaap_LossContingencyActionsTakenByCourtArbitratorOrMediator_1310167" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_519" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_519" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_524" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_519" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_531" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1311859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_519" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1311859" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1311860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_519" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1311860" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_519" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_525" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1312019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_519" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1312019" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_514" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_519" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_514" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_517" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_514" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_517" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_518" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_517" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_518" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_518_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_517" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_518_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PrefundedWarrantsMember" xlink:label="loc_cbay_PrefundedWarrantsMember_1311884" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_518" xlink:to="loc_cbay_PrefundedWarrantsMember_1311884" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1311908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_514" xlink:to="loc_srt_RangeAxis_1311908" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1311909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1311908" xlink:to="loc_srt_RangeMember_1311909" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1311909_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1311908" xlink:to="loc_srt_RangeMember_1311909_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_859726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_514" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_859726" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_859727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_859726" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_859727" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_859727_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_859726" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_859727_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_515" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_514" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_515" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_516" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_515" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_516" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_516_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_515" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_516_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_516" xlink:to="loc_us-gaap_SubsequentEventMember_520" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1311812" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1311813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1311812" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1311813" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1311793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1311812" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1311793" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1311794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1311793" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1311794" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1311795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1311794" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1311795" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1311795_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1311794" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1311795_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PrefundedWarrantsMember" xlink:label="loc_cbay_PrefundedWarrantsMember_1311796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1311795" xlink:to="loc_cbay_PrefundedWarrantsMember_1311796" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1311799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1311793" xlink:to="loc_us-gaap_AwardTypeAxis_1311799" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1311800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1311799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1311800" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1311800_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1311799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1311800_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_OptionsAndIncentiveAwardsMember" xlink:label="loc_cbay_OptionsAndIncentiveAwardsMember_1311802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1311800" xlink:to="loc_cbay_OptionsAndIncentiveAwardsMember_1311802" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1311803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1311793" xlink:to="loc_us-gaap_PlanNameAxis_1311803" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1311804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1311803" xlink:to="loc_us-gaap_PlanNameDomain_1311804" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1311804_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1311803" xlink:to="loc_us-gaap_PlanNameDomain_1311804_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember" xlink:label="loc_cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember_1311815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1311804" xlink:to="loc_cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember_1311815" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember" xlink:label="loc_cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember_1311809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1311804" xlink:to="loc_cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember_1311809" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_586" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_586" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_585" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_587" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_587" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_591" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" xlink:to="loc_us-gaap_PlanNameAxis_556" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_556" xlink:to="loc_us-gaap_PlanNameDomain_557" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_557_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_556" xlink:to="loc_us-gaap_PlanNameDomain_557_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_EquityIncentivePlanTwoThousandAndThirteenMember" xlink:label="loc_cbay_EquityIncentivePlanTwoThousandAndThirteenMember_567" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_557" xlink:to="loc_cbay_EquityIncentivePlanTwoThousandAndThirteenMember_567" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember" xlink:label="loc_cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember_862867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_557" xlink:to="loc_cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember_862867" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncentiveStockAwardsMember" xlink:label="loc_cbay_IncentiveStockAwardsMember_575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_557" xlink:to="loc_cbay_IncentiveStockAwardsMember_575" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" xlink:to="loc_us-gaap_AwardTypeAxis_558" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_558" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_559" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_559_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_558" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_559_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_570" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_559" xlink:to="loc_us-gaap_RestrictedStockMember_570" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NonQualifiedStockOptionsMember" xlink:label="loc_cbay_NonQualifiedStockOptionsMember_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_559" xlink:to="loc_cbay_NonQualifiedStockOptionsMember_569" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember" xlink:label="loc_cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_559" xlink:to="loc_cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember_568" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_StockOptionsToTenPercentShareholdersMember" xlink:label="loc_cbay_StockOptionsToTenPercentShareholdersMember_571" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_559" xlink:to="loc_cbay_StockOptionsToTenPercentShareholdersMember_571" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_560" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_560" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_561" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_561_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_560" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_561_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_863429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" xlink:to="loc_srt_RangeAxis_863429" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_863430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_863429" xlink:to="loc_srt_RangeMember_863430" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_863430_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_863429" xlink:to="loc_srt_RangeMember_863430_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" xlink:to="loc_us-gaap_VestingAxis_564" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_564" xlink:to="loc_us-gaap_VestingDomain_565" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_565_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_564" xlink:to="loc_us-gaap_VestingDomain_565_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" xlink:to="loc_srt_TitleOfIndividualAxis_562" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_625331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_562" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_625331" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_625331_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_562" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_625331_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_582" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_580" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_579" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_590" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_584" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_584" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" xlink:label="loc_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage_581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage_581" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_578" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_595" use="optional" order="38" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_631" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_631" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_634" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_631" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_628" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_628" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_629" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_630" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_629" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_630" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_630_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_629" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_630_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_630" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_633" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_632" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_630" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_632" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_640" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_640" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_645" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_640" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_644" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_640" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_643" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_640" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637" xlink:to="loc_us-gaap_AwardTypeAxis_638" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_638" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_638" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_640" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_647" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_640" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_646" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncomeTaxLineItems" xlink:label="loc_cbay_IncomeTaxLineItems_660" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaap_IncomeTaxExaminationDescription_677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_IncomeTaxExaminationDescription_677" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_676" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_674" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_OperatingLossCarryforwards_673" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_670" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncomeTaxTable" xlink:label="loc_cbay_IncomeTaxTable_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_cbay_IncomeTaxTable_653" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cbay_IncomeTaxTable_653" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_654" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_654" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_655" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_655_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_654" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_655_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_655" xlink:to="loc_us-gaap_DomesticCountryMember_661" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_655" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_662" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FederalAndStateTaxAuthorityMember" xlink:label="loc_cbay_FederalAndStateTaxAuthorityMember_1341998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_655" xlink:to="loc_cbay_FederalAndStateTaxAuthorityMember_1341998" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cbay_IncomeTaxTable_653" xlink:to="loc_srt_RangeAxis_656" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_656" xlink:to="loc_srt_RangeMember_657" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_657_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_656" xlink:to="loc_srt_RangeMember_657_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_657" xlink:to="loc_srt_MaximumMember_664" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_657" xlink:to="loc_srt_MinimumMember_663" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_658" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cbay_IncomeTaxTable_653" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_658" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_658" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_659" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_659_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_658" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_659_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FederalMember" xlink:label="loc_cbay_FederalMember_636645" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_659" xlink:to="loc_cbay_FederalMember_636645" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_OrphanDrugMember" xlink:label="loc_cbay_OrphanDrugMember_665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_659" xlink:to="loc_cbay_OrphanDrugMember_665" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1341990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_Revenues_1341990" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ProvisionForStateAndLocalIncomeTaxes" xlink:label="loc_cbay_ProvisionForStateAndLocalIncomeTaxes_666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_cbay_ProvisionForStateAndLocalIncomeTaxes_666" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NetOperatingLossCarryforwardExpirationYear" xlink:label="loc_cbay_NetOperatingLossCarryforwardExpirationYear_675" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_cbay_NetOperatingLossCarryforwardExpirationYear_675" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_636653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_636653" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AlternateMinimumTaxRate" xlink:label="loc_cbay_AlternateMinimumTaxRate_1341989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_cbay_AlternateMinimumTaxRate_1341989" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_WriteOffOfTaxAttributeDueToLimitation" xlink:label="loc_cbay_WriteOffOfTaxAttributeDueToLimitation_1341995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_cbay_WriteOffOfTaxAttributeDueToLimitation_1341995" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible" xlink:label="loc_cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible_1341996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible_1341996" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage" xlink:label="loc_cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage_1341997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage_1341997" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear_1329185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_OpenTaxYear_1329185" use="optional" order="31" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1341928" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1341951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1341928" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1341951" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1341954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1341928" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1341954" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1341955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1341928" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1341955" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1341927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1341928" xlink:to="loc_us-gaap_SubsequentEventTable_1341927" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AgreementAxis" xlink:label="loc_cbay_AgreementAxis_1341943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_cbay_AgreementAxis_1341943" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AgreementDomain" xlink:label="loc_cbay_AgreementDomain_1341944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cbay_AgreementAxis_1341943" xlink:to="loc_cbay_AgreementDomain_1341944" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AgreementDomain" xlink:label="loc_cbay_AgreementDomain_1341944_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cbay_AgreementAxis_1341943" xlink:to="loc_cbay_AgreementDomain_1341944_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CollaborationAndLicenseAgreementMember" xlink:label="loc_cbay_CollaborationAndLicenseAgreementMember_1341945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cbay_AgreementDomain_1341944" xlink:to="loc_cbay_CollaborationAndLicenseAgreementMember_1341945" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1341946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1341946" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1341947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1341946" xlink:to="loc_us-gaap_EquityComponentDomain_1341947" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1341947_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1341946" xlink:to="loc_us-gaap_EquityComponentDomain_1341947_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1341933" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_srt_RangeAxis_1341933" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1341934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1341933" xlink:to="loc_srt_RangeMember_1341934" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1341934_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1341933" xlink:to="loc_srt_RangeMember_1341934_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1341940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1341940" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1341941" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1341940" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1341941" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1341941_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1341940" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1341941_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1341942" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1341941" xlink:to="loc_us-gaap_SubsequentEventMember_1341942" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1341957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1341957" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1341958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1341957" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1341958" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1341958_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1341957" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1341958_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1341961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1341961" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1341962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1341961" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1341962" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1341962_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1341961" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1341962_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1341972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1341972" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1341973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1341972" xlink:to="loc_us-gaap_RelatedPartyDomain_1341973" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1341973_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1341972" xlink:to="loc_us-gaap_RelatedPartyDomain_1341973_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1341930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1341930" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1341931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1341930" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1341931" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1341931_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1341930" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1341931_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PrefundedWarrantsMember" xlink:label="loc_cbay_PrefundedWarrantsMember_1341932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1341931" xlink:to="loc_cbay_PrefundedWarrantsMember_1341932" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1341975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1341928" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1341975" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PotentialMilestonePayments" xlink:label="loc_cbay_PotentialMilestonePayments_1341968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1341928" xlink:to="loc_cbay_PotentialMilestonePayments_1341968" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_UpfrontCashPayment" xlink:label="loc_cbay_UpfrontCashPayment_1341969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1341928" xlink:to="loc_cbay_UpfrontCashPayment_1341969" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1341999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1341928" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1341999" use="optional" order="35" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>cbay-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 23-March-2023 [11:30:25] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany" xml:lang="en-US">Entity Shell Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFileNumber" xml:lang="en-US">Entity File Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine2" xml:lang="en-US">Entity Address, Address Line Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent" xml:lang="en-US">Entity Interactive Data Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_Security12bTitle" xml:lang="en-US">Title of 12(b) Security</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_SecurityExchangeName" xml:lang="en-US">Security Exchange Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentAnnualReport" xml:lang="en-US">Document Annual Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentTransitionReport" xml:lang="en-US">Document Transition Report</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorName" xml:lang="en-US">Auditor Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorFirmId" xml:lang="en-US">Auditor Firm ID</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AuditorLocation" xml:lang="en-US">Auditor Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.0001 par value: 200,000,000 shares authorized; 84,681,063 and 84,677,939 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance at end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance at beginning of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AccruedResearchAndDevelopmentExpenses" xlink:label="loc_cbay_AccruedResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_AccruedResearchAndDevelopmentExpenses" xml:lang="en-US">Accrued Research And Development Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cbay_AccruedResearchAndDevelopmentExpenses" xml:lang="en-US">Accrued research and development expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_AccruedResearchAndDevelopmentExpenses" xlink:to="lab_cbay_AccruedResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_AccruedResearchAndDevelopmentExpenses" xml:lang="en-US">Accrued research and development expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DevelopmentFinancingLiabilityNonCurrent" xlink:label="loc_cbay_DevelopmentFinancingLiabilityNonCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_DevelopmentFinancingLiabilityNonCurrent" xml:lang="en-US">Development Financing Liability Non current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_DevelopmentFinancingLiabilityNonCurrent" xml:lang="en-US">Development financing liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_DevelopmentFinancingLiabilityNonCurrent" xlink:to="lab_cbay_DevelopmentFinancingLiabilityNonCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_DevelopmentFinancingLiabilityNonCurrent" xml:lang="en-US">Development financing liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term portion of operating lease liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term portion of lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xml:lang="en-US">Non-current marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Marketable securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Estimated Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Total fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Interest expense, net:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total interest expense, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other comprehensive loss:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average common shares outstanding used to calculate diluted net loss per common share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Total, Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average common shares outstanding used to calculate basic net loss per common share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Total, Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted net loss per common share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net loss per share&#8212;diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic net loss per common share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net loss per share&#8212;basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Total other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xml:lang="en-US">Unrealized loss on marketable securities, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xml:lang="en-US">Net unrealized loss on marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement Of Stockholders Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance at end of period (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance at beginning of period (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Issuance of common stock upon exercise of stock options (Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Issuance of common stock upon exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IssuanceOfCommonStockAndPrefundedWarrants" xlink:label="loc_cbay_IssuanceOfCommonStockAndPrefundedWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_IssuanceOfCommonStockAndPrefundedWarrants" xml:lang="en-US">Issuance Of Common Stock And Prefunded Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_IssuanceOfCommonStockAndPrefundedWarrants" xml:lang="en-US">Issuance of common stock and pre-funded warrants, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_IssuanceOfCommonStockAndPrefundedWarrants" xlink:to="lab_cbay_IssuanceOfCommonStockAndPrefundedWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_IssuanceOfCommonStockAndPrefundedWarrants" xml:lang="en-US">Issuance of common stock and pre-funded warrants</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares" xlink:label="loc_cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares" xml:lang="en-US">Issuance Of Common Stock And Prefunded Warrants Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares" xml:lang="en-US">Issuance of common stock and pre-funded warrants, net of issuance costs Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares" xlink:to="lab_cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares" xml:lang="en-US">Issuance of common stock and pre-funded warrants shares</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants" xlink:label="loc_cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants" xml:lang="en-US">Issuance Costs Related To Issuance Of Common Stock And Pre Funded Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants" xml:lang="en-US">Issuance costs related to issuance of common stock and pre-funded warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants" xlink:to="lab_cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants" xml:lang="en-US">Issuance costs related to issuance of common stock and pre funded warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Stock issuance cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xml:lang="en-US">Cash and cash equivalents at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Payments to Acquire Marketable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Purchases of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US">Proceeds from maturities of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash (used in) provided by investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from issuance of common stock pursuant to equity award plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants" xlink:label="loc_cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants" xml:lang="en-US">Proceeds from issuance of common stock and prefundeded warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants" xml:lang="en-US">Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants" xlink:to="lab_cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants" xml:lang="en-US">Proceeds from issuance of common stock and pre-fundeded warrants.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts" xlink:label="loc_cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts" xml:lang="en-US">Proceeds From Development Financing Net O fTransaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts" xml:lang="en-US">Proceeds from development financing, net of transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts" xlink:to="lab_cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts" xml:lang="en-US">ProceedsFromDevelopmentFinancingNetOfTransactionCosts.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Supplemental non-cash investing and financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xml:lang="en-US">Liabilities Assumed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xml:lang="en-US">Unpaid financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xml:lang="en-US">Net accretion and amortization of investments in marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="loc_cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xml:lang="en-US">Increase Decrease In Accrued Research And Development Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xml:lang="en-US">Accrued research and development expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:to="lab_cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xml:lang="en-US">Increase decrease in accrued research and development expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xml:lang="en-US">Other accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AccretionOfDevelopmentFinancingLiability" xlink:label="loc_cbay_AccretionOfDevelopmentFinancingLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_AccretionOfDevelopmentFinancingLiability" xml:lang="en-US">Accretion Of Development Financing Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_AccretionOfDevelopmentFinancingLiability" xml:lang="en-US">Accretion of development financing liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_AccretionOfDevelopmentFinancingLiability" xlink:to="lab_cbay_AccretionOfDevelopmentFinancingLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_AccretionOfDevelopmentFinancingLiability" xml:lang="en-US">Accretion of development financing liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xml:lang="en-US">Write off of Deferred Debt Issuance Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xml:lang="en-US">Write-off of deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash (used in) operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Cash flows from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization and Description of Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xml:lang="en-US">Marketable Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Certain Balance Sheet Items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">In-License Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DisclosureOfDevelopmentFinancingTextBlock" xlink:label="loc_cbay_DisclosureOfDevelopmentFinancingTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_DisclosureOfDevelopmentFinancingTextBlock" xml:lang="en-US">Disclosure Of Development Financing Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_DisclosureOfDevelopmentFinancingTextBlock" xml:lang="en-US">Development Financing Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_DisclosureOfDevelopmentFinancingTextBlock" xlink:to="lab_cbay_DisclosureOfDevelopmentFinancingTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_DisclosureOfDevelopmentFinancingTextBlock" xml:lang="en-US">Disclosure of development financing text block.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock Plans and Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PostemploymentBenefitsAbstract" xml:lang="en-US">Postemployment Benefits [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:to="lab_us-gaap_PostemploymentBenefitsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xml:lang="en-US">Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xml:lang="en-US">401(k) Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss Per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CashEquivalentsAndInvestmentsPolicyTextBlock" xlink:label="loc_cbay_CashEquivalentsAndInvestmentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_CashEquivalentsAndInvestmentsPolicyTextBlock" xml:lang="en-US">Cash Equivalents And Investments Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_CashEquivalentsAndInvestmentsPolicyTextBlock" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_CashEquivalentsAndInvestmentsPolicyTextBlock" xlink:to="lab_cbay_CashEquivalentsAndInvestmentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_CashEquivalentsAndInvestmentsPolicyTextBlock" xml:lang="en-US">Cash equivalents and investments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation and Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DevelopmentFinancingAgreementPolicyTextBlock" xlink:label="loc_cbay_DevelopmentFinancingAgreementPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_DevelopmentFinancingAgreementPolicyTextBlock" xml:lang="en-US">Development Financing Agreement Policy Text Block</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_DevelopmentFinancingAgreementPolicyTextBlock" xml:lang="en-US">Development Financing Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_DevelopmentFinancingAgreementPolicyTextBlock" xlink:to="lab_cbay_DevelopmentFinancingAgreementPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_DevelopmentFinancingAgreementPolicyTextBlock" xml:lang="en-US">Development Financing Agreement Policy Text Block.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PrefundedWarrantsPolicyTextBlock" xlink:label="loc_cbay_PrefundedWarrantsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_PrefundedWarrantsPolicyTextBlock" xml:lang="en-US">Prefunded Warrants [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_PrefundedWarrantsPolicyTextBlock" xml:lang="en-US">Pre-funded&#160;Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_PrefundedWarrantsPolicyTextBlock" xlink:to="lab_cbay_PrefundedWarrantsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_PrefundedWarrantsPolicyTextBlock" xml:lang="en-US">Prefunded warrants.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Computation of Basic and Diluted Net Loss per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Anti-Dilutive Securities Excluded from the Computation of Diluted Net Loss per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value Assets Measured on Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xml:lang="en-US">Marketable Securities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xml:lang="en-US">Marketable Available-for-Sale Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xml:lang="en-US">Schedule of fair value of the Company marketable securities by contractual maturity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ScheduleOfOtherAccruedLiabilitiesTableTextBlock" xlink:label="loc_cbay_ScheduleOfOtherAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_ScheduleOfOtherAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule Of Other Accrued Liabilities Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_ScheduleOfOtherAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Other Accrued Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_ScheduleOfOtherAccruedLiabilitiesTableTextBlock" xlink:to="lab_cbay_ScheduleOfOtherAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_ScheduleOfOtherAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of other accrued liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Schedule of Changes in Fair Value of Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Summary of Maturities of Operating Lease Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ReservedSharesOfCommonStockForIssuanceTableTextBlock" xlink:label="loc_cbay_ReservedSharesOfCommonStockForIssuanceTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_ReservedSharesOfCommonStockForIssuanceTableTextBlock" xml:lang="en-US">Reserved Shares Of Common Stock For Issuance Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_ReservedSharesOfCommonStockForIssuanceTableTextBlock" xml:lang="en-US">Summary of Reserved Shares of Common Stock for Future Issuances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_ReservedSharesOfCommonStockForIssuanceTableTextBlock" xlink:to="lab_cbay_ReservedSharesOfCommonStockForIssuanceTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_ReservedSharesOfCommonStockForIssuanceTableTextBlock" xml:lang="en-US">Reserved shares of common stock for issuance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of Stock Option Grants, Including Performance Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Summary of Stock-Based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Estimated Weighted-Average Grant Date Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Components of Deferred Tax Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xml:lang="en-US">Summary of Gross Unrecognized Tax Benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Summary of Reconciliation of Expected Statutory Federal Income Tax Provision to Actual Income Tax Provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule Of Stock By Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xml:lang="en-US">Lender Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xml:lang="en-US">Line Of Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xml:lang="en-US">Line of Credit Facility[Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AbwCyclopsSpvLpMember" xlink:label="loc_cbay_AbwCyclopsSpvLpMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_AbwCyclopsSpvLpMember" xml:lang="en-US">ABW Cyclops SPV LP [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_AbwCyclopsSpvLpMember" xml:lang="en-US">Abw Cyclops Spv Lp [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cbay_AbwCyclopsSpvLpMember" xml:lang="en-US">ABW Cyclops SPV LP [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_AbwCyclopsSpvLpMember" xlink:to="lab_cbay_AbwCyclopsSpvLpMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Cash and cash equivalents and marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NumberOfFundingInstallments" xlink:label="loc_cbay_NumberOfFundingInstallments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_NumberOfFundingInstallments" xml:lang="en-US">Number of funding installments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cbay_NumberOfFundingInstallments" xml:lang="en-US">Number of funding installments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_NumberOfFundingInstallments" xlink:to="lab_cbay_NumberOfFundingInstallments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_NumberOfFundingInstallments" xml:lang="en-US">Number of funding installments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of Operating Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of operating segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from Lines of Credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Number of new stock issued during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Number of common stock into which the class of warrant or right may be converted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_GrossProceedsFromPublicOffering" xlink:label="loc_cbay_GrossProceedsFromPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_GrossProceedsFromPublicOffering" xml:lang="en-US">Gross Proceeds From Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_GrossProceedsFromPublicOffering" xml:lang="en-US">Total gross offering proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_GrossProceedsFromPublicOffering" xlink:to="lab_cbay_GrossProceedsFromPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_GrossProceedsFromPublicOffering" xml:lang="en-US">Gross proceeds from public offering.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_UpfrontCashPayment" xlink:label="loc_cbay_UpfrontCashPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_UpfrontCashPayment" xml:lang="en-US">Upfront Cash Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cbay_UpfrontCashPayment" xml:lang="en-US">Upfront cash payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_UpfrontCashPayment" xml:lang="en-US">Upfront cash payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_UpfrontCashPayment" xlink:to="lab_cbay_UpfrontCashPayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_UpfrontCashPayment" xml:lang="en-US">upfront cash payment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of public equity offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CbayfinancingAgreementFundingInstallmentsAxis" xlink:label="loc_cbay_CbayfinancingAgreementFundingInstallmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_CbayfinancingAgreementFundingInstallmentsAxis" xml:lang="en-US">CBAYFinancing agreement funding installments [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_CbayfinancingAgreementFundingInstallmentsAxis" xlink:to="lab_cbay_CbayfinancingAgreementFundingInstallmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_CbayfinancingAgreementFundingInstallmentsAxis" xml:lang="en-US">CBAYFinancing Agreement Funding Installments.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CbayfinancingAgreementFundingInstallmentsDomain" xlink:label="loc_cbay_CbayfinancingAgreementFundingInstallmentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_CbayfinancingAgreementFundingInstallmentsDomain" xml:lang="en-US">CBAYFinancing agreement funding installments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_CbayfinancingAgreementFundingInstallmentsDomain" xlink:to="lab_cbay_CbayfinancingAgreementFundingInstallmentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_CbayfinancingAgreementFundingInstallmentsDomain" xml:lang="en-US">CBAYFinancing Agreement Funding Installments.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementFundingInstallmentsTwoMember" xlink:label="loc_cbay_FinancingAgreementFundingInstallmentsTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_FinancingAgreementFundingInstallmentsTwoMember" xml:lang="en-US">Financing agreement funding installments two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_FinancingAgreementFundingInstallmentsTwoMember" xml:lang="en-US">Financing agreement funding installments two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_FinancingAgreementFundingInstallmentsTwoMember" xlink:to="lab_cbay_FinancingAgreementFundingInstallmentsTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_FinancingAgreementFundingInstallmentsTwoMember" xml:lang="en-US">CBAYFinancing Agreement Funding Installments Two.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PrefundedWarrantsMember" xlink:label="loc_cbay_PrefundedWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_PrefundedWarrantsMember" xml:lang="en-US">Prefunded warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_PrefundedWarrantsMember" xml:lang="en-US">Prefunded warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_PrefundedWarrantsMember" xlink:to="lab_cbay_PrefundedWarrantsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_PrefundedWarrantsMember" xml:lang="en-US">Prefunded Warrants.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AgreementAxis" xlink:label="loc_cbay_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_AgreementAxis" xlink:to="lab_cbay_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_AgreementAxis" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AgreementDomain" xlink:label="loc_cbay_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_AgreementDomain" xlink:to="lab_cbay_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_AgreementDomain" xml:lang="en-US">Agreement.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CollaborationAndLicenseAgreementMember" xlink:label="loc_cbay_CollaborationAndLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_CollaborationAndLicenseAgreementMember" xml:lang="en-US">Collaboration and License Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_CollaborationAndLicenseAgreementMember" xlink:to="lab_cbay_CollaborationAndLicenseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_CollaborationAndLicenseAgreementMember" xml:lang="en-US">Collaboration and license agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_KakenPharmaceuticalCo.LtdMember" xlink:label="loc_cbay_KakenPharmaceuticalCo.LtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_KakenPharmaceuticalCo.LtdMember" xml:lang="en-US">Kaken Pharmaceutical Co., Ltd [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_KakenPharmaceuticalCo.LtdMember" xlink:to="lab_cbay_KakenPharmaceuticalCo.LtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_KakenPharmaceuticalCo.LtdMember" xml:lang="en-US">Kaken Pharmaceutical Co., Ltd .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Total assets measured at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US">Liability Class</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US">Fair Value by Liability Class</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xml:lang="en-US">Short-term Investments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xml:lang="en-US">Short-term Investments [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashEquivalentsMember" xml:lang="en-US">Cash Equivalents [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashEquivalentsMember" xml:lang="en-US">Cash Equivalents [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_UsAgencySecuritiesMember" xlink:label="loc_cbay_UsAgencySecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_UsAgencySecuritiesMember" xml:lang="en-US">U.S. agency securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_UsAgencySecuritiesMember" xml:lang="en-US">US Agency Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_UsAgencySecuritiesMember" xlink:to="lab_cbay_UsAgencySecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_UsAgencySecuritiesMember" xml:lang="en-US">US Agency Securities [Member].</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_SupranationalDebtSecuritiesMember" xlink:label="loc_cbay_SupranationalDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_SupranationalDebtSecuritiesMember" xml:lang="en-US">Supranational Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_SupranationalDebtSecuritiesMember" xml:lang="en-US">Supranational Debt Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_SupranationalDebtSecuritiesMember" xlink:to="lab_cbay_SupranationalDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_SupranationalDebtSecuritiesMember" xml:lang="en-US">Supranational Debt Securities [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xml:lang="en-US">US Treasury Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xml:lang="en-US">U.S. Treasury Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xml:lang="en-US">Asset-backed Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xml:lang="en-US">Asset-backed Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xml:lang="en-US">Corporate Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xml:lang="en-US">U.S. and Foreign Corporate Debt Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial Paper [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommercialPaperMember" xml:lang="en-US">U.S. and Foreign Commercial Paper [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xml:lang="en-US">Schedule of Product Information [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xml:lang="en-US">Schedule Of Product Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable" xlink:to="lab_us-gaap_ScheduleOfProductInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Adjustments for New Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Type of Adoption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProductInformationLineItems" xml:lang="en-US">Product Information [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProductInformationLineItems" xml:lang="en-US">Product Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductInformationLineItems" xlink:to="lab_us-gaap_ProductInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property and equipment, estimated useful lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ShortTermInvestmentContractualMaturity" xlink:label="loc_cbay_ShortTermInvestmentContractualMaturity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_ShortTermInvestmentContractualMaturity" xml:lang="en-US">Short Term Investment Contractual Maturity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_ShortTermInvestmentContractualMaturity" xml:lang="en-US">Short-term contractual maturities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_ShortTermInvestmentContractualMaturity" xlink:to="lab_cbay_ShortTermInvestmentContractualMaturity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_ShortTermInvestmentContractualMaturity" xml:lang="en-US">Short-term investment contractual maturity.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CashEquivalentMaturityDescription" xlink:label="loc_cbay_CashEquivalentMaturityDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_CashEquivalentMaturityDescription" xml:lang="en-US">Cash Equivalent Maturity Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_CashEquivalentMaturityDescription" xml:lang="en-US">Cash and cash equivalents, maturity description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_CashEquivalentMaturityDescription" xlink:to="lab_cbay_CashEquivalentMaturityDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_CashEquivalentMaturityDescription" xml:lang="en-US">Cash equivalent maturity description.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xml:lang="en-US">Fair value of development financing liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CashCashEquivalentsAndMarketableSecuritiesAxis" xlink:label="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_CashCashEquivalentsAndMarketableSecuritiesAxis" xml:lang="en-US">Cash Cash Equivalents And Marketable Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesAxis" xlink:to="lab_cbay_CashCashEquivalentsAndMarketableSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_CashCashEquivalentsAndMarketableSecuritiesAxis" xml:lang="en-US">Cash cash equivalents and marketable securities.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CashCashEquivalentsAndMarketableSecuritiesDomain" xlink:label="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_CashCashEquivalentsAndMarketableSecuritiesDomain" xml:lang="en-US">Cash Cash Equivalents And Marketable Securities [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesDomain" xlink:to="lab_cbay_CashCashEquivalentsAndMarketableSecuritiesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_CashCashEquivalentsAndMarketableSecuritiesDomain" xml:lang="en-US">Cash cash equivalents and marketable securities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xml:lang="en-US">Numerator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xml:lang="en-US">Denominator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted" xlink:label="loc_cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number Of Common Stock Share Outstanding Basic And Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted" xml:lang="en-US">Common&#160;stock shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted" xlink:to="lab_cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of common stock share outstanding basic and diluted.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding" xlink:label="loc_cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding" xml:lang="en-US">Weighted Average Number Of Pre Funded Warrants Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding" xml:lang="en-US">Pre-funded&#160;warrants outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding" xlink:to="lab_cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding" xml:lang="en-US">Weighted average number of pre funded warrants outstanding.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncentiveStockAwardsMember" xlink:label="loc_cbay_IncentiveStockAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_IncentiveStockAwardsMember" xml:lang="en-US">Incentive Stock Awards [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_IncentiveStockAwardsMember" xml:lang="en-US">Incentive Awards [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_IncentiveStockAwardsMember" xlink:to="lab_cbay_IncentiveStockAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_IncentiveStockAwardsMember" xml:lang="en-US">Incentive stock awards.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_EmployeeOrNonEmployeeStockOptionsMember" xlink:label="loc_cbay_EmployeeOrNonEmployeeStockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_EmployeeOrNonEmployeeStockOptionsMember" xml:lang="en-US">Employee Or Non Employee Stock Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_EmployeeOrNonEmployeeStockOptionsMember" xml:lang="en-US">Common Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_EmployeeOrNonEmployeeStockOptionsMember" xlink:to="lab_cbay_EmployeeOrNonEmployeeStockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_EmployeeOrNonEmployeeStockOptionsMember" xml:lang="en-US">Employee or non employee stock options.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Anti-dilutive securities excluded from the computation of diluted loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xml:lang="en-US">Schedule Of Available For Sale Securities [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesMember" xml:lang="en-US">Debt Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesMember" xml:lang="en-US">Debt Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments" xlink:label="loc_cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments" xml:lang="en-US">Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses Accumulated In Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments" xml:lang="en-US">Marketable investments continuous unrealized loss position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments" xlink:to="lab_cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments" xml:lang="en-US">Amount of accumulated pre-tax unrealized loss on investments in available-for-sale securities that have been in a loss position for twelve months or longer impacting investments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xml:lang="en-US">Realized gains and losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MarketableSecuritiesAbstract" xml:lang="en-US">Marketable Securities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract" xlink:to="lab_us-gaap_MarketableSecuritiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CurrentMarketableSecuritiesMember" xlink:label="loc_cbay_CurrentMarketableSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_CurrentMarketableSecuritiesMember" xml:lang="en-US">Current Marketable Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_CurrentMarketableSecuritiesMember" xml:lang="en-US">Current marketable securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_CurrentMarketableSecuritiesMember" xlink:to="lab_cbay_CurrentMarketableSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_CurrentMarketableSecuritiesMember" xml:lang="en-US">Current marketable securities.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_MaketableSecuritiesMember" xlink:label="loc_cbay_MaketableSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_MaketableSecuritiesMember" xml:lang="en-US">Maketable Securities [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_MaketableSecuritiesMember" xml:lang="en-US">Maketable Securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_MaketableSecuritiesMember" xlink:to="lab_cbay_MaketableSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_MaketableSecuritiesMember" xml:lang="en-US">Maketable Securities [Member]</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NoncurrentMarketableSecuritiesMember" xlink:label="loc_cbay_NoncurrentMarketableSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_NoncurrentMarketableSecuritiesMember" xml:lang="en-US">Non-current marketable securities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_NoncurrentMarketableSecuritiesMember" xlink:to="lab_cbay_NoncurrentMarketableSecuritiesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_NoncurrentMarketableSecuritiesMember" xml:lang="en-US">Noncurrent marketable securities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xml:lang="en-US">U.S. and Foreign Commercial Paper [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xml:lang="en-US">Amortized Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xml:lang="en-US">Unrealized Losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xml:lang="en-US">Unrealized Gains</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity Schedule [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="lab_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ContractualObligationFiscalYearMaturityScheduleTable" xlink:label="loc_cbay_ContractualObligationFiscalYearMaturityScheduleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_ContractualObligationFiscalYearMaturityScheduleTable" xml:lang="en-US">Contractual Obligation Fiscal Year Maturity Schedule [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_ContractualObligationFiscalYearMaturityScheduleTable" xlink:to="lab_cbay_ContractualObligationFiscalYearMaturityScheduleTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_ContractualObligationFiscalYearMaturityScheduleTable" xml:lang="en-US">Contractual obligation fiscal year maturity schedule</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:label="loc_cbay_ContractualObligationFiscalYearMaturityScheduleLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_ContractualObligationFiscalYearMaturityScheduleLineItems" xml:lang="en-US">Contractual Obligation Fiscal Year Maturity Schedule [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:to="lab_cbay_ContractualObligationFiscalYearMaturityScheduleLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear" xml:lang="en-US">Contractual Obligation, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear" xml:lang="en-US">Due between 1 and 2 years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInSecondYear" xlink:to="lab_us-gaap_ContractualObligationDueInSecondYear" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xml:lang="en-US">Contractual Obligation, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xml:lang="en-US">Due less than 1 year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_OfficeAndComputerEquipmentMember" xlink:label="loc_cbay_OfficeAndComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_OfficeAndComputerEquipmentMember" xml:lang="en-US">Office And Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_OfficeAndComputerEquipmentMember" xml:lang="en-US">Office and Computer Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_OfficeAndComputerEquipmentMember" xlink:to="lab_cbay_OfficeAndComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_OfficeAndComputerEquipmentMember" xml:lang="en-US">Office and computer equipment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Software and Software Development Costs [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US">Purchased Software [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: Accumulated depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:label="loc_us-gaap_DepreciationExpenseOnReclassifiedAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationExpenseOnReclassifiedAssets" xml:lang="en-US">Depreciation Expense on Reclassified Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationExpenseOnReclassifiedAssets" xml:lang="en-US">Depreciation and amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:to="lab_us-gaap_DepreciationExpenseOnReclassifiedAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Accrued compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets" xlink:label="loc_cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets" xml:lang="en-US">Accrued Liabilities For Purchase Of Productive Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets" xml:lang="en-US">Total other accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets" xlink:to="lab_cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets" xml:lang="en-US">Accrued liabilities for purchase of productive assets.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AccruedProfessionalFeesAndOtherCurrent" xlink:label="loc_cbay_AccruedProfessionalFeesAndOtherCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_AccruedProfessionalFeesAndOtherCurrent" xml:lang="en-US">Accrued Professional Fees And Other Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_AccruedProfessionalFeesAndOtherCurrent" xml:lang="en-US">Accrued professional fees and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_AccruedProfessionalFeesAndOtherCurrent" xlink:to="lab_cbay_AccruedProfessionalFeesAndOtherCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_AccruedProfessionalFeesAndOtherCurrent" xml:lang="en-US">Accrued professional fees and other, classified as current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current portion of operating lease liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Less: current portion of operating lease liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Short term portion of operating lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_RoyaltyPercentageBasedOnNetSales" xlink:label="loc_cbay_RoyaltyPercentageBasedOnNetSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_RoyaltyPercentageBasedOnNetSales" xml:lang="en-US">Royalty Percentage Based On Net Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_RoyaltyPercentageBasedOnNetSales" xml:lang="en-US">Percentage of royalty on net sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_RoyaltyPercentageBasedOnNetSales" xlink:to="lab_cbay_RoyaltyPercentageBasedOnNetSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_RoyaltyPercentageBasedOnNetSales" xml:lang="en-US">Royalty percentage based on net sales.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xml:lang="en-US">Accrued Royalties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xml:lang="en-US">Accrued royalties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis" xml:lang="en-US">Contract with Customer, Basis of Pricing [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis" xml:lang="en-US">Contract with Customer, Basis of Pricing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:to="lab_us-gaap_ContractWithCustomerBasisOfPricingAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain" xml:lang="en-US">Contract with Customer, Basis of Pricing [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain" xml:lang="en-US">Contract with Customer, Basis of Pricing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:to="lab_us-gaap_ContractWithCustomerBasisOfPricingDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_CounterpartyNameAxis" xml:lang="en-US">Counterparty Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US">Counterparty Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_JanssenPharmaceuticalNVMember" xlink:label="loc_cbay_JanssenPharmaceuticalNVMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_JanssenPharmaceuticalNVMember" xml:lang="en-US">Janssen Pharmaceutical N V [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_JanssenPharmaceuticalNVMember" xml:lang="en-US">Janssen Pharmaceutical NV [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_JanssenPharmaceuticalNVMember" xlink:to="lab_cbay_JanssenPharmaceuticalNVMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_JanssenPharmaceuticalNVMember" xml:lang="en-US">Janssen Pharmaceutical N V.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductOrServiceAxis" xml:lang="en-US">Product and Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ProductsAndServicesDomain" xml:lang="en-US">Product and Service</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementTerminationEventConditionAxis" xlink:label="loc_cbay_FinancingAgreementTerminationEventConditionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_FinancingAgreementTerminationEventConditionAxis" xml:lang="en-US">Financing Agreement Termination Event Condition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_FinancingAgreementTerminationEventConditionAxis" xlink:to="lab_cbay_FinancingAgreementTerminationEventConditionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_FinancingAgreementTerminationEventConditionAxis" xml:lang="en-US">financing agreement termination event condition [axis].</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementTerminationEventConditionDomain" xlink:label="loc_cbay_FinancingAgreementTerminationEventConditionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_FinancingAgreementTerminationEventConditionDomain" xml:lang="en-US">Financing Agreement Termination Event Condition [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_FinancingAgreementTerminationEventConditionDomain" xlink:to="lab_cbay_FinancingAgreementTerminationEventConditionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_FinancingAgreementTerminationEventConditionDomain" xml:lang="en-US">financing agreement termination event condition [domain].</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementTerminationEventConditionOneMember" xlink:label="loc_cbay_FinancingAgreementTerminationEventConditionOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_FinancingAgreementTerminationEventConditionOneMember" xml:lang="en-US">Financing Agreement Termination Event Condition One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_FinancingAgreementTerminationEventConditionOneMember" xlink:to="lab_cbay_FinancingAgreementTerminationEventConditionOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_FinancingAgreementTerminationEventConditionOneMember" xml:lang="en-US">financing agreement termination event condition one [member].</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementTerminationEventConditionTwoMember" xlink:label="loc_cbay_FinancingAgreementTerminationEventConditionTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_FinancingAgreementTerminationEventConditionTwoMember" xml:lang="en-US">Financing Agreement Termination Event Condition Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_FinancingAgreementTerminationEventConditionTwoMember" xlink:to="lab_cbay_FinancingAgreementTerminationEventConditionTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_FinancingAgreementTerminationEventConditionTwoMember" xml:lang="en-US">financing agreement termination event condition two [member].</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementTerminationEventConditionThreeMember" xlink:label="loc_cbay_FinancingAgreementTerminationEventConditionThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_FinancingAgreementTerminationEventConditionThreeMember" xml:lang="en-US">Financing Agreement Termination Event Condition Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_FinancingAgreementTerminationEventConditionThreeMember" xlink:to="lab_cbay_FinancingAgreementTerminationEventConditionThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_FinancingAgreementTerminationEventConditionThreeMember" xml:lang="en-US">financing agreement termination event condition three [member].</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_SuccessPaymentTypeAxis" xlink:label="loc_cbay_SuccessPaymentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_SuccessPaymentTypeAxis" xml:lang="en-US">Success Payment Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_SuccessPaymentTypeAxis" xlink:to="lab_cbay_SuccessPaymentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_SuccessPaymentTypeAxis" xml:lang="en-US">success payment type [axis].</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_SuccessPaymentTypeDomain" xlink:label="loc_cbay_SuccessPaymentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_SuccessPaymentTypeDomain" xml:lang="en-US">Success Payment Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_SuccessPaymentTypeDomain" xlink:to="lab_cbay_SuccessPaymentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_SuccessPaymentTypeDomain" xml:lang="en-US">success payment type [domain].</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_VariableSuccessPaymentsMember" xlink:label="loc_cbay_VariableSuccessPaymentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_VariableSuccessPaymentsMember" xml:lang="en-US">Variable Success Payments [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_VariableSuccessPaymentsMember" xlink:to="lab_cbay_VariableSuccessPaymentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_VariableSuccessPaymentsMember" xml:lang="en-US">variable success payments [member].</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FixedSuccessPaymentsMember" xlink:label="loc_cbay_FixedSuccessPaymentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_FixedSuccessPaymentsMember" xml:lang="en-US">Fixed Success Payments [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_FixedSuccessPaymentsMember" xlink:to="lab_cbay_FixedSuccessPaymentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_FixedSuccessPaymentsMember" xml:lang="en-US">fixed success payments [member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AnniversaryPaymentsDueYearFive" xlink:label="loc_cbay_AnniversaryPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_AnniversaryPaymentsDueYearFive" xml:lang="en-US">Anniversary Payments Due Year Five</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_AnniversaryPaymentsDueYearFive" xlink:to="lab_cbay_AnniversaryPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_AnniversaryPaymentsDueYearFive" xml:lang="en-US">Anniversary payments due year five.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AnniversaryPaymentsDueYearSix" xlink:label="loc_cbay_AnniversaryPaymentsDueYearSix" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_AnniversaryPaymentsDueYearSix" xml:lang="en-US">Anniversary Payments Due Year Six</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_AnniversaryPaymentsDueYearSix" xlink:to="lab_cbay_AnniversaryPaymentsDueYearSix" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_AnniversaryPaymentsDueYearSix" xml:lang="en-US">Anniversary payments due year six.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AnniversaryPaymentsDueYearTwo" xlink:label="loc_cbay_AnniversaryPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_AnniversaryPaymentsDueYearTwo" xml:lang="en-US">Anniversary Payments Due Year Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_AnniversaryPaymentsDueYearTwo" xlink:to="lab_cbay_AnniversaryPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_AnniversaryPaymentsDueYearTwo" xml:lang="en-US">Anniversary payments due year two.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AnniversaryPaymentsDueYearThree" xlink:label="loc_cbay_AnniversaryPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_AnniversaryPaymentsDueYearThree" xml:lang="en-US">Anniversary Payments Due Year Three</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_AnniversaryPaymentsDueYearThree" xlink:to="lab_cbay_AnniversaryPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_AnniversaryPaymentsDueYearThree" xml:lang="en-US">Anniversary payments due year three.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_Anniversarypaymentsdueyearfour" xlink:label="loc_cbay_Anniversarypaymentsdueyearfour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_Anniversarypaymentsdueyearfour" xml:lang="en-US">Anniversary Payments Due Year Four</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_Anniversarypaymentsdueyearfour" xlink:to="lab_cbay_Anniversarypaymentsdueyearfour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_Anniversarypaymentsdueyearfour" xml:lang="en-US">Anniversary payments due year four.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AggregateReturnPercentageFromTheFundsProvided" xlink:label="loc_cbay_AggregateReturnPercentageFromTheFundsProvided" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_AggregateReturnPercentageFromTheFundsProvided" xml:lang="en-US">Aggregate Return Percentage From The Funds Provided</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_AggregateReturnPercentageFromTheFundsProvided" xlink:to="lab_cbay_AggregateReturnPercentageFromTheFundsProvided" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_AggregateReturnPercentageFromTheFundsProvided" xml:lang="en-US">Aggregate return percentage from the funds provided.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DescriptionOfPercentageFixedSuccessPayments" xlink:label="loc_cbay_DescriptionOfPercentageFixedSuccessPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_DescriptionOfPercentageFixedSuccessPayments" xml:lang="en-US">Description Of Percentage Fixed Success Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_DescriptionOfPercentageFixedSuccessPayments" xlink:to="lab_cbay_DescriptionOfPercentageFixedSuccessPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_DescriptionOfPercentageFixedSuccessPayments" xml:lang="en-US">Description of percentage fixed success payments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xml:lang="en-US">Repayments of Lines of Credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AnniversaryPaymentsDueYearOne" xlink:label="loc_cbay_AnniversaryPaymentsDueYearOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_AnniversaryPaymentsDueYearOne" xml:lang="en-US">Anniversary Payments Due Year One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_AnniversaryPaymentsDueYearOne" xlink:to="lab_cbay_AnniversaryPaymentsDueYearOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_AnniversaryPaymentsDueYearOne" xml:lang="en-US">Anniversary payments due year one.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement" xlink:label="loc_cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement" xml:lang="en-US">Percentage of amount to be paid by entity upon the termination of the agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement" xlink:to="lab_cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement" xml:lang="en-US">Percentage of amount to be paid by entity upon the termination of the agreement.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability" xlink:label="loc_cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability" xml:lang="en-US">Percentage of Unamortized Portion of The Development Financing Liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability" xlink:to="lab_cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability" xml:lang="en-US">Percentage of unamortized portion of the development financing liability.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement" xlink:label="loc_cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement" xml:lang="en-US">Description Repayments On Funds Provided Upon Termination Of Financing Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement" xlink:to="lab_cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement" xml:lang="en-US">Description repayments on funds provided upon termination of financing agreement.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided" xlink:label="loc_cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided" xml:lang="en-US">Percentage of Accelerate Payment Payable On Funds provided</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided" xlink:to="lab_cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided" xml:lang="en-US">Percentage of accelerate payment payable on funds provided.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DescriptionOfAggregateReturnFromTheFundsProvided" xlink:label="loc_cbay_DescriptionOfAggregateReturnFromTheFundsProvided" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_DescriptionOfAggregateReturnFromTheFundsProvided" xml:lang="en-US">Description Of Aggregate Return From The Funds Provided</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_DescriptionOfAggregateReturnFromTheFundsProvided" xlink:to="lab_cbay_DescriptionOfAggregateReturnFromTheFundsProvided" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_DescriptionOfAggregateReturnFromTheFundsProvided" xml:lang="en-US">Description of aggregate return from the funds provided.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PaymentsUponReachingProductSalesRunRate" xlink:label="loc_cbay_PaymentsUponReachingProductSalesRunRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_PaymentsUponReachingProductSalesRunRate" xml:lang="en-US">Payments upon reaching product sales run rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_PaymentsUponReachingProductSalesRunRate" xlink:to="lab_cbay_PaymentsUponReachingProductSalesRunRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_PaymentsUponReachingProductSalesRunRate" xml:lang="en-US">Payments upon reaching product sales run rate.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo" xlink:label="loc_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo" xml:lang="en-US">Payments Upon Reaching Cumulative US Product Sales Thresholds Year Two</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo" xlink:to="lab_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo" xml:lang="en-US">Payments upon reaching cumulative US product sales thresholds year two.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne" xlink:label="loc_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne" xml:lang="en-US">Payments Upon Reaching Cumulative US Product Sales Thresholds Year One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne" xlink:to="lab_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne" xml:lang="en-US">Payments upon reaching cumulative US product sales thresholds year one.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DescriptionOfPercentageVariableSuccessPayments" xlink:label="loc_cbay_DescriptionOfPercentageVariableSuccessPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_DescriptionOfPercentageVariableSuccessPayments" xml:lang="en-US">Description Of Percentage Variable Success Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_DescriptionOfPercentageVariableSuccessPayments" xlink:to="lab_cbay_DescriptionOfPercentageVariableSuccessPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_DescriptionOfPercentageVariableSuccessPayments" xml:lang="en-US">Description of percentage variable success payments.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NumberOfInstallmentFundingAxis" xlink:label="loc_cbay_NumberOfInstallmentFundingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_NumberOfInstallmentFundingAxis" xml:lang="en-US">Number Of Installment Funding [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_NumberOfInstallmentFundingAxis" xlink:to="lab_cbay_NumberOfInstallmentFundingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_NumberOfInstallmentFundingAxis" xml:lang="en-US">Number of installment funding [axis].</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NumberOfInstallmentFundingDomain" xlink:label="loc_cbay_NumberOfInstallmentFundingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_NumberOfInstallmentFundingDomain" xml:lang="en-US">Number Of Installment Funding [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_NumberOfInstallmentFundingDomain" xlink:to="lab_cbay_NumberOfInstallmentFundingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_NumberOfInstallmentFundingDomain" xml:lang="en-US">Number of installment funding [domain].</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_InstallmentFundingNumberOneMember" xlink:label="loc_cbay_InstallmentFundingNumberOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_InstallmentFundingNumberOneMember" xml:lang="en-US">Installment Funding Number One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_InstallmentFundingNumberOneMember" xlink:to="lab_cbay_InstallmentFundingNumberOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_InstallmentFundingNumberOneMember" xml:lang="en-US">Installment funding number one [member]</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_InstallmentFundingNumberTwoMember" xlink:label="loc_cbay_InstallmentFundingNumberTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_InstallmentFundingNumberTwoMember" xml:lang="en-US">Installment Funding Number Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_InstallmentFundingNumberTwoMember" xlink:to="lab_cbay_InstallmentFundingNumberTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_InstallmentFundingNumberTwoMember" xml:lang="en-US">Installment funding number two [member].</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_InstallmentFundingNumberThreeMember" xlink:label="loc_cbay_InstallmentFundingNumberThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_InstallmentFundingNumberThreeMember" xml:lang="en-US">Installment Funding Number Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_InstallmentFundingNumberThreeMember" xlink:to="lab_cbay_InstallmentFundingNumberThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_InstallmentFundingNumberThreeMember" xml:lang="en-US">Installment funding number three [member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Balance, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Balance, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability" xlink:label="loc_cbay_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability" xml:lang="en-US">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accretion of development financing liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability" xml:lang="en-US">Accretion of development financing liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability" xlink:to="lab_cbay_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation recurring basis liability accretion of development financing liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xml:lang="en-US">Cash received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total undiscounted future minimum lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total operating lease liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AreaOfOfficeSpace" xlink:label="loc_cbay_AreaOfOfficeSpace" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_AreaOfOfficeSpace" xml:lang="en-US">Area Of Office Space</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cbay_AreaOfOfficeSpace" xml:lang="en-US">Area of office space</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_AreaOfOfficeSpace" xlink:to="lab_cbay_AreaOfOfficeSpace" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_AreaOfOfficeSpace" xml:lang="en-US">Area of office space.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" xml:lang="en-US">Lease, option to extend</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted average lease discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Lease costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NumberOfLeasedFacilitiesOperatingLeases" xlink:label="loc_cbay_NumberOfLeasedFacilitiesOperatingLeases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_NumberOfLeasedFacilitiesOperatingLeases" xml:lang="en-US">Number Of Leased Facilities Operating Leases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_NumberOfLeasedFacilitiesOperatingLeases" xml:lang="en-US">Number of leased facilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_NumberOfLeasedFacilitiesOperatingLeases" xlink:to="lab_cbay_NumberOfLeasedFacilitiesOperatingLeases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_NumberOfLeasedFacilitiesOperatingLeases" xml:lang="en-US">Number of leased facilities operating leases.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_LeaseStartDate" xlink:label="loc_cbay_LeaseStartDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_LeaseStartDate" xml:lang="en-US">Lease Start Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_LeaseStartDate" xml:lang="en-US">Lease start date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_LeaseStartDate" xlink:to="lab_cbay_LeaseStartDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_LeaseStartDate" xml:lang="en-US">Lease start date.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted average remaining lease term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xml:lang="en-US">Lease Contractual Term [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xml:lang="en-US">Lease Arrangement, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xml:lang="en-US">Lease Arrangement, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xml:lang="en-US">Lease Contractual Term [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xml:lang="en-US">Lease Arrangement, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xml:lang="en-US">Lease Arrangement, Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_LeaseFacilityMember" xlink:label="loc_cbay_LeaseFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_LeaseFacilityMember" xml:lang="en-US">Lease Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_LeaseFacilityMember" xml:lang="en-US">Lease Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_LeaseFacilityMember" xlink:to="lab_cbay_LeaseFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_LeaseFacilityMember" xml:lang="en-US">Lease facility.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenseMember" xml:lang="en-US">Operating Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpenseMember" xml:lang="en-US">Operating Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesTable" xml:lang="en-US">Loss Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingenciesTable" xml:lang="en-US">Loss Contingencies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesLineItems" xml:lang="en-US">Loss Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingenciesLineItems" xml:lang="en-US">Loss Contingencies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyLawsuitFilingDate" xlink:label="loc_us-gaap_LossContingencyLawsuitFilingDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyLawsuitFilingDate" xml:lang="en-US">Loss Contingency, Lawsuit Filing Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyLawsuitFilingDate" xml:lang="en-US">Loss Contingency, Lawsuit Filing Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyLawsuitFilingDate" xlink:to="lab_us-gaap_LossContingencyLawsuitFilingDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:label="loc_us-gaap_LossContingencyNameOfPlaintiff" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyNameOfPlaintiff" xml:lang="en-US">Loss Contingency, Name of Plaintiff</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyNameOfPlaintiff" xml:lang="en-US">Loss Contingency, Name of Plaintiff</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNameOfPlaintiff" xlink:to="lab_us-gaap_LossContingencyNameOfPlaintiff" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IndemnificationLiability" xlink:label="loc_cbay_IndemnificationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_IndemnificationLiability" xml:lang="en-US">Indemnification Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_IndemnificationLiability" xml:lang="en-US">Indemnification liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_IndemnificationLiability" xlink:to="lab_cbay_IndemnificationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_IndemnificationLiability" xml:lang="en-US">Indemnification liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAllegations" xlink:label="loc_us-gaap_LossContingencyAllegations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyAllegations" xml:lang="en-US">Loss Contingency, Allegations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyAllegations" xml:lang="en-US">Loss Contingency, Allegations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAllegations" xlink:to="lab_us-gaap_LossContingencyAllegations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyActionsTakenByDefendant" xlink:label="loc_us-gaap_LossContingencyActionsTakenByDefendant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyActionsTakenByDefendant" xml:lang="en-US">Loss Contingency, Actions Taken by Defendant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyActionsTakenByDefendant" xml:lang="en-US">Loss Contingency, Actions Taken by Defendant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyActionsTakenByDefendant" xlink:to="lab_us-gaap_LossContingencyActionsTakenByDefendant" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyActionsTakenByCourtArbitratorOrMediator" xlink:label="loc_us-gaap_LossContingencyActionsTakenByCourtArbitratorOrMediator" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyActionsTakenByCourtArbitratorOrMediator" xml:lang="en-US">Loss Contingency, Actions Taken by Court, Arbitrator or Mediator</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LossContingencyActionsTakenByCourtArbitratorOrMediator" xml:lang="en-US">Loss Contingency, Actions Taken by Court, Arbitrator or Mediator</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyActionsTakenByCourtArbitratorOrMediator" xlink:to="lab_us-gaap_LossContingencyActionsTakenByCourtArbitratorOrMediator" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LitigationStatusAxis" xml:lang="en-US">Litigation Status [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LitigationStatusDomain" xml:lang="en-US">Litigation Status [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PendingLitigationMember" xml:lang="en-US">Pending Litigation [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_OptionsAndIncentiveAwardsMember" xlink:label="loc_cbay_OptionsAndIncentiveAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_OptionsAndIncentiveAwardsMember" xml:lang="en-US">Options and Incentive awards [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_OptionsAndIncentiveAwardsMember" xlink:to="lab_cbay_OptionsAndIncentiveAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_OptionsAndIncentiveAwardsMember" xml:lang="en-US">Options and Incentive Awards.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember" xlink:label="loc_cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember" xml:lang="en-US">CBAYEquity incentive plan two thousand and twenty plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember" xlink:to="lab_cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember" xml:lang="en-US">CBAYEquity Incentive Plan Two Thousand And Twenty Plan.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember" xlink:label="loc_cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember" xml:lang="en-US">CBAYEquity incentive plan two thousand and thirteen [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember" xlink:to="lab_cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember" xml:lang="en-US">CBAYEquity Incentive Plan Two Thousand And Thirteen.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Share reserved for issue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_EquityIncentivePlanTwoThousandAndThirteenMember" xlink:label="loc_cbay_EquityIncentivePlanTwoThousandAndThirteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_EquityIncentivePlanTwoThousandAndThirteenMember" xml:lang="en-US">Equity Incentive Plan Two Thousand And Thirteen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_EquityIncentivePlanTwoThousandAndThirteenMember" xml:lang="en-US">2013 Equity Incentive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_EquityIncentivePlanTwoThousandAndThirteenMember" xlink:to="lab_cbay_EquityIncentivePlanTwoThousandAndThirteenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_EquityIncentivePlanTwoThousandAndThirteenMember" xml:lang="en-US">Equity incentive plan two thousand and thirteen.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember" xlink:label="loc_cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember" xml:lang="en-US">Equity Incentive Plan Two Thousand and Twenty Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember" xlink:to="lab_cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember" xml:lang="en-US">Equity Incentive Plan Two Thousand and Twenty Plan [Member] .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Unamortized employee and non-employee stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Fair value of options vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Unamortized employee and non-employee stock-based compensation expense recognized period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xml:lang="en-US">Exercisable weighted average price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Shares available for grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share based compensation arrangement by share based payment award, award vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xml:lang="en-US">Share based compensation arrangement by share based payment award, exercise price percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Intrinsic value of options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" xlink:label="loc_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Increase In Shares Reserved Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" xml:lang="en-US">Share based compensation arrangement percentage increase in share reserved</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" xlink:to="lab_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" xml:lang="en-US">Share based compensation arrangement by share based payment award increase in shares reserved percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share based compensation arrangement by share based payment award, expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Stock options outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding as end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding at the beginning of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NonQualifiedStockOptionsMember" xlink:label="loc_cbay_NonQualifiedStockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_NonQualifiedStockOptionsMember" xml:lang="en-US">Non Qualified Stock Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_NonQualifiedStockOptionsMember" xml:lang="en-US">Nonqualified Options to Employees, Directors and Consultants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_NonQualifiedStockOptionsMember" xlink:to="lab_cbay_NonQualifiedStockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_NonQualifiedStockOptionsMember" xml:lang="en-US">Non qualified stock options.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember" xlink:label="loc_cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember" xml:lang="en-US">Incentive Stock Options For Employees And Directors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember" xml:lang="en-US">Incentive Stock Options for Employees and Directors [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember" xlink:to="lab_cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember" xml:lang="en-US">Incentive stock options for employees and directors.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_StockOptionsToTenPercentShareholdersMember" xlink:label="loc_cbay_StockOptionsToTenPercentShareholdersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_StockOptionsToTenPercentShareholdersMember" xml:lang="en-US">Stock Options To Ten Percent Shareholders [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_StockOptionsToTenPercentShareholdersMember" xml:lang="en-US">Stock Options to 10% Stockholders [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_StockOptionsToTenPercentShareholdersMember" xlink:to="lab_cbay_StockOptionsToTenPercentShareholdersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_StockOptionsToTenPercentShareholdersMember" xml:lang="en-US">Stock options to ten percent shareholders.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Shares Subject to Outstanding Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Options forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Options expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Vested and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted-Average Exercise Price of Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding at the beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding as end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xml:lang="en-US">Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Options expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Vested and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US">Aggregate Intrinsic Value (In Thousands)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Vested and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Weighted-Average Remaining Contractual Term (Years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Share based compensation arrangement by share based payment award options weighted average remaining contractual term.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Vested and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Weighted-average grant date fair value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Retirement Benefits [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_EmployerMatchingContributionToQualifiedSavingsPlan" xlink:label="loc_cbay_EmployerMatchingContributionToQualifiedSavingsPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_EmployerMatchingContributionToQualifiedSavingsPlan" xml:lang="en-US">Employer Matching Contribution To Qualified Savings Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_EmployerMatchingContributionToQualifiedSavingsPlan" xml:lang="en-US">Employees contribution to qualified savings plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_EmployerMatchingContributionToQualifiedSavingsPlan" xlink:to="lab_cbay_EmployerMatchingContributionToQualifiedSavingsPlan" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_EmployerMatchingContributionToQualifiedSavingsPlan" xml:lang="en-US">Employer matching contribution to qualified savings plan.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncomeTaxTable" xlink:label="loc_cbay_IncomeTaxTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_IncomeTaxTable" xml:lang="en-US">Income Tax [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_IncomeTaxTable" xml:lang="en-US">Income Tax [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_IncomeTaxTable" xlink:to="lab_cbay_IncomeTaxTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_IncomeTaxTable" xml:lang="en-US">Income Tax [Table]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FederalAndStateTaxAuthorityMember" xlink:label="loc_cbay_FederalAndStateTaxAuthorityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_FederalAndStateTaxAuthorityMember" xml:lang="en-US">Federal And State Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_FederalAndStateTaxAuthorityMember" xml:lang="en-US">Federal And State Tax Authority [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_FederalAndStateTaxAuthorityMember" xlink:to="lab_cbay_FederalAndStateTaxAuthorityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_FederalAndStateTaxAuthorityMember" xml:lang="en-US">Federal and state tax authority [member].</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncomeTaxLineItems" xlink:label="loc_cbay_IncomeTaxLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_IncomeTaxLineItems" xml:lang="en-US">Income Tax [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_IncomeTaxLineItems" xml:lang="en-US">Income Tax [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_IncomeTaxLineItems" xlink:to="lab_cbay_IncomeTaxLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_IncomeTaxLineItems" xml:lang="en-US">Income Tax [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaap_IncomeTaxExaminationDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationDescription" xml:lang="en-US">Income Tax Examination, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExaminationDescription" xml:lang="en-US">Income tax examination years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationDescription" xlink:to="lab_us-gaap_IncomeTaxExaminationDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xml:lang="en-US">Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xml:lang="en-US">Significant change to its unrecognized tax benefits over the next twelve months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:to="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Research and development tax credit carry forwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforward</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Federal net operating loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Net valuation allowance increase (decrease)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ProvisionForStateAndLocalIncomeTaxes" xlink:label="loc_cbay_ProvisionForStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_ProvisionForStateAndLocalIncomeTaxes" xml:lang="en-US">Provision For State And Local Income Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_ProvisionForStateAndLocalIncomeTaxes" xml:lang="en-US">Provision for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_ProvisionForStateAndLocalIncomeTaxes" xlink:to="lab_cbay_ProvisionForStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_ProvisionForStateAndLocalIncomeTaxes" xml:lang="en-US">Provision for state and local income taxes.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NetOperatingLossCarryforwardExpirationYear" xlink:label="loc_cbay_NetOperatingLossCarryforwardExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_NetOperatingLossCarryforwardExpirationYear" xml:lang="en-US">Net Operating Loss Carryforward Expiration Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_NetOperatingLossCarryforwardExpirationYear" xml:lang="en-US">NOL carry forward expiry date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_NetOperatingLossCarryforwardExpirationYear" xlink:to="lab_cbay_NetOperatingLossCarryforwardExpirationYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_NetOperatingLossCarryforwardExpirationYear" xml:lang="en-US">Net operating loss carryforwards expiration year.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xml:lang="en-US">Operating Loss Carryforwards, Limitations on Use</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xml:lang="en-US">Description of net operating loss carryforwards, expire period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AlternateMinimumTaxRate" xlink:label="loc_cbay_AlternateMinimumTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_AlternateMinimumTaxRate" xml:lang="en-US">Alternate Minimum Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_AlternateMinimumTaxRate" xlink:to="lab_cbay_AlternateMinimumTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_AlternateMinimumTaxRate" xml:lang="en-US">Alternate minimum tax rate.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_WriteOffOfTaxAttributeDueToLimitation" xlink:label="loc_cbay_WriteOffOfTaxAttributeDueToLimitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_WriteOffOfTaxAttributeDueToLimitation" xml:lang="en-US">Write Off Of Tax Attribute Due To Limitation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cbay_WriteOffOfTaxAttributeDueToLimitation" xml:lang="en-US">Write off of tax attribute due to limitation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_WriteOffOfTaxAttributeDueToLimitation" xlink:to="lab_cbay_WriteOffOfTaxAttributeDueToLimitation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_WriteOffOfTaxAttributeDueToLimitation" xml:lang="en-US">Write off of tax attribute due to limitation.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible" xlink:label="loc_cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible" xml:lang="en-US">Cumulative Percentage Change In Ownership Percentage Perimissible</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible" xml:lang="en-US">Cumulative percentage change in ownership percentage permissible</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible" xlink:to="lab_cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible" xml:lang="en-US">Cumulative percentage change in ownership percentage perimissible.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage" xlink:label="loc_cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage" xml:lang="en-US">Period For Considering The Cumulative Percentage Change In Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage" xml:lang="en-US">Period for considering the cumulative percentage change in ownership percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage" xlink:to="lab_cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage" xml:lang="en-US">Period for considering the cumulative percentage change in ownership percentage</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OpenTaxYear" xml:lang="en-US">Open Tax Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OpenTaxYear" xml:lang="en-US">Open tax year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FederalMember" xlink:label="loc_cbay_FederalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_FederalMember" xml:lang="en-US">Federal [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_FederalMember" xml:lang="en-US">Federal [member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_FederalMember" xlink:to="lab_cbay_FederalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_FederalMember" xml:lang="en-US">Federal member</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_OrphanDrugMember" xlink:label="loc_cbay_OrphanDrugMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_OrphanDrugMember" xml:lang="en-US">Orphan Drug [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_OrphanDrugMember" xml:lang="en-US">Orphan Drug [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_OrphanDrugMember" xlink:to="lab_cbay_OrphanDrugMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_OrphanDrugMember" xml:lang="en-US">Orphan drug.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred tax assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Federal and state net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xml:lang="en-US">Deferred tax liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Deferred Tax Liabilities, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xml:lang="en-US">Total deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xml:lang="en-US">State and federal research and development tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment" xlink:label="loc_cbay_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment" xml:lang="en-US">Deferred Tax Assets Intangibles And Capitalized Research And Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment" xml:lang="en-US">Intangibles and capitalized research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment" xlink:to="lab_cbay_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment" xml:lang="en-US">Deferred tax assets intangibles and capitalized research and development.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income tax benefit at federal statutory tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xml:lang="en-US">Research credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncomeTaxReconciliationTaxCancelledOptions" xlink:label="loc_cbay_IncomeTaxReconciliationTaxCancelledOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_IncomeTaxReconciliationTaxCancelledOptions" xml:lang="en-US">Income Tax Reconciliation Tax Cancelled Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_IncomeTaxReconciliationTaxCancelledOptions" xml:lang="en-US">Cancelled options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_IncomeTaxReconciliationTaxCancelledOptions" xlink:to="lab_cbay_IncomeTaxReconciliationTaxCancelledOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_IncomeTaxReconciliationTaxCancelledOptions" xml:lang="en-US">Income Tax Reconciliation Tax Cancelled Options .</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncomeTaxReconciliationDevelopmentFinancingLiability" xlink:label="loc_cbay_IncomeTaxReconciliationDevelopmentFinancingLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_IncomeTaxReconciliationDevelopmentFinancingLiability" xml:lang="en-US">Income Tax Reconciliation Development Financing Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_cbay_IncomeTaxReconciliationDevelopmentFinancingLiability" xml:lang="en-US">Development financing liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_IncomeTaxReconciliationDevelopmentFinancingLiability" xlink:to="lab_cbay_IncomeTaxReconciliationDevelopmentFinancingLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_IncomeTaxReconciliationDevelopmentFinancingLiability" xml:lang="en-US">Income tax reconciliation development financing liability.</label>
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncomeTaxReconciliationPermanentDifferences" xlink:label="loc_cbay_IncomeTaxReconciliationPermanentDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_IncomeTaxReconciliationPermanentDifferences" xml:lang="en-US">Income Tax Reconciliation Permanent Differences</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_IncomeTaxReconciliationPermanentDifferences" xml:lang="en-US">Permanent differences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_IncomeTaxReconciliationPermanentDifferences" xlink:to="lab_cbay_IncomeTaxReconciliationPermanentDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_IncomeTaxReconciliationPermanentDifferences" xml:lang="en-US">Income tax reconciliation permanent differences.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Other, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State income taxes, net of federal benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax (benefit) expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xml:lang="en-US">Impairment of tax attributes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Decreases related to prior year tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Balance at end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Balance at beginning of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Increases related to tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Increases related to prior year tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PotentialMilestonePayments" xlink:label="loc_cbay_PotentialMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cbay_PotentialMilestonePayments" xml:lang="en-US">Potential Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_cbay_PotentialMilestonePayments" xml:lang="en-US">Potential milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cbay_PotentialMilestonePayments" xlink:to="lab_cbay_PotentialMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_cbay_PotentialMilestonePayments" xml:lang="en-US">Potential milestone payments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>cbay-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 23-March-2023 [11:30:25] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CoverPage" roleURI="http://www.cymabay.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.cymabay.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cymabay.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#ConsolidatedStatementOfStockholdersEquityParenthetical" roleURI="http://www.cymabay.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#OrganizationAndDescriptionOfBusiness" roleURI="http://www.cymabay.com/role/OrganizationAndDescriptionOfBusiness" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#MarketableSecurities" roleURI="http://www.cymabay.com/role/MarketableSecurities" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CertainBalanceSheetItems" roleURI="http://www.cymabay.com/role/CertainBalanceSheetItems" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#InLicenseAgreement" roleURI="http://www.cymabay.com/role/InLicenseAgreement" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#DevelopmentFinancingAgreement" roleURI="http://www.cymabay.com/role/DevelopmentFinancingAgreement" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#Leases" roleURI="http://www.cymabay.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CommitmentsAndContingencies" roleURI="http://www.cymabay.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockholdersEquity" roleURI="http://www.cymabay.com/role/StockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockPlansAndStockBasedCompensation" roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#KPlan" roleURI="http://www.cymabay.com/role/KPlan" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#IncomeTaxes" roleURI="http://www.cymabay.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SubsequentEvents" roleURI="http://www.cymabay.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#MarketableSecuritiesTables" roleURI="http://www.cymabay.com/role/MarketableSecuritiesTables" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CertainBalanceSheetItemsTables" roleURI="http://www.cymabay.com/role/CertainBalanceSheetItemsTables" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#DevelopmentFinancingAgreementTables" roleURI="http://www.cymabay.com/role/DevelopmentFinancingAgreementTables" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#LeasesTables" roleURI="http://www.cymabay.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockholdersEquityTables" roleURI="http://www.cymabay.com/role/StockholdersEquityTables" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockPlansAndStockBasedCompensationTables" roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#IncomeTaxesTables" roleURI="http://www.cymabay.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail" roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail" roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail" roleURI="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#MarketableSecuritiesAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail" roleURI="http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#MarketableSecuritiesScheduleOfFairValueOfTheCompanyMarketableSecuritiesByContractualMaturityDetail" roleURI="http://www.cymabay.com/role/MarketableSecuritiesScheduleOfFairValueOfTheCompanyMarketableSecuritiesByContractualMaturityDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CertainBalanceSheetItemsPropertyAndEquipmentDetail" roleURI="http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CertainBalanceSheetItemsAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/CertainBalanceSheetItemsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail" roleURI="http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#InLicenseAgreementAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#DevelopmentFinancingAgreementAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#DevelopmentFinancingAgreementScheduleOfChangesInFairValueOfLiabilitiesDetail" roleURI="http://www.cymabay.com/role/DevelopmentFinancingAgreementScheduleOfChangesInFairValueOfLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" roleURI="http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockholdersEquityAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail" roleURI="http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockPlansAndStockBasedCompensationAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail" roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail" roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail" roleURI="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#KPlanAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/KPlanAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#IncomeTaxesComponentsOfDeferredTaxAssetsDetail" roleURI="http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail" roleURI="http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#IncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetail" roleURI="http://www.cymabay.com/role/IncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetail" />
<roleRef xlink:type="simple" xlink:href="cbay-20221231.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_622303" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_622305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_622303" xlink:to="loc_dei_DocumentInformationTable_622305" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_622306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_622305" xlink:to="loc_us-gaap_StatementClassOfStockAxis_622306" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_622307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_622306" xlink:to="loc_us-gaap_ClassOfStockDomain_622307" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_622308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_622305" xlink:to="loc_dei_DocumentInformationLineItems_622308" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_622309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_DocumentType_622309" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_622311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_AmendmentFlag_622311" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_622314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_DocumentPeriodEndDate_622314" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_622315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_DocumentFiscalYearFocus_622315" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_622316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_DocumentFiscalPeriodFocus_622316" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_622317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_TradingSymbol_622317" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_622319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityRegistrantName_622319" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_622320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityCentralIndexKey_622320" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_622321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_CurrentFiscalYearEndDate_622321" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_622397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_622397" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_622322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityFilerCategory_622322" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_622324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityCurrentReportingStatus_622324" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_622399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityVoluntaryFilers_622399" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_622325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntitySmallBusiness_622325" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_622327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityEmergingGrowthCompany_622327" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_622328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_622328" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_622329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityShellCompany_622329" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_622330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityFileNumber_622330" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_622331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityTaxIdentificationNumber_622331" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_622334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityAddressAddressLine1_622334" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_dei_EntityAddressAddressLine2_622335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityAddressAddressLine2_622335" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_622336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityAddressCityOrTown_622336" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_622338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityAddressStateOrProvince_622338" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_622339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityAddressPostalZipCode_622339" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_622345" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_CityAreaCode_622345" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_622346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_LocalPhoneNumber_622346" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_622348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityInteractiveDataCurrent_622348" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_622349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_Security12bTitle_622349" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_622350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_SecurityExchangeName_622350" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_622351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityIncorporationStateCountryCode_622351" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_622353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_DocumentAnnualReport_622353" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_622354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_DocumentTransitionReport_622354" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_626111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_EntityPublicFloat_626111" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_dei_IcfrAuditorAttestationFlag_863789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_IcfrAuditorAttestationFlag_863789" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="loc_dei_AuditorName_1311458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_AuditorName_1311458" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="loc_dei_AuditorFirmId_1311459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_AuditorFirmId_1311459" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="loc_dei_AuditorLocation_1311460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_622308" xlink:to="loc_dei_AuditorLocation_1311460" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_22" xlink:to="loc_us-gaap_AssetsAbstract_23" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_AssetsCurrentAbstract_24" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_28" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_29" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1341987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1341987" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_24" xlink:to="loc_us-gaap_AssetsCurrent_33" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_34" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_1311520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_1311520" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_622438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_622438" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_35" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_23" xlink:to="loc_us-gaap_Assets_36" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_22" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_26" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_AccountsPayableCurrent_37" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AccruedResearchAndDevelopmentExpenses" xlink:label="loc_cbay_AccruedResearchAndDevelopmentExpenses_622444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_cbay_AccruedResearchAndDevelopmentExpenses_622444" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_39" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26" xlink:to="loc_us-gaap_LiabilitiesCurrent_43" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DevelopmentFinancingLiabilityNonCurrent" xlink:label="loc_cbay_DevelopmentFinancingLiabilityNonCurrent_1311530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_cbay_DevelopmentFinancingLiabilityNonCurrent_1311530" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_622447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_622447" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_Liabilities_46" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_623285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_CommitmentsAndContingencies_623285" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_StockholdersEquityAbstract_27" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_PreferredStockValue_47" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_CommonStockValue_48" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_AdditionalPaidInCapital_49" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_50" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_51" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_StockholdersEquity_52" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_25" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_53" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_55" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_56" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_55" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_57" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_55" xlink:to="loc_us-gaap_PreferredStockSharesIssued_58" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_59" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_55" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_59" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_55" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_60" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_55" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_61" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_55" xlink:to="loc_us-gaap_CommonStockSharesIssued_62" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_55" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_63" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_65" xlink:to="loc_us-gaap_OperatingExpensesAbstract_66" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_71" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_71" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_72" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_66" xlink:to="loc_us-gaap_OperatingExpenses_73" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_65" xlink:to="loc_us-gaap_OperatingIncomeLoss_74" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_65" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_67" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_67" xlink:to="loc_us-gaap_InvestmentIncomeInterest_75" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_67" xlink:to="loc_us-gaap_InterestExpense_76" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_67" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_79" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_65" xlink:to="loc_us-gaap_NetIncomeLoss_80" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_65" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_68" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_81" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_68" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_82" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_68" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_83" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_862978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_68" xlink:to="loc_us-gaap_EarningsPerShareBasic_862978" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_85" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_68" xlink:to="loc_us-gaap_EarningsPerShareDiluted_85" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_68" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_87" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_68" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_87" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_89" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_89" xlink:to="loc_us-gaap_StatementTable_90" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_90" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_91" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_91" xlink:to="loc_us-gaap_EquityComponentDomain_92" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_94" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_92" xlink:to="loc_us-gaap_CommonStockMember_94" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_95" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_92" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_95" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_92" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_96" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_92" xlink:to="loc_us-gaap_RetainedEarningsMember_97" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_93" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_90" xlink:to="loc_us-gaap_StatementLineItems_93" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_StockholdersEquity_98" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_SharesOutstanding_99" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_104" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_105" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_106" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IssuanceOfCommonStockAndPrefundedWarrants" xlink:label="loc_cbay_IssuanceOfCommonStockAndPrefundedWarrants_1311634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_cbay_IssuanceOfCommonStockAndPrefundedWarrants_1311634" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares" xlink:label="loc_cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares_1311637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares_1311637" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants" xlink:label="loc_cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants_1341906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants_1341906" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_NetIncomeLoss_109" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_110" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_StockholdersEquity_111" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_93" xlink:to="loc_us-gaap_SharesOutstanding_112" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_114" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_114" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_115" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_117" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_622498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_117" xlink:to="loc_us-gaap_StatementTable_622498" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_622531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622498" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_622531" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_622532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_622531" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_622532" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_622499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622498" xlink:to="loc_us-gaap_StatementClassOfStockAxis_622499" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_622500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_622499" xlink:to="loc_us-gaap_ClassOfStockDomain_622500" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_622501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622498" xlink:to="loc_us-gaap_StatementLineItems_622501" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_622503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622501" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_622503" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_622503" xlink:to="loc_us-gaap_ProfitLoss_125" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_622505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_622503" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_622505" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_622505" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_126" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_622505" xlink:to="loc_us-gaap_ShareBasedCompensation_127" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_1310160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_622505" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_1310160" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AccretionOfDevelopmentFinancingLiability" xlink:label="loc_cbay_AccretionOfDevelopmentFinancingLiability_1310152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_622505" xlink:to="loc_cbay_AccretionOfDevelopmentFinancingLiability_1310152" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_622505" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_128" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_622507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_622505" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_622507" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1329035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_622507" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1329035" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_622507" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_137" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_622507" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_138" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses" xlink:label="loc_cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_1311664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_622507" xlink:to="loc_cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses_1311664" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1311665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_622507" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1311665" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_622503" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_141" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_622515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622501" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_622515" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_622515" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_142" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_622515" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_143" use="optional" order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_622515" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_144" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_622515" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_145" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_622520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622501" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_622520" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_622520" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_147" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants" xlink:label="loc_cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants_1310155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_622520" xlink:to="loc_cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants_1310155" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts" xlink:label="loc_cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts_1310178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_622520" xlink:to="loc_cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts_1310178" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_622520" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_151" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622501" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_152" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622501" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_153" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622501" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_154" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_622521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622501" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_622521" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_622541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_622521" xlink:to="loc_us-gaap_OperatingLeasePayments_622541" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_622522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622501" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_622522" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="loc_us-gaap_LiabilitiesAssumed1_1310157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_622522" xlink:to="loc_us-gaap_LiabilitiesAssumed1_1310157" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/OrganizationAndDescriptionOfBusiness">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_161" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_161" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_162" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_164" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_164" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_165" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/MarketableSecurities">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_167" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_167" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_168" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/CertainBalanceSheetItems">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_170" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_170" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_171" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/InLicenseAgreement">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_173" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_173" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_174" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/DevelopmentFinancingAgreement">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1310217" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DisclosureOfDevelopmentFinancingTextBlock" xlink:label="loc_cbay_DisclosureOfDevelopmentFinancingTextBlock_1310219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1310217" xlink:to="loc_cbay_DisclosureOfDevelopmentFinancingTextBlock_1310219" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_623031" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_623032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_623031" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_623032" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_179" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_179" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_180" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_182" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_182" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_183" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/StockPlansAndStockBasedCompensation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_185" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_185" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_186" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/KPlan">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_188" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_188" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_189" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_194" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_194" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_195" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1341923" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1341924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1341923" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1341924" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_197" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_197" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_199" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_197" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_200" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CashEquivalentsAndInvestmentsPolicyTextBlock" xlink:label="loc_cbay_CashEquivalentsAndInvestmentsPolicyTextBlock_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_197" xlink:to="loc_cbay_CashEquivalentsAndInvestmentsPolicyTextBlock_201" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_197" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_202" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_197" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_203" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_197" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_204" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_197" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_205" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_197" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_207" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DevelopmentFinancingAgreementPolicyTextBlock" xlink:label="loc_cbay_DevelopmentFinancingAgreementPolicyTextBlock_1310185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_197" xlink:to="loc_cbay_DevelopmentFinancingAgreementPolicyTextBlock_1310185" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PrefundedWarrantsPolicyTextBlock" xlink:label="loc_cbay_PrefundedWarrantsPolicyTextBlock_1311510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_197" xlink:to="loc_cbay_PrefundedWarrantsPolicyTextBlock_1311510" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_197" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_208" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_197" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_210" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_197" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_211" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_197" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_212" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_197" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_213" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_215" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_215" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_216" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_215" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_218" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_215" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_219" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/MarketableSecuritiesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_221" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_221" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_222" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1310168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_221" xlink:to="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1310168" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/CertainBalanceSheetItemsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_224" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_224" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_225" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ScheduleOfOtherAccruedLiabilitiesTableTextBlock" xlink:label="loc_cbay_ScheduleOfOtherAccruedLiabilitiesTableTextBlock_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_224" xlink:to="loc_cbay_ScheduleOfOtherAccruedLiabilitiesTableTextBlock_226" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/DevelopmentFinancingAgreementTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1310278" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1310282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1310278" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1310282" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_623034" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_623035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_623034" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_623035" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/StockholdersEquityTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_237" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ReservedSharesOfCommonStockForIssuanceTableTextBlock" xlink:label="loc_cbay_ReservedSharesOfCommonStockForIssuanceTableTextBlock_238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_237" xlink:to="loc_cbay_ReservedSharesOfCommonStockForIssuanceTableTextBlock_238" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_240" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_240" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_241" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_240" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_242" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_240" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_243" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_245" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_245" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_246" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_245" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_247" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_245" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_248" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_253" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_862962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_253" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_862962" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_862963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_862962" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_862963" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_862964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_862963" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_862964" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1341921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_862964" xlink:to="loc_us-gaap_IPOMember_1341921" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_1311677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_862962" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_1311677" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_1311678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_1311677" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_1311678" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AbwCyclopsSpvLpMember" xlink:label="loc_cbay_AbwCyclopsSpvLpMember_1311684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_1311678" xlink:to="loc_cbay_AbwCyclopsSpvLpMember_1311684" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CbayfinancingAgreementFundingInstallmentsAxis" xlink:label="loc_cbay_CbayfinancingAgreementFundingInstallmentsAxis_1311693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_862962" xlink:to="loc_cbay_CbayfinancingAgreementFundingInstallmentsAxis_1311693" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CbayfinancingAgreementFundingInstallmentsDomain" xlink:label="loc_cbay_CbayfinancingAgreementFundingInstallmentsDomain_1311696" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_CbayfinancingAgreementFundingInstallmentsAxis_1311693" xlink:to="loc_cbay_CbayfinancingAgreementFundingInstallmentsDomain_1311696" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementFundingInstallmentsTwoMember" xlink:label="loc_cbay_FinancingAgreementFundingInstallmentsTwoMember_1311701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_CbayfinancingAgreementFundingInstallmentsDomain_1311696" xlink:to="loc_cbay_FinancingAgreementFundingInstallmentsTwoMember_1311701" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1311705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_862962" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1311705" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1311706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1311705" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1311706" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1311708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1311706" xlink:to="loc_us-gaap_SubsequentEventMember_1311708" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1311751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_862962" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1311751" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1311752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1311751" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1311752" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PrefundedWarrantsMember" xlink:label="loc_cbay_PrefundedWarrantsMember_1311753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1311752" xlink:to="loc_cbay_PrefundedWarrantsMember_1311753" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AgreementAxis" xlink:label="loc_cbay_AgreementAxis_1341913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_862962" xlink:to="loc_cbay_AgreementAxis_1341913" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AgreementDomain" xlink:label="loc_cbay_AgreementDomain_1341914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_AgreementAxis_1341913" xlink:to="loc_cbay_AgreementDomain_1341914" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CollaborationAndLicenseAgreementMember" xlink:label="loc_cbay_CollaborationAndLicenseAgreementMember_1341915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_AgreementDomain_1341914" xlink:to="loc_cbay_CollaborationAndLicenseAgreementMember_1341915" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1341917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_862962" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1341917" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1341918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1341917" xlink:to="loc_us-gaap_RelatedPartyDomain_1341918" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_KakenPharmaceuticalCo.LtdMember" xlink:label="loc_cbay_KakenPharmaceuticalCo.LtdMember_1341919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1341918" xlink:to="loc_cbay_KakenPharmaceuticalCo.LtdMember_1341919" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_862967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_862962" xlink:to="loc_us-gaap_ClassOfStockLineItems_862967" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_NumberOfOperatingSegments_254" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_NetIncomeLoss_255" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_256" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_257" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_258" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_1311669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_1311669" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NumberOfFundingInstallments" xlink:label="loc_cbay_NumberOfFundingInstallments_1311721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_cbay_NumberOfFundingInstallments_1311721" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1311739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1311739" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1311740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1311740" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1311741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1311741" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_GrossProceedsFromPublicOffering" xlink:label="loc_cbay_GrossProceedsFromPublicOffering_1312197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_cbay_GrossProceedsFromPublicOffering_1312197" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_UpfrontCashPayment" xlink:label="loc_cbay_UpfrontCashPayment_1341912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_cbay_UpfrontCashPayment_1341912" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1341916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_862967" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1341916" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_260" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_260" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_261" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_261" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_262" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_262" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_271" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_263" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_272" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_261" xlink:to="loc_us-gaap_InvestmentTypeAxis_264" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_264" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_265" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_265" xlink:to="loc_us-gaap_CashEquivalentsMember_274" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_265" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_275" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_261" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_266" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_266" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" xlink:to="loc_us-gaap_MoneyMarketFundsMember_276" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" xlink:to="loc_us-gaap_CommercialPaperMember_277" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_278" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_279" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_UsAgencySecuritiesMember" xlink:label="loc_cbay_UsAgencySecuritiesMember_862947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" xlink:to="loc_cbay_UsAgencySecuritiesMember_862947" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_280" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_SupranationalDebtSecuritiesMember" xlink:label="loc_cbay_SupranationalDebtSecuritiesMember_873482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_267" xlink:to="loc_cbay_SupranationalDebtSecuritiesMember_873482" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_261" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_268" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_268" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_269" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_261" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_270" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_270" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_282" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_285" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_285" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_286" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_286" xlink:to="loc_srt_RangeAxis_287" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_287" xlink:to="loc_srt_RangeMember_288" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_288" xlink:to="loc_srt_MaximumMember_294" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_288" xlink:to="loc_srt_MinimumMember_295" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_286" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_289" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_289" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_290" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_286" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_291" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_291" xlink:to="loc_us-gaap_TypeOfAdoptionMember_292" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CashCashEquivalentsAndMarketableSecuritiesAxis" xlink:label="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesAxis_1310199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_286" xlink:to="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesAxis_1310199" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CashCashEquivalentsAndMarketableSecuritiesDomain" xlink:label="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesDomain_1310202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesAxis_1310199" xlink:to="loc_cbay_CashCashEquivalentsAndMarketableSecuritiesDomain_1310202" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1311649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_286" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1311649" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1311650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1311649" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1311650" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PrefundedWarrantsMember" xlink:label="loc_cbay_PrefundedWarrantsMember_1311652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1311650" xlink:to="loc_cbay_PrefundedWarrantsMember_1311652" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_1311779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_286" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_1311779" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_1311780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_1311779" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_1311780" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaap_ProductInformationLineItems_293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_286" xlink:to="loc_us-gaap_ProductInformationLineItems_293" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CashEquivalentMaturityDescription" xlink:label="loc_cbay_CashEquivalentMaturityDescription_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_293" xlink:to="loc_cbay_CashEquivalentMaturityDescription_299" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ShortTermInvestmentContractualMaturity" xlink:label="loc_cbay_ShortTermInvestmentContractualMaturity_300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_293" xlink:to="loc_cbay_ShortTermInvestmentContractualMaturity_300" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_293" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_302" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1311640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_293" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1311640" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1311641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_293" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1311641" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1311642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_293" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1311642" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_1341993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_293" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_1341993" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_322" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1341979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_322" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1341979" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1341981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1341979" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1341981" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1341982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1341981" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1341982" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1341985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1341979" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_1341985" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="loc_us-gaap_NetIncomeLossAbstract_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1341985" xlink:to="loc_us-gaap_NetIncomeLossAbstract_323" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_862918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_323" xlink:to="loc_us-gaap_NetIncomeLoss_862918" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1341985" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_324" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted" xlink:label="loc_cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted_1341976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_324" xlink:to="loc_cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted_1341976" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding" xlink:label="loc_cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding_1341977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_324" xlink:to="loc_cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding_1341977" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_324" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_329" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1341978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_324" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1341978" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1341985" xlink:to="loc_us-gaap_EarningsPerShareBasic_332" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1341985" xlink:to="loc_us-gaap_EarningsPerShareDiluted_333" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_335" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_335" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_336" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_336" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_337" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_337" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_338" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_EmployeeOrNonEmployeeStockOptionsMember" xlink:label="loc_cbay_EmployeeOrNonEmployeeStockOptionsMember_341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_338" xlink:to="loc_cbay_EmployeeOrNonEmployeeStockOptionsMember_341" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncentiveStockAwardsMember" xlink:label="loc_cbay_IncentiveStockAwardsMember_342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_338" xlink:to="loc_cbay_IncentiveStockAwardsMember_342" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_336" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_339" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_339" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_343" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_359" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_359" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_360" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_360" xlink:to="loc_us-gaap_FinancialInstrumentAxis_361" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_361" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_362" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_362" xlink:to="loc_us-gaap_DebtSecuritiesMember_371" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_360" xlink:to="loc_us-gaap_InvestmentTypeAxis_363" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_363" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_364" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_360" xlink:to="loc_srt_RangeAxis_365" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_365" xlink:to="loc_srt_RangeMember_366" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_360" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_367" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_367" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_376" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments" xlink:label="loc_cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments_377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_367" xlink:to="loc_cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments_377" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="loc_us-gaap_MarketableSecuritiesAbstract_345" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MarketableSecuritiesAbstract_345" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_346" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_636551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_346" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_636551" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_636552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_636551" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_636552" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_636553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_636552" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_636553" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CurrentMarketableSecuritiesMember" xlink:label="loc_cbay_CurrentMarketableSecuritiesMember_636555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_636552" xlink:to="loc_cbay_CurrentMarketableSecuritiesMember_636555" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_MaketableSecuritiesMember" xlink:label="loc_cbay_MaketableSecuritiesMember_637025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_636552" xlink:to="loc_cbay_MaketableSecuritiesMember_637025" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NoncurrentMarketableSecuritiesMember" xlink:label="loc_cbay_NoncurrentMarketableSecuritiesMember_1310173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_636552" xlink:to="loc_cbay_NoncurrentMarketableSecuritiesMember_1310173" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_346" xlink:to="loc_us-gaap_FinancialInstrumentAxis_347" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_347" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_636557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" xlink:to="loc_us-gaap_MoneyMarketFundsMember_636557" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_350" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_351" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_352" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_353" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_UsAgencySecuritiesMember" xlink:label="loc_cbay_UsAgencySecuritiesMember_873410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" xlink:to="loc_cbay_UsAgencySecuritiesMember_873410" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_SupranationalDebtSecuritiesMember" xlink:label="loc_cbay_SupranationalDebtSecuritiesMember_873403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_348" xlink:to="loc_cbay_SupranationalDebtSecuritiesMember_873403" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_346" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_349" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_349" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_354" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_349" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_355" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_349" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_356" use="optional" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_349" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_357" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/MarketableSecuritiesScheduleOfFairValueOfTheCompanyMarketableSecuritiesByContractualMaturityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_1310205" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ContractualObligationFiscalYearMaturityScheduleTable" xlink:label="loc_cbay_ContractualObligationFiscalYearMaturityScheduleTable_1310206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_1310205" xlink:to="loc_cbay_ContractualObligationFiscalYearMaturityScheduleTable_1310206" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ContractualObligationFiscalYearMaturityScheduleLineItems" xlink:label="loc_cbay_ContractualObligationFiscalYearMaturityScheduleLineItems_1311885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_ContractualObligationFiscalYearMaturityScheduleTable_1310206" xlink:to="loc_cbay_ContractualObligationFiscalYearMaturityScheduleLineItems_1311885" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_1310207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_ContractualObligationFiscalYearMaturityScheduleLineItems_1311885" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_1310207" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_1310208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_ContractualObligationFiscalYearMaturityScheduleLineItems_1311885" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_1310208" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1310210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_ContractualObligationFiscalYearMaturityScheduleLineItems_1311885" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_1310210" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_379" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_380" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_379" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_380" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_380" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_381" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_381" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_382" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_382" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_384" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_OfficeAndComputerEquipmentMember" xlink:label="loc_cbay_OfficeAndComputerEquipmentMember_385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_382" xlink:to="loc_cbay_OfficeAndComputerEquipmentMember_385" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_382" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_386" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_382" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_387" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_380" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_383" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_383" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_388" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_383" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_389" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_383" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_390" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/CertainBalanceSheetItemsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_637014" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:label="loc_us-gaap_DepreciationExpenseOnReclassifiedAssets_637015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_637014" xlink:to="loc_us-gaap_DepreciationExpenseOnReclassifiedAssets_637015" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_392" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_622838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_392" xlink:to="loc_us-gaap_StatementTable_622838" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_622844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622838" xlink:to="loc_us-gaap_FinancialInstrumentAxis_622844" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_622847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_622844" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_622847" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_622839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622838" xlink:to="loc_us-gaap_StatementClassOfStockAxis_622839" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_622840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_622839" xlink:to="loc_us-gaap_ClassOfStockDomain_622840" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_622841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_622838" xlink:to="loc_us-gaap_StatementLineItems_622841" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622841" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_393" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AccruedProfessionalFeesAndOtherCurrent" xlink:label="loc_cbay_AccruedProfessionalFeesAndOtherCurrent_394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622841" xlink:to="loc_cbay_AccruedProfessionalFeesAndOtherCurrent_394" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_622834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622841" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_622834" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets" xlink:label="loc_cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_622841" xlink:to="loc_cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets_396" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_398" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_398" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_399" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_400" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_399" xlink:to="loc_srt_CounterpartyNameAxis_400" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_400" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_401" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_JanssenPharmaceuticalNVMember" xlink:label="loc_cbay_JanssenPharmaceuticalNVMember_421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_401" xlink:to="loc_cbay_JanssenPharmaceuticalNVMember_421" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_399" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_402" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_402" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_403" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_399" xlink:to="loc_srt_RangeAxis_404" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_404" xlink:to="loc_srt_RangeMember_405" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_405" xlink:to="loc_srt_MaximumMember_415" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_399" xlink:to="loc_srt_ProductOrServiceAxis_406" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_406" xlink:to="loc_srt_ProductsAndServicesDomain_407" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerBasisOfPricingAxis" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_399" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_408" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerBasisOfPricingDomain" xlink:label="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerBasisOfPricingAxis_408" xlink:to="loc_us-gaap_ContractWithCustomerBasisOfPricingDomain_409" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_399" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_410" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_RoyaltyPercentageBasedOnNetSales" xlink:label="loc_cbay_RoyaltyPercentageBasedOnNetSales_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_410" xlink:to="loc_cbay_RoyaltyPercentageBasedOnNetSales_429" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_410" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_431" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1310223" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1310226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1310223" xlink:to="loc_us-gaap_DebtInstrumentTable_1310226" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementTerminationEventConditionAxis" xlink:label="loc_cbay_FinancingAgreementTerminationEventConditionAxis_1310231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1310226" xlink:to="loc_cbay_FinancingAgreementTerminationEventConditionAxis_1310231" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementTerminationEventConditionDomain" xlink:label="loc_cbay_FinancingAgreementTerminationEventConditionDomain_1310233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_FinancingAgreementTerminationEventConditionAxis_1310231" xlink:to="loc_cbay_FinancingAgreementTerminationEventConditionDomain_1310233" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementTerminationEventConditionOneMember" xlink:label="loc_cbay_FinancingAgreementTerminationEventConditionOneMember_1310236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_FinancingAgreementTerminationEventConditionDomain_1310233" xlink:to="loc_cbay_FinancingAgreementTerminationEventConditionOneMember_1310236" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementTerminationEventConditionTwoMember" xlink:label="loc_cbay_FinancingAgreementTerminationEventConditionTwoMember_1310240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_FinancingAgreementTerminationEventConditionDomain_1310233" xlink:to="loc_cbay_FinancingAgreementTerminationEventConditionTwoMember_1310240" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FinancingAgreementTerminationEventConditionThreeMember" xlink:label="loc_cbay_FinancingAgreementTerminationEventConditionThreeMember_1310242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_FinancingAgreementTerminationEventConditionDomain_1310233" xlink:to="loc_cbay_FinancingAgreementTerminationEventConditionThreeMember_1310242" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_1310248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1310226" xlink:to="loc_srt_CounterpartyNameAxis_1310248" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1310249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1310248" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1310249" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AbwCyclopsSpvLpMember" xlink:label="loc_cbay_AbwCyclopsSpvLpMember_1310250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1310249" xlink:to="loc_cbay_AbwCyclopsSpvLpMember_1310250" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_1310253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1310226" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_1310253" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_1310255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_1310253" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_1310255" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AbwCyclopsSpvLpMember" xlink:label="loc_cbay_AbwCyclopsSpvLpMember_1310256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_1310255" xlink:to="loc_cbay_AbwCyclopsSpvLpMember_1310256" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NumberOfInstallmentFundingAxis" xlink:label="loc_cbay_NumberOfInstallmentFundingAxis_1310318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1310226" xlink:to="loc_cbay_NumberOfInstallmentFundingAxis_1310318" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NumberOfInstallmentFundingDomain" xlink:label="loc_cbay_NumberOfInstallmentFundingDomain_1310319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_NumberOfInstallmentFundingAxis_1310318" xlink:to="loc_cbay_NumberOfInstallmentFundingDomain_1310319" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_InstallmentFundingNumberOneMember" xlink:label="loc_cbay_InstallmentFundingNumberOneMember_1310322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_NumberOfInstallmentFundingDomain_1310319" xlink:to="loc_cbay_InstallmentFundingNumberOneMember_1310322" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_InstallmentFundingNumberTwoMember" xlink:label="loc_cbay_InstallmentFundingNumberTwoMember_1310327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_NumberOfInstallmentFundingDomain_1310319" xlink:to="loc_cbay_InstallmentFundingNumberTwoMember_1310327" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_InstallmentFundingNumberThreeMember" xlink:label="loc_cbay_InstallmentFundingNumberThreeMember_1310329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_NumberOfInstallmentFundingDomain_1310319" xlink:to="loc_cbay_InstallmentFundingNumberThreeMember_1310329" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1310334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1310226" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1310334" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1310335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1310334" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1310335" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_SuccessPaymentTypeAxis" xlink:label="loc_cbay_SuccessPaymentTypeAxis_1310257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1310226" xlink:to="loc_cbay_SuccessPaymentTypeAxis_1310257" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_SuccessPaymentTypeDomain" xlink:label="loc_cbay_SuccessPaymentTypeDomain_1310258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_SuccessPaymentTypeAxis_1310257" xlink:to="loc_cbay_SuccessPaymentTypeDomain_1310258" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FixedSuccessPaymentsMember" xlink:label="loc_cbay_FixedSuccessPaymentsMember_1310259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_SuccessPaymentTypeDomain_1310258" xlink:to="loc_cbay_FixedSuccessPaymentsMember_1310259" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_VariableSuccessPaymentsMember" xlink:label="loc_cbay_VariableSuccessPaymentsMember_1310260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_SuccessPaymentTypeDomain_1310258" xlink:to="loc_cbay_VariableSuccessPaymentsMember_1310260" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1310262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1310226" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1310262" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1310267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1310267" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_1310270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_1310270" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DescriptionOfPercentageFixedSuccessPayments" xlink:label="loc_cbay_DescriptionOfPercentageFixedSuccessPayments_1310271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_DescriptionOfPercentageFixedSuccessPayments_1310271" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_1310272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_1310272" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AnniversaryPaymentsDueYearOne" xlink:label="loc_cbay_AnniversaryPaymentsDueYearOne_1310273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_AnniversaryPaymentsDueYearOne_1310273" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AnniversaryPaymentsDueYearTwo" xlink:label="loc_cbay_AnniversaryPaymentsDueYearTwo_1310274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_AnniversaryPaymentsDueYearTwo_1310274" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AnniversaryPaymentsDueYearThree" xlink:label="loc_cbay_AnniversaryPaymentsDueYearThree_1310275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_AnniversaryPaymentsDueYearThree_1310275" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_Anniversarypaymentsdueyearfour" xlink:label="loc_cbay_Anniversarypaymentsdueyearfour_1310277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_Anniversarypaymentsdueyearfour_1310277" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AnniversaryPaymentsDueYearFive" xlink:label="loc_cbay_AnniversaryPaymentsDueYearFive_1310279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_AnniversaryPaymentsDueYearFive_1310279" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AnniversaryPaymentsDueYearSix" xlink:label="loc_cbay_AnniversaryPaymentsDueYearSix_1310281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_AnniversaryPaymentsDueYearSix_1310281" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DescriptionOfPercentageVariableSuccessPayments" xlink:label="loc_cbay_DescriptionOfPercentageVariableSuccessPayments_1310284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_DescriptionOfPercentageVariableSuccessPayments_1310284" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne" xlink:label="loc_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne_1310289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne_1310289" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo" xlink:label="loc_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo_1310295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo_1310295" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PaymentsUponReachingProductSalesRunRate" xlink:label="loc_cbay_PaymentsUponReachingProductSalesRunRate_1310298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_PaymentsUponReachingProductSalesRunRate_1310298" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DescriptionOfAggregateReturnFromTheFundsProvided" xlink:label="loc_cbay_DescriptionOfAggregateReturnFromTheFundsProvided_1310302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_DescriptionOfAggregateReturnFromTheFundsProvided_1310302" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AggregateReturnPercentageFromTheFundsProvided" xlink:label="loc_cbay_AggregateReturnPercentageFromTheFundsProvided_1310305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_AggregateReturnPercentageFromTheFundsProvided_1310305" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided" xlink:label="loc_cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided_1310355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided_1310355" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement" xlink:label="loc_cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement_1310358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement_1310358" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement" xlink:label="loc_cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement_1310365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement_1310365" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability" xlink:label="loc_cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability_1310376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1310262" xlink:to="loc_cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability_1310376" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/DevelopmentFinancingAgreementScheduleOfChangesInFairValueOfLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1310296" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1310301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1310296" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1310301" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_1310299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1310296" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_1310299" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability" xlink:label="loc_cbay_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability_1310309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1310296" xlink:to="loc_cbay_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability_1310309" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1310311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1310296" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1310311" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_623038" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_623039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_623038" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_623039" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_623040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_623038" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_623040" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_623044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_623038" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_623044" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_623045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_623038" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_623045" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_623046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_623038" xlink:to="loc_us-gaap_OperatingLeaseLiability_623046" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_623047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_623038" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_623047" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1329110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_623038" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1329110" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_623070" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_623090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_623070" xlink:to="loc_us-gaap_StatementTable_623090" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_623094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_623090" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_623094" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_623095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_623094" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_623095" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_623096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_623095" xlink:to="loc_us-gaap_OperatingExpenseMember_623096" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_623098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_623090" xlink:to="loc_us-gaap_LeaseContractualTermAxis_623098" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_623099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_623098" xlink:to="loc_us-gaap_LeaseContractualTermDomain_623099" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_LeaseFacilityMember" xlink:label="loc_cbay_LeaseFacilityMember_623100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_623099" xlink:to="loc_cbay_LeaseFacilityMember_623100" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_623090" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_623111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_623111" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_623113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_623113" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_623114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_623114" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_623115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_623115" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_623116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_OperatingLeaseLiability_623116" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_623117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_623117" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1312172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1312172" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_623124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_us-gaap_OperatingLeaseCost_623124" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NumberOfLeasedFacilitiesOperatingLeases" xlink:label="loc_cbay_NumberOfLeasedFacilitiesOperatingLeases_623125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_cbay_NumberOfLeasedFacilitiesOperatingLeases_623125" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AreaOfOfficeSpace" xlink:label="loc_cbay_AreaOfOfficeSpace_623126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_cbay_AreaOfOfficeSpace_623126" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_LeaseStartDate" xlink:label="loc_cbay_LeaseStartDate_623127" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_623110" xlink:to="loc_cbay_LeaseStartDate_623127" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_488" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_488" xlink:to="loc_us-gaap_LossContingenciesTable_489" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_862874" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_489" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_862874" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_862875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_862874" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_862875" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_1310169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_489" xlink:to="loc_us-gaap_LitigationStatusAxis_1310169" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_1310171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_1310169" xlink:to="loc_us-gaap_LitigationStatusDomain_1310171" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_1310172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_1310171" xlink:to="loc_us-gaap_PendingLitigationMember_1310172" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_489" xlink:to="loc_us-gaap_LeaseContractualTermAxis_490" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_490" xlink:to="loc_us-gaap_LeaseContractualTermDomain_491" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_489" xlink:to="loc_us-gaap_LossContingenciesLineItems_492" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyLawsuitFilingDate" xlink:label="loc_us-gaap_LossContingencyLawsuitFilingDate_862877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_492" xlink:to="loc_us-gaap_LossContingencyLawsuitFilingDate_862877" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:label="loc_us-gaap_LossContingencyNameOfPlaintiff_862879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_492" xlink:to="loc_us-gaap_LossContingencyNameOfPlaintiff_862879" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAllegations" xlink:label="loc_us-gaap_LossContingencyAllegations_862880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_492" xlink:to="loc_us-gaap_LossContingencyAllegations_862880" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyActionsTakenByDefendant" xlink:label="loc_us-gaap_LossContingencyActionsTakenByDefendant_862881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_492" xlink:to="loc_us-gaap_LossContingencyActionsTakenByDefendant_862881" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IndemnificationLiability" xlink:label="loc_cbay_IndemnificationLiability_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_492" xlink:to="loc_cbay_IndemnificationLiability_501" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyActionsTakenByCourtArbitratorOrMediator" xlink:label="loc_us-gaap_LossContingencyActionsTakenByCourtArbitratorOrMediator_1310167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_492" xlink:to="loc_us-gaap_LossContingencyActionsTakenByCourtArbitratorOrMediator_1310167" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_513" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_514" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_513" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_514" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_859726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_514" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_859726" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_859727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_859726" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_859727" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_515" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_514" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_515" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_516" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_515" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_516" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_516" xlink:to="loc_us-gaap_SubsequentEventMember_520" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_517" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_514" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_517" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_518" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_517" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_518" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PrefundedWarrantsMember" xlink:label="loc_cbay_PrefundedWarrantsMember_1311884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_518" xlink:to="loc_cbay_PrefundedWarrantsMember_1311884" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1311908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_514" xlink:to="loc_srt_RangeAxis_1311908" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1311909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1311908" xlink:to="loc_srt_RangeMember_1311909" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_514" xlink:to="loc_us-gaap_ClassOfStockLineItems_519" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_519" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_524" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_519" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_525" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_519" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_531" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1311859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_519" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1311859" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1311860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_519" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1311860" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1312019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_519" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1312019" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1311792" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1311793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1311792" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1311793" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1311794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1311793" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1311794" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1311795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1311794" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1311795" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PrefundedWarrantsMember" xlink:label="loc_cbay_PrefundedWarrantsMember_1311796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1311795" xlink:to="loc_cbay_PrefundedWarrantsMember_1311796" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1311799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1311793" xlink:to="loc_us-gaap_AwardTypeAxis_1311799" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1311800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1311799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1311800" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_OptionsAndIncentiveAwardsMember" xlink:label="loc_cbay_OptionsAndIncentiveAwardsMember_1311802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1311800" xlink:to="loc_cbay_OptionsAndIncentiveAwardsMember_1311802" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1311803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1311793" xlink:to="loc_us-gaap_PlanNameAxis_1311803" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1311804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1311803" xlink:to="loc_us-gaap_PlanNameDomain_1311804" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember" xlink:label="loc_cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember_1311809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1311804" xlink:to="loc_cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember_1311809" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember" xlink:label="loc_cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember_1311815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1311804" xlink:to="loc_cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember_1311815" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1311812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1311793" xlink:to="loc_us-gaap_ClassOfStockLineItems_1311812" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1311813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1311812" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1311813" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_554" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_554" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_863429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" xlink:to="loc_srt_RangeAxis_863429" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_863430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_863429" xlink:to="loc_srt_RangeMember_863430" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" xlink:to="loc_us-gaap_PlanNameAxis_556" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_556" xlink:to="loc_us-gaap_PlanNameDomain_557" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember" xlink:label="loc_cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember_862867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_557" xlink:to="loc_cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember_862867" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_EquityIncentivePlanTwoThousandAndThirteenMember" xlink:label="loc_cbay_EquityIncentivePlanTwoThousandAndThirteenMember_567" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_557" xlink:to="loc_cbay_EquityIncentivePlanTwoThousandAndThirteenMember_567" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncentiveStockAwardsMember" xlink:label="loc_cbay_IncentiveStockAwardsMember_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_557" xlink:to="loc_cbay_IncentiveStockAwardsMember_575" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" xlink:to="loc_us-gaap_AwardTypeAxis_558" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_558" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_559" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember" xlink:label="loc_cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_559" xlink:to="loc_cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember_568" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NonQualifiedStockOptionsMember" xlink:label="loc_cbay_NonQualifiedStockOptionsMember_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_559" xlink:to="loc_cbay_NonQualifiedStockOptionsMember_569" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_570" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_559" xlink:to="loc_us-gaap_RestrictedStockMember_570" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_StockOptionsToTenPercentShareholdersMember" xlink:label="loc_cbay_StockOptionsToTenPercentShareholdersMember_571" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_559" xlink:to="loc_cbay_StockOptionsToTenPercentShareholdersMember_571" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_560" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_560" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_561" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" xlink:to="loc_srt_TitleOfIndividualAxis_562" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_625331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_562" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_625331" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" xlink:to="loc_us-gaap_VestingAxis_564" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_564" xlink:to="loc_us-gaap_VestingDomain_565" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_555" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_578" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_579" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_580" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage" xlink:label="loc_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage_581" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_582" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_584" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_585" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_586" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_586" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_587" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_587" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_590" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_591" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_566" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_595" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_601" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_601" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_602" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_602" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_606" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_602" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_607" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_602" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_608" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_602" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_609" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_623021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_602" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_623021" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_602" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_610" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_602" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_611" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_602" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_612" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_601" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_603" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_603" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_613" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_603" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_614" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_603" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_615" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_603" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_616" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_623258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_603" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_623258" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_603" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_617" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_603" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_618" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_619" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_603" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_619" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_601" xlink:to="loc_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_604" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_604" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_620" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_604" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_621" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_604" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_622" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_601" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_605" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_605" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_623" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_605" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_624" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_605" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_625" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_627" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_627" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_628" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_628" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_629" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_629" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_630" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_632" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_630" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_632" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_630" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_633" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_628" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_631" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_631" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_634" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637" xlink:to="loc_us-gaap_AwardTypeAxis_638" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_638" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_639" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_640" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_640" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_643" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_640" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_644" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_640" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_645" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_640" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_646" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_640" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_647" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/KPlanAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_649" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_EmployerMatchingContributionToQualifiedSavingsPlan" xlink:label="loc_cbay_EmployerMatchingContributionToQualifiedSavingsPlan_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_649" xlink:to="loc_cbay_EmployerMatchingContributionToQualifiedSavingsPlan_650" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_652" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncomeTaxTable" xlink:label="loc_cbay_IncomeTaxTable_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_652" xlink:to="loc_cbay_IncomeTaxTable_653" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxTable_653" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_654" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_654" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_655" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_655" xlink:to="loc_us-gaap_DomesticCountryMember_661" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_655" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_662" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FederalAndStateTaxAuthorityMember" xlink:label="loc_cbay_FederalAndStateTaxAuthorityMember_1341998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_655" xlink:to="loc_cbay_FederalAndStateTaxAuthorityMember_1341998" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxTable_653" xlink:to="loc_srt_RangeAxis_656" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_656" xlink:to="loc_srt_RangeMember_657" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_657" xlink:to="loc_srt_MinimumMember_663" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_657" xlink:to="loc_srt_MaximumMember_664" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxTable_653" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_658" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_658" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_659" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_FederalMember" xlink:label="loc_cbay_FederalMember_636645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_659" xlink:to="loc_cbay_FederalMember_636645" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_OrphanDrugMember" xlink:label="loc_cbay_OrphanDrugMember_665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_659" xlink:to="loc_cbay_OrphanDrugMember_665" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncomeTaxLineItems" xlink:label="loc_cbay_IncomeTaxLineItems_660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxTable_653" xlink:to="loc_cbay_IncomeTaxLineItems_660" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_636651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_OperatingLossCarryforwards_636651" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_636653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_636653" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_ProvisionForStateAndLocalIncomeTaxes" xlink:label="loc_cbay_ProvisionForStateAndLocalIncomeTaxes_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_cbay_ProvisionForStateAndLocalIncomeTaxes_666" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_670" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_OperatingLossCarryforwards_673" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_674" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_NetOperatingLossCarryforwardExpirationYear" xlink:label="loc_cbay_NetOperatingLossCarryforwardExpirationYear_675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_cbay_NetOperatingLossCarryforwardExpirationYear_675" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_676" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaap_IncomeTaxExaminationDescription_677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_IncomeTaxExaminationDescription_677" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OpenTaxYear" xlink:label="loc_us-gaap_OpenTaxYear_1329185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_OpenTaxYear_1329185" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AlternateMinimumTaxRate" xlink:label="loc_cbay_AlternateMinimumTaxRate_1341989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_cbay_AlternateMinimumTaxRate_1341989" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1341990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_us-gaap_Revenues_1341990" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_WriteOffOfTaxAttributeDueToLimitation" xlink:label="loc_cbay_WriteOffOfTaxAttributeDueToLimitation_1341995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_cbay_WriteOffOfTaxAttributeDueToLimitation_1341995" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible" xlink:label="loc_cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible_1341996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible_1341996" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage" xlink:label="loc_cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage_1341997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_IncomeTaxLineItems_660" xlink:to="loc_cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage_1341997" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_679" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_679" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_680" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_680" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_682" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_649597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_680" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_649597" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment" xlink:label="loc_cbay_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment_1342000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_680" xlink:to="loc_cbay_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment_1342000" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_680" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_685" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_680" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_686" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_680" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_687" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_680" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_681" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_681" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_688" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_636627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_681" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_636627" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_681" xlink:to="loc_us-gaap_DeferredTaxLiabilities_689" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_681" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_690" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_680" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_691" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_693" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_693" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_694" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_695" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_693" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_695" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_1341984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_693" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_1341984" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_693" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_699" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncomeTaxReconciliationTaxCancelledOptions" xlink:label="loc_cbay_IncomeTaxReconciliationTaxCancelledOptions_862864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_693" xlink:to="loc_cbay_IncomeTaxReconciliationTaxCancelledOptions_862864" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncomeTaxReconciliationDevelopmentFinancingLiability" xlink:label="loc_cbay_IncomeTaxReconciliationDevelopmentFinancingLiability_1310149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_693" xlink:to="loc_cbay_IncomeTaxReconciliationDevelopmentFinancingLiability_1310149" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_IncomeTaxReconciliationPermanentDifferences" xlink:label="loc_cbay_IncomeTaxReconciliationPermanentDifferences_1329161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_693" xlink:to="loc_cbay_IncomeTaxReconciliationPermanentDifferences_1329161" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_693" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_697" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_648278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_693" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_648278" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_693" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_700" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/IncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_702" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_703" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_703" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_704" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_859717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_859717" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_705" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_705" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_702" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_706" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1341926" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1341927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1341926" xlink:to="loc_us-gaap_SubsequentEventTable_1341927" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1341940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1341940" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1341941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1341940" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1341941" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1341942" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1341941" xlink:to="loc_us-gaap_SubsequentEventMember_1341942" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AgreementAxis" xlink:label="loc_cbay_AgreementAxis_1341943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_cbay_AgreementAxis_1341943" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_AgreementDomain" xlink:label="loc_cbay_AgreementDomain_1341944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_AgreementAxis_1341943" xlink:to="loc_cbay_AgreementDomain_1341944" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_CollaborationAndLicenseAgreementMember" xlink:label="loc_cbay_CollaborationAndLicenseAgreementMember_1341945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cbay_AgreementDomain_1341944" xlink:to="loc_cbay_CollaborationAndLicenseAgreementMember_1341945" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1341972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1341972" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1341973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1341972" xlink:to="loc_us-gaap_RelatedPartyDomain_1341973" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1341930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1341930" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1341931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1341930" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1341931" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PrefundedWarrantsMember" xlink:label="loc_cbay_PrefundedWarrantsMember_1341932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1341931" xlink:to="loc_cbay_PrefundedWarrantsMember_1341932" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1341933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_srt_RangeAxis_1341933" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1341934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1341933" xlink:to="loc_srt_RangeMember_1341934" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1341946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1341946" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1341947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1341946" xlink:to="loc_us-gaap_EquityComponentDomain_1341947" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1341957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1341957" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1341958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1341957" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1341958" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1341961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1341961" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1341962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1341961" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1341962" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1341928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1341927" xlink:to="loc_us-gaap_SubsequentEventLineItems_1341928" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_PotentialMilestonePayments" xlink:label="loc_cbay_PotentialMilestonePayments_1341968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1341928" xlink:to="loc_cbay_PotentialMilestonePayments_1341968" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="cbay-20221231.xsd#cbay_UpfrontCashPayment" xlink:label="loc_cbay_UpfrontCashPayment_1341969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1341928" xlink:to="loc_cbay_UpfrontCashPayment_1341969" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1341951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1341928" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1341951" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1341954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1341928" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1341954" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1341955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1341928" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1341955" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1341975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1341928" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1341975" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1341999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1341928" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1341999" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g446975g00g01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g446975g00g01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1V:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '7Z^=5 X0DE-! 0      "$< 5H  QLE1QP"   "   < @4 #7!R:6YT
M;6=R(&9I;&4 .$))300E       0"<2=# TR":T*.P^V)B,ZT3A"24T$.@
M    Y0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L
M 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N
M0FET8F]O;      +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O
M;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R
M;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP
M<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U='!U
M=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S
M36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M     $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C
M:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M    1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R
M9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M %)S;'15;G1&(U!X;$!9AHD         "G9E8W1O<D1A=&%B;V]L 0    !0
M9U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M        5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M           08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T
M=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E
M8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M       0 [_^-0 "  $#O_XU  (  3A"24T$)@      #@             _
M@   .$))300-       $    >#A"24T$&0      !    !XX0DE- _,
M  D           $ .$))32<0       *  $          3A"24T#]0
M2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M    !@       0 U     0 M    !@       3A"24T#^       <   ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              "(
M  !D          $                          0              9
M "(                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M "(     4F=H=&QO;F<   !D    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M*       #     (_\        #A"24T$%       !     ,X0DE-! P
M$V0    !    9    "(   $L   GV   $T@ &  !_]C_X@Q824-#7U!23T9)
M3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P
M35-&5     !)14,@<U)'0@               0  ]M8  0    #3+4A0("
M
M !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "
M!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD
M   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U    "1L
M=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#   $/
M" QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H
M8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2
M<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N
M,0
M        6%E:(        /-1  $    !%LQ865H@
M %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@
M        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE
M8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                  !D97-C
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O
M;&]U<B!S<&%C92 M('-21T(                             9&5S8P
M       L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V
M+3(N,0              +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I
M;B!)14,V,3DV-BTR+C$                                  '9I97<
M     !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0
M    5Q_G;65A<P         !                         H\    "<VEG
M(     !#4E0@8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W
M #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     /_B__])
M0T-?4%)/1DE,10 !";[,_OX>  B <$%$0D4"$   <')T<D--64M,86(@!]
M!P :  4 *0 U86-S<$%04$P     041"10                    $  /;6
M  $     TRU!1$)%
M                   *9&5S8P   /P   !T8W!R=    7     K=W1P=
M 9P    403)",    ;   *(&03)",@   ;   *(&03)",0  H[@  *(&0C)!
M,  !1<   CBT0C)!,0 #?G0  CBT0C)!,@ %MR@  CBT9V%M=  '[]P  )"1
M9&5S8P         :52Y3+B!796(@0V]A=&5D("A35T]0*2!V,@
M
M                                  !T97AT     $-O<'ER:6=H=" R
M,# P($%D;V)E(%-Y<W1E;7,L($EN8RX  %A96B        "U6@  O&<  )(P
M;69T,@     $ PD   $                    !
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MY ]^5XFRRMM^3X@4L3Y^7(:TER]^@H6;?)-^OH2Z8.E_#X/T0P!_EH-X':*
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MS*^"-L4[M9B!9;Y#G@. RK?+A@F :;'=;7> ,ZR-4\: "*A6-TV "J-<$*Z
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MZ(LX.$&8:HJB'LJ7UXNS  "2>(  JD&LRIRTF-JHF)G"AO.DE)<7='6@SY3
M84V=2Y*P34*:/9$H-[^7N)!K'G67%)!A  N1DH 'J9"L+*7,F"^G_*(QADBC
M^9[B<\J@-9OO8*J<LIE<3*^9CY=K-TV7"I;E'BB67Y18 !N0Q( 2J.*KN:\#
MEZ*G?:JXA<*C<J;#<T"?K*-#8"F<-J!/3$&9')X[-O:6@)U]'?.5R)1  "B0
M&8 ;J$*K8;ATEQFG&[-[A4.C#:[G<LB?2*KD7[N;UJ>I2^&8Q:7C-K"6(Z+K
M'<R53Y0F #./CX BI[FK%<)>EJ:FQ+RKA-:BMK=Q<F*>]K+Z7V.;AJ^Z2YR8
M=:T?-GN5W:36':>5"90- #R/(( HG["ZA'ETCM6UJWDZ?=&P_'DR;&2LBWEG
M6CBH9'G41N^DKGIJ,>NAYGL'%_"B<GN^  "1*(  GJ:YMH&DCD*TPH"]?6*P
M!8 -:_.KC'^>6;BG9']R1FRCKG^#,6R@WG_!%["A.X"Z  "0;H  G?>XRXG5
MC9JSWHA)?,^O&H;N:U6JHX7M61ZF>H4T1>&BQH3,,/J?[(3$%X&@'(8$  "/
MRX  G6BW\Y(0C/BS#X_G?!JN4HW[:JJISHQC6'VEJXLM15FA]HI7,)6?$XHL
M%UR?'(JP  "//H  G-6W1IIIC&*R89>F>WNMII4T:@:I)),85^VD\)%=1.&A
M/Y U,#Z>4I J%SZ>-HZX  ".Q(  G#NVOZ+NB]FQT9^2>OJM#YR/:8NHCYGX
M5WFD6I?61'V@DI9P+_B=GI:D%R>=9X^H  ".7H  F\BV-JN@BW"Q1*>E>IBL
M@J03:2^H!*$%5R6CU)Z71#F@")U)+\2<\)PG%Q6<J(^;  "."H  FTJUU[2,
MBR*PU*_;>E>L ZNK:.FG>:@Q5M^C2Z6P0_R?E:2>+YR<AJ Q%Q6<%X^;  "-
MQ8  FMFUAKWKBLNP=+B#>@ZKH;.V:*RG&Z_C5K*B[ZV@0]^?.*JG+Y&<+Z I
M%Q^;MH^B  "-CH  D?/%8WD8@A^_TGC+<A:Z?'BY8:.U:7CJ4'&PIWE3/@NL
M<WGD*::IEGIJ#V:K67L+  "-0X  D3?$BX#F@;:^\W_X<<*YD']*84JT;7[B
M4 VOGG[$/:VK7W[E*5VH9G\R#X6IPX!$  ",_H  D,W#DHBH@4>^"(<G<5ZX
MGH7<8-NS=83S3Z&NGX19/5*J6H09*2.G2H1.#Z^H3X3N  ",P8  D('"J9!K
M@.B](XY?<.FWO(R58&NRAHLF3SJMLHHE/0"I:HF3*/:F2(GC#]JG!(D"  ",
MC(  D"S!Z)A/@)2\6Y6U<)*V\)-T8 NQNY&53NBLUI F/,.HDH]I*->E8Y ;
M$ 2EX8K4  ",7H  C\?!4*!B@$*[M9TW<$VV0)IS7\^Q"9@L3JZL)I9Q/)6G
MT)6R*,*DEI6\$"NDXXKN  ",.(  CV; U:B4?_R[*J30<!:UJJ&'7Z*P;Y[?
M3HFKDYT'/'VG.IRL*+BCX)IN$$ZD!HL&  ",&8  CR; 4;#U?\RZH:R3;_:U
M'ZC+7XVOXZ783G>K":0:/&^FO*+_*+.C4YN%$&RC1(L;  "+_X  CM2_\+G)
M?ZZZ+;2;;^VTF[ M7X>O4:SZ3GNJ<*M</("F(*?U*-RBR)N@$+"BN(M(  "+
MZX  A+30GWCS==?*67B#9J[$;WA;5Q&^UGA]1K.YDWC:-0>U"'E8(/:R=WFN
M!^NRV7M%  ")^8  A&+/GX!N=9O)?G]G9G##C'ZM5LZ]UGY$1G&X='XI--FS
MS'Y0(/:P_GZ?"&>PZG_G  "*%H  A$K.A8?%=6_(?(9!9D/"A83Z5IF\O80A
M1C^W2X.>-+ZRD8.!(0NOE8/X".:O*(/^  "*+X  A$;-?(\6=5_';(T99B#!
M<HMG5G:[FXH:1B2V*(E(-+6Q9HC^(2RN28GD"5VMFX95  "*18  A#G,F):%
M=5C&>)0'9AW <)'P5FJZEY!)1B&U%8\D-,2P58[?(5JM((]["<RL0H:@  "*
M6(  A!W+U)XA=5#%I)L:9BB_CIB05H.YKY:91CBT+Y5+-..O795*(9*L&)1
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M<AN L) M7#6 A(Y410" :(R\*GB A(P)!J. YH1]P#"![:.^K;B!0*"6FE>
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MVX!E<^V1Y8 <8060'7_Q30&.F'_?-V.-@7_6'7>-_G_S  "'<H  I?67-HI
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M>*U&94&5JJFN4[23*J<.02^1$J4Z+0Z/?9YV% *0#(V'  " BX  C)RO-&X
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M>ZZFEI3-;)BC!9+L7+J?H9$Y3 F<A8_1.C*9W8[T)EN8/X];#4*9)XCW  "
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M<<>TR76,8Y&PGG7I5(JLJ79B1':I"7;P,NNF)G=U'L2E,'>2!B"E(7C%  "
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M< NP$IFV8<:KR9>94KZGKY7$0N*C]I2",=*@WI1Z'GZ?+I*G!TZ=>(3Q  "
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M9:J^<GM%6":YM7K]2=:U)'KW.HBQ WL2*9ZM\GLX%6ZMWGL$ *.GTWTN  "
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M93VYS)X:5[&TU9ON262P%IHZ.CJKTIFV*;>H?9AY%H6G38\Z HV@LX&Z  "
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MELB#1:"(A:V"=IVL<YF!PIK*8,2!-Y@F30" S97R-\> =I2Z'E& ;))7  "
M (  IDJ#CZT(EB."OJFZA/B!YZ8F<N&!)J*,8!* EY]63%. .9S9-S=_WYNU
M'?A_IY1$  "  (  I>.#+;<:E:2"8+,SA%Z!?*[K<CR J:J@7WR $*;O2]=_
MKZ1Z-LU_6*%Y'9Y_#90'  "  (  GJ:5'FE.C]23)FLC?^Z1>6S4;LR0 VYJ
M7(V.L&_V20^-G7%T,]:-$'*R&8>.HG+V  "#%GJ\G>R3E'):CQ:1R'--?Q20
M)W0S;?J.K'446\2-6'7Y2%6,17;9,RB+K7>*&/V- '>#  "!H7X?G1B2$WM.
MCA"08GM]?B&.QGNG;0"-6'O86N",#7P81XZ+ 7Q?,GZ*8WR1&'Z+?'QL  "
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MB?6+V*7I>=R*1*+-:-R(R9^W5Q*'B)T/1$"&BYM)+^:%O9HI%KZ%X8]A  "
M (  F+V-"+)6B82+>Z[Q>5:)W*LY:$Z(4J>05I&'!J240]6&!*+V+X:%.)\=
M%FN%2(\H  "  (  D-B>X6C,@M><3&J-<]^: FPT8\27[VW%4H>6"V])/^R4
MAG"Q*TJ3Z'&S$&R6WG$O  "  'W0D$"=C7%C@DB;$')1<SR8PW,Z8R:6HW0B
M4?"4MG4,/V63*G7I*M.2=79Z$#B4]77R  "  (  CYB<(7G9@769NGH2<GV7
M;7I-8F"54WJ543V3:GKI/LN1X7M *EF1''MQ$ :3+WLE  "  (  CL^:S((]
M@)*8;H';<826+8%Y89"4$X$F4'N2-X#J/BJ0LX#"*=Z/XH"I#]*1DH"J  "
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M?<.4]*K<;I&2FJ>H7H*05J213;2.6Z)1.\^,QJ#U*!^+KYLA#QR+^8HW  "
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M<_"A)(=X9;6>/(:M5I^;>87Q1I:8^H5<-1N7#X4"(5J60H44"+R5WX/1  "
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M:?6P.&D(7("LY6J,3ABIO&P"/H>FXFU<+3VDZVYK&+FEEVYL 8FBJG "  "
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M:"BJ=8QR6J^FXXM83%^C>8I8/1Z@:(F:+%^>&(EH&-*=MHF# R.8MH(?  "
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M7<^Z.6[84/6V0F^<0T6R=W!N-%NO+G$Q(W.M2G&<#K6NZ'#F  "=P'@I  "
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M712T1Y#(4#^P&(^"0I2L&XYL,_&HFXWA(Z>F,HY%$"*F68KI  "8WX    "
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MKW44/3A]+'8=(T-]R7:? ;9_KGAQKAUXU7B1G>!Y37D9C+YYMGF1>DMZ)GH
M9N1ZG'IV4F9['WKM/'![G7M,(IQ\ GM4 7U^*WQ7K+AW$()GG'-WF((EBS=X
M%H'/>/IXEH%R9:YY)X$F45IYO(#E.X]Z.H"C(>9Z9(!6 4M]T7^ZJV9UEXQ
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MDZ"%%F:)@Y>$G&C"<C^$1VK17[B$"VS*2_&#\FZL-H&$('!('&6%87#F  "
M3':ZH9B#N&V#DJ>#16\)@H""Z'!M<36"GW&^7L.":W,$2Q>"6G0[-<""?74X
M&\B#;W5F  "  'JYH(N!V7;5D6:!B'>+@5V!.W@K<!*! WC 7<" WGE52CB
MUWGD-06 \WI/&S>!FGHL  "  'XZGV: &8 ED#-_W8 B@!=_IX #;Q-_>7_>
M7-M_9'_"28!_9G^M-'A_?G^4&LI_X7]7  "  (  GCM^L(E]CR1^?8C/?P=^
M4(?_;>1^*X<=6]9^'H9*2)%^,H69,[)^0H4-&CE^684,  "  (  G41]D)+N
MCB1]99&5?@I].I /;/)]&8YW6O5]#HSX1]=]&8NQ,QQ])(K=&<=\^XIF  "
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MABN+]VW^=PZ*Y6]H9LN)]'# 55F))7(+0I&(DW,_+=^(?70>$V**?7.L  "
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M@9J%>)<7<H6$B94Y8F>#J9-&46V"\I&*/U6"99!"*V^!^Y =$>6"'HP9  "
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M>.Z3B'2E:M*1V75D6WN0478>2PR.]7;4.2Z-^G=T)0Z-U'>["QR.R'=]  "
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M=7:.0IP%9SJ,EYGO6 2*]I?,1^J)DY8:-H^(C)5K(S2'Z905"K:'$(<^  "
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M;#*;NWIA7LV9>'J<4'R76'K<0.R5@7L=+].4/'M/&_>49WLQ!'21P'Q,  "
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M:@*7C:![7(N5)YY<3AR2S)Q$/M*0Q)L9+B>/2YGP&P>.S9)&!-B+4H-&  "
M (  ;@:M.6&38@.J76.253JGMV6#1VFE.V=7.$VC'6CW)S:B%VH;$BJD?VFG
M  "8TVYB  "  (  ;8.L$&D_8;JI&VJ/5/VF1FOA1T"CH&TJ.#>A8&Y3)S^@
M,6\;$G&B+6Z*  "7+7-I  "  (  ;1>J@7"S83FGDW%S5)BDM'(W1MZB W,!
M-^V?N7.Z)QN><G0N$I*@$W.8  "5H'@P  "  (  ;*&HZG@(8*^F WA34_VC
M+'B<1FJ@>GCO-XF>,WE!)MV<W'EL$I>>,GCU  "4,'QC  "  (  ;"BGD']L
M8#BDKW]04X&AV7\K1>.?)G\$-S&<T'[T)IV;<'[R$I*<AG[C  "2Z(    "
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M5?2U?&)22:&RD&08/&&OPV7#+;NMC&<E')*M1&>X"%RNI&=K  "36'+8  "
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M5,>N@8.72*.K)(,J.YNG\8+!+6^E2(*#'26D$(*@"B>CS((Y  "-XX    "
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MDHUQ%WQ/@EAR'WR,<1ES'GRY7KAT)7SI2SQU'GT8-C5UU7TV'/-U=WT#  "
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MC@AK/:ER?<%L5*7R;)=M7Z)K6J5N?9]-1[5OBIT#,U9O_YMX&L1N1Y(9  "
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MA:YW?X+S=H1WZH*P9DUX4H)251]XQX'[0I9Y2(&T+E=YDH%V%.EY38%3  "
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M?A&'K6#';].''6-J8$>&N&7;3W2&<6@G/2N&9FH[*+R&[6NY#@:(_FM'  "
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M>39^V(C3:P)^FX@C6\)^7H=62XU^-X:7.?U^+(8))E%^)(79#0U^>H2C  "
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M<2J.L&>@8[*-F6E_51F,I&M#13:+W&SE,[6+?6Y%'XZ,)V[@!FJ+]F[P  "
M '_>?*Z-UVW1<#J,Q6\C8N2+O'!B5$Z*T'&.1(N*#7*C,RZ)J7.&'S:*(W/,
M!G>)GW0K  "  (  >\F+[77I;T2*[G:J8=Z)^7=44X6)$W?Q0]>(77A[,J.'
M]GCG'MV(1GCM!GR'DGF_  "  (  >NF*2GX%;GB)6'Y$81F(:WYD4K"'CGYJ
M0U&&RWYM,C:&9WYW'IV&C'YC!HR%QGZO  "  (  >B*(^H9$;;F(%H7[8%Z'
M*H6'4@N&0H3X0KJ%?(1Q,?*$]X0@'FZ$^80[!I&$/(+;  "  (  >8.'](Z,
M;3J'&HW.7^.&)XS*47>%,(NG0AF$:8JR,6"#WHHR'BF#HXJ)!HN"\X1L  "
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M9**6:FV.6 Z4RV[,2C^336_[.S22$7$)*E:1@G'*%A62W'&% '..<'0S  "
M (  ;Y.6,7/C8]&4EG2M5RN3!W5E28V1CW82.IF06W:H*>6/P7<)%=Z0V7:M
M **,:WE$  "  (  ;M>4FWN08Q>3#'OB5G&1@GP=2-"0"7Q#.A*.SWQG*76.
M,7Q\%9R/#GPZ ,.*JGVF  "  (  ;C*36X-:8GR1UH,^5=R02(+[2#N.RH*A
M.82-AH)6*3",OH(W%7:-9()H ."))X"7  "  (  ;:R23XLG8?60U8JA552/
M18GD1[.-OXD5.0:,=HAV*,^+G8A1%76+XX@$ 0.'WX"O  "  (  ;4*1BY,*
M8;&0%Y(U51*.>9$!1VF,TX^Q.+R+=([3*'"*GH\$%1F*QXR@ 1J&T8"^  "
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M6&N>XG)Z3&B<R7,\/W6:T7/U,1&92'2-()"8WG3##(Z:&715  ")%'OE  "
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M5K^9KI8D2L67;)3O/;V5*).L+ZN32I-G'[&26Y'O#+^1[(B?  "$G(    "
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M3(JH@G:*002E_W;J-(JCIG<S)KJA]7=M%@FB77<I!,*?!GCA  "$/H    "
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MBC]L0&W'>Q%MO6]5:H5O)G#&6.YP@W(H1AAQR7-T,9ERI71\&&-R)G23  "
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MA+)C.YFA=8YE#I=U96YFPY4Z5%YH;9,]0B]ITI&R+I-J+I$E%E9J%8WE  "
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M?6MQJ'3 ;RERH76M7^ASC7:'3T]T>G=+/6=U3W?[*8YUO7AI$ -V['?P  "
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M>4]J?YZT:PIKGIQ16]!LH9G>2Z=MG9?2.D5N7Y:N)Q5N"95E#J=PD8GH  "
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M</EX"WK<8XQX>7M)52QXVGN91;1Y/WOA-(MYJ7P;(1EYP'P@"*I[H7R6  "
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M:8")^UKP7+*)?%W>3J2))V";/S2(_F,;+?.)2F4I&7^*^67S ?6*%&<8  "
M 'Q?=%B(&U_G:+.'F6)36^B'+F2>3?B&V6;%/JF&JVBY+8Z&XFI+&4^(,&J[
M BR';&OZ  "  '^#<VJ%D6?G9ZR%/FFS6PN$Z6MF32.$H6SY/?B$>&YD+0>$
MH6]]&0"%F6^@ DZ%$W$V  "  (  <G"#/V_?9J&#"'$96?:"QW(X3$J"C',^
M/32"<'0C+&V"CG3*&)R#-G2R EV#"G;-  "  (  <7V!0G?@9;F!'7B160Z
MZGDB2UV MWF8/)F DWG\*^B J7I"&$B _WH3 FZ!1'O   "  (  <*9_D'_R
M9.]_?X C6%)_58 G2K5_(8 ,/ =^^'_P*[-^Z7_E&#-^\W_H HU_O7_X  "
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M71^1%&#]40F0(6,X0\R/465.-1>.S&<?)#Z/'&A;#VF1;6?Z  "&(FYD  "
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M65*'YH1W36B'((0O0':&5(/0,EJ%L(.*(H"%6(.)#S.%(8-'  "  (    "
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M4/69&V7\19^7O6>B.066A&DF*NJ5Q6I6&B:6AVJU!Q>5G&KD  " EW<4  "
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M3B^1.H@[0N>/YH?$-I".AH<V*-R-?H<&&+>-<X='!RN*HX39  "  (    "
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M1*.B66G>.:2@MFL!+:&?26P '\">OVR1#L:@/VPH  "8=V\K  "  'W_  "
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M0RB;E(N&.&29T(L(+(:8$(J.'Q.6\XJO#MF7'HA$ -V/9X"6  "  (    "
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M"9\5;IM0SIP67.M44YER2C57/Y=(-D!8:98@'OY81)+_ TUZ:X(\G8=B)E.
MCJ1D95=8?O9FE5L&;CIHMUZ(7&%JQ6'F25%LJ647-+-N!F?M&]=M@FF;  "
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MASQ5 81D>"M8,8/Z:!5;)8."5PQ=XX,21-5@)(*Y,1I@](*!&4AAI8*A  "
M (  E%%/:(YSAC]3!HU?=T-63XPK9S]96HKR5D)<*XG41"M>;HCF,*E?%(A2
M&/Q@38A)  "  (  DX%-N)@:A7M1;99$=HA4Q91)9I%7VY)259U:MY"30XQ<
M^H\M,"Q=>(Y\&+E?.8SM  "  (  DO1,=Z&7A.U0-Y\$=?=3DYQ$9@=6JYF9
M5259B)=)0RQ;QI6-+\E<$Y3[&%E>9I!V  "  (  D5AIK%-B@YYK3%<O=/-L
M\%K,91MND%XW5!!P(V%X0:QQF&2 +75RI6<)$]%SQF?'  "  ''DC\IEPUR^
M@E-GP%^W<[9IH6*)9 -K;V4W4QEM)V? 0-ANKFH:+,=ODFP"$V%PYVQ2  "
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M>^=:?8J>;<5=&(F\7I9??XC(3F1AKH?M//IC2X="*>EC)X;_$;-GL(9#  "
M (  B%Q5]I2">S%8[9,G;1%;E9&.7>Q> H_J3;]@-HY[/%MASHUQ*6]A;HU)
M$8)FJHIB  "  (  A]E4NIV9>JI7O9N?;():9YE675Y<TI<(345? Y46._I@
MCY/3*0E?[Y-H$21E[XN7  "  (  A3!QDE- >&IREE;S:J5SLUIX6Z5TV%W)
M2UYU]V#G.9=W#F.[)9EW^677"[IZQ&8"  "  '7"@\=MTEP.=S=O,%\#:8%P
MA&'.6J5QS61S2H)S!F;M..%T(FDD)0MTR&JV"XUW]VJJ  "  'GA@G!J763=
M==)L 6<7:%AM@VDR68UN[FLI29AP0&S_."-Q7FZ>)()QO&^R"V5U@F^*  "
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M<+-@U(_V8V1BT(Z[50QDE(UK19]F'HQ0--1G"HNE(BYEV(OI"K-MZH<\  "
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M:7-Q.FU]7+IR3V[^3Q!S17!@/^)T+G&:+R%TWW*6&Z9TNG+B!)]YL70H  "
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M981H&I2.6/=I<),B2V5J@Y&>/+UK6)" +(IKA9!?&=!JM(Z(!&QXAX+]  "
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M751WD'+U45UX)7/U1%%XHG31-B-Y"W6-)<AY8'8#$?5Y^'6>  "  'GB  "
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M5@>+[53<2G>+J5?]/9R+E5KD+QJ+UUUE'@B-*5[Z"8".:E\I  "  &EI  "
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M48A_"G>%1CU_'W@<.=U_%WB.+"-_%'CB'"5_*'CQ"5I_M'F9  "  (    "
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M2;R31%G@/L62IUQ=,HB21%Z;)&>2B&!/$MB4YV"9 =21"F)I  "  ''X  "
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M1@R'N'LM.UB'5'MU+X"&U7N7(@2&DWNF$:B&Y7N+ G"$@GU7  "  (    "
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M/32<+5VL,L*;;U^.)MN:^6$D&,.;O6'J")>;SF)0  ",0VE1  "  'FI  "
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M.FV1]GWM,#*13WWX),.0B'W:%T*0<WW("%*-\'YX  "#18    "  (    "
M (  0X"1!(3&.B60SH3T+_&0,H2S))F/681E%TJ/!82'"(6,68-8  ""<8
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M?L5,VW5[<))0K79C86!4+'<\43177'@-/Y19NWC4+'%9NGE[%-5?YWFL  "
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M>L-D!U(=;+%F)E8779MH.5GL359J+EV1.Z1KVF#O)_)LF&.I#I-PZV1H  "
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M<X!0X7P79C941WQO5]]75GRU2'M9]GSY-[);D'U#)/9:S'V)#5)I?'X)  "
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M;IQFMUG<88-HJ5T+4UAJ?6 50^)L(6+J,M)M965H'T1M3V<*!Q]TZF>_  "
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M:&!5SX'&6^%8L8&F3E!;,H%S/Z!=)H%/+W5=Q(%+'0Q>?H&(!MAT;X%I  "
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M8E)J>&"15C9L(V,12-AMG65I.B9NW6>(*9IOGVDW%<=P?6FM .!^AFPJ  "
M '^\;#5DM&878/AFQ&@25.)HG&GW1]YJ-FN].49KA&U-*/!L$6Z"%5UM;FZI
M /-^97&6  "  (  :N-A(VY&7[AC9F^D4[ME9'#M1LIG%W(6.*-H;G,B*&UH
MPW/G%1MJR7/: 1-^+G<>  "  (  :<5> W: 7LA@=G=04N=BEG?_1?1D7'B0
M-\UEHWD1)]EEJGEX%*YHFGEG 1)^,'OT  "  (  :-Q;2WZK7>U=XW[T4AM@
M'W\,139A\G\+-QMC*W\3)T=BWG\O%'%FNW]F 21^$W_Z  "  (  :"59 X;
M741;NX:/47E>"X871*!?XX6)-HEA"(4I)K1@884F% 9E5(5$ 3!]_H#.  "
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M5AMO468T2K!PEV@=/C=QK&G?,!YR?FM9']5RLVP_##!V6&P@  "  '31  "
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M4B9BJHJE1O]D;HGU.LQEE8DM+4MEV(C,':AE)HDJ"UEM/H:J  "  (    "
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M2BEU4FK./U5V+VPV,V)VT&UL)>)W-VY8%4=WA&Y>!%I[:6_C  "  'QR  "
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M0V"-:DXV.-6-@U%I++V-_U1$'E6/7U97#("1W5;V  ")BEPT  "  &RM  "
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M/DU\L&YP,_Y]-F]H*'%]?7 B&OM]IG!L"Q-^AG"'  "  '95  "  (    "
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M-E25CE'9+"R5F51B($N60%9F$6Z8H5<O PF5%5D_  "!KF1   "  '4!  "
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M,?2%_G#O)_B&=W%Y'(V&OW&T#N>&KG&& I:$Q713  "  'V8  "  (    "
M (  .GR"NW<*,5V#SW=\)W:$97>N'"Z$EW>H#J.$27>2 FZ# GHK  "  (
M  "  (    "  (  .@V JGXG,.>!]GY/)PN"K'XQ&^."S'X!#I&"7'XN HF!
MB'[_  "  (    "  (    "  (    #__P  __\  /__  !M9G0R      0#
M"0   0                    $                    !   !   "   "
M) 0=!=H':0C9"C8+A0S'#?\/,1!>$8L2MQ/B%0L6,A=7&'D9F!JU&](<[QXE
M'UD@AR&R(MHC_R4C)D0G9BB&*:<JQROH+0@N*"](,&DQB3*F,\(TWC7[-Q@X
M-3E1.FT[B3RE/<(^WC_X01%"*4-"1%Q%=4:/1ZE(PTG=2O=,$DTL3D-/65!O
M4892G%.R5,E5WU;V6 U9(UHZ6U%<9EUX7HI?FV"M8;YBSV/@9/%F F<2:"-I
M,VI":U)L7FUG;G%O>G"#<8QRE'.<=*-UJG:Q=[=XO7G#>LA[S7S.?<U^S'_+
M@,F!QX+%@\*$OX6[AK>'LXBNB:F*I(N>C)B-D8Z&CWN0<)%DDEB33)1 E3.6
M)I<9F R8_YGRFN2;UIS(G;N>K9^?H(ZA?*)JHU>D1:4SIB"G#J?\J.JIUZK%
MJ[.LH:V/KGVO:[!9L4>R-K,DM!*U +7MMMJWR+BUN:.ZD+M^O&N]6;Y'OS7
M(L$0P?["[,/:Q,?%M<:CQY'(?LELREG+1,PNS1C. <[KS]70OM&GTI#3>=1A
MU4G6,=<8V #8YMG-VK+;F-Q]W6+>1]\LX!#@].'8XKOCGN1[Y5?F,^<.Y^CH
MP>F:ZG'K2.P=[/#MP^Z6[W;P5?$S\@_RZO/#])SU<_9)]Q[W\_C&^97Z8?LI
M^^O\I_U<_@O^M/]:__\   'H Z<%+ :$![\(YPH$"Q8,' T>#AP/&1 7$102
M$!,+% 04_!7S%N87V!C,&=8:WAOA'.$=WQ[;']8@T2'+(L0COB2X);,FKB>J
M**8IHBJ@*YXLG2V:+I4OD3"-,8DRAC.#-($U?S9_-W\X@#F".G\[?CQ\/7P^
M?#]]0']!@D*%0XE$C4621IA'FDB;29U*GTNC3*9-JDZO3[10NE' 4L=3SE35
M5==6V5?;6-Y9X%KC6^=<ZEWM7O%?]6#X8?QC &0#90%E_V;\9_IH^&GU:O-K
M\&SN;>MNZ&_E<.%QWG+:<]9TS77#=KEWKWBE>9MZD'N%?'I];WYD?UB 38%!
M@C6#*80<A1"%_H;MA]N(RHFXBJ:+E8R#C7&.8(].D#V1+)(;DPJ3^I3IE=F6
MR9>ZF*>9DYJ FVV<6IU(GC:?): 4H02A]:+FH]BDRJ6]IK&GIJB;J9&JAZM_
MK'>M;ZYGKV"P6K%4LD^S3+1)M4:V1;=$N$6Y1KI(NTJ\3KU2OE>_7<!CP6K"
M<L-[Q(3%BL:0QY;(G<FERJW+MLR_S<C.TL_<T.;1\=+[U ;5$M8>URK8-]E$
MVE';7MQKW7G>AM^4X)SAHN*HXZWDLN6VYKKGO>C Z</JU.OE[/7N!.\2\"#Q
M+/(X\T/T3O59]F/W:OAN^6_Z;/MD_%;]1/XO_Q?__P   @4#V 5H!L8(!@DR
M"E(+90QR#7@.>@]Z$'H1>1)U$W 4:!5>%E(711@W&2D:-!L]'$ =/QXZ'S0@
M+"$C(ADC#R0$)/DE[B;C)]@HS"G!*K8KJRR?+9,NAR]\,' Q9#)9,TTT034V
M-BLW(3@6.0LZ #KV.^T\XSW;/M,_RT#$0;U"MT.R1*Q%ID:A1YQ(ETF42I!+
MCDR+38I.B4^(4(A1B5*(4XA4B%6(5HE7BEB+68U:CUN17)-=EEZ87YM@G6&?
M8J!CH62C9:1FIF>G:*AIJ6JJ:ZILJVVK;JMOJW"I<:ARI7.C=*!UG7:9=Y5X
MD7F,>H=[@GQ\?79^;W]I@&&!6H)1@TB$/H4UABN'(8@7B0R* HKWB^V,XHW8
MCLV/PY"YD:^2I9.<E)*5B9: EWB8<)EJFF.;7IQ9G56>4I]0H$^A3Z)0HU*D
M5:59IE^G9JANJ7BJ@JN.K)RMJZZ[K\RPW['SLPFT(+4XME&W;+B'N:2ZPKOA
MO0&^(;]#P&7!A\*JP\[$\<85QSG(7LF"RJ;+RLSMSA#/,M!4T732E-.RU,_5
MZ]<&V![9-MI,VV'<=-V'WIC?I^"SX;[BQ^/-Y-'ETN;0Y\SHQ.FZZJSKF^R'
M[6_N6.]<\%OQ5O),\SWT*O42]?;VUO>S^(WY8OHO^O3[L?QF_1']L_Y-_N'_
M<?__   !V0.-!0D&5 =_")8)H0JD"Y\,DPV"#G /7Q!,$3<2(1,)$_ 4UA6[
M%I\7@QB!&7T:=!MF'%4=01XL'Q<@ "#J(=,BO2.F)) E>B9D)TXH.2DE*A J
M_2OJ+-<MQ"ZQ+YXPC#%Y,F<S531$-3(V(C<1. $X\3GB.M,[Q#RU/:8^F#^*
M0'U!;T)B0U5$244\1C!'(T@720M)_TKS2^A,W$W03L5/N5"M4:%2E5.(5'I5
M;59?5U%80UDU6B9;&%P)7/I=ZU[<7\Q@O6&L8IMCB61X969F5&=":#!I'FH+
M:OAKY6S2;;YNJF^6<()Q;')6<T!T*742=?MVY'?->+9YGGJ&>VY\5GT^?B5_
M#7_T@-N!PH*H@XV$<H57ACN'((@%B.J)SXJSBYB,?8UBCD>/+9 2D/B1WI+$
MDZJ4D95XEF"71Y@OF1B: 9KJF]2<OYVJGI:?@Z!QH5^B3Z,_I#"E(J85IPBG
M_:CSJ>JJXJO;K-6MT*[+K\>PQ+'"LL&SP;3"M<6VR+?-N-.YV[KCN^V\^+X$
MOQ' (,$PPD##4L1FQ7K&C\>FR+[)ULKQS S-*LY'SV/0@-&?TK_3X-4#UB?7
M3-ASV9O:Q-OOW1K>1M]SX*'AS^,"Y$WEF>;GZ#;IANK8["OM@.[7\#'QD/+O
M]$WUJO<$^%KYJ_KV_#K]>_Z[____ (  @ #F3W_.?UC-F7^H?LVTVG^9?GF<
M%'^C?F6#3'_&?H5JA7_^?L!1OX!C?STY ($2@ _\Q7Y\BS3DM7YCB6S,0'Y=
MA\RSFGYNAF::V'Z8A4."&'[9A$]I6G\O@V=0KG^O@J$X%(!V@>;ZO'TVEG'B
M^WTPDY+*RWT^D,^R.GUICEZ9DWVLC"R [WX'BB)H3GYUB!-/P7\,A@ W07_H
M@ZSXXWPNH;?A07PSG;_),WQ-F?"PPGR%EE>817S?DQI_RWU/C_-G5GW1C+5.
M[WY\B4TVAW]GA5SW-WMCK0/?I7MFI^O'JGN'HPJO8'O)GFF6^'PKF?A^LGRO
ME;=F;GU#D4%.+GW]C'LUY7[TAN_UO'K*N%7>+WK'LA3&0WKDK!2N&7LLIF&5
MW'N9H-I]I'PDFUEEE7S(E:A-@GV1CX$U6WZ1B%_T=WI2PZK<['I&O#+%"7I=
MM0JL^7JGKCN4Z7L?IYM\V7NVH.ADV'Q@F=U,[7TUDE TZ'X]B:?S8WGWSP';
MV'GCQD##^GGRO>2K]WHZM>R4 GJXKB1\('M;ID!D2'P0G>5,;WSJE.,TB7WW
MBL7R=7FTVEK:ZWF7T#+##WF?QI2K&'GCO6J3.WIDM&I[=WL-JT!CPGO,H99,
M"7ROES,T/7V^B[;N4XC;?C;7AH?$?<+ GX;#?7"IC(7F?5624H4J?75[!X2&
M?<9CQ(/Q?C5,CX-X?NDUDH,H@ #L/8=]B,O6%(9PAT"_:X6#A>.H8X2[A,&1
M'H0;@]]YU(.4@RUBG(,=@HU+DH+#@A8TV(*0@<'J>H9'DV74=(5-D-J]_(1O
MCG.G"X/$C%B/[8,YBG=XRH+*B+UAMH)IAP-*S8(FA4PT,X('@V_HVX5/G?[2
MX(1?FG2\>H..EQ2EJX+GD^B.M()RD0MWNX(5CD%@UH''BV1*&(&7B&@SHH&+
MA03G7(2+J*#1;(.=I!6[$(+4G[JD6X(WFY2-@('"EY5VNH%XD[M@"($YC[))
M=8$:BV4S)($?AGOF (/QLTO0&X,$K;JYS8(ZJ%BC,H&CHRV,>X$VGB!UR(#N
MF11?2H"^D]M(Y("OCCHRN8#!A\_DU8-SO?C.^H*'MU:XM8&\L.*B+X$FJJB+
MGX#$I(IU$8"#GE5>IX!4E]%(:8!3D-DR8(!RB/OCUH,.R*7.!8(DP.*WQH%7
MN5.A2H"_L?J*T(!AJKMT:X NHUQ>*8 'FY5( H 'DSLR%X PB?[C (*]TU3-
M-X'6REFV^H$'P9J@B(!NN1.*(X 1L*)SVG_BJ 9=MW_&GOU'JW_0E58QW'_[
MBM?>$I'B?+#([H_Q?&.SL8X8?#J>.XQH?$>(C8K>?(]RQ8EI?0I=$8?\?:A'
M>X:9?I,R484Y?_'<*I"TAI?'E([!A5*RDHSTA#R=-HM7@UN'CHGD@K9QTHB(
M@CU<*X<S@=A&N87I@:(QRX2B@9W:HX^.D)7&.8VHCE>Q<HO=C#Z<%8I7BG"&
M>(CXB-EPT(>UAVA;2(9WA?Q&!85&A)\Q5(09@S390HZ;FI?$V(R_EVRP!XL'
ME&N:R(F"D:2%4H@YCQUOV8<%C*A:@X78BB9%;X2ZAX\P[(.@A*_7[HWAI)3#
MAXP)H(&NNHI;G)N9CXC>F.2$.H>-E4]N\(9KD=59SH5*CC1$Z(0]BELPD8,U
MA@O6M8U+KIS"7(MWJ9VMF8G*I,28@HA2H!>#3(<(FWYN&H7AEN)9*X3.DAU$
M<X/0C/\P18+:AT35IXS0N*/!7(K_LK"LH8E1K-J7FX?=IRJ"AH:;H8IM=X5Z
MF]!8H81BE=!$$H-SCVPP!8*-B%;4PHQJPJ; AHJ=N[*KSXCQM-26T8=[KA*!
MSH8]IUMLXX4IH()8-H06F4Y#P8,GD9POT8).B4'4!(P3S*F_U8I-Q*"K'XBC
MO*66)X<MM+Z!-X7QK-YL9X3@I-57U(/9G&U#>(+TDX4OIX(;B@7.3YL;>X"Z
MHIA9>U&F[Y6L>T:3"I,G>W-^Z)#&>]IJJ(YU?'=6B(PB?3E"EHG"?E O0H="
M?^+,G9H/A-*Y@9<\@[ZF!I27@M62-)(@@B1^$X_3@:UIVHV8@6-5QHM9@3%!
M_(D1@3<N[X:F@7K+0ID1CB&X1)9%C"ZD^9.=BEJ1+I$WB-5](([ZAWUI HS1
MADI5#HJEA1]!=(APA HNI88;@OK*(9@>EXZW&)5CE+FCRY+)D@&0&Y!7CXQ\
M'8XMC5%H((P4BRE46(GYB/E \H?;AL$N986?A%[(_Y=FH/:V!Y2MG42BKY(;
MF;^.^H^]EFE[((V)DS-G48M_D!%3OHEMC,U BH==B6$N+H4TA:''[);8JF"T
M_I0BI=>AKI&2H7"."X\YG3%Z3(T)F0)FEXKXE,Y3-HCPD'1 ,(;OB],M_X38
MAL'&^Y9DL[^T().NKE:@UY$?J06-08[(H]%YGHRAGJ=F"HJ3F6-2QHB"D^(_
MYX:/C@TMV(2,A[O&+I8#O1FS99-.ML2@(9# L'R,DHYIJD1X_HQ&I!%EB8I$
MG;I2:X@VEQ8_JH9!D LMN(1,B)#%A96OQG&RS9+\OQR?B9!RM\:+_HX=L'=X
M>XO[J2AE((G^H;)2&H?]F>P_<(81D<(MGX0:B4"_(*2'>JVLR:#Z>HV:?YU\
M>I:(%)H?>MAU<I;>>U9BM).E? Q0*I!;?.D]X8SN?B L:HD[?].]HJ.<@W"K
MXI_R@GR9SIQS@;6';ID?@25TQ97O@-)B"I+'@*Y/B8^/@*8];HPU@-PL28B7
M@5F\@Z*IC#:JW)\&BFZ8[)N%B,^&C)A!AW5S\Y4<AE!A4I(#A5!.\X[9A%L]
M"HN0@X4L+(@%@L2[@J'=E.RIT)Y$DEN7V9K,C_F%E9=^C<)S$Y1DB\U@F)%4
MB>9.9HXTA_H\LHK[AA L$X>$A!&ZI:$:G<.HZ9V.FF66YYHAES2$H9;:E"9R
M/).ID3]?YI"ICFM-X8V4BWT\88IOB'8K_8<5A3VYO*"/IIJH'IS]HFF6))F,
MGF"#WY9)FG]QB),KEJ]?39 BDMI-=HT5CN,\(HG^BK<KZH:WAD6X[: @KUJG
M8)R*JEB5;ID:I7&#-97;H*IP]Y+$F^M>UX^_EQ5-'HRGD@L[\(F;C, KVX9H
MARJX-Y_'N FFP9PMLB>4UIB\K%B"I95^IIQP<Y)KH.1>;8]PFPQ,UXQ9E/,[
MQXE+CHPKSX8HA^NWH)]YP+2F/IO9N=Z45IAJLPZ"*94PK$IP")(@I8E>&H\J
MGJ1,F8P@EX$[GXD<D!0KQ87TB(FPG:XH>B:?BJG->@F.CJ5^>AM]@*%(>FIL
M2ITA>OA;!9CP>\!*"92@?+$Y:I 1??\IT(L<?\2O7*U2@F:>U*C9@8*.!J2$
M@-!\_J!0@%IKOYPR@"):?9@/@!U)C9/*@#8Y(8]+@),IX(IK@3FN=ZQKBI^>
M J?WB/>-4J.=AWM\1Y]SAD=K$YM=A4A9Z9=%A'-)&I,+@ZXXY(Z;@Q I[HG/
M@I&MM*N;DL^=+J<TD&J,<Z+CCC)[>YZQC#5J7)JCBG!95):2B,%(L))@AQ(X
MKXW^A6XI^HE'@\FL[:K]FO6<:J:6E]2+JJ))E.=ZM)X9DBQIL)GYCX-8S97R
MC/A(5)'%BE8X@HUQAZ4J!(C1A."L1*IBHS>;R:7]GU*+"Z&PFYEZ&IV$F AI
M(YEFE(585I51D05( I$PC6LX6HSPB:\J#8ANA=2KGJGOJUZ;1*6 IJB*CJ$M
MHAAYG9T G:]HLYCOF517_93FE.5'Q9"[D$TX/HR(BX<J%(@<AJ6K!JF7LVB:
MPZ4?K=J*&:#*J&QY,9R>HQ]H5)B3G=M7L)25F'Q'DY!JDNPX*HPUC24J&8?8
MAU2J@ZE,NV2:5Z3)M.B)M*!UKH5XU9Q-J$%H!YA&H@E7>)1+F[5';I OE3,X
M%XP#CH(J'H>CA^.BX;?\><>3 ;+,>:.#/*VJ>;AS=:B6>A%CF:-]>JQ3OYY(
M>X-$1IC??(8U2I,<?><G?XS9?[:AY+<M@8V2=['H@+""UJR\@ QS$:>C?ZAC
M*Z*,?X=36)U=?YY#\9?Z?]8U+))$@%4GO(P9@1RA/[9&B4*1V[$)A[""3ZO8
MADURA*;"A3EBJ*&NA%Q2ZYR&@ZY#I9<J@Q0U%I&#@J@G\HMP@F*@M[5RD.:1
M1+ ^CJ6!J:L2C)5Q[*7RBL1B(*#GB2U2@9O&A[%#8)9QACHU!9#9A-HH(8K>
M@XB@++3'F(>0MZ^2E92!&:IIDMEQ6Z5,D$]AIJ SC>E2(YL<BYM#)Y7.B4 T
M^)!#AN0H2(IAA(V?F[1"H"60-Z\$G'F HZG6F0)P[J2ZE;QA1)^DDHE1U9I^
MCU5"^94XC!0T[8^_B,$H:8GWA6Z?+K.ZI["/UJYZHT" 2:E,GP-PG*0UFO)@
M_9\EENY1H9H"DMM"UI2KCJHTY8]&BF8HA8F@AB^>M[-<KQF/C:X,J<V #JC2
MI+1P7J.QG\U@PIZEFOI1<9F:EA%"O)14D04TY8[NB]HHFXE9AL^>3;,*MF>/
M/*VNL#1_RZASJC!P**-7I&1@G)Y0GK116YE(F.]"M)00DPTTZHZVC1(HK8D@
MAU&5[,']>7^',KOR>5!XD;7X>6)I_*__><);9ZGK>FA,[*.A>T\^ZYT.?&(Q
MA98%?=,E=(YO?ZF5/,$F@-B&T;L8?_EX1;44?UQIKJ\/?P=;%:CS?OQ,IJ*G
M?RP^O9P3?X QDY46@!\EW(V=@0&4V< RB ^&:[HSAHMWZ[0KA3MI3:XBA$%:
MO*@#@X1,8J&\@OH^FILM@HDQI91 @DLF-HSF@CB4D;]0CRZ&%+E4C0AW@K-/
MBQEH[:T\B6U::*<EB ),):#EAK4^?II?A70QN).$A%,FA(Q(@TZ40KZ3EDB%
MQKB2DWEW,[**D.IHF:QZCI-:):98C&5+^* GBE0^:YFLB#PQRY+BAC,FQXO"
MA$*3Y+W]G5V%>[?PF=QV];'AEIMH9JO2DY)9]J6UD*5+UI]]C<$^7YD-BM,Q
MW9)5A^8F_HM2A163B;V#I$Z%.K=HH ]VQ+%1G!!H/ZM!F$M9V*4OE*)+Q)[\
MD/$^6)B#C2TQ[)'<B64G+(KUA<:33;T!JQ.%#K;EI@IVI[#-H49H+*J_G+]9
MR:2SF%)+NIZ1D]4^59@9CT0Q^I%QBJ\G48JIAEJ3 +RBL;6$\K9TJ[]VG[!1
MIA)H)ZHYH+E9S*0LFXY+QYX2EE<^;I>ZD1$R&)$PB\8G;XINAM&)E<PD>7![
M]<4V>2AN9KYH>2]@[+>.>8]3D+!X>CQ&::D)>RXYVJ$W?$PN!IC4?<DCI(_A
M?YR)2<LJ@&5[O\1B?W9N+[V.?M5@M+:<?HA36Z]P?HM&2:?V?M$YV: =?SPN
M0Y?'?_0D,X[\@.F),\H:AR)[E\-JA:!N"+R3A%=@A[65@W!3-*YA@LM&-J;J
M@F YY9\7@A(N@);6@?PDL(XV@A.)+\D=C;Y[B<)GBZ=MZ+N0B<]@:K2(B$!3
M'ZU<AOI&,*7PA=<Y]YXLA,4NN98%@]TE&XV-@QJ)(\A"E%![@L& D9IMYKJ?
MCRY@7[.:C0)3':QJBP5&.J42B2HZ$9U@AU$N[I51A94E=8S]A ")"<>$FMA[
M>\"VEW=M\+G-E&1@=;+)D953+ZNDCN=&4*1-C$DZ+YROB:LO'Y2YAR EP8R%
MA,6([,;AH2][=L *G1AM_;D:F51@CK(8E=I32ZL DG]&;J.UCR<Z4)P9B\@O
M2Y0YB'DE_XPBA6J(S<94IU![<;]WHG9N#;B"G?A@JK& F<I3:ZIPE<)&CZ,Y
MD;8Z<INJC:0O=)/1B:$F,HO2A?.(L<70K3)[<;[QIX=N);?ZHCU@TK#YG5=3
MFZGPF*-&PZ+%D^XZI)M+CS<OH9.'BI8F6HN3AF'RSWMC>;#;W7N\>=+$J'P<
M>@>M)7R#>EZ5<7SW>MU]K7U\>X)E\'X5?#Y.1'[9?30VRW_I?GWPLGFYA,_:
M+7HT@\K#*GJS@NBKSWL[@C*4-'O0@:I\B'QV@4)DX7TN@.--57X0@)\V 7\Z
M@&CNS'A9D +8:GCEC=K!GWEXB]*J7GH9BA"2ZGK)B'U[9'N+AP5CY'Q?A89,
M?7U;@_XU3'Z;@C_M!G<SFS'6KG?(E^^_^'AHE-BHX'D9D?*1F'GACU1Z07J[
MC,-B\GNGBAI+N'RYAT<TK7X,@_WK:79'IE75&W;>H@.^<G>%G=ZG=WA!F>R0
M37D6EAUY*'H&DG)B#7L&CI9+ GPLBF\T)'V-A9WJ!'63L6_3OW8GK!&]'G;-
MIM>F-W>/H<^/+WANG.9X'WEIE_UA.7I\DNM*7WNRC6TSKWT?AQ?HVG4%O'O2
MG765M@Z[_W8WK[JE)';[J92./7?DHXUW47CJG7-@@7H&EPQ)U'M+D#,S37S"
MB&CGYW2<QW'1L'4GO^Z[$'7"N'ND-W:"L2N-8'=QJ?AVFWB#HJY?\GFJFOQ)
M7GKVDKLR_'QTB8SG)W15TD'0]G39R9NZ3'5JP/^C;G8DN(",HG<3L!5U]'@K
MIXA?:GE;GHY(^7JQE/HRO'PVBH'BF801>!O-C8.%>'BX'(,.>.&B.(*K>62,
M"8)<>@QUO((?>ME?@('P>\-)58'B?.PS?(($?G7@X8*.@JG,7((7@>:W$H&S
M@3^A*(%E@,&*Z8$K@&MTH($)@#E><X#^@!E(=8$5@!\RX(%:@$G?48%!C4'*
MP8#9BVZUEH""B;B?Q8!-B#Z)LH NAO!SE( IA;Y=CX UA(I'NH!D@U@R5H"_
M@@?=OX HE\7))7_'E/2T 7]\DD*>7']0C[F(=']+C6YRAW]<BS%<MW]_B.-'
M$W_%AG0QW8 T@ZS<1']"HD''LW[BGGNRFGZ@FM*=!WZ ETJ'07Z"D]UQB7ZJ
MD)-;[W[@C2!&>W\YB6TQ='^ZA3#:^GZ0K+[&='XQJ 2Q8WWNHUB;XWW3GL6&
M/7W?FDAPGGX,E=!;.7Y6D39%]'["C#LQ&W]1AH[9Z'X"MS+%;'VDL7ZP7'U>
MJ\>:Y'U#IB&%7GU:H)%OYGV2FO):GGWAE1=%@7Y<CM$PT'[YA\/9#7V7P9C$
MEGTZNN*O?WSMM!::!GS-K4V$D7SGIIMO.7TMG]=:&GV'F,-%(7X(D2LPDWZO
MB,[89GU*R^[#[GSNQ">NQ7R8O#691'QOM#N#X'R(K%ANIGS5I&!9K'T[G!1$
MTWW(DSTP8WYTB:W2[XSK=MF_DHM\=U>KO8HM=]V77XC^>'R"J8?F>4-MT8;>
M>C19&(7>>T9$>X3Q?*$P6H0:?FO1=8N4@,&^9(HU@#RJHXCT?]&66H?5?X:!
MKX;2?V5LZ(7C?V=80(3]?WM#S(0L?[HO[H-N@"K0)HI4BKF]%HD%B36I@X?)
MA\J5-(:_AI. FX70A8-K\83YA)%7;80L@Z)#*X-W@K\OC8+4@=+.SHE"E*6[
MM(?XDC>H$(;.C^*3Z87+C;-_=H3UB[1J^H0SB<)6JH-\A\-"G8+;A:\O.8)+
M@UW-@8AIGH2Z:(<BFS2FR88 E_J2LH4&E-E^9(0QD<YJ%H.%CMI5^H+>B\1"
M'X)0B'DN\8'3A,;,6X>^J&FY3(9ZI#:EM(57H F1K(1BF^U]>8.5E]]I1X+I
MD\Y578)4CYQ!LH'8BQ<NLX%LA@O+9H<SLD2X7H7RK2>DQX3.I_^0R8/:HM]\
MLH,7G<IHI()SF*!4V8'=DSU!5X%RC7XN@($6AR?*H(;'O ^WG(6*M@&D (1C
MK]60!(-JJ:%[_(*JHW=H"X(4G3)4:8&'EJ5!"X$>CZ<N5H#.B!K*"H9UQ<VW
M X4\OL"C6800MWV/68,2L"5[8H)1J-1GC8' H6A4!H$_F;! Q8#AD8@N-("5
MB.3#NY7X==ZQRI.R=G*?;Y&0=Q",E(^1=\EY7(VI>*IE_HO+>;A2RXGK>NH_
MQ(@-?&LM:88D?F#"?)3!?S2PT)*#?MB>A)!M?I.+MHYZ?G)XA8RB?GEE-8K9
M?J52%(D/?N<_.X='?ULM*X5T@ S!69.BB'^OHI%OAT"=>X]:AA**KXUWA1MW
MEHNPA$1D98G\@XI1:(A&@M<^P8:4@C8L](37@9W 19*3D=BN?)!LC[J<2XYE
MC:J)IXQ]B\=VGHK,B@UCD8DIB&)0PH>'AJ\^4(7OA/(LQ81+@Q"_)Y&^FR:M
M=(^8F#&;/(V7E5&(BXO DHEUJ(H.C]=BQ8B C350*8;MBG8][85DAY LG(/2
MA&*^)Y$;I'.L=H[XH*N:0HSXG.B'H8LEF35TUXEXE8MB$H?GD=Q/IH9BC@X]
MF83KB?XL>8-KA8Z]3I"8K:ZKI8YXJ0V9<XQVI&"&VHJDG[9T*(C^FQ)AA8=S
MEEA/.87ID6P]582"C#4L7(,5AI*\GY QMMFJ^HX3L5>8PXP0J[6&+8HYI@=S
MB(B6H%I@_X<7FI1.VX64E(X]&X0LCBXL18+.AW"\&8_?O_>J<HW&N8:8+HO
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M<Y-(A Y1()!#@UA"/HTF@J0S^XGU@?LG#X:A@52;(I[/C[2,X9N>C?E^+)B
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MD$MEO9O-CAM7T)?-B_)*%I/"B<P\[(^FAZ,PC(MRA6PEKH<A@SJ.+:<DF_N
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MBF.9 '&1B-:$"7-#AW5N^W4*AAQ:#W;IA+9%6GCX@S@Q1'M1@7K3HFM'F'W
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M4:+X:X%OHY^E;5UB=IQ);T=5!9C*<5!'E94I<X4ZH9%F=>(N.XU_>) C(8F
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M>0+ [F5%:W^OTV?(;46>!FHJ;P>+GVR <,QXO&[C<IIEKG%D=']2V'0*=GQ
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M<9L*;F(T7Y:.<4LK_)'[=%HD:(UH=Z,>+8D6>OAAO:C>:R18U*5T;+Q/Q:'
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M<GZ.?(DAI'_6?AEO%'8+>G-E?7<.>R%;>W?W>[!1)GC>?"Q&O7G;?+ \:7L
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M?U\NT'[T?Y\G!'^)?]P@G8 K@ YC^WPHA-];:GRTA*]2<7S[A"I)/GT<@WM
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MC'EGLU9GBMA:.UP6B4!,O&(4AZL_WVA*AA8SG&[#A&XHM74P@KN,HD1ZEY:
MP4HKE4AT3D^TDL]G255+D$Y9ZULAC=M,AF%'BV8_KV>JB.DS?&Y.AE$HOG39
M@[R,OF1=4&. <&;)5+=SNFE460YF?FP!76A8WF[88=5+)7'H9FT]X'4Q:S\Q
M)7C7<( EP'R]=EB*[%_X63)_%V+E7,ARD67;8%IEAVCH8^Y8$&PD9Y%*AF^>
M:UL]=G-2;U@Q 7=?<[8E\7N;>(N)5%OQ8@U]IU]39-AQ?6*I9Z!DD681:FA7
M3VFH;3])^FV$<#8])'&=<U<PZW8+=LHF''J<>IF'PEA1:LY\+UP4;,]P$U_
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M^VRD<A9#\G K=& X<W/D=LPMFW??>78D,7O=?%9\.ES\<;%QJ6!G<QEFE6/
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MH'>*@<<B_'M=@3)O.5TDC*IEQV"JB[];UF06BF51CF>(B-M'+FLEAV \\V\
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M=#$      P0A   !                     0                    $
M   ! @,$!08'" D*"PP-#@\0$1(3%!46%Q@9&AL<'1X?("$B(R0E)B<H*2HK
M+"TN+S Q,C,T-38W.#DZ.SP]/C] 04)#1$5&1TA)2DM,34Y/4%%24U155E=8
M65I;7%U>7V!A8F-D969G:&EJ:VQM;F]P<7)S='5V=WAY>GM\?7Y_@(&"@X2%
MAH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@H:*CI*6FIZBIJJNLK:ZOL+&R
ML[2UMK>XN;J[O+V^O\#!PL/$Q<;'R,G*R\S-SL_0T=+3U-76U]C9VMO<W=[?
MX.'BX^3EYN?HZ>KK[.WN[_#Q\O/T]?;W^/GZ^_S]_O\  0$" @,#! 0%!@8'
M!P@("0D*"PL,# T-#@\/$! 1$1(3$Q04%186%Q<8&1D:&AL<'!T>'A\@("$B
M(B,D)"4F)B<H*2DJ*RPM+2XO,#$R,C,T-38W.#DZ.SP]/C] 0D-$149(24I,
M34]04E-55UA:7%Y@8F1F:&IM;W%T=GE\?H&#AHF+CI"2E9>9FYV?H:.EIZBJ
MK*VOL+*SM;:WN;J[O+V_P,'"P\3%QL?(R<K+S,W-SL_0T=+2T]35UM;7V-G9
MVMO;W-W=WM_?X.'AXN/CY.7EYN;GZ.CIZ>KKZ^SL[>[N[^_P\/'R\O/S]/3U
M]O;W]_CX^?GZ^_O\_/W]_O[_  $! @(# P0$!08&!P<(" D)"@L+# P-#0X/
M#Q 0$1$2$Q,4%!46%A<7&!D9&AH;'!P='AX?(" A(B(C)"0E)B8G*"DI*BLL
M+2TN+S Q,C(S-#4V-S@Y.CL\/3X_0$)#1$5&2$E*3$U/4%)355=86EQ>8&)D
M9FAJ;6]Q='9Y?'Z!@X:)BXZ0DI67F9N=GZ&CI:>HJJRMK["RL[6VM[FZN[R]
MO\#!PL/$Q<;'R,G*R\S-S<[/T-'2TM/4U=;6U]C9V=K;V]S=W=[?W^#AX>+C
MX^3EY>;FY^CHZ>GJZ^OL[.WN[N_O\/#Q\O+S\_3T]?;V]_?X^/GY^OO[_/S]
M_?[^__^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]
MIX' NJ6'QK:CA\NSH(?0KYV(UJN:B]VEEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MYO^F.3+_HD9*_:!-8/&D3'+FITR$VJA0EL^F6:;'I62QQ*=OML&G>+N]IX'
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MTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BTZU_HM.M?Z+3K7^BT_^C.2K_GT9
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MV)N)G]B;B9_8FXF?V)N)G]B;B9_8FXF?V)N)G]B;B9_8FXF?V/^C."K_H$5
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M@J2,TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM.
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M@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6
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M2?^B2U?YIDQF\*E.=.>K48+?JU>.UZI?FM"H::3+I7.LQJ-\L\*@A+F^G(C
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MW)9QDM63>YS/D(2DRXZ,J\B*D+#%AY2TPX28M\*!F[G!?YZZP7VBN\![IKS
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M?9ZLQO^@-1K_G4(N_Z)"//^J0$?_LCY1_;I 6?/#1&#HSTYCW]Q99\_88'G
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M>6-3]'QD4O1^9%'T@&51](!E4?2 95'T@&51](!E4?2 95'T@&51](!E4?2
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MGJ'0=*2DSG*JILUPL:C-;[FIRV_!J<-QP:F\<L"JMW/ JK=SP*JW<\"JMW/
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MXT0HPN!-.+7;4TJHU5E:G-!?:)#,97.&R6M]?<9QA77$=XMNPWZ0:<&&E&3
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M6$3\EEE$_)991/R6643\EEE$_)991/R6643\EEE$_)991/R66;V_! "PS@0
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M_X8].O^&/3K_ACTZ_X8].O^&/3K_ACTZ_X8].O^&/?]U) ;_=C40_W=#'/^
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M;4?MP&Y&[<=N1NW';D;MQVY&[<=N1NW';D;MQVY&[<=N1NW';O^G#P#3N@<
MQ<<' +K6"0"M^A,&HOHB$I?Z+Q^-^SHK@_Q#-7K]3#YQ_5%%:/U62V'^6T]<
M_F)35_YH5E3];UA1^W5:3OI\7$SY@UU*^(I?2/>18$?VF6%&]J!B1?6G8T3T
ML61#]+5D0_2U9$/TM61#]+5D0_2U9$/TM61#]+5D0_2U9-:R! #$O@8 M\P&
M *S<"0&@_Q8(E?\E%(O_,A^"_SPI>?]%,F__2CEG_T\_7_]50UK_6T=5_V%*
M4O]G3$__;$Y-_W)/2_]X44G_?E)'_X131?^+5$/_D55"_IA60?V>5T#]IEA
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M(\NK4C+!I5I N)]B3+"9:5>HE'!@H8]W9YN+?FZ6B(9SD86.>(R"EGR(@)^
MA'^J@H%_MX. ?\B$?X#=@W]_WH%_?]^ @'[@?X!^X'^ ?N!_@'[@?X!^X'^
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M9DO(\F9+R/)F2\CR9DO(\F9+R/)F2\CR9O^2#0#>I@0 SK0& ,*_!@"YS @
ML-T, *?E'0.>Y2T+E.4Y%HKD0B"!XTHJ=^)0,V_A6#MIX%]!8^!F1E[?;DI:
MWW5.5M]]45+?AE-/WY!63=^;5TO@IUA)X+592.'&64CAWUE'W_!91MSU6T;<
M]5M&W/5;1MSU6T;<]5M&W/5;1MSU6^V<! #1K00 PK@% +?#!0"MT0@ I.T0
M 9OM( 62[2X.B>PZ&(#L0R%V[$HJ;NQ0,6;K5C=@ZUP\6^MD0%?K:T-3ZW)&
M4.MZ24WL@TM*[(Q-2.R63D7MH5!#[:Y10NZ\44'OS%)![^520.WQ44#M\5%
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M4/]6)P3_43(%_U@T!_]B.P[_9T06_VE-'_]G5B?_8V O_V!K-?]<=SO_6()
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MAW7J</]E'P/_=!H"_X,> O^0)@3_FBT&]*$T">FF-PO@JCT.U*=$&\FA3RG
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M;%J>[6Q:GNUL6I[M;%J>[6Q:GNUL6I[M;/]\$ '_CA  ]IX- -BM"0#-N D
MQ\0( +[*% "URB<$J\@V#Z'%01N7PDLHC;]3,X6]6CQ]NF%%=KAG2W"W;5%J
MM7169;1\6V"RA%]<L8YB6+&9956PI693L+-G4K'&9U*QX6=1K_%H4ZKP:%2I
M\&A4J?!H5*GP:%2I\&A4J?!H5*GP:/^"#@#_E P VZ4& ,ZQ!P#%NP< O<<'
M +70$ "LT",#H\\S#)G-/QB/RD@DALA1+GW&6#AVQ%\_;\)F1FG!;$MDP'-0
M7[][5%N^A%A7O8U;5+V875&\I%]/O+-@3;W%8$W_XO__24-#7U!23T9)3$4
M PF]X%],O/!A3;?U8DVV]6)-MO5B3;;U8DVV]6)-MO5B3;;U8O^)"P#AG ,
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M/#CW[#PX]^P\./?L/#CW[#PX]^P\./?L/+^J  "QLP  I+\  )C* 0",V 0
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M9%N8WF-;F/!C7)7U8EZ3]6)>D_5B7I/U8EZ3]6)>D_5B7I/U8O]U#@#_A@T
MZY8( -6C!P#,K0@ Q;8' +V\$0"TO2,"J[LR"J&Y/Q68MD@@D+-1*XBP6#2
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M347"_TY%PO].1<+_3D7"_TY%PO].1<+_3M^0  #,GP  OZH! +.S 0"IO0(
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M7&N WUQK@/)::X#[66Q^_%AM?OQ8;7[\6&U^_%AM?OQ8;7[\6/]I$ '_> X
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M4U2:_U-4F?]35)G_4U29_U-4F?]35)G_4_]X!@#AB0  T)8" ,:A P"\J0,
ML[ ! *NX" "DNA@ G+HI Y2Y-@N,MT$4A+5*'7RS4B5VL5HL<*]@,FNN9SAF
MK6X\8JMU0%ZJ?41:J89(5JB12E.HG4U1IZI.3ZBZ3TZHST].I^E/3:;W3TVE
M_T].I/]/3J3_3TZD_T].I/]/3J3_3_I_  #8C@  R9L! +ZE @"TK0$ J[4
M *&_! ";P10 E,$E HS ,PB$OSX1?+U(&76\4"%ONE@G:KE?+66X93)@MVPV
M7+9T.EBU?#Y5M(5!4;201$ZSG$9,LZE(2K.Y2$FTSDA)L^E(2+'V24BP_TI(
ML/]*2+#_2DBP_TI(L/]*2+#_2N*&  #.E   PJ$  +:I  "KL0  H;H! )C#
M!0"0R1  BLD@ 8/)+P5[R#L-=,=%%&[&3AMHQ58A8\1=)U[#9"M:PFLO5L%R
M,U/!>S9/P(0Y3,"//$K FSY'P*@_1L"X0$7 S4!%P.@_1+[V04.]_T)#O/]#
M0[S_0T.\_T-#O/]#0[S_0]:-  #&FP  N*4  *VN  "BM@  F+\" (W(!@"#
MT0L ?](: 'G2*@-RTC<(;-%"#V;12Q5AT%,:7,];'UC/8B-4SFDG4<YQ*DW.
M>BU*SH,P2,Z.,D7.FC1#SJ@U0LZX-D'/S35!SN@U0,WU-S_+_CD^R_\Y/LO_
M.3[+_SD^R_\Y/LO_.<J6  "\H@  KZH  *.S  "8O   C<8# (+/!P!XV0L
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M:PX _W8. /N #0#JB T VX\, -"2%0#'DB<"OH\V"+:,0A&NB$T:J(16(J*
M7BJ<?64PEWIL-9-W<SJ/=7L^C'."0HARBT:%<)-)@F^=3']NJ$Y];K5/>VW&
M4'INX%!Y;_).>6_^37EO_TQY;_]+>6__2WEO_TMY;_]+>6__2_]@#P#_;0T
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M36.!_TQD@/]+9(#_2V2 _TMD@/]+9(#_2_]I" #[> 0 W(0! ,^/! #&EP4
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M1$N@_T1+H/]$2Z#_1.-]  #/BP  PI8  +>?  "MI@  HZT  )FU  "0N0X
MB[H> 82Z+0-]N3D)=[A#$'&V3!=KM5,=9K1:(F*S829>LF@K6K%O+E:P=S)3
ML($U3Z^+.$ROESI*KJ0\2*ZS/4>NQSU'KN,\1JWS/4:K_CY%J_\_1:O_/T6K
M_S]%J_\_1:O_/]J#  #'D0  NYP  *^D  "EJP  FK(  )"Z 0"&P0D @<(8
M 'O"* )UPC4&;\% #&G 21)DOU$77[Y8'%N^7R!7O68D5+QN)U&\=BI-NW\M
M2KN*,$B[EC)%NZ,T0[NR-$*[Q35#N^(T0KGS-4&X_3= M_\W0+?_-T"W_S=
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M""#_G0D?_ZL)'O^Z"1W_R0D<_]T)'/_="1S_W0D<_]T)'/_="9BP  "*N@
M?,0  &_-  !BV   5=X  $GD  !$^P4 /_\. #O_%0 X_QP -/\D 3'_*P$M
M_S$!*O\V B?_/ (E_T("(_]( B#_3@,>_U4#'/]= QG_9P07_W($%?]_!!3_
MC 43_YH%$O^F!1'_L@41_[P%$?^\!1'_O 41_[P%$?^\!8RX  !]P@  ;\P
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M08M>X4&*7_- B5__/XE@_SZ(8/\^B&#_/8A@_SV(8/\]B&#_/?]7#P#_8@P
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M0W%O_T%Q;_] <7#_0'%P_T!Q</] <7#_0/]?" #_:P0 X78  -1_ P#+A@4
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M-&^"?3=L@88[:7^0/F9^FT%C?JA#87VV1&!]R41??>5#8'WV0F!]_T%A??]
M87W_0&%]_T!A??] 87W_0/]G  #C=   TG\  ,>( 0"^CP( MI4! *Z8!@"F
MFA4 GYHF IB9,P:1ES\,BY5(%(634!I_D5@@>H]?)7:-92IRBVPN;HIS,FJ(
M>S9FAX0Y8X:./&"%F3]=A*9!6X2T0EJ$QT-:A.-"6H/T05N#_T!;@_] 6X/_
M/UN#_S];@_\_6X/_/_]J  #>>   S8,  ,*,  "YDP  L)@  *>= @"@GQ(
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M%S71NQ<TTM(7-=#L%C3/]Q@SSO\:,\[_&C/._QHSSO\:,\[_&K.9  "FH0
MFJD  (ZQ  "!N0  =<   &K'  !>S0, 5-0( $S=#0!*W1@ 2-XF $;>,@%$
MWSP"0M]% S_?300]X%4%.^!=!CG@9@@WX&\)->%Z"C/AA@PQX90-,.*C#B[B
MLPXNX\<.+>/C#BW@\@XLW_L/+-_]$"S?_1 LW_T0+-_]$*B@  "<IP  C[
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M @S_L (,_[X"#/_" @S_P@(,_\("#/_" H>V  !YOP  :\D  %[3  !0VP
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M+J-.YBZA3_4NGT__+IY/_RZ=3_\NG5#_+IU0_RZ=4/\NG5#_+O],$ #_5 T
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M-GY@_S5^8/\T?F#_-'Y@_S1^8/\T?F#_-/]5" #_8 0 Z&D  -IP P#0=04
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M:/\V<FC_-7)H_S5R:/\U<FC_-?]9 @#V90  W6X  ,]V 0#'>P, P'\$ +F
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M-FAO_S9H;_\V:&__-O]>  #D:@  TW0  ,A\  "_@0$ MX4! *^'!P"HB14
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M)T*DN"A!I,XG0:/J)T"B^"A H?\I0*#_*4"@_RE H/\I0*#_*<E^  "ZBP
MKY0  *.:  "8H   C:4  (*J  !UL   ;+,, &FT& !EM"<!8;0S EZT/01:
MM$8'5K-."E.S50U0LUP03;)C$TJR:Q9'L7081;%^&D*PBAU L)<>/K"F(#RP
MMR \L,P@/*_H(#NN]R$ZK?\B.JS_(SJL_R,ZK/\C.JS_(\"&  "SD@  IYD
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M!B?;[P<FV?D()MC^"2;8_@DFV/X))MC^":2=  "8I0  BZT  'ZT  !QO
M9<,  %G)  !-S0  0],! #K9!@ UY T ,^06 #'D(  PY2H +N8S "WF/  K
MYT0 *N=, 2CH5 $GZ%T!)>EG B/I<P(BZH$"(.J1 Q_KH0,=Z[(#'.S' QSL
MX0,;ZO$#&^GY QOI^0,;Z?D#&^GY YJD  "-K   ?[4  '*]  !EQ0  6<L
M $S0  !!U0  .-P  "_A @ M\0T *_$3 "CR'  F\B0 )/,K "+T,@ A]#D
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M0!, _T43 /])& #_3"  _TPI ?I+,P'R2#X"[$9*!.=$5@;C0V((WT%L"MQ
M=0S9/WX-U3Z&#],]C1#1/901SSR;$LT\HA/,/*D4RCNQ%,@[NQ7'.\@6Q3S<
M%L$\[1>^//D9NSS_&KH\_QNY//\;N#S_&[@\_QNX//\;N#S_&_\^% #_1!
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M)Y!/_R>04/\FCU#_)H]0_R:/4/\FCU#_)O]*"0#_4P4 ^%H$ .)? P#:8@8
MU&,) ,UC$@#$92, O&4R K9C0 6Q84L)K%Y4#JA<71*E6V46H5EL&)]8<QN<
M5GH>FE6"()A4BB*55)(DDU.;)I%2I2>/4K IC5*^*HQ2T"J*4^DJB5/Y*8A4
M_RF'5/\HAU3_*(=4_RB'5/\HAU3_*/],!0#_5@$ Z5T  -QC @#19P4 S&@'
M ,9H$ "]:B  MFDO ;!H/ 2J94<)I6-1#:%A6A*=7V$6FEYI&9=<<!R56W<>
MDEI^(9!9AB.-6(XEBU>7)XE7H2F&5JTKA5:Z+(-6S"R"5^8L@5?W*X!8_RJ
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M*W1@_RMT8/\K=&#_*_]3  #H7@  V6<  ,MM  ##<0$ NW," +5S"0"M=1<
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M*D^"MRM.@LPK3H+H*TZ!^"I/@/\J3X#_*4^ _RE/@/\I3X#_*=MJ  #'=0
MNG\  +"'  "FC   G(\  (^1  "&DP4 @)02 'N5(0!WE2T!<I4X!&V40@=I
MDTH+99)1#F*16!)>D%\56X]F&%B.;1M5CG8>4HV (4^,BR--BY@E2XNE)TF+
MM2A(B\HH2(KG)TF)]RA)B/\G28?_)TF'_R=)A_\G28?_)]%O  #!>P  M80
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M%S>I\Q@WI_X9-J;_&C:F_QHVIO\:-J;_&KJ$  "NCP  HI8  )>;  "+H0
M?Z8  '.K  !GKP  6K0  %.V# !1MQ< 3[<D $VX, !*N#H!2+A# D:X2P-$
MN%($0;A:!C^X8@<]N&L).KAU"SBW@0PVMXX.-+>=#S.WK0\RM\$/,;?>#S&V
M\A PM/P1,+/_$C"S_Q,PL_\3,+/_$[*.  "EE0  FIL  (ZB  ""J   =:T
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M 1/C^@$3X_H!$^/Z 9:B  ")J0  >[$  &ZY  !AP   5,8  $C*   ]SP
M,],  "K9   BW@( 'NL* !SL$  ;[1< &>T? !?N)@ 5[BT %.\U !/P/0 1
M\$8 $/%0  _R6P .\FD #?-X  STB@ +]9P "O6N  GVP@ )]MD "/7M  CU
M[0 (]>T "/7M (NI  !]L@  ;[H  &+"  !5R0  1\X  #O2   QV   )]T
M !_A   9Z   %O@& !3Z#0 2^Q( $/P7  [\'0 -_2, #/TI  K^,  (_S@
M!O]!  /_3   _U@  /]F  #_=P  _XD  /^;  #_JP  _[L  /_.  #_SP
M_\\  /_/ '^R  !QN@  8\,  %;+  !(T0  .M8  "_=   EX0  '.4  !3I
M   1]P  #_\!  W_"0 +_PT "/\0  ;_%  #_Q@  /\>  #_(P  _RH  /\R
M  #_/   _T<  /]4  #_8P  _W,  /^%  #_EP  _Z0  /^R  #_L@  _[(
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M!.,D[03@)/D&WB3_!]PD_PC;)/\)VB3_"=HD_PG:)/\)VB3_"?\N&P#_,1<
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M%:D\_Q:H//\6J#S_%J<\_Q:G//\6ISS_%O\]#0#_0@@ _T@* /]+# #Z3 \
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M'X)0_QZ"4/\>@E#_'O]'  #S40  WU@  -%=  #)8 ( PV $ +U>#0"U8!H
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M  #88   R&@  +QN  "S<0  JW,  *)Q  ";<@X E7,< )!T*@&*<S8"A7)
M!8%P2 A];U +>6U7#G9L7A%S:V04<&IL%VUI<QIK:7P<:&B&'V9GD"%D9YPC
M8F:I)6!FN29?9LTF7V;H)F!F^21@9O\C8&;_(V%F_R)A9O\B86;_(NA8  #3
M8P  Q&L  +EQ  "P=0  IW<  )YU  "6=@T D'<9 (MX)P"&=S,"@78]!'QU
M1@=X<TX+=7)5#G%Q7!%N<&,4:V]J%FEN<1EF;GH<8VV#'F%LCB%?:YHC76NG
M)5MKMR9::\HF6FOG)5MK]R1;:O\C7&K_(EQJ_R)<:O\B7&K_(N-;  #.9@
MP&X  +9T  "L>0  HWL  )AY  "0>@L BGL6 (5\) "!?#$!?'L[!'=Z1 9S
M>4P*<'A3#6QW6A!I=F$39W5H%F1T;QAA<W@;7G*!'5QQC"!:<9@B6'"F)%9P
MM255<,@E57#E)55P]B16;_\C5F__(E=O_R)7;_\B5V__(M]?  #*:0  O'(
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M'D6$\AY%@_X>18+_'D6"_QY%@O\>18+_'LIM  "Z>   KX$  *6'  ":BP
MCXT  (&.  !TD0  ;I,* &F4%0!FE2( 8Y4N 6"5. )<E4$$691)!E:44 A4
MDU<*49->#$Z29@],DFX129%X%$:0@Q9$D) 80H^>&4"/K1H_C\ :/X_<&C^-
M\1H_C/T;/XO_&S^+_QL_B_\;/XO_&\)S  "U?@  JH<  )^,  "4D   B),
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M"RJM_PLJK?\+*JW_"ZV+  "@D@  E9@  (F=  !]HP  <:@  &2M  !9L0
M3;0  $*X   [N@H .+L3 #>\'@ UO"D -+TR #.].P RO40 ,;Y, "^^50$N
MOEX!++YH 2J^= (IOH(")[^1 R:_H@,DO[0#([_+ R.^Z ,CO/<$(KO_!2*[
M_P4BN_\%(KO_!:22  "8F   C)X  ("E  !SJP  9[   %NU  !/N0  1+P
M #K    PQ 0 *L<+ "C($P GR1T )LDG "7),  DRCD (\I" "++2P ARU4
M(,Q? !_,;  =S7H ',V* !O-G  9SJX!&,[% !C-Y  8S/0!&,K\ 1C*_P(8
MRO\"&,K_ IN9  "/GP  @J8  '6M  !HLP  7+D  %"]  !$P0  .<0  ##(
M   HS $ (- & !G5"P 6UQ  %=@9 !79(@ 4V2L $]HT !/:/0 2VT@ $=Q3
M !'=7P 0W6T $-Y^  [?D0 .X*0 #>"X  S@T@ +W^T #-[W  S=^P ,W?L
M#-W[ )*?  "%IP  =ZX  &JU  !=O   4,$  $3%   XR0  +LT  "71   >
MU0  %MH! !'>!@ 0YPT #N<2  WH&0 ,Z"$ "^DI  KJ,0 )ZCL !^M%  7K
M40 $ZUX  ^MN  'K@   ZI0  .JG  #KO   Z](  .OI  #L[P  [.\  .SO
M (>G  !YKP  :[<  %Z^  !1Q0  0\D  #?-   MT0  (]8  !O;   3WP
M#N,   SN @ *]@H !_8.  7V$@ #]A@  /4>  #U)0  ]2X  /4W  #V0@
M]DX  /9=  #V;@  ]H$  /:5  #WIP  ][<  /C'  #XT   ^-   /C0 'NO
M  !MN   8,   %+(  !$S0  -]$  "O7   AW   &.   !'D   ,YP  !^\
M  3Z   !_P,  /\(  #_#0  _A   /X4  #_&@  _R$  /\I  #_,P  _SX
M /]+  #_6P  _VP  /^   #_D@  _Z$  /^M  #_LP  _[,  /^S /\<)@#_
M'"0 _QHE /\5)P#_$2X _Q Z /\.1P'_#5,!_PM? ?\*:P'_"G4!_PI_ ?\*
MAP'_"HX!_PJ5 ?\*FP'_": !_PFE /\)JP#_";$ _PFX /\)P0#^"<P _ G>
M /D)ZP#U"?8 \PG_ /(*_P#Q"O\!\0O_ ?$+_P'Q"_\!\0O_ ?\?(P#_'R$
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M!,@C_P7'(_\&QB/_!L8C_P;&(_\&QB/_!O\L$@#_+@\ _S 0 /\S% #_,QL
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M$9@\_Q&8//\1F#S_$?\Z 0#_0   [T4  .%(  #92 4 TT8) ,Q%$@#$1R(
MO4@Q +A(/P&S1TH"L$94!*Q%706J1&0'IT-L"*5"<PJC0GH+H4&!#*!!B V>
M0) /G$"8$)I H1&80*P2ET"X$I5 R!.30.$3D4'S%)!!_Q2/0?\4CD+_$XY"
M_Q..0O\3CD+_$_\\  #Y1   Y$H  -A.  #.3P( R4T& ,-+#P"[31T M4XM
M *]..@&K348"ITQ/!*1+6 :A2F (GDEG"9Q(;@N:1W4-F$9\#I9&@P^418L1
MDD64$I!%G1..1:@4C$6T%8M%Q!:*1=P6B$;P%H9&_1:&1O\6A4?_%85'_Q6%
M1_\5A4?_%?\_  #L2   W4\  ,]3  #&50  P%,# +M1# "S4AD K5,I *A3
M-@&C4D("GU%+!)Q05 :93UP(EDYC"I1-:@R13'$.CTMX#XU+?Q&+2H<2B4J0
M%(=)FA6%2:47@TFQ&())P!B!2M89?TKM&'Y+_!A^2_\7?4O_%WU+_Q9]2_\6
M?4O_%O]#  #F3   UE,  ,E8  # 60  NE@! +16"0"L5Q8 IE@E *%8,@&=
M5SX"F%9(!)5540:25%@(CU)?"HQ29@R*46T.B%!T$(5/>Q*#3X03@4Z-%7].
MEQ=]3J$8>TVN&7I.O1IX3M$:=T[K&G=/^AEV3_\9=D__&'9/_Q=V3_\7=D__
M%_A&  #B4   T%<  ,1<  "[7@  M%T  *Y:!@"F6Q, H%PB )M<+P"76SL"
MDEI% X]930:+6%4(B%=<"H968PR#56H.@51Q$'Y4>!)\4X 4>E*)%GA2E!AV
M4I\9=%*K&G)2NAMQ4LT<<%+H&W!3^1IP4_\:<%/_&7!3_QAP4_\8<%/_&.])
M  #=4P  RUH  ,!?  "W8@  KV$  *A> @"A7Q  FV > )9@+ "18#@!C5Y"
M XE=2P6%7%('@EM9"H!:8 Q]66<.>UAN$'A8=1)V5WT4=%>'%G)6D1AO5IP:
M;E:I&VQ6N!QK5LL=:E;F'&I7]QMJ5_\::E?_&6M7_QEK5_\9:U?_&>M,  #8
M5@  R%X  +QB  "S90  JV4  *-B  "<8@X EF,< )%D*0",8S4!B&(_ X1A
M2 6 8% '?5]7"7I>70MW760-=5QK$'-<<A)P6WL4;EN$%VQ:CQAJ6IH::%JG
M'&9:MAUE6L@=95KD'65:]AQE6O\;95K_&F5:_QEE6O\995K_&>A/  #360
MQ&$  +EF  "P:   IVD  )YE  "79@T D6<9 (QH)P"'9S(!@V8] G]E1@1[
M9$T&>&-4"75B6PMR86$-<&%I#VU@<!)K7WD4:5^"%F=>C1EE7I@:8UZE'&%>
MM!U@7L<=8%[C'6!>]1Q@7O\;8%[_&F%>_QIA7O\:85[_&N12  #/7   P&0
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M'%%K\1M2:_X:4FK_&E)J_QE2:O\94FK_&=1<  ##9@  MFX  *QT  "B=P
MEG8  (EU  "!=@$ >G</ '9X&P!R>2< ;WDR 6MX/ )H>$0$97=,!F)W4PA?
M=EH*775A#%IU: ]8=' 157-Y$U-SA!91<I 83W*>&4UQK1I,<;\;2W'9&TQQ
M\!I,</T:37#_&4UO_QE-;_\936__&<Y@  "^:@  LG(  *AX  "=>P  D'H
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M$SN&_Q,[AO\3.X;_$[QQ  "O>P  I8,  )F'  ",B   ?XD  '.,  !ED
M7),  %>5# !4EA8 4I8B %"7+0!-ES8 2Y<_ 4F71P)'ETX#1995!$.6705!
MEF4&/I5O"#R5>@DZE8<+.)65##:4I0TUE+8.-)3,#323Z0TTDO@.-)#_#S20
M_P\TD/\/-)#_#[5X  "J@@  GH@  ).-  "&C@  >9   &V3  !AEP  59L
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M I^/  "4E0  B)L  'NA  !NI@  8JL  %:P  !*LP  /[8  #6Y   LO
M)+\& !_"#0 =PA0 ',(> !O#)@ :PR\ &<0X !C$00 7Q$H %L55 !7%80 4
MQF\ $\9_ !+&D0 1QZ0 $,>Y  _'U  0QNX $,3Z !##_P 0P_\ $,/_ )>6
M  "+G   ?J(  '&I  !DKP  6+0  $NX  ! NP  -;X  "O!   CQ0  &\D!
M !3,!@ 0T L #M$1  W1&0 -T2$ #-$J  S1-  +TCX "M))  G350 )TV(
M"--R  ;4A  %U)@ !-2K  /5P  !U=P  =7M  '5]@ !U?8  =7V (Z=  "
MI   <ZL  &:Q  !9N   3+T  #_    TPP  *L<  "'*   9S@  $M(   W6
M 0 )VP4 !MP-  3<$0 #W1@  =X@  #>*   WS$  . \  #A1P  XE0  .-C
M  #C=   Y(@  .2;  #EK@  Y<$  .75  #FYP  YN<  .;G (.D  !UK
M:+,  %J[  !-P0  0,0  #/(   HS   ']   !?4   0V0  "]T   7A
MY    .4'  #F#0  YQ$  .@6  #I'0  ZB4  .LN  #M.0  [T4  /!3  #Q
M9   \78  /**  #SG   \ZT  /2[  #TR   ],@  /3( '>M  !JM0  7+T
M $_$  ! R0  ,\T  "?1   =U@  %-P   [@   (XP   >8   #J    [@
M .X   #O!   \ H  /$.  #S$@  ]!@  /8@  #X*@  ^C4  /U#  #^4@
M_V,  /]V  #_B0  _YH  /^F  #_L   _[   /^P /\6(P#_%2$ _Q$A /\-
M) #_"2L _P8W /\#1 #_ %$ _P!= /\ : #_ '( _P![ /\ @P#_ (H _P"1
M /\ E@#_ )P _P"A /T I@#[ *P ^0"S /< NP#U ,4 \P#1 /( Y #Q /$
M[P#Z .X _P#N /\ [0#_ .T _P#M /\ [0#_ /\9( #_&!T _Q4= /\0'P#_
M#BD _PPT /\*00#_!TT _P59 /\$9 #_!&X _P-W /\#@ #_ X< _P.- /T"
MDP#[ ID ^0*> /<"I #U JH \P&P /$!N #O <( [0'/ .L!XP#J >\ Z +[
M .<$_P#F!?\ Y@;_ .8&_P#F!O\ Y@;_ /\<&P#_&QD _Q<8 /\5'0#_$R4
M_Q$P /\0/0#_#DD _PQ5 /\+8 #_"VH _0MS /L+? #Y"H, ]PJ* /4*D #T
M"I8 \PJ; /$*H0#O":< [0FN .L)M@#H"<  Y@G- .0)X@#B"O  WPO[ -X,
M_P#<#?\ W W_ -L-_P';#?\!VPW_ ?\?%P#_'A, _QL2 /\<&0#_&R( _Q@L
M /\5. #_$T0 _A)0 /D16P#U$&8 \Q!O / 0=P#N$'\ [!"& .H0C #I$)(
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M!+,C_P2S(_\$LR/_!/\I"P#_*@4 _RX( /\O# #_+1  \RL7 .@H(@#@)B\
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M$G1)MA)S2<@3<DKC$W%*]1)Q2O\1<4O_$7%+_Q!Q2_\0<4O_$.Q#  #93
MR%,  +U7  "T6   K%<  *52 0">4P\ F%0< )-4*0"/5#4 BU-  8A32 *%
M4E $@E%7!7]07@9]4&0(>T]K"7E/<@MW3GL-=4Z$#G--CA!Q39D1;TVE$VU-
MLQ1L3<44:T[A%&M.]!-K3O\2:T[_$FM._Q%K3O\1:T[_$>A&  #34   Q%8
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M%EM9[Q5;6?T47%G_$UQ9_Q)<6?\27%G_$MQ0  #'60  NF   *]D  "D90
MF60  )!@  "(808 @F(1 'YC'0!Z8RH =F,T 7-B/0%O8D8";&%-!&IA5 5G
M8%H'96!A"&-?:0IA7W$,7UYZ#EU>A1!;7I$265V>%%A=K!577;T65EW5%E9=
M[A577?P45UW_$U==_Q)77?\25UW_$M93  #$7   MV,  *QH  "@:   E6<
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M$DAJ_Q%(:O\12&K_$<=>  "X9P  K&X  *%R  "3<@  AW$  'IQ  !Q<@
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M";!V  "E?P  F(0  (J$  !]A0  <(<  &6*  !:C@  3Y(  $:5  !!F P
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M !:RD  5LJ( %+*V !.RS@ 3L>L $Z_Y !.N_P$3KO\!$Z[_ 9J-  "0D@
MA)<  '6:  !HGP  6Z,  %"H  !%K   .[   #&R   GM0  (+@  !BZ!P 4
MO X $[P5 !*\'@ 1O28 $;TN !"]-P 0OD$ #KY,  Z^5P -OF4 #+]T  N_
MA@ *OID "+ZL  >^P@ 'OM\ "+[P  B]^@ (O?P "+W\ ).4  "'F0  >I\
M &RE  !@J@  4Z\  $>S   \M@  ,;@  ">[   ?O@  %\$  !'$ 0 ,R @
M",D.  ?)%  &R1P !<DD  3*+  #RC8  LI   #+3   RUD  ,MH  #+>0
MS(P  ,N?  #+LP  R\@  ,SB  #,[P  S/$  ,SQ (J:  !\H0  ;Z<  &*M
M  !5LP  2+@  #N[   PO@  )L$  !W$   5R   #\L   K.   $T@(  -,*
M  #3#P  U!0  -4:  #6(@  URH  -DT  #:/P  W$L  -Q:  #=:@  W7T
M -V1  #=I   WK8  -[(  #>W@  WN(  -[B '^B  !QJ0  9+   %:W  !)
MO   /,   "_$   DQP  &\L  !//   -T@  !]8   #;    W@   -\#  #@
M"0  X0X  .(2  #C%P  Y1X  .8G  #H,0  ZCT  .Q+  #L6@  [6P  .Z
M  #NE   [J4  .ZT  #NP@  [L8  .[& '2J  !FL@  6+D  $O    ]Q0
M+\D  "3-   9T0  $=8   O;   #W@   .$   #E    Z    .D   #J
MZP8  .T+  #O#P  \!,  /(:  #T(P  ]RX  /D[  #[2@  _%L  /UM  #]
M@   _I,  /ZB  #^K0  _J\  /ZO /\0'P#_#AT _PH= /\!( #_ "@ _P U
M /\ 00#_ $X _P!: /\ 90#_ &X _P!W /\ ?P#^ (8 _ ", /L D@#Y )<
M^ "< /< H@#V *< ]0"M /, M0#R +T \0#) .\ W #N .L [0#W .P _P#K
M /\ Z@#_ .H _P#J /\ Z@#_ /\3' #_$1D _PT9 /\&' #_ R4 _P Q /\
M/@#_ $H _P!6 /\ 80#_ &L _0!S /H >P#W (, ]0") /0 CP#R )0 \0"9
M /  GP#N *0 [0"K .P L@#J +H Z #& .< U@#E .@ Y #U ., _@#B /\
MX0#_ .$ _P#A /\ X0#_ /\5& #_$Q0 _P\4 /\-&0#_"R( _P@M /\$.0#_
M 48 _P!1 /X 7 #Z &8 ]@!O /( =P#O 'X [0"% .L BP#J )$ Z "6 .<
MG #F *$ Y "H ., KP#A +@ WP## -T T0#; .8 V0#S -< _0#5 O\ U +_
M -0#_P#4 _\ U /_ /\8$P#_%1  _Q(/ /\2%0#_$1T _PXH /\,- #_"D$
M^0A, /4&5P#Q!F$ [09J .D%<@#F!7H Y 6! .(%AP#@!HT WP:2 -T&F #;
M!IX V0:E -<&K0#4!K4 T@;  - 'SP#.".4 S GT ,H+_P#(#/\ QPS_ ,<,
M_P#&#/\ Q@S_ /\;#@#_&0P _Q@- /\8$0#_%Q@ _Q0B /L1+@#S$#H [0Y&
M .@-4@#E#5P X0UE -X-;0#;#74 V U\ -4-@@#3#8D T0V/ - -E0#.#9P
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M O\E  #_*   \BH  .4K  #?* 4 W"$+ -(A% #))"0 PR4R +XF/P"Z)TH
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M!HHUN0:(-<H'AS;E!X4V]@>$-_\'@S?_!X,W_P>"-_\'@C?_!_0R  #C.P
MTD$  ,9$  "]0P  MS\  +$["0"J.Q0 I3PB * ], "=/3L F3U% )8]3@&4
M/%8!DCQ= I \8P*..VH#C#MQ!(H[> 2(.H %ASJ(!H4ZD@:#.IP'@3JH"( Z
MM0E^.\8)?3OA"7L\\PE[//\)>CS_"'H\_PAZ//\(>CS_".XW  #=00  RT8
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M#F5)[0UE2OP,94K_"V5*_PME2O\+94K_"^!$  #+30  O5(  +)6  "F50
MG%(  )5.  ".3@D B4\4 (50( "!4"P ?E W 'M00 %X4$@!=4]/ G-.50-Q
M3EP$;TYC!6U-:@9K37(':4U["&=-A0IE39$+9$R=#&)-JPUA3;L.8$W1#F!-
M[ Y@3?L-8$W_#&!-_PM@3?\+8$W_"]Q'  #'4   N58  *Y9  "B6   F%8
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M#5)8_PQ26/\,4EC_#,U1  "\60  L%\  *-A  "68   BU\  (%;  !Y70
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M"KI@  "M:0  H&X  )%M  "$;0  >&T  &QN  !A<   6W(  %9T"@!2=1(
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M BR)EP,JB*<#*8BZ RF(U ,IANX#*87\!"F$_P0IA/\$*83_!*IT  ">>P
MCGH  (!Z  !T>P  :'X  %V!  !2A0  28D  $&,   YD 4 -9$/ #.2%P R
MDB$ ,9(I #"3,@ NDSH +9-! "R32@ KE%( *I1< "B49P GE',!)92" 224
MDP$BDZ0!(9.W 2"3SP$ADNP!()#Z B"/_P(@C_\"((__ J1\  "7@   AW\
M 'N   !N@@  8H4  %>)  !-C@  0I(  #J6   RF0  *IP) "B=$0 FG1D
M)9TB "2>*@ CGC( (IXZ "&>0@ @GDL 'Y]5 !Z?8  <GVT &Y]\ !J?C0 8
MGY\ %Y^R !:?R0 6GN@ %ISW !:;_P$7F_\!%YO_ 9V#  "/A@  @H8  '2'
M  !GBP  6X\  %"3  !&F   /)P  #.@   KHP  (Z8  !RH"P :J1$ &*D8
M !>I(0 6JBD %:HQ !2J.0 3JD, $ZM- !*K6  1JV4 $*MT  ZKA@ .JYD
M#:NL  RKP0 ,JM\ #*GR  VH_  -J/\ #:C_ ):*  ")C   >HT  &R1  !@
ME0  5)H  $F?   _HP  -:<  "NJ   CK@  &[   !2S 0 /M0H #;80  RV
M%@ +MA\ "K8G  FV+P (MCD ![=#  :W3P $MUL  [=J  *W>P  MXX  +>A
M  "VM   MLL  +;E  "U\0  M?<  +7W (^1  "!E   <I<  &6<  !8H0
M3*8  $&K   WKP  ++(  ".U   :N   $[L   Z]   )P 4  \$-  #!$0
MP1<  ,(>  #")@  PB\  ,,Y  #$1   Q%   ,1>  #%;P  Q8$  ,65  #%
MJ   Q;P  ,31  #$Y@  Q.X  ,3N (:8  !YG@  :Z,  %VI  !0K@  1+,
M #>V   LN0  (KP  !F_   1P@  #,4   ;(    RP   ,P'  #,#0  S1$
M ,T6  #.'0  SR0  - M  #2.   U$0  -12  #580  U7,  -:'  #6FP
MUJT  ->_  #8S@  V-T  -C= 'N@  !NI@  8*T  %.S  !%N   .+P  "N_
M   AP@  %\8  !#)   *S    M    #4    UP   -@   #:!0  VPL  -P.
M  #>$P  WQD  .$A  #C*@  Y38  .=#  #G4P  Z&0  .EW  #IC   ZI\
M .JN  #JN@  ZL,  .K# '"H  !BKP  5;8  $>\   YP   +,0  "#(   6
MS   #M    ?4    V0   -T   #A    XP   .0   #F    YP$  .D'  #K
M#   [!   .X5  #P'0  \R<  /8S  #W0P  ^%0  /EF  #Y>@  ^HX  /J>
M  #[J0  ^[   /NP /\+&P#_!QD _P 9 /\ ' #_ "4 _P R /\ /P#_ $L
M_P!7 /\ 8@#_ &L _P!S /T >P#[ (( ^@"( /@ C0#W )( ]@"8 /4 G0#T
M *( \P"I /$ L #O +@ [@## .P T0#K .8 Z0#S .@ _@#H /\ Z #_ .@
M_P#H /\ Z #_ /\.& #_"A4 _P$4 /\ & #_ "( _P N /\ .P#_ $< _P!3
M /T 7@#Z &< ]P!O /4 =P#S 'X \@"$ /  B0#O (\ [@"4 .P F@#K )\
MZ0"E .@ K #F +0 Y "_ ., S #A .( WP#P -X ^P#> /\ W0#_ -T _P#<
M /\ W #_ /\0$P#_#1$ _P80 /\"%0#_ !X _P I /\ -@#_ $( ^@!. /0
M60#Q &( [@!K .P <@#J 'D Z !_ .< A0#E (L Y "0 .( E@#A )P WP"B
M -T J0#: +$ V "[ -4 R #2 -T T0#M -  ^0#/ /\ S@#_ ,T _P#- /\
MS0#_ /\1#P#_#@T _PP- /\+$@#_!QD _P(D /\ , #V #P [P!) .H 4P#G
M %T Y !F .$ ;0#? '0 W0![ -L @0#9 (8 U@", -0 D@#2 )@ T "> ,X
MI@#, *X R@"X ,@ Q #& -< Q0#J ,, ]P#" /\ P0'_ , "_P#  O\ P +_
M /\4"P#_$ 8 _Q ) /\0#@#_#A0 _PH> /4&*0#K!#8 XP-" -\#3@#;!%<
MU@1@ -,$: #0!&\ S@5V ,P%? #*!8( R06( ,<%C@#&!90 Q 6; ,(%HP#
M!JL O@:U +T&P@"["-0 N@GI +<+^ "U#/\ M S_ +0,_P"T#/\ M S_ /\7
M! #_%   _Q8# /\4"0#_$0X \@X5 .@,(0#>"BX U@L[ - ,1P#,#%$ R0Q:
M ,8-8@#$#6H P@UQ , -=P"_#7T O0Z# +P.B@"Z#I$ N0Z8 +<.H "V#JD
MM ^T +(/P0"Q$-0 KA'K *L2^@"I$O\ J!/_ *<3_P"G$_\ IQ/_ /\:  #_
M&P  ^1L  .L9  #E% 8 Y1 . -D.%P#/$28 R!(T ,030 "_%$L O!14 +D5
M70"W%60 M15K +05<0"R%7@ L19^ *\6A0"N%HP K!:4 *L7G "I%Z8 IQBP
M *88O0"D&,\ HAKG )\:]P"=&_\!G!O_ 9P;_P&;&_\!FQO_ ?\=  #W(0
MZ"0  -TE  #4(0$ SQL( ,H7$0#"&B  O!PM +<=.@"S'D4 L!Y/ *T>5P"K
M'E\ J1]F *@?; "F'W, I1]Y *,?@ "B'X< H""/ )\@F "=(*( FR"L 9HA
MN0&8(<H!EB+D 90C]0&2(_\!D2/_ 9 C_P&0(_\!D"/_ ?\B  #K*0  W2X
M ,\O  #'+0  P2<# +TB#0"V(QH L"4H *PF- "H)D  I2=) *(G4@"@)UH
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M!78V[05T-_P%=#?_!'0W_P1T-_\$=#?_!.<U  #2/0  PT(  +A$  "L0@
MI#X  )\Y  ":. X E#H9 ) Z)@"-.S$ BCL[ (<[1 "$.TP @CM3 8 Z6@%^
M.F !?3IG GLZ;@)Y.G4"=SI^ W8ZB 1T.I,$<CJ>!7$ZJP5O.[L&;CO/!FT[
MZ@9M//H&;#S_!6P\_P5L//\%;#S_!>(Y  #,0@  OD<  +%(  "E1@  G4,
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M!UI(_P9:2/\&6DC_!M%%  "_3   LE(  *-1  "74   C4X  (9*  " 2@$
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M!L%1  "R60  HUP  )1;  "'6P  ?5H  ')8  !K60  95H# &!;#@!=7!<
M6EPA %A=*P!6730 5%X\ %->1 !17DL!4%Y2 4Y>60),7F$"2UUJ TE== 1'
M78 %15V-!D1=G =#7:P'0EV^"$)=V@A"7/$'0ES^!T-;_P9#6_\&0UO_!KU5
M  "O70  GU\  )!>  "#7@  >%T  &U<  !E70  7U\  %I@# !7810 56(>
M %)B* !18S$ 3V,Y $YC00!,8T@ 2V-/ 4EC5@%'8UX"16-G D1C<0-"8WT$
M0&*+!3]BF@8^8JH&/6*\!SQBU@<]8>\&/6']!CY@_P8^8/\&/F#_!KE9  "K
M80  FF$  (MA  !_80  =&$  &EA  !?8@  660  %1F"0!19Q$ 3F<: $QH
M) !+:2T 26DV $AI/@!&:D4 16I, $-J5 %":EP!0&EE CYI;P(\:7L#.VF)
M!#EIF 4X:*@%-VBZ!3=ITP4W:.X%-V?\!3AF_P4X9O\%.&;_!;1>  "G90
ME64  (9D  !Z90  ;V4  &1F  !9:   4FH  $UL! !);@X 1VX6 $5O( !$
M<"D 0G R $%P.@! <4( /W%) #UQ40 \<5D!.G%B 3AQ; (V<'@"-7"& S-P
ME0,R<*8$,7"X!#!PT 0Q;^P$,6[[!#%M_P0Q;/\$,6S_!*]D  "A:0  CV@
M (%H  !U:0  :VD  &!K  !5;@  37$  $9S  !"=0L /W82 #UW'  \=R4
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M !B,Q  8C., &8KU !F)_P$9B/\!&8C_ 9UW  ",=@  ?78  ')W  !E>0
M6GP  %"   !&A   /(D  #2,   MD   )9," !^5#  =EA( ')8: !N7(@ :
MERH &9<R !B8.@ 7F$, %IA- !686  4F&0 $YAS !&8A  0F)8 $)BI  Z8
MOP .E]T #Y;R !"5_  0E/\ $)3_ )5]  "%?   >'P  &M^  !?@0  5(8
M $J*  ! CP  -I,  "V7   FF@  'IT  !>@ P 2H@P $*,2 !"C&0 /HR$
M#J0I  ZD,0 -I#H #*1%  ND4  *I%P ":1J  >D>P &HXX !*.A  *CM  #
MHLL  Z+F  .A\P #H?L  Z'[ (V#  !_@@  <80  &2'  !8C   39$  $*6
M   XF@  +YX  ":B   >I0  %Z@  !&K   ,K@< !Z\-  .O$@ "KQD  :\A
M  "O*0  L#(  + \  "P1P  L%,  +!A  "P<0  L(,  *^7  "OJ@  K[\
M *[9  "NZP  KO0  *[T (>)  !XB@  :HX  %V3  !1F   19T  #NB   P
MI@  )ZH  !ZN   6L0  $+0   NV   %N0,  +H*  "Z#@  NA,  +L9  "[
M(0  O"@  +PQ  "]/   OD@  +Y6  "^90  OG<  +Z,  "^GP  O;,  +['
M  "^W@  O>L  +WK '^2  !PE0  8IH  %6?  !)I0  /:L  #*O   HM
M'K8  !6Y   .O   ";\   +"    Q    ,4$  #&"@  Q@X  ,<2  #(&
MR1\  ,HG  #,,   SCP  ,Y)  #/60  SVH  ,]^  #/DP  SZ8  ,^X  #/
MR   S]L  ,_; '><  !HH0  6Z<  $ZN  !!M   -+<  "BZ   =O0  $\
M  W$   &QP   ,H   #.    T    -$   #2 @  TP@  -4,  #6$   V14
M -L<  #=)   X"\  .(\  #C2P  Y%P  .1O  #E@P  Y9@  .6I  #EM@
MY<,  .7# &RE  !?K   4;(  $2Y   UO   *,   !S$   2R   #,L   //
M    TP   -@   #<    WP   -\   #A    XP   .0#  #F"   Z T  .D1
M  #L&   [B(  /$N  #S/   ]$T  /5?  #V<P  ]X<  />9  #XI0  ^+
M /BP /\#%P#_ !4 _P 5 /\ & #_ ", _P O /\ / #_ $@ _P!4 /\ 7@#_
M &< _0!O /L =@#Y 'T ^ "# /8 B #U (X ] "3 /( F #Q )X \ "D .X
MJP#M +, ZP"] .H RP#H .$ YP#Q .8 _0#E /\ Y #_ .0 _P#D /\ Y #_
M /\'$P#_ !$ _P 1 /\ %0#_ !\ _P K /\ -P#_ $0 _@!/ /H 6@#W &,
M] !K /( <@#P 'D [P!_ .T A #K (H Z@"/ .@ E #G )H Y0"@ .0 IP#B
M *\ X "Y -X Q@#< -H V@#L -@ ^0#6 /\ U@#_ -< _P#8 /\ V #_ /\*
M$ #_ PX _P - /\ $@#_ !H _P F /P ,@#W #\ ] !* /$ 50#M %X Z@!F
M .@ ;@#E '0 XP!Z .( @ #@ (4 W@"+ -P D #; )8 V "< -4 HP#3 *L
MT0"U ,X P0#, -$ RP#G ,D ]0#( /\ R #_ ,@ _P#( /\ R #_ /\,# #_
M!@@ _P(* /\ #P#_ !4 _  @ /$ + #L #D Z0!% .4 3P#A %D W@!A -L
M: #7 &\ U !U -( >P#0 (  S@"& ,P C #+ )( R0"8 ,< H #% *@ PP"Q
M ,$ O "_ ,L O0#C +P \@"[ /T NP#_ +H _P"Z /\ N@#_ /\.!0#_"0
M_PD% /\&"P#_ 1  \  9 .8 )0#A #( W  _ -8 20#1 %, S@!; ,L 8P#(
M &H Q@!P ,4 =@## 'L P0"! ,  AP"^ (X O "4 +L G "Y *0 MP"N +4
MN0"S ,@ L0#? + ![P"O ?L K@+_ *T#_P"M _\ K0/_ /\0  #_#@  _PT
M /8+ P#R!PH X@$1 -L"'0#2 RL S ,W ,@$0P#$!$T P016 +X%70"\!60
MN@5K +@%<0"W!78 M05\ +,&@P"R!HD L :1 *\'F0"M!Z$ JP>K *D(MP"H
M"<8 I@K= *4+\ "C#/T H@W_ *$-_P"A#?\ H W_ /\1  #\$@  [!,  .(3
M  #;#P, U@D+ ,X(% #&"B( P PP +P-/ "X#48 M0U/ +(.5P"P#E\ K@YE
M *T.:P"K#G$ J@YX *@.?@"G#X4 I0^- *0/E@"B$)\ H!"I )\0M0"=$<4
MFQ'> )D2\0"7$_\ EA3_ )44_P"5%/\ E!3_ /\5  #M&P  X!\  -(?  #)
M&P  Q!0% ,$0#@"Z$AL M!,I + 4-0"L%4  J15) *854@"D%ED HA9@ *$6
M9@"?%FP GA9R )P6>0";%X  F1>( )@7D0"6&)L E!BF ),9L@"1&<$ D!K8
M (T;[@"+'/T BAS_ (H<_P")'/\ B1S_ /0=  #D)0  TRD  ,<J  "\)@
MMB   +09"P"N&A4 J!PC *0=+P"A'CH GAY$ )L>3 "9'E0 EQ]; )4?80"4
M'V< DA]M )$?= "/('P CB"$ (P@C0"*()< B2&B (<AK@"&(KT A2+1 8(C
MZP&!)/L!@"3_ 7\D_P%_)/\!?R3_ >PE  #;+0  R3$  +PQ  "Q+@  JRD
M *<D!0"C(Q$ GB0= )HE*@"6)C4 DR8_ )$F1P"/)D\ C296 (LG7 "))V(
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M F8V_P)F-O\"9C;_ M@W  #$/@  M4(  *9!  ";/P  DSP  (TX  "(-@<
MA#<1 ( W' !\."< >C@Q '<Y.@!U.4( <SE) '$Y4 !P.5< ;CE= &PY9 %K
M.6L!:3ET 6@Y?@)F.8D"9#F5 V,ZH@-B.K$#83K# V [X 1?._,#7SO_ U\[
M_P-?._\"7SO_ M$[  # 0@  L$4  *%$  "50P  C4   (<]  "".P( ?3L.
M 'D\& !U/2, <STM ' ]-@!N/3\ ;#U& &L]30!I/5, 9SU: &8]80%D/6@!
M8SUQ 6$^>P)?/H8"7CZ3 UP^H -;/Z\$6C_!!%H_W019/_($63__ UD__P-9
M/_\#63__ \P_  "\1@  JT@  )Q'  "11@  B$0  ()   !\/P  =T , '-
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M \1%  "U30  HTT  )5,  ")2P  ?TH  'A&  !Q1P  ;$<' &A($ !D2!H
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M T-3EP-"4Z<$05.X!$%3SP1!4^P$05+[ T)2_P-"4O\#0E'_ [I/  "J5
MF%0  (E4  !]4P  <U,  &E1  !B4@  7%,  %A4"@!451( 4E4; $]6) !.
M5BT 3%<U $M7/ !*5T0 2%=+ $=84@!&6%H!1%AC 4-8;0%!6'D"0%B& CY8
ME0,]6*4#/%BW!#Q8S00\5^H#/%?Z SU6_P,]5O\#/5;_ [93  "E5P  E%<
M (56  !Y5@  ;U8  &55  !<5@  5U@  %)9!P!.6A  3%H8 $I;(0!(7"H
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M 2IJQ@$J:>4!*FCV BMG_P(K9_\"*V?_ JEA  "58   A&   '=@  !L80
M8F$  %AC  !.9@  1V@  $!K   Z;@4 -F\. #1P%0 S<!X ,G$F #!Q+@ O
M<34 +G(] "UR10 L<DT *W)7 "IR80 I<FT )W)[ "9RBP D<IP!(W*N 2-R
MPP$C<>(!(W#T 2-O_P$C;O\!(V[_ :%E  ".9   ?V0  ')D  !H90  7F8
M %1I  !);   0F\  #MR   T=0  +G@* "MY$0 J>1@ *7HA "=Z*  F>C
M)7LX "1[0  C>T@ (GM2 "%[7  @>V@ 'WQV !U\A@ <>Y@ &WNJ !I[OP :
M>]X &GGR !MX_@ ;=_\!&W?_ 9EI  "(:0  >6D  &UI  !C:@  66P  $]O
M  !%<P  /7<  #5Z   N?0  )X$# "*##0 @A!( 'X0: !V$(@ <A2H &X4Q
M !J%.0 9A4( &(9, !>&5@ 6AF, %89Q !2&@0 2AI, $8:F !&%NP 0A=8
M$8/O !&"^P 2@O\ $H'_ )%N  "!;0  =&X  &EN  !=<   4W,  $EW  !
M?   -X   "^#   GAP  (8H  !J-!@ 5CPT $Y 3 !*0&@ 2D"( $9 J !"1
M,@ 0D3L #Y%$  Z13P -D5P #)%J  N1>@ *D8T ")"?  >0LP 'C\D !X_F
M  >.]  (C?P "(W_ (ES  ![<P  ;W,  &-U  !7>   37T  $.!   YA@
M,(H  "B.   AD0  &I4  !.7   .F@@ "YP.  F<$P (G!H !YPB  :<*@ $
MG#,  YP]  *=2   G50  )UB  "<<@  G(0  )R7  ";J@  F[\  )K;  ":
M[   FO4  )GX ()Y  !V>0  :'H  %Q^  !1@@  1H<  #R,   RD0  *94
M "&9   9G0  $J    ZC   )I@4  Z<,  "G$   IQ4  *@<  "H(P  J"L
M *DT  "I/P  J4L  *E9  "I:   J7H  *F.  "IH0  J+4  *C+  "GY
MI^\  *?S 'V   !O@0  880  %6)  !)C@  /I0  #29   JG@  (:(  !FF
M   2J0  #:P   >O    L@   +,'  "S#   LQ   +05  "T&P  M2(  +8K
M  "W-0  MT   +A.  "X70  N&X  +B"  "XEP  N*H  +>^  "WT@  M^8
M +?J ':(  !GBP  6I   $Z6  !"G   -Z(  "RG   BJP  &:\  !&S   +
MM@  !+D   "\    O@   +X   "_!@  P L  ,$/  #"$P  PQD  ,0@  #%
M*0  QS0  ,A"  #)40  R6(  ,EU  #)B@  R9\  ,JQ  #*P0  R=$  ,G9
M &Z3  !@F   4YX  $:D   ZJP  +[   "2U   9N   $+P   J_   !P0
M ,0   #(    R@   ,H   #,    S0,  ,X(  #0#0  T1   -,6  #6'@
MVB@  -TT  #>0P  WU0  -]G  #@?   X)$  ."D  #@L@  X+X  .## &:?
M  !9I@  3*T  #^T   RN   )+P  !B_   0PP  ",<   #*    S0   -$
M  #5    V    -D   #;    W0   -\   #A!   XPH  .4.  #G$P  ZAP
M .TG  #P-0  \48  /)8  #S:P  \X   /24  #THP  ]*X  /2R /\ $P#_
M !$ _P 1 /\ %0#_ !\ _P L /\ .0#_ $4 _P!0 /\ 6@#^ &, ^P!K /D
M<@#W '@ ]0!^ /0 A #R (D \0". /  DP#N )D [0"? .P I@#J *X Z "X
M .8 Q0#E -L XP#M .( ^P#B /\ X0#_ .$ _P#A /\ X0#_ /\ $ #_  X
M_P - /\ $@#_ !L _P H /\ - #^ $$ ^P!, /< 5@#T %\ \0!F .\ ;0#L
M '0 Z@!Z .D ?P#G (4 Y@"* .4 CP#C )4 X0"; .  H@#> *H VP"T -D
MP #6 -  TP#H -( ]P#1 /\ T0#_ -  _P#0 /\ T #_ /\ #0#_  D _P *
M /\ #P#_ !8 ^P B /< +P#T #L \ !' .T 40#I %H Y0!B .( :0#@ &\
MW@!U -P >@#: (  V "% -4 BP#3 )$ T0"7 ,\ G@#- *8 RP"O ,D N@#'
M ,D Q0#B ,0 \@## /X P@#_ ,$ _P#" /\ P@#_ /\#!@#_  $ _P & /\
M# #Y !$ \0 = .L *0#G #8 XP!! -\ 2P#; %0 U0!< -( 8P#/ &H S0!P
M ,L =0#) 'L R "  ,8 A@#% (P PP"3 ,$ F@"_ *( O0"K +L M@"Y ,0
MMP#: +8 [0"T /H M #_ +0 _P"T /\ M #_ /\$  #_    _P   /\ !@#L
M  T Y0 6 -X (@#7 "\ T0 [ ,T 10#* $X Q@!7 ,0 7@#! &0 OP!J +T
M< "\ '4 N@![ +D @0"W (< M0". +, E0"R )X L "G *X L@"L +\ J@#1
M *@ Z "H /< IP#_ *< _P"F /\ I@#_ /\&  #_!0  \0,  .@   #A  <
MU0 0 ,T &P#' "< PP S +\ /@"\ $@ N0!1 +8 6 "T %\ L@!E +  :@"O
M '  K0!V *P ? "J (( J0") *< D0"E )H HP"D *$ K@"@ +L G@'- )T"
MY@"<!/0 FP3_ )H%_P":!?\ F07_ /\*  #Q#@  Y!   -D/  #."P  R ,+
M ,( $P"\ A\ MP,L +,$-P"P!4( K09* *H&4@"H!UD I@=? *4'90"C!VL
MH@AQ * (=P"?"'X G0B% )L)C@":"9< F JA )8*K "5"[H DPO, )(,Y0"0
M#?8 CP[_ (X._P".#O\ C0[_ /81  #F%P  UAL  ,<9  "^%0  N1   +<*
M#0"Q"Q< K TD *@., "E#CL H@Y$ )\/3 "=#U, FP]: )H/8 "8$&8 EQ!L
M )40<@"3$'D DA"! ) 0B@"/$90 C1&? (L1J@"*$K@ B!++ (83Y@"%%/<
M@Q7_ (,5_P""%?\ @A7_ .T:  #<(0  RB4  +LB  "Q'P  JQH  *D4!@"E
M$A$ H!0> )P5*@"9%34 EA8^ )061P"2%DX D!95 (X76P",%V$ BQ=G (D7
M;0"(%W0 AAA\ (48A@"#&9  @1F; ( :IP!^&K4 ?1O' 'P<X@!Z'?4 >1W_
M '@=_P!X'?\ >!W_ .4B  #0*0  ORP  + J  "G)P  H",  )T?  ":&@X
ME1P8 )$=) ".'B\ C!XY (D>00"''TD A1]0 (,?5@""'UP @!]B '\?:0!]
M('  ?"!X 'H@@0!Y(8P =R&7 '4BI !T(K( <R/# '(CWP!P)/, ;R3_ &\D
M_P!N)/\ ;B3_ -TI  #(,   MS(  *@P  ">+@  ERH  ),G  "0(PH C",3
M (@D'P"$)2H @B4T ( F/0!])D0 ?"9+ 'HF4@!X)E@ =R9> '4F90!T)VP
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M <@X  "W/@  I#X  )8]  "+/   @SH  'TW  !X-   =#0+ ' U$P!M-1T
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M 4M!E@%*0:4"24*U DE"RP))0N@"24+Y DE!_P))0?\!24'_ ;U#  "J10
MF$4  (I%  !_10  =D,  &]   !H0   8T$! %]!#0!<010 64(= %=")@!5
M0BX 4T(V %%"/0!/0D, 3T-+ $Y#4@!-1%H 3$1C $I$;0%)17@!2$6% 4=%
ME %%1:,"14:T D1&R0)$1N<"1$7X D1%_P)%1?\"147_ ;I&  "F2   E$@
M (9(  ![1P  <D8  &I"  !C0P  7D0  %I%"P!611( 5$8; %%&(P!/1BL
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M 352Q $U4N(!-E+U 391_P$V4/\!-U#_ :Y/  "93P  B4\  'M/  !P3P
M9D\  %Q.  !43P  3U$  $I2 0!&4PP 0U02 $%4&P! 52, /E4K #U6,@ \
M5CH .U9! #I620 Y5U$ .%=: #978P U5V\ -%=\ 3-7C $Q5YP!,%>M 3!7
MP@$P5^ !,%;T 3%6_P$Q5?\!,57_ :A2  "54@  A%(  '=2  !L4@  8E(
M %A3  !/5   258  $17  ! 60@ /5H0 #M:%P Y6R  .%LG #=<+P V7#8
M-5P^ #1<1@ S74X ,5U7 #!=80 O76P +EUZ "Q=B0 K79H!*EVK 2I=OP$I
M7=X!*ESR 2I;_@$K6_\!*UK_ :-5  "/50  ?U4  ')5  !G5@  7E8  %17
M  !,60  15L  #]=   Z7P0 -F - #1A$P R8AP ,6(C #!B*P O8S( +F,Z
M "UC0@ L8TH *F13 "ED70 H9&D )V1V "9DA@ E9)< )&2I "-DO0 B9-H
M(V/Q "-B_0$D8?\!)&'_ 9Q8  ")6   >ED  &Y9  !C60  6EH  %!<  !(
M7@  06   #IC   T9@  +V@* "QI$  J:1< *6H? "AJ)@ G:BX )FLU "5K
M/0 D:T8 (VM/ ")L60 @;&4 'VQR !YL@@ =;)0 '&RF !MKN@ ::]0 &VKN
M !QI_  <:/\ '&C_ )5<  "#7   =5P  &E=  !?70  5EX  $QA  !#9
M/&<  #5J   O;0  *' $ "-R#0 A<A( (',: !]S(0 ><R@ '70P !QT.  ;
M=$  &G1* !ET5  7=6  %G5N !5U?@ 4=9  $W2B !)TM@ 1=,\ $G/L !)R
M^@ 3<?\ $W'_ (Y@  !]8   ;V$  &5A  !;8@  460  $AG   ^:P  -VX
M #!Q   I=0  (G@  !Q[!P 7?0X %GT3 !5]&P 4?B( $WXJ !)^,0 1?CH
M$7Y$ !!_3@ /?UH #G]H  U_>  ,?XH "WZ=  I^L  )?<8 "GWD  I\]  +
M>_T "WK_ (9E  !W90  :F4  &%F  !6:   3&L  $)O   Y<P  ,7<  "IZ
M   C?@  '($  !6$   0AP@ #8D.  R)%  ,B1L "XDC  J)*P )B3, "(D]
M  :)2  %B50 !(EA  *)<0 !B8,  (F6  "(J0  A[X  (?:  "&[   AO4
M (;Z 'YJ  !Q:@  9VL  %ML  !0<   1G0  #QX   S?0  *H$  ".%   <
MB   %8P  !"/   ,D@8 !I,,  *3$0  E!8  )0=  "4)   E2P  )4U  "5
M0   E4P  )99  "6:0  E7H  )6.  "4H0  E+4  )/,  "2Y@  DO(  )+W
M 'AP  !M<   8'(  %1U  !)>0  /WX  #6#   LB   (XT  !N1   4E
M#Y<   J:   $G0,  )X)  "?#@  GQ(  * 7  "@'0  H24  *(M  "B-P
MHT,  *-0  "C7P  HW$  *.$  "BF0  HJT  *'"  "AW   H>L  *#R '-V
M  !F=P  67L  $V   !"A0  .(L  "Z0   DE0  &YH  !2>   .H0  ":0
M  *G    J@   *L$  "K"@  K T  *T1  "M%@  KAP  *\D  "P+0  L3D
M +%&  "R50  LF8  +)Y  "RC@  L:,  +*W  "QR@  L>   +'I &Q^  !?
M@@  4H<  $:-   [DP  ,)D  ":>   <HP  $Z<   VK   'K@   +(   "U
M    MP   +@   "Y @  N0@  +H,  "[$   O!0  +T;  "_(P  P2T  ,(Z
M  #"20  PUH  ,-L  #$@@  Q)<  ,2K  #$O   Q,L  ,3: &6)  !8C@
M2Y4  #^;   SH@  **@  !VM   4L0  #;8   :Y    O    +\   ##
MQ    ,4   #&    QP   ,D$  #*"0  RPT  ,T1  #/&   TB$  -4M  #6
M/   V$T  -E?  #:<P  VHH  -N>  #;K@  V[H  -S# %Z6  !1G   1*,
M #BJ   LL0  (+<  !6[   -O@  !,(   #%    R0   ,T   #0    T@
M -(   #5    U@   -D   #;    W@4  . *  #B#P  Y18  .@@  #L+0
M[3X  .U1  #N90  [WH  .^/  #PGP  \*L  /"S /\ $ #_  X _P . /\
M$@#_ !T _P I /\ -0#_ $$ _P!- /X 5@#[ %\ ^ !F /8 ;0#T '0 \@!Y
M /$ ?P#P (0 [@") .T CP#K )4 Z@"; .@ H@#F *H Y0"S ., P #A -(
MX #J -\ ^0#= /\ W0#_ -T _P#> /\ W@#_ /\ #0#_  H _P ) /\ #P#_
M !@ _P D /X ,0#[ #T ^ !( /0 4@#P %H [0!B .L :0#I &\ YP!U .4
M>@#C '\ X@"% .  B@#> )  W "6 -H G0#8 *4 U0"O -( N@#0 ,H S@#C
M ,T ] #+ /\ RP#_ ,L _P#+ /\ RP#_ /\ " #_  , _P % /\ # #\ !0
M]P ? /( *P#O #< ZP!" .< 3 #D %4 X != -T 9 #: &H V !P -4 =0#2
M 'H T "  ,\ A0#- (L RP"2 ,D F0#' *$ Q0"J ,, M0#! ,, OP#: +X
M[@"] /P O #_ +P _P"\ /\ O #_ /\   #_    _P   /D !P#Q !  Z@ :
M .0 )0#? #$ VP \ -< 1P#2 %  S@!7 ,L 7@#) &4 Q@!J ,4 < ## '4
MP0!Z ,  @ "^ (8 O "- +H E "Y )P MP"E +4 L "S +T L0#/ *\ Z "N
M /@ K@#_ *T _P"M /\ K0#_ /\   #_    _0   .X  0#C  P V@ 4 -$
M'P#, "L R  V ,4 0 #" $H OP!2 +P 60"Z %\ N !E +8 :@"T &\ LP!U
M +$ >@"P ($ K@"( *T CP"K )@ J0"A *< JP"E +@ HP#( *( X@"A /,
MH #^ *  _P"@ /\ H #_ /\   #V    Z@   .    #3  8 R0 / ,( & "]
M "0 N0 O +8 .@"T $, L0!, *X 4P"L %D J@!? *D 9 "G &H I@!O *0
M=0"C 'L H0"" *  B@"> ), G "= )H IP"8 +0 E@## )4 W "4 .\ DP#[
M ), _P"3 /\ D@#_ /D%  #J"P  W T  ,L*  #"!0  O  * +8 $0"Q !P
MK@ H *H ,P"G #T I !% *( 30"@ %, G@!9 )P 7P"; &0 F@!J )@ < "7
M '8 E0!^ ), A@"2 8\ D &9 (X"I ", K$ BP/  (D%U@"(!NT B ?Z (<(
M_P"&"/\ A@C_ .\/  #>%   RA4  +P2  "S$   K@P  *L&#0"G Q4 H@4@
M )\'+ "<"#8 F0@_ )<)1P"5"4X DPE4 )$*6@"0"E\ C@IE (T*:P"+"G(
MB@MY (@+@@"'"XP A0R7 (,,H@"!#;  @ W  '\-V !]#N\ ? _] 'L/_P![
M$/\ >Q#_ .87  #1'@  O1T  *\<  "F&0  H14  )X0! "=#0\ F X9 )0.
M)0"1#R\ CQ Y (P000"*$$@ B!!/ (<050"%$%L A!%A ((19P" $6X ?Q%U
M 'T1?@!\$H@ >A*4 '@2H !W$ZX =1.^ '04U0!S%>X <1;] '$6_P!Q%O\
M<!;_ -P?  #&)0  LR4  *4C  "<(0  EAX  )(9  "1% L C104 (D5'P"&
M%BD @Q8S ($7/ " %T, ?A=* 'P74 !Z%U8 >1A< '<88@!V&&D =!AQ ',9
M>@!Q&80 ;QJ0 &X:G0!L&ZL :QR[ &H<T !I'>P :![[ &@>_P!G'O\ 9Q[_
M -$F  "]*@  JRH  )TJ  "3*   C24  (@B  "&'08 @QL0 '\<&@!\'20
M>ATN '<>-@!V'CX =!Y% '(?2P!Q'U$ ;Q]8 &X?7@!L'V4 :R!M &D@=@!H
M(8$ 9B&- &4BF@!C(J@ 8B.X &$CS0!@).D 8"3Z %\D_P!?)/\ 7R3_ ,HL
M  "V+P  I"\  )8O  ",+0  A2H  ( H  !])   >B(- '8C%0!S(R  <20I
M &\D,@!M)#H :R5! &HE1P!H)4T 9B54 &4E6@!D)F$ 8B9I &$F<@!?)WT
M7B>* %THEP!;*:4 6BFU %HJR@!9*N< 6"KX %@J_P!8*O\ 6"K_ ,4Q  "O
M,P  GC,  ) S  "&,@  ?R\  'DM  !U*@  <B@* &\H$@!K*1L :2DE &<J
M+0!E*C4 8RH] &(J0P!@*DH 7RM0 %XK5P!<*UX 6RQF %DL;P!8+7H 5RV'
M %8NE0!4+J, 4R^S %,OQP!2+^4 4B_W %(O_P!2+_\ 4B__ ,$V  "J-@
MF38  (LV  "!-0  >3,  ',Q  !O+P  :RX& &@M$ !D+A@ 8BXA & O*@!>
M+S$ 7"\Y %LO0 !9+T8 6"]- %<P4P!6,%L 5#%C %,Q; !2,G< 43*$ $\S
MD@!.,Z$ 33.Q $TTQ0%,-.,!3#3V $PT_P!,-/\ 3#/_ +LY  "F.0  E3D
M (<Y  !\.0  =#<  &XT  !I,P  93(" &$R#0!>,A0 7#,> %HS)@!8,RX
M5C,U %4T/ !3-$, 4C1* %$T4 !0-5@ 3C5@ $TV:@!,-G4 2S>" $HWD !)
M.)\ 2#BP 4<XPP%'..$!1SCU 4<X_P%'./\!1SC_ ;<[  "B/   D3P  (,\
M  !X/   <#H  &HW  !D-@  8#8  %PV"P!9-Q( 5C<: %0W(P!2-RL 4#<R
M $\X.0!-.$  3#A' $LX3@!*.54 23E> $@Z: !'.G, 1CN  $4[C@!$/)X
M0SRN 4(\P@%"/=\!0CSS 4(\_P%"//\!0CO_ ;,]  ">/@  C3X  '\^  !U
M/@  ;#T  &8Z  !@.0  6SH  %<Z" !3.Q  43L8 $X[( !,.R@ 2SLO $D\
M-@!'/#T 1SQ$ $8]2P!%/5, 1#Y< $,^9@!"/W$ 03]^ $ _C0 _0)P /D"M
M 3U P $]0-T!/4#R 3U _P$^/_\!/C__ :Y   ":0   B4$  'Q!  !Q00
M:$   &$\  !;/0  5CX  %(^!0!./PX 3#\5 $D_'0!'0"4 1D L $1 ,P!#
M0#H 0D%" $%!20! 05$ /T): #Y"8P ]0V\ /$-\ #M#BP Z1)L .42K 3E$
MO@$X1-L!.43Q 3E#_@$Y0_\!.4/_ :I"  "60P  AD,  'A#  !N0P  94,
M %U   !60   44(  $U" @!)0PP 1D,2 $1$&@!"1"( 040J #]%,0 ^13@
M/44_ #Q&1P [1D\ .D97 #E'80 X1VP -T=Z #9(B0 U2)D -$BJ #1(O0 S
M2-D -$CP #1'_0 T1_\ -4;_ *9$  "210  @D8  '5&  !J1@  844  %E$
M  !11   3$8  $A'  !$1PH 04@0 #])&  ]22  /$DG #I*+@ Y2C8 .$H]
M #=+1  V2TP -4M5 #1,7P S3&H ,DQW #%,A@ P3)< +TVH "Y-NP N3=4
M+DSO "],_0 O2_\ ,$O_ *%'  ".2   ?D@  '%(  !F20  74@  %5(  !,
M20  1TH  $)+   _3 8 .TT. #E.%0 W3AT -D\D #5/*P S3S, ,E Z #%0
M0@ P4$H +U%2 "Y17  M46< +%%U "M1A  J4I4 *5*F "E2N0 H4M( *5'N
M "E0_  J4/\ *D__ )Q*  ")2@  >DL  &U+  !C3   6DP  %%,  !(30
M0T\  #U0   Y4@( -5,, #-4$@ Q5!D ,%4A "Y5*  M52\ +%8W "M6/@ J
M5D8 *59/ "A760 G5V0 )E=R "57@0 D5Y( (U>D ")7MP B5\\ (E?L "-6
M^@ C5?\ )%7_ )9-  "$3@  =4X  &E.  !?3P  5D\  $U0  !%4@  /U,
M #E6   S6   +UH( "M;#P J6Q4 *%P= "=<)  F7"L )5PS "1=.@ C74,
M(EU, "%=5@ @7F$ 'UYN !Y>?@ =7H\ '%ZA !M>M  :7<P &UWI !M<^0 <
M6_\ '%O_ )!1  !^40  <%$  &12  !;4@  4E,  $I4  !!5P  .UD  #5;
M   N7@  *& # "1B#  B8Q$ (6,8 !]D(  >9"< '60N !QD-@ ;93X &F5'
M !EE40 895T %V5J !9E>@ 598L %&6> !-EL0 29<@ $F3G !-C]P 48O\
M%&+_ (E4  !X50  :U4  &!6  !75@  3U<  $99   ]7   -E\  #!B   I
M9   (V<  !UJ!P 9; X &&P3 !9M&@ 5;2$ %&TI !1M,  3;3D $FY" !%N
M3  0;E@ #VYE  YN=0 -;H< #6Z:  QMK0 +;<( "VS@  QK\P -:_T #6K_
M ()9  !R60  9ED  %Q:  !46@  2EP  $%?   Y8P  ,68  "II   D;
M'6\  !=R   2=0D #W</  YW%  .=QL #7<C  QW*@ +=S, "G<\  EW1P (
M=U( !W=?  5W;P $=X   W>4  %VIP  =KL  775  %TZP "=/8  G3\ 'M=
M  !M70  8EX  %E>  !.8   16,  #QG   S:P  *VX  "1R   >=0  %WD
M !)\   -?P8 "8$,  6!$0 #@18  H$=  &!)   @2T  ((V  ""0   @DP
M ()9  "":   @GD  (*-  "!H   @+0  (#+  !_YP  ?O(  '[Y '1B  !H
M8@  7F(  %-D  !)9P  /VL  #9P   M=   )7@  !Y\   7@   $8,   V&
M   (B00  HL*  "+#@  BQ,  (P8  ",'P  C28  (TO  "..0  CD0  (Y1
M  ".8   CG$  (Z%  ".F0  C:T  (S#  ",WP  B^X  (OV &YH  !D9P
M6&D  $UL  !"<0  .'8  "][   F?P  'H0  !:(   0C   #(\   :2
ME0   )8'  "7#   EP\  )@3  "9&   FA\  )LF  ";,   G#L  )Q(  "<
M5P  G&@  )Q[  "<D   FZ4  )NZ  ":T   FN<  )KQ &IM  !>;P  47(
M $9W   [?   ,8(  ">'   >C   %I$  !"5   *F0  !)P   "@    H@
M *,!  "C!@  I L  *4.  "F$@  IQ<  *@>  "J)@  JS$  *L^  "L30
MK%T  *QP  "LA0  K)L  *NO  "KPP  J]D  *KH &1U  !7>0  2WX  #^$
M   TB@  *9   !^6   6FP  $)\   FC   !IP   *H   "N    L    +
M  "Q    L@,  +0(  "U#0  MA   +<5  "Y'0  NR8  +PS  "]00  O5(
M +UD  "^>0  OI   +VD  "]MP  O<8  +W7 %Q_  !0A0  1(L  #B2   L
MF0  (9\  !>D   0J0  ":X   "R    M@   +D   "]    OP   +\   #
M    P0   ,,   #$!0  Q@H  ,<.  #)$P  RQP  ,XF  #0-0  T44  -)7
M  #2:P  TX(  -.7  #3J0  TK@  -+$ %6,  !)DP  /9H  #"B   EJ
M&JX  !&T   )N0   +T   #!    Q    ,@   #+    S0   ,T   #/
MT    -(   #4    V    -H&  #=#   X!$  .,:  #F)P  YS@  .A*  #I
M70  ZG(  .N(  #KFP  [*@  .RR /\ #0#_  L _P + /\ $ #_ !H _P F
M /\ ,@#_ #T _P!( /L 4@#X %H ]@!B /, :0#Q &\ \ !U .X >@#L '\
MZP"$ .D B@#H )  Y@"6 .0 G0#B *4 X0"O -\ NP#= ,L VP#F -D ]P#8
M /\ V #_ -< _P#7 /\ U #_ /\ " #_  0 _P $ /\ #0#_ !4 _@ A /H
M+ #W #@ ] !# /  30#M %4 Z@!= .< 9 #D &H X@!P .  =0#> 'H W0!_
M -L A0#9 (L U0"1 -, F0#1 *  SP"J ,T M0#+ ,0 R0#= ,@ \0#' /\
MQ@#_ ,8 _P#& /\ QP#_ /\   #_    _P   /\ "@#X !$ \0 < .P )P#I
M #( Y@ ] .( 1P#= %  V0!8 -4 7P#2 &4 T !J ,X < #, '4 R@!Z ,D
M?P#' (4 Q0", ,, E #! )P OP"E +T L "[ +T N@#0 +@ ZP"W /L M@#_
M +8 _P"V /\ M@#_ /\   #_    _0   /, !0#I  X X0 6 -L (0#5 "T
MT0 W ,X 00#* $H QP!2 ,0 60#" %\ P !E +X :@"\ &\ NP!T +D >@"W
M (  M@"' +0 C@"R )< L "@ *X J@"M +< JP#( *D XP"H /4 IP#_ *<
M_P"G /\ I@#_ /\   #^    \0   .4   #7  H S0 1 ,< ' #" "8 OP Q
M +P .P"Z $0 MP!, +0 4P"R %D L0!? *\ 9 "M &D K !O *H = "I 'H
MIP"! *8 B0"D )$ H@"; *  I0"> +( G0#! )L V@": .\ F0#] )@ _P"8
M /\ F #_ /T   #P    X0   -$   #&  0 O0 - +< %0"S "  L  K *T
M-0"K #X J !& *8 30"D %0 HP!9 *$ 7P"@ &0 G@!I )T ;@"; '4 F@![
M )@ @P"6 (P E0"6 ), H0"1 *T CP"[ (T SP", .D BP#X (P _P", /\
MC #_ /,"  #B!P  S <  +\$  "W    L0 ( *L $ "G !D I  D *  +@">
M #< G !  )H 1P"8 $X E@!4 )4 60"3 %X D@!D )  :0"/ &\ C0!V (L
M?@"* (@ B "2 (8 G0"% *D @P"X ($ R@"  .4 @ #U '\ _P!_ /\ ?P#_
M .@-  #0$   OA   +$.  "H#0  HP@  * "# "< !, F  = )4 )P"2 #$
MD  Y (X!00", 4@ B@). (D"5 "' ED A@)? (0#9 "# VL @0-R ( $>@!^
M!(0 ?06. 'L%F@!Y!J< > :U '8'R !U"., =0GT '0*_P!S"O\ <PK_ -T5
M  #$%P  L1<  *46  "<$P  EA$  )0-! "3" T C@<5 (L)( "("2H A0HS
M (,+.P"!"T( @ M) 'X+3P!]#%0 >PQ: 'H,8 !X#&< =PQN '4-=@!T#8
M<@V, ' -F0!O#J8 ;0ZU &P.R0!K#^8 :A#W &D0_P!I$/\ :1#_ - =  "Y
M'@  J!X  )L=  "2&P  BQD  (@5  "'$0< A0X0 ($/&@!^$"0 >Q M 'D0
M-@!W$3T =A%$ '012@!S$5  <1%6 ' 17 !N$F( ;1)J &L2<P!I$WT :!.)
M &83E@!E%*, 8Q6S &(5Q@!B%N, 81;V & 7_P!@%_\ 8!?_ ,<B  "P(P
MGR0  )(C  ")(@  @B   'X=  !\&0  >A4- '<5%0!T%A\ <18H &\7, !N
M%S@ ;!<_ &L710!I&$L :!A1 &886 !E&%X 8QEF &(9;P!@&7D 7QJ% %T;
MD@!<&Z$ 6QRP %H<PP!9'>  6![T %@>_P!8'O\ 6![_ +\G  "I*   F2@
M (LH  "")P  >R4  '8C  !S(   <1P) &X<$0!K'!H :1TC &<=+ !E'3,
M8QXZ &(>00!@'D< 7QY- %X>5 !<'UL 6Q]B %D@:P!8('8 5B&" %4AD !4
M(IX 4R*N %(CP !1(]T 423R %$D_P!1)/\ 42/_ +DK  "C+   DRP  (8M
M  !\+   ="H  &\H  !K)0  :2(% &8A#@!C(A8 82(? %\C)P!=(R\ 7",V
M %HC/0!9)$, 5R1* %8D4 !5)%< 4R5? %(E: !1)G, 3R9_ $XGC0!-*)P
M3"BL $LIO@!+*=H 2BGQ $HI_P!+*?\ 2RG_ +,N  ">+P  CC   ($P  !W
M+P  ;RX  &HK  !E*@  8R<! %\G# !<)Q, 6B<; %@H) !6*"L 52@R %,H
M.0!2*4  4"E& $\I30!.*50 32I< $PJ90!**W  22M\ $@LBP!'+9H 1BVJ
M $4NO !%+M8 12[O $4N_@!%+O\ 12W_ *XQ  ":,@  B3,  'PS  !R,P
M:S$  &4O  !@+0  72P  %DL"0!6+!  5"P8 %(L( !0+"@ 3BTO $TM-@!,
M+3P 2BU# $DM2@!(+E$ 1RY9 $8O8P!%,&T 0S!Z $(QB0!!,9@ 03*H $ R
MNP _,M, /S+N $ R_0! ,O\ 0#+_ *HS  "6-0  AC4  'DV  !N-0  9C4
M &$R  !<,   5S   %0P!@!1, X 3C 5 $PQ'0!*,24 2#$L $<Q,@!&,3D
M1#%  $,R1P!",D\ 03-7 $ S8  _-&L /C5X #TUAP \-I8 .S:G #LVN0 Z
M-M$ .C;M #LV_  [-O\ .S;_ *8V  "2-P  @C@  '4X  !K.   8S<  %TV
M  !7,P  4S0  $\T P!+- P 2302 $8U&@!%-2( 0S4I $$U+P! -38 /S8]
M #XV1  ]-TP /#=5 #LX7@ Z.&D .3EV #@YA0 W.I4 -SJE #8ZN  U.L\
M-CKL #8Z^P V.?\ -SG_ *(X  "..0  ?CH  '([  !H.P  7SH  %DY  !3
M-@  3C<  $HX  !&. H 1#D0 $$Y%P _.1\ /CDF #PY+0 [.C0 .CH[ #D[
M0@ X.TH -SM3 #8\7  U/&< -#UT #,]@P S/I, ,CZD #$^M@ Q/LT ,3[J
M #$^^@ R/?\ ,CW_ )X[  "+/   >SP  &X]  !D/0  7#T  %4\  !..@
M23L  $4\  !!/0< /CT. #P]%0 Z/AP .3XC #<^*@ V/S$ -3\X #0_0  S
M0$@ ,D!0 #% 6@ P064 +T%R "Y"@0 M0I$ +4*B "Q"M0 K0LL +$+I "Q"
M^0 M0?\ +4'_ )D]  "'/@  =S\  &L_  !A0   63\  %(_  !)/@  1#\
M $!    \000 .4(- #="$@ U0QD ,T,A #)#*  Q1"\ ,$0V "]$/0 N144
M+45. "Q%6  K1F, *D9O "E&?@ H1H\ )T>A "9'LP F1\D )D;G "=&^  H
M1?\ *$7_ )5   ""00  <T(  &="  !>0@  54(  $Y"  !%0@  /T0  #M%
M   W1@  -$<* #%($  O2!8 +DD> "Q))0 K22P *DDS "E*.@ H2D( )TI+
M "9+50 E2V  )$MM "-+?  B2XT (4R? "%,L0 @3,< ($OF "%+]P B2O\
M(DK_ )!#  !^1   ;T0  &1%  !:10  4D4  $I&  !!1P  /$@  #=)   R
M2P  +DT' "M.#@ I3A, )T\: "9/(0 E3R@ )$\P "-0-P B4#\ (5!( "!0
M4@ ?45T 'E%J !U1>0 <48H &U&< !I1KP 94<4 &5'D !I0]@ ;3_\ '$__
M (I&  !Y1P  :T<  &!(  !62   3D@  $=)   ^2P  .4P  #-.   N4
M*%," "14"P B51  (%46 !]6'@ >5B0 '58L !Q6,P ;5SL &E=$ !E73@ 8
M5UD %UAF !58=0 46(< %%B: !-7K  25\( $E?A !-6]  45?\ %%7_ (1)
M  !T2@  9DL  %Q+  !32P  2TP  $1-   \3P  -5$  "]4   I5@  )%D
M !Y;!P :70T &%T2 !==&0 67B  %5XG !1>+@ 37C< $EY  !%?2@ 17U4
M$%]B  ]?<0 .7X, #5^6  U?J0 ,7KX #%[:  U=\  -7/P #ES_ 'Y-  !N
M3@  8DX  %A/  !/3P  2%   $!2   X5   ,%<  "I:   D70  'U\  !EB
M 0 390D $68/ !!F%  /9AL #F<B  UG*0 -9S( #&<[  MG10 *9U  "6==
M  =G;  &9WT !6>0  1FHP "9K<  V7/  1EZ0 $9/4 !&3\ '=1  !I4@
M75(  %12  !,4P  0U4  #M8   S6P  *UX  "5A   ?9   &6<  !-J   /
M;08 "W ,  AP$0 '<!8 !7 =  1P)  #<"P  G U  !P/P  <$H  '!7  !P
M90  <'8  '"*  !OG@  ;[(  &[(  !MY0  ;?(  &WY '!6  !C5@  658
M /_B__])0T-?4%)/1DE,10 $"5%7  !'6   /EL  #9?   N8@  )F8  !]J
M   9;0  $W    YS   +=@0 !7@+  %X#P  >1,  'D9  !Y'P  >B8  'HO
M  !Z.0  >D0  'I0  !Z7P  >G   'J#  !ZF   >JP  'G"  !XWP  >.\
M '?W &I;  !?6P  5EL  $Q<  !"8   .6,  #!H   H;   ('   !ET   3
M=P  #GL   E^   $@0(  (((  "##0  @Q   (04  "%&0  AB   (8H  "'
M,0  ASP  (=)  "'5P  AV@  (=[  "'D   AJ4  (6Z  "%TP  A.H  (3T
M &5@  !<8   46$  $9D   \:0  ,FT  "ER   A=P  &7L  !*    -@P
M"(<   **    C0   (X$  "."0  CPT  ) 0  "1%   DAD  ),@  "4*0
ME3,  )5   "63@  EE\  )5R  "5B   E9T  )2R  "4R   D^(  )/N &%E
M  !69@  2FH  #]N   U=   *WD  "%_   9A   $8D   R-   &D0   )0
M  "8    F@   )L   "< @  G0<  )X+  "?#@  H1(  *(8  "C(   I2D
M *8V  "F1   IE4  *9H  "F?0  II0  *6I  "DO0  I-$  *3D %ML  !/
M<   0W4  #A[   M@0  (X<  !F-   1D@  "Y<   2<    H    *,   "F
M    J    *D   "J    K    *T$  "N"0  L T  +$1  "S%P  M2   +8K
M  "W.@  MTL  +A<  "X<0  N(@  +B=  "XL0  M\(  +?0 %1V  !(?
M/((  #&)   FD   &Y<  !*=   ,H@   Z<   "K    K@   +(   "V
MN    +@   "Z    NP   +T   "^    P 4  ,$+  ##$   QA8  ,D@  #*
M+@  RSX  ,Q0  #,9   S7H  ,V1  #-I   S;0  ,W  $V#  !!B@  -9$
M "F9   >H   $Z8   RL   #L0   +8   "Z    O@   ,(   #&    R
M ,@   #*    RP   ,T   #.    T    -(!  #5"   V0X  -T5  #A(0
MXC$  .1#  #E5@  YFL  .:"  #GE@  YZ4  .:P /\ "0#_  4 _P & /\
M#@#_ !8 _P A /\ +0#_ #@ _0!# /D 30#U %4 \@!= /  8P#N &D [ !O
M .H = #I 'H YP!_ .8 A0#D (L XP"1 .$ F0#? *$ W "J -H M@#7 ,8
MU0#A -, ] #2 /\ T0#_ -$ _P#/ /\ R@#_ /\  0#_    _P ! /\ # #_
M !( ^@ = /8 * #S #, \  ^ .P 2 #H %  Y0!8 .( 7@#? &0 W0!J -L
M;P#9 '0 U@!Z -0 ?P#2 (4 T ", ,X DP#, )P R0"E ,< L #& +X Q #4
M ,( [@#! /X P #_ ,  _P"_ /\ O@#_ /\   #_    _P   /H !P#Q  \
MZP 8 .8 (P#B "X X  X -L 0@#5 $L T0!2 ,X 60#+ %\ R0!E ,< :@#&
M &\ Q !T ,( >@#! (  OP"& +T C@"[ )8 N0"@ +< J@"V +< M #* +(
MY@"Q /@ L #_ *\ _P"O /\ L #_ /\   #_    ]P   .H  @#A  P UP 3
M -  '0#, "@ R0 R ,8 / #" $4 OP!- +P 4P"Z %D N !? +< 9 "U &D
MM !N +( = "Q 'H KP"  *T B "L )$ J@": *@ I0"F +$ I #! *, W "A
M /( H0#_ *  _P"@ /\ H0#_ /\   #W    Z    -D   #+  @ PP 0 +T
M& "Y "( M@ L +0 -@"R #\ KP!' *P 30"K %0 J0!9 *< 7@"F &, I0!H
M *, ;@"B '0 H !Z )X @@"< (L FP"5 )D GP"8 *P E@"Z )0 SP"3 .L
MD@#[ )( _P"2 /\ D0#_ /<   #G    TP   ,8   "[  ( LP , *T $@"J
M !P IP F *0 , "C #@ H !  )X 1P"< $X F@!3 )D 6 "7 %T E@!C )4
M: "3 &X D@!T )  ? "/ (4 C0"/ (L F@"* *< B "U (8 QP"% .0 A #U
M (0 _P"# /\ @P#_ .P   #3    P0$  +0   "L    I@ ' *  #@"= !8
MF@ @ )< *0"5 #( DP Z )$ 00"/ $@ C0!- (P 4P"+ %@ B0!= (@ 8P"'
M &D A0!O (, =P"" (  @ "* 'X E@!] *, >P"P 'H P@!Y -T > #Q '<
M_0!X /\ > #_ -X*  #$"P  L@P  *8+  "="   F00  )4 "@"1 !$ C@ 9
M (L (P") "P AP T (4 .P"# $( @@!( (  3@!_ %, ?0!8 'P 7@![ &0
M>0!J '@ <@!V 'L = "& ', D@!Q )\ < "M &X O@!M =8 ;0+M &P#^@!L
M _\ ; /_ ,X0  "W$0  IA(  )H1  "1$   BPX  (D+ P"'!0P A $3 ($!
M' !^ B4 ? ,N 'H#-@!X!#P =P1# '4%2 !T!4X <P54 '$%60!P!E\ ;@9F
M &T&;@!K!W@ :@># &@(D !G"9T 90FL &0)O !C"M0 8POL &(,^@!B#/\
M8@S_ ,,6  "M%P  G1@  ) 8  "'%@  @10  'T1  !\#@8 ? H. '@*%@!U
M"Q\ <@LH ' ,, !O##< ;0P^ &P,1 !K#4H :0U/ &@-50!G#5P 90UC &,.
M:P!B#G4 8 Z! %\.C@!=#YP 7!"K %L0O0!:$-8 61'P %D1_0!9$?\ 61'_
M +D;  "E'0  E!X  (@>  !^'0  >!L  '08  !Q%0  <1$) &\0$0!L$!D
M:1 B &<1*@!F$3( 9!$Y &,1/P!B$44 8!)+ %\240!=$E@ 7!)? %H3: !9
M$W( 5Q1] %84BP!4%9D 4Q6I %(6N@!1%M( 41?M %$7_0!1%_\ 41?_ +(@
M  ">(@  CB(  ($C  !W(@  <"$  &P>  !I&P  9Q@$ &85#@!C%A4 818>
M %\6)@!=%BT 7!<T %H7.P!9%T$ 6!A' %8830!5&%0 4QA< %(99 !1&6X
M3QIZ $X;B !-&Y< 2QRF $H<N !*'<\ 21WK $D=^P!)'?\ 2AW_ *PD  "8
M)0  B"8  'LG  !Q)@  :B4  &8C  !B(0  8!X  %X<"P!;&Q( 61P: %<<
M(@!5'"D 5!PP %,=-P!1'3T 4!U# $\=2@!-'E$ 3!Y8 $L?80!)'VL 2"!W
M $<@A0!&(90 1"*D $0BM@!#(LP 0R/I $,C^@!#(_\ 0R+_ *8G  "3*0
M@RH  '8J  !M*@  92D  & G  !<)0  62,  %<A!P!5(0\ 4B$6 % A'@!.
M(24 32(L $PB,P!*(CD 22)  $@B1@!'(TT 12-5 $0D7@!#)&D 0B5U $ F
M@P _)I( /B>C #XGM  ])\H /2CH #TH^0 ])_\ /B?_ *(J  ".*P  ?RT
M '(M  !H+0  82P  %PK  !8*   5"8  %$F! !.)0T 3"43 $HF&@!()B(
M1R8I $4F+P!$)C8 0R<\ $$G0P! )TL /RA3 #XI7  ]*68 /"IR #LJ@0 Z
M*Y  .2NA #@LL@ W+,@ -RSF #@L^  X+/\ ."S_ )TL  "*+@  >R\  &\P
M  !E,   72\  %@N  !3*P  4"H  $PJ  !)*@L 1BH1 $0J%P!"*A\ 02HE
M #\J+  ^*S, /2LY #PK0  [+$@ .BQ0 #DM60 X+F0 -RYP #8O?P U+X\
M-#"? #,PL0 R,,< ,C#E #,P]P S,/\ -"__ )DO  "',0  =S(  &LR  !B
M,@  6C(  %0Q  !/+P  2RT  $<N  !$+@@ 02X. #\N%  ]+AP .RXB #DO
M*0 X+R\ -R\V #8P/@ U,$8 -3%. #0Q5P S,F( ,C)N #$S?0 P,XT +S2>
M "XTL  M-,4 +33C "XT]@ O,_\ +S/_ )4Q  "#,P  =#0  &@U  !>-0
M5S0  %$T  !+,@  1C$  $(R   _,@4 /#(- #DS$@ X,QD -C,@ #0S)@ S
M,RT ,C0T #$T.P P-4, ,#5, "\V50 N-F  +3=L "PW>P K-XL *CB< "DX
MK@ H.,, *#CB "DX]0 J-_\ *C?_ )(T  !_-0  <38  &4W  !;-P  5#<
M $TV  !'-@  0C4  #TV   Z-@( -S<+ #0W$  R-Q8 ,3@= "\X)  N."L
M+3DR "PY.0 K.4$ *CI) "HZ4P I.UX *#MJ "<[>0 F/(D )3R; "0\K0 C
M/,( (SS@ "0\]  E._\ )3O_ (TV  !\.   ;3D  &(Y  !8.@  43D  $HY
M  !$.0  /3D  #DZ   U.P  ,CL( "\\#@ M/10 +#T: "H](0 I/2@ *#XO
M "<^-@ F/CX )3]' "0_4  C0%L (D!H "% =@ @0(< 'T&9 !]!JP >0<
M'D'> !] \P ?0/X (#__ (DY  !X.@  :3L  %X\  !5/   33P  $<\  !
M/   .#T  #0^   P0   +4$% "I"#  G0A$ )D,8 "1#'@ C0R4 (D,L "%$
M,P @1#L 'T1$ !Y%3@ =15D '$5E !M%=  :184 &4:7 !E&J0 81KX %T7<
M !A%\0 91/T &D3_ (0\  !S/0  9CX  %L_  !2/P  2C\  $0_   ]0
M-D$  #%#   L1   )T8! "1'"@ A2 \ ($D4 !Y)&P =22( '$DI !M*,  :
M2C@ &4I! !A*2P 72U4 %DMB !5+<0 42X( $TN4 !)+IP 22[P $4O9 !)*
M\  32OP %$G_ '\_  !O0   84$  %="  !.0@  1T(  $%"   Z0P  ,D4
M "U'   H20  (TL  !Y-!@ ;3PT &% 1 !=0%P 64!X %5 E !10+  3430
M$E$] !%11P 145( $%%?  ]2;0 .4GX #5&1  U1I  ,4;@ #%'1  U0[  -
M4/H #D__ 'E#  !J1   740  %-%  !+10  1$4  #Y&   V2   +TH  "E,
M   D3P  'U$  !I3   45@D $5<. !!8$P 06!D #U@@  Y8*  -6#  #5@Y
M  Q80P +6$X "EA:  A8:  '6'D !EB,  58GP $6+, !%?*  57Y@ %5_,
M!E;\ '-&  !D1P  64@  %!(  !(2   04D  #I*   R30  *U   "52   @
M50  &E@  !5:   0708 #& ,  I@$  )8!4 "& <  =@(P %8"L !& T  -@
M/0 !8$D  &!5  !@8P  8',  &"&  !?F@  7ZX  %_$  !>X@  7O   %[X
M &Q*  !?2P  54L  $Q,  !%3   /4X  #50   N4P  )U8  "!9   :7
M%5\  !!B   -900 "&<+  -G#@  :!,  &@8  !H'P  :28  &DN  !I.
M:4,  &E/  !I70  :6T  &F   !IE   :*D  &B_  !GW   9NX  &;W &9/
M  !:3P  44\  $I/  !!40  .%0  #!7   H6P  (5X  !IB   490  $&@
M  QK   ';@,  7 )  !P#0  <1   '$4  !R&@  <R$  ',H  !S,0  <SP
M '1(  !S5@  <V8  '-Y  !SC@  <Z,  '*Y  !QT@  <>L  '#T &%3  !6
M4P  3U,  $55   [6   ,EP  "I@   B9   &V@  !1L   /;P  "W(   9V
M    >0   'H&  !Z"@  >PX  'P1  !]%0  ?AL  '\B  " *@  @#4  (!!
M  " 3P  @%\  (!Q  " A@  @)T  '^R  !^R@  ?N4  'WQ %Q8  !46
M25H  #]=   U80  +&4  "-J   ;;P  %',   YW   )>P   W\   ""
MA    (8!  "&!@  B H  (D-  "*$   BQ4  (P;  ".(@  CRP  (\X  "/
M1@  CU8  (]H  "/?@  CY4  (ZK  "-P0  C=P  (SK %E=  !.7P  0V(
M #AF   N;   )'$  !QW   4?   #H$   B%    B0   (T   "0    D@
M ),   "4    E@,  )<(  "8#   F@\  )L3  "=&@  GR,  * N  "@/
MH$P  *!>  "@=   GXP  )^B  "?MP  GLL  )[@ %-D  !':   /&T  #%S
M   G>0  '7\  !2%   -BP  !I    "4    F    )P   "?    H0   *(
M  "D    I0   *<   "H!   J@D  *P-  "M$@  L!D  +(C  "R,0  LD(
M +)4  "R:0  LH   +*8  "QK   LK\  +'. $QN  ! <P  -7H  "J!   ?
MB   %8X   Z5   &F@   )\   "D    J    *P   "O    L0   +$   "S
M    M0   +8   "X    N@   +P&  "^#   P!$  ,,9  #%)@  Q3<  ,9)
M  #&70  QW(  ,>*  #(GP  R*\  ,B\ $9Z   Y@0  +HD  "*0   7F
M#Y\   >E    J@   *\   "S    MP   +P   "_    P0   ,(   #$
MQ0   ,<   #)    RP   ,T   #/ P  T@H  -80  #<&@  W2H  -X\  #?
M4   X&4  .%[  #AD0  XJ(  .*M /\  @#_    _P # /\ # #_ !, _P =
M /\ * #^ #, ^P ^ /< 2 #S %  \ !7 .T 7@#K &0 Z !I .< ;P#E '0
MXP!Y .( ?P#@ (4 W@", -P DP#9 )P U@"F -, L0#1 ,  SP#: ,X \0#,
M /\ RP#_ ,L _P#& /\ P0#_ /\   #_    _P   /\ " #[ !  ]@ 9 /(
M) #O "X [0 Y .@ 0@#C $L X !2 -T 60#9 %\ U@!D -, :0#1 &X SP!T
M ,X >0#, '\ R@"& ,@ C@#& )8 Q "@ ,( JP#  +D O@#- +P Z@"[ /P
MN@#_ +H _P"Z /\ M@#_ /\   #_    _@   /0 ! #K  T Y  4 -\ 'P#;
M "D V  S -, /0#. $4 R@!- ,< 4P#% %D PP!? ,$ 9 "_ &D O0!N +L
M<P"Z 'D N "  +8 B "T )  L@": +$ I0"O +( K0#$ *P X0"K /8 J@#_
M *H _P"J /\ J@#_ /\   #]    [@   .(   #5  H S0 1 ,< &0#$ ",
MP0 M +\ -P"[ #\ MP!' +4 3@"R %, L !9 *\ 7@"M &, K !H *L ;0"I
M ', J !Z *8 @0"D (H HP"4 *$ GP"? *P G@"[ )P T@"; .X F@#_ )H
M_P"9 /\ F0#_ /X   #N    W@   ,L   #!  4 N0 - +0 % "Q !X K@ G
M *L , "J #D IP!! *0 2 "B $T H0!3 )\ 6 "> %T G0!B )L 9P": &T
MF !S )< >P"5 (0 E ". )( F0"0 *8 C@"T (T R ", .8 BP#Y (H _P"*
M /\ BP#_ /    #;    QP   +H   "P    J  * *0 $ "@ !@ G0 A )L
M*@": #, F  [ )8 00"4 $@ D@!- )$ 4@"/ %< C@!< (P 80"+ &< B@!N
M (@ =0"' 'X A0"( (, E "" *  @ "O '\ P !^ -T ?0#R 'T _P!] /\
M?0#_ .    #&    M0   *H   "B    FP % )4 #0"2 !, D  < (T ) "+
M "T B@ T (@ .P"& $( A0!' (, 30"" %( @0!7 '\ 7 !^ &( ?0!H 'L
M< !Z 'D > "# '8 CP!U )P = "J '( N@!Q -$ < #L '  ^P!P /\ < #_
M ,T$  "W!@  IP<  )L&  "3!   C@   (H " "&  \ A  6 ($ '@!_ "<
M?0 N 'P -@!Z #P >0!" '< 1P!V $P =0!2 ', 5P!R %T <0!C &\ :P!N
M '0 ; !^ &L B@!I )@ : "F &< M@!F ,L 90#G &4 ]P!E /\ 90#_ , ,
M  "K#0  FPX  (\.  "&#0  @0L  'X' 0!\ 0L >0 1 '< & !U "$ <P I
M '$ , !O #8 ;@ \ &P 0@!K $< :@!- &D 4@!H %@ 9@!? &4 9P!C '
M8@%Z & !AP!? I4 7@*C %P#LP!< \< 6P3D %L%] !;!OX 6P;_ +40  "A
M$@  D1,  (43  !\$@  =A$  ',.  !R# 0 <0<- &X$$@!L!!L :04C &<%
M*@!F!C$ 9 8W &,&/0!B!T, 80=) %\'3@!>"%4 70A< %L)8P!:"6T 6 IX
M %<*A0!6"Y, 5 NB %,+LP!2#,< 4@SD %$-]0!1#?\ 40W_ *T5  "9%P
MB1@  'T9  !T&   ;1<  &H4  !G$0  9PX' &8,#@!C#!4 80P= %\,)0!=
M#2P 7 TS %L-.0!:#3\ 6 U% %<-2P!6#E$ 50Y9 %,.80!2#FL 4 ]V $X0
M@P!-$)( 3!"B $L0L@!*$<@ 21'E $D1]P!)$O\ 21'_ *49  "2'   @QT
M '8>  !M'0  9AP  &(:  !?%P  7A0! %X1"@!;$!$ 61$8 %<1( !5$2<
M5!$N %,1- !1$3L 4!)! $\21P!.$DX 3!)5 $L37@!)$V< 2!1S $84@ !%
M%8\ 1!6? $,6L !"%L4 0A?C $(7]@!"%_\ 0A?_ )\=  ",(   ?2$  '$B
M  !H(@  82$  %P?  !9'   5QD  %46!@!4%0X 4144 $\6' !.%B, 3!8J
M $L6, !*%C< 21<] $<70P!&%TH 11A2 $,86@!"&60 01EP #\:?0 ^&XT
M/1N= #P<K@ [',, .QSA #L=]0 ['/\ /!S_ )HA  "'(P  >"0  &PE  !C
M)0  7"0  %<C  !3(   41X  $\< @!-&PP 2QH1 $@;& !'&R  11LF $0;
M+0!#'#, 0APY $ <0  _'4< /AU/ #T>6  \'F( .A]M #D?>P X((L -R&;
M #8AK0 U(<$ -2'? #4A\P V(?\ -B'_ )8C  "#)@  ="<  &@H  !?*
M6"<  %,F  !/)   3"(  $D@  !'( D 1!\/ $(?%0! (!P /R C #X@*0 \
M("\ .R$V #HA/0 Y(40 ."), #<B50 V(U\ -"-K #,D>0 R)8D ,26: # E
MJP P)K\ +R;< # F\@ P)O\ ,27_ )$F  !_*   <2H  &4J  !<*@  52H
M $\I  !+*   2"4  $0D  !!) 4 /R0- #TD$@ [)!D .20? #<D)@ V)"P
M-24S #0E.@ S)D$ ,B9* #$G4P P)UT +RAI "XI=P M*8< +"F8 "LJJ@ J
M*KT *BK: "LJ\0 K*OX +"G_ (TH  !\*@  ;2P  &(M  !9+0  42T  $PL
M  !'*P  0R@  #\H   \* ( .2@+ #<H$  U*!8 ,R@< #(H(P P*"D +RDP
M "\J-P N*C\ +2M' "PK40 K+%L *BQG "DM=0 H+84 )RV7 "8NJ  E+KP
M)2[8 "8N\  F+OT )RW_ (HK  !X+0  :BX  %\O  !6+P  3B\  $@N  !#
M+0  /RP  #LL   W+   -"P) #(L#@ P+1, +BT: "TM(  K+2< *BXM "HN
M-0 I+ST *"]% "<P3@ F,%D )3%E "0Q<P C,8, (C*5 "$RIP A,KL (#+4
M "$R[P B,?P (C'_ (8M  !U+P  9S   %PQ  !3,0  2S$  $4Q  ! ,
M.S   #8P   S,   ,#$& "TQ#0 K,1$ *3(7 "@R'@ G,B0 )3,K "4S,@ D
M,SH (S1# "(T3  A-5< (#5C !\U<0 >-H$ '3:3 !PVI0 ;-KD &S;2 !PV
M[0 =-OL '37_ ((P  !Q,@  8S,  %DT  !0-   230  $(S   ],P  -S,
M #$T   N-0  *S4" "@V"P E-Q  )#<5 "(W&P A."( (#@H !\X,  >.#<
M'3E  !PY20 ;.E0 &CI@ !DZ;@ 8.G\ %SN1 !<[I  6.[< %3O0 !8Z[  7
M.OH &#G_ 'TR  !M-   8#4  %4V  !--@  1C8  $ V   Z-@  -#8  "XX
M   J.0  )CH  ",["  @/ X 'CT2 !T]&  </1\ &SXE !H^+0 9/C0 %SX]
M !8_1P 5/U$ %#]> !0_;  30'P $D"/ !% H@ 10+8 $$#. !$_ZP 2/_D
M$C[_ 'DU  !I-P  7#@  %(Y  !*.0  0SD  #TY   W.0  ,3H  "L\   G
M/0  (C\  !Y!!  :0@L &$,0 !=#%0 51!L %$0B !-$*0 31#$ $D0Z !%%
M0P 014X $$5;  Y%:0 .17D #46,  U%GP ,1;( "T7)  Q%Y0 -1/8 #43_
M '0Y  !E.@  6#L  $\[  !'/   0#P  #H\   T/   +CX  "A    C0@
M'T0  !I&   52 @ $DH- !%*$@ 02A@ #TL>  Y+)0 -2RT #4LV  Q+0  +
M2TH "DM6  E+9  (2W0 !TN'  5+F@ $2ZX !$K$  5*X  %2O  !DGZ &X\
M  !@/0  5#X  $L^  !$/@  /3X  #<_   Q0   *D(  "1%   ?1P  &DD
M !5,   13@4 #E$+  M1$  *410 "5$;  A1(@ '42D !5$R  12.P #4D8
M 5)2  !27P  4F\  %*!  !1E@  4:D  %&_  !0W   4.X  %#W &A   !;
M00  4$$  $A!  !!00  .T(  #1#   M10  )D@  "!+   ;30  %E   !%3
M   .500 "E@*  98#@ "6!(  %D7  !9'0  624  %DM  !9-@  64$  %E-
M  !:6@  6FD  %E\  !9D   6:4  %BZ  !8U0  5^P  %?V &-$  !610
M344  $5%   _10  -T<  "])   H3   (D\  !M2   650  $5@   U:   )
M70, !%\)  !@#0  8!   &$4  !A&0  8B   &(G  !B,0  8CL  &)'  !B
M50  8V0  &)V  !BBP  8J   &&V  !ASP  8.H  &#U %U(  !220  2D@
M $-(   Z2@  ,DT  "I0   C4P  '%<  !9:   170  #6    AC   #9@$
M &<&  !H"P  :0X  &H1  !K%0  ;!L  &TB  !M*@  ;30  &U   !M3@
M;5T  &UO  !MA   ;)H  &RP  !KR   :^8  &KS %A-  !.30  2$P  #Y.
M   U40  +%0  "18   =7   %F   !!D   ,9P  !VL   %N    <    '(#
M  !R!P  <PL  '4.  !V$0  =Q8  '@<  !Y(P  >BT  'HY  !Z1P  >E8
M 'EH  !Z?   >90  'BJ  !XP0  =]\  '?O %11  !,40  0E(  #A5   O
M60  )EX  !YB   69P  $&L   MO   %<P   '<   !Z    ?    'X   !_
M @  @ 8  ($*  "##0  A!$  (85  "('   B24  (HP  "*/@  B4T  (E?
M  ")<P  B(L  (BB  "'N0  A]$  (;H %)6  !'5P  /%H  #)?   H9
M'VD  !9O   0=   "GD   )]    @0   (4   "(    B@   (P   "-
MCP   ) $  "2"   DPP  )40  "7%0  F1T  )LG  ";-   FT0  )I6  ":
M:@  F8(  )J:  "8L   F,<  )?> $M<  ! 8   -64  "MJ   A<0  %W<
M !!]   )@P   8@   ",    D0   )4   "8    F@   )L   "=    GP
M *    "B    I 4  *8*  "H#@  JA0  *T=  "M*@  K3D  *U+  "M7P
MK7<  *R0  "KIP  J[H  *O+ $5F   Y:P  +G$  "-X   9?P  $(8   F-
M    DP   )@   "=    H0   *4   "H    JP   *L   "N    KP   +$
M  "S    M0   +<!  "Y!P  O T  +\3  #"'P  PBX  ,)   #"5   P6L
M ,&#  # FP  P:T  ,&\ #YR   R>   )X   !R(   2D   "I<   "=
MHP   *@   "M    L@   +8   "Y    NP   +P   "^    P    ,(   #$
M    Q@   ,@   #+    S@4  -$-  #6%   UR,  -@U  #920  VEX  -MU
M  #;C   W)\  -RK /\   #_    _P   /\ "0#_ !  _P 9 /X ) #\ "\
M^0 Y /0 0P#P $L [0!2 .H 60#G %\ Y !D .( :0#@ &X W@!S -P >0#:
M '\ UP"& -0 C@#1 )8 SP"A ,P K #* +L R #2 ,8 [@#& /\ Q0#_ ,4
M_P"_ /\ N@#_ /\   #_    _P   /X !0#W  X \@ 5 .X 'P#K "H Z0 T
M ., /0#> $4 V0!- -0 4P#1 %D S@!> ,P 8P#* &@ R0!M ,< <P#% 'D
MPP"  ,$ B "_ )  O0"; +L I@"Y +0 MP#( +8 Y@"U /L M #_ +0 _P"S
M /\ K@#_ /\   #_    ^    .T   #E  L W0 1 -< &@#2 "0 SP N ,L
M-P#' $  PP!' ,  3@"^ %, O !9 +H 7@"X &, M@!H +4 ;0"S ', L0!Y
M *\ @0"M (H JP"4 *D H "H *T I@"^ *4 VP"D /0 I #_ *, _P"C /\
MH@#_ /\   #V    Y@   -<   #+  8 Q  . +X %0"[ !\ N0 H +< ,0"T
M #H L !! *T 2 "K $X J0!3 *< 6 "F %P I !A *, 9P"A &P H !S )X
M>@"= (, FP". )D F0"7 *8 E@"V )4 S "4 .L DP#] ), _P"3 /\ DP#_
M /<   #D    T    ,$   "W  ( KP + *L $0"G !D I0 B *, *P"B #,
MGP [ )P 0@"; $@ F0!- )< 4@"6 %< E0!; ), 80"2 &8 D !M (\ = "-
M 'T C "' (H DP"( *  AP"O (4 P@"% .( A #W (0 _P"$ /\ A #_ .4
M  #-    O    *\   "F    G@ ' )H #@"6 !0 E  = )( )0"1 "T D  U
M (T / ", $( B@!' (@ 3 "' %$ A@!6 (0 6P"# &  @0!G (  ;@!^ '<
M?0"! 'L C0!Z )H > "I '< N@!V -, =@#O '8 _@!U /\ =0#_ -    "[
M    JP   )\   "7    D  " (L "P"( !  A@ 7 (0 ( "" "< @0 O '\
M-0!] #P ? !! 'L 1@!Y $L > !0 '< 50!V %L = !A ', :0!Q '$ < ![
M &X AP!M )4 :P"C &H M !J ,D :0#H &D ^0!I /\ :0#_ ,    "L
MG (  ) "  "(    @P   '\ !@![  T >0 2 '< &@!V "( =  I ', , !Q
M #8 <  \ &\ 00!M $8 ; !+ &L 4 !J %8 : !< &< 9 !E &P 9 !V &,
M@@!A )  8 "? %\ KP!> ,, 7@#A %X ] != /\ 70#_ +0'  "@"0  D L
M (0+  !\"@  =P<  '0$  !Q  D ;P / &T %0!K !P :0 C &@ *@!G #$
M90 V &0 / !C $$ 8@!& &  3 !? %( 7@!8 %T 7P!; &@ 6@!R %@ ?@!7
M (P 5@"; %4 JP!4 +X 5 #: %, [P!4 /L 5 #_ *D-  "6#@  AQ   'H0
M  !R$   ; X  &D,  !G"0, 9@0+ &0 $ !B !< 8  > %X )0!= "L 7  Q
M %H -P!9 #P 6 !" %<!1P!6 4X 50)4 %,"7 !2 V4 40-O $\$>P!.!(H
M3069 $P%J0!+!;P 2@;4 $H'[0!*!_D 2@?_ *$0  ".$@  ?A0  ',4  !J
M%   9!,  & 1  !>#P  70T% %T)#0!:!A( 6 <9 %8'( !5!R< 4P<M %((
M,P!1"#@ 4 @^ $\)1 !."4H 3 E1 $L*60!*"F( 2 MM $<+>@!&#(@ 1 R8
M $,,J0!"#;P 0@W5 $(-[@!"#?L 0@W_ )H4  "'%@  >!@  &P9  !C&0
M71@  %D6  !6$P  5!$  %0." !3#0X 40T4 $\-&P!-#2( 3 TH $L-+@!*
M#30 20TZ $<.00!&#D< 10Y/ $0.5P!"#V$ 01!L #\0>0 ^$(@ /1&8 #L1
MJ0 [$;P .A'6 #H1\  Z$OT .Q'_ ),8  "!&@  <QP  &<=  !>'0  6!P
M %,;  !0&   3A8  $P3 P!,$0L 2A 0 $@1%P!&$1X 11$D $01*@!"$3
M01$W $ 2/0 _$D0 /1), #P35  [$UX .11I #@4=@ W%84 -A66 #06IP T
M%KH ,Q;3 #,6[@ T%OP -!;_ (X;  !\'0  ;A\  &,@  !:(   4R   $X>
M  !*'0  2!H  $88  !%%@< 0Q4. $$5$P _%1H /A4@ #T5)P [%2T .A8S
M #D6.@ X%D$ -Q=) #4740 T&%L ,QEF #(9<P P&H, +QJ4 "X;I0 M&[@
M+1O0 "T;[  N&_L +AO_ (H>  !X(   :B(  %\C  !6(P  3R(  $HA  !&
M(   0QX  $$;   _&@, /1H, #L9$0 Y&18 -QH= #8:(P U&BD -!HP #,;
M-@ Q&SX ,!Q& "\<3P N'5D +1UD "P><0 K'X$ *A^2 "D?I  H(+< )R#.
M "<@ZP H(/H *1__ (8@  !T(P  9R0  %PE  !3)0  3"4  $<D  !"(P
M/R$  #T?   Z'@  -QX) #4>#@ S'A, ,1X: # >(  O'B8 +A\M "T?,P L
M(#L *R!# "HA3  I(58 *")B "8B;P E(W\ )".0 ",CH@ B)+4 (B3, "(D
MZ0 C)/D )"/_ ((C  !Q)0  8R8  %DG  !0*   22<  $,G   _)@  .R0
M #@B   U(@  ,B(& # B#0 N(A$ +"(7 "HB'0 I(B, *",J "<C,0 F)#@
M)25! "0E2@ C)E0 (B9@ "$G;0 @)WT 'R>/ !XHH0 >*+0 '2C* !THZ  >
M*/@ 'R?_ 'XE  !N)P  8"D  %8I  !-*@  1BH  $$I   \*   -R<  #0F
M   P)@  +28# "LG"P H)Q  )R<4 "4G&@ D)R$ (R@G "(H+@ A*38 ("D^
M !\J2  >*E( '2M> !PK:P ;*WL &BR- !DLGP 8++( &"S) !@LYP 9*_<
M&BO_ 'HG  !J*@  72L  %,L  !*+   0RP  #XK   Y*P  -"H  # J   K
M*@  *2L  "8K"  C+ X (BP2 " L&  ?+!X 'BTE !TM+  <+3, &RX\ !HN
M10 9+U  &"]< !<O:0 6,'D %3"+ !0PG@ 4,+$ $S#' !,PY0 4,/8 %2__
M '8J  !G+   6BT  % N  !(+@  02X  #LN   V+0  ,2T  "PM   G+P
M)"\  "$P!0 ?,0P '#$0 !LR%0 :,AP &3(B !@R*0 7,S$ %C,Y !4S0P 4
M-$T $S19 !(T9P 1-7< $36) ! UG  0-;  #C7&  \TY  0-/4 $#3_ '(L
M  !C+@  5S   $TP  !%,   /C   #@P   S,   +S   "DQ   D,@  (3,
M !TU @ :-@D %S<. !4W$P 4.!D $S@? !(X)@ 2."X $3DV ! Y0  0.4L
M#CE7  XZ9  -.G0 ##J&  PZF0 +.:P "CG!  HYW@ +.?$ ##C\ &XO  !?
M,0  4S(  $HS  !",P  .S,  #8S   Q,@  +#,  "<T   A-@  '3@  !DY
M   5.P8 $CT, ! ^$  0/A4 #CX<  X^(P -/BH ##XS  P^/  +/T< "C]2
M  @_8  '/V\ !C^!  4_E  $/Z@  SZ\  0^UP %/NP !3[W &DS  !;-
M4#4  $<U   _-0  .34  #0U   N-0  *3<  ",X   >.P  &CP  !8_   2
M000 #D,*  Q$#@ *1!, "409  A$(  '1"< !D0O  5$.  #14(  D5.  !%
M6P  16H  $5\  !%D   1*0  $2Y  !$T0  1.H  $/U &0V  !7-P  3#@
M $,X   \.   -S@  #$X   K.0  )3L  " ]   :0   %D(  !)$   .1P0
M"TD)  =*#0 $2Q$  4L6  !+'   2R,  $LK  !+-   2SX  $Q)  !,5P
M3&8  $QW  !+C   2Z$  $NU  !*S@  2ND  $KU %\Z  !2.P  2#L  $ [
M   Z.P  -#L  "X\   G/@  (D$  !Q#   61@  $DD   Y+   +3@, !U (
M  )1#   41   %(3  !3&   4Q\  %,F  !3+P  4SD  %-%  !34@  4V$
M %-R  !3AP  4IP  %*Q  !1R@  4><  %'T %D^  !./@  13X  #X^   X
M/@  ,$   "E"   C1   '4<  !=*   230  #E    M3   &50(  %<'  !8
M"P  60X  %H1  !:%0  6QH  %PA  !<*@  7#0  %P_  !<30  7%L  %QL
M  !<@0  6Y<  %NM  !:Q0  6N0  %GS %1"  !*0@  0D(  #Q"   T0P
M+$8  "5)   >3   %T\  !)3   .5@  "ED   5;    7@   & $  !A"
M8@P  &,.  !D$0  918  &8<  !G(P  9RT  &<Y  !G1@  9U4  &=F  !G
M>@  9I$  &6H  !EP   9-X  &3P $]&  !'1@  0$4  #='   O2@  )DT
M !]1   850  $ED   U<   (8    F,   !F    :    &H   !K!   ; @
M &T,  !O#@  <!(  '(7  !S'0  ="8  '0R  !T/P  =$X  '-?  !T<@
M<XH  '*A  !QN   <=0  '#L $Q*  !%2@  .TL  #).   I4@  (%8  !A;
M   27P  #60   =H    :P   &\   !R    =0   '8   !W    >0(  'H&
M  !\"@  ?@X  ( 1  ""%@  A!X  (0I  "$-@  A$4  (16  "#:@  @X$
M (*9  "!L0  @,D  (#E $I.   _4   -5,  "M7   B7   &6(  !)G   ,
M;   !7$   !U    >0   'T   "!    @P   (4   "&    B    (D   "+
M!   C0@  (\-  "2$   E!8  )8@  "6+   ECL  )9,  "58   E78  )20
M  "3IP  DKT  )+5 $15   Y60  +UT  "1C   ::0  $F\   QU   $>P
M (    "%    B0   (T   "1    DP   )0   "6    F    )H   "<
MG@   * &  "B"P  I1   *@7  "I(P  J3$  *E#  "I5@  J&T  *:'  "G
MG@  IK,  *7' #Y>   R8P  )VH  !UP   3>   #'\   .%    BP   )$
M  "6    FP   )\   "B    I    *4   "G    J0   *L   "M    L
M +(   "U @  MPD  +L0  "^&   OB8  +XX  "^2P  O6$  +QZ  "[E
MNJD  +JY #=J   K<   ('@  !:    -B   !8\   "6    G    *(   "G
M    K    +    "S    M@   +<   "Y    NP   +T   "_    P@   ,4
M  #(    R@   ,X(  #2$   U1L  -4L  #40   U%<  --N  #4A@  U)L
M -.K /\   #_    _P   /\ !0#_  X _P 5 /P ( #Y "H ]@ T /$ /0#M
M $8 Z0!- .8 4P#D %D X0!> -X 8P#< &@ V0!N -4 <P#3 'D T "  ,X
MB #+ )$ R0"< ,8 IP#$ +< P@#, ,  [ "_ /\ O@#_ +T _P"W /\ L@#_
M /\   #_    _P   /H  0#S  L [0 2 .@ &P#E "4 Y  N -\ . #8 $
MT@!' ,X 3@#+ %0 R !9 ,8 7@#$ &, P@!G ,  ;0"_ ', O0!Z +L @0"Y
M (L M@"5 +0 H0"R *\ L #" *X XP"N /H K #_ *T _P"I /\ I@#_ /\
M  #_    \@   .8   #=  < T@ . ,T %@#* "  R  I ,4 ,@#  #H O !"
M +D 2 "W $X M0!3 +, 6 "Q %T L !B *X 9P"L &P J@!S *D >P"G (0
MI0". *, F@"A *@ GP"Y )X T@"= /( G #_ )T _P"< /\ F0#_ /P   #N
M    W0   ,P   #!  ( N@ , +8 $@"R !H L  C *\ + "M #0 J0 \ *8
M0@"D $@ H@!- *  4@"> %< G0!; )P 8 ": &8 F0!L )< = "5 'T DP"'
M )$ DP"0 *$ C@"Q (T Q@", .@ BP#] (P _P", /\ C #_ .T   #8
MQ0   +<   "L    I@ ( *$ #@"? !4 G0 > )L )@": "X EP U )4 / "3
M $( D0!' )  3 ". %$ C0!5 (L 6@"* &  B0!F (< ;0"% '8 A "  ((
MC "  )H ?P"I 'T O !\ -P ? #U 'P _P!\ /\ ? #_ -D   #!    L0
M *0   "<    E  # )  # "- !$ BP 8 (D ( ") "@ AP O (4 -@"# #P
M@@!! (  1@!_ $L ?0!/ 'P 5 ![ %H >0!@ '@ 9P!V '  =0!Z ', A@!Q
M ), < "B &\ M !N ,P ;@#M &X _@!N /\ ;@#_ ,0   "O    H    )0
M  ",    A@   ($ " !^  X ?  4 'L &P!Y "( >  I '< , !U #8 =  [
M '( 0 !Q $4 < !* &\ 3P!M %0 ; !; &L 8@!I &H : !T &8 @ !E (X
M8P"= &( K0!A ,( 80#D &$ ^ !A /\ 80#_ +0   "@    D0   (8   !^
M    >0   '4  P!Q  L ;P 0 &T %@!L !T :P D &L *@!I #  :  V &8
M.P!E $  9 !% &, 2@!A $\ 8 !6 %\ 70!= &4 7 !O %H >@!9 (@ 6 "8
M %< J !6 +L 5@#8 %8 \0!6 /\ 5@#_ *@!  "4!0  A0<  'H'  !R!@
M; 0  &D!  !G  < 9  - &, $0!A !@ 8  ? %\ )0!> "L 70 P %L -@!:
M #L 60!  %@ 10!7 $L 5@!1 %4 6 !3 &$ 4@!J %  =@!/ (0 3@"3 $T
MI !, +8 3 #- $P ZP!, /H 3 #_ )T)  "+"P  ? T  ' -  !H#0  8@P
M %\*  !=!@$ 7 $) %H #@!8 !, 5P 9 %8 ( !5 "8 4P K %( ,0!1 #8
M4  [ $\ 00!. $< 30!- $L 50!* %T 20!G $< <P!& (  10"0 $0 H0!#
M +( 0P#( $, Y@!# /4 0P#_ )4-  "##P  =!   &D1  !@$0  6A   %8.
M  !4#0  4PH$ %,&"P!1 Q  3P$5 $X!&P!, 2$ 2P$G $H"+ !) C( 2 (W
M $<#/0!% T, 1 -* $,$40!"!%H 0 5D #\%<  ^!GX /0:. #P'GP [![$
M.@?& #H'XP Z!_, .@C\ (X0  !\$@  ;A0  &(5  !:%0  5!0  % 3  !-
M$0  2PX  $L-!@!*"@P 20@1 $<(%@!%"!T 1 @C $((* !!"2X 0 DS #\)
M.0 ^"D  /0I' #P*3P Z"U@ .0MC #@,;P V#'X -0R. #0-GP S#;$ ,@W'
M #(-XP R#?0 ,@W^ (@3  !W%0  :1<  %X8  !5&   3Q@  $H6  !'%0
M11,  $,0 @!##@@ 0@T. $ -$@ _#1@ /0T? #P-)  [#2H .0TP #@.-P W
M#CT -@Y% #4.30 S#U< ,@]B #$0;@ O$'T +A". "T1H  L$;( *Q'( "L1
MY@ K$?8 +!'_ (,6  !R&0  9!H  %D;  !1&P  2QL  $8:  !"&   /Q<
M #X4   \$@0 .Q$* #H0$  X$!4 -Q ; #41(0 T$2< ,Q$M #(1,P P$3H
M+Q)" "X22P M$U0 *Q-? "H4;  I%'L *!2, "<5G@ F%;  )17& "45Y  E
M%?8 )A7_ 'X9  !N&P  8!T  %8>  !-'@  1QX  $(=   ^'   .AH  #@8
M   W%@  -14' #04#0 R%!( ,!07 "\4'0 M%", +!4J "L5,  J%3< *18_
M "@62  G%U( )AA= "08:@ C&7D (AF* "$9G  @&:\ 'QG$ !\9X@ @&?0
M(!G_ 'H;  !J'@  71\  %,@  !*(   1"   #X?   Z'@  -QT  #0<   R
M&0  ,!D$ "X8"P L&!  *A@4 "D8&@ G&"  )ADF "49+0 D&C4 (QH] "(;
M1@ A&U  (!Q; !\=:  >'7< '1V( !P>FP ;'JT &A[# !H>X  :'?, &QW_
M '<=  !G(   6B$  % B  !((@  02(  #LB   W(0  ,R   # ?   M'0
M*QT  "@="  F'0X )1T2 ",=%P A'1T (1TD " >*@ ?'C( 'A\Z !T?0P <
M($T &R%9 !HA9@ 9(74 &"*' !<BF0 6(JP %2+! !4BWP 5(?( %B'^ ',@
M  !D(@  5R,  $TD  !%)0  /B0  #DD   T(P  ,"(  "PB   I(0  )B$
M "0A!@ B(0P ("$0 !XA%0 =(AL &R(A !LB*  :(R\ &2,X !@D00 7)$L
M%B57 !4E9  4)G, $R:% !(FF  1)JL $2;  ! FW0 1)?$ $B7] ' B  !A
M)   5"8  $HF  !")P  /"8  #8F   Q)0  +24  "DD   F)   (B4  !\E
M P =)@H &R8. !DG$@ 8)Q@ %R<? !8G)0 5*"T %"@U !,I/@ 2*4D $2E5
M !$J8@ 0*G$ #RJ#  XJE@ .*JD #2J]  TJUP -*NX #BG[ &PD  !=)@
M42@  $@H  ! *0  .2@  #0H   O*   *R<  "<G   B*   'BD  !LJ   8
M*P< %BL- !0L$0 3+!8 $BP< !$M(P 0+2H $"TR  \N/  .+D8 #2Y2  TN
M7P ,+VX "R]_  HOD@ )+Z4 "2ZY  @NT  )+ND "B[W &@G  !:*0  3BH
M $4K   ]*P  -RL  #$J   M*@  *2H  "0J   @*P  &RT  !@N   5+P0
M$C$* ! R#@ /,A, #C(9  TR(  -,B< ##(O  LS.  *,T( "3-.  @S6P &
M-&H !31[  0SC@ #,Z(  C.V  (SS0 #,^< !#+S &0J  !6+   2RT  $(M
M   Z+0  -"T  "\L   K+   )BP  "(M   =+P  &3$  !4R   2- , #S8)
M  PX#0 *.!$ "3@6  @X'0 '."0 !C@L  0X-  #.#X  CE*   Y5P  .64
M #EW   YBP  .)\  #BS   XR@  ..8  #?R %\M  !2+@  2"\  #\P   X
M+P  ,B\  "TO   I+P  )#   !\Q   :,P  %34  !(W   /.0, ##L(  @]
M#0 %/A   SX4   ^&@  /B$  #XH   ^,0  /SL  #]&   _4P  /V$  #]S
M   _AP  /IP  #ZP   ]QP  />0  #WR %HP  !.,@  1#(  #PR   U,@
M,#$  "LQ   F,@  (#0  !LV   6.   $CL   \]   ,/P, "$$(  1##
M0PX  $02  !%%@  11T  $4D  !%+0  1C8  $9"  !&3@  1ET  $9N  !%
M@@  19@  $2M  !$Q   0^,  $/R %4T  !*-0  034  #DU   S-   +C0
M "@U   B-P  '3H  !<\   2/P  #T$   Q$   (1@$  T@&  !)"@  2@T
M $L0  !,%   31D  $X@  !.*   3C(  $T]  !.2@  3E@  $UI  !-?0
M3)0  $RJ  !+P0  2^$  $KR % X  !&.   /3@  #<X   Q-P  *CD  "0[
M   >/0  &$   !-#   /1@  "TD   =+   "3@   % $  !1"   4@L  %,.
M  !4$0  514  %8;  !7(P  5RP  %<X  !71   5U(  %9C  !6=P  5HX
M %6E  !4O0  4]T  %/P $L\  !"/   .SL  #4[   M/   )C\  !]"   9
M10  $T@   Y+   +3P  !5$   !4    5P   %@!  !:!0  6P@  %P,  !=
M#@  7Q$  & 6  !B'0  8B8  &(Q  !B/@  84P  &%=  !A<   8(@  &"@
M  !?MP  7M0  %WN $=    _/P  .C\  #%    I0P  (48  !I*   33@
M#E$   I5   $6    %L   !>    80   &,   !D 0  900  &<(  !H"P
M:@X  &P2  !N%P  ;R   &\J  !O-@  ;D4  &Y5  !N:   ;7\  &V8  !L
ML   :\H  &KH $1$   ^0P  -40  "M'   C2P  &T\  !-4   .6   "%P
M  )@    9    &<   !K    ;0   &\   !P    <@   '0"  !U!@  =PH
M 'D.  !\$@  ?A@  '\B  !_+@  ?ST  'Y-  !]80  ?7<  'R0  ![J
M>L   'G? $-'   Y20  +TP  "50   <50  %%L   Y@   '90   &H   !N
M    <@   '8   !Y    ?    'X   !_    @0   (,   "%    AP,  (H(
M  ",#0  CQ$  )(9  "2)0  DC,  ))$  "15P  D&T  (^&  ".GP  C;4
M (S- #U.   R40  *%8  !Y<   58@  #F@   =N    =    'D   !^
M@@   (8   ")    C    (X   "0    D@   )0   "6    F    )L   ">
M!@  H0P  *01  "F&P  IBD  *8Z  "E30  I6(  *1[  "CE   H:L  *&_
M #97   L7   (6(  !=I   /<   !W<   !^    A    (H   "/    E
M )@   ";    G@   )\   "B    I    *8   "H    JP   *T   "P
MLP0  +<,  "[$@  NQ\  +LP  "[0P  NE@  +EP  "WBP  MZ$  +>S #!B
M   E:0  &G   !!X   )@    (@   "/    E@   )L   "A    I@   *H
M  "N    L    +$   "T    M@   +@   "[    O0   ,    ##    QP
M ,L#  #/#   TQ4  -(E  #2.   T4X  -!E  #/?@  S98  ,RI /\   #_
M    _P   /\  P#_  L _  1 /D &P#W "4 \P O .X . #I $  Y@!( .(
M3@#? %0 W !9 -D 7@#5 &, TP!H -  ;0#. ', RP!Z ,@ @@#& (P PP"7
M ,  HP"^ +( O #( +H Z@"Y /\ N #_ +$ _P"J /\ IP#_ /\   #_
M^P   /8   #M  < YP / .( %@#? "  W@ I -D ,P#1 #L S !" ,@ 2 #%
M $X P@!3 ,  6 "^ %T O !B +H 9P"Y &T MP!T +4 >P"R (4 L "0 *X
MG "L *H J0"] *< W@"F /D I0#_ *, _P"= /\ FP#_ /T   #V    ZP
M -\   #1  , R@ , ,4 $@## !L P  D +X + "Y #4 M@ \ +, 0P"P $@
MK@!. *P 4@"K %< J0!< *< 80"F &< I !M *( = "@ 'T G@"( )P E0":
M *, F "T )8 S0"5 /$ E #_ )4 _P"0 /\ C@#_ /,   #F    T0   ,(
M  "X    L0 ( *T #P"J !8 J  > *@ )P"F "\ H@ V )\ / "= $( FP!'
M )D 3 "7 %$ E@!5 )0 6@"3 &  D0!F )  ;@". '8 C "! (H C0"( )L
MA@"L (4 P0"$ .8 @P#] (0 _P"# /\ @0#_ .0   #+    N@   *P   "B
M    G  $ )@ # "6 !$ E  9 ), (0"2 "@ CP P (T -@"+ #P B0!! (@
M1@"& $L A0!/ (0 5 "" %H @0!@ '\ 9P!^ &\ ? !Z 'H A@!X )0 =P"D
M '4 MP!T -0 <P#T '0 _P!T /\ = #_ ,L   "V    I@   )H   "2
MB@   (8 " "#  X @0 4 ($ &P"  ", ?P J 'T , ![ #8 >@ [ '@ 0 !W
M $4 =0!) '0 3@!S %0 <0!: '  80!N &D ;0!S &L ?P!I (T : "= &<
MK@!F ,< 90#J &8 _P!F /\ 9P#_ +@   "D    E0   (H   "!    ?
M '8 ! !T  P <@ 0 '$ %@!P !T <  D &X *@!M #  :P U &H .@!I #\
M: !$ &< 20!E $X 9 !4 &, 6P!A &, 8 !M %X >0!= (< 6P"6 %H J !9
M +T 60#? %D ^ !: /\ 6@#_ *@   "5    AP   'L   !S    ;@   &H
M 0!G  @ 90 . &0 $@!C !@ 8P ? &( )0!A "H 7P P %X -0!= #H 7  ^
M %L 1 !9 $D 6 !/ %< 5@!6 %X 5 !H %, <P!1 ($ 4 "1 $\ H@!. +4
M3@#0 $X \ !. /\ 3P#_ )P   ")    >P,  ' #  !H P  8@$  %\   !=
M  0 6P + %D #P!8 !0 5P 9 %< ( !6 "4 50 J %, , !2 #0 40 Y %
M/P!/ $0 3@!+ $T 4@!+ %H 2@!C $D ;P!' 'P 1@", $4 G0!% +  1 #'
M $0 Z !$ /H 10#_ )($  " !P  <0H  &8*  !>"@  60D  %4'  !4!
M4@ ' %  # !/ !  3@ 5 $T &P!, "  2P F $H *P!) #  2  U $< .@!&
M $  10!& $, 3@!" %8 00!? $  :P ^ '@ /0"( #P F0 \ *L / #! #L
MX  [ /0 .P#_ (D*  !X#   :@X  %\.  !7#@  40X  $T,  !+"P  2@@"
M $D$"0!(  T 1@ 1 $4 %@!$ !P 0P A $( )@!! "L /P Q #X -@ ] #P
M/ !# #L 2@ Z %( .0!< #@ :  V '4 -0"% #0 E@ T *@ ,P"\ #, V  S
M .\ ,P#[ ((-  !Q#P  9!   %D1  !1$0  2Q$  $<0  !$#@  0@T  $$+
M!0!!!PL /P4. #X#$@ \ A@ .P(= #H#(@ Y R@ . ,M #<#,@ V!#D -00_
M #0%1P S!5  ,09: # &9@ O!W, +@># "T'E0 L!Z< *P>Z "L'T@ K!^L
M*P?W 'T0  !L$0  7Q,  %04  !,%   1A0  $(3   ^$@  /!   #H. 0 Z
M#08 .@H, #@)$  V"!0 -0@9 #0)'P R"20 ,0DI # )+P O"C8 +@H] "T*
M10 L"TX *PM9 "D,90 H#', )PR# "8-E0 E#:< ) V[ ",-T@ C#>L (PWW
M '@2  !H%   6Q8  %$7  !(%P  0A8  #T6   Y%0  -Q,  #41   S$ ,
M,PX( #(-#0 P#1$ +PT6 "T-&P L#2$ *PTG "H-+0 I#C0 * X[ "<.1  E
M#DX ) ]9 ",090 A$', (!"$ !\0E@ >$*D '1"] !P0V  =$.X '1#Y ',4
M  !D%@  5Q@  $T9  !%&0  /QD  #H8   U%P  ,A8  # 5   N$P  +1$$
M "P0"@ K$ X *1 2 "@0&  F$!X )1 D "00*@ C$3$ (A$Y "$10@ @$DL
M'A)6 !T38P <$W$ &A." !D4E0 8%*< %Q2[ !<3U  7$^X &!/Z ' 6  !@
M&0  5!H  $H;  !"'   /!L  #8;   R&@  +QD  "P8   J%@  *!0! "83
M!P E$PP (Q,0 "(3%0 @$QH 'Q,A !X4)P =%"X '!4V !L5/P :%DD &194
M !@780 6%W  %1B! !08DP 3&*8 $ABZ !(7T@ 2%^P $Q?Z &P9  !=&P
M41T  $<=   _'@  .1T  #0=   O'   *QL  "@:   F&0  )!@  "(7!  @
M%PH 'A<. !P7$@ :%Q< &1@> !D8)  8&2P %QDT !8:/0 5&D< %!M2 !,;
M7P 2'&X $1Q_ ! <D@ 0'*4 #QRY  X<T  .&^H #QOX &D;  !:'0  3A\
M $4?   ](   -A\  #$?   M'@  *1T  "4=   C'   (!L  !T; 0 ;&P<
M&1P- !<<$  6'!4 %1P; !0=(@ 3'2D $AXQ !$>.@ 1'T4 $!]0  \@70 .
M(&P #2!\  T@CP ,(*( "R"U  L@R@ +(.4 #!_T &4=  !7'P  3"$  $(A
M   Z(0  -"$  "\A   J(   )A\  ",?   @'@  '1X  !D@   6( 0 %" +
M !(A#@ 1(1, $2(9 ! B'P /(B8 #B,O  XC-P -(T$ #"1-  LD60 *)&<
M"21X  @DBP '))X !R2Q  8DQP &(^, !R/Q &(?  !4(0  22,  $ C   X
M(P  ,B,  "PC   H(@  )"$  "$A   >(0  &B$  !8C   3) , $24(  \F
M#0 .)Q$ #2<6  PG'0 +)R, "B<K  DH-  (*#X !RA)  8H50 %*60 !"ET
M  ,IAP "*9L  2BO   HQ0 !*.$  2?P %XB  !1)   1B4  #TE   U)0
M+R4  "HD   F)   (B,  !\C   ;)   &"4  !0F   1* , #RD(  PL#  *
M+!  ""P4  <L&@ &+"$ !2PH  ,M,  "+3H  2U%   M4@  +F   "YQ   M
MA   +9D  "VM   LP@  +.   "SP %HD  !-)@  0R<  #HG   S)P  +2<
M "@F   D)@  (28  !TF   9)P  %2D  !$K   /+ , #2X'  DP#  &,0X
M S$2  $R%P  ,AX  #(E   R+0  ,C8  #-"   S3@  ,UT  #-M   S@0
M,I8  #*K   QP0  ,=\  #'P %8G  !**0  /RH  #<J   P*@  *RD  "<H
M   C*   'BD  !HJ   6+   $BX   \P   -,0( "C0'  4U"P "-@X  #<0
M   X%   .!H  #@B   X*@  .3,  #D^   Y2@  .5D  #EI   Y?0  .),
M #BH   WOP  -]X  #;P %$K  !&+   /"P  #0L   N+   *BL  "4K   @
M+   &RT  !<O   3,0  $#,   TU   )-P( !3H&  $["@  / T  #T/   ^
M$@  /Q<  $ >  ! )0  0"\  $ Z  ! 1@  0%0  $!E   _>   /X\  #ZF
M   ^O0  /=P  #WP $TN  !"+P  .2\  #(O   M+@  *"X  "(O   =,
M&#(  !,U   0-P  ##H   D\   %/@   $$$  !""   0PL  $0-  !&$
M1Q0  $@9  !((0  2"H  $@U  !(00  2$\  $A@  !'<P  1XH  $:B  !%
MN0  1=D  $3P $@R   ^,@  -C(  # Q   K,0  )3(  !\T   9-@  $SD
M ! \   ,/P  "$(   -$    1@   $@"  !*!0  2P@  $P+  !.#@  3Q$
M %$5  !2'   4B4  %(P  !2/   44H  %%:  !1;0  4(0  $^=  !.M0
M3=(  $WN $,V   [-@  -#4  "\T   G-0  (3@  !H[   4/@  $$$   Q$
M   '1P   DH   !-    3P   %$   !3 @  5 4  %4(  !7"P  60X  %L1
M  !=%P  71\  %TJ  !=-@  7$0  %Q4  !;9P  6WX  %J7  !9KP  6,L
M %?J #\Y   X.0  ,S@  "LY   C/   '#\  !5#   01P  "TH   5.
M40   %0   !7    6@   %P   !=    7P   & $  !B!P  9 L  &8.  !H
M$@  :QD  &LC  !J+@  :CP  &I-  !I7P  :'4  &>/  !FJ   9<(  &3C
M #T]   W/   +CT  "5    =1   %DD  !!-   *40  !%4   !:    70
M &    !C    9@   &@   !J    :P   &T   !O @  <08  '0*  !V#@
M>1,  'L;  ![)P  >C4  'E%  !X60  >&T  '>&  !VGP  =;<  '32 #Q!
M   R0@  *$4  "!*   73@  $%0   I9   "7@   &,   !G    :P   &\
M  !R    =0   '<   !Y    >P   'T   !_    @@   (0#  "'"0  B@X
M (X3  "/'@  CBL  (X[  "-3@  BV,  (I\  "*E0  B*T  (?% #9'   L
M2P  (D\  !E5   06P  "F$   %G    ;0   '(   !W    >P   '\   "#
M    A@   (@   "*    C0   (\   "1    E    )<   ": 0  G0<  *$-
M  "E%   I"$  *0Q  "C1   HED  *!P  "?BP  G:(  )VW #!0   E50
M&UL  !)B   +:0   7    !W    ?0   (,   "(    C0   )$   "5
MF    )H   "<    GP   *$   "C    I@   *D   "L    L    +0'  "X
M#@  NA@  +HG  "Y.0  N$X  +=E  "V?@  M98  +.K "E;   >8@  %&D
M  QQ   ">0   ($   ")    CP   )8   ";    H    *0   "H    JP
M *P   "O    L@   +0   "V    N0   +P   #     Q    ,@   #-!P
MTA   -(=  #1+P  T$0  ,];  #-<P  RXT  ,JA /\   #_    ^P   /H
M  #\  @ ^  / /4 %P#T "  \0 J .L ,P#F #L X@!# -X 20#: $\ U@!4
M -, 60#0 %X S@!C ,L : #) &X Q@!U ,, ?0#! (8 O@"2 +L G@"Y *X
MM@## +0 Z "S /\ KP#_ *4 _P"> /\ FP#_ /T   #W    \@   /    #G
M  , X0 , -P $@#8 !L U@ D -( +0#, #8 Q@ ] ,( 0P"_ $D O !. +H
M4P"X %@ M@!= +4 8@"S &< L0!N *\ =@"L '\ J@"* *@ EP"E *8 HP"Y
M *$ V0"@ /D G@#_ )@ _P"2 /\ CP#_ /,   #L    XP   -,   #(
MP0 ) +T #P"[ !8 N0 ? +< )P"S "\ KP W *P /0"J $, J !( *8 30"D
M %( HP!6 *$ 6P"? &$ G@!G )P ;P": '@ EP"# )4 D "3 )X D0"P )
MR ". /  C0#_ (H _P"% /\ @@#_ .<   #=    Q@   +@   "N    J  $
M *4 # "A !( H0 9 *  (@"? "D FP P )@ -P"6 #T DP!" )( 1P"0 $L
MCP!0 (T 50", %H B@!A (@ : "' '  A0![ (, B "! )8 ?P"G 'T O !\
M ., ? #] 'P _P!X /\ =@#_ -8   #     KP   *,   "9    DP   (\
M"0"-  X BP 4 (H ' "* ", B  J (4 , "# #8 @@ [ (  0 !_ $4 ?@!*
M 'P 3P![ %0 >@!: '@ 80!V &D =0!S ', @ !Q (X ;P"? &X L@!M ,\
M; #T &P _P!K /\ :0#_ ,    "K    FP   (\   "'    @    'P ! !Z
M  P >  1 '@ %P!X !X =P D '4 *@!S #  <0 U '  .@!N #\ ;0!$ &P
M20!K $X :@!4 &@ 6P!G &, 90!M &0 > !B (< 8 "7 %\ J@!> ,( 7@#I
M %X _P!> /\ 70#_ *P   "9    B@   '\   !W    <0   &T   !J  @
M:0 . &@ $@!G !@ 9P ? &< )0!E "H 8P O &( - !A #D 8  ^ %\ 0P!>
M $@ 70!. %L 50!: %T 6 !G %< <@!5 ($ 5 "1 %, HP!2 +@ 40#< %$
M^0!2 /\ 4@#_ )T   "+    ?    '$   !I    9    &    !>  4 7  +
M %L #P!; !0 6@ 9 %H 'P!9 "4 5P J %8 +P!5 #0 5  X %, /0!2 $,
M4 !) $\ 4 !. %@ 30!B $L ;0!* 'H 20"+ $@ G0!' +$ 1P#, $8 \ !'
M /\ 1P#_ )    !^    <    &8   !>    60   %8   !3  $ 4@ ( %
M#0!/ !  3P 5 $X &@!. "  30 E $P *@!* "X 20 S $@ . !' #X 1@!$
M $4 2P!$ %, 0P!= $$ : !  '4 /P"% #X EP ] *L /0## #T Y@ ] /L
M/@#_ (<   !U P  : 8  %T'  !5!@  4 8  $P$  !* 0  20 $ $< "@!&
M  X 10 1 $4 %@!$ !L 0P @ $( )0!! "H 0  O #\ -  ^ #H /0!  #L
M1P Z $\ .0!9 #@ 9  W '$ -@"! #4 DP T *8 - "[ #0 W0 T /4 -0#_
M 'X&  !M"0  8 L  %8,  !.#   2 L  $0*  !""   0 4! #\!!P ^  L
M/0 . #P $@ [ !< .P < #H (0 Y "4 -P J #8 ,  U #4 -  \ #, 0P R
M $P ,0!5 #  8  O &T +@!] "T CP L *( + "V "P T  L .X + #\ '<*
M  !G#   6@X  % .  !)#@  0PX  #X-   [#   .0L  #@) P W!0@ -@(-
M #4!$  T !, ,P 8 #( '0 Q "( ,  G "\ +  N #( +0 X "P 0  K $D
M*@!2 "D 70 H &L )P%Z "8!C  E )\ )0"R "4 R@ E .@ )0#W '(-  !B
M#@  5A   $P1  !$$0  /A$  #D0   V#P  ,PX  #$- 0 P"P4 , @* "\&
M#0 N!1$ + 04 "L#&0 J QX *0,C "@$*0 G!"\ )@4U "4%/0 D!48 (P90
M "(&7  A!VD ( =Y !\'BP >!YT '@>P !T&Q@ =!N, '07S &T.  !>$0
M4A(  $@3  ! $P  .A,  #42   Q$0  +A   "P/   J#@, *@T' "D+"P H
M"0X )PD1 "4(%@ D"!L (PD@ "())@ A"2P ( HS !\*.P >"T0 '0M/ !P,
M6P ;#&D &@QY !@,BP 8#)X %PRP !8,Q0 6#.$ %@OP &D0  !:$@  3A0
M $45   ]%0  -Q4  #$4   M$P  *A(  "@1   F$ $ )! $ ",."  C#0P
M(@P/ " ,$P ?#!@ '@T= !T-(P <#2H &PTR !H..@ 8#D0 %PY0 !8/7  5
M#VH $Q![ !(0C0 1$*  $1"S ! /R0 0#^0 $0_R &42  !7%   2Q8  $(7
M   Z%P  -!<  "\6   J%0  )Q0  "03   B$P  (!(# !X1!@ =$ D '! -
M !L/$  9$!4 &! ; !<0(0 6$"@ %1$P !01.0 3$4, $A). !$26@ 0$FD
M$!-Y  X3C  .$YX #1.Q  T2Q0 ,$N$ #1+Q &(4  !4%@  21@  #\9   W
M&0  ,1D  "P8   H%P  )!8  "$6   ?%0  '!0" !H3!  9$@8 %Q(+ !42
M#@ 4$A( $Q,8 !(3'P 1$R8 $10M ! 4-@ /%4$ #A5,  X65P -%F4 #!=U
M  L7AP *%YH "1:M  @6P0 (%MT "17N %\6  !1&   1AH  #T:   U&P
M+QH  "H:   E&0  (A@  !\8   <%P  &18! !<6 P 5%@0 $Q8) !$6#0 0
M%Q$ #Q<6  X7'  .&", #1@J  P9,P ,&3P "QI'  H:4P )&F$ !QMQ  8;
M@P %&Y< !!JJ  ,:OP #&=H !!GL %P8  !.&@  0QP  #H<   S'   +!P
M "<<   C&P  (!H  !T9   :&0  %Q@! !48 @ 2&00 $!L'  X;#  -'!
M#!P3  L<&0 *'!\ "1TG  @=+P ''CD !AY#  0>4  #'UX  A]N  $?@
M'Y4  !ZI   >O0  '=@  !WL %@:  !+'   01X  #@>   P'@  *AX  "4=
M   A'   'AP  !L;   8&P  %AL! !,; @ 1' 0 #AX'  P?"P *( X "" 2
M  8A%P %(1T !"$D  (B+  !(C4  ")    C30  (UH  "-K   C?@  (Y,
M "*G   BO   (=<  "'M %4=  !('P  /B   #4@   N(   *"   ",?   @
M'@  '1T  !H=   6'0  $QX  !$? @ .( 0 #2('  HD"P &)0T !"40  (F
M%   )AH  "8A   G*0  )S(  "<]   G20  *%<  "AG   G>P  )Y   ">E
M   FNP  )M8  "7M %$@  !%(0  .R(  #(B   L(@  )B$  "(A   >(
M&Q\  !@@   4(   $2(   \C   -)0, "B8&  8H"@ #*0T  "L/   L$@
M+!<  "P>   L)@  +2\  "TY   M1@  +50  "UD   M=P  +(T  "RD   K
MN@  *]8  "KN $TB  !!)   ."0  # D   I)   )",  "$B   =(@  &2(
M !4C   2)   #R8   TH   **@( !BP%  (N"0  +PL  # .   R$   ,Q4
M #,;   S(@  ,RL  #,V   S0@  ,U   #-@   S<P  ,HH  #*A   QN
M,-8  ##O $DE   ^)@  -"<  "TG   H)@  (R4  !\D   ;)0  %B8  !(H
M   0*@  #2P   HN   &, $  C($   T!P  -0H  #<,   X#@  .A(  #H7
M   Z'P  .B<  #HR   Z/@  .DP  #I<   Z;P  .88  #B>   XM@  -]0
M #;O $0I   Z*0  ,2D  "LI   F*   (B<  !TH   8*0  $RL  ! N   -
M,   "3(   4U   !-P   #D"   [!0  / @  #X+   _#0  01   $,4  !#
M&P  0R,  $,N  !#.0  0T<  $)7  !":@  08$  $":   _L@  /L\  #[O
M #\L   V+   +RP  "HK   E*@  'RL  !DM   4+P  $#(   TU   (.
M!#H    \    /P   $$   !# @  104  $8(  !("P  2@X  $P1  !-%@
M31X  $TH  !--   3$(  $Q1  !+9   2WL  $J4  !)K0  2,H  $?L #LP
M   S+P  +2\  "@M   B+P  &S$  !4T   0-P  #3H   @]   "0    $,
M  !&    2    $H   !,    3@$  $\$  !1!P  4PL  %4.  !8$@  61D
M %@B  !8+@  5SP  %=+  !67@  5G,  %6-  !4IP  4L(  %+F #@S   Q
M,@  +#$  "4R   =-0  %C@  !$\   ,0   !T0   !'    2@   $T   !0
M    4P   %4   !7    60   %H   !< P  7@<  &$+  !D#@  9A,  &<<
M  !F)P  9C0  &5$  !D5P  9&L  &*%  !AGP  8+D  %[< #4W   P-0
M*#<  " Z   8/0  $4(   Q&   &2@   $\   !3    5@   %D   !<
M7P   &$   !D    90   &<   !I    ; $  &X&  !Q"P  = \  '<5  !W
M(   =BT  '8]  !U3P  =&,  '-[  !RE0  <*\  &_) #4Z   K.P  (C\
M !I#   22   #$T   52    5P   %P   !@    9    &@   !K    ;@
M '$   !S    =0   '<   !Z    ?    '\   ""!   A@H  (H/  ",%P
MBR0  (HS  ")10  AUL  (9R  "%BP  @Z4  (*\ "]    E1   '$D  !-.
M   -5   !%H   !A    9@   &L   !O    =    'D   !]    @    (,
M  "%    AP   (H   ",    CP   )(   "6    F0(  )X)  "B$   HAH
M *$I  "@.P  GU   )UG  ":@0  FID  )FO "E)   ?3@  %50   Y;   %
M8@   &D   !P    =P   'T   ""    A@   (L   "/    DP   )4   "7
M    F@   )T   "@    HP   *8   "J    K@   +(   "W"@  NQ$  +H?
M  "Y,   MT4  +5<  "T=   L8X  *^D ")4   86P  $&(   =J    <P
M 'L   ""    B0   )    "5    F@   )\   "C    I@   *@   "K
MK@   +    "S    M@   +H   "]    P@   ,<   #, 0  TPL  -05  #3
M)@  T3H  -!1  #-:   RX$  ,J6 /P   #V    \@   /$   #S  4 ]  ,
M /( $P#P !P [0 E .@ +@#B #8 W@ ^ -D 1 #4 $H T0!/ ,X 5 #+ %D
MR0!> ,8 8P#$ &D P0!P +X > "\ ($ N0"- +8 F@"S *L L0#  *\ Y@"N
M /\ I0#_ )H _P"4 /\ CP#_ /0   #L    Z    .<   #?    V0 ) -(
M$ #/ !< SP @ ,P * #& #  P  W +P /@"Y $0 MP!) +4 3@"S %, L0!7
M *\ 70"M &( JP!I *D <0"G 'H I0"% *( DP"@ *( G0"V )L U "9 /D
ME@#_ (T _P"( /\ A #_ .@   #?    V0   ,D   "_    N  $ +4 #0"S
M !( L0 : +  (@"M "H J0 Q *8 . "D #T H@!# *  2 "> $P G !1 )L
M5@"9 %P EP!B )4 :0"3 '( D0!] (\ BP"- )H BP"L (D Q0"( .X A@#_
M '\ _P!Z /\ > #_ -D   #-    NP   *X   "E    GP   )P "0"9  \
MF0 5 )D '0"8 "0 E  K )$ ,0". #< C  \ (L 00") $8 B !+ (8 4 "%
M %4 @P!; (( 8@"  &L ?@!U 'P @@!Z )( > "C '< N0!V .  =0#_ '(
M_P!N /\ ; #_ ,<   "U    I0   )D   "/    B0   (4 ! "$  P @@ 1
M (( %P"" !X @  E 'X *P!\ #$ >@ V 'D .P!W $  =@!$ '4 20!S $\
M<@!5 '  7 !O &0 ;0!N &P >@!J (H : "; &< KP!F ,P 90#U &0 _P!A
M /\ 8 #_ +0   "@    D    (4   !]    =P   ',   !P  @ ;P . &\
M$@!O !@ ;P ? &T )0!K "H :0 P &@ - !G #D 9@ ^ &4 0P!C $@ 8@!.
M &$ 50!? %X 7@!G %P <P!; (( 60"3 %@ I@!7 +\ 5P#J %< _P!6 /\
M5 #_ *$   ".    ?P   '4   !L    :    &0   !A  0 8  + %\ #P!?
M !, 7P 9 %\ 'P!= "4 7  J %L +P!9 #, 6  X %< /0!6 $, 50!) %,
M4 !2 %@ 40!A %  ;0!. 'L 30", $P GP!+ +4 2@#< $H ^@!* /\ 2@#_
M )(   "     <@   &<   !?    6@   %<   !5  $ 4P ' %( # !2 !
M4@ 4 %( &@!1 !\ 3P D $X *0!- "X 3  S $L . !* #T 20!# $@ 2@!&
M %( 10!< $0 9P!# '4 0@"& $$ F !  *X 0 #+ #\ \@!  /\ 0 #_ (4
M  !T    9P   %T   !5    3P   $P   !*    2  $ $< "@!'  T 1@ 1
M $8 %0!& !H 10 ? $0 ) !# "D 0@ M $$ ,P _ #@ /@ ^ #T 10 \ $X
M.P!7 #H 8@ Y &\ . "  #< DP V *< -@#  #8 Z  V /X -@#_ 'P   !K
M    7@(  %0#  !- P  1P,  $,!  !!    /P ! #X !P ]  L /0 . #P
M$0 \ !8 /  : #H 'P Y "0 .  I #< +@ V #, -0 Z #0 00 S $D ,@!3
M #$ 7@ P &L +P![ "X C@ M *( +0"X "T W0 M /@ +@#_ ',!  !D!0
M5P<  $T(  !&"   0 @  #L'   X!0  -P,  #8 !  U  @ -  , #0 #P T
M !( ,P 6 #( &P Q "  ,  D "\ *0 N "\ +0 V "P /0 K $4 *@!/ "D
M6@ H &< )P!W "8 B0 F )T )0"S "4 SP E /  )@#_ &T&  !>"0  4@L
M $@,  ! #   .@L  #8+   R"@  , @  "X& @ N P8 +0 * "P #0 L !
M*P 3 "H %P I !P *  @ "< )0 F "L )0 R "0 .0 C $( (@!+ "( 5P A
M &0 ( !S !\ A0 ? )D '@"N !X QP > .D 'P#Z &@)  !9#   30T  $,.
M   \#@  -@X  #$-   M#0  *@P  "@+   G"00 )@8( "8$"P E PX ) $0
M "0!%  B 1@ (0$= "$ (@ @ "@ 'P N !X!-@ = 3\ ' %) !L!5  : 6$
M&@%P !D!@@ 8 )8 & "J !@ P0 8 .$ & #T &,,  !5#@  20\  $ 0   X
M$   ,A   "T/   I#@  )@X  ",-   B# , ( L& " )"0 ?!PP '@8. !X%
M$0 <!14 &P4: !H%'P :!24 &04K !@%,P 7!CP %@9& !8&4@ 5!U\ % =N
M !,'@  2!Y0 $@:G !(%O  2!-D $@/O %\.  !1#P  1A   #P1   U$0
M+Q$  "H1   F$   (A   " /   =#@( ' T% !H-!P :"PH &0H- !@)$  7
M"1( %@D7 !4)'  4"2( % HI !,*,0 2"CH $@M% !$+40 0#%\ #PQN  X,
M@  .#)0 #0NG  T+N@ -"M( #0KJ %P/  !.$0  0Q(  #H3   R$P  +!,
M "<2   C$0  'Q$  !P0   :$ ( & \$ !8.!P 5#@D % T+ !,,#0 2#!
M$@P4 !$,&@ 1#2  $ TH  \-,  .#CL #0Y&  T.40 ,#UX "P]M  H/?P )
M#Y, "0^F  @.N0 (#M  !P[H %@1  !+$@  0!,  #<4   P%   *10  "44
M   A$P  '1(  !H2   7$0( %1$% !,0!P 2$ D $0\* ! .#  .#@X #@\2
M  T0&  -$!X #! E  P0+0 +$38 "A%!  D130 ($EH !Q)J  82?  %$I
M!!*D  ,1N  #$<\  A'H %42  !)%   /A4  #46   M%@  )Q8  "(5   >
M%   &Q0  !@3   5$@, $Q(% !(1!P 0$0D #Q$*  T1"P ,$@X "Q(1  H2
M%0 )$QL "1,B  @3*@ '%#, !10^  052@ #%5@  A5G  $5>@  %8X  !6C
M   4MP  %,\  !/I %(4  !&%@  .Q<  #(7   K%P  )1<  "$6   <%@
M&14  !84 0 4$P0 $A,& !$2"  /$@@ #A,)  P4"@ *%0T "!80  86$P %
M%AD !!<?  ,7)P "&#   1@[   91P  &54  !ED   9=P  &8P  !BB   8
MMP  %\\  !?J $\6  !#&   .1D  # 9   I&0  (QD  !\8   ;%P  &!8
M !45 @ 3%04 $10& ! 4!@ .%0< #!8(  H7"@ '&0P !!H.  (;$@ !&Q8
M !L=   <)   '"T  !PX   =1   '5(  !UB   ==0  '8H  !R@   <M@
M&]   !KK $P8  ! &@  -AL  "T;   F&P  (1H  !T9   9&0  %Q@  !07
M P 2%@0 $!<$  X7!  ,&04 "AH'  <<"0 #'0L  !\-   @$   (!0  "$:
M   A(@  (2H  "$U   B00  (D\  ")?   B<@  (8@  "&?   @M@  ']$
M !_M $@:   ]'   ,QT  "L=   D'0  (!P  !P;   8&@  %AD! !,9 0 1
M&0$ #AH!  P< @ *'0, !Q\%  ,A"   (@H  "0,   F#@  )A(  "88   G
M'P  )R<  "<R   G/@  )TL  "=<   G;@  )H4  ":=   EM   )-$  "/N
M $0=   Y'P  ,!\  "@?   C'@  'AT  !L<   8&P  %!P  !$<   .'0
M#1\   HA   &(@$  R0$   F!@  * @  "H+   K#0  +1   "T5   M'
M+20  "XN   N.@  +D@  "U8   M:@  +8$  "R:   KL@  *M   "GO $ @
M   V(0  +2$  "8A   A(   '1\  !H>   6'@  $A\   \A   -(@  "B0
M  8F   "*    "L"   M!   +P8  # )   R#   - X  #42   U&   -2
M #4J   U-@  -4,  #53   T9@  -'P  #.6   RKP  ,<T  ##O #PC   R
M)   *B0  "0C   @(@  '"$  !<A   3(P  $"4   TG   )*0  !2L   $N
M    ,    #(    T 0  -@0  #@&   Z"0  / T  #X0   ^%   /AP  #XF
M   ^,0  /C\  #U.   ]80  /'<  #N1   ZJP  .<D  #CM #<G   O)P
M*"8  ",E   ?)   &24  !0F   0*   #2L   DN   %,    #,    U
M.    #H    \    /@$  $ #  !"!P  1 H  $8-  !)$0  21<  $@A  !(
M+   1SH  $=)  !&6P  17$  $2+  !#I0  0L,  $'H #0J   L*@  )R@
M "(G   <*   %BH  !$M   -,   "3,   ,V    .0   #P    ^    00
M $,   !&    2    $H   !, P  3@8  % *  !3#@  5!,  %0<  !3)P
M4S0  %-#  !250  46H  %"#  !/G@  3;D  $S@ # M   K+   )BL  !\L
M   8+@  $C(   TU   (.0   CT   !     0P   $8   !)    3    $X
M  !1    4P   %4   !7    60$  %P&  !?"@  8@X  &,5  !C'P  8BP
M &$\  !@3@  7V(  %Y[  !<E@  6[   %G/ "\P   J+P  (C   !HS   3
M-P  #CL   @_   !1    $@   !,    3P   %(   !5    6    %L   !=
M    8    &(   !D    9@   &D   !M!0  < L  '00  !T&   <R4  '(T
M  !R10  <%D  &]Q  !MBP  :Z8  &K  "XS   E-0  '3@  !0\   .00
M!T<   !,    40   %4   !9    70   &$   !E    :    &L   !M
M;P   '(   !T    =P   'H   !^    @@0  (8+  "*$0  B1P  (@K  "&
M/0  A%(  (-G  "!@0  ?YL  'ZR "DZ   @/0  %D(   ](   (3@   %0
M  !:    8    &0   !I    ;@   '(   !V    >@   'T   "     @@
M (4   "(    BP   (X   "2    E@   )L#  "@#   HA,  * A  "?,P
MG4<  )I>  "8=P  EX\  )6G "-#   92   $4X   E5    7    &,   !J
M    <0   '8   ![    @    (8   "*    C@   )$   "3    E@   )D
M  "<    H    *,   "G    JP   +    "V!   O T  +H7  "Y*   MSP
M +12  "R:@  KX4  *V< !Q.   35   "UP   %D    ;    '0   !\
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M^_S^______________________________________________________\
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M________________________________________
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M_O]M9G0Q      ,$(0   0                    $
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MI9>2YJ67DN:EEY+FI9>2YJ67DN;:RPD;Z,T..NG,$&#<R Z2R[HRK,:W4+3
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M@*/2K("CTJR H]*L@*/2K("CTJR H]*L@*/2K("CTJR H]*L@*/2K("CTJR
MH]+_N1,._[D<)_^V*$;WL#1JW:A D,>=8+'$G'&VPIQ\NK^>A;Z\G(C"NIF(
MQ;B5B<FVD8K,M(Z,S[*+CM&QB)'3L(:4U:^$F=:O@Y_7JH*AU:>"HM.G@J+3
MIX*BTZ>"HM.G@J+3IX*BTZ>"HM.G@J+3IX*BTZ>"HM.G@J+3IX*BTZ>"HM/_
MN1,._[D<)_^V*$;WL3-JW:D_D<>=8+'$G7"VPIY[NK^?@[Z\GHC"N9N(Q[>7
MB,JUE(G.LY"+T;&-C=.OBI#6KHB3V*V&F=FJA9[9I82AU:2$HM2DA*+4I(2B
MU*2$HM2DA*+4I(2BU*2$HM2DA*+4I(2BU*2$HM2DA*+4I(2BU*2$HM3_NA(.
M_[H;)_^W)T;WL3)JW:D^D<>>7['$G6^VP9]YNKZ@@K^[H(C#N)R'R+:9B,RS
MEHC0L9**TZ^/C-:NC([8K(J3VZN)F=RFAYW:HH:@UJ"&HM2@AJ+4H(:BU*"&
MHM2@AJ+4H(:BU*"&HM2@AJ+4H(:BU*"&HM2@AJ+4H(:BU*"&HM3_NA(._[H;
M)O^W)D;VLC%JW:H]D<>>7K'$G6^VP:!XNKZA@;^[H8C$N)Z'R;6;A\VRF(C1
ML)6)U:Z2B]BLCXW;JHV2WJB,FM^BBIW:GHF@UIR)H=2<B:'4G(FAU)R)H=2<
MB:'4G(FAU)R)H=2<B:'4G(FAU)R)H=2<B:'4G(FAU)R)H=3^NA$._[L:)O^X
M)D;VLC!JW:H\D<>>7;'$GFZVP:%VNKZB?[^[HXC$MZ"'RK2=A\^QFH?3KIB(
MUZR5BMNJDXW>J)&2XJ20F>">C9W;FHR@UYF+H=69BZ'5F8NAU9F+H=69BZ'5
MF8NAU9F+H=69BZ'5F8NAU9F+H=69BZ'5F8NAU9F+H=7^NQ$._KL:)O^X)4;V
MLS!JW*L[DL>?7;'$GVRVP:)TNKZD?K^ZI(?%MZ*'RK.?A]"PG(?5K9J(V:J9
MBMZHF([BI9>3YI^5F>":D9S;EX^?UY:.H=66CJ'5EHZAU9:.H=66CJ'5EHZA
MU9:.H=66CJ'5EHZAU9:.H=66CJ'5EHZAU9:.H=7]NQ$._KL:)O^Y)4;VLR]J
MW*LZDL>?7+'$H&JVP:-SNKZE?,"ZI87%MJ.'R[.AA]&OGX?6K)Z)VZB<B]^D
MFHWAGYF/XYR:F.&7EIS<E).?V).2H-:3DJ#6DY*@UI.2H-:3DJ#6DY*@UI.2
MH-:3DJ#6DY*@UI.2H-:3DJ#6DY*@UI.2H-;]NQ$-_;P9)OZY)$;VM"YJW*LZ
MDL>@7+'$H6BVP:5QNKZG>L"ZIX3%MJ:'S+*DA]&NHH?7J9^(VZ2=B=Z@FXK@
MFIJ,X9:;D^&5FYO=DI>>V)&5H->1E:#7D96@UY&5H->1E:#7D96@UY&5H->1
ME:#7D96@UY&5H->1E:#7D96@UY&5H-?\O! -_;P9)OZZ(T;VM"UJW*PYDL>@
M6['$HV:UP:9NNKZI>,"ZJ8+%MJB(S+"EA]*JHH?7II^'VJ&>A]R;G8C>EIR*
MWY&;D-^1G9G=CYN>V8^9G]>/F9_7CYF?UX^9G]>/F9_7CYF?UX^9G]>/F9_7
MCYF?UX^9G]>/F9_7CYF?UX^9G]?\O! -_+P8)OVZ(D7VM2QJW*TWD\>A6K'%
MI6.UPJEKNKZL=;^ZK7_%LZF'S*VEAM*GHH;6HJ&&V)V?AMJ8GH?;DIV)W8Z=
MC=V,GI3<C:">V8R>G]>,GI_7C)Z?UXR>G]>,GI_7C)Z?UXR>G]>,GI_7C)Z?
MUXR>G]>,GI_7C)Z?UXR>G]?[O1 -^[T7)?V[(D7VMBMJVZTVD\>B6;'%IU^U
MPJUFN;^Q<+ZWK7[&L*F'S:JFAM&DI(74GJ*%UIFAA=B4H(;9CY^'VHN?B]N(
MGY#;B*"8V(BAG=>(H9W7B*&=UXBAG=>(H9W7B*&=UXBAG=>(H9W7B*&=UXBA
MG=>(H9W7B*&=UXBAG=?ZO0X-^KX6)?R\($7VMRIJVZ\TE,BD5;'&JUBTP[-?
MM[NR;K^RK7['K*F&S*:GA="@I832FZ2$U):CA-61HH76C:&&UXFAB=B&H8W8
MA*&3UX2BE]:$HI?6A**7UH2BE]:$HI?6A**7UH2BE]:$HI?6A**7UH2BE]:$
MHI?6A**7UH2BE];YO@X,^;\5)?J]'T7VN"=JV[ QE,BH3:_'LDZRP;A8N+2Q
M<,&MK7_'J:J%RZ*HA,Z=IX/0EZ:#T9*EA-*.I(73BZ.&U(BCB-6$HXO5@J.0
MU8&CD]6!HY/5@:.3U8&CD]6!HY/5@:.3U8&CD]6!HY/5@:.3U8&CD]6!HY/5
M@:.3U8&CD]7TP T,]\ 3)/F_'43VNB5JVK(NE<JO0*W(O3VOM[9=NJZQ<L*I
MK7_&I:N%R9^J@\N9J8/-E*B#SI"GA,^,IH70B::&T8:EA]*$I8K2@:6-TH"E
MC]* I8_2@*6/TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/TH"EC]* I8_2@*6/
MTH"EC]+LP0L,]<(2)/;!&D3WO2%JVK0IELV\**F[NT.SKK5AO*BQ<\&EKG_%
MH:V$QYNL@\F6JX/*D:J$RXZIA,R+J87-B*B&SH:HA\Z#J(G.@:>,SX"GC<^
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MBK*'P(BRB,"&L8C!A;&)P82QBL&"L8O!@;&,PH"QC,* L8S"@+&,PH"QC,*
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ME7*PQ95]M<.7A;C!EXN[OY.,O;Z/CL"\C(_"NXF2Q+J&E,6Y@Y;&N8&9Q[B
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MT82BH]'_MQ$'_[@:'/^V)3G_L3%:ZJL\?M>L.YG*K42MR;E%KKVX6;BRLF_
MK*Y^QJBKA<JAJ83-FZ>#SY6F@]"/I832BJ2&TX:CB-2#HXS4@:.1U("DF=.
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MAY++M(.7SK. G="R?Z31K'ZESZA^I\RD?ZG)H8"LQJ& K,:A@*S&H8"LQJ&
MK,:A@*S&H8"LQJ& K,:A@*S&H8"LQJ& K,;_K1@%_ZTC%O^K,2__IC]+^*!-
M9^>=58'9G%R7RIEHK,6:<K3#G'JXP)R#N[Z<B;^[EXG#N9.+Q[>.C<NTB9#.
MLH26T;&!G=.L@*+3IX"ET*2 I\V@@:G*GH&KQIZ!J\:>@:O&GH&KQIZ!J\:>
M@:O&GH&KQIZ!J\:>@:O&GH&KQIZ!J\;_K1@%_ZTB%O^K,2__IS]+^*%,9^>>
M4X'9G5F7RIMEK,6<;[3#G7BXP)Z!O+V>B,"[FHC$N)6)R;60B\VRBX_1L(:5
MU:Z$GM>G@J'4HX*DT9^"I\V<@ZG*FH.KQYJ#J\>:@ZO'FH.KQYJ#J\>:@ZO'
MFH.KQYJ#J\>:@ZO'FH.KQYJ#J\?_K1<%_ZXB%O^K,"__ISY+^*%+:.>?48'9
MGU:7RIQBK,6=;+3#GW6XP*!^O+V@A\&ZG8C&MYB(R[.3B<^PCHW4K8F4V:B&
MG=JBA:'5GH6DT9N%ILZ9A:G*EX6KQY>%J\>7A:O'EX6KQY>%J\>7A:O'EX6K
MQY>%J\>7A:O'EX6KQY>%J\?_KA<$_ZXB%O^L,"__ISY+^*)+:.BA3X'9H%.7
MRIY?K,:?:;3#H7*XP*)\O+VBA,&YH(?'M9R'S;*7B-*NDXO8JHZ3WZ*+G-R<
MB:#6F8BCTI>(ILZ5B*G*E(BKQY2(J\>4B*O'E(BKQY2(J\>4B*O'E(BKQY2(
MJ\>4B*O'E(BKQY2(J\?_KA<$_ZXA%O^L+R__J#U+^*)*:.BB38#9HE"7RZ!<
MK,:A9;/#I&ZWP*5XO+RE@L*XI(?(M*"'SK"=B-6KF8K=I9>3YIN1F]V6CZ#7
ME(VCTY*,IL^1BZC+D(JKR)"*J\B0BJO(D(JKR)"*J\B0BJO(D(JKR)"*J\B0
MBJO(D(JKR)"*J\C_KA8$_Z\A%O^M+R__J#Q+]Z)):.BD2H#9I$V6RZ)8J\:D
M8;/$IVJWP*ETO+RI?L*XJ(?(LZ:'SZRBA]>DG8G=FIJ-X96:F]Z1E9_8CY.B
MTXZ0I=".CZC,C8ZJR8V.JLF-CJK)C8ZJR8V.JLF-CJK)C8ZJR8V.JLF-CJK)
MC8ZJR8V.JLG_KQ8$_Z\A%O^M+B__J3Q+]Z-):>BF2'_:ITB5S*53JL>H7++$
MK&2VP:YNN[VO>,"VK(3)KJ>'T*:CAM6=H(;9DYV)W8V=E-V-G9_8BYFAU(N6
MI-"*DZ?-BI&IR8J1J<F*D:G)BI&IR8J1J<F*D:G)BI&IR8J1J<F*D:G)BI&I
MR8J1J<G_KQ4$_[ @%O^N+B__J3M+]Z1':>FH1'[;JT.4S:E,J<BM5+#&LURS
MPK=FN;>P=\*PJX3)J:>&SZ&DA-.7HH36CJ"'V8B?C]J'H9K8AZ"AU(>;I-&'
MF*;.AY6IRH>5J<J'E:G*AY6IRH>5J<J'E:G*AY6IRH>5J<J'E:G*AY6IRH>5
MJ<K_L!4$_[ @%?^N+2__JCI+^*9$:.JK0'W<KSR2SZ]"ILJU2:W&O%*QN;5G
MN["P>,.KK(3)I*F$S9RF@]"3I(33BZ.&U86BC-:"HI36@Z2=U(.BI-&#GJ;.
MA)JHRX2:J,N$FJC+A)JHRX2:J,N$FJC+A)JHRX2:J,N$FJC+A)JHRX2:J,O_
ML!0$_[$?%?^O+"[_JSE+^*E 9^NO.WO>MC./TKHTH<S".:J[NE6UL+1JO:JP
M><.GK83'GZJ$RYBH@\V0IX30B:6&TH2DBM. I)#3?Z67TG^FH-!_I:;.@*"H
MRX"@J,N H*C+@*"HRX"@J,N H*C+@*"HRX"@J,N H*C+@*"HRX"@J,O_L1,$
M_[(>%?^P*R[_K#=,^JP[9>VU-'CBORF)V,P@F+Z_/:ZPN%FXJ;-LOJ6P>L*B
MKH3%FZR#R)2JA,J.J83,B*B&SH.GB<^ IXW/?J>3SWRHFLY\J:+-?*>HRWRG
MJ,M\IZC+?*>HRWRGJ,M\IZC+?*>HRWRGJ,M\IZC+?*>HRWRGJ,O_LA($_[,=
M%?^Q*2[_K39,_+$U8O&]*G+FS1^ R,PAF[&\1;*HMUZYH[-OOJ"Q>\&>KX3#
MEZZ$QI&LA,>,JX7)AZJ'RH.JB<N JHS,?:F0S'RJE<MZJIS*>:NDRGFKI,IY
MJZ3*>:NDRGFKI,IYJZ3*>:NDRGFKI,IYJZ3*>:NDRGFKI,K_LQ$$_[0;%/^S
M)B[_KS-,_;DK7>O*'VG2WQ%_N<PGG*>]3+&@MV*YG;1QO9NR?+^:L83!E+"$
MPX^OA<6*KH;&AJV'QX.LB<> K(O(?JR.R'RLDLA[K)?(>:V>QWFMGL=YK9['
M>:V>QWFMGL=YK9['>:V>QWFMGL=YK9['>:V>QWFMGL?_M1 #_[89%/^U)"W_
MM"Q)\L4?5-;=$F+!WQ.!K,TNFI_ 3ZN:N&6WE[5RNY:T?+V5LH._D;&%P8VQ
MAL*)L(?#AJ^(PX.OB<2!KXO$?ZZ-Q7VND,5[KI3%>J^9Q'JOF<1ZKYG$>J^9
MQ'JOF<1ZKYG$>J^9Q'JOF<1ZKYG$>J^9Q'JOF<3_MPX#_[@6$_^W("WYOQ]!
MW-D11,3K$F:QWQB!H- SE9?&4*.3P&.MD;MQLY&X>[B0MH*[CK2%O8NSAK^(
MLH? AK*)P(2QBL&"L8O!@+&-P7ZQC\)\L9+">[&5P7NQE<%[L97!>[&5P7NQ
ME<%[L97!>[&5P7NQE<%[L97!>[&5P7NQE<'TN@L#_;L2$OZ[&RSET \RR.D/
M2K3R%6>BXB)]EM8WC8_.3YB,R&&@BL1NIHK!>*J'OWVMA+Z L(&\@K%_NX2S
M?;N%M'NZA[5ZN8FU>;F+MG>YC;9VN(^W=+B3MW2XD[=TN).W=+B3MW2XD[=T
MN).W=+B3MW2XD[=TN).W=+B3MW2XD[?<O@8"^, .$>[(#B++VPLNMO@13*7U
M'6.7Z"QUC=\]@8?84(N#TV"2@L]LEW_-<YM\RW>=><EZH'?(?:%UQW^C<\:"
MI'+%A*5PQ8:E;\2(IF[$BJ=MPXVG:\.0J&O#D*AKPY"H:\.0J&O#D*AKPY"H
M:\.0J&O#D*AKPY"H:\.0J&O#D*C7P 8!V\8(#LO3"A6XZ PRIO\52ICZ)ER-
M\#=IA>E&='_D4WM\WV"!>-QHA73:;8EPV'&+;M9UC6S5>(]JU'N0:=-^D6?3
M@))FTH.39=*%E&31AY1CT(J58M".EF+0CI9BT(Z68M".EF+0CI9BT(Z68M".
MEF+0CI9BT(Z68M".EF+0CI;1P@8!S<L)!;K:!QFH_@XQF?\=0X[_+U&%^C]<
M?O1-9'GP6&IS[%]O;>IC<VGG:79GY6YY9>1R>V/C=GUBXGE^8.%\?U_@?H!>
MWX&!7=^#@ES>AH-;W8F$6MV-A5K=C85:W8V%6MV-A5K=C85:W8V%6MV-A5K=
MC85:W8V%6MV-A5K=C87+Q 8 N]$&!ZGG!AJ:_Q,KCO\D.87_-D1^_T1->?]1
M57'[5UMK]UU@9?1B9&+R:&=?\&UJ7>]Q;%OM=6U:[7AO6>Q[<%CK?G%7ZH%R
M5NJ$<E7IAW-4Z8IT4^B.=5/HCG53Z(YU4^B.=5/HCG53Z(YU4^B.=5/HCG53
MZ(YU4^B.=5/HCG6\R04 J]L!")K_"Q:/_QDCA?\K+7[_.3=X_T9 </].1VG_
M5$UB_UI27OYA5EK\9EE8^VM;5?EP753X=%Y2]WA?4?=[8%#V?F%/]8%B3_6$
M8T[TAV1-](ME3/.09DSSD&9,\Y!F3/.09DSSD&9,\Y!F3/.09DSSD&9,\Y!F
M3/.09DSSD&;_H!@#_Z(L$/^@.R7_G$D\_Y=74_B29&?LD&QYXH]UB=F.?I?1
MC8>BS(R-JL>*D;'$B)2VPX66N,*#F;G"@9NYP7^>NL%]H;O!>Z2[P'JGN\!Y
MJKS >*Z\P'>TN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BT
MN[QXM+O_H!@#_Z(L$/^@.R7_G$D\_Y=74_B29&?LD&QYXH]UB=F.?I?1C8>B
MS(R-JL>*D;'$B)2VPX66N,*#F;G"@9NYP7^>NL%]H;O!>Z2[P'JGN\!YJKS
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M5?>96FGKF5Y\WY=ECM25;YW+E'FKQ9."M,24BK?"D8ZYP(R0O+^(D[Z]A)?
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M?*?-J7VIRJ5^J\>B?ZW$GW^OPIV L;^=@+&_G8"QOYV L;^=@+&_G8"QOYV
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MRYJ#JLB9@ZW%EX2OPI:$L,"6A+# EH2PP):$L,"6A+# EH2PP):$L,"6A+#
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M]R!@H>HK<Y7?.8*-UTR-B-%=E8;,:IN$R72@@,9YI'W$?:9ZPH"I=\&#JG7
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M\)=A=.>6:(+>DW*/UI%[FM"/A*/+C8RKQXJ1L<2&E;;#@YFXP7^>NL%[I+O
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M6D;[DUM%^IA<1?J87$7ZF%Q%^IA<1?J87$7ZF%Q%^IA<1?J87$7ZF%R]O0,
MK<T! )[?  &2_PT(A_\9$G[_*1MU_S4C;/\\*F3_0R]>_THT6/]0-U3_5CI1
M_UL\3O]@/DO_9$!*_VA!2/]L0D;_<$-%_W1$1/]X14+_?49!_X%'0/^&2#__
MC$D]_Y%*/?^12CW_D4H]_Y%*/?^12CW_D4H]_Y%*/?^12CW_D4JNQ0  GM<
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MOJRW=+ZMLG6^K*YVOZRJ=K^KJ'? JJAWP*JH=\"JJ'? JJAWP*JH=\"JJ'?
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M:Y)XS7>:<,B"H6K%CJ5FPYNH9<.LIV'"O:ICN+^K9K"_K&FJOZQLI;^K;:+
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M<^YGGW?L9:5YZV2J>^IBKWWI8;5^Z&"]?^A?Q8#H7M"!XE_:@-MAWH#28M^
MRV/?@<IDWX'*9-^!RF3?@<IDWX'*9-^!RF3?@<IDWX'_>!0"_W4?!/]V,0W_
M=$(:_WI,)_]_533_@%U _WYE3/]Z;E;^=G=?^72!9O5PBFWQ;9%R[FN8=NQI
MGGGK9Z1\Z66I?NACKX#G8K:"YF&]@^9@QX3E7].$W6':A--CW8/,9-R$QF7<
MA,5EW(3%9=R$Q67<A,5EW(3%9=R$Q67<A,5EW(3_>10!_W8> _]W, W_=D(:
M_WY+)_^"4S3_@UQ _X)D3/]_;%;]>G1@^'=_:/-SB&_P<(]T[6V6>>IKG7SH
M:*-_YV:I@N5EKX3D8[:%Y&*_A^-AR8?@8=6'U63:A\UEVHC'9MF(P6?9B+]G
MV8B_9]F(OV?9B+]GV8B_9]F(OV?9B+]GV8C_>A0!_W@> _]Y, W_>$$:_X%)
M)_^&4C/_B%I _X=B3/^#:5?\?G%A]WM[:?)WA7'N<XUWZW"4?.AMFX#F:J*#
MY&BHAN-FKXCB9+>*X6/!B^%BSHO89-:+S6;6B\9GUHS :-:,NVG6C+IIUHRZ
M:=:,NFG6C+IIUHRZ:=:,NFG6C+IIUHS_>Q,!_WD= _]Z, W_?#\:_X5()O^*
M4#/_C%A _XM?3/^(9U?\A&YA]G]X:O%[@G+M=XIYZ7.2?N9OF8/D;*&'XFJH
MBN!GKXS?9;B.WF3$C]MDTH_.9]./QFC3D+]JTY"Z:].0M6S3D+1LTX^T;-./
MM&S3C[1LTX^T;-./M&S3C[1LTX__?!,!_WH= _][, W_?SX:_XE&)O^/3C+_
MD58__Y!=2_^.9%;\B6MA]H1S:_!_?G/L>X=ZZ':0@>1REX;A;I^*WVNGCMUH
ML)#<9KN2VV7*D]!HT9/&:M"4OFO0E+ALT)2S;="4KV[1DZYNT9.N;M&3KF[1
MDZYNT9.N;M&3KF[1DZYNT9/_?1(!_WL< _]\+PW_@SP9_XU%)?^333'_E5,^
M_Y192O^28%7]CVA@]HIP:O"$>73K?X-\YGJ,@^)UE8C?<9Z-W6VGD=MIL939
M9[^6U&?.E\=KS9B];,V8MF[-F+!OS9BL<,Z7J7'.EJAQSY:H<<^6J''/EJAQ
MSY:H<<^6J''/EJAQSY;_?A(!_WP< _]^+PW_ACL9_Y%#)/^62S#_F% \_YA5
M2/^67%3]DV-?]X]K:?"*='/KA']\YGZ)A.%XDHO=<YR0VFZFE=AJLYG6:,6;
MR6O+F[UNRIRT;\J<KG'*G*IRRYNF<\N:HW/,F:)TS9BB=,V8HG3-F*)TS9BB
M=,V8HG3-F*)TS9C_?Q(!_WT; _]_+PW_B3H8_Y1"(_^91R__FTP[_YQ21O^;
M6%+_F5]=^)5F:/&0;G+KBGE[Y8.$A.!\CXS<=IJ3V&^FF=)KM9W.:LB?OF[(
MG[-QQZ"L<L>@IW3(GZ-UR9Z@=LJ=GG;+FYUVRYJ==LN:G7;+FIUVRYJ==LN:
MG7;+FIUVRYK_@!$!_WX; _^ +PW_C#@8_Y= (O^<1"W_GTDY_Z!.1/^@54_\
MGEM:]9QB9>Z7:F_HD71YX8I_@]F#BHS/>Y65R'6@G,-PKJ&^;[^CLW+%HZIT
MQ:.D=L6CH'?&H9UXQZ";>,B>F7G*G9AYRIR8><J<F'G*G)AYRIR8><J<F'G*
MG)AYRIS_@!$!_W\; _^!+PW_CS<7_YH_(?^?0BS_HD8W_Z1,0O^D4DSWI%A7
M[Z-?8>>@9FO@FG%UU9-\@<N*A8W#@H^6NWN:GK5VIZ2P=+BGJ';"IZ%XPZ:=
M><2EFGK%HYA[QJ*6>\>@E'O)GI1\R9V4?,F=E'S)G91\R9V4?,F=E'S)G91\
MR9W_@1$!_X ; _^"+@[_D386_YP\(/^A0"K_I40T_ZA*/_JI4$GRJE92ZJI=
M7.*I9F;7HF]RRYEX@<&0@8VXB(J7KX&5H*A\HJ:C>K*IGGK!J9E\P:B6?<.F
ME'[$I))^Q:.1?L>AD'[(GY!^R9Z0?LF>D'[)GI!^R9Z0?LF>D'[)GI!^R9[_
M@A$!_X$; _^$+@W_E#46_YXZ'O^D/BC_J$(R_ZQ'._:O343ML51-Y;-;5=RP
M96'.J&QQPY]T@+B6?(VNCX:8I8B1H9V#G:>7@*VKDX"_JY&!P:F/@<*GCH'#
MI8V!Q:.-@<:BC('(GXR!R)^,@<B?C('(GXR!R)^,@<B?C('(GXR!R)__@A$!
M_X$: _^&+0W_EC05_Z Y'?^F/";_JT O^[!%./*T2S_IN5-&X;U<3=.V8F#&
MK6EPNZ5Q?["=>8REE8*7FX^-H9.*F:>,AZFKB(>_K(B'P*J(AL*HB(7#IHB%
MQ:2(A,:BB(3(H(B$R)^(A,B?B(3(GXB$R)^(A,B?B(3(GXB$R)__@Q !_X(:
M _^(*PS_F3(4_Z(W&_^I.23_KSTL][5",^V[23GEPE(^VL)83,RZ8%^_LF=O
MLZMN?JBC=HN=G'Z7DI>)H(F2EJ>"CZ6K?H^ZK("-P*J!B\*H@HK#IH.)Q:2#
MB,:BA(?(H(2'R)^$A\B?A(?(GX2'R)^$A\B?A(?(GX2'R)__A! !_X,: _^+
M*@S_G#$2_Z4T&O^L-B'^LSHH\[M +>G#2#'ARU$WTL=62\7 7EVXN&5NK+%L
M?:"J<XJ4I'N5BI^&GH";DJ5YF**J=)BWJW>5P:EZD<*G?(_#I7V-Q:-^C,:A
M?XK(GW^*R)]_BLB??XK(GW^*R)]_BLB??XK(GW^*R)__A1 !_X0: _^.* O_
MGS$1_Z<R%_^P,QWYN38B[L(])N;-1R;;TTPUR\Q42;[%7%NQOF-LI+AJ>IBR
M<8>,K'F3@:B"G'>DCZ-PHI^G;**TJ&Z?PJ=RF<.F=97$I'>2QJ)XD,>A>H[(
MGWJ.R9YZCLF>>H[)GGJ.R9YZCLF>>H[)GGJ.R9[_AA !_X49 _^1)@K_H2\/
M_ZLN%?^U+QGTOS(<Z<LZ'-_91!W1VDHSQ-)21[?+6EFIQF%IG,!G>)"Z;H2$
MMG:/>;* F&^OC9]HK9VC9*VRI&6JQ:1JHL6C;9W&HG"9QZ%RELB?=)/)G763
MRIUUD\J==9/*G763RIUUD\J==9/*G763RIW_AP\!_X<9 _^5) G_I"L-_Z\I
M$?J[*1/LR"P3WM@W$-/A01[)WTDPO-I11*_36%:AS5]FE,AE=(C$;(!\P'2*
M<;U_DVF[C)EBN9R=7KJQGEVXR9YBKLB?9J;(GVFAR9YKG<J=;IK+FVZ9RYMN
MF<N;;IG+FVZ9RYMNF<N;;IG+FVZ9RYO_B \!_XD9 _^:(P?_J"<*_[4B#/'$
M( S@U20)T>$P%,?F/22]XT8TLN!.1*;<5E*9UUUAC-)C;X#/:WITS'.$:\I^
MBV+(C)%<R)R56<BQEE?(SI9;N\V87K+,F6&KS)EDILV99Z+-F&>@S9=GH,V7
M9Z#-EV>@S9=GH,V79Z#-EV>@S9?_B@X!_XL8 _^?(07_KB &^+T8!N/1$P30
MX1X)Q>HN&;KI.BFPYT,YI.1*2)CB4%:,X%=B@-U?;';;:'5LVG)]8]A^@US8
MC(A7V)V+5->PC538S8Q5R]./5\#2D5JXT9-<LM&37ZS1DV"JT9-@JM&38*K1
MDV"JT9-@JM&38*K1DV"JT9/_C X!_X\6 O^E'@/_M14#VLH+ M#A#@+$ZQX-
MN.\L':WN-RZB[$ ]E^M(2HSI3U:!Z%9@=N=>:6SG97!DYG!W7N-\?%G@B8!6
MWI>#4]VFA%'<N(51W=2$4]#:AU3&V(E6O]>*6+C6BUFVUHM9MM:+6;;6BUFV
MUHM9MM:+6;;6BUFVUHO_C@T _Y<2 ?^M%0'9OPD S,X) ,/K#@2V]1X1J_4L
M(:'T-S"6\T ^B_-(2H'S4%1W\U==;?-=9&7P9FI?[7!N6NIZ<E;GA793Y9%Y
M4>2>>T_CK'Q-X[U\3>/9?%#8X'Q1SN!_4L;>@5/$WH%3Q-Z!4\3>@5/$WH%3
MQ-Z!4\3>@5/$WH'_D@P _Z - -NW!@#*PP< P-() +7T$ :I^Q\4G_PL(Y3\
M-S&*_$$]@?U)1WC]45!N_5=79?I>7&#V9F%;]&]E5O%X:%/O@FM0[HQM3NR7
M;TSKHW%*ZK!R2>K!<DCJV')+X^1R3MCF<T[5YW1.U>=T3M7G=$[5YW1.U>=T
M3M7G=$[5YW3_E@H WJP" ,NZ!0"]QP8 LM@( :?_$@B<_R$6DO\N(XG_.2^
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M.#+_G#DQ_Z0Z,/^O.S#_LCLP_[([,/^R.S#_LCLP_[([,/^R.S#_LCNPN
MH,<  )'8  "$[P  ?/\- 6__$0-F_QD&7O\A"E;_*0]0_S(32_\Z%D;_01E"
M_T@;/_].'3S_4QXY_UD@-_]>(37_9"(S_VDC,?]P)"__=R4M_WXF+/^')RK_
MCR@I_Y<I*/^@*BC_HRHH_Z,J*/^C*BC_HRHH_Z,J*/^C*BC_HRJAP@  D=$
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M"_^K,!#ULS04Z[LZ%^+$1!C5Q$@KR+U3/;RV6TZQL&-=IJIJ:IRD<7:2GWJ
MB9J#B8&6CI!YDYR5=)*LEW&2PYASD<^6=H[0E'B+TI%YBM.0>HC5CGN'UHQ[
MA]:,>X?6C'N'UHQ[A]:,>X?6C'N'UHS_>!(!_W8; _^(&P/_FB4&_Z8K"?ZO
M+ SQN2\.YL,V#]W-/!;.R$<IPL)1.[:\64RJMF%;G[!H:)6K;W2+IG=^@:*
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M[=!I2.;H:4O9ZVI,S^QM3L?K;T_ ZG!/P.IP3\#J<$_ ZG!/P.IP3\#J<$_
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M53O^X54\^?!50/#T54/G]U1#Y_=40^?W5$/G]U1#Y_=40^?W5$/G]U3;H0
MQ;   +6Z @"HQP( G=8$ )/\#@&+_QT&@_\K#WK_-1=Q_SP?:/]")F#_22Q9
M_T\Q4_]6-4[_73A)_V4[1?]M/4'_=C\^_X!!._^+0SG_F$4X_Z1&-O^R1S7_
MQ$@U_]U)-/_P23?^^$DW_OA)-_[X23?^^$DW_OA)-_[X23?^^$G)JP  MK0
M *C!  ";SP  CM\! (?_$0%^_QT$=?\G"VS_+Q)D_S<87/\^'5;_12)0_TLE
M2_]2*$;_6"M!_U\M/O]G+SO_;S$X_W@S-O^"-#/_C38Q_YDW,/^E."__LCHN
M_\ [+O_3.RW_ZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/"W_ZSRXL   J+P  )K)
M  ",V0  @?4# 'G_$ %N_Q8#9?\?!E[_)PM7_S /4?\W$TO_/A=&_T490?],
M&SW_4ATY_U@?-O]?(33_9B(Q_VXD+_]W)2W_@"8K_XPH*?^7*2C_HBHG_ZTK
M)O^Y+";_R2TF_\DM)O_)+2;_R2TF_\DM)O_)+2;_R2VJMP  FL4  (O3  !]
MX@  =?\% &G_# %?_Q$"5_\7 U#_'P5)_R8'1/\N"3__-@L[_ST--_]##S/_
M21$P_T\2+O]5$RS_6Q0J_V(5)_]I%B7_<A<C_WL8(?^&&1__D1H>_YP;'O^E
M'!W_L!T=_[ ='?^P'1W_L!T=_[ ='?^P'1W_L!V<P   C,X  'S>  !P]0
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M8DO(\F9-O_%H3[CP:5&R\&E2K^]I4J_O:5*O[VE2K^]I4J_O:5*O[VG_?PH
M[98  -*F 0#$L@, N;P# +#)!@"IV H H><9 IGG*@F0YS<4A^9"'WWE2BET
MY%$S:^-9.F3B84%>XFM'6.)U2U/A@$]/XHU32^*;54GCK%='Y,171N/I5T;=
M]EE'T/=<2<CW7DK!]F!+O?9@2[WV8$N]]F!+O?9@2[WV8$N]]F#_B0  V9X
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M.3'__SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.3/\_SG!J   K[$  **]  "4R@
MA]@  'WS!P!V_Q(!;?\: V7_) 5>_RT*6/\V#U+_/1-,_T462/],&4/_4QL_
M_UH>//]A(#C_:2$U_W(C,?]])2[_BB8K_YDH*?^G*2?_N2LF_](L)?_O+"3_
M_RTD__\M)/__+23__RTD__\M)/__+23__RVQK@  H[D  )3&  "&TP  >>$
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M3T7"_U!'N_]21[O_4D>[_U)'N_]21[O_4D>[_U+FB@  SYL  +^G  "RL
MI[L  )S& P"3T08 B^H. (7H'P)^Z"T&=N@X#F[H019FYTH=7^=2(UGG6RE5
MYV0M4.=M,4SG>#5)YX0X1NB1.D/HH#Q Z;(^/^K+/C[H[SX]YO\_/>#_0C_7
M_T1 SO]&0,[_1D#._T9 SO]&0,[_1D#._T;6DP  Q*,  +2L  "GM@  F\$
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M'R+__Q\B__\?(O__'R+__Q^LJP  G;8  (_"  " S@  <]P  &?I  !?_P8
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M18\N_T29,/]"HC/_0:LT_T&T-O] O3?_/\DX_S_;./\_ZCG_/_4Y_S__.?M
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M5U6:_597EOY66)7^55B5_E58E?Y56)7^55B5_E7_;P0 YH(  -*1  #&G0
MNZ8! +*N  "JMP$ HL(% )S$& "5PRH$C<(Y#87 1!A]ODXA=;Q6*FZZ7C)H
MN68X8K=N/EVV>$-8M8)'5+2/2U"TG4Y-LZY02[3%4$NSZE!*L?]13*O_4DZE
M_U)0H?]249[_45&>_U%1GO]149[_45&>_U'_=@  W8D  ,J7  "^H@  LZH
M *FS  "@O ( F,8& )',$@"+S"4"A,LT"7S)0!)UR$H;;<=3(V?%7"IAQ&0P
M7,-M-E?"=CI3PH$_3\&.0DO!G45(P:Y&1\'%1D?!ZD9$OO])1;G_2D>S_TM)
MK?],2JO_3$JK_TQ*J_],2JO_3$JK_TSI?P  T9   ,*>  "UIP  JJ\  *"X
M  "6P0( C,L' (35#0" U1X!>=4N!7+4/ QLTT<49=)0&U_162%:T6(G5=!K
M+%'0=3!-SX$T2<^.-T;/G3E$T*X[0M#&.T/0ZCI S?T^/LO_0$##_T)!O?]#
M0KG_1$*Y_T1"N?]$0KG_1$*Y_T3=B   QY@  +BC  "KJP  H+0  )6^  "+
MR , @-$' 'CA#0!TX1T!;N$K VC@-PAAX$(.7.!-%%?@5AE3X%\=3^!I(DO@
M<R5'X'XH1."+*T+@FBT_X:LO/N+!+S[BY2\\W_HQ.=[_-#G9_S8ZT/\X.\S_
M.3O,_SD[S/\Y.\S_.3O,_SG-D@  O*   *VH  "AL0  E;L  (G%  !^SP(
M=-H& &[K$0!HZQX!8NLJ UWL-097[#\+4NQ(#TWL41-*[5H61NUC&4/M;1Q
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M"A/__PJ:L0  B[T  'S(  !MU   7^   %'F  !']0  0?\  #S_"0 W_Q
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M5GQOZU1\</]2>W#_4'MO_TY[;_]->V[_2WMN_TM[;O]+>V[_2WMN_TO_5Q$
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M4&6!_T]F?_]-9W[_3&=^_TQG?O],9W[_3&=^_TS_80H _V\  .!^  #0B0
MQI,! +^; P"XH0( L:8+ *JH'@&CIR\%FZ4]#Y2B2!F,GU$BA9Q9*W^:83)Y
MF&DY=)5Q/V^3>41JDH-(99".3&&/FT]>CJI26XZ]4EJ.WE);C?A07(O_3UZ(
M_TY@A?],88/_2V&#_TMA@_]+88/_2V&#_TO_9 4 ]70  -J"  #+C@  P9<
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M1$V<_T1-G/]$39S_1$V<_T3J=0  TH8  ,.3  "WG0  K*0  **K  "8LP
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M("WB_R"ZF@  JJ,  )VK  "0M   @[T  '?&  !KSP  7]8  %3>! !1\!
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M!!'_DP00_Z<$#_^]!0[_X 4.__8%#O__!0[__P4.__\%#O__!0[__P65KP
MAKH  '?%  !HT   6ML  $SA  ! YP  -_,  #+_   N_P< *O\. ";_$P C
M_QH '_\@ !O_)@ 8_RL!%?\R 1+_. $0_T !#O]( 0S_4@$)_UT"!O]K @3_
M?0("_Y " ?^C @#_M@( _\T# /_L P#_[ , _^P# /_L P#_[ .(N0  >,0
M &G0  !;W0  2^,  #[I   R[@  *_\  ";_   A_P  '?\( !K_#0 6_Q$
M$_\6 !#_&@ ._Q\ "_\D  G_*@ &_S   O\W 0#_0 $ _TH! /]6 0#_9 $
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M0Y!=Z$./7OQ!CE__0(M?_SZ*7_\]B%__/(A?_SN(7_\[B%__.XA?_SO_3A$
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M1')P_T)R;_]!<F[_/W)N_SYR;O\^<F[_/G)N_S[_5@H _V(  .9O  #7>0
MS($! ,6' P"_BP0 N8X. +*0( &KCS$%I(P_#9V*2A:6AU,>D81<)8N!9"R&
M?VLQ@GUS-GY[?#MZ>88_=G>00G)VG$5O=:E(;'6Z26MUU$EK=?)':W7_16QU
M_T-M<_]!;7+_/VUR_S]M<O\_;7+_/VUR_S__60< _V4  .)R  #1?   QX0
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M/EV _SY=@/\^78#_/EV _S[_8@  Y'$  ,]^  ##B   N9$  +"7  "GFP
MGJ$  )BC$P"3HR4!C:(T!H:A0 V GTH5>9U3''2;6B-OF6(H:IAJ+F:6<C)A
ME7PW792&.EF2DSY6DJ% 4Y&R05*2R4)2D>M!4I#_0%*/_S]5B_\^5HC_/5>'
M_SU7A_\]5X?_/5>'_SWY9P  W78  ,F#  "]C0  LY4  *F;  "@H   EJ<
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M,D&F_S+5?   PHH  +66  "HG0  G:,  )*J  "'L0  ?+<  '"^ P!HP@X
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M#2[AO XMXN .+=[X#RO=_Q(JW/\4*=K_%BC:_Q8HVO\6*-K_%BC:_Q:SF
MI:   )FG  "+L   ?K@  ''   !ER   6<X  $[3  !$VP0 /^D- #WI%P [
MZB, .>HN #;K. $TZT(!,>Q+ B_M50,M[5\#*NYK!"CN> 4F[X@&)>^:!R/P
MK@<B\<@'(O#M!R'L_P<AZ_\((.O_"A_J_PL?ZO\+'^K_"Q_J_PNHGP  FZ8
M (VO  !_N   <<$  &3*  !8T   3-8  $'=   XY   -?8, #/W%  P]QX
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M 0#_L@$ _\H! /_J 0#_\P$ __,! /_S 0#_\P&$MP  =,$  &7,  !6V
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M*JQ+ZRNI2_PLIDO_+*5,_RNC3/\JGTW_*IU-_RF=3?\IG4W_*9U-_RG_0Q$
M_TL, /]3" #_6@L _UX- /E@$ #K818 X6(A -9B,0'.84$%QU]."\)<61&]
M6F07N5AM&[96=A^S57XBL%.'):Y2CRBK49@JJ5"B+*=0K"VE3[DOHT_++Z!0
MYB^>4/DPG%#_+YI1_RZ84?\MEE+_+)12_RN44O\KE%+_*Y12_RO_1A  _TX)
M /]6!0#^7@8 [V(' .=E"@#D9@X UF<9 ,UH+0'%9ST%OV5*"[EC51*T8%\7
ML%YI'*Q<<2&I6GHDIEF"**18BRNA5I0MGU6=+YQ5J#&:5+0SF%3%,Y94X323
M5?8SDE7_,I%6_S&/5O\PC5;_+HQ7_RV,5_\MC%?_+8Q7_RW_20X _U$% /]:
M 0#N8@  WV<# -AJ!@#5:PH S6T5 ,5N*0&^;3D$MVM'"[%H4A&L9EP8J&1E
M':1B;2*A8'4FGEY^*9M=ABV87(\OE5J9,I-9I#206; VCEG -HQ9VS>*6?,V
MB5K_-(A;_S.'6_\QAEO_,(5;_R^%6_\OA5O_+X5;_R__2PP _U0  /M>  #B
M90  V&L! ,]N!0#,< @ QG(2 +YS)@&W<S8$L7!$"JMN3Q&F:UD8H6EA'9UG
M:B*997(GEF-Z*I-B@RZ08(PQC5^5-(I>H#:'7JTXA5V\.8-=U#F"7O X@5__
M-H!?_S2 7_\S?U__,7Y?_S!^7_\P?E__,'Y?_S#_30D _U8  .YA  #=:0
MT6\  ,IS P#%=08 P'80 +AX(P"Q>#,#JW9!":5S3!"?<%87FVY?'99L9R*3
M:F\GCVAW*XQG?R^)98@RA622-8)CG3> 8JHY?6*Y.GMBSSMZ8NXY>F/_.'IC
M_S9Y8_\T>6/_,GEB_S%Y8O\Q>6+_,7EB_S'_3P< _UD  .9D  #7;   S',
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M-&EN_S-I;O\S:6[_,VEN_S/_5@  ZV(  -AN  #)=@  OWT  +>"  "PA0
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M,5*$_S'J90  TG,  ,)_  "VB   K)   **4  "8F   C)P  (2?"@" H!D
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M(CZMN2,]K=@B/:OU(SRI_R4[I_\F.Z;_)CND_R8[I/\F.Z3_)CND_R;,>@
MNX@  *Z2  "BF0  EYX  (RD  " J@  =:\  &FT  !>N08 6[H4 %F[) !6
MNS$!4[L] U"[1P5-NU '2KI9"D>Z8@U$NFP00;IW$SZYA!4\N9,7.;FC&#BY
MMQDWNM89-[CT&C6V_QPTM/\>,[/_'S.R_R SLO\@,[+_(#.R_R#!@P  M)$
M *:8  ";G@  CZ4  (*K  !VL0  :[8  %^\  !4P0, 3,4- $O%&0!)QB@
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M AKF_ (9Y?\#&>3_!!CC_P48X_\%&./_!1CC_P6CG0  EJ0  (BL  !ZM0
M;+T  %_$  !3R@  1\X  #S3   RV@  *M\  "7N"0 C\!$ (?$9 !_Q(@ =
M\BL &_,T !GT/@ 7]$@ %?52 !/V7P 2]FX!$?>  1#XE $/^:H!#OG& 0[Y
M[0$-]O\!#?3_ 0WS_P$-\_\!#?/_ 0WS_P&9HP  BZP  'RU  !MO@  7\8
M %+-  !%T@  .=@  "_>   FX@  '^H  !S[!@ 9_PX %_\3 !3_&@ 2_R$
M$/\H  [_,  -_SD "_]#  G_3@ &_UP !/]L  +_@  !_Y8  /^M  #_R@
M__   /__  #__P  __\  /__  #__P"-JP  ?;4  &Z_  !@R   4M   $/7
M   WW0  *^(  "+F   9Z@  %?D  !+_   0_P@ #O\.  S_$0 )_Q8 !O\<
M  /_(@  _RH  /\S  #_/0  _TD  /]7  #_:0  _WX  /^5  #_K   _\<
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M#<XT\ _*-/T2QS3_$\4T_Q3#-/\5PS/_%< T_Q6_-/\4OS3_%+\T_Q3_-A4
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M))5,_R243/\CDTS_(I%-_R&13?\AD4W_(9%-_R'_0@H _TD  /]1  #F5P
MW5L! -5<!0#26PD RUP4 ,->* "\7C@"MEU&!K%;40JM65L/J5AD$Z96;!>C
M570:H%1]'9Y3A1^;4HXBF5&7))=0H2:54*TGDE"\*)%0T"B.4.PHC5'^)XM1
M_R:+4?\EBE+_)(E2_R.(4O\CB%+_(XA2_R/_10< _TL  /!5  #?6P  TV
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M*'5>_R9U7O\F=5[_)G5>_R;_2P  \%4  -Y?  #-9P  PVP  +MO  "U<
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M*&!N_RCQ50  WF(  ,IM  "]=0  LWL  *N   "B@@  F($  )&##P"-A1\
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M*4V&M"I+ALPJ2X7N*4R$_RE,@_\H3(/_)TV!_R9.@?\F3H'_)DZ!_R;A8P
MR7   +M[  "PA   IHH  )N.  "1D0  A),  'J5 @!UEQ( <I@B &^8, )J
MESL$9I=%"&*63@Q?E58/6Y1=$UB391=5DVX:49)X'4Z1A"!+D)$C29"A)$>0
MLB9%D,HF18_M)46-_R5%C/\E1HO_)$:*_R1&BO\D1HK_)$:*_R38:0  PW8
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M$#&P_A(PKO\4+ZW_%2^L_Q8OK/\6+ZS_%B^L_Q:[@0  KHX  *&5  "6F@
MB:   'VF  !QJP  9:\  %FT  !.MP  0[P% $"]$0 _O1X /KXK #R^-@ [
MOT$ .;]+ 3>_5 (UP%\",\!J!#' =P4OP(8&+<"7!RO J@@JP<((*L#G!RF]
M_0HHO/\,)[K_#2>Y_PXGN?\.)[G_#B>Y_PZRC   I90  )F:  "-H0  ?Z<
M '*M  !FLP  6K@  $^[  !$OP  .L0" ##)"  NRA$ +<H= "S+*0 KRS4
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M  /M_P #[?\  ^W_  /M_P"5H0  AJD  'BR  !IN@  6\(  $W(  ! S
M--$  "K6   AVP  &>   !+D   /\ $ #?D*  OZ#P )^Q4 !_L<  3\)  !
M_"P  /PW  #\0@  _%   /QA  #]=0  _(P  /RD  #\P0  _.L  /S_  #]
M_P  _?\  /W_  #]_P")J0  >;(  &J[  !<Q   3LP  #_1   RUP  )]T
M !WA   5Y0  #N@   KQ   (_0  !?\#  '_"0  _PX  /\2  #_%P  _Q\
M /\G  #_,0  _SX  /]-  #_7P  _W4  /^-  #_I@  _\(  /_G  #__
M__\  /__  #__P!\LP  ;+P  %W&  !.SP  /]8  #'=   EX@  &N8  !'J
M   ,[@  !?(   #_    _P   /\   #_    _P4  /\*  #_#@  _Q(  /\8
M  #_(0  _RL  /\Y  #_2@  _UT  /]S  #_C   _Z0  /^Y  #_U   _]X
M /_>  #_W@#_&"P _QDI /\9* #_%2L _Q P /\+. '_ T0!_P!1 ?\ 7@'_
M &P!_P!X ?\ @@'_ (P!_P"4 ?\ G #_ *( _P"H /\ KP#_ +8 _P"^ /\
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M ?\*>@'_"H0!_PJ- ?\*E '_"IL!_PJB ?\*J '_"J\!_PJW ?\*P #_"LP
M_PK@ /L*[P#W"OH ]0O_ ?4,_P'T#?\!] W_ O0-_P+T#?\"] W_ O0-_P+_
M(B( _R0= /\D' #_(AT _QXB /\<+ #_&3@ _Q9% ?\34@'_$EX!_Q!J ?\0
M=0'_$'\!_Q"( ?\0D '_$)<!_Q"> ?\0I0']$*P!_!"S ?H0O0'Y$<D!]1'=
M ?$1[0'N$?D![!+_ NL3_P+J$_\#Z1/_ ^D3_P/I$_\#Z1/_ ^D3_P/_)AT
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M#[$T_P^P-/\0KS3_$*XT_P^N-/\/KC3_#ZXT_P__-0X _S@' /\\ @#_0 8
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M&H5,_QF%3/\9A4S_&85,_QG_0   _$<  .50  #55@  RED  ,):  "]6 ,
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M'6I>_QWY2@  XU4  ,]?  #!90  MVH  *]L  "G;   GVH! )EK$0"4;2(
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M)%ILLB59;,<E6&SH)5EL_2-9:_\A6FO_'UMK_QY;:O\>6VK_'EMJ_Q[K4P
MTV   ,)I  "V<0  K'8  *-Y  "9>0  C7<  (=Y"P"#>Q@ ?WPH 'M\-0)W
M>T %<WI)"&]Y40QL>%D/:'=A$V5V:!9B=7 97W1Z'%QTA1]:<Y$A5W*@(U5R
ML"13<L4D4W+G)%-Q_")4<?\@5'#_'U5P_QY5;_\=56__'55O_QWE5P  S60
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M&T&(^1M!AO\;087_&T*%_QI"A/\:0H3_&D*$_QK-9P  O'0  *]^  "EA@
MFHH  (Z,  ""C0  =9   &>4  !AE0@ 7I<4 %R7(P!:F"\ 5Y@Z 5281 -2
METP%3Y=4!TR77 E)EF4,1Y9O#D25>A%!E8@3/Y27%3V4J!8[E+T6.Y3?%CJ2
M^!<ZD/\7.H__%SJ._Q<ZCO\7.H[_%SJ._Q?%;@  MGL  *J%  ">BP  E(\
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M!B&S_P<ALO\'(;+_!R&R_P>MB@  H)$  )67  "(G0  >Z,  &ZH  !AK0
M5;$  $JT   _MP  -+L  "N^ P DP@P (L(4 "+#'P APRH (,0T !_$/P >
MQ4H '<96 !S&8P ;QW, &L>% !G'F0 8R*X %\C+ !?&\0$7Q/\!%L/_ A;!
M_P,6P?\#%L'_ Q;!_P.CD0  F)@  (N>  !]I0  <*L  &*Q  !6M@  2KD
M #Z]   TP   *L0  "+(   9S 0 $] * !'2$0 0TAH $-,E  _3,  .U#P
M#M1(  W55@ -U64 #-9X  S6C0 +V*0 "MB^  G9Y@ *UOX "]3_  O2_P +
MTO\!"]+_ 0O2_P&:F   CI\  ("F  !RK0  9+0  %>Z  !)OP  /<(  #+&
M   HR0  '\T  !?1   1U@  #-L%  C>"P &WQ$ !=\:  3@)  "X2X  >(Z
M  #C1P  Y%8  .1G  #E>P  YI(  .:J  #GR   Y_   .C_  #H_P  Z/\
M .C_  #H_P"1GP  @J<  '2O  !EMP  5[X  $G#   \QP  ,,L  "7/   <
MU   %-D   [=   )X0   N4   #I!@  Z0T  .D1  #J&   ZR$  .TK  #O
M-P  \44  /)6  #S:   \WX  /27  #UL   ]M   /?S  #W_P  ]_\  /?_
M  #W_P"%IP  =K   &:X  !8P0  2L@  #O,   NT0  (]8  !G<   1X
M#.,   3G    Z@   /4   #T    ]04  /4+  #V#P  ]A0  /@=  #Z)P
M_#0  /]#  #_50  _VD  /^!  #_F@  _[(  /_/  #_[0  __D  /_Y  #_
M^0!XL   :+H  %G#  !+RP  .]$  "W8   AW0  %N(   [F   (Z@   .T
M  #P    ^    /\   #_    _P   /\   #_!@  _PP  /\0  #_&   _R(
M /\P  #_0   _U,  /]I  #_@0  _YD  /^O  #_PP  _]4  /_5  #_U0#_
M$R@ _Q,E /\1)0#_#2< _P8M /\ -0#_ $$ _P!/ /\ 7 #_ &D _P!T /\
M?@#_ (@ _P"0 /\ EP#_ )T _P"D /\ J@#_ +  _P"W /\ P #_ ,P _P#?
M /\ [ #_ /@ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_%B4
M_Q8B /\4(0#_$", _PHH /\ , #_ #T _P!+ /\ 6 #_ &0 _P!P /\ >@#_
M (0 _P", /\ DP#_ )H _P"@ /\ I@#_ *T _P"T /\ O #^ ,@ _0#9 /L
MZ0#Z /8 ^0#_ /@ _P#X /\ ^ #_ /@ _P#Y /\ ^0#_ /D _P#_&B( _QH>
M /\8'0#_$QX _PXB /\*+ #_!SD _P-& /\ 4P#_ &  _P!K /\ =@#_ '\
M_P"( /\ CP#_ )8 _P"= /\ HP#^ *D _ "P /H N0#W ,0 ]0#2 /, Y@#R
M /0 \0#_ /  _P#O /\ [P#_ .\ _P#P /\ \ #_ /  _P#_'AT _QX9 /\<
M%P#_%Q@ _Q,> /\1* #_#C0 _PQ! /\*3@#_"%L _P=F /\&<0#_!GH _P:#
M /X&BP#\!I( ^@:9 /@&GP#V!J8 ] :M /(&M0#P!<  [07. .L%Y #I!O,
MY@C_ .4*_P#D"_\ Y O_ >0+_P'D"_\!Y O_ >0+_P'_(1@ _R$3 /\@$0#_
M&Q( _QP: /\:) #_%B\ _Q,\ /\120#_$%4 _ YA /D.:P#V#G4 ] Y^ /(.
MA@#P#HX [@Z5 .T.FP#K#J( Z@ZJ .@.LP#F#[T Y0_, .$/XP#=$/, V1'_
M =82_P'4$_\!TQ/_ M(3_P+2$_\"TA/_ M(3_P+_)1, _R40 /\D#0#_(PX
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M"YPU_PN<-?\+G#7_"YPU_PO_,P( _S4  /8Z  #E/@  W$   -0]! #2-PD
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M$G=,_Q+_/@  Z$<  -50  #&5@  O%@  +19  "M5@  IU,' *%4%0"<5B4
MF%<T 9170 *05TH$C593!HI56PF'5&,+A%1J#H)3<A" 4GH2?5*#%'M1CA9X
M4)D8=E"F&710M1IS4,D:<5#H&G!1_!AP4?\7<%'_%7!1_Q1Q4/\3<5#_$W%0
M_Q/U0   Y$L  ,]4  #!6@  MUT  *]>  "G6P  H5@# )M9$@"66R( DEPQ
M 8Y</0**7$<$AUM0!H-:6 F!66 ,?EEG#GM8;Q!Y5W<3=E: %716BQ=R5989
M;U6C&FU4LAML5,8;:E7F&VI5^QEJ5?\7:E7_%FI5_Q5K5?\4:U7_%&M5_Q3R
M0P  WT\  ,M8  "]70  LV$  *MB  "B8   FUP  )5>$ "08!\ C&$N (AA
M.@*$8$4$@6!.!GY?5@E[7ET+>%UE#G9<;!!S7'03<%M]%6Y:B!=K6I09:5FA
M&V=9L!QE6<,<9%GC'&19^AID6?\89%G_%V59_Q5E6?\495G_%&59_Q3O1@
MVE(  ,9;  "Z80  L&4  *9F  "=8P  E6$  (]B#@"+9!P AV4K (-E-P%_
M94(#?&1+!GAC4PAU8UL+<V)B#G!A:A!M8'(3:V![%6A?AA=F7I$98UZ?&V%=
MKAQ@7<$<7UWA'%]=^!I?7?\87UW_%V!=_Q9@7?\58%W_%6!=_Q7K2@  U%8
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M&DYL]!E/:_\83VO_%U!J_Q90:O\54&K_%5!J_Q7=50  Q6$  +=J  "L<0
MHG4  )1T  ")=   ?',  '9U  !Q=Q  ;W@= &QY*P!I>3<!9GE  V-Y205@
M>%$'77=8"5MW8 Q8=F@.575Q$5)U?!-0=(@63727%TMSIAA)<[D92'/5&4ER
M\QA)<?\72G'_%DIP_Q5+</\42W#_%$MP_Q346@  P&8  +-O  "H=@  G7D
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M#S6(_P\VA_\/-H?_#S:'_P^^;0  L'D  *6"  "9AP  C(@  '^(  !RB@
M9HT  %J1  !0E0  29<) $>8$P!%F"  1)DK $.9-@!!FD  0)I( 3Z:40(\
MFEH".IID S>:;P4UF7T&,YF,!S&9G0@OF; (+IG*""Z8[0@NEO\*+93_"BV3
M_PLMDO\++9+_"RV2_PNV=0  JH$  )Z(  "3C0  AHX  'B/  !KD@  7Y4
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M 1"Z_P&?CP  E)4  (>;  !YH0  :Z<  %ZL  !2L0  1;0  #JV   ON0
M);P  !V_   5PP  #\8%  O*#0 )RA0 ",H=  ?*)P 'RC( !LL^  7+2P $
MS%H  \QJ  +,?@ !S)0  ,RK  #-R   S.T  ,S_  #+_P !RO\  <K_  '*
M_P"7E@  BIP  'RC  !NJ@  8+   %*V  !%N0  .;P  "Z_   CPP  &\8
M !/*   -S0  "-$   '4"0  U X  -45  #6'@  V"<  -DQ  #;/@  W$L
M -U;  #>;@  WH0  -^;  #?M   WMD  -_W  #?_P  W_\  -__  #?_P"-
MG0  ?Z4  '"L  !ALP  4[H  $6_   XP@  +,8  "')   8S0  $-$   O5
M   $V@   -X   #@ 0  X0D  .(.  #D$P  Y1L  .<D  #I+P  ZSP  .U+
M  #N70  [G$  .^)  #PH@  \+P  /#C  #O^0  \/\  /#_  #P_P"!I0
M<JT  &.U  !4O0  1L0  #?(   JS   ']   !75   .V@  !]X   #B
MY@   .D   #J    [    .X%  #O#   \1   /,7  #U(   ^"L  /LY  #]
M2@  _EX  /]T  #_C0  _Z8  /_   #_X0  __4  /_U  #_]0!TK@  9;<
M %;   !'R   .,T  "K2   =V   $]T   SB   #Y@   .D   #L    \
M /,   #T    ]@   /@   #Z    _0<  /\-  #_$@  _QL  /\H  #_-P
M_TH  /]>  #_=@  _X\  /^F  #_N@  _]$  /_1  #_T0#_#R0 _PXB /\+
M(0#_ R0 _P I /\ ,@#_ #X _P!, /\ 60#_ &4 _P!P /\ >@#_ (0 _P",
M /\ D@#_ )D _P"? /\ I0#_ *L _P"R /\ N@#_ ,4 _P#3 /\ YP#_ /0
M_P#_ /X _P#_ /\ _@#_ /X _P#^ /\ _@#_ /X _P#_$2$ _Q > /\-'0#_
M!Q\ _P C /\ +0#_ #H _P!( /\ 50#_ &$ _P!L /\ =@#_ '\ _P"' /\
MC@#_ )4 _P"; /\ H0#_ *< _@"N /T M@#\ ,  ^P#- /D X@#X /  ]P#\
M /8 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /4 _P#_%1T _Q,: /\0&0#_"QD
M_P = /\ *0#_ #8 _P!# /\ 4 #_ %P _P!G /\ <0#_ 'H _@"# /P B@#Z
M )$ ^0"7 /@ G0#W *, ]0"J /0 L@#R +L \0#( .\ W #N .P [0#Z .L
M_P#J /\ Z@#_ .H _P#J /\ Z@#_ .H _P#_&!D _Q85 /\3$P#_#A, _PL:
M /\') #_ C  _P ^ /\ 2P#_ %< _P!B /P ; #X '4 ]0!^ /( A0#Q (P
M[P"3 .X F0#L *  ZP"F .D K@#G +< Y@## .0 U #B .D X0#W -\ _P#=
M /\ W0#_ -T _P#= /\ W0#_ -T _P#_&Q, _QH0 /\6#@#_$@X _Q(5 /\/
M'P#_#"L _PDX /\&10#[ U$ ]P)< /("9@#N G  Z@)X .<"@ #F X< Y ..
M .(#E0#A YP WP2C -T$JP#;!+0 V 7  -8%T #3!N< T CX ,X*_P#,"_\
MRPS_ ,L,_P#+"_\ RPO_ ,L+_P#_'Q  _QX+ /\:!P#_&0L _Q@1 /\6&0#_
M$B0 ^A P /,./@#N#4H Z0Q6 .4,80#B#&H W@US -L->P#9#8, U@V* -0-
MD0#2#9D T Z@ ,\.J0#-#K, RPZ_ ,H/T #&$>D PA+Y +\3_P"]$_\!O!/_
M ;P3_P&\$_\!NQ/_ ;L3_P'_(@P _R$$ /\@  #_(04 _Q\, /\<$0#V&!P
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M!XHU_P?_+P  \C0  .(\  #200  QT(  ,!   "[.@$ MC8. + Y' "J.RP
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M#W9&L!!U1L(0<T;@$')']P]Q1_\.<4?_#7%'_PQQ1_\+<4;_"W%&_POS.0
MX$0  ,Q,  "^40  M%,  *I2  "B3@  G4H! )=+$0"332  CT\N (Q/.@&(
M3T4"A4]. X-/5@2 3ET&?DYD!WQ-; EY370+=TQ]#'5,APYS3)(/<4N?$6]+
MK1)M2[\2;$O<$FM,]1%J3/\/:DS_#FI+_PUJ2_\,:DO_#&I+_PSP/0  VT@
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M%%E8\!-96/\16EC_$%I8_PY:5_\-6E?_#5I7_PWC2   RU,  +M;  "P80
MI&(  )=A  ".7P  A5P  ']>!P![7Q, >&$A '5B+@!R8CD!;V)# FQA2P-J
M85,%9V%:!V5@8@EC8&H+8%]S#5Y>?0];7HD165V6$E==I1-57;845%W.%%1=
M[A-47?\155S_$%5<_PY56_\.5EO_#59;_PW>3   QU8  +A?  "M9   H&4
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M#D5K_PU%:O\-16K_#45J_PW+6   NF,  *UL  "A<0  DG   (5O  !Z;P
M;G   &5S  !@=0< 7782 %MW'P!9>"L 5W@V %5X/P%3>$@"47A/ T]W5P1,
M=U\%2G=H!TAV<PE%=G\+0W6-#$%UG0X_=:X./G7%#CUUZ X^<_T-/G+_#3YQ
M_PP_<?\,/W#_##]P_PS%7@  M6D  *EQ  "<=0  C70  (!T  !U=   :78
M %YY  !8? $ 5'T. %)^&@!1?R8 3W\Q $V .P!,@$,!2H!+ DA_5 )&?UP$
M0W]E!4%_< 8_?GP(/'Z*"3I^F@HY?JP+-W[#"S=]Y@LW>_P+-WK_"S=Y_PHX
M>/\*.'C_"CAX_PJ^9   L&\  *5X  "6>0  AWD  'MY  !P>@  9'P  %B
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M!2>,_P6Q=   I7X  )F%  "*A   ?80  &^%  !CB   6(L  $V/  !#DP
M.I<  #*:!P NFQ  +9L: "R<)  KG"X *ITX "F=00 HG4L )YY5 ":>80 E
MGFX (YY^ 2*>D $@GJ,!'YZY 1Z>W0$>G/@"'IK_ AZ9_P,>E_\#'I?_ QZ7
M_P.J?0  GH4  ).+  "%B@  =8L  &B.  !;D0  4)4  $:9   [G0  ,J
M "JC   BI@D 'Z<1 !ZG&@ =J"0 '*@M !NH-P :J4$ &:E, !BI6  7JF8
M%JIV !6JB0 4JIX $ZNT !*KTP 2J/4 $Z?_ 1.E_P$3I?\!$Z3_ 1.D_P&C
MA@  EXP  (V1  !]D@  ;94  &"8  !4G   2*   #ZD   TIP  *JL  "&N
M   9L0  $K,'  ^U$  .M1< #K4A  VU*P -M38 #+9!  NV3@ *MEP ";9L
M  BV?P 'MI0 !K:J  6VQ0 &MNH ![7_  BT_P (L_\ ";+_  FR_P":C0
MD),  (28  !TG   9:   %>D  !+J   0*P  #6P   JLP  (;4  !BX   1
MNP  #+X"  ; "P "P!$  <$9  #!(@  PBL  ,(V  ##0@  PU   ,1?  #$
M<0  Q(<  ,2=  #$M0  Q-H  ,3V  ##_P  P_\  ,/_  ##_P"3E   AYH
M 'B@  !JI@  7*P  $^Q  !!M0  -;<  "FZ   ?O0  %L   !##   *Q@
M \H   #,!0  S P  ,T1  #.&   SB$  - J  #1-0  TT,  -12  #48P
MU7@  -6/  #5IP  UL(  -;I  #6_0  UO\  -;_  #6_P"*FP  >Z(  &RI
M  !>L   4+8  $*Z   TO0  *,$  !W$   4QP  #<L   ;.    T@   -<
M  #9    V@4  -P+  #=$   WQ4  .$=  #C)P  Y3,  .="  #H5   Z&<
M .E^  #IEP  ZJ\  .K.  #K[P  Z_X  .O_  #K_P!]HP  ;JL  %^R  !1
MN@  0L   #3#   GQP  &\L  !+/   +TP   M@   #=    X0   .0   #E
M    YP   .D   #K!P  [0T  .\1  #Q&0  ]"0  /<Q  #Y00  ^E4  /IJ
M  #[A   ^YT  /RV  #\T@  _>T  /WT  #]] !QK   8;4  %*]  !$Q
M-,D  ";-   :T@  $-@   C=    X0   .4   #H    [    .\   #Q
M\P   /4   #W    ^0$  /L(  #^#@  _Q4  /\A  #_+P  _T$  /]6  #_
M;0  _X<  /^@  #_M@  _\H  /_4  #_U #_"R  _P<> /\ '0#_ "  _P E
M /\ +@#_ #L _P!) /\ 5@#_ &( _P!M /\ =@#_ '\ _P"' /\ C@#_ )0
M_P": /\ H #_ *8 _P"M /\ M0#_ +X _P#+ /\ X0#_ /  _@#] /T _P#]
M /\ _0#_ /T _P#\ /\ ^0#_ /D _P#_#1T _PL: /\$&0#_ !H _P ? /\
M*@#_ #< _P!% /\ 40#_ %X _P!H /\ <@#_ 'H _P"" /\ B0#_ )  _P"6
M /\ G #^ *( _ "I /L L #Y +D ^ #& /8 V0#U .L ] #Y /, _P#R /\
M\P#_ /, _P#S /\ \P#_ /, _P#_$!D _PX5 /\(% #_ !0 _P 9 /\ )0#_
M #( _P!  /\ 3 #_ %D _P!C /X ;0#\ '4 ^@!] /D A #W (L ]@"1 /0
MEP#S )X \@"D /  K #N +0 [0#  .L SP#I .8 Z #U .8 _P#G /\ Y@#_
M .4 _P#E /\ Y0#_ .4 _P#_$A0 _Q 0 /\,#P#_ Q  _P 5 /\ ( #_ "P
M_P Z /\ 1P#Z %, ]P!> /0 9P#Q '  [P!X .T ?P#K (8 Z@", .@ DP#G
M )D Y0"@ ., IP#A +  WP"Z -T R0#; .  V #P -< _@#5 /\ U #_ -,
M_P#3 /\ TP#_ -, _P#_%1  _Q(, /\."0#_"PP _PD2 /\#&@#_ "8 _0 S
M /0 0 #O $T ZP!8 .@ 80#E &H X@!R .  >@#> (  W "' -H C@#8 )4
MU "< -( HP#0 *P S@"V ,P Q #* -D R #M ,< ^P#% /\ Q '_ ,,!_P#$
M ?\ Q '_ ,0!_P#_& L _Q4% /\0  #_$ 8 _P\- /\,% #\!Q\ \0,K .<
M.0#B $8 W@%1 -H"6P#5 F0 T@-L ,\#= #-!'L RP2" ,H$B0#(!9  Q@68
M ,0%H #"!JD P0:T +\&P0"]"-4 NPGL +@+_0"V#/\ M0W_ +0-_P"T#?\
MM W_ +0-_P#_&P4 _Q@  /\7  #_%@  ^Q,& /H0#@#N#!8 XPDB -H), #3
M"CX S@M* ,H,50#'#5X Q0UG ,(.;P#!#G8 OPY^ +T/A0"\#XT NA"5 +@0
MG0"W$*< M1&R +,1P "R$=4 KA/N *L4_@"I%?\ IQ7_ *<5_P"F%/\!IA3_
M :84_P'_'P  _QP  /H>  #K'@  XQP  -\5!0#>#@T TPX8 ,L1* #%$S<
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M XTNLP.,+L4#BB_A!(<O]@2%+_\$A"__ X0O_P.#+_\#@R__ X,O_P/[*0
MZS$  -DX  #)/   OSP  +8Y  "P,@  K"T+ *<O%P"B,28 GC,T )HT0 "8
M-4H E353 ),U6P&1-6(!CS5I HTU<0*,-7D#BC6" X@UBP2&-98$A#6B!8(U
MKP6!-< &?S;<!GTV] 9[-O\%>S;_!7HV_P1Z-O\$>C7_!'HU_P3U+0  Y#<
M - _  #"0P  MT0  *U   "G.@  HS8& )TW$P"9.2( E3HO )(\.P"//$8
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M"V5&[ MD1_\)9$;_"&1&_P=D1O\&9$7_!F1%_P;H.P  T$8  +]-  "S40
MI5$  )I.  "22P  C4<  (=("P"#2A8 ?TLD 'U,,0!Z33P =TU% 75-30)S
M354"<4U< V]-8P1M3&L%:TQS!VE+?0AF2XD)9$N6"F)+I MA2[0,7TO*#%Y+
MZ@M>2_X*7DO_"5Y*_PA>2O\'7DK_!UY*_P?C/P  RTD  +Q1  "P50  H50
M )92  "-4   ATP  (%-" !]3Q, >E A '=1+@!T4CD <E)" 6]22P%M4E("
M:U%9 VE1801G46@&95!Q!V-0>PAA4(8*7T^3"UU/H0Q;3[(-64_'#5E/Z Q8
M3_T+6$__"5E/_PA93O\'64[_!UE._P??0P  QTT  +A4  "L60  G5<  )%5
M  "(5   @5   'M2! !W4Q$ =%0> '%5*P!O5C8 ;%9  6I62 %H5E "9E97
M V167@1B568%8%5O!UU5> A;5(0*6521"U=4H Q54[ -5%/%#5-3Y@Q34_P+
M4U/_"512_PA44O\(5%+_!U12_P?:1@  PU   +58  "H6P  F5H  (U8  "$
M5P  >U0  '96 0!Q5P\ ;ED; &Q:* !I6C, 9UL] 65;10%C6TT"85I5 U]:
M7 1=6F0%6UEL!EA9=@A668()5%B/"U)8G@Q06*X-3UC##4Y8Y Q.6/L+3U?_
M"4]7_PA/5O\(4%;_!U!6_P?32@  P%0  +)<  "C7@  E5T  (E<  !_6P
M=ED  '!:  !K7 T :%T8 &9>) !D7S  8E\Z &!?0P%>7TL"7%]2 EI?6@-8
M7V$%55YJ!E->= =177\)3UV-"DU=G M+7:P,2EW!#$E=XPQ)7/H*25O_"4I;
M_PA*6O\(2EK_!TI:_P?.3@  O%@  *Y@  "?80  D6   (5?  ![7P  <%T
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M!CEJ_P:]7   KV8  *)M  "1;   @FL  '=K  !L;   86X  %=P  !0<P
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M 22+BP$CBYX!(HNS 2&,S@$ABO$!((C_ B"&_P(@A?\"(87_ B&%_P*K<@
MH7P  (][  " >@  <WH  &9\  !;?P  4((  $:&   \B@  -(T  "R1   F
MDPP ))03 ".4'  BE28 (94O ""5.  ?ED( 'I9, !V66  <EF0 &I=T !F7
MA@ 8EYD %Y>N !67R0 6E>X %I/_ 1:2_P$6D?\!%I#_ 1:0_P&E>P  F8,
M (F!  ![@   ;((  %^$  !4B   28L  #^0   UE   +9<  "6:   =G@$
M%J , !2A$@ 4H1L $Z$E !*A+@ 1HC@ $:)# !"B3P /HEP #J-K  VC?0 -
MHY( #*.G  JBP  +HN8 #*#^  V?_P -GO\ #9W_  V=_P">A   DHD  (.(
M  !SB   98L  %B.  !,D@  09<  #>;   NG@  )*(  !RE   5J   #ZL$
M  JN#  'K1( !JT;  6M)  $KBX  JXY  &N10  KE(  *YA  "N<P  KH<
M *Z=  "NM   KM4  *WT  "M_P  K/\  *O_  "K_P"6BP  C)   'N0  !K
MD@  798  %":  !$GP  .:,  "^G   EJP  '*X  !2Q   .M   ";<   &X
M"0  N X  +D4  "Y'   NB4  +HO  "[.@  O$<  +Q6  "\9P  O'L  +R1
M  "\J0  O,0  +SK  "[_@  N_\  +O_  "[_P"0D@  @Y@  '.;  !CGP
M5:,  $>H   [K0  ,+$  "6T   ;MP  $KH   R]   %OP   ,,   #$ @
MQ0H  ,4.  #&%   QQL  ,@D  #*+@  S#H  ,U)  #-60  S6P  ,Z#  #.
MFP  S;4  ,[:  #.]@  S?\  ,W_  #-_P"&F0  =Z   &FF  !:K   3+(
M #ZV   PN0  )+P  !F_   1P@  "L4   +)    S    -    #1    T@$
M -,(  #5#0  UQ$  -H8  #<(0  WRP  .$Z  #B2@  XUT  .1R  #DBP
MY:4  .7   #EY@  Y?@  .7_  #E_P!ZH0  :ZD  %RO  !-M@  /[P  #"_
M   CPP  %\<   _*   'S@   -$   #6    W    -\   #@    X@   .0
M  #F P  Z D  .D.  #L%0  [AX  /$K  #T.@  ]4T  /9A  #W>0  ^),
M /BM  #YQ@  ^>0  /GS  #Y\P!MJ@  7K(  $^Z  ! P0  ,<4  "+)   6
MS@  #=(   38    W0   .$   #D    Z    .L   #M    [P   /$   #S
M    ]@   /@#  #Z"P  _1$  /\;  #_*0  _SL  /]/  #_9@  _W\  /^9
M  #_KP  _\,  /_6  #_U@#_!!P _P 9 /\ &0#_ !P _P B /\ *P#_ #@
M_P!& /\ 4P#_ %X _P!I /\ <@#_ 'H _P"" /\ B0#_ (\ _P"5 /\ FP#_
M *$ _P"H /\ KP#_ +D _P#% /\ V0#^ .P _0#[ /L _P#[ /\ ^P#_ /H
M_P#T /\ \ #_ /  _P#_!Q@ _P$5 /\ % #_ !8 _P ; /\ )@#_ #0 _P!"
M /\ 3@#_ %H _P!D /\ ;0#_ '4 _P!] /\ A #_ (H _0"0 /P E@#Z )T
M^0"C /@ JP#W +0 ]0"_ /0 S@#S .8 \0#V /  _P#O /\ [P#_ .X _P#N
M /\ Z@#_ .H _P#_"Q0 _P81 /\ $ #_ !  _P 6 /\ (@#_ "X _P \ /\
M20#_ %0 _@!? /L : #Y '  ]P!X /4 ?P#S (4 \@"+ /  D@#O )@ [0"?
M .P I@#J *X Z "Y .< QP#E -X XP#P .( _@#@ /\ X #_ .$ _P#A /\
MX0#_ .$ _P#_#1  _PD- /\!# #_  P _P 2 /\ ' #_ "@ _  V /D 0P#V
M $X \@!9 .\ 8@#L &L Z@!R .@ >0#F (  Y "& .( C #A ), WP": -T
MH0#; *H V "T -4 P #2 -, T #J ,X ^@#- /\ S0#_ ,T _P#, /\ S #_
M ,P _P#_$ P _PP' /\# @#_  @ _P . /\ %@#V "( \  O .P / #I $@
MY0!3 .$ 7 #> &4 VP!L -< <P#4 'H T@"  -  AP#. (X S "5 ,H G0#(
M *4 Q@"O ,0 NP#" ,L P #E +X ]0"] /\ O #_ +P _P"\ /\ O #_ +P
M_P#_$04 _PX  /\*  #_" $ _P0* /@ $ #I !H XP H -X -0#9 $$ TP!,
M ,\ 5@#+ %\ R0!F ,8 ;@#$ '0 P@![ ,$ @@"_ (D O0"0 +P F "Z *$
MN "K +8 MP"T ,< L@#@ +$!\@"O O\ K@/_ *T$_P"M!/\ K03_ *T$_P#_
M%   _Q   /\/  #R#0  Z@H  .D#"0#= !( U  ? ,T!+0#( CH Q -% , #
M4 "]!%D NP5A +D%: "W!F\ M09V +0'?0"R!X0 L0B, *\(E0"M"9X JPFH
M *H*M0"H"L4 I@O? *0-] "B#O\ H [_ )\._P"?#O\ GP[_ )\._P#_%P
M_Q,  .\8  #D&0  VQ8  -(0 @#/"0L R @6 ,$*) "\##( MPT^ +0.20"Q
M#E, KQ!; *T08P"K$&H J1%Q *@1> "F$8  I1&( *,2D0"A$IL H!.F )X3
MLP"<$\, FQ3> )<6] "5%O\ E!?_ ),7_P"2%_\ DA;_ )(6_P#_&@  ]!T
M .4C  #5)0  RB0  ,(=  "^%@0 NQ 0 +03'0"O%2L JQ8X *<80P"E&4T
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M G8PZ@)U,/X"<S#_ G,P_P)S+_\"<R__ G,O_P+P*@  W#4  ,<[  "Z/P
MK#P  *(X  "<,P  F"\  )4N$ "0,!P C#(I (DS-0"&-#\ A#5) ((U40"
M-5@ ?C5? 7TU9@%[-FX!>35V G@U@ )V-8L#=#67 W(VI -P-K0$;S;(!&TV
MYP1L-OP#:S;_ VLV_P)J-O\":C7_ FHU_P+J,   TSH  ,)!  "S0P  I4$
M )L^  "5.@  D#8  (PU#0"(-Q@ A#@E ($Z,0!_.SP ?#M% 'H\30!X/%4!
M=SQ< 74\8P%S/&H"<3QS G \? -N.X<#;#N4!&H[H01H.[$%9SS%!64\Y05D
M//H$9#S_ V,[_P-C._\#8SO_ F,[_P+E-0  S3\  +U&  "N1P  GT4  )5#
M  ".0   B3P  (0\"@" /10 ?3XB 'H_+@!X0#@ =4%" '-!2@!R05$!<$%9
M 6Y!8 )L06<":D%P VA!>0-G080$94&1!6-!GP5A0:X&8$'"!EY!X@9>0?D%
M74'_!%U _P-=0/\#74#_ UU _P/?.0  R$,  +E*  "I2P  FTD  )!'  "(
M1   @T$  'Y!!@!Z0A$ =D,> '1%*@!Q134 ;T8_ &U&1P!K1D\!:D96 6A&
M70)F1F4"9$9M V)&=@1@1H($7D:.!5Q%G 9;1:P&64:_!UA&WP981O<%5T7_
M!%=%_P171/\#6$3_ UA$_P/:/0  Q$<  +5.  "D3@  EDP  (M+  "#20
M?44  'A& @!T1Q  <$@; &Y))P!K2C( :DL\ &A+1 !F2TP!9$M3 6)+6@)@
M2V("7TMJ UU+= 1;2G\%64J,!5=*F@952JH'5$J]!U-*W =22O8&4DK_!5))
M_P122?\#4DC_ U-(_P/400  P$L  +)1  "@4   DD\  (=.  !^3   >$@
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M T14_P/&3   M58  *5:  "460  AE@  'M8  !Q5P  9E8  &%8  !=600
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M C9IC0,T:9\#,VFR S%IRP,Q:.T#,6?_ S%F_P,R9?\#,F3_ S)D_P.W6P
MJ60  )9D  "&8P  >&,  &UC  !D9   664  %!H  !):P  0VT$ $!N#@ ^
M;Q@ /6\B #QP*P Z<#0 .7$] #AQ10 W<4X -G%7 #1Q80$R<6T!,7%Z 2]Q
MB@(M<9P"*W&O BIQR (J<.L"*F__ BIM_P(J;/\"*VS_ BML_P*Q80  I&D
M )!H  " 9P  =&<  &EG  !?:   56L  $MN  !#<0  /'0  #=V"@ T=Q(
M,W@< #)X)0 Q>2X ,'DW "]Y/P N>4@ +'I2 "MZ7  J>F@ *'IV "9ZAP$E
M>ID!(WJL 2)ZQ0$B>>D!(G?_ 2)V_P$B=?\"(G3_ B-T_P*L:   G6X  (IM
M  ![;   ;VP  &5L  !:;@  4'$  $5U   ]>   -GP  "Y_ @ I@0T )X(4
M ":"'@ E@B< )((O ".#.  B@T( (8-+ ""$5@ ?A&( 'H1Q !R$@@ ;A)4
M&H2I !B$P0 8@^8 &('] !F _P$9?_\!&7[_ 1E^_P&F<   E7,  (1R  !V
M<0  :W$  %YS  !4=@  27D  #]]   W@0  +X0  ">(   @BP4 &XT. !J-
M%0 9C1X &(XG !>.,  6CCD %8Y# !2/3P 3CUL $H]J !&/>P 0CX\ #X^D
M  Z/NP -C^  #HWZ  ^+_P 0BO\ $(G_ !")_P"A>@  CGD  'YW  !R=P
M9'@  %A[  !-?@  0H(  #F&   OB@  )XX  ""1   8E0  $I@%  Z:#@ -
MFA0 #)H=  N:)@ +FC  "IH[  F:1@ (FE, !IMA  6:<@ $FH8  IJ;  ":
ML0 !F<\  IGP  *8_P $E_\ !9;_  66_P"9@0  AW\  'I^  !K?@  78$
M %"%  !%B0  .XT  #&2   HE@  'YD  !B=   1H   #*,"  :E"@ !I1
M *46  "F'P  IB@  *8R  "G/0  ITH  *=8  "G:   IWP  *>1  "FJ
MIL,  *7I  "E_   I?\  *3_  "D_P"1AP  @H8  '*&  !CB   58P  $F1
M   ]E@  ,IH  "B>   ?H@  %Z8  !"I   +K   !*\   "Q!@  L0P  +(1
M  "R%P  LQ\  +,H  "T,@  M3\  +5-  "U70  M7   +6&  "UG0  M;8
M +7<  "T]P  M/\  +3_  "T_P"+CP  >HX  &J1  !;E0  39H  $"?   U
MI   *J@  ""L   6L   #[0   FW   !N0   +T   "^    O@8  +\,  #
M$   P18  ,(=  ##)P  Q3(  ,9   #&40  QV,  ,=X  #'D0  QZD  ,?'
M  #'[   Q_X  ,?_  #'_P"#EP  <9H  &&>  !2HP  1:D  #BN   LLP
M(+<  !:Z   .O0  !L    ##    QP   ,D   #*    S    ,T#  #."0
MT X  -(3  #4&P  V"4  -LR  #=0@  W50  -YI  #>@0  WIP  -^U  #?
MV0  W_,  -__  #?_P!WGP  :*8  %FM  !*LP  .[@  "V[   ?OP  %,(
M  S&   #R0   ,P   #0    U0   -D   #:    W    -X   #@    X@4
M .0+  #G$   ZA@  .TD  #P,@  \40  /)8  #S;P  ](H  /2D  #TOP
M]-\  /3S  #T] !JJ   6Z\  $RW   ]O0  +<$  !_&   3R@  "\X   #2
M    UP   -P   #@    Y0   .<   #I    ZP   .T   #O    \0   /,
M  #V!P  ^0X  /P6  #_(@  _S,  /]'  #_70  _W8  /^1  #_J0  _[X
M /_8  #_VP#_ !@ _P 6 /\ %0#_ !@ _P > /\ )P#_ #8 _P!# /\ 3P#_
M %H _P!D /\ ;0#_ '4 _P!] /\ A #_ (H _P"0 /\ E@#_ )P _P"C /\
MJP#_ +0 _@"_ /T SP#[ .< ^@#X /D _P#Y /\ ^0#_ /4 _P#N /\ Z0#_
M .< _P#_ !0 _P 1 /\ $0#_ !( _P 7 /\ (P#_ #$ _P ^ /\ 2@#_ %8
M_P!@ /\ : #_ '  _P!X /T ?@#\ (4 ^@"+ /D D0#X )@ ]P"> /4 I@#T
M *X \@"Y /$ QP#O .  [@#R .P _P#L /\ [ #_ .L _P#E /\ X #_ -X
M_P#_ Q  _P . /\ #0#_  T _P 3 /\ '@#_ "L _P X /\ 10#^ %  ^P!:
M /@ 8P#U &L \P!R /$ >0#O '\ [@"& .P C #J )( Z0"9 .< H #F *D
MY "S .$ P #@ -, W@#K -P ^P#; /\ V@#_ -H _P#9 /\ U #_ -( _P#_
M!PT _P ) /\ !@#_  D _P / /\ & #[ "4 ^  R /4 /P#R $H [0!4 .H
M70#G &4 Y !L .( <P#@ 'H W@"  -P A@#: (T UP"4 -0 FP#2 *0 SP"M
M ,T N0#+ ,D R0#D ,@ ]@#& /\ Q0#_ ,8 _P#' /\ QP#_ ,< _P#_"@8
M_P$  /\   #_  0 _P + /0 $@#O !\ Z@ L .4 . #B $, W0!. -D 5P#4
M %\ T0!G ,X ;0#, '0 R@!Z ,@ @ #& (< Q0". ,, E@#! )X OP"H +T
MLP"Z ,( N0#; +< \ "U /\ M@#_ +4 _P"U /\ M0#_ +4 _P#_#   _P0
M /\   #^    ]@ # .@ #0#@ !< V0 D -$ ,0#- #P R@!' ,8 40## %D
MP !@ +X 9P"\ &X N@!T +D >P"W (( M0") +, D0"R )H L "D *X KP"L
M +T J@#0 *@ ZP"G /L I@#_ *8 _P"E /\ I0#_ *4 _P#_#0  _P<  /0)
M  #J"0  X@0  -H !P#/ !$ R  < ,( *0"^ #4 NP!  +< 2@"T %, L@!;
M +  8@"N &@ K !O *L =0"I 'T J "$ *8 C0"D )8 HP"@ *$ JP"? ;D
MG0/, )P$Z ":!OD F0?_ )@(_P"7"/\ EPC_ )<(_P#_$   ]Q   .@4  #<
M%0  SA$  ,8-  #"! L O  4 +<!(0"R RX K@4Z *L&1 "H"$T I@A5 *0)
M7 "B"F, H IJ )\+<0"="W@ G N  )H,B0"9#), EPR> )4-J@"4#;@ D@W,
M ) .Z@".$/P C!#_ (L0_P"+$/\ BQ#_ (H0_P#[$P  [1H  -T@  #,(0
MOQT  +<7  "S$0  L@L- *L-&0"G#B8 HP\S )\0/@"=$4< FA%0 )@25P"6
M$EX E1-E ),3; "2$W, D!1\ (\4A0"-%8\ BQ6: (H5IP"(%K4 AA;) (07
MYP""&/L @!G_ '\9_P!_&?\ ?QC_ '\8_P#U&@  Y",  ,\I  # *@  LR8
M *HB  "E'   I!4( * 4$P";%B$ EQ@M )09. "1&D( CQM+ (T<4@"+'%D
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M 6,P_P%C+_\!8R__ 6,O_P'B+@  RC@  +H]  "H/   FCH  )$W  "*,P
MAC   (,N"0!_+Q, >S ? '@R*P!V,S4 =#,^ '(T1@!P-$X ;S55 &TU7 !L
M-60 :C5L 6@U=0%G-8 !936, 6,UF@)A-JD"8#:[ E\VU@)=-O,"73;_ EPV
M_P%<-?\!7#7_ 5PT_P'<,P  Q3P  +1!  "B0   E3X  (L\  "$.0  ?S8
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M3T9)3$4 !@G_ E __P)0/_\"43[_ 5$^_P'/.P  O44  *I'  "91@  BT4
M (%$  !Y0@  =#X  &\_  !K0 P 9T$5 &5"(0!C0RL 84,U %]$/@!>1$4
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M D%,_P)"2_\"0DK_ D)*_P+"1P  LT\  )Y/  "-3@  @$X  '5-  !L3
M8TH  %Y,  !:30( 5DX. %1/& !24"( 45$L $]1-0!.4CT 35)% $Q230!*
M4E0 25)= 4=29@%%4G$!0U)^ D%2C0(_4IT#/E*O SU2Q@,\4ND"/%'^ CQ0
M_P(]3_\"/4__ CU._P*^2P  KE,  )I2  ")40  ?%$  '%0  !H4   7DX
M %A1  !44@  45,, $Y4% !,51\ 2U8I $E6,@!(5CH 1U=" $972@!$5U(
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M 2M>_P&Q60  GEP  (M<  ![6P  ;UL  &5;  !<7   45X  $E@  !#8@
M/&4  #AG"@ U:!( -&@; #-I)  R:2T ,6DU "]J/0 N:D8 +6I/ "QJ60 K
M:V4 *6MR "AK@@ F:Y, )&NG "-KO0 B:N  (VGY 2-G_P$C9O\!(V;_ 21E
M_P&L8   F&   (5@  !V7P  :E\  &%@  !78   36,  $1F   ]:   -FL
M #!N!  L< X *G$5 "EQ'@ H<28 )W(O "9R-P E<D  )')* ")R5  A<V
M('-M !YS?0 =<Y  &W.C !ISN0 9<]P &G'W !IP_P ;;_\ &V[_ 1MM_P&F
M9@  D64  ']D  !Q9   9F0  %UD  !29@  2&D  #]L   W;P  ,',  "EV
M   B>0@ 'WL0 !Y[%P <>Q\ &WLH !I[,  9?#D &'Q# !=\3@ 6?%H %7QG
M !1]>  2?8L $7V? !!]M0 /?=4 $'OU !%Y_P 1>/\ $G?_ !)W_P">:P
MBFH  'II  !M:0  8FD  %=J  !,;0  0W   #ET   Q>   *7L  ")_   ;
M@@  %(4) !&&$  1AA< $(<? !"'*  .AS$ #H<[  V'1@ ,AU, "X=A  J'
M<0 )AX0 !X>8  :&K@ %ALD !H7L  >$_P (@_\ "8+_  F"_P"5<0  @V\
M '1N  !I;@  7&\  %!R  !&=0  /'D  #)]   J@0  (H4  !N)   4C
M#X\#  J2"P &DA$ !)(8  *2(  !DBD  )(S  "3/@  DTL  )-9  "3:0
MDWL  )*0  "2I@  D;\  )'E  "0^@  C_\  (__  "/_P"-=P  ?74  '!T
M  !B=0  57@  $E\   _@   -(0  "N)   BC0  &I$  !.4   .EP  "9L
M  &="   G0X  )T3  ">&@  GB(  )\K  "?-0  H$(  *!0  "@7P  H'$
M *"'  "?G0  G[4  )[:  "=]@  G?\  )S_  "<_P"&?0  >'P  &E\  !;
M?P  3H,  $&(   VC   +)$  ".6   :F@  $IX   VA   &I    *<   "I
M P  J0H  *H.  "K$P  K!D  *TB  "N*P  KS<  *]%  "O5   KV8  *][
M  "NE   KJL  *[)  "N[P  K?\  *W_  "M_P"!A   <80  &&'  !3BP
M1I   #F6   NFP  (Z   !JD   2J   #*P   2O    L@   +8   "W
MMP(  +@(  "Y#0  NA(  +L8  "](0  OBL  , X  # 2   P%H  ,%N  #!
MA@  P:   ,&Z  #!XP  P/D  ,#_  # _P!YC0  :)   %F4  !+F@  /:
M #&E   EJP  &J\  !&S   +N    KL   "^    P0   ,0   #%    Q@
M ,<   #(!0  R@L  ,P/  #.%0  T!\  -,K  #5.@  U4P  -9@  #8=P
MV)(  -BL  #9R0  V>P  -G[  #8_P!PF0  8)X  %&D  !#J@  -;   "BV
M   <N@  $;X   G!    Q0   ,@   #+    SP   -(   #3    U@   -@
M  #;    W0   -\'  #B#0  Y1,  .@=  #L*@  [3P  .U1  #N9P  [X$
M .^<  #PMP  \-,  /#L  #P] !GI@  6*T  $FT   ZN@  *KX  !S"   0
MQ@  !\H   #.    T@   -8   #<    X    .,   #D    Y@   .@   #K
M    [0   .\   #R @  ]0H  /@1  #\'   _RP  /\_  #_50  _VX  /^*
M  #_I   _[H  /_1  #_X0#_ !0 _P 2 /\ $@#_ !0 _P 9 /\ )0#_ #(
M_P _ /\ 2P#_ %8 _P!@ /\ : #_ '  _P!X /\ ?P#_ (4 _P"+ /\ D0#_
M )@ _P"> /X I@#] *X _ "Y /H R #Y .( ^ #T /< _P#V /\ ]@#_ .\
M_P#G /\ X@#_ -X _P#_ !$ _P . /\ #@#_  \ _P 4 /\ ( #_ "T _P Z
M /\ 1@#_ %$ _P!; /\ 8P#^ &L _ !S /H >0#Y (  ]P"& /8 C #U )(
M\P"9 /( H #P *D [@"S .T P0#K -8 Z@#N .D _@#G /\ YP#_ .4 _P#=
M /\ U0#_ -$ _P#_  T _P * /\ " #_  D _P 0 /\ &P#_ "@ _P U /\
M0 #Z $L ]@!5 /, 7@#Q &8 [@!M .P = #K 'H Z0"  .< A@#F (T Y "3
M .( FP#@ *, W@"M -P N0#: ,H UP#F -0 ^ #2 /\ T@#_ -( _P#. /\
MR0#_ ,8 _P#_  @ _P # /\   #_  , _P - /P %@#W "( \P N .\ .@#L
M $4 Z !/ .0 6 #A &  W@!G -L ;0#9 '0 U0!Z -, @ #1 (< SP". ,T
ME0#+ )X R0"G ,< LP#% ,( PP#< ,$ \0"_ /\ OP#_ +X _P"^ /\ O0#_
M +L _P#_    _P   /\   #_    ]@ ( .X $0#G !L X0 G -T ,P#9 #X
MTP!) ,\ 4@#+ %D R !A ,8 9P#$ &T P@!S ,  >@"_ (  O0"( +L D "Y
M )@ N "B +4 K0"S +L L0#. +  Z@"O /P K0#_ *T _P"N /\ K@#_ *X
M_P#_ @  _P   /T   #R    Z    -X # #3 !4 S  A ,@ + #$ #@ P0!"
M +T 2P"Z %, N !: +8 80"T &< L@!M +  = "O 'H K0"" *P B@"J ),
MJ "= *8 J "D +4 H@#& *$ XP"? /8 G@#_ )X _P"> /\ G@#_ )X _P#_
M!@  ^P   .X%  #B!   U0   ,L !@##  \ O0 9 +@ )0"T #$ L0 [ *X
M10"L $T J0!5 *< 6P"E &( I !H *( ;@"A '4 GP!\ )X A0"< (X F@"8
M )@ I "6 +  E0#! ), W "2 /( D0#_ )  _P"0 /\ CP#_ (\ _P#]"@
M\ X  .$1  #.$   P@T  +L'  "W  H L0 2 *P '@"H "D I0 T *( /@"?
M $< G0!/ )L 5@"9 5P EP%C )8":0"4 G  DP-X )$#@ "0!(H C@25 (P%
MH0"*!:X B0:^ (<(V "&"?  A K_ (,+_P"#"_\ @PO_ (,+_P#V$   YA<
M -(<  # &@  LQ8  *P2  "H#0  I@<- *(%%@"=!R( F0DN )8*. "4"T$
MD@Q* ) ,40".#5@ C U> (L-90")#6P B YT (8.?0"%#H< @PZ3 ($/GP"
M$*T ?A"^ 'T0VP!Z$?0 >!+_ '<2_P!W$O\ =Q+_ '<2_P#O%P  VR$  ,8D
M  "T(P  J"   * <  ";%P  F1$$ )@.$ "3$!L CQ$G (P2,@")$SP AQ-$
M (443 "#%%, @15: ( 58 !^%F@ ?19O 'L6> !Y%X, >!>/ '88G !T&*H
M<QF[ '(9U !O&O$ ;AO_ &T;_P!M&O\ ;1K_ &T:_P#G(   T"D  +PK  "K
M*@  GB@  )8D  "0(   C1P  (P7# "(&!8 A!HB ($;+0!^'#< ?!U  'H=
M2 !Y'D\ =QY5 '8?7 !T'V, <Q]K '$@= !P('\ ;B&+ &PAF !K(:< :2*X
M &@BSP!F(NX 92/_ &0C_P!D(O\ 9"+_ &0A_P#@)@  R"\  +0Q  "C,
MEBX  (TK  "'*   A"0  ((@" !^(!( >R(> '@C*0!U)#, <R4\ '$E0P!P
M)DL ;B92 &TG60!K)V  :B=H &DH<0!G*'L 92B( &0IE0!B*:0 8"FU %\I
MRP!>*NP 7"K_ %PI_P!<*?\ 7"G_ %PH_P#8+   PS4  *TU  "=-   D#,
M (8Q  " +0  ?"L  'DH P!V)Q  <BD: ' J)0!M*R\ :RPX &HL0 !H+4<
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M 4DY_P%).?\!23C_ 4HX_P''.@  LT   )X_  "./P  @3X  '<]  !P.P
M:C@  &8X  !B.0< 7SH1 %P[&P!:.R4 63PN %<]-P!6/3X 5#Y& %,^30!2
M/E4 43Y= $\_9@!-/W  3#]] 4H_BP%(/YL!1S^L 44_P0%$/^,!1#[[ 40^
M_P%$/?\!1#W_ 44\_P'#/@  KT,  )I"  "*0@  ?4$  '-   !K/P  93P
M & \  !</@0 63X/ %<_& !50"( 4T$K %)!- !00CP 3T)# $Y"2P!-0U(
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M 39)_P&X20  HDL  (Y*  !^2@  <DH  &A*  !?20  54@  %!*  !,2P
M24P' $9-$ !$3AD 0D\B $%/*P! 4#, /U [ #Y00P \44H .U%3 #I17  X
M46< -U%S #51@@ S49,!,E&E 3!1N@$O4=H!+U#V 2]/_P$P3O\!,$[_ 3!-
M_P&T30  G4T  (I-  !Z30  ;DT  &1-  !;30  44T  $M/  !&4   0E(#
M #]3#0 ]5!4 /%0> #I5)P Y52\ .%4W #=6/P V5D< -590 #-660 R5V0
M,%=Q "]7@  M5Y$ *U>C "I7N  I5]8 *5;U "E5_P J5/\!*E/_ 2I2_P&O
M40  F%$  (51  !V4   :E   &!0  !840  3E(  $=3  !!50  .U@  #A9
M"@ U6A$ -%H: #-;(@ R6RL ,5LS "]<.P N7$, +5Q, "Q<5@ K76  *5UM
M "A=?  F78X )%VA "-=M0 B7=( (ESS ");_P C6O\ (UG_ "18_P"H50
MDE0  (!4  !Q5   9E0  %Q4  !450  2E8  $-8   \6P  -ET  #!@!0 M
M80X *V$5 "IB'0 I8B4 *&(N "=C-@ F8SX )6-' "-C40 B9%P (61I !]D
M>0 >9(H '&2> !MDLP 99,X &F/Q !MA_P ;8/\ '&#_ !Q?_P"A60  C%@
M 'M8  !M6   8E@  %E8  !060  1UL  #Y>   W8   ,6,  "IF   D:0D
M(6H0 "!J%P ?:B  'FLH !UK,  <:SD &VM" !IL3  9;%@ %VQE !9L=  4
M;(8 $VR: !)LKP 1;,H $6OO !)I_P 3:/\ $VC_ !-G_P"970  A5T  '5<
M  !H7   7EP  %5<  !+7@  0F$  #ED   R9P  *VH  "1M   >< $ %W,+
M !5T$0 4=!@ $W0A !)U*0 1=3( $74[ !!U1@ /=5( #G5?  UU;@ ,=8$
M"W65  IUJ@ (=,, "73G  IS_0 +<?\ #''_  QP_P"18@  ?V$  '!A  !D
M80  6F$  $]B  !%90  /&@  #-L   K;P  )'(  !UV   7>0  $7P$  U_
M#  +?Q( "G\9  E_(@ (?RH !G\T  5_/P $?TL  G]8  %_9P  ?WD  '^.
M  !_HP  ?KL  'W@  !]]P  ?/\  'O_  ![_P")9P  >&<  &MF  !A9@
M5&<  $EI   _;0  -7$  "QU   D>0  '7P  !:    0@P  #(8"  :)"@ !
MB0\  (D4  "*&P  BB,  (LL  "+-P  BT,  (M0  "+7P  BW$  (N&  "+
MG   BK,  (G3  "(\P  B/\  (?_  "'_P"";0  <VP  &AL  !:;0  3F\
M $)S   X=P  +GL  "6    =A   %8@  !",   +CP  !)(   "4!@  E0P
M )40  "6%0  EQP  )@D  "8+@  F3D  )E'  "95@  F6@  )E]  "9E
MF*L  )?(  "6[@  EO\  )7_  "5_P![=   ;W,  &%S  !3=@  1GH  #M_
M   PA   )H@  !V-   4D@  #I8   F9   !G    *    "A    H@8  *(,
M  "D$   I10  *4<  "G)   J"\  *@]  "I3   J5X  *ER  "HB0  J*(
M *B\  "GY0  IOL  *;_  "E_P!W>P  :'L  %E^  !+@@  /H<  #*-   G
MD@  '9<  !2<   .H   !Z0   "H    JP   *X   "O    L    +$$  "S
M"@  M X  +43  "V&P  N"0  +HQ  "Z0   NE(  +ME  "[?0  NI<  +JQ
M  "ZT@  NO,  +G_  "Y_P!O@P  7X8  %&+  !#D   -I<  "J=   ?H@
M%:<   VL   %L    +0   "W    NP   +X   "_    P    ,$   ## 0
MQ <  ,4-  #'$0  RAD  ,TD  #.,P  ST0  -!8  #0;@  T8@  -"D  #0
MP0  T>8  -'X  #1_P!GCP  5Y0  $F:   [H0  +J<  "&M   6LP  #K@
M  :\    P    ,,   #&    RP   ,T   #.    T    -$   #4    U@
M -H"  #<"0  WP\  .,7  #F)   YS8  .A)  #I7P  ZG@  .N4  #KKP
MZ\P  .SH  #L]@!?G@  4*0  $*K   TL@  )KD  !F^   .P@  !,4   #*
M    S0   -$   #8    VP   -\   #@    X@   .0   #F    Z0   .L
M  #N    \04  /4-  #Y%@  _"4  /TY  #^3P  _V<  /^"  #_G0  _[4
M /_+  #_Y #_ !$ _P / /\ #P#_ !$ _P 6 /\ (@#_ "\ _P [ /\ 1P#_
M %( _P!; /\ 9 #_ &P _P!S /\ >@#_ (  _P"& /\ C #^ ), _0"9 /L
MH0#Z *D ^ "T /< P@#V -H ]0#Q /0 _P#S /\ \P#_ .D _P#@ /\ V #_
M -, _P#_  X _P + /\ "@#_  L _P 1 /\ '0#_ "H _P V /\ 00#_ $P
M_P!6 /X 7P#[ &8 ^0!M /< = #U 'H ] "  /( A@#P (T [P"4 .T FP#L
M *0 Z@"N .D N@#G ,T Y0#I .0 ^P#C /\ X@#_ -X _P#1 /\ S #_ ,@
M_P#_  D _P $ /\  0#_  0 _P . /\ & #_ "0 _0 P /L .P#W $8 \P!0
M .\ 60#L &  Z@!G .< ;@#F '0 Y !Z .( @ #@ (< W@". -P E0#: )X
MU@"H -0 LP#1 ,, SP#? ,X ] #, /\ RP#_ ,L _P#% /\ OP#_ +P _P#_
M  ( _P   /\   #_    _0 + /< $P#Q !X [0 J .H -0#G $  X@!* -T
M4@#9 %H U0!A -( 9P#0 &T S@!S ,P >@#* (  R "' ,8 CP#$ )@ P@"A
M ,  K0"^ +L O #0 +H [0"Y /X N #_ +@ _P"W /\ LP#_ +  _P#_
M_P   /\   #Y    [@ % .4 #@#> !@ V  C -( +@#/ #D RP!# ,< 3 #$
M %0 P0!; +\ 80"\ &< NP!M +D <P"W 'H M0"! +0 B0"R )( L "; *\
MIP"L +0 JP#& *D Y "G /@ I@#_ *8 _P"E /\ I0#_ *0 _P#_    _P
M /4   #J    W@   -  "@#( !( P@ = +X * "[ #, N0 ] +4 1@"R $T
ML !5 *T 6P"L &$ J@!G *@ ;0"G ', I0!Z *0 @@"B (P H "6 )\ H0"=
M *X FP"^ )D V "7 /$ E@#_ )8 _P"7 /\ EP#_ )< _P#_    ]0   .<!
M  #4    R0   ,  ! "X  X LP 6 *\ (0"K "P J  V *8 /P"C $< H0!/
M )\ 50"= %L FP!A )H 9P"8 &X EP!U )4 ?0"4 (8 D@"1 )  G ". *D
MC "X (L S0") .L B #] (@ _P"( /\ B #_ (@ _P#Y!@  Z0P  -0.  ##
M#   MPD  + "  "K  D I@ 0 *( &@"> "4 FP P )@ .0"6 $$ E !) )(
M4 "0 %8 C@!< (T 8@"+ &D B@!P (@ > "' ($ A0", (0 F "" *4 @ "T
M 'X R !] >< ? +Y 'L#_P![!/\ >P3_ 'L$_P#Q#@  WA4  ,45  "T%
MJ1$  *$.  ">"@  FP,, )< $P"3 !X D $I (T",P"* SP B 1# (8%2P"%
M!E$ @P97 (('7@" !V0 ?PAL 'T(= !\"'X >@F) '@)E@!W"J, =0JS ',+
MQP!R#.8 < W[ ' -_P!O#?\ ;PW_ &\-_P#H%@  T!X  +D=  "I'   G1H
M )46  "0$P  CPX# (X*#@")"Q< A@PC (,-+0" #38 ?@X^ 'P.1@![#DT
M>0]3 '@06@!V$&$ =1!H ',0<0!Q$7L <!&' &X1E !L$:( :Q*R &D2QP!H
M$^< 9A/] &44_P!E%/\ 91/_ &43_P#?'@  QB0  + D  "@(P  E"$  (L?
M  "&&P  @Q<  ((2" !_$1( ?!(= 'D4* !V%#$ =!4Z '(600!Q%D@ ;Q=/
M &X75@!L%UT :QAD &D8;0!H&7< 9AF# &09D !C&I\ 81JO & :Q !>&^0
M71S[ %P<_P!<&_\ 7!O_ %P;_P#5)0  O2H  *@I  "8*0  C"@  (,E  !]
M(@  >1\  '@; P!V&0\ <AH8 &\<(P!M'2T :QTU &D>/0!H'D0 9A]+ &4?
M4@!C(%D 8B!A &$@:0!?(7, 72%_ %PAC0!:(IP 62*L %<BP !6(^$ 52/Y
M %0C_P!4(O\ 5"+_ %0B_P#-*P  MBX  *(N  "2+@  A2T  'PK  !V*
M<B8  &\C  !M(0P :B(5 &<C'P!E)"D 8R0Q &(E.0!@)D$ 7R9( %TF3P!<
M)U8 6R== %DG9@!8*'  5BA\ %0HB@!3*9D 42FJ % IO@!/*=X 3BGW $TI
M_P!-*?\ 32C_ $XH_P#(,   L#(  )PR  ",,@  @#$  '8P  !P+0  :RL
M &@I  !F* D 8R@1 & I' !>*B4 7"LN %LK-@!9+#T 6"Q$ %<M3 !5+5,
M5"U; %,M8P!1+FX 4"YZ $XNB !,+Y< 2R^H $DONP!(+]L 2"_V $<O_P!'
M+O\ 1RW_ $@M_P#$-   JS4  )<U  "'-0  >S4  '(T  !K,@  9B\  &(N
M  !?+04 7"X0 %HO& !8,"( 5C K %4Q,P!3,3H 4C)" %$R20!0,E  3C-8
M $TS80!+,VL 2C-W $@TA0!'-)4 132F $,TN0!"--8 0C3T $(T_P!",_\
M0C+_ $(R_P# .   IS@  ),X  "#.   =S@  &TW  !F-@  83,  %TR  !9
M,@( 5S,- %0T%0!2-1\ 434H $\V, !.-C@ 3#<_ $LW1@!*-TX 23A6 $<X
M7P!&.&D 1#AU $,X@P!!.9, 0#FD #XYN  ].=, /#GS #PX_P ]-_\ /3?_
M #TV_P"[.P  HCL  (\[  !_.P  <SL  &HZ  !B.0  73<  %@V  !4-P
M43@+ $\Y$P!-.1P 2SHE $HZ+0!(.S4 1SL\ $8\1 !%/$L 1#Q3 $(\7 !!
M/6< /SUS #X]@0 \/9$ .CVC #D]M@ X/=$ -SWR #<\_P X._\ .#O_ #@Z
M_P"V/0  GCX  (L^  !\/@  ;SX  &8]  !>/0  6#L  %,Z  !/.P  3#P(
M $D]$0!'/AD 1C\B $0_*@!#/S( 0D Z $% 00! 0$D /D%1 #U!6@ \060
M.D%P #A!?P W08\ -4*A #1"M  R0LX ,D'P #) _P S0/\ ,S__ #0^_P"Q
M0   FD   (=   !X00  ;$$  &)   !;0   5#\  $X_  !*0   1D$% $1"
M#@!"0Q8 0$,? #]$)P ^1"\ /$0W #M%/@ Z148 .45. #A&6  V1F( -49N
M #-&?  Q1HT ,$:? "Y&LP M1LP +4;O "U%_P N1/\ +D/_ "Y#_P"L0P
MED,  (-#  !T0P  :$,  %]#  !70P  4$,  $A#  !$10  048! #Y'#  \
M2!, .D@< #E))  X22P -DDT #5*.P T2D, ,TI, #)*50 P2U\ +TMK "U+
M>@ L2XL *DN= "A+L0 G2\H )TOM "=*_P H2?\ *$C_ "E'_P"G1@  D48
M ']&  !P1@  948  %M&  !41@  3$<  $1(   _2@  .TL  #=,"0 U31
M,TX8 #).(  Q3R@ ,$\P "]/.  N3T  +%!( "M04@ J4%P *%!H "=0=P E
M4(@ )%"; ")0KP A4,@ (%#K "%/_P B3O\ (DW_ "--_P"A20  C$D  'I)
M  !L2@  84H  %A*  !02@  24L  $!,   [3@  -5   #%2!  M4PT +%04
M "I4'  I520 *%4L "=5,P F53P )59% "163@ B5ED (59E !]6=  >5H4
M'%:8 !M6K  95L4 &5;I !I5_P ;5/\ &U/_ !Q2_P";30  ADT  '5-  !H
M30  74T  %1-  !-3@  14\  #Q1   V4P  ,54  "M8   F6@D (UL0 ");
M%P A7!\ (%PG !]<+@ =7#< '%U  !M=2@ :754 &%UA !==<  578$ %%V5
M !-=J@ 17<( $5WG !);_@ 36O\ $UK_ !19_P"440  @%$  '!1  !D40
M65$  %%1  !)4@  05,  #A6   R60  *UL  "5>   ?80, &F,, !AD$0 7
M9!D %F0A !5D*0 493$ $V4Z !)E1  195  $&5=  ]E:P .97T #661  QE
MI0 *9+P "F3@  MC^0 ,8O\ #6'_  UA_P"-50  >E4  &M5  !?50  5E4
M $Y5  !$5P  /%D  #1<   L7P  )F(  !]E   9:   $VL% !!M#0 .;A(
M#6X:  QN(@ ,;BL "VXT  IN/@ (;DH !VY7  9N90 $;G8  FZ*  !MGP
M;;8  &S6  !L\P !:_\  FK_  -J_P"%6@  =%H  &9:  !<60  4UD  $A:
M   _70  -F   "YC   F9P  'VH  !EM   3<0  #G0#  IW"@ %=Q   7<5
M  !W'   =R0  '@M  !X-P  >$,  'A0  !X7@  >&\  'B$  !XF0  =[
M ';-  !U\   =?\  '3_  !T_P!^7P  ;E\  &)>  !97@  35\  $)B   Y
M90  ,&@  "=L   ?<   &'0  !)W   ->P  "'X   * "   @0T  ($1  ""
M%P  @QX  (,F  "$,   A#L  (1(  "$5P  A&@  (1\  "$DP  @ZH  (+%
M  "!ZP  @?X  (#_  " _P!W90  :60  %]C  !29   1V<  #QK   Q;P
M*',  "!W   8?   $7\   R#   &AP   (H   ", P  C D  (T.  ".$0
MCQ<  ) >  "1)P  DC(  )(_  "23@  DE\  ))S  "2BP  D:(  )&\  "0
MY0  C_P  ([_  "._P!Q:P  9FH  %AK  !+;0  /W$  #1V   J>P  ((
M !>%   0B0  "XT   21    E0   )@   "9    F@,  )L(  "<#0  GA$
M )\6  "@'@  HB@  *(U  "C1   HU4  *-I  "B@   HIH  *&S  "@V
MH/8  )__  "?_P!N<0  7W(  %%U  !$>0  -WX  "R$   AB@  %X\  !"4
M   *F0   9T   "@    I    *<   "H    J0   *H   "L!@  K0L  *\0
M  "P%0  LAX  +0I  "T.0  M$H  +5=  "U<P  M8X  +6H  "TQ@  L^T
M ++_  "R_P!F>@  5WT  $F"   \AP  +XX  ".4   8F@  $)\   FD
MJ0   *T   "P    M    +<   "X    N0   +L   "\    O@(  , (  #"
M#@  Q!0  ,<>  #(+   R3T  ,I0  #*9@  RG\  ,J;  #*N   RMT  ,KU
M  #*_P!>A@  3XL  $&1   SF   )Y\  !NE   1JP  ";    "U    N0
M +T   #!    Q@   ,@   #)    RP   ,P   #.    T    -(   #4!0
MV0P  -T2  #A'@  XBX  .-"  #D5P  Y6\  .:,  #FJ   Y<4  .7G  #F
M]@!6E   2)L  #JB   LJ0  '[   !.V   +O    ,$   #%    R0   ,T
M  #2    U@   -H   #;    W@   .    #B    Y    .<   #I    [0
M / *  #T$0  ^!\  /DR  #Z2   ^U\  /QZ  #]EP  _:\  /W'  #]Y #_
M  X _P - /\ # #_  X _P 3 /\ '@#_ "H _P V /\ 0@#_ $T _P!7 /\
M7P#_ &< _P!N /\ = #_ 'H _P"! /T AP#\ (T ^@"4 /D G #W *4 ]0"O
M /0 O #S ,\ \0#L /  _@#O /\ [P#_ ., _P#7 /\ S@#_ ,H _P#_  H
M_P & /\ ! #_  @ _P 0 /\ &0#_ "4 _P Q /\ /0#_ $< _@!1 /L 60#Y
M &$ ]@!H /0 ;@#S '0 \0!Z .\ @0#N (< [ ". .H E@#H )\ Y@"I .,
MM0#B ,8 X #C -\ ^ #= /\ W0#_ -0 _P#) /\ P@#_ +X _P#_  , _P
M /\   #_  $ _P - /\ % #] "  ^@ K /< -@#S $$ [P!+ .P 5 #H %L
MY@!B ., : #A &X WP!T -P >@#: ($ V "( -0 D #2 )@ SP"B ,T K@#+
M +P R0#3 ,< \ #& /\ Q #_ ,0 _P"[ /\ M@#_ +, _P#_    _P   /\
M  #_    ]P ( /  $ #K !H YP E .0 , #A #L W !% -4 30#1 %4 S@!;
M ,L 8@#) &< QP!M ,4 <P## 'H P0"! +\ B0"] )( NP"< +D IP"W +4
MM0#( +, Y@"R /L L0#_ +  _P"N /\ J@#_ *< _P#_    _P   /X   #Q
M    Y0 " -P #0#3 !0 S0 ? ,H *@#' #0 Q  ^ ,  1P"\ $X N@!5 +<
M6P"U &$ LP!G +( ;0"P ', K@!Z *P @@"J (L J "5 *< H "E *T HP"^
M *$ VP"@ /0 GP#_ )X _P"? /\ G0#_ )L _P#_    _    .X   #@
MT    ,4 " "^ !  N0 9 +4 (P"S "X L  W *T 0 "J $@ J !/ *4 50"C
M %L H@!@ *  9@"? &P G0!S )L >P": (0 F ". )8 F@"5 *< DP"W )$
MS "0 .P CP#_ (X _P". /\ C@#_ (\ _P#\    [P   -L   #)    O0
M +4  @"N  P J0 3 *4 '0"B "< H  Q )T .@": $( F !) )8 3P"4 %4
MDP!; )$ 8 "0 &< C@!M (T =0"+ 'X B0") (@ E0"& *( A0"Q (, Q "!
M .0 @ #Y '\ _P"  /\ @ #_ (  _P#T @  X D  ,<(  "W!P  K ,  *8
M  "@  < FP / )@ %P"5 "$ D@ J (\ ,P"- #P BP!# (D 20"' %  A@!5
M (0 6P"# &$ @0!H (  < !^ 'D ? "$ 'L D !Y )T > "L '8 O@!U -T
M<P#T ', _P!S /\ <P#_ ', _P#I#0  SQ   +D0  "I$   G@X  )<+  "3
M!@  D  + (P $0") !H A@ D (, +@"! #8 ?P ^ 'T 1 !\ $L >@!1 'D
M5P!W %T =@!D '0 ; !S 74 <0&  &\"C0!N IH ; .J &L#NP!I!-8 : ;Q
M &@'_P!G!_\ 9P?_ &<'_P#?%   PQ<  *X7  ">%@  DQ4  (L2  "&$
MA P" (,&#0"  Q0 ? 4> 'D'* !W"#  =0@X ',)0 !R"48 < I, &\*4P!M
M"UD ; MA &H+:0!I#'( 9PQ^ &8,BP!D#9D 8@VI &$-NP!@#=@ 7@[S %T.
M_P!=#O\ 70[_ %T._P#4'   N1T  *0>  "5'0  B1P  ($:  ![%P  >!,
M '@0!@!W#0\ <PX8 ' .(@!N#RL ;! S &H0.P!I$$( 9Q%) &813P!D$58
M8Q)= &$29@!@$F\ 7A)[ %P3B !;$Y< 61.G %<4N@!6%-4 517S %05_P!4
M%?\ 5!7_ %04_P#*(@  L"(  )TC  "-(P  @2(  'DA  !S'@  ;QL  &X7
M  !M$PP :A04 &<5'@!E%B< 8Q8O &$7-P!@%SX 7AA% %T82P!<&5( 6AE:
M %D98@!7&FP 5AIW %0:A0!2&Y0 41ND $\;MP!.&]  31SQ $P<_P!,'/\
M31S_ $T;_P##)@  JB<  )8G  "'*   >R<  '(F  !L)   :"$  &8>  !D
M&P@ 8AL1 %\<&@!='2, 6QXK %H>,P!8'SH 5Q]! %8@2 !4($\ 4R!7 %$A
M7P!0(6D 3B%T $TA@@!+(I$ 22*B $@BM !'(LT 1B/O $4C_P!%(O\ 1B+_
M $8A_P"\*@  I"L  )$K  ""+   =BL  &TJ  !F*0  8B8  %\D  !=(@0
M6R$. %@B%@!6(Q\ 5"0H %,D, !2)3< 4"4^ $\F10!.)DP 3"94 $LG7 !)
M)V8 2"=Q $8G?P!%*(\ 0RB@ $$HL@! *,L /RCM #\H_P _*/\ 0"?_ $ G
M_P"W+0  GRX  (PO  !]+P  <2\  &@N  !A+0  72L  %HH  !7)P  5"<,
M %(H$P!0*1P 3BDE $TJ+ !+*C0 2BL[ $DK0@!(+$D 1BQ1 $4L6@!$+&0
M0BUO $ M?0 _+8T /2V> #PML  Z+<@ .BWK #HM_P Z+?\ .BS_ #HL_P"R
M,   FS$  (@R  !Y,@  ;3(  &0R  !=,0  6"\  %4L  !1+   3RT) $PM
M$0!*+AD 22\B $<O*@!&,#$ 13 X $,P/P!",4< 03%/ $ Q5P ^,6$ /3)M
M #LR>P Y,HL .#*< #8RKP U,L< -#+I #0R_P U,?\ -3'_ #4P_P"M,P
MEC0  (0U  !U-0  :34  & U  !9-   5#,  % P  !,,0  23$& $<R#P!%
M,Q8 0S,? $(T)P! -"X /S4V #XU/0 ]-40 /#9, #HV50 Y-E\ -S9K #8V
M>  T-XD ,C>: #$WK0 O-\4 +S?H "\V_@ P-?\ ,#7_ # T_P"I-@  DC8
M ( W  !R.   9C@  %TW  !6-P  4#8  $LT  !'-0  1#8# $$W#0 _.!0
M/C@< #PY)  [.2P .CDS #DZ.@ X.D( -CI* #4Z4P T.UT ,CMH # [=@ O
M.X< +3N9 "P[K  J.\, *3OF "HZ_0 J.O\ *SG_ "PX_P"D.   CCD  'PZ
M  !N.@  8SH  %HZ  !3.@  33H  $8X  !".@  /SL  #P\"P Z/!$ .#T9
M #<](0 V/BD -#XP #,^-P R/S\ ,3]' # _4  N/UH +4!F "M =  I0(0
M*$"7 "9 J@ E0,$ )$#E "0__  E/O\ )CW_ "8]_P"?.P  BCP  '@]  !J
M/0  7ST  %8]  !//0  23T  $(]   \/@  .3\  #9!"  T00\ ,D(6 #%"
M'@ O0R4 +D,M "U#-  L1#P *T1$ "I$30 H1%@ )T5C "5%<0 C18( (D65
M "!%J  ?1;\ 'D3C !]$^P ?0_\ ($+_ "%!_P":/@  A3\  '1   !G0
M7$   %-   !,0   1D   #Y!   X0P  -$4  #!& P M1PT *T@2 "I(&@ I
M2"( *$DI "=),0 E23D )$E! "-*2@ B2E4 ($IA !]*;P =2G\ &TJ2 !I*
MI@ 82KT %TK@ !A)^@ 92/\ &D?_ !I'_P"50@  @$(  '!#  !C0P  6$,
M %!#  !)0P  0D0  #M%   U1P  ,$D  "M+   F30D )$X0 ").%@ A3QT
M($\E !]/+  >3S4 '4\] !Q01P :4%$ &5!= !=0:P 64'P %%"/ !-0I  1
M4+H $5#> !%/^  23O\ $TW_ !1-_P"/10  >T8  &M&  !?1P  54<  $U'
M  !&1P  /T<  #=*   Q3   *TX  "90   @4P, '%4, !I6$0 95A@ %U8@
M !96)P 55C  %%8Y !-70@ 25TT $5=9 !!7:  /5WD #E>,  U7H  +5[8
M"U;4  M6]  ,5?\ #53_  Y3_P"(20  =DH  &=*  !;2@  44H  $I*  !#
M2@  .TP  #-.   L40  )E0  "%6   ;60  %5P' !%>#0 07A, $%X:  Y>
M(@ .7BH #5XS  Q>/0 +7D@ "EY4  A>8@ '7G, !5Z&  ->FP "7K$  EW,
M  )=[@ #7/\ !%O_  5;_P"!3@  <$X  &).  !73@  3DX  $=.   ^3P
M-E$  "Y4   G5P  (5H  !M=   58   $&,#  QF"P (9Q  !F<5  5G'  $
M9R0  F<M  %G-P  9T(  &=.  !G7   9VT  &>   !FE0  9JP  &7'  !E
MZP  9/P  &3_  !C_P!Z4@  :E,  %U2  !44@  2U(  $)3   Y50  ,%@
M "A;   A7P  &F(  !1E   0:   #&L!  9N"0  ;PX  &\2  !O&   <!\
M ' G  !Q,   <3L  '%(  !Q5@  <68  '%Y  !QCP  <*<  &_!  !OYP
M;OP  &W_  !M_P!S6   95<  %I7  !15@  1E<  #Q:   R70  *F$  ")D
M   ::   %&P   YO   *<@  !'8   !X!0  > L  'D.  !Z$P  >QD  'P@
M  !]*0  ?3,  'U   !]3@  ?5X  'UR  !]B   ?*$  'RZ  ![X@  >OH
M 'G_  !X_P!M70  8%P  %=<  !+70  0%\  #5C   K9P  (VL  !IO   3
M<P  #G<   A[   "?@   ((   "# 0  A 8  (4+  "&#P  B!,  (D9  "*
M(0  BRL  (LW  ",1@  BU8  (MI  "+@   BYD  (JS  ")V   B/<  (C_
M  "'_P!H8P  7F(  %%B  !$90  .&D  "YN   D<P  &G@  !-]   -@0
M!H4   ")    C0   )    "2    D@   )0%  "5"@  EPX  )@2  ":&
MFR$  )PM  "=/   G4P  )Q?  "<=@  FY$  )NK  ":R0  FO   )G_  "8
M_P!E:0  5VD  $EL   ]<0  ,'8  "5\   ;@0  $H<   R,   $D0   )4
M  "9    G0   *    "A    H@   *0   "E 0  IP<  *D,  "J$0  K1@
M *\B  "O,   KT$  *]4  "O:P  KH4  *ZA  "NO@  K>8  *S\  "L_P!>
M<0  3W0  $)Y   U?P  *(4  !V,   3D@  #)@   .=    H@   *8   "J
M    K@   +    "Q    LP   +0   "V    N    +H$  "\"@  OA   ,$7
M  ##)   PS4  ,1)  #$7@  Q7<  ,63  #%KP  Q=$  ,/R  ##_P!6?
M1X(  #J(   LCP  ()8  !2=   -HP   ZD   "N    L@   +<   "[
MOP   ,(   #"    Q0   ,8   #(    R@   ,T   #/    T@@  -4.  #;
M&   W2<  -XZ  #?4   X&@  ."$  #AH0  X;T  .'B  #@] !.BP  0)(
M #*9   EH0  &*@   ZO   %M0   +H   "_    Q    ,@   #.    T0
M -0   #5    V    -H   #=    WP   .(   #D    YP   .L%  #O#@
M]!D  /4K  #V00  ]U@  /AR  #YD   ^:L  /C$  #XX0#_  L _P ( /\
M"0#_  P _P 2 /\ &@#_ "8 _P R /\ /@#_ $@ _P!2 /\ 6@#_ &( _P!I
M /\ ;P#_ '4 _@![ /P @0#[ (@ ^0"/ /< EP#U *  \P"J /( MP#O ,D
M[0#F .P ^P#K /\ ZP#_ -T _P#. /\ Q@#_ ,( _P#_  0 _P   /\   #_
M  4 _P - /\ %0#_ "$ _P L /\ . #_ $, _0!, /D 5 #W %P ] !C /(
M:0#P &\ [@!U .P >P#J (( Z ") .< D0#D )H X@"D .  L #= ,  V@#<
M -@ ] #5 /\ TP#_ ,L _P#! /\ NP#_ +< _P#_    _P   /\   #_
M_P * /T $0#Y !L ]@ G /0 ,@#P #P [ !& .@ 3@#D %8 X0!< -X 8P#<
M &@ V0!N -4 = #2 'L T "" ,T B@#+ ), R "= ,8 J #$ +< P0#, ,
MZP"^ /\ O0#_ +T _P"T /\ K@#_ *L _P#_    _P   /\   #Z    \@ %
M .H #@#E !8 X  A -T *P#; #8 TP _ ,X 2 #* $\ QP!6 ,0 7 #" &$
MP !G +X ;0"\ ', N@!Z +@ @@"V (L M "6 +( H0"P *\ K@#! *T X "K
M /< J@#_ *D _P"F /\ H0#_ )\ _P#_    _P   /<   #H    W    -
M"@#* !$ Q0 ; ,( )0"_ "\ O  X +@ 00"U $@ L@!/ +  50"N %L K !A
M *H 9@"H &P IP!S *4 >P"C (0 H0". )\ F@"= *< FP"X )H T "9 .\
MF #_ )< _P"6 /\ E #_ )( _P#_    ]@   .0   #2    Q0   +L !0"U
M  X L  5 *P 'P"J "D J  R *4 .@"B $( H !) )X 3P"< %4 F@!: )@
M8 "6 &8 E0!L ), = "2 'T D "' (X DP", *$ BP"P (H Q0"( .8 AP#[
M (8 _P"' /\ AP#_ (8 _P#X    Y0   ,T   "]    LP   *H   "C  H
MGP 1 )L &0"9 ", EP L )4 - "2 #P D !# (X 20", $\ B@!4 (D 6@"'
M &  A@!F (0 ;@"# '< @0"! '\ C0!^ )L ? "J 'L O !Z -L > #U '@
M_P!X /\ > #_ '@ _P#M    T0(  +L"  "L 0  H@   )L   "6  4 D0 -
M (T % "+ !T B  F (8 +@"$ #8 @@ ] (  0P!^ $D ?0!/ 'P 50!Z %L
M>0!A '< :0!U '$ = !\ '( B !Q )8 ;P"E &X M@!M ,X ; #N &L _P!K
M /\ :P#_ &L _P#?"P  P@P  *X,  ">#   DPL  (P'  "( @  A0 ) ($
M$ !_ !< ?  @ 'H * !X #  =@ X '0 /@!S $0 <0!* '  4 !N %8 ;0!=
M &P 9 !J &T : !W &< A !E )( 9 "A &, L@!A ,D 8 #I &  _ !@ /\
M8 #_ &  _P#0$   MA$  *(2  "3$@  B!$  ( /  !\#0  >0D! '@#"P!U
M !$ <P : '  (P!N 2L ; $S &H".0!I T  9P-& &8$3 !E!%( 8P59 &(%
M80!@!6H 7P9T %T&@0!<!X\ 6@>? %D'L !7!\8 5@GG %8*^P!5"O\ 50K_
M %8*_P#&%0  K1<  )D8  "*&   ?Q<  '86  !Q$P  ;A   &T-!0!M"0T
M:@D4 &<*'0!E"B8 8PLN &(,-0!@##P 7PQ" %X-2 !<#4\ 6PU6 %D-7@!8
M#F@ 5@YS %4.@ !3#H\ 40Z? % .L0!.#L@ 31#J $T0_0!-$/\ 31#_ $T0
M_P"\&P  I1P  )(=  "#'@  =QT  &\<  !I&@  9A<  &04  !D$ @ 8@\0
M %\0& !=$"$ 6Q$I %H1,0!8$C@ 5Q(^ %8210!4$DP 4Q-3 %$36P!0$V4
M3A1P $P4?0!+%(P 212< $<5K@!&%<4 117H $46_@!%%O\ 117_ $45_P"U
M'P  GB$  (LB  !\(@  <2(  &@A  !B'P  7QT  %P:  !;%P( 6A4- %<6
M% !5%AT 5!<E %(8+0!1&#0 3Q@[ $X90@!-&4@ 2QI0 $H:6 !(&F( 1QIM
M $4;>@!#&XD 0AN: $ ;K  _&\( /ASE #T<_  ^'/\ /AO_ #X;_P"O(P
MF"0  (8E  !W)@  ;"8  &,E  !=)   62(  %8?  !4'0  4QP+ %$<$@!.
M'1H 31TB $L>*0!*'C$ 21\W $<?/@!&($4 12!- $,@50!"(%\ 0"%J #\A
M=P ](8< .R&8 #DAJ@ X(L  -R+C #<B^P W(O\ ."'_ #@A_P"J)@  E"<
M ($I  !S*0  9RD  %\I  !8*   5"8  %$C  !/(@  3"(' $HB$ !((A<
M1R,? $4D)@!$)"X 0B0T $$E.P! )4, /R5* #TF4P \)EP .B9G #DF=0 W
M)X0 -2>6 #0GJ  R)[X ,2?A #$G^0 R)O\ ,B;_ #,E_P"E*0  CRH  'TL
M  !O+   9"T  %LL  !5*P  4"H  $PH  !*)@  1R<$ $0G#0!"*!0 02@<
M #\I(P ^*2L /2DR #PJ.0 [*D  .2I( #@K4  V*UH -2ME #,K<@ Q*X(
M,"R4 "XLIP L++P *RS> "PL^  L*_\ +2K_ "TJ_P"A+   BRT  'DN  !K
M+P  8"\  %@O  !1+@  3"X  $@L  !%*P  02L  #\L"P ]+!$ .RT9 #HN
M(0 Y+B@ -RXO #8O-@ U+SX -"]% #,O3@ Q,%@ ,#!C "XP<  L,(  *C"2
M "DPI0 G,+H )C#< "8P]P G+_\ *"__ "@N_P"<+@  AS   '8Q  !H,@
M73(  %4R  !.,0  2#$  $0P  ! +P  /#   #HQ"0 W,1  -C(6 #4R'@ S
M,R4 ,C,L #$S,P P-#L +S1# "TT3  L-%8 *C5A "DU;@ G-7X )360 ",U
MHP B-;D (379 "$T]@ B-/\ (S/_ ",R_P"8,0  @S,  '(T  !E-   6C4
M %$U  !+-   130  $ T   Z,P  -S0  #0U!@ R-@X ,#<3 "\W&P N-R(
M+3@I "LX,0 J.#@ *3E  "@Y20 F.5, )3E? ",Y;  A.GP (#J. !XZH@ <
M.K< &SG5 !PY]0 =./\ '3C_ !XW_P"3-   ?S8  &XW  !A-P  5S<  $XW
M  !(-P  0C<  #PW   U.   ,CD  "\Z @ L.PL *CP1 "D\&  H/1\ )CTF
M "4]+@ D/34 (SX] "(^1@ @/E  'SY< !T_:0 ;/WD &C^, !@_H  6/[4
M%3[2 !8^\P 7/?\ &#S_ !@\_P".-P  >C@  &HY  !>.@  4SH  $LZ  !%
M.@  /SH  #DZ   R/   +CX  "E    F00@ )$(. ")"%  A0AL ($,C !]#
M*@ >0S( '$,Z !M$0P :1$T &$19 !=$9P 51'< $T2* !)$G@ 11+, $$30
M !!#\@ 10O\ $D+_ !-!_P").P  =CP  &8]  !:/0  4#T  $@]  !"/0
M/#T  #8^   O0   *D(  "5$   A1@, '4@, !M)$0 921< &$D> !=))@ 6
M22X %4HV !1*0  32DH $4I6 !!*9  /2G0 #DJ'  U*FP ,2K  "DK*  M)
M[  ,2/\ #4?_  U'_P"#/@  <3\  &)   !60   34   $5    _0   .4$
M #)"   K10  )D<  "%)   <2P  %DX' !-0#@ 24!, $5 9 !!0(0 /4"D
M#E Q  U0.P -448 "U%1  I17P )46\ !U"!  50E@ #4*L  E#%  -/Z  #
M3_L !4[_  9-_P!]0@  :T,  %U$  !21   2D0  $-#   \1   -44  "Y'
M   G2@  (4P  !Q/   740  $E0#  Y7"@ +6!  "E@5  A8'  '6"0 !E@L
M  58-@ #6$   5A,  !86@  6&D  %A\  !8D0  5Z<  %?   !6Y0  5OD
M %7_  !5_P!V1P  9D<  %E(  !/1P  1T<  $!'   X2   ,$H  "E-   B
M4   '%,  !95   16   #5L"  E>"0 $7PX  %\2  !?&   8!\  & G  !@
M,   8#L  &!'  !@5   8&,  &!V  !@BP  7Z(  %^[  !?X@  7OD  %W_
M  !=_P!O2P  84P  %5,  !,2P  1$L  #M,   R3@  *U$  "-4   <5P
M%EL  !%>   -8   "&,   )F!P  9PP  &</  !H$P  :1D  &HA  !J*0
M:C0  &I   !J30  :ET  &IO  !JA0  :IT  &FV  !HW0  :/<  &?_  !F
M_P!I40  7%   %)0  !*3P  /U   #53   M5@  )%D  !U=   68   $&0
M  QG   &:@   &X   !O P  < @  '$-  !R$   =!0  '4;  !V(P  =RP
M '<X  !V1@  =E8  '9H  !V?@  =I<  '6Q  !TTP  <_4  '/_  !R_P!C
M5@  6%4  %!4  !$50  .5@  "];   F7P  '6,  !5G   0;   "G    1S
M    =@   'H   !\    ? ,  'X(  !_#   @1   ((4  "$&P  A20  (8O
M  "&/0  ADT  (5?  "%=0  A8\  (2I  "#R0  @O$  ('_  " _P!?6P
M5EH  $E;   ]7@  ,F$  "=F   >:P  %7    YU   )>0   7X   "!
MA0   (@   "*    BP   (T!  ".!@  D L  )$/  "3%   E1L  )<F  "7
M-   ET0  )=6  "6;   E88  )6B  "4P0  D^H  )+_  "2_P!=80  3V$
M $)D   V:0  *FX  !]T   5>0  #G\   >$    B0   (X   "2    E@
M )@   ":    FP   )T   "?    H0,  *,(  "E#0  IQ,  *D<  "J*
MJCD  *I+  "J80  J7H  *B9  "HM0  I]T  *?X  "F_P!6:   2&P  #IP
M   N=@  (GT  !>$   .B@  !Y    "6    F@   )\   "C    IP   *H
M  "K    K0   *\   "Q    LP   +4   "X!0  N@P  +T2  # '   P"T
M ,!   "_50  OVX  +Z+  "^J   OLD  +WO  "\_@!.=   0'D  #)_   E
MAP  &8X  !"5   'G    *(   "G    K    +    "U    N0   +P   "]
M    OP   ,$   ##    Q@   ,@   #*    S0(  - +  #5$@  UB$  -<T
M  #820  V6   -I\  #:F@  V[4  -O9  #;\@!&@@  .(D  "N0   =F
M$J    JG    K@   +0   "Y    O@   ,(   #(    RP   ,X   #/
MT@   -0   #6    V@   -T   #?    X@   .8   #J"@  [Q,  / E  #R
M.@  \U$  /1K  #TB0  ]:4  /6_  #UW0#_  8 _P # /\ !0#_  L _P 0
M /\ %P#_ "( _P M /\ .0#_ $0 _P!- /\ 50#_ %T _P!D /\ :@#_ '
M_0!V /L ? #Y (, ]P"* /4 D@#S )L \ "F .X LP#K ,0 Z0#D .< ^0#F
M /\ Y0#_ -, _P#' /\ OP#_ +L _P#_    _P   /\   #_  ( _P + /\
M$@#_ !T _P H /\ ,P#_ #X _ !' /@ 3P#T %< \0!= .X 8P#L &D Z@!O
M .@ =0#F 'P Y "# .( BP#? )4 W "? -D JP#5 +L T@#4 ,\ \@#- /\
MS #_ ,4 _P"Z /\ M #_ +  _P#_    _P   /\   #_    _P & /D #P#U
M !< \P B /$ +0#M #< YP!  .( 20#? %  VP!7 -< 70#4 &, T0!H ,\
M;@#, '4 R@!\ ,@ A #% (T P@"8 ,  I "] +( NP#& +D Z "X /T MP#_
M +8 _P"M /\ IP#_ *, _P#_    _P   /\   #U    ZP ! .0 # #> !,
MV0 < -, )@#1 #  S  Z ,@ 0@#$ $H P !0 +T 5@"[ %P N0!A +< 9P"U
M &T LP!T +$ ? "O (4 K0"0 *H G "H *H I@"[ *4 V@"C /4 HP#_ *(
M_P"> /\ F@#_ )< _P#_    _@   .\   #?    T    ,< !P#!  \ O  7
M +D ( "W "H M0 S +  .P"M $, JP!) *@ 3P"F %4 I !: *, 8 "A &8
MGP!M )T = "< 'T F@"( )@ E "6 *( E "R )( R0"1 .L D0#_ )  _P"0
M /\ C #_ (H _P#\    [    -D   #'    N@   +$  @"K  P IP 2 *0
M&P"A "0 H  L )X -0"; #P F !# )8 20"4 $\ D@!4 )  6@"/ %\ C0!F
M (L ;0") '8 B "  (8 C "$ )H @@"J ($ O@"  .  @ #Y '\ _P!_ /\
M?P#_ 'X _P#Q    V    ,(   "S    J    *    "9  < E0 . )( %0"0
M !X C@ F (T +@"* #8 AP ] (4 0P"$ $D @@!. ($ 5 !_ %D ?@!@ 'P
M9P!Z &\ >0!Z '< A@!U )0 = "C '( M0!R ,\ <0#Q '  _P!P /\ < #_
M '$ _P#A    Q    +    "B    EP   )$   "+  ( A@ + (, $0"! !@
M?P A 'T *0!\ #  >0 W '@ /0!V $, = !) ', 3@!R %0 < !: &\ 8@!M
M &H :P!T &H @ !H (X 9P"= &4 KP!E ,8 9 #H &0 _0!C /\ 8P#_ &0
M_P#/!0  M@<  *,(  "4"   B0<  ((#  !^    >P & '< #@!U !, <@ ;
M '$ (P!O "L ;0 R &P . !J #X :0!$ &< 20!F $\ 90!6 &, 70!B &4
M8 !O %\ >P!= (D 7 "9 %L J@!9 +\ 60#A %@ ^ !8 /\ 6 #_ %D _P#"
M#   J@T  )<.  ")#@  ?0X  '8-  !Q"@  ;P8  &T "@!K !  :0 6 &<
M'@!E "8 8P M &$ ,P!@ #D 7P _ %T 10!< $L 6P!2 %H 60!8 &( 5P!L
M %4 > !3 (8 4@"6 %$ IP!0 +L 3P'; $X"] !. _\ 3@3_ $X#_P"X$
MH1(  (X3  !_$P  =!,  &P2  !G$   90X  &,+ P!C!@P 8001 %X#&0!<
M!"$ 6P4H %D&+P!8!C4 5@<[ %4'0@!4!T@ 4PA/ %$(5@!0"5\ 3@EI $T)
M=@!+"H0 20J4 $@*I@!'"KH 1@K8 $4+\P!%#/\ 10S_ $4,_P"P%   F18
M (<8  !X&0  ;1@  &47  !?%@  7!,  %H1  !:#@8 6@P- %<,% !5#!P
M4PTD %(-*P!0#3$ 3PXX $X./@!-#D4 2PY- $H.50!(#UX 1P]H $4/=0!#
M$(0 01"5 $ 0I@ ^$+L /1#< #T1]@ ]$?\ /1#_ #X0_P"I&0  DAL  ($<
M  !R'0  9QT  %\<  !9&P  51D  %,6  !2$P  4A$* % 0$ !.$1@ 3!$@
M $H2)P!)$BX 2!,T $<3.P!%$T( 1!-) $,44@!!%%L /Q1E #X5<@ \%8$
M.A62 #@5I  W%;D -178 #46]0 V%O\ -A;_ #<5_P"C'   C1X  'L@  !M
M(0  8B$  %HA  !4'P  4!X  $T;  !,&0  2Q8& $D6#@!'%Q4 11<< $08
M) !"&"H 01@Q $ 9.  _&3\ /1E& #P:3P Z&E@ .1IC #<;;P U&WX ,QN0
M #(;H@ P&[< +QO3 "\<\P O&_\ ,!O_ # ;_P"='P  B"(  '<C  !I)
M7B0  %8D  !0(P  2R(  $@@  !&'0  11P" $,<# !!'!( /QT9 #X=(0 \
M'B< .QXN #H?-0 Y'SP -Q]$ #8?3  T(%8 ,R!@ #$@;0 O('P +2&. "PA
MH  J(;4 *2'0 "DA\@ I(?\ *B#_ "L@_P"9(@  A"4  ',F  !E)P  6R<
M %,G  !,)@  1R4  $0D  !"(0  /R$  #TA"0 [(1  .2(6 #@B'@ V(R4
M-2,K #0D,@ S)#D ,B1! # D2@ O)5, +25> "LE:P J)7H *"6, "8EGP D
M);, (R7. ",E\  D)?\ )23_ "4D_P"4)0  @"<  &\I  !B*@  5RH  $\J
M  !)*0  1"@  $ G   ])@  .B4  #<F!@ U)@X -"<4 #(G&P Q*"( ,"@I
M "\H,  M*3< +"D_ "LI1P I*5$ *"I< "8J:0 D*G@ (RJ* "$JG0 ?*K(
M'BK, !XJ[P ?*?\ ("G_ "$H_P"0*   ?"H  &PK  !?+   5"P  $PL  !&
M+   02L  #PK   X*@  -2H  #(K P P*PP +BP1 "TL&  L+!\ *BTF "DM
M+0 H+30 )RX\ "8N10 D+D\ (RY: "$O9P ?+W8 '2^( !POFP :+[  &"_*
M !@N[0 9+O\ &RW_ !LM_P",*P  >"T  &@N  !;+P  42\  $DO  !#+P
M/BX  #DN   T+@  ,"X  "TO   K, H *3$0 "<Q%0 F,1P )3(C "0R*@ C
M,C$ (3,Y " S0@ ?,TP '3-7 !LS9  :-'0 &#2& !8TF@ 4,ZX $S/( !,S
M[  4,_\ %3+_ !8Q_P"'+@  ="\  &4Q  !8,0  3C(  $8R  ! ,0  .S$
M #8Q   Q,0  *S,  "@T   E-08 (S8- "$V$@ @-QD 'S<@ !XW)P =."X
M&S@V !HX/P 9.$D %SE5 !4Y8@ 4.7$ $CF$ !$YF  0.:T #CC'  XXZP 0
M./\ $#?_ !$V_P"#,0  <#(  &$T  !5-   2S0  $0T   ]-   .#0  #,T
M   M-0  *#<  "0Y   @.@( '3L+ !L\$  9/14 &#T< !<](P 6/2L %3XS
M !0^/  2/D8 $3Y2 ! ^7P //F\ #CZ!  P^E0 +/JD "C[!  H]Y  +/?L
M##S_  T[_P!]-   :S8  %TW  !1-P  2#<  $$W   [-P  -3<  # W   J
M.0  )3L  " ]   </P  %T$& !1##0 20Q( $4,8 !%#'P 01"< #T0O  Y$
M.0 -1$, #$1.  M$6P )1&H !T1\  9$D  $0Z4  D.]  -#X  #0_8 !$+_
M  9!_P!X.   9SD  %DZ  !..@  13H  #XZ   X.@  ,SH  "T[   G/0
M(4   !Q"   71   $T8#  ])"@ -2@\ #$H4  M*&P )2B, "$HK  =*-  %
M2CX !$I)  )*5@  2F4  $IW  !*BP  2J$  $FY  !)W0  2?4  $C_  !(
M_P!R/   8CT  %4^  !*/@  0CT  #P]   V/0  +SX  "E    C0@  '44
M !='   32@  #TP"  M/"0 '4 T  U$1  !1%P  41X  %$F  !1+P  43D
M %%$  !240  4F   %%R  !1AP  49T  %&U  !0V   4/4  $__  !/_P!L
M0   74$  %%!  !'00  0$   #E    R00  *D,  "1&   >2   %TL  !).
M   .40  "U,!  96!P  5PP  %@0  !8$P  61D  %HA  !:*0  6C,  %H_
M  !:3   6EH  %IL  !:@0  69D  %FQ  !8T0  6/0  %?_  !7_P!E10
M6$4  $U%  !%1   /D0  #5%   M1P  )4H  !Y-   84   $E,   Y6   *
M60  !%P   !>!   7PD  & -  !A$   8A4  &,;  !D(P  9"T  &0X  !D
M10  9%0  &1F  !D>P  8Y,  &.M  !BS   8?(  &'_  !@_P!?2@  4TH
M $I)  !#2   .4D  "],   G3P  'U(  !A5   260  #5T   A@   "8P
M &8   !H 0  :04  &H*  !K#0  ;1$  &X6  !P'0  <28  '$Q  !P/@
M<$X  '!?  !P<P  ;XT  &^G  !NQ@  ;>\  &S_  !L_P!:3P  4$X  $A-
M   ]3@  ,U$  "E4   @6   &%P  !%@   ,9   !F@   !K    ;P   '(
M  !T    =0   '<$  !X"0  >@T  'P0  !]%@  ?QX  ( H  " -0  @$4
M ']6  !_:P  ?X0  'Z@  !]O@  ?.D  'O_  !Z_P!65   3E,  $)4   W
M5@  +%H  ")?   88P  $6@   MM   #<@   '8   !Z    ?0   (    "#
M    A    (8   "' @  B0<  (L,  "-$   D!8  )(?  "2+   DCL  ))-
M  "18@  D7H  (^7  "/M   CN$  (S[  ",_P!560  2%H  #M=   O80
M)&8  !EL   1<@  "G<   )]    @@   (8   "+    C@   )$   "3
ME0   )<   "9    FP   )T$  "?"@  H@\  *06  "F(0  IC$  *9#  "E
M5P  I'   *..  "CJP  H=   *#U  "?_P!.80  0&0  #-I   G;@  &W4
M !%\   +@P   (D   ".    DP   )@   "=    H0   *0   "E    IP
M *D   "K    K0   +    "R    M0@  +@.  "\%@  O"4  +PW  "[3
MNF0  +F!  "WH@  M\   +?J  "W_ !&:P  .7   "MW   ??P  $X8   N.
M   !E0   )L   "A    I@   *L   "P    LP   +<   "W    N@   +P
M  "_    P0   ,0   #'    R@   ,T%  #1#@  U!D  -0K  #40   TU@
M --T  #3D@  TK   -+3  #2\@ ^>0  ,8   ".(   7D0  #9D   .@
MIP   *X   "S    N    +T   #"    Q@   ,H   #*    S0   ,\   #2
M    U0   -D   #=    WP   .,   #G!0  ZP\  .P?  #M,P  [DL  .]D
M  #O@@  \)\  /&Y  #QV #_    _P   /\ ! #_  D _P . /\ %0#_ !X
M_P I /\ - #_ #\ _P!( /\ 4 #_ %@ _P!> /\ 90#] &L ^P!Q /D =P#X
M 'X ]@"% /, C0#Q )< [@"B .L KP#H ,  Y@#@ ., ^ #B /\ VP#_ ,L
M_P#! /\ N0#_ +0 _P#_    _P   /\   #_    _P ) /\ $ #_ !D _P C
M /\ +@#] #D ^0!" /4 2@#R %( [@!8 .L 7@#I &0 Y@!J .0 < #B '8
MWP!] -T A@#9 (\ U0": -$ IP#. +8 RP#. ,D \ #' /\ Q0#_ +L _P"T
M /\ K0#_ *D _P#_    _P   /\   #_    ^P " /8 #0#Q !, [0 > .P
M* #I #( XP [ -T 1 #8 $L TP!1 -  6 #- %T RP!C ,D : #& &\ Q !V
M ,( ?@"_ (< O "2 +H GP"W *T M0#! +( Y "Q /T KP#_ *P _P"E /\
MH #_ )P _P#_    _P   /L   #N    Y    -P " #3 !  SP 8 ,L (@#)
M "L Q@ T ,$ /0"] $0 N@!+ +< 40"U %8 L@!< +  80"N &< K !N *H
M=@"H '\ I@"* *, E@"A *4 GP"V )T T0"< /, FP#_ )P _P"6 /\ DP#_
M )  _P#_    ]@   .<   #3    Q@   +T  P"X  T LP 3 +$ ' "O "4
MK@ N *D -@"F #T HP!$ *$ 2@"? $\ G0!5 )L 6@": &  F !F )8 ;@"4
M '< D@"! )  C@". )P C "M (H PP") .@ B #_ (D _P"' /\ A0#_ ((
M_P#S    XP   ,P   "\    L    *<   "A  @ G@ / )L %@"9 !\ F  G
M )8 +P"3 #< D0 ] (X 0P", $D BP!. (D 5 "' %D A0!@ (0 9P"" &\
M@ !Z 'X A@!\ )0 >@"D 'D N !X -@ =P#W '@ _P!X /\ =P#_ '4 _P#F
M    RP   +<   "H    G@   )8   "/  0 BP , (@ $@"' !D A0 A (0
M*0"" #  ?P W 'T /0!\ $, >@!( 'D 30!W %, =@!9 '0 80!R &D <0!S
M &\ ?P!M (T ; "= &H KP!I ,@ : #M &D _P!I /\ :0#_ &D _P#2
MN    *4   "7    C0   (8   "!    ?  ( 'D #@!W !0 =@ < '0 (P!S
M "L <0 Q &\ -P!N #T ; !# &L 2 !J $X : !4 &< 6P!E &, 8P!M &(
M> !@ (< 7P"6 %T J != +X 7 #D %P ^P!< /\ 7 #_ %P _P#"    J@$
M )@#  ")!   ?P(  '@   !T    <  $ &T # !K !$ :0 7 &@ '@!F "4
M90 L &, ,@!B #@ 8  ] %\ 0P!> $D 7 !/ %L 5@!: %X 6 !H %< <P!5
M ($ 5 "1 %( HP!1 +< 40#6 %$ ]0!1 /\ 40#_ %( _P"V!P  GPD  (T+
M  !^#   <PL  &P*  !H!P  90,  &, !P!A  T 7P 3 %T &@!< "$ 6P G
M %D +0!8 #, 5@ Y %4 /P!4 $4 4P!+ %$ 4@!0 %H 3P!D $T ;P!, 'T
M2@"- $D GP!( +( 1P#, $< [P!& /\ 1P#_ $< _P"L#   E0X  (,0  !U
M$   :Q   &,/  !>#@  6PP  %H) @!9! H 5P / %4 %0!3 !P 4@ C %$
M*0!/ "\ 3@ U $T!.P!, 4$ 2@)( $D"3P!( E< 1@-A $4#;0!# WH 0@.+
M $ #G  _ Z\ /@/( #T$Z@ ]!?P /0;_ #X&_P"D$   CA(  'P3  !N%
M9!0  %P3  !6$@  4Q$  %$.  !0# 4 4 D, $\'$0!-!Q< 2P@? $D()0!(
M"2L 1PDQ $8). !$"CX 0PI% $(*30! "U4 /PM? #T+:P \"WD .@R* #@,
MG  W#*\ -0S' #4,Z0 U#?T -0W_ #8,_P"=$P  AQ4  '87  !I&   7A@
M %88  !0%P  314  $H3  !)$0  20X' $@-#@!&#1, 1 T: $,.(0!"#B@
M0 XN #\.-0 ^#SP /0]# #L02P Z$%0 .!!> #80:P T$'D ,A"* #$0G  O
M$+  +1#) "T1[  M$?\ +A'_ "\0_P"7%@  @AD  '$;  !D'   61P  %$<
M  !,&P  1QH  $08  !#%0  0A," $$2"P! $1  /A(7 #P2'@ [$R4 .A,K
M #@3,@ W$SD -A1  #042  S%%$ ,11< # 5:  N%7< +!6( "H5F@ H%:X
M)Q7' "85Z@ G%?\ *!7_ "D5_P"1&@  ?1P  &T>  !@'P  5A\  $X?  !(
M'@  0QT  $ <   ^&@  /1@  #L7!P Y%@X .!<4 #87&P U&"( ,Q@H #(8
M+P Q&38 ,!D] "X91@ M&D\ *QI9 "H:9@ H&G0 )AJ& "0:F0 B&JT (1K%
M " :Z  A&OX (AK_ ",:_P"-'0  >1\  &DA  !<(@  4B(  $HB  !$(0
M/R$  #P@   Y'@  .!L  #4<!  T' T ,AP2 # =&  O'1\ +ATE "T>+  K
M'C, *AX[ "D?0P G'TT )A]7 "0?9  B'W( (!^$ !\?EP ='ZL &Q_# !L?
MYP ;'_T '1__ !X>_P")(   =2(  &4C  !9)   3R4  $<E  !!)   /",
M #@C   U(@  ,R   # @ 0 N(0H +"$0 "LA%0 J(AP *"(C "<B*0 F(S
M)2,X ",C00 B)$H (215 !\D80 =)'  &R2" !DDE0 7)*H %B3! !4DY0 6
M)/P %R/_ !DC_P"%(@  <20  &(F  !6)P  3"<  $0G   ^)P  .28  #4F
M   Q)0  +B0  "LE   I)0< )R8. "4F$P D)QD (R<@ "(G)P A*"X ("@V
M !XH/@ =*$@ &RE3 !DI7P 8*6X %BF  !0IE  2*:@ $2G  !$HY  1*/L
M$RC_ !0G_P" )0  ;B<  %\H  !3*0  22H  $(I   [*0  -BD  #(H   N
M*   *B@  "8I   D*@0 (BL, " K$0 ?+!8 '2P= !PL)  ;+2L &BTS !@M
M/  7+44 %BY0 !0N70 2+FP $2Y^ ! ND@ .+J< #2V]  TMWP -+?D #BS_
M ! L_P!\*   :BH  %LK  !0+   1BP  #\L   Y+   -"L  "\K   K*P
M)BP  "(N   ?+P  '# ) !HQ#@ 9,1, %S$: !8R(0 5,B@ %#(P !,R.0 2
M,T, $3-. ! S6P .,VD #3-Z  PSC@ *,Z( "#*Y  @RV0 (,O0 "C'_  LQ
M_P!W*P  9BT  %@N  !-+P  0R\  #PN   V+@  ,2X  "TN   I+@  (S
M !\R   ;,P  %S4% !0V#  2-Q$ $3<6 !$W'0 0."0 #S@L  XX-0 -.#\
M##A*  LX5P ).&4 !SAV  4XB@ #.)\  3>U  $WTP "-_$  S;_  4V_P!S
M+@  8C   %0Q  !),0  03$  #DQ   T,0  +S   "LP   E,@  (#,  !LV
M   7.   $SH" ! \"0 -/0X ##T3  L]&0 */2$ "3TI  @],0 &/CL !3Y&
M  ,^4@ !/F$  #YR   ^A@  /9P  #VR   ]T   //   #S_   \_P!M,@
M73,  % T  !&-   /C0  #<T   R,P  +3,  "<T   B-@  '3@  !@Z   4
M/0  $#\"  U!"  )0PT !D01  -$%@ "1!T  $0D  !$+0  1#8  $1!  !$
M3@  1%P  $1M  !$@0  1)@  $.O  !#S0  0O   $+_  !"_P!H-@  6#<
M $PX  !#.   .S<  #4V   P-@  *3<  ",Y   >.P  &#T  !-    00@
M#44!  A'!P #20P  $D/  !*$P  2QD  $L@  !+*   2S(  $L]  !,20
M3%<  $MH  !+?0  2Y0  $JL  !*R@  2>\  $G_  !)_P!B.@  5#L  $D[
M  ! .P  .3H  #,Y   L.@  )3P  !\_   900  $T0  !!'   ,20  "$P
M  )/!0  4 H  % -  !1$   4A4  %0;  !4(P  5"P  %0W  !41   5%(
M %1C  !4=P  5(\  %.H  !2Q@  4NT  %'_  !1_P!</P  3S\  $4_   ^
M/@  -ST  "\^   G0   ($,  !E&   320  #TP   M/   &4@   %0   !7
M @  6 <  %D+  !:#@  6Q$  %T6  !>'0  7R8  %\Q  !>/0  7DP  %Y=
M  !><0  78D  %VC  !<P0  6^L  %K_  !:_P!61   2T,  $-"   \00
M,D(  "E%   A2   &DL  !-.   .4@  "E4   -9    6P   %X   !@
M8@(  &,&  !E"@  9@X  &@1  !J%P  :Q\  &LI  !K-@  :T4  &M6  !J
M:@  :H(  &F=  !HNP  9^<  &;_  !E_P!12   2$@  $%&   W1P  +$H
M "--   ;40  $U4   Y9   (70   6$   !D    9P   &H   !L    ;@
M '    !R!0  <PD  '4-  !W$0  >A@  'LA  ![+@  >CT  'I.  !Y8@
M>7D  'B6  !WLP  =>   '3\  !S_P!.30  1TP  #M-   P3P  )E,  !Q8
M   37   #6$   9F    :@   &\   !R    =@   'D   !\    ?0   '\
M  "!    @P(  (8'  "(#   BQ$  (X8  ".)   CC,  (U$  ",6   BV\
M (J,  ")J@  B,\  (;W  "%_P!-40  05,  #15   I6@  'E\  !1E   -
M:@  !7    !V    >P   '\   "#    AP   (H   "-    C@   )$   "3
M    E0   )@   ":!0  G0P  * 1  "C&@  HR@  *(Z  "A3@  H&4  *"!
M  ">H   G<$  )ON  ":_P!&60  .5P  "UA   A9P  %FX   YU   %>P
M ($   "'    C0   )(   "6    F@   )T   "?    H0   *0   "F
MJ    *L   "N    L0,  +0+  "X$0  N1X  +DO  "X0P  MUH  +5V  "T
MEP  M+4  +'B  "P_  _9   ,6D  "5O   8=P  #W\   :'    C@   )0
M  ":    H    *4   "J    K@   +$   "R    M0   +<   "Z    O
M +\   ##    Q@   ,D   #."@  TA,  -(C  #1-P  T$\  ,YJ  #-B@
MRJL  ,O+  #+[P W<0  *7@  !V    1B0  ")$   ":    H0   *<   "M
M    LP   +D   "^    P@   ,4   #&    R0   ,P   #.    T@   -4
M  #:    W@   .$   #E    Z@L  .L7  #J*P  ZD,  .I>  #J>@  ZYD
M .NU  #KU0#_    _P   /\  0#_  < _P - /\ $@#_ !L _P E /\ +P#_
M #H _P!# /\ 2P#_ %, _P!: /T 8 #[ &8 ^@!K /@ <@#V '@ ] "  /$
MB0#O )( [ "= .D J@#F +P XP#< -\ ]P#= /\ S #_ +X _P"U /\ L #_
M *T _P#_    _P   /\   #_    _P & /\ #0#_ !0 _P ? /\ *0#[ #,
M]P ] /, 10#O $T [ !3 .@ 60#E %\ XP!E .  :@#= '$ V@!X -8 @ #2
M (H SP"5 ,P H@#( +( Q0#) ,( [0#  /\ NP#_ +  _P"H /\ I #_ *$
M_P#_    _P   /T   #Z    ^    /  "0#L !$ Z  9 .< (P#E "T W@ V
M -8 /@#1 $8 S0!, ,H 4@#( %@ Q0!= ,, 8P#  &D O@!P +P > "Y ($
MMP"- +0 F@"Q *D K@"\ *P X0"J /P J #_ *  _P"9 /\ E@#_ )0 _P#_
M    ^0   /(   #G    VP   -$ ! #*  T QP 4 ,0 '0#" "8 OP O +L
M-P"W #\ M !% +$ 2P"N %$ K !6 *H 7 "H &$ I@!H *, < "A 'D GP"$
M )T D0": *  F "Q )8 S "5 /$ E #_ )$ _P"+ /\ B #_ (8 _P#W
M[    -X   #)    O    +0   "O  H JP 0 *D %P"H "  IP H *( , "?
M #@ G  ^ )H 1 "8 $H E@!/ )0 50"3 %H D0!A (\ : "- '$ BP![ (D
MB "' )< A0"H (, O@"! .0 @ #_ (  _P!\ /\ >P#_ 'D _P#I    UP
M ,$   "Q    I@   )T   "7  4 E  - )( $@"0 !H CP B (X *@"+ #$
MB0 X (< /@"% $, @P!( ($ 3@!_ %0 ?@!: 'P 80!Z &D > !S '8 ?P!U
M (X <P"? '$ LP!P -  ;P#V &\ _P!O /\ ;0#_ &P _P#:    OP   *P
M  ">    DP   (P   "%    @@ ) '\ #P!^ !4 ?0 < 'P ) !Z "L =P Q
M '4 -P!T #T <@!" '$ 2 !O $T ;@!3 &P 6@!K &( :0!L &< > !F (8
M9 "7 &( J@!A ,( 8 #K &$ _P!A /\ 80#_ &  _P#%    K0   )L   "-
M    @P   'P   !W    <@ % '  # !N !$ ;  7 &P '@!K "4 :0 L &<
M,0!F #< 9  ] &, 0@!B $@ 8 !. %\ 50!= %T 7 !F %H <@!9 (  5P"0
M %8 HP!5 +D 5 #> %0 ^P!4 /\ 50#_ %4 _P"V    GP   (T   !_
M=0   &X   !I    9@ ! &, "0!A  X 8  3 %\ &0!> "  70 F %L + !:
M #( 6  W %< /0!6 $, 50!) %, 4 !2 %@ 40!A $\ ; !. 'H 3 "* $L
MG !* +$ 20#. $D \P!) /\ 20#_ $H _P"J 0  E 4  (('  !T"   :@@
M &,&  !>!   6P   %D !0!7  P 5@ 0 %0 %0!3 !L 4@ B %$ * !0 "T
M3@ S $T . !, #X 2P!% $H 3 !( %0 1P!= $8 : !$ '4 0P"% $$ F !
M *L 0 #% #\ Z@ _ /\ 0 #_ $  _P"@"   B@L  'D-  !L#0  80T  %H-
M  !5"P  4@D  % &  !/ @@ 3@ - $P $@!+ !< 2@ > $D (P!' "D 1@ O
M $4 - !$ #H 0@!! $$ 2 !  %  /@!: #T 9  \ '( .@"" #D E  X *<
M-P"^ #8 XP V /D -@#_ #< _P"8#0  @PX  '(0  !E$0  6Q$  %,0  !.
M$   2@X  $@-  !'"@, 1P<* $4$#@!$ A, 0@(: $$"( !  R4 /@,K #T$
M,0 \!#< .P0^ #H%10 Y!4X -P57 #8%8@ T!G  ,@:  #$&D@ P!J4 +P6[
M "X%W0 N!O4 +0?_ "X'_P"1$   ?1$  &P3  !?%   510  $X4  !($P
M1!(  $$0  ! #@  0 T& $ *#  ^"1  / D6 #L*'  Y"B( . HH #<++@ V
M"S4 -0L[ #,+0P R#$P , Q6 "\,80 M#&\ *PQ_ "H,D@ H#*4 )PR[ "4,
MW0 E#?4 )@W_ "<-_P"+$@  =Q0  &<6  !;%P  41@  $D7  !#%P  /Q4
M #P4   Z$@  .1$! #D/"  X#@T -PX2 #4.&  T#A\ ,@XE #$/+  P#S(
M+Q Z "T00@ L$$L *A!5 "@080 F$&\ )!"  ",0DP A$*< 'Q"] !X0X  >
M$?< 'Q#_ " 0_P"&%   <Q<  &,9  !7&@  31L  $4:  ! &@  .QD  #@8
M   U%@  -!0  #,2!  R$@L ,1(0 "\2%0 M$AP +!,B "L3*0 J$S  *!,W
M "<4/P F%$@ )!13 "(47P @%6T 'Q5^ !T5D0 ;%:4 &16[ !@5W@ 8%?@
M&13_ !H4_P""%P  ;QH  %\<  !3'0  2AT  $(=   \'0  -QP  #0;   Q
M&@  +QD  "X6   L%P@ *Q8. "D7$P H%QD )Q@@ "48)@ D&"T (Q@T "(9
M/0 @&48 'AE1 !T970 ;&FL &1I\ !<:CP 5&J, %!FZ !(9VP 3&?8 %!G_
M !48_P!]&@  :QT  %P?  !0(   1R   #\@   Y'P  -!\  #$>   M'0
M*QP  "D;   G&P4 )1L, "0<$0 B'!8 (1P= " =(P ?'2H 'ATR !P>.@ ;
M'D0 &1Y. !<>6P 6'FD %!]Z !(>C0 1'J( $!ZX  X>V  /'O4 $!W_ !$=
M_P!Z'0  9Q\  %DA  !-(@  1"(  #PB   V(@  ,B$  "XA   J(   )R
M "0?   B( ( (" * !XA#P =(10 '"$: !LB(0 9(B< &"(O !<B.  5(T$
M%"-, !(C6  1(V< $"-X  XCBP -(Y\ #".T  LCT  +(O  #"+_  TA_P!V
M'P  9"(  %8C  !+)   020  #HD   T)   +R,  "LC   H(P  )",  " C
M   =)   &R4' !DF#0 7)A$ %B87 !4G'@ 4)R4 $R<L !(G-0 1*#\ $"A*
M  XH5@ -*&0 #"AT  HHAP )*)L !R>Q  4GS  &)^P !R;^  @F_P!Q(@
M8"0  %,F  !()P  /R<  #<F   Q)@  +28  "DE   E)0  (B4  !TG   9
M*   %BH$ !0K"P 2+!  $2P4 ! L&P 0+"( #BPI  XM,@ -+3L "RU&  HM
M4@ (+6  !BUP  0M@P "+9@  "RN   LR0  +.L  2O\  (K_P!M)0  72<
M $\H  !%*0  /"D  #4I   O*   *R@  "<G   C)P  'R@  !LJ   7+
M$RX" ! P"  .,0T #3$2  PQ%P +,1X "C$F  @R+@ ',C< !3)"  ,R3@ !
M,EP  #)L   R?P  ,I4  #&L   QQP  ,.H  ##\   P_P!H*0  6"H  $PK
M  !!+   .2P  #(K   M*P  *2H  "4J   @*P  '"P  !<N   3,   $#("
M  XT!P *-PP !S<0  4W%  #-QL  C<B   W*@  .#,  #@^   X2@  .%@
M #AH   X?   -Y(  #>I   VQ0  -NH  #;]   U_P!C+   5"X  $@O   ^
M+P  -BX  # N   K+0  )RT  "(M   =+P  &#$  !0S   0-0  #C<!  HZ
M!P &.PL  CP.   ]$@  /A<  #X>   ^)@  /B\  #XZ   ^1@  /E0  #YD
M   ^=P  /H\  #VG   ]PP  /.D  #S]   [_P!>,   4#$  $0R   [,@
M-#$  "XP   I+P  )#   !XR   9-   %#8  ! Y   -.P  "CT   5 !0
M00H  $(-  !#$   1!0  $4:  !&(@  1BL  $8U  !&00  1D\  $9?  !&
M<P  18H  $6D  !$P   0^@  $/^  !"_P!8-   2S4  $$U   Y-0  ,C0
M "TS   F-   (#4  !HX   4.@  $#T   U    )0@  !$4   !' P  2 <
M $H+  !+#@  3!$  $X5  !/'   3R4  $\O  !//   3TH  $]:  !.;0
M3H4  $V@  !,O   2^<  $O^  !*_P!3.0  1SD  #XY   W.   ,3<  "DW
M   A.0  &SP  !4_   00@  #$4   =(   "2@   $T   !/    400  %('
M  !4"P  50X  %<1  !9%P  6A\  %DI  !9-@  640  %E4  !89P  6'\
M %>:  !6MP  5>,  %3]  !4_P!./0  0ST  #P\   U.P  +#P  "0^   <
M00  %40  !!(   +2P  !4X   !1    5    %<   !9    6P   %T"  !>
M!@  8 L  &(.  !D$@  9Q@  &<B  !F+@  9CP  &9-  !E8   97<  &23
M  !CL0  8=T  &#\  !?_P!)0@  04$  #H_   P0   )D,  !Y&   52@
M$$X   I2   #5@   %H   !=    8    &,   !E    9P   &D   !K 0
M;04  &\*  !R#@  =1(  '<;  !V)@  =C4  '5&  !T60  =&\  '.+  !R
MJ0  <,T  &_W  !N_P!&1@  0$4  #5&   J2   ($P  !=1   05@  "5H
M  %?    8P   &@   !K    ;P   '(   !U    =P   'D   ![    ?0
M ( #  "#"   A@T  (D3  "*'0  BBL  (D\  "(3P  AF8  (6!  "$H
M@L(  ('P  !__P!&2P  .DP  "Y/   C4P  &%@  !!>   )9    &D   !O
M    =    '@   !\    @0   (0   "'    B    (L   ".    D    ),
M  "6    F0<  )T-  "A%   H"$  * Q  ">1   G5L  )QV  "9E@  F;4
M );E  "5_@ _4@  ,E4  "9:   ;8   $6<   EM    =    'L   "!
MA@   (L   "0    E    )<   "9    G    )\   "A    I    *<   "J
M    K0   +$&  "U#0  N!8  +<F  "V.0  M5   +1J  "RB0  L*H  *[/
M  "M]0 W7   *V$  !YH   3<   "W@   "     AP   (X   "5    F@
M )\   "D    J    *P   "M    L    +,   "U    N    +L   "_
MPP   ,<   #+!0  T0X  -$;  #0+@  ST4  ,U?  #+?@  R9X  ,B^  #%
MZ0 O:0  (W   !9Y   -@0   8L   "3    FP   *(   "H    K@   +0
M  "X    O0   ,    #"    Q0   ,@   #+    S@   -$   #6    VP
M -\   #D    Z 8  .L1  #J(P  ZCH  .E4  #G<@  Y9,  ..S  #CU #_
M    _P   /\   #_  0 _P + /\ $ #_ !< _P A /\ *P#_ #4 _P ^ /\
M1P#_ $X _P!5 /P 6P#Z &$ ^ !F /8 ;0#T ', \@![ .\ A #M (X Z@"9
M .8 IP#C +D WP#5 -L ]P#6 /\ P #_ +( _P"J /\ I0#_ *( _P#_
M_P   /X   #\    _  # /X "P#_ !$ _P : /T ) #Y "X ]  X /  0 #L
M $@ Z0!. .8 5 #B %H WP!? -P 90#8 &L U !R -  >P#- (4 R@"1 ,<
MG@## *X P #% +T ZP"[ /\ L #_ *0 _P"< /\ F #_ )4 _P#_    ^@
M /0   #Q    \@   .H !0#G  X X@ 5 .$ '@#A "@ V  Q -  .0#+ $
MR !' ,4 30#" %, OP!8 +T 7@"[ &0 N0!K +8 <P"T 'P L0"( *X E0"K
M *0 J "X *8 W "C /L GP#_ )4 _P"/ /\ BP#_ (D _P#Y    [P   .<
M  #?    SP   ,@   #!  H OP 1 +P & "[ "$ N0 J +0 ,@"Q #H K@!
M *L 1@"H $P I@!1 *, 5@"A %P GP!C )T :@"; ', F0!^ )8 C "4 )L
MD@"M )  QP". /  C0#_ (8 _P"  /\ ?0#_ 'P _P#M    X    -$   "_
M    LP   *H   "F  4 H@ - *$ $P"@ !L GP C )L *P"8 #( E0 Y ),
M/P"1 $0 CP!* (X 3P", %4 B@!; (@ 8P"& &L A !V (( @@"  )( ?@"C
M 'P N@!Z .$ >0#_ '< _P!R /\ < #_ &\ _P#=    RP   +8   "G
MG0   )0   ".  $ BP * (D $ "( !4 AP = (< )0"$ "P @@ R '\ . !]
M #T >P!# 'D 2 !X $X =@!4 '4 6P!S &, <0!N &\ >@!M (D ; ": &H
MK@!I ,P : #V &< _P!E /\ 9 #_ &, _P#*    M    *$   "3    B0
M ((   ![    >  % '8 # !U !$ =  8 ', 'P!R "4 <  L &X ,@!L #<
M:@ \ &D 0@!H $@ 9@!. &4 50!C %T 8@!F &  <@!> (  70"2 %L I0!:
M +X 60#I %D _P!9 /\ 6 #_ %@ _P"Y    H@   )    "#    >0   '$
M  !M    :0 ! &8 "0!E  X 9  3 &, &0!C "  80 F &  + !> #$ 7  W
M %L / !: $( 6 !( %< 3P!6 %< 5 !@ %, ; !1 'D 4 "* $\ G@!. +0
M30#: $T ^P!- /\ 30#_ $T _P"J    E    ((   !U    :P   &0   !@
M    70   %H !0!8  P 5P 0 %8 %0!6 !L 50 A %, )P!2 "P 40 Q $\
M-P!. #T 30!# $P 2@!* %( 20!; $@ 9@!& ', 10"$ $0 EP!# *P 0@#)
M $( \0!" /\ 0P#_ $, _P">    B0   '@#  !J!   800  %H#  !5 0
M4@   %   @!.  D 30 - $P $0!+ !< 2@ < $D (@!( "< 1P M $4 ,@!$
M #@ 0P ^ $( 10!! $T /P!6 #X 80 ] &X .P!^ #H D0 Y *8 . "_ #@
MZ  X /\ .0#_ #D _P"5 P  @ <  &\)  !B"@  6 L  %$*  !,"   208
M $<#  !&  8 1  + $, #P!" !, 00 8 $$ '@ _ ", /@ I #T +@ [ #0
M.@ Z #D 00 X $D -P!2 #8 70 T &H ,P!Z #( C  Q *$ , "X "\ W@ O
M /D +P#_ #  _P","0  > P  &@-  !<#@  4@X  $L.  !%#0  00P  #\*
M   ^" ( /00( #P!#0 [ !  .@ 5 #D &@ X "  -@ E #4 *P T #  ,P W
M #( /@ Q $8 +P!0 "X 6@ M &< *P!W "H B0 I )T * "S "< T0 G /(
M)P#_ "< _P"&#   <@X  &,0  !6$0  31$  $41  ! $   / \  #D.   W
M#0  -@L$ #8("@ U!@X - 42 #($%P Q!1P , 4B "\%*  N!BX +08T "L&
M/  J!D0 *0=. "<'60 F!V4 ) =U ",'AP B!YL ( :P " &RP ?!>T 'P;^
M !\'_P" #@  ;1$  %X2  !2$P  2!,  $$3   [$P  -Q(  #01   R$
M, \! # -!@ P"PL +PH0 "T*%  L"QD *@L? "D+)0 H#"L )PPR "8,.@ D
M#$, (PQ- "$-6  @#64 '@UU !P-B  :#9P &0VQ !@,R@ 7#.L %PW\ !@,
M_P![$0  :1,  %H5  !.%@  118  #T6   X%0  ,Q4  # 4   M$P  *Q(
M "H0 P J#P@ *0X- "@.$0 F#A8 )0\= "0/(P C#RD (1 Q " 0.0 >$$(
M'1!, !L06  9$&8 %Q!V !40B0 4$)X $A"S !$0S@ 1$.X $A#^ !(0_P!W
M$P  914  %<7  !+&   0AD  #H9   T&   ,!<  "P7   I%@  )Q4  "84
M 0 E$@0 (Q(+ "(2#P A$A0 (!(: !X3(  =$R< '!,N !H3-@ 9%$  %Q1*
M !845@ 4%&0 $A1T !$4AP 0%)P #A2Q  T4R@ -%.L #A/^  X3_P!S%0
M81@  %,:  !(&P  /QL  #<;   R&@  +1H  "D9   F&   )!@  "(7   @
M%@$ 'A8( !T6#0 ;%Q( &A<7 !D7'0 8&"0 %A@K !48-  4&#T $AE( !$9
M5  0&6( #AER  T9A  ,&9@ "AFM  D8Q@ )&.< "1CZ  H7_P!O&   7AH
M % <  !%'0  /!T  #4=   O'0  *AP  "8;   C&P  (1H  !X:   <&@
M&AL% !@;#  6'!  %1P5 !0<&P 3'"( $ATI !$=,0 0'3L #AU%  T>40 ,
M'EX "AYM  D>@  ''I0 !1VJ  ,=P@ #'>8 !!SX  4<_P!K&@  6QT  $T>
M  !"'P  .A\  #(?   M'P  *!X  "0>   A'0  'AT  !P=   8'@  %1\"
M !,@"0 2(0X $"$2 ! A&  .(1\ #B(F  TB+@ ,(C< "B)!  DB30 '(EH
M!2)I  ,B?  !(I$  "*H   AP   (>4  "#X   @_P!G'0  5Q\  $HA  !
M(0  -R(  # A   J(0  )B   "(@   ?'P  '!\  !D@   6(0  $B," ! D
M!P .)@P #"80  LF%0 *)AP "28B  @F*@ &)S, !"<]  ,G20 !)U8  "=F
M   G>0  )X\  ":F   FOP  )>0  "7Y   D_P!C(   5"(  $<C   ])
M-"0  "XC   H(P  )"(  "$B   >(0  &B(  !<C   3)   $"8"  XH!P +
M*@L ""L.  8K$P $*Q@  BL?  $L)P  +#   "PZ   L10  +%,  "QC   L
M=@  +(P  "ND   KO@  *N0  "KZ   I_P!?(P  4"4  $0F   Z)@  ,B8
M "LF   F)0  (R0  !\D   ;)   %R4  !0G   1*0  #BL"  LM!@ '+PL
M!# .   P$0  ,14  #$<   Q(P  ,BP  #(V   R0@  ,D\  #)?   R<@
M,8D  #&B   PO   ,.0  "_[   O_P!:)P  3"@  $ I   W*0  +RD  "DH
M   E)P  (28  !PG   8*   %"H  !$L   .+@  "S !  <R!0 #- D  #4,
M   V#P  -Q(  #@8   X(   ."@  #@R   Y/0  .4L  #E;   X;@  .(4
M #>?   WN@  -N0  #7\   U_P!5*@  2"P  #TL   T+   +2L  "@J   D
M*0  'BH  !DK   4+0  $2\   TQ   *-   !S8   (X!   .@<  #L*   ]
M#0  /A   $ 4  ! &P  0"0  $ N  ! .0  0$<  $!6  ! :0  0(   #^;
M   ^MP  />,  #S\   \_P!0+P  0R\  #DO   R+P  +"T  "<L   @+0
M&B\  !4Q   1,P  #38   DX   %.P   #T   !  0  000  $,'  !%"P
M1@X  $@1  !*%@  2AX  $HH  !*-   24(  $E1  !)9   2'L  $B7  !'
MM   1N   $7\  !$_P!*,P  /S,  #8S   P,0  *C   ",Q   <,P  %C4
M !$X   -.P  "#X   -!    0P   $8   !(    2@   $P$  !.!P  3PL
M %$.  !4$@  51D  %4B  !4+@  5#P  %1+  !37@  4W0  %*0  !1K@
M4-<  $_[  !._P!%-P  /#<  #4V   O-   )C4  !XW   7.@  $3T   Q!
M   '1    $@   !*    30   %    !3    50   %<   !8 @  6P8  %T+
M  !?#@  8A,  &(;  !B)P  8C0  &%%  !@5P  8&T  %^)  !=IP  7,P
M %KX  !9_P!!/   .CL  #0Y   J.@  (3P  !A    10P  #$<   9+
M3P   %,   !6    60   %P   !?    80   &,   !E    9P$  &H%  !M
M"@  < X  ',5  !R(   <BT  '$]  !P3P  ;V4  &Z   !MGP  :\$  &GQ
M  !H_P _0   .3X  "X_   D0@  &D8  !)*   ,3P  !%0   !8    70
M &$   !E    :    &L   !N    <0   ',   !U    >    'L   !^ P
M@0H  (4/  "'%P  AB0  (4T  "$1@  @ET  (%V  !_E@  ?K8  'SG  !Z
M_P _1   ,T4  "A(   =3   $U(   Q7   #70   &,   !H    ;0   '$
M  !V    >@   'X   "!    @P   (8   ")    BP   (X   "2    E0$
M )D)  ">$   GAH  )TI  "</   FE(  )AL  "6BP  E*H  )+4  "0^@ X
M2P  +$X  "!3   560  #6    -G    ;@   '0   !Z    @    (0   "*
M    C@   )(   "5    EP   )H   "=    H    *,   "G    JP   *\
M  "T"0  N!   +<>  "U,   LT8  +%@  "O?@  K*   *O!  "I[@ Q50
M)%L  !AA   .:0  !7$   !Y    @0   (@   "/    E    )H   "?
MI    *@   "I    K    *\   "S    M0   +D   "]    P0   ,8   #+
M    T0H  -,4  #1)0  T#L  ,U4  #*<0  R)(  ,6S  ##W@ I8@  '&D
M !%Q   '>P   (0   "-    E0   )T   "C    J0   *\   "T    N0
M +P   "^    P@   ,4   #(    S    -    #4    V@   -\   #D
MZ@   .X,  #M&@  ["\  .I)  #H90  YH8  .2E  #BQ@#_    _P   /\
M  #\  $ _  ( /X #@#_ !0 _P = /\ )@#_ #  _P Z /\ 0@#_ $D _@!0
M /L 5@#Y %P ]@!B /0 : #R &\ \ !V .T ?P#J (D YP"5 .0 HP#@ +4
MVP#0 -4 ]@#* /\ M@#_ *@ _P"? /\ F@#_ )8 _P#_    ^P   /8   #S
M    \P   /8 "0#Z  X _0 6 /L ( #W "H \@ S .T .P#I $, Y@!) .(
M3P#> %4 VP!; -8 8 #2 &< SP!N ,P =@#) (  Q@", ,( F@"_ *H NP#!
M +@ Z0"V /\ IP#_ )H _P"2 /\ C0#_ (H _P#Z    \0   .H   #G
MYP   .0  0#@  L VP 1 -H &@#; ", T0 L ,H - #& #L P@!" +\ 2 "\
M $X N@!3 +@ 60"V %\ LP!F +$ ;@"N '< K "# *D D0"F *$ HP"U *
MV "> /L E0#_ (L _P"% /\ @ #_ 'X _P#O    XP   -H   #3    Q@
M +\   "Y  8 MP . +0 % "T !T LP E *X +0"K #0 IP [ *0 00"A $8
MGP!, )T 40"; %< F0!> )< 90"5 &X DP!Y )  AP". )< C "I (D Q "(
M .\ A0#_ 'P _P!V /\ <P#_ '( _P#@    T    ,8   "V    J0   *$
M  "=  $ F0 * )@ $ "8 !8 EP > )0 )@"1 "T CP T (P .@"* #\ B !%
M (< 2@"% %  @P!6 ($ 7@"  &8 ?@!Q 'P ?0!Y (T =P"@ '4 M@!S -\
M<@#_ &X _P!I /\ 9P#_ &4 _P#,    O@   *L   "=    DP   (H   "%
M    @@ % (  #0!_ !$ ?P 8 (  ( !] "8 >@ M '< ,P!U #@ =  ^ '(
M0P!P $D ;P!/ &T 5@!L %X :@!H &@ =0!G (0 90"6 &0 JP!B ,D 80#V
M &  _P!< /\ 6P#_ %H _P"]    J0   )<   ")    ?@   '@   !S
M;P ! &T "0!L  X :P 3 &L &0!J "  :  F &8 + !E #( 8P W &( / !@
M $( 7P!( %T 3P!< %< 6@!A %D ;0!7 'L 5@". %4 H@!3 +L 4@#I %(
M_P!0 /\ 3P#_ $\ _P"M    F    (8   !X    ;@   &<   !C    8
M %T !0!<  L 6P 0 %L %0!; !L 6@ A %@ )@!6 "P 5  Q %, -@!2 #P
M40!" $\ 20!. %$ 30!; $L 9@!* '0 20"% $@ F0!' +$ 1@#8 $8 _ !%
M /\ 10#_ $4 _P"?    B0   '@   !L    8@   %L   !6    4P   %$
M @!/  @ 3P - $X $0!. !8 30 < $P (0!* "8 20 L $@ ,0!' #< 10 ]
M $0 1 !# $P 0@!5 $  8  _ &X /@!^ #T D@ \ *D .P#' #L \P [ /\
M.P#_ #P _P"3    ?@   &X   !A    6    %$   !,    20   $<   !%
M  4 1  + $, #@!# !( 0P 7 $( '0!  "( /P G #X +  ] #( .P X #H
M/P Y $< . !0 #< 6P U &@ - !X #, C  R *( ,0"\ #$ YP Q /\ ,@#_
M #, _P")    =@,  &8%  !9!P  4 <  $D&  !#!0  0 ,  #X!   \  ,
M.P ( #H #0 Z !  .0 4 #D &0 W !X -@ C #4 *  T "X ,P T #( .P P
M $, +P!, "X 5P M &0 + !S "L AP J )P *0"U "D W  I /L *0#_ "H
M_P"!!   ;@@  %\*  !3"P  2@L  $(+   ]"@  .0D  #8(   U!0  - (&
M #, "@ R  X ,0 1 #$ %0 P !H +P ? "X )  L "H *P P "H -P I #\
M* !) "< 5  F &  ) !O ", @@ B )< (0"N "$ S  A /, (0#_ "( _P![
M"0  : P  %H-  !.#@  10X  #T.   X#0  ,PT  # ,   N"P  +0D# "T&
M"  L! P *P(/ "H!$@ I 1< * $< "< (0 F "< )0 M "0 -  C 3T (@%&
M "$!40 ? 5T '@%L !P!?P ; )0 &@"J !H Q0 : .L &0#_ !H _P!U#
M9 X  %4/  !*$   0!   #D0   S$   +P\  "P.   I#@  )PT! "<,!0 G
M"@H )@@- "4'$  D!A0 (@89 "$&'P @!R0 'P<K !X',@ =!SH ' A$ !H(
M3P 9"%P %PAK !8(?0 5!Y$ % >G !,&OP 2!>0 $@7Z !(%_P!Q#@  7Q
M %$1  !&$@  /1(  #82   P$@  *Q$  "@1   E$   (Q   "(.!  A#0<
M(0P+ " +#@ ?"Q( '0L7 !P,'  ;#"( &@PI !D,,0 8##D %@U# !4-3P 3
M#5P $@UK ! -?@ /#9( #@VG  T,O@ -#.  #0SU  T,_P!M$   7!$  $X3
M  !#%   .A0  #(4   M%   *!,  "43   B$@  (!$  !X1 P <$ 4 ' \(
M !L/#  :#A  &0\4 !</&@ 6#R$ %1 H !00,  2$#D $1!$ ! 04  .$%T
M#1!K  P0?  +$)  "1"E  @0O  '$-\ !Q#T  </_P!I$0  6!0  $L5  !
M%@  -Q8  # 6   J%@  )A4  "(5   ?%   '1,  !H3 @ 9$@0 %Q(& !82
M"@ 5$@X %!(2 !(2&  1$QX $1,E ! 3+@ .$S< #11   P42P +%%@ "11G
M  <4>  &%(T !!2C  ,3NP "$]T  1+T  (2_P!E$P  518  $@7   ]&
M-!@  "T8   H&   (Q<  " 7   =%@  &A4  !@5 @ 6%00 %!4% !(6"  1
M%@T $!<0  X7%0 .%QL #1<B  P7*0 +&#( "1@\  <81P %&%0 !!AC  (8
M=0 !&(L  !>A   7N0  %]T  !;U   6_P!A%@  4A@  $4:   [&@  ,AH
M "L:   E&@  (1D  !X8   ;&   &!<  !87 @ 4%P, $A@% ! 9!P .&PL
M#!L/  L;$P *&Q@ "!P?  <<)@ %'"\ !!PX  (<1   '5$  !U@   =<@
M'(@  !R@   ;N0  &]X  !KV   :_P!>&   3QH  $(<   X'   +QT  "D<
M   C'   'QL  !P:   9&0  %QD! !09 @ 2&@, $!L$  X=!P ,'@L "1\.
M  8@$0 %(!8  R <  $A(P  (2L  "$U   A0   (4X  "%=   A;P  (88
M "">   @N   ']X  ![X   >_P!:&P  2QT  #\>   U'P  +1\  "<>   B
M'0  'AT  !L<   8&P  %1L  !(<   0'0( #A\$  PA!@ )(@H !2,-  (D
M$   )1,  "49   F(   )B@  "8R   F/0  )DH  "9:   F;   )H,  "6<
M   EMP  )-\  "/Y   C_P!5'@  1R   #PA   R(0  *R$  "4@   @'P
M'1X  !H=   6'@  $QX  ! @   .(0  #","  @E!0 %)PD  "@+   J#@
M*Q$  "P6   L'0  +"4  "PN   L.@  +$<  "Q6   L:0  +(   "N:   J
MM0  *=\  "G[   H_P!1(@  1",  #@D   O)   *",  ",B   ?(0  '"
M !<@   3(0  $",   XD   +)@  ""@   0J!   + <  "X)   P#   ,0\
M #,3   S&0  ,R$  #,J   S-0  ,T,  #-2   S90  ,GL  #*7   QLP
M,-X  "_[   N_P!,)0  /R8  #4G   M)@  )R4  "(D   >(P  &2,  !0D
M   1)@  #B@   LJ   '+    R\    Q @  ,P0  #4'   W"@  .0T  #H0
M   [%0  .QT  #LF   [,0  .SX  #M.   [8   .G<  #F2   XL   -]L
M #;\   U_P!'*0  .RH  #(J   K*0  )2<  "$F   ;)P  %2@  !$J   .
M+   "B\   8Q   !-    #8    X    .P$  #T$   _!P  00H  $,.  !%
M$0  11@  $4A  !%+   1#D  $1(  !$6P  0W$  $*-  !!JP  0-(  #_Z
M   ^_P!"+0  ."X  "\M   I*P  )"H  !TJ   7+   $2X   TQ   )-
M!#<    Z    /    #\   !!    1    $8   !( P  2@<  $P+  !.#@
M4!,  % <  !0)P  3S0  $]#  !/50  3FH  $V&  !,I   2LH  $GX  !(
M_P ^,@  -3$  "XO   I+@  ("X  !DQ   2,P  #C<   DZ   "/0   $
M  !$    1P   $D   !,    3P   %$   !3    50$  %@&  !:"P  70X
M %\5  !>(   7BP  %T\  !<3@  6V,  %I^  !8G0  5\   %7R  !4_P Z
M-@  ,S0  "TR   D,P  &S8  !,Y   ./0  "$$   !%    20   $P   !0
M    4P   %8   !9    6P   %T   !@    8@   &4   !H!0  :PL  &\0
M  !O&   ;B4  &TT  !M1@  :UL  &IU  !HE   9K8  &3I  !B_P X.0
M,C<  "@Y   >.P  %3\   Y$   '20   $T   !2    5@   %H   !>
M8@   &4   !H    :P   &T   !P    <P   '8   !Y    ?00  ($+  "%
M$0  A!T  ((L  " /@  ?E0  'YK  ![B@  >JH  '?6  !U_0 X/0  +#X
M ")!   71@  #TL   =1    5P   %P   !B    9@   &L   !O    =
M '@   ![    ?@   (    "#    A@   (H   "-    D0   )8#  ";#
MG1,  )LA  ":,P  ETD  )1B  "3?P  D*   ([%  ",\P Q1   )4@  !I-
M   04P  "%H   !A    :    &X   !T    >0   '\   "$    B0   (T
M  "1    DP   )8   "9    G0   *    "D    J    *P   "R P  MPT
M +<7  "U*   LCX  +!6  "L<P  JI0  *FT  "EY0 J3P  'E0  !);   *
M8@   &H   !S    >P   ((   ")    C@   )0   ":    GP   *0   "F
M    J0   *T   "P    LP   +<   "[    P    ,4   #+    T00  -4.
M  #3'0  T#(  ,U+  #*9@  QH<  ,*I  #!RP B6P  %F(   QK   !=
M 'T   "'    D    )<   ">    I    *L   "Q    M@   +H   "\
MP    ,0   #(    RP   ,\   #4    V@   .    #F    ZP   /$&  #P
M$P  [B<  .P_  #J6P  YWH  .2;  #@NP#_    ^P   /8   #S    ]  %
M /8 # #Z !$ _P 9 /\ (@#_ "P _P U /\ /0#_ $4 _ !, /H 4@#W %@
M]0!> /, 9 #Q &H [@!R .P >@#I (4 Y0"1 .$ H #= +( V #. -( ]@#!
M /\ K0#_ )X _P"6 /\ D #_ (P _P#Z    \@   .P   #I    Z0   .P
M!0#R  P ^  2 /< &P#U "4 \  N .L -P#F #X X@!% -T 2P#8 %  TP!6
M -  7 #- &( R@!J ,@ <@#% 'P P@"( +X E@"Z *@ MP"_ +0 Z "N /\
MG0#_ )  _P"( /\ @P#_ (  _P#P    Y0   -X   #:    VP   -P   #8
M  < T0 . -$ %0#2 !X RP G ,4 +P#  #< O0 ] +H 1 "W $D M0!/ +(
M50"P %L K@!A *P :0"I ', IP!_ *0 C0"A )X G@"R )L U0"9 /P C #_
M (( _P![ /\ =@#_ '0 _P#B    TP   ,H   #'    O    +8   "P  $
MKP + *P $0"M !@ K0 @ *@ * "D "\ H  V )T / "; $( F0!' )< 30"5
M %, DP!9 )$ 80"/ &H C !U (H @P"( )0 A@"G (, P@"" /  ? #_ ',
M_P!M /\ :@#_ &@ _P#/    P0   +D   "M    H    )@   "4    D0 &
M )  #0"0 !( CP 9 (X (0"+ "@ B  O (8 -0"$ #H @@!  (  10!^ $L
M? !2 'H 60!X &( =@!L '0 >0!R (D <0"= &\ M !M -\ ; #_ &4 _P!@
M /\ 7@#_ %P _P"^    L0   *    "2    B0   ((   !\    >@ ! '@
M"0!W  X >  4 '< &@!T "$ <@ G '  +0!N #, ;  X &L /@!I $0 : !*
M &8 40!D %H 8P!D &$ < !? '\ 7@"3 %T J0!< ,@ 6P#W %< _P!4 /\
M4@#_ %$ _P"P    GP   (T   !_    =    &X   !J    9@   &4 ! !C
M  L 8P 0 &, %0!C !L 80 A %\ )P!= "P 7  R %H -P!9 #T 5P!# %8
M2P!5 %, 4P!< %( : !0 '< 3P") $X GP!- +H 3 #I $L _P!) /\ 1P#_
M $< _P"B    C0   'P   !N    90   %X   !9    5P   %4  0!4  <
M4P - %, $0!4 !8 4@ ; %$ (0!/ "8 3@ K $P ,0!+ #< 2@ ] $D 1 !'
M $P 1@!6 $0 80!# '  0@"! $$ EP!  *\ /P#7 #\ _P ^ /\ /0#_ #X
M_P"4    ?P   &\   !C    60   %$   !-    2@   $@   !'  0 1P *
M $8 #@!& !$ 1P 6 $4 ' !$ "$ 0@ F $$ *P!  #$ /@ W #T /@ \ $<
M.@!0 #D 6P X &D -P!Z #8 CP U *< -0#& #0 ]0 T /\ - #_ #4 _P"(
M    =    &4   !8    3P   $@   !#    /P   #T    \  ( /  ' #L
M#  [  \ .P 2 #H %P Y !P -P A #8 )@ U "P -  R #, .0 Q $$ , !+
M "\ 5@ N &, +0!S "P B  L *  *P"[ "L Z@ K /\ *P#_ "P _P!_
M;    %T!  !1 @  2 ,  $ #   [ @  -P   #0    S    ,@ % #( "0 R
M  T ,0 0 #$ $P P !@ +P = "T (@ L "@ *P N "H -0 I #T * !& "<
M40 F %X )0!N "0 @@ C )D (P"S "( W@ B /\ (P#_ "0 _P!W    900
M %8&  !+!P  0@@  #H(   U!P  , 8  "T%   L P  *P # "H !P I  L
M*0 . "D $0 H !4 )P 9 "8 '@ E "0 )  J ", ,0 B #D (0!# "  3@ ?
M %H '@!I !T ?  < ), &P"L !L S0 ; /8 &P#_ !P _P!P!0  7P@  %$*
M  !&"P  /0L  #4+   P"P  *PH  "@)   E"   ) <" ",$!@ C @D (@$,
M "( #P A !( (  6 !\ &P > "  '0 F !P +@ ; #8 &@ _ !D 2@ 8 %<
M%P!F !8 >  5 (\ %0"F !0 PP 4 .X % #_ !4 _P!K"   6PL  $T,  !"
M#0  .0T  #$-   L#0  )PT  ",,   A#   'PL! !X*!0 =" @ '08+ !P%
M#0 <!!  &P04 !D$&  9!!X & 0C !<$*P 6!#, %00\ !0$1P 3 U0 $@-C
M !$#=0 0 HH $ &B  \ O  / .4 #P#^ !  _P!G"P  5PT  $D.   ^#P
M-0\  "X/   H#P  ) X  " .   =#@  &PT! !D-!  8# < & L) !<)#  7
M"0X %@D2 !4)%@ 4"1L $PDA !()*  2"3  $0DZ ! )10 /"5( #@EA  T)
M<P ,"(@ "PB?  H'MP *!ML "@7V  H$_P!C#0  4PX  $80   [$0  ,A$
M "L1   E$   (1   !T0   :#P  & \! !8.!  5#@< % T) !,-"P 3# T
M$@P0 !$,%  0#!D $ P?  \,)P .#2\ #0TY  P-10 +#5$ "0U@  @-<0 &
M#88 !0V=  0,M  ##-(  @SQ  (+_P!?#@  4!   $,1   X$@  +Q(  "@2
M   C$@  'A$  !L1   8$0  %1 " !00!0 2$ < $0\) ! /"@ 0#@P #@X.
M  X/$@ -#Q< #! =  P0)  *$"P "1 V  @000 &$$X !1!=  ,0;P !$(0
M !"<   /M   #M0   [S   ._P!<$   31(  $ 3   V%   +10  "84   A
M$P  '!,  !D2   6$@  %!$# !(1!@ 1$0@ $! *  X0"P -$0L #!$-  L2
M$0 *$A4 "1(:  @2(0 &$RD !1,S  ,3/@ "$TL  !-:   3;   $X(  !*;
M   2M   $=<  !'U   1_P!8$@  210  #T5   S%@  *Q8  "05   ?%0
M&A0  !<4   4$P$ $Q($ !$2!P 0$@D #A()  T2"0 +$PH "10-  <5#P &
M%A, !!88  ,6'P "%B<  !<P   7.P  %T@  !=8   7:@  %H   !:9   5
MM   %=D  !3W   3_P!5%   1A8  #H7   P&   *!@  "(7   =%@  &18
M !85   3% , $A,& ! 3!P /$P< #10'  L5"  )%@D !A@,  ,:#@ !&A$
M !H6   ;'   &R0  !LM   ;.   &T8  !Q5   ;9P  &WT  !N7   :LP
M&=L  !CY   7_P!1%@  0Q@  #<9   N&@  )AH  " 9   ;&   &!<  !46
M 0 3%04 $14$  \5!  -%@0 "Q<%  D9!@ &&@@  AP*   >#0  (!   " 3
M   @&0  ("$  "$J   A-0  (4(  "%2   @9   ('H  !^5   ?L0  'ML
M !WZ   <_P!-&0  /QL  #0<   K'   )!P  !X;   :&@  %Q@  !07 @ 2
M%P( $!@!  T9 0 +&@( "!P#  4=!  "'P8  "$(   C"P  )0X  "81   F
M%@  )AX  "<G   G,@  )S\  "9.   F8   )G<  "62   DKP  (]H  "+[
M   A_P!('0  /!X  #$?   H'@  (AX  !T<   9&P  %AH  !(:   0&P
M#1P   L=   ('P  !"$   $C @  )00  "<&   I"0  + P  "X/   N$P
M+AH  "XC   N+@  +CL  "Y*   M7   +7(  "R.   KK   *M0  "G[   H
M_P!$(   ."$  "XA   F(0  ("   !P>   8'0  %!T  ! >   .'P  "R$
M  <C   #)0   "<    I    + $  "X#   P!@  ,PH  #4-   V$0  -A<
M #8?   V*0  -C8  #9%   U5P  -6T  #2)   RJ   ,<\  ##Z   O_P _
M)   -"0  "LD   D(P  'R$  !L@   6(   $2$   XC   *)0  !B@   (J
M    +0   "\    R    -    #<    Y P  .P8  #X*  ! #@  01(  $$:
M  ! )0  0#$  $!    _4@  /F<  #V"   \H@  .L<  #GX   X_P Z*
M,"@  "DG   C)0  'R,  !@D   2)0  #B@   HJ   %+0   #     S
M-@   #@    [    /@   $    !"    10(  $<&  !*"@  30X  $T5  !,
M'P  3"L  $LZ  !*3   26$  $A\  !'FP  1;\  $/S  !"_P V+   +2L
M "<I   C)P  &R@  !0J   .+0  "C    0S    -P   #H    ]    0
M $,   !&    2    $L   !-    4    %,!  !6!@  60L  %L0  !;&0
M6B4  %DT  !81@  5UH  %5T  !4DP  4K4  %#J  !/_P S,   +"X  "<L
M   >+0  %B\  ! R   *-@   SH    _    0@   $8   !)    3    $\
M  !2    50   %@   !:    70   &    !C    9P8  &L,  !L$@  :QX
M &LL  !I/0  9U(  &9J  !DB0  8:L  %_<  !=_P Q,P  +#$  "(R   9
M-0  $3D   H]   "0@   $<   !,    4    %0   !8    6P   %\   !B
M    90   &@   !K    ;@   '$   !U    >0   'T&  ""#0  @A8  ( D
M  !^-0  ?$D  'MA  !X?P  =I\  '/&  !P]P Q-@  )C@  !P[   20
M"T4   )+    40   %8   !;    8    &4   !I    ;@   '(   !V
M>0   'P   !^    @@   (4   ")    C@   ),   "8!@  G X  )L:  "8
M*P  ED   ))9  "1<P  C94  (NU  "(Z  K/@  ($$  !5'   -30   E0
M  !;    80   &@   !N    <P   'D   !^    @P   (@   ",    CP
M )(   "5    F0   )T   "A    I0   *H   "P    MP<  +@1  "U(0
MLC4  *]-  "J:0  J(@  *:H  "BT0 C2   &$X   Y4   $7    &0   !M
M    =0   'P   "#    B0   (\   "5    FP   *    "C    I@   *D
M  "M    L0   +4   "Y    O@   ,0   #*    T@   -H*  #6%@  TBD
M ,Y!  #*7   Q7P  ,*=  #!O0 <50  $5P   =E    ;@   '<   !_
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M_____________________________________________P
M       ! P0%!@@)"@L-#@\1$A,4%A<8&AL<'1\@(2(D)28H*2HK+2XO,#(S
M-#8W.#D[/#T^0$%"1$5&1TE*2TU.3U!24U155UA96UQ=7F!A8F-E9F=I:FML
M;F]P<7-T=7=X>7I\?7Z @8*#A8:'B(J+C(Z/D)&3E)66F)F:G)V>GZ&BHZ2F
MIZBJJZRMK["QL[2UMKBYNKN]OK_!PL/$QL?(R<O,S<_0T=+4U=;7V=K;W=[?
MX.+CY.;GZ.GK[.WN\/'R]/7V]_GZ^_S^____________________________
M__________________________\  0(#! 4&!P@)"@L,#0X/$!$2$Q05%A<8
M&1H;'!T>'R A(B,D)28G*"DJ*RPM+B\P,3(S-#4V-S@Y.CL\/3X_0$%"0T1%
M1D=(24I+3$U.3U!14E-455976%E:6UQ=7E]@86)C9&5F9VAI:FML;6YO<'%R
M<W1U=G=X>7I[?'U^?X"!@H.$A8:'B(F*BXR-CH^0D9*3E)66EYB9FIN<G9Z?
MH*&BHZ2EIJ>HJ:JKK*VNK["QLK.TM;:WN+FZN[R]OK_ P<+#Q,7&Q\C)RLO,
MS<[/T-'2T]35UM?8V=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_P\?+S]/7V]_CY
M^OO\_?[_;69T,0     #!"$   $                    !
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M* G_EC$/_Z$Y%?^J0A__LDHL_[93//^W74[[MF5A\+1N=.2M=8;9I'N6SYN
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MP:"4D<::D9C)EH^ARY"+J,R,B:S%C(FPP(R)L,",B;# C(FPP(R)L,",B;#
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M<5SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ_ZP5 ?/#$ #1V@L
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MTF^RH=!MN://;,.FQ6?#IL!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ'
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MF:"$M9*=B[J,FI.^AYB;P(27I<* EJ_"?Y*SO("1N+6 D;BU@)&XM8"1N+6
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M6U3[L5M4^[%;5/NQ6U3[L5M4^[%;5/NQ6U3[L5M4^[%;\*\( ,V_!P# S0@
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M@E'9W()1V=R"4=G<@E'9W()1V=R"4=G<@E'9W()1V=R"_X\3 O^D$P'^N!(
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MN4\TW[191=*M85;'I6EEO9YP<K27=WRMD7Z%IHR&C*"(C9&:A966EH*>FI*
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M=%BRYW18LN=T6++G=%BRYW18LN=T_X 2 ?^4$ #_I@\ X[@+ -+&"@#,UPL
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MBQ@L_Y,8*_^<&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9H;\
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M;&J4[6QJE.UL:I3M;&J4[6QJE.UL_W$6 O^#$0'_E!,!_Z(4 /6P% #FOA0
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MKC-!_[LT0/_+-#__XS0__^\U/__O-3__[S4__^\U/__O-3__[S4__^\UQ*H
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M$R/_HQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4G+X  (W+  !^V@
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MN51(S\]42,[K4TG.^%!*R_].2LK_34K*_TU*RO]-2LK_34K*_TU*RO]-YX\
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M*SO]XBLZ_/0K.OSW*SK\]RLZ_/<K.OSW*SK\]RLZ_/<KO:@  *ZP  "AO
ME<@  (G4  !^Z 4 =_\2 6__' )G_R8%8/\O"%G_-PM4_S\.3_]'$4O_3A-'
M_U851/]=%D+_9!A _VP9/?]U&CO_?ALY_XD<-_^4'3;_H!XU_ZP?,_^Y'S/_
MR!\R_^(@,O_G(#+_YR R_^<@,O_G(#+_YR R_^<@L*T  **W  "5Q   A]
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M'0'\D20"\)<L!.6:- C<FC\1SY1,'\:.5RR^B& WMX)I0+%^<4BL>GE.IW>
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M1T?)]T5'R/]#2,?_0DC'_T)(Q_]"2,?_0DC'_T)(Q_]"WHT  ,N<  "]IP
ML;   *:Z  "<Q , D\\' (K=# "%WQT!?M\L!7;>-PMOWD,3:-U-&F+<52!=
MVUTF6-ME*E3:;2Y0VG8R3=J -4K:BS='VI<Y1=JD.T/;M#Q"W,@\0MOE.T+:
M]#I"V?XZ0]C_.4/8_SE#V/\Y0]C_.4/8_SE#V/\YT)8  ,&C  "RK   I[4
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M&"S_[Q@L_^\8+/_O&"S_[Q@L_^\8JZL  )ZU  "0P0  @LP  '79  !IY
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M/^4=_S_O'?\_]Q[_/_X=_S__'?\__QW_0/\<_D#_&_Y _QO^0/\;_D#_&_Y
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M1+EBD4BV8)E*LU^A3;%=JD^N7+11K%S!4JI<U%*H7>M0J&#Z2:AC_T2H9/]
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M_T5]?/]%_V$0 ?]O"P#_?0L ]8@* -^3" #8FPH TZ(, ,FC'P&_H#('MIQ
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M4E6?\TY7H/]*6:#_1EF?_T59G_]%69__15F?_T59G_]%_W4  ."&  #/DP
MQ)\! +JG 0"QK@  J;8  *&]#0";O2 !E+PQ!XNZ/1"#MT@:?+50(G6S6"IO
MLE\P:K!F-F6O;3M@K74_7*Q^0UBKAT=5JI-*4:J?3$^JKDU-JL!-3:K<34ZJ
M\DE0JOY&4JG_0U*I_T)2J?]"4JG_0E*I_T)2J?]"\GP  ->,  #(F0  O:,
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M+C_0_RX_T/\N/]#_+C_0_RX_T/\NRI0  +NA  "MJ0  HK$  ):[  "+Q
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M"QK_WPL:_]\+F[$  (V\  !^QP  <-(  &/>  !5Y   2_4  $;_!0! _PX
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M8?\QHV'_,:-A_S&C8?\Q_U,5 ?]=$ #_: \ _W 2 /]W%@#[?!P![G\D >2
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M3V2$\DEFA?]#:(;_/VJ&_SQJAO\\:H;_/&J&_SQJAO\\_V<$ /9V  #<@@
MSHT  ,65 @"^G , MZ$" *^D$0"HI"0"H*(T")B?0!&1G$H:BIE3(H276RE^
ME6(P>9)I-760<#IPCW<^;(U_0FB,B49EBI-)88F?2UZ)K$U=B;U.7(G635Z*
M\$A@B_Y#8HO_/V.,_SQCC/\\8XS_/&.,_SQCC/\\_VH  .9Z  #5A@  R9$
M ,"9 0"XGP$ L*4  *BI#@"BJ2$!FJ@Q!I.E/@^+HT@8A*!1('Z>62=XG& M
M<YIG,F^8;C=JEG4\9I5]/V*4AT-?DI%&6Y*=25F1JTI7D;M+5I'32U>2[T=:
MDOU"7)/_/EV3_SM=D_\[79/_.UV3_SM=D_\[_VX  .!^  #.BP  Q)4  +J=
M  "QHP  J:D  *&N"P";KQT!E*XN!(RL.PR%JD85?JA.''BF5B-RI%TJ;:)D
M+VFA:S1DGW,X8)Y[/%R=A3]9G(]"59N<15.;JD=1F[I'4)O11U&;[D13F_Q
M59O_/%:;_SI6F_\Z5IO_.E:;_SI6F_\Z\70  -F#  #(D   OIH  +.A  "J
MIP  H:X  )>U!@"2MA@ C+4J X6T-PE^LD(1=[!,&'&N5!]LK5LE9ZMB*F*J
M:2]>J7$S6JAZ-U:G@SI3IHX]4*:;0$VEJ4%+I;I"2Z;10DNE[3]-I?P\3J3_
M.4^D_S=/I/\W3Z3_-T^D_S=/I/\WY'H  ,^)  #"E0  MI\  *RE  "BK
MF+,  (Z[ @"(O1( @[TE 7R\,P9VNS\-;[I)%&JX41IEMUD?8+9@)%RU9RE8
MM&\L5+-X,%&S@C--LHTV2K*:.$BQJ#I&LKDZ1;+1.D:Q[3E'L/PV1[#_-$BO
M_S-(K_\S2*__,TBO_S-(K_\SVX(  ,>0  "[G   KJ,  *2J  "9L0  C[D
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M&S3<_QLTW/\;N9P  *JD  ">JP  DK4  (6^  !YQP  ;<\  &+6 P!8X0@
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M; (,_WL#"_^+ PK_F@,*_Z@#"?^U PC_P@,(_\(#"/_" PC_P@,(_\(#BK@
M 'O#  !LS@  7ML  $_B  !"YP  -NP  #'_   L_P  )_\' "/_#@ @_Q(
M'/\8 !C_'0 5_R$ $O\F !#_+ $._S$!#?\W 0K_/@$(_T8!!?]/ 0'_60$
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M17)P\3]S<O\Y=7/_-79T_S%V=/\Q=G3_,79T_S%V=/\Q_UT& /]I  #B=
MU'T  ,N% @#$B@0 OXT% +>/$P"PCR8!J(TU!Z"*0@Z:ADP6DX-5'8Z!722)
M?F0IA7QK+8%Z<C)]>'DU>G>".79VBSQS=95 <'2@0FUSK41K<[U%:G/516QT
M[T!N=OXZ;W?_-G%X_S)Q>/\Q<7C_,7%X_S%Q>/\Q_U\" /=L  #>=P  T($
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M-E^'_S)?A_\R7X?_,E^'_S)?A_\R_6@  .!V  #-@@  PHP  +F3  "PF0
MJ)T  )^@"0"9H1H DZ K XR?. B%G4,0?YI,%WF85!UTEUPB<)5C)VN3:BQG
MDG$P9)%Y,V"/@C=<CHTZ68V9/5>-IC]4C;9 4XW+0%2-Z3U6C?HY5XW_-5F.
M_S)9CO\Q68[_,5F._S%9CO\Q[6T  -E[  #(AP  O9   +28  "JG0  H:$
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M*42J_RE$JO\IT8   ,&-  "UF   J9\  )ZE  "3K   B+(  'VX  !QO@8
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ME@DIZJ<**.JZ"B?KU@HGZ? *)^?]"2;F_PHFYO\*)N;_"B;F_PHFYO\*J*
M )RG  "/L   @KD  '3"  !HR@  6]$  $_7  !%W0  /NX) #SR$0 Y\QL
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M 0+_E@$!_Z8! /^U 0#_Q@$ _\H! /_* 0#_R@$ _\H!AK<  '?!  !HS
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M.(!?\C.!8?\M@F+_*8)C_R:"9/\E@F3_)8)D_R6"9/\E_U,& /]=  #G9P
MVV\  -!T @#*> 4 QGD' +YZ%0"V>B@!KW@W!:AV1 NB<TX2G'!7&)AM7QV4
M:V<AD&IN)8UH=2B*9WTKAV6%+H1DCC&!8Y<T?V*B-GQBKSAZ8KXY>6+5.7EC
M[S1Z9?XO>V;_*WQG_RA\9_\F?&?_)GQG_R9\9_\F_U4# /]@  #C:@  U7(
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M+6QS_RIL<_\H;'/_*&QS_RAL<_\H_UP  .=H  #5<P  R7L  ,""  "XA@
ML8@  *F)#0"BBAT G(DN I6'.P>/A44.B8)/%(2 5QE_?EX>>WQE(GA[;"9T
M>7,J<7A[+6YWA#!K=HXS:'6:-F5TICAC=+4Y873).F%TYSAC=ODR97;_+F9W
M_RMG=_\I9W?_*6=W_REG=_\I_U\  .-L  #0=@  Q7\  +R%  "TB@  K(P
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M*%6(_RA5B/\HYFL  -!X  #"@P  MXP  *V2  "CE@  FIH  (Z>  "'GQ
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MG!P[M:P<.K7 '3FUWQPYL_0<.;+_'#FQ_QLYL/\;.;#_&SFP_QLYL/\;P88
M +23  "GF@  G*   )&G  "%K0  >;,  &VX  !BO0$ 5L(' %/#% !2PR,
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M!"'ES00@Y.P$(.+[!!_A_P4?X/\%'^#_!1_@_P4?X/\%I)X  )BE  "+K@
M?;8  '"^  !CQ@  5LL  $O0  ! U0  -MP  "_E!P M[1  *^X8 "GN(@ G
M[RL )>\T "/P/  A\$4 '_%. !WR6 $;\F0!&?-Q 1CS@0$7])("%?2E A3U
MN@(3]=8"$_3O A+R_ (2\/\"$O#_ A+P_P(2\/\"FJ0  (VM  !_M@  <;\
M &/'  !6S@  2=,  #W:   SWP  *N,  ";T!0 D^PT (?P3 ![]&P <_2(
M&?XI !?^,0 5_SD $_]! !'_2@ 0_U4 #O]A  S_;P$,_X !"O^3 0G_I@$(
M_[H!!__4 0?_ZP$&__8!!O_V 0;_]@$&__8!CZP  ("V  !ROP  8\D  %;1
M  !(V   .]T  ##B   FY@  '_   !S_   9_PD %O\. !3_$P 1_QD #_\>
M  W_)  +_RL "?\R  ;_.P #_T0  /]/  #_7   _VL  /]]  #_D   _Z,
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M)I5.]2*43_\?E%#_')11_QJ44?\8E%'_&)11_QB44?\8_TD( /]0  #[6
MY5X  -UB P#68P< U&$* ,IB&0#"8RP!NV([ [1@2 BO75,,JEM<$:9:9!6C
M6&P8H%=T&YU5>QV;5(,@F52+(I93DR244ITEDE&G)Y!1LRB.4<,IC5'=*HQ2
M\B:+5/\BBU7_'HM6_QR+5O\:BU;_&HM6_QJ+5O\:_TP$ /]3  #L7   WV(
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M(W=B_R!W8O\>=V+_'G=B_QYW8O\>_U(  .Q<  #<9@  SFT  ,1R  "]=
MMW0! +!T#@"I=1\ HG0O IQR/067<$<*D6Y1#XUL612):F 7A6EG&X)H;AY_
M9G4A?65])'IDAB=W8Y I=6.;+')BIRYP8K8O;V+)+VYBYBYO9/DH<&7_)'%F
M_R%Q9O\?<6;_'W%F_Q]Q9O\?_U0  .A?  #7:0  RG   ,!U  "Y>   LG@
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M(&)R_R!B<O\@[UP  -QI  #*<@  OGH  +6   "MA   I(4  )J% P"4A10
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MFB5)C:DF2(V[)T>-U"='C/ D2(S_(DF+_R!*B_\>2HO_'DJ+_QY*B_\>U6X
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M%#6PT10UKN\4-*W^%#2L_Q0TJ_\4-*O_%#2K_Q0TJ_\4NX4  *^0  "CEP
MF)T  (RC  " J   =*T  &BR  !<M@  4+H! $F\#0!(O!D 1KTG $6],P!#
MO3T!0;U' 3^]4 (]O5@#.KUA!3B]:P8VO7<(-+V$"3*]DPHPO:0++[VW#"Z^
MT LNO.X,+;K^#2RY_PTLN/\.++C_#BRX_PXLN/\.LX\  *:7  ";G0  CZ,
M (.J  !VL   :K4  %ZZ  !2O@  1\(! #W'!@ XR1  -\D; #;*)P URC,
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M  SM_  ,Z_\ #.O_  SK_P ,Z_\ EZ,  (FK  ![M   ;;P  %_$  !2R@
M1<X  #G3   OV   )=T  !WA   8[ ( %O<+ !3W$0 1^!< $/@>  [Y)0 -
M^2T "_HU  G[/P '^TH !/Q7  /]9@ "_G<  /V+  #]GP  _+4  /S1  #\
M[0  _/P  /S]  #\_0  _/T BZL  'VT  !NO0  8,8  %+-  !$T@  -]@
M "S=   BX0  &>4  !/J   0^@  #O\&  W_#  *_Q  !_\4  3_&@ !_R
M /\G  #_,   _SH  /]%  #_4P  _V(  /]U  #_B@  _Y\  /^S  #_QP
M_^4  /_E  #_Y0  _^4 ?[0  '"]  !AQP  4]   $/6   VW0  *N(  !_F
M   6Z@  $.T   SZ   )_P  !O\   +_!   _PD  /\-  #_$   _Q0  /\:
M  #_(0  _RD  /\T  #_0   _TX  /]>  #_<@  _X<  /^:  #_J@  _[D
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M$+(Y^P^P.O\.KSK_#:XZ_PRM.O\+K3K_"ZTZ_PNM.O\+_SP- /] !@#_100
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M&(90_Q:&4/\4AE'_%(91_Q2&4?\4_T<  /A/  #D5P  U5T  ,Q@  #%8 (
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M&&QA_QAL8?\8]5$  .)<  #/90  PVL  +EO  "Q<0  JG$  *)O" ";;Q<
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MFB)7<:@D57&Y)51QT"54<>XB5G'^'E=Q_QQ7<?\:6''_&5AQ_QE8<?\9XUX
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M'4.(RAU#A^H<1(;[&D2&_QA%AO\7187_%T6%_Q=%A?\7S6T  +UX  "Q@@
MIXH  )R.  "2D   AI,  'F5  !LEP  9I<. &.8&P!AF"D 7I@U 5J7/@-7
MET<%599/!U*65@E/E5X,3)1F#DJ4;Q!'DWD31).%%4*2DQ= DJ(8/I*S&3V2
MR1D]D>D8/9#Z%SZ/_Q8^C_\5/H__%3Z/_Q4^C_\5Q7,  +=_  "LB0  H8\
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M!R:S_P<FLO\()K+_"":R_P@FLO\(KXT  **4  "7F@  BZ   'ZF  !QJP
M9;   %FT  !-MP  0KL  #B^ 0 OP@D +<,2 "S#'@ KPRD *L0S "G$/0 H
MQ4< )\51 ";%7  EQF@ (\9V 2+&A@$@QI@!'\:K 1['P0$>QN0!'<3X AS"
M_P,<P?\#','_!!S!_P0<P?\$I90  )J:  ".H0  @:<  '.N  !GM   6KD
M $Z]  !"P   .,,  "_'   FRP0 'M * !O1$0 :TAH &=(E !C3+P 8TSH
M%]1$ !;44  5U5T %-5K !/6?  2UX\ $=BD !#9NP 0V=X $-7S !#3_P 0
MTO\!$-'_ 1#1_P$0T?\!G)H  )&A  "#J   =;   &BW  !;O0  3L$  $+%
M   WR   +<P  "30   <U0  %=H% !#B"P 0XQ$ #N0:  [D(P -Y2T #.4W
M  OF0@ *YD\ ">==  CG;0 &YH  !>:5  3FJP "YL0  >;F  #G^0  Y_\
M .;_  #F_P  YO\ DZ$  (6I  !WL0  :;D  %O   !.Q@  0<H  #7.   J
MT@  (=8  !G;   2WP  #>,   OQ"  )\PX !_,3  3R&@ "\B(  /(J  #R
M-   \C\  /),  #R7   \FT  /*"  #RF   \ZT  //&  #TY0  ]/8  /3[
M  #T^P  ]/L AZD  'FR  !JN@  7,(  $[)  ! S@  ,],  "C8   >W0
M%>$   _D   *Z   !?,   /] 0  _ @  /L-  #[$0  ^Q8  /P>  #\)@
M_#   /T\  #^20  _EH  /YM  #_@@  _Y@  /^L  #_P   _]@  /_D  #_
MY   _^0 >[(  &R[  !=Q   3\T  $#2   RV0  )MX  !OB   2Y@  #.H
M  7M    ]    /\   #_    _P   /\$  #_"0  _PX  /\2  #_&   _R$
M /\K  #_-P  _T8  /]8  #_:P  _X   /^5  #_I@  _[,  /^[  #_NP
M_[L _QLF /\<) #_&B0 _Q4G /\0+0#_"C8 _P5# /\!4 '_ %X!_P!K ?\
M=@'_ ($ _P"* /\ D@#_ )H _P"@ /\ I@#_ *P _P"R /\ N0#_ ,( _P#-
M /\ WP#_ .P _P#X /\ _P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#] /\
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M ?\0A@']$(X!_!"5 ?H0FP'Y$*$!]Q"H ?80KP'T$+< \Q#" /$0T #M$.4
MZ!'R .81_@'D$O\!XQ+_ >(2_P'B$O\!X1+_ >$2_P'A$O\!_RD6 /\J$P#_
M*1( _R<3 /\H' #_)R< _R,S /\@/P#_'4P _QM8 ?P99 'X&6X!]AAX ?,8
M@0'Q&(D![QB0 >X8EP'L&)X!ZABD >D8K 'G&+0!YAB_ >08S0'@&>,!W!KQ
M =@:_@+4&_\"TAO_ M$;_P+0&_\"T!O_ M ;_P+0&_\"_RT2 /\N#P#_+@T
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M#0#].Q, \3@= .@U*0#@-#< V3-& -$T4@'-,UT!R3-G L8S< /$,G@$P3*
M!+\RAP6^,H\&O#*6!KHQG@>X,:8'MS&P"+4RO BS,LP)L3+E":TS]0FK,_\)
MJC/_"*@S_P>H,_\'IS/_!Z<S_P>G,_\'_S<' /\Z  #_/@  ^D$! /%!!@#Q
M/PT YCP2 -LZ'P#0.S$ RCQ  ,0\30' /%@"O#MA [D[:@6V.G(&M#IZ![(Y
M@0BP.8@)KSF0"JTXF JK.*$+J3BJ#*@XM@VF.,4-I#C>#J$Y\0V?.O\,GCK_
M"YTZ_PJ<.O\)G#K_"9PZ_PF<.O\)_SL" /\^  #W1   YD<  -]( 0#:1@8
MV4 + ,U"&0#%1"L OD0[ +E$2 &U0U,#L4)<!*Y"90:K06P'J4!T":9 >PJD
M/X,+HS^*#:$^DPZ?/IP/G3ZE$)L^L1&:/K\1F#[4$I8_[1&4/_P/DT#_#I)
M_PR20?\+DD'_"Y)!_PN20?\+_ST  /]#  #I20  WDX  --/  #-3@, RDD(
M ,))% "[2B8 M4LV *]+0P*K2DX#ITE7!:1(8 >A1V<)GD9O"IQ&=@R:17T.
MF$6%#Y9$CA"41)<2DD.A$Y!#K!2/0[H5C4/-%8M$Z!6*1?H2B4;_$(E&_PZ(
M1O\-B$;_#8A&_PV(1O\-_T   /)'  #C3P  U%,  ,M5  #$5   P% $ +E/
M$0"R4"( K%$R *=1/P*B4$H#GD]3!9M.7 B836,*E4QJ#)-+<0V12GD/CDJ
M$8Q)B1**29(4B$B<%89(J!:%2+47@TC'&(%(Y!B!2O<5@$K_$H!+_Q" 2_\/
M@$O_#H!+_PZ 2_\._T,  .Q+  #=4P  SE@  ,1:  "]6@  N%<! +%4#@"J
M5AX I58N )]6.P&;548#EU10!9-36 B04E\*C5%F#(M0;0Z(3W00AD]\$H1.
MA1."3HX5@$V9%WY-I!A\3;(9>DW#&GE-WQIX3O07>$__%'A/_Q)X4/\0>%#_
M#WA0_P]X4/\/_48  .=/  #65P  R%P  +]?  "W7P  L5P  *I9# "D6AH
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MFAMB7J@<85ZX'5]>SAU?7NP;8%_]&&%?_Q5A7_\38E__$F)?_Q)B7_\2ZE$
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M'%!LR!Q/;.<;46SZ&%%L_Q52;/\44FS_$U)L_Q-2;/\3W%P  ,=G  "Y;P
MKW8  *5[  "<?   D7P  ()X  !Z>0< =7D4 ')Z(P!N>B\!:WDZ FAY0P-D
M>$L%87=2"%]W60I<=F ,675H#U=T<!%4='H34G.&%D]SDQA-<J$93'*Q&DIR
MQAI*<N4:2W+Y%TQR_Q5,<O\337+_$DUR_Q)-<O\2U&   ,)K  "U=   JWL
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M$#B*_P\YB?\/.8G_#CF)_PXYB?\.OW(  +)]  "GA@  G(H  )&.  "&D0
M>I,  &V5  !?EP  5)D! $^9#P!.FAH 3)HG $J:,@!(FCP!1II$ 42:3 )"
MFE0#0)E<!#Z99@4[F7 '.9A\"#>8B@HUF)H+,YBK"S*8OPPRF-\+,9;U"S&5
M_PLQE/\+,9/_"S&3_PLQD_\+N'H  *R%  "ABP  EI   (N4  !_EP  <IL
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M A2Z_P(4NO\"H9(  ):8  "*G@  ?:0  &^J  !BKP  5K0  $JW   ^N@
M,[T  "K    AQ   &<<% !/+"P 1S!( $<P; !#,)0 /S2\ #LTZ  [-1@ -
MS5( #<Y@  S.<  +SH, "LZ7  G.K  (SL8 ",[H  C-^P )R_\ "<O_  G+
M_P )R_\ F)@  (V>  !_I0  <:P  &2S  !7N0  2KT  #[    RPP  *,8
M !_*   7S0  $=$   S6!0 (V0P !MD2  7:&P $VB0  ]LN  ';.0  W$4
M -U2  #>8@  WG,  -Z(  #?G0  W[,  -_.  #@[@  W_H  -__  #?_P
MW_\ CY\  (&F  !SK@  9;4  %B]  !*P@  /<4  #')   FS   '=   !34
M   .V0  "=T   /A    XP<  .,-  #D$@  Y1D  .8B  #G*P  Z38  .M#
M  #L4@  [&(  .UV  #NC   [J$  .^W  #OT0  [^L  /#V  #P]@  \/8
MA*<  '6O  !GMP  6;\  $O&   \R@  +\X  "32   :V   $MP   S@   %
MXP   .<   #K    ZP   .T%  #N"P  \!   /$5  #S'@  ]"<  /<S  #Y
M0   ^E$  /MC  #\=P  _8T  /VC  #^M@  _LD  /_?  #_WP  _]\ =[
M &BY  !:P0  3,H  #S/   NU   (MH  !?>   0X@  ">8   #I    [
M /    #V    ]@   /<   #X    ^@<  /L-  #]$0  _QD  /\C  #_+P
M_SX  /]/  #_8@  _W<  /^-  #_GP  _ZX  /^Z  #_N@  _[H _Q8C /\5
M(0#_$B$ _PXD /\&*@#_ #, _P!! /\ 3@#_ %P _P!H /\ = #_ 'X _P"'
M /\ CP#_ )8 _P"< /\ H@#_ *@ _P"N /\ M0#_ +T _P#' /\ U@#_ .<
M_@#S /X _@#] /\ _ #_ /L _P#[ /\ ^P#_ /L _P#[ /\ _QH@ /\9'@#_
M%AX _Q @ /\*)0#_!#  _P ] /\ 2P#_ %@ _P!D /\ < #_ 'H _P"# /\
MBP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L0#] +D ^P## /H T #X ., ]P#Q
M /8 _ #T /\ ] #_ /, _P#S /\ \P#_ /, _P#S /\ _QT< /\<&0#_&1D
M_Q0; /\.(0#_#"P _PDY /\%1@#_ E, _P!? /\ :P#_ '4 _P!^ /\ A@#_
M (X _P"4 /X FP#\ *$ ^@"G /@ K@#U +4 \P"_ /$ RP#P -\ [@#N .P
M^0#K /\ Z@#_ .H!_P#I ?\ Z0'_ .D!_P#I ?\ _R 7 /\?% #_'!, _Q<5
M /\6'0#_$R@ _Q T /\-00#_#$X _PE: /\(9@#_"'  _@=Y /P'@0#Z!XD
M^ >0 /8&E@#S!IT \0:C .\&J@#M!K( _^+__TE#0U]04D]&24Q%  @)Z@:[
M .@&R #F!MP Y ;L .((^@#@"O\ W@O_ -T+_P#=#/\ W S_ -P,_P#<#/\
M_R,2 /\C$ #_(0X _QX0 /\>& #_'", _Q@O /\4.P#_$DD _!!5 /@/8 #T
M#VH \0]T .\.? #M#H0 ZPZ+ .D.D@#G#ID Y@Z@ .0.IP#B#J\ X ZX -X.
MQ0#<#MH UA#L -(1^@#/$O\ S1+_ <P2_P'+$_\!RA/_ <H2_P'*$O\!_R</
M /\G# #_)0D _R8- /\E$P#_(QP _R H /L<-0#U&D( [QA/ .H76@#F%F4
MXQ9N . 6=P#>%G\ W!:' -D6C@#6%I4 U!:< -(7HP#0%ZL SABU ,P8P0#+
M&-( QQKH <,;^ ' &_\!OAS_ ;T<_P*\'/\"O!O_ KP;_P*\&_\"_RL, /\K
M!0#_*P, _RT) /\L#@#_*14 ]R8@ .XC+0#G(3H X1]( -L?5 #5(%\ T2!H
M ,X@<0#,(7D RB&! <@AB '&(8\!Q"&6 <,AG@'!(J8!OR*O ;TBNP*\(\H"
MN2/C K4D] *S)/\#L23_ Z\D_P.O)/\#KB3_ ZXD_P.N)/\#_R\& /\O  #_
M,@  _S," /DR" #W+PX ZRL6 .$G(@#8)S( T"E! ,LJ3@#&*ED PRIB < J
M:P&]*G,!NRIZ KDJ@@*X*HD"MBJ0 K0JF .S*J$#L2JJ Z\KM02N*\0$K"O;
M!*@L[P2F+/X%I"S_!*,M_P2B+?\$HBS_!*(L_P2B+/\$_S(  /\S  #Y.
MZ3D  .(Y  #>-0< WBX- -$O&P#),2P PS,[ +TS2 "Y-%,!MC-< ;,S90*P
M,VT"KC-T ZPR>P.K,H,$J3**!*<RDP6E,IL&I#*E!J(RL >@,KX'GS+1!YPS
MZ@>:,_L'F#3_!Y<T_P:6-/\&EC3_!98T_P66-/\%_S4  /\X  #J/@  WT(
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M#7I&_PMZ1O\*>D;_"7I&_PEZ1O\)]3X  .9(  #33P  QU0  +U5  "V5
ML%   *E,"P"B31@ G4XH )A.-@"43D$!D$U+ HU-4P2*3%H%ATMA!H5+: B#
M2F\)@$IW"WY)?PQ\28D.>DB3#WA(GQ!W2*P2=4B\$G1)TA-S2>X1<DK_#W)*
M_PUR2O\+<DK_"W)*_PIR2O\*\D(  .!,  #.4P  P5@  +A:  "P60  J58
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M#6%7_PQA5_\,YTP  -%6  #!7@  MF,  *UF  "D9@  FV0  )!>  ")7@X
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MCQ%.9YT336>L%$MHP!1+:-X42V?U$DQG_P],9_\.36?_#4UG_PU-9_\-TEH
M ,!D  "S;   J7(  *!V  "6=P  BG8  'EQ  !Q<0  :W$/ &AQ' !F<B@
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M#3I]N@XZ?M8-.GSQ#3I[_PPZ>_\+.GK_"SIZ_PLZ>O\+P&D  +)T  "G?
MG8$  )*$  "'A@  >X<  &Z'  !@AP  58<! %"(#@!.B!H 38DF $N), !)
MB3H 2(E" 4:)2@%$B5("0HE: T"(8P0]B&T%.XAX!CF'A@@WAY4)-8>F"C2'
MN0HSA],*,X;P"3.%_PDSA/\),X/_"3.#_PDS@_\)N7   *UZ  "B@@  EX<
M (V*  "!C   =8X  &B/  !:D   3Y$  $>2"@!$DA, 0Y,? $&3*@! DS0
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M 1FH_0$8I_\"&*;_ ABF_P(8IO\"I8D  )F/  "/E   @YD  '6>  !HH@
M7*8  %"I  !$K   .:X  "^P   FLP  'K4& !FW#P 8MQ< %[<A !:W*@ 5
MMS0 %+@^ !.X20 2N%0 $KEB !&Y<0 0N8, #[F7  ZYK  -N<0 #;CG  ZV
M^P .M?\ #K3_  ZT_P .M/\ G)   )*5  "&FP  >:   &NF  !>JP  4J\
M $:R   ZM0  +[<  "6Z   =O0  %<   !##!@ +Q@X "L45  G%'@ (Q2@
M!\4R  ;&/0 %QDD !<97  /&9@ "QG<  <:+  #&H   Q;8  ,;2  #%[P
MQ?P  ,7_  #%_P  Q?\ E98  (F<  ![HP  ;:D  &"O  !3M   1K@  #J[
M   NO@  ),$  !O$   3QP  #LH   C. 0 !T H  - 0  #0%@  T1X  -(G
M  #3,0  U#P  -5)  #66   UFD  -9\  #6D@  UJ<  -:_  #6X   UO,
M -;^  #6_P  UO\ C)T  'ZD  !OJP  8;(  %2Y  !&O0  .<$  "W$   B
MQP  &<L  !'.   ,T@  !=4   #;    W ,  -T*  #>#P  WQ0  .$<  #B
M)   Y"X  .8Z  #G20  Z%D  .AK  #I@0  Z9@  .FM  #IQ0  Z>(  .GR
M  #I]0  Z?4 @*4  '&M  !CM0  5;P  $?"   YQ@  +,H  "#.   6T@
M#]8   C;    WP   .,   #E    YP   .@!  #J!P  ZPT  .T1  #O&
M\2$  /,K  #V.   ]T@  /A:  #Y;0  ^H0  /J;  #ZKP  ^L(  /K:  #Z
MWP  ^M\ =*X  &6V  !6O@  2,8  #G+   KT   ']0  !3:   -WP  !>,
M  #F    Z0   .T   #O    \0   /,   #U    ]@(  /@)  #Z#@  _1,
M /\<  #_*   _S8  /]'  #_6@  _VX  /^%  #_F@  _ZL  /^Y  #_O
M_[P _Q$@ /\0'@#_#!X _P0A /\ )P#_ #  _P ^ /\ 3 #_ %D _P!E /\
M< #_ 'H _P"# /\ BP#_ )( _P"8 /\ G@#_ *0 _P"J /\ L #_ +@ _P#"
M /\ S@#_ .( _@#P /T ^P#[ /\ ^P#_ /L _P#Z /\ ^@#_ /H _P#Z /\
M_Q0< /\2&@#_#AH _P@< /\ (0#_ "T _P Z /\ 2 #_ %4 _P!A /\ ; #_
M '8 _P!_ /\ AP#_ (X _P"4 /\ F@#^ *  _0"F /P K #[ +0 ^0"] /@
MR0#W -P ]0#L /, ^ #S /\ \@#_ /$ _P#P /\ \ #_ /  _P#P /\ _Q<8
M /\5%@#_$14 _PP7 /\%'0#_ "@ _P V /\ 0P#_ %  _P!< /\ 9P#_ '$
M_P!Z /P @@#Z (D ^ "0 /< E@#U )P ] "B /, J #Q +  \ "X .X PP#L
M -, Z@#G .D ]0#G /\ Y@#_ .4 _P#E /\ Y0#_ .4 _P#E /\ _QH3 /\8
M$0#_%!  _P\1 /\-&0#_"B0 _P4P /\!/@#_ $L _P!7 /X 8@#Z &P ]0!U
M /( ?0#P (0 [@"+ .P D0#K )< Z0"> .< I #F *P Y "T .( OP#@ ,T
MW@#C -P \@#: /T V #_ -8 _P#5 ?\ U0'_ -4"_P#5 O\ _QX0 /\<#0#_
M%PL _Q4. /\4%0#_$1\ _PXJ /\+. #]"$4 ^ 91 /0$7 #N!&8 Z@1O .8#
M=P#D!'\ X@2& . $C #>!), W06: -L%H #8!:@ U06Q -(%NP#0!LD S@?@
M ,P(\0#)"O\ QPO_ ,8,_P#%#/\ Q0S_ ,4,_P#%#/\ _R$, /\@!@#_' ,
M_QT* /\;$ #_&!@ _Q0C /81, #O#CX Z@Y* .4-5@#A#6  W0UI -D-<0#5
M#7D TPV! -$-B #/#8\ S0Z6 ,L.G0#*#J4 R ZN ,8/N0#$$,@ PA#? +X1
M\@"[$O\ N1/_ +<3_P&V$_\!MA/_ ;83_P&V$_\!_R4& /\C  #_(P  _R0#
M /\A"@#]'1$ \1H; .@6)P#A%#4 VA-# -,43P#.%5D RQ5C ,@6:P#%%G,
MPQ=[ ,$7@@# &(D OAB0 +P8F "[&:  N1FI +<9M "U&L( M!K6 + ;[0&M
M'/P!JQW_ :D=_P&I'?\!J!W_ :@=_P&H'?\!_R@  /\G  #^*@  [RH  .<G
M 0#G(@D Y!T0 -D;'0#/'2T R1X\ ,0@20"_(%, O"%= +DA90"W(FT M2)T
M +,B? "Q(H,!L"** :XBD@&L(YL!JR.D :DCKP&G([P!IB3. :,DZ *@)?D"
MGB7_ ITE_P*<)?\"FR7_ ILE_P*;)?\"_RP  /\M  #M,@  XC0  -HS  #3
M+@, TB4* ,DE%P#!)R< NRDV +8J0P"R*TX KRM7 *PK8 "J*V<!J"MO :8K
M=@&D*WT!HRN$ J$KC0*?*Y4"GBN? IPKJ@.:*[8#F2S' Y<LX@.4+?4$DBW_
M Y$M_P.0+O\#D"W_ Y M_P.0+?\#_S   /(S  #D.@  UCT  ,P\  #'.0
MPS$% +TN$0"U,"$ L#(P *LS/0"G,TD I#-2 *$S6@&?,V(!G#-I IHS< *9
M,W<"ES)_ Y4RAP.3,I $DC*:!) RI06.,K$%C3/"!HLSW :)-/(&AS3_!88T
M_P6&-/\$A33_!(4T_P2%-/\$_#,  .LZ  #<00  S40  ,-$  "]00  N#L!
M +(W#@"K.!P I3DK *$Z. "=.T0 FCM- 9<Z5@&4.ET"DCID I Z:P...7(#
MC#EZ!(HY@@6).8L%ASF5!H4YH >#.:T'@CF\"($YTPA_.NX(?3K^!WP[_P9\
M._\%?#O_!7P[_P5\._\%]#<  .5   #21P  Q4H  +Q+  "U20  KT,  *D^
M"P"B/Q< G4 F )A!- "403\ D4%) 8Y!40&+0%D"B4!@ X= 9P.%/VT$@S]U
M!8$_?09_/H<'?3Z1"'L^G EZ/JD)>#ZX"G<_S0IU/^H*=$#\"'1 _P=T0/\&
M<T#_!G- _P9S0/\&\3L  -]%  #,3   OT\  +90  "N3P  ITH  *!$!P":
M110 E48B )!&, ",1SP B49% 89&3@&#1E4"@45< WY%8P1\1&H$>D1Q!7E$
M>09W1(((=4.-"7-#F0IQ0Z8+<$.U#&Y$R0QM1.<,;47Z"FQ%_PAL1?\';$7_
M!VQ%_P=L1?\'[#\  -A)  #'4   NU0  +%5  "I5   H5   )E* @"221$
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MC@Q959P-5U6K#E95O@]55=L/557S#555_PM65?\)5E7_"595_PA65?\(VTT
M ,57  "X7@  K6(  *-E  ":90  D&,  (-<  ![6P8 =5L2 '%;'P!N7"L
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M#$=CN U&8]$-1F/O#$9B_PI'8O\)1V+_"4=B_PA'8O\(RE@  +IB  "N:0
MHVX  )IQ  "0<@  A'$  '1K  !I:0  8VD+ %]I%0!<:B$ 6FHM %AK-@!6
M:S\!56M' 5-J3@)1:E4#3VI=!$UJ905*:6X&2&EY!T9IA@E$:94*0VBE"T%I
MMPQ :<\,0&CN"T%H_PI!9_\)06?_"$)G_PA"9_\(Q5T  +9F  "J;0  H',
M )9V  "+=P  @'8  '!R  !E<0  7' ' %AP$0!6<!T 5'$H %)Q,P!0<3P
M3W)$ 4UQ2P%+<5,"27%: T=Q8@1%<&P%0W!W!D%PA <_<),(/6^C"3MPM0H[
M<,T*.F_L"3MN_@@[;O\(.VW_!SMM_P<[;?\'OV(  +%K  "F<P  G7D  ))[
M  "'?   >WP  &UZ  !@>   5G<! %!W#@!.>!@ 3'@D $MY+@!)>3< 2'E
M $9Y2 %$>4\!0GE7 D%Y8 (_>&D#/'AT!#IX@@4X>)$&-WBA!S5XLP<T>,L'
M-'?K!S1V_0<T=?\'-77_!C5T_P8U=/\&N6@  *UQ  "B>0  F'X  (V   ""
M@0  =H(  &F!  !;@0  48$  $B "@!%@1, 0X$> $*"*0!!@C( 0(([ #Z"
M0P ]@DL .X)3 3F"7 $W@F8"-8)Q S."?P,Q@8X$,(&?!"Z!L04M@<@%+8'I
M!"U__ 4M?O\%+7W_!2U]_P4M??\%LVX  *AX  "=?P  DH,  (B&  !]AP
M<(@  &.)  !5B@  2XH  $&* @ [BPX .8L7 #B,(@ WC"P -HPU #2,/0 S
MC$8 ,HU/ #&-6  OC6(!+8QN 2N,>P$JC(L"*(R< B:,KP(EC,8")8OH B6*
M^P,EB/\#)8C_ R6'_P,EA_\#K78  *.   "7A0  C8D  (*,  !VC@  :9
M %R2  !0DP  1)0  #J5   QE@@ +9<1 "R7&@ KER0 *I<M "F7-@ HF#\
M)YA( ":84@ EF%P (YAH "*8=P @F(< 'YB9 1V8K $<F,,!')?E 1R5^@$;
ME/\!&Y/_ AN3_P(;D_\"IW\  )R&  "1BP  AX\  'J2  !ME0  89@  %6;
M  !)G0  /9X  #.?   JH0  (:,* !^C$0 >HQH ':0D !RD+0 ;I#8 &J0_
M !FD2@ 8I%4 %J5A !6E<  4I8$ $Z64 !*EJ  1I;\ $*3B !&B^  1H?\
M$:#_ 1&@_P$1H/\!H(8  )6,  ",D0  ?Y4  '&:  !DG@  6*$  $RD  !
MI@  -:<  "JI   BK   &:X  !*P"0 0L1  $+$8  ZQ(@ .L2L #;$U  VQ
M0  ,L4L "[%8  JQ9P (L7@ ![&+  6QH  $L+4 !+#0  2P[P %K_X !J[_
M  :N_P &KO\ F(X  (^3  ""F   =9T  &>B  !:IP  3JL  $&M   UKP
M*[$  "&T   8M@  $;D   V\ P 'O@P  [T2  &]&0  OB(  +XK  "^-@
MOD$  +].  "_7   OVT  +^   "^E0  OJH  +["  "]Y   O?8  +W_  "]
M_P  O?\ DI0  (6:  !XH   :J8  %RK  !/L   0K,  #6V   JN   (+L
M !>^   0P0  "\0   3'    R0<  ,D-  #)$@  RAD  ,LB  #+*P  S34
M ,Y!  #.4   SV   ,]R  #/AP  SYT  ,^S  #/S@  S^L  ,[X  #._@
MSOX B)L  'JB  !LJ   7J\  %"U  !"N0  -;P  "F_   >P@  %<8   [)
M   (S    -    #3    U0   -8&  #8#   V1$  -L6  #<'P  WB@  . T
M  #B00  XE$  .-C  #C=P  Y(X  .2D  #DN@  Y=0  .7J  #E\P  Y?,
M?*,  &ZJ  !@L@  4;D  $.^   UP@  *,8  !S)   3S0  #-$   35
MV@   -X   #A    X@   .0   #E P  YPD  .D.  #K$@  [1H  .\D  #R
M,0  ]$$  /13  #U9@  ]7P  /:3  #VJ0  ][P  /?.  #WWP  ]]\ <*P
M &&T  !3NP  1<,  #;'   GS   &]   !'5   *VP   -\   #B    Y0
M .D   #L    [0   /    #Q    \P   /4$  #W"@  ^A   /P6  #_(0
M_RX  /]   #_4P  _V@  /^   #_E@  _Z@  /^V  #_OP  _[\ _PT< /\*
M&P#_ AL _P > /\ ) #_ "X _P \ /\ 2@#_ %8 _P!C /\ ;0#_ '< _P!_
M /\ AP#_ (X _P"4 /\ F@#_ *  _P"F /\ K #_ +0 _P"] /\ R0#^ -T
M_0#M /P ^@#[ /\ ^@#_ /D _P#Z /\ ^@#_ /H _P#Z /\ _Q 9 /\-%P#_
M!A8 _P 8 /\ '@#_ "H _P W /\ 10#_ %( _P!> /\ :0#_ '( _P![ /\
M@@#_ (D _P"0 /X E@#] )P _ "A /L J #Y *\ ^ "X /8 PP#T -( \P#G
M /( ]@#P /\ [P#_ /  _P#O /\ [P#_ .X _P#N /\ _Q(4 /\/$@#_"Q(
M_P 2 /\ &@#_ "4 _P S /\ 0 #_ $T _P!9 /\ 9 #] &T ^P!V /D ?0#W
M (0 ]0"+ /0 D0#S )< \0"= /  HP#N *H [ "S .H O0#H ,L YP#A .4
M\0#C /T XP#_ .( _P#A /\ X0#_ .  _P#@ /\ _Q00 /\1#@#_#0T _P</
M /\"%0#_ "  _P M /\ .@#_ $< ^0!3 /4 7@#R &@ \ !P .T > #K '\
MZ0"% .@ C #F )( Y0"8 ., GP#A *8 WP"N -P N #: ,4 U@#9 -0 [ #2
M /D T0#_ ,\ _P#. /\ S@#_ ,X _P#. /\ _Q<, /\4" #_#P4 _PX+ /\,
M$0#_!QH _P$F /P - #T $$ [0!- .D 6 #F &( XP!J .  <@#> 'D VP"
M -D A@#6 (T TP"3 -$ F@#/ *$ S0"J ,L LP#) +\ Q@#0 ,4 Z ## /8
MP0#_ , "_P"_ _\ OP/_ +\#_P"_ _\ _QL& /\7  #_%   _Q,% /\1#0#_
M#A0 ^0H? / &+ #F SD X -& -P#40#6!%L T@1D ,\%; #,!7, R@5Z ,@%
M@0#&!8< Q0:. ,,&E@#!!IT OP:F +T&L "[![P N0C- +@*Y0"U"_< LPW_
M +$-_P"P#?\ L [_ *\._P"O#O\ _QX  /\;  #_&P  ^AH  /46!0#V$0T
MZPX5 .(+(@#8"S$ T P^ ,L-2@#'#54 Q Y> ,$.9@"_#FT O0YT +L/>P"Y
M#X( MQ"* +80D0"T$)H LA"C + 1K0"O$;H K1'* *H2Y0"G%/< I17_ *,5
M_P"B%?\ HA7_ *(5_P"B%?\ _R(  /\@  #P(P  YB0  . A  #<&04 VQ ,
M - 1&0#($RD PA4W +T61 "Y%TX M1=7 +,88 "P&&< KAAN *P9=0"K&7P
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M GXN_P)^+O\"]"X  .0W  #2/0  Q3\  +L_  "T/   KS4  *DO"P"C+Q<
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MCP9D0YT'8T.K!V%#O0A@1-D(8$3S!V!$_P9?1/\%7T3_!&!$_P1@1/\$X$$
M ,I*  "[4   L%,  *=5  ">4P  E4\  (M)  "#1PL ?4<5 'E'(@!V2"X
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M"%!0MPE04,X)3U#M"%!0_P=04/\&4%#_!5!0_P504/\%T$L  +]4  "R6@
MIUX  )U@  "48   B5T  'Q7  !R5   ;%,. &A4&0!E5"0 8E0O &!4. !>
M5$  7%1( 5I43P%95%8!5U1= E5490-45&X$4E1Y!5!4A@9.5)0'352D"$M4
MM0A+5,P)2E3K"$M4_@=+5/\&2U3_!4M4_P5+5/\%S$X  +M7  "N7@  I&(
M )ID  "19   AF(  '=;  !M6   9E@, &)8%@!?6"( 75DL %M9-@!963X
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M!CMC^@4[8O\%.V+_!3QA_P0\8?\$OEL  +!C  "E:@  FV\  )%R  "&<@
M>W$  &QM  !@:P  56D  $]H#0!-:1< 2VDA $EJ*P!(:C0 1VH] $5K1 !$
M:TP 0FM4 4%K7 $_:F4"/6IP CMJ?0,Y:HP$-VJ<!#9JK@4U:L0%-6KE!35I
M^00U:?\$-6C_!#5H_P0U:/\$N6   *QI  "A<   F'4  (UW  ""=P  =W<
M &ET  !<<P  47$  $AP"@!%<!( 0W$= $)Q)P! <C  /W(X #YR0  ]<D@
M.W)0 #IR60$X<F,!-G)M C1R>@(S<HD#,7*: R]RK ,N<L$#+G+C RYQ^ ,N
M</\#+F__ RYO_P,N;_\#LV8  *=O  "==@  DWH  (A\  !^?0  <GT  &1\
M  !7>P  3'H  $)Y P \>0X .GH7 #EZ(0 X>BH -WLS #9[.P T>T0 ,WM,
M #)[50 P>U\ +WMJ 2U[=P$K>X<!*GN8 BA[J@(G>[\")GOA B9Z]P(F>/\"
M)GC_ B=W_P(G=_\"KFP  *-V  "9?   CG\  (2"  !X@P  ;(0  %^$  !1
MA   1X0  #R$   SA D ,(01 "^$&@ MA"0 +(4M "N%-0 JA3X *85' "B&
M4  GAEH )H9F "2&<P CAH, (8:5 ""&IP$>AKP!'H;> !Z$]0$>@O\!'H+_
M 1Z!_P$>@?\!J'0  )Y]  "3@@  B84  'Z(  !QB@  98L  %B,  !,C0
M0(X  #:.   LCP  )9 , ".0$P BD!P (9 E ""1+@ ?D38 'I%  !V120 <
MD50 &I%@ !F1;@ 8D7X %I*0 !62I  4D;D $Y'8 !./]  4CO\ %(W_ !2,
M_P$4C/\!HWT  )B#  ".B   A(P  '>/  !ID0  79,  %"5  !%EP  .9@
M "Z9   EF@  '9L" !:=#  5G1, %)T; !.=)  2G2T $9XW !&>00 0GDP
M#YY8  Z>9P -GG< #)Z*  N=G@ *G;( "9W,  F<[  *F_X "YK_  N9_P +
MF?\ G(0  )&*  "(C@  >Y(  &V6  !@F0  5)P  $B?   \H   ,*$  ":C
M   =I0  %:<  !"I!0 +JPT "*H3  >J&P &JB0 !:HN  2J.  "JD0  :I0
M  "J7@  JFX  *J!  "JE0  J:H  *G!  "HY   J/8  *?_  "G_P  I_\
ME8L  (R0  !_E0  <9H  &.>  !6H@  2J8  #VH   QJ@  )JL  !VM   4
ML   #K(   FU 0 "M@H  +8/  "V%0  MQT  +<E  "W+P  N#D  +A&  "X
M5   N&0  +AV  "XBP  MZ   +>V  "WTP  MN\  +;\  "V_P  MO\ CY(
M (*7  !TG0  9J(  %BG  !+K   /J\  #&Q   FLP  '+8  !.X   -NP
M!KX   #!    P@0  ,(+  ##$   Q!4  ,0<  #%)   QBX  ,@Z  #)1P
MR5<  ,EI  #)?0  R90  ,BJ  #(PP  R.0  ,CT  #(_0  R/T A9D  '>?
M  !HI@  6JL  $VQ   _M0  ,;@  "6Z   :O0  $<    O#   #QP   ,H
M  #-    S@   ,\#  #0"0  T0X  -,2  #5&0  UR(  -HM  #=.0  WDD
M -Y:  #?;@  WX4  -^<  #?L@  WLL  -[F  #?]   W_0 >:$  &NH  !<
MKP  3K4  $"[   QO@  ),$  !G%   0R   "<P   #/    TP   -D   #<
M    W0   -\   #A    X@4  .0+  #F$   Z!8  .H@  #M*P  \#H  /%+
M  #Q7@  \G,  /.+  #SH@  \[8  //)  #SX0  \^$ ;:H  %ZQ  !0N0
M0;\  #+$   DR   %\P   [0   &U0   -H   #>    X@   .8   #I
MZ@   .P   #N    \    /(   #T!@  ]@P  /D2  #\'   _RD  /\Z  #_
M30  _V(  /]X  #_D   _Z,  /^S  #_P0  _\$ _P<9 /\!%P#_ !< _P :
M /\ (0#_ "L _P Y /\ 1P#_ %0 _P!? /\ :@#_ ', _P![ /\ @P#_ (H
M_P"0 /\ E@#_ )L _P"A /\ J #_ *\ _P"X /\ Q #^ -4 _ #J /L ^ #Z
M /\ ^0#_ /@ _P#X /\ ]@#_ /, _P#Q /\ _PL5 /\%$P#_ !, _P 4 /\
M&@#_ "< _P T /\ 0@#_ $\ _P!; /\ 90#_ &X _P!V /\ ?@#_ (4 _@"+
M /T D0#[ )< ^@"= /@ HP#W *L ]@"S /0 O@#S ,P \0#C .\ \P#N /\
M[0#_ .P _P#K /\ [ #_ .P _P#K /\ _PT1 /\)$ #_  \ _P 0 /\ %@#_
M "( _P O /\ /0#_ $H _P!5 /T 8 #Z &D ^ !Q /8 >0#T '\ \P"& /$
MC #O )( [@"8 .P GP#K *8 Z0"N .< N #E ,4 XP#: .$ [0#? /L W@#_
M -T _P#= /\ W0#_ -T _P#= /\ _P\- /\,"P#_ PD _P , /\ $@#_ !T
M_P I /L -P#X $0 ]0!0 /( 6@#N &, [ !K .D <P#G 'H Y0"  ., A@#A
M (P WP"3 -T F0#; *$ V0"I -4 L@#2 +X T #. ,X Y@#, /8 R@#_ ,H
M_P#) /\ R #_ ,@ _P#( /\ _Q$( /\- @#_!P  _P4( /\ #@#_ !8 ]P B
M .\ , #K #T Z !) .0 5 #@ %T W0!E -D ;0#5 ', T@!Z -  @ #. (<
MS "- ,H E #( )L Q@"D ,0 K0#" +@ P #' +T WP"\ /$ NP#^ +D _P"X
M /\ N #_ +@ _P"X /\ _Q0  /\/  #_#0  _PP  /\'"0#X 1  Z  : .,
M* #= #8 V !" -( 30#. %< R@!? ,< 9@#% &T PP!T ,$ >@"_ ($ O0"(
M +L CP"Y )< MP"? +4 J "S +, L0#" *\ V "N NT K /[ *L%_P"J!O\
MJ0;_ *D&_P"I!O\ _Q8  /\2  #W$@  [!$  .8.  #E!@@ W0,2 -0#( #-
M!"T R 0Z ,,%1@"_!5  O 98 +D&8 "W!V< M0=N +,'=0"Q"'L KPB" *X)
MB@"L"9( J@F; *@*I0"F"K  I0N_ *,,U "A#>T GP[^ )T._P"<#_\ FP__
M )L/_P";#_\ _QH  /<9  #J'@  WQX  -4:  #0$P( S@P+ ,<+%@# #24
MN@XR +8./P"R#TD KQ!2 *P06@"J$&$ J!%H *81;P"D$78 HA%] *$1A0"?
M$HX G1*7 )P2H@":$ZT F!.\ )<4T "4%>P DA;] ) 7_P"/%_\ CA?_ (X7
M_P".%_\ ^AT  .XC  #?*   T"H  ,<G  #!(0  O1D% +D2$ "R%1X K18L
M *@7. "D&$, H1E, )\95 "<&EP FAIB )D::0"7&W  E1MW )0;?P"2'(@
MD!R2 (\<G0"-':D BQVW (H>R@"('^< AB#Z (0@_P&#(/\!@R#_ 8(@_P&"
M(/\!]20  .4L  #3,0  QC,  +PQ  "V+0  L"4  *P=# "F'A@ H2 F )PA
M,@"9(CT E2)' ),C3P"1(U8 CR-= (TD9 "+)&L B21R (@D>@"&)(, A"6-
M (,EF &!):0!@":R 7XFQ0%])^(!>R?W 7DH_P%X*/\!>"C_ 7@H_P%X*/\!
M[RL  -TS  #*.0  OCL  +0Z  "M-@  IB\  *$H!P";)Q, EB@@ )$I+0".
M*C@ BRM" (@K2@"&*U( A"M8 ((L7P" +&8 ?RQM 'TL=0![+'X!>BR( 7@L
ME %V+: !=2VN G0MP )R+MT"<2[T G O_P)O+_\";R__ 6XO_P%N+_\!Z#$
M -,Z  ##/P  MT$  *Y!  "F/@  GC@  )<Q 0"1+A  C"\< (@P* "$,3,
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M UL^M@1:/LP$6C_L!%D__@-9/_\#63__ ED__P)9/O\"UC\  ,-'  "U3
MJE   *!0  "73P  CDL  (1%  !Z0 8 =3\1 '% ' !M0"@ :T$R &E!.P!G
M04( 94%) &-!4 !A05< 8$%> 5Y!9@%=0F\"6T)Z EI"A@-80I0#5T*C!%5#
MLP140\D$5$/I!%-#_0-30_\#5$/_ U1#_P)40_\"T$(  +]*  "R4   IU,
M )U4  "44P  BE   ']*  !U10( ;D,. &M$&0!G120 944N &)%-P!A13\
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M!$1/^01%3_\#14__ T5._P-%3O\#Q$P  +55  "I6P  GUX  )5@  "+8
M@%X  ')7  !G4P  7E$' %E1$0!741L 5%$E %)2+P!14C< 3U(_ $Y21@!-
M4TT 3%-5 $I370%)4V8!1U-P D53?0)$4XL#0E.; T%4K 1 5,$$/U3B!#]4
M^ - 4_\#0%/_ T!3_P- 4O\#P%   +)8  "F7@  G&(  ))E  "(90  ?6(
M &Y<  !C60  658# %16#@!15A@ 3U8B $U7+ !,5S0 2E<\ $E81 !(6$L
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M B]B_P(O8O\"LUX  *=F  "<;0  DW$  (AS  !]<P  <G(  &1P  !8;@
M36P  $)J P \:0X .FH6 #EJ(  X:B@ -FLQ #5K.0 T:T$ ,VQ) #)L4@ Q
M;%P +VQF "YL<P L;((!*FR3 2ELI0$H;+D!)VW6 2=K\@$G:O\!)VK_ 2AI
M_P(H:?\"KF0  *-L  "9<P  CG8  (1X  !Y>0  ;7@  &!W  !3=@  2'4
M #YS   T<@H ,7,1 #!S&@ O<R, +G,K "UT-  L=#P *W1$ "ET30 H=5<
M)W5C "5U;P D=7\ (G60 "%UH@ @=;< 'W72 !]T\0 ?<_\!'W+_ 2!Q_P$@
M<?\!J6L  )YS  "4>0  BGP  (!^  !T?P  9W\  %I_  !-?@  0WX  #A]
M   O?0( *'T- "9]%  D?1P (WXE ")^+0 A?C8 (7X_ !]_2  >?U( '7]>
M !Q_:P :?WH &7^, !=_GP 6?[, %7_. !5^[P 6?/\ %GO_ !9[_P 7>_\
MI'(  )IZ  "/?P  A8(  'N$  !MA@  8(<  %2'  !(B   /(@  #*(   H
MB   ((@% !J)#@ 9B14 &(D= !>*)@ 6BBX %8HW !2*00 3BDP $HM8 !&+
M90 0BW4 #XN'  Z*FP -BJ\ #(K(  R)Z@ -A_P #H?_  Z&_P .AO\ GWL
M )2!  "*A0  @(@  '.+  !EC0  68\  $R0  !!D@  -)(  "J2   ADP
M&90  !*6!@ .EPX #9<5  R7'0 ,ER8 "Y<O  J7.0 )ET0 ")=0  :77@ %
MEVX  Y:   &6E   E:@  )6^  "4X   E/0  )/_  &2_P !DO\ F((  (Z(
M  "%C   =X\  &J2  !=E0  4)@  $2:   XFP  +)P  "*=   9G@  $J
M  VB @ 'HPL  :,0  "C%P  HQ\  *,G  "C,0  I#P  *1(  "D5@  I&4
M *-W  "CBP  HZ   **V  "AT@  H?   *#[  "@_P  H/\ D8H  (F.  ![
MD@  ;9<  &";  !3G@  1J$  #FC   MI   (Z8  !FH   1J@  #*P   6N
M    KP<  *\-  "O$0  L!@  + @  "Q*   L3(  +(^  "R3   LEL  +)L
M  "R@0  L9<  +&L  "PQ@  L.@  *_W  "O_P  K_\ C)   '^5  !QF@
M8Y\  %6D  !'J   .JH  "VL   BK@  &+   !"S   *M0   K@   "[
MNP   +P'  "\#0  O1$  +X6  "_'@  P"<  ,$R  #"0   PT\  ,-@  ##
M=   PXL  ,.A  ##N   PM<  ,+O  #"^@  P?X @9<  '.=  !EHP  5Z@
M $FM   [L0  +;,  "&V   6N0  #KL   >^    P0   ,4   #'    R
M ,D   #*!0  RPL  ,T/  #.%   T!P  -,F  #6,@  V$$  -A3  #99@
MV7P  -F4  #9JP  V<,  -GA  #9\   V?0 =I\  &>F  !9K   2[(  #RW
M   NN@  (;T  !7    -Q   !<<   #*    S@   -(   #5    U@   -D
M  #;    W0   -\'  #A#   XQ$  .89  #I)   [#(  .U#  #N5@  [VL
M .^$  #OG   [[(  ._&  #OW0  [^0 :J@  %NO  !,M@  /KP  "_    @
MQ   %,@   S,   "T    -0   #9    W@   .(   #E    Y@   .@   #I
M    [    .X   #P @  \@D  /4/  #X%P  _",  /\S  #_1@  _UH  /]Q
M  #_B0  _Y\  /^Q  #_P   _\8 _P 5 /\ % #_ !0 _P 7 /\ '0#_ "@
M_P W /\ 1 #_ %$ _P!< /\ 9@#_ &\ _P!W /\ ?@#_ (4 _P"+ /\ D0#_
M )< _P"= /\ I #_ *L _P"T /X OP#] ,X ^P#F /D ]@#X /\ ]P#_ /<
M_P#W /\ \ #_ .P _P#I /\ _P,2 /\ $ #_ !  _P 1 /\ %P#_ "0 _P R
M /\ /P#_ $P _P!7 /\ 80#_ &H _P!R /\ >0#] (  _ "& /H C #Y )(
M^ "8 /8 GP#U *8 ] "N /( N0#P ,8 [@#> .T \ #K /X Z@#_ .D _P#I
M /\ YP#_ ., _P#@ /\ _P<. /\ #0#_  L _P , /\ $P#_ !\ _P L /\
M.@#_ $8 _@!2 /L 7 #X &4 ]0!L /, = #Q 'H [P"! .X AP#L (T Z@"3
M .D F@#G *$ Y@"I ., LP#A +\ WP#0 -T Z0#: /D V0#_ -< _P#5 /\
MU0#_ -4 _P#4 /\ _PD* /\!!0#_  , _P ) /\ $ #_ !D ^P F /< - #T
M $  \@!, .X 5@#J %\ YP!G .0 ;@#B '0 X ![ -X @0#< (< V@"- -8
ME #4 )L T0"C ,\ K0#, +@ R@#' ,@ X #& /, Q0#_ ,, _P## /\ PP#_
M ,, _P## /\ _PL! /\#  #_    _P # /\ "P#S !( [@ ? .H +0#F #H
MX@!% -X 3P#9 %@ U !@ -$ : #. &X S !T ,H >P#( ($ Q@"' ,0 C@#"
M )8 P "> +X IP"[ +( N0#  +< U "U .P LP#[ +, _P"R /\ L@#_ +$
M_P"Q /\ _PT  /\&  #_ P  ]P   /0  P#G  T X  8 -H )0#3 #( S@ ^
M ,H 20#& %( PP!: ,  80"^ &@ O !N +H = "X 'L M@"! +0 B "R )
ML "9 *X H@"L *T J@"Z *@ RP"F .8 I0#W *0 _P"C /\ H@#_ *( _P"B
M /\ _Q   /L,  #O#@  Y@T  -\)  #:  8 T  1 ,D '0#$ "H OP W +L
M0@"W $L M !4 +( 6P"O &( K0!H *L ;@"I '4 J ![ *8 @P"D (L H@"4
M *  G@"> :@ G *U )L#Q@"9!>( F ;T )8(_P"5"?\ E G_ )0)_P"4"?\
M_!$  /$5  #C&0  UAD  ,P5  #'$   Q <* +T#% "W!"$ L@8N *X(.@"J
M"40 IPE- *0*50"B"EP H IB )X+:0"<"V\ FPMV )D,?@"7#(8 E@R0 )0,
MF@"2#:8 D0VS (\-Q0"-#N( BQ#V (D0_P"($?\ AQ'_ (<1_P"'$?\ ]AD
M .<@  #6)   R"4  +\B  "Y'   M!0! +$-#@"J#AD I0\G *$0,P"=$3X
MFA%' )@23P"5$E8 DQ)< )$28P"0$VD CA-P (P3> "+$X$ B12+ (<4E@"&
M%:( A!6P (,6P0"!%]T ?QCT 'T9_P!\&?\ ?!G_ 'L9_P![&?\ [R$  -TI
M  #*+0  OB\  +4L  "N)P  J"   *,7" ">%A, F1<A )09+0"1&C@ CAI!
M (L;20")&U  AQM7 (4<7@"$'&0 @AQK ( <<P!_'7P ?1V& 'P>D0!Z'IX
M>!^K '<?O !V(-0 ="'P '(A_P!Q(O\ <2'_ '$A_P!Q(?\ Z"@  -(P  #"
M-0  MS<  *TU  "E,0  GBL  )@C @"2'A  C2 ; (DA)P"&(C( @R,\ ($C
M1 !^(TL ?"12 'LD60!Y)%\ =R1F '8E;@!T)7< <R6! '$FC0!O)ID ;B:G
M &TGN !L)\X!:BCM 6DI_P%H*?\!:"G_ 6@H_P%H*/\!X2X  ,LV  "\.P
ML3T  *<]  "?.0  ES,  (\M  "()PP @R<6 '\H(@!\*2T >2HW '<J/P!U
M*D< <RM. '$K5 !P*UL ;BMB &PK:@!K+'( :2Q] &@LB0!F+98!92VD 60N
MM %C+LH!82_I 6 O_0%@+_\!8"__ 6 O_P%@+O\!VC0  ,4\  "W00  K$,
M *)#  "90   D#H  (@T  " +@@ >BT2 '<N'@!S+RD <3 S &\P.P!M,$,
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M DT^^ )-/O\!33[_ 4T]_P%-/?\!R4   +A(  "L30  H5   )=1  ".3P
MA$L  'E%  !N0   9CT+ &(]% !?/1X 7#XH %H^,0!8/C@ 5SY  %4_1@!4
M/TT 4S]5 %) 70!00&8 3T!P 4Y ? %,08H!2T&: DI!JP))0KX"2$+> DA"
M]@)(0O\"2$+_ 4A!_P%(0?\!Q40  +5+  "I4   GE0  )54  "+4P  @%
M '5*  !J1@  84(( %Q!$0!90AL 5T(E %5"+@!30C4 44(] $]"0P!/0TL
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M 3E-_P$Z3?\!NDX  *Q6  "A6P  EU\  (UA  "#80  >%X  &E8  !?5@
M5%(  $Q/"P!)3Q( 1U < $50)0!#4"T 0E U $%1/ ! 440 /U%, #Y25  \
M4ET .U)G #I2<P X4X(!-U.2 353I $T4[<!,U31 3-3\0$T4_\!-%+_ 312
M_P$T4O\!ME(  *E:  ">8   E&0  (MF  " 90  =&,  &9>  !<7   45@
M $=5!P!"51  0%48 #]6(0 ]5BH /%8R #M6.0 Z5T$ .5=) #A740 W6%H
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M:P D9GH (V:+ ")FG0 @9K$ 'V;) !]FZP @9?X (&3_ "!C_P$A8_\!J6(
M )YJ  "5<   BG,  (!U  !U=0  :70  %QR  !/<0  1&\  #IN   P;0,
M*6P- "=L%  F;!P )6TD "1M+  C;30 (FT] "%N1@ @;E  'FY; !UN9P <
M;G8 &FZ' !EOF@ 8;ZX %F_& !9NZ0 7;?P &&S_ !AK_P 8:_\ I&D  )IQ
M  "0=@  AGD  'Q[  !Q>P  9'L  %=Z  !*>0  /W@  #5X   K=P  (G8'
M !UV#P <=Q8 &W<> !IW)@ 9=RX &'<W !=X0  5>$H %'A6 !-X8P 2>'(
M$7B# !!XEP />*L #GC#  YWY@ .=OH #W7_ !!U_P 0=/\ GW$  )5X  "+
M?   @G\  '>!  !J@@  78(  %""  !$@@  .((  "Z"   D@@  '((  !2"
M"0 1@Q  $(,6 !"#'@ .@R< #H,P  V#.0 -@T0 #(-0  N#70 )@VP "(-^
M  :#D0 %@J4  X*[  2!VP $@?( !8#_  9__P &?_\ FGD  )!^  "&@P
M?84  &^'  !BB0  58H  $F+   ]C   ,8P  ":,   =C0  %8X   ^/ P *
MD P !I 1  2/&  #CR   8\I  "/,@  D#T  )!)  "/5@  CV4  (]V  "/
MB@  CI\  (ZT  "-SP  C.X  (S[  "+_P  B_\ E(   (N%  ""B0  =(P
M &:/  !9D0  3),  $"5   TE@  *)8  !Z7   5F   #YH   J;   "G D
M )P.  "<$P  G!H  )PB  "=*P  G34  )U   "=3@  G5P  )UN  "<@0
MG)<  )RL  ";Q@  FN@  )GY  "9_P  F/\ CH@  (:,  !XD   :I0  %R7
M  !/F@  0IT  #:>   IGP  'Z$  !6B   .I   "*8   "H    J00  *D*
M  "I#@  J1,  *H:  "J(@  JRL  *PV  "L1   K%,  *QC  "L=P  JXX
M *ND  "KO   JMX  *GT  "I_0  J?\ B8X  'N3  !MEP  7YP  %&@  !$
MI   -J8  "JH   >J0  %*L   VN   &L    +(   "U    M0   +4#  "V
M"0  MPX  +@2  "X&0  NB$  +LK  "\.   O4<  +U8  "]:P  O8$  +V9
M  "]L   O<P  +SJ  "\]P  N_X ?I4  '";  !BH   4Z4  $:J   XK0
M*J\  !ZQ   3M   #+<   .Y    O    +\   #"    P@   ,,   #$
MQ@8  ,<,  #($   RA8  ,P@  #/*P  T#H  -%+  #17@  TG,  -*+  #2
MI   T[L  -/8  #3[0  T_8 <YT  &2C  !6J0  1Z\  #FS   JM@  ';D
M !*\   *OP   ,,   #&    R0   ,T   #/    T    -(   #4    U@
M -D"  #;"   W@X  .$3  #D'0  Z"H  .@\  #I3P  Z60  .I\  #KE0
MZZP  .O"  #LU0  [.4 9J8  %BL  !)LP  .[D  "N\   =P   $<0   G(
M    S    ,\   #3    V0   -T   #@    X0   .,   #E    YP   .H
M  #L    [@0  /$+  #U$@  ^!P  /LK  #]/@  _E,  /YJ  #_@P  _YL
M /^N  #_O@  _\H _P 2 /\ $ #_ !$ _P 3 /\ &0#_ "8 _P T /\ 00#_
M $T _P!8 /\ 8@#_ &L _P!S /\ >@#_ ($ _P"' /\ C0#_ ), _P"9 /\
MH #_ *< _@"O /P N@#Z ,D ^0#A /@ \P#W /\ ]@#_ /4 _P#Q /\ Z0#_
M .0 _P#A /\ _P / /\ #0#_  T _P . /\ % #_ "$ _P N /\ / #_ $@
M_P!3 /\ 70#_ &8 _@!M /P =0#[ 'L ^0"" /@ B #W (X ]@"4 /0 FP#S
M *( \0"J .\ M #M ,$ ZP#5 .H [ #H /P YP#_ .4 _P#F /\ X #_ -D
M_P#4 /\ _P + /\ " #_  8 _P ) /\ $ #_ !P _P I /\ -@#_ $( ^P!.
M /< 5P#T &  \@!H .\ ;P#M '8 [ !\ .H @@#H (@ YP". .4 E0#C )P
MX0"D -\ K@#= +D V@#* -< Y #4 /8 T0#_ -  _P#0 /\ SP#_ ,L _P#'
M /\ _P # /\   #_    _P $ /\ #0#Z !8 ]@ C /, , #P #P [0!' .D
M40#E %H X@!B -\ :0#= &\ V@!V -@ ? #4 (( T@"( -  CP#- )8 RP">
M ,D J #' +, Q0#! ,( V #  .\ OP#^ +X _P"] /\ O #_ +P _P"\ /\
M_P(  /\   #_    _P   /0 !P#M !$ Z  < ., *0#? #4 VP!! -8 2P#1
M %0 S0!< ,H 8P#( &D Q@!O ,, =0#! 'L OP"" +X B "\ )  N@"8 +@
MH@"U *P LP"Y +$ RP"O .< K@#X *P _P"K /\ K #_ *P _P"K /\ _P0
M /\   #V    [@   .<   #?  P U@ 5 ,\ (@#* "X QP Z ,, 1 #  $T
MO !5 +D 7 "W &, M0!I +, ;P"Q '4 KP![ *T @@"K (H J0"2 *< G "E
M *8 HP"S *$ PP"? -X G@#R )T _P"< /\ G #_ )L _P"; /\ _P<  /8)
M  #I"P  WPH  -4$  #.  4 Q@ 0 ,  &@"[ "< MP R +, /0"P $8 K0!/
M *H 5@"H %P I@!C *0 : "B &\ H0!U )\ ? "= (0 FP"- )D EP"7 *(
ME0"N ), O0"1 -, D #M (\ _ ". /\ C0'_ (T!_P"- ?\ ^0X  .H2  #<
M%0  S14  ,01  "^#   N@(* +0 $@"N !X J@ J *8 -0"B #\ H !( )T!
M4 "; E8 F0)< )<#8P"5 VD DP-O )$$=@"0!'\ C@6( (P%D@"*!IX B :J
M (8'N@"%",\ A KK ((+_ "!#/\ @ S_ ( ,_P" #/\ \14  . =  #-(
MP2$  +@=  "Q%P  K!   *@)#0"B!Q8 G0DC )D*+@"5"S@ DPQ! ) ,20".
M#5  C U7 (H-70"(#6, APUJ (4.<0"##GH @@Z$ ( .CP!^#YL ? ^H 'L0
MN !Z$,X >!'L '82_P!U$O\ =!/_ '03_P!T$_\ Z!X  -,F  ##*@  N"H
M *XH  "G(P  H!P  )L3 P"6#Q  D! ; (P1)P")$C( AA,[ (030P""%$L
M@!11 'X45P!\%%X >Q5E 'D5; !W%70 =A9^ '06B@!R%Y8 <1>D &\8M !N
M&,D ;1GH &L:_ !J&_\ :AO_ &H;_P!J&_\ X"8  ,HM  "\,0  L#,  *<Q
M  "?+   ER8  ) ?  "*%PP A1@6 ($9(@!^&BP >QLV 'D;/@!W'$4 =1Q,
M ',<4P!Q'5D <!U@ &X=9P!M'G  :QYZ &H>A0!H'Y( 9Q^@ &4@L !D(<4
M8R'D &(B^@!A(O\ 82+_ &$B_P!A(O\ URP  ,,T  "V.   JCD  *$X  "8
M-0  D"\  (@H  " (0@ >R 2 '<A'0!T(B< <2(Q &\C.0!M(T$ :R-( &DC
M3@!H)%4 9B1; &4D8P!C)6L 8B5U &$E@0!?)HX 7B:= %TGK0!;*,$ 6RC@
M %HI]P!9*?\ 62G_ %DI_P!9*/\ SS(  +XY  "Q/0  IC\  )P_  "3/
MBC8  ($P  !Y*@, <B8/ &XG&0!K*", :2@L &8I-0!E*3P 8RE# &$J2@!@
M*E$ 7BI7 %TJ7P!<*V@ 6BMR %DL?0!8+(L 5BV: %4MJ@!4+KT 4R[< %(O
M]0!2+_\ 4B[_ %(N_P!2+O\ RC8  +H]  "M0@  HD0  )A$  "/00  A3P
M 'LW  !R,0  :RP, &<M%0!D+1\ 82XH %\N,0!=+CD 7"]  %HO1@!8+TT
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M 4$\_P%!//\ OD(  *])  "C3@  F5   (]1  "%4   >TP  &]&  !E0@
M6CT" %0[#@!1.Q4 3SL? $T[)P!+.R\ 23PV $<\/0!'/$0 1CU+ $4]5 !$
M/EP 0SYG $(_<P! /X$ /S^1 #Y H@ ]0+4!/$'. 3Q![@$\0?\!/$#_ 3Q
M_P$]/_\!ND4  *Q,  "A40  EU0  (U5  "#5   >%$  &Q+  !A1P  5D(
M $] # !,/Q, 24 < $= ) !&0"P 1$ S $- .@!"04( 04%) $!"40 _0EH
M/D-E #U#<0 [0W\ .D2/ #E$H  X1;,!-T7+ 3=%[ $W1?\!-T3_ 3A$_P$X
M0_\ MTD  *E0  ">50  E%@  (M9  " 6   =E8  &A0  !=3   4T@  $I%
M"0!&1!$ 1$09 $)$(@!!12D /T4Q #Y%.  ]13\ /$9' #M&3P Z1U@ .4=B
M #A(;@ V2'P -4B- #1)G@ S2;$ ,DG) #%)ZP R2?X ,DC_ #)(_P S2/\
MM$P  *=4  "<60  DEP  (A=  !^70  <UH  &55  !;4@  4$X  $9*!0!
M20X /DD6 #U)'@ [2B8 .DHN #E*-0 X2ST -TM$ #9+30 T3%8 ,TQ@ #),
M;  Q37H ,$V+ "Y-G  M3J\ +$[' "Q.Z0 L3?T +4W_ "U,_P M3/\ L%
M *18  "970  CV$  (9B  ![80  <%\  &);  !86   3E4  $-1 0 [3PP
M.$\3 #9/&P U3R, -% K #-0,@ R4#H ,5!" #!12@ N45, +5)= "Q2:0 K
M4G@ *5*( "A3F@ G4ZT )E/% "93YP F4_P )U+_ "=1_P G4?\ K%4  *!<
M  "68@  C68  (-G  !X9@  ;64  &!A  !57@  2EL  #]8   U5@@ ,540
M #!6%P N5A\ +58G "Q6+P K5S8 *E<^ "E71P H5U  )EA: "589P D6'4
M(UF& "%9F  @6:L 'UG" !]9Y0 ?6/H (%C_ "!7_P A5_\ J%H  )UB  "3
M9P  BFL  ']L  !U;   :FL  %UH  !190  1F,  #M@   Q7@, *ET- "A=
M$P F71L )5XC "1>*@ C7C( (EXZ "%>0P @7TP 'U]7 !Y?8P <8'$ &V""
M !E@E0 88*D %V#  !9@X@ 77_D &%[_ !E>_P 97?\ I&   )EH  "0;@
MAG   'QR  !R<@  9G$  %AN  !,;   06L  #9I   M9P  (V8( !]F#P =
M9A4 '&8= !MF)0 :9BT &6<U !AG/@ 79T@ %F=3 !5H7P 3:&X $FA_ !%H
MD@ 0:*8 #VB]  YHX  09_< $&;_ !%E_P 19?\ GV<  )9O  ",<P  @G8
M 'AX  !M>   8'<  %-V  !&=   .W,  #%R   G<0  'G$  !9P"@ 3<!
M$W 7 !)P'P 1<2< $'$O !!Q.  .<4( #G%.  UQ6P ,<6D "W%Z  IQC0 (
M<:$ !G&V  9PT@ '<.\ "&__  EN_P );O\ FV\  )%U  "'>0  ?GP  '1^
M  !F?@  67X  $U^  ! ?0  -7T  "I\   A?   &'P  !%\!  ,? P "GP1
M  E\&0 (?"$ !WPI  9\,@ $?#T  WQ(  %\50  ?&,  'QT  !\AP  >YP
M 'NQ  !ZRP  >>L  'GZ  !Y_P  >/\ EG<  (Q\  "#@   >8,  &R$  !>
MA0  488  $6'   YAP  +8<  ".'   :AP  $H<   V( 0 &B0H  8D/  ")
M%   B!L  (@C  ")+   B38  (E"  "(3@  B%T  (AM  "(@0  AY4  (>K
M  "&Q   A>8  (3X  "$_P  A/\ D'X  (>#  !^AP  <8D  &.+  !6C0
M28\  #R1   PD0  ))$  !J2   2DP  #90   :5    E@8  )8,  "5$
MEA4  )8=  "6)   EBX  )8Y  "61@  EE4  )9E  "6>   E8X  )6D  "4
MO   D]\  )/U  "2_P  DO\ BX8  (.*  !UC0  9Y   %F4  !,EP  /YD
M #*:   FFP  &YP  !*=   ,GP  !*    "B    HP$  *,'  "C#   HQ
M *05  "D'   I24  *8O  "F/   IDL  *9;  "F;@  I80  *6;  "DLP
MH]   */O  "B_   HO\ AHT  'B1  !JE0  7)D  $Z=  !!H   ,Z(  ":C
M   ;I0  $:<   JI   !JP   *T   "O    L    +    "P!0  L0L  +(/
M  "S%   M!L  +4D  "W,   MS\  +=0  "W8@  MW@  +>0  "VJ0  ML(
M +;D  "V]0  M?X >Y,  &V8  !?G0  4*(  $*F   TJ0  )JL  !JM   0
MKP  ";(   "T    MP   +H   "\    O0   +X   "^    P (  ,$(  #"
M#0  Q!(  ,89  #))   RC(  ,M#  #+50  S&H  ,R#  #,G   R[4  ,S.
M  #,Z0  S/8 <)L  &&A  !2I@  1*L  #:P   GL@  &K4  !"X   'NP
M +X   #!    Q    ,@   #+    RP   ,T   #.    T    -(   #5 P
MV H  -L0  #>&   XB0  .,U  #D2   Y5P  .9S  #FC0  YJ4  .:\  #F
MTP  Y^< 8Z0  %6J  !&L   .+4  "BY   :O   #\    7$    QP   ,L
M  #/    U    -@   #<    W0   -\   #A    XP   .4   #H    Z@
M .T&  #Q#@  ]18  /@E  #Y.   ^4T  /IC  #[?   _)4  /RJ  #\NP
M_<L _P / /\ #@#_  X _P 0 /\ %@#_ ", _P P /\ /0#_ $D _P!4 /\
M7@#_ &8 _P!N /\ =@#_ 'P _P"" /\ B0#_ (\ _P"5 /X FP#] *, ^P"K
M /H M0#Y ,, ]P#; /8 \ #T /\ \P#_ /( _P#L /\ X@#_ -P _P#6 /\
M_P , /\ "0#_  @ _P * /\ $@#_ !X _P K /\ . #_ $0 _P!/ /\ 60#^
M &$ _ !I /H < #X '< ]P!] /8 @P#T (D \@"/ /$ E@#O )T [0"E .P
MKP#J +P Z #- .8 Z #D /H XP#_ .( _P#@ /\ U0#_ ,X _P#+ /\ _P &
M /\  0#_    _P $ /\ #@#_ !D _P E /T ,@#[ #X ]P!) /, 4P#P %P
M[@!C .P :@#J '$ Z !W .8 ?0#D (, X@") .  D #> )< W "? -D J0#6
M +0 TP#$ -  W@#. /, S #_ ,L _P#* /\ R #_ ,( _P"^ /\ _P   /\
M  #_    _P   /L "P#V !, \0 @ .T + #J #@ YP!# ., 30#@ %8 W !=
M -D 9 #5 &L T@!Q -  =@#. 'P S "# ,H B0#( )$ Q@"9 ,0 HP#! *T
MOP"[ +T SP"[ .L N0#\ +< _P"W /\ M@#_ +0 _P"Q /\ _P   /\   #_
M    ]@   .X !0#G  \ X0 9 -L )0#5 #$ T@ \ ,X 1@#* $\ QP!7 ,0
M7@#! &0 OP!J +T < "[ '8 N0!\ +@ @P"V (H LP"3 +$ G "O *< K0"S
M *L Q0"I .$ IP#U *8 _P"E /\ I #_ *0 _P"D /\ _P   /P   #Q
MZ    .    #4  L S  3 ,< 'P#" "H OP U +P /P"X $@ M0!0 +, 5P"P
M %X K@!D *P :0"K &\ J0!U *< ? "E (0 HP", *$ E@"? *$ G0"M )H
MO "8 -( EP#N )4 _@"4 /\ E0#_ )4 _P"5 /\ _ $  / %  #C!P  U04
M ,P   #%  0 O@ . +@ %P"S ", KP N *L . "I $$ I@!* *, 40"A %<
MGP!= )T 8P"; &D F@!O )@ =@"6 'T E "& )( D "0 )L C@"G (P M@"*
M ,D B #G (< ^0"' /\ A@#_ (8 _P"& /\ ] P  .00  #1$@  Q1$  +T.
M  "V"   L0 ( *L $0"F !L H0 F )X ,0": #H F !# )4 2@"3 %$ D0!7
M (\ 70". &, C !I (H < "( '< A@"  (0 BP"" )8 @ "C 'X L0!] ,0
M>P+A 'H#]0!Z!?\ >07_ '@&_P!X!O\ ZA,  -8:  #&'0  NAP  +$9  "J
M$P  I T  )\%# "9 !0 E0 ? )$"*0"- S, BP0\ (@%1 "&!DL A 91 (('
M5P"!!UT ?P=C 'T(:@!["'( >@A\ '@)A@!V"9( = J@ ',*KP!Q"\$ < S?
M &\-]@!N#O\ ;0[_ &T._P!M#O\ X1P  ,LC  "\)@  L28  *@D  "@'@
MF1@  ),0 @"."PX B L7 (0,(@"!#2P ?@TU 'P./0!Z#D4 > Y+ '<.40!U
M#U@ <P]> '$090!P$&X ;A!W &P0@@!K$(\ :1&= &@1K0!F$L  91+? &03
M]@!C%/\ 8Q3_ &(4_P!B%/\ UB0  ,,J  "U+@  JB\  * M  "8*   D"(
M (D;  ""$P@ ?1$2 'D2' !V$R< <Q0P '$4. !O%3\ ;15& &P53 !J%E,
M:!99 &<680!E%FD 9!=R &(7?@!A&(L 7QB9 %X9J0!<&;P 7!K8 %H;\P!:
M'/\ 61S_ %D<_P!9'/\ S2H  +TQ  "O-0  I#8  )LT  "2,0  B2L  ($E
M  !Y'0, <Q@. &\9& !L&B( :1LK &<;,P!E'#L 9!Q! &(=2 !@'4X 7QU5
M %T=7 !<'F0 6QYN %D?>0!8'X< 5B"6 %4@I@!4(;@ 4R'2 %(B\0!2(_\
M4B/_ %(B_P!2(O\ R"\  +@V  "K.@  H#P  )8[  "-.   @S(  'HM  !R
M)@  :B , &8@$P!C(1T 82$F %\B+P!=(C8 6R(] %HC1 !8(TH 5R-1 %4C
M6 !4)&$ 4R1J %$E=@!0)8, 3R:3 $XGHP!,)[4 3"C. $LH[@!+*?\ 2RC_
M $LH_P!+*/\ PS0  +,[  "G/P  G$$  ))   ")/@  ?SD  '4S  !L+0
M8R<( %XF$0!<)AD 62<B %<G*P!5*#( 5"@Y %(H0 !1*$8 4"E- $XI50!-
M*5T 3"IG $LJ<P!)*X  2"N0 $<LH0!&+;, 12W+ $4N[ !$+O\ 1"[_ $4M
M_P!%+?\ OC@  + _  "D0P  F44  (]%  "%0P  >SX  '$Y  !G-   7BX$
M %@K#@!5*Q8 4BP? % L)P!/+"\ 32TV $PM/ !*+4, 22U* $@N4@!'+EH
M1B]D $4O< !#,'X 0C"- $$QG@! ,K$ /S+( #\SZ@ _,_X /S+_ #\R_P _
M,O\ NSP  *U#  "A1P  EDD  (Q)  "#2   >$0  &T^  !C.0  6C0  %(P
M# !/,!, 3# < $HP) !),2L 1S$R $8Q.0!$,4  0S)' $(R3P!!,U@ 0#-B
M #\T;0 ^-'L /36+ #PVG  [-J\ .C?& #DWZ  Y-_P .C?_ #HV_P Z-O\
MMT   *I&  ">2P  E$T  (I.  " 3   =4@  &I#  !@/@  5CD  $TU"0!)
M-!$ 1S49 $4U(0!#-2@ 034O $ U-@ _-CT /C9% #TW30 \-U4 .SA@ #HX
M:P Y.7D .#F) #<ZFP U.JT -3O$ #0[Y@ T._L -3O_ #4Z_P U.O\ M$,
M *=*  "<3@  DE$  (A2  !^4   <TT  &=(  !<1   4C\  $@Z!@!$.0\
M03D6 #\Y'@ ^.28 /#DM #LZ-  Z.CL .3M" #@[2@ W/%, -CQ= #4]:0 T
M/7< ,SZ' #$^F0 P/ZL +S_" "\_Y  O/_H ,#__ # ^_P P/O\ L4<  *1-
M  "94@  CU4  (96  !\50  <5(  &1,  !920  3T4  $5  P _/@T /#X3
M #H^&P Y/B, -SXJ #8_,0 U/S@ -#]  #- 2  R0%$ ,4%; #!!9P N0G4
M+4*% "Q#EP K0ZH *D/  "E$X@ J0_D *D/_ "M"_P K0O\ KDH  *%1  "7
M5@  C5D  (-:  !Y6@  ;E<  &%2  !73@  34L  $-'   Z0PH -D,1 #1#
M&  S0R  ,D0G #%$+P P1#8 +T4] "U%1@ L14\ *T99 "I&9  I1W( *$>#
M "9'E0 E2*@ )$B^ "-(X  D2/< )4?_ "5'_P F1_\ JD\  )]5  "46@
MBUX  (%?  !W7@  :UP  %]8  !550  2U$  $!-   U2@< ,$D. "Y)%0 M
M21T +$DD "M**P J2C, *$H[ "=+0P F2TP )4M6 "1,8@ C3'  (4R  "!-
MDP ?3:8 'DV[ !U.W0 >3?8 'DS_ !],_P @2_\ IU,  )Q:  "27P  B&,
M 'YD  !T8P  :6$  %Q>  !26P  1U@  #Q5   R4@( *E , "=/$@ F4!D
M)5 @ "10*  C4"\ (E$W "%10  @44D 'E)3 !U27P <4FT &E-] !E3D  8
M4Z0 %E.Y !53V0 64_0 %U+_ !A1_P 94?\ HUD  )A@  "/90  A6@  'MI
M  !Q:0  9F<  %ED  !-80  0E\  #A<   N6@  )5@( "!7#@ >5Q0 '5<<
M !Q8(P ;6"L &E@S !E8/  86$4 %EE0 !596P 466D $UIZ !):C0 16J$
M$%JW  Y:U0 06?, $%G_ !%8_P 16/\ GU\  )5F  ",:P  @FT  'AN  !N
M;P  8FT  %5J  !(:   /F8  #-E   I8P  (&$! !A@"P 58!  %& 7 !-@
M'@ 28"8 $F N !%A-P 084  #V%+  YA6  -868 #&)V  MBB0 *89T "6&R
M  AARP (8>L "6#]  I?_P +7_\ FV8  ))M  "(<0  ?G,  '5U  !J=
M7',  $]R  !#<   .&\  "UN   D;   &VL  !-K!  .:@P #6H2  QJ&0 +
M:B$ "FHI  EJ,@ (:CP !VM'  5K4P $:V$  FMQ  !JA   :I@  &JM  !I
MQ@  :><  &GX  !H_P  :/\ EVT  (US  "$=P  >WH  '![  !C>P  5GH
M $EZ   ]>0  ,7@  "=W   ==@  %78   ]V @ )=@H !'8/  !V%0  =AP
M '8D  !U+   =38  '5!  !U3@  =5P  '5L  !U?@  =),  '2H  !SP
M<^,  '+W  !R_P  <?\ DG4  (EZ  " ?@  =H   &F!  !;@@  3H(  $&"
M   U@P  *8(  !^!   6@0  $((   J"   "@P<  ((-  ""$0  @A<  ((>
M  "")@  @B\  (([  ""1P  @E4  (%E  "!>   @8T  ("B  !_N@  ?]T
M '[T  !]_P  ??\ C7P  (2!  ![A   ;H8  &"(  !2B@  18L  #F,   L
MC   (8P  !>,   0C0  "8X   */    D ,  (\)  "/#@  CQ(  ) 8  "0
M'P  D"@  ) R  "0/P  D$T  )!=  "/<   CX4  (Z<  ".LP  C=   (SP
M  "+_@  B_\ B(0  ("(  !RBP  9(T  %:0  !(DP  .Y4  "Z6   BE@
M%Y<   ^8   (F0   )L   "=    G0   )T#  "="0  G0T  )X1  ">%P
MGQ\  )\I  "@-0  H$,  *!4  "@9@  GWL  )Z3  ">JP  G<8  )WI  "<
M^0  G/\ @XL  '6.  !GD@  698  $N9   ]G   ,)X  ".?   7H   #J(
M  >D    I@   *@   "J    J@   *H   "K 0  JP<  *P,  "M$   KA8
M *\>  "Q*0  L3@  +%(  "Q6@  L6\  +&(  "QH   L+H  *_=  "O\@
MK_T >)$  &J6  !<F@  39\  #^C   QI@  (Z<  !>I   .JP  !:X   "P
M    L@   +4   "W    MP   +@   "Y    N@   +P#  "]"0  O@X  , 4
M  ##'@  Q2L  ,4\  #&3@  QF(  ,9Z  #&E   QJT  ,;(  #%Y0  Q?,
M;)D  %Z>  !/I   0:@  #*L   DKP  %K$   VT   #MP   +H   "]
MP    ,0   #&    Q@   ,@   #)    RP   ,P   #.    T 8  -,-  #8
M$P  W!X  -XM  #?0   X%0  .%K  #AA0  X9\  .&W  #ASP  X>8 8*$
M %*G  !#K0  -+(  "6U   7N0  #;P   &_    PP   ,<   #*    SP
M -,   #6    UP   -H   #<    WP   .$   #C    Y@   .D!  #L"P
M\!(  /,?  #T,0  ]D8  /=<  #X=   ^(\  /FF  #YN   ^,D _P - /\
M"P#_  L _P . /\ $P#_ !\ _P L /\ .0#_ $4 _P!0 /\ 60#_ &( _P!J
M /\ <0#_ '< _P!^ /\ A #^ (H _0"0 /P EP#Z )X ^0"G /< L0#V +X
M]0#2 /, [ #Q /X \ #_ /  _P#F /\ W #_ -( _P#- /\ _P ' /\ ! #_
M  ( _P & /\ $ #_ !L _P G /\ ,P#_ #\ _P!* /X 5 #[ %T ^0!D /<
M:P#U '( \P!X /( ?@#P (0 [P"* .T D0#L )D Z@"A .@ JP#F +8 Y #'
M .( XP#@ /< W@#_ -T _P#9 /\ S #_ ,4 _P#! /\ _P   /\   #_
M_P ! /\ #0#_ !8 _  B /D +@#V #D \P!% .\ 3@#L %< Z0!> .8 90#D
M &P X@!R .  =P#? 'X W0"$ -L BP#8 )( U0"; -( I #/ *\ S0"^ ,L
MU0#) .\ QP#_ ,4 _P#$ /\ O@#_ +@ _P"U /\ _P   /\   #_    _@
M /< "0#Q !$ ZP < .< * #D #, X0 ^ -T 2 #8 %$ TP!8 -  7P#. &4
MS !K ,H <0#( '< Q@!] ,0 A #" (P P "4 +X G@"[ *@ N0"V +< R "U
M .8 LP#Z +$ _P"P /\ L #_ *P _P"I /\ _P   /\   #Z    \0   .@
M P#@  T V  6 -$ (@#- "T R@ W ,8 00#" $H OP!2 +T 60"Z %\ N !E
M +< :@"U '  LP!V +$ ?0"O (4 K0"- *L EP"I *$ IP"N *4 O@"B -@
MH #R )\ _P"> /\ G@#_ )X _P"< /\ _P   /<   #K    X0   -8   #+
M  D Q0 1 +\ &P"[ "8 MP Q +0 .@"Q $, K@!+ *L 4@"I %@ IP!> *8
M9 "D &D H@!P *  =@"> 'X G "& )H D "8 )L E@"G )0 M@"2 ,H D #I
M (\ _ ". /\ C0#_ (P _P"- /\ ^    .D"  #; P  S $  ,0   "]  (
MM@ - +  %0"K "  IP J *0 - "A #P G@!$ )P 2P": %( F !8 )8 70"5
M &, DP!I )$ < "/ '< C0"  (L B@") )4 AP"A (4 KP"# ,$ @0#@ (
M]0!_ /\ ?P#_ '\ _P!_ /\ [@H  -P.  #*$   O@X  +4+  "O P  J0 '
M *, $ "> !@ F0 C )8 + "3 #4 D  ^ (X 10", $L B@!1 (@ 5P"& %T
MA0!C (, :@"! '$ ?P!Z 'T A ![ (\ >0"< '< J@!U +L = #4 '( \ !R
M /\ <@#_ '$ _P!Q /\ XQ$  ,T7  "_&0  LQD  *H5  "C$   G0H  )<!
M"@"1 !( C0 ; (D )0"% "\ @P W (  /@!^ $4 ?0!+ 'L 40!Y %< > !=
M '8 9 !T 6L <@%T ' "?P!N HL ; .8 &L#I@!I!+< : 7. &<'[ !F"/T
M9@G_ &4)_P!E"?\ UAH  ,0@  "V(P  JR,  *$@  "9&P  DA0  (P. 0"&
M!PT @ 04 'P&'@!Y!R@ =@@P '0(. !R"3\ < E% &\*3 !M"E( ; I8 &H+
M7P!H"V< 9PMP &4,>@!C#(< 8@R5 & -I !?#;8 7@W. %P.[0!<#_\ 6Q#_
M %L0_P!;$/\ S2$  +PH  "O*P  I"L  )HI  "2)   B1\  ((8  ![$04
M=0T/ '$-%P!N#B$ :PXJ &D/,@!G$#D 91!  &001@!C$$T 81!3 %\16@!>
M$6( 7!%K %L1=@!9$H, 6!*2 %83H@!5$[0 5!/+ %,4[ !2%?\ 4A;_ %(5
M_P!2%?\ QB@  +8N  "I,@  GS(  )4Q  ",+0  @R<  'HA  !R&@  :Q,+
M &<3$P!D%!P 810E %\5+0!=%30 7!4[ %L60@!9%D@ 6!9/ %875@!5%UX
M4Q=G %(8<@!0&'\ 3QF. $X:GP!,&K  2QO' $L;Z0!*'/T 2AS_ $H<_P!*
M'/\ P2T  +$T  "E-P  FC@  ) W  "'-   ?2\  '0I  !L(P  9!P' %X9
M$ !;&A@ 61LA %<;*0!5&S  5!PW %(</0!1'$0 3QU+ $X=4@!-'5H 2QYC
M $H>;@!)'WP 1Q^+ $8@G !%(:X 1"'$ $,BY@!#(OP 0R+_ $,B_P!#(O\
MO#(  *TX  "A/   ESX  (T]  "#.@  >34  &\P  !F*@  7B0" %<@#0!4
M(!0 42 = $\A)0!.(2P 3"$S $LB.@!)(D  2")' $<B3@!&(U< 1"-@ $,D
M:P!")'D 026( #\FF0 ^)JL /2?! #TGXP ]*/H /2C_ #TG_P ])_\ N#8
M *H]  ">0   E$(  (I"  " /P  =CL  &PV  !B,   62H  %$E"P!-)1$
M2R49 $DE(0!')B@ 128O $0F-@!#)CT 0B=$ $$G2P _*%0 /BA= #TI:0 \
M*78 .RJ& #DKEP X*ZD -RR_ #<LX  W+/@ -RS_ #<L_P X+/\ M3H  *=
M  "<1   D48  (=&  !]1   <T   &@[  !?-@  53$  $PK!P!'*0\ 12H6
M $,J'@!!*B4 /RHL #XK,P ]*SD /"M! #LL2  Z+%$ .2U; #@N9@ V+G,
M-2^# #0OE0 S,*< ,C"] #$QW@ Q,?< ,C'_ #(P_P S,/\ L3X  *1$  "9
M2   CTH  (5*  ![20  <$4  &5   !;.P  4C8  $@Q! !"+@T /RX3 #TN
M&P [+B( .2\I #@O+P W+S8 -C ^ #4P1@ T,4\ ,S%9 #(R9  Q,G$ ,#.!
M "\TDP N-*8 +#6[ "PUVP L-?4 +37_ "TT_P N-/\ KD$  *)(  "73
MC4X  (-.  !Y30  ;DH  &)%  !80   3CP  $4W   ],PL .3,1 #<S&  V
M,Q\ -#,F #,S+0 R-#0 ,30\ # U1  O-4P +C96 "TV8@ L-V\ *S=_ "HX
MD0 H.*0 )SFY "8YV  G.?0 *#G_ "@X_P I./\ JT4  )]+  "43P  BU(
M (%3  !W4@  ;$\  %])  !61@  3$(  $(]   X. @ -#@/ #(X%0 Q.!T
M+S@D "XX*P M.3( +#DY "LZ00 J.DH *3M4 "@[7P G/&T )3Q] "0]CP C
M/:( (CVW "$^U  A/O, (CW_ ",]_P C//\ J$D  )U/  "24P  B58  ']7
M  !U5@  :E,  %U/  !33   2D@  $!$   V0 4 +ST- "T]$P K/1H *CXA
M "D^*  H/B\ )SXW "8_/P D/T@ (T!2 ") 70 A06H ($%Z !Y!C0 =0J
M'$*U !M"T0 ;0O$ '$+_ !U!_P >0?\ I4T  )I3  "06   AEL  'U<  !R
M6P  9U@  %M4  !14@  2$X  #U*   S1P  *D,+ "9#$  E0Q8 )$,> "-$
M)0 B1"P (40T "!%/  >144 '45/ !Q&6@ ;1F@ &49X !A'B@ 71YX %D>S
M !1(S@ 51^\ %D?_ !=&_P 71O\ HE(  )=8  "-70  A&   'IA  !P8
M95X  %E:  !/6   1%0  #E1   O3@  )DL& "!*#@ >2A, '4H: !Q*(0 ;
M2R@ &DLP !E+.  72T( %DQ, !5,5P 43&4 $TUU !)-B  139P $$VQ  Y.
MS  /3>X $$W_ !%,_P 13/\ GE<  )1=  "+8@  @64  '=F  !M9@  8V0
M %9A  !*7@  /UL  #58   K5@  (E0! !I2"@ 64A  %5(6 !12'0 34B0
M$E(L !%2-  14CX $%-(  ]35  .4V( #51R  Q4A  +5)@ "52M  A4Q0 )
M5.< "E/[  M2_P +4O\ FUT  )%D  "(:   ?FL  '1L  !K;   7VH  %)G
M  !%9   .F(  #!@   F7@  '5T  !5;!0 06@P #EH1  Y:&  -6R  #%LG
M  M;,  *6SH "5M%  =;40 &6UX !%MM  -;@  !6Y0  %NH  !;P   6N(
M %KV  %:_P "6?\ EV0  (YK  "$;@  >W   ')R  !G<0  67   $QN  !
M;   -6L  "II   A9P  &&8  !%F 0 ,90H !V4/  1E%  #9!L  F0C  !D
M+   9#4  &1   !D3   9%H  &1I  !D>P  9(\  &.D  !CNP  8MT  &+T
M  !B_P  8?\ DVP  (EQ  " =0  >'<  &UX  !@=P  4G8  $9U   Y=
M+G0  "-R   :<0  $G$   UQ   &<0@  ' -  !P$@  <!<  &\?  !O)@
M;S   &\[  !O1P  ;U0  &]D  !O=0  ;HH  &V@  !MM@  ;-8  &OR  !K
M_P  :_\ CG,  (5X  !]>P  <WT  &5^  !8?@  2WX  #Y^   R?@  )GT
M !Q\   3?   #7P   9]    ?04  'P+  !\#P  ?!,  'P9  !\(0  ?"D
M 'PT  ![0   >TX  'M>  ![;P  >H0  'J:  !YL0  >,X  '?O  !V_@
M=O\ B7H  (%_  !X@@  :X,  %V%  !/A@  0H<  #6(   IAP  '8<  !2'
M   -B   !HD   "*    B@   (D&  ")#   B0\  (D3  ")&@  BB(  (HL
M  "*.   BD8  (E6  "):   B7P  (B4  "'JP  AL8  (7J  "%^P  A/\
MA8(  'V&  !OB   88L  %.-  !%CP  .)$  "N1   ?D@  %)(   V3   $
ME    )8   "7    F    )<   "7!0  EPL  )@.  "8$P  F1H  )DB  ":
M+@  FCT  )E-  "97@  F7,  )B+  "8HP  E[P  );B  "6]P  E?\ @(D
M '*,  !DCP  5I,  $B6   ZF0  +)H  !^;   4G   #)X   .?    H0
M *,   "E    I0   *4   "E    I@(  *<(  "G#0  J!$  *D9  "K(P
MJS$  *M!  "L4P  K&<  *N   "JF@  JK,  *K0  "I[P  J?L =8\  &>4
M  !9F   2IP  #R?   MH@  (*,  !.E   +IP   :D   "K    K@   +$
M  "R    L@   +,   "T    M0   +8   "X!   N0L  +L0  "]&   OR0
M +\U  # 1P  P%L  ,!R  # C0  P:8  ,#!  "_XP  OO, :I<  %N<  !-
MH0  /J4  "^I   AJP  $ZT   NP    LP   +4   "X    O    +\   #!
M    P0   ,,   #$    Q@   ,<   #)    RP   ,X(  #1#P  U1@  -@G
M  #9.0  VDT  -MD  #;?@  W)D  -RP  #<R0  W., 79\  $^E  ! J@
M,J\  "*R   4M0  "K@   "[    OP   ,,   #&    RP   ,X   #1
MT0   -0   #6    V0   -L   #>    X    .0   #G!@  ZPX  .\9  #P
M*@  \C\  /-5  #T;0  ](@  /2A  #TM@  ],< _P ) /\ !@#_  < _P ,
M /\ $0#_ !P _P H /\ - #_ $$ _P!, /\ 50#_ %T _P!E /\ ; #_ '(
M_@!X /P ?@#[ (0 ^@"+ /D D@#W )D ]@"B /0 K #S +D \0#+ /  Z #N
M /L [0#_ .P _P#A /\ T@#_ ,D _P#$ /\ _P ! /\   #_    _P $ /\
M#@#_ !< _P C /\ +P#_ #L _0!& /H 4 #W %@ ] !? /( 9@#P &P [P!R
M .T > #L 'X Z@"% .D C #G ), Y0"< ., I@#A +$ WP#! -T W0#; /0
MV0#_ -8 _P#/ /\ Q #_ +T _P"Y /\ _P   /\   #_    _P   /\ "P#\
M !, ]P > /0 *@#R #4 [@!  .D 2@#F %( XP!9 .  8 #> &8 W !L -H
M<@#7 '@ U !^ -( A0#0 (T S@"5 ,P GP#) *H QP"X ,4 S0## .L P #^
M +\ _P"^ /\ M@#_ +  _P"M /\ _P   /\   #_    ^0   /( !@#K  \
MY@ 9 .$ ) #> "\ V@ Y -, 0P#/ $P S !3 ,D 6@#' &  Q0!F ,, :P#!
M '$ OP!W +T ?@"[ (8 N0". +< F "U *, LP"P +$ P@"N .  K #W *L
M_P"J /\ J #_ *, _P"@ /\ _P   /\   #U    ZP   .$   #6  P SP 3
M ,H '@#& "D P@ S +\ /0"[ $4 N !- +8 5 "S %H L0!? +  90"N &H
MK !P *L =P"I '\ IP"' *4 D0"C )P H "I )X N "< ,X F@#N )D _P"7
M /\ E@#_ )8 _P"3 /\ _0   /$   #E    V0   ,T   #$  8 O0 / +<
M& "S "( L  L *T -@"I #X IP!& *0 30"B %, H !9 )\ 7@"= &0 FP!J
M )H < "8 '< E@"  )0 B@"1 )4 CP"B (T L "+ ,, B0#C (@ ^0"& /\
MA@#_ (8 _P"& /\ \P   .,   #1    Q0   +T   "V    K@ + *@ $@"D
M !P H  F )P +P": #< EP _ )4 1@"2 $P D0!2 (\ 6 "- %T BP!C (H
M:@"( '$ A@!Y (0 @P"" (\ ?P"; 'X J0!\ +L >@#5 '@ \@!X /\ =P#_
M '< _P!W /\ YP<  -$,  ###0  N P  *X(  "H    H@ % )L #@"6 !4
MD@ ? (X * "+ #$ B  Y (8 0 "$ $8 @@!, (  4@!_ %< ?0!= 'L 8P!Z
M &L > !S '8 ?0!T (@ <0"5 '  I !N +0 ; #* &L Z@!J /P :@#_ &H
M_P!J /\ VA   ,84  "X%@  K14  *02  "<#@  E@<  )  "0"* !  A0 8
M ($ (0!^ "H >P R 'D .0!W $  =0!& ', 3 !R %$ < !7 &X 7@!M &4
M:P!N &D =P!G (, 90"1 &, GP!B *\ 8 #$ %\ Y !? ?@ 7@+_ %X"_P!>
M O\ SA@  +T=  "P(   I1\  )L<  "3%P  BQ$  (0,  !^! L >0 2 '4
M&P!R ", ;P K &T!,P!K 3H :0)  &<#1@!F TP 9 12 &,$60!A!&  7P5I
M %X%<P!<!G\ 6@:- %D'G !7"*T 5@C! %4)X0!4"_8 5 O_ %0+_P!4"_\
MQA\  +8E  "I*   GB@  )0E  "+(0  @QL  'L4  !T#@, ;@D- &D(% !F
M"1T 9 HE &(*+0!@"S0 7@LZ %T+0 !;#$< 6@Q- %@,5 !7#5P 50UD %0-
M;P!2#7L 4 Z* $\.F@!.#JP 3 _" $P0XP!+$/D 2Q#_ $L1_P!+$/\ OR8
M + K  "D+P  F2\  (\M  "&*0  ?20  '0>  !L%P  91$' %\.$ !<#Q<
M6A ? %@0)P!6$"X 5! U %,0.P!2$4( 4!%( $\14 !.$5< 3!)@ $L2:P!)
M$G@ 2!.' $83EP!%%*D 1!2^ $,5WP!#%O@ 0Q;_ $,6_P!#%O\ NBL  *LQ
M  "@-   E34  (LT  "!,0  >"L  &\F  !F(   7AD! %<4#0!4%!, 410;
M $\5(P!.%2H 3!4Q $L6-P!)%CX 2!9$ $<73 !%%U0 1!== $,89P!!&'0
M0!F# #\:E  ]&J8 /!N[ #L;VP ['/8 /!S_ #P<_P \'/\ M3   *@V  "<
M.0  D3L  (<Z  !^-P  <S(  &HM  !A)P  62$  %$;"0!,&1  2AH7 $@:
M'P!&&B8 11LM $,;,P!"&SH 01Q! $ <2  ^'%  /1U9 #P>9  ['G$ .1^
M #@?D@ W(*0 -B"X #4AU@ U(?0 -2+_ #4A_P V(?\ LC0  *0Z  "9/@
MCS\  (4_  ![/   <#@  &<R  !=+0  5"@  $PB!0!&'PX 0Q\4 $$?&P _
M'R( /B I #T@,  [(#8 .B$] #DA10 X(DT -R)7 #8C8@ T(VX ,R1^ #(D
MCP Q):( +R6V "\FT@ O)O( +R;_ # F_P P)O\ KS@  *(^  "60@  C$,
M ()#  !X00  ;CT  &,X  !:,P  42X  $@H 0! ) P /2,1 #LD&  Y)!\
M."0F #8D+  U)3, -"4Z #,F0@ R)DH ,2=4 # G7P O*&P +BA[ "PIC0 K
M*J  *BJT "DJSP I*_  *BO_ "HJ_P K*O\ K#P  )]"  "41@  BD<  (!'
M  !V10  ;$(  &$]  !7.   3C,  $0N   \*0D -R@0 #4H%0 S*!P ,B@C
M # H*0 O*3  +RHW "XJ/P M*T@ +"M2 "LL70 J+&H *"UY "<MBP F+IX
M)2ZS "0OS0 D+^X )2__ "4O_P F+O\ J3\  )U%  "220  B$L  'Y,  !T
M2@  :D<  %Y"  !4/0  2SD  $$T   X+P8 ,BT- # M$P N+1D +2T@ "LM
M)P J+BX *2XU "DO/0 H+T8 )S!/ "4P6P D,6@ (S%W "(RB0 A,IT 'S.Q
M !XSRP >,^T 'S/_ " S_P A,O\ ID,  )I)  "030  AD\  'Q0  !S3P
M:$P  %Q&  !20P  23\  #\[   V-@( +C(, "LR$0 I,A< *#(> "8R)  E
M,RL )#,R ",T.@ B-$, (35- " U6  ?-F4 'C9U !PWAP ;-YL &C>O !DX
MR  9..L &CC_ !LW_P ;-_\ HT<  )A-  ".40  A%,  'M4  !Q4P  9E
M %I,  !020  1T4  #U!   S/0  *CD) "4W#@ C-Q0 (C@; "$X(@ @."@
M'S@P !XY.  =.4$ '#I+ !HZ5@ 9.V, &#MR !8[A0 5/)D %#RM !,]Q@ 3
M/>D %#S] !4\_P 6._\ H$L  )51  "+50  @E@  'E9  !N6   9%8  %A1
M  !.3P  14L  #I'   P0P  )T % " ^#0 =/A$ '#X7 !L^'@ :/B4 &3XM
M !@_-0 6/SX %3]( !1 4P 30&  $D%P !%!@@ 009< #T&L  Y"Q  .0N<
M#T'\ !!!_P 00/\ G5   )-6  ")6@  @%T  '9>  !L70  8EL  %97  !,
M50  05$  #9.   L2P  (T@  !M%"0 71 \ %404 !1%&P 312( $D4I !%%
M,0 113L $$9%  ]&4  .1UX #4=M  Q'?P +1Y, "4>G  A'O@ (1^  "4?V
M  I&_P +1O\ FE4  )!;  "'8   ?6(  '-C  !J8@  8&$  %->  !'6@
M/%<  #)5   H4@  'U   !=.!  13 P #TP1  Y,%P .3!X #4TE  Q-+@ +
M33< "DU"  E-30 '3EH !DYI  1.>P "3H\  4ZD  !-N@  3=L  4WR  %-
M_P "3/\ EEL  (UB  "$9@  >F@  '%I  !H:0  7&<  $]D  !"80  -U\
M "U<   C6@  &E@  !)7 0 -5@D "54.  =5$P &51H !%4B  -5*@ "530
M %4^  !52@  5E<  %9E  !5=P  58L  %6@  !5M@  5-0  %3Q  !3_0
M4_\ DV(  (IH  " ;   =VX  &]O  !C;@  5FP  $EJ   ]:   ,F8  "=E
M   =8P  %6(   YA   )8 @  V -  !?$0  7Q<  %\>  !?)@  7R\  %\Z
M  !?10  7U,  %]A  !><@  7H<  %V<  !=L@  7,\  %SO  !;_0  6_\
MD&H  (9O  !]<@  =70  &IU  !==   3W,  $)R   V<   *V\  "!N   7
M;0  $&P   IL   ":P8  &L+  !J#P  :A0  &H:  !J(0  :2H  &DT  !I
M0   :4X  &E<  !I;0  :((  &B8  !GK@  9LH  &7M  !E_   9/\ BW$
M ()V  !Z>0  <'L  &)[  !5>P  2'H  #MZ   O>@  (WD  !EX   1=P
M"G<   -W    =P(  '<(  !V#0  =A   '85  !V&P  =B,  '8N  !U.@
M=4<  '56  !U:   ='P  '22  !SJ@  <L0  ''I  !P^P  </\ AGD  ']]
M  !V?P  :($  %J"  !,@@  /X,  #*$   E@P  &H,  !&#   *@P   H,
M  "$    A0   (0#  "#"   @PT  (,0  "#%0  A!P  (0F  "$,@  A#\
M (-/  "#8   @G4  (*,  "!I   @+T  '_C  !^^0  ?O\ @H   'J$  !L
MA@  7H@  %"*  !"BP  -8T  ">-   ;C0  $8X   J.    CP   )$   "2
M    D@   )(   "2 0  D@<  )(,  "2$   DQ4  ),=  "4*   E#8  )1%
M  "35P  DVL  )."  "2G   D;8  )#8  "/\P  C_\ ?H<  '"*  !AC0
M4Y   $63   WE0  *98  !R7   1F   "9D   ";    G    )X   "@
MH    *    "@    H0   *$$  "B"0  HPX  *04  "E'0  IBH  *8Z  "F
M3   I6   *5X  "ED@  I*P  *3)  "CZP  HOH <XX  &21  !6E0  1YD
M #F<   JG@  ':   !&A   (HP   *4   "G    J0   *P   "N    K@
M *X   "O    L    +$   "R    LP8  +4-  "W$P  N1X  +DN  "Z0
MNE0  +MJ  "ZA0  N:$  +F[  "ZW@  N?( 9Y4  %B9  !*G@  .Z(  "RF
M   =J   $:H   >L    KP   +$   "T    N    +L   "\    O    +X
M  "_    P    ,(   #$    Q@   ,@#  #+"P  SQ(  -$@  #1,@  TD8
M --=  #4=@  U)(  -6K  #5Q   U.( 6YT  $RB   ]IP  +ZP  !^O   1
ML0  ![4   "X    NP   +X   #"    QP   ,H   #,    S    ,X   #0
M    T@   -4   #8    VP   -\   #B    Y@L  .L3  #L)   [3@  .Y.
M  #O9P  \((  /"<  #PL@  \<4 _P # /\  0#_  0 _P ) /\ #P#_ !@
M_P D /\ , #_ #P _P!' /\ 40#_ %D _P!@ /T 9P#\ &T ^@!S /D >0#X
M '\ ]@"% /4 C #S )0 \@"= /  IP#N +, [ #$ .L X0#J /@ Z0#_ .<
M_P#9 /\ RP#_ ,( _P"] /\ _P   /\   #_    _P   /\ # #_ !0 _P @
M /\ *P#^ #< ^@!" /8 2P#R %, \ !; .X 80#L &< Z@!M .@ <P#G 'D
MY0!_ ., A@#A (X WP"6 -T H #; *P V "[ -0 T0#3 /  T #_ ,X _P#(
M /\ O0#_ +8 _P"R /\ _P   /\   #_    _P   /T " #W !  \P : .\
M)@#M #$ Z  [ ., 10#@ $T W !5 -D 6P#6 &$ TP!G -$ ; #/ '( S0!X
M ,L ?P#) (< QP"0 ,4 F@## *4 P "R +X Q0"\ .4 N@#[ +@ _P"W /\
ML #_ *D _P"E /\ _P   /\   #^    ]0   .P  P#E  T WP 5 -H ( #4
M "H T  U ,L /@#( $< Q0!. ,( 50#  %L O@!A +P 9@"Z &P N !R +8
M> "U (  LP"( +$ D@"N )X K "J *D NP"H -4 I@#S *0 _P"C /\ H0#_
M )L _P"8 /\ _P   /L   #P    Y0   -@   #.  D QP 1 ,( &@"^ "0
MNP N +< . "T $  L0!( *X 3@"L %0 J@!: *D 7P"G &4 I0!K *0 <0"B
M '@ H "! )X BP"< )8 F0"C )< L@"6 ,< DP#H )( _@"1 /\ D #_ (T
M_P"+ /\ ^0   .L   #=    SP   ,8   "\  0 M0 - +  %0"L !X J  H
M *4 ,0"B #D GP!! )T 2 "; $X F0!3 )< 60"6 %X E !D )( :@"0 '$
MC@!Z (P @P"* (\ B "< (8 J@"$ +P @@#< ($ ]@"  /\ ?P#_ '\ _P!^
M /\ [    -H   #)    O@   +8   "N    IP ) *$ $ "< !@ F  B )4
M*@"2 #( D  Z (T 00"+ $< B0!- (< 4@"& %@ A != (( 9 "! &L ?P!S
M 'T ?0![ (@ > "5 '8 HP!U +0 <P#, '$ [0!P /\ < #_ '  _P!P /\
MWP4  ,H*  "\"P  L0D  *@$  "A    FP # )0 # "/ !, B@ ; (< ) "$
M "P @0 S '\ .@!] $$ >P!' 'D 3 !W %( =@!7 '0 70!R &0 < !M &\
M=@!L (( :@"/ &D G0!G *X 90## &0 Y !C /H 8P#_ &( _P!C /\ T X
M +\2  "R$P  IQ(  )T0  "5"P  CP,  (D !P""  X ?@ 5 'H '@!V "4
M=  M '$ - !O #H ;@!  &P 1@!J $P :0!2 &< 6 !F %\ 9 !G &( <0!@
M 'P 7@") %P F !; *D 60"\ %@ W !8 /0 6 #_ %< _P!7 /\ QA8  +8:
M  "J'0  GQP  )49  "-%   A0\  'X)  !W 0H <@ 0 &X %P!J !\ :  G
M &4 +@!D #0 8@ [ &  0 !? $8 70!, %P 4P!: %H 6 !B %< ; !5 '<
M4P"% %( E !0 :4 3P&X $X"T@!-!/  307_ $T%_P!-!?\ OQT  + B  "C
M)0  F24  (\B  "%'0  ?1@  '42  !N#0( 9P8, &,#$0!? AD 70,A %L$
M* !9!"\ 5P4U %8%.P!4!D$ 4P9' %$&3@!0!U4 3@=> $T(9P!+"', 20F!
M $@)D@!'"J, 10JV $0+T !$#.\ 0PW_ $,-_P!$#?\ N20  *HI  ">+
ME"P  (HJ  " )@  =R$  &X;  !F%   7P\% %D+#0!5"A, 4PL; %$+(@!/
M#"D 30PO $P,-@!+#3P 20U" $@-20!&#5$ 10Y: $0.9 !"#G  0 Y_ #\/
MD  ^$*( /!"V #L0T0 [$?$ .Q'_ #L1_P \$?\ M"D  *8O  ":,@  D#(
M (8Q  !\+0  <B@  &DC  !A'0  618  %$1" !,#Q  2A 6 $@0'0!&$"0
M11 K $,1,0!"$3< 01$^ $ 110 ^$DT /1)6 #P280 Z$VT .1-\ #<4C0 V
M%)\ -16S #05S0 S%NX -!;_ #06_P T%O\ KRX  *(T  "7-P  C#@  ((V
M  !X-   ;BX  &4J  !<)   5!X  $P8! !&% T 0A02 $ 4&0 _%"  /14G
M #P5+0 [%30 .18Z #@60@ W%DH -A=3 #477@ S&&H ,AEY # 9B@ O&IT
M+AJQ "T;R@ M&^P +1S_ "X;_P N&_\ K#(  )\X  "4.P  BCP  ( \  !V
M.0  :S0  &(O  !9*@  4"4  $<?  ! &@H /!D0 #H9%@ X&1T -AHC #4:
M*0 T&C  ,QHW #(;/@ Q&T< +QQ0 "X=6P M'6< +!YV "H>B  I'YL *!^N
M "<@QP F(.H )R#^ "@@_P H(/\ J38  )T\  "2/P  AT$  'U   !T/@
M:3H  %\U  !6,   32L  $0E   [( < -AX. #,>$P R'AD ,!X@ "\>)@ N
M'RT +1\T "P@.P K($0 *B%. "DA6  G(F4 )B)T "4CA0 C(YD (B2M "$D
MQ0 A)>@ (B7] "(D_P C)/\ ICH  )H_  "/0P  A44  'M$  !R0P  9S\
M %TZ  !3-@  2C$  $$L   X)@, ,2,, "XB$0 L(A8 *B(= "DB(P H(RH
M)R,Q "8D.0 E)4$ )"5+ ",F5@ B)F, (2=R !\G@P >*)< '2BK !LIPP ;
M*>8 '"G[ !TI_P >*/\ HSX  )A#  "-1P  @TD  'I)  !P1P  9D0  %H_
M  !1.P  1S<  #XR   U+0  +"@) "@G#P G)Q0 )2<: "0G(0 C*"< (B@N
M "$I-@ @*3\ 'RI) !XJ5  =*V  &RMO !HL@0 9+)4 %RVI !8MP0 6+>0
M%RWZ !@M_P 9+?\ H4$  )5'  "+2P  @DT  'A-  !N3   9$D  %A$  !/
M0   1CT  #TX   S-   *B\& "0L#0 A+!( ("P8 !\M'@ >+24 '2TL !PN
M-  ;+CP &B]& !@O40 7,%X %C!M !4Q?P 3,9, $C&H !$ROP 1,N( $C+Y
M !,Q_P 3,?\ GD4  )-+  ")3P  @%$  '92  !M4   8DX  %9)  !-1@
M1$,  #L_   Q.@  )S8# !\R"P <,A  &S(5 !DR&P 8,B( %S,I !8S,0 5
M-#H %#1$ !,T3P 2-5P $35K ! V?0 /-I$ #C:F  TWO  --]T #3;V  XV
M_P /-O\ FTD  )%/  "'4P  ?E8  '56  !J50  8%,  %5/  !,3   0DD
M #A%   N00  )#T  !PZ"  6. X %3@2 !0X&  3.1\ $CDF !$Y+@ 0.3<
M#SI!  XZ3  -.UD #3MH  L[>@ *.XT "3RB  <\N  '/-4 "#SP  D[_P *
M._\ F$X  (Y4  "%6   ?%L  ');  !H6@  7E@  %-5  !)4@  /DX  #1+
M   J1P  (40  !A" P 20 L $#\0  X_%0 ./QP #4 C  Q *P +0#0 "D ^
M  E!2@ '058 !D%E  1!=@ #08H  4&?  !!M   0=   4'N  %!_  "0/\
ME50  (Q9  "#7@  >6   '!@  !F8   75X  %%;  !%5P  .E0  "]1   E
M3P  '$P  !1*   .2 @ "T<.  A'$@ '1QD !D<@  5(*  #2#$  D@[  !(
M1P  2%,  $AB  !(<P  2(8  $B;  !(L0  1\P  $?M  !'^P  1_\ DEH
M (E@  " 8P  =V4  &YF  !E9@  660  $Q@  ! 70  -5L  "I9   @5P
M%U4  !!3   +4@< !5$-  %0$0  4!8  % =  !0)0  4"X  % X  !00P
M4%   %!>  !0;P  4(,  $^8  !/K@  3LD  $[K  !-^P  3?\ CV$  (9F
M  !]:0  =&P  &QM  !A:P  4VD  $9G   Z9   +V,  "1A   :7P  $EX
M  Q<   &7 8  %L+  !:#P  6A,  %H9  !9(0  62D  %DS  !9/P  64P
M %E:  !9:P  6'X  %B4  !7JP  5\4  %;I  !5^P  5?\ C&@  ()M  !Z
M<   <G(  &=R  !:<0  3'   #]N   S;0  *&L  !UJ   4:   #6<   =G
M    9@,  &8)  !E#0  91$  &05  !D'   9"0  &0N  !D.@  8T<  &-5
M  !C9@  8WH  &*0  !AIP  8,$  %_F  !?^@  7O\ AV\  ']T  !X=P
M;G@  &!X  !2=P  17<  #AV   K=@  ('0  !9S   .<P  !W(   !R
M<@   '$%  !Q"@  <0X  ' 1  !P%P  <!X  ' G  !P,P  ;T   &]0  !O
M8   ;G0  &Z+  !MH@  ;+P  &OB  !J^   :?\ @W<  'Q[  !S?0  97X
M %=_  !)?P  /'\  "^    B?P  %WX   ]^   '?@   '\   !_    ?P
M 'X   !^!0  ?@H  'X-  !^$0  ?A<  'X@  !^*P  ?3D  'U(  !]60
M?&T  'R$  ![G   >K8  'G:  !X]0  =_\ @'\  '>"  !I@P  6X4  $V&
M   _B   ,HD  "2)   8B0  #XD   >*    BP   (P   "-    C0   (P
M  ",    C ,  (P(  "-#0  C1$  (T7  ".(@  CB\  (X_  "-4   C60
M (Q[  ",E0  BZX  (K-  ")[P  B?\ >X4  &V(  !>B@  4(T  $*/   T
MD0  )I(  !F3   .E   !I4   "6    F    )H   ";    FP   )L   ";
M    FP   )P   "=!0  G0L  )X0  "?%P  H"0  * T  "@1@  H%D  )]P
M  "?B@  GJ4  )["  "=Z   G/D <(P  &&/  !3D@  1)8  #:9   GFP
M&9P   ^=   %GP   *$   "C    I0   *@   "I    J0   *D   "J
MJP   *P   "M    K@$  + )  "R#P  LQ@  +0G  "T.0  M4T  +1D  "T
M?@  LYH  +.T  "SU0  L_  9),  %67  !'FP  .)\  "FB   :I   #J8
M  2H    JP   *T   "P    M    +8   "X    N    +D   "Z    O
M +T   "_    P    ,,   #%!P  R0\  ,H:  #++   S$   ,U6  #.;P
MS8L  ,RH  #,P@  S.( 6)L  $F@   ZI0  +*D  !RK   /K@  !+$   "T
M    MP   +H   "^    PP   ,8   #(    R    ,H   #+    S0   ,\
M  #2    U0   -D   #=    X04  .8/  #G'@  Z#(  .E(  #J8   ZWL
M .N7  #LK@  [,( _P   /\   #_    _P & /\ #0#_ !4 _P A /\ + #_
M #@ _P!# /\ 3 #^ %0 ^P!; /H 8@#X &@ ]@!N /4 = #T 'H \@"  /$
MAP#O (\ [0"7 .L H0#I *T YP"] .4 V #D /, X@#_ .  _P#0 /\ Q #_
M +P _P"V /\ _P   /\   #_    _P   /\ "0#_ !$ _P < /T )P#Y #(
M]0 ] /$ 1@#M $\ ZP!6 .@ 7 #F &( Y !H ., ;@#A ', WP!Y -T @ #:
M (@ V "1 -0 FP#2 *8 SP"T ,P R0#) .D R #_ ,< _P#! /\ MP#_ *\
M_P"K /\ _P   /\   #_    _P   /@ !0#R  X [@ 7 .H (@#F "P X0 W
M -T 0 #8 $D TP!0 -  5@#. %P S !B ,H 9P#( &T Q@!S ,0 >0#" ($
MP "* +X E "\ )\ N0"L +8 O@"T -T LP#W +$ _P"P /\ J #_ *( _P">
M /\ _P   /\   #Y    [P   .8   #?  L U@ 2 -  ' #, "8 R  P ,0
M.@#  $( O0!* +L 4 "X %8 M@!; +4 80"S &8 L0!L +  <@"N 'H K ""
M *D C "G )@ I0"E *, M "@ ,L GP#N )T _P"< /\ F0#_ )0 _P"1 /\
M_P   /8   #J    W0   ,\   #'  8 P  / +L %P"W "  LP J +  ,P"M
M #L J@!# *< 20"E $\ HP!5 *( 6@"@ %\ G@!E )T :P"; '( F0![ )<
MA0"4 )  D@"= )  K ". +\ C #B (L ^@") /\ B0#_ (8 _P"# /\ ]
M .0   #4    R    +\   "U  $ K@ + *D $@"E !L H0 C )X + "; #0
MF  \ )8 0P"4 $D D@!. )  4P". %D C0!> (L 9 ") &L AP!S (4 ?0"#
M (@ @0"5 '\ I !] +4 >P#/ 'D \0!X /\ =P#_ '< _P!U /\ Y0   -$
M  ##    N    *\   "H    H  & )H #@"5 !4 D0 > (X )@"+ "T B  U
M (8 / "$ $( @@!' (  30!_ %( ?0!8 'L 7@!Y &4 > !M '8 =@!S ($
M<0". &\ G0!M *X ; #$ &H YP!I /T : #_ &@ _P!I /\ U0,  ,,'  "V
M"   JP8  *(   ";    E    (T "@"( !  @P 8 '\ ( !\ "< >@ N '<
M-0!U #L = !! '( 1P!P $P ;P!2 &T 6 !K %\ :0!F &< < !E 'L 8P"(
M &( EP!@ *< 7@"[ %T W !< /8 7 #_ %L _P!; /\ R0T  +D0  "L$0
MH1   )<-  "/"   B    (( !0![  T =P 2 ', &@!O "$ ;  H &H +P!H
M #4 9P [ &4 00!C $8 8@!, &  4@!? %D 70!A %L :@!9 '4 5P"" %4
MD0!4 *( 4P"U %$ SP!0 .\ 4 #_ %  _P!0 /\ OQ0  + 8  "D&@  F1D
M (\6  "'$0  ?PT  '<&  !Q  @ :P . &< % !D !L 80 B %X *0!= "\
M6P U %D .P!8 $$ 5@!& %4 30!3 %0 4@!< %  90!. '  3 !] $L C0!)
M )X 2 "P $< QP!& .D 1@#[ $8 _P!% /\ N!L  *H@  ">(@  DR(  (D?
M  " &@  =Q4  &\0  !H"P  800* %T $ !9 !8 5@ = %0 (P!2 "H 4  P
M $\ -0!. #L 3 !! $L 2 !) $\ 1P%7 $8!80!$ FP 0P)Y $$#B0!  YH
M/@2M #T$Q  \!>4 / ?X #P'_P \!_\ LB(  *4G  "9*0  CBD  (0G  ![
M(P  <1X  &D8  !A$@  6@T# %,(# !/!1$ 3 47 $H&'@!(!B0 1P8J $4'
M, !$!S8 0P@] $$(0P! "$L /@E3 #T)70 ["F@ .@IV #@+AP W"YD -0NL
M #0,P@ S#.0 ,PWY #,-_P T#?\ K2<  * L  "5+P  BR\  ( N  !W*@
M;24  &0@  !<&@  5!0  $P/!@!&# T 0PP2 $$,&  _#!\ /@PE #P-*P [
M#3( .@TX #@-/P W#D< -@Y0 #0.6@ S#F8 ,0]T # /A0 N$)@ +1"K "P0
MPP K$>4 +!'Z "P1_P M$?\ JBP  )TQ  "2-   AS4  'TT  !T,0  :BL
M & G  !8(0  3QL  $<6  ! $0D .Q / #D0%  W$!L -A A #00)P S$2T
M,A$T #$1.P P$4, +A)- "T25P L$F, *A-Q "D3@@ G%)4 )A2I "45P  D
M%>, )1;Z "86_P F%?\ IC$  )HV  "/.0  A3H  'LY  !Q-@  9S$  %TM
M  !4*   3"(  $,=   [%P4 -10- #(3$0 Q%!< +Q0= "X4)  L%"H *Q4Q
M "H5.  I%D  *!9* "<75  F%V  )!AO ",8@  A&9, (!FG !\9O@ >&N
M'QKX " :_P @&O\ HS0  )@Z  "-/0  @SX  'D]  !O.P  93<  %LR  !2
M+0  22@  $ C   X'@$ ,!D* "P8#P J&!0 *1@: "<8(  F&2< )1DM "0:
M-0 C&CX (AM' "$;4@ @'%X 'QUL !T=?@ <'9$ &AZE !D>O  8']T &1_V
M !H?_P ;'O\ H3@  )4]  "+00  @4(  '="  !M0   8SP  %DW  !/,P
M1BX  #TI   U)   +2 ' "<=#0 E'1( (QT7 "$='0 A'20 (!XK !\>,@ >
M'SL '1]% !P@3P :(5P &2%J !@B>P 6(H\ %2*C !0CN@ 3(]H %"/U !4C
M_P 6(_\ GCP  )-!  ")1   ?T8  '5&  !L1   8D$  %<\  !-.   1#0
M #PP   S*P  *B8# ",B"P @(1  'B$5 !PB&P ;(B$ &B(H !HC,  9(S@
M&"1" !8E30 5)5D %"9H !,F>0 2)HT $2>B ! GN  .)]8 $"CT !$G_P 1
M)_\ G$   )%%  "'2   ?4H  '1*  !J20  8$8  %5!  !,/@  0SH  #HV
M   Q,@  *"T  " I"0 ;)PX &2<2 !@G&  6)Q\ %2@E !0H+0 3*#8 $BE
M !(I2P 1*E< $"IF  XK=P .*XL #2R?  PLM0 ++,\ #"SO  TL_P -*_\
MF40  (])  "%3   ?$X  '-/  !I3@  7DL  %-'  !*1   0D   #D]   O
M.   )30  !TP!0 6+0P %"P0 !,M%0 2+1P $2TC ! M*@ /+C, #BX]  TO
M2  -+U4 ##!C  HP=  ),(@ "#&<  8QL0 &,<L !C'K  <P_  (,/\ ET@
M (U-  "#40  >E,  '%4  !G4@  75   %),  !)2@  0$8  #5"   K/@
M(CH  !HW 0 2- D #S,.  XS$P -,QD #3,@  PT*  +-#$ "C4[  @U1@ '
M-5( !39@  0V<0 "-H0  #:9   VKP  -L@  #;H   V^0 !-?\ E$T  (I2
M  "!5@  >%@  &]9  !E6   6U4  %%2  !'3P  /$P  #%(   G1   'D$
M !8_   0/ < "SH-  DZ$0 (.Q< !CL>  4[)@ $.RX  CLX  $\0P  /$\
M #Q>   \;@  /($  #R7   \K   .\4  #OG   [^   ._\ D5(  (A8  !_
M7   =ET  &U>  !C70  6EP  $Y8  !"5   -U$  "U.   C2P  &DD  !)&
M   -1 8 !T,,  -#$   0Q4  $,;  !#(P  0RL  $,U  !#0   0TT  $-;
M  !#:P  0WX  $.4  !"J@  0L,  $'F  !!^0  0?\ CE@  (9>  !]80
M<V,  &MD  !B8P  5V$  $E=   ]6@  ,E@  "=5   >4P  %5$   Y/   )
M304  DT+  !,#@  3!,  $L8  !+'P  2R@  $LR  !+/0  2TD  $M7  !+
M9P  2GL  $J0  !)IP  2<   $CD  !(^   1_\ BU\  (-D  !Z9P  <6D
M &EJ  !>:0  4&8  $-D   W80  +%\  "%=   86P  $%D   I8   #5P,
M %<)  !6#0  51   %45  !4&P  5",  %0M  !4.0  5$4  %13  !49
M4W<  %.-  !2I   4;T  %#B  !0^   3_\ B&<  ']K  !W;@  ;W   &5P
M  !7;@  2FP  #UK   P:0  )6@  !IF   19   "V,   1B    8@$  &$&
M  !@"P  8 X  %\2  !?%P  7QX  %XH  !>,P  7D   %Y/  !>7P  77(
M %V(  !<H   6[D  %K?  !9]P  6/\ A&X  'QR  !U=0  :W8  %UU  !/
M=   0G,  #5S   H<@  '7   !-O   ,;@  !&X   !N    ;@   &P"  !L
M!P  :PL  &L.  !K$@  :AD  &HB  !J+0  :CH  &E)  !I6@  :6P  &B#
M  !GFP  9K4  &78  !D]0  9/\ @'4  'IY  !P>P  8GL  %1\  !&?
M.7P  "Q\   ?>P  %'H   UZ   $>@   'H   !Z    >@   'D   !Y 0
M> 8  '@+  !X#@  >!,  '@:  !X)0  >#(  '=!  !W4@  =V4  '9\  !U
ME0  =*\  '/.  !R\0  <?\ ?GT  '6   !G@0  6((  $J#   \A   +H4
M "&%   5A0  #84   .%    A@   (<   "(    B    (<   "'    AP
M (<$  "'"0  APX  (@3  "('   B"D  (@X  "'2@  AUT  (9S  "&C0
MA:<  (3%  "#[   @OX >(0  &J&  !<B   38H  #^,   QC@  (X\  !:/
M   -D    I$   "2    DP   )4   "6    E@   )8   "6    E@   )<
M  "7    EP<  )@-  "9$P  FA\  )HM  ":/P  FE(  )IH  "9@P  F9\
M )BZ  "7X@  EO@ ;8H  %^-  !0D   09,  #.6   DEP  %I@   V9   !
MFP   )T   "?    H0   *0   "E    I    *4   "E    I@   *<   "H
M    J0   *H$  "L#   KA,  *XA  "N,P  KD<  *Y=  "N=@  KI,  *ZN
M  "MS0  K.\ 89$  %.5  !$F   -9P  ":?   7H0  #:,   "E    IP
M *H   "L    L    +(   "T    LP   +0   "U    MP   +@   "Y
MNP   +T   "_ 0  PPL  ,45  #%)0  QCD  ,=/  #':   QH4  ,:B  #&
MO   QMX 59D  $>=   XH@  *:8  !FH   -JP   *T   "Q    M    +<
M  "Z    OP   ,$   #$    PP   ,4   #&    R    ,H   #-    SP
M -(   #6    VP   . ,  #A&   XRL  .1!  #E6@  YG0  .:1  #EK
MY<0 _P   /\   #_    _P ! /\ "@#_ !( _P = /\ * #_ #0 _P ^ /T
M2 #Z %  ]P!7 /4 70#T &, \@!I /  ;P#O '0 [0![ .L @0#I (D Z "2
M .8 G #D *@ X@"W -\ S0#< .X V0#_ -D _P#* /\ O@#_ +4 _P"P /\
M_P   /\   #_    _P   /\ !@#_  \ _  8 /@ (P#T "X \  X .L 0@#H
M $H Y0!1 .( 6 #@ %T W@!C -P : #9 &X U@!T -0 >P#1 (( SP"+ ,T
ME0#* *$ R "O ,4 P0#" ., P #[ ,  _P"[ /\ L #_ *@ _P"D /\ _P
M /\   #_    ^P   /,  0#M  P Z  3 ., '@#@ "@ V@ R -, / #/ $0
MS !+ ,D 40#& %< Q != ,( 8@#! &< OP!M +T = "[ 'L N0"$ +< C@"T
M )D L@"G *\ MP"M -  JP#R *H _P"I /\ H0#_ )L _P"7 /\ _P   /\
M  #T    Z0   .    #5  @ S@ 0 ,D & #% "( P0 K +P -0"Y #T M@!%
M +, 2P"Q %$ KP!6 *X 6P"L &$ J@!F *D ;0"F '0 I !\ *( A@"@ )(
MG@"? )P K@"9 ,, EP#G )8 _P"5 /\ D@#_ (T _P"* /\ _    /    #C
M    U    ,@   "_  , N0 - +, $P"O !P K  E *D +@"E #8 HP ^ *
M1 "> $H G0!0 )L 50"9 %H EP!? )8 9@"4 &P D@!U )  ?@". (H BP"7
M (D I@"' +@ A0#6 (0 ]@"" /\ @0#_ 'X _P!\ /\ [0   -T   #,
MP0   +@   "N    IP ) *( $ "> !< F@ ? )< )P"4 "\ D0 W (\ /0"-
M $, BP!) (D 3@"( %, A@!9 (0 7P"" &4 @ !M 'X =P!\ (( >@"/ '@
MG@!U *\ <P#' '( [ !Q /\ < #_ '  _P!N /\ W0   ,D   "\    L0
M *D   "A    F0 # ), # ". !( B@ 9 (< (0"$ "D @0 P '\ -P!] #T
M>P!" 'D 2 !X $T =@!2 '0 6 !R %\ <0!G &\ < !L 'L :@"( &@ EP!F
M *@ 90"\ &, X0!B /H 80#_ &$ _P!A /\ S0$  +P%  "O!0  I0(  )P
M  "4    C0   (8 " "!  X ?  4 '@ &P!U ", <@ I '  , !N #8 ;0 \
M &L 00!I $< : !, &8 4@!D %D 8P!@ &$ :0!? '0 70"! %L D !9 *$
M5P"T %8 T !5 /( 50#_ %0 _P!5 /\ P0P  +(.  "F#P  FPX  )(+  ")
M!0  @@   'L  @!U  L <  0 &P %@!H !T 9@ C &, *@!A #  8  V %X
M.P!= $$ 6P!& %H 3 !8 %, 5@!; %0 9 !2 &X 40![ $\ B@!- )L 3 "N
M $L Q@!* .H 20#^ $D _P!) /\ N1(  *H6  ">%P  E!8  (H3  "!$
M>0L  '$#  !K  8 90 - &$ $0!= !@ 6@ > %@ ) !6 "H 5  P %, -@!1
M #L 4 !! $X 1P!- $X 2P!6 $D 7P!' &D 1@!V $0 A0!# )< 00"I $
MOP _ .( /P#X #X _P _ /\ LAD  *0>  "8'P  CA\  (0<  !Z&   <A(
M &H.  !B"   7 $( %< #@!3 !, 4  9 $X 'P!, "4 2@ K $@ , !' #8
M1@ \ $0 0@!# $D 00!1 #\ 6@ ^ &4 / !R #H @0 Y ), . "E #8 N@ V
M -L -0#T #4 _P U /\ K"   )\D  "4)@  B28  '\D  !U(   ;!L  &05
M  !<$   5 P! $X&"@!* @\ 1P 4 $0 &@!" "  0  E #\ *P ^ 3$ / $W
M #L"/@ Y D4 . -- #8#5@ U!&$ ,P1N #$%?@ P!9  +P6C "T&N  L!M0
M+ ?P "P(_P L"/\ J"4  )LJ  "0+   ABT  'LK  !R)P  :"(  %\=  !7
M%P  3Q(  $@.! !!"@L /@<0 #L&%0 Y!QL . <A #8()@ U""P ,P@R #()
M.0 Q"4$ +PE) "X*4P L"EX *PML "D+?  H#(\ )@RB "4,MP D#-, (PWP
M "0-_P E#?\ I"H  )@O  "-,@  @S(  'DQ  !O+@  92D  %PD  !3'P
M2QD  $,3   \$ 8 -0T, #,,$0 Q#!8 +PP< "X-(@ M#2@ *PTN "H--0 I
M#3T )PY& "8.4  D#EP (P]J "(/>P @$(X 'Q"B !T0MP <$-0 '1'R !T1
M_P >$?\ H2\  )4S  "*-@  @#<  '8V  !M,P  8R\  %DJ  !0)0  2"
M #\:   X%0  ,!$( "P0#@ J$!( *! 8 "<0'@ E$"0 )! J ",1,@ B$3H
M(1%# " 23@ >$EH '1-H !L3>  :$XL &!2@ !<4M0 6%-$ %A7Q !<5_P 8
M%/\ GC,  ),W  "(.@  ?CL  '0[  !K.   830  %<O  !.*P  128  #TA
M   T'   +1<% "83#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4+P <%3< &Q5!
M !H62P 9%E< %Q=E !87=@ 4&(D $QB> !(8LP 1&<X $1GO !(9_P 3&?\
MG#8  )$[  "&/@  ?#\  ',_  !I/0  7SD  %4U  !,,   0RP  #HG   R
M(@  *AX! "(9"0 >%PX '!<2 !H7%P 9&!X &1@D !@9+  7&30 %AH^ !4:
M20 3&U4 $AMC !$<=  0'(< #QV<  X=L0 -'<L #1WL  X=_P /'?\ F3H
M (\_  "$0@  >T0  '%#  !H0@  7CX  %,Z  !*-@  03(  #DM   Q*0
M*"4  " @!@ :'0P %QP0 !4<%0 4'1L %!TB !,=*0 2'C( $1\\ ! ?1@ 0
M(%, #B!A  TA<0 ,(84 "R*9  HBK@ )(L< "2+G  HB^P +(?\ ESX  (Q#
M  "#1@  >4@  '!(  !G1@  7$0  %(_  !).P  0#@  #@T   O,   )RP
M !XG P 6(PH $B$. !$A$P 0(AD $"(@  \B)P .(R\ #20Y  PD1  +)5
M"B5>  DF;P ')H( !B:6  0FK  #)L0 !";E  0F]P &)O\ E4(  (I'  "!
M2@  >$P  &],  !E2P  6T@  %!$  !'00  /SX  #<[   M-@  )#$  !LM
M   3*@< #R@-  TG$0 -*!8 #"@=  LH)0 **2T "2DW  <J0@ &*DX !"M<
M  ,K;  !*W\  "N4   KJ0  *\$  "OC   K]@  *O\ DD8  (A+  !_3P
M=E$  &U1  !C4   6DT  $]*  !'1P  /D0  #-    I/   (#@  !<T   1
M,04 #"\,  DN$  '+A4 !B\;  4O(P #+RL  C U   P/P  ,$P  #%9   Q
M:0  ,7P  #&1   QIP  ,+\  ##A   P]0  +_\ D$L  (90  !]5   =58
M &M6  !B50  6%,  $Y0  !%30  .DD  "]%   E0@  '#X  !0[   ..04
M"3<+  0V#P !-A,  #89   V(   -BD  #8R   W/0  -TD  #=7   W9P
M-WD  #>/   VI0  -KT  #;@   U]0  -?\ C5   (16  !\6@  <EL  &E;
M  !@6P  5UD  $Q6  ! 4@  -4X  "I+   @2   %T8  !!#   +000 !$ *
M   _#@  /A$  #X6   ^'0  /B8  #XO   ^.@  /D8  #Y4   ^9   /G8
M #V,   ]HP  /+L  #S>   []0  ._\ BE<  ()<  !Y7P  <&$  &AA  !?
M80  5%X  $=;   Z5P  +U4  "52   ;4   $DT   Q+   &2@,  $D)  !(
M#0  1Q   $<4  !&&@  1B(  $8L  !&-P  1D,  $91  !&8   17,  $6)
M  !$H   1+@  $/<  !"]0  0O\ B%T  ']B  !W90  ;F<  &=H  !;9@
M3F,  $%A   T7@  *5P  !]:   55P  #E8   =4    4P$  %(&  !1"P
M40X  % 1  !/%@  3QX  $\G  !/,@  3S\  $]-  !.70  3F\  $Z%  !-
MG0  3+4  $O8  !*]0  2O\ A64  'QI  !T;   ;6X  &)M  !4:P  1VD
M #IG   M90  (F0  !AB   08   "5\   !>    7@   %T#  !<"   6PP
M %H/  !:$P  61D  %DB  !9+0  63H  %E(  !86   6&L  %>!  !7F0
M5K(  %72  !4]   4_\ @6P  'EP  !S<P  :',  %IR  !,<0  /W   #)O
M   E;@  &FP  !%K   ):@   &H   !I    :0   &@   !G P  9@@  &8,
M  !F#P  910  &4<  !E)P  9#0  &1#  !D4P  9&4  &-[  !BE   8:T
M &#-  !?\0  7O\ ?70  '=W  !N>0  7WD  %%Y  !#>0  -G@  "EX   <
M=P  $78   IU    =0   '4   !V    =0   '0   !T    <P(  ','  !S
M#   <A   '(5  !R(   <BP  '([  !Q3   <5\  '%T  !PC@  ;Z@  &[&
M  !L[0  :_\ >WL  ')^  !D?@  57\  $>    Y@0  *X(  !Z!   2@0
M"H$   "!    @@   (,   "#    @P   ((   ""    @@   ((   ""!0
M@@H  ((/  ""%P  @B,  ((R  ""0P  @58  (%L  " A@  ?Z$  'Z]  !]
MY@  ?/P =H(  &B#  !9A0  2X<  #R)   NB@  ((L  !.+   *BP   (P
M  "-    CP   )$   "2    D0   )$   "1    D0   )$   "2    D@(
M ),)  "4#P  E!D  )0G  "4.   E$P  )-B  "3?   DY@  )*S  "1V
MD/8 :H@  %R*  !-C0  /Y   #"2   AE   %)4   J6    EP   )D   ";
M    G0   )\   "@    H    *    "@    H0   *(   "C    I    *4
M  "F!P  J!   *@<  "H+0  J4   *E6  "I;P  J8L  *BH  "GQP  INP
M7X\  %"2  !!E@  ,YD  ".<   4G0  "I\   "A    HP   *8   "H
MK    *X   "O    KP   +    "P    L@   +,   "T    M@   +<   "Z
M    O0<  +\0  "_'P  P#,  ,!)  # 8@  P'X  ,";  # MP  O]@ 4Y<
M $2;   UGP  )J,  !:E   +IP   *H   "M    L    +,   "V    NP
M +T   #     OP   ,$   #"    Q    ,8   #(    R@   ,P   #/
MTP   -H'  #;$P  W24  -X[  #?4P  X&X  -^,  #=J0  W<( _P   /\
M  #_    _P   /\ !P#_ !  _P 9 /\ ) #_ "\ _  Z /D 0P#U $L \P!2
M /$ 60#O %X [0!D .L :0#I &\ YP!U .8 ? #D (0 X@"- .  EP#= *(
MV@"Q -4 Q0#2 .@ T #_ ,\ _P#$ /\ N #_ *\ _P"I /\ _P   /\   #_
M    _P   /\  @#[  T ]P 5 /, 'P#O "D Z@ T .8 /0#B $4 W@!, -L
M4P#8 %@ U !> -( 8P#0 &D S@!N ,P =0#* 'T R "% ,8 D #" )L P "I
M +X N@"[ -D N0#W +@ _P"T /\ J0#_ *( _P"= /\ _P   /\   #_
M]@   .X   #G  H X0 1 -P &@#7 ", T  N ,L -P#' #\ Q !& ,$ 30"_
M %( O0!8 +L 70"Y &( N !H +8 ;@"T '4 L0!^ *\ B "M ), J@"A *@
ML0"F ,@ I #M *( _P"B /\ FP#_ )4 _P"1 /\ _P   /P   #N    XP
M -@   #-  4 Q@ . ,$ %0"] !X N0 G +4 , "R #@ KP!  *P 1@"J $P
MJ !1 *< 5@"E %L HP!A *$ 9P"? &X G@!V )L @ "9 (P EP"9 )0 J "2
M +P D #? (X ^P". /\ BP#_ (8 _P"# /\ ^    .D   #<    S    ,$
M  "X    L@ * *P $0"H !@ I0 A *( *0"> #( G  Y )D /P"7 $4 E0!*
M )0 4 "2 %4 D !: (\ 8 "- &< BP!O (D > "& (0 A "1 (( H "  +(
M?0#, 'P \0![ /\ >@#_ '< _P!U /\ Y@   -,   #&    NP   +$   "G
M    H0 % )L #0"7 !, DP ; )  (P", "L B@ R (@ . "& #X A !$ ((
M20"! $X ?P!3 'T 60![ &  >0!H '< <0!U 'P <P") '  F !O *D ;0"_
M &L Y@!J /\ :0#_ &D _P!G /\ TP   ,,   "U    JP   *,   ";
MD@   (P "@"' !  @P 6 '\ '0!] "0 >@ K '@ ,@!V #@ =  ] '( 0@!Q
M $@ ;P!- &T 4P!L %D :@!A &@ :@!F '0 9 "! &$ D0!? *( 7@"V %P
MU0!; /< 6P#_ %H _P!: /\ Q0   +8"  "I @  GP   )8   ".    AP
M (  !0!Z  P =0 1 '$ & !N !X :P E &D *P!G #$ 9@ W &0 / !C $$
M80!' %\ 30!> %, 7 !; %H 9 !8 &X 5@![ %0 B@!2 )L 40"N %  R !/
M .X 3@#_ $X _P!- /\ NPH  *P-  "@#0  E0P  (P(  "# @  ?    '4
M  !N  @ :0 . &4 $P!B !D 7P ? %T )0!; "L 60 Q %@ -@!6 #L 50!!
M %, 1P!1 $X 4 !5 $X 7@!, &@ 2@!U $@ A !' )4 10"H $0 OP!# .0
M0@#\ $( _P!" /\ LA$  *44  "9%0  CA,  (01  ![#0  <P@  &P   !E
M  , 7P + %L #P!7 !0 5  : %$ 'P!/ "4 3@ K $P , !+ #8 20 \ $@
M0@!& $@ 10!0 $, 60!! &, /P!O #X ?@ \ )  .P"C #H N  Y -D . #U
M #@ _P X /\ K!<  )\;  "3'0  B1P  '\9  !U%0  ;!   &0,  !=!@
M5@ & %$ # !- !  2@ 5 $< &@!% "  1  F $( *P!! #$ /P V #X /0 \
M $0 .P!+ #D 5  W %\ -@!K #0 >@ R (P ,0"> #  LP O ,X +P#O "X
M_P N /\ IQX  )HB  "/)   A"0  'HA  !Q'0  9Q@  %\3  !7#@  4 H
M $D#" !%  T 00 1 #X %@ \ !L .@ A #D )@ W "P -@ R #0 .  S #\
M,0!' #  4  N %L +0!G "L =@ J (@ * "< "< L  F ,D )0#J "4!^P E
M ?\ HB,  )8H  "+*@  @2H  '<H  !M)0  9"   %L;  !2%0  2Q   $,,
M @ ]!PD .0,. #8!$@ S 1< ,0$< # !(@ O B< +0(M "P#-  J SL *01#
M "@$30 F!5@ )05E ",&=  B!H8 ( :: !\'K@ >!\8 '0?G !T(^  ="?\
MGR@  ),M  "(+P  ?B\  '0N  !J*P  828  %@A  !/'   1Q<  #\2   X
M#@0 ,0L* "X(#@ K!Q( *0<7 "@('0 G"", )0@I "0),  C"3< (0I  " *
M2@ ?"U4 '0MB !L,<@ :#(4 & R9 !<,K0 6#,8 %0WF !4-^0 6#?\ G"T
M ) Q  "&-   ?#0  '(S  !H,0  7RP  %4G  !,(P  1!T  #P8   T$P
M+1 & "8-"P D# \ (@P3 "$,&0 ?#!\ '@TE !T-+  ;#30 &@X] !D.1P 7
M#E, %@YA !0/<0 3$(0 $A"8 !$0K@ 0$,8 $!#H ! 0^P 1$/\ F3$  (XU
M  "$.   >CD  ' X  !G-@  73(  %,M  !**   0B0  #D?   Q&@  *A4!
M ",1!P =$ T &P\0 !D/%0 8$!L %Q A !80*0 5$#$ %!$Z !,110 2$E$
M$1)? ! 2;P .$X( #A.6  T3JP +$\( "Q3C  P4^@ -$_\ ES4  (PY  ""
M/   >#T  &\]  !E.@  6S<  %(R  !)+@  0"H  #<E   O(0  *!P  " 8
M P 9% H %1(. !02$@ 3$Q@ $A,? !$4)@ 1%"X $!0X  \50@ .%D\ #19<
M  P7;  +%W\ "1B3  @8J  &&+\ !QC@  <8]0 )&/\ E3@  (H]  " 0
M=T$  &U!  !D/P  6CP  % X  !',P  /C   #8K   N)P  )R,  !\?   7
M&@@ $A<- ! 7$0 /%Q8 #A@<  X8(P -&2P #!HU  L:0  *&TP "1M:  <<
M:0 %''P !!V1  (=I@ !';P  AS=  (<\@ #'/\ DSP  (A!  !_1   =44
M &Q%  !C1   64$  $\]  !&.0  /C8  #4R   N+@  )2H  !TE   4(00
M#QT+  T=$  ,'10 "QT:  H>(@ ('BH !Q\S  8@/@ $($H  R%7  $A9P
M(7D  "&.   AI   (;H  "';   A\@  (/X D$   (9%  !]2   =$H  &M*
M  !B20  6$8  $Y"  !%/P  /3P  #4Y   K-   (B\  !DK   2* 0 #20*
M  DC#@ &(Q( !2,9  0D(  ")"@  24Q   E/   )4@  "95   F90  )G<
M ":,   FH@  )KD  ";9   E\@  )?X CD4  (1)  ![30  <T\  &I/  !@
M3@  5TL  $U(  !$10  /$(  #$]   G.0  'C4  !4R   /+@, "BP*  4K
M#@ !*A$  "H6   J'@  *B8  "LO   K.0  *T4  "Q3   L8@  +'4  "R*
M   KH   *[<  "O6   J\@  *O\ C$D  ().  !Z4@  <50  &A4  !?4P
M5E$  $Q.  !#2P  -T<  "U#   C/P  &CP  !(X   ,-@, !C,)   R#0
M,A   #$4   Q&P  ,2,  #$L   R-P  ,D,  #)0   R8   ,G(  #*'   Q
MG@  ,;4  ##4   P\@  +_\ B4\  (!4  !X5P  ;UD  &99  !>60  55<
M $E3   ^3P  ,DP  "A(   >10  %4(   Y    (/0(  3P(   [#   .@\
M #D2   Y&   .2   #DI   Y-   .4   #E.   Y70  .6\  #B%   XG
M-[,  #?2   V\@  -?\ AU4  ']:  !V70  ;5\  &5?  !=7P  4EP  $18
M   X50  +5(  ")/   83   $$H   I(   #1@$  $4&  !$"@  0PT  $(0
M  !!%0  01T  $$F  !!,0  03T  $%*  !!6@  06P  $"!   _F0  /[$
M #[0   ]\@  //\ A%P  'Q@  !S8P  ;&4  &1F  !99   2V$  #Y>   R
M6P  )ED  !Q6   25   #%(   11    3P   $X#  !-"   3 P  $L.  !+
M$@  2AD  $HB  !*+   2CD  $I'  !*5@  26@  $E^  !(E@  1Z\  $;-
M  !%\0  1/\ @6,  'EG  !R:@  :VP  &!K  !2:0  1&8  #=D   J8@
M'V   !5>   -70  !EL   !:    60   %@   !7!   5@@  %8,  !5$
M5!0  %0=  !4)P  5#0  %1"  !34@  4V0  %)Y  !2D@  4:L  %#*  !/
M[P  3O\ ?FH  '=N  !P<0  9G$  %AP  !*;P  /&T  "]L   B:@  %VD
M  YG   &9@   &4   !E    90   &,   !B    8@0  &$(  !A#0  8!
M & 7  !@(0  7RX  %\\  !?30  7EX  %YT  !=C0  7*<  %O%  !:[0
M6?\ >W(  '5V  !K=P  778  $]V  !!=0  ,W4  "9T   9<P  $'(   =Q
M    <0   '$   !Q    <0   &\   !O    ;@   &X"  !N"   ;0P  &T1
M  !M&@  ;28  &PU  !L1@  :U@  &MM  !JA@  ::$  &B^  !GZ   9OX
M>7H  '!\  !A?   4WT  $1]   V?@  *'X  !M]   0?0  !WT   !]
M?0   'X   !_    ?@   'T   !]    ?    'P   !\    ? 8  'P,  !\
M$@  ?!T  'PL  !\/   ?$\  'ME  ![?@  >IH  'FV  !XWP  =_H <X
M &6!  !6@P  2(0  #F&   KAP  '8<  !&'   'B    (@   ")    B@
M (P   "-    C0   (P   ",    C    (P   ",    C0   (T$  ".#
MCA,  (\A  ".,@  CD8  (Y;  "-=   C9   (RM  "+S@  BO, :(8  %J(
M  !+BP  /(T  "V/   >D   $9$   >2    DP   )4   "7    F0   )L
M  "<    FP   )L   "<    G    )T   ">    G@   )\   "A P  H@P
M *(6  "C)@  HSH  *-/  "C:   HH8  **B  "BP   H>@ 7(T  $V0   _
MDP  ,)8  "&9   2F@  !YL   "=    H    *(   "D    J    *H   "K
M    J@   *L   "L    K0   *X   "O    L0   +(   "T    MP$  +D-
M  "Y&@  NBT  +I#  "Z6P  NG<  +N4  "[L0  N=( 4)4  $&8   RG
M(Z   !.B   (I    *<   "J    K    *\   "R    MP   +D   "[
MN@   +P   "]    OP   ,    #"    Q    ,8   #)    S0   -(!  #4
M#P  U1\  -<U  #830  V&D  ->&  #7HP  UKT _P   /\   #_    _P
M /\  P#_  T _P 5 /\ ( #\ "L ^  U /0 /P#P $< [@!. .L 5 #I %H
MYP!? .4 9 #C &H X0!P -\ =@#= 'X VP"' -@ D0#3 )T SP"K ,T O0#+
M .  R0#[ ,< _P"] /\ L0#_ *D _P"C /\ _P   /\   #_    _P   /P
M  #V  L \0 1 .T &P#I "4 Y  P -\ .0#: $$ U0!( -$ 3@#/ %0 S0!9
M ,L 7@#) &, QP!I ,4 ;P## '< P !_ +X B@"[ )4 N "C +8 M "T ,T
ML@#R +  _P"L /\ HP#_ )P _P"7 /\ _P   /\   #Z    \0   .@   #@
M  8 V0 . -( %@#. !\ R  I ,0 ,@#  #H O0!! +H 2 "X $T M@!3 +0
M6 "R %T L !B *X :0"L &\ J@!X *@ @@"F (X I "; *$ JP"? ,  G0#F
M )L _P": /\ E #_ (X _P"* /\ _P   /8   #H    W    ,X   #&  $
MOP + +H $0"V !H L@ B *X *P"J #0 J  [ *4 00"C $< H0!, )\ 40">
M %8 G !< )H 8@"9 &@ EP!P )4 >@"2 (8 D "3 (T H@"+ +4 B0#3 (<
M]P"& /\ A #_ '\ _P!\ /\ \@   .,   #2    Q0   +H   "Q    JP '
M *4 #@"A !0 G@ < )H )0"7 "T E  T )( .@"0 $  C@!% (T 2@"+ %
MB0!5 (@ 6P"& &$ A !I (( <@!_ 'T ?0"+ 'L F@!X *L =@#$ '0 ZP!S
M /\ <P#_ '  _P!N /\ WP   ,P   "_    M    *L   "A    F@ " )0
M"P"0 !  C  7 (@ '@"% "8 @P M ($ ,P!_ #D ?0 _ 'L 1 !Y $D > !.
M '8 5 !T %H <P!B '  :P!N '4 ; "# &H D@!H *, 9@"X &0 W@!C /L
M8@#_ &( _P!@ /\ S    +P   "O    I0   )T   "4    C    (8 !P"!
M  T ?  2 '@ &0!U !\ <P F '$ +0!O #( ;0 X &L /0!J $( : !( &<
M3@!E %0 8P!; &$ 9 !? &X 70![ %L B@!9 )L 5P"O %8 RP!5 /( 5 #_
M %0 _P!4 /\ O@   +    "D    F0   )    "(    @0   'D  @!S  H
M;P / &L % !G !H 90 @ &, )@!A "P 7P R %X -P!< #P 6P!" %D 1P!7
M $X 5@!5 %0 7@!2 &@ 4 !T $X @P!, )4 2@"H $D P !( .@ 1P#_ $<
M_P!' /\ M D  *8+  ";#   D H  (8%  !^    =@   &\   !H  4 8P ,
M %\ $ !; !4 6  : %8 (0!4 "8 4P L %$ ,0!0 #8 3@ \ $T 0@!+ $@
M20!0 $@ 6 !& &( 1 !N $( ?0!  (X /P"B #T N  ] -T / #X #P _P \
M /\ K!   )\2  "4$@  B1$  '\/  !V#   ;@4  &8   !@  $ 60 ( %4
M#0!1 !$ 3@ 6 $L &P!) "$ 2  F $8 *P!% #$ 0P V $( / !  $, /@!+
M #T 4P [ %T .0!I #< >  V (D - "< #, L0 R ,X ,@#Q #$ _P Q /\
MIA8  )H9  ".&@  A!H  'H6  !P$@  : X  %\*  !8 P  40 $ $P "@!(
M  X 1  2 $$ %@ _ !L /0 A #P )@ Z "P .0 Q #< -P V #X - !& #,
M3P Q %D +P!E "X <P L (4 *P"8 "H K0 I ,8 * #J "@ _@ H /\ H1P
M )4@  "*(0  ?R$  '4?  !L&@  8Q8  %H1  !2#0  2P<  $0 !@!   L
M/  / #@ $@ V !< -  < #, (0 Q "< ,  L "X ,P M #H *P!" "H 2P H
M %4 )@!A "4 <  D ($ (@"5 "$ J0 @ ,$ ( #D !\ ^0 ? /\ G2(  )$F
M  "&*   ?"<  '(E  !I(@  7QT  %<8  !.$P  1@X  #\+   X!0< -  ,
M #$ $  N !, +  8 "H '0 I "( )P H "8 +@ D #8 (P ^ "( 1P @ %(
M'P!> !T ;0 < 'X &@"2 !D IP 8 +T %P#? !<!]0 7 O\ FB<  (XK  "$
M+0  >2T  ' K  !F*   720  %0?  !+&@  0Q0  #L0   T#0( +0D) "D%
M#0 F Q  ) $3 "("&0 A AX ( (D !X#*@ = S( &P0Z !H%1  9!4\ %P9<
M !8&:@ 4!WP $P>0 !('I0 1![L $ ?; ! (\@ 0"?\ ERL  (PO  "!,0
M=S(  &XQ  !D+@  6RH  %$E  !)(   0!L  #@6   Q$@  *0X$ ",,"0 ?
M"0T '0<0 !L'%0 9"!H & @@ !<))P 6"2X %0HW !,*00 2"TT $0M: ! +
M:0 .#'L #@R0  T,I0 ,#;L "PW9  L-\0 ,#?\ E2\  (HS  !_-@  =C8
M &PU  !C,P  62\  % K  !')@  /B$  #8=   N&   )Q,  " 0!0 9#@H
M%0P. !0,$0 3#!8 $@P< !$-(P 0#2L #PTT  X./P -#DH # ]8  L/9P *
M$'D "!"-  <0H@ &$+@ !1#4  40[P &$/\ DC,  (@W  !^.@  =#L  &LZ
M  !A.   6#4  $XP  !%+   /2<  #4C   M'P  )AH  !X6 0 7$P8 $1 +
M  X.#@ .#Q, #1 9  T0(  ,$"@ "Q$R  H1/  ($D@ !Q)5  8390 $$W8
M Q.+  $4H   $[8  !/1   3[@  $_L D#8  (8[  !\/@  <S\  &H_  !@
M/0  5SD  $TV  !$,0  /"X  #0J   L)@  )2(  !X>   6&@( $!4)  P3
M#@ *$Q( "107  @4'P '%28 !A4O  06.@ #%D8  1=3   78@  &'0  !B)
M   8GP  &+4  !?0   7[0  %_L CCH  (0_  ![0@  <D,  &A#  !?0@
M5C\  $P[  !#-P  .S0  #,P   L+   )"D  !LD   3'P( #1L)  D9#0 &
M&1$ !!D6  (9'0 !&B0  !HM   ;.   &T0  !Q1   <8   '7(  !V'   <
MG0  '+,  !S.   ;[0  &_P C#X  ()#  !Y1@  <$@  &A(  !>1@  540
M $M   !#/0  .SH  #,W   J,@  ("T  !<I   0)0( "R()  4@#0 !'Q
M !\4   ?&P  ("(  " K   A-@  (4$  "%/   A7@  (G   "*%   AFP
M(;(  "'-   @[0  '_P BD,  (!(  !X2P  ;TP  &9-  !=2P  5$D  $I&
M  !"0P  .D   "\[   E-P  '#,  !,O   -+ ( !RD(  $G#   )@X  "42
M   F&0  )B$  "8I   F,P  )S\  "=-   G7   )VT  ">"   GF0  )K
M "7,   E[@  )/T B$@  '],  !V4   ;E$  &52  !<40  4T\  $I,  !!
M20  -40  "M    A/   %SD  ! V   *,@$  S '   O"P  +@X  "T1   M
M%@  +1X  "TG   M,0  +3T  "U*   M60  +6L  "V    LEP  +*\  "O+
M   J[@  *OX A4T  'U2  !U50  ;%<  &-7  !;5@  4U4  $=1   [30
M,$D  "5&   <0P  $S\   T]   &.@   #@%   W"0  -@T  #4/   T%
M-!L  #0D   T+@  -#H  #1'   T5P  -&@  #1]   SE0  ,JT  #'*   Q
M[@  ,/\ @U,  'M8  !S6P  :ET  &)=  !;70  3UH  $)6   V4@  *D\
M "!,   620  #D<   A$    0@   $$#   _!P  /@L  #T.   ]$0  /!@
M #PA   \*P  /#<  #Q$   \4P  /&4  #MZ   ZD@  .JL  #G(   X[0
M-_\ @5H  'E>  !Q80  :6,  &)D  !78@  25X  #Q;   O6   )%4  !E3
M   040  "D\   %-    3    $H   !)!   2 @  $<,  !&#P  1A0  $4<
M  !%)P  13,  $5   !%4   1&$  $1V  !#CP  0J@  $'&  ! [   /_\
M?F$  '9E  !O:   :&H  %UI  !/9@  0F0  #1A   H7P  '5T  !);   +
M60   E@   !6    5@   %0   !3    4@0  %$)  !0#0  4!   $\8  !/
M(@  3RX  $\\  !/2P  3ET  $YR  !-BP  3*4  $O"  !)Z@  2/\ >VD
M '1L  !N;P  9&\  %5M  !';   .6H  "QI   @9P  %&4   UD   #8@
M &(   !A    8    %\   !>    70   %P$  !<"0  6PT  %L2  !;'
M6B@  %HV  !:1@  65@  %EM  !8A0  5Z   %:]  !5Z   4_X >7   '-T
M  !I=0  6W0  $QS   ^<P  ,'(  "-Q   6;P  #6X   1M    ;0   &T
M  !M    ;    &L   !J    :0   &D   !I P  : D  &@.  !H%0  9R$
M &<O  !G/P  9E(  &9F  !E?P  9)H  &.W  !BX0  8?P =W@  &UZ  !?
M>@  4'H  $)Z   S>P  )7L  !AZ   .>0  !'D   !Y    >0   'H   !Z
M    >@   '@   !X    =P   '<   !W    =P$  '<(  !W#@  =Q@  '<F
M  !V-@  =DD  '5?  !U=P  =),  '.O  !RTP  <?< <7X  &-_  !4@
M18(  #:#   HA   &H0   Z#   $A    (0   "%    A@   (@   ")
MB    (<   "'    AP   (<   "'    B    (@   "(!P  B1   (D<  ")
M+   B#\  (A5  "(;0  AXD  (:G  "%QP  A.\ 9H0  %>&  !(B   .8H
M "J,   ;C0  #XT   2.    D    )$   "3    E0   )<   "8    E@
M )<   "7    EP   )@   "8    F0   )H   ";    G0<  )T1  "=(0
MG3,  )U)  "<8@  G'\  )R<  "<N0  F^( 6HL  $N.   \D0  +9,  !Z5
M   0E@  !)@   ":    G    )X   "A    I    *8   "G    I@   *<
M  "G    J    *D   "J    K    *T   "O    L0   +,)  "S%0  M"<
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M__________________________________________________\
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M]O?X^?K[_/W^_VUF=#$      P$A   !                     0
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MT]35UM?8V=K;W-W>W^#AXN/DY>;GZ.GJZ^SM[N_Q\O/T]?;W^/GZ^_S]_O\
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M______N ,0        EAS/___________________________]): @
M  !=S/___________________________Z@U          !<T___________
M_________________WT-          !4UO__________________________
M[GU%          !$U/___________________________*ID+P(   0B-TE8
MSO___________________________^FD:T$H/V-_E:>ZVO______________
M________________U;*LLLSD^O__________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
MY;N7=V+(_________________________________]N>9S8*  *,________
M________________________R'\_!0    !>S_______________________
M_______9@3D        \JO____________________________^>3
M   CD/___________________________]QO&@         0??G_________
M_________________Z](            ;^[_________________________
M_X03            9.;_________________________[%$
M5][_________________________N!4             2-;_____________
M____________=!0             .,_________________________YHEH3
M            (\7_________________________WYM<+           #;K_
M_________________________^^Q?54Y(A$' 0(1(K+_________________
M_____________]^_I9F8FJ"LO=K_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________^.^G8!\^_______________________
M__________*WA%<P#@ =K/______________________________THI,%0
M    <O/____________________________6?S8         2\G_________
M__________________J1/@          +ZO_________________________
M_\!:            &I7__________________________XTD
M"(3_________________________YUX              '?_____________
M____________M"4              &K_________________________?0
M             %OT_______________________]*P               $SK
M______________________^E                 #SA________________
M______\P#                "W9_____________________YF*82<
M         "?7_______________________MOHE5)P           "7<____
M______________________[*G79=2CPR+2PP.4?>____________________
M___________]YMW6TM#3V>3_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M[]2[UO_________________________________GN(]J2R\5;___________
M____________________Y*%G- <     /,G_________________________
M___6@CL         $I?__________________________^V%,0
M &___________________________Z9"             %#A____________
M____________[&D              #?)________________________LR\
M             "*V________________________>0               !"G
M_______________________R-                 "9________________
M______^I                  ",______________________]&
M          !______________________]\                   !T____
M_________________Y<                   !J____________________
M_\X                   !C______________________\I(@$
M      !A______________________^YHX!7-Q<           !H________
M___________________ZTZZ4AGQU<7!R=X&4________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________]NZG8)I:=/______________________________\B393T9
M'9[____________________________;CDP3         &[_____________
M_____________]M\+            $77_________________________XLJ
M             "*T________________________PD0               .7
M________________________?0$               !_________________
M_______G-@                !J______________________^=
M          !8______________________]&                  !'^/__
M_________________^D                    UZ?__________________
M_Y8                    EV____________________[P
M       8SO___________________^L                    /PO______
M______________\                    *N?____________________\G
M                   *M?____________________]P
M   -N?_____________________@G(QP54(S)AL4#PT.$AHFO___________
M__________________GDV-+.S,O,S];@_/__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^O3O./_____________
M___________________2J85E2"P2 87____________________________Q
MJW$\#P       $_@_________________________]5_-0           !^R
M________________________XW4=              ")________________
M________D",               !G_______________________50P
M          !(]O____________________^*                   NW?__
M__________________\X                   7R/__________________
M_[X                    $MO___________________YP
M        I?___________________[H                     D_______
M_____________]P                     @O____________________\
M                    =/____________________\3
M    :/____________________]"                    8/__________
M__________]Z                    7?_____________________1
M                8?______________________)
M9O______________________R:R9B7UV<6QI9V9G:W!ZC/______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________^+%JI%Y87?_
M____________________________W:9W4"P,     #'$________________
M_________^"23A,           "/________________________TG =
M          !@_______________________N;P\                WXO__
M__________________^6'                  4P/__________________
M__]                     H____________________ZX
M        B?___________________YX                     <O______
M_____________[P                     7____________________]H
M                    3?____________________H
M    ._____________________\.                    *OG_________
M__________\S                    &^G___________________]>
M                #]O___________________^/
M!M#____________________0                     ,K_____________
M________*P                   ,C_____________________@
M             ,O_____________________]Q8!!04# 0       08-&,O_
M______________________SKX=C/S,W/T-+4U]SBZO__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________QVL;_______________________________'&
MHX1H33(8 !6K__________________________^Y?$88          !Q____
M____________________UWPO               [X___________________
M___?9 D                ,M?____________________]T P
M        C?___________________\45                    :O______
M_____________YD                     2____________________[8
M                    ,/W__________________]<
M    &>?___________________8                     !=/_________
M__________\.                     ,'___________________\O
M                 *____________________]2
M )[___________________]Y                     ([_____________
M______^E                     (#____________________8
M             '3_____________________-@                   &W_
M____________________?                    &G_________________
M____UPT                  &C______________________W
M         &'_______________________]0/$9.5%E=861H;'!V?HG_____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________^_5NZ.+<UJ5____________________
M_______XOXYD02$%      !2_/______________________]YU6&
M       7P?_____________________E;!8                 C?______
M______________]C                    7O___________________YT
M                    -?S__________________Z$
M    $=G__________________\H                      +O_________
M_________^X                      *'___________________\,
M                 (K___________________\M
M ';___________________]-                     &3_____________
M______]O                     %+___________________^4
M             $#___________________^\                     ##_
M___________________J#@                   "+_________________
M____1                    !7_____________________@0
M          OU____________________R L                   +L____
M_________________UX                   #E____________________
M_\D<                  #:______________________^= 0
M   '#A?%________________________U;F\P<?.U=OAYNWT^___________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____^-_/_____________________________^S&I8AM5#LA!P RWO______
M_________________]>262D             H/______________________
MB38                 9_____________________]F
M    ,O;__________________Y4                      \C_________
M_________Z<                      *#__________________]<
M                 'S___________________\
M %[___________________\E                     $/_____________
M______](                     "S___________________]J
M             !C___________________^+                      7S
M__________________^O                      #A________________
M___5                      #/____________________)
M          "^____________________5                     "N____
M________________BP                    "?____________________
MRPX                   "2_____________________U<
M      "&_____________________ZH*                  !Y________
M______________]M                  !F_______________________W
M50                !%_________________________VHC*S4_2E5@:G5^
MAY&<________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________HS[:=@VE.N?_________________________LLH-<.AT"
M    >_______________________Q6TI                0/__________
M__________^#&P                  !\O__________________Y(
M                 )C__________________Z0
M &K__________________]T                      $'_____________
M______\.                     !W___________________\Y
M              #H__________________]@                      #.
M__________________^%                      "W________________
M__^H                      "C___________________+
M          "0___________________O%@                    !]____
M________________/@                    !L____________________
M:0                    !:____________________F0
M      !)____________________TA8                    Y________
M_____________U@                    I_____________________Z(
M                   9______________________56
M   $______________________^[+P                  ^/__________
M____________JRD                 S________________________\E'
M      <3("X^4FB$[?__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________35R?__________
M__________________K2L))W74(H#   2O_______________________\5]
M11<             $=C____________________$4
M )___________________Z(,                     &C_____________
M_____Y0                      #;__________________]H
M              ?L__________________\5                      #$
M__________________](                      "B________________
M__]U                      "#__________________^=
M          !I___________________#                      !2____
M_______________G#P                     ^____________________
M,P                     K____________________6
M       8____________________@0                     %________
M____________K                       ____________________WB(
M                    \O___________________UP
M    W____________________Y\                     S/__________
M_________^A*                    M_____________________^@%@
M                G/______________________>@(
M=________________________WH+               %3/______________
M__________^B5VAT@(V<J[S0Y___________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________M
MX___________________________TJ-Z6#HI(QP6#@8  )______________
M________K%(.                 &G__________________^1#
M             #3__________________WD                       #C
M_________________\T                       "R________________
M__\3                      "%__________________]/
M          !=__________________^#                       Z____
M______________^R                       <___________________;
M P                     "____________________*@
M        ^___________________3P                      Y_______
M____________=                       U/__________________FP
M                    P/__________________Q <
M    K?__________________\#,                     FO__________
M_________V<                     AO___________________Z,
M                <O___________________^-$
M7/____________________^1!@                  0?______________
M_______K7P                  '?______________________RDL
M             /_______________________\M7   ,&"0Q/TY@=(NGQ___
M________________________U^?R________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________Z]3-Q\*^NK>SL*VIJ*7_
M___________________=?E,_,",9$0D"          #;________________
M_W8                       "G_________________[H
M          !U__________________\'                      !&____
M______________].                       :__________________^,
M                        _?_________________!
M        V__________________Q&0                      OO______
M____________1                       I/__________________:P
M                    C?__________________D0
M    >?__________________MP                      9O__________
M________WB$                     4____________________TH
M                /____________________W<
M*____________________ZP*                    %O______________
M_____^=%                     /____________________^*
M             /_____________________630                   /W_
M____________________IRX                  -7_________________
M_____Y@J           &&"U%8.#_______________________^H8W2!CYRK
MN\WB^O______________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________Y\NWJ9V5CHF$@'QX='!L:&60____
M_____________[QJ2"T9"@                 Q__________________\
M                       #__________________]"
M        W/________________^.                        LO______
M___________.                        C?__________________*0
M                    :___________________6@
M    3O__________________A@                      -/__________
M________K@                      'O__________________U!<
M                "O__________________^CT
M /___________________V4                      /______________
M_____XX                      /___________________[P9
M             .____________________%.                     -C_
M__________________^+                     +__________________
M___,0P                   *'_____________________D1D
M         'K_____________________\G0*                $5______
M_________________^AT$Q\L.$538G*%F[32]?______________________
M____U^CT____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________[]_/Q
M[NSKZ^SQ___________________9LIF'>6UD75912T9!/#@R+2@CQ/______
M__________]+)0L                     DO________________^(
M                    9O_________________7
M    /?__________________,P                      &/__________
M________;                        /__________________G0
M                 /__________________R0P
M /;_________________\34                      -______________
M_____UL                      ,O__________________X(
M             +?__________________ZD&                     */_
M_________________],O                     (W_________________
M__]>                     '?___________________^3!P
M         %[____________________-0P                   $#_____
M________________AQ                   !S_____________________
MV%X                   #______________________[].       .'"P^
M4FJ&I<C________________________"?(R:I[;%UNC]________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________NX=?/R<.^NK:QK:FG
MIJ:GKO________________^^AFU;3$ W+R@B'!80"P0     %/__________
M_______7!0                       /__________________-
M                 /;_________________=@
M -+_________________L                        ++_____________
M____X20                      );__________________U$
M             'S__________________WD                      &;_
M_________________Z                       %'_________________
M_\<C                     #S__________________^Y+
M         "?___________________]T                     !#_____
M______________^C%@                    #____________________8
M3                     #_____________________B \
M      #_____________________RU,                   #_________
M_____________Z4X           )'31.:XS_______________________^9
M.4-17VY]CJ"UR^7_____________________________Z_G_____________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________Z\RYK*&9D8N&@7QX='!K:&9F
M:/'_________________844R(Q@.!@               )[_____________
M____?@                       '7_________________PP
M             %+_________________^S<                      #+_
M_________________VH                      !;_________________
M_Y8                       #__________________[\;
M          #__________________^9"                      #_____
M______________]I                      #___________________^0
M @                    #___________________^Y+
M      #T___________________H7                     #9________
M____________D1@                   "\____________________RE,
M                  "=_____________________Y@N             ! I
M1F;$_____________________^Y_'0P:*#=&5VE^E:_,[O______________
M___________GH*JYR-CI_/______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________________WU\.OF
MXM_;V-32T=#2U^#_________________SIZ*?'%I85M644Q(0SXZ-C(O+C'_
M________________TB41 P                    #_________________
M_T(                       #__________________WT
M          #__________________[ +                      #V____
M_____________]TY                      #<__________________]B
M                      #%__________________^)
M      "O__________________^O(@                    "9________
M___________62                     ""____________________<@
M                  !I____________________H2@
M  !.____________________TUP                    S____________
M_________Y8N               5,E)W_____________________^!R$P
M 0\?+T)8<(NHR.S________________________*;VY^CIZPP]CO________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________G@TLC NK6PK*BE
MHI^=FYN<H*?__________________X)D5DM#/#8P*R<B'1@3#@D$  #4____
M_____________Y(                       "M_________________\P>
M                      "+__________________M2
M      !M__________________^                       !1________
M__________^I&P                     Z___________________00@
M                   C___________________U:
M   ,____________________CQ0                     ____________
M________N#X                     ____________________Y6T#
M                _____________________Y\W               0+U!T
M_____________________]UR%      &%RI!6G64MMK_________________
M______^\6$149'6&FJ_(X_______________________________TLWA\?__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________/OZ^_W______________________^ZYJ)V6CXJ&@G][>'9T
M<G-U>'^0_________________^M/.C H(1L5$ L' @         C________
M__________]I                        __________________^;"@
M                    ___________________(.0
M    ___________________P8P                      ____________
M________B@X                     ____________________L#0
M                ____________________U5L
M_____________________X4:                   #[/______________
M_____[%)               8.5V!_____________________^5['@
M#"$X4F^/L]G_______________________^[6"DY25IL@)>PS>W_________
M____________________LYZTQ=?K________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________________^N_G
MX=S9UM32T-#0T=/9X.OW__________________^XBGYW<6QH9&%>6UE85U=9
M7F5Q__________________^_,1\6$ H%                ____________
M_______M5@                      Z/__________________@@0
M                S/__________________JR\
ML___________________TE<                     F_______________
M____]WP0                    A?___________________Z(W
M          4KE/___________________\MA @            PL4':>T?__
M__________________6-,       #2,[5W:9ON7_____________________
M___#8Q@J.TQ?=(VGQN?_____________________________J'^6J+O0Y___
M__________________________________W_________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________W<[%O[RY
MMK2SL;*RM;G R=7C____________________EVQD7EE544],2DA'1DA+4%EF
MH?__________________IR8.!P(                 5O______________
M____SE                      .O__________________]'D+
M            (?___________________Y\R                    #O__
M_________________\18                "#%:A/__________________
M_^E_'P          !B=+<9K"Z?____________________^G20     "%R]*
M:(JNU?S________________________3=1XF.$I>=8^KR^______________
M________________KG*%F*S"V_;_________________________________
M_]_O________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________[^RJJ:CH:"?
MGZ&CIJRTP,W=[/___________________XI:4T]+2$9$0T)!0D-'3EEI??__
M_________________YXN!@                   /__________________
M_\-6                   50?___________________^=[&@
M   )-&"+M/____________________^?/P         $)4IQF<+K________
M_______________&9@\    3*D1B@Z?-]?_________________________K
MCC4K/E%H@9V\WO______________________________OG9_E*G!W/G_____
M_____________________________]+8\___________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____]O+P[^_O\?/X_?____________________________BPGYJ7EI:6F)N?
MI*RVPM'A[O____________________Z.4$I'141$1$5&1TM16FB#J?______
M______________^F00$           <V8X^ZX?_____________________&
M90H       0G3'.<Q.S________________________EB"\  !,J1&*"ILST
M____________________________JU V2F%[EK36^O__________________
M____________TH=\F+'+Z?___________________________________]3.
M[?__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M[>7CX^3FZ.WQ^?_____________________________]L922DI69G:.ILKS0
M[?__________________________G5-'24U15F!SBJ_6_/______________
M____________LE8 &C50;8NNTO?_____________________________S6\^
M7WN9M]?Y________________________________[I^#IL+A____________
M_________________________^/.Z_______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________P
M
M
M            ________________________________________________
M____________________________________________________________
M____________________________________________________________
M__\     _^% =&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C
M:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B
M/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T
M:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R
M+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8]
M(FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIP9&9X/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9G@O,2XS
M+R(^"B @(" @(" @(#QP9&9X.D%05$M615(^,3$N,2XP+C(R,3,Y(%!R;R!0
M<F]D=6-T:6]N+3,R/"]P9&9X.D%05$M615(^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\B/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,RTP,RTR,50P
M,#HU,CHR,"TP-#HP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z
M0W)E871O<E1O;VP^5&]O;&MI="!H='1P.B\O=W=W+F%C=&EV97!D9BYC;VT\
M+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P
M,C,M,#,M,C%4,C$Z,3$Z-# K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @
M(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(S+3 S+3(Q5#(Q.C$Q.C0P*S U
M.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O
M(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY4;V]L:VET(&AT=' Z+R]W=W<N
M86-T:79E<&1F+F-O;3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M
M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \
M<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD
M969A=6QT(CYP<FEN=&UG<B!F:6QE/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F9O
M<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*(" @
M(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP34TZ26YS
M=&%N8V5)1#YX;7 N:6ED.C@W0S@W,40W1D5#-T5$,3$X1#0W045$,4%!1#)#
M,S<W/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE
M;G1)1#YX;7 N9&ED.C@U0S@W,40W1D5#-T5$,3$X1#0W045$,4%!1#)#,S<W
M/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/GAM<"YD:60Z.#5#.#<Q1#=&14,W140Q,3A$-#=!140Q04%$
M,D,S-S<\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM
M<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.C@U0S@W,40W1D5#-T5$,3$X1#0W045$,4%!1#)#,S<W/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 S
M+3(Q5#(Q.C$Q.C(V*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.#9#.#<Q1#=&14,W140Q
M,3A$-#=!140Q04%$,D,S-S<\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C,M,#,M,C%4,C$Z,3$Z-# K,#4Z
M,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T
M=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R
M=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP
M87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO
M<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO
M;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A
M<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.C@W0S@W,40W1D5#-T5$,3$X1#0W045$,4%!1#)#,S<W/"]S=$5V=#II;G-T
M86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(S+3 S
M+3(Q5#(Q.C$Q.C0P*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @
M(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E
M9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \
M<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C@V0S@W,40W1D5#-T5$,3$X1#0W
M045$,4%!1#)#,S<W/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \
M<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C@U0S@W,40W1D5#-T5$,3$X1#0W
M045$,4%!1#)#,S<W/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z.#5#.#<Q1#=&14,W
M140Q,3A$-#=!140Q04%$,D,S-S<\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z
M0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @(" @(#QP
M:&]T;W-H;W Z24-#4')O9FEL93Y5+E,N(%=E8B!#;V%T960@*%-73U I('8R
M/"]P:&]T;W-H;W Z24-#4')O9FEL93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M"  @ %X# 1$  A$! Q$!_\0 '0   @$% 0$             " D&  $$!0<*
M O_$ "H0   & @$$ 00# 0$       $" P0%!@<($0 )$B$3%2(Q010642-Q
M_\0 ' $  @(# 0$              @0 !0$#!@<(_\0 -1$  @(! P,"! 0%
M P4      0(#$2$ !!(%,4$&41,B87$'%$*!%2,RL? 7D=$S-%)BH?_:  P#
M 0 "$0,1 #\ ]_'4U-8[LQBMU3$(50Q2\@0P@4IA 0'Q,(_@!XX$?T \AUD5
M8NP+%D=P/?SV^V@<,5(50['LI_4?"_N<'Z$Z'//>?:9@3'$MD.UJ.'** %:0
MD4V;F6E;!8'(G2C(9BV* G4>O7@)H) !#>*9OE,'@'ET<H$0)(Y 8XAKY>0H
M'<W=X]C[:ZCT3Z3ZCZZZK!TC8/'MU(+S[O=%(TVVW0\I]RR2M$A_+A698@P,
MK+Q%$WI!F;,QY3S(\=J;/[0*:K5)^W*Y@\#X@;35KOY(Q<A3IKWT:HJDL@_<
MD$AB)/C'8I N)!0*L4P]4^]CGE*/+N#MT)(7;Q)S9@5P'?)7O>.Q'GQ];>CN
MC=#]()^6].^CMCZY]0;/XC'U7U;KLOI>#DLHC$NT&YFGV<X+*\?PH&8KR$C$
M\10S5?6#6B^6 &FNFZ$JRRZ(@I%0^2Z])4.3D)0Q!. HV0QTGA'K@P ")CE$
M04 /O+[Z47; TVVW3Q2*<6 .1.>S4Q-^1W\@U6O3YOQ(]3^F-J7]4_ASLM_T
MW=C\O-)TGU5%UEMKM6!C/./I>RFF*+$0: %A3;"B01^&NX-LYI%DIAA;<LDQ
M;J*=RVCO[#+G/(V*":N52%).Q$XH=;^VP94_,[CR %&R91,)_+CH(^I[[;[@
M0;J(R D<9.-,5)*AB5  ':[-@$76N ]8?@[^'/XB>E)/6?X7F/IO4U$OYWIQ
MDW,22[\QF>2)TZMO"ZD%N/+;[>) 5 X+?$^EBH66%MU9BK37Y)G,0LY'I2T7
M+,E/F:NV3E,%&[@AA,?[3D.!PY^[GR 0#]= &=B"8PH-6+J@<_Y>?/C7P[O=
MEO\ I^ZGZ=OE:/?02O$\9 /%U)%*4^4@8((8C(-YU,&AQ403.8Y3F,0!$Y0
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M9[9^VJ Q1]@8H@'H>! ??'/'H?\ /?\ YU 0>Q!KO1O4U<! ?P(#^O0\^_\
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MJ'2K&1[(13,QCB=J+-LHD4J?!;3<3P'I,6]C"B69C$S+>+F;CDTQ)X-6"0
MQJB5(]NDD[)(U_"HJI!-V PR10/&_O6,FM0S;O#61ML=O-N\SX+92H97[=%0
MP\XUI&"354C;)>H,KBZWND,R)G0;+/)V*1/55V:1^4U7#80(H<I2"UMMS%M-
MCMH=T@^-O978%ZS')$W!F86 &)44S K7S!>^LLTQGFCB4E(45@!0R2%/>A@6
M>XNB!G7!<Y3V4-_ZQDSN:!5;C3:AJ8CC6-UYK,W'2D6<;)6+-"3F=KN6,?(M
MW3U%BH>3JC1^FT3.9LP5!3DZ"Q2:XIAT]VZ>(U>:</RB;!/);4<KXFP5-<C=
MDUWUKB;<RN6"?(@R>2]@!R))8'MG%^+&F5]Q+-=ZVRJF&M&-7RR$]9]E*M$9
M SU8:X[%DM0->T8YI)2;>1FSH'9UJ<R4LX;5ZO.'[EN8Z"SU<43(E,<J6QVJ
M0-+N-_\ R(5D:%2WS\3RY$U%\0X J@,@FK.FY)EF!@A8'<<0QCR/TFK8TE70
M_J([ Z%32,N=NW1MZZK>8-<RZQZ@[7O(N I4;'9 BLBTS'V9X*,291JK^<AA
M3C:H3($>S(5%"13;INYGS325456(!K3?)TO>;1EV&Z&YW"*95 CF0LH(# _$
MBC%!2?()(Q9QI';1S[=[W%HO)5!8AJ):[PQ.*\XK.11/"L-VW&2E7SCC^R]P
M>QZ0VVO;J;!6IW#UQ%=)_<X&>?-4HMV\*NS<(.8\#(JKM%&HGX%/R5*4GB8[
M)V^]>#:B'8?$";=4+M) I'\R1Z D8FJ<$$4*.!8H!--MQ+(&W!Y&0GB$<@4B
M^0*LU56;UOM?(YE6>XOAC,+/:B^;X8HH^+\C/\@9?OE8L;&D:X-&\69=.3+=
M%&S.FHS5C32%L2-,Z^H+<%*1#DY"F7W[3C9_ FA2"4N$4"2)N5T 1P LGE1J
M^UD5K,2AS&T1^(BGDU@J0%!-D-1P,X\X'UBV<==]P.XJ&6]N:UKC*7-_E!=.
MMZG3L]D&*QC(8 Q[C*Q)VFB9(@H>Q"D]FY"_6!HWEOL,P(O&+N$0<>"B J;-
MF_2-E$D&YW*)N(^1DC6.23XC<2"A>.-E!#4;YBB,F@=;MTLTU20#G$%%."HQ
MB\,RG [X.3VL#1R2<_,;KZ.QN<9@RV)>X1H!]1?V=)PW4;6&M9%QZU%.?AYI
MC]LH[I&3HF.%V)BB9F^1?"X8F72!-0:9DBBWZ9#;7<M\0 *:4,3\M58 Q0 [
M$6<'6Y)';:..[IAKP<5[^1V.>X%#-:,_M780F4\2O=M\P236Z[%;;M8C(.0K
M,9L<C6#AE416KF/JLD]#^3'U2O-E0,W9\)@L]57<J)\_&!%=^T G:.&UC0X(
=!'+_ .7C(_MK; )&16(P5Q=?3O9(L]\=LXSK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239390308784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 15, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CBAY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CYMABAY THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001042074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,293,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3103561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7575 Gateway Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newark<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">293-8800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218,053,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Mateo, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239390388832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 20,291<span></span>
</td>
<td class="nump">$ 125,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">115,194<span></span>
</td>
<td class="nump">60,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,588<span></span>
</td>
<td class="nump">4,564<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">138,073<span></span>
</td>
<td class="nump">191,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">701<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Non-current marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,909<span></span>
</td>
<td class="nump">1,720<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">141,852<span></span>
</td>
<td class="nump">202,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">2,728<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">6,530<span></span>
</td>
<td class="nump">9,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">7,815<span></span>
</td>
<td class="nump">5,886<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">15,441<span></span>
</td>
<td class="nump">18,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_DevelopmentFinancingLiabilityNonCurrent', window );">Development financing liability</a></td>
<td class="nump">90,227<span></span>
</td>
<td class="nump">50,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liability</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">105,698<span></span>
</td>
<td class="nump">69,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value: 200,000,000 shares authorized; 84,681,063 and 84,677,939 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">909,329<span></span>
</td>
<td class="nump">899,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(326)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(872,857)<span></span>
</td>
<td class="num">(766,856)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">36,154<span></span>
</td>
<td class="nump">132,937<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 141,852<span></span>
</td>
<td class="nump">$ 202,318<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_DevelopmentFinancingLiabilityNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_DevelopmentFinancingLiabilityNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239390392816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">84,681,063<span></span>
</td>
<td class="nump">84,677,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">84,681,063<span></span>
</td>
<td class="nump">84,677,939<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239391464688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 67,995<span></span>
</td>
<td class="nump">$ 64,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">25,116<span></span>
</td>
<td class="nump">23,040<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">93,111<span></span>
</td>
<td class="nump">87,582<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(93,111)<span></span>
</td>
<td class="num">(87,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Interest expense, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2,017<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(14,907)<span></span>
</td>
<td class="num">(2,583)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total interest expense, net</a></td>
<td class="num">(12,890)<span></span>
</td>
<td class="num">(2,416)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(106,001)<span></span>
</td>
<td class="num">(89,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(313)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss</a></td>
<td class="num">(313)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (106,314)<span></span>
</td>
<td class="num">$ (90,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share</a></td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share</a></td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding used to calculate basic net loss per common share</a></td>
<td class="nump">87,804,063<span></span>
</td>
<td class="nump">71,055,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding used to calculate diluted net loss per common share</a></td>
<td class="nump">87,804,063<span></span>
</td>
<td class="nump">71,055,331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239391524400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">$ 142,706<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 819,549<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="num">$ (676,858)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,946,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IssuanceOfCommonStockAndPrefundedWarrants', window );">Issuance of common stock and pre-funded warrants, net of issuance costs</a></td>
<td class="nump">70,035<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">70,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares', window );">Issuance of common stock and pre-funded warrants, net of issuance costs Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(89,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized loss on marketable securities</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">132,937<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">899,798<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(766,856)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,677,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (Shares)</a></td>
<td class="nump">3,124<span></span>
</td>
<td class="nump">3,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 9,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants', window );">Issuance costs related to issuance of common stock and pre-funded warrants</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(106,001)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106,001)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized loss on marketable securities</a></td>
<td class="num">(313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2022</a></td>
<td class="nump">$ 36,154<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 909,329<span></span>
</td>
<td class="num">$ (326)<span></span>
</td>
<td class="num">$ (872,857)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,681,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance costs related to issuance of common stock and pre funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_IssuanceOfCommonStockAndPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and pre-funded warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_IssuanceOfCommonStockAndPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and pre-funded warrants shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239392738304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="nump">$ 4,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239387511376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (106,001)<span></span>
</td>
<td class="num">$ (89,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">710<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,517<span></span>
</td>
<td class="nump">9,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write-off of deferred financing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_AccretionOfDevelopmentFinancingLiability', window );">Accretion of development financing liability</a></td>
<td class="nump">14,907<span></span>
</td>
<td class="nump">2,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion and amortization of investments in marketable securities</a></td>
<td class="num">(874)<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,976<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(1,189)<span></span>
</td>
<td class="num">(1,513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,444)<span></span>
</td>
<td class="nump">2,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="num">(3,222)<span></span>
</td>
<td class="nump">5,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="nump">1,540<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) operating activities</a></td>
<td class="num">(84,080)<span></span>
</td>
<td class="num">(69,431)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(174,977)<span></span>
</td>
<td class="num">(78,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable securities</a></td>
<td class="nump">129,140<span></span>
</td>
<td class="nump">126,760<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(45,985)<span></span>
</td>
<td class="nump">48,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock pursuant to equity award plans</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants', window );">Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs</a></td>
<td class="num">(459)<span></span>
</td>
<td class="nump">70,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts', window );">Proceeds from development financing, net of transaction costs</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">47,737<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">24,550<span></span>
</td>
<td class="nump">118,455<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(105,515)<span></span>
</td>
<td class="nump">97,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">125,806<span></span>
</td>
<td class="nump">28,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">20,291<span></span>
</td>
<td class="nump">125,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">686<span></span>
</td>
<td class="nump">666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Unpaid financing costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_AccretionOfDevelopmentFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion of development financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_AccretionOfDevelopmentFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ProceedsFromDevelopmentFinancingNetOfTransactionCosts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and pre-fundeded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239392909280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 5%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Organization and Description of Business </div></div></div></div></td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="font-weight:bold;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">CymaBay Therapeutics, Inc. (the Company or CymaBay) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. The Company&#8217;s lead clinical development candidate is seladelpar. Seladelpar has been primarily under development for the treatment primary biliary cholangitis (PBC), a rare liver disease. The Company was incorporated in Delaware in October 1988 as Transtech Corporation. The Company&#8217;s headquarters and operations are located in Newark, California and it operates<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in </div>one<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> segment.</div></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Liquidity </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred net operating losses and negative cash flows from operations since its inception. During the year ended December&#160;31, 2022, the Company incurred a net loss of $106.0&#160;million and used $84.1&#160;million of cash in operations. At December&#160;31, 2022, the Company had an accumulated deficit of $872.9&#160;million. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, the Company has incurred substantial research and development expenses in the course of studying its product candidates in clinical trials. To date, none of the Company&#8217;s product candidates have been approved for marketing and sale, and the Company has not recorded any revenue from product sales. Generally, the Company&#8217;s ability to achieve profitability is dependent on its ability to successfully develop, acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> additional product candidates, conduct clinical trials for those product candidates, obtain regulatory approvals, and support commercialization activities for those product candidates. Any products developed will require approval of the U.S. Food and Drug Administration (FDA) or a foreign regulatory authority prior to commercial sale. The regulatory approval process is expensive, time-consuming, and uncertain, and any denial or delay of approval could have a material adverse effect on the Company. Even if approved, the Company&#8217;s products may not achieve market acceptance and will face competition from both generic and branded pharmaceutical products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During and subsequent to the year ended December&#160;31, 2022, the Company completed certain transactions as follows: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In January 2022, the Company received the third installment of&#160;</div>$25.0&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million of the Company&#8217;s Development Financing Agreement (the Financing Agreement) with ABW Cyclops SPV LP, an affiliate of Abingworth LLP (Abingworth), pursuant to which Abingworth committed to provide&#160;</div>$75.0&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million in funding in&#160;</div>three <div style="letter-spacing: 0px; top: 0px;;display:inline;">equal quarterly installments. For further details, refer to<div style="font-style:italic;display:inline;"> Note 6&#8212;Development Financing Agreement.&#160;</div></div> </div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On January 6, 2023, the Company entered into a Collaboration and License Agreement with Kaken Pharmaceutical Co., Ltd (Kaken). Pursuant to the agreement, the Company granted Kaken an exclusive license to commercialize seladelpar for the treatment of PBC in Japan and received an upfront cash payment of&#160;</div>$34.2&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million. For further details, refer to <div style="font-style:italic;display:inline;">Note 13&#8212;Subsequent Events.&#160;</div></div> </div></td></tr></table> <div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;;text-indent: 0px;">On January&#160;23, 2023, the Company sold 11,821,428 shares of common stock at $7.00 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">per share and a pre-funded warrant to purchas</div>e 2,142,857 shares of common stock at $6.9999 <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">per share in a public equity offering, for total net proceeds of</div>&#160;</div>$92.4&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">million, after deducting underwriting and other offering expenses. For further details, refer to <div style="font-style:italic;display:inline;">Note 13&#8212;Subsequent Events.&#160;</div></div> </div></td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022, the Company had cash, cash equivalents and marketable securities totaling<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div>135.5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">million. As the Company continues to advance its clinical studies of seladelpar, the Company believes its existing funds, together with the </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div>34.2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million upfront payment received from Kaken in January 2023 pursuant to the Collaboration and License Agreement and the </div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div>92.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million in net proceeds raised in connection with the January 2023 public equity offering, are sufficient to fund the Company&#8217;s current operating plan for at least twelve months from the issuance date of its financial </div></div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">statements. </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">The Company has <div style="display:inline;">historically </div>obtained, and expects to obtain in the future, additional <div style="display:inline;">financing </div>to fund its business strategy through: future equity offerings; debt financing; one or more possible licenses, collaborations or other similar arrangements with respect to development and/or commercialization rights of the Company&#8217;s product candidates; or a combination of the above. It is unclear if or when any such transactions will occur, on satisfactory terms or at all. The Company&#8217;s failure to raise capital as and when needed could have a negative impact on its financial condition and its ability to pursue its business strategies. If adequate funds are not available to the Company, it could have a material adverse effect on the Company&#8217;s business, results of operations, and financial condition. Market volatility could also adversely impact the Company&#8217;s ability to access capital when and as needed. Failure to raise sufficient capital when needed could require the Company to significantly delay, scale back or discontinue its product development programs or commercialization efforts or other aspects of its business plans, and its operating results and financial condition would be adversely </div></div></div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">affected. </div></div></div><br/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239387479296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of Significant Accounting <div style="letter-spacing: 0px; top: 0px;;display:inline;">Policies</div> </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Basis of Presentation and Use of Estimates </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements are comprised of the accounts of CymaBay and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company has no unconsolidated subsidiaries or investments accounted for under the equity method. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These consolidated statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), which requires management to make informed estimates and assumptions that impact the amounts and disclosures reported in the consolidated financial statements and accompanying notes. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting estimates and assumptions are inherently uncertain. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ materially from those estimates and assumptions. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each reporting period and updated to reflect current information. </div></div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial instruments during the periods reported consist of cash, cash equivalents, marketable securities, accounts payable, certain accrued liabilities, and the development financing liability. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs and is as follows: </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2&#8212;Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3&#8212;Inputs that are significant to the fair value measurement and are unobservable (i.e. supported by little market activity), which requires the reporting entity to develop its own valuation techniques and </div></div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assumptions. </div></div></div>   <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of cash equivalents approximate their related fair value due to the short-term nature of these instruments. Cash equivalents are classified as level 1 under the fair value hierarchy. </div></div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> following tables present the Company&#8217;s financial assets that are measured at fair value on a recurring basis using the above input categories (in thousands): </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents:</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities:</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign commercial paper</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">46,121</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">46,121</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign corporate debt securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">24,807</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">24,807</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supranational debt securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">12,890</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">12,890</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. agency securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,759</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,759</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasury securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">23,617</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">23,617</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total marketable securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">115,194</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">115,194</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">115,194</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">124,964</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"/>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities:</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign commercial paper</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">28,760</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">28,760</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign corporate debt securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">23,535</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">23,535</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">8,522</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">8,522</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasury securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,979</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,979</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total marketable securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">68,796</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">68,796</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">68,796</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">154,434</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="padding: 0px;">&#160;</td> </tr> </table>  <div style="clear:both;max-height:0pt;"/> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div> <div style="display: inline; background-color: white;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"> <div style="display: inline;"> <div style="top: 0px; letter-spacing: 0px; font-family: 'Times New Roman'; font-size: 10pt; display: inline;"> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> </div> </div> </div> </div> </div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="margin-top: 1em; margin-bottom: 1em"/> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimates the fair value of its money market funds, corporate debt, asset-backed securities, commercial paper, U.S. treasury and agency securities, and supranational debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s development financing liability is $79.5&#160;million. The development financing liability is classified as level 3 under the fair value hierarchy as its valuation is based on a discounted cash flow model that uses unobservable inputs such as the estimated timing of regulatory approval, attainment of certain sales milestones and the discount </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">rate. </div></div></div>    <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, Cash Equivalents, and Marketable Securities </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking, interest-bearing, and money market funds. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company invests excess cash in marketable securities with high credit ratings. These securities consist primarily of corporate debt, commercial paper, asset-backed securities, U.S. treasury, U.S. agency securities and supranational debt securities and are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;available-for-sale.&#8221;</div></div> The Company considers marketable securities as short-term investments if the maturity date </div>is less than or equal to one year from the balance sheet date. The Company considers marketable securities as long-term investments if the maturity date is in excess of one year from the balance sheet date.<br/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Realized </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">gains</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;and losses from the sale of marketable securities, if any, are calculated using the specific-identification method. Realized gains and losses and declines in value judged to be other-than-temporary are included in interest income or expense in the consolidated statements of operations and comprehensive loss. Unrealized holding gains and losses are reported in accumulated other comprehensive loss in the consolidated balance sheets. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. In determining whether a decline in market value is other-than-temporary, various factors are considered, including the cause, duration of time and severity of the impairment, any adverse changes in the investees&#8217; financial condition, and the Company&#8217;s intent and ability to hold the security for a period of time sufficient to allow for an anticipated recovery in market value.</div></div>  <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Concentration of Risk </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, <div style="letter-spacing: 0px; top: 0px;;display:inline;">and market</div>able securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded on the balance sheet. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the consolidated balance sheets. <div style="background-color:rgba(255, 255, 255, .0);;display:inline;">The Company maintains deposits in excess of FDIC insured deposit limits with its financial institutions. </div></div> <div style="background-color:rgba(255, 255, 255, .0);;display:inline;"> </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an NDA filed with the FDA for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.&#160;</div></div>   <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property </div></div>and equipment are recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method, and the costs are amortized over the estimated useful lives of the respective assets, which are generally <span style="-sec-ix-hidden:hidden71088416">three</span> to seven years. Leasehold improvements are amortized over the shorter of the useful lives or the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> term of the related lease. Maintenance and repair costs are charged as expense in the consolidated statements of operations and comprehensive loss as incurred. </div>   <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Lived Assets </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company reviews the carrying value long-lived assets, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> operating lease assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assets </div></div></div>   <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> may not be fully recoverable. If a change in circumstance occurs, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. If cash flows cannot be separately and independently identified for a single asset, the Company will determine whether impairment has occurred for the group of assets for which the Company can identify the projected cash flows. If the carrying values are in excess of undiscounted expected future cash flows, the Company measures any impairment by comparing the fair value of the asset or asset group to its carrying value. There were no indicators of impairment of long-lived assets for any periods <div style="display:inline;">presented</div>.</div></div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The Company has one lease, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> operating lease agreement for its corporate office. The Company recognizes a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. The Company determines whether an arrangement is or contains a lease at contract inception. Operating leases are included in operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, other accrued liabilities, and long-term portion of operating lease liabilities in the Company&#8217;s consolidated balance sheets at December&#160;31, 2022 and 2021. Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date. The incremental borrowing rate represents the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company considers a lease term to be the noncancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets also include any lease payments made and exclude lease incentives. Lease expense is recognized on a straight-line basis over the expected lease term. The Company has elected to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for its leased assets and accounts for all lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components of its agreements as a single lease component. The Company does not record leases on its consolidated balance sheets when a lease has a term of one year or less. </div></div> <div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Expenses</div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses consist of costs incurred in identifying, developing, and testing product candidates. These expenses consist primarily of costs for research and development personnel, including related stock-based compensation; contract research organizations (CRO) and other third parties that assist in managing, monitoring, and analyzing clinical trials; investigator and site fees; laboratory services; consultants; contract manufacturing services; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies, including materials; and allocated expenses, such as depreciation of assets, and facilities and information technology that support research and development activities. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are recorded as prepaid assets until the goods are received or services are rendered. Such payments are evaluated for current or long-term classification based on when they will be realized. Additionally, if expectations change such that the Company does not expect goods to be delivered or services to be rendered, such prepayments are charged to expense to the extent they are nonrefundable. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records expenses related to clinical studies and manufacturing development activities based on its estimates of the services received and efforts expended pursuant to contracts with multiple CROs and manufacturing vendors that conduct and manage these activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical trial milestones. In expensing service fees, the Company estimates the time period over which services will be performed, enrollment of subjects, number of </div></div></div>   <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company&#8217;s estimate, the Company will adjust the accrued or prepaid expense balance accordingly. In 2022 and 2021, there have been no material differences from the Company&#8217;s estimates to the amounts actually incurred. </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"> </div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Development Financing Agreement </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for the Development Financing Agreement with Abingworth as a debt instrument. Accordingly, the Company has recorded payments received under the Financing Agreement as part of a development financing liability in the Company&#8217;s consolidated balance sheet. The liability is recorded at amortized cost and accreted to the contractual success fee amounts based on the estimated timing of regulatory approval and attainment of certain sales milestones using an imputed interest rate. Certain transaction fees incurred specifically to complete the Financing Agreement were capitalized and recorded as a reduction to the carrying amount of the development financing liability and are being amortized to interest expense using the effective interest rate method. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are several factors that could affect the estimated timing of regulatory approval and attainment of sales milestones, some of which are not entirely within the Company&#8217;s control. Therefore, the Company periodically reassesses the estimated timing of regulatory approval and attainment of sales milestones, and the expected contractual success fee payments due therefrom. If the timing and/or amount of such expected payments is materially different than original estimates, the Company will prospectively adjust the accretion of the development financing liability and the imputed interest rate. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company identified certain contingent repayment features in the Financing Agreement that are required to be bifurcated from the debt host instrument as embedded derivative liabilities; however, the Company determined the fair value of these features, both individually and in the aggregate, was immaterial at inception and as of December&#160;31, 2022. The fair value of these features will be assessed at each reporting date and will be marked to market, if material. To determine the amount to record for the embedded derivative liabilities, the Company must assess the probability of occurrence of various potential <div style="letter-spacing: 0px; top: 0px;;display:inline;">future </div>events that could affect the timing and/or amount of future cash flows related to the Financing Agreement. </div></div></div>   <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded</div> Warrants </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Company&#8217;s public equity offering co<div style="letter-spacing: 0px; top: 0px;;display:inline;">mpleted in </div>November 2021, the Company issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase 3,125,000 shares of common stock at a price of $3.9999 per share. These <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants have an exercise price of $0.0001<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>per share, were fully exercisable upon issuance, and have no expiration date. The Company determined that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants should be equity classified because they are freestanding financial instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. In addition, such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants do not provide any guarantee of value or return. Accordingly, the proceeds from the issuance of the warrants were recorded as additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital on the Company&#8217;s consolidated balance sheet as of December&#160;31, 2022. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 9&#8212;Stockholders&#8217; Equity</div></div> for additional </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">information. </div></div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-Based Compensation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation is measured at fair value on the grant date of the award. Compensation cost is recognized as expense on a straight-line basis over the vesting period for options with service conditions and forfeitures are accounted for as they occur. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock option awards. The determination of fair value for stock-based awards using an option-pricing model requires management to make certain assumptions regarding subjective input variables such as expected term, dividends, volatility and risk-free rate. If actual results are not consistent with the </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/>  <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company&#8217;s assumptions used in making these estimates, the Company may be required to increase or decrease compensation expense, which could be material to the Company&#8217;s results of operations.</div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/></div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <div style="display:inline;">Company </div>utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and the tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when it is more likely than not that all or part of a deferred tax asset will not be realized. When the Company establishes or reduces the valuation allowance related to the deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination based on the technical merits of the position. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to file federal and state income tax returns in the United States. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect that could affect the amount of tax paid to these jurisdictions. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records interest related to income tax reserves, if any, as interest expense, and any penalties would be recorded as other expense in the consolidated statements of operations and comprehensive loss. </div>   <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Comprehensive Loss </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss includes net loss and net unrealized gains and losses on marketable securities, which are presented in a single continuous statement. Other comprehensive (loss) gain is also disclosed in the consolidated balance sheets and statements of stockholders&#8217; equity in accumulated other comprehensive income (loss), and is stated net of related tax effects, if any. <br/></div>  <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss Per Common Share </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per share of common stock is based on the weighted average number of shares of common stock and common stock equivalents outstanding during the period. The weighted-average common shares outstanding as of December 31, 2022 and 2021 includes pre-funded warrants to purchase up to&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">3,125,000<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">shares of common stock that were issued in connection with the November 2021 public offering, as </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">discussed in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note&#160;9&#8212;Stockholders&#8217; Equity</div></div>. Diluted </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> net loss per share of common stock is calculated as the weighted average number of shares of common stock outstanding adjusted to include the assumed exercises of stock options, if dilutive. In all periods presented, the Company&#8217;s outstanding stock options and incentive awards were excluded from the calculation of net loss per share because the effect would be antidilutive. </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/><br/></div>   <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share amounts): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div></div></td>
<td style="vertical-align: bottom; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(106,001</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(89,998</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of:</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock shares outstanding</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">84,679,063</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">70,712,865</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded warrants outstanding</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">3,125,000</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">342,466</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 63%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">87,804,063</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">71,055,331</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1.21</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1.27</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>   <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock options</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">13,930</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">10,791</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Incentive awards</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Total</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">14,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">10,892</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>  <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Issued Accounting Pronouncements </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> Financial Instruments&#8212;Credit Losses (Topic 326): <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Measurement of Credit Losses on Financial Instruments</div></div>, an amendment which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. Accordingly, these financial assets will be presented at the net amount expected to be collected. The amendment also requires that credit losses related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. In November 2019, FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2019-10,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842)</div></div>, which deferred the adoption deadline for smaller reporting companies to fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years. Early adoption is permitted, and entities are required to use a modified retrospective approach, with certain exceptions. The Company intends to adopt this ASU on January&#160;1, 2023 and does not expect a material impact to its consolidated financial statements and related disclosures. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239488488928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Marketable <div style="letter-spacing: 0px; top: 0px;;display:inline;">Securities</div> </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">Marketable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities consist of the following (in&#160;thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/>Cost</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Gains</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Losses</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/>Fair Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Money market funds</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Current marketable securities:</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">U.S. and foreign commercial paper</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">46,121</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">46,121</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">U.S. and foreign corporate debt securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">24,964</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(157</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">24,807</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Supranational debt securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">12,946</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(56</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">12,890</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">U.S. agency securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,782</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">16</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(39</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,759</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">U.S. treasury securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">23,707</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">2</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(92</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">23,617</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Total current marketable securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">115,520</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">18</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(344</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">115,194</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">125,290</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">18</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(344</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">124,964</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/>Cost</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/>Unrealized<br/>Gains</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/>Unrealized<br/>Losses</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/>Fair Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash equivalents</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current marketable securities:</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign commercial paper</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">28,760</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">28,760</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign corporate debt securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">15,476</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">&#8212;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(8</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">15,468</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">8,524</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">1</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(3</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">8,522</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasury securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,982</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">&#8212;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(3</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,979</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current marketable securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">60,742</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">1</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(14</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">60,729</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> marketable securities:</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. corporate debt securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">8,067</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">3</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(2</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">8,068</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total marketable securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">154,447</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">4</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(16</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">154,435</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="text-align: center;;text-indent: 0px;"/> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>  <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s commercial paper and corporate debt securities consist of U.S. and foreign securities from issuers in various sectors, including finance and industry and have similar credit quality and risk characteristics. The Company&#8217;s asset-backed securities are collateralized by credit card receivables and have investment-grade ratings. The Company&#8217;s government securities are issued by the U.S. treasury and certain U.S. government-backed agencies. Supranational debt securities consist of securities issued with funding from various national governments. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no realized gains and losses for the years ended December&#160;31, 2022 and 2021. None<div style="display:inline;">&#160;of our investments have been in a continuous unrealized loss position for more than 12 months as of December 31, 2022 and 2021. The Company may sell certain of its marketable securities prior to their stated maturities for reasons including, but not limited to, managing liquidity, credit risk, duration and asset allocation.&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div>  <div style="display:inline;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table shows the fair value of the Company&#8217;s marketable securities, by contractual maturity, as of December&#160;31, 2022 (in thousands): </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="vertical-align: bottom; width: 7%;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 83%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due less than 1 year</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">115,194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 83%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due between 1 and 2 years</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 83%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total fair value</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">115,194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239488488928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Certain Balance Sheet Items</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Certain Balance Sheet Items </div></div>  <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are recorded at cost and consist of the following (in thousands):</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">2,429</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">2,429</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Office and computer equipment</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">290</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">290</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Purchased software</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">44</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">44</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Furniture and fixtures</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">687</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">539</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt; width: 66%;"><div style="margin-top: 0px; margin-bottom: 0px; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt; width: 11%;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt; width: 11%;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">3,450</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">3,302</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Less: Accumulated depreciation and amortization</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(2,749</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(2,124</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">701</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">1,178</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense for the years ended December&#160;31, 2022 and 2021 was approximately $0.7&#160;million and $0.7&#160;million, respectively, and was recorded straight-line in both research and development expense and general and administrative expense in the consolidated statements of operations and comprehensive loss. All the Company&#8217;s property and equipment is located in the U.S. </div>  <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued liabilities consist of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued compensation</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">5,779</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">3,986</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional fees and other</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">1,372</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">1,333</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of operating lease liability</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">664</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">567</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other accrued liabilities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,815</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">5,886</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239488488928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>In-License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">In-License Agreement</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">In-License</div> Agreement </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Janssen Pharmaceutica NV </div></div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In June&#160;2006, the Company entered into an exclusive worldwide, royalty-bearing license to seladelpar and certain other PPAR<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">d</div> compounds (the PPAR<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">d</div> Products) with Janssen Pharmaceutica NV (Janssen NV), with the right to grant sublicenses to third parties to make, use and sell such PPAR<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">d</div> Products. Under the terms of the agreement, the Company has full control and responsibility over the research, development and registration of any PPAR<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">d</div> Products and is required to use diligent efforts to conduct all such activities. Janssen NV has the sole responsibility for the preparation, filing, prosecution, maintenance of, and defense of the patents with respect to, the PPAR<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">d</div> Products. Under the terms of the agreement Janssen NV is entitled to receive up to an </div>8.0% royalty on net sales of PPAR<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">d</div> Products. No amounts were incurred or accrued for this agreement as of and for the years ended <div style="letter-spacing: 0px; top: 0px;;display:inline;">December&#160;</div>31, 2022 and <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"/> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239392999040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development Financing Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_DisclosureOfDevelopmentFinancingTextBlock', window );">Development Financing Agreement</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Development Financing Agreement </div></div></div></div> <div style="letter-spacing: 0px; font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;30, 2021 (the Effective Date), the Company entered into a Development Financing Agreement (the Financing Agreement) with Abingworth to provide funding to the Company to support its development of seladelpar for the treatment of primary biliary cholangitis (PBC). The Financing Agreement provided the Company up to </div></div>$75.0&#160;<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">million in base funding</div>, of which $25.0&#160;million was provided in August 2021, $25.0&#160;million was provided in November 2021, and $25.0&#160;million was provided in <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">January 2022. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The use of proceeds from the funding is limited to PBC &#8220;Development Program&#8221; costs incurred or paid as defined in the Financing Agreement. In return, the Company will pay to Abingworth:</div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) contingent upon the first to occur of regulatory approval of seladelpar for the treatment of PBC in the U.S., U.K., Germany, Spain, Italy or France (Regulatory Approval), fixed success payments equal to 2.0x of the funding provided, consisting of $10&#160;million payable in 90 days after the Regulatory Approval and thereafter, payments due on the first six anniversaries of the Regulatory Approval in the amounts of $15.0&#160;million, $22.5&#160;million, $22.5&#160;million, $25.0&#160;million, $27.5&#160;million and $27.5&#160;million, respectively and </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) variable success payments equal to 1.1x of the funding provided, consisting of sales milestone payments of (x) $17.5&#160;million and $27.5&#160;million, respectively upon first reaching certain cumulative U.S. product sales thresholds, and (y) $37.5&#160;million upon first reaching a specified U.S. product sales run rate. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Promptly following receipt of Regulatory Approval, the Company is required to execute a note agreement and deliver a promissory note to Abingworth within two business days to convert the fixed and variable success payments into a note payable. At the time that Abingworth receives, collectively, an aggregate of 3.1x of the funding provided (approximately $232.5&#160;million), the Company&#8217;s payment obligations under the Financing Agreement will be fully satisfied. The Company has the option to satisfy its payment obligations to Abingworth upon Regulatory Approval, or a change of control of the Company, by paying an amount equal to the remaining payments payable to Abingworth subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single-digit</div> discount rate. Upon a change of control of the Company, an acceleration payment of 1.35x of the funding provided is payable, net of payments already made to Abingworth and creditable against future payments to Abingworth. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Financing Agreement, the Company granted Abingworth a security interest in all its assets (other than intellectual property not related to seladelpar), provided that the Company is permitted to incur certain indebtedness. The security interest will terminate when the Company has paid Abingworth 2.0x<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>of the funding provided or upon termination of the Financing Agreement. </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Financing Agreement provides for negative, affirmative and additional covenants, which the Company must comply with for the duration of the Financing Agreement term. As of December&#160;31, 2022, the Company was in compliance with all covenants stipulated in the Financing Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In certain instances, upon the termination of the Financing Agreement, the Company will be obligated to pay Abingworth a multiple of the amounts paid to the Company under the Financing Agreement, including specifically: </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) 310% of such amounts in the event that Abingworth terminates the Financing Agreement due to (x)&#160;a Fundamental Breach, as defined in the Financing Agreement, (y)&#160;the bankruptcy of the Company, or (z)&#160;a safety concern resulting from gross negligence on the part of the Company or due to a safety concern that was material on the Effective Date and the material data showing such safety concern was not publicly known, disclosed to Abingworth, or in the diligence room made available to <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Abingworth, </div></div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">(ii) 200% of such amounts in the event the Financing Agreement is terminated due to (x)&#160;Material Breach, as defined in the Financing Agreement, <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by the Company or (y)&#160;the security interests of Abingworth being invalidated or terminated other than as set forth in the Financing Agreement, and </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(iii)</div></div>&#160;100% of such amounts in the event of certain irresolvable disagreements within the executive review committee overseeing the Company&#8217;s development of seladelpar. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if, following certain terminations, the Company continues to develop seladelpar for the treatment of PBC and obtains regulatory approval, it will make the payments to Abingworth as if the Financing Agreement had not been terminated, less any payments made upon termination. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall not be obligated to make any payments to Abingworth under certain instances of technical or regulatory failure of the PBC development program as defined in the Financing Agreement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the arrangement, an executive review committee was established between the Company and Abingworth to discuss the Company&#8217;s development of seladelpar.<br/></div><div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><br/></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated the Financing Agreement and determined it to be a research and development funding arrangement with the characteristics of a debt instrument as the transfer of financial risk to Abingworth was not considered substantive and genuine. Accordingly, the Company has recorded payments received under the Financing Agreement as part of a development financing liability in its consolidated balance sheets. The Company accounts for the overall development financing liability at amortized cost based on the estimated timing of regulatory approval and attainment of certain sales milestones and the contractual success fee payments expected to be due therefrom, as discounted using an imputed interest rate. The development financing liability is being accreted as interest expense to its expected future repayment amount over the expected life of the agreement using the effective interest rate method. Certain legal and financial advisory fees incurred specifically to complete the Financing Agreement were capitalized and recorded as a reduction to the carrying amount of the development financing liability and are also being amortized to interest expense using the effective interest method. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are several factors that could affect the estimated timing of regulatory approval and attainment of sales milestones, some of which are not entirely within the Company&#8217;s control. Therefore, the Company periodically reassesses the estimated timing of regulatory approval and attainment of sales milestones, and the expected contractual success fee payments due therefrom. If the timing and/or amount of such expected payments is materially different than original estimates, the Company will prospectively adjust the accretion of the development financing liability and the imputed interest rate. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company identified certain contingent repayment features in the agreement that are required to be bifurcated from the debt host instrument as embedded derivative liabilities; however, the fair value of these features was immaterial at the Effective Date and as of December&#160;31, 2022 and 2021. The fair value of the embedded derivative liabilities will be assessed at subsequent reporting dates if material. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of the changes in the carrying value of the Company&#8217;s development financing liability (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 88%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="vertical-align: bottom; width: 6%;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Balance at December 31, 2021</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">50,320</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Cash received</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">25,000</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Accretion of development financing liability</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">14,907</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 85%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Balance at December 31, 2022</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">90,227</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 85%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>  <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"/> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, the development financing liability was classified as a long-term liability as the Company expects the related repayments to take place between 2024 and 2030 for purposes of the <div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">model used to </div></div></div>   <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin-left: 0in;"/><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin-left: 0in;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">calc</div></div>ulate its carrying value. The imputed interest rate on the unamortized portion <div style="letter-spacing: 0px; top: 0px;;display:inline;">of </div>the development financing liability was approximately 19.2% as of December&#160;31, 2022.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_DisclosureOfDevelopmentFinancingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of development financing text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_DisclosureOfDevelopmentFinancingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239489400560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Leases </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has one operating lease pertaining to 17,698 square feet of corporate office space in Newark, California pursuant to a lease agreement that commenced January 16, 2014 and was amended on April&#160;16, 2018. At December&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s lease portfolio had a weighted average remaining term of 1.1 years, and 2.1 years, respectively, with an option to extend for an additional 5 years. The lease requires monthly lease payments that are subject to annual increases throughout the lease term. The optional period has not been considered in the determination of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets or lease liabilities associated with this lease as the Company did not consider it reasonably certain it would exercise the option. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company cannot determine the implicit rate in its lease, and therefore the Company uses its incremental borrowing rate of 12.6% as the <span style="-sec-ix-hidden:hidden71088836">discount</span> <span style="-sec-ix-hidden:hidden71088837">rate</span> when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a particular currency environment. The Company used an incremental borrowing rate as of the date of adoption for leases that commenced prior to January&#160;1, 2019. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&#160;31, 2022 and 2021, the Company incurred $0.7&#160;million and $0.6&#160;million, respectively,&#160;of lease costs included in operating expenses in the consolidated statements of operations and comprehensive loss in relation to its operating lease, a portion of which was variable rent expense and not included within the measurement of the Company&#8217;s operating ROU assets and lease liabilities. The variable rent expense consists primarily of the Company&#8217;s proportionate share of operating expenses, property taxes, and insurance and is classified as lease expense due to the Company&#8217;s election to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. Short-term lease costs were not material. At December&#160;31, 2022 and December&#160;31, 2021, the Company&#8217;s operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset totaled $0.2&#160;million and $0.3&#160;million, respectively, and the operating lease liability totaled $0.7&#160;million and $1.3&#160;million, respectively. As of December&#160;31, 2022, the short-term portion of the operating lease liability was 0.7&#160;million and is contained within other accrued liabilities on the balance sheet, with an immaterial amount reported on the balance sheet as the long-term portion of operating lease liability. <br/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/><br/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 92%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 89%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Year ending December&#160;31,</div></td>
<td style="vertical-align: bottom; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">2023</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align:bottom;text-align:right;">707</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">2024</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 89%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 89%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total undiscounted future minimum lease payments</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">737</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 89%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 89%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 89%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease liability</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 89%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current portion of operating lease liability</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">664</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 89%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 89%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term portion of lease liability</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 89%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239485529072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Commitments and Contingencies </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Indemnification </div></div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification, including indemnification associated </div></div></div>   <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">with product liability or infringement of intellectual property rights. The Company&#8217;s exposure under these agreements is unknown because it involves future claims that may be made against the Company that may be, but have not yet been, made. To date, the Company has not paid any claims or been required to defend any action related to these indemnification obligations, and no amounts have been accrued in the accompanying consolidated balance sheets related to these indemnification obligations. </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has agreed to indemnify its officers and directors for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments the Company could be required to make under this indemnification is unlimited; however, the Company maintains insurance policies that may limit its exposure and may enable it to recover a portion of any future amounts paid. Assuming <div style="letter-spacing: 0px; top: 0px;;display:inline;">the</div> applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits, and other policy provisions, the Company believes the fair value of these indemnification obligations is not material. Accordingly, the Company has not recognized any liabilities relating to these obligations as of December&#160;31, 2022 and 2021. No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case the Company may incur substantial liabilities as a result of these indemnification obligations. </div> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Genfit Litigation </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 15, 2021, Genfit S.A. (Genfit) filed a complaint against the Company in the U.S. District Court for the Northern District of California, alleging misappropriation of trade secrets and related causes of action based on the Company&#8217;s receipt of a Genfit protocol synopsis for Genfit&#8217;s Phase 3 clinical trial of its drug candidate elafibranor in patients with primary biliary cholangitis. An Amended Complaint was filed on April 16, 2021 with substantially the same allegations. Genfit <div style="letter-spacing: 0px; top: 0px;;display:inline;">was </div>seek<div style="letter-spacing: 0px; top: 0px;;display:inline;">ing</div> damages in an unspecified amount as well as injunctive relief. On March 12, 2021, the Court granted a Temporary Restraining Order (later converted to a Preliminary Injunction), prohibiting the Company from accessing or disseminating the protocol synopsis, using any Genfit trade secrets contained therein or destroying any evidence related thereto. The Company filed a Motion to Dismiss the Amended Complaint that was granted on September&#160;9, 2021, with leave to amend. Genfit filed a Second Amended Complaint on October&#160;15, 2021 with substantially the same allegations and claims for relief as in the original complaint. The Company filed a Motion to Dismiss most of the Second Amended Complaint that was granted on January&#160;21, 2022, without further leave to amend. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">What remained in the complaint was an alleged misappropriation of the protocol synopsis as a whole. The Company filed its Answer to what remained of the Second Amended Complaint on February&#160;4, 2022</div></div>.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>On February 21, 2023, the parties entered into a Settlement Agreement and the action was dismissed with prejudice. The Company did not admit to any liability and the litigation has been resolved completely.</div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239485529072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div>. Stockholders&#8217; Equity </div></div> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preferred and Common Stock Authorized </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue 10,000,000 shares of preferred stock as of December&#160;31, 2022 and 2021, and 200,000,000 shares of common stock as of December&#160;31, 2022 and 2021.</div>    <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Common Stock Reserved for Future Issuance </div></div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022 and 2021, the Company had reserved shares of common stock for future issuances as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded</div> warrants to purchase common stock</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3,125,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3,125,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Equity award plans:</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options and incentive awards outstanding, all equity plans</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">14,031,377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">10,892,613</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Equity awards available for future grant - 2013 Plan</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2,680,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1,588,613</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Equity awards available for future grant - 2020 Plan</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total shares of common stock reserved for future issuance</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">19,836,998</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">15,606,226</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sale of Common Stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded</div> Warrants &#160;&#160;&#160;&#160; </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">In November 2021, pursuant to a shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3,</div> the Company completed the sale of common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants pursuant to an underwritten public equity offering. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchas</div>e 3,125,000 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">shares of common stock were issued at a price of </div></div>$3.9999 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">per share, have an exercise price of </div></div>$0.0001 <div style="letter-spacing: 0px; top: 0px;;display:inline;">per share, were fully exercisable upon issuance, and have no expiration date. The Company determined that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants should be equity classified because they are freestanding financial instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. In addition, such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants do not provide any guarantee of value or return. Accordingly, the proceeds from the issuance of the warrants were recorded as additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital on the Company&#8217;s consolidated balance sheet as of December&#160;31, 2022. None of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants have been exercised, and therefore they remain outstanding as of December&#160;31, 2022. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;23, 2023, the Company issue</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">d 11,821,428 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">shares of its common stock at </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">$7.00 </div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">per share in an underwritten public offering. The Company also issued a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrant to purchase up to an aggregate o</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">f 2,142,857 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">shares of common stock at a purchase price o</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">f $6.9999 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per share and has an exercise price of </div>$0.0001</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;per share. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 13&#8212;Subsequent Events</div></div> for further information. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239396657360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans and Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Plans and Stock-Based Compensation</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10. Stock Plans and Stock-Based Compensation </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Plans </div></div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2013, the Company&#8217;s stockholders approved the 2013 Equity Incentive Plan (the 2013 Plan), under which shares of common stock are reserved for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other stock awards by the Company. These awards may be granted to employees, members of the Board of Directors, and consultants. The 2013 Plan has a term of ten years and <div style="letter-spacing: 0px; top: 0px;;display:inline;">replaced </div>the 2003 Equity Incentive Plan, which had similar terms. The 2013 Plan permits the Company to (i)&#160;grant incentive stock options to directors and employees at not less than 100% of the fair value of common stock on the date of grant; (ii)&#160;grant nonqualified options to employees, directors, and consultants at not less than 85% of fair value; (iii)&#160;award stock bonuses; and (iv)&#160;grant rights to acquire restricted stock at not less than 85% of fair value. Options generally vest over a four-year period and have a term of ten years. Options granted to <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10% </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div>   <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;">stockholders have a maximum term of five years and require an exercise price equal to at least 110<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the fair value on the date of grant. The exercise price of all options granted to date has been at least equal to the fair value of common stock on the date of grant. Stock option exercises are settled with shares reserved under the 2013 Plan. The share reserve under the 2013 Plan will automatically increase on </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">January&#160;1<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">st</div> o</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">f each year, for a period of not more </div></div>than ten years, in an amount equal to 5% <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the total number of shares of capital stock outstanding on December&#160;31<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">st</div> of the preceding calendar year, unless the Board determines otherwise prior to December&#160;31<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">st</div> of such calendar year. </div></div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2020, the Company&#8217;s board of directors approved the 2020 New Hire Plan (the 2020 Plan), under which shares of common stock are reserved for the granting of nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other stock awards by the Company as an inducement to prospective new hire employees of the Company. The 2020 Plan has a term of ten years. The 2020 Plan permits the Company to (i)&#160;grant nonqualified options to new hire employees at not less than 85<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of fair value; (ii)&#160;award stock bonuses; and (iii)&#160;grant rights to acquire restricted stock at not less than 85% of fair value. Options generally vest over a four-year period and have a term of ten years. The share reserve under the 2020 Plan may be increased at the discretion of and approval by the board of directors.</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Plan Activity </div></div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, there were 2,680,621 and no shares available for grant under the 2013 and 2020 Plans, respectively. On January&#160;1, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>, in accordance with the annual share increase provision in the 2013 Plan, the Company added 4,234,053 shares to the 2013 Plan share reserve. </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes activity in the Company&#8217;s stock option grants: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">&#160;</div></div></div><div style="background-color:#ffffff;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/>Subject to<br/>Outstanding<br/>Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Exercise<br/>Price of<br/>Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value (in<br/>thousands)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December 31, 2021</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,791,431</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">6.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 51%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options granted</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,692,868</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.94</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercised</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3,124</td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.94</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options forfeited</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(403,210</td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options expired</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(147,770</td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">5.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December 31, 2022</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,930,195</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">5.26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">26,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested and expected to vest as of December&#160;31, 2022</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,930,195</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">5.26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">26,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable as of December&#160;31, 2022</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,004,373</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">6.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">13,858</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"/> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>  <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total </div></div>intrinsic value of options exercised was immaterial and $0.2&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total fair value of options vested was $0.6&#160;million and $0.7&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2022, unamortized stock-based compensation expense of $14.7&#160;million is expected to be recognized over a weighted average period of 2.4 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">years. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div>   <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"/> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Incentive Awards </div></div></div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2013,&#160;January 2014, and April 2014, as permitted by the 2013 Plan, the Company issued certain incentive awards to directors, employees and a consultant which are subject to 252,752 shares of the Company&#8217;s common stock and are exercisable at a weighted average price of $5.21 <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per share when vested. The Company may determine at its option whether to settle exercised awards in shares of common stock or in cash. The incentive awards were fully vested as of December&#160;31, 2022 and 2021 and have a term of 10 years.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Incentive awards outstanding totaled 101,182 as of December&#160;31, 2022 and 2021. </div></div><br/></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><br/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation Expense </div></div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense is included in the consolidated statements of operations and comprehensive loss and is as follows (in </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">thousands): </div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">4,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">4,470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">5,243</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">5,526</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">9,517</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">9,996</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="clear:both;max-height:0pt;"/><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Valuation Assumptions </div></div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the weighted-average assumptions the Company used in the Black-Scholes option-pricing model to derive the grant date fair values of stock options granted in each of the years <div style="display:inline;">presented </div>along with the resulting estimated weighted-average grant date fair values per share: </div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (years)</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">104</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Weighted-average grant date fair value per share</div></td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">2.33</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3.91</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Term </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company does not believe it can currently place reliance on its historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term due to the lack of sufficient prior exercise data available. Therefore, for stock option grants made during the years ended December&#160;31, 2022 and 2021, the Company has elected to use the simplified method for estimating the expected term, which is an</div></div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">average of the contractual term of the options and its ordinary vesting period. The Company will reevaluate this methodology at a point in time when sufficient exercise data becomes available. The expected term represents the period of time that options are expected to be outstanding.</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Volatility </div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimates expected volatility by measuring the historical volatility of its common stock price over a historical period commensurate with the expected term of the related award. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;">Risk-Free Interest Rate</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk-free interest rate assumption was based on U.S. treasury instruments with constant maturities whose term was consistent with the expected term of stock options granted by the Company. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected Dividend Yield </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The Company has never declared or paid cash dividends and does not plan to pay cash dividends <div style="letter-spacing: 0px; top: 0px;;display:inline;">in </div>the foreseeable future. Consequently, the Company uses an expected dividend yield of zero.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239392972416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">401(k) Plan</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11. 401(k) Plan </div></div></div></div><div style="null;text-indent: 0px;;font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company provides a qualified 401(k) savings plan for its employees. All employees are eligible to participate, provided they meet the requirements of the plan. As is permitted under the plan, the Company has elected to match employee contributions up to $750 and accordingly matching contributions totaling an insignificant amount were made in the years ended December&#160;31, 2022 and 2021.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239394844368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12. Income Taxes&#160;</div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No provision for U.S. income taxes exists due to tax losses incurred in all periods presented. All losses incurred were U.S. based. <div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 32.6667px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">Significant</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">components of the Company&#8217;s <div style="display:inline;">deferred </div>tax assets are as follows (in thousands): </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Federal and state net operating loss carryforwards</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87,681</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129,898</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap; width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">State and federal research and development tax credit carryforwards</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Intangibles and capitalized research and development</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">16,912</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">5,670</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Stock-based compensation</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">6,624</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">5,329</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Other</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,574</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,222</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Total deferred tax assets</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">144,807</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">174,070</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Deferred tax liabilities:</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Depreciation and amortization</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(79</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(158</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Other</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(36</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(53</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Total deferred tax liabilities</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(115</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(211</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Valuation allowance</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(144,692</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(173,859</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Net deferred tax assets</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 69%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="clear:both;max-height:0pt;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">Realization of the net deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which is uncertain. Based on the weight of available positive and negative objective evidence, management believes it more likely than not that the Company&#8217;s deferred tax assets are not realizable. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance decreased by $</div></div>29.2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million primarily due primarily to a $</div></div><div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">38.4</div><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million write-off of tax attributes pursuant to certain Section 382 limitations and to a lesser extent the utilization of net operating losses during the year ended December 31, 2022, These valuation allowance reductions were offset in part by valuation allowance increases to cover additions to the Company&#8217;s capitalized research and development and other deferred tax assets during the year ended December 31, 2022. The valuation allowance increased by $</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">14.7<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;million primarily due to an increase in the Company&#8217;s taxable loss during the year ended </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2021. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a reconciliation of the expected statutory federal income tax provision to the actual income tax provision (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Income tax benefit at federal statutory tax rate</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22,260</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,900</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Change in valuation allowance</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,165</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Impairment of tax attributes</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,398</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Research credits</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,640</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,802</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Cancelled options</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Development financing liability</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,654</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Permanent differences</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">429</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">State income taxes, net of federal benefit</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,806</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(267</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Other, net</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Income tax (benefit) expense</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-block: 0em;">&#160;</div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Internal Revenue Code (IRC) Sections&#160;382 and 383 and similar state laws, use of the Company&#8217;s U.S. federal and state net operating loss and research and credit carryforwards may be limited in the<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">event</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of a cumulative change in ownership of more than&#160;50% within a&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;">three</div>-year</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;period. In 2022, the Company completed an ownership change analysis and determined that its net operating losses and research and development credits were subject to limitations due to historical changes in ownership that occurred through December&#160;31, 2022. Accordingly, the net operating loss carryforwards reflected in the deferred tax assets at December&#160;31, 2022 have been reduced to reflect Section&#160;382 limitations resulting from these changes. As the Company is expected to incur additional losses in the future, any future ownership changes that might occur could further restrict the Company&#8217;s ability to utilize its net operating loss and research and development carryforwards. </div></div></div> <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;31, 2022, the Company had federal net operating loss carryforwards of $</div>346.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million and state net operating loss carryforwards of $</div>214.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million to offset future taxable income, if any. In addition, the Company had federal research and development tax credit carryforwards of $</div>4.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, federal orphan drug tax credit carryforwards of $</div>28.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, and state research and development tax credit carryforwards of $</div>9.2<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. If not utilized, the federal net operating losses for the years beginning before January&#160;1, 2018 of $</div>79.1<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million will expire beginning in </div>2024<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> through </div>2037<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, and the federal net operating losses for the tax years beginning after January&#160;1, 2018 of $</div>266.9<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million will be carried forward indefinitely (subject to certain utilization limitations).</div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>The state net operating loss carryforwards will expire beginning in 2028 through 2040. The federal research and development and federal orphan drug tax credit carryforwards expire 2033 through 2042, and the state tax credit will carry forward indefinitely. The following table summarizes activity related to the Company&#8217;s gross unrecognized tax benefits (in&#160;thousands):</div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 89%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 86%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Balances as of December 31, 2020</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Increases related to prior year tax positions</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Increases related to 2021 tax positions</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">783</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Balances as of December 31, 2021</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,997</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Decreases related to prior year tax positions</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,223</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Increases related to 2022 tax positions</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">730</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Balances as of December 31, 2022</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,504</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div>  <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The unrecognized tax benefits, if recognized, would not have an impact on the Company&#8217;s effective tax rate assuming the Company continues to maintain a full valuation allowance position. Based on prior year&#8217;s operations and experience, the Company does&#160;</div>not<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;expect a significant change to its </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unrecognized tax benefits </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">over the next twelve months. The unrecognized tax benefits may increase or change in the future for unexpected or unusual items for items that may arise in the ordinary course of business.&#160;</div> </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The Company&#8217;s major income tax filing jurisdictions are the U.S. federal&#160;and California state and is not currently under examination by federal, state, or local taxing authorities for any open tax years. Due to net operating loss carryforwards</div></div>, the tax years 2004 to 2022 remain open for income tax examination by tax authorities in the U.S. and states in which the Company files tax <div style="letter-spacing: 0px; top: 0px;;display:inline;">returns. Interest and penalties for the years ended December 31, 2022 and 2021 were not material.&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">In August 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law. The IRA provides several tax incentives, including the expanded Internal Revenue Code (IRC) Section&#160;179D deduction, increased ability to leverage the R&amp;D credit to offset payroll taxes for eligible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">start-up</div> businesses, and 15% alternative minimum tax (AMT) for corporations with average income of more than $1<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;billion for the past three tax periods. The IRA did not have a material impact on the Company&#8217;s consolidated financial statements; however, the Company continues to examine the impacts the above-mentioned tax legislations may have on its business, results of operations, financial condition and liquidity.&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"/></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239395729632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13. Subsequent Events </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Collaboration and License Agreement with Kaken Pharmaceutical Co., Ltd. </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January&#160;2023, the Company entered into a Collaboration and License Agreement (the License Agreement) with Kaken Pharmaceutical Co., Ltd. (Kaken). Pursuant to the License Agreement, the Company granted Kaken an exclusive license to commercialize seladelpar (the&#160;Licensed Product) for the treatment of PBC in Japan. </div></div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kaken will bear the cost of, and be responsible for, conducting clinical studies and other developmental activities, preparing and filing applications for regulatory approval and commercializing seladelpar in Japan. The Company is generally obligated to supply seladelpar to Kaken for use in Japan, at a supply price per unit as defined in the agreement. </div></div><br/></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">In consideration of the license and other rights granted by the Company, Kaken made an upfront cash payment to the Company of $</div></div></div>34.2<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million in January 2023 and is obligated to make potential milestone payments to the Company totaling up to &#165;</div>17.0<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#160;billion (approximately $</div>128.0<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;million using exchange rates in effect at the contract inception date) contingent upon Kaken&#8217;s achievement of certain regulatory and sales milestones as defined in the agreement.&#160;</div><div style="letter-spacing: 0px; top: 0px; text-indent: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sale of Common Stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded</div> Warrant </div></div></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&#160;23, 2023, pursuant to a shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">S-3,</div> the Company <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">sold</div> 11,821,428&#160;of its common <div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">shares</div> at $7.00 <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">per share in an underwritten public<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">equity&#160;</div>offering&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">and a</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrant to purchase&#160;</div>2,142,857 <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">shares of common stock at a purchase price of </div></div>$6.9999 <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per share, which represents the per share public offering price for the common stock less the </div></div>$0.0001 <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">per share exercise price of the pre-funded warrant. The Company received net proceeds</div></div>&#160;<div style="letter-spacing: 0px; top: 0px;;display:inline;">of</div> $92.4&#160;<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">million from this public equity offering after deducting underwriting and other offering expenses. </div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239391545680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Use of Estimates</a></td>
<td class="text"> <div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Basis of Presentation and Use of Estimates </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial statements are comprised of the accounts of CymaBay and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company has no unconsolidated subsidiaries or investments accounted for under the equity method. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These consolidated statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), which requires management to make informed estimates and assumptions that impact the amounts and disclosures reported in the consolidated financial statements and accompanying notes. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting estimates and assumptions are inherently uncertain. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ materially from those estimates and assumptions. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each reporting period and updated to reflect current information. </div></div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial instruments during the periods reported consist of cash, cash equivalents, marketable securities, accounts payable, certain accrued liabilities, and the development financing liability. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs and is as follows: </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1&#8212;Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2&#8212;Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3&#8212;Inputs that are significant to the fair value measurement and are unobservable (i.e. supported by little market activity), which requires the reporting entity to develop its own valuation techniques and </div></div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assumptions. </div></div></div>   <div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The carrying amounts of cash equivalents approximate their related fair value due to the short-term nature of these instruments. Cash equivalents are classified as level 1 under the fair value hierarchy. </div></div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> following tables present the Company&#8217;s financial assets that are measured at fair value on a recurring basis using the above input categories (in thousands): </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents:</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities:</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign commercial paper</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">46,121</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">46,121</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign corporate debt securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">24,807</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">24,807</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supranational debt securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">12,890</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">12,890</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. agency securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,759</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,759</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasury securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">23,617</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">23,617</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total marketable securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">115,194</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">115,194</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">115,194</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">124,964</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"/>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities:</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign commercial paper</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">28,760</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">28,760</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign corporate debt securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">23,535</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">23,535</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">8,522</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">8,522</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasury securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,979</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,979</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total marketable securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">68,796</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">68,796</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">68,796</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">154,434</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="padding: 0px;">&#160;</td> </tr> </table>  <div style="clear:both;max-height:0pt;"/> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div> <div style="display: inline; background-color: white;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"> <div style="display: inline;"> <div style="top: 0px; letter-spacing: 0px; font-family: 'Times New Roman'; font-size: 10pt; display: inline;"> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> </div> </div> </div> </div> </div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="margin-top: 1em; margin-bottom: 1em"/> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimates the fair value of its money market funds, corporate debt, asset-backed securities, commercial paper, U.S. treasury and agency securities, and supranational debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s development financing liability is $79.5&#160;million. The development financing liability is classified as level 3 under the fair value hierarchy as its valuation is based on a discounted cash flow model that uses unobservable inputs such as the estimated timing of regulatory approval, attainment of certain sales milestones and the discount </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">rate. </div></div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_CashEquivalentsAndInvestmentsPolicyTextBlock', window );">Cash, Cash Equivalents, and Marketable Securities</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, Cash Equivalents, and Marketable Securities </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking, interest-bearing, and money market funds. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company invests excess cash in marketable securities with high credit ratings. These securities consist primarily of corporate debt, commercial paper, asset-backed securities, U.S. treasury, U.S. agency securities and supranational debt securities and are classified as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;available-for-sale.&#8221;</div></div> The Company considers marketable securities as short-term investments if the maturity date </div>is less than or equal to one year from the balance sheet date. The Company considers marketable securities as long-term investments if the maturity date is in excess of one year from the balance sheet date.<br/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Realized </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">gains</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;and losses from the sale of marketable securities, if any, are calculated using the specific-identification method. Realized gains and losses and declines in value judged to be other-than-temporary are included in interest income or expense in the consolidated statements of operations and comprehensive loss. Unrealized holding gains and losses are reported in accumulated other comprehensive loss in the consolidated balance sheets. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. In determining whether a decline in market value is other-than-temporary, various factors are considered, including the cause, duration of time and severity of the impairment, any adverse changes in the investees&#8217; financial condition, and the Company&#8217;s intent and ability to hold the security for a period of time sufficient to allow for an anticipated recovery in market value.</div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;;text-indent: 0px;"><div style="font-weight:bold;display:inline;">Concentration of Risk </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, <div style="letter-spacing: 0px; top: 0px;;display:inline;">and market</div>able securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded on the balance sheet. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the consolidated balance sheets. <div style="background-color:rgba(255, 255, 255, .0);;display:inline;">The Company maintains deposits in excess of FDIC insured deposit limits with its financial institutions. </div></div> <div style="background-color:rgba(255, 255, 255, .0);;display:inline;"> </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an NDA filed with the FDA for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.&#160;</div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property </div></div>and equipment are recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method, and the costs are amortized over the estimated useful lives of the respective assets, which are generally <span style="-sec-ix-hidden:hidden71088416">three</span> to seven years. Leasehold improvements are amortized over the shorter of the useful lives or the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> term of the related lease. Maintenance and repair costs are charged as expense in the consolidated statements of operations and comprehensive loss as incurred. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Lived Assets </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company reviews the carrying value long-lived assets, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> operating lease assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assets </div></div></div>    <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> may not be fully recoverable. If a change in circumstance occurs, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. If cash flows cannot be separately and independently identified for a single asset, the Company will determine whether impairment has occurred for the group of assets for which the Company can identify the projected cash flows. If the carrying values are in excess of undiscounted expected future cash flows, the Company measures any impairment by comparing the fair value of the asset or asset group to its carrying value. There were no indicators of impairment of long-lived assets for any periods <div style="display:inline;">presented</div>.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">The Company has one lease, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cancelable</div> operating lease agreement for its corporate office. The Company recognizes a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. The Company determines whether an arrangement is or contains a lease at contract inception. Operating leases are included in operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, other accrued liabilities, and long-term portion of operating lease liabilities in the Company&#8217;s consolidated balance sheets at December&#160;31, 2022 and 2021. Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date. The incremental borrowing rate represents the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company considers a lease term to be the noncancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets also include any lease payments made and exclude lease incentives. Lease expense is recognized on a straight-line basis over the expected lease term. The Company has elected to not separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for its leased assets and accounts for all lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components of its agreements as a single lease component. The Company does not record leases on its consolidated balance sheets when a lease has a term of one year or less. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Expenses</div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses consist of costs incurred in identifying, developing, and testing product candidates. These expenses consist primarily of costs for research and development personnel, including related stock-based compensation; contract research organizations (CRO) and other third parties that assist in managing, monitoring, and analyzing clinical trials; investigator and site fees; laboratory services; consultants; contract manufacturing services; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies, including materials; and allocated expenses, such as depreciation of assets, and facilities and information technology that support research and development activities. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are recorded as prepaid assets until the goods are received or services are rendered. Such payments are evaluated for current or long-term classification based on when they will be realized. Additionally, if expectations change such that the Company does not expect goods to be delivered or services to be rendered, such prepayments are charged to expense to the extent they are nonrefundable. </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records expenses related to clinical studies and manufacturing development activities based on its estimates of the services received and efforts expended pursuant to contracts with multiple CROs and manufacturing vendors that conduct and manage these activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to the Company&#8217;s vendors will exceed the level of services provided and result in a prepayment. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical trial milestones. In expensing service fees, the Company estimates the time period over which services will be performed, enrollment of subjects, number of </div></div></div>    <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company&#8217;s estimate, the Company will adjust the accrued or prepaid expense balance accordingly. In 2022 and 2021, there have been no material differences from the Company&#8217;s estimates to the amounts actually incurred. </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_DevelopmentFinancingAgreementPolicyTextBlock', window );">Development Financing Agreement</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Development Financing Agreement </div></div></div></div> <div style="font-weight:bold;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for the Development Financing Agreement with Abingworth as a debt instrument. Accordingly, the Company has recorded payments received under the Financing Agreement as part of a development financing liability in the Company&#8217;s consolidated balance sheet. The liability is recorded at amortized cost and accreted to the contractual success fee amounts based on the estimated timing of regulatory approval and attainment of certain sales milestones using an imputed interest rate. Certain transaction fees incurred specifically to complete the Financing Agreement were capitalized and recorded as a reduction to the carrying amount of the development financing liability and are being amortized to interest expense using the effective interest rate method. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are several factors that could affect the estimated timing of regulatory approval and attainment of sales milestones, some of which are not entirely within the Company&#8217;s control. Therefore, the Company periodically reassesses the estimated timing of regulatory approval and attainment of sales milestones, and the expected contractual success fee payments due therefrom. If the timing and/or amount of such expected payments is materially different than original estimates, the Company will prospectively adjust the accretion of the development financing liability and the imputed interest rate. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company identified certain contingent repayment features in the Financing Agreement that are required to be bifurcated from the debt host instrument as embedded derivative liabilities; however, the Company determined the fair value of these features, both individually and in the aggregate, was immaterial at inception and as of December&#160;31, 2022. The fair value of these features will be assessed at each reporting date and will be marked to market, if material. To determine the amount to record for the embedded derivative liabilities, the Company must assess the probability of occurrence of various potential <div style="letter-spacing: 0px; top: 0px;;display:inline;">future </div>events that could affect the timing and/or amount of future cash flows related to the Financing Agreement. </div></div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_PrefundedWarrantsPolicyTextBlock', window );">Pre-funded&#160;Warrants</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded</div> Warrants </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Company&#8217;s public equity offering co<div style="letter-spacing: 0px; top: 0px;;display:inline;">mpleted in </div>November 2021, the Company issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants to purchase 3,125,000 shares of common stock at a price of $3.9999 per share. These <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants have an exercise price of $0.0001<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>per share, were fully exercisable upon issuance, and have no expiration date. The Company determined that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants should be equity classified because they are freestanding financial instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Company&#8217;s common stock and meet the equity classification criteria. In addition, such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-funded</div> warrants do not provide any guarantee of value or return. Accordingly, the proceeds from the issuance of the warrants were recorded as additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital on the Company&#8217;s consolidated balance sheet as of December&#160;31, 2022. Refer to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note 9&#8212;Stockholders&#8217; Equity</div></div> for additional </div><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">information. </div></div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-Based Compensation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation is measured at fair value on the grant date of the award. Compensation cost is recognized as expense on a straight-line basis over the vesting period for options with service conditions and forfeitures are accounted for as they occur. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock option awards. The determination of fair value for stock-based awards using an option-pricing model requires management to make certain assumptions regarding subjective input variables such as expected term, dividends, volatility and risk-free rate. If actual results are not consistent with the </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/>   <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company&#8217;s assumptions used in making these estimates, the Company may be required to increase or decrease compensation expense, which could be material to the Company&#8217;s results of operations.</div></div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Income Taxes </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <div style="display:inline;">Company </div>utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and the tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when it is more likely than not that all or part of a deferred tax asset will not be realized. When the Company establishes or reduces the valuation allowance related to the deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination based on the technical merits of the position. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to file federal and state income tax returns in the United States. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect that could affect the amount of tax paid to these jurisdictions. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records interest related to income tax reserves, if any, as interest expense, and any penalties would be recorded as other expense in the consolidated statements of operations and comprehensive loss. </div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Comprehensive Loss </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss includes net loss and net unrealized gains and losses on marketable securities, which are presented in a single continuous statement. Other comprehensive (loss) gain is also disclosed in the consolidated balance sheets and statements of stockholders&#8217; equity in accumulated other comprehensive income (loss), and is stated net of related tax effects, if any. <br/></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Loss Per Common Share </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per share of common stock is based on the weighted average number of shares of common stock and common stock equivalents outstanding during the period. The weighted-average common shares outstanding as of December 31, 2022 and 2021 includes pre-funded warrants to purchase up to&#160;</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">3,125,000<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">shares of common stock that were issued in connection with the November 2021 public offering, as </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">discussed in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note&#160;9&#8212;Stockholders&#8217; Equity</div></div>. Diluted </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> net loss per share of common stock is calculated as the weighted average number of shares of common stock outstanding adjusted to include the assumed exercises of stock options, if dilutive. In all periods presented, the Company&#8217;s outstanding stock options and incentive awards were excluded from the calculation of net loss per share because the effect would be antidilutive. </div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/><br/></div>    <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share amounts): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div></div></td>
<td style="vertical-align: bottom; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(106,001</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(89,998</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of:</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock shares outstanding</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">84,679,063</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">70,712,865</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded warrants outstanding</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">3,125,000</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">342,466</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 63%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">87,804,063</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">71,055,331</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1.21</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1.27</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>   <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock options</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">13,930</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">10,791</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Incentive awards</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Total</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">14,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">10,892</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Issued Accounting Pronouncements </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> Financial Instruments&#8212;Credit Losses (Topic 326): <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Measurement of Credit Losses on Financial Instruments</div></div>, an amendment which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#8220;incurred loss&#8221; model with an &#8220;expected loss&#8221; model. Accordingly, these financial assets will be presented at the net amount expected to be collected. The amendment also requires that credit losses related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div> debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. In November 2019, FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2019-10,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842)</div></div>, which deferred the adoption deadline for smaller reporting companies to fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years. Early adoption is permitted, and entities are required to use a modified retrospective approach, with certain exceptions. The Company intends to adopt this ASU on January&#160;1, 2023 and does not expect a material impact to its consolidated financial statements and related disclosures. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_CashEquivalentsAndInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_CashEquivalentsAndInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_DevelopmentFinancingAgreementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development Financing Agreement Policy Text Block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_DevelopmentFinancingAgreementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_PrefundedWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_PrefundedWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239395717232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value Assets Measured on Recurring Basis</a></td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;">The</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> following tables present the Company&#8217;s financial assets that are measured at fair value on a recurring basis using the above input categories (in thousands): </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents:</div></div></div> </td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities:</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign commercial paper</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">46,121</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">46,121</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign corporate debt securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">24,807</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">24,807</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supranational debt securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">12,890</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">12,890</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. agency securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,759</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,759</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasury securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">23,617</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">23,617</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total marketable securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">115,194</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">115,194</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">115,194</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">124,964</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"/>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="14" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities:</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;">&#160;</td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign commercial paper</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">28,760</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">28,760</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign corporate debt securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">23,535</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">23,535</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">8,522</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">8,522</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasury securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,979</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,979</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total marketable securities</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">68,796</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">68,796</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets measured at fair value</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">68,796</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">154,434</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 59%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="padding: 0px;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Loss per Share</a></td>
<td class="text"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share amounts): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div></div></td>
<td style="vertical-align: bottom; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom; width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(106,001</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">(89,998</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></div></div></td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 9%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr>
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average number of:</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock shares outstanding</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">84,679,063</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">70,712,865</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded warrants outstanding</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">3,125,000</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">342,466</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 63%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">87,804,063</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">71,055,331</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share</div></div></div></div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1.21</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">$</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(1.27</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-Dilutive Securities Excluded from the Computation of Diluted Net Loss per Share</a></td>
<td class="text"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock options</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">13,930</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">10,791</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Incentive awards</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 78%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Total</div></td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">14,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">10,892</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239392776800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Available-for-Sale Securities</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;">Marketable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities consist of the following (in&#160;thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/>Cost</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Gains</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/>Losses</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/>Fair Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Money market funds</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Total cash equivalents</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">9,770</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Current marketable securities:</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">U.S. and foreign commercial paper</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">46,121</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">46,121</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">U.S. and foreign corporate debt securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">24,964</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(157</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">24,807</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Supranational debt securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">12,946</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(56</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">12,890</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">U.S. agency securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,782</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">16</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(39</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,759</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">U.S. treasury securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">23,707</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">2</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(92</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">23,617</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Total current marketable securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">115,520</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">18</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(344</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">115,194</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total marketable securities</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">125,290</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">18</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(344</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">124,964</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/>Cost</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/>Unrealized<br/>Gains</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/>Unrealized<br/>Losses</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/>Fair Value</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="display:inline;"/></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash equivalents</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">85,638</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current marketable securities:</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign commercial paper</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">28,760</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">28,760</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. and foreign corporate debt securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">15,476</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">&#8212;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(8</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">15,468</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset-backed securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">8,524</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">1</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(3</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">8,522</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. treasury securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,982</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">&#8212;<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(3</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,979</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current marketable securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">60,742</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">1</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(14</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">60,729</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> marketable securities:</div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="break-inside: avoid; font-size: 10pt;">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. corporate debt securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">8,067</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">3</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(2</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">8,068</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total marketable securities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">154,447</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">4</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(16</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">154,435</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 57%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="text-align: center;;text-indent: 0px;"/> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of fair value of the Company marketable securities by contractual maturity</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table shows the fair value of the Company&#8217;s marketable securities, by contractual maturity, as of December&#160;31, 2022 (in thousands): </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="vertical-align: bottom; width: 7%;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 83%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due less than 1 year</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">115,194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 83%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Due between 1 and 2 years</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 83%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total fair value</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">115,194</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239392741952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment are recorded at cost and consist of the following (in thousands):</div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">2,429</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">2,429</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Office and computer equipment</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">290</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">290</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Purchased software</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">44</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">44</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Furniture and fixtures</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">687</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">539</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr>
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt; width: 66%;"><div style="margin-top: 0px; margin-bottom: 0px; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt; width: 11%;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt; width: 11%;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt;"><div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">3,450</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">3,302</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Less: Accumulated depreciation and amortization</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(2,749</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">(2,124</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">701</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">1,178</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_ScheduleOfOtherAccruedLiabilitiesTableTextBlock', window );">Other Accrued Liabilities</a></td>
<td class="text"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued liabilities consist of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued compensation</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">5,779</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">3,986</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued professional fees and other</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">1,372</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">1,333</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current portion of operating lease liability</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">664</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">567</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other accrued liabilities</div></div></div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">7,815</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">5,886</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 66%;">&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 11%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_ScheduleOfOtherAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of other accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_ScheduleOfOtherAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239390297888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development Financing Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Fair Value of Liabilities</a></td>
<td class="text"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of the changes in the carrying value of the Company&#8217;s development financing liability (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 88%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="vertical-align: bottom; width: 6%;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Balance at December 31, 2021</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">50,320</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Cash received</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">25,000</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Accretion of development financing liability</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">14,907</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 85%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Balance at December 31, 2022</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;">90,227</td>
<td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 85%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239392734288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Operating Lease Liabilities</a></td>
<td class="text"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 92%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 89%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Year ending December&#160;31,</div></td>
<td style="vertical-align: bottom; width: 8%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">2023</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align:bottom;text-align:right;">707</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">2024</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 89%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 89%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total undiscounted future minimum lease payments</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">737</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 89%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less imputed interest</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 89%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 89%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating lease liability</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">694</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 89%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: current portion of operating lease liability</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">664</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 89%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 89%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term portion of lease liability</div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">30</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 89%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239391532080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_ReservedSharesOfCommonStockForIssuanceTableTextBlock', window );">Summary of Reserved Shares of Common Stock for Future Issuances</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2022 and 2021, the Company had reserved shares of common stock for future issuances as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 2%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-funded</div> warrants to purchase common stock</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3,125,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">3,125,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Equity award plans:</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options and incentive awards outstanding, all equity plans</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">14,031,377</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">10,892,613</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Equity awards available for future grant - 2013 Plan</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2,680,621</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1,588,613</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Equity awards available for future grant - 2020 Plan</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 70%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total shares of common stock reserved for future issuance</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">19,836,998</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">15,606,226</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align:bottom"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_ReservedSharesOfCommonStockForIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reserved shares of common stock for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_ReservedSharesOfCommonStockForIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239391101968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans and Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Grants, Including Performance Options</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes activity in the Company&#8217;s stock option grants: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:#ffffff;;display:inline;">&#160;</div></div></div><div style="background-color:#ffffff;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/>Subject to<br/>Outstanding<br/>Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Exercise<br/>Price of<br/>Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/>Intrinsic<br/>Value (in<br/>thousands)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December 31, 2021</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">10,791,431</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">6.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 51%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options granted</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">3,692,868</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.94</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercised</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(3,124</td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">2.94</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options forfeited</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(403,210</td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">4.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options expired</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(147,770</td>
<td style="white-space: nowrap; vertical-align: bottom;">)&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">5.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding as of December 31, 2022</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,930,195</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">5.26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">26,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested and expected to vest as of December&#160;31, 2022</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">13,930,195</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">5.26</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.96</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">26,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 51%;"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercisable as of December&#160;31, 2022</div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">9,004,373</td>
<td style="white-space: nowrap; vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">6.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">13,858</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 51%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"/> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock-based compensation expense is included in the consolidated statements of operations and comprehensive loss and is as follows (in </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">thousands): </div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 82%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">4,274</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">4,470</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">5,243</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">5,526</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 78%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total stock-based compensation expense</div></td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">9,517</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right;">9,996</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 5%;">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="clear:both;max-height:0pt;"/><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Estimated Weighted-Average Grant Date Fair Value</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the weighted-average assumptions the Company used in the Black-Scholes option-pricing model to derive the grant date fair values of stock options granted in each of the years <div style="display:inline;">presented </div>along with the resulting estimated weighted-average grant date fair values per share: </div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (years)</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">6.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">101</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">104</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; width: 81%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">1.8</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right;">0.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; width: 81%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Weighted-average grant date fair value per share</div></td>
<td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">2.33</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">3.91</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239393334464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets</a></td>
<td class="text"><div style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 32.6667px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;">Significant</div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">components of the Company&#8217;s <div style="display:inline;">deferred </div>tax assets are as follows (in thousands): </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"/></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Federal and state net operating loss carryforwards</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87,681</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129,898</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap; width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">State and federal research and development tax credit carryforwards</div></td>
<td style="vertical-align: bottom; white-space: nowrap; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,016</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Intangibles and capitalized research and development</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">16,912</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">5,670</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Stock-based compensation</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">6,624</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">5,329</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Other</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,574</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">1,222</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Total deferred tax assets</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">144,807</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">174,070</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Deferred tax liabilities:</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Depreciation and amortization</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(79</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(158</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Other</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(36</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(53</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Total deferred tax liabilities</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(115</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(211</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">)&#160;</td></tr>
<tr style="break-inside: avoid; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
<td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Valuation allowance</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(144,692</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;">(173,859</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Net deferred tax assets</div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 69%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="background-color: rgba(255, 255, 255, 0);">&#160;</td></tr></table><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="clear:both;max-height:0pt;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="clear:both;max-height:0pt;;text-indent: 0px;"/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Reconciliation of Expected Statutory Federal Income Tax Provision to Actual Income Tax Provision</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a reconciliation of the expected statutory federal income tax provision to the actual income tax provision (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Income tax benefit at federal statutory tax rate</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22,260</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,900</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Change in valuation allowance</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,165</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Impairment of tax attributes</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,398</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Research credits</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,640</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,802</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Cancelled options</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Development financing liability</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,301</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,654</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Permanent differences</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">511</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">429</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">State income taxes, net of federal benefit</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,806</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(267</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Other, net</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Income tax (benefit) expense</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="margin-block: 0em;">&#160;</div> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of Gross Unrecognized Tax Benefits</a></td>
<td class="text">The following table summarizes activity related to the Company&#8217;s gross unrecognized tax benefits (in&#160;thousands):<div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 89%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 86%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Balances as of December 31, 2020</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,205</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Increases related to prior year tax positions</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Increases related to 2021 tax positions</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">783</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Balances as of December 31, 2021</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,997</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Decreases related to prior year tax positions</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,223</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Increases related to 2022 tax positions</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">730</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;">&#160;</div></td>
<td style="white-space: nowrap;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align: top; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal; white-space: nowrap;">Balances as of December 31, 2022</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,504</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239387135792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 23, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>INSTALLMENTS</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 06, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 22, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106,001)<span></span>
</td>
<td class="num">$ (89,998)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,080)<span></span>
</td>
<td class="num">(69,431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(872,857)<span></span>
</td>
<td class="num">$ (766,856)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cbay_PrefundedWarrantsMember', window );">Prefunded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9999<span></span>
</td>
<td class="nump">$ 3.9999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock into which the class of warrant or right may be converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of new stock issued during the period. | shares</a></td>
<td class="nump">11,821,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share | $ / shares</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_GrossProceedsFromPublicOffering', window );">Total gross offering proceeds</a></td>
<td class="nump">$ 92,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Collaboration and License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Collaboration and License Agreement [Member] | Kaken Pharmaceutical Co., Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Prefunded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share | $ / shares</a></td>
<td class="nump">$ 6.9999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock into which the class of warrant or right may be converted | shares</a></td>
<td class="nump">2,142,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cbay_AbwCyclopsSpvLpMember', window );">Abw Cyclops Spv Lp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_NumberOfFundingInstallments', window );">Number of funding installments | INSTALLMENTS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cbay_AbwCyclopsSpvLpMember', window );">Abw Cyclops Spv Lp [Member] | Financing agreement funding installments two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Subsequent Event [Member] | Collaboration and License Agreement [Member] | Kaken Pharmaceutical Co., Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of public equity offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_GrossProceedsFromPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_GrossProceedsFromPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_NumberOfFundingInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of funding installments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_NumberOfFundingInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cbay_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cbay_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_AgreementAxis=cbay_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_AgreementAxis=cbay_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbay_KakenPharmaceuticalCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbay_KakenPharmaceuticalCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cbay_AbwCyclopsSpvLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cbay_AbwCyclopsSpvLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_CbayfinancingAgreementFundingInstallmentsAxis=cbay_FinancingAgreementFundingInstallmentsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_CbayfinancingAgreementFundingInstallmentsAxis=cbay_FinancingAgreementFundingInstallmentsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239386834816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Fair Value Assets Measured on Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 124,964<span></span>
</td>
<td class="nump">$ 154,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">9,770<span></span>
</td>
<td class="nump">85,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">9,770<span></span>
</td>
<td class="nump">85,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">115,194<span></span>
</td>
<td class="nump">68,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | U.S. and Foreign Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">46,121<span></span>
</td>
<td class="nump">28,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | U.S. and Foreign Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">24,807<span></span>
</td>
<td class="nump">23,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Asset-backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | US Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">7,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">23,617<span></span>
</td>
<td class="nump">7,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Supranational Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">12,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">9,770<span></span>
</td>
<td class="nump">85,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">9,770<span></span>
</td>
<td class="nump">85,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Cash Equivalents [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">9,770<span></span>
</td>
<td class="nump">85,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">115,194<span></span>
</td>
<td class="nump">68,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Short-term Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">115,194<span></span>
</td>
<td class="nump">68,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Short-term Investments [Member] | U.S. and Foreign Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">46,121<span></span>
</td>
<td class="nump">28,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Short-term Investments [Member] | U.S. and Foreign Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">24,807<span></span>
</td>
<td class="nump">23,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Short-term Investments [Member] | Asset-backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Short-term Investments [Member] | US Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">7,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Short-term Investments [Member] | U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">23,617<span></span>
</td>
<td class="nump">$ 7,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Short-term Investments [Member] | Supranational Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 12,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=cbay_UsAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=cbay_UsAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=cbay_SupranationalDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=cbay_SupranationalDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239390342304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Nov. 22, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_CashEquivalentMaturityDescription', window );">Cash and cash equivalents, maturity description</a></td>
<td class="text">90 days or less<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value of development financing liability</a></td>
<td class="nump">$ 79.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cbay_PrefundedWarrantsMember', window );">Prefunded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock into which the class of warrant or right may be converted</a></td>
<td class="nump">3,125,000<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9999<span></span>
</td>
<td class="nump">$ 3.9999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_ShortTermInvestmentContractualMaturity', window );">Short-term contractual maturities</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_ShortTermInvestmentContractualMaturity', window );">Short-term contractual maturities</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_CashEquivalentMaturityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalent maturity description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_CashEquivalentMaturityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_ShortTermInvestmentContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term investment contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_ShortTermInvestmentContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cbay_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cbay_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239391496544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Computation of Basic and Diluted Net Loss per Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (106,001)<span></span>
</td>
<td class="num">$ (89,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted', window );">Common&#160;stock shares outstanding</a></td>
<td class="nump">84,679,063<span></span>
</td>
<td class="nump">70,712,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding', window );">Pre-funded&#160;warrants outstanding</a></td>
<td class="nump">3,125,000<span></span>
</td>
<td class="nump">342,466<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Total, Basic</a></td>
<td class="nump">87,804,063<span></span>
</td>
<td class="nump">71,055,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Total, Diluted</a></td>
<td class="nump">87,804,063<span></span>
</td>
<td class="nump">71,055,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share&#8212;basic</a></td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share&#8212;diluted</a></td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.27)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of common stock share outstanding basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of pre funded warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239390379424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Anti-Dilutive Securities Excluded from the Computation of Diluted Net Loss per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted loss per share</a></td>
<td class="nump">14,031<span></span>
</td>
<td class="nump">10,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbay_EmployeeOrNonEmployeeStockOptionsMember', window );">Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted loss per share</a></td>
<td class="nump">13,930<span></span>
</td>
<td class="nump">10,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbay_IncentiveStockAwardsMember', window );">Incentive Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from the computation of diluted loss per share</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbay_EmployeeOrNonEmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbay_EmployeeOrNonEmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbay_IncentiveStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbay_IncentiveStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239390386176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Detail) - Debt Securities [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gains and losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments', window );">Marketable investments continuous unrealized loss position</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated pre-tax unrealized loss on investments in available-for-sale securities that have been in a loss position for twelve months or longer impacting investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239391228432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Marketable Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">$ 115,194<span></span>
</td>
<td class="nump">60,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">9,770<span></span>
</td>
<td class="nump">85,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">9,770<span></span>
</td>
<td class="nump">85,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">9,770<span></span>
</td>
<td class="nump">85,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">9,770<span></span>
</td>
<td class="nump">85,638<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=cbay_CurrentMarketableSecuritiesMember', window );">Current marketable securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">115,520<span></span>
</td>
<td class="nump">60,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(344)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">115,194<span></span>
</td>
<td class="nump">60,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=cbay_CurrentMarketableSecuritiesMember', window );">Current marketable securities [Member] | U.S. and Foreign Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">46,121<span></span>
</td>
<td class="nump">28,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">46,121<span></span>
</td>
<td class="nump">28,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=cbay_CurrentMarketableSecuritiesMember', window );">Current marketable securities [Member] | U.S. and Foreign Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">24,964<span></span>
</td>
<td class="nump">15,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(157)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">24,807<span></span>
</td>
<td class="nump">15,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=cbay_CurrentMarketableSecuritiesMember', window );">Current marketable securities [Member] | Asset-backed Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=cbay_CurrentMarketableSecuritiesMember', window );">Current marketable securities [Member] | U.S. Treasury Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">23,707<span></span>
</td>
<td class="nump">7,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">23,617<span></span>
</td>
<td class="nump">7,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=cbay_CurrentMarketableSecuritiesMember', window );">Current marketable securities [Member] | U.S. agency securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">7,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">7,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=cbay_CurrentMarketableSecuritiesMember', window );">Current marketable securities [Member] | Supranational Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">12,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">12,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=cbay_MaketableSecuritiesMember', window );">Maketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">125,290<span></span>
</td>
<td class="nump">154,447<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(344)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">$ 124,964<span></span>
</td>
<td class="nump">154,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=cbay_NoncurrentMarketableSecuritiesMember', window );">Non-current marketable securities [Member] | U.S. and Foreign Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,068<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=cbay_CurrentMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=cbay_CurrentMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cbay_UsAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cbay_UsAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cbay_SupranationalDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cbay_SupranationalDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=cbay_MaketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=cbay_MaketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=cbay_NoncurrentMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=cbay_NoncurrentMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239478515744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule Of Fair Value Of The Company  Marketable Securities By Contractual Maturity (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_ContractualObligationFiscalYearMaturityScheduleLineItems', window );"><strong>Contractual Obligation Fiscal Year Maturity Schedule [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Due less than 1 year</a></td>
<td class="nump">$ 115,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">Due between 1 and 2 years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Total fair value</a></td>
<td class="nump">$ 115,194<span></span>
</td>
<td class="nump">$ 60,729<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_ContractualObligationFiscalYearMaturityScheduleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_ContractualObligationFiscalYearMaturityScheduleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239391441744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 3,450<span></span>
</td>
<td class="nump">$ 3,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(2,749)<span></span>
</td>
<td class="num">(2,124)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">701<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,429<span></span>
</td>
<td class="nump">2,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cbay_OfficeAndComputerEquipmentMember', window );">Office and Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Purchased Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 687<span></span>
</td>
<td class="nump">$ 539<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cbay_OfficeAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cbay_OfficeAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239391104512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationExpenseOnReclassifiedAssets', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationExpenseOnReclassifiedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 44<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=29634951&amp;loc=d3e1756-110224<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2459-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationExpenseOnReclassifiedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239391536384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Other Accrued Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 5,779<span></span>
</td>
<td class="nump">$ 3,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_AccruedProfessionalFeesAndOtherCurrent', window );">Accrued professional fees and other</a></td>
<td class="nump">1,372<span></span>
</td>
<td class="nump">1,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">664<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets', window );">Total other accrued liabilities</a></td>
<td class="nump">$ 7,815<span></span>
</td>
<td class="nump">$ 5,886<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities for purchase of productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_AccruedProfessionalFeesAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued professional fees and other, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_AccruedProfessionalFeesAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239390332800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>In-License Agreement - Additional Information (Detail) - Janssen Pharmaceutical NV [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2006</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Accrued royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbay_JanssenPharmaceuticalNVMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_RoyaltyPercentageBasedOnNetSales', window );">Percentage of royalty on net sales</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_RoyaltyPercentageBasedOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage based on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_RoyaltyPercentageBasedOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbay_JanssenPharmaceuticalNVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbay_JanssenPharmaceuticalNVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239390922240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development Financing Agreement - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_DescriptionOfPercentageFixedSuccessPayments', window );">Description Of Percentage Fixed Success Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of Lines of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_DescriptionOfPercentageVariableSuccessPayments', window );">Description Of Percentage Variable Success Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_DescriptionOfAggregateReturnFromTheFundsProvided', window );">Description Of Aggregate Return From The Funds Provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_AggregateReturnPercentageFromTheFundsProvided', window );">Aggregate Return Percentage From The Funds Provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 232.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided', window );">Percentage of Accelerate Payment Payable On Funds provided</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement', window );">Description Repayments On Funds Provided Upon Termination Of Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability', window );">Percentage of Unamortized Portion of The Development Financing Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_SuccessPaymentTypeAxis=cbay_FixedSuccessPaymentsMember', window );">Fixed Success Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_AnniversaryPaymentsDueYearOne', window );">Anniversary Payments Due Year One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_AnniversaryPaymentsDueYearTwo', window );">Anniversary Payments Due Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_AnniversaryPaymentsDueYearThree', window );">Anniversary Payments Due Year Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_Anniversarypaymentsdueyearfour', window );">Anniversary Payments Due Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_AnniversaryPaymentsDueYearFive', window );">Anniversary Payments Due Year Five</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_AnniversaryPaymentsDueYearSix', window );">Anniversary Payments Due Year Six</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_SuccessPaymentTypeAxis=cbay_VariableSuccessPaymentsMember', window );">Variable Success Payments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne', window );">Payments Upon Reaching Cumulative US Product Sales Thresholds Year One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo', window );">Payments Upon Reaching Cumulative US Product Sales Thresholds Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_PaymentsUponReachingProductSalesRunRate', window );">Payments upon reaching product sales run rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_NumberOfInstallmentFundingAxis=cbay_InstallmentFundingNumberThreeMember', window );">Installment Funding Number Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cbay_AbwCyclopsSpvLpMember', window );">ABW Cyclops SPV LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cbay_AbwCyclopsSpvLpMember', window );">ABW Cyclops SPV LP [Member] | Installment Funding Number One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=cbay_AbwCyclopsSpvLpMember', window );">ABW Cyclops SPV LP [Member] | Installment Funding Number Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_FinancingAgreementTerminationEventConditionAxis=cbay_FinancingAgreementTerminationEventConditionOneMember', window );">Financing Agreement Termination Event Condition One [Member] | ABW Cyclops SPV LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement', window );">Percentage of amount to be paid by entity upon the termination of the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_FinancingAgreementTerminationEventConditionAxis=cbay_FinancingAgreementTerminationEventConditionTwoMember', window );">Financing Agreement Termination Event Condition Two [Member] | ABW Cyclops SPV LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement', window );">Percentage of amount to be paid by entity upon the termination of the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_FinancingAgreementTerminationEventConditionAxis=cbay_FinancingAgreementTerminationEventConditionThreeMember', window );">Financing Agreement Termination Event Condition Three [Member] | ABW Cyclops SPV LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement', window );">Percentage of amount to be paid by entity upon the termination of the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_AggregateReturnPercentageFromTheFundsProvided">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate return percentage from the funds provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_AggregateReturnPercentageFromTheFundsProvided</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_AnniversaryPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Anniversary payments due year five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_AnniversaryPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_AnniversaryPaymentsDueYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Anniversary payments due year one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_AnniversaryPaymentsDueYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_AnniversaryPaymentsDueYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Anniversary payments due year six.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_AnniversaryPaymentsDueYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_AnniversaryPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Anniversary payments due year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_AnniversaryPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_AnniversaryPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Anniversary payments due year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_AnniversaryPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_Anniversarypaymentsdueyearfour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Anniversary payments due year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_Anniversarypaymentsdueyearfour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_DescriptionOfAggregateReturnFromTheFundsProvided">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of aggregate return from the funds provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_DescriptionOfAggregateReturnFromTheFundsProvided</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_DescriptionOfPercentageFixedSuccessPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of percentage fixed success payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_DescriptionOfPercentageFixedSuccessPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_DescriptionOfPercentageVariableSuccessPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of percentage variable success payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_DescriptionOfPercentageVariableSuccessPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description repayments on funds provided upon termination of financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments upon reaching cumulative US product sales thresholds year one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments upon reaching cumulative US product sales thresholds year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_PaymentsUponReachingProductSalesRunRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments upon reaching product sales run rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_PaymentsUponReachingProductSalesRunRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of accelerate payment payable on funds provided.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount to be paid by entity upon the termination of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of unamortized portion of the development financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_SuccessPaymentTypeAxis=cbay_FixedSuccessPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_SuccessPaymentTypeAxis=cbay_FixedSuccessPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_SuccessPaymentTypeAxis=cbay_VariableSuccessPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_SuccessPaymentTypeAxis=cbay_VariableSuccessPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_NumberOfInstallmentFundingAxis=cbay_InstallmentFundingNumberThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_NumberOfInstallmentFundingAxis=cbay_InstallmentFundingNumberThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=cbay_AbwCyclopsSpvLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=cbay_AbwCyclopsSpvLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_NumberOfInstallmentFundingAxis=cbay_InstallmentFundingNumberOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_NumberOfInstallmentFundingAxis=cbay_InstallmentFundingNumberOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_NumberOfInstallmentFundingAxis=cbay_InstallmentFundingNumberTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_NumberOfInstallmentFundingAxis=cbay_InstallmentFundingNumberTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_FinancingAgreementTerminationEventConditionAxis=cbay_FinancingAgreementTerminationEventConditionOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_FinancingAgreementTerminationEventConditionAxis=cbay_FinancingAgreementTerminationEventConditionOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbay_AbwCyclopsSpvLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbay_AbwCyclopsSpvLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_FinancingAgreementTerminationEventConditionAxis=cbay_FinancingAgreementTerminationEventConditionTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_FinancingAgreementTerminationEventConditionAxis=cbay_FinancingAgreementTerminationEventConditionTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_FinancingAgreementTerminationEventConditionAxis=cbay_FinancingAgreementTerminationEventConditionThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_FinancingAgreementTerminationEventConditionAxis=cbay_FinancingAgreementTerminationEventConditionThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239390398928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development Financing Agreement - Schedule of Changes in Fair Value of Liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of period</a></td>
<td class="nump">$ 50,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Cash received</a></td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability', window );">Accretion of development financing liability</a></td>
<td class="nump">14,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of period</a></td>
<td class="nump">$ 90,227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation recurring basis liability accretion of development financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239394137520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturities of Operating Lease Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted future minimum lease payments</a></td>
<td class="nump">737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion of operating lease liability</a></td>
<td class="nump">664<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liability</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 695<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239386785792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Facility</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lease, option to extend</a></td>
<td class="text">option to extend for an additional 5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average lease discount rate</a></td>
<td class="nump">12.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">694<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short term portion of operating lease liability</a></td>
<td class="nump">$ 664<span></span>
</td>
<td class="nump">$ 567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other Accrued Liabilities, Current<span></span>
</td>
<td class="text">Other Accrued Liabilities, Current<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=cbay_LeaseFacilityMember', window );">Lease Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_NumberOfLeasedFacilitiesOperatingLeases', window );">Number of leased facilities | Facility</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="nump">17,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_LeaseStartDate', window );">Lease start date</a></td>
<td class="text">Jan. 16,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease costs</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_AreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of office space.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_AreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_LeaseStartDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease start date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_LeaseStartDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_NumberOfLeasedFacilitiesOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of leased facilities operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_NumberOfLeasedFacilitiesOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cbay_LeaseFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cbay_LeaseFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239386657360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 12, 2021</div></th>
<th class="th"><div>Jan. 15, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyLawsuitFilingDate', window );">Loss Contingency, Lawsuit Filing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">January 15, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNameOfPlaintiff', window );">Loss Contingency, Name of Plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Genfit S.A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAllegations', window );">Loss Contingency, Allegations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">alleging misappropriation of trade secrets and related causes of action based on the Company&#8217;s receipt of a Genfit protocol synopsis for Genfit&#8217;s Phase 3 clinical trial of its drug candidate elafibranor in patients with primary biliary cholangitis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyActionsTakenByDefendant', window );">Loss Contingency, Actions Taken by Defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On February 21, 2023, the parties entered into a Settlement Agreement and the action was dismissed with prejudice. The Company did not admit to any liability and the litigation has been resolved completely.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IndemnificationLiability', window );">Indemnification liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyActionsTakenByCourtArbitratorOrMediator', window );">Loss Contingency, Actions Taken by Court, Arbitrator or Mediator</a></td>
<td class="text">On March 12, 2021, the Court granted a Temporary Restraining Order (later converted to a Preliminary Injunction), prohibiting the Company from accessing or disseminating the protocol synopsis, using any Genfit trade secrets contained therein or destroying any evidence related thereto.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyLawsuitFilingDate', window );">Loss Contingency, Lawsuit Filing Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">April 16, 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_IndemnificationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indemnification liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_IndemnificationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyActionsTakenByCourtArbitratorOrMediator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes important rulings or decisions made by the judge, arbitrator or mediator in the legal matter that could impact the outcome of the case.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyActionsTakenByCourtArbitratorOrMediator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyActionsTakenByDefendant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describe actions taken by the defendant in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyActionsTakenByDefendant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAllegations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Presents an assertion of a fact by a plaintiff in a pleading or complaint, which the plaintiff claims it will prove upon presentation of evidence at the proceeding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAllegations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLawsuitFilingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>States the date the complaint was formally filed in a court of law, in arbitration or mediation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLawsuitFilingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNameOfPlaintiff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identifies the plaintiff in the lawsuit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNameOfPlaintiff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239387014112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - $ / shares<br></strong></div></th>
<th class="th"><div>Jan. 23, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Nov. 22, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cbay_PrefundedWarrantsMember', window );">Prefunded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock into which the class of warrant or right may be converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9999<span></span>
</td>
<td class="nump">$ 3.9999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of new stock issued during the period.</a></td>
<td class="nump">11,821,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Prefunded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock into which the class of warrant or right may be converted</a></td>
<td class="nump">2,142,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">$ 6.9999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cbay_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cbay_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239391286784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholder's Equity - Summary of Reserved Shares of Common Stock for Future Issuances (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">19,836,998<span></span>
</td>
<td class="nump">15,606,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember', window );">CBAYEquity incentive plan two thousand and thirteen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">2,680,621<span></span>
</td>
<td class="nump">1,588,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember', window );">CBAYEquity incentive plan two thousand and twenty plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cbay_OptionsAndIncentiveAwardsMember', window );">Options and Incentive awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">14,031,377<span></span>
</td>
<td class="nump">10,892,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cbay_PrefundedWarrantsMember', window );">Prefunded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">3,125,000<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cbay_OptionsAndIncentiveAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cbay_OptionsAndIncentiveAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cbay_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cbay_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239390492032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans and Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Apr. 30, 2014</div></th>
<th class="th"><div>Jan. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unamortized employee and non-employee stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unamortized employee and non-employee stock-based compensation expense recognized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Share reserved for issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,836,998<span></span>
</td>
<td class="nump">15,606,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,930,195<span></span>
</td>
<td class="nump">10,791,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember', window );">Equity Incentive Plan Two Thousand and Twenty Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based compensation arrangement by share based payment award, expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share based compensation arrangement by share based payment award, exercise price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbay_EquityIncentivePlanTwoThousandAndThirteenMember', window );">2013 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage', window );">Share based compensation arrangement percentage increase in share reserved</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,680,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Share reserved for issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,234,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbay_EquityIncentivePlanTwoThousandAndThirteenMember', window );">2013 Equity Incentive Plan [Member] | Incentive Stock Options for Employees and Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share based compensation arrangement by share based payment award, exercise price percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbay_EquityIncentivePlanTwoThousandAndThirteenMember', window );">2013 Equity Incentive Plan [Member] | Nonqualified Options to Employees, Directors and Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share based compensation arrangement by share based payment award, exercise price percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbay_EquityIncentivePlanTwoThousandAndThirteenMember', window );">2013 Equity Incentive Plan [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share based compensation arrangement by share based payment award, exercise price percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation arrangement by share based payment award, award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbay_EquityIncentivePlanTwoThousandAndThirteenMember', window );">2013 Equity Incentive Plan [Member] | Stock Options to 10% Stockholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share based compensation arrangement by share based payment award, exercise price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share based compensation arrangement by share based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbay_IncentiveStockAwardsMember', window );">Incentive Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Share reserved for issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable weighted average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,182<span></span>
</td>
<td class="nump">101,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award increase in shares reserved percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cbay_EquityIncentivePlanTwoThousandAndThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cbay_EquityIncentivePlanTwoThousandAndThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cbay_NonQualifiedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cbay_NonQualifiedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cbay_StockOptionsToTenPercentShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cbay_StockOptionsToTenPercentShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cbay_IncentiveStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cbay_IncentiveStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239391057264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans and Stock-Based Compensation - Summary of Stock Option Grants, Including Performance Options (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares Subject to Outstanding Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of period | shares</a></td>
<td class="nump">10,791,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted | shares</a></td>
<td class="nump">3,692,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised | shares</a></td>
<td class="num">(3,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited | shares</a></td>
<td class="num">(403,210)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired | shares</a></td>
<td class="num">(147,770)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding as end of period | shares</a></td>
<td class="nump">13,930,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest | shares</a></td>
<td class="nump">13,930,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable | shares</a></td>
<td class="nump">9,004,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of period | $ / shares</a></td>
<td class="nump">$ 6.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted | $ / shares</a></td>
<td class="nump">2.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised | $ / shares</a></td>
<td class="nump">2.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited | $ / shares</a></td>
<td class="nump">4.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options expired | $ / shares</a></td>
<td class="nump">5.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding as end of period | $ / shares</a></td>
<td class="nump">5.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest | $ / shares</a></td>
<td class="nump">5.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable | $ / shares</a></td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">6 years 11 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">6 years 11 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value (In Thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding | $</a></td>
<td class="nump">$ 26,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and expected to vest | $</a></td>
<td class="nump">26,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable | $</a></td>
<td class="nump">$ 13,858<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239391503648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans and Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 9,517<span></span>
</td>
<td class="nump">$ 9,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">4,274<span></span>
</td>
<td class="nump">4,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 5,243<span></span>
</td>
<td class="nump">$ 5,526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239387465392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans and Stock-Based Compensation - Estimated Weighted-Average Grant Date Fair Value (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="nump">104.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted-average grant date fair value per share</a></td>
<td class="nump">$ 2.33<span></span>
</td>
<td class="nump">$ 3.91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239395601008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_EmployerMatchingContributionToQualifiedSavingsPlan', window );">Employees contribution to qualified savings plan</a></td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_EmployerMatchingContributionToQualifiedSavingsPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employer matching contribution to qualified savings plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_EmployerMatchingContributionToQualifiedSavingsPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239387146448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Description of net operating loss carryforwards, expire period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The state net operating loss carryforwards will expire beginning in 2028 through 2040. The federal research and development and federal orphan drug tax credit carryforwards expire 2033 through 2042, and the state tax credit will carry forward indefinitely.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_ProvisionForStateAndLocalIncomeTaxes', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net valuation allowance increase (decrease)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,200)<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit', window );">Significant change to its unrecognized tax benefits over the next twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax examination years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the tax years 2004 to 2022 remain open for income tax examination by tax authorities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_AlternateMinimumTaxRate', window );">Alternate Minimum Tax Rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_WriteOffOfTaxAttributeDueToLimitation', window );">Write off of tax attribute due to limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal net operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Description of net operating loss carryforwards, expire period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">federal research and development and federal orphan drug tax credit carryforwards expire 2033 through 2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 346,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Orphan Drug [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_NetOperatingLossCarryforwardExpirationYear', window );">NOL carry forward expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_NetOperatingLossCarryforwardExpirationYear', window );">NOL carry forward expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal net operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Federal [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal net operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266,900<span></span>
</td>
<td class="nump">$ 79,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266,900<span></span>
</td>
<td class="nump">$ 79,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Minimum [Member] | Federal [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_NetOperatingLossCarryforwardExpirationYear', window );">NOL carry forward expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Maximum [Member] | Federal [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_NetOperatingLossCarryforwardExpirationYear', window );">NOL carry forward expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=cbay_FederalAndStateTaxAuthorityMember', window );">Federal And State Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible', window );">Cumulative percentage change in ownership percentage permissible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage', window );">Period for considering the cumulative percentage change in ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_AlternateMinimumTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Alternate minimum tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_AlternateMinimumTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative percentage change in ownership percentage perimissible.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_NetOperatingLossCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_NetOperatingLossCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period for considering the cumulative percentage change in ownership percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_ProvisionForStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision for state and local income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_ProvisionForStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_WriteOffOfTaxAttributeDueToLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write off of tax attribute due to limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_WriteOffOfTaxAttributeDueToLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cbay_OrphanDrugMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cbay_OrphanDrugMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cbay_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cbay_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=cbay_FederalAndStateTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=cbay_FederalAndStateTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239387515024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state net operating loss carryforwards</a></td>
<td class="nump">$ 87,681<span></span>
</td>
<td class="nump">$ 129,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">State and federal research and development tax credit carryforwards</a></td>
<td class="nump">32,016<span></span>
</td>
<td class="nump">31,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment', window );">Intangibles and capitalized research and development</a></td>
<td class="nump">16,912<span></span>
</td>
<td class="nump">5,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">6,624<span></span>
</td>
<td class="nump">5,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,574<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">144,807<span></span>
</td>
<td class="nump">174,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="num">(79)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(144,692)<span></span>
</td>
<td class="num">(173,859)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets intangibles and capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239394136816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Reconciliation of Expected Statutory Federal Income Tax Provision to Actual Income Tax Provision (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at federal statutory tax rate</a></td>
<td class="num">$ (22,260)<span></span>
</td>
<td class="num">$ (18,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(29,165)<span></span>
</td>
<td class="nump">14,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses', window );">Impairment of tax attributes</a></td>
<td class="nump">38,398<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="num">(2,640)<span></span>
</td>
<td class="num">(2,802)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IncomeTaxReconciliationTaxCancelledOptions', window );">Cancelled options</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IncomeTaxReconciliationDevelopmentFinancingLiability', window );">Development financing liability</a></td>
<td class="nump">12,301<span></span>
</td>
<td class="nump">6,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_IncomeTaxReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">2,806<span></span>
</td>
<td class="num">(267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_IncomeTaxReconciliationDevelopmentFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation development financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_IncomeTaxReconciliationDevelopmentFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_IncomeTaxReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_IncomeTaxReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_IncomeTaxReconciliationTaxCancelledOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation Tax Cancelled Options .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_IncomeTaxReconciliationTaxCancelledOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239390429920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Gross Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of period</a></td>
<td class="nump">$ 7,997<span></span>
</td>
<td class="nump">$ 7,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases related to prior year tax positions</a></td>
<td class="num">(1,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to tax positions</a></td>
<td class="nump">730<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of period</a></td>
<td class="nump">$ 7,504<span></span>
</td>
<td class="nump">$ 7,997<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140239390484480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail)<br> $ / shares in Units, $ in Millions, &#165; in Billions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 23, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 06, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 22, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cbay_PrefundedWarrantsMember', window );">Prefunded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9999<span></span>
</td>
<td class="nump">$ 3.9999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock into which the class of warrant or right may be converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of new stock issued during the period. | shares</a></td>
<td class="nump">11,821,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Prefunded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
<td class="nump">6.9999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of common stock into which the class of warrant or right may be converted | shares</a></td>
<td class="nump">2,142,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Collaboration and License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128.0<span></span>
</td>
<td class="nump">&#165; 17.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cbay_UpfrontCashPayment', window );">Upfront cash payment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_PotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_PotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>upfront cash payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbay_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cbay_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cbay_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbay_AgreementAxis=cbay_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbay_AgreementAxis=cbay_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>d446975d10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cbay="http://www.cymabay.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cbay-20221231.xsd" xlink:type="simple"/>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_15_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
        </entity>
        <period>
            <instant>2023-03-15</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="P01_15_2021To01_15_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
        </entity>
        <period>
            <startDate>2021-01-15</startDate>
            <endDate>2021-01-15</endDate>
        </period>
    </context>
    <context id="P03_12_2021To03_12_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
        </entity>
        <period>
            <startDate>2021-03-12</startDate>
            <endDate>2021-03-12</endDate>
        </period>
    </context>
    <context id="P08_31_2021To08_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
        </entity>
        <period>
            <startDate>2021-08-31</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="P08_01_2022To08_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OfficeAndComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cbay:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:MaketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_SupranationalDebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cbay:SupranationalDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_UsAgencySecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cbay:UsAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_OrphanDrugMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbay:OrphanDrugMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashEquivalentsMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashEquivalentsMemberusgaapInvestmentTypeAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashEquivalentsMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CashEquivalentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_SupranationalDebtSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:SupranationalDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_SupranationalDebtSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:SupranationalDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_UsAgencySecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:UsAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_UsAgencySecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:UsAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EquityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:EquityIncentivePlanTwoThousandAndTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_JanssenPharmaceuticalNVMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbay:JanssenPharmaceuticalNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_IncentiveStockAwardsMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:IncentiveStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cbay:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_OptionsAndIncentiveAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cbay:OptionsAndIncentiveAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CbayequityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:CbayequityIncentivePlanTwoThousandAndTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CbayequityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:CbayequityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_LeaseFacilityMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cbay:LeaseFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_FederalAndStateTaxAuthorityMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cbay:FederalAndStateTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OfficeAndComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cbay:OfficeAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:CurrentMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:MaketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_NoncurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">cbay:NoncurrentMarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashEquivalentsMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashEquivalentsMemberusgaapInvestmentTypeAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashEquivalentsMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CashEquivalentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_JanssenPharmaceuticalNVMembersrtCounterpartyNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbay:JanssenPharmaceuticalNVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_IncentiveStockAwardsMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:IncentiveStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AbwCyclopsSpvLpMembersrtCounterpartyNameAxis_FinancingAgreementTerminationEventConditionOneMemberCBAYFinancingAgreementTerminationEventConditionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cbay:FinancingAgreementTerminationEventConditionAxis">cbay:FinancingAgreementTerminationEventConditionOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AbwCyclopsSpvLpMembersrtCounterpartyNameAxis_FinancingAgreementTerminationEventConditionTwoMemberCBAYFinancingAgreementTerminationEventConditionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cbay:FinancingAgreementTerminationEventConditionAxis">cbay:FinancingAgreementTerminationEventConditionTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AbwCyclopsSpvLpMembersrtCounterpartyNameAxis_FinancingAgreementTerminationEventConditionThreeMemberCBAYFinancingAgreementTerminationEventConditionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cbay:FinancingAgreementTerminationEventConditionAxis">cbay:FinancingAgreementTerminationEventConditionThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cbay:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_OptionsAndIncentiveAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cbay:OptionsAndIncentiveAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CbayequityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:CbayequityIncentivePlanTwoThousandAndTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CbayequityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:CbayequityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PendingLitigationMemberusgaapLitigationStatusAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_EmployeeOrNonEmployeeStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbay:EmployeeOrNonEmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_IncentiveStockAwardsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbay:IncentiveStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FederalMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbay:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FederalMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MinimumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbay:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_OperatingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_LeaseFacilityMemberusgaapLeaseContractualTermAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cbay:LeaseFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_FederalAndStateTaxAuthorityMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">cbay:FederalAndStateTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EmployeeOrNonEmployeeStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbay:EmployeeOrNonEmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_IncentiveStockAwardsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbay:IncentiveStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DebtSecuritiesMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OperatingExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn11_22_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cbay:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="P06_01_2006To06_30_2006_JanssenPharmaceuticalNVMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbay:JanssenPharmaceuticalNVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-06-01</startDate>
            <endDate>2006-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn07_30_2021_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-30</instant>
        </period>
    </context>
    <context id="P08_31_2021To08_31_2021_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis_InstallmentFundingNumberOneMemberCBAYNumberOfInstallmentFundingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cbay:NumberOfInstallmentFundingAxis">cbay:InstallmentFundingNumberOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-31</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="P08_31_2021To08_31_2021_FixedSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cbay:SuccessPaymentTypeAxis">cbay:FixedSuccessPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-31</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="P08_31_2021To08_31_2021_VariableSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cbay:SuccessPaymentTypeAxis">cbay:VariableSuccessPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-31</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="P11_30_2021To11_30_2021_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis_InstallmentFundingNumberTwoMemberCBAYNumberOfInstallmentFundingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cbay:NumberOfInstallmentFundingAxis">cbay:InstallmentFundingNumberTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-30</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="P01_31_2022To01_31_2022_InstallmentFundingNumberThreeMemberCBAYNumberOfInstallmentFundingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cbay:NumberOfInstallmentFundingAxis">cbay:InstallmentFundingNumberThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="P01_31_2022To01_31_2022_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis_FinancingAgreementFundingInstallmentsTwoMemberCBAYCbayfinancingAgreementFundingInstallmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cbay:CbayfinancingAgreementFundingInstallmentsAxis">cbay:FinancingAgreementFundingInstallmentsTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="P01_31_2022To01_31_2022_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:EquityIncentivePlanTwoThousandAndTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-09-01</startDate>
            <endDate>2013-09-30</endDate>
        </period>
    </context>
    <context id="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-09-01</startDate>
            <endDate>2013-09-30</endDate>
        </period>
    </context>
    <context id="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_NonQualifiedStockOptionsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cbay:NonQualifiedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-09-01</startDate>
            <endDate>2013-09-30</endDate>
        </period>
    </context>
    <context id="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_IncentiveStockOptionsForEmployeesAndDirectorsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cbay:IncentiveStockOptionsForEmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-09-01</startDate>
            <endDate>2013-09-30</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-09-30</instant>
        </period>
    </context>
    <context id="P01_01_2017To12_31_2017_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_StockOptionsToTenPercentShareholdersMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cbay:StockOptionsToTenPercentShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_EquityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:EquityIncentivePlanTwoThousandAndTwentyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_01_2022_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:EquityIncentivePlanTwoThousandAndThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="PAsOn01_31_2014_IncentiveStockAwardsMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:IncentiveStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-31</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2014_IncentiveStockAwardsMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbay:IncentiveStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-04-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2017_FederalMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbay:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2018_FederalMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbay:FederalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="P01_23_2023To01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-23</startDate>
            <endDate>2023-01-23</endDate>
        </period>
    </context>
    <context id="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cbay:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-23</instant>
        </period>
    </context>
    <context id="PAsOn01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-23</instant>
        </period>
    </context>
    <context id="PAsOn01_06_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cbay:AgreementAxis">cbay:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-06</instant>
        </period>
    </context>
    <context id="P01_01_2023To01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_KakenPharmaceuticalCo.LtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbay:KakenPharmaceuticalCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cbay:AgreementAxis">cbay:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cbay:AgreementAxis">cbay:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_KakenPharmaceuticalCo.LtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbay:KakenPharmaceuticalCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cbay:AgreementAxis">cbay:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="PAsOn01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cbay:AgreementAxis">cbay:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cbay:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="PAsOn01_31_2022_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">cbay:AbwCyclopsSpvLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cbay:AgreementAxis">cbay:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001042074</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_JPY">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_segment">
        <measure>cbay:segment</measure>
    </unit>
    <unit id="Unit_INSTALLMENTS">
        <measure>cbay:INSTALLMENTS</measure>
    </unit>
    <unit id="Unit_Facility">
        <measure>cbay:Facility</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2022To12_31_2022">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2022To12_31_2022">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="P01_01_2022To12_31_2022">0001042074</dei:EntityCentralIndexKey>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2022To12_31_2022" id="hidden71088888">CA</dei:EntityAddressStateOrProvince>
    <dei:DocumentType contextRef="P01_01_2022To12_31_2022">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="P01_01_2022To12_31_2022">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="P01_01_2022To12_31_2022">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="P01_01_2022To12_31_2022">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2022To12_31_2022">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="P01_01_2022To12_31_2022">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="P01_01_2022To12_31_2022">001-36500</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="P01_01_2022To12_31_2022">CYMABAY THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2022To12_31_2022">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2022To12_31_2022">94-3103561</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2022To12_31_2022">7575 Gateway Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="P01_01_2022To12_31_2022">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2022To12_31_2022">Newark</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2022To12_31_2022">94560</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2022To12_31_2022">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2022To12_31_2022">293-8800</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="P01_01_2022To12_31_2022">Common stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="P01_01_2022To12_31_2022">CBAY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="P01_01_2022To12_31_2022">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="P01_01_2022To12_31_2022">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="P01_01_2022To12_31_2022">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="P01_01_2022To12_31_2022">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="P01_01_2022To12_31_2022">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="P01_01_2022To12_31_2022">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2022To12_31_2022">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2022To12_31_2022">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="P01_01_2022To12_31_2022">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="P01_01_2022To12_31_2022">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="PAsOn06_30_2022"
      decimals="0"
      unitRef="Unit_USD">218053044</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="PAsOn03_15_2023"
      decimals="INF"
      unitRef="Unit_shares">97293397</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2022" id="hidden71088836">http://fasb.org/us-gaap/2022#OtherAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="PAsOn12_31_2021" id="hidden71088837">http://fasb.org/us-gaap/2022#OtherAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis"
      id="hidden71088416">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:AuditorFirmId contextRef="P01_01_2022To12_31_2022">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="P01_01_2022To12_31_2022">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="P01_01_2022To12_31_2022">San Mateo, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20291000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">125806000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">115194000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">60729000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2588000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4564000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">138073000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">191099000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">701000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1178000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8067000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">169000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">254000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2909000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1720000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">141852000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">202318000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1096000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2728000</us-gaap:AccountsPayableCurrent>
    <cbay:AccruedResearchAndDevelopmentExpenses
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6530000</cbay:AccruedResearchAndDevelopmentExpenses>
    <cbay:AccruedResearchAndDevelopmentExpenses
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9752000</cbay:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7815000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5886000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">15441000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">18366000</us-gaap:LiabilitiesCurrent>
    <cbay:DevelopmentFinancingLiabilityNonCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">90227000</cbay:DevelopmentFinancingLiabilityNonCurrent>
    <cbay:DevelopmentFinancingLiabilityNonCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">50320000</cbay:DevelopmentFinancingLiabilityNonCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">30000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">695000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">105698000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">69381000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2022"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">84681063</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">84681063</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">84677939</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">84677939</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">909329000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">899798000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-326000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-13000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-872857000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-766856000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">36154000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">132937000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">141852000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">202318000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">67995000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">64542000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">25116000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">23040000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">93111000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">87582000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-93111000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-87582000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2017000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">167000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">14907000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2583000</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-12890000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-2416000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-106001000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-89998000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-313000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-21000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-313000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-21000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-106314000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-90019000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-1.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-1.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">87804063</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">87804063</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">71055331</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">71055331</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">68946092</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">819549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-676858000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">142706000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">106847</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">219000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">219000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">9996000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9996000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4965000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <cbay:IssuanceOfCommonStockAndPrefundedWarrantsShares
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">15625000</cbay:IssuanceOfCommonStockAndPrefundedWarrantsShares>
    <cbay:IssuanceOfCommonStockAndPrefundedWarrants
      contextRef="P01_01_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</cbay:IssuanceOfCommonStockAndPrefundedWarrants>
    <cbay:IssuanceOfCommonStockAndPrefundedWarrants
      contextRef="P01_01_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">70034000</cbay:IssuanceOfCommonStockAndPrefundedWarrants>
    <cbay:IssuanceOfCommonStockAndPrefundedWarrants
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">70035000</cbay:IssuanceOfCommonStockAndPrefundedWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-89998000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-89998000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="P01_01_2021To12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-21000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-21000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">84677939</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">899798000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-766856000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">132937000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">3124</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <cbay:IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5000</cbay:IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants>
    <cbay:IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5000</cbay:IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">9517000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9517000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-106001000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-106001000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="P01_01_2022To12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-313000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-313000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">84681063</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">909329000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-326000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-872857000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">36154000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-106001000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-89998000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">710000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">688000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9517000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9996000</us-gaap:ShareBasedCompensation>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">312000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <cbay:AccretionOfDevelopmentFinancingLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">14907000</cbay:AccretionOfDevelopmentFinancingLiability>
    <cbay:AccretionOfDevelopmentFinancingLiability
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2583000</cbay:AccretionOfDevelopmentFinancingLiability>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">874000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-637000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-1976000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-386000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1189000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1513000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-1444000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2309000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <cbay:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-3222000</cbay:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <cbay:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5054000</cbay:IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1540000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">115000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-84080000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-69431000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">148000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">87000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">174977000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">78084000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">129140000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">126760000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-45985000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">48589000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">219000</us-gaap:ProceedsFromStockOptionsExercised>
    <cbay:ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-459000</cbay:ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants>
    <cbay:ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">70499000</cbay:ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants>
    <cbay:ProceedsFromDevelopmentFinancingNetOFtransactionCosts
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">25000000</cbay:ProceedsFromDevelopmentFinancingNetOFtransactionCosts>
    <cbay:ProceedsFromDevelopmentFinancingNetOFtransactionCosts
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">47737000</cbay:ProceedsFromDevelopmentFinancingNetOFtransactionCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">24550000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">118455000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-105515000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">97613000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">125806000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">28193000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20291000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">125806000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">686000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">666000</us-gaap:OperatingLeasePayments>
    <us-gaap:LiabilitiesAssumed1
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">464000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 5%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Organization and Description of Business &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;CymaBay Therapeutics, Inc. (the Company or CymaBay) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. The Company&#x2019;s lead clinical development candidate is seladelpar. Seladelpar has been primarily under development for the treatment primary biliary cholangitis (PBC), a rare liver disease. The Company was incorporated in Delaware in October 1988 as Transtech Corporation. The Company&#x2019;s headquarters and operations are located in Newark, California and it operates&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in &lt;/div&gt;one&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; segment.&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Liquidity &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has incurred net operating losses and negative cash flows from operations since its inception. During the year ended December&#160;31, 2022, the Company incurred a net loss of $106.0&#160;million and used $84.1&#160;million of cash in operations. At December&#160;31, 2022, the Company had an accumulated deficit of $872.9&#160;million. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Historically, the Company has incurred substantial research and development expenses in the course of studying its product candidates in clinical trials. To date, none of the Company&#x2019;s product candidates have been approved for marketing and sale, and the Company has not recorded any revenue from product sales. Generally, the Company&#x2019;s ability to achieve profitability is dependent on its ability to successfully develop, acquire or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-license&lt;/div&gt; additional product candidates, conduct clinical trials for those product candidates, obtain regulatory approvals, and support commercialization activities for those product candidates. Any products developed will require approval of the U.S. Food and Drug Administration (FDA) or a foreign regulatory authority prior to commercial sale. The regulatory approval process is expensive, time-consuming, and uncertain, and any denial or delay of approval could have a material adverse effect on the Company. Even if approved, the Company&#x2019;s products may not achieve market acceptance and will face competition from both generic and branded pharmaceutical products. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During and subsequent to the year ended December&#160;31, 2022, the Company completed certain transactions as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In January 2022, the Company received the third installment of&#160;&lt;/div&gt;$25.0&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million of the Company&#x2019;s Development Financing Agreement (the Financing Agreement) with ABW Cyclops SPV LP, an affiliate of Abingworth LLP (Abingworth), pursuant to which Abingworth committed to provide&#160;&lt;/div&gt;$75.0&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million in funding in&#160;&lt;/div&gt;three &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;equal quarterly installments. For further details, refer to&lt;div style="font-style:italic;display:inline;"&gt; Note 6&#x2014;Development Financing Agreement.&#160;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January 6, 2023, the Company entered into a Collaboration and License Agreement with Kaken Pharmaceutical Co., Ltd (Kaken). Pursuant to the agreement, the Company granted Kaken an exclusive license to commercialize seladelpar for the treatment of PBC in Japan and received an upfront cash payment of&#160;&lt;/div&gt;$34.2&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million. For further details, refer to &lt;div style="font-style:italic;display:inline;"&gt;Note 13&#x2014;Subsequent Events.&#160;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 6pt; margin-top: 0px; margin-bottom: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;;text-indent: 0px;"&gt;On January&#160;23, 2023, the Company sold 11,821,428 shares of common stock at $7.00 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per share and a pre-funded warrant to purchas&lt;/div&gt;e 2,142,857 shares of common stock at $6.9999 &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;per share in a public equity offering, for total net proceeds of&lt;/div&gt;&#160;&lt;/div&gt;$92.4&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million, after deducting underwriting and other offering expenses. For further details, refer to &lt;div style="font-style:italic;display:inline;"&gt;Note 13&#x2014;Subsequent Events.&#160;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2022, the Company had cash, cash equivalents and marketable securities totaling&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;135.5&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;million. As the Company continues to advance its clinical studies of seladelpar, the Company believes its existing funds, together with the &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;34.2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million upfront payment received from Kaken in January 2023 pursuant to the Collaboration and License Agreement and the &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;92.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million in net proceeds raised in connection with the January 2023 public equity offering, are sufficient to fund the Company&#x2019;s current operating plan for at least twelve months from the issuance date of its financial &lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;The Company has &lt;div style="display:inline;"&gt;historically &lt;/div&gt;obtained, and expects to obtain in the future, additional &lt;div style="display:inline;"&gt;financing &lt;/div&gt;to fund its business strategy through: future equity offerings; debt financing; one or more possible licenses, collaborations or other similar arrangements with respect to development and/or commercialization rights of the Company&#x2019;s product candidates; or a combination of the above. It is unclear if or when any such transactions will occur, on satisfactory terms or at all. The Company&#x2019;s failure to raise capital as and when needed could have a negative impact on its financial condition and its ability to pursue its business strategies. If adequate funds are not available to the Company, it could have a material adverse effect on the Company&#x2019;s business, results of operations, and financial condition. Market volatility could also adversely impact the Company&#x2019;s ability to access capital when and as needed. Failure to raise sufficient capital when needed could require the Company to significantly delay, scale back or discontinue its product development programs or commercialization efforts or other aspects of its business plans, and its operating results and financial condition would be adversely &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;affected. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">-106000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">-84100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">-872900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P01_31_2022To01_31_2022_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis_FinancingAgreementFundingInstallmentsTwoMemberCBAYCbayfinancingAgreementFundingInstallmentsAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P01_31_2022To01_31_2022_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">75000000</us-gaap:ProceedsFromLinesOfCredit>
    <cbay:NumberOfFundingInstallments
      contextRef="PAsOn01_31_2022_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis"
      decimals="0"
      unitRef="Unit_INSTALLMENTS">3</cbay:NumberOfFundingInstallments>
    <cbay:UpfrontCashPayment
      contextRef="PAsOn01_06_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">34200000</cbay:UpfrontCashPayment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_23_2023To01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">11821428</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">2142857</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">6.9999</us-gaap:SaleOfStockPricePerShare>
    <cbay:GrossProceedsFromPublicOffering
      contextRef="P01_23_2023To01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">92400000</cbay:GrossProceedsFromPublicOffering>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">135500000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <cbay:UpfrontCashPayment
      contextRef="PAsOn01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_KakenPharmaceuticalCo.LtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">34200000</cbay:UpfrontCashPayment>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_KakenPharmaceuticalCo.LtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">92400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2. Summary of Significant Accounting &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Policies&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of Presentation and Use of Estimates &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements are comprised of the accounts of CymaBay and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company has no unconsolidated subsidiaries or investments accounted for under the equity method. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;These consolidated statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), which requires management to make informed estimates and assumptions that impact the amounts and disclosures reported in the consolidated financial statements and accompanying notes. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounting estimates and assumptions are inherently uncertain. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ materially from those estimates and assumptions. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each reporting period and updated to reflect current information. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s financial instruments during the periods reported consist of cash, cash equivalents, marketable securities, accounts payable, certain accrued liabilities, and the development financing liability. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs and is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 2&#x2014;Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 3&#x2014;Inputs that are significant to the fair value measurement and are unobservable (i.e. supported by little market activity), which requires the reporting entity to develop its own valuation techniques and &lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;assumptions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;   &lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts of cash equivalents approximate their related fair value due to the short-term nature of these instruments. Cash equivalents are classified as level 1 under the fair value hierarchy. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; following tables present the Company&#x2019;s financial assets that are measured at fair value on a recurring basis using the above input categories (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and foreign commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;46,121&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;46,121&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and foreign corporate debt securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;24,807&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;24,807&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supranational debt securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;12,890&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;12,890&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. agency securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,759&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,759&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. treasury securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;23,617&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;23,617&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total marketable securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;115,194&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;115,194&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;115,194&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;124,964&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and foreign commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;28,760&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;28,760&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and foreign corporate debt securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;23,535&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;23,535&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset-backed securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;8,522&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;8,522&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. treasury securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,979&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,979&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total marketable securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;68,796&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;68,796&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;68,796&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;154,434&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear:both;max-height:0pt;"/&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div&gt; &lt;div style="display: inline; background-color: white;"&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt; &lt;div style="display: inline;"&gt; &lt;div style="top: 0px; letter-spacing: 0px; font-family: 'Times New Roman'; font-size: 10pt; display: inline;"&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="margin-top: 1em; margin-bottom: 1em"/&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company estimates the fair value of its money market funds, corporate debt, asset-backed securities, commercial paper, U.S. treasury and agency securities, and supranational debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s development financing liability is $79.5&#160;million. The development financing liability is classified as level 3 under the fair value hierarchy as its valuation is based on a discounted cash flow model that uses unobservable inputs such as the estimated timing of regulatory approval, attainment of certain sales milestones and the discount &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;rate. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;    &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, Cash Equivalents, and Marketable Securities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking, interest-bearing, and money market funds. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company invests excess cash in marketable securities with high credit ratings. These securities consist primarily of corporate debt, commercial paper, asset-backed securities, U.S. treasury, U.S. agency securities and supranational debt securities and are classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;available-for-sale.&#x201d;&lt;/div&gt;&lt;/div&gt; The Company considers marketable securities as short-term investments if the maturity date &lt;/div&gt;is less than or equal to one year from the balance sheet date. The Company considers marketable securities as long-term investments if the maturity date is in excess of one year from the balance sheet date.&lt;br/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Realized &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;gains&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and losses from the sale of marketable securities, if any, are calculated using the specific-identification method. Realized gains and losses and declines in value judged to be other-than-temporary are included in interest income or expense in the consolidated statements of operations and comprehensive loss. Unrealized holding gains and losses are reported in accumulated other comprehensive loss in the consolidated balance sheets. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. In determining whether a decline in market value is other-than-temporary, various factors are considered, including the cause, duration of time and severity of the impairment, any adverse changes in the investees&#x2019; financial condition, and the Company&#x2019;s intent and ability to hold the security for a period of time sufficient to allow for an anticipated recovery in market value.&lt;/div&gt;&lt;/div&gt;  &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Concentration of Risk &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Cash, cash equivalents, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;and market&lt;/div&gt;able securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded on the balance sheet. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the consolidated balance sheets. &lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt;The Company maintains deposits in excess of FDIC insured deposit limits with its financial institutions. &lt;/div&gt;&lt;/div&gt; &lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt;Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an NDA filed with the FDA for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#x2019;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.&#160;&lt;/div&gt;&lt;/div&gt;   &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property &lt;/div&gt;&lt;/div&gt;and equipment are recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method, and the costs are amortized over the estimated useful lives of the respective assets, which are generally &lt;span style="-sec-ix-hidden:hidden71088416"&gt;three&lt;/span&gt; to seven years. Leasehold improvements are amortized over the shorter of the useful lives or the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancelable&lt;/div&gt; term of the related lease. Maintenance and repair costs are charged as expense in the consolidated statements of operations and comprehensive loss as incurred. &lt;/div&gt;   &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company reviews the carrying value long-lived assets, including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; operating lease assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;   &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; may not be fully recoverable. If a change in circumstance occurs, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. If cash flows cannot be separately and independently identified for a single asset, the Company will determine whether impairment has occurred for the group of assets for which the Company can identify the projected cash flows. If the carrying values are in excess of undiscounted expected future cash flows, the Company measures any impairment by comparing the fair value of the asset or asset group to its carrying value. There were no indicators of impairment of long-lived assets for any periods &lt;div style="display:inline;"&gt;presented&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;The Company has one lease, a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancelable&lt;/div&gt; operating lease agreement for its corporate office. The Company recognizes a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. The Company determines whether an arrangement is or contains a lease at contract inception. Operating leases are included in operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets, other accrued liabilities, and long-term portion of operating lease liabilities in the Company&#x2019;s consolidated balance sheets at December&#160;31, 2022 and 2021. Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date. The incremental borrowing rate represents the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company considers a lease term to be the noncancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets also include any lease payments made and exclude lease incentives. Lease expense is recognized on a straight-line basis over the expected lease term. The Company has elected to not separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components for its leased assets and accounts for all lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components of its agreements as a single lease component. The Company does not record leases on its consolidated balance sheets when a lease has a term of one year or less. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and Development Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses consist of costs incurred in identifying, developing, and testing product candidates. These expenses consist primarily of costs for research and development personnel, including related stock-based compensation; contract research organizations (CRO) and other third parties that assist in managing, monitoring, and analyzing clinical trials; investigator and site fees; laboratory services; consultants; contract manufacturing services; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-clinical&lt;/div&gt; studies, including materials; and allocated expenses, such as depreciation of assets, and facilities and information technology that support research and development activities. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are recorded as prepaid assets until the goods are received or services are rendered. Such payments are evaluated for current or long-term classification based on when they will be realized. Additionally, if expectations change such that the Company does not expect goods to be delivered or services to be rendered, such prepayments are charged to expense to the extent they are nonrefundable. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records expenses related to clinical studies and manufacturing development activities based on its estimates of the services received and efforts expended pursuant to contracts with multiple CROs and manufacturing vendors that conduct and manage these activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to the Company&#x2019;s vendors will exceed the level of services provided and result in a prepayment. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical trial milestones. In expensing service fees, the Company estimates the time period over which services will be performed, enrollment of subjects, number of &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;   &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company&#x2019;s estimate, the Company will adjust the accrued or prepaid expense balance accordingly. In 2022 and 2021, there have been no material differences from the Company&#x2019;s estimates to the amounts actually incurred. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt; &lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Development Financing Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for the Development Financing Agreement with Abingworth as a debt instrument. Accordingly, the Company has recorded payments received under the Financing Agreement as part of a development financing liability in the Company&#x2019;s consolidated balance sheet. The liability is recorded at amortized cost and accreted to the contractual success fee amounts based on the estimated timing of regulatory approval and attainment of certain sales milestones using an imputed interest rate. Certain transaction fees incurred specifically to complete the Financing Agreement were capitalized and recorded as a reduction to the carrying amount of the development financing liability and are being amortized to interest expense using the effective interest rate method. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There are several factors that could affect the estimated timing of regulatory approval and attainment of sales milestones, some of which are not entirely within the Company&#x2019;s control. Therefore, the Company periodically reassesses the estimated timing of regulatory approval and attainment of sales milestones, and the expected contractual success fee payments due therefrom. If the timing and/or amount of such expected payments is materially different than original estimates, the Company will prospectively adjust the accretion of the development financing liability and the imputed interest rate. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company identified certain contingent repayment features in the Financing Agreement that are required to be bifurcated from the debt host instrument as embedded derivative liabilities; however, the Company determined the fair value of these features, both individually and in the aggregate, was immaterial at inception and as of December&#160;31, 2022. The fair value of these features will be assessed at each reporting date and will be marked to market, if material. To determine the amount to record for the embedded derivative liabilities, the Company must assess the probability of occurrence of various potential &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;future &lt;/div&gt;events that could affect the timing and/or amount of future cash flows related to the Financing Agreement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;   &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-funded&lt;/div&gt; Warrants &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Company&#x2019;s public equity offering co&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;mpleted in &lt;/div&gt;November 2021, the Company issued &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase 3,125,000 shares of common stock at a price of $3.9999 per share. These &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants have an exercise price of $0.0001&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;per share, were fully exercisable upon issuance, and have no expiration date. The Company determined that the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants should be equity classified because they are freestanding financial instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Company&#x2019;s common stock and meet the equity classification criteria. In addition, such &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants do not provide any guarantee of value or return. Accordingly, the proceeds from the issuance of the warrants were recorded as additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital on the Company&#x2019;s consolidated balance sheet as of December&#160;31, 2022. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 9&#x2014;Stockholders&#x2019; Equity&lt;/div&gt;&lt;/div&gt; for additional &lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;information. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation is measured at fair value on the grant date of the award. Compensation cost is recognized as expense on a straight-line basis over the vesting period for options with service conditions and forfeitures are accounted for as they occur. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock option awards. The determination of fair value for stock-based awards using an option-pricing model requires management to make certain assumptions regarding subjective input variables such as expected term, dividends, volatility and risk-free rate. If actual results are not consistent with the &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;  &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company&#x2019;s assumptions used in making these estimates, the Company may be required to increase or decrease compensation expense, which could be material to the Company&#x2019;s results of operations.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The &lt;div style="display:inline;"&gt;Company &lt;/div&gt;utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and the tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when it is more likely than not that all or part of a deferred tax asset will not be realized. When the Company establishes or reduces the valuation allowance related to the deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination based on the technical merits of the position. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is required to file federal and state income tax returns in the United States. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect that could affect the amount of tax paid to these jurisdictions. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records interest related to income tax reserves, if any, as interest expense, and any penalties would be recorded as other expense in the consolidated statements of operations and comprehensive loss. &lt;/div&gt;   &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Comprehensive loss includes net loss and net unrealized gains and losses on marketable securities, which are presented in a single continuous statement. Other comprehensive (loss) gain is also disclosed in the consolidated balance sheets and statements of stockholders&#x2019; equity in accumulated other comprehensive income (loss), and is stated net of related tax effects, if any. &lt;br/&gt;&lt;/div&gt;  &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net Loss Per Common Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net loss per share of common stock is based on the weighted average number of shares of common stock and common stock equivalents outstanding during the period. The weighted-average common shares outstanding as of December 31, 2022 and 2021 includes pre-funded warrants to purchase up to&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;3,125,000&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares of common stock that were issued in connection with the November 2021 public offering, as &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;discussed in &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note&#160;9&#x2014;Stockholders&#x2019; Equity&lt;/div&gt;&lt;/div&gt;. Diluted &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; net loss per share of common stock is calculated as the weighted average number of shares of common stock outstanding adjusted to include the assumed exercises of stock options, if dilutive. In all periods presented, the Company&#x2019;s outstanding stock options and incentive awards were excluded from the calculation of net loss per share because the effect would be antidilutive. &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;   &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(106,001&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(89,998&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common stock shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;84,679,063&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;70,712,865&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-funded warrants outstanding&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;3,125,000&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;342,466&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;87,804,063&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;71,055,331&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1.21&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1.27&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;   &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Common stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;13,930&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;10,791&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Incentive awards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;14,031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;10,892&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;  &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently Issued Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13,&lt;/div&gt; Financial Instruments&#x2014;Credit Losses (Topic 326): &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Measurement of Credit Losses on Financial Instruments&lt;/div&gt;&lt;/div&gt;, an amendment which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#x201c;incurred loss&#x201d; model with an &#x201c;expected loss&#x201d; model. Accordingly, these financial assets will be presented at the net amount expected to be collected. The amendment also requires that credit losses related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt; debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. In November 2019, FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2019-10,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842)&lt;/div&gt;&lt;/div&gt;, which deferred the adoption deadline for smaller reporting companies to fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years. Early adoption is permitted, and entities are required to use a modified retrospective approach, with certain exceptions. The Company intends to adopt this ASU on January&#160;1, 2023 and does not expect a material impact to its consolidated financial statements and related disclosures. &lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Basis of Presentation and Use of Estimates &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accompanying consolidated financial statements are comprised of the accounts of CymaBay and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company has no unconsolidated subsidiaries or investments accounted for under the equity method. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;These consolidated statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), which requires management to make informed estimates and assumptions that impact the amounts and disclosures reported in the consolidated financial statements and accompanying notes. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accounting estimates and assumptions are inherently uncertain. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Actual results could differ materially from those estimates and assumptions. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each reporting period and updated to reflect current information. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s financial instruments during the periods reported consist of cash, cash equivalents, marketable securities, accounts payable, certain accrued liabilities, and the development financing liability. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs and is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 1&#x2014;Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 2&#x2014;Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level 3&#x2014;Inputs that are significant to the fair value measurement and are unobservable (i.e. supported by little market activity), which requires the reporting entity to develop its own valuation techniques and &lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;assumptions. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;   &lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The carrying amounts of cash equivalents approximate their related fair value due to the short-term nature of these instruments. Cash equivalents are classified as level 1 under the fair value hierarchy. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; following tables present the Company&#x2019;s financial assets that are measured at fair value on a recurring basis using the above input categories (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and foreign commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;46,121&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;46,121&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and foreign corporate debt securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;24,807&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;24,807&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supranational debt securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;12,890&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;12,890&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. agency securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,759&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,759&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. treasury securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;23,617&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;23,617&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total marketable securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;115,194&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;115,194&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;115,194&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;124,964&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and foreign commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;28,760&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;28,760&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and foreign corporate debt securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;23,535&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;23,535&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset-backed securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;8,522&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;8,522&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. treasury securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,979&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,979&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total marketable securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;68,796&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;68,796&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;68,796&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;154,434&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="clear:both;max-height:0pt;"/&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div&gt; &lt;div style="display: inline; background-color: white;"&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt; &lt;div style="display: inline;"&gt; &lt;div style="top: 0px; letter-spacing: 0px; font-family: 'Times New Roman'; font-size: 10pt; display: inline;"&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="margin-top: 1em; margin-bottom: 1em"/&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company estimates the fair value of its money market funds, corporate debt, asset-backed securities, commercial paper, U.S. treasury and agency securities, and supranational debt securities by taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s development financing liability is $79.5&#160;million. The development financing liability is classified as level 3 under the fair value hierarchy as its valuation is based on a discounted cash flow model that uses unobservable inputs such as the estimated timing of regulatory approval, attainment of certain sales milestones and the discount &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;rate. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; following tables present the Company&#x2019;s financial assets that are measured at fair value on a recurring basis using the above input categories (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and foreign commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;46,121&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;46,121&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and foreign corporate debt securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;24,807&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;24,807&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Supranational debt securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;12,890&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;12,890&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. agency securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,759&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,759&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. treasury securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;23,617&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;23,617&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total marketable securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;115,194&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;115,194&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;115,194&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;124,964&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"/&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and foreign commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;28,760&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;28,760&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and foreign corporate debt securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;23,535&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;23,535&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset-backed securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;8,522&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;8,522&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. treasury securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,979&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,979&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total marketable securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;68,796&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;68,796&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 59%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;68,796&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 4%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;154,434&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; margin-top: 0pt; margin-bottom: 0pt; line-height: 11pt;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 59%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="padding: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CashEquivalentsMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">9770000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CashEquivalentsMemberusgaapInvestmentTypeAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">9770000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CashEquivalentsMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">9770000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CashEquivalentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">9770000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">46121000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CommercialPaperMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">46121000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">24807000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">24807000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_SupranationalDebtSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">12890000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_SupranationalDebtSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">12890000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_UsAgencySecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">7759000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_UsAgencySecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">7759000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">23617000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">23617000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">115194000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">115194000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">9770000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">115194000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">124964000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CashEquivalentsMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">85638000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CashEquivalentsMemberusgaapInvestmentTypeAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">85638000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CashEquivalentsMemberusgaapInvestmentTypeAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">85638000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CashEquivalentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">85638000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">28760000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CommercialPaperMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">28760000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">23535000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">23535000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">8522000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFairValueByAssetClassAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">8522000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">7979000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis_USTreasurySecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">7979000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">68796000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_ShortTermInvestmentsMemberusgaapInvestmentTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">68796000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">85638000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">68796000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">154434000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">79500000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <cbay:CashEquivalentsAndInvestmentsPolicyTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, Cash Equivalents, and Marketable Securities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits with commercial banks in checking, interest-bearing, and money market funds. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company invests excess cash in marketable securities with high credit ratings. These securities consist primarily of corporate debt, commercial paper, asset-backed securities, U.S. treasury, U.S. agency securities and supranational debt securities and are classified as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;available-for-sale.&#x201d;&lt;/div&gt;&lt;/div&gt; The Company considers marketable securities as short-term investments if the maturity date &lt;/div&gt;is less than or equal to one year from the balance sheet date. The Company considers marketable securities as long-term investments if the maturity date is in excess of one year from the balance sheet date.&lt;br/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Realized &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;gains&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;and losses from the sale of marketable securities, if any, are calculated using the specific-identification method. Realized gains and losses and declines in value judged to be other-than-temporary are included in interest income or expense in the consolidated statements of operations and comprehensive loss. Unrealized holding gains and losses are reported in accumulated other comprehensive loss in the consolidated balance sheets. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value. In determining whether a decline in market value is other-than-temporary, various factors are considered, including the cause, duration of time and severity of the impairment, any adverse changes in the investees&#x2019; financial condition, and the Company&#x2019;s intent and ability to hold the security for a period of time sufficient to allow for an anticipated recovery in market value.&lt;/div&gt;&lt;/div&gt; </cbay:CashEquivalentsAndInvestmentsPolicyTextBlock>
    <cbay:CashEquivalentMaturityDescription contextRef="P01_01_2022To12_31_2022">90 days or less</cbay:CashEquivalentMaturityDescription>
    <cbay:ShortTermInvestmentContractualMaturity contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis">P1Y</cbay:ShortTermInvestmentContractualMaturity>
    <cbay:ShortTermInvestmentContractualMaturity contextRef="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis">P1Y</cbay:ShortTermInvestmentContractualMaturity>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Concentration of Risk &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Cash, cash equivalents, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;and market&lt;/div&gt;able securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded on the balance sheet. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established guidelines relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments and issuers of investments to the extent recorded on the consolidated balance sheets. &lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt;The Company maintains deposits in excess of FDIC insured deposit limits with its financial institutions. &lt;/div&gt;&lt;/div&gt; &lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt;Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an NDA filed with the FDA for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#x2019;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.&#160;&lt;/div&gt;&lt;/div&gt; </us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property &lt;/div&gt;&lt;/div&gt;and equipment are recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are calculated using the straight-line method, and the costs are amortized over the estimated useful lives of the respective assets, which are generally &lt;span style="-sec-ix-hidden:hidden71088416"&gt;three&lt;/span&gt; to seven years. Leasehold improvements are amortized over the shorter of the useful lives or the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancelable&lt;/div&gt; term of the related lease. Maintenance and repair costs are charged as expense in the consolidated statements of operations and comprehensive loss as incurred. &lt;/div&gt; </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company reviews the carrying value long-lived assets, including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; operating lease assets, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;    &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; font-size: 10pt; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; may not be fully recoverable. If a change in circumstance occurs, the Company performs a test of recoverability by comparing the carrying value of the asset or asset group to its undiscounted expected future cash flows. If cash flows cannot be separately and independently identified for a single asset, the Company will determine whether impairment has occurred for the group of assets for which the Company can identify the projected cash flows. If the carrying values are in excess of undiscounted expected future cash flows, the Company measures any impairment by comparing the fair value of the asset or asset group to its carrying value. There were no indicators of impairment of long-lived assets for any periods &lt;div style="display:inline;"&gt;presented&lt;/div&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;The Company has one lease, a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cancelable&lt;/div&gt; operating lease agreement for its corporate office. The Company recognizes a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. The Company determines whether an arrangement is or contains a lease at contract inception. Operating leases are included in operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets, other accrued liabilities, and long-term portion of operating lease liabilities in the Company&#x2019;s consolidated balance sheets at December&#160;31, 2022 and 2021. Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the net present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date. The incremental borrowing rate represents the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company considers a lease term to be the noncancelable period that it has the right to use the underlying asset, including any periods where it is reasonably assured the Company will exercise the option to extend the contract. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets also include any lease payments made and exclude lease incentives. Lease expense is recognized on a straight-line basis over the expected lease term. The Company has elected to not separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components for its leased assets and accounts for all lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components of its agreements as a single lease component. The Company does not record leases on its consolidated balance sheets when a lease has a term of one year or less. &lt;/div&gt;&lt;/div&gt; </us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and Development Expenses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses consist of costs incurred in identifying, developing, and testing product candidates. These expenses consist primarily of costs for research and development personnel, including related stock-based compensation; contract research organizations (CRO) and other third parties that assist in managing, monitoring, and analyzing clinical trials; investigator and site fees; laboratory services; consultants; contract manufacturing services; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-clinical&lt;/div&gt; studies, including materials; and allocated expenses, such as depreciation of assets, and facilities and information technology that support research and development activities. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are recorded as prepaid assets until the goods are received or services are rendered. Such payments are evaluated for current or long-term classification based on when they will be realized. Additionally, if expectations change such that the Company does not expect goods to be delivered or services to be rendered, such prepayments are charged to expense to the extent they are nonrefundable. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records expenses related to clinical studies and manufacturing development activities based on its estimates of the services received and efforts expended pursuant to contracts with multiple CROs and manufacturing vendors that conduct and manage these activities on its behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows. There may be instances in which payments made to the Company&#x2019;s vendors will exceed the level of services provided and result in a prepayment. Payments under some of these contracts depend on factors such as the successful enrollment of subjects and the completion of clinical trial milestones. In expensing service fees, the Company estimates the time period over which services will be performed, enrollment of subjects, number of &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;    &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sites activated and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the Company&#x2019;s estimate, the Company will adjust the accrued or prepaid expense balance accordingly. In 2022 and 2021, there have been no material differences from the Company&#x2019;s estimates to the amounts actually incurred. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <cbay:DevelopmentFinancingAgreementPolicyTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Development Financing Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for the Development Financing Agreement with Abingworth as a debt instrument. Accordingly, the Company has recorded payments received under the Financing Agreement as part of a development financing liability in the Company&#x2019;s consolidated balance sheet. The liability is recorded at amortized cost and accreted to the contractual success fee amounts based on the estimated timing of regulatory approval and attainment of certain sales milestones using an imputed interest rate. Certain transaction fees incurred specifically to complete the Financing Agreement were capitalized and recorded as a reduction to the carrying amount of the development financing liability and are being amortized to interest expense using the effective interest rate method. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There are several factors that could affect the estimated timing of regulatory approval and attainment of sales milestones, some of which are not entirely within the Company&#x2019;s control. Therefore, the Company periodically reassesses the estimated timing of regulatory approval and attainment of sales milestones, and the expected contractual success fee payments due therefrom. If the timing and/or amount of such expected payments is materially different than original estimates, the Company will prospectively adjust the accretion of the development financing liability and the imputed interest rate. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company identified certain contingent repayment features in the Financing Agreement that are required to be bifurcated from the debt host instrument as embedded derivative liabilities; however, the Company determined the fair value of these features, both individually and in the aggregate, was immaterial at inception and as of December&#160;31, 2022. The fair value of these features will be assessed at each reporting date and will be marked to market, if material. To determine the amount to record for the embedded derivative liabilities, the Company must assess the probability of occurrence of various potential &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;future &lt;/div&gt;events that could affect the timing and/or amount of future cash flows related to the Financing Agreement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </cbay:DevelopmentFinancingAgreementPolicyTextBlock>
    <cbay:PrefundedWarrantsPolicyTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-funded&lt;/div&gt; Warrants &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Company&#x2019;s public equity offering co&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;mpleted in &lt;/div&gt;November 2021, the Company issued &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchase 3,125,000 shares of common stock at a price of $3.9999 per share. These &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants have an exercise price of $0.0001&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;per share, were fully exercisable upon issuance, and have no expiration date. The Company determined that the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants should be equity classified because they are freestanding financial instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Company&#x2019;s common stock and meet the equity classification criteria. In addition, such &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants do not provide any guarantee of value or return. Accordingly, the proceeds from the issuance of the warrants were recorded as additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital on the Company&#x2019;s consolidated balance sheet as of December&#160;31, 2022. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 9&#x2014;Stockholders&#x2019; Equity&lt;/div&gt;&lt;/div&gt; for additional &lt;/div&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;information. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </cbay:PrefundedWarrantsPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn11_22_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">3125000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn11_22_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">3.9999</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn11_22_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation is measured at fair value on the grant date of the award. Compensation cost is recognized as expense on a straight-line basis over the vesting period for options with service conditions and forfeitures are accounted for as they occur. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock option awards. The determination of fair value for stock-based awards using an option-pricing model requires management to make certain assumptions regarding subjective input variables such as expected term, dividends, volatility and risk-free rate. If actual results are not consistent with the &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;   &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company&#x2019;s assumptions used in making these estimates, the Company may be required to increase or decrease compensation expense, which could be material to the Company&#x2019;s results of operations.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The &lt;div style="display:inline;"&gt;Company &lt;/div&gt;utilizes the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and the tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when it is more likely than not that all or part of a deferred tax asset will not be realized. When the Company establishes or reduces the valuation allowance related to the deferred tax assets, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination based on the technical merits of the position. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is required to file federal and state income tax returns in the United States. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect that could affect the amount of tax paid to these jurisdictions. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records interest related to income tax reserves, if any, as interest expense, and any penalties would be recorded as other expense in the consolidated statements of operations and comprehensive loss. &lt;/div&gt; </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Comprehensive loss includes net loss and net unrealized gains and losses on marketable securities, which are presented in a single continuous statement. Other comprehensive (loss) gain is also disclosed in the consolidated balance sheets and statements of stockholders&#x2019; equity in accumulated other comprehensive income (loss), and is stated net of related tax effects, if any. &lt;br/&gt;&lt;/div&gt; </us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net Loss Per Common Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net loss per share of common stock is based on the weighted average number of shares of common stock and common stock equivalents outstanding during the period. The weighted-average common shares outstanding as of December 31, 2022 and 2021 includes pre-funded warrants to purchase up to&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;3,125,000&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares of common stock that were issued in connection with the November 2021 public offering, as &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;discussed in &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note&#160;9&#x2014;Stockholders&#x2019; Equity&lt;/div&gt;&lt;/div&gt;. Diluted &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt; net loss per share of common stock is calculated as the weighted average number of shares of common stock outstanding adjusted to include the assumed exercises of stock options, if dilutive. In all periods presented, the Company&#x2019;s outstanding stock options and incentive awards were excluded from the calculation of net loss per share because the effect would be antidilutive. &lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;    &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(106,001&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(89,998&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common stock shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;84,679,063&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;70,712,865&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-funded warrants outstanding&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;3,125,000&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;342,466&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;87,804,063&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;71,055,331&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1.21&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1.27&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;   &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Common stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;13,930&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;10,791&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Incentive awards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;14,031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;10,892&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn12_31_2022_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">3125000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 63%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(106,001&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;(89,998&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average number of:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common stock shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;84,679,063&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;70,712,865&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-funded warrants outstanding&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;3,125,000&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;342,466&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 63%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;87,804,063&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;71,055,331&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; background-color: rgba(255, 255, 255, 0); width: 63%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1.21&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 9%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(1.27&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-106001000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-89998000</us-gaap:NetIncomeLoss>
    <cbay:WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">84679063</cbay:WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted>
    <cbay:WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">70712865</cbay:WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted>
    <cbay:WeightedAverageNumberOfPreFundedWarrantsOutstanding
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_shares">3125000</cbay:WeightedAverageNumberOfPreFundedWarrantsOutstanding>
    <cbay:WeightedAverageNumberOfPreFundedWarrantsOutstanding
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_shares">342466</cbay:WeightedAverageNumberOfPreFundedWarrantsOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">87804063</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">87804063</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">71055331</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">71055331</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-1.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">-1.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-1.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-1.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Common stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;13,930&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;10,791&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Incentive awards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;14,031&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;10,892&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_EmployeeOrNonEmployeeStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-3"
      unitRef="Unit_shares">13930000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_EmployeeOrNonEmployeeStockOptionsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-3"
      unitRef="Unit_shares">10791000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022_IncentiveStockAwardsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-3"
      unitRef="Unit_shares">101000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021_IncentiveStockAwardsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="-3"
      unitRef="Unit_shares">101000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_shares">14031000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_shares">10892000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently Issued Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-13&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13,&lt;/div&gt; Financial Instruments&#x2014;Credit Losses (Topic 326): &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Measurement of Credit Losses on Financial Instruments&lt;/div&gt;&lt;/div&gt;, an amendment which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The amendment updates the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the &#x201c;incurred loss&#x201d; model with an &#x201c;expected loss&#x201d; model. Accordingly, these financial assets will be presented at the net amount expected to be collected. The amendment also requires that credit losses related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt; debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. In November 2019, FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2019-10,&lt;/div&gt; &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842)&lt;/div&gt;&lt;/div&gt;, which deferred the adoption deadline for smaller reporting companies to fiscal years beginning after December&#160;15, 2022, including interim periods within those fiscal years. Early adoption is permitted, and entities are required to use a modified retrospective approach, with certain exceptions. The Company intends to adopt this ASU on January&#160;1, 2023 and does not expect a material impact to its consolidated financial statements and related disclosures. &lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3. Marketable &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Securities&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Marketable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities consist of the following (in&#160;thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt;Gains&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2022:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;Total cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Current marketable securities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;U.S. and foreign commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;46,121&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;46,121&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;U.S. and foreign corporate debt securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;24,964&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(157&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;24,807&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Supranational debt securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;12,946&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(56&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;12,890&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;U.S. agency securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,782&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(39&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,759&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;U.S. treasury securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;23,707&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(92&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;23,617&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;Total current marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;115,520&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(344&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;115,194&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;125,290&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(344&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;124,964&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current marketable securities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and foreign commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;28,760&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;28,760&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and foreign corporate debt securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;15,476&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&#x2014;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;15,468&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset-backed securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;8,524&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;8,522&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. treasury securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,982&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&#x2014;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,979&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current marketable securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;60,742&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;60,729&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; marketable securities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. corporate debt securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;8,067&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;8,068&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total marketable securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;154,447&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;154,435&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="text-align: center;;text-indent: 0px;"/&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;  &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s commercial paper and corporate debt securities consist of U.S. and foreign securities from issuers in various sectors, including finance and industry and have similar credit quality and risk characteristics. The Company&#x2019;s asset-backed securities are collateralized by credit card receivables and have investment-grade ratings. The Company&#x2019;s government securities are issued by the U.S. treasury and certain U.S. government-backed agencies. Supranational debt securities consist of securities issued with funding from various national governments. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;There were no realized gains and losses for the years ended December&#160;31, 2022 and 2021. None&lt;div style="display:inline;"&gt;&#160;of our investments have been in a continuous unrealized loss position for more than 12 months as of December 31, 2022 and 2021. The Company may sell certain of its marketable securities prior to their stated maturities for reasons including, but not limited to, managing liquidity, credit risk, duration and asset allocation.&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows the fair value of the Company&#x2019;s marketable securities, by contractual maturity, as of December&#160;31, 2022 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="vertical-align: bottom; width: 7%;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Due less than 1 year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;115,194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Due between 1 and 2 years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;115,194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; </us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;Marketable &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities consist of the following (in&#160;thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt;Gains&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Unrealized&lt;br/&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2022:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Money market funds&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;Total cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;9,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Current marketable securities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;U.S. and foreign commercial paper&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;46,121&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;46,121&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;U.S. and foreign corporate debt securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;24,964&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(157&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;24,807&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Supranational debt securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;12,946&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(56&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;12,890&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;U.S. agency securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,782&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;16&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(39&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,759&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;U.S. treasury securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;23,707&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;2&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(92&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;23,617&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;Total current marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;115,520&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(344&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;115,194&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Total marketable securities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;125,290&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;18&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(344&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;124,964&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 57%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amortized&lt;br/&gt;Cost&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Estimated&lt;br/&gt;Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash equivalents:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total cash equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;85,638&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current marketable securities:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and foreign commercial paper&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;28,760&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;28,760&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. and foreign corporate debt securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;15,476&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&#x2014;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(8&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;15,468&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Asset-backed securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;8,524&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;8,522&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. treasury securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,982&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;&#x2014;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(3&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,979&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current marketable securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;60,742&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(14&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;60,729&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-current&lt;/div&gt; marketable securities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;U.S. corporate debt securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;8,067&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;3&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(2&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;8,068&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 1px solid rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-size: 10pt; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 57%;"&gt;&lt;div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total marketable securities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;154,447&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;4&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(16&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 5%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;154,435&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 57%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="border-top: 3px double rgb(0, 0, 0); line-height: normal; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="text-align: center;;text-indent: 0px;"/&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; </us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">9770000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">9770000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">9770000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">9770000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">46121000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">46121000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">24964000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">157000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">24807000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_SupranationalDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">12946000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_SupranationalDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">56000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_SupranationalDebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">12890000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_UsAgencySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">7782000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_UsAgencySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_UsAgencySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">39000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_UsAgencySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">7759000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">23707000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">92000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">23617000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">115520000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">344000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">115194000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2022_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">125290000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2022_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2022_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">344000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">124964000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">85638000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis_MoneyMarketFundsMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">85638000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">85638000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_CashAndCashEquivalentsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">85638000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">28760000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">28760000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">15476000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">15468000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">8524000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_AssetBackedSecuritiesMemberusgaapFinancialInstrumentAxis_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">8522000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">7982000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis_USTreasurySecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-3"
      unitRef="Unit_USD">7979000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">60742000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_CurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">60729000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8067000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_NoncurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_NoncurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_CorporateDebtSecuritiesMemberusgaapFinancialInstrumentAxis_NoncurrentMarketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">8068000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="PAsOn12_31_2021_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">154447000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="PAsOn12_31_2021_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="PAsOn12_31_2021_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2021_MaketableSecuritiesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">154435000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="P01_01_2021To12_31_2021_DebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="P01_01_2022To12_31_2022_DebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <cbay:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments
      contextRef="PAsOn12_31_2021_DebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">0</cbay:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments>
    <cbay:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments
      contextRef="PAsOn12_31_2022_DebtSecuritiesMemberusgaapFinancialInstrumentAxis"
      decimals="-6"
      unitRef="Unit_USD">0</cbay:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table shows the fair value of the Company&#x2019;s marketable securities, by contractual maturity, as of December&#160;31, 2022 (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="vertical-align: bottom; width: 7%;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Due less than 1 year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;115,194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Due between 1 and 2 years&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total fair value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;115,194&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; </srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">115194000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">115194000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4. Certain Balance Sheet Items &lt;/div&gt;&lt;/div&gt;  &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are recorded at cost and consist of the following (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;2,429&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;2,429&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Office and computer equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;290&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;290&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Purchased software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;44&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;44&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;687&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;539&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt; width: 66%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;3,450&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;3,302&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Less: Accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(2,749&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(2,124&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;701&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;1,178&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Depreciation and amortization expense for the years ended December&#160;31, 2022 and 2021 was approximately $0.7&#160;million and $0.7&#160;million, respectively, and was recorded straight-line in both research and development expense and general and administrative expense in the consolidated statements of operations and comprehensive loss. All the Company&#x2019;s property and equipment is located in the U.S. &lt;/div&gt;  &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other accrued liabilities consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;5,779&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;3,986&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued professional fees and other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;1,372&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;1,333&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion of operating lease liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;664&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;567&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total other accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,815&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;5,886&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; </us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment are recorded at cost and consist of the following (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;2,429&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;2,429&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Office and computer equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;290&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;290&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Purchased software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;44&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;44&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;687&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;539&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt; width: 66%;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; border-bottom: 0.75pt solid black;"&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt; padding-bottom: 0.375pt;"&gt;&lt;div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;3,450&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;3,302&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Less: Accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(2,749&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;(2,124&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;701&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;1,178&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2429000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2429000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_OfficeAndComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">290000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_OfficeAndComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">290000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">44000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_SoftwareAndSoftwareDevelopmentCostsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">44000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">687000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">539000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3450000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3302000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2749000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2124000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">701000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1178000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <cbay:ScheduleOfOtherAccruedLiabilitiesTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other accrued liabilities consist of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 1pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;5,779&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;3,986&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued professional fees and other&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;1,372&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;1,333&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current portion of operating lease liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;664&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;567&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; line-height: 10pt; font-size: 10pt; width: 66%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total other accrued liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;7,815&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 11%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;5,886&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 66%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 11%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; </cbay:ScheduleOfOtherAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5779000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3986000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cbay:AccruedProfessionalFeesAndOtherCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1372000</cbay:AccruedProfessionalFeesAndOtherCurrent>
    <cbay:AccruedProfessionalFeesAndOtherCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1333000</cbay:AccruedProfessionalFeesAndOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">664000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">567000</us-gaap:OperatingLeaseLiabilityCurrent>
    <cbay:AccruedLiabilitiesForPurchaseOfProductiveAssets
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7815000</cbay:AccruedLiabilitiesForPurchaseOfProductiveAssets>
    <cbay:AccruedLiabilitiesForPurchaseOfProductiveAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5886000</cbay:AccruedLiabilitiesForPurchaseOfProductiveAssets>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In-License&lt;/div&gt; Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Janssen Pharmaceutica NV &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June&#160;2006, the Company entered into an exclusive worldwide, royalty-bearing license to seladelpar and certain other PPAR&lt;div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt; compounds (the PPAR&lt;div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt; Products) with Janssen Pharmaceutica NV (Janssen NV), with the right to grant sublicenses to third parties to make, use and sell such PPAR&lt;div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt; Products. Under the terms of the agreement, the Company has full control and responsibility over the research, development and registration of any PPAR&lt;div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt; Products and is required to use diligent efforts to conduct all such activities. Janssen NV has the sole responsibility for the preparation, filing, prosecution, maintenance of, and defense of the patents with respect to, the PPAR&lt;div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt; Products. Under the terms of the agreement Janssen NV is entitled to receive up to an &lt;/div&gt;8.0% royalty on net sales of PPAR&lt;div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;"&gt;d&lt;/div&gt; Products. No amounts were incurred or accrued for this agreement as of and for the years ended &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;&lt;/div&gt;31, 2022 and &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"/&gt; </us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <cbay:RoyaltyPercentageBasedOnNetSales
      contextRef="P06_01_2006To06_30_2006_JanssenPharmaceuticalNVMembersrtCounterpartyNameAxis_MaximumMembersrtRangeAxis"
      decimals="3"
      unitRef="Unit_pure">0.08</cbay:RoyaltyPercentageBasedOnNetSales>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2021_JanssenPharmaceuticalNVMembersrtCounterpartyNameAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2022_JanssenPharmaceuticalNVMembersrtCounterpartyNameAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <cbay:DisclosureOfDevelopmentFinancingTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;6. Development Financing Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; font-size: 10pt;;font-weight:bold;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On July&#160;30, 2021 (the Effective Date), the Company entered into a Development Financing Agreement (the Financing Agreement) with Abingworth to provide funding to the Company to support its development of seladelpar for the treatment of primary biliary cholangitis (PBC). The Financing Agreement provided the Company up to &lt;/div&gt;&lt;/div&gt;$75.0&#160;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million in base funding&lt;/div&gt;, of which $25.0&#160;million was provided in August 2021, $25.0&#160;million was provided in November 2021, and $25.0&#160;million was provided in &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;January 2022. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The use of proceeds from the funding is limited to PBC &#x201c;Development Program&#x201d; costs incurred or paid as defined in the Financing Agreement. In return, the Company will pay to Abingworth:&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;(1) contingent upon the first to occur of regulatory approval of seladelpar for the treatment of PBC in the U.S., U.K., Germany, Spain, Italy or France (Regulatory Approval), fixed success payments equal to 2.0x of the funding provided, consisting of $10&#160;million payable in 90 days after the Regulatory Approval and thereafter, payments due on the first six anniversaries of the Regulatory Approval in the amounts of $15.0&#160;million, $22.5&#160;million, $22.5&#160;million, $25.0&#160;million, $27.5&#160;million and $27.5&#160;million, respectively and &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;(2) variable success payments equal to 1.1x of the funding provided, consisting of sales milestone payments of (x) $17.5&#160;million and $27.5&#160;million, respectively upon first reaching certain cumulative U.S. product sales thresholds, and (y) $37.5&#160;million upon first reaching a specified U.S. product sales run rate. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Promptly following receipt of Regulatory Approval, the Company is required to execute a note agreement and deliver a promissory note to Abingworth within two business days to convert the fixed and variable success payments into a note payable. At the time that Abingworth receives, collectively, an aggregate of 3.1x of the funding provided (approximately $232.5&#160;million), the Company&#x2019;s payment obligations under the Financing Agreement will be fully satisfied. The Company has the option to satisfy its payment obligations to Abingworth upon Regulatory Approval, or a change of control of the Company, by paying an amount equal to the remaining payments payable to Abingworth subject to a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-single-digit&lt;/div&gt; discount rate. Upon a change of control of the Company, an acceleration payment of 1.35x of the funding provided is payable, net of payments already made to Abingworth and creditable against future payments to Abingworth. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to the Financing Agreement, the Company granted Abingworth a security interest in all its assets (other than intellectual property not related to seladelpar), provided that the Company is permitted to incur certain indebtedness. The security interest will terminate when the Company has paid Abingworth 2.0x&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;of the funding provided or upon termination of the Financing Agreement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Financing Agreement provides for negative, affirmative and additional covenants, which the Company must comply with for the duration of the Financing Agreement term. As of December&#160;31, 2022, the Company was in compliance with all covenants stipulated in the Financing Agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In certain instances, upon the termination of the Financing Agreement, the Company will be obligated to pay Abingworth a multiple of the amounts paid to the Company under the Financing Agreement, including specifically: &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;(i) 310% of such amounts in the event that Abingworth terminates the Financing Agreement due to (x)&#160;a Fundamental Breach, as defined in the Financing Agreement, (y)&#160;the bankruptcy of the Company, or (z)&#160;a safety concern resulting from gross negligence on the part of the Company or due to a safety concern that was material on the Effective Date and the material data showing such safety concern was not publicly known, disclosed to Abingworth, or in the diligence room made available to &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Abingworth, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;(ii) 200% of such amounts in the event the Financing Agreement is terminated due to (x)&#160;Material Breach, as defined in the Financing Agreement, &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;by the Company or (y)&#160;the security interests of Abingworth being invalidated or terminated other than as set forth in the Financing Agreement, and &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(iii)&lt;/div&gt;&lt;/div&gt;&#160;100% of such amounts in the event of certain irresolvable disagreements within the executive review committee overseeing the Company&#x2019;s development of seladelpar. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In addition, if, following certain terminations, the Company continues to develop seladelpar for the treatment of PBC and obtains regulatory approval, it will make the payments to Abingworth as if the Financing Agreement had not been terminated, less any payments made upon termination. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company shall not be obligated to make any payments to Abingworth under certain instances of technical or regulatory failure of the PBC development program as defined in the Financing Agreement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As part of the arrangement, an executive review committee was established between the Company and Abingworth to discuss the Company&#x2019;s development of seladelpar.&lt;br/&gt;&lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 4%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluated the Financing Agreement and determined it to be a research and development funding arrangement with the characteristics of a debt instrument as the transfer of financial risk to Abingworth was not considered substantive and genuine. Accordingly, the Company has recorded payments received under the Financing Agreement as part of a development financing liability in its consolidated balance sheets. The Company accounts for the overall development financing liability at amortized cost based on the estimated timing of regulatory approval and attainment of certain sales milestones and the contractual success fee payments expected to be due therefrom, as discounted using an imputed interest rate. The development financing liability is being accreted as interest expense to its expected future repayment amount over the expected life of the agreement using the effective interest rate method. Certain legal and financial advisory fees incurred specifically to complete the Financing Agreement were capitalized and recorded as a reduction to the carrying amount of the development financing liability and are also being amortized to interest expense using the effective interest method. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There are several factors that could affect the estimated timing of regulatory approval and attainment of sales milestones, some of which are not entirely within the Company&#x2019;s control. Therefore, the Company periodically reassesses the estimated timing of regulatory approval and attainment of sales milestones, and the expected contractual success fee payments due therefrom. If the timing and/or amount of such expected payments is materially different than original estimates, the Company will prospectively adjust the accretion of the development financing liability and the imputed interest rate. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company identified certain contingent repayment features in the agreement that are required to be bifurcated from the debt host instrument as embedded derivative liabilities; however, the fair value of these features was immaterial at the Effective Date and as of December&#160;31, 2022 and 2021. The fair value of the embedded derivative liabilities will be assessed at subsequent reporting dates if material. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth a summary of the changes in the carrying value of the Company&#x2019;s development financing liability (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 88%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="vertical-align: bottom; width: 6%;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Balance at December 31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;50,320&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Cash received&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Accretion of development financing liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;14,907&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 85%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Balance at December 31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;90,227&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 85%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;  &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"/&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, the development financing liability was classified as a long-term liability as the Company expects the related repayments to take place between 2024 and 2030 for purposes of the &lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;model used to &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;   &lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin-left: 0in;"/&gt;&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; margin-left: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;calc&lt;/div&gt;&lt;/div&gt;ulate its carrying value. The imputed interest rate on the unamortized portion &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;of &lt;/div&gt;the development financing liability was approximately 19.2% as of December&#160;31, 2022.&lt;/div&gt;</cbay:DisclosureOfDevelopmentFinancingTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn07_30_2021_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis"
      decimals="-5"
      unitRef="Unit_USD">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P08_31_2021To08_31_2021_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis_InstallmentFundingNumberOneMemberCBAYNumberOfInstallmentFundingAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P11_30_2021To11_30_2021_AbwCyclopsSpvLpMemberusgaapLineOfCreditFacilityAxis_InstallmentFundingNumberTwoMemberCBAYNumberOfInstallmentFundingAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P01_31_2022To01_31_2022_InstallmentFundingNumberThreeMemberCBAYNumberOfInstallmentFundingAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</us-gaap:ProceedsFromLinesOfCredit>
    <cbay:DescriptionOfPercentageFixedSuccessPayments contextRef="P08_31_2021To08_31_2021">2.0</cbay:DescriptionOfPercentageFixedSuccessPayments>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="P08_31_2021To08_31_2021"
      decimals="-6"
      unitRef="Unit_USD">10000000</us-gaap:RepaymentsOfLinesOfCredit>
    <cbay:AnniversaryPaymentsDueYearOne
      contextRef="P08_31_2021To08_31_2021_FixedSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000</cbay:AnniversaryPaymentsDueYearOne>
    <cbay:AnniversaryPaymentsDueYearTwo
      contextRef="P08_31_2021To08_31_2021_FixedSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">22500000</cbay:AnniversaryPaymentsDueYearTwo>
    <cbay:AnniversaryPaymentsDueYearThree
      contextRef="P08_31_2021To08_31_2021_FixedSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">22500000</cbay:AnniversaryPaymentsDueYearThree>
    <cbay:Anniversarypaymentsdueyearfour
      contextRef="P08_31_2021To08_31_2021_FixedSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">25000000</cbay:Anniversarypaymentsdueyearfour>
    <cbay:AnniversaryPaymentsDueYearFive
      contextRef="P08_31_2021To08_31_2021_FixedSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">27500000</cbay:AnniversaryPaymentsDueYearFive>
    <cbay:AnniversaryPaymentsDueYearSix
      contextRef="P08_31_2021To08_31_2021_FixedSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">27500000</cbay:AnniversaryPaymentsDueYearSix>
    <cbay:DescriptionOfPercentageVariableSuccessPayments contextRef="P08_31_2021To08_31_2021">1.1</cbay:DescriptionOfPercentageVariableSuccessPayments>
    <cbay:PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne
      contextRef="P08_31_2021To08_31_2021_VariableSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">17500000</cbay:PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne>
    <cbay:PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo
      contextRef="P08_31_2021To08_31_2021_VariableSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">27500000</cbay:PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo>
    <cbay:PaymentsUponReachingProductSalesRunRate
      contextRef="P08_31_2021To08_31_2021_VariableSuccessPaymentsMemberCBAYSuccessPaymentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">37500000</cbay:PaymentsUponReachingProductSalesRunRate>
    <cbay:DescriptionOfAggregateReturnFromTheFundsProvided contextRef="P08_31_2021To08_31_2021">3.1</cbay:DescriptionOfAggregateReturnFromTheFundsProvided>
    <cbay:AggregateReturnPercentageFromTheFundsProvided
      contextRef="P08_31_2021To08_31_2021"
      decimals="-5"
      unitRef="Unit_USD">232500000</cbay:AggregateReturnPercentageFromTheFundsProvided>
    <cbay:PercentageOfAcceleratePaymentPayableOnFundsProvided contextRef="P08_31_2021To08_31_2021">1.35</cbay:PercentageOfAcceleratePaymentPayableOnFundsProvided>
    <cbay:DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement contextRef="P08_31_2021To08_31_2021">2.0</cbay:DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement>
    <cbay:PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement
      contextRef="PAsOn12_31_2021_AbwCyclopsSpvLpMembersrtCounterpartyNameAxis_FinancingAgreementTerminationEventConditionOneMemberCBAYFinancingAgreementTerminationEventConditionAxis"
      decimals="2"
      unitRef="Unit_pure">3.10</cbay:PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement>
    <cbay:PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement
      contextRef="PAsOn12_31_2021_AbwCyclopsSpvLpMembersrtCounterpartyNameAxis_FinancingAgreementTerminationEventConditionTwoMemberCBAYFinancingAgreementTerminationEventConditionAxis"
      decimals="2"
      unitRef="Unit_pure">2</cbay:PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement>
    <cbay:PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement
      contextRef="PAsOn12_31_2021_AbwCyclopsSpvLpMembersrtCounterpartyNameAxis_FinancingAgreementTerminationEventConditionThreeMemberCBAYFinancingAgreementTerminationEventConditionAxis"
      decimals="2"
      unitRef="Unit_pure">1</cbay:PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth a summary of the changes in the carrying value of the Company&#x2019;s development financing liability (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 88%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="vertical-align: bottom; width: 6%;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Balance at December 31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;50,320&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Cash received&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;25,000&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Accretion of development financing liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;14,907&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 85%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Balance at December 31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt; width: 6%;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 10pt; font-size: 10pt;;text-align:right;"&gt;90,227&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; line-height: 10pt; font-size: 10pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 85%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">50320000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">25000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <cbay:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">14907000</cbay:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">90227000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <cbay:PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.192</cbay:PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7. Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company has one operating lease pertaining to 17,698 square feet of corporate office space in Newark, California pursuant to a lease agreement that commenced January 16, 2014 and was amended on April&#160;16, 2018. At December&#160;31, 2022 and December&#160;31, 2021, the Company&#x2019;s lease portfolio had a weighted average remaining term of 1.1 years, and 2.1 years, respectively, with an option to extend for an additional 5 years. The lease requires monthly lease payments that are subject to annual increases throughout the lease term. The optional period has not been considered in the determination of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets or lease liabilities associated with this lease as the Company did not consider it reasonably certain it would exercise the option. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company cannot determine the implicit rate in its lease, and therefore the Company uses its incremental borrowing rate of 12.6% as the &lt;span style="-sec-ix-hidden:hidden71088836"&gt;discount&lt;/span&gt; &lt;span style="-sec-ix-hidden:hidden71088837"&gt;rate&lt;/span&gt; when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a particular currency environment. The Company used an incremental borrowing rate as of the date of adoption for leases that commenced prior to January&#160;1, 2019. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For the years ended December&#160;31, 2022 and 2021, the Company incurred $0.7&#160;million and $0.6&#160;million, respectively,&#160;of lease costs included in operating expenses in the consolidated statements of operations and comprehensive loss in relation to its operating lease, a portion of which was variable rent expense and not included within the measurement of the Company&#x2019;s operating ROU assets and lease liabilities. The variable rent expense consists primarily of the Company&#x2019;s proportionate share of operating expenses, property taxes, and insurance and is classified as lease expense due to the Company&#x2019;s election to not separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components. Short-term lease costs were not material. At December&#160;31, 2022 and December&#160;31, 2021, the Company&#x2019;s operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset totaled $0.2&#160;million and $0.3&#160;million, respectively, and the operating lease liability totaled $0.7&#160;million and $1.3&#160;million, respectively. As of December&#160;31, 2022, the short-term portion of the operating lease liability was 0.7&#160;million and is contained within other accrued liabilities on the balance sheet, with an immaterial amount reported on the balance sheet as the long-term portion of operating lease liability. &lt;br/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2022, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 92%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 89%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Year ending December&#160;31,&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;707&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 89%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 89%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total undiscounted future minimum lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;737&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 89%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less imputed interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 89%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 89%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total operating lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;694&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 89%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: current portion of operating lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;664&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 89%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 89%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term portion of lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 89%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:LesseeOperatingLeasesTextBlock>
    <cbay:NumberOfLeasedFacilitiesOperatingLeases
      contextRef="PAsOn12_31_2022_LeaseFacilityMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_Facility">1</cbay:NumberOfLeasedFacilitiesOperatingLeases>
    <cbay:AreaOfOfficeSpace
      contextRef="P01_01_2022To12_31_2022_LeaseFacilityMemberusgaapLeaseContractualTermAxis"
      decimals="0"
      unitRef="Unit_sqft">17698</cbay:AreaOfOfficeSpace>
    <cbay:LeaseStartDate contextRef="P01_01_2022To12_31_2022_LeaseFacilityMemberusgaapLeaseContractualTermAxis">2014-01-16</cbay:LeaseStartDate>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2022">P1Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2021">P2Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="P01_01_2022To12_31_2022">option to extend for an additional 5 years</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.126</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2021To12_31_2021_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">600000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">1300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2022To12_31_2022_OperatingExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2022, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 92%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 89%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Year ending December&#160;31,&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;707&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 89%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 89%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total undiscounted future minimum lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;737&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 89%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less imputed interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;43&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 89%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 89%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total operating lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;694&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 89%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: current portion of operating lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;664&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 89%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 89%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term portion of lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 89%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">707000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">30000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">737000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">43000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">694000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">664000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">30000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8. Commitments and Contingencies &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Indemnification &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification, including indemnification associated &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;   &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;with product liability or infringement of intellectual property rights. The Company&#x2019;s exposure under these agreements is unknown because it involves future claims that may be made against the Company that may be, but have not yet been, made. To date, the Company has not paid any claims or been required to defend any action related to these indemnification obligations, and no amounts have been accrued in the accompanying consolidated balance sheets related to these indemnification obligations. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company has agreed to indemnify its officers and directors for losses and costs incurred in connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The maximum potential amount of future payments the Company could be required to make under this indemnification is unlimited; however, the Company maintains insurance policies that may limit its exposure and may enable it to recover a portion of any future amounts paid. Assuming &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&lt;/div&gt; applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits, and other policy provisions, the Company believes the fair value of these indemnification obligations is not material. Accordingly, the Company has not recognized any liabilities relating to these obligations as of December&#160;31, 2022 and 2021. No assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case the Company may incur substantial liabilities as a result of these indemnification obligations. &lt;/div&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Genfit Litigation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On January 15, 2021, Genfit S.A. (Genfit) filed a complaint against the Company in the U.S. District Court for the Northern District of California, alleging misappropriation of trade secrets and related causes of action based on the Company&#x2019;s receipt of a Genfit protocol synopsis for Genfit&#x2019;s Phase 3 clinical trial of its drug candidate elafibranor in patients with primary biliary cholangitis. An Amended Complaint was filed on April 16, 2021 with substantially the same allegations. Genfit &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;was &lt;/div&gt;seek&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ing&lt;/div&gt; damages in an unspecified amount as well as injunctive relief. On March 12, 2021, the Court granted a Temporary Restraining Order (later converted to a Preliminary Injunction), prohibiting the Company from accessing or disseminating the protocol synopsis, using any Genfit trade secrets contained therein or destroying any evidence related thereto. The Company filed a Motion to Dismiss the Amended Complaint that was granted on September&#160;9, 2021, with leave to amend. Genfit filed a Second Amended Complaint on October&#160;15, 2021 with substantially the same allegations and claims for relief as in the original complaint. The Company filed a Motion to Dismiss most of the Second Amended Complaint that was granted on January&#160;21, 2022, without further leave to amend. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;What remained in the complaint was an alleged misappropriation of the protocol synopsis as a whole. The Company filed its Answer to what remained of the Second Amended Complaint on February&#160;4, 2022&lt;/div&gt;&lt;/div&gt;.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;On February 21, 2023, the parties entered into a Settlement Agreement and the action was dismissed with prejudice. The Company did not admit to any liability and the litigation has been resolved completely.&lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <cbay:IndemnificationLiability
      contextRef="PAsOn12_31_2022"
      decimals="0"
      unitRef="Unit_USD">0</cbay:IndemnificationLiability>
    <cbay:IndemnificationLiability
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</cbay:IndemnificationLiability>
    <us-gaap:LossContingencyLawsuitFilingDate contextRef="P01_15_2021To01_15_2021">January 15, 2021</us-gaap:LossContingencyLawsuitFilingDate>
    <us-gaap:LossContingencyNameOfPlaintiff contextRef="P01_15_2021To01_15_2021">Genfit S.A</us-gaap:LossContingencyNameOfPlaintiff>
    <us-gaap:LossContingencyAllegations contextRef="P01_15_2021To01_15_2021">alleging misappropriation of trade secrets and related causes of action based on the Company&#x2019;s receipt of a Genfit protocol synopsis for Genfit&#x2019;s Phase 3 clinical trial of its drug candidate elafibranor in patients with primary biliary cholangitis</us-gaap:LossContingencyAllegations>
    <us-gaap:LossContingencyLawsuitFilingDate contextRef="P01_01_2022To12_31_2022_PendingLitigationMemberusgaapLitigationStatusAxis">April 16, 2021</us-gaap:LossContingencyLawsuitFilingDate>
    <us-gaap:LossContingencyActionsTakenByCourtArbitratorOrMediator contextRef="P03_12_2021To03_12_2021">On March 12, 2021, the Court granted a Temporary Restraining Order (later converted to a Preliminary Injunction), prohibiting the Company from accessing or disseminating the protocol synopsis, using any Genfit trade secrets contained therein or destroying any evidence related thereto.</us-gaap:LossContingencyActionsTakenByCourtArbitratorOrMediator>
    <us-gaap:LossContingencyActionsTakenByDefendant contextRef="P01_15_2021To01_15_2021">On February 21, 2023, the parties entered into a Settlement Agreement and the action was dismissed with prejudice. The Company did not admit to any liability and the litigation has been resolved completely.</us-gaap:LossContingencyActionsTakenByDefendant>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;9&lt;/div&gt;. Stockholders&#x2019; Equity &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Preferred and Common Stock Authorized &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is authorized to issue 10,000,000 shares of preferred stock as of December&#160;31, 2022 and 2021, and 200,000,000 shares of common stock as of December&#160;31, 2022 and 2021.&lt;/div&gt;    &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Common Stock Reserved for Future Issuance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2022 and 2021, the Company had reserved shares of common stock for future issuances as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-funded&lt;/div&gt; warrants to purchase common stock&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3,125,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3,125,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Equity award plans:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options and incentive awards outstanding, all equity plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;14,031,377&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;10,892,613&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Equity awards available for future grant - 2013 Plan&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2,680,621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1,588,613&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Equity awards available for future grant - 2020 Plan&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total shares of common stock reserved for future issuance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;19,836,998&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;15,606,226&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sale of Common Stock and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-funded&lt;/div&gt; Warrants &#160;&#160;&#160;&#160; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In November 2021, pursuant to a shelf registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;S-3,&lt;/div&gt; the Company completed the sale of common stock and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants pursuant to an underwritten public equity offering. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants to purchas&lt;/div&gt;e 3,125,000 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;shares of common stock were issued at a price of &lt;/div&gt;&lt;/div&gt;$3.9999 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;per share, have an exercise price of &lt;/div&gt;&lt;/div&gt;$0.0001 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;per share, were fully exercisable upon issuance, and have no expiration date. The Company determined that the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants should be equity classified because they are freestanding financial instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of shares of common stock upon exercise, are indexed to the Company&#x2019;s common stock and meet the equity classification criteria. In addition, such &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants do not provide any guarantee of value or return. Accordingly, the proceeds from the issuance of the warrants were recorded as additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital on the Company&#x2019;s consolidated balance sheet as of December&#160;31, 2022. None of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrants have been exercised, and therefore they remain outstanding as of December&#160;31, 2022. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;23, 2023, the Company issue&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;d 11,821,428 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;shares of its common stock at &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$7.00 &lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per share in an underwritten public offering. The Company also issued a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrant to purchase up to an aggregate o&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;f 2,142,857 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;shares of common stock at a purchase price o&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;f $6.9999 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per share and has an exercise price of &lt;/div&gt;$0.0001&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;per share. Refer to &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Note 13&#x2014;Subsequent Events&lt;/div&gt;&lt;/div&gt; for further information. &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <cbay:ReservedSharesOfCommonStockForIssuanceTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2022 and 2021, the Company had reserved shares of common stock for future issuances as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-funded&lt;/div&gt; warrants to purchase common stock&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3,125,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;3,125,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Equity award plans:&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options and incentive awards outstanding, all equity plans&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;14,031,377&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;10,892,613&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Equity awards available for future grant - 2013 Plan&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2,680,621&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1,588,613&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Equity awards available for future grant - 2020 Plan&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total shares of common stock reserved for future issuance&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;19,836,998&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;15,606,226&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 3%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </cbay:ReservedSharesOfCommonStockForIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">3125000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="INF"
      unitRef="Unit_shares">3125000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022_OptionsAndIncentiveAwardsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">14031377</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2021_OptionsAndIncentiveAwardsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">10892613</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022_CbayequityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">2680621</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2021_CbayequityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">1588613</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022_CbayequityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2021_CbayequityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">19836998</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">15606226</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn11_30_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="0"
      unitRef="Unit_shares">3125000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn11_30_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">3.9999</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn11_30_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_23_2023To01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">11821428</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">2142857</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">6.9999</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10. Stock Plans and Stock-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In September 2013, the Company&#x2019;s stockholders approved the 2013 Equity Incentive Plan (the 2013 Plan), under which shares of common stock are reserved for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other stock awards by the Company. These awards may be granted to employees, members of the Board of Directors, and consultants. The 2013 Plan has a term of ten years and &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;replaced &lt;/div&gt;the 2003 Equity Incentive Plan, which had similar terms. The 2013 Plan permits the Company to (i)&#160;grant incentive stock options to directors and employees at not less than 100% of the fair value of common stock on the date of grant; (ii)&#160;grant nonqualified options to employees, directors, and consultants at not less than 85% of fair value; (iii)&#160;award stock bonuses; and (iv)&#160;grant rights to acquire restricted stock at not less than 85% of fair value. Options generally vest over a four-year period and have a term of ten years. Options granted to &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10% &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;   &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;stockholders have a maximum term of five years and require an exercise price equal to at least 110&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the fair value on the date of grant. The exercise price of all options granted to date has been at least equal to the fair value of common stock on the date of grant. Stock option exercises are settled with shares reserved under the 2013 Plan. The share reserve under the 2013 Plan will automatically increase on &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;January&#160;1&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;st&lt;/div&gt; o&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;f each year, for a period of not more &lt;/div&gt;&lt;/div&gt;than ten years, in an amount equal to 5% &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of the total number of shares of capital stock outstanding on December&#160;31&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;st&lt;/div&gt; of the preceding calendar year, unless the Board determines otherwise prior to December&#160;31&lt;div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"&gt;st&lt;/div&gt; of such calendar year. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In October 2020, the Company&#x2019;s board of directors approved the 2020 New Hire Plan (the 2020 Plan), under which shares of common stock are reserved for the granting of nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other stock awards by the Company as an inducement to prospective new hire employees of the Company. The 2020 Plan has a term of ten years. The 2020 Plan permits the Company to (i)&#160;grant nonqualified options to new hire employees at not less than 85&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of fair value; (ii)&#160;award stock bonuses; and (iii)&#160;grant rights to acquire restricted stock at not less than 85% of fair value. Options generally vest over a four-year period and have a term of ten years. The share reserve under the 2020 Plan may be increased at the discretion of and approval by the board of directors.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Plan Activity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, there were 2,680,621 and no shares available for grant under the 2013 and 2020 Plans, respectively. On January&#160;1, 202&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;3&lt;/div&gt;, in accordance with the annual share increase provision in the 2013 Plan, the Company added 4,234,053 shares to the 2013 Plan share reserve. &lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes activity in the Company&#x2019;s stock option grants: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;br/&gt;Subject to&lt;br/&gt;Outstanding&lt;br/&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price of&lt;br/&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in&lt;br/&gt;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of December 31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,791,431&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.01&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 51%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options granted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,692,868&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options exercised&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(3,124&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options forfeited&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(403,210&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4.08&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options expired&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(147,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;5.24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 51%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of December 31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,930,195&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;5.26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.96&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;26,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 51%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested and expected to vest as of December&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,930,195&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;5.26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.96&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;26,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 51%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable as of December&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,004,373&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.08&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;13,858&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 51%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"/&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;  &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The total &lt;/div&gt;&lt;/div&gt;intrinsic value of options exercised was immaterial and $0.2&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The total fair value of options vested was $0.6&#160;million and $0.7&#160;million for the years ended December&#160;31, 2022 and 2021, respectively. &lt;/div&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2022, unamortized stock-based compensation expense of $14.7&#160;million is expected to be recognized over a weighted average period of 2.4 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;years. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;   &lt;div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"/&gt; &lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Incentive Awards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2013,&#160;January 2014, and April 2014, as permitted by the 2013 Plan, the Company issued certain incentive awards to directors, employees and a consultant which are subject to 252,752 shares of the Company&#x2019;s common stock and are exercisable at a weighted average price of $5.21 &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per share when vested. The Company may determine at its option whether to settle exercised awards in shares of common stock or in cash. The incentive awards were fully vested as of December&#160;31, 2022 and 2021 and have a term of 10 years.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Incentive awards outstanding totaled 101,182 as of December&#160;31, 2022 and 2021. &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock-Based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation expense is included in the consolidated statements of operations and comprehensive loss and is as follows (in &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4,274&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4,470&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;5,243&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;5,526&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,517&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,996&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Valuation Assumptions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the weighted-average assumptions the Company used in the Black-Scholes option-pricing model to derive the grant date fair values of stock options granted in each of the years &lt;div style="display:inline;"&gt;presented &lt;/div&gt;along with the resulting estimated weighted-average grant date fair values per share: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Weighted-average grant date fair value per share&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2.33&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3.91&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Term &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company does not believe it can currently place reliance on its historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term due to the lack of sufficient prior exercise data available. Therefore, for stock option grants made during the years ended December&#160;31, 2022 and 2021, the Company has elected to use the simplified method for estimating the expected term, which is an&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;average of the contractual term of the options and its ordinary vesting period. The Company will reevaluate this methodology at a point in time when sufficient exercise data becomes available. The expected term represents the period of time that options are expected to be outstanding.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Volatility &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company estimates expected volatility by measuring the historical volatility of its common stock price over a historical period commensurate with the expected term of the related award. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; font-size: 10pt;;font-style:italic;display:inline;"&gt;Risk-Free Interest Rate&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The risk-free interest rate assumption was based on U.S. treasury instruments with constant maturities whose term was consistent with the expected term of stock options granted by the Company. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected Dividend Yield &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The Company has never declared or paid cash dividends and does not plan to pay cash dividends &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;in &lt;/div&gt;the foreseeable future. Consequently, the Company uses an expected dividend yield of zero.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_IncentiveStockOptionsForEmployeesAndDirectorsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_NonQualifiedStockOptionsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_RestrictedStockMemberusgaapAwardTypeAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P01_01_2017To12_31_2017_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_StockOptionsToTenPercentShareholdersMemberusgaapAwardTypeAxis">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P01_01_2017To12_31_2017_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis_StockOptionsToTenPercentShareholdersMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P09_01_2013To09_30_2013_EquityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <cbay:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage
      contextRef="PAsOn09_30_2013_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.05</cbay:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="P01_01_2020To12_31_2020_EquityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn12_31_2022_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">2680621</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn12_31_2022_EquityIncentivePlanTwoThousandAndTwentyPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn01_01_2022_EquityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">4234053</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes activity in the Company&#x2019;s stock option grants: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color:#ffffff;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;br/&gt;Subject to&lt;br/&gt;Outstanding&lt;br/&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price of&lt;br/&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value (in&lt;br/&gt;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of December 31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;10,791,431&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.01&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 51%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options granted&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,692,868&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options exercised&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(3,124&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;2.94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options forfeited&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(403,210&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4.08&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options expired&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(147,770&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;5.24&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 51%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding as of December 31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,930,195&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;5.26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.96&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;26,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 51%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested and expected to vest as of December&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,930,195&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;5.26&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.96&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;26,089&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 51%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 51%;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercisable as of December&#160;31, 2022&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;9,004,373&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.08&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;13,858&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 51%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear:both;max-height:0pt;"/&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">10791431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">3692868</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">3124</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">403210</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">147770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">13930195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2022To12_31_2022">P6Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">26089000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">13930195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2022To12_31_2022">P6Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">26089000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2022"
      decimals="INF"
      unitRef="Unit_shares">9004373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="PAsOn12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">6</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2022To12_31_2022">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">13858000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">14700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2022To12_31_2022">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn04_30_2014_IncentiveStockAwardsMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">252752</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="PAsOn01_31_2014_IncentiveStockAwardsMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2022_IncentiveStockAwardsMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">101182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2021_IncentiveStockAwardsMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">101182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock-based compensation expense is included in the consolidated statements of operations and comprehensive loss and is as follows (in &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 82%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4,274&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;4,470&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;5,243&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;5,526&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 78%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total stock-based compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,517&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;9,996&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; width: 78%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 5%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">4274000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">4470000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">5243000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">5526000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9517000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9996000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents the weighted-average assumptions the Company used in the Black-Scholes option-pricing model to derive the grant date fair values of stock options granted in each of the years &lt;div style="display:inline;"&gt;presented &lt;/div&gt;along with the resulting estimated weighted-average grant date fair values per share: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;6.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;1.8&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right;"&gt;0.9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Weighted-average grant date fair value per share&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;2.33&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;3.91&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2022To12_31_2022">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="2"
      unitRef="Unit_pure">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_pure">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;11. 401(k) Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="null;text-indent: 0px;;font-weight:bold;display:inline;"&gt; &lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company provides a qualified 401(k) savings plan for its employees. All employees are eligible to participate, provided they meet the requirements of the plan. As is permitted under the plan, the Company has elected to match employee contributions up to $750 and accordingly matching contributions totaling an insignificant amount were made in the years ended December&#160;31, 2022 and 2021.&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
    <cbay:EmployerMatchingContributionToQualifiedSavingsPlan
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_USD">750000</cbay:EmployerMatchingContributionToQualifiedSavingsPlan>
    <cbay:EmployerMatchingContributionToQualifiedSavingsPlan
      contextRef="P01_01_2022To12_31_2022"
      decimals="INF"
      unitRef="Unit_USD">750000</cbay:EmployerMatchingContributionToQualifiedSavingsPlan>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;12. Income Taxes&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;No provision for U.S. income taxes exists due to tax losses incurred in all periods presented. All losses incurred were U.S. based. &lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 32.6667px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;Significant&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;components of the Company&#x2019;s &lt;div style="display:inline;"&gt;deferred &lt;/div&gt;tax assets are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Federal and state net operating loss carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87,681&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;129,898&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;State and federal research and development tax credit carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,016&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Intangibles and capitalized research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;16,912&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;5,670&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Stock-based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6,624&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;5,329&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,574&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,222&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;144,807&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;174,070&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(79&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(158&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(36&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(115&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(211&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(144,692&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(173,859&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;Realization of the net deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which is uncertain. Based on the weight of available positive and negative objective evidence, management believes it more likely than not that the Company&#x2019;s deferred tax assets are not realizable. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance decreased by $&lt;/div&gt;&lt;/div&gt;29.2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million primarily due primarily to a $&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;38.4&lt;/div&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million write-off of tax attributes pursuant to certain Section 382 limitations and to a lesser extent the utilization of net operating losses during the year ended December 31, 2022, These valuation allowance reductions were offset in part by valuation allowance increases to cover additions to the Company&#x2019;s capitalized research and development and other deferred tax assets during the year ended December 31, 2022. The valuation allowance increased by $&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;14.7&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million primarily due to an increase in the Company&#x2019;s taxable loss during the year ended &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following is a reconciliation of the expected statutory federal income tax provision to the actual income tax provision (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Income tax benefit at federal statutory tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22,260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18,900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,739&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Impairment of tax attributes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,398&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Research credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,640&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,802&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Cancelled options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Development financing liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,654&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Permanent differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;511&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;429&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;State income taxes, net of federal benefit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,806&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(267&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Other, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Income tax (benefit) expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-block: 0em;"&gt;&#160;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to Internal Revenue Code (IRC) Sections&#160;382 and 383 and similar state laws, use of the Company&#x2019;s U.S. federal and state net operating loss and research and credit carryforwards may be limited in the&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;event&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; of a cumulative change in ownership of more than&#160;50% within a&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;three&lt;/div&gt;-year&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;period. In 2022, the Company completed an ownership change analysis and determined that its net operating losses and research and development credits were subject to limitations due to historical changes in ownership that occurred through December&#160;31, 2022. Accordingly, the net operating loss carryforwards reflected in the deferred tax assets at December&#160;31, 2022 have been reduced to reflect Section&#160;382 limitations resulting from these changes. As the Company is expected to incur additional losses in the future, any future ownership changes that might occur could further restrict the Company&#x2019;s ability to utilize its net operating loss and research and development carryforwards. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;31, 2022, the Company had federal net operating loss carryforwards of $&lt;/div&gt;346.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million and state net operating loss carryforwards of $&lt;/div&gt;214.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million to offset future taxable income, if any. In addition, the Company had federal research and development tax credit carryforwards of $&lt;/div&gt;4.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, federal orphan drug tax credit carryforwards of $&lt;/div&gt;28.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, and state research and development tax credit carryforwards of $&lt;/div&gt;9.2&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. If not utilized, the federal net operating losses for the years beginning before January&#160;1, 2018 of $&lt;/div&gt;79.1&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million will expire beginning in &lt;/div&gt;2024&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; through &lt;/div&gt;2037&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;, and the federal net operating losses for the tax years beginning after January&#160;1, 2018 of $&lt;/div&gt;266.9&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million will be carried forward indefinitely (subject to certain utilization limitations).&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;The state net operating loss carryforwards will expire beginning in 2028 through 2040. The federal research and development and federal orphan drug tax credit carryforwards expire 2033 through 2042, and the state tax credit will carry forward indefinitely. The following table summarizes activity related to the Company&#x2019;s gross unrecognized tax benefits (in&#160;thousands):&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 89%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 86%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Balances as of December 31, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,205&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Increases related to prior year tax positions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Increases related to 2021 tax positions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;783&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Balances as of December 31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,997&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Decreases related to prior year tax positions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,223&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Increases related to 2022 tax positions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;730&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Balances as of December 31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,504&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;  &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The unrecognized tax benefits, if recognized, would not have an impact on the Company&#x2019;s effective tax rate assuming the Company continues to maintain a full valuation allowance position. Based on prior year&#x2019;s operations and experience, the Company does&#160;&lt;/div&gt;not&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;expect a significant change to its &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;unrecognized tax benefits &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;over the next twelve months. The unrecognized tax benefits may increase or change in the future for unexpected or unusual items for items that may arise in the ordinary course of business.&#160;&lt;/div&gt; &lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;The Company&#x2019;s major income tax filing jurisdictions are the U.S. federal&#160;and California state and is not currently under examination by federal, state, or local taxing authorities for any open tax years. Due to net operating loss carryforwards&lt;/div&gt;&lt;/div&gt;, the tax years 2004 to 2022 remain open for income tax examination by tax authorities in the U.S. and states in which the Company files tax &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;returns. Interest and penalties for the years ended December 31, 2022 and 2021 were not material.&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;In August 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law. The IRA provides several tax incentives, including the expanded Internal Revenue Code (IRC) Section&#160;179D deduction, increased ability to leverage the R&amp;amp;D credit to offset payroll taxes for eligible &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;start-up&lt;/div&gt; businesses, and 15% alternative minimum tax (AMT) for corporations with average income of more than $1&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;billion for the past three tax periods. The IRA did not have a material impact on the Company&#x2019;s consolidated financial statements; however, the Company continues to examine the impacts the above-mentioned tax legislations may have on its business, results of operations, financial condition and liquidity.&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-indent: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; </us-gaap:IncomeTaxDisclosureTextBlock>
    <cbay:ProvisionForStateAndLocalIncomeTaxes
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</cbay:ProvisionForStateAndLocalIncomeTaxes>
    <cbay:ProvisionForStateAndLocalIncomeTaxes
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</cbay:ProvisionForStateAndLocalIncomeTaxes>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, serif; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 32.6667px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; top: 0px;;display:inline;"&gt;Significant&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;components of the Company&#x2019;s &lt;div style="display:inline;"&gt;deferred &lt;/div&gt;tax assets are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Federal and state net operating loss carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87,681&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;129,898&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;State and federal research and development tax credit carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32,016&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;31,951&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Intangibles and capitalized research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;16,912&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;5,670&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Stock-based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;6,624&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;5,329&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,574&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;1,222&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;144,807&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;174,070&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Depreciation and amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(79&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(158&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(36&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(53&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(115&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;(211&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="break-inside: avoid; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(144,692&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);;text-align:right;"&gt;(173,859&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap; background-color: rgb(204, 238, 255); width: 69%;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Net deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space: nowrap; vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 69%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="background-color: rgba(255, 255, 255, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="clear:both;max-height:0pt;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">87681000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">129898000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">32016000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">31951000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <cbay:DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">16912000</cbay:DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment>
    <cbay:DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5670000</cbay:DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">6624000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5329000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1574000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1222000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">144807000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">174070000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">79000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">158000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">36000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">53000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">115000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">211000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">144692000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">173859000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">-29200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <cbay:WriteOffOfTaxAttributeDueToLimitation
      contextRef="P01_01_2022To12_31_2022"
      decimals="-5"
      unitRef="Unit_USD">38400000</cbay:WriteOffOfTaxAttributeDueToLimitation>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P01_01_2021To12_31_2021"
      decimals="-5"
      unitRef="Unit_USD">14700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following is a reconciliation of the expected statutory federal income tax provision to the actual income tax provision (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Income tax benefit at federal statutory tax rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22,260&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(18,900&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,739&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Impairment of tax attributes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,398&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Research credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,640&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,802&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Cancelled options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;49&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Development financing liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,301&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,654&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Permanent differences&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;511&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;429&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;State income taxes, net of federal benefit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,806&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(267&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Other, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Income tax (benefit) expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="margin-block: 0em;"&gt;&#160;&lt;/div&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-22260000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-18900000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-29165000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14739000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">38398000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2640000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2802000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <cbay:IncomeTaxReconciliationTaxCancelledOptions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">49000</cbay:IncomeTaxReconciliationTaxCancelledOptions>
    <cbay:IncomeTaxReconciliationTaxCancelledOptions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">141000</cbay:IncomeTaxReconciliationTaxCancelledOptions>
    <cbay:IncomeTaxReconciliationDevelopmentFinancingLiability
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">12301000</cbay:IncomeTaxReconciliationDevelopmentFinancingLiability>
    <cbay:IncomeTaxReconciliationDevelopmentFinancingLiability
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6654000</cbay:IncomeTaxReconciliationDevelopmentFinancingLiability>
    <cbay:IncomeTaxReconciliationPermanentDifferences
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">511000</cbay:IncomeTaxReconciliationPermanentDifferences>
    <cbay:IncomeTaxReconciliationPermanentDifferences
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">429000</cbay:IncomeTaxReconciliationPermanentDifferences>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2806000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-267000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <cbay:CumulativePercentageChangeInOwnershipPercentagePerimissible
      contextRef="PAsOn12_31_2022_FederalAndStateTaxAuthorityMemberusgaapIncomeTaxAuthorityAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</cbay:CumulativePercentageChangeInOwnershipPercentagePerimissible>
    <cbay:PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage contextRef="P01_01_2022To12_31_2022_FederalAndStateTaxAuthorityMemberusgaapIncomeTaxAuthorityAxis">P3Y</cbay:PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">346000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">214900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_OrphanDrugMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">4100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">28100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2022_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">9200000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2017_FederalMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">79100000</us-gaap:OperatingLossCarryforwards>
    <cbay:NetOperatingLossCarryforwardExpirationYear contextRef="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_MinimumMembersrtRangeAxis">2024</cbay:NetOperatingLossCarryforwardExpirationYear>
    <cbay:NetOperatingLossCarryforwardExpirationYear contextRef="P01_01_2021To12_31_2021_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis_MaximumMembersrtRangeAxis">2037</cbay:NetOperatingLossCarryforwardExpirationYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2018_FederalMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">266900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="P01_01_2022To12_31_2022">The state net operating loss carryforwards will expire beginning in 2028 through 2040. The federal research and development and federal orphan drug tax credit carryforwards expire 2033 through 2042, and the state tax credit will carry forward indefinitely.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <cbay:NetOperatingLossCarryforwardExpirationYear contextRef="P01_01_2022To12_31_2022_FederalMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MinimumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2028</cbay:NetOperatingLossCarryforwardExpirationYear>
    <cbay:NetOperatingLossCarryforwardExpirationYear contextRef="P01_01_2022To12_31_2022_FederalMemberusgaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_MaximumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2040</cbay:NetOperatingLossCarryforwardExpirationYear>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="P01_01_2022To12_31_2022_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">federal research and development and federal orphan drug tax credit carryforwards expire 2033 through 2042</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="P01_01_2022To12_31_2022">The following table summarizes activity related to the Company&#x2019;s gross unrecognized tax benefits (in&#160;thousands):&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 89%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 86%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Balances as of December 31, 2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,205&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Increases related to prior year tax positions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Increases related to 2021 tax positions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;783&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Balances as of December 31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,997&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Decreases related to prior year tax positions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,223&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Increases related to 2022 tax positions&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;730&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align: top; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal; white-space: nowrap;"&gt;Balances as of December 31, 2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,504&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; </us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7205000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">783000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7997000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1223000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">730000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7504000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit>
    <us-gaap:IncomeTaxExaminationDescription contextRef="P01_01_2022To12_31_2022">the tax years 2004 to 2022 remain open for income tax examination by tax authorities</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:OpenTaxYear contextRef="P01_01_2022To12_31_2022_MinimumMembersrtRangeAxis">2004</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear contextRef="P01_01_2022To12_31_2022_MaximumMembersrtRangeAxis">2022</us-gaap:OpenTaxYear>
    <cbay:AlternateMinimumTaxRate
      contextRef="P08_01_2022To08_31_2022"
      decimals="2"
      unitRef="Unit_pure">0.15</cbay:AlternateMinimumTaxRate>
    <us-gaap:Revenues
      contextRef="P08_01_2022To08_31_2022"
      decimals="-9"
      unitRef="Unit_USD">1000000000</us-gaap:Revenues>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2022To12_31_2022"> &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;13. Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Collaboration and License Agreement with Kaken Pharmaceutical Co., Ltd. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 9%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In January&#160;2023, the Company entered into a Collaboration and License Agreement (the License Agreement) with Kaken Pharmaceutical Co., Ltd. (Kaken). Pursuant to the License Agreement, the Company granted Kaken an exclusive license to commercialize seladelpar (the&#160;Licensed Product) for the treatment of PBC in Japan. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Kaken will bear the cost of, and be responsible for, conducting clinical studies and other developmental activities, preparing and filing applications for regulatory approval and commercializing seladelpar in Japan. The Company is generally obligated to supply seladelpar to Kaken for use in Japan, at a supply price per unit as defined in the agreement. &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In consideration of the license and other rights granted by the Company, Kaken made an upfront cash payment to the Company of $&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;34.2&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million in January 2023 and is obligated to make potential milestone payments to the Company totaling up to &#xa5;&lt;/div&gt;17.0&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;billion (approximately $&lt;/div&gt;128.0&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million using exchange rates in effect at the contract inception date) contingent upon Kaken&#x2019;s achievement of certain regulatory and sales milestones as defined in the agreement.&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px; text-indent: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Sale of Common Stock and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-funded&lt;/div&gt; Warrant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On January&#160;23, 2023, pursuant to a shelf registration statement on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;S-3,&lt;/div&gt; the Company &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sold&lt;/div&gt; 11,821,428&#160;of its common &lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares&lt;/div&gt; at $7.00 &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;per share in an underwritten public&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;equity&#160;&lt;/div&gt;offering&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;and a&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-funded&lt;/div&gt; warrant to purchase&#160;&lt;/div&gt;2,142,857 &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;shares of common stock at a purchase price of &lt;/div&gt;&lt;/div&gt;$6.9999 &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per share, which represents the per share public offering price for the common stock less the &lt;/div&gt;&lt;/div&gt;$0.0001 &lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;per share exercise price of the pre-funded warrant. The Company received net proceeds&lt;/div&gt;&lt;/div&gt;&#160;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;of&lt;/div&gt; $92.4&#160;&lt;div style="letter-spacing: 0px; top: 0px;;text-indent: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;million from this public equity offering after deducting underwriting and other offering expenses. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <cbay:UpfrontCashPayment
      contextRef="PAsOn01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">34200000</cbay:UpfrontCashPayment>
    <cbay:PotentialMilestonePayments
      contextRef="P01_01_2023To01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-8"
      unitRef="Unit_JPY">17000000000</cbay:PotentialMilestonePayments>
    <cbay:PotentialMilestonePayments
      contextRef="P01_01_2023To01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">128000000</cbay:PotentialMilestonePayments>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_23_2023To01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">11821428</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_23_2023_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">2142857</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">6.9999</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn01_23_2023_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_01_2023To12_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">92400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,R =U8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #,@'=6I4S[\NT    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M:L0@$(9?I7A/QAC8@V2]=.FIA4(76GH3G=V5QB@Z)=FWKTEWLY3V 0I>G/G]
MYANP,U&:D/ YA8B)'.:[R?=#EB9NV8DH2H!L3NAUKDMB*,U#2%Y3N:8C1&T^
M]!%!<+X!CZ2M)@TSL(HKD:G.&FD2:@KI@K=FQ<?/U"\P:P![]#A0AJ9N@*EY
M8CQ/?0<WP PC3#Y_%]"NQ*7Z)W;I +LDI^S6U#B.]=@NN;)# V]/CR_+NI4;
M,NG!8'F5G:1SQ"V[3GYM[W?[!Z8$%VW%VTJT>\$EWY3S/KO^\+L)^V#=P?UC
MXZN@ZN#7OU!?4$L#!!0    ( ,R =U:97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MWT*T4QY3%;Y]OU$?Y8V7C7G$*?%9_#,*Q>*\<])!(9GA+!9W;/6%% WJ*[V
MQ6G^%ZW6^WI>!P59*EA2%,LS2"*Z?L4O!8BW!4Y#@5,4.+\4V$U'<(L"=]<"
MKRCP<C+KIN0<AEC@BS/.5HBKO:6:>I/#S*ME\R.J_N]3P>6WD:P3%SY[)AQ-
MY+\8=='WZ1!]>/?[64](9?5]+RA4+M<J3H.*[: ;1L4B15<T)&%=H"=/J3PO
M9W->EPZH."3!(7+M ^18CJ,Y(1\NO\'\$-G]O-S5E _A\C\R*H]NZ8Y>:XU;
M4G9S/;>I-2S(Y& 1:$S70U5U^;^OY5YH+$B2_J-#OI;T]))J/OB8+G% SCMR
MP*>$/Y/.Q?O?["/KDPZ72;&A(;$:2J]$Z4'J%<K[UR7188/+;:O[5<<'K&K+
MQY!8C4^_Y-,'&SB0<,(<T"C&<QT@N'Z&XU3'U0?+VA(R)%8C=%02.MJM!TT(
MCUBHIBPDYTYM9]JBM)FD&F<IL+XM-$-B-6C');3CW:"-HC3 ,7H@F*.1_##5
M88.UFF"!56UA&1*KP3HI89VT@E5TM$9<L-KH00<+K&D+RY!8#=9I">L4;-X]
MQV%$YVCZFCRR6(<'KO<O!UI 8%5;0(;$:H!LJ_)H%MC$*RHB\8KNR#Q*!<>R
M8]WB1#M?;1'R'VX&$A>Z_W)U-YA<?;\?^],#-+[U#W4$8;&V"$VIU1F^\;GV
M+@Q].2RY'))CZ5-?T%?RJJ4(2UF695N>8QU[6FI@<6MJAM3JU)R*F@-WF(SS
M7V=]Z'JY1:[;M9VN:VNQ@96ML1E2JV.K[+X-6N!-9_LIXVSWB;(515."4T9)
MB,9IFA&N90=K/A#=M<.'JUISVX>UMRMO;\/NO. VBF(92GW9Q^:,ZT<HK'/+
M:!<' 9$R4B1<"VKI&?7]IM3J]"KG;\/6?3/%%6/VCBP9%_FE56"A=QY;%)OZ
MG-$L8$JM3JU* S9LX@MJ/UB<48%YT?OTM&"E6Z:%930#F%*KPZI2@ U;]P+6
M-,%QC"ZS5'Z=ZE'!.H)GVI )E[6&M8\08%<IP(:->P'K*B%\KH;A9ZD@%LAG
MR1)3_;0&"S9F<[BN-;9]Q &[R@,V;.@WTQA+$B8OG((%3P=HNL#R6.A;)E*!
MJ0H,6GXF3;]?J/5S-74#_?GB]-@Y==W3X[/><XW8/O*!4^4#9Z=\,%U(OP%U
MKRTRC=T+KFO;O4RIU6%50<#9*0BH61[=9LFCWHQM$9$)H.L>]2U+B\MH C"E
M5L=5)0 'MNP%KGO\@L:AM!71+ K6]Z\!>+#DJ2<S@.7VC[1! "YN36\?0<"I
M@H"S4Q 8A*%43P\V;U!^Z_\;U6:H+9+'_>,^^BQM[0J_HLOX.=1"-)H*3*G5
M(5:IP-DI%>@AWJ]TKNMRB^0TBP1!MJT?OT9#@2FU.KPJ%#@[A8(2GJ^V&$?W
M,I5JP<%RM[+;\2<M-:.AP)1:G5H5"IR=0D%)324HHK!-.'N.:* ?N+"F/]!B
M,QH/3*G5L57QP-DI'I38)DRZM1C]%2VE+0GUT&#%4Z]_I!^D1I."*;4ZMRHI
M.+"QSP?E@!/<C D6Z#?,9$9S@2FU.J0J%SAP+KAF^;.4!:.@<8-%I'WOGIPT
M^#:CCPQ,J=47'%29P-TI$XRI('R]N$;=M,6;NT/:!0>P8L/-(+BJ]=*"?80#
MMPH'+NSK[R,A8P&;(=OY\/@[FI(@XQ*CEA:L5,37=!U?WUF'ZJD!6F*.GG&<
M$;0D'*4JU&J9&DT0IM3J3*L$X<)V?P,17;T$"TSGI/'IU1:AV\%T./A3R\MH
M9C"E5N?U9JW03IEA3 /&EXSG8>N- _%91@5_;;Q2;%$?7FD!FET?M(^\X%9Y
MP87-??GX?4!I)B\9ZQOA6E:P4--=2KBL-:U]! 2W"@@N[.BK!54<TS3*HSU
M['^N'H+K6B/;1SIPJW3@[I0.)MEC' 5H%#.L9V72VOM&U8:%VM&;>YN.?6+U
M7<OSRIN;=3Q5"G!ASS[V1W=HD(61D-/50 @B0T#>K9I6I&W1:^Y41C. *;4Z
MM2H#N+"%WP!KO#AN>=C :2K0>YPL/Z$'>8F8H^OKB1::T4Q@2JT.K<H$+FSG
M-]!&$4_0>*CE!BMXVJ5H<%%K2/N( EX5!3S8N&\@J0"EQJ&.TA:)*:;H1AH0
M=H!\'$<SQFF$=>!@G=8+:8VF@=Z;9?+JF5S^<X,4!<I0K5?,EY^6/VD8Y OY
M>]7NZ]]#W&#U2"]%,9G)4NOP6%Z0^/HG!NL-P9;YHOM')@1+\K<+@D/"U0[R
M^QEC8K.A#E#^T./B/U!+ P04    " #,@'=6=+H8J\H%  #(%P  &    'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;*U8;6_;-A#^*X17[ 6P8Y*RWM+$0)M@
MV(!U"YIV^\Q(=$Q$$EV2<IK]^AUE1[)%2G'7?+ MR7?'YT['>^YX\2C5@UYS
M;M#7LJCTY61MS.9\/M?9FI=,G\D-K^"?E50E,W"K[N=ZHSC+&Z6RF%.,HWG)
M1#597C3/;M3R0M:F$!6_44C79<G4TWM>R,?+"9D\/_@H[M?&/I@O+S;LGM]R
M\WESH^!NWEK)1<DK+62%%%]=3MZ1\RN:6(5&XF_!'_7!-;*NW$GY8&]^SR\G
MV"+B!<^,-<'@9\NO>%%82X#CR][HI%W3*AY>/UO_M7$>G+ECFE_)XA^1F_7E
M))F@G*]879B/\O$WOG<HM/8R6>CF&SWN9?$$9;4VLMPK X)25+M?]G4?B ,%
MLAA0H'L%>JI"L%<(&D=WR!JWKIEARPLE'Y&RTF#-7C2Q:;3!&U'9UWAK%/PK
M0,\LKV2E92%R9GB.WK."51E'M]:<1C/T^?8:_?SF%_0&B0I]6LM:LRK7%W,#
M*UO]>;9?Y?UN%3JPRC7/SE! IHAB2CWJ5Z>KDV/U.?C;.DU;IVEC+QARNE:*
M5P8QK<'/<Y\_.P,+OP&[M\[UAF7\<@*;1W.UY9/ECS^0"+_U>?=*QHY\#5I?
M@S'KRRNFUPC>&LKL!?]2BRTKP'GO6]R9BAI3M@!LEQ#Q%$*^/73'E2(T3'#4
MBAT!7;1 %Z- /S#UP V[*SC2/*N5,()[0>[,A(?+DY"DBQY*5RS",4W](,,6
M9#@*\D;Q#1,YXE^ACFJNF\A*L^8*-NMA4OF APXB"%O2@^T*+<)HX4<=M:BC
M4=2?I&'%"0 C-[)!@N.@!]$CEA*<#H0V;D'&+X06N$F9IR:D-D\WP!9FBBIN
M?%AC!T2,^XGJRA 2)WZ820LS&87YIZQFSY$L3TW9Q &">U!="=A0L1]JVD)-
M1Z'^!?%D1E3WJ.# =$A92IO)U:R&FR8+?%A3-VA1VD/KRM!P($<)[I@(C\-M
MMM%P=N[5CU9-<1^:1XK$% ^ .Z!)<L(6&@%'W&47) EI'YXK!R4V( -923I*
M(Z=Q6B'8G2B:3/02&WE59GLM:\=.=]Q&QLGM79;)&K@,;=B3W89>AP/WS> T
MZK\75XK&=.BM=)Q&QDD- *H:.BOK/%/9CHESOH7VN2EO+9%XD7LH+ SZE<,C
ME<8'>7>,O",Z,LYT^]VXQW^055ZD+FO%"0G[2%TIX+^!MH%TY$:^A=U>0NHA
MKW"QZ#.'3RP)HB&L'<>1<9*[/GCU*U%!M]V4YSWF)R]BE\52Z*+C/F)7+,3!
M8.'KZ(Z,\]T?LKJ?&:Y*M)&JF;SD"LD>LXP[X'*;F\2N3)2& ]@[_B/C!+C+
MC)<RPD-X.(S2?F/FD8O2("%^D+2C/3I.>U>R+(6Q&;'K)C-9V<AR2 T_X'%[
M_IJ+O&/)]QLZ]KEC4TI&R>K6R.QA+8N<*_U3T^R9)_\8-LK*WSR'O9*U8Z\/
MILY1-K3#PXI#E<J1MOY/T1M\AC$FP%X*P516\W-$\!0>V0_2:Z;LA%&;M53B
M7YZ_195\?BJTMG6Y&3]JHPU<0-)X0_@_*-J?+M]OZ#AP'<W3%V98V")0>(:C
M1O%HV)+%-$K(%$=!$S![&\?3-$C'HPGMGBUVUSSCY1V0X?,!1B/7?PK?8&G#
MFV.IPEL(J=MC](O,J,AQ]+H>A+[0@^2YL(4;2J&=76>B0AG;""B-7I">=@*G
M >WWV1ZY)$WC= ANUWC0\<8#6J:ZK(OF0&H_6<L2,FIMSPZWP#52^\NBVUW,
M MKO\WQ2)!C W+4@=+P%.<2<\Y7(A'>THFY7,4N@RPS[9.X3C*,H"0<:$-HU
M('2\ =E1HO;47R]@MZD((A+VCUH\8@0R)AB87VG7?-#QYL,A\&;KG8P^<0^J
M?#.91\X[D\T/CEGM&?<'INY%I:$'6H$B/HLA &IW;+R[,7+3G+S>26-DV5RN
M.0/85@#^7TEIGF_L86Y[>+_\#U!+ P04    " #,@'=6U#01L]\"  #E"0
M&    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*V6T6[:,!2&7\7*IFF3.N(D
M0*"#2"U5U5U,0D7;+J9=F.1 K#IV9AOH]O2SDS0C;8!0C0MB)^?\_G[G./9D
M)^2#2@$T>LP85U,GU3J_=%T5IY 1U1,Y</-D)61&M.G*M:MR"20IDC+F^A@/
MW8Q0[D23XMY<1A.QT8QRF$ND-EE&Y.]K8&(W=3SGZ<8]7:?:WG"C24[6L #]
M-9]+TW-KE81FP!45'$E839TK[W+F89M01'RCL%-[;62M+(5XL)W/R=3!E@@8
MQ-I*$'/9P@P8LTJ&XU<EZM1CVL3]]I/Z;6'>F%D2!3/!OM-$IU-GY* $5F3#
M]+W8W4%E:&#U8L%4\8]V9>P@=%"\45ID5;(AR"@OK^2QFHB]!*]_(,&O$ORN
M"4&5$!1&2[+"U@W1))I(L4/21ALUVRCFIL@V;BBWKW&AI7E*39Z.9H(KP6A"
M-"3HFC#"8T +*Z?0^SF1P'4*FL:$?4 ?T5OD(I6:NVKB:C.ZU7#C:J3K<B3_
MP$@W$/=0X%T@'_M^2_JL>[K73'>-Y]JX7QOW"[W@@-Y"&\NF'C42*W1+N3%.
M"4-SH6A17S^NEDI+4V4_VZR6VOUV;;OT+E5.8I@Z9FTID%MPHG=OO"'^U&;\
M/XDUIB&HIR$XIA[-S:H!*<W+-Z46/UR@G$BT)6P#;;9+K;#0LA^(;81[&&/S
M/K;[ADZ&-5#[-6K_/-2R$A'9Z%1(^@>2-N12<[#'XN'R]PRZ0V #>U!C#UZ%
M397:M",/7I \9ST6T8 <UI##5T&:#[_2A">4K]M(AR=)CT4T2,.:-#Q*.A-9
M9I9GEVH-NU7KR; &YZCF')W!V:E41R_FRL?MM=HELD$]KJG'YU,?KM3Q"XY1
M?SCR\#!X!MP:&(;C8-S.Z^%_^Q<^G_A$V5:2';C;(]O W;T]V!Z OA"YIEPA
M!BN3BGNAT9#EF:+L:)$7V_)2:+/)%\W4G,- V@#S?"6$?NK8G;X^V45_ 5!+
M P04    " #,@'=6DRCIQ(($  "9$0  &    'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;*V8;7.C-A" _XJ&WG3:F;N !,:0VIZY.'VYF5Z;22Z]SPK(ACE
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M5)=KC%),I8'X?44(?[J1WU3L/^N9_P=02P,$%     @ S(!W5A;,N*$_ @
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M.RK9FE=_EH7:7LW2&2K8AK:5^L(??V5[@V*M+^>5-'_1XUXVF*&\E8K7^\6
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M<G)S5=YSBD/6G<$]I5*^)=HG<ZUJOL,.8<>K]DNSLE^+,@!VP<28<D_88"K
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MD8YZ,>YCJ'3>> ONN<+0'.-AT5.#V17=S.GF(S&8]5I).:@[7I:&-\>.W<I
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M<5"#H@$TZ]4O26T#CKM@!58D:-;MP[ /M'2RB%*B2E*QO5^_(R6K*> 8&S#
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M<?^\0[\*N5,N*V;Q0LL?(G?E//H808YKUDAWKS=?L,OGU.-Q+6WXATUG.XJ
M-];IJG,F!I50[9>]='5XBT/2.22!=QLHL+QDCJ4SHS=@O#6A^4-(-7@3.:'\
MHSPX0[>"_%QZK4YN!:<B(RP*@TCU=K/8$;*_CWF'LFQ1DE=0Q@G<:>5*"Y]5
MCOG_ #%1ZGDE.U[+Y"CB)?(A3,8#2$9)<@1OTN<Y"7B35_"^F8(I\8?Y5AC
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M-C;%M9O?$!#!$:UT_A6PL2W55[E&Y10?6NM:6?LD=L)C8^BB=M54X 8:D#7
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MR=!D=,ZSQG;3J-N0:<($6!OB>1+,B@<X6N_ ]Z4QU&]\@.$O8?X'4$L#!!0
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MR]XS&TRB$,NJ<C:?X\YHDULTP/9E#M2FC4Y+&SM:HMD 3PS\5)14U9U7ZBW
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MIM8AZBN(\,?<+>4NTA32O<TZX.?L>S[*V&Q'^2@+"P-L T)J'P'&,\2T=]O
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M*1Q<@."#@O,G8?'G++).)N@8BN4'O/'&+TJ@9#;J88_\G1=2.BK#S'5<!"<
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MT:WEDV]RT50K_LS:M&J::LD_%UI!:>@%/)]5<&KN@B8(']Y[]_]02P,$%
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M"9 OW%Z&,EY55&0%Q*E)#6D$D>UA[R?T=OF0OZBY@/. =V&A]F(A'-AI%/0
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M^^<=^IWOW?:24(U+R7^RS)2SX"J #'/:</,HUU]QV\_(X:62:_\+ZS9V>!U
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MID87XU$ JMTWK6%D[36>2&,WAC^6=D6C<@'V/I?2[ Q7H%OZ\5]02P,$%
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M[H\N:+M36'J%Y:M"6*-&8 8*55+KTQOCDCA4;9C,S?&X]Q.9!I2Y0V\+Z)&
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MR[!+ZNX.W#U8U;I[YUQ9O,6ZX1+_-H"F /R]4LIN'BC!\$=D]A]02P,$%
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M<#0<AT=R7LLP#]9AS^2\_.3_>C8]*U=87D#)RZ,,7>5IRG@4RW!OZ9)QN$#
MZ:W7V!&:29;6?Q[N5H$X%9&NT$SRM(ST0+'5N$!()?%QZ*F+-[,^JF;^:!@.
MCM2'UG >+.(:U0=?YIP*AJ[9G4!3M>B;Y  +!?3#>JT=H9FL:2'I#;M5*$[U
MIBLTDSRM.#U0ES4NE%&U O!H,#PLE!JS@ 3D2*%HN>?!>N_Y0BD3X<T=C1YD
M.*=6!3BI]<(Z0C.WBK2^] >=J@K?J3AUA6:2I\6I#^JWIE4!HUISX-5<>:A]
MR+K:\?<V$6'M>,*7S!1=WK,L^G5JX< S6L?=QE:AKT6J'W2K<)R*5E=H)GE:
MM/KPKF73PL&55!\.R?C@VP2>NVEL6E/ZL*8\49U]X678IQ>/TSU(5V@F1UK!
M^F&WBL>ID'6%9I*GA:P/;XDV+9YAC<@*O4,M5F,V' _'1[Y.M(#T80'Y?%5,
M5TM.,ZI:JC(\F\L4>&KKU6UCA]+7FM4?=ZLTG*I95VAF_TZKV0#>+6W:P1M4
M-[S\T?APBQ>>O&EP6FT&L-K\Q-8L01Y8"C"$[6JZ0C,#UA(TZ%8C.W"J3UVA
MF>3M];+;:68'IS0[:JR ;D>@=6$ Z\+#%)=?"U8-;AC>>@7;$)*!%I)!MYK<
M@5.%Z0K-)$\KS*"51G=P4J>[Q@I*?ZWL EC9V:2_??\;GMQZ?=O8D RTG@RZ
MU0,/G&I,5V@F>5IC!JWTP8.3&N$U5D!Q8*WM,*SM-L7APP><G.XNND(S ]9Z
M#W>K]8V=:D=7:"9Y6COB5EK?^,36=XT=T/K&6K5A6+4=)KFZ+K8_ 0)/8KV2
M;>P5XKT#CMUJ<&.WIR3;T)!8:TC<2H,;5SO7]650M8/*0*LW#*LW^S+XWX="
M8(^LE[V-+4*LA23N5J\;.Y66KM!,\K2TQ*WTNG&UB5UW**3&##@4@K6FP["F
M<U4R3<Z)P*Y9+W\;>XA$ZTS2K8XX<:I97:&9Y&G-2EKIB)-J#[ONG$B=V?%S
M(D2+10*+Q4:UT^3H".R']5JWL<-(M%8EW>J $Z>JUA6:29Y6M:25#CB,:LU!
MM9]^_.@(V?MQ#BPZFWT5V9XF@9VPIJ*-[4JB!2_I5D.<.%6[KM!,\K3:):TT
MQ$E-I[MZF@2>NVEL6HP26(PVEW6V!TQ@1ZQ3HHT=3J+5,.E6%YTX5<"NT,R?
M"&H%'+;210^K7?2Z R9;L_T?PAX_8!)JY1F>TAVW+)3F9TY@;VP7W!6:R9W6
MOV&W&NVA4QGL"LTD3\O@L)5&>UCWL_'JF1-X<MO@^GNW9U#WQKBA_#[."I2P
MN80?G UE\?+-[28V3T2^+._8<)<+D:?EPP6C,\:5@7Q_GN?BZ8FZ"<3NIA^3
M_P!02P,$%     @ S(!W5BM=5,_'!   1A@  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&ULM9EM;^(X$,>_BI5;G7:E+GG@J?0 J26[NDK'"BWJ[8O5
MO3")(583F[4=*-_^QDF:D"IUR\G7%R4),_]X?K;'8S,]<O$H$T(4>LI2)F=.
MHM3^QG5EE) ,RQ[?$P;?;+G(L();L7/E7A <%TY9Z@:>-W(S3)DSGQ;/5F(^
MY;E**2,K@62>95B<[DC*CS/'=YX??*>[1.D'[GRZQSNR)NIAOQ)PY]8J,<T(
MDY0S),AVYMSZ-Z%_K1T*B[\I.<JS:Z1#V7#^J&_NXYGCZ1:1E$1*2V#X.) %
M25.M!.WX58DZ]3NUX_GUL_K7(G@(9H,E6?#T!XU5,G.N'123+<Y3]9T?_R15
M0$.M%_%4%O_1L;+U'!3E4O&L<H869)25G_BI G'FX(]><0@JA^"EP^ 5AW[E
MT'^OPZ!R&!1DRE *#B%6>#X5_(B$M@8U?5' ++PA?,ITOZ^5@&\I^*GYNNQO
MQ+=H37>,;FF$F4*W4<1SIBC;H15/:42)1)_1;1Q3W5LX1?>L''.Z[SZ&1&&:
M?@*+AW6(/G[XA#X@%\D$"W"C##TPJN05/(3K)4U3<))35T'S=2/<J&KJ7=G4
MX)6F^@%:<J82B;ZPF,1M 1?BKH,/GH._"XR*(8EZJ.]?H< +@HX&+<SNW_@!
MW+W"W>]P#]_A'@1=[JUH^G57]@N]_BMZ*\'C/%*MKOGY%QBA>T4R^4\7\5)Q
MT*VH<\Z-W..(S!Q(*I*( W'FO__FC[P_NFC9% LMB;5(#FJ2 Y/Z?(%E@C"+
M4:0OR*^<'G!*F![#P#475)T@M\A(T+VFW 76_(*)AV)\DH@+E!+9-1<61H%+
M85H2:\$<UC"'QEB_8BH0\,N)3C(Q.<!:LX>50Z$M99A%.L>D%&]H"EB[4);R
MDT)>+V.'^7C2&T[=PSDN8QLNQ65)K(5K5.,:&7&M8-W+=7Y#1RP$Y&*)?BY)
MMB&B<P(;Q2Z=P#;%0DMB+8CC&N+8>BH<VR1I4RRT)-8B>5V3O#8.QV^Y'GIZ
MYD8\RP C5"31(RSDBJ-C0J,$J82@*,52:J-JS.K$)G3%!?GRA#9@P-F!"/5R
MU2[)ERT8GDWPOA\,/<][,<??:1>^;==",:E13(PHUK &%'62)G"%5H)&!*T
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M"<$Q$=H OM]RKIYO] OJGP[F_P)02P,$%     @ S(!W5LU^PX5O P  ZPH
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M:U*7^IO8?:*M0Z'ART2I["_:M;;805FMM*A:,"BH&&_^R<\V$ < +QH ^"W
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M->Q@ ]:!P&BF+@:9J;@!V^ &\Y 4RTQ(#YUS?E/4$A$8F[ YO9/P)6@#*]K
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M(M"261'6-9'$'W.V1EQ;*S0]*+0IO%4T--5IG$NN[E+E)_TI<*F2C:Y(3-(
MT+RHG5L)B4"OT8RK>N'R 9$T1.]^YS13&93HY34HI_B5LO@ZOT8OG[]"SY$"
M^1*Q7"A3,3:EXJ:?8 85CZN2A_T(CVL(SI&#SY!MV7:+^_3?W7'3W52*U++8
MM2QV@><\@K<)_ S-E"YR+_X?'Y1Y*=+/ME!+;+<=6R_,2Y&1 ":&6GD"^ H,
M_\4S/+3>M 7>$UA#!J>6P>E"]QOYATW\9VC)F6A-<@DW+.#T#K+R'7=@C<W5
M;D0M1HYEUT8-IF[-U.UD^@&$N$1O@R!/\IA("-5:5H($E)2[A>)/$L8E_5-<
M:.->/F"P0^NU[;D7>^3;K+#MMK,?U.P'_Z5S"K*-Z>" @V?A/9Z'-AA[HW::
MPYKF\ F1U889L3A$MTG&V0HT2X%^?(3D#GCK4N@$/'8I] 36B-VK8_=.N"-X
M?<K0$UA#AE$MPZC?'6%T4(>V:^\OJB>,&DPO:J87G4P_+194O= TSRE+LEP"
MWTU81\UVXAZ;K)[ &A)@:_MVMTY8M15X3TKTA=:48J?1P?U6;H77J,J+_7?9
M$T9-KMON W>^U?U9SH-([;4AFK.%7!,.G07;C79TGD[1<>!MRX&=4Y9L9T-S
MM!0]H36EV/8TN+NI.;YD#[L3U]VOV$Z;)M-M_X*[&YB;G*=4YKS<;V_HO1YW
M=P;=B$=GJB>T9OS;Q@@/3UFTO79)?:$UI=CV2;BS__B/HO4.S@/#D;=?M8=&
M V>_0S!WSL'Z(\1'PI<T%2B&A?*RSCU5)+P\UY<3R;+B:'S'I#IH%\,(2 A<
M&ZC["\;D9J)/V_77%?\O4$L#!!0    ( ,R =U9J*[#F> (  -P%   9
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MY(4F9,KSRV6R=!* IBSYC!97E"L%G,QCBKLA9)J%:'WS0!YGD"Y /J'1_5U
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M3I#& />70NC=Q!Q0MK'^'U!+ P04    " #,@'=64V"_]ED)  !19@  &0
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M4-8 ][=2FL/$!FA?FN@W4$L#!!0    ( ,R =U9;7^3G^ (  *L)   9
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M-;RFB- =H'W)N7HNZ N[?I]%?P!02P,$%     @ S(!W5M?'M2N(!   C!(
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M0+L(H%,5J"Z'9?JV,Q)5[&NQWSCS02%!\+J9S^8[8C+DRU2!H JK],A025;
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MRSG2"(5IH-]/.5?K&S- <0 U_ 502P,$%     @ S(!W5DP'Q!1E!0  )!<
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MI*P ?8^E- \/=H+Z8GSR-U!+ P04    " #,@'=6R1[L+M4$  !L(P  &0
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M1+(K'C!UEPB1;(O%#0]6/,UWD-OODT0\O<@;.#[);?$?4$L#!!0    ( ,R
M=U:T._%(L00   (3   9    >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;*V8
M;6^C.!#'OXK%5:>NM W8) 1Z2:0^[-WUQ6JC9MO5O71@DG %G+.=I)7NPY\-
M%.A"3%K=FP2#9_SS>/P?\.3 ^)/8 $CTG":9F%H;*;>7MBW"#:14#-@6,O5D
MQ7A*I6KRM2VV'&B4&Z6)31S'LU,:9]9LDM^;\]F$[6029S#G2.S2E/*7:TC8
M86IAZ_7&?;S>2'W#GDVV= T+D _;.5<MN_(2Q2ED(F89XK":6E?X\IKXVB#O
M\1C#032ND9[*DK$GW;B+II:CB2"!4&H75/WMX0:21'M2'/^43JUJ3&W8O'[U
M_GL^>369)15PPY(?<20W4\NW4 0KNDOD/3O\">6$1MI?R!*1_Z)#V=>Q4+@3
MDJ6EL2)(XZSXI\]E(!H&PV,&I#0@.7<Q4$YY2R6=33@[(*Y[*V_Z(I]J;JW@
MXDRORD)R]316=G*VD"Q\0O.$9@+1+$)Y^^):S3-"-RQ5BR]H'KX+M"@6#K%5
MT0M]V^9/_N TD^(SNLO"9!?%V1K-@>?YDH50=A+H_!8DC9-/Z S92&PH!X'B
M##UDL;8]T]??-VPG%(28V%)-30/:83F-ZV(:Y,@T,$%?628W GW)(HC>.K!5
M3*K D-? 7!.CQUL(!\C%GQ%Q"$$/BUMT?O8&OO@SC.162^#F([G'EJ#PM]@M
M_U:IBB1#WW922!4('<LR?ETA*=P.N]WJ[7PIMC2$J:7VJP"^!VOVZR_8<WXS
M0 \KZ*')^ZR)2!7T!M 2UG&6Z1LJ0[; 8Q:A?SO#5. 7 XSR ;1X[&?8&0=X
MZ.*)O>] &U5H(S-:F7%KG9=@9ABU&%PO(+[G=R-X%8)W$@(\ P]CT0/AM2 N
M7$R&W0CC"F%\$H+:B"N(^^(P;B,,'9=@IQO"KR#\$^.PC7D/@M]&P,/Q>'P$
M(:@0@M,359$HC3LM/8-V>KJ!Z^!@U V$G5IR'2/2(PB]'EIN56#4GE<-M>OW
MZK:1J'3[#J1&%<!&I"]%HM)E F8$W$(('&?HCMTC!*0F($85_)'73X@NKO;
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MR^JE#I#?/Y:E6&VH#-:_\G#Q)U!+ P04    " #,@'=6?]P.[+P#  #:#
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M1I%5H\BJ4635*++J_Y3UR=KU7__;T-_SUM3=>SX;?B"Y>@502P$"% ,4
M" #,@'=6!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( ,R =U:E3/OR[0   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,R =U:97)PC
M$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ S(!W5E90+PV=!P  ]#$  !@              ("!# @
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ,R =U9TNABK
MR@4  ,@7   8              " @=\/  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    " #,@'=6U#01L]\"  #E"0  &
M@('?%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ S(!W
M5I,HZ<2"!   F1$  !@              ("!]!@  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( ,R =U;>NUE:Y 4  .(C   8
M      " @:P=  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" #,@'=6%LRXH3\"  #6!   &               @('&(P  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ S(!W5MXQFOC:!@  <!T  !@
M             ("!.R8  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( ,R =U90H%V;9P<   02   8              " @4LM  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #,@'=6Y,>^K@@8  "H
M1@  &               @('H-   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ S(!W5@9Q1K.T!0  DPX  !D              ("!)DT
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #,@'=6=U/+
MPQH$   C"0  &0              @($14P  >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( ,R =U98(4,'CP(  )D%   9
M  " @6)7  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
MS(!W5IJ?GL*0"P  OB   !D              ("!*%H  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    " #,@'=66BVGM@D%  "M"P  &0
M            @('O90  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( ,R =U;Z-6:6?P4  *T,   9              " @2]K  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ S(!W5O:^$UQ"!
M2 H  !D              ("!Y7   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    " #,@'=6%QO6%B,*  !Z&P  &0              @(%>
M=0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ,R =U:K
MXLR+TP(  !X&   9              " @;A_  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ S(!W5O^6JM=E"@  X1L  !D
M     ("!PH(  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M" #,@'=6K<RE8.($  !G"P  &0              @(%>C0  >&PO=V]R:W-H
M965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( ,R =U8RME[U-1D  (1/   9
M              " @7>2  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L!
M A0#%     @ S(!W5B&(VOEB!0  O X  !D              ("!XZL  'AL
M+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #,@'=6X2WH+ED$
M  !W"P  &0              @(%\L0  >&PO=V]R:W-H965T<R]S:&5E=#(S
M+GAM;%!+ 0(4 Q0    ( ,R =U:>[A- C0,  !T(   9              "
M@0RV  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ S(!W
M5N"]3M>\ @    8  !D              ("!T+D  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    " #,@'=64 63\,("   R!@  &0
M        @('#O   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( ,R =U9#!#Z@_P(  *<&   9              " @;R_  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ S(!W5H_,F_'&!   1PL
M !D              ("!\L(  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    " #,@'=61YP(+2,%  "4#   &0              @('OQP
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ,R =U9#GX[F
MA0D  "UH   9              " @4G-  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ S(!W5A+IQZ!0!P   $0  !D
M ("!!=<  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #,
M@'=6*UU4S\<$  !&&   &0              @(&,W@  >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( ,R =U;-?L.%;P,  .L*   9
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M970S-RYX;6Q02P$"% ,4    " #,@'=6A,^$-ZL#  !I$0  &0
M    @('E]P  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M ,R =U9J*[#F> (  -P%   9              " @<?[  !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ S(!W5A;^ZWM\ @  .@8  !D
M             ("!=OX  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    " #,@'=6I;8'PP4#  #2"@  &0              @($I 0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ,R =U938+_V60D
M %%F   9              " @64$ 0!X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ S(!W5LC\^,^S @  =08  !D              ("!
M]0T! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #,@'=6
M6U_DY_@"  "K"0  &0              @('?$ $ >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    ( ,R =U;7Q[4KB 0  (P2   9
M      " @0X4 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ S(!W5DP'Q!1E!0  )!<  !D              ("!S1@! 'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #,@'=6R1[L+M4$  !L(P
M&0              @(%I'@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    ( ,R =U:$;2<7?0,  *D0   9              " @74C 0!X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ S(!W5J[S*MF/
M"0  U6T  !D              ("!*2<! 'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    " #,@'=6M#OQ2+$$   "$P  &0
M@('O, $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( ,R
M=U8Y$F5G+0,   X,   9              " @=<U 0!X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#%     @ S(!W5E%X]MXQ P  ]0@  !D
M         ("!.SD! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
M    " #,@'=6 B0AY&P"  #%!0  &0              @(&C/ $ >&PO=V]R
M:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( ,R =U9]!22ATPD  /%A
M   9              " @48_ 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL
M4$L! A0#%     @ S(!W5G_<#NR\ P  V@P  !D              ("!4$D!
M 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #,@'=6IX</
MGMP#   ##   &0              @(%#30$ >&PO=V]R:W-H965T<R]S:&5E
M=#4V+GAM;%!+ 0(4 Q0    ( ,R =U:#1$DM^0(  .D(   9
M  " @591 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @
MS(!W5O*H\VR0!@  >#L  !D              ("!AE0! 'AL+W=O<FMS:&5E
M=',O<VAE970U."YX;6Q02P$"% ,4    " #,@'=6FIUKXF@#  "L%@  #0
M            @ %-6P$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,R =U:7
MBKL<P    !,"   +              "  >!> 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( ,R =U80360SA 0  +$F   /              "  <E? 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " #,@'=6$R?LNN\!  "E(@  &@
M        @ %Z9 $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " #,@'=68B/G&-@!  !((@  $P              @ &A9@$ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     0@!"  42  "J: $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>170</ContextCount>
  <ElementCount>314</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statement of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Certain Balance Sheet Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/CertainBalanceSheetItems</Role>
      <ShortName>Certain Balance Sheet Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - In-License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/InLicenseAgreement</Role>
      <ShortName>In-License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Development Financing Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/DevelopmentFinancingAgreement</Role>
      <ShortName>Development Financing Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Stock Plans and Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/StockPlansAndStockBasedCompensation</Role>
      <ShortName>Stock Plans and Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/KPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cymabay.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cymabay.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cymabay.com/role/MarketableSecurities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Certain Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/CertainBalanceSheetItemsTables</Role>
      <ShortName>Certain Balance Sheet Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cymabay.com/role/CertainBalanceSheetItems</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Development Financing Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/DevelopmentFinancingAgreementTables</Role>
      <ShortName>Development Financing Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cymabay.com/role/DevelopmentFinancingAgreement</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cymabay.com/role/Leases</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cymabay.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Stock Plans and Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/StockPlansAndStockBasedCompensationTables</Role>
      <ShortName>Stock Plans and Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cymabay.com/role/StockPlansAndStockBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cymabay.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Organization and Description of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Organization and Description of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Assets Measured on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Fair Value Assets Measured on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Summary of Significant Accounting Policies - Computation of Basic and Diluted Net Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Computation of Basic and Diluted Net Loss per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Summary of Significant Accounting Policies - Anti-Dilutive Securities Excluded from the Computation of Diluted Net Loss per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Anti-Dilutive Securities Excluded from the Computation of Diluted Net Loss per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Marketable Securities - Marketable Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail</Role>
      <ShortName>Marketable Securities - Marketable Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Marketable Securities - Schedule Of Fair Value Of The Company  Marketable Securities By Contractual Maturity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/MarketableSecuritiesScheduleOfFairValueOfTheCompanyMarketableSecuritiesByContractualMaturityDetail</Role>
      <ShortName>Marketable Securities - Schedule Of Fair Value Of The Company  Marketable Securities By Contractual Maturity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail</Role>
      <ShortName>Certain Balance Sheet Items - Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Certain Balance Sheet Items - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/CertainBalanceSheetItemsAdditionalInformationDetail</Role>
      <ShortName>Certain Balance Sheet Items - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Certain Balance Sheet Items - Other Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail</Role>
      <ShortName>Certain Balance Sheet Items - Other Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - In-License Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail</Role>
      <ShortName>In-License Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Development Financing Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail</Role>
      <ShortName>Development Financing Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Development Financing Agreement - Schedule of Changes in Fair Value of Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/DevelopmentFinancingAgreementScheduleOfChangesInFairValueOfLiabilitiesDetail</Role>
      <ShortName>Development Financing Agreement - Schedule of Changes in Fair Value of Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Summary of Maturities of Operating Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Stockholder's Equity - Summary of Reserved Shares of Common Stock for Future Issuances (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail</Role>
      <ShortName>Stockholder's Equity - Summary of Reserved Shares of Common Stock for Future Issuances (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Stock Plans and Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Plans and Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Stock Plans and Stock-Based Compensation - Summary of Stock Option Grants, Including Performance Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail</Role>
      <ShortName>Stock Plans and Stock-Based Compensation - Summary of Stock Option Grants, Including Performance Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Stock Plans and Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock Plans and Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Stock Plans and Stock-Based Compensation - Estimated Weighted-Average Grant Date Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail</Role>
      <ShortName>Stock Plans and Stock-Based Compensation - Estimated Weighted-Average Grant Date Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - 401(k) Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/KPlanAdditionalInformationDetail</Role>
      <ShortName>401(k) Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Income Taxes - Summary of Reconciliation of Expected Statutory Federal Income Tax Provision to Actual Income Tax Provision (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail</Role>
      <ShortName>Income Taxes - Summary of Reconciliation of Expected Statutory Federal Income Tax Provision to Actual Income Tax Provision (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Income Taxes - Summary of Gross Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/IncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Summary of Gross Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d446975d10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince, us-gaap:PropertyPlantAndEquipmentUsefulLife -  d446975d10k.htm 9, 4288</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="d446975d10k.htm">d446975d10k.htm</File>
    <File>cbay-20221231.xsd</File>
    <File>cbay-20221231_cal.xml</File>
    <File>cbay-20221231_def.xml</File>
    <File>cbay-20221231_lab.xml</File>
    <File>cbay-20221231_pre.xml</File>
    <File>d446975dex1012.htm</File>
    <File>d446975dex211.htm</File>
    <File>d446975dex231.htm</File>
    <File>d446975dex311.htm</File>
    <File>d446975dex312.htm</File>
    <File>d446975dex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g446975g00g01.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="540">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d446975d10k.htm": {
   "axisCustom": 5,
   "axisStandard": 21,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 540,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 170,
   "dts": {
    "calculationLink": {
     "local": [
      "cbay-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cbay-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d446975d10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cbay-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cbay-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cbay-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 526,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 3,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 7
   },
   "keyCustom": 61,
   "keyStandard": 253,
   "memberCustom": 34,
   "memberStandard": 30,
   "nsprefix": "cbay",
   "nsuri": "http://www.cymabay.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cymabay.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Marketable Securities",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.cymabay.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Certain Balance Sheet Items",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.cymabay.com/role/CertainBalanceSheetItems",
     "shortName": "Certain Balance Sheet Items",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - In-License Agreement",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.cymabay.com/role/InLicenseAgreement",
     "shortName": "In-License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbay:DisclosureOfDevelopmentFinancingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Development Financing Agreement",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.cymabay.com/role/DevelopmentFinancingAgreement",
     "shortName": "Development Financing Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbay:DisclosureOfDevelopmentFinancingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.cymabay.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.cymabay.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.cymabay.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Stock Plans and Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.cymabay.com/role/StockPlansAndStockBasedCompensation",
     "shortName": "Stock Plans and Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - 401(k) Plan",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.cymabay.com/role/KPlan",
     "shortName": "401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.cymabay.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.cymabay.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.cymabay.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.cymabay.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Certain Balance Sheet Items (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.cymabay.com/role/CertainBalanceSheetItemsTables",
     "shortName": "Certain Balance Sheet Items (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Development Financing Agreement (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.cymabay.com/role/DevelopmentFinancingAgreementTables",
     "shortName": "Development Financing Agreement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.cymabay.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbay:ReservedSharesOfCommonStockForIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.cymabay.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbay:ReservedSharesOfCommonStockForIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Stock Plans and Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationTables",
     "shortName": "Stock Plans and Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.cymabay.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.cymabay.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Organization and Description of Business - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
     "shortName": "Organization and Description of Business - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_segment",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Assets Measured on Recurring Basis (Detail)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Fair Value Assets Measured on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "cbay:CashEquivalentsAndInvestmentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbay:CashEquivalentMaturityDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "cbay:CashEquivalentsAndInvestmentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbay:CashEquivalentMaturityDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Summary of Significant Accounting Policies - Computation of Basic and Diluted Net Loss per Share (Detail)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail",
     "shortName": "Summary of Significant Accounting Policies - Computation of Basic and Diluted Net Loss per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "0",
      "lang": null,
      "name": "cbay:WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Summary of Significant Accounting Policies - Anti-Dilutive Securities Excluded from the Computation of Diluted Net Loss per Share (Detail)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail",
     "shortName": "Summary of Significant Accounting Policies - Anti-Dilutive Securities Excluded from the Computation of Diluted Net Loss per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022_DebtSecuritiesMemberusgaapFinancialInstrumentAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Marketable Securities - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail",
     "shortName": "Marketable Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
       "div",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022_DebtSecuritiesMemberusgaapFinancialInstrumentAxis",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Marketable Securities - Marketable Available-for-Sale Securities (Detail)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail",
     "shortName": "Marketable Securities - Marketable Available-for-Sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Marketable Securities - Schedule Of Fair Value Of The Company  Marketable Securities By Contractual Maturity (Detail)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.cymabay.com/role/MarketableSecuritiesScheduleOfFairValueOfTheCompanyMarketableSecuritiesByContractualMaturityDetail",
     "shortName": "Marketable Securities - Schedule Of Fair Value Of The Company  Marketable Securities By Contractual Maturity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Certain Balance Sheet Items - Property and Equipment (Detail)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail",
     "shortName": "Certain Balance Sheet Items - Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationExpenseOnReclassifiedAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Certain Balance Sheet Items - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.cymabay.com/role/CertainBalanceSheetItemsAdditionalInformationDetail",
     "shortName": "Certain Balance Sheet Items - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationExpenseOnReclassifiedAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "cbay:ScheduleOfOtherAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Certain Balance Sheet Items - Other Accrued Liabilities (Detail)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail",
     "shortName": "Certain Balance Sheet Items - Other Accrued Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "cbay:ScheduleOfOtherAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022_JanssenPharmaceuticalNVMembersrtCounterpartyNameAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - In-License Agreement - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail",
     "shortName": "In-License Agreement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022_JanssenPharmaceuticalNVMembersrtCounterpartyNameAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P08_31_2021To08_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbay:DescriptionOfPercentageFixedSuccessPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Development Financing Agreement - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail",
     "shortName": "Development Financing Agreement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P08_31_2021To08_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbay:DescriptionOfPercentageFixedSuccessPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Development Financing Agreement - Schedule of Changes in Fair Value of Liabilities (Detail)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.cymabay.com/role/DevelopmentFinancingAgreementScheduleOfChangesInFairValueOfLiabilitiesDetail",
     "shortName": "Development Financing Agreement - Schedule of Changes in Fair Value of Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities (Detail)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail",
     "shortName": "Leases - Summary of Maturities of Operating Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Leases - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.cymabay.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_15_2021To01_15_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyLawsuitFilingDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_15_2021To01_15_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyLawsuitFilingDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "cbay:ReservedSharesOfCommonStockForIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Stockholder's Equity - Summary of Reserved Shares of Common Stock for Future Issuances (Detail)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail",
     "shortName": "Stockholder's Equity - Summary of Reserved Shares of Common Stock for Future Issuances (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "cbay:ReservedSharesOfCommonStockForIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022_CbayequityIncentivePlanTwoThousandAndThirteenMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Stock Plans and Stock-Based Compensation - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock Plans and Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Stock Plans and Stock-Based Compensation - Summary of Stock Option Grants, Including Performance Options (Detail)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail",
     "shortName": "Stock Plans and Stock-Based Compensation - Summary of Stock Option Grants, Including Performance Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Stock Plans and Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail",
     "shortName": "Stock Plans and Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Stock Plans and Stock-Based Compensation - Estimated Weighted-Average Grant Date Fair Value (Detail)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail",
     "shortName": "Stock Plans and Stock-Based Compensation - Estimated Weighted-Average Grant Date Fair Value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "cbay:EmployerMatchingContributionToQualifiedSavingsPlan",
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cbay:EmployerMatchingContributionToQualifiedSavingsPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - 401(k) Plan - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.cymabay.com/role/KPlanAdditionalInformationDetail",
     "shortName": "401(k) Plan - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "cbay:EmployerMatchingContributionToQualifiedSavingsPlan",
       "div",
       "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cbay:EmployerMatchingContributionToQualifiedSavingsPlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwardsLimitationsOnUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Income Taxes - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwardsLimitationsOnUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Income Taxes - Components of Deferred Tax Assets (Detail)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail",
     "shortName": "Income Taxes - Components of Deferred Tax Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Income Taxes - Summary of Reconciliation of Expected Statutory Federal Income Tax Provision to Actual Income Tax Provision (Detail)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail",
     "shortName": "Income Taxes - Summary of Reconciliation of Expected Statutory Federal Income Tax Provision to Actual Income Tax Provision (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Income Taxes - Summary of Gross Unrecognized Tax Benefits (Detail)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.cymabay.com/role/IncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetail",
     "shortName": "Income Taxes - Summary of Gross Unrecognized Tax Benefits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "PAsOn11_30_2021_PrefundedWarrantsMemberusgaapClassOfWarrantOrRightAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2023To01_31_2023_CollaborationAndLicenseAgreementMemberCBAYAgreementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "decimals": "-5",
      "lang": null,
      "name": "cbay:PotentialMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Consolidated Statement of Stockholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.cymabay.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical",
     "shortName": "Consolidated Statement of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Organization and Description of Business",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.cymabay.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d446975d10k.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 72,
   "tag": {
    "cbay_AbwCyclopsSpvLpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ABW Cyclops SPV LP [Member]",
        "terseLabel": "Abw Cyclops Spv Lp [Member]",
        "verboseLabel": "ABW Cyclops SPV LP [Member]"
       }
      }
     },
     "localname": "AbwCyclopsSpvLpMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail",
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_AccretionOfDevelopmentFinancingLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion of development financing liability.",
        "label": "Accretion Of Development Financing Liability",
        "terseLabel": "Accretion of development financing liability"
       }
      }
     },
     "localname": "AccretionOfDevelopmentFinancingLiability",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued liabilities for purchase of productive assets.",
        "label": "Accrued Liabilities For Purchase Of Productive Assets",
        "totalLabel": "Total other accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesForPurchaseOfProductiveAssets",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_AccruedProfessionalFeesAndOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued professional fees and other, classified as current.",
        "label": "Accrued Professional Fees And Other Current",
        "terseLabel": "Accrued professional fees and other"
       }
      }
     },
     "localname": "AccruedProfessionalFeesAndOtherCurrent",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "verboseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_AggregateReturnPercentageFromTheFundsProvided": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate return percentage from the funds provided.",
        "label": "Aggregate Return Percentage From The Funds Provided"
       }
      }
     },
     "localname": "AggregateReturnPercentageFromTheFundsProvided",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_AlternateMinimumTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alternate minimum tax rate.",
        "label": "Alternate Minimum Tax Rate"
       }
      }
     },
     "localname": "AlternateMinimumTaxRate",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "cbay_AnniversaryPaymentsDueYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anniversary payments due year five.",
        "label": "Anniversary Payments Due Year Five"
       }
      }
     },
     "localname": "AnniversaryPaymentsDueYearFive",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_AnniversaryPaymentsDueYearOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anniversary payments due year one.",
        "label": "Anniversary Payments Due Year One"
       }
      }
     },
     "localname": "AnniversaryPaymentsDueYearOne",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_AnniversaryPaymentsDueYearSix": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anniversary payments due year six.",
        "label": "Anniversary Payments Due Year Six"
       }
      }
     },
     "localname": "AnniversaryPaymentsDueYearSix",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_AnniversaryPaymentsDueYearThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anniversary payments due year three.",
        "label": "Anniversary Payments Due Year Three"
       }
      }
     },
     "localname": "AnniversaryPaymentsDueYearThree",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_AnniversaryPaymentsDueYearTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anniversary payments due year two.",
        "label": "Anniversary Payments Due Year Two"
       }
      }
     },
     "localname": "AnniversaryPaymentsDueYearTwo",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_Anniversarypaymentsdueyearfour": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Anniversary payments due year four.",
        "label": "Anniversary Payments Due Year Four"
       }
      }
     },
     "localname": "Anniversarypaymentsdueyearfour",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_AreaOfOfficeSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of office space.",
        "label": "Area Of Office Space",
        "verboseLabel": "Area of office space"
       }
      }
     },
     "localname": "AreaOfOfficeSpace",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "cbay_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated pre-tax unrealized loss on investments in available-for-sale securities that have been in a loss position for twelve months or longer impacting investments.",
        "label": "Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses Accumulated In Investments",
        "terseLabel": "Marketable investments continuous unrealized loss position"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLossesAccumulatedInInvestments",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_CashCashEquivalentsAndMarketableSecuritiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and marketable securities.",
        "label": "Cash Cash Equivalents And Marketable Securities [Axis]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesAxis",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_CashCashEquivalentsAndMarketableSecuritiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash cash equivalents and marketable securities.",
        "label": "Cash Cash Equivalents And Marketable Securities [Domain]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesDomain",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_CashEquivalentMaturityDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalent maturity description.",
        "label": "Cash Equivalent Maturity Description",
        "terseLabel": "Cash and cash equivalents, maturity description"
       }
      }
     },
     "localname": "CashEquivalentMaturityDescription",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_CashEquivalentsAndInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and investments.",
        "label": "Cash Equivalents And Investments Policy [Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Marketable Securities"
       }
      }
     },
     "localname": "CashEquivalentsAndInvestmentsPolicyTextBlock",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbay_CbayequityIncentivePlanTwoThousandAndThirteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CBAYEquity Incentive Plan Two Thousand And Thirteen.",
        "label": "CBAYEquity incentive plan two thousand and thirteen [Member]"
       }
      }
     },
     "localname": "CbayequityIncentivePlanTwoThousandAndThirteenMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_CbayequityIncentivePlanTwoThousandAndTwentyPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CBAYEquity Incentive Plan Two Thousand And Twenty Plan.",
        "label": "CBAYEquity incentive plan two thousand and twenty plan [Member]"
       }
      }
     },
     "localname": "CbayequityIncentivePlanTwoThousandAndTwentyPlanMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_CbayfinancingAgreementFundingInstallmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CBAYFinancing Agreement Funding Installments.",
        "label": "CBAYFinancing agreement funding installments [Axis]"
       }
      }
     },
     "localname": "CbayfinancingAgreementFundingInstallmentsAxis",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_CbayfinancingAgreementFundingInstallmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CBAYFinancing Agreement Funding Installments.",
        "label": "CBAYFinancing agreement funding installments [Domain]"
       }
      }
     },
     "localname": "CbayfinancingAgreementFundingInstallmentsDomain",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration and License Agreement [Member]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_ContractualObligationFiscalYearMaturityScheduleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation Fiscal Year Maturity Schedule [Line Items]"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleLineItems",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesScheduleOfFairValueOfTheCompanyMarketableSecuritiesByContractualMaturityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_ContractualObligationFiscalYearMaturityScheduleTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation fiscal year maturity schedule",
        "label": "Contractual Obligation Fiscal Year Maturity Schedule [Table]"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTable",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesScheduleOfFairValueOfTheCompanyMarketableSecuritiesByContractualMaturityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_CumulativePercentageChangeInOwnershipPercentagePerimissible": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative percentage change in ownership percentage perimissible.",
        "label": "Cumulative Percentage Change In Ownership Percentage Perimissible",
        "verboseLabel": "Cumulative percentage change in ownership percentage permissible"
       }
      }
     },
     "localname": "CumulativePercentageChangeInOwnershipPercentagePerimissible",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "cbay_CurrentMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current marketable securities.",
        "label": "Current Marketable Securities [Member]",
        "terseLabel": "Current marketable securities [Member]"
       }
      }
     },
     "localname": "CurrentMarketableSecuritiesMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets intangibles and capitalized research and development.",
        "label": "Deferred Tax Assets Intangibles And Capitalized Research And Development",
        "terseLabel": "Intangibles and capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsIntangiblesAndCapitalizedResearchAndDevelopment",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_DescriptionOfAggregateReturnFromTheFundsProvided": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of aggregate return from the funds provided.",
        "label": "Description Of Aggregate Return From The Funds Provided"
       }
      }
     },
     "localname": "DescriptionOfAggregateReturnFromTheFundsProvided",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_DescriptionOfPercentageFixedSuccessPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of percentage fixed success payments.",
        "label": "Description Of Percentage Fixed Success Payments"
       }
      }
     },
     "localname": "DescriptionOfPercentageFixedSuccessPayments",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_DescriptionOfPercentageVariableSuccessPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of percentage variable success payments.",
        "label": "Description Of Percentage Variable Success Payments"
       }
      }
     },
     "localname": "DescriptionOfPercentageVariableSuccessPayments",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description repayments on funds provided upon termination of financing agreement.",
        "label": "Description Repayments On Funds Provided Upon Termination Of Financing Agreement"
       }
      }
     },
     "localname": "DescriptionRepaymentsOnFundsProvidedUponTerminationOfFinancingAgreement",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_DevelopmentFinancingAgreementPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Financing Agreement Policy Text Block.",
        "label": "Development Financing Agreement Policy Text Block",
        "terseLabel": "Development Financing Agreement"
       }
      }
     },
     "localname": "DevelopmentFinancingAgreementPolicyTextBlock",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbay_DevelopmentFinancingLiabilityNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development financing liability.",
        "label": "Development Financing Liability Non current",
        "terseLabel": "Development financing liability"
       }
      }
     },
     "localname": "DevelopmentFinancingLiabilityNonCurrent",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_DisclosureOfDevelopmentFinancingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of development financing text block.",
        "label": "Disclosure Of Development Financing Text Block",
        "terseLabel": "Development Financing Agreement"
       }
      }
     },
     "localname": "DisclosureOfDevelopmentFinancingTextBlock",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbay_EmployeeOrNonEmployeeStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee or non employee stock options.",
        "label": "Employee Or Non Employee Stock Options [Member]",
        "terseLabel": "Common Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeOrNonEmployeeStockOptionsMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_EmployerMatchingContributionToQualifiedSavingsPlan": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employer matching contribution to qualified savings plan.",
        "label": "Employer Matching Contribution To Qualified Savings Plan",
        "terseLabel": "Employees contribution to qualified savings plan"
       }
      }
     },
     "localname": "EmployerMatchingContributionToQualifiedSavingsPlan",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_EquityIncentivePlanTwoThousandAndThirteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity incentive plan two thousand and thirteen.",
        "label": "Equity Incentive Plan Two Thousand And Thirteen [Member]",
        "terseLabel": "2013 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlanTwoThousandAndThirteenMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_EquityIncentivePlanTwoThousandAndTwentyPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan Two Thousand and Twenty Plan [Member] .",
        "label": "Equity Incentive Plan Two Thousand and Twenty Plan [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlanTwoThousandAndTwentyPlanMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs reconciliation recurring basis liability accretion of development financing liability.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accretion of development financing liability",
        "terseLabel": "Accretion of development financing liability"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccretionOfDevelopmentFinancingLiability",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementScheduleOfChangesInFairValueOfLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_FederalAndStateTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal and state tax authority [member].",
        "label": "Federal And State Tax Authority [Member]",
        "terseLabel": "Federal And State Tax Authority [Member]"
       }
      }
     },
     "localname": "FederalAndStateTaxAuthorityMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_FederalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal member",
        "label": "Federal [Member]",
        "terseLabel": "Federal [member]"
       }
      }
     },
     "localname": "FederalMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_FinancingAgreementFundingInstallmentsTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CBAYFinancing Agreement Funding Installments Two.",
        "label": "Financing agreement funding installments two [Member]",
        "terseLabel": "Financing agreement funding installments two [Member]"
       }
      }
     },
     "localname": "FinancingAgreementFundingInstallmentsTwoMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_FinancingAgreementTerminationEventConditionAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "financing agreement termination event condition [axis].",
        "label": "Financing Agreement Termination Event Condition [Axis]"
       }
      }
     },
     "localname": "FinancingAgreementTerminationEventConditionAxis",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_FinancingAgreementTerminationEventConditionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "financing agreement termination event condition [domain].",
        "label": "Financing Agreement Termination Event Condition [Domain]"
       }
      }
     },
     "localname": "FinancingAgreementTerminationEventConditionDomain",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_FinancingAgreementTerminationEventConditionOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "financing agreement termination event condition one [member].",
        "label": "Financing Agreement Termination Event Condition One [Member]"
       }
      }
     },
     "localname": "FinancingAgreementTerminationEventConditionOneMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_FinancingAgreementTerminationEventConditionThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "financing agreement termination event condition three [member].",
        "label": "Financing Agreement Termination Event Condition Three [Member]"
       }
      }
     },
     "localname": "FinancingAgreementTerminationEventConditionThreeMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_FinancingAgreementTerminationEventConditionTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "financing agreement termination event condition two [member].",
        "label": "Financing Agreement Termination Event Condition Two [Member]"
       }
      }
     },
     "localname": "FinancingAgreementTerminationEventConditionTwoMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_FixedSuccessPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "fixed success payments [member].",
        "label": "Fixed Success Payments [Member]"
       }
      }
     },
     "localname": "FixedSuccessPaymentsMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_GrossProceedsFromPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from public offering.",
        "label": "Gross Proceeds From Public Offering",
        "terseLabel": "Total gross offering proceeds"
       }
      }
     },
     "localname": "GrossProceedsFromPublicOffering",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_IncentiveStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock awards.",
        "label": "Incentive Stock Awards [Member]",
        "terseLabel": "Incentive Awards [Member]"
       }
      }
     },
     "localname": "IncentiveStockAwardsMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_IncentiveStockOptionsForEmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive stock options for employees and directors.",
        "label": "Incentive Stock Options For Employees And Directors [Member]",
        "terseLabel": "Incentive Stock Options for Employees and Directors [Member]"
       }
      }
     },
     "localname": "IncentiveStockOptionsForEmployeesAndDirectorsMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Line Items]",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_IncomeTaxReconciliationDevelopmentFinancingLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation development financing liability.",
        "label": "Income Tax Reconciliation Development Financing Liability",
        "verboseLabel": "Development financing liability"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDevelopmentFinancingLiability",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_IncomeTaxReconciliationPermanentDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation permanent differences.",
        "label": "Income Tax Reconciliation Permanent Differences",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPermanentDifferences",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_IncomeTaxReconciliationTaxCancelledOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation Tax Cancelled Options .",
        "label": "Income Tax Reconciliation Tax Cancelled Options",
        "terseLabel": "Cancelled options"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCancelledOptions",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Table]",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in accrued research and development expenses.",
        "label": "Increase Decrease In Accrued Research And Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_IndemnificationLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification liability.",
        "label": "Indemnification Liability",
        "terseLabel": "Indemnification liabilities"
       }
      }
     },
     "localname": "IndemnificationLiability",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_InstallmentFundingNumberOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Installment funding number one [member]",
        "label": "Installment Funding Number One [Member]"
       }
      }
     },
     "localname": "InstallmentFundingNumberOneMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_InstallmentFundingNumberThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Installment funding number three [member].",
        "label": "Installment Funding Number Three [Member]"
       }
      }
     },
     "localname": "InstallmentFundingNumberThreeMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_InstallmentFundingNumberTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Installment funding number two [member].",
        "label": "Installment Funding Number Two [Member]"
       }
      }
     },
     "localname": "InstallmentFundingNumberTwoMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance costs related to issuance of common stock and pre funded warrants.",
        "label": "Issuance Costs Related To Issuance Of Common Stock And Pre Funded Warrants",
        "terseLabel": "Issuance costs related to issuance of common stock and pre-funded warrants"
       }
      }
     },
     "localname": "IssuanceCostsRelatedToIssuanceOfCommonStockAndPreFundedWarrants",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_IssuanceOfCommonStockAndPrefundedWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock and pre-funded warrants",
        "label": "Issuance Of Common Stock And Prefunded Warrants",
        "terseLabel": "Issuance of common stock and pre-funded warrants, net of issuance costs"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndPrefundedWarrants",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_IssuanceOfCommonStockAndPrefundedWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock and pre-funded warrants shares",
        "label": "Issuance Of Common Stock And Prefunded Warrants Shares",
        "terseLabel": "Issuance of common stock and pre-funded warrants, net of issuance costs Shares"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndPrefundedWarrantsShares",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cbay_JanssenPharmaceuticalNVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Pharmaceutical N V.",
        "label": "Janssen Pharmaceutical N V [Member]",
        "terseLabel": "Janssen Pharmaceutical NV [Member]"
       }
      }
     },
     "localname": "JanssenPharmaceuticalNVMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_KakenPharmaceuticalCo.LtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kaken Pharmaceutical Co., Ltd .",
        "label": "Kaken Pharmaceutical Co., Ltd [Member]"
       }
      }
     },
     "localname": "KakenPharmaceuticalCo.LtdMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_LeaseFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease facility.",
        "label": "Lease Facility [Member]",
        "terseLabel": "Lease Facility [Member]"
       }
      }
     },
     "localname": "LeaseFacilityMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_LeaseStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease start date.",
        "label": "Lease Start Date",
        "terseLabel": "Lease start date"
       }
      }
     },
     "localname": "LeaseStartDate",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "cbay_MaketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maketable Securities [Member]",
        "label": "Maketable Securities [Member]",
        "terseLabel": "Maketable Securities [Member]"
       }
      }
     },
     "localname": "MaketableSecuritiesMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_NetOperatingLossCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryforwards expiration year.",
        "label": "Net Operating Loss Carryforward Expiration Year",
        "terseLabel": "NOL carry forward expiry date"
       }
      }
     },
     "localname": "NetOperatingLossCarryforwardExpirationYear",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "cbay_NonQualifiedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non qualified stock options.",
        "label": "Non Qualified Stock Options [Member]",
        "terseLabel": "Nonqualified Options to Employees, Directors and Consultants [Member]"
       }
      }
     },
     "localname": "NonQualifiedStockOptionsMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_NoncurrentMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent marketable securities.",
        "label": "Non-current marketable securities [Member]"
       }
      }
     },
     "localname": "NoncurrentMarketableSecuritiesMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_NumberOfFundingInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of funding installments.",
        "label": "Number of funding installments",
        "verboseLabel": "Number of funding installments"
       }
      }
     },
     "localname": "NumberOfFundingInstallments",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "cbay_NumberOfInstallmentFundingAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of installment funding [axis].",
        "label": "Number Of Installment Funding [Axis]"
       }
      }
     },
     "localname": "NumberOfInstallmentFundingAxis",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_NumberOfInstallmentFundingDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of installment funding [domain].",
        "label": "Number Of Installment Funding [Domain]"
       }
      }
     },
     "localname": "NumberOfInstallmentFundingDomain",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_NumberOfLeasedFacilitiesOperatingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of leased facilities operating leases.",
        "label": "Number Of Leased Facilities Operating Leases",
        "terseLabel": "Number of leased facilities"
       }
      }
     },
     "localname": "NumberOfLeasedFacilitiesOperatingLeases",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "cbay_OfficeAndComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and computer equipment.",
        "label": "Office And Computer Equipment [Member]",
        "terseLabel": "Office and Computer Equipment [Member]"
       }
      }
     },
     "localname": "OfficeAndComputerEquipmentMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_OptionsAndIncentiveAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options and Incentive Awards.",
        "label": "Options and Incentive awards [Member]"
       }
      }
     },
     "localname": "OptionsAndIncentiveAwardsMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_OrphanDrugMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orphan drug.",
        "label": "Orphan Drug [Member]",
        "terseLabel": "Orphan Drug [Member]"
       }
      }
     },
     "localname": "OrphanDrugMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments upon reaching cumulative US product sales thresholds year one.",
        "label": "Payments Upon Reaching Cumulative US Product Sales Thresholds Year One"
       }
      }
     },
     "localname": "PaymentsUponReachingCumulativeUsProductSalesThresholdsYearOne",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments upon reaching cumulative US product sales thresholds year two.",
        "label": "Payments Upon Reaching Cumulative US Product Sales Thresholds Year Two"
       }
      }
     },
     "localname": "PaymentsUponReachingCumulativeUsProductSalesThresholdsYearTwo",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_PaymentsUponReachingProductSalesRunRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments upon reaching product sales run rate.",
        "label": "Payments upon reaching product sales run rate"
       }
      }
     },
     "localname": "PaymentsUponReachingProductSalesRunRate",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_PercentageOfAcceleratePaymentPayableOnFundsProvided": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of accelerate payment payable on funds provided.",
        "label": "Percentage of Accelerate Payment Payable On Funds provided"
       }
      }
     },
     "localname": "PercentageOfAcceleratePaymentPayableOnFundsProvided",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of amount to be paid by entity upon the termination of the agreement.",
        "label": "Percentage of amount to be paid by entity upon the termination of the agreement"
       }
      }
     },
     "localname": "PercentageOfAmountToBePaidByEntityUponTheTerminationOfTheAgreement",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "cbay_PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of unamortized portion of the development financing liability.",
        "label": "Percentage of Unamortized Portion of The Development Financing Liability"
       }
      }
     },
     "localname": "PercentageOfUnamortizedPortionOfTheDevelopmentFinancingLiability",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "cbay_PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for considering the cumulative percentage change in ownership percentage",
        "label": "Period For Considering The Cumulative Percentage Change In Ownership Percentage",
        "terseLabel": "Period for considering the cumulative percentage change in ownership percentage"
       }
      }
     },
     "localname": "PeriodForConsideringTheCumulativePercentageChangeInOwnershipPercentage",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cbay_PotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone payments.",
        "label": "Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "PotentialMilestonePayments",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_PrefundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prefunded Warrants.",
        "label": "Prefunded warrants [Member]",
        "terseLabel": "Prefunded warrants [Member]"
       }
      }
     },
     "localname": "PrefundedWarrantsMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_PrefundedWarrantsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prefunded warrants.",
        "label": "Prefunded Warrants [Policy Text Block]",
        "terseLabel": "Pre-funded\u00a0Warrants"
       }
      }
     },
     "localname": "PrefundedWarrantsPolicyTextBlock",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbay_ProceedsFromDevelopmentFinancingNetOFtransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProceedsFromDevelopmentFinancingNetOfTransactionCosts.",
        "label": "Proceeds From Development Financing Net O fTransaction Costs",
        "terseLabel": "Proceeds from development financing, net of transaction costs"
       }
      }
     },
     "localname": "ProceedsFromDevelopmentFinancingNetOFtransactionCosts",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and pre-fundeded warrants.",
        "label": "Proceeds from issuance of common stock and prefundeded warrants",
        "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndPrefundededWarrants",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_ProvisionForStateAndLocalIncomeTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision for state and local income taxes.",
        "label": "Provision For State And Local Income Taxes",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "ProvisionForStateAndLocalIncomeTaxes",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_ReservedSharesOfCommonStockForIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserved shares of common stock for issuance.",
        "label": "Reserved Shares Of Common Stock For Issuance Table [Text Block]",
        "terseLabel": "Summary of Reserved Shares of Common Stock for Future Issuances"
       }
      }
     },
     "localname": "ReservedSharesOfCommonStockForIssuanceTableTextBlock",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbay_RoyaltyPercentageBasedOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty percentage based on net sales.",
        "label": "Royalty Percentage Based On Net Sales",
        "terseLabel": "Percentage of royalty on net sales"
       }
      }
     },
     "localname": "RoyaltyPercentageBasedOnNetSales",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "cbay_ScheduleOfOtherAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of other accrued liabilities.",
        "label": "Schedule Of Other Accrued Liabilities Table [Text Block]",
        "terseLabel": "Other Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfOtherAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award increase in shares reserved percentage.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Increase In Shares Reserved Percentage",
        "terseLabel": "Share based compensation arrangement percentage increase in share reserved"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedPercentage",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "cbay_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_ShortTermInvestmentContractualMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term investment contractual maturity.",
        "label": "Short Term Investment Contractual Maturity",
        "terseLabel": "Short-term contractual maturities"
       }
      }
     },
     "localname": "ShortTermInvestmentContractualMaturity",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cbay_StockOptionsToTenPercentShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options to ten percent shareholders.",
        "label": "Stock Options To Ten Percent Shareholders [Member]",
        "terseLabel": "Stock Options to 10% Stockholders [Member]"
       }
      }
     },
     "localname": "StockOptionsToTenPercentShareholdersMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_SuccessPaymentTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "success payment type [axis].",
        "label": "Success Payment Type [Axis]"
       }
      }
     },
     "localname": "SuccessPaymentTypeAxis",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbay_SuccessPaymentTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "success payment type [domain].",
        "label": "Success Payment Type [Domain]"
       }
      }
     },
     "localname": "SuccessPaymentTypeDomain",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_SupranationalDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supranational Debt Securities [Member].",
        "label": "Supranational Debt Securities [Member]",
        "terseLabel": "Supranational Debt Securities [Member]"
       }
      }
     },
     "localname": "SupranationalDebtSecuritiesMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_UpfrontCashPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "upfront cash payment.",
        "label": "Upfront Cash Payment",
        "terseLabel": "Upfront cash payment",
        "verboseLabel": "Upfront cash payment"
       }
      }
     },
     "localname": "UpfrontCashPayment",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbay_UsAgencySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "US Agency Securities [Member].",
        "label": "U.S. agency securities [Member]",
        "terseLabel": "US Agency Securities [Member]"
       }
      }
     },
     "localname": "UsAgencySecuritiesMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_VariableSuccessPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "variable success payments [member].",
        "label": "Variable Success Payments [Member]"
       }
      }
     },
     "localname": "VariableSuccessPaymentsMember",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbay_WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average number of common stock share outstanding basic and diluted.",
        "label": "Weighted Average Number Of Common Stock Share Outstanding Basic And Diluted",
        "verboseLabel": "Common\u00a0stock shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfCommonStockShareOutstandingBasicAndDiluted",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "cbay_WeightedAverageNumberOfPreFundedWarrantsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average number of pre funded warrants outstanding.",
        "label": "Weighted Average Number Of Pre Funded Warrants Outstanding",
        "terseLabel": "Pre-funded\u00a0warrants outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfPreFundedWarrantsOutstanding",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "cbay_WriteOffOfTaxAttributeDueToLimitation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write off of tax attribute due to limitation.",
        "label": "Write Off Of Tax Attribute Due To Limitation",
        "verboseLabel": "Write off of tax attribute due to limitation"
       }
      }
     },
     "localname": "WriteOffOfTaxAttributeDueToLimitation",
     "nsuri": "http://www.cymabay.com/20221231",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r596",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r596",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r596",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r596",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r596",
      "r597",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of fair value of the Company marketable securities by contractual maturity"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r280",
      "r296",
      "r561",
      "r563",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail",
      "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r320",
      "r500",
      "r527",
      "r558",
      "r559",
      "r576",
      "r582",
      "r591",
      "r633",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail",
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r320",
      "r500",
      "r527",
      "r558",
      "r559",
      "r576",
      "r582",
      "r591",
      "r633",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r235",
      "r501",
      "r577",
      "r590",
      "r628",
      "r629",
      "r634",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r235",
      "r501",
      "r577",
      "r590",
      "r628",
      "r629",
      "r634",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r312",
      "r320",
      "r349",
      "r350",
      "r351",
      "r476",
      "r500",
      "r527",
      "r558",
      "r559",
      "r576",
      "r582",
      "r591",
      "r624",
      "r633",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range",
        "verboseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail",
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r312",
      "r320",
      "r349",
      "r350",
      "r351",
      "r476",
      "r500",
      "r527",
      "r558",
      "r559",
      "r576",
      "r582",
      "r591",
      "r624",
      "r633",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range",
        "verboseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail",
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r280",
      "r296",
      "r564",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail",
      "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r617",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r589"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net accretion and amortization of investments in marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r128",
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r64",
      "r155"
     ],
     "calculation": {
      "http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r161",
      "r522",
      "r535",
      "r539"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r17",
      "r20",
      "r113",
      "r464",
      "r530",
      "r531",
      "r605",
      "r606",
      "r607",
      "r611",
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r3",
      "r589"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r358",
      "r359",
      "r360",
      "r611",
      "r612",
      "r613",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r193",
      "r194",
      "r195",
      "r196",
      "r205",
      "r238",
      "r239",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r358",
      "r359",
      "r360",
      "r381",
      "r382",
      "r383",
      "r384",
      "r392",
      "r393",
      "r394",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r502",
      "r503",
      "r504",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r77",
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Stock issuance cost"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from the computation of diluted loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r579",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed Securities [Member]"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r126",
      "r136",
      "r157",
      "r184",
      "r226",
      "r229",
      "r233",
      "r243",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r399",
      "r403",
      "r422",
      "r589",
      "r631",
      "r632",
      "r675"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r150",
      "r162",
      "r184",
      "r243",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r399",
      "r403",
      "r422",
      "r589",
      "r631",
      "r632",
      "r675"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "verboseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r240",
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r50",
      "r255"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "presentationGuidance": "Total fair value",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets",
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail",
      "http://www.cymabay.com/role/MarketableSecuritiesScheduleOfFairValueOfTheCompanyMarketableSecuritiesByContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r50",
      "r153",
      "r255"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Non-current marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail",
      "http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Use of Estimates"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r38",
      "r152",
      "r562"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents [Member]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r603"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash and cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r33",
      "r38",
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r33",
      "r121"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents [Member]"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r184",
      "r208",
      "r209",
      "r211",
      "r213",
      "r217",
      "r218",
      "r243",
      "r268",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r294",
      "r295",
      "r298",
      "r302",
      "r309",
      "r422",
      "r560",
      "r602",
      "r608",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail",
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r85",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of common stock into which the class of warrant or right may be converted"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "In-License Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/InLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "U.S. and Foreign Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r635",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "U.S. and Foreign Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r14",
      "r129",
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r261",
      "r262",
      "r555",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Share reserved for issue"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r611",
      "r612",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r589"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.0001 par value: 200,000,000 shares authorized; 84,681,063 and 84,677,939 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": {
     "auth_ref": [
      "r87",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r21",
      "r168",
      "r170",
      "r178",
      "r518",
      "r524"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r135",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerBasisOfPricingAxis": {
     "auth_ref": [
      "r578",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer.",
        "label": "Contract with Customer, Basis of Pricing [Axis]",
        "terseLabel": "Contract with Customer, Basis of Pricing"
       }
      }
     },
     "localname": "ContractWithCustomerBasisOfPricingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerBasisOfPricingDomain": {
     "auth_ref": [
      "r578",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and-materials contracts.",
        "label": "Contract with Customer, Basis of Pricing [Domain]",
        "terseLabel": "Contract with Customer, Basis of Pricing"
       }
      }
     },
     "localname": "ContractWithCustomerBasisOfPricingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year One",
        "terseLabel": "Due less than 1 year"
       }
      }
     },
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesScheduleOfFairValueOfTheCompanyMarketableSecuritiesByContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Two",
        "terseLabel": "Due between 1 and 2 years"
       }
      }
     },
     "localname": "ContractualObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesScheduleOfFairValueOfTheCompanyMarketableSecuritiesByContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, Fiscal Year Maturity Schedule [Abstract]"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r579",
      "r581",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "U.S. and Foreign Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r13",
      "r78",
      "r81",
      "r82",
      "r83",
      "r122",
      "r123",
      "r125",
      "r134",
      "r189",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r442",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r619"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)",
        "terseLabel": "Realized gains and losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Debt Securities [Member]"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r375"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r665"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r112",
      "r666"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Federal and state net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r112",
      "r666"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r111",
      "r112",
      "r666"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "verboseLabel": "State and federal research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r111",
      "r112",
      "r666"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credit carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r112",
      "r666"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r105",
      "r665"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r112",
      "r666"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r112",
      "r666"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r36",
      "r224"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationExpenseOnReclassifiedAssets": {
     "auth_ref": [
      "r61",
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense).",
        "label": "Depreciation Expense on Reclassified Assets",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationExpenseOnReclassifiedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r323",
      "r354",
      "r355",
      "r357",
      "r362",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Plans and Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r179",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r206",
      "r208",
      "r211",
      "r212",
      "r213",
      "r215",
      "r416",
      "r417",
      "r519",
      "r525",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Basic net loss per common share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net loss per share\u2014basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r179",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r208",
      "r211",
      "r212",
      "r213",
      "r215",
      "r416",
      "r417",
      "r519",
      "r525",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per common share",
        "verboseLabel": "Net loss per share\u2014diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r45",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unamortized employee and non-employee stock-based compensation expense recognized period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r662"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unamortized employee and non-employee stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r77",
      "r146",
      "r172",
      "r173",
      "r174",
      "r190",
      "r191",
      "r192",
      "r194",
      "r202",
      "r204",
      "r216",
      "r247",
      "r311",
      "r358",
      "r359",
      "r360",
      "r383",
      "r384",
      "r415",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r464",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r116",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r285",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r420",
      "r473",
      "r474",
      "r475",
      "r572",
      "r573",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r285",
      "r313",
      "r318",
      "r420",
      "r473",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r285",
      "r313",
      "r318",
      "r420",
      "r474",
      "r572",
      "r573",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r117",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Cash received"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementScheduleOfChangesInFairValueOfLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementScheduleOfChangesInFairValueOfLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r285",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r473",
      "r474",
      "r475",
      "r572",
      "r573",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r241",
      "r242",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r293",
      "r307",
      "r405",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r570",
      "r620",
      "r621",
      "r622",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument",
        "verboseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail",
      "http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail",
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "verboseLabel": "Fair value of development financing liability"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 8.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r259",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location",
        "verboseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location",
        "verboseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r185",
      "r368",
      "r373",
      "r379",
      "r385",
      "r387",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.",
        "label": "Income Tax Examination, Description",
        "terseLabel": "Income tax examination years"
       }
      }
     },
     "localname": "IncomeTaxExaminationDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r186",
      "r203",
      "r204",
      "r225",
      "r366",
      "r386",
      "r388",
      "r526"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r171",
      "r364",
      "r365",
      "r373",
      "r374",
      "r378",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r663"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax benefit at federal statutory tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r663"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount",
        "terseLabel": "Impairment of tax attributes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r663"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "verboseLabel": "Other, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r663"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r663"
     ],
     "calculation": {
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfReconciliationOfExpectedStatutoryFederalIncomeTaxProvisionToActualIncomeTaxProvisionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r124",
      "r131",
      "r175",
      "r223",
      "r441"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r26",
      "r222"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Arrangement, Type",
        "verboseLabel": "Lease Arrangement, Type [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Arrangement, Type",
        "verboseLabel": "Lease Arrangement, Type [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r457"
     ],
     "calculation": {
      "http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total undiscounted future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r457"
     ],
     "calculation": {
      "http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r457"
     ],
     "calculation": {
      "http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "verboseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r10",
      "r184",
      "r243",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r400",
      "r403",
      "r404",
      "r422",
      "r568",
      "r631",
      "r675",
      "r676"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r127",
      "r138",
      "r589",
      "r610",
      "r623",
      "r670"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r39",
      "r40",
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "terseLabel": "Unpaid financing costs"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r151",
      "r184",
      "r243",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r400",
      "r403",
      "r404",
      "r422",
      "r589",
      "r631",
      "r675",
      "r676"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r9",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "verboseLabel": "Line Of Credit Facility [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail",
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r9",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility[Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail",
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r71",
      "r72",
      "r263",
      "r264",
      "r265",
      "r626",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyActionsTakenByCourtArbitratorOrMediator": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes important rulings or decisions made by the judge, arbitrator or mediator in the legal matter that could impact the outcome of the case.",
        "label": "Loss Contingency, Actions Taken by Court, Arbitrator or Mediator",
        "terseLabel": "Loss Contingency, Actions Taken by Court, Arbitrator or Mediator"
       }
      }
     },
     "localname": "LossContingencyActionsTakenByCourtArbitratorOrMediator",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyActionsTakenByDefendant": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describe actions taken by the defendant in the legal matter.",
        "label": "Loss Contingency, Actions Taken by Defendant",
        "terseLabel": "Loss Contingency, Actions Taken by Defendant"
       }
      }
     },
     "localname": "LossContingencyActionsTakenByDefendant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAllegations": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Presents an assertion of a fact by a plaintiff in a pleading or complaint, which the plaintiff claims it will prove upon presentation of evidence at the proceeding.",
        "label": "Loss Contingency, Allegations",
        "terseLabel": "Loss Contingency, Allegations"
       }
      }
     },
     "localname": "LossContingencyAllegations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyLawsuitFilingDate": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "States the date the complaint was formally filed in a court of law, in arbitration or mediation.",
        "label": "Loss Contingency, Lawsuit Filing Date",
        "terseLabel": "Loss Contingency, Lawsuit Filing Date"
       }
      }
     },
     "localname": "LossContingencyLawsuitFilingDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNameOfPlaintiff": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies the plaintiff in the lawsuit.",
        "label": "Loss Contingency, Name of Plaintiff",
        "terseLabel": "Loss Contingency, Name of Plaintiff"
       }
      }
     },
     "localname": "LossContingencyNameOfPlaintiff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Abstract]"
       }
      }
     },
     "localname": "MarketableSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Marketable Available-for-Sale Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r33",
      "r34",
      "r37"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Cash flows from operating activities",
        "totalLabel": "Net cash (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r23",
      "r37",
      "r130",
      "r142",
      "r149",
      "r166",
      "r169",
      "r174",
      "r184",
      "r193",
      "r197",
      "r198",
      "r199",
      "r200",
      "r203",
      "r204",
      "r210",
      "r226",
      "r228",
      "r232",
      "r234",
      "r243",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r417",
      "r422",
      "r569",
      "r631"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental non-cash investing and financing activities"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total interest expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Interest expense, net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open tax year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating Expense [Member]"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r226",
      "r228",
      "r232",
      "r234",
      "r569"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r453",
      "r588"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liability",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail",
      "http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "cbay_AccruedLiabilitiesForPurchaseOfProductiveAssets",
       "weight": 1.0
      },
      "http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "positiveLabel": "Less: current portion of operating lease liability",
        "presentationGuidance": "Short term portion of operating lease liability",
        "verboseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail",
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail",
      "http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Long-term portion of lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Long-term portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets",
      "http://www.cymabay.com/role/LeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r450",
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "presentationGuidance": "Operating lease right-of-use asset",
        "verboseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets",
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r456",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average lease discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r455",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward",
        "verboseLabel": "Federal net operating loss"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "terseLabel": "Description of net operating loss carryforwards, expire period"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r156"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r163",
      "r164",
      "r165"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax",
        "terseLabel": "Unrealized loss on marketable securities, net of tax",
        "verboseLabel": "Net unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r77",
      "r167",
      "r170",
      "r177",
      "r431",
      "r436",
      "r437",
      "r517",
      "r523",
      "r605",
      "r606"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 9.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits [Abstract]"
       }
      }
     },
     "localname": "PostemploymentBenefitsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r1",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r1",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r1",
      "r589"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r31",
      "r609"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from Lines of Credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail",
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r30",
      "r100"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock pursuant to equity award plans"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]",
        "terseLabel": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r149",
      "r166",
      "r169",
      "r180",
      "r184",
      "r193",
      "r203",
      "r204",
      "r226",
      "r228",
      "r232",
      "r234",
      "r243",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r398",
      "r401",
      "r402",
      "r417",
      "r422",
      "r520",
      "r569",
      "r586",
      "r587",
      "r607",
      "r631"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r63",
      "r154"
     ],
     "calculation": {
      "http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r65",
      "r139",
      "r521",
      "r589"
     ],
     "calculation": {
      "http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail",
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r65",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r319",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r319",
      "r465",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r32",
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail",
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail",
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r102",
      "r143",
      "r683"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r84",
      "r137",
      "r534",
      "r539",
      "r589"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets",
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r146",
      "r190",
      "r191",
      "r192",
      "r194",
      "r202",
      "r204",
      "r247",
      "r358",
      "r359",
      "r360",
      "r383",
      "r384",
      "r415",
      "r530",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r176",
      "r184",
      "r220",
      "r221",
      "r227",
      "r230",
      "r231",
      "r235",
      "r236",
      "r237",
      "r243",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r422",
      "r520",
      "r631"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "verboseLabel": "Sale of Stock, Consideration Received on Transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of Stock, Price Per Share",
        "verboseLabel": "Sale of Stock, Price Per Share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAntiDilutiveSecuritiesExcludedFromTheComputationOfDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Anti-Dilutive Securities Excluded from the Computation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail",
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule Of Available For Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail",
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/InLicenseAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r44",
      "r47",
      "r208",
      "r209",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Reconciliation of Expected Statutory Federal Income Tax Provision to Actual Income Tax Provision"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r98",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]",
        "terseLabel": "Schedule Of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r91",
      "r93",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Grants, Including Performance Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Estimated Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r84",
      "r158",
      "r159",
      "r160",
      "r217",
      "r294",
      "r295",
      "r296",
      "r298",
      "r302",
      "r307",
      "r309",
      "r576",
      "r602",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r585",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Summary of Gross Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense, Total",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Share based compensation arrangement by share based payment award, award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Weighted-average grant date fair value per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (In Thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding as end of period",
        "periodStartLabel": "Outstanding at the beginning of period",
        "terseLabel": "Stock options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares Subject to Outstanding Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding as end of period",
        "periodStartLabel": "Outstanding at the beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable weighted average price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r324",
      "r325",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail",
      "http://www.cymabay.com/role/StockholdersEquitySummaryOfReservedSharesOfCommonStockForFutureIssuancesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r327",
      "r346",
      "r347",
      "r348",
      "r349",
      "r352",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Share based compensation arrangement by share based payment award, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationEstimatedWeightedAverageGrantDateFairValueDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Share based compensation arrangement by share based payment award, exercise price percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r552",
      "r553",
      "r554",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term Investments [Member]"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r43",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.",
        "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit",
        "terseLabel": "Significant change to its unrecognized tax benefits over the next twelve months"
       }
      }
     },
     "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Purchased Software [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsPropertyAndEquipmentDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r184",
      "r208",
      "r209",
      "r211",
      "r213",
      "r217",
      "r218",
      "r243",
      "r268",
      "r270",
      "r271",
      "r272",
      "r275",
      "r276",
      "r294",
      "r295",
      "r298",
      "r302",
      "r309",
      "r422",
      "r560",
      "r602",
      "r608",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail",
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.cymabay.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r16",
      "r77",
      "r146",
      "r172",
      "r173",
      "r174",
      "r190",
      "r191",
      "r192",
      "r194",
      "r202",
      "r204",
      "r216",
      "r247",
      "r311",
      "r358",
      "r359",
      "r360",
      "r383",
      "r384",
      "r415",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r464",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail",
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r216",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail",
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.cymabay.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r77",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of new stock issued during the period."
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r77",
      "r84",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options (Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationSummaryOfStockOptionGrantsIncludingPerformanceOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r77",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of public equity offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r1",
      "r2",
      "r84",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r77",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r48",
      "r589",
      "r610",
      "r623",
      "r670"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets",
      "http://www.cymabay.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r183",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r311",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r438",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r438",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r438",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail",
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r438",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.cymabay.com/role/DevelopmentFinancingAgreementAdditionalInformationDetail",
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r467",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/OrganizationAndDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.cymabay.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.cymabay.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Certain Balance Sheet Items"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItems"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r241",
      "r242",
      "r293",
      "r307",
      "r405",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r620",
      "r621",
      "r622",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments",
        "verboseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/CertainBalanceSheetItemsOtherAccruedLiabilitiesDetail",
      "http://www.cymabay.com/role/MarketableSecuritiesAdditionalInformationDetail",
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r193",
      "r194",
      "r195",
      "r196",
      "r205",
      "r238",
      "r239",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r358",
      "r359",
      "r360",
      "r381",
      "r382",
      "r383",
      "r384",
      "r392",
      "r393",
      "r394",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r439",
      "r440",
      "r443",
      "r444",
      "r445",
      "r446",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r502",
      "r503",
      "r504",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r566",
      "r579",
      "r581",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Securities [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/MarketableSecuritiesMarketableAvailableForSaleSecuritiesDetail",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r363",
      "r370"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Decreases related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesSummaryOfGrossUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "verboseLabel": "Net valuation allowance increase (decrease)"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/StockPlansAndStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r207",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding used to calculate diluted net loss per common share",
        "verboseLabel": "Total, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r206",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding used to calculate basic net loss per common share",
        "verboseLabel": "Total, Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.",
        "label": "Write off of Deferred Debt Issuance Cost",
        "terseLabel": "Write-off of deferred financing costs"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cymabay.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r594": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r595": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r596": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r597": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r598": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r599": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r601": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=29634951&loc=d3e1756-110224",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2459-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001193125-23-077859-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-077859-xbrl.zip
M4$L#!!0    ( ,R =U:2#G()R10   ;?   1    8V)A>2TR,#(R,3(S,2YX
M<V3M76UOZ[BQ_GZ!_@?=?.D6N$Y.DCW;GF"S15X7;I,X37QVM[BX*&B)MH4C
MDSZDE,0M^M\[0[U;HD3)BGQP[2^)+)$S#V?((6?X]N.?WQ:>]4*%=#D[/S@^
M_'!@469SQV6S\X/ GP[^=/#GGW[W7S_^]V#P,V54$)\ZUF1E7=\.'ZS?+I_N
MK"&3/F$VM:ZY'2PH\ZV!-??]Y=G1T>OKZZ$S=9GD7N # WEH\\41?/\E9&@]
MG1Y^@)_P='(ZN"?"G@]./IR<6O][?'QV^N'LY./_6?]ZO/_W8( 0I#VG"V+Y
M1,RH_T 65"Z)3<\/,LSLU8),R$JQ 4(GQR>GQU @CR*N6RX6UW1* L\_/_@:
M$,^=NM0YL$ "3)[9D,^ EDJ<2_=Z>LC%#))\.#[Z[?[N6:&,J7HN^Y)+_381
M7IS^] @_3XBD<?*W0OJ(^O&G3Y^.U-<D*1!R*TB[D5JRZ1T_R9!-_/$H_)BB
MJ*#[VUT&1" ',T*62?(ID1.5-/J@!)=(F ?,%ZL\!$GMPQE_.8H^YC,$0D!E
MU.6(ON:R.-0M3PT?<@GIFSTO3XE?<DD9<6U9GE9]RB66KEV>%#[D$H*$_-62
MRE+9J2]YNOY2: C#ES49+ 6UL:%JU?CI"-J:X!X%KK8_H&]+CS#B<[&ZA=\)
M3^$7T<'+/##AZPJ2?,K#\\5:AAPZ^'R$GS'/A\&'X\')\5IM&\A@N0R;M+;B
M81K%]>MI%FA5SNA[G LM#F&,^P0ME_JU7+ILRO$1&^(9RF\,2"U\^/PTU%H/
M)>@K#E;VD<R@0;J@F/1G0L^A8"I=Q>T8C G8Q8Q%5>DMS/#CT7KJF$ @J3-B
M/ZEGJ (2<BKPV&*C7%&2LAPI0;/T-O'LP-,S.,H)J;74L/-P':S-E\1#@_8\
MI]27L11UGS52/0%1/H-4:"+6E( 54;!"$GLYHQ0>"1A9?TY]%W#4"#V?5J.!
M4W,-6-_E*/YA9S62R$N.IJ,E#L)P,'7!G"N^@.+.*9/N"[WCLJ19-,BKT=CW
M51I+R5M\:J4,+,(<*\?"0AY[%8(:GGUN?YESSX%1\,W7P/57U6HK2:]1U4=S
M566)_MX*R>ZU4R;L&A/8(*]&:S\8:4VGM+V5+&DR5T3.;SW^6F,0TV0:U?S1
MO$$A+4L1VRD-C,2,,/>?B@OT*M=4VL)=XJ_1]#*0+J-QKV244J.'/^%HV)6V
MQV4@*/S($E-]388<:B,FN%.Z> X6"R)68(C<&7.G8 Z8?V$KU]IELT>HN+9+
M(VT8IM7HX].Z/B)RRDBE!*V4HA63W"F-W!/QA?IDXM%G:@<"X,7R+_U2+NWC
M#^O23C-;:>Z=$NP5%3YQ6=;_&((QCNV][JM&P,?K HX(Y!T22]'8*3$/@;8-
MXW=Z,1-4]76A@$O>:T1[LB[:(1M$>:TD\T[)])J^4(\O54C:95"]P#JNB;<Z
MB4;2I^N2SE"Q$C([*O0[2F1L>J-GC1B_7Q=CF'RGI 6.^\+UU=!610I4#TY9
M.GJH2J"1Z\>"C4UI1-&"#)6=$K<N(&#L^!__4!B/[;I[KP3P"+TW5E#UXQ*:
ML8IZ0=^CF&>$7)-0(_4_EDK=4L14E5:_!XJ>E26X4YKX*\HCE'7XJ)%FP<?[
M_L/Q=U_^H,2Y4P(;,GBD8_(66]OL"XWP"@Y9F,=2F79*>L_!1-*O 93DY@7[
MEMC=77M;+L>3@JN59K3"G#LF3),H09O(0DV$X:3@DIE'&*SOXJ?="H::"7Z,
M88-&JHIR:!15</":*"HDO5MJ*HO\9)52\5VC@H+G5QH?VDUIZT)!68G7I-%(
MO> H5@2-=E/VE6&,K ),$FJT4' K:Z(>NZF),(:1%7GNC4:V!:\RS+2;(BPZ
MX[F>5/=5(]IRU[$PM;NS@JYVR N2-TJN447![S3UXG=3/1EG-*N&XFN-N"L]
MU=T4J<G,^(7C*-C$&[(I%PN5^!H&>:YG/KU>1:1<7:<%A]ATYAV2INRL##_K
MNY#C;NG8S-7"W0-.X-'1]):XXA?B!?1"2NK+>^AY0?Z Z D'] +R@$%R9;8&
MO"\+3?W8Q$^'Q!$83(UP+(7'"@%9,2+<())@LA2H?272:[C65&Q.1E,9-HD%
M[,U%<TWC:"0(RPI&'MJ%C9;?]0*?.@_4QQ6WCU0\SXF@S?7?G+BF5A3"$XUJ
M10:&ZEX02-COA% LP*+6%EM+*BP%9U]E*EHU_%*2<U\R\:6;-]L+'.K<"KX8
MSVE.]5W5IXXY:RI;(2K3S 3!FT$,,AL[BV%:4\!I^7.Z7B_WM;$^REG;,37-
MI*D#A9A0>3QTW^/4*2Q]=_$" L&'6RZ>239-G?X:T-"HLQ"&TJDS\S[A-0"U
M#I!;+A*^5W HB1)G8#2-S#!AJ[(LERM<J".([0?$NR<^OE[558*.^6@J2B&H
MIJLHB=LQRKD=\&L<678 96FR7ZZL##(KAK:;E4HW=?(H.'2 _@J&C!C+5.'X
M;"5ID4^C]$+XKFH:9F#%#-00,F&Q5UY6";7]=)N,&O45PH'5ZMOWV/7J&\'P
M5,#X5@34N7/)Q/4*'76[K.4J_+X0(JQ6H>)A14RL#)?=U&)Q*7UM\VN61:.U
M0N"N;&'^OL693VC7JJUU;HT&"]&VNJGOO3*-E9D.6*_FA,VH'++,R%5C53NE
MJ%%ZTUT>:T'VB+<%UCDS\(4/.V^'P[4-22@K&M:#.))S$]A,I=$H?X/\&E5K
M=J+D8UHIG\P!#% !5-J]5D.1U9KF^F0:'15"38F.]J;6:#]1O:_1+J]&7X58
M4N4NI+T::Y9 U4\U-LJB49K98JF]KJIUE71-3U! \4(=-3N!IV! $^!,9;CE
MXC: #H4.I0S0=Y/5RMR(ID;;Y>NQ0K:_EZFV,YU@S#V<< F/XU  HK5<4!>L
M$(.5@-CA:E&]6LZL3;>GH5%[\4@)TV5X^X;?4,/I?"U^'JFE6S\+ EW@D.$T
M)T[:4J'D""TE_%XT!._'H[R&?"SNS3*O(=E98)4KY&B%D/['2D!9&511HKVI
M,%-RX?/-&S[2C6I.#5%-52FN2FM?5<I212#V%4.CPQOINPL\).M7ZL[F\/_B
M!1S3&57-[1H^)*&/AI6C,6%-!2FN5#.O( D&*P8QB%"$YL1"'-GPRD[6$K77
MNW8L49M*H[]"&"RS67P_(- MV#>863!*JU%*(6"56]J_UXI&*VA>. M/)+RF
M4RH$=>!#N A:HQV3/!HM%4)6:UI*2:MU;1%Q_!ROR]YUA66\7ILSV_7<:,$B
M#@OLZ(S)0!VG3L%IQ184Y7T4_,7%JP_&_$(M'RE^T2B\#YZ:"E.(F:U5F)PC
MG@6';V)X5H+/B@!FR%@)$LOG5HBR_/.^ZD75X&?!I?S,! A\QMQ_JM9_21G
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M  'V9.]TC#<Q:T6:O5HO/?OF>OF%"%?Y9#F:_?J(-1C:M+DWZFRS1%4 6C@
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ML@C<P\PA<(5#"]^)0=="!:6,H.7@R=12QNGJA8MM4F=VM6-4$W\44#=.<=I
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ME&MT<7?2T+':X;78%-EE@4 IK^H&> ) MJ]2G&ZB2]U:N(RTM"Q759+2I)&
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M6'YR_O7XY.B''K)J^$TDA.=P]50N$<2 -JTXU-0J$NF__-"+L:8BO,@-+W+
MK<M>&?@UW+<D+:%IIT_._.J.6DJX)<GE73AE;Q6R,5./IU44WR!=L:K@,.0I
MR151!LDVW;2>XS;OBF[;\O@EB6=D1-W$>1@D?P<!7']M+?6=P#.[57LDQ^IY
MQWD>W8U*?!,P<+/(&J+)S"C=Z,$'MVVF4JY*<)L^X9NA"&M&N >65Z> OSA)
M6V.5>#WP/OA9\R6^1S/]\QM(7@%]"-:(\_U&*O!.%F-'S/-58,!5VLQZQO.%
M;MQ6A;%#OV@KY!K ;\%?VO9^;01@@?WZ@P0=1\#3'("":.D!9DOTTPH=:+#Q
M9HD!=/YP;BW$0X)31=0D$>W)U"M/CL]=/57@"J?^4D'<!,+F('2AJL[9TZH>
M-K_"%9KHU9<KA5AD"K61?KQZK:#$)K-'*(/U87?%AXD^*O4>4*B-H+I^1J!,
MB":?^R!]>%C6"9^^.'ET0ZQ?,2#O0)"#>99$MXLES%[) B*_]Q'40A"=OD-7
M'EYL$J7([ 7>'T^G<0CP;2$) P[@1G3QY8"L'I+;J;-U0T8TL/GP?NHIFQ9O
M.$Q[&JW_> 5>09(1:7&T OFP4FX#P7;ZB+_E(-/$Z</[I)L2(BV71.:;^!W_
M2<XGOQ("YO1^IB6!,F ^1'[D0KP'(I.^J-KD^,+I!7F[HZ4<F0\1%VNQ%Z[
M$H(PKE))+!- U)U&50P8\N]<4*);&T.?0,JVD\:ZD^Y@5@M>!%?DRDBB>#09
M]*0B0NCDYL;RL*]ADSQ,<F6 '1=S %$_A26([N+@)4X<!2\KT"A1M;D>%IZ<
M#0;G)]T:V-:9J1X!&>$U[<EOM:5UT6KAU-5(H&+V&%!$9, RR@LK>M");S+X
M4,)PCHZ;Q#H8E2%.#$7?+O*.>IK-(%1N8WVI\M0<G &CIY@R]-DIR'/2_@W
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MD.U[YJ<B"__ X4D S*__+''69"^NET=)D.?C*1'O3N%FF5E^<MJQS\<#:@9
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MZZ(\9\\ 7RQC*0GH*CZ"F'7U%M!<Y/>MD4FR==7B:R"@I@&;+.5 \._ )]3
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M6>1%D$;HY$-/WA87V(-OH;W+CQX5Q[RZ.-UN/6X]B/^V23K%_AD'D$AST'E
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M_/2%W[D_XY9?@AS\\_\'4$L#!!0    ( ,R =U9GO^?&:'D  /X<!P 5
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M8=$QG:6L(VC04TZ0=Q,%CU%,OH_S\R1DMQN>TS@DZXJ/?SW07>MA])FS<(A
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M9*_IF(#T2)F>3#@RMDD9C*2]ZD$HTONI82#2.ZF3,/0QR!+RX;PZ%E+&1DW
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MHT%2/5 .!4?1O*HTDC^D"E]J'3;HI,FTP7X*6Z=CP23]Q0A;LZ.SKE[ 14W
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M8X[_>B#SP8\OACD[-8G3NQ]*N<5['E53Q-MZ$C"'3"]>=M#;'00O9A>(E#2
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MW;'S&.GAY2"DQH_2&=3@ 8/^NU'0?^<)]-^-@/X[#Z&OUF-(9FCHO[.'_CL
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MO>-=#>"?#Z_I;/[9XN6A?[8UG>J?A-=)^:?0RV/]<YDNGML_=5UMZY\%[6I
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M0D!D!BW$-PG(5J/I$(KA_;8UWG_&;\7#*XY?\*<T*9YU"^OQ+'WQ7KW>DR?
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M#,O'3[8Z0,:IY_7G<4P?$*>%DLU'H0X1W C4E7TX9K?:>S'NS"@_X&@C0=#
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M^G-'V0E^?Q)1UOHP&<04=TXA3R@FS]HWGAZG_=KB^*)]YO/>H"\V6V04F#\
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M;#\ %L'P4YY230O",0KB3U&,\R)-\&UP_/^':W$)01UTN_(4GZLQEF7!%"O
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M>-'1$PXQHV2WTUXR7;<-_SQ@9=<5O2SQ\Y)YEOXT?0O"#:&S)%ZHQ%9^.#8
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M^=RZ4[)0XJ&C%/*A"(CKG:VE7!V*Z>6)+..$^J>QJU?1,4)6I<#OWIE>"Y.
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M4RT=SS;1*I[)G%U>2/@5UID,3Y"O\N4T\:E5P!%PZTZ^@ZQX&7 ?IU)2J^4
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M"A-%$79+Q-YAR?+VH!_.6/J$R8 (.'+G,:-@D\+BJS?8Q.W6+^7EH#7.$)Y
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MU.%1IT.2=F7[,$7EL\(I7?8:V=J@DBA_"$GA]"S8_J'ROY!D$12)_&[>BZN
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M.7B&!<)ET'KXV+@Q]X])#&>P;$7#D64TL_P_\T"T(:W9$@@/.Y.P'K\FRJ%
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MK1TY4>B+M]G#ZN=.F 9)-"Z?G/PR-T$GC2(@@VF_D-_F?B+NG$'YX_A-[M'
M]IRX_%GZ*O=P[#GEC\(7^0>3433E2?@F]V@:U_NV/=)/]^RX2_LHO\@]?.?/
M.*?_.C6H+$VB&<<#WQ;>7X_3T<@70Q$D4Z>"S]!T_M[1"XV2F;^4WT_^JO31
M/&'>35M "\D=KI3XKT^7I]GC2?GSV:-OD\@.XEX8#>T$6 R^K5EOMNNMMGG+
M9FUQD4/ 2^MPLKE?J).>]=[67KWYOJX9TW3&@9SN#;$\8;OXOXF7^.*75K/^
M^T]O^6_X<"@2VW+"(*$S2,1=\A9_^-%R!G84B^3GK]?'R#SQ+77Q=^K=_/SF
MD!^O7X]'XLU;'.6M>D<W=,=6G(Q]\?,;?OG>+S_9UB 2O9_?_",)G3>_7-M=
M7UAASY+#Q#^]M7^!$?;P<=>[D3__'ZX7CWQ[_,$*PD#\CU]^\NX^X%M$Q']Z
MKBL"^A.^/TN'(O(<*["'\&+@4Q\Z0%0N$M:Q;_??\ KODDN<QD6S]0W^@P1S
M';;:WW;X[S>_]&P_%C^]S0TY_0V?0R>E%WBQ8_L7\&WH'L-G\8)O._YKX5<=
M!7!>XT-X663[)X$K[GX7XP5?TP3AT-QM-]_M+OFZCNM&(HZO$F#!Y]%%%-YX
M)"0\9-ZT^^]:S??X?PO.Y+ S,8.W^9,$*A'(DD7\RT]X7S[$)-%@6(ODX(<$
M*.[G-[$W!*[Q1G[&M(7"O*Z$=N,N!J'Q5@ZB;M[2PWP# =2 6Z8>0;$TXX:3
MU(*?Q'!.=%M/LQ>K(:1PFRWN89!P)*+$$_&D8K&XMK"PRO+PC7)%;]F-@I]X
M@?>ZMLFWN\MN$_Q$^*]GAX"3+KM#\!,G]9_;A7M;8'?TSSA,(_H7J>P?)%<E
MCCN-JUJ_6/)I05Q;_]-S\8.>)R*+N*@HU30.3W[/BXCBCV&\MZ7CCTC@Z7^"
M"1$EGT%4_(+3JC=;\!_UR^R[;*YN]FRK#>I,]A97/OFV\)ZWN4TIW:-.?!XT
M=[ZU]G!O=C9F;]C 2G"U._7F3KVUI\>2W]Q[M1M("<9J"V>[NM6V-G&UK16N
M5M_VEG';-V?5N=O>6N*VMU9]V_>_[30WF/Z;^_6=YJHH@OD:4$3V]\:L>I(B
M,BXWAR)RSSZ((I#WM]4>Z;\W=H] $K07W2/SV8?MT7O%36"/WF\\9WEO<(MY
M>_1^59P%]D7K6GJ/-H?#%'6M]XOK6JO;HYP\;F[,WAC<M[DN[:/][52 'C\(
M??=D"*;##7DPXR]BV!51&J._\X(-BO&%#Z_L!.[1WZDWPJ<^C=%KUKGSXL?8
M,DD3HH^OEO]VX7UW(]]SO(1G;+D>?,V1$^FN_;#8_-73,[;CI[>E[\QV/9O<
MQFB7[6_GO9[G"%CW83@<I8F(]/I?WR&C@?YAWH8\SV.^"GO)K1WANM2?G\6-
M\$-:V6$8O^9+O?#F/,^S/TZCP$M26M^Q=X=_O>+#GKX;S_-T#^UX@-P*_@<7
M?F/[10E];'O1'[:?BD_C3AR+Y-"WXQAWY=N7,!#C+W;T723':>#F?^4%=N!X
M&(6)DXCB/QM/"5-7:IS_K/V:3@&+3V'JMJDGRC?]U1'?*R6DC3[-<#@4$1+O
MA0W#G(7)2>#XJ2O</[UDL,!9E]/^MT-*/TF8YC$F?B6<-/(P"/&R2844RKFK
M?Q2N<_^S?:ZT'(W""&S^SZ*;3*&W5TFN"U#*C)U;!:VN\<)L-$4^D*R^?;VZ
MCH0=I]%X*7I^YN0X?=45+3X9+6XV3;W20_UBO\;#G+KJYWF(#Y825^DHL@-*
M$K+]I96?S::%J7,F2IB[\DI@/*'R$G?Z6(+P@JAQLPT_FL*T77^>1/A:N)EZ
M8CD>MLDG1ZGUG< ]#1W;_Q<L*'8]!QFU>8@G@1,.Q;5]UTF301AA8OZFG^'4
M*>O0TNR%/\_3_ QKCA//.>1"M)=^AJ7+?24G]^T\&@WLX'.4]LV'+T4L[,A!
MGZ$1*>U$H'_U!0=-L8+'2:[#"Q%A4==Q&)TG Q'%SR2HN*H5<DY!81-7(/A?
M$]7."#F<!#>P2IRRVO-O6B\["49I$I_BZ;6F**GZS]^ 7/"XQ_3X_.#H<[>E
M9RS<C)5/W\HUVU+W#98N<7^*A%,([;V4.,A2=^?ET?PJS_E)*?OE$-F*&'1%
M=D_#WU\,(;X: MKH$\OG)2SF3"RCV_8]5+PKT)R3:Q$-L]U^L30S?:V/)/!*
M3WI3N%[[U=VABO8WE_8WF]CF)U95C/ME$>^C)82]6@;^@#M5W87-OPN;3'Q/
MQY,7SE5YEIZGN?D!CY&OLA&WZ95R]>I"O(8+L<D4^(2L?4Z^U\LDX.73K2I&
M_@RN447^+X_\-YG>GI)MSZLQ>I:4NQ',<ZI-^5@53A7W?MVWX,EIL6+BE:O[
M<?A119*KX80;34JOZNQ>0])4E;^T(J'Q\D_Y66NDF+J5C$\"!R=S(Q"W[/HV
MO!Z$:6P';B=PKV_A&\(S,\\>_WUF#S>?,1<F2KZ!I=?\4H]VX$6)$*_I8',K
M?I['^B\[ (LIN!C8T=!V1)IXCNV?_<%SCZ.$BFQ$-+*C9+S1)PES_3!ELG2:
M,Q?Z/,].D^95$CK?.[=VE*]K>-:W;_KBGN=A742BEP:(2F9CJ5W>/B&'Q7E/
M?G4>77K]P>;7><^:-9WAE#4_SP,\'V'X-@:^KTES\LK1)\_"QBS.E,LY9Z_Q
M>1[<(:Q,O$+%]%[K?LE'_-(4U'NL^GD>+_4F.+8=SX>IF,='7ZAZ]=3VT2VV
M\4<Y8])TK"6K?9['=BQ<$=D^@L\C6(A9TI]WSKX<9 TZP+GK?H['V:H:IN2=
M=T_3,&65#>H*YULU3-F<ABEK/.:J8<J&-TQ9X]E7#5.>O&'*&D^W:IBRSFXE
MB[]Z<UML;";Q;38AO<[3K!JFO#C<W(UNF+)66JX:ICQK<GV:PN0U4B1M]R?;
M^2[<BAZ7((49^[9FO>W)$?#7R1^K]CW/ECG>IZKA)=/BJZ6I33[4JGW/"SC$
M!VC19V'@O.A[O?F=!Q<Y@N=)EU7KE.=Z<A7X_0:5G53@]R_X[KP\FG]J%/+-
M ;_?&")[#76<3TUVFUP\NBF$^&H(:*-/K *_WRS];G7 $D^)B+]YP B;=H=>
M+NU7Q/;4[KV*<;\"QKU>1V5UIUXI^'U%?(],?/-S3"IVOD+;[<FQ-A\M-V:3
MH8TV\SZ]L'OP]-3XJAAYA9E<J>6O#+QVG=6/U2VHR.XU,?'G0H2;P(I?%4F^
M,%)Z56?W&F+M5=B[PDQ^#8Z%"H'U^9Y=A<#ZC ZKT[T]'#M^.(JO1C>GHYD7
M[)M,Q [ZG7XD"-L)U0>/>S@>W0@$@PE<#_]U'@@>Z_!3YZ\E?K>Q1,$@9DLO
M9-F?Z7U[@.8^C^>4GGE%ON8Q7-^&+XM\5TP3FW)=]#E5Y)O;E@$\41'P<R#@
M[*2>)PE7$.[/W&U20;@_TX.K(-PW \+]R8^X@G!_+L?;;'UK,@[X=6A@@G\.
MAR)./(?TF^C%XH#K:NVRY:[Z!.&4HN2SG0@& &^VX#]Z*/U=MHMN]FSNO-4W
MJSSO"Q@4M,-3T #[I!.:)YY]BD#IZ>8'S:=,6-_P\L6^IO/^5002^[[C@AG@
MQ4ED(U<[NAO!9HK)^TX0^;CZT]"Q-]HLRU_Z:?-63RVT$:^),BY%+#"J SMB
M0&J_.KI88!M>$U4<#4=^.!;B/#H+ _4/"CA(0R9GFL$R7<]/*2BA,Y*.[AB]
M]#@*AXS43_M^WCNRHP#8<7PAHJN!'6&F4^D &T]9ZUTW-[M<[!Q>$VG."^Y5
MU+@V:GR\T.,F$^ 7^\X;ID/M*K^T@_[FFKGHM39GB/_.K>!5'1UH?,_\Z,P5
MO*:CZ[@<KL!R<L\]"0[MD9?8OLGYM8['+:*1W84!_'/S>?>\F6L>/VL37A,U
M(+@ 6OL@AEX7!4PL_#6=>@4J^;K.6W9L- ^ZW$[O8!"T3_='=?"\#D&S[871
M\#B,SI,!B/NLV=1T%>X;W4,8'-T$_K]@YV/7<XH.TI?H$I^S\ ?D,3Q  UUX
M>2LABS?Y1J'5?5O=?9NF=U?W[9'NVV)F0W7?'E>?63;J^GH,V-5=M%<?Z[T4
MB>T%PE4>O]=E,)6O_C6=?\=QTF'JP[ N<6#<JD@,<$-O!%^?UT42"V_(:Z*2
M<QC#3N"&O+K0;_G*7]/9GPH[%L>VX_FP@%PF$'ZA5+G4]C&)?.-/?<:D2=TL
M6>UK.FRI;6,K=;P8IN;T4FTNT\J8ONZ7300M@PA:53[8YN2#M9:@C-;Z*:/*
M!]N(?+ -HXHJ'VPS,G V(1]LPTBSR@=[;?E@&T: 56;*DV:F;!@U5)DICY*9
MLF&G7F6FO++S7CYR]ZRRAM<579O[XJ=-5]XP*JLB=X\<N=NP\Z\B=QL9N=LP
M*JDB=X\8N7NJLR=8#CCP=H5Y]*B81ZUZNZW7^2#@C7V^O,W]ZQ#^WFG2W_>"
MF7UFNN0Z\W\W"MS69!3-_3K^9R%&P<_N-%?&*)KOF+ZFX?LIF(] G/<.(^%Z
MB0J';RP195 ?4R?]1,BBS7?&T3V,1;Q7,AU8Q/M,"US^"+^AX6[[/BX*^]V#
MB#Q+\6<Y4%SY46_RX8TE SKCN?.6SNDY6_  MK-1U%C43]X;.L<<_23W[,-T
MTW+:/?;NA'N5.HZ(XPM[C,N*,P+,?['1X'YTG%/G*S$WIZWU-9WX'W;DV5U?
MO))#G[G<%WGN8(5(Y0*LT-9#%(VI4BJ'??TZI=0"L-+/6DJ!895I3?.LZ-:J
ME&.PP'942F3V]W0ZS(-8OU)*7!\^]&2&Y(+\K/#L.FCB/OQL$G5;[J2QMW&.
MN2'0:&^17VTLA:V)R2Q&V<MNWQ1L]%FG5-%\Y2QX 0=^P-['U@X<^ $K;:V=
M;T>O$+Q[Z36ODR!:._7FP8)N0GYV59K0?0EB#M0WYH\GD><D8 H7<Z">#X3_
M_>AF03SPA6=1W"\C-WURBRLJ789*S\+@_Z2VCX3B3DUCK\CU0>3*ML?,C:Z(
M=AFBS:=;RXT\#B-5!X#=13Y[D7"2,*HH>=64?(_=?Y'D30'&%9+UZZ7'AP8?
MB\>ZDL8@K7=9<E'KW0JXEGE=KL-K$5R("$>C*I-!Z+NB8E8K9U:+;_I:>=2[
MQ;.EX-DU9,HUC4RY9F7N/K6YVVXND3[77''Z7(:'4 FM)^QF54!">'"S,N6_
M;.U6?;]7KF'LYGV0#S^L7:DX5H>UEL/:794Z:+8!!#5P;<B@+Q7_\RD ,A>>
MW/K 21],PP4M<'4T_+ZBX947_ZT/P_;YX<P:-/Q^M?TZVSNHM.Y0I%;^_>TJ
M[<;B[Q2F1,V\34(K?/4L+.GI<Y[RQ".8*CNH^K1W%C)5"L^NPE11)WV_2I^7
M1B"K+PYZ;K1I6% %:EN%!57QE>=[=LU]/KO#T/?M;AAQI21(9<_!HDB=Y91E
MG>F/7A*KX(P><V6*-RRV,2^7533W5QHAD*H(.U7O3W8G%^=%4O-<SX[&5[8O
MSGML...#O]O?BQ5\AV'C-''SFCQ5A5]@$> U"(#8)D44M$#SFY=$[VLCNN=P
MTQ8_;C6U.52THMM?2L'&46BB7[_JNJ"7?6>U::6KY! OY*)NP'79$,&T$41J
MQ@P>0)R55-I48M]4V; !%["H&:XRLE/Q^\VY B^?W(S*TPH+Y]&P<%887*S*
MCAX-HZ2]PKMGJO@ZL^K5L_R7:(L_NHJ_8K"TJEGX^B&9<TQF/8%[E \5P/HC
M ZP_TKE6\*8; F_Z..==P1FO'\[X,4ZR69WDXYYD<WTG6?'@#>3!ZSSO2I=Z
M.EUJC>=:V3B/8..L[?RJMD&/<GZM]9U?Q5>?D*^N\UPK_6CS]*,UGG=EV3RJ
M9?/ DTP#CX_Q*_SQ+<;B=O,@AL*.TTC\(F=)7ZN1U'=Z:!RK?-RO5Y]+!O7B
M<+?=>O<!OKW'F'\).RH9-$VB#_C5/48<P7-3UXY?WF/,^.]>,F66^-4]1OS7
MQ5\S]A*^O=_Y? -"^4;@!L;HKG<#UT?_$W]TE@ZQ94P8W?LX)T? 3S^+(!QZ
M0>G("U-??I"WA47,/RR^A27;2_$@^?4]]O?D[.JZ<WKZY>CL^FK:Z.8S]WB%
M"I-.&UY]/V?HM][=!]CE,(T<$?,_!\)V@5?]]!8V\I>?X+^L.!G[P(.1C]1M
MW^L''RPLUA71QS>Y!VX]-QE\L-XW]KS@HV4^[HM>\M$:VE'?"^H1QN8_6'::
MA/HS?$!^E!_3!^Y:'PC^26N4C9*$HP]6T_B@&R9).)2?=<,(%B$_JSNA'T8?
MK*C?W6K6+/S/=O$1.??6Z*[X#4WD@Q6'ON=^_$BK\@(4,OBJN^)T10+[4H]'
M-N*E\A.6G.K=QX^N%X]\.!TOP'6M\+==V_G>C\(T<,W%MO?V:I;Z+UCRLF_X
MYS]:^\V/DA(F_WO:,>TL<DSMZI@>_YA*KK#5 PVAWK.'GC_^8/WS[S1,/EZ#
M0A1;9^+6N@R'=L ?RB=C[[]AFUO[Q3/>G7(5UWD4-*%;IKINZ+L+/'V_A6[>
MF7\].[D^^FR!#+D^NK*FGOUC4L T9EQ1P%HHX.KH\.OER?4)''_G[+-U]%^'
MOW7.?CVR#L^_?#FYNCHY/WL2LEA81C]WLFAM)EG\:<<#># )@YKUN7'8L-K-
MO=V#)4C!6.-"@OQ1SM*8S^9M^8/D[[RMX]VF;2;]F!4GJ0>U6S_F%6UU=W/Z
MV/[#5*V)'^=4K5>L6*V1B[XOWKR=C>>BZSF"X_/++];D3M\.O$30*+!;07@;
MV:--Y P_@3T=A &Y0#S'"FST9;K"^_ Y=%)T+F#"ZQM+.NDN1<],&&X;"</M
M-[^TFO7?R4#/!IQ*B.M9S70A4HF/2GQ4XN.AXJ.Z.JO=X?_\CY\2;#4(9.W[
M(]O%ED4_OVF^H7_+=]"_U1R)3.E=EI-&$6PIS57?EU:S^>-]);KIEG2PTF 4
MP\?J+_U5;NEEAXN+BM2,1W9?U+N1L+_#4['GPHCV34C7"I]S"Y[979C]C8BH
M7E-=>=A=^1[^@%RU3W@K'TF6S97,G2!(;?]2C,(H64Q"6XBF9B<_O_%@,V/A
M@,X4^EW;]\.D&]XAL1Z\V]W_.$6&KW3/[CF"_._$S5///4AFTOG_@%NSD,<_
M)[("/ G_F3D4FIO)8SMG9U\[I];ET<7YY;5U\?7RZFOG[-JZ/K>NC@ZOT<W4
MVK'.+ZW6WI:[;9T?6]>_'5F&<TH[ICJ'U_AUZV!G=YX[ DD0_@NC4,3!<\MT
M?&%'< K)X./0OE-G/E48KL]*.WA^1MK]U[EYA'D<1E8R$%;/BX$Y66.@"DM@
MB:\UE[E?4);$$9?,+<_=/[CPL_H0?C7 L>NN/:[CZ^LBF"%9#EFE.*;I8L["
M2M^/K_XL',YHP021O)2IS=^4;&+'\$F\H%F*_STITO+_?A)'](3H>*&W<U/E
M!HB$RO2I3)_*]'EVI@]A %%>\LK-G]W*_*G,GV<EQJXO.V=7)V3G5";02S"!
MUD,F6)7CQ9A$#O8(R-T@147\PPL,71U1JOHQ+/*,UKB@G=!$2)W]O6:SBF&]
M.FVTBF&]QAC6[H9=G=WG?G6,M2RL&#[2WFZH\O:PS.BGWM_9O[6R+4,] GX]
M>S2UK<)=?A_!'O*&?<OVP;Q[8\61\_.;_N[N_L&[O7ZSV6^V&O\>];4O07+-
M@UT<5-<$M'%KWCZ&XC)7GY#;Q5+#%8Z$?%,?KT6E6)G&W6X_/Y7[ 0O=/)XR
M1S&^%'TO3A!B%%L<+J@<'_[UI?.I\Q?:C9>=BZ.OUR>'5S7KY.RPL0FN] DC
M[X6F=&]HG&OKZ,YV$B(T*^P! U<$9MFQ%8^$@]7.KN4%EI?$EC.P(QA^NW*^
M;ZI>49D[+]+<J:[.$\2MLKMR)PN*UQG)>K^.0%;.BE+?%L-7>S#G-R6Q";6F
MDN@6D]RL7^V^UX.2IWER6FJ#"ELS*347C<;-BZ64UI4_%8O9!+_R'&T3\6.B
MD31@"+3D$&:01./#T+U'8@G%[6(<9A2%-_@R3BOQ[5L;\3!F>&Z7"J%EM/GL
MI,&RT<%G3-$O(U)Q;=^=2$P@AZ[)4F&+@]WZ3JNYL[<_D5&U:/SN?ESU_=JY
MZLK,PXE:M9<;I'Z_F3K5%G%^*XRL$!'&K'\;G<7!9'P"E\%"--&J:&)]-.&9
MF@&11M2W ^^_Z=_;"S"O2H!7S/,U7)2MD\9EXZIA'0U'?CA&\+Z*6[XZ(LAK
MB-99V%B$14[1[V1"VR@IZFD:QZP]>G"B:9&;P6; CX.?W[3?K/=U&^TJ>/R8
MQ_._DAL:]IACUG5<-Q)Q+/_G%'[36M"D>[?W;L_Z%13F6WML??)OW"5J9::]
MN[W@NZ]2,*FM5FMV%MP&A?5>AM1YUB1^"'^>1]?A;; @D<%.V-'W":IF9?BP
M4^G^\Y;V0OQW3TFT%V&<V/[_]4:+.Z)_.=C=VU^",6ZZ@^TU$\F6) -,6!A%
M7N!X(]NWQ)UPTL2[P3P&T+5%/$/)?L5<J**N>=0%?,5"QC*;?JKRF>=SHM.K
MYE&F (=>0H[L3:K7VR^P$.<T!)YQ,0B#Y0IQV@<[]??OGT4=SN-[63?GGKTD
M[]I6EA3[SW^\;[?>?8RM1/ABA,0K2^5J%F@)?HH)/Y8-]QV(&?C[1J2[;CY3
M?DE&\17HB)&7>#![3G45D7"M41K%*>:\)J$%3Z"7EE6K5GNKNXUJ)D+!=)SD
M0Y7X6F7O;5CVWLYN>?;>\BE[.^TUY $:@SZ502TGN;:<9:M,V=NP*._+<+5N
MJ IR[24^E4\(VQE8CF_'\8K\H)9D=)F4:.P]/-ZVD8Z)==_2#;N0+R.\MZD7
M,K+QUE39%J_P[./Q$!:\-<O]6['@B@57+'B]]'<F*TI))1)WSL .^J)BR*^0
M$L( #22@@LSCLM[RAJIH[$E"!M*W-FZUNV00+0I/$ Z'0")Q$CK?:]8/S0:V
MW8;CBZP;VT^%-<).W8.J0JP*[ZZ7?*7-<$7JXZ*T^ZGS5T66%5D^ E<]DBK4
MXL O$[6WJ(6ILMLS.W;MOZU?_;!K^]:5\(636%_LZ+M(ED^2JM(@-D#[>S$1
MM_Y](VX5)M'+()DS#-Q7@=:G"K3.N5(5PM#S4LWF'J\ZRMUB['NNC;V(5%WQ
MO7HA+.XD<+$<4%C=L>4,A/,=M^Z[Y;'<,U#8O-BRK5OA^_7O07@+9K*P8V"/
M+GP1IYC89,>6*WI>P"!MEZDOK-WFGI*@AO0%8=I@^IC\[SEI]W_"^W_'UU_)
MMY_0RQ<TDOX2<5&ES,^ .M=-F]I9./'P[L?%$_PJXMYLX@["!#[Y._50*P1A
M0?CV$74&B6=HB3L(.I#_B-HC9(KC5%H'<BRAJ'O>C#]"/PT2.R+(^FC1ME9G
MX0(7HJ+Q9TCCMP-!("D%0M]J;?/9#H!=(XF[ENW[FL[-"] 5\@$8N(3F<V1N
M<'?E'D#2QZ^I"X@+WP9]>G04"4=0_FNK;5%SM]C:@O%Z\/]QZ@RL>! BM">Z
M6[T09C*PD^(J;NUX\J[2C^5"MD$<!:ZUU396VQ4"I%;:_3<Z&.!']#S\$J<B
M!\.V0#'-A&9JQXEUT+1<>QS?5V#);GC<80B=>HF=+-QTKI)7S^16(7D!90T]
M>(EKD0LK"@-T._IC2]R(:&R=H'5A.U06]ME.;.N8Y4ONOF5CF +'5*4N13_U
M&;WAV99Z7-6O'[D*8POOP+N/5GNGW= ZJ4<HPJ,$482G\">^.BMB4GRXFNV(
M>/N^3,6@)20ER6,VBZE4;I%7FG]^\&3YYZV]-62-[[?6,&CK8 V#KB2]_4$9
M"\\D;'@*]T'P%;,=N#/ 2T'D\@?(F O86*\X6/ILEB9[;K[(M1EJP4M<8*>Z
M@B]B:>57\+[8<3N/"AU7O6W#4?%6?@N>B:F\0'O2Z!!89S^,QO?-Q:&1B.DZ
M<B1*RPF#NJ$=69(KST_(>3$,[67SZOV7NK87KBX]9'970]N'6\R[$RF7-/_3
M"8<@0,;5C7Z.2YLC)NC</Z4Q/!PO&'N8$!/=,/2[,$R8=,,[@X?,$@B5_O?2
MWO:\];^7=>F?CI^]Q'U\R=+A ;,[ K[>UTK"KU%XFPPDPFZE,#S?I<U1&-2I
M\WG+DUZAXK"[H.*PMG*.YY+<\*(2E7J6'5A"DI;5)]JRI-V!N'@+YNIAL@6E
M6 B7DO:2T$IC04_!T0HX6=?")V./TB1DA!XC]_@N?XPOO_7@U?!:*X!]A&\B
M<>/%Y.4([,#Q;-^R'0=;#.+#<6('KAVYL87M CUW9M7(SI:MLZ+,5*C&@G'S
MBEXWAEZ73@&2^70R"<T"XL,D-!M>B\TFD1B!7+![->P#*,*8;::!(NTX!N,,
M/U+4(WH]03D>@428QE]ZF/H1 'TB+XY"WPI! AEDJZUZ"W9#%#)3=YN[!HK@
ME1UU;1B[?G[GBS&EZVVU]JROC:O&8<-ZU]Y'R,%M7'VV5%DRU?5!:!@WI.=%
M0\Z!&<$$;'P(+A4EAKLT;3MUO41.+G<3I@JB$Z<7=?!78=3)-O#8M_MKE4/5
ME=SH*]FSXBS3%.CL7MB94V6->;6S*T6-8CDS-)Q,'"<T5RYYX)_)?-(>U;'B
M1TX814(U*201&$6881KB9;GQPC3VQ^JNE+WU=4B.)^'AJ '0F8:@0/"Q9*>E
M",PX?V)Q.J</&;T34G8G\'-_''O,I@,L)0.^7>_:J%.@UB&"F 4 )A?"5Y14
MK=]N4I06",4N E%L9BE&H '=( 'J*4@]Q[P%SS9#E-,UV[O-1JOYN=Z"ZUMV
M"1XYB;2Z;"M5F*B>+!X(WU<V@+554D+V;&FXU>[6VX],HIF,FYY;O%S543[?
M=UZ< 4_SWMZ"#SWO3KAP9?Q83 TP5+=PWANN@0#L?A]N&E[%(0%I2  C21XW
M(2GM:)L\V]L%)%'G=3SR%7,8) IU@&1L <&3*'_6^VCW4&L%:HF?AET90H$U
MIG04LC;M^&&,I#J"JR^4"2QANJX0ILN2#\X D<%'_I4&,N%WIPFS!<Y3H_*,
MA]SD'R0S/*9*#'A)D1M>D)E\[(=VL32C$Y\'S?UO.TW)!-/ XV^^PA_?OEY]
M?@-BT/&&P DYC]^Q<8;-/+L,TF'=#9.Z?/3-+^W6^UIS;Z?6W-U5;%--3IYI
MP[K&LA=Q1T9+;.W =NRWWC&J68EYHY71W)XKHI_44&N6ZZ'V'(*RBNR%H-0&
MH>^B]JK)S&7W6_9HF";D8R.NE)2<5@-=:7X:2QM*5N#0G.-!F/KL".RBK17
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MH2CN@4T38F[ J3)[#\=#^Y,]GH6!VWJ_ALL-5YEV0F4= )4@;YU6^'IHCU
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M;HARV.K"G0 Q"JS"$=VPCJ D#-M1 RD6H,7WW_BW6E#)0HSB)$+*+0$,F9-
MJ=?% Z)F_XS][>\J?_NF^]LU-$T.6NAV$+*LMH/24D+9,31?3EBS4$S4&)>H
M_:&E;XV.#(<17IP0'W=M-(J-JT#!*<*$XOO'UT A.DOQB AF,1KWJML4MV(<
MCD#A3PBCW!F I8!RE^?J(C(S]>E-K+VVA=<^1K],]BUUM^H1="[)4;D'M 4V
MF%&@F) IC3*?M!2+^FQC8U2KU=A_9R4>BVU$" 83 20K6*U(/@%V,?&E9IB@
MA@URU[9:>S]JAPH[O;OP%\ECY!0#FH7\+;^0_"K2=\/Z!BPA0RC"7EQ:?<",
M!\5K:),(&C;BG:*=T#-3!Z,4&MPA9A2T33IBZ5!;F<)459 BY_U&[SGH\A03
M+T.8'8)J07.@+ %0SD3NM]D^(!1US/8C%D$,1<1G*@L_X6]A;9U=7FV3RR-R
ME0:'"CC6?2C@6B =<AEGN$J,7"7NCUNU\7J"A)/:!"V!$;YO93=CN/88B\Z"
M[UG%KQ*5,X/PI2B:IK1$RQ*&)+5:/:>C2B-J=:PB2O2<?#7]5G5J5?J$"M/3
MM[GT##VTU'K8AE,A)B >34CD?Y"E,"JC0H:O>-KRJ!+R;I%=S)67B@],QPU3
M!F?&!7)114?VCN0!"E=@ 6BQ#):LH29)S 2-$,]%.VCB_9KKD/>"C]-$1V/K
MB/8XMT%JHQ/&VJ.-5H!PQ"BZJ8<=U*P(75;3WM+E.ZUQV/ U9Y\[Z(D>>NSE
M*(W@F/YIX\M<OA+MSB[L3AIX?Z?BX0&^Q^4':H,W@2$827?OBWQA$4-!YQ,M
M92>H';@ET<K:?EUJ^Z9F/ZGY+VQ+Z*K3)>R /51X\$.I^N28'7IFX9;)*94C
M&+*6YLY1TFX%!4.DII;0Q^0#*$;'N3D<J'"/[TSJY%I.M/?WC-7B]+-38AE.
M&9IJ<VJ\D[G]HY67[&O#NE # U71[[A]ELZ!HHXG4COCB(@K>Y84: ?]GG80
M"'@7S(G?9?=05]A7&I!'/LXQ'1*&'L8$FI_,U5JQV9@.KIAJL C<$4B(1))R
M-H;Z7:U<F65%ED6+H<E2;?1"6FRM5(W5&31YY; FT^VD$EO07?.J.'8-R)Q*
M:GWRV'$Z.-N\OLKZ/,I6V>]P0C/-DE1@%Z3)0,HDJ(R35^GA. =*KX4;4F>]
MM@!R4*;E/OXM P:L.JM0:C9R8%3$@'F@OJ#8)&5,UVB>E)VCDC,&P(X1P8'=
MK=U81#<J8F(T'S&*1[O3BD8#U!B<D#V,'.D8"#P4RF(XZUS]MDW)H5]L<C(U
M.3DT",*49(52O-AV(>Z7-2BFI"H,XV%C8IG8@=R/B F'IN;@9L-PCO.X.H>3
M[WJ_#P*(,H9=CV^OTBW8K>P%_TZQ#7K6J-OD,N0B V+4L\_:K&2OH=Q+G*?.
M\^3)Q!Q2,'"[;4R(B[->-,>?._(=OMHAE3;N>SWEK=8^:.P6B"<I$VO[D3WD
MGLW(.+P <TI-5_KT]@H+I+VLBW([:3\%QH.+S5,#<4 4!Y%9PRR)684ZC20O
M=8S&LMB!#E*Z1EI^G64E!=4,H>V%V(A>B\LIYDA'!9X3;9<@LS;N&5LBDB+S
MM#P_]7L@2H"C]*0TOP'1$;HU.0>89,Q]8CBLX<7<<X>$R)#!C^%EOC#F'(DA
M7VDEZV"^MOOO5 (I* W':%DI113GQH?DE2AC['#E_H2)6ZTV,O(!)3O 7.BS
MO3:(NW"4M\OU'JO2CU9;%M:"HL!B1*5BWA;JRJF(W(K"+DZ[F$-=*TF@UFG5
MS+ I_B%+SPIJQ!584Y3GZ".O?/>^T?Z17"&&=E&FUDEOC'17M-H-D*+PJ%+S
MI,/)S>UH)N65%XS5C!VE9FR-_NDG'YN-9K/9VF:2;;]K[-QC0LW<;)38A6]1
M"H/\+']E(9'?)*(;8:,:;= @>OV,5MLR>U;9SM-\3:8 G9S$WG:>4AXNT7$W
M9(.M"=G.GV..14'*RTC\1 T"[WM>HW_6X-WO*[_^H_OU'SEBRB:K"IP^5:ZF
M*2E=8+BQ#"1H:8J\(:?3DK)%QD.N;&@"Q;]$,]6Z@EWB1U2V-H%2<1<$-TLU
MEOW7ZF2$A<A.T3[7OKZ+,I>A42,TX8TTFO(-94XH\$TRUW*^2-FO,*_PX.)E
M\8,N$<U4X/*=4)T7R?$-QT!_RTTFIMYJ[F>;@1NARR0+'EIM(H*8EGP:!=)>
M:\F?MW?ESZ6'USRV6]FW4'H)7<ME5R'.?KJ5(OWZVC@A8T"N_M&[;RI-7NO?
M2MO.*>XS-7%M6Y1[UTM=Z@8J42F)$_& U.U[2$ :,HONX=2J.=.):E"D"2/T
MJOSM<OG$&8PCHZ8CY.4V-TS-_F%.^HWW0BM".$="."5"N")">#IGM"DW]NDB
ML:>#\ AS]9O+IFW<RNQK3?1Y/S,Z%.L15FU@U*'H,0:VV:^9SF'X W]1+"I6
MX5GM&U2NY9R3$+-HJ?2)%6N/W7\Y_3J?<"+=R>SRD47.:&1)FQ)'8!8"7"NB
M"?/DB'.@S<BNH)K531-IJ/#S_!A[6[M".UG9LHRYKRC\+RO+S'F0E9C4+M.6
MK3XIVE&YYY2$ S;+=3EK#O:'W#B)1 7C8CN$(.^RFS3Q5)2A#P;FB%#NE-U:
MR"J4EEG>^E4^FK+ZP7ROZYK,G46$.SA"L+W1K9/C=I-)WW'JT,9D)E#@3N9D
M/\'],7$+WN=],OE2:":M(NB;M-F+-7<9:_>E6PV,=W9%+%D%33<S"&6N*$%,
M&[D*RIN0N:+S)OU$.@05* BJ@3 J-?$V$>G/-2GKN^]^7*HLT\PYEKK+WENX
M'AF]9L$CIMR);MH%+XSR']S*PN_)^$'F+:?#(I\,7#M2*8VD&;YC95DSN.>X
M)VB94V#ASOIZ>E:S_OF/]^^;>Q]SR2^\?34#)BT+$M#SNQ_AM[",+&!@[1W\
M2,^_:^7=&Y-A%<T&[[=WR!,G"(Y)J\"(<3-4SK:L?$J,K.+) (81 "$];I>7
MU#[(+^F>\\['\TR!@54:65(Y23G3-Y;WA"F_%R?NH T2Y(J1C6NPB..ROM-:
MDOIW=AY(_8^NTPLZ?ET%HTL,<*Y+1Y*UJ[; 1J4;OY02PV!F?;8G8X9EQ44J
M<9_8<588I!$E%%GJ4,5D59!D ?"[7EVO7=>X*Q5!MMB#K])8V<&:*=]X<2K=
MU"%6-LE,KS\Z5]M4)]=LY8N/R@E#AWZ5/#^9P"F=D8B&;U/LRMIM@LF476J_
MZ*\L_]7<LVXWZ\2;= :RO$O;Q$QBK.6#P??>,V,XV%D)8R#]AR1SG/;[P-(F
M9"\0" :ZBG41"/*#MR*E<(NIAF35$8H!YE6C$BB3#&Q$X;L:5'NO2[M"PV41
M8/%'+I]?>GX) 0#$UJ\*^JX..O?(-W&ML?^<;*% 51UY>&FJ'+:U!@5*-M?N
ML^(:6]\#JM^!FP,F*@%1*V#I>A:&]8(X!1:3U0H#@X#7:,<&DJ&L^9)5U4LO
ME-@9DY,!]XTYQOZX+J><;[;'+U+US9D.:*O4+A>YSU"@L>3%Q!-MSF]@MHA[
MXGJP#&3ODA%W!:P$:[BI0C?0JDUA^;*H3VY8K/-0I<>'?I@L4HOVZ^E%O:6V
M0,N&?IH\ZXC"0151V/1* =7,%NL:,13NCXW^#46@,#+@E[[1=G:CR?N0B[6[
MU&8%:[OSA9%+OP5$K(GZ4B-/J<R'H&LL@_]/HD$JZWCI52%* FGX=$AIPK!)
MP%$0:!\S%S08/X/R*-T+.$=-IK0L<F3P>)V>UF=V)]$7L,@@ ]@!O0_N%;XD
M.\^0E(44?4LBYH2"&ZH=,=S<3^W)F$@VLI7[PL@XS8.FW8O4<^*3 P$Y@3
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MAE*E+^'2&*6-QZ67\QH9>Y?D,_4B5-DB8#JQDJFB!543EDH&K%D&'.:IFE@
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M.S+Z-XCF82@C9U1Y]SB2:"@LYD&IG>6(K,R&DYPUYLRTJ$P#4L2C!R:S).#
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M2"JS)+?]-7TJY0?!RTP4)-&LF7&OS7#@=3W98=V+=3BGE_MISJJP:<)* LJ
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M8R[FU\Z8)L6:.$*LTOV '/Y-H,%Q(EB[1342Z5A585'_6U7KXE">38SDB'M
MV0<4F%3OT'+ <-#.O*WE<HD8#MKJ!+SBI#&2$W6?&V'X-$@4@Y?0,EE=+7!)
M"HH"%=/L)'"G-,%,X'$]*"V2\H$Y<4J6I>.I##ERPPRD$+JK3:&;B39VCT\8
M<Z(W_PH'(*4#5=\T^^'%GN*+^$][./IHR>%S\2#N#=C<+XL#:1>4H??"R96*
M2'X/RDGU]=D?U (,4Q,\WY,8,7(*);,R5$4*\<JN++EPSVT8^>XM''7&1S#*
M06!%622H4".H/$5\]!<7G<O<EAV?GUW7CSM?3D[_^G#UUY=/YZ>T:4V,*JA4
M&IDMQ";&/490G&@[:YQ(D@-GRSSX.<="VE4L9--C(:!FR L2LTSR(ME!BC]
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M+30R;%EY^XF3_S@1DHN)R+5H9_F!"GJ.(F4U,T60G ;<\&[B:8DZDL>K*[_
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M@HKC'.$0RF]Z.!$J#RLG6W?3N\>Z468;X*$'04_!?DA)H$ ;1)A3[YET*&[
M%:N0+!.5'UPGH?(U*74J.C#+0MQ+F4_O['L$[1G"3RMJR:HM;<D8-"FH?I/M
MIENPF]Y:T/? FVAA,UE6RCTU4;V0MV(&=5N,.L+C+M/&RQ9=[6_V3,J?;&K5
M"<26+A'Z(X><18AZ[5YAT>8/7UO1)X:^'[U@X!%.>2+1CG6#N"I3"EIQ[3FQ
MX/](/TQF-1GXK-/5^_:%)IS(#:B]H9S_(LN^ZG3!@Z,Q7?!UI0M.S/F-Y#L0
MK;$+ND]?.7V7XQ[Q\1(^9YVRJ9%_4%?I7$W$.$@67UB^Q_*N7=N+.X7;*113
M"B'3H)FEO1C)$C0JFCH'UH.98$T7<K/<<-9)Y6F+,:00/-#R1,JA69C,<DFL
M0IC;&>W$8(P7O[H17'Z!+A&*7CW"_@N I)_LA8U:I^ R\_)JK:1&$=V*L3;,
MP@&R:NS4J*)P"'H5]T&-<OY)Z&C*C5ZD_--7[9I[UD+4G5PH].6E@#<FW6:.
M@SG4I"4B>0V!44K4BW\3D>[$0V3NVEQQ^7I9H0"EKIP1)#,4@A-(?Q>J^ .X
MH?<@&OE&>\(*^L&WA>V-0</"B#='R]PDD]"+8'$3"LEK/S!W[YVU3CZ)Y*#I
MUEGMY9AQK%'[6C<%]-[FV$>I4Z)@SA4RV#6<!@C-V2-R%?:9)1VH>;,09[^Z
M,X+7KC[3=>]]21:B4T?73AX%^D<_5(O% ;ZN<W8#QI^.?[A/$C_OJ)KB0'!(
M)'8P*9'R@.BY$6G;+2%6UJH/O^?QGSCF[^NJZ+8LLW9O%U#%H7H)([,7 ?<R
M6S)-'+CHR#F"%6^\!SEF['0"6F@;14J+S% PCT.NT3LY^/&-\3PC[+N68?QG
MUZ!'AIOL/]P67_71G[@NF):%^>+.P5)(/9A^^NG\_N0-G6"8&Z\8@^.>]R-3
M90(MPT?>G;Y:0)OV"#'IQKHK?9*)"VNJ&7-OXDQ>V56S(%#8<F4Y.>ERW-0B
MD;Y?<8B+7"7TUPK?D-0U43_J.I2@\S$MV),J_;_$&60V$R=H&?MO?^[=G]__
M?QW-E1R)K@ZK&+&C]$Z$ 5BP5VTA4_%1X:*7H%"B[B\,3#--AON_T8<-7W>]
M?N&0,H_7);=4V-]"Z3*'W6J!T3.&&#%(;8!F[Q<GO=V:F2#)T!ONLMR3&(.@
M#47.R##Z%3!?V+T/HPS?%6V=[<ZX]2+4'IS,O Z</>O8>U::"+U5I?7SDK/H
MB:?J- 8)<RDX/=NY!2HKZC$P-QV$&ELLL?_1GI-G!Y085LO9FZ0%M)4<P1MZ
M1U%+J)R!E&G>BJ J3JH3RI5FWA"A,B99:S>?M-= V J)"@X".SF79V%@AO=Y
M\CQO$#7=RH.<U*]E64/X+.[;+,E>Y8+6%+K>VVFPL.PD043JHS&^R7(VY^A3
MN%7B;LPV#.0O$E9-/>]$4"@:.QJ&0 9Z9,U6(ZT3Q_<DRLLP?-^67!#=<DBW
M&P[V]-[:3V";H!?8A- FS<(5V%SSJ)B J:&J-Y+;@2[GFJ_?TXOD[FJR,% +
M!=B02Q.<14$&)!-O1O5@"PE#QH5A5P(]+-F;0C'\$::@!R7P2<A8Q%2"Z#(#
M\B> \2&RH>6WP#AVP2&Q(JLC,+KB0SY_H?;AN3/LI(G\J5/]W:8U_2>I>NL.
M\ 77CPI1PY>G9R?![&^\?K4)*2@]N6NLDNBH>(/4 =DFZD"D6_P7T ;IV.E^
MAW>EG;/ ZOP/7^@0BGW3<HLKEWYFV(]43"YD!J;'>H60+QC3!HTF1-$9G#A!
M1A<_3;LF+P6 3;66E)O?D$+5/ NG:+!L>RU@MI;I(^?9C$IUU UX\8%UD%OI
MM<"P,>7S%Z<)&_)NV2A;QV14=(<:(YUO%-'X9#F8BFC:H,/)O_)*[161=_I]
M[Q(HB#U3C&#<E3M6L'BN<J[D:US8TNL8GPIOS-:PYVRZ5KQN6CE-9*!"("?S
MAI)B-J"LCPC)^04?^P+1)_ZT=VJ\DIYG4V>5:,X-8+N*"Y6)DZBF6#I-,5M>
M8]%^FM/^4AK>T-C@!8G;<TJ7Q,_.QOC<A]W<OR0S?!_%UD!0_F1?#-M\"=,,
MTH4?7ZYB:=$NR]29_XE*FF!4&608K'8U&45OJT;Q!W#CE9"84-.\Z@U*77(V
M;2C:S/DM98O#:ST[HU--!^_SV?MI.GL_T6983C4YD9/*]<;\&AAC$B'/@<E'
M>8NGPI;_FA,1QV,BXDLG!_*NHO,>G7=> XP.D0X5PW(W-J$@@+LH^/O1!]0]
M>3D.I/Q:CHH_LB=T1OZI9^2<#T.X]H>=7S(0X2EQG:RS]KB$4>_V<-LW*')G
MX[&2/E87[*FONU+N"FGVT,T4<N=NYJ[F1,BFJ]T%RB8$T1?*D^;R'KJS:[=:
M2RTVA_G W\GX&QD^A:^(06&7A18O],T@YS9?3[NZ@=AQ2N)U1@X!!0+XIWR>
MA,67=2RV<M51K_)HT8')Y#6GE,I$(H]V_A)Q#/0-R X5IOZ!=S/HM9Y-9&VO
M"-N_S!>TAX1 <1YT*Z6ASD,IG8\N3P!K2,YQ6G(,A,V&,[>RNAJ@#L*WH#9.
MJT19,#AION6O.N_!_6J5;W@"3-/H67DY%B\S "DEF$C(]*( 6IK7&MS"W'CI
MAL74+UAOH0*UAAF]^V1[21_N72FQKR^PRQ5<-BG:1A"00HDJ6!I6E*Y\-1DR
MI5.(_'V?*3>A1<9FP5TTF%Z^>] .\$.VW@2?TZ!V4%OK1CPE4LU-Z+T2L.SK
MM?AA$F)6RYNNKX!OZ;TA>BQ02LZI+R>E6['JDCD;YQ*4TTM9(Y)"[S(#WA_8
M"5,=$=4%#<ZOJNW+_900YO+ODC)Q;MT4ZPIM$T+%W 49>W/I!&0!?:).=/=8
M)\GN-:J*HD)L+74(CKS[IEN_<BO94<)L8/Z"K59R%C^UWLS(%;@08[8C(UZL
M?2.I*]^B,_  X):S@4Q&J*2*?&$-1C+JYH-69N)-!U$W289HZ?+&+$WM*6_<
M]P<,.$7KJ766V.&&DW<!_T-KC67TGJM#A&+X]%+>F)&Y2(:7H0+J3')%9UXV
MF-^,O*$Y-#.,:KBJ])"UX?)0LYL_ A=,DS23MQD5F^5%SO]45Y?\#DXL%/+^
MLY/3$[J\)$-%P<B&-UC0@&4U(0XO=XP9,T1W+6TOZ1&WCG1!%ME\*4&(W)N9
MD!$MFI'5<M^5501NH)2[2A^IE *$E;E0;V^@Y@2##CAMG[8W#C+<K<;IKU8G
M!B/8W!YB2_C[L!%WT!/SFC%XNK\K30GRY$#<"N HF]X C:<=-6%PH^(QR&5/
M$AU8C>&QOL1W3ME<!^4-W6==TP#R6527]^\FIJ;SWAE?")J VHEE!ZL7#"=A
MV5 C9I9VC01%IEEH>Y;X)3.+),$1"0/H*,(V'Y*< RL97+?>G1="I=&)5S[8
MX+?I->+Q&6UPLZ#_6 ,76W.Y+XB3QF,[JXG;*K?H=#GZ?, P)CE\CMDZ"#FL
MTXNJ6Z*PWAO,XYK!+\P:1^X?+[AEIZ*/^>"A?ZPHZ-ACCL+?%'4L-::92(BB
MNT$NFIH]6K,SB5-S X67.!:4=VC)]@A!'%4RW..RL>$=HDQO6BN0U),P;P+2
M9^XU3NBZ)ZOFKUC3CT\D$MCZ^/KPZ)Y05\-O).EO!+%,&TS_GDA/!IA_L2F.
MKU^F"I,4KX;ZD KG7(7"S@&5$KLX<A^\*B4K-SFK:L\?BGME!NM8?W7"?8Z/
MO_ON"<[F3Z_.3DY@$*?,7N[S ?H&'T_S#;<Q=M4#>_TE9SJ0B0:8)W6E66?,
M<829]#T5;7HAJVMM?@0MP'&:U_,#"E%2,YNM)@7WO9Y6CHO$$FY/FA8^H7[!
M0=INXX:FX"Z*TK5<1OQ>K'@+_,)&),X/FE%$6 K(C)Y'O$CL$WI?*5=[P-AF
M1:[)+J/H0.>^LPX4<.Y?5G=[#YPI?,#9+^(FG7<E^5EBJJ@$&6XW-C2TA,!G
MLV(85I/XE(U:_>M^_APE:-0J! N1>(ROANG7<%V+X.T%B)BN,R$6/<!AG^NK
M@.+355[,ZZSTANON*1,M<"_&4P&&3I.ZS\% !&Y]2X*(WR^#98DK1+Z]&_Q
MJ&0AB[ ; #&0CGM4N%W&GK0'B:#* UW$JPU=0FW-_]I4S#>I+NS,G; *+I'[
MVOUD]Q)U+U]D"//3RM_3T+49AS/ <A3H21_E#B =>#XT[0S/9;[C= 8G>54U
M&X(ALN-"^6>/9Z_C?$P,U*0:$(/59)[8:;9*BX6O#[$#V_-.R5XJZF(7=$!-
M!S8F4N->NG27YA^*\MK=9MW/$"E@M@IJ(+'VI80('*RR I9]?Z#(E>3K-0A!
MB1J)#J@3<_*M[T 1_)9%E8;&C=P?5HZ!EFXHJST6G<]W-(RN\D2.EY[P&KZZ
M^FJ'>F?M=8Y>F7/V+INM2M(6[-*^<$^LU@)P\XVEY'OJ,OWTZMV+TY]NHKG4
M%@GH?]MKH?1^YE >4;\S%,9,O+5!J6<>B35FBRRE&\Q9&HTB3%AF)(V&(F+-
M//B.#G)SLZ9.%#J;!(A&)2IG#5=-CQYI+F&"L(TPON9TP8,Q7?"EIPOL9;E
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MHYP%H/>H26OH*#=HLDL1S"16VBMWGSEGJW8#$YW.7$Q9S8$\#:52!I VJ^0
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MNE%P!%<09L).@D(Q3]H,OG_!HG-Z.)3L-=+,&^<?_.J4WD<C*>K<R!,'0$Z
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MT697R=/G/]B1B3.\\5PHB^-"IJQ>ZWIF3,6**& ^..;WJOCX26BG(B%D9W.
M!B_6B!Y=XZG ^"B1]I@A*SOMY8Q"*(H\ .7_AP:)ZGQ?4"%QOIC(1;(F=L\K
M)5[GC>?:J:8%<Q'9DP1N)P3?#.:!CR!3Y)09ZI'U NMA84"LE(I^8)<G+;'4
M5!"=3;95M[<(NG^]]B\9-+#2N03:"D.WAB=>2_X$TS0HN&#2L\;\FO-0QV,>
MZDO.0_T)X_VM<T9AGNSBW<#3@!MC[IQ(O6E(#V0?\D8Z55:S]\1_GY$2H3!B
M3<J^QRY7U7K]"2RG)A"*^T6S$D"J/M@S@\IE]^68ZK^"]-J[8=[.3.C&9C5D
MG?<I):?;W%R30<$3@,IK:4OL 2*X$C1,2M"V0P/18W1J$F8LL@QN43$:D5"$
M=J(%X^ BFC=3G&;QPVO?F 5^&95CYE.6 OL-:]*S[UMN?<!MCH(/=+EBI@8@
MG(G3A!DH2=EN:F:" E"K*YDB1*(8_LI*U*2E*J:/97'Z"P1-9CT&S)T["$4-
MS-QSQ%BPFYV=7SJZO'963%<KL Q&3"4W$B;J,30L3[X4,H@3=^O;)TT#-#"7
MV7Y,KIX3I#12UO)A8FZW$>!&N+@_R>JRE*9(40J$5L^JM6"'D1(DZTZ3BKX8
MU/VCB6@:P< *F2+603><>:\PU%G%[OPR+3+F*&&V EU9,K&713=29-H,B,BV
M[(EGXRV<%'[Y155<F*2NO$8'1?PV[NONUZ!"D6U1_:WA<1.::!&5$K#!Q//5
MJ,L2S#JS1[3B-!R4'>J&P;MU'W'&FL".Y\Y73O%==\T2Z_F\T59?X+$EQP:C
MU-MD)S D74>%;L<+8W9E#80YVA$TFE> 0X6>@CALC\;SXA$(H5DO-OK9'97%
MX%D1!2$GY:_<#A]YFA69FM=S=L>SH(UP5\2FP$5:=.S]1S;!X"8FD:F0]&*-
M-*DL7;-)PAU\E2E@V*J "@-WJ,I.$U#]D ,3J0UA"D!T[FJ?8S^;J3X&+*\0
M]I<C2"'0?C@ZNGUC;N?$,.W/(K)D'Z19V%=Z*F@#\.MK-X1H;E)Z$8MN[\8*
M-@_1TY>PG$@_BX1-8T@VXC():Y+$<W:9E/9>ZK+(J]VIR?""@X5NC/ J'-/4
MOPPXT-ZWQ+J%W>(K8L]SW%#=<EY<4X-Q-^S4)Y(QLK4^LN^ VZXR(U'H*,^P
MV'G'%"%ZIPCAN^1Y^#8GB$XCMQL8+'&Y(O(]SQ:IQ@S+JCR0T!F,Z^G6O)*
MH^[^L=*Z<_M:1KE]XN_V\G?(\C##^MVX*2?1HMF%8L:S@05+=I;+J_ET:"O9
M7N%U&E[5Q!++8=TZLK#D"@B/WVE?<85<3)2?^XJ/2(^A@D%H7ES(LNG6U%3
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M#1"X;T5C\&)<9JC5R$&>Z@[\FOCWO^Z0[X,QY/M5A7QOU /E5,-<MG233O(
M\.O+LS IXNBY7IGG?Z9J9D^:JH>WN2+7S;UO(I"$P8[LKX2^TY8I-"=6W:0/
MO4/.H%VT- "P3G):K&M[B^;UX%40'.N*W&QA>F\RPP@?NRE][\C5.[)5_%6V
MBG"V)UE)K0$M[P)!:,2$WNT_H&*8J*TT2QE,\?;%^=F;7\Y?)!:TV713\@[%
M71+CUMDZA,BA?I_-R" T"O5M4K 8P1;BOPRW%U>(B]>6.KM]V^1LD/N"J%$.
M1SF\%3F$FMO -3?IXP 4U8Z]RCHY (-#@*AK:3N8$*)$W.J\A1D7>G+U3(A1
MA$<1OA41SBC64>0-DW4$,-LZ(JZ>I1NVB@%6V&J2<T_RZT 9#_0163W>_:/
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M>9MS[&&GRU8Z#.(G1'@ \E]1/YTWOC!M@;:36X7:I],*=>E"ET3?MX4)7$K
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M[3N,.17$!W3FB7/X0(V]24=GY9.PG<:87[**Z&:>U^FEV#3!D&'#6VTI)8H
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MT.2R")FBU'Q'P+4OE_A"@\]P+PP\!B62\Y5FD7U7LFL=2(42W-]/QH7=F&.
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M]SK5,L/M$Q$#GR)#"'5@B7D;#( 57%N^&'13097*&Z*]J;3V8V9.C_VU3,U
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M[QU9KSO(@R6:0MK(?L^+)J8-\M5!\?0J%Y&8\(BF+;LM$/?U&MI_#!JL 4\
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M2H"LT%0-/>ACLH-?D/RL(@[G)NHY(/GCTJ6*6ET76T)ZI+KQ\YULMK2[L30
M(LIV*\!FSZ !]I*AGY-3L[7=(9RY["_6;7[%-Y(DRME+D;H,\=WLWV:+N[-V
M9U!LFOH-DX+"W0EG-"K^5 \W&!6=LN46?.?J"F=KG*WQ3JS17SZVX=[4DQ3$
M5;AW,/>;,G1;DH5N&+-#G$WP3OGUR]HEY(Z3.L\Y]MGN[DZMMN'$BO99/H04
M.QCN\[;=3R2/PJH/+;7EZ]5[G),[77P_M'#2E&%"-KRF5%_Q^R[R1>I#3&.%
MJ:ZK05C^0 DIJGR*88_@?]\<8)G\LI/<O+ (7JLA<;KXL;F"?/HT:ZLD^7M0
M7EXW!2!O=DE$8>",G-B2G23VQL,W)E"V0/&-+AIL[>&TZS9,.QI_U6CW\[;L
MBM/%BQI@SKRC=I&*H*Z_#>MS1D92_G )C6XZ1%GR.)R9P=1R*U>X=*>ELRDU
M*_!PGF00A"68C3!Y9SZ_?R3!B%_H"L*.TI6&,H*'F7)I3*9<)Y.!]LWJK5#A
M4%D$]D6%T0PK']]1) VF[2DS E='GQYFBR%W-S)D?KH8]Z]GC/M'Q[C_ 5_[
M'O4HU:H@+0"R7)5;L#(MQ<Q#VX'GW5/W'#A"=0.KR*.RR4OFLN7:+\4^]22V
MVG\UE06A$F"DD\='(Q,RM[9!Q,?*-%7YMJC*BZ99PP;$M]RBJ/7!D.8Z!CU!
M+/?'G/R=W(1!H3SLA,78A8Y$B%!N]EG2XI4&E%.'TG<%^\$K:1O4A;5N"&W7
M4QT5AQ=&+U2S8FV&;E>LT+(SM6Q8"/MWMX#!J\?"NAV+V//G5/QF*FRRJI*[
M$48]9>&4DP:%25O1XOC(8BHR &+_M<*7FH4__!6<;UHM\K)0Q6#M*@%NZ1:8
M-EKZ372OHKFZVL<?IO,_GFKW)2<ADADYVC1XA$4(;C@R2.G&8[L"F(UP_O?:
M1$CAS[7[WM:W!1_2OP90C]/O8+<J5*'AV3IT&OT%'>-.:XR#D'!DASL!<RWQ
M<K?-/J_Z?<KOCE"$VM+"']@EE+UG+.>X1>7"FX%M=J 1"8<XNCINQH[*FURW
MEH^_^@"8@JF#^17Q3K^*E6]TW3WW4)&7"A5Y#\O[X B( Z43"9&;5C$PU^->
M7,G_ $%RN$V/"9NHFH)!6(C"GI[(IG^/0 @JX=-AD&.<R[(VT :#A8S6M$-,
MFF"'V'KK#9\;.1TC3D,-I[E,,F<I)B?ZG6:8X4-=WQ;U>7_A!JF5^K03EAZ2
M(K<W95&M51.BLS9U[D(G#0X2GJ%CYE\#(![P^?2FP=B6CKB%QR*(JG"?J](3
M E3[:&F^D5ISU9R$#RJQ9G,+;3&$@N2T"OT6G2P2 3FRI"Z$4FN;(A8JX1L-
MJY3@UN$UBVP:$UH9#ID6GA%))9_HJGF%P CK!^^?@?L G6;HQ@USZ/N:5RJR
M8"2Z>J%*M<?>:*A5-] 3D#L2P\$J!;_%DX1NL%4!QRMT!>$(2:Z$]'B9!;*)
MB46[R#MVX=36K_Q3X>H6O'SQ>]GU71P_ "Y\]0^G#Q\NN3Z47 NA3.+?424"
MJQ'94Q8DB46TK>.QG"Z> 0Q41N->C[30:&&SD=@(;$"Y! K!I]'PPK8,JU(3
M[Y!$>YEJ>U'?/<N4>?VL:$,DS6>>0'(G\:A-_WE9X(WJ<&PV5ZSY$6=H;0D6
MA-D9 Y[*#0/QV$G;Z-?9K99,7:UF(3@PZO5F/.UPW/J017>\(-R(3JF9EG@=
M.$>$S6*J*5-C0,S;5/2NLB=YGX49W(F,PQ$DE>Y76DR:*P5UXN:ZAGMK4U<7
M/6^)'4SA9HW)(M@=Y0WP,#CKR $@(K\6\JABT: X2'[,^"YPG3;@KX;E:D ^
M3!D?VZ>@](%B$1D3Y3["/V?."0&ZI:^LJF%XPH&WXA03LVR(';$4C-DRM'-,
MD,F,![PAZ=8@&;+PL2.&$M_,4H ,OBMJ<G>%7"/(/2;-S>UD^W3&UA+\']\,
MH=.S6#.*U$A(5/^$%>+\T3=0:_ A5-?<CW#<G2Y>EW",4V8YZ<?I%D9ZG*DK
M%\*6>)!K*)Z^0;[A%O>*&MKIK(3^FLC$=DT8>%_*XJXSA_C#ZO"9&8_&5E(
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MY/0%$>URKL2^_(>S\\G.CYCUP^/,.W[9RW2;NC',TS%W?&G' =TQ&\UNKY_
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M1N3["65RWTIU-CCT )+J#35WEQUQ?_$!]4O>K?-_+9X()NAG1Q-)8O?$(%3
M+(&&;WNN&))S+WOR#R1-H;.;/O4'OB^_YH9)>7;T%-U^&U91^UF>?'?V3^ED
M83>&.DC3BF_GQ],"6.DS><<;W^>F<;F$/;ST*I?6'\? 4R$Q3<1G?/8=#(*"
M1];62"YV!H08$;3W3O"D,2Y=)A.*KK(D##$]V[NK;B 4&7+V8N-"A'0;4Z<N
MYZM@#.'L6EO02UY)GL+?_K0;!1[/&?B'G(%_ST9(MF#>DB'(N"0ES:J(U3G?
MMZ^Y*]Y6##FLXZ<4;?U 7/=U?F_2[9D'UEG@&Y*?(DK_>>1V$JA<H;+O^F9%
MS(A0T-P#1K?=@I.TFUQZN"U@_OOXT(_O^W5T#D=]1>(;@F5S,YD\ZKL7KYX^
M>W7RY,5//YV]?/WL[_J'ZXUJ/./+)H2H[=^_2+;>JJBJ'8*T^OP___0%_S=@
MS?+?/!;;S6[G,Q;B[Z3O*A];IYOM+_\17ZI?3W[DR__X%C!;K+%LR#!!?UK0
M'__S3]B0>$0X"[\^_HQ'D\^8^&7_5'W$U#?=&B[295L<W^BW7(.1Z_G3?W$I
MFS/S1/>CU[]7SUZ_?/'+ZV?CBYUU6U!@/DK??TM&2"\=_J?%_\".9K.<S?+=
MS%+R4 *U4(K<X#U5,$#KK5IC2.UP!#K")X[8\VRQL\7>I<4>-51586>%\K:(
M9@@*ZOI\-L39$._$$,O:EX=%'2MFP38#-?W-YC:;V]WXO7K/CHTZOIE]/-P<
MG],U3Z  P>SPQ*?H2?WL^2]//T\(&H-G_.7IV9@K18IL1[JI2/-,/&[2[N9K
M]5,?&.N.(=3]_NF9W$Y1C=56%;S$+T]E=/-VF;?+G6P75YPMH@X9V.MB'P5N
M_[/!S09WIP;'@*5#EMC&>&&+V"@_U@ZZ3M=AMM394N_:-28\3M?HJUX7)\QV
M.=OEG=CE*D+C#V&<G2=Q)U%@;XZS$<Y&>.=&2"5[:\%G01W""Q& 6Q0)I&5T
MMK_9_CY@5JGXUP"@NQZ^0$)4L3U_XNXNS1+)TY@=09I<A<62 2:S]<[6>Z?)
M>0=4A*!E]\XW;8+/S58V6]FTC^R%(HR1TLCJ:""8:7\X^T"EX "4=;D?JY[,
M?F^VR+N^4F^+@B6A?T?WEN^990XY;KIAE)(2[FA'$@$19Z.<C?(#&R7!<+N^
MW%J=QQNG0( =@%!8?/K];)NS;=Z);4KC$^XA<HC3WZ1$^2I:@),[^L<,+6-E
M5^4]<T?%5AJ#O<^F.YON!RS$CV27O2!/OOK74#+)$$+1@UY5""EEB]^:$,*B
MA['7WG/EJ/5<Z4DE:8Y:9TO^J);<>*Y=='PRA<2Z6/9"0D[V.1OC;(P?QAA'
M>'A(X$E-B(&>LWN<+?+#MFR4';@PG8:8 [BE?"*>RIC1&K[%7G1\,T^+)GJ#
M4XSHDO4_U&37?+_/:LW6/EO[':7N&;HL"'H$K(,HLD*MRZD2-8F>@2F%S98X
M6^*=6&(BZII?=4,YY4YAAE[,-/K6V1!G0_P06!"A%T"_=&Z94A5K- G'V?IF
MZ[L;-TB7[*D>^.3FXWO_4Q*.;RFXG*UQML:[2-@+,P-(5K>3U RG-YO:;?B1
M[DYW,ZKJZN -U,<,1N3.P]^):(%PVYF((724>_"<":\$=I.\?L(?020R]-UF
M$R(3IJ<8:E6<9Y4&W!#!(=G41.[*!=^H#^]%LHPOT%[@=/&=L/X9NX_51H2A
M0B3QF'(T5;K<WJ R3R64O%U73@TSYQ:$R0%^VA0Y7\X4.?\?H\CYGJ'@41D3
M;*)Y?90XJW7\A+NA#5$>[S6W(=QE8VCQL%[U)203#JZPFCFHD)?,#MA_72?P
MNA1>:JURHNY9LV;[E12%=*3):<Z-&'@NJU$T(Z(;P.#SJKHO[AXO.^<II:64
M)1R!D.DD90\7F7C1^:-*&"HY LH4IXBDI+ C/G/*HSG9V#>-)QN#WE%>CJBO
M99PAFH+!8+%E<86;E&AL#Q9E)'3KU3QUH4VCLRNJ:F19X;7I+*>HR7XGIA@/
MAD#,&S7Q';#H(SB*C;VY5XHX/A-(;X04SZ"&5D"C'BQ/1/NJ"J/X_R2 DB[)
M57$GP\V,S\WTHKV<!&:(Z?DQ<40Z+>4DXL#K=!L;OZWGT[YRSP8A-I9,MG(W
M8$68@YU5,TMB>TC6[G3Q\I:[6>B#A1GWWRQS032GZD1VD3[;S\3)DB6/KHAR
M6G\E2MVNR[:8U.QB"L"H448T\9T3<D/RUX0H,1#F%3S^%J Z#0]Z6JP*/)3/
MVR\?98O'7SQ^3!2)C[.O__9%]O7C1_)K#U NXRR\T E494G_B_!R7<)Y?\$<
MC<I0R_/*4_,T!&!7I"J07YG.R-N"^0.M3(\YBJKA8K++$!$&SX9-+6OH[2CC
MG6@:UR8F:U)]+&%ED-/$@9"X05BA5<'5K&US622Z;S&Y>E^>_>7A/,,)P-?W
M!7.@KYIV)SW45L-8[JEOBZE!*Q;4LRF9F/1#ZMNN\&N\)<WF@5$4Z</V=S;'
M3(#\EJX'_7AA-\WQ!V]I6UF,L6P@XTCJAK+%85,-L^>KR+;LXWRW P)$*<!&
M3_*Z $6^'<V2N"8F7F=7*L3;.FWA,:^Y8L1[_O$77VKH85M":;"?N&7\*;_2
M;1">=E$N*>]*1 [$ @WPX,Z0+6Y2&F;'+6OZ"%\B'OWE/TQR>NB)A9^OC]$K
M\[&T+6"[YRR^N%VR5Z<?A8%\7]8X.+(CF]TXQL%!09>GNH&:R"'I=MV$DU N
M;/CO0C1;3#?L8/E4*(:*>TW'!*-<M*,;7XA[2!R9]&:&'?9!GV2D ;J$& $T
MS,,Y C6^*[B6JBPNBT-K[YOS0L6F"17,1!U..UN$48AU@W0VPH>7Y9JV +]P
MPN'-&ZX5LPUWPS UV$@TN<=,-HQ@O[ABCGIJ,L*.6Y1L/DVX5+;J(W%X06X&
M-AC=)4YV&$MZ[CX 4F>U>"9W?G#$S;^2>BVX<A%,KLH=]7OE>Z)5SX.!$X]Z
M4:]%N35?K4BZ]QR;(PU0F2F<56%YHX65# M<YE9%A@-MBQ!,U,(C7+8.-'F/
MDDZWG(,#&9FH] I=;^0__"LGI,:3&9!X^M<%(@T2 LR8)UCW8ZY3AL;YQ+R?
M6UC:%<7;B>%V%[2C\&H\S5&S9YQ >U#AUZ]35._N'A"+;CJ%$&(BQ7KXJ'B!
M)>&;Y-@U48K[9 T7,:9I9EV5M,B[/DDF6KK/IPKEJQR'3Z;=>)<IB^UEP7G"
MZ7E=53DD+$6 Q";9+I9+)BKOPY04O4@:AY'M=_1+#F8RVB>OIY;.JPN-TQC^
M>LM:4:3@P:N9!BM&[322&^'KD>ER@K(O1"XC==2N((&9L'%)S-/K='W\;;$H
MU__YI_[W_*NOOO[FKW_Y?[[ZTW\]#[$F!U./OCM=_*,.$]14EZP?L]F0)@!%
M&A_9A'^!JS1:A'N?J+_XB7I\"GD5$-C VNY%$8!#6PI;9(-7S2IGG5E\.FS0
M;/$D>+IP)-9E+EH[_.&*U,I8="[L]TV^$GP6I52XQ[I>_'=>#WF[%]/X"]VM
MOV)=/NC.U)(G8+&-L"NX/2$^.T\I ^$S]T6.(^57'RGF?7)YD<&4(IK7#1AR
M2?\B14$DW;K%=9)YGW(*_ZLYA?]II?!'?N)K[R>^/%W\1!)0+YW>W;N[BP\;
M!X7+PZ;L%S_%,_.>8I9IE_,H6\@(7Y^>G2X^X__X'#212$8RY3@HQ_Q1KPJ@
MIZ]/%T]+$:MZ H$W<QR_A(MG.+SK^.\P7W.8(4RJT(N%FW'9(>(&"C:&W*0+
M$J*:$#:K(!"71*F<T:E*$B3F*&O:U"))'&ZXNYXU[^6]@()MPNY;=/NZV74E
M.S?^1PL\7E(EY\LQ<ASYJC" -5@QC2)C$8:R*9=M7A.1<!15I=MQ>(TML+P
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M]_W3,XM;\U:)/\,5HO;XJK X]:HL#LAH[4BB9IWP Q:0<5$\WX]H=V3CT29
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M;U,  -W^T!>T*="]+C@$:L>7Y.VW7G#NVZGL"?<+ZJ=OC*?KIC[107E<JN@
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M+6&U_;B0#KU\*6,AEM3$PAHH,, C<;VPBD\XP?!U,G=?4-+'A4%8.::,59Q
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MU *Q2Y1&IAB6+'B((>A'%+&,+FV\1T!FT416)3$=(VQ)]PNBTX59O*, C;;
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MQA=(*I T#Y*J)T)2=0V2_AUO241P*O/6>22)G;R;'OSM .Q4.MH2K.T.B88
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MHZ89*EC&RIDO7#+#X/,CD;XXG@>3<FE^R@O17$]"-<T0@%5'P.H*P!* 50/
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M.OB2!'/ 2U83:4FW "Q+OS*I;X<\(X"@P(; $YZXR\-ES@AO$!KX"T0N>I"
M%,+!@C/5I 73;1/".D7=UHVU7RKD^#:N!H<HE%"';Q\!Q9'MN=YV]H=M1KYR
M[YRG<[)66/A:%Y&>8_$$BT;$:C=]&P?$L!=U^$;$37BI:]!3+IH7!: I,1"
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M'NW6Y4CNJ*)E=?.9ILAS8S22!\=*4!4^J9/5F WF@86.&LFAU05U9[YPR8P
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M$X?/(6[<A#]V\;S-'1LN)N5M#5^S,\\EA36-:]N&8"-LK(ORG.&2A<\FCFL
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MNHI>E6Z?#0>J/.PUH?Z0D+5&R%JAHE:<3MCIRTJOVP Q$0D*V2& SN)9,IP
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M'GP<_BWZ*D6'K(U8%WA(?FTL*;%#A0;B,F(OD>=@7<0E];-=_E[.T.MB+KL
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M4;NP7I9W( $27C !U<GV,;2.7B[-U5FMB:0F09X7Q$;TX+<Z="=P/1J=]/S
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M+."$ K^X6D!^_/SP[?;3)ZJ(6BNZ&(V <(U*3_4&<PA,2Q%1=J>J5 S1'P@
MQ %%]&T,+*"3$K A0_M^Q5)VX[,/K'0A^G06L&P[;T\82Z7IYMM5Q<."9D;^
M:(M%6RP[L5CN4XOE@KR-?M9HH0IPRN5@$ 4^=EUS(+)#Y,]\XN$*1=.1/ON_
MYD_P8+]DO<<[O]TR/@$.7M'7K]O&%T5KX6M-^93L*A[Q^'I8!7\JZ$6&!WJ@
MBVZ(<$G6UP>P*CFY@A0;:-,O;^]0>O_#G)A\)XE]!G_'$W"+/7G>*!^HL)R%
M1A+^.[^=@LC\YF+!WKE P=[_D0'KK6<+H"8P36VJY".RR1X29Q(#!I&J$&:^
M^C:=L&H5:_^LW=N>8ET@]POD[5S!3W*_VQ>"/X4-!5I RVA1KT5]$T1]*J[Y
M9E%<YX5VZ+NV,=^D?XA\Z^?',(R9S8-3_."D!Q#8+(0=T%<%Z2T05O@^LN_%
M[Q5(H9!>NXP]6G1@:PN8NG76N\I)(X,_EU)AH!L ""%N&^=Q+_!X'N#5]T,"
MTI< A#% AT!3+,:K P2(XQ\3%OP0+TOAT5L:'I?M3M[A*8_3DI1:54C#$CEL
M>00<7$IVBFX0!OC-(! *'5Q2:V2*:0AL 4'>N68(?N6_^.WWP5?D!>DI/3 +
MB!2S#G?@&&!&5EP7B@M+'">)F"^@-VAY\C85-85OKDB];D+8O5;WK->Z.K_<
M.UWO#7RE['"V-!0OVM?POVTSQ"863\I,8(X"+\4#,&'H_( (,TE@\%#JB8Q8
M/Z)RM8BGJYB--,#Y:UG3]'\"/PS5@,X7>M^]>,^N)/[Z=N=UKYT?A5"9W=DR
MS&%$%B?FN3 >0!5[SRA]1 :'%Q=*Q"19]X98K#I)5_;:6Q*HRQ;'H&?8*CCJ
M PB$9U_)I@\3Q<5Y%Q92^X+'7Y8I=RPXT@#\UH>1'T3?6##^2./8RD*::Y;Z
MS#<#^^?M@F-@JP1,!OI5/GB#A^6'I"QHU*K"-0=.R6:D>3L<S00Q[2=3UB0F
M52E8?^1P@R4-RV1Y:L!<+%T(Z48&&H/D+9H=($0C_Y&16*78$MYV.%C8+K^N
M%([B3+E^.(K"<]F8WYW?_A39JH'PE5$AX!<SB*;?E,J%MU/UFWJ&MW8B3AJB
M+F4&3(9*990T":-281&/V#J9O'@_DZSD0F!Q6%D6"^Y7[Y7$3?YINC&;$S;A
M5<%])2VZ/I=]_'(_RPF.C8TBBG-W<.Q8:/5K=BQ,2&?\P\!T0MZ+ S3I\2[U
M5(W.<&6QYXFN:1@/L7!;E*VA6BZL@A#]S$I# ZS2X[/G(YHK#_<_,Q=K%&''
M(]'1@(]R0A0)8#G8HMP!#8%TH%@9V]<%_G/G+OUM2/\KN&WE.6D-(<?,+H!M
M*6%GEV=/],RWK<Y\NYP)%"@8D5)5S-O(84Y8]UPUXVBCDH$7<Z9BW$ZPQCZY
M]$?W)$,36Y@^E]^ANHTE]I5?\@K[Z\WL;^.A=Y5OI[?*=OHG2['P=B;PS1^Q
M-Q\NBSBQ:+*=P4?;%>3H\K/L9J9.TT<G:V"C7S"OH:(0W9H"HUE*=+:W<N[6
M1DK'E5"YO!\&NRS0R<" +C95@)TC&F5$/]4PCN( VY;2GIRY;TJG@O/72,,)
M#9N!' 5!K2WL<0IO@,T^ @'RU\R:8>$-&,Z#*!TU?F-07U8 AA1</?'#T$%&
M$?4PU!ND^!<A7LDCUZ$#J#3!(,.$S2,W/KA%&+ 0MXX[5_O* "B_P=WY9B!B
MA7#YWK ;WKD##QK +N14#*K[&?A/K&U\C+#_)O9HT 7VO\#USR,J^9EB-]8H
MV^M #2V^!49G"SMH0GAD.(0OL;$'Z&Y,FP:[$U!=W,D^-!T780T;)CL9UCK!
M@#QV45#'#+X;IP-@MX7:QY/TYCKP0"OI'4O-56S,<A)O=J:OC-Q?5D@'#B82
M/@Z!QK J,F(\ D8F.#7X/,&*22 FGC/MJ(4M]6MT&B60D.O A$48NQRK:=]H
M2SU60]U>V_B3]QH]^> M\AWR=8"'Y\N78U$G!]3"-CUJPI)H$+BW$1\<#6WC
MPRS.%-<D<U\&;[+E3 TY8H<?R'<'[C:]B%K\@'];W"6EH6;4T94>LYMIGU0Y
M!#Y[#$Q.;WDV <C[0:1PH!ER"2.<G(0&T%<2H,;/4R=*XJ0$"<8S[7' %'C/
M3Q(T7.";1,M(#07;3.<:%UD$\X;+/:34<&M9>%0:!GA\%ZDKW/;(N+/*D+#<
M](5CG!;::QL/\9B&JP#O*>@V4GQOY&U+8IG)R,YU$9<?RC2/=M^:H1/>#V?H
M=LI_;D2[Y:,]"@9E['JR!VV;RGF5X8\D)[_SUO?W8>2,J3%]KZ,_,@/T%\[,
M)WV/-P04O)-&$L<M;5>.8I*ZXGD$UM[TU'_VQ+0 "@F3-7$+1I*#_HX<LC0P
M70RT<762,:C2WGWF@I7HR3$^ECII,SMGB/?LH\VF;DI= >H])\T'RVV(N0!\
M(!)N3QB\8Q:-?'L_TQA@8^',D08*4E+H3 (V,7E9/&TGL"ER24:TF4H20!]@
M=N+"2Q[EI +1E)V>O8F!<?B+II02:F^)O4WC%;7#_\_M[9?7+='2):P8;/CV
M3&ZZHQ4S-G]B\1 &T.%)+*%X;CF%\7C"T1N-P!A6##%Y'"@-DDAFHX;P&NS^
M3Y>X!+WBFW)G1.@N\=4*4%+**<<AKQ,#*Y*1R9H,(T!#/*&) 8T[HTQZ\B 0
MBZGK2TXN,*<<#8 R4WF)2,93N^  YR68(;B[Z':D[&HY@16/0QHO$'*9(%Z&
M$EB.4_"'$? +SB>8.@R] H.<3J3SB8_A'(>80GF#LF(N]L#RI0^D8^S'$0X;
M$H:RP@GC.(RPO@#='.SI(.KF1#^$MW GET@:/DF64?1J$)I6%/-9*V1X<R?"
M=M 93UPK6+?(7N 0C%*4$6PR%R"CTM8&I+WX>)2?B/?_Q/:CX*@![),#&AQU
MXJDG3#(26.#I3'"=<DHO=WLB>IFX5OJ-L$D;Q\^9$Y1;.'6.!DGQ>( ?!X3"
M5%5292\.HD+MPTR2/"@22*A1PI-/PIAPD8"N&!L2W&4"B$LCH2^*#*#9J/,\
MVP9<OH RK'^FYQ179MXL-LTO.R<%%ML6;?,CL,01I0;A%.DYF=5M8#-L$',6
M6,IZKE*=E-FSC=0FA?&N!,Z. F<[G1?'F5NQ %#U@]:0T\3R%8^MXG+'5FJM
M3LPI?ME*YI7 -\!X&=&5SH+*C,9, JCRTFFQ,-'FQ;(L1WJ!S[T:8L@;(VMD
M?+]8(]*($VP+X"HRB2JE)3T83_6X^C%H_JI#TI^<"%2-9HHIXQ7U:3H1?^1K
M:4P*HYB/2QK[0%M4,HB#8?TXE*.+9,MF\JKTN0YU@%+_&F@TQ7^!I4;/C,P-
M>@:HNLC!5Y$^C7(GW:/RPF+&0EU*$$ ]*.ZP#3(C$A#B5PF78 #O$39/S?&G
M+I*P>NW( =L_L$93_E0:3@5O^2_CL'>\20PKH,F$:,WS%RH/0 L"4)8^9FR^
M@'LF[X^YI^L/0A8\$1^*)Y)]Y'CY2V.O^&)G]?E!U4K:;$)MXT'R>^*T3T0
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MVT[0BL*'VLPLYKH3T[9A87\_Z9S0WV*A]'=&/M*"#3..?"D,^2=6' 0 2.I
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M2^DG)1?ECU4,RPY^IA3Q#1@>*_X&3(1G<QHJ?DGF97G2S9K&,U\;COWWDV^
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M2V3$["FAUN"X74[#+7A-#I)E*9:&J4W5[0K8D\.>0Q$1#8(I*A$>%*!4H$M
ME=(^C:#6/^=,D;Y3?W@*LC5# 6E$@N1<LCD>MTC"WL\@DS ,S-UTDLI*N'>
MZI9J#IP ]#EV0%CTC8V^!$N=IP2HH 3B-/C2V,R26<9?ABX+UF7!1:^]ZNRM
M++B\N:R@4'B5A,?"Q$&J_I=,&,"E/[KKI"0N5TE)7-6^)/EJE>U<[[,D6;[(
MBUVWB- VJEC.0[+&F3%.NRL0>F\=0K]>A3*ZG?IHD*STRTN6E9*K2HYUK13K
M CK:=X(5\+8*EE>6F)+Z#MTC6L?SR;UT\?,W 6-)D7JU%M,B=[@N^**8/Z91
M!\P8QAA%$Z4:J$0H\V *]X.JO16G@^<SPFP& 5P<#&2%<%?$>((Y>1XO+1GP
ME N5B!=Y?\)/(7,??1_^"XJ8"<;I, <!PB;MS,0 D$6)C3B* Y9V:H:T^O1/
M3%F(C88,W@_>DCL5>4N;(:<"JC ]+"K 9*Y$II-H(=G=/CNNFQ01L:2$2''F
M,%5,<)():KR=;P9S/MRG21O/U8=CRDBLA2=G14^VVHW*]YB'8BC*RY0\YI)
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M">MW6P9*3%H!CC/-H:;YD.?050 G\[G$7;9L\N.[I3XP@!C1-'7&)+,KN+E
MNB[5ROPN,>DE3%."_'-$9ZXH&K_V6+3H65FC@<9B\#HJ*Z#58<,@<+#_C,\,
M<BMU/)[\I.2R;-5:L%?.\W/>$#"QZ%"\0Y37!SQ*KAAQ?HRY4TS\X3L+WH=5
M_/1P$B0\G)ZT;J5K3"'K45VDBTG-0-3<PX8=!>8R^VG*G&=)1ZJ"'-%,0"CQ
MO52&RXIL7A/)34Y*JBZ2N6I:1;6@GLD:<R)>@X150O :');":^!R!C![P6Y$
M\1*?I"85,&)]GTS]<[$ZIR!N#ZU!=;%7OJ5IF8V=V\-31H;IAGXR)@N);H;;
MQJ;-RP1$6%-\[U!9,M8UB!*)M%0@5$4J,6NV<F6&5Q-G2164N7I@EU\#A(].
MIO0PI6D!R]N**4>/%_!2*AFEW45?VZIR 9V.\DOX3<"]^UF@J"9,#$TJODA<
M[40&\\MG[#N?J7U#TBH374+S3 K,K"8B=63R( 67P[)-4[;7STJJV3Q-]2&M
M^6[F5U!E.+/JUK/?I<.PWG.*YG[G5NI(.F=7E<E%7492WOW)L4MLJ.#7$ @.
ME_)E-P%-&L9'=H>O;VH"+".W,E[(;B/SD\DH%UQ6*-_PCMKJT%V'Z,=&G*&.
M 13*/-/*Q L$90D?=0N(^"F-(Q&W)Z-),$"-AE*^I%U.YLB]9&8N1RCT:%"V
M2C#&P'SVF*O:VK+:,8Q\ZZ>80XJZ#EY%!'V3AB&2!_O!H^F) MS0>'7W]?ZU
M,GV39JD:.$N5FH?0$< Y'=1,S%N&:--CWW-P@*<$ 'SA3O^+2YHIW[\1_3H8
M7Z'P*BS6P2FF#,>%@M>!K(?3"^5H5EIR&+N1":I<63^\.\:NV#A0![G>;"FL
M)38A"#V, -PL4SR6-'?PT:78K6J9,AZ.B&XEHQLS%=))J)[##7:4^.>4/DC=
MUXA9(\]W_<<I1P,V4/A!5$XA./3RB9Z%3>8E%Z65KV*A=K96]4O&%@8BQ;"9
M+TIK+>9,B#T>??3N<&"L'*C+/<HXY,Q2OL9,47G(Y\4ZB5D)YJ3C\L0&O4%<
MSBA*K[Z.?^%15W3;>$!()U8\;8X/XA29$MJ<1RF$--XD!]"(OIDDC$"F'2Q!
MN*0#?!'WO-O&K<T[H+%&G$8!<(->\))(;A'><YU'B:W);Q$;Y& 3'3DS>^3?
MR5T*>DH'[&;KE\E+YDY)MBF.=F)2.L0+&(Y-XNFXRI1!41/9T2G$_:^_X<O7
M$9RBPF84E&%J.R@3*A(U*W23Z#A4=62Q;D@%'?JXZ9AXD6M-I$\B=BD>,@0Q
M&HF5H.B>Q$$8FSR@*56T:&(=@^YV)N!Z@V51M*PG> (F9$E"XDP)-)C$9=B0
M')&]I"Q8+'7 1J8[Y Y\VB2+HEPN7DTW<>F8M)K[AL<>_<@1'=-/.,^#6AX3
M^T+9B.RH1@R@)8(:+?:H<4;(7IDQY]EFT>N(_;JRA%HDX;.1)2&89U,7$B B
M FHQ$1GEDZ>IFUO@!'MR'%O@)%V;J6@%18/SB=6A/V8I?%)<\3H%!*Z<-:*.
MFH;?,=N/#3W,"WS7E5ES =%T>#2:FT#DLF,_8_TIPZ8I'\ )6;'?R S,AORS
M!Q?08! Y)P2C:!RN"42DBA;%(J@FB]?;,KP8$T TY6NGA=]'6ME=%X%ZU:WC
M1.<E"K7%SR7+M#&ZMFS5X=G5>F7:W:4+9.GJ7NT+M6&)JVRHW]SIT:O68N^]
MAG:E*>7=LY7?03RP L/TY@BPXRKSQ/!-R.TS,D:E(9"8*]Q8%.YK8C%B!:&)
M)A$I\Z38D,_/5 ZTH'H#KLUY::AB__A!X9MP:)HZP6_6P)(F14'%I6G_!V=S
M\)7P$A5XB8Q*2(]:)G\PXQ5@^,>=DCV3J2&AIP>8#7J".Q@8BYZ?SM>PG>$0
MOB7S<.%"D\$VO$(@%%"B@4/9IN*#\@#G"JE=<=S*8@0E0Y'$+<_$T4!9)3?S
M09Y#<RN]EX,K_SS(7)N:7DMP:"1(W.94^_JG6VH0/\D4** X780PBE_<#N##
M9] K(UY(0 /,T[EN;>,VU0+Y*:1)<#MQ_9- 2GJ"5-&[,1AN!LDLM06G5*U:
M!,G#)IECKM39+NET#\P/R.J.@(E@DUIXA=I:1 ?0>T]45*8,;\F3JOB+ECNL
MBL^&P4:&\23F0V65,KRV(>>!P2*]4!Q8AM&%-(DG!_.2(J5P#T4N6"E*J(L
M1*H3B<H['G9)LQ<F_(7A*U&F-J=7?A%"Y53\ 1/W"G1@EX/<I[1&TBDY8/^(
M63;9FD0Y:GB'%>N'-4.;Q_4H@HCS$W ^F@B2B:@EUGF:!/T-Z7V6SEM)P"X=
M2T19(S N NPR0AE5SOY1X+LB+(FAB%Q'%9C>@@&P'#-D-*NYZAU(CR"I=BN3
M'8F,M&/&K6<TC1/?0*P$'O<;IHX3AJ) 9?+PY"%.F)C;L#]I<"."U*-6$AN[
MP!N /<KI4%BEFO4-DACGLOP<\:G+1<)*,V8%ZEWIKI-:@]O@CWP8:!*K9S@;
M-6T=*!+UO-"!DLIB!"QW7P?., YX8C_QVL@@&/FA:A70_*CQ@-DVC40+T#>F
M85!I ?X-W/.,TB1+>$F/B5W<_1:R9 ,M>0 MP-ZQN4/(JP8XD3["=A[)SWW&
MG/XX<3Y-I0N%<S"E3(J;(D2&9<XZDJB[D"!D0I!SSR>^4_()]1"^2EY+,X1M
M/G@6IPE3^ERND(]U3[H?4]<7KQ?%F=*(6P#FF:Y#Y&"^3-GX.) \BK6:O)]2
MQ!GD\/5D6/%&.6'1#\G96PS@*=8>97(NUU&I)@!+*+G\_,N%D\?(+?W":P28
M_2]J<]K"B6O;GNJ]B?-820$1@/"4PU" 7X)R?X/!ORCIVB++81(/ ,LT_)$8
M S0GU7+YFS  MZY)//$M?\:)@IB#2\)ERJ#I$&-OE>-B,HN+9XD+@$1RL-G\
M@X[OL%#H?BBP>!]\16+Z3-G$^V%ZB-T=R&-FOYU*;(L+PZ(#D(%->L@IW1\Y
M?N,#'>,07UWX9C[C,7MN<C@"W16J1R=WDI.3.PM.3NZWNKWS5J?3R1V?;/#'
M\@+%\=CW>)TA.8QTI#I)S07'1#_ (@!,>.,7O.4+"Q[PL;L R_>'=S_ Z/TA
M7IA"YVQYZ+2OX7]YT$PPM8Z/E06>.R1=BC";7MHMM2PN"@'W7CR%L)-\F9!O
MMR&(ZK2!A+LY1%5EXVZ2F$]HI<5#"GPXAL >9?7B"9T8CC+:8MR!(B1[5-7G
MB!,1\J>A98Q'47"X0T(,1V3*8)J':P[E4+\!H]-ITOK#(5@H6"!#Y;.%1T7P
M0Y62<Q>R,&H9-N^' OKR[2D=GYFT;2?&H7*^ =BB4KX[M%:33.@) HQ#"B?=
M8FLDMS$9S02&E;W ZM-BD1(92!B3#"@6#B!Z28VSO'>NBE L,,)#VLBBS0)/
M%*1:H%;0.*9,DVG+HW?(^=TAC@741>D1=<T]QB9^QX313#X"5JZ#M>H5A$?A
M5HO.S4@\*$GITIM.7D;LD8FP)06W6]BSZ=A@4<F.,A[GDQ',Y4.K"YPI$'*,
M2JCSU0+X.RX?I)J[6?>D\CP*5EKYRS^#4V-<TWYZ-Z2.!?G+@Y[>$Q5F3%1J
M[%,PD$LSUB4LH-3-+^4 S6V0(R7T%L/9=THKQ3UYSW0:M>@&Q1'>X18;YKKG
M%S7+XC4S34?$?DH(-52,-F:LRU[AEF\JHD KG^9$D1\U5.2)J52FG",A1SB!
MB+?;6?!3JBG;0:U,85_<3/TDFZYX>2@**SXR0!0BRQK3Y-PZ7K0*UPV9PP-9
M--G>DJ.L2-R%W&*AR%#6V(IEK/RM:P)@'BP0H&@9T#M/T0:GQB#?9C3-(1O.
MRL;3N!$@!AP0;'@Q<7)3TBRDW(?+4QN]^'UI8JQP(2*>&8KJ:CF$8FS^9$G4
M%,<QC 7D,()(VEM6SO+LTB3F939HB:65PDD,'A=-!U-A3-8&*^O)Q\.KDE X
M'AEUB@:@B'_C+#B>#N!5S&&2YQ#M<4DV-IJ=:%!5]Z(>];SO@N"KGEB@>D1Q
M4^IR5YB?O/2!BW#IFH6Y9RM52Y[7OS#W?*4-7>@9RG6IVUWI=-'NY>JS;SF+
M''IIV9:K.YNQ93U85QQU.!.+4.TUV7$-!IVH"@I968V#Z%-34]PT]8Q&( 88
M=0V2:3F)E2[L<7E,EB4C?DERN23<)0V[S'%)!5-2%\BX>M8E+'VL3FIKEA_T
M1(>T?S-?#C[3RG=JP%;9'G.AWV9BY&7L)E:8G!@:90HH>8D=56MR_Y&BVC@K
MBV\RPDVVC>^BYI-<9GZ(G8T!06(_\V7>K$8EMI_45JI=! ,6/3,^JD )IZ<5
M&+($"5\SX'.MAJ7O$^6'B5O/G4KFF=R]@T<$U)= -YK/HI)!UG9@;P<O9Y##
M$S(KE=,FY%2S@-'1\]SC%3?ZV>G@Z1MQUTM +!M'P'DM' ^B-B8SV) /@!-U
M;[A%913DK<$G1Y!CCD?04Z!7+9>E+?*1AF/P*F 5/S%5055FZ,'R4B( ##:2
M*!6]LWO@T!-CQ-,1$_^2$%0:8L7QT"$/L]NQ)19?M-29$I$"V"51^2<GE+D3
ME6KYPHHT0TLY/I$&8&2 2U&!; ##X9W/[:(2]JT?-/QMQ%3FQ*.U"4*XW]@3
MP0]>3)W9/@[[M )GP'B!+Q$5+_$%JS^DXQ%Y^H9XA5=_11'<$$<LR=HD&2F5
M-=-'S3X PV2 (#H2FO1Z9/YD6+6881R<V4F?4],W\8A(NGR@M_G8J\0\-G2B
M='R(9(J6N$6^(SF5N)B*Z>X0+N$'(HM\EYF@-E/O3;-JJ.\;-5R43!.0[]H?
M 2@GF:MV#YZ\; R93;6]-)0(#WA4Z$! -BD:Q#0UW/H0)4.=>)=8>E@]-[T*
MGI"$X&82E%03"@\1):9XS++%3TN&FTG(\GIS*L(EHDCE;'$AF5)SCHC&%C8N
M!F!A_XD#)[0=B]MA>\>'G&V1%L:F<BL#0XSBTNBE(>8>6WQ:4;8B7HZ@P@IG
MSW1)'SQ+.U7-)O(15Q6>\[GFV9YWZH.X5<2-OX,W 3,[-S[A4:E[,P3O<NA,
M30.<5,T/<@6\XQ^Q)U6T\<A'O=/P\E#,"^4UK<2]85(1IAXMG!P7P66WF$XJ
MW!XL.DTHKVW<$YEFJ>T5ONLUO1ME&4VRQ5,XX&-F%Y+R[!!T;Y:ZPX(DL"A%
MP#4J9SS[!0L23,K7Q3G0$;O@$*,& L'3P,E<<"6,#)PS&_;-L,^"X.LLS1SF
M05(KG8O7%0?CE4J=]V: D]A#68&WD\.#S\Z.,EI7J[3]0<+\,X@8TA] SFA5
M8&T5D75=T_H5A)0VP.E;,T2!(-5:4I*8*VQS9EHY.>[1?L)&./#.%Y;&"5,I
M_0"5"KBJ7._$45($:,?)H4]R*L0WY8VG\HWR8>)URA.RI5=&[ER/5*&G!6[%
M)>!THE1!\K0DDU1MD'#++]EU=7NB+6I=W5Y5=6]]>+S:I%$)=_/ 'QWKP7LV
M>-N=Q[5^6K21:?:0#2:RLX3<N,V7B 9P' H#N ;UE9PL5BNR;!OO')=Z1#>'
MQY+R'3C'$I:]&/>WNI#/2&%JE$U\=SHY@\(1F*>BD<B\3#J<+7WBWH"-^P>7
M@A<Z8QNN.#TF\9DR::PDPZ0N(?-4T10IRC1EG131K,BU*]V<$A@BBE, 0:62
M/0ESR^@"""XG7?]NQ'E#Y,V6M[YMHWUAC=3ZAGR9';\A-I12DJO^3&5)KLZJ
MOI552Q=6G2U=]027KEE8M=)1[MV9L]SK6%BUT@GDO8XNK*I)+$BB8H52J93H
MRUL=K!&S8VS0G T.D;^(1P1QXX1@76%<NIYE'4<S8+WIZZ\R>K.CFN[=S4<9
M^E@,0)$5D9#@(]"$8X9A_#A*#-X!!8;HG [AAQ28P*\HP>#'H4G5_3BD?!*)
M[_#6]$HQ#NSUFT55^^I6>\OB9.N13G5!E97>_[__S^\<$Q9SW0DVU'F/%+G
MO\7C>4Q#-<+H-5R%X)FAX$7R3\1A)F0WW!C"L+B\F&6"U>B,O^"43AJ=A/"Q
M_"WY*@.&(CS@+H,"8*;?VC/6T$7_5V+RR"[\^AJV!.YHA'4%TA+GQ)"Y:^&O
MU3\6?@0%^UU&_I#MKQC0#IW/"G;!D^_8LW J6:8A:"AEC?;YQ@(K2[VSL-O]
M2DK6 W0)#_+^?G)QLFAM@G 3PQ,E%F9'R=;NM S\[_7-3<[8JU"F;#?S\F\\
M9?)]VK2MNGD[6T2N[[DH_;)_<E)6HKEW_]S;T]R+/E+M>46340/(J%M[,MI
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M73KRA\+&8+9>7>M.6IVTSR?M'YEG3;5[?^1B<L_N_??PENAP3^+QLG5YU3M
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M2BK[%I *TF' 'O'\8Q_8C@[.><*FH,6F(9*E<E9)"W[^7_CY/PR$F#=M&0]
M?T!.'T$J3I$<06AA2O+5U_1UM^)UKS&5^8+'K,26Q<(028X?ML+^BF$U:#*6
M1S)8: 7.!&%^/TPS?!_P@0_\>5_$XY8R7D#4II)6$O5+<OJ"8%$I9UOR> ;\
M$*Y9H).^,KFU^^'J=M4B;7*QM#;I+M(EL$P*8@&&KSN&;4Y#PQQ&(F-;@$)2
MR%B]P>BR5HI".V9&AO9"YP6N]L!5"D(S<%B2^RUZK* PF6\JAS#OPD@>.Y4X
M?Q>S?S,3K<CE3-<BNDFU??:+;]/),JFW%;1\=Z&6+[4M%P  [+PF  #4?K[E
MJQH H-UV9""03 @\B+G6H1\'C8# UKC@ WS>" A<+J*!>1[0 B \."^' 8/L
M07$\TY]+<6[?TNJ]-IY D9&^K-""^:=XYGI&3+?=7=N(X:5"L%L61K['TLW
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M=7&B/"2090.R2"B9\9E<Z3K#-"&8D 5?.5V89"8RBS?&+!KY=MNX$Q!UV:.
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M3ZXL:65/A)IJS!C/2$/K%$,W B\0N!-C''-,!U8GJ<8[5FR!FZCB#V$]@]@
MJ_*K"\ &K=K#0N<WN87I,@'0F#N^K>B [)V*>AQN;!Y\DL+YR8[##\A- AR%
MK(R4"J,/%>XP69&= Y2= Q=]N3UZA-F26=0BRQ[DSJ64 0!/)VL ZM2Q4UDK
M J^DUR.;V1/#E6K+MV4@-CC8"DN?N#A%>Y(;NT/)1KL=.=7DQ ;<61=X4GR7
MK$J%2@YRK\>>(XNWN]G'N/?!&:%R%!8_S.UWZ:'_BP:\>H@K014K.L0]BK-:
M320HPH+Y8U$$CRG9KL,7Z/UB-1\0<H:$C(X:)=NKI[T1<?/.8Y.W%3L(S3OU
MRAA58X\^@HRUKI*QUJW&.*CS3., -XZL4[;UAVR)@]9-3ME&PY(G0.%11[&C
MC=6>4R!2,M$B\):H,)Y\.I/#-R0#Z#["FX2^A!U4*H.T2NT<]1E$1F?@[?-B
M[]WO:\Q'VUL'YL/(1],N<;O"Q)P&Y:6MZO2MBZ)643U<8*O:Q#4+RYC(PKD,
M$*<_.NX_4=6M1DRNW"^K"_=>9'H=) 5KA0VF< '0,0P7V$Z:=M+XC:.1BXTP
M$9R3G>G%7B/,56DC6F #)DN,!9=OHX@&0F!%*(/*\\G"I7 C#LJP;3_ ](PB
MA%3RS^G4QXX'%N/%SL8$B_7K!UB,ZA6:)E"G>G]PJG>'Z>8! 5/(H'$4FHV9
M(!TM0Z,>B*&8.@C/#QF.9VSB4U5>I@Y1ST:"+8B.2K<J8#E$X_O @TX[0<&K
M"=]A3R1#KV3J6);SA!$1PGK4N#^'Z<%#84\)+#(S&YU$#9F(+8?_4"+U*4;+
M_9K(ZH"J*=<)>J),Z7_%/)B4Y&WU.$+UI"4=,\N2+19I5\'/<GJBK%PUIFF:
M(C=#HHR*;\:^ZP+Y:1PA+NM%/RE.Y1A6PIC"0RUCP>'KX*_P4FP97N6B!:N7
M(U1B,<BSWG>D'M*HQ>)Z5C16XL_&?E;D[\2C3^M[=(VCKNC1>?#.130O!072
MD/@:8>*G%GJ__=7W/)2\ 8$HP9-L$45</3@I:^+CB9)!%V$)QV\)TN\4&997
M9/B 4*O>ODWEBE6HN&N&_24+FD)"M_[]'^ GP;/IXW5T6B4^"]LQ*U[1 .YH
MT%!:1JV#47^CBVQR0LQX"90#K4E_!S@3].&+3#YJ6;9EV>:R[ WA @::%1.5
M,:3A&Q9]OF/NG/YX_3N>JKQI^;?EWWWP[V4 ;T;,^ F8%,W3,7WZ#^5FOC9M
M^N3)V.!!\.K*=BRM@]6\1S>ZM>NP=TCMQ:YSD6@U>=[7"TMERC:O.2O?O";B
MAK*_*-^%:N.C-6E%*J03AVV[[%+5U<\O>OKIH'0S[1 )LS+*QY9[=U9$T$/H
MV_KZE%7((8'I)XV^&!1>*;ZI -;UK).)1;>''G4;:(C->M35=_^!3FFUS=/+
ML'G6S%ML>U6 ].U)[VSFPVRRTV_>8W5?;D+>F4T)HZ E5&3$[M[3WL\6K=CV
M.]0+Q_RVANB\XR5PNYQ'1>#JWM:$SN65A!8&.PLMQ"N]VS!"MI-(Z;C\DZS/
M_:?K\(P6,IF)=U4&% ;ZV45?'YV5;EY^=/&$NIN?K^477HIA2@06BO%1!0&&
M?N?BM TPM &&XX[1[WPC#5O+'>Y6^GJ+#FMJPGJ@YE)X%CO9*GO]TNIM_3;Y
MIMTGJ]TG QYIM\ICVE>.<$JM:[GIC@BB-67F03N7ZW;$+;W+CX)"OANIP3UL
MF:?=@=[/PL!K-\V&;9H9_-+$;?.TTRT=J6BWS>.:4NMAUN!A+DRWW4U7N!0!
MFN(^=]/>Z;E^?M[NILW?33/XI8F[Z;!3/J#1[J;'-:65"6$]A&#<(!ULAS0K
ME&?TG+'I/F^39Z3JK:J2H78VR.,^F6LE_/BG=#21LP;5>_0/U_IO4+U'U2;_
M0+\8=/7>10;:Z0O+SSCN>H^:S/NS%V;>KUC[BALLK%WZL+1;J>K&@NY^06\O
MHXT"8NMB&<_%6;H[V6&MZF$(<UCI3$7.9<57%=J302BU@W4GPV=Z=W11G]RV
M#E_K\#5\JV^*ZW&@WM$13NGXSWRZ9A84Y[9N'S9!9 *KGSTC^+'HO$; _L8*
MK._6%\PV#@0]+VWLKT74O'/PJ]9%;,2^T6"K<CWCM)[CR_(<2W-$GD.9U]NV
M=2@;+?I2P!&P.,37:AW.UN%L'<[6X3PP[^P(I]2>,)9U-97]K'4M-\HQ#.FW
M<Q_R0N]V3_7!>;JS3NM"5FM'IAP&V:?+]V8.-B&9_(H]K)221^I=%7,&;Y"A
M%&Z1_+/*?TRZ"+4[D&>=;ND\U<;Y% UW(!46V)VG&)5?M)YB=1UZTRL:]P1+
MR^^&KF!OH(^&-1;8M*Z@N&D 7M;$\=%4:K O6-$HFZ^Z6^_G^*<D5 _\B]HU
M+AAC"S8W_-'L[=QX#AA;-KE+=W3+OSVS;5L-+2>WZMX61Z>,[^6'WQE3&4/;
M!C'OM=@&T7,\PXHU+S0#DT,TA$</WDDBT&A/X-J;<[ @@%_@]WBP_.U._.*H
M+OD.1[XR4A[:M3W%KLU"U(Z92</03#I;8R8U=\+K*L8VG'"WT\\P"A-?"&T+
M_&LA3; K,_;01,<!&,C&YL79 :&@3W,OV:%Y=?_S+)'<O@%Z)!I3PW33DO H
M$BI0#(KP_=;G@P$/?(319+H"]2]]^B0XOM)%=< .:5&3W'<[Y\?)]9<KXK4Z
MD,^8.V!@_<W0X'+&?Y[0.@'MH[6D]"*;DZRL888/\X7E+!F[9>ZC.6;9ZO*S
M8PM1(S;@I +5ZU<.]SX[WN\,%G;L/-@X.!4H;"N'N3A']$[7LH3)8ZE7]]B.
M/!BQYH#EJAG:DXS?:(8(X&@+8G0DYLH04FVDE(+FN/(KO&_KZ%&_<WH,!B?)
M=B=F.JWN^SPJVO:YEB;/HXV,:E@F]CRV_ D+O2CEJS5S5P)GFFQUMHWQO2-R
M[<A=4<AXT5]+5?5R3BR'CO.2Y&'S6#OA>P92B>V$K2=CR16O27F^\ 91Q$W;
M-Z2-)]W$<##J9<V<_./5':SU+;,8J;[+!6B5R=?S7G<TZHZZ7P="9< /0/MX
M:VX^C1/GQUD8(PPZ['6[L+$%<:<!$EIIS]<;#G0M^.?-VU??_Y0@;FIRI:=S
M6F8ZP_AT<IO"#SK]D1*-$TO:.3O/6%7Y]5NU8Y]&+?O@788V<U$O?P.[8-CD
MT/8M*RLJ<4?'M+"]X D! EK\^+T1"PKDDRU/TH6@)V*.8N5&G:%IJ^%T/)I^
M&SNFIO[K\AM73 R_>K7!*@W+K-+9J_I79J5!I_5&>>?XFQ_1EVWPF*8 _AW&
M=LLKN>SGF6!YF./T[9]L9!ZP?S5AHF3LK:N)>%:'4?S)CFJD^]W>0!<;X;\,
MX$1WB5^=ZF3%7RY<TPH^<[3=YJ:'UMS]DIP!_+&&Y[@Z?43;R["78!@BWBUL
MD*YGF,#7(1$,000P%B<FV(J>XW)=8]+4X_1* UF<^Y9GV)[V-#/',PU,/XV'
MG;NUU38XC&'NV&0P7QD+7!=Q#GW#.)B2#"V_CSZBP2$HKV%G9B!W3[\.NE]Q
MVE_#!:0GBD7\A2CG<WP?3OXS#.#RV>359B[TAWW]?)B.3FCBL:CB%)K_SS>C
M?N_\+4?7!>8OO!E!4* >4S-8O$RS7#:5KCOFM3YEM&2V.!CJ9)]ON5;5I):G
MF] =HAL =!!,!O+';!D8ZFAWBH3/C270R$-]8!-+F1Z7D23\$3"FBZ+*X<T6
M4X*L4@& 4HBX.,:QCHL7QP:?B1>F=,<3@W%-8?-?!A&K52E982R"_I@9^!P-
MAXT_Z75%-*-3Q.AOP^T9K_V47!U' >.@8".L3Y,P+/:HSQM$AMX>R=#K]O3>
MJ$#0O9A<)Z(5V*F[M 27DY'C]=\+$/( I[+>^8__AWZI##M51TL)0N$[M<RY
M9GB/^W8>S\HXC^<'S\%IW[<^<<_,CJB2?$UV<6D'.:%]25/W+NV#/#?)<WGE
MOR^%3L5<_T.<QN'O$"N3F<<S-O$M=CTM="9U:5G.F/ZZGB9/G? \BJ/>?0?W
M_%GPT(F!8;7 +<7UV<%KY2,:?I5>84:4[W#MR-MU!^DF!@ H"#]!9Q^C6!CS
MP]I,PZ.3>/@/@5&+_!0F :?)Z,<GNFP&#T*WTW*X^!J>:6#W%)"^)ZZ]AL<>
M.-MY,\?G,#/^YH>LG2,SL$_!!86ONM''*'8<3V?&9%,*"XZ992V,"3J0Y,3A
M9SE8^AP+3=.@A7$J\ZK%-V/?=6'=R$X.TVC/SS9UN$9*RW1XIF4L.'P;_!5>
MBM'TU4\Y2?C*U4G<#M=&?2K)PFS:K,LHW+F)Z-&OUOY9_6,I]3<]WR)*B&B;
M+OS4J/(S2:?\86XA6*DRMEV],N?%P%?P()M28XJ74,HL@.HT=;U&\._,<+4/
MF+V598[N<!&45^Z9BS6I]J*=MS/<>N_=B+EK',G6/!\H6_'Q1$E/B*IGXK<$
MN0V*$I=7I,="._XA"U,J-KF%3.V&"UM1V[^H]5M1*R]J$;Y"@Z6K9;RC9+Q>
MXQDO1ZV_(+^G;LS4PM VYZ,DO$>#D6TP*<IP,<7*GF@3]L@L9X&!E[),'E2M
M9Q;,%H<NJ .Y0,9CV20[7"L/*0K%8K\&Y+JT)^\C8LE'J,?GG^RQ,V>W01SK
M9QD1SDD\VA#2X%3OG^<T.=L>T.!E+WNLRJIQRWZ:UREQ^V6O2;$>J_[\)[.9
M*XN%C<G<M$WN8;#ZD>U<@Y:Z?;]J5%(-Q.DR1K-]2=10[Y_FX(,=BB)M].K'
MM6GS5G^8!PE=ASY-H *580^A&G?.6WM"73V<\;5+TKCQ[<"F>7'.(I57:^O*
MY%O7<1/4BN+;U84^[*4+\P_*6&GJBI7"UBBS8A<7K8%1UVZQ!93? 0VP790&
M#C EAP$&7SD(OFT1^%8BCY1[?45Y\KF%WR\Z41Z!G82I=,FY/Y>P6VNRXXME
M)F>7AJFH0>'+E7<35$*;CGP<PV_3D7->BU7$(B^8BE(IV77A,D[YQ9A['-3"
MGP2U\(8BGBJL@<^CA.5W%GA_)R"!CL6"RN<3+*+'E\R=";,(Y0"D]I'1#QY<
M!#3 !&<%?X\2G&7ALWPAW2?>PXSQ+"CS%[!K*@G39=MB4EAQ2]QA6 Z,Y<GT
M9O0$N.I;'@Z/<<^<4Z9U:NHYHPPKPE]N+K)@OI+)R%G[W0;'],.5Q_3# SJF
M;].3V_3D-CVYS9ELTY-W($QM>G(K:FV6Z*ZR1-OTY+(C:5FN34P^>H^G,6?-
MH]X!G35_"''%$:OM-44_WFQXM'R^]ZRJBKODA5T"E%AN"*=843.\S%YXNSU@
M5MHOO=@52QQ)KUBQ7DTKMO^,X,-47(^.!=QAF=[R8-56U5"%JZ3@/R&Y;@QO
MLYR:A9^'W'K27P]*6&F"QG<'J/*:M]HK\W&V6NUJRV:^JU]=OC@#\,;D?YY,
M788(P& #,NYI+K!*JTM72!?2[".0[).D6&6:=%!"MCHY379;3;JWM2ZE1TNL
M=;=S<6AZ]%C596AVPG"!-/9$6YK,FM2G+K?W_HH^H2$FRWM)V,J4:C=7T*;F
M,YN<_,U<!ZDWZO?Z;W,ZL=6W.MNHUY8WME7"C>.-M#K..F7;(K.FB&).V<!T
M M#OGNI:?S""?X;#-PF5G:=[Z\."SM@ LE7V;X5RKZ+4J\UU>5'"E3*0HZ.9
M8@]?7_11[HE[%_W5;6E6EOYLVVFFWQF4K5?6I*CG'7"4XY%-]HNZWM#RWTK^
MRRIDVI;_!IV+LO&R&OAO@Y*+%444%?Z^HO:FHE705OGAR2.!!A%IFQY*>RLO
MD;D#.RH8"9TZ/"+*+Q1IBP"*%0$$:?P3!UYA.YYVSRR3/3+-]+2Q80<)X]92
M@]^.,6'>,K%!H(;=53RNS4SN.2[JKK"A&0&_+!SNG6 O,JHOH)9HHLP'%>.C
MZ2VQ$F#A.N@CP'?P&C3QP,XSJ*FZS,:G'\^8TE$;%WT"%B#\&B]@P0&5"_C3
MJ3DV8:38M \?$ R&'FD\&J:%*I'ZI[G4'5>G%ZEU!L+8Y+"^,*:)[P9O+]7=
M7:V-F!GP,ROL!>YS4?7 S?G",J<F?#MGWLR9K)VR+IL^(J"[O;[,8+,FT+$\
ME0J?FZ?)-^+9P"^0%2"XQ>->ZP/_!1WL\/N@<(10\!$RWYT  [JB/1Z26'1<
MC_?O>S(M"QB</5)9&*X5T%NL$&R^#TO1)7+AF,!E6/$"8BF: 2K<%^>[>X98
M+3S!?PEV=EFL\B;J!4\O\&;PUG Z+DMVEU>:RV6T[&LWE\TVE^@LKM 6<R *
MO]TAM]@A@P(Q'DE@E,Z O7_GS.#1IJ%LC,IM(-6HCF+=/66765!LH%V4GTE%
M@/>"7R0VR+!P+:Y"I-:#S9DJV*CO9*=P59HV*AK'J5JXM]A4E*;EP<85ZV.^
MUB*4KI9,<-V&Y8^KX:%"Q8O!.J*J5W,.A7H9_=.[;!ZK2[@GB^P'S;">C"57
M--7*UO3)D91K_7=>IO7?*$Z8'V=AR#?(J>YV06\&\<P!$EGQV'O#@:X%_X#'
M_OW:J96>SJC,="Y>Y2Z=RD"#3G^D $>(Y>R<G6>LJ/SZK9JBK5&.-KP*U)J+
MH99O0-^!4J5R5E!95QB? ;/GQ^^-@@N>+<--:29YL4)HJ]$H&YE;R3>]+6 (
M4:8)'J5KP5FZ=J-DFK0&1 D#PLW.VE$JZK4G<!0%>AA\^+5SV]$\EZR))?R&
M>ZXO&G_1[H]=P3P\% %C!,P-SX2!/\T<]"W1%,!'X2U@1Z _DF\P9%?8@QVC
M>+"%;(C6I2CD4@3GH=KOF(301JY*B%6*(U9;ZAAVL1G:TQ,VML!G!K%RP=PP
MP9@V^"Q,!Q'A@3#R!0^T*2IE+)/W;4.BL.N>1Y@;Z.HSV@&G/L@OZ^ VR-E?
M/D79]"2V!HXQDMUX(@M*,1YZ9_G]J;VS1.OORAAK/5I/[-#'G@3-1-\QFTU-
M#QNN\VN@B'LW,^SLHZ+JH'I>&,[3;C; 7J^CG79[K_]\H^%J%E)[MF]9&3*_
M?HYJN_(,5R2#4VE.ZJM"88BRC%>ETL45CXQG@\QJ?_F&#/'*V7/C$0C&A9;!
M>"_& 9CD=][1+BTK^B@"?6"QFJ@H2"?A :&Y +M!#UXS05V!80?F2>__+]]T
MHQZA%$R$M\&S.4:.%QB%]U"-^#!7-[R^,F8-1L9X%@Y,Q%O->U\8#?X";_DV
M^X1W? ]+(P7:_04? _._4GY_Y_Q?0*1;01SDD"IP*#]]_E@8B'(G@R\#>UIF
M\.?#K*8'B2\$$/]X3#'P!VLIUA3C5/'5]!#*%K\&!L44I@<;IC=&2].8.S[:
MDF"\BL,1B?=4XF"DH^Q+,5B^5;N#@#J_,Y[?FWQL.6 /;X?,ML)#%EY<;]AK
M]X3Z]X1^1Q-+J\':,AXOD%ZU,]2MS%<H@R^H=#E\^=%Q"7P?S!7$WK=")F6\
M5M1CJFT$#? $<LQ9?8.M!/ W-=C/3@%%M0B&31LD^<&FX!,/1PQV,'BU/#S_
M-9ZIU36CSMEX3DT <885A,ZY%J*_B?TU>3<I-'H-.=^=HCWOW[,IPP< '2_A
MB1Y'\IK&/<;XP1W?'D)RK:+J]\[CXIN)_E!4IG6-PWRG<=$>= ;PORB %/>:
MZ;M'PS5A?S@!0P5C$8SG7(>9)2\%(<+3;C>M0((['7<!=C_\M"_E6L;LN0?F
M4**&8-#OG)V=G9/JP>\]%WZ)'(F/ [6C)1*OQ!N>S(GS)%Z K)K083#*^S]-
M>!8^D'NN\R<+,#3H>DYZUG!(F5DR/4L,!V3&$1W;3[R9.?[39AQ>:X),F3B.
MY#V2VKG7Y>O"ZU/+,;Q@IH'"U83&U?Z?.5\X+L:,5K>HCW;\##NZF9&!U&L1
M?1^(H)C TK"EO/#SMVO@(B=2L@.7'52,01).%CF8Q@(TDVNOR03*ZT:?+#HO
M=D*1(]K-R9QK^J!2#][;F>:&\U(>5DRW;(=%DTW%7;VY13;-QODY/SL:G)\6
MJ*[%A#P U+ 6$[(5M183<B>BUF)"MHS7(D/6H-:%P9JKUXN6DJTM.#Z84N(#
M#%X$<44MBCO\L&?(]ST _K<O:]>O\2_;'Q1/LQ3P(%\!?V23L \\QT,HS698
MRL1<4>6&IS':V'#=Y=1QL6*!ET9SR*JEWAC=;.5C2]7*9SV@?&E\ZI3I.B#=
MST"Y*Y5P9;$6-FS:.3K7ST;5@D)6L3;MDA> -]APR7O]"WUT42U\7=.1(5>P
MV-G%]OAG@]W@G^7P-*4#D$Z>2OV,9^2&.YZ);%CVR"QG@4ED9(6.@1NI%/Q0
MU'053ZE <.&/*R+=/O3TH*]W>[5U5V[7O+(UKU!1#WKZQ;"VO;D)4&<'8_A^
MLCW#IM1=46$P-A94'?(W>/9YRK82G9H9XS'B1[<B^E>/)!8?0$4*I?#[BDLW
MY<^E1%M9TDM[<A4MZ(U<3_CV?;2:.]+SO3/]HM??">A4$Q9Q0R3674RXGO<U
MB&LKW*F&^MEY5MKZ'M9PGX#*A44A&:0_)E_$&?]Y(@I?QTI-5WV;81XM=[(1
M5@ <N?&[JC%O@^^PJ-7F+%&])ZOV>':AWI7#=[4OGNEG_;+=+/:&!=KR[N'S
M;J6[XZ!?MH- 73BB^\:VKL9<//Q]DDJ@6P^Q(1YB?K >EVE7KI\^/-_-%M>$
MQ6FYL09NK/*42._W&Q*'R$FA$K[9XKE@?FN5.\^+$Y7\K?8Y8ZM]#C,.1:GT
MXEDD&R;R%4MLEYOE<Q[WK ]+_;5,W#)QO4S\XB-_.^K"EK/.=X@UHDW2^:YM
MZ*^)X9-_N@[?5?)"[_14'W7/]Q\":?GO</BO2E_F_%3O[NB J@W!'<J&%2O-
ML"*LEQ_:L%S[OG9!#^1]+][JW^\YQGOL=#,V92,H1"6<.T"JO]M#_]U97J\+
MFUX*HMD7%\MVO"5B7'J(T_N7;^XRT>U\7R>B;UI_X,BXLDI/85BV+J8.MFS=
MA ;M<.U)_7[.1C?2'[L\KQ^4+<>I\GBTQEVLY<B=<F25B6:[Z9:^GB/;$_N]
MBTNSC_U>YJP/2P6V3-PR<7MB_[).[)5CD#9XU]PPR:[.[7O#!D1#6NX[(.ZK
MT)OI]\IB'[2QN",_LO^/8<E."P;V;##L,7MQD;G=P^+N,Y(BDH7"=;\,EGV'
MF6MG%_NL@WAY@;Z6P=<Q>*6I<0-]--S-66P;-SPPZ6M>\.%ESKJ-&Q[5<K[,
M6;=QPV/QPCXS[V#J?.H(#V1@"%?_F@I*+)20#2Q9/1[3U'QFDY._F>O@2HSZ
MO?[;E"VY^Q5J9/2P9<4BK+BY;]-X5JS&N]F1([-+<V]7-LX ;)R)XV.#RO5&
MSJ96W$%.ID9GHF6DEI$*&?3P#_:.C?= MYCA(GKU[.W<> X&@Z9M5F/6=./;
M_-]GW=W(#LC;DJ YD_H^T2[[ /IYI2B\>HH'T%Z]Y(QR\=E/DVV8UW>R4S53
MK)FWZN@>0I>W C2\80C++,XJ9==Z.]MMUDP.7R\8/4[S%_"#J>_Y+L-[J)FV
M:8^=.=,U<ZH9]E*GAQEST+$>5=QYYAQ[+\%;P'X=S_!YOCV&3<4P[8Y&P)>:
M8].O1#M%O-5X-$R+GKYP.-CECZ*!B,T>#/K@W/^!'>SA+_9HPLC&\'Z@F/'
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MZN(Y1O2:HDWJSD8'V*1NM+I)72V]08H-[&SEP,[;IB6'D07_SK 0/PL4>.S
M3)-'6MWF%8_7T(=BM9>9LP>OBD-VJRM=.]?[W6HAZX^WH*1K9AURUU4] D3"
M&(=B\"Q<TW$IT"&ZTSK<;.$:UTM22,N;($WEH^O,OR Q14H9W/LEH.6.*T</
M#0RE<=O;OF42V:&5QJVE\4J8U'N7Q_/1H*WE;BMW#VDN:SGBR*RP1CLTO5;[
M;^S55*G&]8N+:M&.6M.J7O3DUMTI#SR6(V,A,;?Q=^K"5];[_6HMK"/N5MD
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MS4R*)325^J/$ ?XN Y(7YYI,&L"I)&JE?OS^WIDLL0S)FUL__7]02P,$%
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M=CX':F1LQW_S@^-A9R4@.!AEF)>9]"6[?+<NRZ-'W1[^7M4?DW>SK+RK#CY
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MGS*>BN]AA;S=$0/[X?W \_.*>G9G3JU=>I4/[P<.'<].Z F_.L&++75/6R7
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MN(8NJEMS3MRBFE[O"53*V95#W1GDKS3$RMQ*TB"DL U6!*.WU#3FD&\@-3K
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M0Z0)>ZJ9N*0]!NCAGG-*3V^7955WHH0\DPZLX\*G^2*N$SX.0Z3M!!;%V!+
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M=5LGS)?:8WO_R_W'=_^L;FV!V8=\A8Z/ZO$)1:\\:Z8]<GS%.;./.EU*0?+
M.&OEGR,,EEM$N8XF6C8:#FSH,QV1[AE0ZX24R27E2^6-_N#.Z<)_Z5,P'+0>
M@VS#*5"_,!=B& S(7F.*@%S:]=S)3BY3#O[0ND>)G<GZ;(SS51) ^.3V;"G8
M-B:W*D'@E_*9PJ!IMZ=DC'HU/-U!(M^D=)-Q8W+;1EG(R@/-M!@]O%),,Q6X
M] T C2E%\5T*0F,[G\U"@V24<J6\3>'$)0]RRO'@G)#G5=17 X^3%0U200;]
MYJ2=",>2[ @M T]+X@T)2C"? @M3Y]=N+@66D_.314S3_,,*B&9L"UG!@)?
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M^,P-]"; '62UB=]/[Z1?W#%>&0X*LYXT#ALH9W%.][)/8#8*]20^7DYN69M
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MVOWGZ!YL4#]H14R/\,2V3]ZU;H]FS<WEV0& ,:3*--O1M;,FGS$<: R8(,[
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M-&U0]SS+W??_E<_*B3-T\O):/I<+(V ,:-G@O?3>A\OC!AMO]YF+X>"8@9'
M=M9N!;2]! &*8WD1)*GWG^UF=T6^-"F<[ T&9>W]YNK]^[PLJL4*C2R)Q8Y,
MPR,C@^)7[.Y!!.RO3X#82DM#FY&V)7LU\TV*ZSMAIMRJP__"._SO(?;[?JYG
MFZQB"X=.!')#KYI5-&VOL#^D5 G'F;4,'1@/Z-+"I5_YVNLV,2_W$,G"Q(QH
MO@>&S:K%$@^,B+$"'I3BK2BOH9NOWL26"\"7GB(:OD <9C7N$!5;V^@##[.
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M;<ZFR!PSQM0$M8TG=##@ <>XMB!6G"EZB0F4Y6J.'^ IA:@B_@L<I)H$T*S
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MJFA\V>\$>!VD#78L  \@#6V7:V03]2&>AZYR8^QAFL;J/2'(77.1H@+.HR>
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M:C:=MV8,^%S.<SHG$@@?ES?ES"G^90E1^=G(@ M'P4ZB3IU1<@.T*T2[W%<
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MDRUJZ![PFI4!5F3G^;18X6J.G=L *R#^\HTX ,< 7<K'_DNPU&3ZD%%SY%P
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M"NOG4.Y MYYX;XPREC,)==)KSY22>-$.7B8Y?49TUW@HFDOKEY ;V[G;9=+
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M\G#P<)G,<>&D1$X?B2\JD[.$2 YW@(4R;WA_F=P*2_@R$OG>16LJ6T8AV5*
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MYPAAA=. 9.**B)9W TYTO.'YI1O:57;RK^0*(I7-<& 31Y*-GV>'%Q< <$&
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MR'7CUQ*=;(^BR:[Y-3&BC6/CD:*F0HAX@%'@E]*');E1/)=&<6.-0C+]0H
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M4M"F2/%DC^341K\WDS!%Q!E&J<!&$+<G%"I@$*.\OD!BSK3($U\U[6V2WP2
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M+S'?2\*:#7%P?.P)8%-W@S*T&C*NA&R0F3?FM"7&%W?>?,? TRI['^H!C;;
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M9"OHPU]!5]9\.</63)C-1BT<YIA/J.&>VV)<4)->/IRN&$_$WZ&9BMD6M2R
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MH09VH@K.MR.HV(6S;GIG*5?A?1G?R>$_/4+;,V[.Y;/\!_ -,*6#,CNT4P]
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MH@=O MS6@;;X;1% D_7CO.V28Q05B,V7VVST*E:D!BD4VQEJ FF!K>ED/>L
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M2Q2-F*/&<VB,9+A2UF]J]4B0*/=25&"0B2'25\UWG,_FT2KWL/[+X@='JM#
MA1C^9*,%MT;J4>HY,B076&V5GRU*&BZ$=6;IP-T:I5_0G$[=P5TA[@1FVT7&
M%R$[+KB15R4W$2]^G1W@Z_EOF62JK1RBB9+EQ<BHFJ^$9BO]*MZS>]DYVOWR
M!J@- QL=&$3G^=W>(@:+W>\R?)O!0@]>1;# <8YT%N$JT232#"IR2R[2N?IZ
M8<(2/4&C@^"K5Z2KPJL[>,'.(QCED\;]0'HV+S#AY>9E,B1H6NJG5$G ,6/4
MP8. 3+F#*7 T5=-AINX&\)!65,L&^J:K%)K<A3L@ T;*4 7AY/5K:]P!C<$(
M!WH9^+2X,,^!$9B<1V;!Q1N[XZD"@KH!">H@F\,R9P!X9_:AY5@A%\;S0LSU
MI;HO<Y4!!PYX>$9-!2\)4..-?>'YYZ^6SMZ $8!GJ;()&I0_IP-&13FK4+HQ
MS6I.]8+9O"I'X/W1W?(1]K.X&:?VK4$VSG#'H6* SPY+,M>#VRT?1\AC (F(
MC=W&.-5KG6"PM+'_C]/?U1SXO?WDD=OJ;B8Q-[J%):KGSDK\\K)R(:C[QLO-
MQ%Q3GJ-&BB,_^9.;TD6P>SP('.26EU0PD]=#_B00MT*3&Y!F^5-(+1Y?8V0R
M_74&05"RL7?+YRE:GJ<GXW>K^P7-/^5@6H9.>=U1EDV8L.M[K*H^_EE5_7JN
M3U)[Z+OS H#7#>I)(K?1E<Z"X@V;@WQ7XV':Q_SDN[)P$<UPVDO>G40!7]-F
MI3=@J^J2!=O@<L[(GM=4K2OR"^@N<*<7+FS BN+Y@8;@G"C>0'JV@6+*O/,J
M^YO:+U0W GF..#,RI30)M(%GF"#[<^H"B4%N$@8*@N.& ?RF@$?]:>^.IJO\
M/"<STDQH[Q)28SMYDT'TVR]KSH.X*U#_.CC>=GHJ.3<'N15H(_D"9G0+<5]N
MUHJL>FX[+@"@+BE^L_O= =V_*H&P*!(#7N+S8HF#L*"^(@:UF8+'[ME8;P,$
M%=TMK#%9B9!27JVD-83/=Q*M."R$M73@MW6J%X$C5'#ZP1K0($%\933X>I1M
M)OT;,QQ[@;!RTIEE(W^:SPM+W;HREUC;;8_=NAW@<F_XQ2L1G<7!<>H"];N(
M \G[H-B\'2@5N7,R>"$>LJ= O86  R4=287((N1.IGQH:VD5HZT+22T.O*\<
MF %B^6/B)8J'K,8)L7*C%:&W8;^\X0)D]7G]"VNF-PP[<QCMHVT1^"M_O2DW
MN+XF0GY+,A;S2A*T*Z(:KN8*&098VOGOH@5@F6RT3$.P;G4JZ*#2M!)<@CJS
M^U^*\L;%+9>\EA"B:^@X9?#TKEMO$\CQ^J8&/-WB#JA[YV6[R[:B%-(9G#Z-
M9>3=:(S\N(OD(JTG6^ZQ^U]Z<EP'2[,CP-/#[*Y,/+M/O^)I-])-?-#&*SO/
M"%@SQ3!AOJ?3,W8D#%*=N9&3T:QP<C\8KQNHO6)YMB3\!<\Y'?$AR8J/2L.U
M&\15SL-SLSH,3G5:>C;Z&4VQB3CU:PZD.,(\*W*",PD[;0_*Q-E I&%(I%M4
M.2MA,NC.D:\1.HHF2L-#_X(X(MT8W?RH )WVSJ'*Q%^0B2"$/$\B53!YLL_S
M,L30P'6Y\16+Q9,$.I& = H*N+NB4SASL36^2W\#N7YT/3 70^>_)G4_IYX
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MR21D,77K/4.%6MRLK 8X\#(3;(G#&\L,2)\R7&V#$$>XGQDD7**4D'LE15Z
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MZV7_"N9M8'HMS?OVO@/F9_'&G>VZ_L)20HA-@Z>4B]>I3='B@-U;/'6ARP#
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M*?0I?@H\ 75:'T[ \V7IE=(I^<<))2E&:[L-@E6EV"1 -6J>4DGWBVE54%]
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MH9QU&%&',B.F&&=HN[H8B4:8)(8>4A7]BWO6'DMK3^0RJ78DI1[S+/S/0"W
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MKQZB*$'O?^I*'-OM1WZ*RY/RUN4M5MJK.VW9F/3B_BN-ZMK\"U!+ P04
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MADX!KMV\!!4Z1Q_K-PI\V2M').591?F6^:A].L0<?OL!91WL+/@QQ?"[0NG
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M39JI %MUK%(YQJN5=8E0.,(8KI<D$_!O @.7C!JTN? &8_H4 &@0$G"D=I(
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M::J5B2!)A%08$.YC(73'L#=AV.3=,^S%,>,!T9[1K%:*<&,)QU[ -Y!TCO>
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M%"%_*'23%+<KRU8M?RK0X#/KV\>Z3%[4U<,>-NKWP+\!4$L#!!0    ( ,R
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M\W]31L;VE_9VV^B8Z4T9_,OVW\IE%($1!ZYA!H*_;#&Y -!*!8"IPW_9YA6
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M[3B"D)@DS#R8*7P5OK]#+@CPF]T\F3]O15_==M[-V3NK[?AHL\$J;UH!2.T
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M0+:I3-4ALNW+'$KOQB"TL[3'M\W4I!5RUY]2K2OH6#R<>T+UV<HD;P_'&:3
M%@J_UJ):4TDG*JT;)T"&2L_4O(Y97-13B0F^IC&KR%ZO5EXH/;GX0&Z<ZKZ5
M<>X#CA, 4.\0 $9.S_WL;<C;'>^SJ_=?:?&!+MFUH/X$=#"05:V&T=W$NDDY
M?O-"RI?DM)KOT)G K<%[C0$IVQXC]#)D>X<IZL+^FN:UJ*J=[^HJ42V!6ZO2
M42_<HLJ'T#[S5I0>11/-->7+,#'@O5H( /U&UQO28V1,VW?BN_U[F^R)RW;*
M:OF$YH /E9L)4+?I956$U'D32X@$B?G-4C+1'J120$I^X"%+@=1K?<^T27[8
M.(=^8:=##9%V*4"B\Z(M776Z-)\Z-/=-\2[:5 OK$A/J-I!:!%+K#YB+]B%*
M6J<(8I(I#5Z\TLB#U6KN\@"/BB#.C%7\DBJV;.XE;3AGO46@MIU>! "4UP2
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M(M5B6\X%Y&/\9S8=Y9%RD16%J@C7,1/0\SS-&<UHQ?P&QA?T._VK# HVN3F
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MCNYIUEXU3'"XIXGZ]U[$K5OV@UB0#YLB( Z%[)X'4'F*:^=N^.A5HK:[B,+
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MNB)ZEEI%9@B_11XE?Q7ZSTLD/Q8,C_)DNK(/=FW$0PQ++>,)8ZK)XG,$C=9
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M:QPS5?03<9_I+W(ON,R<*TQ:IV$N%9A#-C-C!)-G+6?F"2:-J-I8AEK[4KF
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M=_^F6Q+/"<"F)*'XEPKY3UW;E*.-S]S<<U+#7&?J7*<F1@E:OZ@D@>N;UZB
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M3O=CV@<"2<&T)?KOV.\=<[@[<:I6*8Z!>]^DJ\C"I]6KTC/P1ZS?5X<0EM=
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M;E<U\APP;GD?N4>Q$1N2N'+<JI6A7#3>*P#!5>)/N%IY8?C-HXMX$XBG;'4
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MI%' ;NXN1"HPD7,&M H4S+&+Z<I:P6;[NH)+6"_M\R$*%GU' [B!Q=<\"[_
MG%]EDF:J3/HXOQ]P5?(E P2\*!Z)60Y2BK)]JK.V",/MKH(U!8T[+#*G!<\U
M^W-?<.:M%*(@):Y4GF^3UE*R#7@SO;$H,)J9 5*F^QB#'LNOVV$S#\OUMY\&
M 641FMEP$&?>TL;^PKV)_)VKC@?&2@ K" L2OD1,$7I2C#W]B!# 5JL_) ]@
MUZ8'Y!S03G4F]3EH3F[@MF'ZT8 D_^S/F-VIEFDK,1\ ;\/_8 ]FL#R4.%+F
M$RL4W@_\8A.7L!CR7KV<; R=BTD1CZ!)R!49Q; >E%[FU92?A<O '\-^%KZ
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M9(+R7_N> >L5K-M3#X$C=^S.A1Q'/EVK#SN-G%%;0[; ;/E+02=2%Z&IJ:<
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MW@$LS^"!L)E96=%@3X@5= M,"S:;_3CG<NYA>%M>43X=D5,0BW1'&1?J%/Y
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MTI<P\I[=9(55_KY\CYE6AAK%,\3%NHWM]*>*9^(!>H%,"S-"7ROV %RGG12
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M]#"(;T]U::OG?J)<*DKD7*.P:=WLRY3,G&>LAQ1PO#OS%X7@=8YI1AFV?,.
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M@L9 EF 1;X_3*VX.N\\$QQI@+NI!E;77S-1H%/=49DHV*R^7?B=-RC<4U>8
M)51%9)*F\*?D3Z ^'R.4.?5PWG(_F.2S EGKNT?*+%IQU1'%]HW.8J@RIN8C
MR5!66=&7/2E95E*8J!#RE+L")GB_)!U.= Z3_\T$ROS 7MJ]O72R]W?5H:*K
M'2]%5Q4?F@\3%3*'.FZVO[BA,CIQI]"B9$D GM<HYS@E<4R%XR89S#;VY:ZV
M4MHPNLJWB#M $T4KZKL2B#K2ARV;8%/B\-K["6<%M\O% 0Z\=)6FDQ7[@SC
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M"V&P?PLXPL,Z]8(&.*]C!'[9<+*6 B\PGQ<QN;&U(OH;2*]?4K$!FJ5NWF(
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M6T9@AT1&;3S7$'9(>Y&[RF>GT@GJ=N%+RJ"XM:/\5O!_S"6=;,DD[ YKB>A
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M.Z^_S'BT[HZJ'IAE?TZZC96SVD&0P.XL?]G3Q-J0M[Q#S K/=&MU8FU*\&Z
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M*+\OVU?QMVPQZVOE-TE U;N:6%%.SC7<&0$[80D1Y!D#3E"HB-Q%1A_DIO5
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M+%4-,_UV3P4VZV;T/$?FUURH/X0 U$?H7H2H/2V^B:QD+:3RD;M<N. JZB3
M$CM01+PQ:"<V7![J\AT[K [M_@FELO99+T%<S@MD'[20]U/T"7HH_(>R# X3
MVQ2$POW2HD1'Q$.^.@A%[JKB7<>B1S4>7>\U+F)#79]&([D/[]&<E;D(?X(!
M<B;Y!KA:L26_$XI734_8 7U0-P3EP!<U/J[SD"?@K\YSZA @UJ)4KP4N076
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M05#=2#'D_L*T2AYMM\K 4N<IZSMV,!;R4]KZ64>H.2V-G&\E#YOX_*C,@(9
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M):&#)7>C%[3FU7*92YO"B[=P(^OGIEB$8\PO0^]*/0QU'K5*G7;88EIY6?]
MR[0J<(F;=C896! I6T2K[W:G?V&\;I];3.)T-8](B1 0UJNARR3[37(/LC)0
M^W=!O[BSO+[)07*FVA:_)9M),4L/RY7T>W0WQ5M6=!%=9>#N2_H!I @EP5_
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MM6'GZ_VQ+_Y^EC!L@4>-,1.K<<K0]6.S;2L(&GJ!9.D4&K_DG6EW-U+23K3
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M*WRVP-'82]<9\#N,:W<,V8H^H75K/"S_5$S0G#3G%LP#'4VSTWZ ^88UL;?
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M&,MTD5_-3>?L5\8FT@7S5?O#;"5] ,G;J'@,SG*JTDR'OFA<RPO5NT5KJ_X
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M3+QJ0/W<L-<%Z/8$ ,OV_8\ZMZ1>'=N2N["PL7QH?A?#.A(LU3B239)62+/
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MB3$YG"-T=!?HF^QE-ETCHDMBQ [4:$BC54KZ)%7./4"2RV8(0M4T4:":6FY
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M-!25< J.CC^%1,>?1&/B3N*PL8OX93<V_=9OVT[_\>]:\.X* ?AT<R58ZT8
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M^Y9[)N528!'Z3!0<MIB"*U[()D&.%%!SYTLKL^;@S(Q9-"MM!L]..4"N3CY
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M 33,!R#"O)^AP[V>X2(\GY(B/9Y2EU3SR._>T![YW6^$X.T_,,'[?R6"KSZ
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M ?B>JX# =S,0!+N VDCO)S7QH?<Y:;$W*_/2KI#+\L]CL*6GX#3D0@D'?ZA
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M$++L#?X4$O3GRAWTYNH=]7XW_M7E'E'DY"51I.FN&%(^LTPX%S8O2H;]:Z)
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MN,!."1(<6((#A176H+;:#'36&8+1!EVPV*0%F,WJ@-MR!!RWJ@!EFQ+0MRL
M:X<\N$O)@H_480C8>1 $NV0@>O=^2-PM#9E[_@9H>T6!+"\.=(UEX*Z_'KPM
M=@ />P"\R8K@P=0 -E<?F"&F0(NU J=T6R#EX\"QG  .=8Y@WTP"?"<9<-T4
MP)YU^F-WQ?FWW6WJ+]LQZG?;-]19NRGJ!]PT=1+_B3I!F%G0_\G@HKX,//76
M \]\!_C:'0 >21&\&!K \=('5I IT&.LP3G-#LCY>""6.8!#+1$(362P[Z0
MOMOI#Z[?>0Y[A?K;[B[MI^T+VE>[-[1/V ^T=_B/M)>$3[3G#C,+ CJ:@8)F
M8*DM Z[N.N";[@!_V_W =U0 '[H&>+CK SO #!A1UD!+P8)3KCV02AW!L88$
M#DV4/X0.YSE\-W4.UT_[C;M&_XE]X/+=;L)E%OO690K_P>45X:/+F..TRV/'
M3XR%@ N:P4E.'-BJRX"GLPX"3;9#D,U^""0H )^J 5R./KC[F8%KN VX).&
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M!D<PW((#\^TV@-EI ?9[3("\SQ!HTGK@>D '/&0TP?>@.@0?5H4H665(EE-
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M:;P>7&UV --1&N@N<N#,50%2L"8XQ.H"/L,0[ I- %-I!C8-%F#=9@E6)ZS
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MF,*JYN>XE?N6>!7[U/H4>+?[YGGW^N5XW_#+]GGEE^GSQC>=]Y:7QGOGD[H
M8*"S?=&^&8EVWW1I,2B0D_Q>KKIDJEIS^42=WNJ16I.M-\OM9 8*2$?ZLEP,
M3J2Z6[4G^.(;HX/)M1&1M I!(JLD.-.](+#0*\>_RB?3K\4OS:^'G^)WS3^9
M_X*?Q)_T2_1_XYO@_Y:'\ID/L-#9?+3OQ6Q'NPYZCQ8?%O]<I;SH3?V1)6--
MVLOO-1AMN5:%.7"NQ%&U)X]FT)')L6Q,\<;5) 20RF/":461<:S<L#3WS-!\
M;FIP!2\IJ-$O/O"$?VS@0$!,T*A_3- D/SKHC5]TT%O>0H"-[D,@VGGCM@I#
M#GJ?EAT4^U0K+_ZJ24GR2=N1I;>:##</U-GL[ZUP4.DJHNHWY[I:U&9ZX<I3
M^*3"Q%!:3EP,*STZQ3TY,H<;'U[*BPYKX$<(NOS#!!<#!&&/49/\,,&D7YC@
MC6^8X"UO/N"&S@Y&.V?"%K1[[Q;Y57E ],/10Z+C[7)B_QQ37C+4JK_I_%$K
MZ>X:>^7V,B>]AB*F>46N![8HTY>8DQ9,34^.9"8E)+K%QF5Y1<84\P31M?S@
MJ,Z P*AS 0%1#U"O^8%1DWY!D6]\@R+>\N8#'NCLT W"D+Q9" IW"G^OV2?R
MMD5:9/3X 9$[)Q077^G0V]C;8KFOJP&GU%1-UJDN8Y@5%[G9Y>;Y.*9G!SHG
M9H0S8]+BW<*3T[U"D@IY 0G5?G[Q;?Z\^+X [X0[ 3X)DWQ>W*2?;^P;7[_8
MM[SY@!>Z#^'KA2!MHQ"4;!?ZW+!+^%6'E-#(Z9U"-WH4%ETXKK.AI\-\3ULS
M5J&NGJ1=5DTWS2OG8-)+N Z)A?Y.T7D"1EA.+"<H,]63GY'GXY-6Z>N5VL)W
M3SWC[Y9V$S7)]TAYX^>5]);GE3@_\$'7(&J=$&2B.<HW"TTW;Q%Z<7(]<K=O
MF]#5,W*2?3U:Z[J.F^YN[+"5KVQVU"P\2C7.K'6U2:KRM(\N]R.'E8;0 XNB
M7'T+DMVY^3E<]]QRGFMNDQ\SI\>/D3N$>N7+RG[+8V>\]6&GSP_\T.X?MT8(
M<M<BOVO6(6\[5B./SBY%;IS?(G3AW&&)GCZ--6VG3';6GL <+NXDJ&>W.1LF
M-S.M8HZZXP1U/&) 31"55Q7!\*Q(X'#*LSR89:5<6NE1'^?2DSRGTFNH"1_G
MXG<^M/QWWO2\]_."0+3[)ZT2@J)5R.S1Y<@_)Q8CM\XO1BX/;$1Z+\F(';N@
MMJJAWVA[^1GK@[D]]JHI)RAZL<=<S 7M;K8!K=X$G^8 LD=3&,WU:#S3I2&#
M[5Q?[$ZNJ_=TK#OAY5!_!?7"TZ%VRI-4@2J?'PC0[I^^$OE:O@QYV+H(N=&S
M"+ER21(Y.[@6.3$H+=I\575%U8#^EH(+EOO3^G%*<7TDK;#3=.. 'K:E3[>7
MG?L)/H%U7$"F'8NE4CK371P[BUCV'76NN(XN-K;S,NHYVZ[]$P?7-,W!-\X/
MHI<CD+L4>5PGCMSLE$ &SD@@?5<DD!/#*Y&6X=TB-;>4EA;=T-V8,6BV)_ZJ
MG6S894>U@$M47>\+KB9NYSTMF>?\;*G]H7CRV5A'A[XT,KZOT,FNMY:*Z>VB
M6?<-T*SA!8"YH2'5%HLQ,;<R1D06]8U1K7JGZ=;=7URL3\X/DI8@STM%D.$F
M,63@A!ARIE\4.38DB30_7(;4/)(2+GXHMRCS@=;:A'LF.\+O8 X$#!,4O6\Y
MJW-N,'49USV,G*_[F9.&0JP(@S$8[& :%C-8B+<>K"-8#G8Y6 P-.)@/C1',
MKTT[FE[Y230;^$6:S[<L4>1>M3!RI5T4.7U*!.FX)(8T#"]"*IZO1 J?[Q3)
M&)-?%#^FN3ILU&B+_S/K/=RG]@?93RB*+H^91YP>>V@21WQU[4="#+$C,<8V
M(VEF5B.%%N8C=99FC[NL3)]<LC)Y\LS*9&3*RNCA#XSAPU_S>ER,((.-PLB9
M+F&DHT\$J;LFAI0\6(3D3JX52GVS5S1V4FE)Z*366K])HRT>DY:[F*^Q^YU?
M$P\37],4[5]S5+"OO=4PKP,UK5Y':IN_3M(UG<S5-YJL,#!XTV*H_^:TD=[;
M&Z@)([W)+T9ZK[\;SN=&#8+TM0DA'3U"2.TE8:1H6 S)>+X82?JT62CJTWZQ
MH!G%I3XSFFO<9@PWN<Q8[*#,VNXFS#I(8V>=#V)F68>M/GO*FW_V4S3Y'*IL
M^#E65?]+^A&=+T7JVE]K-32_=FAJ?.O74O]^2TOMVR3J_;SZFQ"DLPM!:OL1
MI'!0"$E]*(K$_ER."'YM$>;_VB?F^5M^,>NWVDKG.;UUCG],-^'^6&_# %[*
M$DB[S("^UQC8^PS :[\>^,MH0]A!#8@_K 99LJI0(J<,]?)*<$Q!$<XJ*L P
MZL&\CK4C2-UI=/YE!$FY@R 1H\)(,*P2\H9-PFS8)4J#0Q(D4%Z*!ZT5&#!<
M8P'FZTP!L\$0[#?I 7F+#M"W:H+K=G7PVJ$*?"EE"-NI /&[Y2!KSV$HV7L(
MZO8=A/9],G!&^@"<G5?]273^!73^300)?XP@_C\D$ ]8(>0"ZX7)L%T$#_O$
M;$!6W!Q4)(U!:XD^&"[3 ;/EFF"S4@UPJU3 <;42.*]1 .9:M"JN.P2^ZV4@
M9(,TQ&S<"^F;]D#AYMU0N7D7-&W9":WS*CZ+SA]$Y_^#(#[C",(&4<09EB$$
M6"V$0=?"'*1$#$%:5!=DQ31 6?P(:$@H@:Z$/!A)RH+YHD-@L^@ X!9+@^/B
MO>"\9#<PE^P$SZ4[@+]L&X0MWP()RS=!QHJ-4(0J63D?L)(1 3,E,< HBP/^
MB"20])<#Q6(]D/#;P(&V!_ >,F ;) ?6L4I@D:$*ID7J8%*E"<:-6F#4H0.&
MW;I@< YU30_T[^N#_@3J@P'H?T7-&0#Z\P\CT/]L @8?3><'U@=$P$+QWY,1
M<7!0E02*[G)P-E\/3KAM0'+> PYN,H#SEP/;*&6P3CL"%@4:8%:A!:8-VF#2
MI@O&)_3 J$\?C"X;@.%MU M#,'R/^H+Z;?C;"/V=*1A^- .C=^;S^R^#E;PH
MX!7$@*@L^=\)$=UT/="PV\")L@=([(- \),'7(0R8)+5P#I7$RS+M,&B5A?,
M6O3 K$L?3,\8@,E%0S"Y:03&HZBWQG/&L\:_T!_?3,!HVAS]$PLP>6D)IO,!
M&S0#1E;TOU,))T4)8&@N!Y;)>F#9;@,Z<0\X,0\"R4<>" (5P"6H@VV6%M@4
MZX)UM1Y8-AJ 18<A6'0;@?DY8S ;-)DS>VSRT^RUZ7>S&=,O9C]-/IF#Z5M+
M,!NW O-GUF Q'\#L%P'L(='_3B7H<A+ _O>$R&@=N-ML!;;#'G"A'P1G+P4@
M!ZF"0XP&X-.T 9NO![;E!G\P=4:_;5J-?UD?-_UIU6OVP^J*V5?+>^:SEB_-
MIRVGS:>L?IB]L0*+YS9@.8(!J[NV8#T?L$4SV,N(@M,!,6 =E@!/M67@;; 6
MO"VW@J?];N XRP##30&H?-4Y2H3F+V*2[@]"ML$W?+'1%URUR6=LH]F,7:?Y
M)]M3%A\Q%RT_8&Y9OL.\L'R-^6 Y@?EN/8KY8W/?#C WL6![#3<_L),6 4=I
M4:"CW ^) T]U*?#UU@#??#/X8G<!EWQ@CL.4_\'R4?U*#]6<=8[3FR:G&WX@
MYIN\=R@W>VM?;S&);[5ZC3MA_1+7;S..NV[S'#=J\Q0WA7F(_69W&S>''<3_
MP5TB *[?87Z 13/\>S+"VB,*7!EQ"%!> B':JR#$9",$8:1^\1WW?_6FRWWR
M\%2=8@=HO6%$ZKVB)1M/.&6;/2<76XP2JZV?.C9A1AR.V3XD]-K=M[^*O6/_
M&'>3\ XW1/AJ?YDP1^AWG".<)LXYG"3-#W#[1("Z2^2_OXWWVR\&H8J+(4)S
M)40:K?\5;K7]<RA^[X< I\-O>!SE"2]?S3$W@?X35IS)0Y=TBWO4?.O;3F6V
M-REUV.ND5OPUXDG"%>(%A\O$88<+Q%>._<19XAG2+^()\B]2A],O4JO3+^)\
M@("V+1>TA7JA M'V%R$O";'JR^;B]==^B3/?\B':;M?K,)+,\R"FXA,_KL8]
M;J#^L'NDZ777)*NKS"S; 9="W$5:I?TYYZ..9YTZB6><>LFG*-<HW90QRG&G
MCY0.YQ].S=0?3D=I/RAU]/F!([H&K.TBP$.;:"B:)U96 I)4EWQ/T5GU,<5D
MPV2BS?;GL0[['H73%6X'N6L,^?D97/86F%WPC+4^ZY9J=\8UQ[Z'6>)X@E%#
MZJ*W4#IHW<YMM$O4%MI#:B/]';6!_HU:S?A&K6!^HY8QOSO/!\A2PL!!&R!_
M&]I^=HM XD&QN33E1;.9FLO?9AJN?9%AL7DD&;]W.,9)_EHX6^-BD+?!67Z0
MV2E>I,T);B+VF$<&H=VM@-3"KJ TLHY2ZYG'Z+7,?I=JYK!+)?.U2SGKBTNQ
MZQ=Z(?LK+9\S/W#:(0SN:!,/1'-$[Q2&E .B/[(4)#[FJ2UYE:^[\FFNZ88[
MZ79[!A/)<A=BF.J]X9[ZW<%\LV/^ ILVWUA<DW>*0[U7#KG&H\2YTKV65L9I
M8Y1P3C.+.$.L LXX,\]MEIGC_IF1Y?'%)=/C"WT^0$5?OQ?:@D/0)AJ'YDF7
M%OF2)ROVKDA%\GFIYM('A8;KK^=@=EU*<Y3M2Z"KG8QVT^\(YYDUAP3;- 1&
MXFKXB8X5O$QRB7<AM9!;Y9+GU<S,]NQVS?2\[)KA.>J:[O6)E<J=9:9P/S.2
MN9]=YH-^!!$&[_7"($!;<.)V(?2CA_!,T4'1U^4*8D\K51?=+M5?=Z7 >F=_
M%N%P=RKU2&<"6Z\YFFM6%QY@4QD:ABL-BG,L#$BCY/+SJ%F^Y2[IO*.L%)_C
M["2?BYP$G\?L>-X'UWC?&5:<[RPSUO<S8S[ 0/>!AS;0"+0%)V\5^IV[4_A#
MJ;3P>/4AD8>UBI+7*_367BRVE#J=9W^H*]/I2$L*2[<NP=.T,L;/NB0R%)<?
M%NV0'9),20_*IB4'E# 2_.M<8_F=[&C^.4XD_SXGTO\].R)@QC7"?Y:%8LX'
M6&@3YZ\5@J@-:!O?+/2C8+O0N\K=0J/U^X3O-,A+7*W16=-?;K[C9!'N8%LN
M6;4A@Z%;F>)N4I+ L\Z+#<)F1D4XI$8D4!+#,FFQH46,R) :U_#@=DYH<)];
M2/!MM^"0MYR0D!G7D. 95DCP+',^P$:;> ":(19MXID;A+Z4;!9Z7;M-Z''S
M#J&;37+BE^JU5Y^N,MM^K,Q.IJF0J%R=2]<IS>08YZ=Z6V4F!6!3XL,<XF/C
MR-'1:=3PR )&2$25:V!X"\<_[(R;7_A-U"2''_[)E1\VP_(7S#+G V[H[""T
MB2>L12!G'?*I?!TR?G0]<K]MB]!@ZV'Q<XV:JT[6F6QKK;(]4%?JJ%1>2-4J
MR'4URLSRLDQ)Y]O%IX82HI)BR(*$%&I0?*X+/[:"Q8MI8GO']+AYQ0RA7G&X
M,3.NWM$S+)^H6>9\P -=@U"TC2>O1B!_-3)5O1)YUKH<&>[<A QT'!0[TZJ^
MXEBCT9;&.AOIRBJ"8E&9LV9V,=,PI<##(C[7US8R.]@^-".2%)B6Y.R;FDWG
M)I<R/9*.LMV23G+825=1XVQ.THRK6\(LRSU^ECD?X*+SPU<BD+82^5:\''G<
ML!BYV[$$&3R^'CEW_(#HR<XCRUO;##?7-EGM+:FWE\^IH:BG5C+TX\O<S"*+
M?6Q""P-Q ?GACKS<>(IG=B:-DU7,8&76LQB9QUWIF9=1SU$S+$;Z+).9^IDQ
M'^"M%(+H%0AD+4.>52Q"[C8M0JYW+4(N]:Q!3O?L$^D\J;*TH4M_8WF[Q>[\
M%IQL>B/I2$(]73>REFT24L6U\J_PM_,I$]A[E,:27(O3G1A%A31J8:V+4^$Q
M)KGP(NH9@UPXS:#D?7%QSID?^"]'('X9\BY?$KE?(X%<;Y5$!DY*('V]JY#C
M?;N%F\\H+JXZI;NN\*295&:7W<'$#D?ER#:J5DBSJR&_T=/,^ZB?C7M]")95
M%TV@UZ22G*KS*:3J:JI#50>-4'6>9E_]A&9?]9%&J/A&=2B='X0L1>92%B$C
M):+(S09QY%*'.-)[2A0Y<7XYTG)!2JCVO+QD<;_6FJP^DVU)IS'243T$^9"3
M3FI^QYFZW&/N1IQ.GCFS(]B:VA9E1VY-QCNVYCG@6ZJ(V)9VLFW+.=0("=/\
M@8QI^DFVJY\?1"Y"GF<+(;<K19'+S6)([W%1I OMW\U7EB"UU[8*E5X]))YS
M17U%\H#1IJB+UKM#SN,/^?63E;S.NJBS>]UT7,[X&#J?#C0EG8JT))Q*LL'U
MY-K:]E1BK7O:\%8]_7C+4P_QEMU3>(N3/^PMNOX0YO,S01AY4(@@U^I$D+YV
M$:0+[=^-%T21JAN22/'P>B1[>+]H\BW5I5$W]=<%7[?8[CN$W><Y2#KL>HVN
M2+_*.4*YXJWE>#E U_YRA*'=0)*QS4"NF>5 I87Y0)NEV4"_I>GEAY:F U.6
M)A=_6!M? )OYC&8BR/4*!.EO$D*ZNM#Y?<)(Q14Q)/_.(B1]9#62^'B/<.2(
MHF30(YV5O(=F&]W_L=W!?."XEWJ?*D.^QY9SN,=5PMT-4+6]&Z%N=3=1T^)N
MKH[IW4I=XWMM>D;W^O4-[S_4,[K[7L_@SE<#_=M_C.9S&UV#BW4(<J(-01K_
M_5; 16$D]X8XDOQH,1([OE$H;&*?B/^$HB1W7&L%>]QX'7W<>@MEW%[*8=QI
M#WZ<*6W[PD/&^H7?88MQ@;S9>+RB\7BFLN%XJ8K^1*.JWD3/$=V70ZB)([KC
MLZK:+WZIS>=R%8)T-R-(TW%T/MI_<ZX)(XGWQ)&(#\N1X*DM0KPI:1'W#XJ2
MS ^:RYP_&*YQ_&"Y ?<!N]GV(W&[U4>:E/E']F[3C]Y[C:8#I?6G(P_H3B?+
M:'_*.Z3YJ>JP^DR;K-K,6;DCL\.HUW*JGV;G=:H!09H[$*3B#()D7T:0^&$A
M)/2I&,+_M@KQ^K95R/7[/A'J=SEQT@^UQ?@?>LMM?YJNLOIIL];LE_UZXU_D
MC0:_7#;K_>9LU?[MLTUC+FB'VERTE.I<VB[E/X6[%?_4[E& SKWRT+]/#F[M
MDX7Q>;6VHO.[T?D7T/DW$"1X!$%\9B01#JQ"Z+!9B 2[1?!P4!0#2N(6H"F)
MUN<EAF"^3 \PR[7!?J4&D%>I 7V-"G#6*H'W.GD(6B\+T1L.0=HF&2C:? !J
M-^^']BW2<'KK/K@RKRIT#W+ZT?F#"!+T $$\7R (X[<$0H$5B#VL%\+ =F%S
MV"=B!+*B>J LI@6:XNJ@+Z$*)I)*8"6I ':+9,%A\2%P6BP#S"7[P7/I7O!?
MMALBEN^$Y!52D+=R.U2BCJ[:!IWSRNM%YU]!7_]=!/$80Q#G*00A@ B"@:6(
M.:P6,H1-0CH@):P.TB(J<%A$$91$94%-]"!HB^T' [%]8"JV!ZS$=X&=N!0X
MB&\#9XDMP)+8!%S)#1 DN0YB)-= VJ(UD+]H-93/"PP.BX"!HBB8H:Q4Q<%&
M2Q)L39>#+78=V% W@Z7'#C +W /&,=)@D"X#^@6'0+=2%G0;Y$"G31ZT3RB
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MYU)&ES_*&%Y"V>5VDAW,D1V,SP/TD#O0L(_D'P/(/$N#N-^8(>PN%]#OBD+
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M1:7+#GN4+CJ<4+[@<%WE%\>G*B<=WJL==R"_EQQ0\S!QB#BX##J0ON]!>G\
M$4IF$2E/Q6AUVI=H0\8WD=8L?X>Y<3ZD!_'=#8H1O.6?+GK-IT#RBE>ES"7/
M)KD+[IV*Y]P&E'YQ6Z5RVG5&]:3+@MIQEQWJQUP.:1QQN:!YT/4OS;TN;[1W
MNZ#.$K'#%76W_P=T(7W?A_1>.NG^4606\=*4;XG*U#>).K2G"69,]V.=V&]%
M^?%<#0\7_#4D2>QL4+;4Z8 2N1-^-8I'?5I4#GMWJQWT&M+8[SFAN==SK?9N
MC\TZ.SWVZ.[P.*6WS>..WA:/E_H;/;\:+'BBP3PQ]Q_0G71_?](Y(U8"Q@L!
MIHA3/J3)49ZEJU'OIQDPW$BQ9;F4X,GS2RQ=\$1DK/B1L#29@R'Y"GN#RY5W
M!]:I+06T:6[W[]7>ZC>JN\5W6F^3SX+!@L\.PWF?HT;K??XPFO5Y9KS&]Y/Q
ME"\:3Q(3?FBT''JNI& PZ;LQI/LGD^?($(97V9+P(%>!<B-7FWHQRY+E=)HK
M]]&D ,$#\9'BNV.29'9$9BEN#2]2W1Q:J;$AI%%[/KA#=WW0@/YLX+CAFL"U
MQE,!BR83 0=,QP-^-1L+>&0V$OC!;#@0S8:"T'3P'R8_0A\R@U#2][[W_S1>
M^)2S$IX4",'M(DFX5*1./9UOQGPDVXEK7X:OP%)*J/AB8IS,QK@TQ?F8/-5U
M4:6:,Q&U.E/A+?H383V&JT)'C$=#IDV'Z!O-!^B[+?KI9RQ[Z?<MNT/>6G2%
MH$5G*)H39AW+H#\O8 3I>TGD.;*XX&T!#SPHX86K94)PMDR%>K3$F&E?@3W7
MCEPO_LV9P6(+:=$R:Y.3%-<D9JE-Q!=JKHJMU!V);C 8C.HPZH\<-.V)F##O
M"I^S[ A?LFH+/V'=$G['NCGBM553!%HV1:)%XS_,?X2!I'='<P"F<L"'7 YX
M5,P!-\LYX-<J?CA1I4@Y4&' M%1JP[FET)U_/B] =#8[0F8R(UYQ56JZVDAR
MGM9 8JEN;T*M05=<JW%[;)]9:\PJBZ;HM58-T=MLZJ*/VM1&W[2MB7EI4QWS
MU;HZ%JT(R^4PF)P_EATPG0T>%[# M3(6N%1-NG\M'QRNDZ/LKM%C7*RTXE@H
M=5TY4^0G.I$?*CV:$ZLPF)6BVIN1K=F55J3;GE)ET)+<9-R8V&U6ES!B61T_
M8UT9O\6V//Z@75G\5;O2A.>VI0E?K$L3T>K_6/X(0\@,$ECA?18SW"QFA$N5
MS'"VCG3_!M+]&V4HVQNT&3;66K"OK7)>,5GF(S):3)<:*(A2Z,E+5.W(R=!L
MR2K0;<PH-ZA+KS>I3NLPKT@9LBQ-F;(I2MYD6YB\WRX_^9)]?LHSV_R4SS;Y
M*6B=GTI^\RR#8:1W)S'#TUP:_%'* .=KF.!D(S,<;N:&72U2E"W-F@QSC69L
MTW6.?&-57L*#Y4&2/:41\NU%\2K-!6D:]7FY.M6YI085V;7&I5EMYD69_5;Y
M&1,VN>D;[++3]]IGIE^PS\QX8I>9\<DV*P.M":NLS'_#"!;R,X$![N0#7*J@
MP>EZ1CC:P@3[VCAA6X<$;&A7I\VTFK".-]GS#M5["/74!$BT5X;)-97'*M>5
MIJA7%6?KE!46Z1<75!L7Y+>8Y>3U66;ECMNDY\S;I>;LMD_).4L\LDO)^6";
MDH,VJ3EH35C]"*,8X5,Z!6X4 9ROIL+Q)@8XT,X .[LX8'.W**SK5J5-=AJQ
MC+39<O<VNPFV-_J)-]6%R-;61"M55B6IEU9D:A>6%^CGE588994TFJ47=UNF
M%(U9)Q:NMXTO7+*+*SQC'U?X%WE]3_X;;0AKPNI'&$N#O[-([R7]_W0=%0ZW
MTF!W%PT6>UEAOE\(UO0K4<=Z#9C[NZVY.CM<^)O;?,1J6^@R%4V1BB4-"6H%
M=>E:.35Y>AG598:I5?6F216=%O'E(]8QY6MMH\JVVT66G;2+*+MO&UGVSB:R
M#*VCRM!J.4P N)L+\&L%Z9V-%-C7087M?138,,@$,\/\,#ZL0!T<TF7J&K#D
M:.ES6EG7XR52T14D5=P1(9_?%J>2W9*JD=Z<HY/<6&(0WU!K'%/?;A99-V09
M5CMC'5*[U89>>]R67GO7AE[SQCJD!JW^C^6/,!G@9B' +Z3['FH%V$FZWR;2
M/V?'J+!ZG ^&QF4I/:NT&5O'S-CK1ASX*H8\A(H' B3R^L-D,WMCE%*[D]42
MN[*TXCJ+]*+:JPW#VUI-Z*T#YD&MTY8!+5NL_%J.$G>L_)I?6_HW?[/T;T*+
MY9YG /Q&]G"B 6 OZ=];2?YZTO]6D_XU-,T#/6ND**W3&K2Z*6/6BDE;[J+5
M;@*YX[ZB&6-TJ>31*/GXX43EF*$,]8C! JV0@4J]H/YF0_^^/F.?ODE3K]Y-
MYIZ]AXE;9IX]K\P\N[\2:.;9]6_WR![.5?TS@Z5^@ 62/T4Z^"#I7YWK.:%E
M3A3JYE2HY>L-F K767-DKW7F2YOU%DJ:"1*+G8Z0CIR*EP^;3%,.GLA3"Y@H
MU_1=W:CC.=ZC[SZ^VM!UU48CEU4'C9Q7W3!R'GMAY#SZQ<AY!(V7NU;\SPSV
M= -L'@:864WZ/^G@7:0#-VQF@:HM E"ZJ$#)WZ++D+7%G#5ELR-7_";/%=$;
M X3"-X2)T1=BI0+G4V3]YG,4O.9*E=W7UZNYK._6=%HWKN6P;D''?MU^';OU
M?^C8K7VN8SO[6==V!G5MUZ#>C\Z3&1QL!]A&=K!N'&#5&M*_27XCZ:"E.ZF0
MOXL7LG=+0_IN#6KB;A.FV%VV;!&[W+A"=OKR!2[1!?R6HH2]=R2)>>S(DG3=
M7BSCM+U6WGY[IZ+MMC%EZVWS*E;;]ZE8;K^B8KGU;Q6+Q4]JYEM0W7SSOQUO
M(O>P#V!^C/3O:=)_YTC_)/D5I /F[*=!\A$.2#@J C%'E2@11_5I(4<M&0./
M.K'Z'?'B\#H2Q.U^)(+/Y7 \O]/A=$'[PX4B-H>KQ:P.MTM8'!Z5-#L\)V5Z
M>(^TR>'+TJ:'_I8V/O!1QF@_RBWW_1YN&@&8)G=P<#U ZV: RIT >?L!DH\Q
M0/@9%@@^QP>!YZ7!_[P&Q?N\,=7CO"V#ZWDW)N?SOBP.YT/8;<_'<%J?3^&V
M.)_':W:A<H7)A=:51A>&!0PNK!/4O[!;4._77P7USS\5T#OW7DCW+(HLMSA$
M[@"Y@\/K -I)?M7W_ ,D_SA ^"\T\+O$ FXW.,'EAA XW50 AYLZ%+M;9E2;
M6_8TRUON#.:W_1E-;X<Q&=^.9S&\G<&J?Z>83?=./8?VG5Y.K3^GN#3^7.32
MN'N<2_WN72[UVZ^XU&Y]YE:[]97G1VN_W\%9@(Y- #5D_OD'2?Y)DG\.P/<R
M!9RO,X'](VZP>20,5H_EP/RQ!I@\,: 8/;6@&#QUH.H^<Z=I/_.G:?X=QJ#^
M=QRCZM^9C,K/2YB4GC<Q*[P88)9_,<LB]W*)1?;E&1:95_=99%Z\9I%Y_O9?
M5GW_#&P$J"7Y!?^7'W8>P/MW (<; ):/&<'L'1<8OQ,$@_=2H/M>";0_:('&
M1P.*ZD=SBO(G.XKB)Q>J_&<?JNQG.E7J2PQ-XDLZ3>QK"4WT6Q.#\+=!!B%<
MRR"(.Q@$\ 1QF[CW+ST; .IV !0>^+_\7P&\K@+8W0(PN0>@_YX&.L@!&L@'
MJB@"2B@-"J@(LJ@.4J@+$FA,$4-+BC#:4P31G<*/_I05&$'AQ60J#Q92N;"!
MZ*=RXC25 S<1^XA#_]*P':"(W+^4[_._2/*O =C>!C"Z#Z#Y D@N@"*R@!QR
M@32N()G"((H2((2RP(]*L((\"R_J  \: 1=: @<Z4-C0D\*,P10&C*-0,)L"
M6$5T$"/$++'N7U!-DX)::A344:.BKA85M0UHJ&5-0TUW!E2G,Z%J/#,JY["@
M4CD;*C:RHV(7!RH.<:+".+&&"Q7FB,W<J+!$'"!.$K\3#X@7W-\4/G)_5D3N
MC]\I(.^'?_#]"#5(OJXR!?55J&B@3NA14=^2AKJN#*@3R(1:L<RHD<F*:B5L
MJ%;'@:KMG*C:SX4J8]RH,D6LXT&5C3RHO)W8RXO*QXF+O-^4[_)^5GG.^T'E
M \\[5>1YHX)\Q(K7*KCRM?*_H3;)-U"@H#%AHOS]^R#"G(;&3HQHZ,>$^I',
MJ)O*BCH%'*A5S8E:+5RHV<.-FL,\J+&:%S5FB'ERED6^;QJ[^+YJ'.'[K'%N
MQ0>-.WQO-9[QO=1\S_=<$U?\K8'\SS10X*D&"BZ'>M_S2?\W)RP4J&C]_=^F
M&-/0TIX!S;V8T#24!8T3V= PAQ,-RKE0OX'GJUX'[Q>]?KY/NF,K/NI.K?B@
MNV[E>]U-*]_I[ECY1O? RM>Z9U:^T+VY\IGNDY6/]-[Q_Z6+@@]T4>B>#@K?
MTT61NSK_AD;?\TG_MY:DH/WW[R+(O7 D=\+!B@'MW)C0.H@%+6/9/UMD<'TT
M*^)Y9UK#^\:D9<5KXYZ5+XV'5KXP6LW_M]&,P#.C!8&G1EL%'AOM%7AD=%+@
M+Z-K G>-'PO<-GHK=,,(1:X9HMA50Q3_G?C-$"5^A*;?\\5(/NG?KN2]NQ(%
M/<@^W,T8T,61Z9.3+\L[APCV5W;)7,]M<GF?6I>O>&S5L/*A93O_ XM^@?L6
MHX)WS:>$_C1?+W3;?(O0+?/=PC?,CPE?,[\B\IOY(Y%?S=^*GS7_)GG&#*5.
MFZ'TR?^ EM_S2?=V);S$*>@K1T$_<C=]#6GOO6T87WJXLSQUH[,_=(GCON^4
MP?NG8]'*6_;5 C?LF@7_L.T2OF(S)'+99ESTHO6,V 7K#>+GK'=(G+4^*''&
M^KSD29O[DD=M7DL?LOXF>\ :Y?81>ZU1?CFT$:*@\PI +]*Y X0!@\DLZ$J4
M]W0=ZO,@<X:'_L[,=WW]V6YZ1W)=]4CFN^26*W#>M53HK'.MZ!FG5K%3CCT2
M)QR')8\Y3$@?<5@G<\A^L^Q!^SVR^^U/RNUUN"6_T^&YPG:'SXI;'5!ID=A"
M;%X&'?@!W4GO]2?=/T0 ,%P4/D;*4IY'JE$>A!O0;H7:,5X)]F*[$!C"?<8O
M;N4)GW2AHUX%HH<]*\0/>-1+[G-OE][CUB>[RW54;LEE6F&[R[SB5I?M2HO.
MAY4W._^FO,'EL<J<RP?5=2ZHNM8556?_ SJ3;"_2.;]_!Q%!WL<(P*LX<?@K
M3AYNQFI3+D5;,OX2Z<IV/"R ^Q ]DG]?4)+P[H LL26_(LGMOE4RBSZ-<IN]
M.A4V>@TH+7B.*\]YK%5=Y[%%;=9CG_J,QUF-*8\'&A.>;S7&/5%C%3'VG=>_
MH1O)]B/=/XP\1PPW?$S@A2=)_' K60PN)JM13B>:,AR-<V3='^W#O2LRE'][
M6)SPEI T\8W!>=+S0:6RZP-J%&;]6Y36^/6H3/F.J$WX3FF,^RQHCOGLU!KQ
M.:D]Y/.G]H#O*^U^7]3N\T/M7C_46@X]2780Z=V1[/ YG@->I'#"O30N^"U=
M ,YD*%&.I!DR[$VQ8]V1Z,F])2Z(?T-TE,CZR"2)V?!,Z>FP0OF)D K%<7J#
MRFAPN]IPT(#&8.!JK;Z ]3H] =MTNP*.ZG4&W-!K#WRAUQ;X5;<U"+_3(;1_
MA-ZD=X>PDAFPP)-D9KB1S@)7LMC@7/8*.)8C3]F7K4?;D6G-LCG-C6L^V7_E
M;$*X\%1<G,3JF#29T:A<^>'($J6!\!K5WK 6]>[0'JV.D%&=-OJ,7@M]BWX3
M_:!! _TW@_J09P9U(9_UZT)1KS84=9=#7]*[PYC@;3P#W$JCP>5L)CB?QPHG
M\WGA0($,+.5KTS;G6C#/93ESS:3[K)Q(#1$>2XH6'TI(ENF/SY+OB2U4ZHRI
M4&V+:M!HCNS4:HP8TJV+F-*O"=]H4!6^SZ@R_()11<1CP_*(3P;ED:A/Z"V'
M_J1W1S+ PR2 /S)I))\13A62[E_,#;M+)&&Q6),Z7VC&/)/GP#F1X[5B-#-(
M:" ]4KPG)4&Z,SE=OBTQ3ZDYH52U(;Y6HS:V3;LJIE^O(F;"H#1ZP; X>K=Q
M4?19X\*8AT:%,1\,"V/1@-!?#@,9 :,I<">5=/\<*IPN9("C)8RPKXP3MI>+
MP\9R->K:4F.FB2([CM$"#[Z!W "A[NPPL?;,6*GF]!2YAM1LI=J48M6JY&J-
M\J1F[9+$7KW"A'&#_/CU1KGQ.XUSXD^;9,<_,,Y.>&^4G8"&V8EH0.C_"(.I
M\"X.R#T@?2N? L=+:'"@@G3_2M+]JT5@?;4*=:K2D'&LS(9]H,25M[O03[ M
M/T2T*3=:JBX[2:XJ*U.Q/*- M22]0J,PK5$[/[5;+R=EU" S>:U1>O(.D[3D
MDR:IR?=,TE+>&J6EH"%AL!R& #PAW?LJZ?]GB@ .EU-A=S4-MM:RPD*=$,S4
M*5'&:_49AZJMV'HJG'G:RGP$FDJ"16N+(B4K"Q)D2_/2%8MR\U3R<\HT<K+K
MM3.S.O72,D<,4C)FC9(RMIDD9APW2<CXDWACE)B!AH3!<A@.<(]T[XND=YX@
MW7<_^6/7CCH*;&Q@AK5-_##1)$\9:=1EZ*VW8&VO=>1NJO+BKZT(%*DH#Y<H
M*8V3*2Q.5<@MRE')*BQ13R^HU4K);]=-S!LRB,]=8Q2;LV@<G7/$)#KG-O':
M*"8'#0F#Y3 *X'8:V4,!P)$*@-UU (ND>ZUOH<%4ZPH8;9.E]+=JT3I;S%B:
MF^RY:AL\5E34^0N5U(2*%U3'2.=4)LMG5&0IIY85J2655FO&E[3HQ!0/Z$<6
M31F&%VTV"BLZ9!Q:=,,XK.BE45CA-\/P0C0@]'_T-A;@>B; *=)]#]0 ;"?Y
M&]I([^H &.OB@8%N*>CJTJ U=QHSU[;;<E2TN?$5M_@*YC711;,:HZ32ZQ-E
MD^LR%!-J"U1C:BHT(JN;M,.J>G5#*B<,@BLV&@96'# *K/B#O+XP#"K_:A!4
MCOK+/4HDGP>RAV/E9 :D?V\A^6M)_UO52[IG/Q=T#8A!RX JM:[?D+&BUYJM
MJ,>9)[?;FS^S,T@XM2-"/+$]7CJN-4T^JB57*;RY3"VDJ4$SJ+%;V[]A7->W
M84'?IV&?OG?#;_K>]7_K^]1]UO.IP^]T?W27?";/DKMX\/L,6DCW)?F3I ,/
MD [8,<(.S6-"4#NF2"D?U6,H&K%@R1EVY,P8\N1+'@P0C!\($XWIBY&(Z$V6
M">W)E@_N+E'R[ZI3]>GJU/#J'-/RZ)S3=NO<H^/6>5''K>.9CEO[)QVW-M1V
M:_VWZ^3S<.+[#!H!-I/\F7[2_88!.L<!&B:9H&IJ)91.RU(*IK5HV5.F3&F3
M=NR)$V[<L:O]5D2.TP7#5D6)!H\E2@2,94K[CA;)>8W4*+H/MRN[#(^H.0VO
M4W<<VJ7N,'Q>W6'PB;K#P$<-AW[\R05R%P_6DAFTDWM(SK^:=/ ^DM\\#5!&
M>G#!' _DS$E QKP:)7G.D"%NSIHY:KTS>]@Z;V[ZNJ 5@6LC!'QGXX6]9M/%
MW&?R)5W65$D[K6F5LU\SI& [O5;19GI)R7KZK*+UU&-%J\D/2E83J&RU^M].
MDAGL(CO82/8_1<X_2#IPVQJ ZO6D?Y,>G+K( 4E;A2!NJR(E:JLN-7RK.0-]
MJP-SP*('F^^B/Z?78BB/^Y:8%2Y;4@0<-^<*V6\N%['9U"QNM6E PF+3C)39
MIAW$&2FSC0^E3#>\ES990!F3>93]T8%Z\EGL!I@E^Q\EY^\D';AVGO2_S0!I
MI(=&[6&$L+U\0-\G!4'[U"E^^XRHWOML&#SVN3"Y[?-A<=X7S.:P+Y+#;E\B
ME_7>+%[+O:4KS/8V\IOL[1,PVCLM:+AWFY#!WE-"AGO^$M3?_4Y8?Q>*Z.U$
MT1\MD<_@^D& <9+?0_(;2'[)(D#&3H"8?0!!1QC ZP0'N)\0!+>3\N!R2AL<
M3YE2[$_946U/N=&L3_DQ6)P*93([%<ML<CJ=U>AT(9O!Z3H.O=/=G#JG)[FT
M3V_AUCISG%OK]'TNS9-ON35.?.75.(Y\/]HP #"QBMP!,O^F!8#2K0"9NP%B
M#P($'P/P.$T#^_,L8'&9"\POBX#9;PI@^KLV&%\Q!:.K]A2#J^X4_:L!5-T_
MPJG:?R32M*[E,&A<JV!4N];&J')]C$GY^@*3THV#Q$TFQ6O/F16N?F11N/*-
M]4?38^0.D/P6DE].\K/V ,0=)OFDA[O_0CKX10J87&4"_7N<H'M/ +3O28'6
M?170>* +Z@_,0/4O.U#YRXVB]-"/HO@PC"+_*($J^RB'*O.XBBKUN(LF^62"
M)OYD"TWLZ7'B#DWT\4N:Z*./_S),[G\;F7_%-H#LO23_*,D_#>!V'L#Z,H#1
M=0#-.U10?\D)JB]7@-(K,5!X)0=RKU5!YHT.2+\Q!LFWUB#^UAE$WWF#\'LZ
M1?!]'(7_0S9EY<<JRHJ/W12^3Y-4WD^+5)[/QX@;Q*-_Z9@#J"+GSR'Y\63V
MP>3LKA<!K*X"Z-\$4+L+H/ 20.X;&T@C#TBB (BA& BC# BB$O"C!JQ ?>!#
M,^!!6^!"-^#$ &#':&#%#&#!"@HS=E(8<36% 3<0>R@T//XO-20_C^0GD'SZ
M.9)/SFY)SJY[!T#Y/H#T4P")KP BR$@R.4@F#\E;2?*$29X$R9,E>4HD2P-(
M20<:F@.@ ^%-A!$I1 E!?@ @^? A63S._PLJJE%0186"JH2*!@45]*@H;TE%
M65<:2@?14"J6 24R&5"\A*AC1/%VHI\894+Q22846TML8$:QK<1NXC!QEAG%
M;Q%/F+^(OV7^*/Z-Z;T$,K\71Y9WXLBZ'"J3;#5%"FH0ZM_?ZY#G,:>BLC,-
M%?UI*!_%@+)I#"A3R(@RU8PHW<*$TCW$,#-*KR;6$',L*+V96"(.$J=9ODA?
M9_DH_8CEG?0;EM<R7YE?R2#K2QED>RF-["^6034%"FJ1GJM->K\V>:^C25Y-
MJ*CI0$-U'QJJAC.@<A(C*N4QHF(%$RHV,J-")]'/@@IC+-\4IEB_*JQC_:*P
MD?6SPG;63PK[6#\HG&!]IW"5]97"0];GBJ]9GRE^97NB@.R/%9#S$?%0 ;E^
MA)HD6Y?T7'U)"AJ2]T9D-T:&5#2PH:*>!PUUZ RH%<>(&IE,W]1+F+^HU[)\
M4FME_:#6P_I>;8CMG>IJMC>J,VRO5>?97ZDNLK]4W<W^7/48^]]JE]@?JSU@
M?Z#VBOV>VA?./]60^XX:\MPF;JDA[X]0]WNV* 5-1/[Y+L12B2#[,+>@HBG9
MA[$_PV?#**;W^JG,;_7R65[I5K"^T&E@>Z[3P?Y,IY_]J?8HQV/M28Y'VNLX
M'FIOXGR@O9/SOO9ASKLZ%SAOZ=SGN*[SDON*]A?>R]K(]ZLVKKB@C2O/+_._
M?%-!0$O2N6W%R)4F>W$@=]/.F/K%QH[VSM*+X:5Y*-,SLP3FQZ99K ]-BMGN
M&]>PWS5JX?C3J)OSMN$0YRW#<:X;AC-<UPP7N*\:;.?YW> @SV6#LSP7#._R
M_F+X<L4IP\_\)PQ1X)@A"AXU1*$CR_POWVH%H#WA+ 3H)D4H4SZYZE)>.5E0
MGSJX,/QE%\!TUS::Y99U*MMUJSR.JY;EG)<MZKDOFK?Q7##OY3UG-L+WB]GD
MBC-FZU:>,MV\\H3I;O[CIB<$CII=%SAH]DQPG]E'X=UF*+++#$5W$DO+H,5*
M0#O2O5UX 3W)>V]1^.PC"R^]U2F//(TH?[K;TZZ[>C/^YAS*<L$QGOVL0R;7
M:?M"GA-VE7S';!M6'K%IYS]LTR=PT'I4<+_UM-!>JWGA/5;;1799'1)9LOI5
M=)OU0]$MUN_$-UFCQ 9B@9A?!FU(MB/I_M_[MR]Y'\ /KP/%X&& /-SVUZ;\
M[FM)/>?CQGC**Y#UF$<4YV&W9)X#+ME\>YV+^7<[50OL=&P2VN'8*;S-84!T
MT6%<;+/]K/@F^\T2&^SW2,[;GY%<;W]7:M;AM?0:!Y2><D"92?*Z'-J3;%?2
M>WU)_P[DA(]T'G@2LA)NT<7@$ET5SM!-J<>"G!@/!OBR[O$+Y=SI$\>[S2MM
MY:)GGN FCU+A#>ZU(O-N+6+K7;LEUKH,2\ZX3$E/.\_+3#DOR4XX'Y,;=[DI
M-^;R0F[$Y:O\D"O*?3>X##J1;$_2>P-8X&T(*SP*9X-[X9QP.8(?3D<JPI$(
M ^J^<%O&I1 /UJW!05R; J/XYOV3^-?[90K-^A:*K/&I$)OTKI=8[=4NM<JS
M7V;48UQVV&.M_*#'HL* QR'%/H_?%'L\GBIV>7Y6[/1$Q4XO5.A8!EU8R0P8
MX0.= ?Z,H,$?T4QP*885?HGA@R-QLK G3H>Z/<:*<7.4*^M\N!_7VM POC4A
M<0(3P:E"XT$YHJ,!Q1+#_M52@W[-,GU^W7(]OB,*73YK%#M\-BFW^>Q3:?4Y
MK]+L^TBER?>C<J,?*C?XH=)RZ$9Z=P %'I%?+]=CJ' A@1'.)#+#L40>V)LL
M!=N3-"F;$LT8UL<YLJZ)\>:<B*+SC45$"0R')PD/A&:*]8442'33RZ4[@^ME
MVX+:Y5L"!Q2; B>4ZP,65.L"=JG5!)Q1JPY\H%85^%ZU,@A5_H_RC]"3"E^#
M ?Z,!+A,NN^99!H<2V6$ ZE<L"--'#:EJU'6IQHSK$FV8UF=Z,$Y$A_(.Q ;
MSM\;'2?<%9DJUAZ1(]$27B+=%%8M5Q_:HE ;TJM4%;)*I8*^7JV,OD.]E'Y2
MHYA^5Z,XY*UZ<2BJ%86B*GE5^='W7[&O2/>^23K?.=)]CZ=3X4 F ^S*Y( M
M62(PEZ5,69-I2!M/MV$>3G7EZ$_VX^U.#.5OCX\1:HE+$FV,R92HBRZ4KHZJ
MD*N,;%0HB^A2+HD852T,GU7/#]^FD1=^3#,W_(YF;L1KC=P(5,N-1-7ET!?@
M(>G>5\D,3I/N>SB+ KMSJ+ MAW3_/$&8S5.D3.3JT4:R+9G[,IW9N])]>%I3
M@U<V)4<*U24EB%8GIDM4Q.=)E\65R17'UBD4Q'8HY\4,JV9'KU'/C%[4S(@^
MHID>?5,S/>:51GK,-_7T&%0C5'^$_@#WR1XN)I&^1;KO?M(]=Q108%,!Z?Z%
M_#!9) >CA3K4_GQSIJY<1_;6;$_NQLS %;49X8*5:;$B9:DIXL4I.5(%R<6R
MN4DU"MF);<H9"0-J:0E3&BGQFS63X@]J)<5?TTI*>*&9E/!5/2D!U9(34/5'
MWX( [L20/9#>>22'=+Y"TC=(!Y\K9H#I$CY852H#@Z6:U.YB4\;60GNVA@)W
MKIH\?[Z*G%"!DNQHD<+,)/&\C$RI[/1"V8RT*H6TU!;EY-1^U<24"8WXE(V:
ML<G[M6)2KA#/-6-3OJC'IJ!Z7 JJ_>@-N0LWXLD>,DCWSR<S('_LVDBZUTPY
M!<8K>&"H4A)Z*M6I;17&C(UEMJPU):Z<Y<6^?,6%=('\@BCAG+P$L<S<=,FT
MG'R9Y.P*A<2L)J6XS%[5Z,S5ZI$9"YH1&7LUPS,N$<_(^\_J$1FH%KG,$W(7
MKI ]',\&V$/Z]V(%F4$UZ1S$4 T7]-:*0WNM*J6QQH"AIMJ*I;S2F:.HPILG
MKRQH979IA%!Z29QH2G&J1&)1KDQ<89E\=$&#8F1^MTI8WBJUD+PY#7KN;LW@
MO N:P;E/-8)S/ZG3<U&-4/W1@RB "]_O(IG!SC(R@QHR ]+_1HG>1@YH;Q*&
MIB8E2DV3'JV\P8*YJ-Z1/;?.DSNS-F!%6G688%)5C$A\9;)X3$6V5&1YL6Q8
M6:T"O;1#.:AD5#6@9)V:7\E.==^2L^I^Q8^)CVI^1:CJ7X0J/[H31WXFD/Z_
MG]R!K>3L<PUD!LVD=Y$_!K>UL4)#NP!4=\A1RCJTJ87MIHPY;7:L&:UNG"G-
M?KP)373^V,8HH:B&1-'P^DR)D+I"Z:#::CG_VC8%GYIA9:_J617/ZAVJ'M5G
MB(>J'E4?5#PK\3OE'UW[_C,ACW1OLH--)'^FE<R =-".+H#Z'D:H[.6#DCYI
M*.A3IV3W&3&D]=HP)_6XL,=U>W-%=P7QA7=&\(=TQ L%M:>)^K?G2_BT54I[
MMK;(NK<,RKNVK%%T;MFFY-1R2LFI^2]%YZ;W2LZ-J.C<\&\7R%T\2.[AMEHR
M Y*_NI/,H)=T3])#RX<!"D:X(&=4##+&E"DIH_K4^%%+QN@11Y:(84_VT.$
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M<DQAUSMFLVL=BGFK':KXJQQ&\E?8-PN6V[<)EME/$RZQGR-:9+]8U&V_1KS
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M/Q"<T&[49S:1!5I>3?LRT4J,)-W26O+>I!U'%BUL#'G/%L"S51%N;6IPG6
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M7/ &FO,Y1NL+"\?1OMA*ZY$8T49K83+-PVE .-E"W[GD?Q< @Q<#_98!9BL
M_552Z*Y6@?9J;6BM-H'F&BMHK!D(]37#H+;&"VIK0Z"Z-AXJ:W.@O'8$Y&M;
MB7F0K5T'Q;6'H;CF5RBN?@[9JK\)[A.S)]%ZI%J/:J>U0/8\?1;-PRX:@T6
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M]4_4+_[\.9QT^J<HTO:A?(>2;C_Z,1/2U3H!*)\&%,X!['>D?87X#_$C\;,
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M16&5!\6AE1?%(94OB4,J/A.'5OPJ#BV7B\,4E,G%YZF]KXS>GS9@@@R6*O>
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M$9QZ[PI./?<%IVZYX-2E9#_[N+:!:P+I(RW\NHK:!:WT?1WTOK1'$7WT7H.
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M>Y!+O3+JU+$?K=3HIL8@WF4<;V,QAV89AV@5==:S_:UX%7LX=$?P$L[@%I[
M3?[]''_S66;M&?9L]CH,<F,.N5B-?PM$\:K-7!NPOS;X$A[L8PC[%LOA3F>?
M"JA3P;[44Z.-&CW4&&3KHYRFB_$\IJBSFAH;V?X./,5<7,5)/(G'\#C5+S':
MQ]B;1_$;D?\OY)Q*<CQ C7G687]-V4]'_(NY>)VY>(7SXD5D4:>8K551HX$:
M;=3HX:$ZR)Z.4F>".LMQD7/C L?D/'-Q%D<Y*\[C%'_Z!%LZQO$XQ@P?I9*"
M(W/(>8C+53EUQ<I;O_X+=?97G[I6S*$;^Q7(%J*HE4*=7/:EA+%7L^5&:K0Q
MVSUX!/.ILY ZDSC..7J48W*8N3B(0]C/*/8Q&WN$5[!;] EVJ=S'3A4Y=J@J
MV:ZJV!-3/FKG(\46)Y>:?W#)>4&LQ7$RPA61'2Z)O7!!)11G5>/PB%H:3JCE
MX9AZ*8ZH5^.P>B,.JK?C@$8O]FD,8:_&&'9K+,/.>6NQ8]Y6;-/<CRV:I[!9
MZPELU'H9&[0_QHS.3UBG*\?:.=:0GPR 3\RXK'"IO<EE[AJ7W<<9SR5-'9S3
M,L,I'6<<T_7#8=T('-!-P%Z]#.S6R\=.O3+LT*O!-OTF;-7OP&;]/FS4'\8&
M_0G,Z*_$.H--6&.P%ZL,3F"EX66L,'P)4T:?8)GQSUAB(I]E<HZO+(%W';@,
MN=![<[D_9T??Q\^.&ZOAL*$!]AG;8I>)!-M-@K'%- J;3).QP30+,Z:%6&M6
MCM5FM5AEUHQILTZL,!O E/E"+#.?PA*+&4Q8[,1BRZ,8L[R(158WL=#Z+D9L
M?L2PC1P+'N)CZK[&Y?TI+_I>"4]C7-KV\12XF['LL-3%9FMSK+=QQEI;7ZRV
ME6+:-A;+[5*QS"X'2^R*,&E7@<5V=1BW:\4B^QXLM%^ $?L)##NLQI##5@PZ
M'L* XWGT.SV#/J</T./\ [J=Y;-TS?$>]5_P8^X#>$KEZQX?8"MCV<A89IPT
ML=K)""N<[;#418))ER L=I5AD6L"%KJF8\0U#PM<2S#D6H5!UT8,N'6@SVT
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MH#)="]%T+X3I)1QP&NH5-._+Z3&7O\T%\1[YD?R&,>:YES13M[R#\Z"'WG>
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MV,S= _+@F2"9=.M%^)T>\Y?99V%TXCX&Z.*'Z<_'\2V6XFMZS*^PCEY],[[
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M?V.1[C=8J/<G1O7D&-57HMB#>=V62RQ/.6>XW!^QX*F$\>S15\%N'3ULT[7
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M05M80-*H'4MM:3W@3[LJH7UWIEVTZ0;,Z,\-!^=!;T@/ND/&Q HZ0T[0'I)
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MY@:Y-[<ZCUEMACPU0Q";(0Y-&YT_-]D$SVN"=S=^YS@E:#!Z>J&G$52#,E
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M=NR/1'X2K<C&[F)D5V-WP[_W8:R%7ZZ&3:Z"7:Z$"2YG EN&'4MAQT\PD)?
MN1_C_XNP8B'6+L!SC^#A^?KG?YR,8=1_WG*%TB%UW@/BR[<LV!Z"_%B&1"KR
M<Y%=@NQJI#8@NQNR>R&[#=D#D3M,\[!C+G88;'\VD]@L8N-AM#S(MQ^@!??A
MR1E$T Q]!Z[]&V^[ZB_[7$-NI6/H>R#?A&P;LL.1&P_2D9V'[%*FJ&ID=T%V
M5V2W(+L/L@;0 \.(RC&ZBWZY0].8VNZA9^; WY?P:CW3K''WT'GP!?@7N.;
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M'L1%-SS;E0AMIC^:&55-]$>36"_U-\?O=2]F2GW01YK.DG<#& 6&^I%F<&T
M[_5CONA+G_2A3UH5@OPH1D,\.E+1D86.?$9J"7HJT5./S*Z,WE9&SB"B=C17
M;L)+=ZF&"*YF)%4SFJL9'U7Z$!B_E7U-<]%YE\FY](\&@T$;Z,VU%E*"GK[N
MZN'IAQXSTFWH",7^:/0DH"<5/5EXH  ]I>BIYE\C<GMB43^\,X(9UJA<W8Z5
ML_'8DV K,]Y18-R%]T?'78D/&[<%!Y(>D!(.99EK,^H>H!NOF["E@?>[!'BI
MBT^ ZKPLJO6PJ]H]7%7N,:KT2%2%1[K*/7)4YE&H4L\*E7C6J=BKFXJ\^JK
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M?.#G[H@BB4$&,.HA_;%C '8,Q([!KGTIP[%C9)BS #XRTWDL]0@$C* _AD\
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M!9!X)KP)OM! XUXT:%EM//T <D%Z_(_J/[P?"4)!$*]M<>ZRQ'O*G.@C_^0
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M])1'R!"YATR06\@]SL/S0TC&@@\!>%;0[]7/V ^%SBICZP#( BEASOI/-(C
MEM!@-P4'><H>Y"V;W5>!P!+D)U.PO_Q#S/(-M<H[-$A>H1'R#(N31UB:W,/S
MY19.#AO1S?D'PPA6H CC1R1)?L/7 VP(PX:PS]0'/8WAT$?'O4_T TB*<-9_
MHK EG/=#0MP5%.(E6["WK, 2XB-3J*_\P_SE$V&29Z1%[E%VN47QX:@8C">7
MCX931)<[_V@; U&((6&-856,(0F/9J6.)OF,NDA'?ZY>Z*J/=.Y%R@&I(,%5
M_XEPU']P69B'[*&>LH9YR@),$5[RC_213[2?/&*8/.(8O/'&  IV?MDH'"1
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M'KE!0!LI=2@#K0YA8#Q6@^%GG[[8..GUGYI>F-<]-&FU^X?)255G7B\M[U[
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M9OHJC(BP1(]M9&FPK<1J? >JBM8%KR[O@JM5'0B5NA4ITS2C1-H&=+D^,I:
MYC7(\ %D^&(ZJ/SV6Z!=O 58%QR\Y9N;<JUE3MZIH8]+(QU?"\RA+=IJYQ&'
MPIKCE9J0H7(#-C+R_F!D]D?54-M*:MAMT,S?6J2M:BFNUC25*+6-<*D^,I:
MYM4G@/;]R:#F\^F@^IMO@?&KC7?=7^S]J>FSN#.#,]-;3\W V]N^$:E#.[4R
MUU&[R);K'?D]!%PC-DPSX"+0[-^ AN9^N*X,FOG+H9E?UEB@KVXLT.@:BBKU
MD;$$M%.> +KW)@/MK&E ^]5B8)^]]M?(1]O.]L_8U7;Q@RS/T$=$3=MRD:QN
M=XW FVSF.?)='"O*QS3C@A03/C3R[F!D[D?4,A[,_,)(H4$>R3-41W+UM75C
M">A>>0+HWYT,=)]. \;9"^X$IB^_V/W>ZHZ+;^_W_?!!KG[H,Y*L8[6 W[!/
MQ0ZFZ)F>?$N9$^F@V;$>DA7OPYF)@9&Y'VFBAT9F_F(3+U1D$H4*S8I@KJDZ
M-)9 [4OC@.'MYT#M1]. <]J<JZUOSN\Z_]K*P,VW8PQ7IN?)3\XA\+K7<LI:
M#DAI]2F5E%"^AN2'&W!>E+G4C;$B7'A[B9/D*')0G04.ABO?SG;GV?GN7+O$
MG>-0N<82,+XP#IC>? Z8IG_X:^2UF;W#+WP:^NFUM<;;[QU27/TTASN\L)1V
M8B.-V'V0BV]+$6&;<^6HAB(5/ *O*@ZC:@I"&$U>$*_+"9#U60%:[3%_F2'#
MSS&D^06&5+]\3 '+Y'' ^NJ_[GI?>[._?]*K=3^^\(7Y[AOKE7].C^'].#>#
M^OWR8MR9+1CT8 P9V9?"*#Z>R<[OS./G=!0)LMK@HF.M*$EZ"U::VDR0)3>3
MY4E-=$5B(TN9T,A3QC>**\;2;_:)XX#SI4E];1,G14Y.?,-\]\6Y%>#MM;R[
MG^VA_KHX 7M]W3'$Y>C\X@N'2O*&$]%9I].QZ2>S"2F#^:2D@6+*T1-P6GP_
MFGZD#\LXW$LL.]1#8<;V,%@QQSFL \<%[+%TRO-4U$#=LT]%NL<_:[DR<6H%
M>&4.#TQ;207SMF+_6K$/?FM+7.'/^Y*R;L2FIUZ+STK\(3DW_G)&?MREG,)#
MWQ<4Q5XLAAV\@"@Y<!X-WW\>A]AWCHC<>Y:"VGVV#+5KF(L>2[V^IZ,B3<]&
M60>?GEAQ[[FI//#F9Q3PZ2(,6+2J!*S=E >V[\CX>_>>Q#L'#QRY'1=[Z%9B
MW,'?4N/W_WHL8>\O.8F[?RY(VO5S<7+T37C*SI]0J3M^PJ9NOT%(VWJ#DK[E
MQ[*,L=00?#K*VO74N(H+3TSD@1=>IX#WII6"+V87@Z4+LL':;U/ YI7Q8.?:
M&+!WXWX0NV4/B-\>#9)W[@#IT=OO9>W>^G?NGBUW"_=N_@NV;]-?R/T;[V .
M;/@3?W#=GY28M7^4Q8XE6^,34:JAJ'$\\,RS9/#*BV@P[<TB,/>#3+#XDR2P
M8LYAL/ZK V#;XMU@]](=X."*K2!NU6:0N&8C2%N['F2N6P=RUZ\%!1O6 -C&
MU0"Y:17 ;%X)")M7 ,J6Y8"Y=2P!)O3_ W?F),!=/!6P-\P&C+TK 35^YU_4
MU"._D+.SKA)+X!?P6,*94C)C",G@]<,YHI[B<EEWH5C952!3=>0IJ]ISJ]3M
MV34U;5EZ35NF6=N::=>V'O-JFS*#VDA64/.H_C'\'S*P( -OYD3 @PR<#5^
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M%NR>O08<_&(5./SE"G!T[C*0,G\IR/AJ"<A9\ TH^'HQ*%FX"* 7?0WPBQ8
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M'1/@_ 6J0C=&G^%D6Y*<:GNRV6D_5NVPYRB<MGRQRUHH<%N*>1X3C.LU/BS
MA@R\=Y\&@KFO@,HOI@+#%Q_^[9[]\<V&+V==Z%W\6?_998M:OU^[,7AN\P'+
MZ5UIE0,'B\N/)Q#)'>D<>'.^+">"J4X+,G6)?H4AP6\W'+5Z3*E:CRFCTF/*
MDGN-.1*?(5?HJWU8@ ,9RM]Y&DCFO 1J9KT!K)^\\WOXXP\N=L]ZO^_LW,^:
MKWRSU']EY3;3]^L.J\YOR>0/[X*3APX143VIK,+V F%F4ZDBI9Y>>;1.I$ZH
MTU4?#OLT1YP![5%C0)>L">C2*@/:=&50\[  %YI A9!AY-)7_]&4OSP?OGZE
M_;W7^H:GO]UTY8LYWI\6KC)>7Q9=<75-//_*IBS*A6@X^M1A?%%?&CV[NX";
MUHX6)K90I/%-//GAI@K%H2:+XF!C746L/U)YV%Y7&6^LJTS0/3S APQBR% U
MXSE@?>_YGQI>>[[_]*N3FW[X\ //KY]_9?CMJ[7*7[[=P_]Y30+EVI9,]/=[
MBHN'XTMSAM*)Z?WYM*0>)"N^B\@]U,DJC^F0" ZTUPCW=[@$>]N;A/OJ6\0'
M?,V2&&>S]&$!X;^B@.SMIX'NW?%_^%\>/] _Z:FF*U->=O_VP<S:.[,6*N]\
MM9YW9^D>RN]KCY3>V)Y>?.5 7O;%>%CZV714TND\7/P0@GAH $\YV,^@[>LK
M9^SI59;M[JUE[NKUENWJ;2_;U=[-VMW4S7Y80#PI"E2\_12PO?1D;_/$)YJ&
M)CWC^NW5UW3@PT\4X//%7/#U.@I8$5WZQ\;8XE]V)>;<B$E/O1J???1R6D'<
MQ=SBV/,E\ /G,,A]PY32W6?8F.C38MS.4Y7X[:<,4![\ME-MN.U#0P\-R"=&
M ?W+XWJ#XZ,:.L9'N2Y,&J\%K[TA ],^X8 O%I+!HM5HL&9+\=_;]F3_L2<F
M]?>8(PF_)"0=^BDM]>"/V1G[KA5E[KZ*&GD%D;L#^O%KVR5>P=9+TL+-WU<7
M;?K>4+SIHJ=XX\7ZAP94ST8-.)^*BD2>B7+T/#M.\^MSDZ3@S3?98.9')#!W
M/@HL75H$UG^7";9M3@:[=\3]?7!WS%_Q^_?]F1*S^W;FH9VW\N.V_U82O_57
M3,+F7\B)&W]F)FVX69Z\_J8L9=U/U:EK?S*F?7?#\=!.&Z*BZKU/1=E:GHI2
MGWSZ"3%X81(3O/T: 7SR(0)\-2L?+/\J':S]YBC8LN(0B%ZS'^Q?OQL<WK@#
M)&[9!M*A'[^RMV\$A3O7 T3TVGO87=_]3=FS^BYK[ZJ_RO>M_$NV?\6=Z@/+
M[^@>6I-]7)0M]&14=?>X*,&UIY]@@)<FX,![+Y6 S][* ?,_3 %+/HD#J[XX
M #;,VPVV?[T#[%F\!<0LV0B.+%T/DI9]!]*A;[#9*U>!@E4K 'SU,FB,70K(
M:Y> LI%S_G6+@73]8E"QX6'9W4]$5;5$196?BHJB@O'C,."5IPO!.__* #->
M2@"SWS@(%KRS&RS]8#M8,V,3V/C1>K#]TS5@SZQ5X.#G*\#AV<O T3G?@M0O
MOP&9<Q>!O'D+0?'\!0#UU5< OV ^H'X]%W"@RA<^K.JZJ"A^;U04\6)4% I,
M')<-)C^1"%Y^.A:\/6$WF/'<-C#[Q8U@P93OP+>OK02KWU@&-KRU!&Q]>S&(
M?F<AV/ON A#S_GP0]\$\D/CAER!MVAR0/7TV*)CQ.8#/G 6P'WT**!]_"I@/
M#>1/>0+DO/<4R)[S+Y"U\@V0M74&R-L[%^3%+04Y*>M 9NX.D('8?S>5</C/
M9$;BK41>ZF\)XHQ?CBBR?HZKROGIL#;OQB%C_HT86\&/,9["ZP?KBJX?:"V^
MMG^@^-+!,\7#,>>*!@Y=*.I[2/]W#.\^!7+G/ >R5[P!<K?,!(5[YH*B0TM!
M0?)ZD).U$V25'/@K W_D=BH]^;=D3OHOB:*LFPGRW)_B*_-_C-,47C]L++IV
MR :[%NLMN1H3@5\]V Z_?' 0?B[V#'SHT-F2[KAS\,Z'! H@0RYDR(,,.2O>
M! 6;9@+8KGF@)'89*$[<  J.1=_+*8ZYDX5)N)5!3?TUE9UY,UF0<R-15G ]
MH;+H6KP&=C7. /_AL UQY9 />26V'G4EI@M]/G8(=?+P&=3QN&%4ZY%A=$O\
M_QXH?.4)D <9\B%#+F0HWCAS=$.$.K@,(!(V@N*,7??R"V+_S$4?_3V3G/YS
M.C/[1FIY_O5D:=&U1%7)#PDUB"M'#*C+<?;22X=]F$N'&K'?Q_9@3Q\>PO8<
M.8UIBS^%;4@XA:U_2*#HE7$@_YTG0<$7SX%\R(#8,!.4[I@', >6@=+XC0"9
MMNOOXMQ#?Q0@DW[-(1Z[F<G(_3&=5W0U55)R):D">?EH3>GW"0;LQ2-VW,6X
M .'"X6;"V<-]A+[X(4)[PA"Q\>@@,90X2 P\)% ,&0HA0Q%D*%S^)D"OFPGP
MV^<"XKYE@!"W$6"2=]]%9!V^#8,E_U* R[J10RNXELDIN9(N0EU*46(N)JGQ
M%XX:B.?C'>1S1T*4<W$=E('X?DK[T7Y*0V(_-9C43_4D]U/=#PG 7AX'BMY^
M$A1#AI*E;P+<VAF O'4NH.Y9!BBQ&P$Q<?==;,;A6\C"E)]AI=D_%I"+?LAA
M(2X=$V NIBD(YU/4Y+.)!NIP@I-^)C[".!E_G-&1V,-H2.HI"Z3TE+E3>\IL
M:3UEUK0>QO\6*($,Q9 !!AF0W[X)2&MF ,;F+P%SUU)0=G #H,?ONDM*/7P+
MFY-Z$XG(N0XC%%_)+T-?S.;CSV7(R,.IU?332<:R4T<]K),)+>RNI&YV0TH7
MQY_:Q7&F=7$LZ5T<0T8WN_8A ?A+XP!LZI.@9/9S //-&X"V>CI@;YH#N#N^
M!9R]ZP'K4/3?C*1#M\B9*3>Q1;G7D)B22\54S/D\+G$X2TH[G5[-/)ELX@PF
M!GB]B1W\QM3V<E]:>[D]H[W<>*R]7)?9P:_)ZN"ILSK_UP ",I1 !@1DP"]^
M S"A:7SD8JA\ZS>@/'HMX!W8^3?[2.QM1FKR37)NSC4LLN02@H0]5\BBG,X1
MEPUE5'$'4BR"_J1Z47-JJ\B7T2*V'FL1UV:UB#79K:*JG%9A14Z;0)G;7OZ_
M!9"0 ?[6DP )&4B+7@><%1\"P7>S@6CC8B#>O@:(]FP'@MB#?W"/)OU<EI%]
MC5P$^QZ#Q8YL[$[E"]D#QZH$QU-MDHZ4)ID_HTEFR6J4Z[(;Y=6Y3;**O&:I
M/+]%(LUO%4GR6X7_6P#UXCB @ PHR$#]^G7 7_8!$*^:!63K%@+YYE5 'KWE
MKG3_OM_%<0DW^"G'KC!SB\Z1D9A!#)G:">-RF_+DXKK,6H7_6*#"DEU?H<FM
MKU#EUU?("QH4DL)&N:BP22HH:I&4%[6(_[=&#4C(@(8,C 6O0;/W^T"VXC.@
M7+, J#:N *KM&V^K]NS^J2+V\&7YT=2SPJR\/G8)NI6,H]65_C\^[CNJJ>Q]
M _U.Z%;L%<6&H/3>>^\D!$)(2( 0.J'WWGL'0>E501%%%,6&6+!WQZY80%%$
M410!?>_6[^_>/V;@KEF?-<X_OL_9^X2<9Z_#%)3WQNRNZ0YO;>H,[6G=&WZN
MM3ZROZ4ZZGSS[N@+C14Q%QO*8R[5E<9<KBF-O5P]%TC"&1)QAF3I15"DO!*J
M-$6A7G<'-!LJPEYSG:E]MF;C;0ZDD38&_=4^#N>?!F[PU<K(I+["I+R>S.Q=
M!Y/*ZO;&-K0T1A_>5Q/=MZ\RMF]O>5Q_2VG\^:;B^ N-1?&7Z@OC!VH+XR_7
MS 62<88DG"%5>B&4*JV$&O4-T*0M#GOUY6&_B<;W@U:&HX?LK=YV.5.>=GJX
MWMCK%]1?&YK84QZ;UU&07M&<651?G5+=NBOQ0'M)XIGVHJ2^?05)YUKSD_J;
M\Y(N-.8E76S(31JH_?_SOPQK>2!=:B&4X_Y?IR8"+9IBT*XK,]UII#I^Q$+G
M_7&R\> INM7=HVZLBP>\ WN;@Q(ZJZ-RF\N2=^TIR*LOR:YLS<W8UYZ9<69_
M9L;9MLST<WLST_I;,M,N-&6F7FS(3!VHPVKG BG"!$C&&3)W+H!*^>70H+(.
M]JEMA8-:DC^Z]15&>\W4WIXC:3\^1[6\=H+%/'/8D]O5'A"_MS$\I[HJ?E?Q
MKJRZK.+RUN2"YO;X@A/[$_/.MB7EG-N;G-W?DI)UH2DE\V)#:L9 '58[%TC%
M&5)PAIP="Z *]]YFQ;6P7WG3[RYU\:^]NE+O^TWE!J_:J=RYY&!QX:P+HZ?'
M(V#_(;^XNK:0[-*FF++LVO2:Q#W%S5$5#6VA%<?:(\KZ]D47G6N-+>AOCLN[
MT!B?>[$^(7N@]O\/I.$,J3A#OOA\J)5; JWRJZ!30>3G<>7-G\YIB0U=-Q%[
M<M=2Z>HU>[/3%^C.ATZ[^S7U^$17' [*R-T?59*T-[DJHJF@,;"AMM6OX<C>
M@-ISK<&5_2UA9>>;(HHO-D067JJ/SA^HC<Z_7#,72,<9TM;P0-&?MT-D%D.[
M] KHEEGS[8S\^O=7U=>_>&0H<ONQN<+Y.R238U=I3OLNNGI7G?6,+#P1D)IZ
M-+P@ZG!B!?=@7JW7@>I&]H'#31YM%YI\&BXT^E=?; BLO%0?7#Y0&UIRN3JL
MY,J<(&,Q 3)PAK*M0M"T<R$<E%@RU2NQ[.. Y++G#U6$[P[J;;C\PDSVY&,[
MPX-WJ0[UUYF<T@&/T,SS?HFQ9T.S@TXEE'CWYE:Z':^J=CEQJ(:!>[1;QT M
MIV6@UKO^<HUO]97J@-U7]P14S@TR<88LG&'W%@'8NWT>=&]>\.6\Z(*7][<*
MW1Z477YI2&OKJ=?&BH=?6ANV/'4@5?[#<,V]X\Y-O.D;'7HM)-7W2GR.VT!N
M$7V@JLQIX%"YX\"-<N?>ZQ4NAZ]5NK9?JV2W7*_T;+A>X5EW?==<('L1 7)6
M\T#M)C[H$.6?/+6:__7M9;RW!C<(71B17G/BO;I$Y["!6M,;<].*5[8.N2\=
MW1*?,?W"GWB%^3T.CG-_&)]"?YB;Z?BP.L?^G\X\^X?7<RE7[Q8XGKU31.NY
M74(_?+N$N?]V":MM;I"+,Q2L)$(S?I;J7L'S^,I\XJW!1<3S'S8L[!F3%#GP
M246ZX:.NUJX/IN:Y[VT<DMXYL,*'7;S]ACT"V4.!$2ZO8V.=7F8E.CS?E4)^
MUI)J][0GS>[9O53RK<<9]A<?9CF<^2>;VO,@Q^GHW"!_(8)=^+OSP K"HS-"
MZ-H-(=3_81'OT8D-2]HG)#?5?U.1+?^JJYWSU=0\Z:NM?<171X;_5P;;XS/'
MASD:&$ ;B0YV&$X+)[\MBK)[4Q-C\WI_K-7K4]BC6-N'+V/M;KQ,(%U\GD0^
M/S<H7H"@;B%Z<HP?7>D70&?O"*'N;\+\^Z8W+J^=D=Q2.J,BESVCIY7TR\PD
M\I>=;< O1T>/*1<ZZSO'U?D;U\/A2Z07>2S9U_93KK_UQUU<RP^-0>8CG<%F
M(WW!IB,/@RU>OPFV?C@48GU_.'0N4#X//=]/1%=/\*%3E_C1X8>"A%98*E@%
MFU86@_26+%"3201]M0@PU_<'6S,/<+!F@@N9]MO#@3+C3R--A=%M)N.9EC\R
M7,TGBMQ,OU6QC;^V>!B-=W$,Q_L\#<;O>1I]&O8T_O!N3I\:$+I^A(A.GN9%
M!Z_SHJ;G H3=L$*H$+:NR !9T7C0V!$*^O*^8*KF#M8Z#* 84(%A0@:VN2WX
M6EE!L(TY1-F9X$)@!#GV!K]+'?1^U3CJ_MI+U9GI<M*>.4/3GKY-TYI^,J<[
M!Q ZU4-$'1>(J/X^$97_F$_,@]6"J2"V)!;DU@:!ZF8OT)9@@9$,#2P5[(&L
M8@LT=4M@:9H!1]L8_'4-<3G2@Q@#'4@QTH)<8PTH,U&'&OP0U&JN"H?,5>"T
MA0J<F].9+H0Z3B-4=QVAXN<(9<%"0A*LY8N +0O\8<<R-LBMH8/J!@KH;K8%
M4S%+L)$P!<I.0W"6^G/^H .><EK@+Z\!(0K_.WM(5E:"')4_YP[R4*4F!TWJ
MLG!00Q8.SZFS!\^_A%#10X12QQ"*Q1FXL(2' VOX76#3/ >06&P+\LLL0'VE
M,>BMT0?3=3I@+:()Y#_G#Z+_.W]@;U8 [RUR$+A5!B*V24&\F"1D;-\!!>(2
ML$M"'.IVB$/CG.K/X?FW$4H>1"@2$/(#00(+%A(=<0X;6,UG"J+\!B AJ -R
M\S1 =8$J:"]2 L/%\F F+ O62Z2!O%02J,MV &.Y!+BOV [>*[<!=]56B%BU
M&>)7;\)?1ANA8.U&*)H3>*TA GL++S!E^,%%5QC<+=:"I_TV\&+( ,=3#=C!
M>N 69PJL#&M@%)+ N<(!:#5.0&UR!L<VQF^'3N8O2C=KQOZDZXS]>;=I\G7W
MGZ2G[M])0^Y?R"/N'^U'W8<<QMQ>.GYVGPMXKR:"!\[ DN8')L[ ,5L+/N1M
MX$N7!6\/=? ,U =VC!FXI=D ,]\>&.54<*YV!EHCXQ=U'W/&\:#KM$.WVQ3E
M)'N*<M[CI_T-CQ_D9YROY"'.)\H(9]AAU&.0^LGCB=,89R[@@S-P-O."J[0
ML'2$P=MT'?C;B4& LRSXL=7!.\  /*,L@)UB!ZZY#L LHP&CBO'+N8$U3=OG
M-N5TD/V3VNWQT_&DYZ3#!:\?E)M>$_8OO3]3AKS?.XYXO7+ZZ/6$-NI]U_G3
MG/YF\,09W' &=VUA\#->]_<\*-@)WV)N&N#G:PC>X9;@F40"=@X57$OHOYA[
M6-.,>K<IY[T>/VD=GI-.W5X_J">]OSM>])EPN.T[3AGT^^@X[/?&Z;WO4^</
MOO?H'_VN,T;G!+ZKB."UB0?<I03 4U,8 HW60:BU&(0[RD$H2P,"O8W /\0*
M?.+M@9-)^^U>Y#+M6NGVDUGG,<EH]?I./^ S03OB]\WIE/\WZJ6 <<=[W$^.
MK[A#3D/<9_3W 7<9(]SK+A\"+S'G!GXX@S?.X($S^*H+0ZC!.HBR%(-HBAQ$
M,30AC&,$@8'6X!_C #YI]!E.@>L4>Y?'#]=:K^_,%M]OC /^7^E'N..T4T%?
MG"X'CU$?A[RCO0YYSA@*ONOR+N0J\UWH1=:[T#[7N8$__M[V$>4!#L[ 517^
M>PX29[X-$DAR$.^L"3'NQA#N9P-!$8Z__9-=IGURW2<Y95X3[&J_KZY-W''F
M_J#/C",A8_0S89^<KX:/.#^+>,EX'7Z7]3;BBNO;R/-N;R-/N[^-/,&>&P3@
M#+XX@Y>D (0H"T.<SEI(-MD&J;:RD$K5@"26$<1ZVT!XL./OH#CF3_],C^\^
MQ3Y?.7NX7]P;@_^<#8XRNR,_,OJB/M)O1;]FO(BYY_HJYHK;J]AS[,&XDQZ#
M<<<XKV*[/.<&@2L(X+>1![QQA@C%Q9"DN08RC+9"MI4,9%'4(8-A!,D>-A ;
M0/T5'LF:#$[UG/#/]__B71$\QJD/_^C>'O6!=33VO<OY^&&7APD/75_$7W%_
MD=CG\3SIN.?SI"->SY,ZO5\D[O=^D3 7",(9_'$&WYT"$"._&-)Q_\\UV P%
M%E)00%:%/)H!9+E9_3F7^A4;S)H,3_#\%I0=\-FO+'34JS9JA-T6]\[U6.(0
M<R#YF>N3O^=P9SE/TWJ\GJ0=\GF2=L#W:>H^OV<I+7[/DN<"P<L)P,7/<5P)
M 4B07039JJN@2&\3E)I+0IF=,I10]:"093&=XTF92.4R/\=%>WZ(2.,.!Q>&
MO_;?$_O<JR7IL4=7ZGWW\^DWV8\S_IS!'?-^F'70]V%6F_^CS): QQF- 8_3
MZ[A/TN;R-T,@SA L+H"[]T+(Q]V[3'<C5)I*0*6-(E10M*?*Z6;?BMGDT5Q?
M!GYLXPPF)'&?1.9&W TNC[_N7Y]ZV>= U@6OWIP^KUNY1WWOYW7XW\]KY3[(
M;0Q\D%,;]#"[.NA1UI[@QQES@9 _&41X($R,'](E%^+^OP(J=46@RG@[5%O*
MS523-+Y5.1F-5K)LADJ]G%[DA[C?3X\+N)Z0$7DQLBCQ;,B>C%YN:^Y1_R,%
M77X#1?L#[A0U!]XMK N^5U 5<C^O,O1![J[0A]GE88^RY@*ARP@0A#-$;N6'
M+-Q[RY26097V.J@SV H-9M(_&FU5QAH<](;K&>8OJCWM[Y5QW:[F10;TIR5'
M]2;D)G='E6<=#*O/;PL^6-P2U%=:'W*KM"KT=G%%^)VB\HB[!:41]_.*(Q[D
M%D4^S)X+A.$,P>MY(&8+/^1*S(<*Q:50BS\;C7J;IUN,=XSOM5(8V6>O^6J?
ML^$_C>[D:[O]W,Z5A 6<R(F/.IR6D=*64)3=%%-56!/95KH[O+=\5\3-\M*H
M6Z5%T;>+"Z+O%N9'WRO(B[Z?EQO]3\Y<_F8(P1GB<,?)EY@'>Q2%H4%M%;1H
M;_S19BCVJ<-<^NTADM+3@TYZ-_>ZDB[4>;OV5@0''"J*CMJ7DY)2GY:7LSNI
MHJ@TOKF\,/9H15[<]5VY\3?+LN-OE63'WRG*BK];D!5W/R\S[D'.7" <=XM0
MG"%1E ^*Q(6@1F$Q-*FL^-VFL>[K0;W-(T=,Q5\=MY6^=\1!]_(!IMWI9D_6
MD1JN?]NNB,CZHL3DRMSLG**,LJ*<U(;R])3#E2FI5RM24VZ4IZ;<*DU-OE.<
MFG2W,#7I7GYJXH/<N4#$GPQ_SJ,V\$+I=D&HDU\(K8K+ICI45X]U:ZT?.FF\
MZ>D92\D;Q^UU^@\Q;(^U>3 /-/GY-5:'1E16Q"85E:1G9Q44%R7GUI;'91^L
MB,ZY5!&;=:,\+O-6:7SZG>*$M+N%":GW\A-3'N3.!2)QAC"<(6T]+^P2$X!&
MF?G0+BL\T:6X_$.O^JI7YPU7WS]ONG/@%%GKY%%GZT.=[HR6-A^?JJ:@\.+:
MZ,2LW2E92>7YA5$E566AQ?MW!17W5X04W2P/S[]5&IESIR@J^VYA=.;]_)B,
M![ES^9LA'&?(Q'9OXX>6G4*_#THN^')<9M%0O_+B9]<U5]X8,)$X=\Y.X^A)
M)\NVHZ[.M9U>7F7MW-"<EHCXI(;$]*C:G+R@JLIBOSW[RKSWG"GWK;Q5&E!Z
MNSBHZ$Y12,&]@K"\^WGA.0]RY@)12P@0N98(N;C_U^!GNC8Q_LDCVP0_G!47
M'+PN*W#OCLKR@>M&VWL';-0.GG,T;SS%I%;T<#SRNOR#4@Z&Q42WQZ<$[<W*
M]FDI+_!H;BUV:SE5[-YXI\BS^FZA3\6] O^R^WD!Q0]R PL?9L\%8G"&6/P,
M48@UX.>(#E'>\5X1WK=7-O \?K*5Y]HCI:5G[QIL/7+#2GGO98I)U7D&I>@L
MVRW]I*]_3$](>'!W;+Q/5T::^Z&R;)?.YESG0R?SG _>SV.VWL]SKW^0RZGZ
M)\>K\F&V3_FCS+E K# !DI83H0Q_=[6*$&>Z5Q(_7!0F/'ZR&%U_N8VW_X7R
MXIXG>IOVW[=0J+M--BB]3K/+NNS&B+_H[1G:'Q3HVQ<3R3Z3'L\X79I,/=6<
MYG"Z-YURZDDZM>MQ!KW]<0:SY7&&:_V3=/?J)VES@7B<(>//;[<N07!@.7I\
M>AZZ?7T>NOI&F-#W9IO L==*RPX,ZFYJ?&XFL^L)23OG'R>+Q'LLQ_#;7J[^
M-P.]/:Y'![I<2P^C7BN+LK_6$F-W_62L[;57L>2^EPF48R\2J8>>)]':GR?1
M6U[,"1(7$R!_$0$:</_O%D0W^@31Q5M"Z/3[I<0C[[?-:WNGL*IN2'M;^5L3
M^9S7UCJ)@Q2S\)<,LO]SCK/',ZZKR[-H3^K3=%_RTS*N[;.6(*OGO<%6+P:#
MK&\/A]I>'(H@G7X32>YY$T4Y_#IZ+I#RY[V@^>A9.R^ZWL./SIWG1R?N":%#
M8\MY6C]M6UCS26%MZ:C6]NR/Q@J)'ZRUPS]03/Q&G*W9(^X4QH@_C3H2X4(>
M27&S'BGR,/]0[VGRL<O;>/26M^G0.V^+1Q]\+&]^]+>^](%K<W8D<"Z0-1^]
MKR.@6X=X4=])/G3L,C_J>"R$FB96\>V9V"Y</*&X/O.[]O:$[R;RX=^M-?R^
MV^NSO]-,&=_=K!R_^]J1OH=1K'XD4DTG\VA&DWOH^I/M+GH_3C-U?[Q@&7SZ
MR#)Y_85I^N2+J]F=<?>Y_"Y#Z-X^A,YU\_Q]!Z'M)A^J&YY/J/BUEK_@MX1P
M.BBMBP?=;:%@+.4+EDKN0%*G@Y.. [ ,;,'+Q!*"S$T@QO+/_X%!%TIMM:&>
MI 6=]AK03]'X/4C1_/F9HOOY&\5@^(?]7)[4(W2A$Z'N$T2T]Q(153_@124S
MBP@Y(,*? CL71X/2JB#0W.@%^F(L,)-T ALY,C@HX?*I:@8>&KA\:.E!N(XV
M).II0(Z!&E08J4*3L3(<-E&"\Z9*\,Q,$3Z;J?R>G-/E=H2.'D%H;Q]">VXB
ME/^"@#)@"2$>1'C#8/M\/Y!9R@:5U730%G$ H\VV8+'- DCBQD#=J0=,*6WP
ME-$ KIPJ1"HH0[*B N0IRT&EBBPTJ\K 875I.*LA#7<UI."#YEQZ\!KL/8G0
M[LL(Y3Y"*&F"!T6!,"$ 5O)XP$9^%YS#$607VX'*,@O07F4,1FOTP'*=%I!$
MU("Z41F8FQ1Q896#@/\[>T@4VPFY_W?NT+!C.QS8*0;')<7@LM1<VH[A^1<0
MRKF+4-PKA,* #WG# @(3EA =816/+6SD,P,Q 4.0%M(!Y?D:H+50!0P6*X#9
M$EFP62H-E&62X+Q\![C]W]E#\*HM$+-Z$Z2O^7.VL &JUFV YO4BT"DREZJS
M^/IO(!3['*' "80\ "$:\!/L8"'!#.<PP#FT8".O*HCQ*8(4ORPH"$B!FL .
MT!;<#@:"V\!,: M8"VT">Z&-0)LG J[SUH'W_#40O& 5Q"Y<">D+ET/!HN6P
M>_%<@+Z>"(YB/& GSP_6FH+@:"0,SM9K@$[=#,[N.\&)*P^.T:I@GX:7OU /
M;"N-P*;.!*Q;S<"JPP(LCUB"1:\5F/=;@]EU&S![9@NF[[%QVVFS[[;?+7[:
M?K::MAFQF;8=MIF9U=\,5)R!A#/8J0L"S4 8F%9K@.FX!5Q<=P+=7P&<HM3!
M,54'[/,-@+3+!&QKS<"FQ0*L#UB!U1$;L.S%MVJ_'5C<(('Y"Q*8C9!_F8^3
M)RV^D[]839(^V$R1WMI.D5_9S0X8ZXC@A#.0Y?C!7DT0&/K"X&:Q%MPH6X#%
ME 2FKR+0(S3 *5D7''*-P+[,%$@U%F#7; VV^VW ILL.K'M)8'6>#)8W[<'B
M)04L/E"F+,<IWZR^4S[:3MH/V4U27I!^.CPESPY<< ;:-AZPQQFH*H+@JKL$
M/,S6 H>\!=@,*7#S4@)FJ";0$_3!*=L$'$HLP+[*&LA-MF#73@+;+GNP.4$!
MZ_,.8'7+$:Q>46<L1ZG?K<>IGVPGJ$/D[]07]C^<_J%,.MV= S#Q\XLSSD"1
MY0>ZHB!X:"T!'Y.UX&NW%;QI4L!A*X-[H!8P8PV GF$&3D56X+C;%B@-9""W
M48!TV!'L3CB![04:V-QQGK%^XSQI,TK_;#?N/&S_S?DY98)^W^$[XP;U!^/J
M'("%,]"W\H"##!^PY 7!1T,8N(9K(=!Z"W =I<#751D\_;3!/=((6"D60,^W
M 5H%&1SK',!AGQ/8'W(&\@GZ;[N++C.V#Y@_;8>9XZ1/S&'*%^8SQW'6'>I7
MUZM.$VX7G"?<^N< KFN(P-C" S0I/O"0$?Q[#A*JMP;"+;9 F+T4!#&4P<]3
M![Q"C(&=8 FL;!(PRO[O?+"5_O=LT/X$:X9\R>W/F>!7\COW]Y1/[L^IG]FW
M:%\\!NCCG'.,<<XIEW%.[QS #6=PP1E<=O"!MY0@A"HMAFCMU1!KNAEB["0A
MDJ8,(>XZX.]O M[1UL!.MP=6$1485?1?M&;6-+73;<JAUV.2<H4S8?_2\Z/#
MB.<+VJCG+?J8]T7&F,\9YIC/<=:83[?KF$_7',!]-1%8FWG ;3L?!.P0@"CY
M19"@N0J2C3=!LLU.2* J00Q+&\*\38 ;:CWMDT29Y.3B%=S%_,JL=_],;^=\
MHAWU_NATWN<]];'O(&W$]Q;CH_\%YL> DZX?N$?=/G(/N7\,.,#^&-#.'O6?
M#;!Q!E><@;.-%X*W"T"\[$)(TU@)F48;(=-* M(I"I#LHC4=QS'^'AYH/1X<
M2_GDGT$?\2IV&V)7<5Z[MOB\9![V?\8XPWW,N!MXQV4D\#SK?? )MW<A7>QW
M(0<\WH?LX[P/;O$<"6KR' F<#7C@YVDW_#SMC9_K(W"_2)99 -EJRR'?0 0*
M+,4@CRS[,]M9_6N:N^%H@I_5NZ@(RNO09,;S@#SW1]Z[O.]RZ@-NNN\/NNIZ
M/'3 ]4K8!=>WX<?90Q&=G+<1;5Y#$<W>0^$-/L-AM3[O0FI\W\\*.*L(X(XS
M^(ORXN[-!QG2\Z% =2F4Z*V%,O,M4Z5V4E^+G%0^YK'TWF9XF[]("B4_B(YG
MW S-]+C"+?*[X+LGJ,^K)>P4YW#D"8]ST<<\GL5T>+V.:?5Y'=/@^R:ZQN]M
MY![_MQ&5_L/A%0'#8;,!SY4$8(OR_#V+B=_,!SF20E"B(@P5NJM_[385_;;;
M6N)C!47A;1E#\UD!Q^1N)I=\-2G*Y4),"N=,6&[ \:#RT.Z ^LA.W_VQ!WQZ
MX]M\[B0T^;V,K_$?C-O-?16[*_!U=%G@FZB2P+<1)4%#LP*O_\OPI_\GX;7(
MWRD(NY060;7VBLE:P_5C=1;;AFM)4B^J:2IWR]R-K^3[D?LSPEQZD^(]NV,R
MN0<CBL+:0JJBFP/WQM=SCR;5<*\D[PE\GE0>]"*Q)'@POBCD56QAR.OH_) W
M4?DA;R-G@[_R"<#!:Q"^E@=2-_) ,?YL[%%<\+M.8^G71KW5(RVFHJ]:;;8_
M;'!0OK:;9=1?XDWJS0MVZ4J/]MR?E,IMB<L+KXNJB-T3WIBX*_102FGHA=2B
ML&<I!>'/D_+"7R;D1 S&94>\BLD*?Q.-1<T&O'&_\OYS%H1_3F3@+&7B_% C
M/V^J267QV%ZMY4/[#=<^.V"Q]5:+O=+%6A?#DY4<TI%B+F-_;H1G4T8BMR8Y
M.Z(BOC2N.*8N*2_Z0&IVU-FTS.BGJ1G1SY+3HU\DID>_C$^+?A6;%O4Z.BWJ
M3=1LP =G\,7?6S'X\Y&-O\<KQ/B@059P8J_"@@\=:L*ONO26/SADLN5*.TGQ
M;!/=X&@-V^Y A1^]N3B44YT7QRW/3 \O2"N*RTZN2DY+;$M+2CB9GICX)"TQ
M\5E*8L+SI,3XEPF)<8-QB7&O8Q)CWT3/!GS_G)'B-8A?080\G&7/5I[?S9+\
M7_;+" YW*<Y_=D)=^%:W\:8+!^WD3^RCZ7<VNMFT5OLXUU0$>Y271 <4%*2$
M9^;DQR9G5B;%IK>F1:4?3X_(^"<M,NU92G3*\Z3HY)<),4F#<;&)KV-B$UY'
MSP9\_YP-XI]32?C?A6L(4+N9.+5/C'?TD 3?JQ,R_ _.*"^^<L)0],P1&[DC
M'53=MKTLZ_I&3UI%#9==L#O"/[,\,2RQ."<FNJ \,32_*34H[V@:-_]V6E#.
MLY20K!=)81DOX\/3!N,B4E_'1*2\B9X-^.'9(2N)D+:, *7X_FS80)@X($H<
M[ME$?-8O1KS5K[CP_&G]#<>/6\ET=#EH-W6X6.[>Y^%8U.SOEE4?YIM8'1\<
MM3LS*GA7:;Q_>4.R=UE7JF?Y]13ODN?)?@4O$KFY@_&!V:]B@S-?1P=GO(F:
M#?CCV>%8YE("5"Q#T+J&,-:UDO#J[ IT_\H&PN5+\@M.]^NN[SIM(;GWA+UF
M33?=K+33G9*]WY>9M"_8*ZHYAAO<F!;N6U<4PZFM37"K/93$JKV2Z%;U,L%C
MUV"\5\FK6)_"US%^>6^B_'/?1LX& O#\/^<@><((JH71U/XEZ''O?'3_\GQT
M_<8ZPKEK,O..7=9:L_^"F43]69+JKI,TX[P>5[N4;B_GZ,.![."#4;Z^^U."
MV.T%X<Q]-='.^P[&.K5=CJ6UOHIQJ7L=X[KG=;3[KC=1G-*W$9SBH5E!(+[^
M1-R]BQ>A\<;YZ%&7$+IY6@A=O2:$SM]=A4[<D13HO*FQLOF:L=CN 5NE@O-4
MO;0^IE7L:4^'D)-<%]_C$1[LGF1?EZ/Y@4[=U2&4[HXP^Z,#8>2NX7#']J%P
M6M-0.+UN.(Q9-1S*VOUN5A",,Z0O0-,50NC1/GYTHUL 7>P30&=O"J$33Y:A
M0X\E^%H?JBRMNF>XJ?BVE6S&#8IFW%6&2>AE#UN_2_Z.'A?"75S.)[D[]>=[
MV?=7^]KU=_C9G!_PMSXWZF_;\X%+[OP02&D?":2V? AT:IP=1"S&^R"(GM<1
MT<T./G3^.!_JO<"/NN_.0QV#*PDM@Q+\U2]5EI0\UQ?)>FHID?#87BGL'[J.
M_WVVJ<==/QOFG7![ISM)3O:W\QFVMZM95G<ZW2SN7G8SOS/J9C$PSK$Z\\7+
MIN>SM]WAS]ZD@V.S@H1Y:+0<H3LM!'3^, \Z?I('=5[F1_L>SD/UPVN(E<,[
MA J'599G#.EOC'MK+A'ZQD[!][63.ON5JY[+*U\3ZJLP"_)@HHW-JSRRQ:L]
M%+/7^QU-WIQW-'[]WM'XV7<GDUL_Z&8#/US,^[ZS+$[-#K(0>E2#T*7]!'3\
M*!%U]/&@YAO\J.K- E0V)L*3-R8Y/VU,;47LF-Z&D#&S[3Z?;&7</CDJT3\Q
MU1T^>>F0/@7I6XW%&IN-99D9?RZW,/C<8J7[Y;BUSO@3&^W//ZSUAZ9M#)Y-
MVQG>FR$;W9RQG\U@&4)76Q#JQ?V[HY> &@:(J.(^'RJ<7$S(FA3E39Z4GA_U
M4V59X$^==5X_C3>SIJS$:5/V4O93=#F;:0\EBVE_59.9" V#F10MG5^%.IJ_
M:O74?Q\T4(6+ABHP8J0\\\M(8QP,M4>P(3">S:U:A$[MQ_.[$6HXAU#9382R
MG_&@5%A*B($-/*&P0\@/%!:S06,E PS6.8*YJ!W8;;4$ZG938.TP!"])70B2
MUH08.37(E%>"<D4%:%*6@Z,J,G!+51K&U*0 U.0PA9G9]>U%Z. A//\40J57
M$,IXB%#<5P$4CC/XPUH>#]C*YP)2\ZB@O)@$6LLLP6BE*5BN,0#R.AV@;= $
M5U%5\-ZD!,%;Y"!NFS1DB^V$2G$):)78#L=WBL$=R6TP)KD50&HNASH0:CR.
MYU]$*/TN0E&#" 6!(/*$Q00FK" ZXK6PP[W? J0%C$%YGAYH+= "PT5J8"&L
M#'9+Y8&Z3 :8*R3Q YD$!*T2@]C56R!KK2A4K-L(+>M%X)C(>KBR83T,;5P'
MGV?5A/>@#.]!.MZ#B.<(^7Y#R UXD!/,)]C!$H(YK"(:PD8>'1#C50<I/F50
MY)<'=0%IT!7<"<:"XF IM U(0IO!:9XHN,T7 =\%:R%\X2I(7;0"BA<OASKA
M97!@R3(X@?4OG<VNTWC^-3S_"4+>PPC1?R%D#PA9 !\R@ 4$+5A"5,$YY/%Z
M2,-6GAVP@W<;R/!N!B6^C:#.)P(Z?&O!B'\U6/"O!!+_<J )+ 4W 6'P$U@,
M$8(+(55P 11B55C#K,!6E @6.WC 4)D/3-3YP5Q'$*S-%H.-_2JP86T *[^M
M8!ZU TS3I,&X4!X,=RN"08,*Z+>I@MXA== ]K@&Z?9J@<U4+M)]J@_8[;=#Z
MBDWK /XOT 7M*0/0^F8(VI^,06<V_U\&(R4^,%?E!RLM0; S70PDTBJP<]D
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M@]TP98CTW>&Q_4_J-8<IIW[J-.TD;9IVS'G:J8L^.Z#B3D'>QO/W+,83]__
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M"=0+MH+J[NV@TB@!ROMW@/(125 Z)06* ]*@^$ :%(9D0&%<!N1G9$$>)U
M&3Q?!M1 YJ<&R'[3P@EG <8X@ZX4#^C)\X"Q B^8JO*#J:X@F%DN E/J<C#R
M6 OZP1M!-V$+:.6*@4:%!*C7[P2U-BE0[9(&E5-XSB594+XO!\I#\J#T!9O&
M< IE3!WDIK1 X:LV*([J@N*(WG^!R68BZ$GR@)$,#YC)\H*ETO_.@ZQ-%X&5
M_0JP<%T'I@&B8!2S#?0SQ4&G="=HUTB#5JL,:!Z4 \T>>=#H5P#UFXJ@/J@$
MZI^P20S^FM8&I7$]4/F@#ZIO#4%UT.B_P!1G,, 93#%K*5ZPD^,#LIH@4(P6
M =EN!=@QUH.USR:PB! #TY2=8%0@#8:5LJ#?H !Z[8J@=T09=$^I@,YE5=!Y
M@HVH@<X$!FK3NJ#ZQ0#4WQF!YJ ):#XV!:W[9O\%9KAK&N[@ 2MQ'B!+\(*C
M%!\X*0L"77\1.%NO *K3>J!X; 92L#C8Q$N!9;8LF)<J@&F-,IBTJ(+Q034P
MZM$ H_.:8'A'<\;PK=:DX;C6A-%OS2]&H#UD"KI/S4'OC@7H7;,"O<NS '-1
M(IAN)X(=[O]4C+&#%U@* N"NLPC<S%< B[(>Z*Y;P,E? BA1TD!*50#; N5?
MUI5JTY8-&E,6;5J3YD=T?IB?UITPNZ;[Q6Q0;]3\L]Z(^8S^&W,P?&@)1M=L
MP/BB+1B?M0/CT[, 2YS!$G\^*7@]&']^/VD[+WC*\8./Y@+P,5D.GJ1UX$[?
M DRO'=/T4-D?3@E*$P[9:N/VI9J?2=4ZG^Q:]#[:'C08L3EA^,[ZDN&0S3.C
M09M/1L^LITWOV8#9@!V8GR6#^0E[,#]* ?,C#O\%5KA?VN+YM U$<,.\\5KX
MX_T(4IL/089+@6N]=MJ7NGF"XR[QQ9TK.\J*5GY/3],8HA7HO*%6Z \Z-!B^
MH+0;/R4?-7U,ZC=_0'IH?IO\T>(:><KJ@CU8GW0 FVY'L.FD@O5^)[!JH_T7
M6..Y?\[F_KPGY8D%;.:!$+P?$4I"$*DK_#/"?/5XB+WH1ZZ+^+"OC^PKSS#E
MY^Z)FH^8V7KW&"7&MYVKS6XXM5A>I79:#SB>M+WH<-VNWW'([K3C#U(/%<B=
M-""WTX'4R@!2(P/L&AA@^V]@@^<[XMENN&?XX>X;BO<F:CL/Q,L+_$S47/@E
MP7C%2(RMR)L(9[%G(1SI^_Z!*K>\H[6O>J0:7G++-SO/VF5UUJ7.]A2CC=SK
M?)32XWS!H=OYA<-A^E?'_8Q?CBTNOQSJ6;\I-2RPKW(%\NY9@*T(W@?<O3UP
MSPC$.2)Q[T[82OR5*LWW-5UUWDBZ_I+7J19KGB0X;KD=Y29S-=1/]0(W7/>L
M7X+Q2:],BQY.D6VW^Q[R(==FAPY6IU,[\PQM'_.><PMKS+G!=8I6[3[M5,F>
MH9:S?SF6>?RFE,[B;P8&GNW]Y_</<(ZXM01(W43XD;6#9S1/4>!-GM;"ISFF
M*V^GV6^YG. B?2[:2_5D6)#NL:!HD\,!J58=OGFD-J]RAU9.G5.C1SN]CGW<
MI89]W64/>\2E@C/)*/7\22_VFJ85>LTXY7O]<L0<_@U(ZPG Q'W;[\][][C[
M)N$\F2*$\8)MQ.$2&=[G9:I"=PN-5ES)L=M\+LU9NC?10_5(3(#>P8@(T[;0
M!.OFP$QR?4"Q8[5OE7.E3ZM+N7<WJ]1KP+78>XA5X/.#F><[R<CQ_4G/\INF
M9?K-4#-]_POL\76[X=E<W'5BEB)(6XZF\M:@T9*-A%>5XL2'E0J"U\KTEY\O
MM-YT,L=)ZDB:FTI'DJ_NWM@0TX:H6.OJ\#3[RI!\:EE0!;V(V\3*"SCDEN/?
M[YX5\,HM@_O=-9W[@YG&_<E(Y4XYIW"GG5*X,]1_ P?<_=EX#8)QY_W3O3.7
MH(FBY>A=Q1KTK$:4<+M&3N#2;MUEI\LL18\6.DAVY+!46M.]=.N3 TVKXJ.L
MRV.2[8LC<YSRPLL86:%UKFDA'>[)P6?8B2'/V8FA$VX)H=]9"2&3+O$A/^GQ
MP5.T^.!IIW\#*EY[3^$_O1=!$I:["'TI$T:OJY>@!XWKT-5Z&?YS-=I+CU>:
M;^@LM=^YKY"AW)##T=F3$6!2EAIN79B88)\3G^F4'E/,2(JJ<8V+;&='1Y[T
MB(I\Y!$9]<TM*O([*RIBTB4J_"<]*FR*%A4V_1] ^_,^#)X=B7MOZ@(T5C@?
M/=L]#SUJF(]NM:Q&%YLE^4XU: H?J3$5::\D2326.2M6%;EKE^7Y&A=DA5AE
MI<>24U/3J E)A8SHA#VNX?%[V2%QQSV"XN]BX^[!<=]9(3$_7$*C?])#HZ:<
MPZ*F:?\&#'PO^.'.&3,??<\4PIV+']VO%D*WF^>A*VTK4-^^';S'6M07=S08
MKVNIL16OV>VD4%[NJEE0XFV851!DF9(718K+3G&,S,RCAZ17LKBI+>Y^J<?8
M/JDWL<]N?LG?6?Z)/URX"3_IW+@IY\#8:=J_ 1/?"]QY^%X01*]S>="#77SH
M9IT NK)7$/??9:CWP':>P^TJ"_>U&JZI:[(6JZASE"NJ8JIG5WH:I)1SS>-*
M(FPCBA(=@@NR:?YYY2Y>.8VN'CE'W-USKF&?7#VR?C ]TR==O%-_TGV2IVB^
M2=/_ 6[X/@P60)/)/.A) 1'=W,V'+C?RH_[]_.C486'4?7@K<7^GTOS& _JK
M]K19;BENH4AG-S)44^H\=..J_4S"]X1:!5;&D7W+,ZF<LE*Z6VD]DUERF,4H
MN8R-,ET*)UU<<W_2W;.GG-D9TS2/]&FG?P,.WH<('O0Z W?O$@*Z4L.+SK7B
M_G^0%W4?78@ZCFTB-A^5%ZKNTEE1VFDNFGN O#.US5DQ;J^[9GBSCT%@8["Y
M3WV,C4==NCVKIHCJ7%WK3*WN9#A47\(^T!UW3SG3RJ9H]*)I)Y?\&2HS;\;Q
MW\ '[T,L[MZX_U^O0*B_D0>=:".BKBX"VG]R'FHY)4*H.2G#7WY"<TE>C\GZ
MM&[;[7%=3K+AAUBJW(->.MX' HW<VZ/,7=I2;6C["DF4O3444NM!1[N]%QUM
M6T<<;9MG',FUOQPINW\Y.);_=J"6_:;\&W!YT5 R0G>*$+I8C5!O"P$=QMVO
M[1@!-9SC0U7G5Z.R_AV\>>?4%J:=-5P==]IZ4]A)AQT!)USDO8YS5-V.!6@S
MCD8:4+N33>R/%%C8'JFVMNKJL+4X<L'6HFO$UOP0V%FV \FZ&4BV]4"RJP&[
M?X-PA)YE(71E%T*G&Q#J:D-H'^Y>=2>)J.(B/RJZMA3E7-M&3+VJ*!1[67=I
MV(#Y.O]+Y"V>%^@[7,^S9>G]_LJ.Y\+5R>>2=&SZ\O4M^JJ-3/LZC$WZ+F C
MQH:GP<SH.)B;=(&%V0&P-&__K_<)"-TN1.@<[M_=K?CZ#^+Y/0B5]Q%1[E4!
ME'I_(4J\OX$0=5^:+_B>Y@*_NR;+/>[8KF/>=MI$N^VVG7++5]+N5IBLU<TD
M1;.;^2K&-ZO5#&]U:.C?NJAA<&M$7??Z+VWMJZ"KVP_Z>J? 0/\X&/[;LTR$
M+N'[H*<1H7;<?^N.(%1V&J&< 1Z4>%L 10XN1*&#(H2 P9T\7B]5!%U?ZB^B
MO[1:[OC280WY)5/$YJ7W9HN7(=M,7L:+&[[,V:G_<K>4SF"[C/:K/NRMC.:+
M*3FUYZ"H]@B4U6^!JL8U4/NWZ\4(G:Q#Z,!>A.H/X?F]"&5=0"C^)A&%/N9'
M 1^6(*\/&PAN'W;P,#XJ\3M^U)E/^FBZV.JCW3+S4=I*XU'W-0:C_NMU1R,W
M:'U*VZ3^J62+ZECC5N7/1\64OMP14QS[*J;X$<3D/X"X_##L5'@#DO_65X50
M9PM"C?@^+,=[D-6/4-QUA((>(N0YQ(_<OB]!]!\B!,<?VXFD'W*\5I/J_*8_
M]84,?UK,UYNR7Z0]11?6F/98JCK-7:XT';-2?B9KM>ROBC72O]K62?X^LWXG
MO!;9,3,ELF,*1';\@/68R+]UX3UHPGNPZRB>WX=0S%6$N \0<G^!D/,$/Z*
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M%% ;9-& D4)S1AQM&5%T9831AQ'$,(8/$UG<F,?B8 .+A8,L!E>R '<1%]F
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ML^+F[O",F7O>,Z;KZ:R8+O2([4"W^%9T36Q!Y\3FKYF>A;LE )<;O]1@[Q#
M5LI?NP1@&?G/R$H)F+]2B^E;8<G=,>$JU#SN)U4S%JY8OB1.HVAQFF[N2*YQ
MUL)2\]3A>IO$!1WVL?/F.T?-FW -']KN%C;OK'O8T!.WL$%T#1M E\@>=([J
MHKNBSJ]YG_VE#V=; 0Z2?T^1_ZZG_.7+ 1:2_PRL%X&>#6I,^WI33M,Z1_[J
MM=[B9:M#9 M6QBCGK$C1S)C(UDM>7FP<OZS&/'JLS3I\Z9!=R-)QAZ E6YT"
MEIYV"ECRV#%@,3H&C*!CX# Z!@^A0\C USRA/GQ/LWA\+L!NZL$D^><*<O#%
MY,#]Y*#M6P6@99L"U&\S8%5MM>4IV>(AE+<Y4#)K4Z1<ZF2B<N+&3(W8#84Z
MD>NK#$+7S3$)7#M@[K=VF97/VBW6WFM/67NM>63MN>JSC>=*M/%:CC8^2]'&
M=_1K[I0#?1X!'!B@'HR0_R\#6+**_'<ZGQRP=@\'*O=*0NE>+:9@KP4G9X\+
M;_H>7^&DW6$2<;OB9*-VI2F&[<Q3#=I1H>F_HUG'9ZI?WW-JS-!]:K.1V]1)
M8[>I1T:N6S^;N&Q!,^=-:.ZZ#LW=UGS-CU2#8]T .Q>2_X^1?Y.#S]L T$GY
M];L!B@^Q(>>8,&0=5X+TXT9,TG$[3MSQ6;Q1QX($PXY%BP8?39;T/SI;QN=H
MF;SGD48E]R.]JBY'EJ@['=FDX7CTA(;CD4<:]H<^:]L>0%V;_:AGNP?U;7>A
MP4S.MM,<3O=@*<W "H %E-\UG;\'H.000-9)-L2?YX7HBQ(0=4D#PB^9,R&7
MG-F!EWVX?"^'\7I=CA?PN)PI['JY2-3Y<IV$P^6Y4G:7%\O87-XH:WWEN*SU
MY8>REA?_43 _CTIFYU#%]"RJF9SYFD/4@RW3,T#GP,+U -U; 1JF\P]3/GEX
M_ 46A%SE >_K@N!U0Q8\;^C K)M6C-M-5Y;+;_YLI]\B.?:WDKEM;\WFL;I5
MR6?Q>YN V>\+!$UNKQ$ROGU V.C.[\)&O_TM8G 3Q?5OH*3>=936_8:IZ1F@
M<V QG0,]E-\XG7\$(/,,0.PE@*#O 6;]R@&71T+@]$@&'!YK@-UC8[!^8LM8
M/G%GS/[T9YD\C60;/4UFZS_+X^@^J^;2?M[%K?5\E$?CQ68>]9=G>-1?/.51
M^Q-YU)X@K^H3Y%=YC (S64?GP)(U 'U; )JF\X\"9)P#B"$/#_@)P(U<W/8N
M@-4[0;#X2Q),_U(&X[]UP."]*>B^MV6T/[@R&O_X,FK_A#'*'Q-9BI]FL^0_
MU;!E/_>P97 96PJG.)+X/4?R\QN.Q$=D2WP@WG_-&)V# YL!FBF_]!CEGP>(
MHKW[7@=PO@5@2?G&;Z:? _"#+HJ"%LJ .CF_"FJ#(AH!B1;(H"-(XBQ&'(,8
M48QEA#&;$<0J1@"[6?PXSN+#G2Q>_)'%@V\(_!^&-@',H?RRZ?P+E/\C@ _M
MW>$.@.D# )UG !H(H(H<RA2D3#&01FF00 400S401AT00F/@1VO@06?@H _0
M33J1Q@"6$9W$&+&=.$<\)EY_11N=?^54_\SI_&L WK1WNWL 1H\IF_(5/P'(
MTAJD"#%:AP@*4*8P\-%:N%$*V"A/>:J$-F%,V!!N1""10-"'(,XAZ.3'=<0^
MXOA7H*8)@UJ$+J%CQJ"F-0M5G5DH[\M&F2@V2F6P4:*4@^)-1#>Q@!CC0O%5
MQ"0WBD\1^XCCW"AQB0<E;A%/B'<$3L/]'R3IM23RTFM>E$*^K] R9E#/B$$#
M0V+ZM04+-1U8J.+%1J5P-BJD<E"ND(,R=40G%\H,$:/<*#-!K.=!F:W$;EZ4
M.<*+LN>(7XF'Q!OB$R_*X;_P$?PHBP(H_PW:E&](_F^LRZ")/H-&)BS4LV&A
MC@<;-4/8J)[(0=5<+E2N(EJY4;F/!Y47$LMX47DU'RI/$E/$ 7Y4/D5\3]PC
M7O*CRD?^SRK(_TD%!3ZJH.!'912BH_!?:E^#^I1KHLV@.?FWA18=IY_+3#^7
M<F&C40 ;]6,YJ)O%A=JEW*C5R(-:<WE1:Q[5;Y0?M28$4&N= &IN%43-/8*H
M=92X)$2F+_11Z[G0>^T/@N^T4>BM-HJ\T4)10NR5-HH_U?D:-*9\2_)]&_)O
M.S4&;6D==E0+6^J'E3<;+2*XT"R5&TT*>-"XA@^-VOC1J$\0#1<*H>$8L5KX
MD^&DR$?#'2+_&!X4>6]X5O2=X4W1UT9_BCPW^EODJ1&*/S%$R<>&*/7($*7O
M&:'T[\9?@^;DV+;DWH[DV\Z$*ZW'S8".-)O.[FRZXG.A70(WVN;P?K(N$_C'
MJE'P;ZLNX;\LAT3>6BX6?6VY7.R5Q3KQ%Q9;Q9];[)5X9G%2XHGESQ(/+!^+
M_V'YE^1M2Y3YS0+E;EB@_*_$#Y8H?\GJ:]!:A?+E*%<:<!;AK<R@KPZ#/N8L
M]')BXRQ?K@_N43SO7-/X7KD4"CYWJA%YZM@J^MBQ5_RAPP*)!PY+)>\YK)+Z
MPWZ3U!W[7=*_.QR3ON5P5?JZPT.9'^S?R5^Q1\6+]JA\GCAGCRHG'%#EB",J
MSP3MIO<N!>A)SN='SATD!QA"M0@Q9#X%V;#>^7MP7OB&\#SQ2>1_X#5;Z _/
M<M'?9S5*W/3HE/K5?5#FFMN([(^NR^6^=UVO\)WK=L7+K@>5+KI>4#KG=E?Y
ME.L;U6.NJ'[8%34.$ON)76ZH,>6.ZC-!)QG:_W0^^58(N7\$K2=*"3Y%:3.O
M(\V8)^%.['MA_MRW0F+XKP>E"_\04"AQQ:]:^J)OB]QYGVZ%,][SE$YYCZJ<
M\%JI=LQK4OV(YVZ-0YXG-0]XWM#<X_5":Z<7ZFPGMA*;B0W>J+W6YVO0E=S?
MA_*#!  CZ1A+ZTF0AC>)*O X09^Y$V_#NA[GQ74U.ES@0F22Z)GP'*D3H:5R
M1T/J% \%MZD<".Q5WQLXK+D[8$Q[I_]:G2G_;7K;_ [K;_'[3G_2_XG!>O^/
MAFO\:7(#T&!E .J/!Z+^6"#JS00]*-.??"^<%S".UI$D!.]31.%)JC3<3E.#
MG]+,F$NI;ERGDX,$CB7$BAV,RY#9&U.@L"NJ4F4JLE%]:WBGUN:P =V-H2/Z
MZT-6&*X-F31:';S79&7P>9/E(?=-EH6\-UT:@B:CH6@\$HI&"\/0<$$8&LP$
MO:C^07Q4?R[XG,0-S]-XX$$F/]S-$H:?LN7@8HX1<S+;B>MPII_ WO1(\1TI
MR3);DV8K3B:4J*V/J]5<$SM'=U5,C\%$U *C\<@QDZ61Z\Q&(W98C$2<M%@8
M<=MR?N0[BWF1:#X4A68#46C:%X7&O=%H-!/TI?J'<E$-&'A&KG$KFPW7<KGA
MQSQ^N%@@!2<+]9A#!7:<W7G> MMRPL0FLQ)DUV5D*JU**U"?2*G07I;4J+<D
ML<-H)&' 9#ANL?G\V%66@[%;K?MCCUCWQOYJTQW[VGIN'%IVQ:-%9SR:=<2C
M:7L\FLSD/WV@2^T_Y%MWR#NOY3%PN9 ++A3SPJE2<3A4ILWL+K/F;"N>Q;^Q
M,%AL35ZL[,3L5*6Q[%SUQ9FE.@O3:_7GI[4:#Z;TFO4E#UMV)RVW[DS:9-N>
M>,"N-?$'NSE)+VQ;DM&Z.1DM"8NF9#1K3$;3F6#@=!\ GJ62ZY!W?D?^?:Z,
M#2<KN.%(I2CLJ=: ;=46[(V5;GRKRP)$QXNC9)84)BLMS,]6GY];I#.04V70
MF]UD,C>SR[P]8Y[5G/0QF^:T#78-:7OMZ](N.]2F/;.K34=;PKHF'2T)\YHT
M-)L)!I-WQY+[9Y#[YY/[EP&<J&+!X1IR_UIR_WI5F*PW8Z^N=>8;K_83':T(
MEQDN2U :*LE0[RO*UYE;4&[0GE]O,B>WW;QI]H!5?<X2VYKLM?:56;L<RK,N
M.)9E/W$HRT;;LART)JSHM459%IK/!$,Y_[G5N$/.=[68W)^\[T@MP+X&%NQH
M$H1-+4JPML68M;S)D7>TP5MDN#94>K Z3K&G,DVMLWRV=FMIB4%32:U)?5&K
M>75AGU5%P8AM:?YJA^*\'8Z%>6<="_(>.13D?[8KR$>;PGRT*LQ#R\)<-)\)
MA@.\20;X+9?<GVIPG/+WD__N;"'W;N6#=>WRL*+=@+6DS9YG>(ZG\&!3L%1W
M0XQ"1UVR:DM-ME9#59%^;665<65YLWE968]54>E"V_R2E?:SB[<[YA2?<LPN
M?N"07?+1+J<$;7**T6IV$5K.+D2+F4S/PA,Z'ZX5DO=2#0XWD'?2K==6<I]U
MG=RP8JX,+.W68Q;.M>$>[/00[&D/E&B?$RG7W)RH4M^4J5G=4*!77E=A5%S;
M:%90TV4YNVJ!35;EA'UZY5:'U,H3CJF5]^CXCUU:)=JD5Z!5>AE:9I2BQ4PP
MAF8AB_I _G]RN@:T_^V= !O)_U;TLF!IOR0L&M!FAOHMN7IZ707:N_W$FKO"
M9>LZXI4JV]/52UMS=0KGE!KD-M>99#=U6*0W#EFG-"RS2ZS?;!]??]0AOOX/
M.GZP3:A#F\0ZM$JJ0<OD*K28R6>:A=O3?:B@.: >[.J@'O20]_23=PP!#,\7
M@\$%ZDS/?#-V^SPGOJ8A'Y':@5#IBKY8A9+>%-7\[ARMG+G%>AF=-4:I':UF
MB>T#EG%M2ZVC6R=M(UL/VT6VWK:-G//>)FH.6D6UH&5,$UK$-J#Y3)ZG /Q*
M?3@]70/R[^V4OVX08)P<= '="O<M%H:YH\K0-FK,:EQLSU.SR%.H?&&01-%P
ME&SN_"2EK'F9:FE#!=I) Y7Z\?TM1M%]?:81O:,6H;T;K()[#Q*_607W_&49
MW(T6(7/1/+0#S<+:ON8Q?2Y=I5D\UD0UZ"+WI?P5"P!&R %[R8/;QOFA>;D<
MU$_H,57+K;E*Q]WX"Y;YB^2,A4MF+(V72UF2KI0PFJ<6L[A<*W*D42]T4;=A
MT,(18_^%ZTS]%AXP\UUXP]1WP3M3W_EHZCL/3?T&T<2_[VONY-%G4@W  9K!
M;>2_:RA_R6* H3& #O+PVC5LJ%PK 67K-*%PG3D[=YT3=^9:;X'4-2$BB:MC
M)&-7I<A&KLQ1#%M9HA*THE[#?Z)+VV=BH:[G\C7ZLR;V&7A,7-?W&']KX#Z&
M!NY+T=!]"1K.6H0&,_FYE,['9JI!+\ &RA^G_ 7+ .:N)/\E)2DF#\S=*@PY
MVY0@<YLAD[K-EIVXU8,[=FL ?^26".&P+8EB09LSI?PW%\GZ;*I1\-S4H>P^
M.:SJ,KE:W7G37@VG3=?4G3:^U7!<CUH.:U';80VQZFLN3,\!]6#S/.H!Y2^B
M_-Y5Y)\; "K(@V?O $C:RPWQ^R0A=K\F1.TW8\+W.[%#]GMS!>X/X?';%\OO
MO2]-:-:^?%&W?542SGO;I!SWSI>QV[M2UG;O;CF;?3_)V>QY(V^U"Q4M=Z"R
MQ12J6&Q'U9D<I3G<0?._AOJ_A/('R('G; 2HW :0MPL@^0! Q%$V!)P4 O^3
M<N![2A=\3EF!YVE7QN.T']OU=#C'^70BM\/I;%Z[TV7\-J>;!2U/#PJ9GYX0
M-CNS4\3TS/<BIJ?>B!J?0 FC8RAE>!2E#8Z@S$SV]%$/%@$LH_PARF^;!*C>
M3OE[ 5(.4SXIH=\9%KA>Y '[J\)@=U4!;+_7!9OOK<#Z!U>P_-&?L?@QDC'[
M*85E\E,^V^CG6H[!M1XN_6MC7+J_;./6N7Z16^?GY]S:/R"?UE44T/P.!36N
MH-!,-M/YMYSF;P'5OX/R:ZCV^?LIGSP\XA0Y^'D YRL 5C]RP.@F/QC>E@"#
M.RJ@]X<^Z-ZU IV[+J!]SP\T[T>"QOU41NU!(:/ZH)&E_'"0I?1H%4OAT0&6
M_.,[+/G['UER]Y M=Q<YLG\@UTQ64OY"RN^B_-J=E'^0ZG\"(/P<.?@E ,?O
M <RO ^B3CVL]XP.-%V*@]E(.5%ZJ@](K U!X;0ER;YQ!YHT/2+T- XEWR2#^
MKI 1^ZN9$?U[ 2/R?@,C_/X4\901>H>,T!OB]=<LIOGOH?QZRB\X1/FT]["+
M )Y7 >RN 9C\!J!]!T#E,8#B/]P@1]XO@Q(@2<XOCFH@BKH@C*8@A'8@@![
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M@\-A-[ [[,_8'(Y@61U)9ED<R>68':GB,CG2P6UT9!&/P9$-O/I'C_'J'WG
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M(@U_.*K#=2<SN.KL!A><@UEGG./8)YPRN(XZ%?(<=JSD/>#8R+_/H5-@C\.
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M7O#'>;$=9X<Z3H]YG%[W^%GR,A<G]+G'Z+>/DB-:-E%S%>O:LE9[#B=[$]N
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M#&0M8JB53IT":E128RXUFEG#=G:13I:_BF6M9U?M9]?9A3=P&*\R%R_C!E[
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M.+H+S8'.B42:R0T[KL>.&\PNE6#'/XO=C!VWD!3=PL)W*[S_5@+K5CKREK/
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M7H;,-<C<C,S=.F9G_4>(C&-V2R["X@L8Q.?3FV;/Q9&38#X;_1\ZA]JOG-/
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ML(?LN9NL$9R'CMTM<'\PC:XAT U: -VK,FA201?ZH8ZI4)7X 3=%#_DJ<CA
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M6&W>-ZG5^Q&U>+^J9I]/U>QK^P%WL=Q?'@K?(R7<03JVEM>Y,%(^KDUBSW@
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M551YJ2++:Q51WJZPBB&%5"Q1<,5&!5:<IH"*RV2I^*G\RY\%[\E23M989E-
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M%9K;I^#<*07FKE% [BFRY%XH_]R;Y9?S,_ :^%K^V61+8 ^R5Z%WPNP#<M:
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MS&S*,3=S@7H @6V"M#9!&)O(!IH@2HUW DA! S8TV.Q8P<]'H4%=Z&@L=]:
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M(JW0"SPG,O)? 4J<4;8)Y&U$B+0<[LX" *$CF8+W$X"QX*.-ST<"6N S7$F
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M0F2"J#C1$98BXP4'DW$"<F2L@#(9(Z &69J0-1JCV 3(FTI&",PC6@)+B:;
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MD 8DY0<1"05I(J8XF(@JR1-A)14BI#2,""K!9U/6!1 L*+.#(S'Z*6,&4@H
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M.1>>TVQXT+,^0 &(_5&V+C"6[</"5X9!I@KXR(WBY7\&0:X(DZO+G\3_RL$
M"!^Y>0F8'3% VRP#CY7@L5J&=P"6X3#>IBOV\*.5AA@$$,@N9P\=Q1AAT('.
M\):[)V@Z?QW.Z+&\O6!#^6N 9"!W$.0*Z_'K.IOOT.B3_UZ/LHK\Q]H0 9X3
MP,XIV8%^LH.=%SN*]T#R;?C"5HQ5F^$Q;4*PO(&=4_N,>SZMGBXOC<?6X6A
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M<FJK4V[,48_2T :_&O^ZD ;/FNBC+M6)+0[5V:UVU16MMN4-S7;%S?7?"IH
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M&?,HCWCB5AL]2FZ)?>3:%?_ 92#AMM.UI$''&PF7B+?X?P.$H@Y<M'&XQY<
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MS&6F5:0'Y1<FA9=EQ?.K4_C)]0)>3E-L5%E+=%1C:T18:U-$>&=E1'AO\=\
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MX@^36N(&2;WQ \XW!%W$6[%MSO<B&TF/N+4NSUC5KN-^\P$^J(/77C%@[UL
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MSX#EW3-@\>0LF#^7!;,I.3"=D?MA,BO_Q>2K_*SQ3_D/QC G_^-P6 PPD@L
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M,?WH4&/QP;[5>@;7@YVV';9[@WUB_Q(SA7^*>6]_W^:3S4WL-\MKMC]-A^S
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M^T1>-AT5&STOO>AZN](_?8UZA]NK+61K2NVTB_.)9ME9%-N4-)I37)(?)4K
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MTFN!"8,Z6#*H@!VC$C@SR8,'DRSX,4M#*+,$Q+*(0?H6$2C<(@2UK(+0P2H
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MJJ[[@5P#U_T5QH[[F\WL]_5;V.Z;L2+O.V9%WG_7TF;?1W/;O6!JMQ>,[/:
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M +8_,X!M3PV!^XDA<&T$AF($L! B@ WN;P?\U4F*",[X/)ST:8%BQ0!VKLQ
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MX/1^OTO35_@]-%D>\%Y_>1#1[@LF&HA:7PB9-A7BA34(0M^+8L*'1#8\3>/
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M\GA68=JGZ47IQ+ X ^]^&41G*B0$X'4"P'7<:EPJ0N=#[SM20X/]M73862>
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M-]1K!C8LUO9;L%+79\$F?:\%!Y#_Z'O5/]/QJ2>:OO5$'9DVE6O8A]-X+1S
M'FS'^6]H ^A?@NZ)'MS0#5#=(P9E/?)0U*-+Y?7,I&=VV[)2E[F*)B[UY<5U
MA4A$=4;+A"])%H9T9"L&+BY1\6NO4_5N;]/P:%NNY=:V4=NU;;^.2]OW.BZ+
M_M!T7434W5J)JGLK49G*%?Q,.H;7P3CV?Q3SUW0"]&#V(O3@FI4 10-,R%TE
M!5FK-"!MU70J:<":$3?@Q([J]Q(-7QG("UD1*1&X/$':;WF&G'=?H;Q';XV2
M:V^KBE-/GZI#SP8U^YY]ZO-ZOE.?U_U4U7[99Q7[943982E1FLJYR1K4X3K
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MV_\HYJ,FSST#8/XM PR^YX#V57'0NBH/6C]I@>9/TT'C9VO$"=1_\06U7R-
M]==44+E6#,K7FBBEZWV4PO512O[Z<4IX[3XE_.4M)?R9T.1^^B>KL?]+,;]I
MY,L95";./>8(YF.V,V9;7P"8@3ZN=Q5 [1H35![P0?F!#"C^I@+RO^F \.%T
MD'UH"3*_.X#T(V^0?!0.$H]30/"D!%D(_*<#P/]C!_#^. _<IX^ ^_@C<'\G
M_Z '\UM&OIQ!91W _..8C]E.F&V)V28_ FC]"J!\$T#XB :R;\1 ^HT$2+R5
M \%;%>"_TP+>.R,0>S\3.!]L@?W!'1@?0X#^*1EHGTL /K4B>)%]Q.9^O(0\
M1CXBG_Y+*^9739Z!30#$XMS]SP,X7@:8C=F&F*V.V?)W :0> @C> _ )"WB$
M"Z)$ &PB#0RB !11!2 ZR'3$"G&"/S>(!&_(D_\@T9]G#S@.@H4FIY"[_Z &
M\W,Q/PY_*^ B@,,/ +,P6_\6P+1[@'7&;!PZ%_,Y!("%T @#_U\.PD,$B#2B
M@*@A>H@Y8H=X__4L"-X021.R',%%3_;^ Z**;JFN\X5I^A21GTX124N*")PH
MP@N@"#>6(J)9-,(I0Q8@[13A="/]R%ID([*-(B+CR$'D&^0'Y![R#/D :+5?
MX!#J?Z*!KJ^%?CF)!HY#V9 BPID4D;''L?CB6*)HA)^.%".UR$*D$UF.K$:&
M<:R;D1W(?N0$<@FYC3RE/O/>4^]YA'K'_YNW_X)H:P#15?V"MCH0=5ULKRE%
ME&RQ)IX4D0NC$9DD&I'*0RJ11J2=1B2[D7YD+;(1V8:,(T>0<]0GR>O4.ZG'
MU"NIM]0+*4(]1YY)$=H?TO\W1!]=WU )0=\V4,9V8CTFSX.TK+$_KMB?0!I1
MCJ,11>R'0@E2AV M%+ 6"GVT3PJK:!\5AFD?%$9I[Q1VTMXJ3-!>*WQ#>Z'P
M,^VIPD/:(\4WM-\4">V!(J'?5R+T>\C=213_AAAA]G0Y(#-D\!6=>P;68[H^
M$.-9%#%PH(BN#PUW/S2BF4+[J)%/?Z=127^CWD!_I=Y&?Z&^C/Y<?07]#_4U
M]*?J&^F/U<?HC]3WTA^JGZ _4+]"OZ/Q&_V&QFO&-0W"^%F3,*XB/R+_07Z8
M IF!N>:20&:A;\^6 F(Y>2:CA;^>01&SN=2G&>[46^-@VDNC>/H?AEGTQP8E
M](<&M8P'^LV,>_H=C+OZ/8S;^@/,F_KKF#?T-S.OZ>]F_J)_E/F3_F76%8/[
MK(L&K]CG#0G[+'(:^08Y94A84R$S,=\2W=L*O=]&@)<4CLD6:S%7']Y9SZ:>
M6SA2CV;YT>[/C*3?-D^AWS#+9_QJ5L'\R;2>]8-I*^M[TR[VY1G+12[.&!2Y
M,&,CY]R,[9RS,PZ(GIYQ1O2DZ4VQHZ;/Q Z9?1:;,".B^Y%]9H3S;X@EYLY%
M][;C ''$<3AC/9SDX8VC!CR99P+W;.=0-VS<J9_FAM"^FQ//^-8ZDW7.JHA]
MVJJ*<\JR0?2$Y2*Q8Q9+N4<L5O .6ZSE';08Y1^PV"V^S^*8^%Z+_PAV63P2
M;+?\(+[-BO"W6A'>%BO"W6Q%Q*9"YF"N'0MST7W=<!P>/'CG+@&/W13@MK,V
M_.0\"RXY.U%GG?SH)QTCF4?MDT4.V>>('IA7(K;/KH:WQ[:1O]NV7;#39IG$
M=IM^R6TVPU);;;9);[:9D!ZQ.2^ST>:>S+#M&ZDA.[R"[(A@C1T11_AKYOT-
ML9V</WY<N0.\\:;!(U\6//01@]N> OC!4P7.>TV'DUZVU&%/3\9^CQ#6N%L<
M9Z=K&G?,)8^_Q;E,,.I<*[')J5EJ@V.']+!CK^R0PZ#<&H<1X6J'<?E5#J?D
M^QUN**QP?"'7YT1D>IV)%"*!"'JF0.R9?SYB]\8'W1L_XG\-HN _02RXXB\&
M9P/DX5B@ 1P(M*9V^[LRQOS\V9M](T4W>B?RAKTRQ8<\"R4&/2JD5KG/E^EW
M7RBWPJU+V.>V4J''=5AQF>MVI:6N1Y0[77]4[G![JKC8_;-PL0>1;?<@TNV>
M1'(J?]Y>/ !^P_QKH0#?10"<CV# F5 V' V5@7WA.K C?#:U)=21L3'$AST4
M%"HZ&!C+&PA(%:SPRY'J]2V6Z?:MEEOJTRC?Z=VNL-B[5ZG-:XURJ]>6:0N]
M#J@V>UU4;?+Z?5JCST?%1E\B1&01Z4:_OYFLP5NLP1WTSBM1 .?0>4[$TN!(
M-!/V14G CA@-&(TQHX:C[>B#D1[L_O! T;ZP2'YW:*)$5W"&5$=0OFQ[8+FP
M-7"^0DO 0J4F_Z4J#?X#T^K]-JG5^>U1K_$[JU[M?U^M.N"=<G4@4:@.(G*(
M+"+SE<EU\ 3]_QK._]LX]%YTGD/HG_L2:+ C7AQ&$U1A.&$ZM3I^+GU%G"NK
M.\9/M#,ZC+<X,DYB442J5$MXCFQC6+%P06BUPOR0)J6:D(YI5<$KU"J"UZN7
M!>_2* D^I5D<?$>S..3-M))0HE@21N01.43V*\03^Q ,<!7]_RQF'TG%?/2>
MG?BZ.84'PZE*L#K5B%J>8D5?EN3$ZDCP%ET4'\)KB8L6-,8D2=5'9\K61A4(
MJR,K%"HBZY7+(MJF%8?WJA6&#VGDAV_7S L_KI43?E,K-^*U:EXD4<J+(@J(
M$)'[RJ?)M8CN_1UN-TYA[@2ZY^XLW&OCZ_H,,5B=*0\K,O6I91FS:1UI#LS6
M5$].4W(@MSXI0E";$"]5%9\F4QZ7*RR-*U4HBJU3+HAIG98;W:V>';U&,S-Z
MFU9&]!'MM.AKVNDQ+]4R8HER1AQ1S(PC\HCP*Z_\ &ZA>W^+-3B6@>Z?@[Z3
MA[Z!K,D1@14Y<M"=JP,=.3-IK=EVS,9,-Y'YZ?[<ZK0P\8K46,F2Y&3IHN1L
MN?RD8H7<Q&KEK(3F:1D)7>II\:LUD^.W:"7%']).C/]).S'AN7I2(E%)3B2*
M*8E$/B6)"+_RQ^3U.-D'K,$AS-]= + %MU_#2'\!$[H+I&%)H2:T%IC2&O-M
M&'6Y+B)5.3YB95DA_.+,:(F"C$3IW/1,N:ST H6,M$JEU-3&:<DI2]034@8T
MXY)'M6*3)[1C4GY GJG'IA*5N%2B%)]*%!#YKSS"Z^'J9!^P!@=PR[4#MZ&;
MR@ &D9X2"CI*):"U5 T:2TVHNA)K1F61$[NTT$NT,#^(GY<7*9&=FR"=D9,N
MFYJ=)Y^<7:Z4D+5 )39SL5ITYDJ-R(Q-6N$9^[7#,K_3#L]\JA&12:9%9A&E
MJ"RB@,A_Y4$XP.5D[ /68$\QK@/TW^%JK &R!#UP8:4X-%2I0%V5$559:4DO
M*7=@%91Y<')+ [B9)>&"M.(XJ>2B5-F$PAQA7$&I8G3^?)6(_#;5L+SEZB%Y
M&S2#\O9J!>9=1)ZH!^=]5@G)(TJ(0F@>D?_*;=QRGL?KX!#V8&<YP$@-KH/Y
MZ'WU *WHP@OJ>% S7P$JYNM1Q76S:/EU=LSL&C>1]&I?L92J$'YB9;1$7$6R
M='1YEEQ$>;%\6%FM4G!IZ[2 TEXUOY)A==^2<0V?D@O((S7?DD\J?B5$T;^$
MR$_E&O;A&_3__=B#;9B_?@'6 +? G<@"I*J) Z7-LE#8K VYS::TS*:YC-1&
M9U92@S<GKB&(&[T@4CRB/D$R;'Z&3'!=H5Q ;;6";VV+DG=-MXIGS3I5]YK=
M:FXUY]3<JG^?YE[]4<FCFB@@\I[51/B5*RG8!ZS!;JS[*.:O00?O12UI:P.H
M1(K:&9"S6!*R.M0@K<.82EIL28MOMV=$MWNP(]K\14,7A7&#6^/$ UI3)7T7
MYDE[M53(N;<TR;LV+U-T;EZK[-B\4]FA^8RR0]-#)<?&#PJ.C43HU$CDG!K^
MYGS6E_/ ,:S_>E21E>U8 _3PQBYTOV7H?NC#R3U\2.A5A+A>/8CNG4F%]]C0
M0WI<F$'=/FS_[F".S[)HKN?29+[[TAR!2U>9E&-7@XQ]9Y><7><:H4WG#OFY
MG:?EYR[Y33BWX[V<S6(BB\A,Y0368!Q[,(KS'T0'[\;L5O3@FCZ  G311-2C
MR-4<"%LM#2&#ZA T: +^@Y:4[Z #S6NU!\-]=0#3=74XVVE5 L=A5::8W4 Q
MWV:@7F ]L$3"LG^UI$7_=JG9 ]](S>Y_(#EKQ7O)6<N)Y*P^(C%["@?Q.AC#
MOJ_#_!5+ 3IZ<1U@=LEJ].\A],_UZ'^H1EXC?/ 840#W$1UP'3$#YY&YE..(
M,V4_XDVS&PFFVXS$,*U'4EF6FPI$9F^JY9AO6BQFNFD5=\:F;=SIFTYQIV^\
MSS59_YYG,DQX)NO^R6Y< YNP_@.8OQ3GWC2 _HL>G+,!(&$4(&0K@,=V@'F[
M6&"S6P+F[E8!Z]UZ8#5N#I;C-C![W 5FC?M2YN/AE.EX(FWZ> [=>+R283C>
MRM0?7\G4&]_"TMUS@JD[?H^IL^L=6WL'86MO)R)3V3IY#H;Y/:B"K:LGGP,"
MR$,/3MH&$(8NZC4.8+\?P.(@!29'.6!T3!(,CZF P3$]T#]N!GK'YX+N"1?0
M.>$'VB<B0>MD*FB<+*;43S92JB=[J6DG1RB54T<HE9-W*.7C;VE*1PE=Z<B?
M,+ZR;NE?ST(- M1AW0NV *1@=CCJJ#>ZL/UAS#\&8().K'V6 2H714'QD@0H
M7%8 ^<M:(/S.!+$"N>\=0?9[7Y#!38CTE0R0^J$2)/^S&"1^' +!U?W(-1!<
M>0&"[P@(+A-*<.EO5F+^$LROQ]H7X=Q3<=X1F.U]!/-/ ,S^!L#H'( F.KG2
M%0"9GY@@N"4&@ML2P+^C@&@ [ZX1<._.!K%[]B!ZSP<X]Z- Y'X6L.[5 O/>
M,F#<&P':O>- W4.1O_\.07F_]S==F-^P\<MS2&DX]PB<M_=)[/\9@)D7 /0O
M ZC] "#_,X#D=0#>;0"Q9R+ ><$']@LI8#Q7 -IS=8#G^@@Z_W-;!#<ES_%F
M_!PO_.=XT3_'A?YB,X)O_/(N\AKY\%^:,+\,UUSZ/KP&CV+^:0 [S#;[#D#W
M1P"57W'N-P'$[P"(/@!@O@"@?Z( /HH ?. A$H@L_EH%T4:F WR: _#9#<&;
MT>?)GT/!<1 <!\%%3G"2!-^8W/DO%9B?B6LNZCB SWG,QWF;7L7>7P-0O(5S
MQ_)Q'V+V8\ Q(V0J7\]"^(@D(OSK'&3R>9#9B#,2^M<S*;4(?NB1X;_.8_;_
M%Z*H#40)75L!D=$!(C "(CH+"-,!".5+$8A&,I!BI ZC%R*=R')D-3*,C"+;
MD;W(4>0\<AUYA+Q%"'SZ_T"F:2!J0%00>?Q:2@^G90J$:X=3]*((.YPBC!2*
MT N0*J0)60R$UHVL1-8@&Y"M..;=R$'D-/(SOOM#^ BO_QS%&QI")_":\1?,
MOR'JTQ E+"&B@E\+)^MA@J6=@S5QP_$$4X0;3Q&Q;*0,F8^T(IT4$>U#5F'=
MUB$C"-9"=#]\$CT)'T2_AS>B]^&%Z$OX0Y3 4S$"3[@$'G,)]6^(%KJ^MA"(
MEAR. U]5)VMB@+V9#7A7 R+M1Q%)[(=$&E*(8"T$C=0G03OU4;",>B]80;T3
M#%)O!!NHUX*MU$O!.+P0'(5G@HOP6' 7'D@\AWL2GZD[DH2ZC=SZBYM3('KH
M^OI20/0D@>C@JR[60P?7A889CL<6B+(GKIE0ZJ-\(O56/IMZ+2RE7@CKJ&?"
M%NJIL(-Z(NRA'@D'J(?"(>HWX2AU7[B3NB<\1-T1GJ=NR-^F?E%X1OVH\)GV
MO2*A748N(1?_!3'";&-Q!/W;1(!@/8RQ%H:X-O4LX9VV,[S4#*">JD=3OZNG
M40_4"JA[:I74;;4%U$VU1=0-M2[JFMIRZA>U0>HGM8W4CVICM"MJ!VC?J9^F
M752_3CNG\0?]&XU/]).:A'X<.88<18Y,@4S'?%,Q(&8B0&;A.&;AF&8JP"=3
M+7@YW10>&]G"?4-/N&402OUJD$!=U<^BKN@7TR[KU] NZC?2+NBWT\_I+Z.?
MT5])/ZV_EG%*?Y1Q0G\WXYC^,>91_2O,@P:_,_<9O&/M,22LW8:$N0O9^2^(
M.1=ST;TMZ4#FX#CF\."3M10\LU"&!S/UX(;Y;+AJY@R7S/VI\V91U&FS%-I)
MLUSZ<=-2QA'36L8ATR;F0=/%K .FW:Q],P;8>V8,L\=G;!/997I 9(?I.<Z8
MZ5W.9K-7G!$SPMED1D0VF!'V).NG0&:SOQSOV@"\GT?!LWDL>&;+@WMS).%G
MJVEPT7H&G)EC!\?G>%&'YX32#EC'T?=:IS-W6^6S=EJ5L[=;UHELLVSF;+7L
M$-ULT2LZ8C$HMM%B$W>#Q6[>L,4)WI#%-?Z@Y3/>*BO"'; B8OU61'2E%>%,
MA5C3_LQ_XXBW#W3PZZX4_.3,@JMV8G#>7AY..!K 04=KV.OH2NUR"*"/V4<R
MMM@GL4;F9;(WVA5RANTJ1(=LZ\76VB[D#=IT\5?9K!3OMUDG6&$S)K'<YI!$
MK\WWDMVVCR66VGX4[[(C_$X[PNV<AU?V%/Y\O,X!O1<_WJ]YHW>B?Y[WIL,9
M-Q$XZB8-^]VU89?'+-CJX4 ;<?>FKW<+80ZYQK('75(X \XYHBN=B[G+G:KX
MO4X-XMV.[8*ECCV2G0Z#4AT.H]*+'?;)M#F<EVEU?""ST.F]9(LS$2#\9F?"
MF\KDT?9SG/]MS/X>O>]L$,#Q0(##O@S8ZR,!VWW58=3/%-;[V=+6^+K3!WP"
MF"N\(T5ZO1)$EWFF<[L\\GA+W,O$V]UK)1:YM4@N=.N4;G9=*=/HND&VP767
M7+WK*6&=ZQUAG?L;F5IW(EGK002(.,+_RF0-'GF@<V+^!;R]',=;W02R)X2"
ML4 ^; I6@77!QK JV)I:$>1,[PGT978%A(IT^,>(MODE<UM]L_C-/H6"1I]*
MR07>#5+SO=ME:KWZY*J]AH257MOER[V.*91Y75<H]7XI5^I#I!')4E\B0,2_
M\@EO;?>Q!C^@=WZ#M_Q#Z+_CR!A^O2F,"T/A"C 0H0]]$1;4TG '>D>8)W-1
M:)!(2TBD:&-P K<^*)U?%Y@GJ DHDZP*J),N]V^5+?5?)BSV&Y0O]-NJ6.!W
M6#'/[V>E//_G\GD!1"8OD$CE!Q()1/"5%Z[8!ZS!Q0BL0>SD^0MZ+S(:!S 4
MS8'^&#GHC=&!KIB95'NT'7UAE#NS,=*?71\1)EH;'LNM"DOA5X1F"TI#BR2+
M0ZJE"X.;Y?*#NX0YP:L4LH-&%3.#)I0R@J\H9P3_H9 10N0R0HET9BB11"2^
M\@S[<#T8X!QZY^%$K %ZUY94]!WTX%7Q+.A-D(;.1$UH2S"E6N+GTA;$N3#J
M8GW853'!G/+H*+&2J$1>462&H""R0#(WHD(Z.Z)!+C.\0SX]?*5B:M@FI>3P
M?<I)X9>0)XI)$9_EDB.(3'(DD4J))))?>8S7PD]AV ><]P',WY&.WIN)>VU\
M[4NA06>*!+2EJ$%SB@FU(-F:5I/DR*A(]&*5)@1RBN(CQ/+CXGBY<6GB6;&Y
MDADQ9=)I,?5RR='M\HG1RQ7CHS<HQ47O48Z)OH \4HR-^22,BR$RB%1\#)'\
MRD,_O!ZP]\>Q!GLQ=QOZ[_I<] U\78K;G[9T 31EJ$!]AB%49UC0RM/MZ<5I
M[JR"5'^1W)0PT:SD6%Y&4HIX:F*V1')BB71B0IUL7,(B84Q\KT)4_+!21/QN
MY?#X<\A#I8B$C\+(!"*+2$<E$*FOW,-K\=N8+V=ANS%W-!_702'N]]$!VW/0
M>7)X,#]'$:IR]: L9R95E&U+S\]R969G^K(S,D-$TS*BN<GI2?S$M$R)N+0B
MJ9C4&MG(U(7"\)1NA="4(:7@E)W*02EGD >*P2D?A"$I1#8DE4B'IA"IK]S$
MZ_$LKL$)G/-VS-]8#+ :';B[!* 9QU%7( :5A7)06J@-A86F5&[!7%I6@3,C
M/=^;G9(7Q$G,C12+RTW@Q^2D"R*S"R3#LRME0K*:Y8(RE\H'9*Y5],O<H>2;
M^8V23^9]_/J]T"^3R/AG$FE$ZBN_8!].I7PY"]N*^>O0/U=6?CF#F8]C*2]C
M0U&9-.27:T!VN0F5469%2RUSH">6>C#C2OQ%8DK"1".+8[EA1:GB(86Y$H&%
MY5+^!8VR/@5=0J_\07G/_#$%]_R3R%T%C_QW<I[Y1 :1\LHGDE_Y'J_'HUB#
M75C_$<Q?@P[>4P>P""FO1N^JH4%VC01DU*I :JTA)-7.IN)K[>@Q-:Z,R&I?
M5EAUB$A(5;188&4RSZ\R6]RGHE3"LZ)>VKU\B:QK^2HYY_*M0J?RXT+'\CM"
MI[*WLLYE1-JYE$BZE!*)KYQ/PC[@&APKP[6(V^^5Z,"=C0"-2 F2@20W\2"A
M21YBFW4@NMF,BFB>0PMM<J('-WDQ AH#6;Z-$2+>#0FB'@LRN6X+BL6=Z^LD
M'.L72]G7]TO;S=\B8UM_5,9F_BT9V[HW4K9U1-*NED@@@J^<Q!J,8P]&)\^A
M&K &+5B#5EP'Z,(%Z.-)B]$]%G,@O$,:0CO4('B)$01T6%!^'?-HWAUN=,\.
M7X;[XE"FR^)8ME-[&L>^O4#,KJV&9]/6)CZG;:7 JFU4PK+MB(1%VTV!1>MK
M@<5"(F[9\B?\KQS"=;B]"FN \UVY$-<!YC8NP3YT 62ADL3T  3V4>#3)P[>
MRQ7 <[D.N"\W!=?E<RCGY8Z4XW)/FOWR0+I=7R3#IB^9:=V7R[;LK129W;M0
M=&;O<C&SWA$QT]Y#7-/>ZV(SNE^)S5A&Q&8L1;K^9D\YU@#G/XAS[^Y _T</
MK\'<_!78@W[T[]7H?VL G(8X8#\D!79#T\!V2!]LUIG#G'4V8+W.A;)<YT/-
M7A=*F[DNCF:V+I,^8UT9PV2HB6DTU,,R'-K(,AB:8.D/76/IKWG%UALD;+W5
M1$1OU=],GD.MP_SE./>.;O1O]/#B5>B?F!N-6N://NH\ C 'E77F5BZ8;9,!
MTVUJ,&.; 9ALFPG&8S9@-.8*AF-^8# 6 7IC*93.6"&E/59/:8XMI6F,#=/4
MM^^GJ6W_F::V]05==0NAJVXFC&FC?[.I]:]GD7#N32NQ!YB=M1X@%G.#M@*X
MH8_;[$0''D<'WT<'S0,\4)^0 ;4)540?5"?,8-K!N:!RT 64#_J#TJ%H4#B4
M"?*'*D%XJ!WD#@^"[.'=('WX.Y Y^ QD#A!*9C^AI/<1VE<&.R=_'@U@X0!
MU1! SB: >,P.QEQWS+5!'S>;P'S4937T8OE33) Z*P82YR0111"<TP+Q\R;
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MQW$@THI8"ZP'UQ (QQ((TQD(+0#_5 R2@13]58M&I!U9BC-<@0F#F+D>,[?
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MZ;-)7N%[4%[F>U%>ZO>JO,3O>T*4%_N)LL?Q(>/_7#APD4O]<2ZS>Q.H=>*
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M*$^/6BU/C=JE2(D^I4B.?DZ1%/TE\1<ARB4DJ_$2T\]+U/\GR+TW6UV#X>L
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MW)U.,$GZB@O?5YP(O^;#]PV=_H;CXALZ\>U;Q.>H8LQS^%$LN?W)ZTA>BZ<
M(_JG+=5[_GL?BE1S^42]!^7Q^TG^O2^$X^1'7>!7]LT?%"I_,1Y_!P$/.38>
M<C(4^0"*6]0WI5XE7E#O-7A4>S 9U=PB-;=J#X9T4ZIT!D2ZI;0,JAM"I;T@
MTKT@TE^-D<[$K"#6$IN@.A-S  ^I!!]09]YGX/ZDL=)-'%+=0]K[\2M4>S^D
M&L0=J,Z"J/9>Z*MAH*['2/M1'IW)D>X$D6XI+1RMQ3Q$(]OOH(+N8?O];'\I
MVU_)]M=1+V\AVVYR',8]*M/O\#2^P5L,T;>XRV])=0_I[HTOU+6/=Q_5'T9K
M']*^!XW'Z@_2W233H+H3)(Q\2>3))D?)Z%F4>VAF^[/9<B_;[V?[2]G^2K:_
MGMVSE;[M'3V+\B&5_WM4[/]'C]^DE=(YE%?5D,ZCO C5O;*JFL.C^H-B-![W
M8<IO6-.GF?B!L?@.T8Q=*CGR\!G[Y&/4LOUFMC\;[]".-VG'Z[3C5:SBD-W
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M:'D=FBWWH-7,++Y)A='S4!W DFX^#Y1BL^8Q!D3N/-4^E)"Y' ?$=/[.DIA
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MEU$P\1WD3?H9>>:<\1[#R^2_XJJZ@V0O4Z M'DPK^/,R1VIO3O7=%G*T3S!
ML]D$-$RT0NTD1U1/<D>EN3\JS$-19A&#$HLD%%MDHM"B  63*Y _N0FY4[J1
M,V4)LJ9N0.;4_<BPO(!TR]>19O4CTJQ%%:Q4>%XZ@DON(WZ, =..#?[4&5QB
M%G+9G<.8M+%_ZJ;JH6JJ"<HM+5!J:8=BJQDHM/)"OE4@\JPCD&,=AVSK5&1:
MYR##IA3I-G5(M9V-%-N%2+9;BR3[/4BP/XL$A]N(=_@>\=-$OOX#J0YTAKP'
MI!I,*&,0PA@$46<P'>MP9WY).\KMM5!D9X0".S/DVELAV]X1F0YNR'#P19I#
M"%(=HI R+1%)TS*1.*T0"=.K$3^]';&.\Q'C.(QHIUV(<CZ#2.<7$>GR+2)<
MQ%%$.JMPE3Z?)/]>:1\,-?@J8C'?]]".5MI131N+7!3(<31 IJ,ITIRF(,7)
M'LE.,Y#H[(4$YP#$.8<CUCD.,2YIB';)0]2,"D3.:$'XS'D(F[D"H:[;$>)V
M"L%NSR/8_6OB(=^+_\:E -5],+NH\3=0@P])]Y PY>B*8'Y%.\II1Q[M2)NI
MA^29)DB8:8ZXF3:(=75$M*L;HEQ]$>$:@G"W:(2Y)2/4/0<A[F4(]FA$D$</
M CT'$>"U%?Y>)^#G?1.^WG>)!WPOPL]+A?.,_6&I#L3T<QW3C.5,R>=3BW?0
MCCK:5D([LFA'HJ<V8CV,$.UIADA/2X1[.B#4<P9"/+T0[!6((*](!'HG(L [
M$_X^)?#SJ8>O;S=\?)?!VV\+//V.P=/_67C\/[;. SRNXFK#GRQ9?:55[[WW
MWGN752Q;DBW;LBWW)O?>>\$V+KC@ A@PO<>AA!8P"24)-0E)^ ,)$%H($ @!
M0DFR_SN[*W!('C_'=_?N[GQGSCDS<[[1S-RJ=Y%O>&WCGD/N:W*<R7LUV,?&
M0P7@^EM)0U>A#[1-4[%'+[YJKW17<X6_&BI"55<1J]J*5%57Y*BJLEB5E56J
MJ&I4>56'RJK[5%H]324U"U5<LTY%M?M44'M&^75W**_N)\C;R->\)TNJ=<@%
M?' C>&? /D+JN7<BM,BL0^']'.PQ&=_T$",M]:ZJJ[6HNC9(E;51JJA-4EEM
MIDKK"E125Z[BNGH5U;>KL'Z\"AH&E=\P7[F-:Y33N$?93:>4U72[,ILN*J/Y
M3UR_0LB2&AUR=X=S'FBBXSR67?#P#<C2 7)=]!C /MWXJ0E=*YN\5=H4H.*F
M<!4UQ:NP.4T%S7G*;RY57DN-<EI:E=W2HZS6R<ILG:.,MI5*;]NEU+:32FF_
M5<GMCRFI_0VN_U!*F\TNJ<CM/8P+9AX(W(/3Z9>&I'5<ATF#AR:1[_)9)SK6
M8ZN2#@_EC_%3[I@0Y8R)4?:89&5U9"FSHTCI'55*ZVQ2:F>74CHG*KEKEI*Z
MEBNA:[OBNX\KKOMFQ78_HIBQ?^#ZA6*[;(I#XCMM]GUA5X-_#.S+2'NWSG&L
M0UDXDUA EUYH4ANZ5*-+8>\H98[S55I/H%+'12AE7+R2QZ4K:5R>$L>7*6%\
MO>+'CU%L;Y]B>H<4W;M$D7U;%-%W5.%]-RJT[R&%]/T?U\\4UFM3^'BR1L2<
MS7-ZAN-/]'L6T"\L)!:0>?.)!?3I1I=&]"O'+C1]I4SR5/R GV('@A4S$*WH
M24F*FI2ER$E%BIA4K?!)+0J=/$XADP<5/'FA@J9L5."40PJ8<KVL4WXDORF_
MD77RWQ&; B8YQ#P?ZN0\^H5AQB<H\GJHX=)ETBQ>3X :M:-7+9\7H6,&]HF?
MZ:+P&3X*F6%5\(PP!<V(5>",5"17 3/+9)U9+_^9G?*;.4F6F?/D.VNM?&;M
ME_?,:^0U\X?RG/DL\H&\9OQ+WD,V^2!74?XQ0\]7X(=5CG4HBYSGH?2L)!:7
M8P-TRD&WY,7P3W0-&G:3WR)?618%RG=1A'P6)<A[48:\%A7*<U&U/(;;-'JX
M3V[#,S5JF((7P7<702@701X7/HV\A\#]%]CL<@K\0^#M7H<?-DK+-]$W(A-Y
M/0:IV2 50%?3^#QFK12"^*\=):^UWG);"\]="]]>2Q*REB1@33;" +B&@6<-
M#6K-5,?DUAJSR0=BN_I6.AX(W"J(V<I_(.BPPJ9CU'O_1L=>H+7;G6?2[H1_
M(PU("30U@VL<]T,14A-Y(Z-VD8#N)-G:20*X,PPA\=G)(+LSS['H<2>->2>!
MO ,G[ECO>!3R=DCU-DCS-HCBUL^D+3:['(+^[=[AV NTU.P%NHRV<( ^Z:!4
M<;F4C20@88B58KP.@W^$Q/<H_/:(%T(">H1D]&BXXP\_1TT"9-:DF(VPW8[%
M;T=PZ)$]TF$X]^%[,3PD^?)/Z S^;5^+<MENQUZ@E6#. 6/B4>(0LU5!2W.O
ME!*1L%/8'W=ZG@$;GDXR[13TN 8]KL$>Y[#'.>QQ+7I<FT$R0E)T'0/!=?V(
M>5P\#CY'P><@]]<0$]? ^Z_^"K%IUT''<XGF'Z,M@M<)3@WJYI^3DJX%_SK)
M#Q-ZP,\UL@[E]DOD#LC!'?CE3A+TNTC0[X9KWX-?+J#'!1*#"PPZ%VC4%PCL
M"U3V @7^ '_<@S_N^13YEV,.!NRI9^D+P*R[@1@$*^D6\&\#_P[G'J!+UZ'\
MR"EF;\Y#(_,BV.3'V.0Q?',QF"05/9[*<BS6?9KX?'H60N ]?0*A?3S],SY[
M!_F[%E/OZ=2YAWHV4,?".VF#]Q!_%R3+?9+KR-R+F7>YZ)P'>=HI(WMRGG6N
MU;#/A[A+O\8WKT 07D.//Y*(O4Z"\ 8^>9.&_29Q\2:5?9."WWP1>5<SS!P,
M=6Y"M6+JF4(]P^SGX$HN(^M01O;CC*P',6M/?B?'.2&O?6\NQ'Y>"/[YT#S)
MEUC]._'Q&4GR%R0I_Z"M?DGG\R5!_17&_@I#?OES?;?_P\?)^R_= V+.!#%G
MDHZ3XSQ0LQ;$[$4QST49V1.S&P9Y0/^"V?W3?B;'.=C<+?H'W.H+&./G]C-)
M/X3/_OO;9["\ZYS_^!7RO)WS>CCG'48YYR+,7(PYH]6<"6+.)#7[83HHH5_?
MP.N^@N?^ ][_N592]GI]BA[FV2@?H\='L+\/869_@1W^&:;X+CSS;8SX)PST
M!K\:.8O#K/\P<Q%F3\@3_S7_X.*T2RAU2@0OE[I4@-4"QEC*']#[\.UW-9>R
M%U/V2LI>ARNV4O9NO0K'? 6V^QL:\*]@]2_"EI_'%L]RY^>4\(P3]TGGW(<Y
M ^/^[^E CX&V7M@M0!\H&I:<#E81KJX%HYWRQQ,.D_22A@B_N=1EF#!906BN
M(T0-J]VMG\!^+\*\'\,GC]"0'\(6/^(;]Z/YO7C*S'G\P"EF#<9ME^CP];=S
M$*[4S0)>J'Z)+9Y7#CAE8#10?H<>5R]-9#)-98AZS*7\192_G/+7VMGU/=JC
MNW0(3YRB_.N)C+MU$QJ=I\3K\-RU<CQ9:$2N=NI@]L!\X SMW]J;FA<V"P O
MBKJD@E.@^^#]%^#]=ZN3\GLI?Q+E3Z?;FH/5%X*Q'(RUE+N5<O?J+#%Z&I]<
MR;=.8(MCU.0HGOQV#09RN?-J'D3]OEGB11?SG(NC^?^8^'P 6_Q (>#%4THF
M.,74JAJ,9C ZP>@%8Q(8TW12LW4</:Y CR/XY9"V$QD'M)]/]O&K/5AG%]&W
M PMO)YK-:<.7RE^]:>)T;;^P.KJX^VG6]Z#/;;27&V@CYQ1.I">!E0U."76I
MI1XMU*$3E/&ZC#C=BQY[T&,7?ME!?&S31KRR6YO0: ,:KZ-37X-%5^MEHO@3
M^RZSE<X6;L1L\7N>H>;Q"'BGF?\(<4S#7X-NIUR\J5L@]8JB3BG@Y(%31EUJ
ML7@+.)W@C =G@%8Z#4_,T6J78:UT6:WEH[9IZ:B#6NQZ6L.N-VNAVX^T8/0+
MFN_QH>9Y_DOSO&R:ZQ0S!_-DO/1 $D,/<CVOST216]'E7^[GHKT>%FUW"]9F
M]UAM\$C76L]\K?8LUTJO.BWW:M$R[RXM\>[58N])6N0SI 4^\S7?9[GF^F[4
M;-]]FN5[4C,L-VK(\H"F6U[05+^/--7?ID'K=_)\ L,-0_X]#"\W(F<9[HZ1
M$NVGB]U)2K I8+366/RUPA*FI7X)&O;+U$+_0LVW5FBNM5YSK*V:;>W63&N?
MA@*F:'K +$T-&-9@P%I-#MRE28''-#'HO"8$W:?^H&?5%_RA>D-LZ@VU.:[(
MT^ _D(O_23NN14[2M5_.,+,K3=J(?BNQTW"0C^8'!6E.<+1F!J=H*"1'TT**
M-36D2H.AC9H<VJY)H3V:&#91$\*FJR]LOGK#5VI<^#;U1!S6V,AKU17Y W5&
M/8.\KX[H?R&V;^4)\"[ JV\JPP8,]T>Y[N/]%E*RU=AD,?Z9$^VAZ1%6#4:&
M:W)4@@:B,C0A*E_]T67JC:[1^.AF]<1T:FQ,K[ICIJ@S=K8Z8I=J3-QFM<4=
M5&O\U6I)N%O-"4^J*?%=Y)^([5MYE+K?!?;U#/.GX-B':K!!I=D#(RW+AV=D
M,K8GC]) O$7]\<$:'Q^CGH04C4W(5E="D3H3*S4FL5[MB6UJ2QRKUJ0!-2?-
M4%/RL!J3-Z@AY3+5I9Y1;>H=JDE[ GE+->E?(S9>.\3, ]T.[CF&^!.-<']D
M.ZG@6K,'AL]FH<=D]!B?XJ/NE !UID1H3$J"VE+3U9*:I^;44C6EUJ@QK5D-
M:9VJ2^]7;?HTU60L5'7&6E5E[E5%UBF59]VFLNS'D3>0+Q&;7<J1^ZGS+>!?
M#<>_HM6Y#X?7J[BW #V&T&,",=*5Y:&V#'^U9(:J*3-6#9DIJLO,5FU6D6JR
M*E2=U:"J['959H]71<Z@RG/GJ31WE4KR=JDX[Z2*\F]18?Z/55#P1^0?*BRP
M\9Z1&;F _6\$\PQIWQ$X^!YD$WQ_.7Q_+GH,HD<O>K07N*DQUZ*ZW"#5Y$:I
M*C=1%7D9*L_+4UE>J4KS:U62WZKB@AX5%4Q68>$<%12N4'[1#N45'U=N\<W*
M+GD$>17Y7#DE-N44V[AOLY^+<Q[\4UW$ FG?+F0#*?E2=)F%'I/08RRQTD*L
MUA3YJ*(H0&5%X2HMBE-Q4:J*BG)46%RL@N)JY9<T*Z^D2[FE$Y53.DO99<N4
M5;9-F>57*+W\1J55/*34BE>X?J;T"AOW;,I [@#G6C,/9,[$[76>!\MU,>^'
ML,=$?--%C#02,^7EGBHN]U=A>8@*RF.45YZLW/(LY504*KNB0EF5#<JL[%!&
M5;_2JX:45KU$*=5;E%QS1$DUYY58\R,EU+Z,_)W7-NXAU3;="LXUX!T#>_]$
M*-  N3[71;R?QOT^[-.!G>KQ5VG]:.756)13$Z2LFDAEUB8HHS9=Z;5Y2JLM
M4VI=G9+KVI54WZO$^FE*:%BD^(:-BFTXI)C&ZQ3=>+^B&G^)_(W7-L4TV/C,
MIINP^UGPCDZ2]@X2CZ2=*[G.Y_T@J?!X;-*.?VKP31'T+;/)1ZE-5J4TA2JY
M*59)S2E*;,Y60G.QXENJ%=O2HIB6'D6W3E%4ZP)%M*Y7>-L!A;6=4VC;O0IN
M?T$A;1_SVJ:P5H><!^,4>(>@9+MGT#>:=2A<YTZG34)->OBL&5TJQDMYZ)+:
MZ:[X#C_%=@0IIB-2T1T)BNI,5V1GOB(ZRQ76V:C0KBZ%= THN&NN@KK7*+#[
M,@5T7RUK]P7YC7U._MU_Y;5- 5T..8?M3TQS/)O9T--U9AT*,GL.L8 ^'>A2
MAUU*T"4+'R7VNRBRUUNAO5:%](8JN#=&0;W)"NS-5D!O,5(K:U^[_/OZY=<W
M2Y;^E?+MWRV?_M/RZK]+GOU/<7U/WGW?R*?79I>KICG.Y;UL 508"K(:JCZ,
M#"VB3<ZG/?!9)?KE8YM4](GA^R&#HV6=XBN_*0%(N"R#\?(=3)//8+Z\!ROE
M-=@BC\'Q<A^<+K?!)7(=W"Z70?C5H-G8#U&:\B?D"[E,(9N?;-,I, Z#O7LI
M_<)RQSJ4^2OP Z^[N%>//B5\GKD0_HU.X=@H8)Z+?.=ZRV.NO]SF!LMU3I1&
MS3$#2S9")S^GWC&Q. =GSEGHV%@S!UYC_J@\^Q$:/5QS%MQ_%IGD3)N.@[%_
MA6,OT/IUWZU#Z37K4+A7 2W*19+0+9+O!2(6Q'V%)X$#IUL.EUI.$K2,P7Y9
MJF.064;'MHP 7M;O>.#2,@I:>H#"X;M+'J#AD[4.PW>';78YO(J^$=PMJ+IJ
M"[&XE7X)Z41JD4(DE?O1FZ4@Q(*X\UY;1DN;2?PV^R-PR\TD89L9[#<SV&YF
MX-U4[SAX:1,.W 3GWK@;@5AO@,BNAYBN^YA!"3:QUF:?@]FQC=L[46D7?0*4
MM&<O?=(^? !5S^ :@P3;UZ" OQ_\ T[9#[_=#^>WKTE!C_TD&P<2$7QR@,'X
M0*NCT]E/L.U'^<M..->C0)CW_ 7YQKX6Q9S'L@7,990_\R!]TB'B$-?1O2H+
MB3L&/F(Y+KE1!,DMC1DY[;R>PAZGL,=I$N+3Z'$&/<Z@QUD2H[-TKF?,1/1T
MQR$XIP$X?0/?AU!?25Q>":LX:=-VZK7R<D?(3 2G'8S*,U(V9HN["ORK)=]S
MDBMTG32=A!>YZ7MR,^3@%N+C%N+C5I+DVR(<R>D=#+AW-#CWY1#0=VPG4:#@
MV^]%7N)[^..V;[0&[/G4;S+UZ@"O&JR<\U(\6$&4[W.+Y'*;F6]!S%S(!>=<
MB!&*LJ\/,?,B#Y@Y$3?I(6SR"(GYCTE&'R<Q?9QV<I'XO$@G<Y' OHBAGX#W
M7WR"S]Z"4/Q=B[#G(-C=U+$6S#SP$L +N@O\'SAQ[G?.N8SLQWG"*=_NQW'.
M48S,A[R 37Y)C/P&/5XA,?V_"NGW^.15VLBK!/EK&/HU"G^-'[SVEJ91[QZP
MZV^G#=Q#/TC]@L'T'CF#Y=+].,\ZYUI^Z91O]^+(<3:).2_D#3F>6?,>\?H!
M,?(Q?OF$1.Q3DK._3Y ^6X(0?)]1Z<\PWF>&C7LYYQW,/(19CV'VQ)@](.9,
MD)'],.8\#O-\6K,7Q9Q+NMC.E/X-L_DG;.<;.-77L#MS)L<_8&5?P#X_@U7_
M'=;]-Q3_!";]5[XU<A[IF\[YCY\[YP&^6W]QZ1H,<R:(68]BSB2MTK_4"L8X
MRI]$V4.PYWF4NU@?HX=Y-LJ'Z/$76-C[,,#W8(3OP._>@@V_2?"\CM/^P+]7
M^:69^S!K3UYT8IN]( _]UQR(['-"_U00>+'\*A.\$NI03_D=>A>>^Q:\_PW-
MP.SS]!IZ_!X]?H<>+Z/'K]#C)9CA"W#=YV#Y/X=G/D,@/:7G<><'NF@_+<4Q
M__& <P[BKN_I\)7,4;?N?-L?O CJD0Q6'C@5^C6\_T5\\ISZ*'L*9<^@['F4
M/4Q-5U#V.NJUE1#:2]T.ZT=T(/?;=X#\P'X>Z-UH?J?]Y%C'$XW-2;;F/(SK
M+M'A\_^8@_ %+TB_P!9/*X,2BL"HH?P6:M5-'?HI>PIE#X$PE_(74?YRRE\'
M7]^F6V#\-\&6;\ GUW'G'+^Z&NN<Q:)F!Y4Y3>9*IYA=5?]RSK^\XPSOY^W-
MS9TZ^5.7<+ 2P<G&9J645DOYK;H1/<YCC^OPR[6:KFO@VU>AQUGT.(T>9M7#
M"3KS*_#)$;YYB!(.8K']>/(RK'WI^@LC?W=.*YJF]I0<4Z$/V+LC'^P5"%XT
M6*G4(P^,,NI01\FMM( N,'K!F 3&-#!F@[H(C!64NX&6LDL[^70;VFU%^\U8
M<:-^8Y_)6R_'S.*(O.<!/L/.3^EF'^1ZMZ=C2OJ\1O-K/^H4 EX<'DX'IP",
M"C#JP6@%HXL:]X(SH"WHL0D]-A(?Z[5*:[FSVJ[12:QSHY;2H2[&N\.TH$5$
MO9GE')'?TZT^'0Q^*+S3+#\,=&P-O1+=CM)W')"5: _7#B50GTQP"JEE!?K7
M:PUZK$*/E1H/S@ XT[6$^!CFU4*^,1];S,5:L_'8+-U#%#])!+VM(9<O-7V4
M[5MY@>[TQS&.8[!N(@VY*EHZ3DIRD*%G-W;9ZN8#9B!X46 E"=:B)2Y%&G:I
MU,)1]9KOVJIYKEV:X]:KV6Z3-=-MAH9&+]3TT:LTU7V;IK@?TF2/JS7@>9<F
M>CZA"5YOJM_G"\3VK3P-[@,I#%_I\%[D!*\/DHKLBB+UP#ZK_5RUU,NBA9[!
MFN<5HSG>*9KEG:,9/L6:[E.I:3[U&O1MTQ3?;DWR[=> 9:HF6.:HW[),O99-
M&N=W0#U^9S76[TYU^?]$7=:WU&G]"K&I,\!FOSY.^O4#,P>3QQ"?YS@#9"^I
MT!:&O-6QI%W89&Z AX;\K)KJ'Z8IUCA-LJ9IHC57_=82]5FKU!O0J'$![>H)
M&*>Q 0/J"IRASL!AC0E<K_:@?6H-.J66X-O4'/R8FD)>5U/HEXCM6WDXRS',
M7T?Z=9)A]B#7';Q?G^5(#^?AH^D1+AH(MJ@_.$CC@Z/4$Y*DL2&9Z@HI4&=H
MF<:$UJH]M%EM85UJ">M7<]@T-87/5T/X:M5'[%)=Y G51-ZLZJA'5!7UJJJB
MOU!UM.U;N9\4]%9X]=4,KU>0BNZK) ;@MZL*X7O89"9#[V1\,S[*2UT15G5$
MAJD],DZMD:EJB<I14U21&J,JU1#=H/KH=M5&CU--S&15Q\Y15>P*5<1M5SG)
M6%G\C2J-?U E";]%/E-)HHVK3:7(#ZGWC>">J<4/#*][D$WP[.6D@_/18QIZ
M]!,G78FCU1KGIZ:X8#7$1:DN+E&U\1FJB<]757RI*A-J5)'0HO+$;I4E#J@T
M:9:*DY:J*'FK"I./J"#EO/)2'E!>ZJ^03Q&;\IUR#UCGP;\2;GUYD[0364_Z
MM914<#:?32G"!J2&[>DNJD_V54U2@*J2PU61'*?RY%25)F>K)*5(Q2F5*DIM
M5&%JAPK2^I6?-J2\],7*3=^D[(Q#RLJ\3IF9]RDC\T5E9'VBS"P;[VW<M^E.
MZGPM^"=(@0^0<FU'UK80B]R;B1X#Z#$6/9K1HSK#2V7I5I6DAZ@H/5J%Z4G*
M3\]07D:^\C++E)M9IYRL=F5G]2HK>YHRLQ<I/6>#TG(.*C7WG%)R[U5RWO/(
M7Y629[-+:JY-MV'[:\ \-L:Y%PAZM-J<18(NT]&C'STZB94&?%:>YZ["'(OR
M<X*4FQ.AG)QX9>6D*3,W5QFY)<K(JU%Z7JO2\GN4DC^HY((%2BI8I\3"_4HH
MO$9Q11<46_0L\A&O;8I'$@IMNAG;GQWC^'/HWA[HB5F'PG5!ESF+!+[%YV/0
MLXYX+2T=I=Q"7V45!BBC,$SIA;%*+4Q62E&6DHL*E51<J<3B)B64="L>DAQ7
M.E>QI6L47;9/4657*;+L'D64_PSY0)'E-NXYY ;J>QK\PW#[W:3@FZ!G*[C.
M0Y<IZ#$._=JP4PTQ4H1-,BN\E%+FIZ2R8"661RFA/%'QY>F**\]7;$6Y8BH:
M%%W9J<C*B8JHFJWPJI4*K=JCD.HS"JZ^2T$U3R/O\_I?W+/Q&3D$]C\)_D'2
MS9WP^PV3B4>N<Z!'D[@_%INT\)U*=,W')FGUHQ5?:U%,;8"B:\,451NKR-H4
M1=3F*+RN1*%UM0JI:U=P?9^"ZF<HL&&Y AIVRMIP2OX-=\JO\4GD/5[_DWLV
M6>MMNH;Z'C=T#(J\'5Z_%DJT>)IC+\[$ =HDNC6@2RG4,1M=DMJEJ!8OA37[
M*Z0Y6,$M40IJ251@2X8"6@J0*EE;6^3?.DY^;=-E:5LBW[9M\FD[+J^V6^39
M]ACR!J^_D'<KF2-R%HRCX.V;X3B3=M5LXG&68R].'_JTH5LUNA3RO?1>N!<Z
MAXUU4T"7K_R[ N37%8;$RM*=(M_N7/ETE\F[NU%>W=WR&#M%[F,7RFWL)HT:
M>T0N8^'^W0\CK\JE^U/$IE%=Y%/@'P)S]SQH\0+'.I0%YDQ8J%D/E*017<J&
MX%Y3L0'Z1.*GP $7629ZR6N"GSPF!,E]0J3<)B3*=4*F1DV@ 4V@PYG0X3#D
MQ+F\7H? -2? _2>0(?5#3/K)WOK(XOK(Y\ _ /;VQ=#QI8P1T/397"?R?LPB
M8I'/"M$OC:)BL%$(W_=#+Z\9GG*=0>(SQ" _Q, VQ  WQ  SQ, W1,<[1" /
M$=Q#?'DZ'&\ZQ'T:A&X:)&KJBPA<<Q =!FTZ"LY><+?PM36K\<,:OL:U!YK<
MR+W2Y?!O/H]'KS HDA7=O)%1P_"H8;CE(CC=(@;Y1?#M10PL"^%4"['%PGJ$
M(%J( 1?RPP40_ 60VOF0UGF_8##^"/DGP6_3P16.O4 ;-SC6H<Q")B#M&Z4J
M) ])XK.(]5( )O5&7!&M@VNO(_%;BRW66IUK4D@ZUL*WU]*IKL$6:]H<DYUK
M,.9JL]GG& $'J5P)25WQ/H#?(#;[>2S;MO"S;:BY@SX!=;N0NEWX8+>4PC42
M"4"\=YDU*.!SGP2/JRO)#GKL0H]=Z+$+/7:3B.W&)[L9\';3N>VB<>\BX'>N
M<3R > =QN9W,>1N9]%88S5:;=FYW3-,LWHO+H*+C#N #PJ<$BIZ&1"$!A\%'
M9-:@7($<NU1<$)+/8R1^Q]#C.'H<)SD\89(RDH(3Q,5Q8O/XL.-!0,>(B2N(
MRZ.O4!Y9_1&;?2_0<G!G@M5WE/[H..W@I)1QI11]"GQ<Z#6R!H6?0UA(>+XG
M9F[D>C<&8"_I!A+B&XF/F]#C9F+C9GQR,QWN3=CB)AQZ$XK?>"<"[[\!5G7^
M:ZVB?G.HVT1PV\"J "<3G!C*#J!LSY%YEUMD_N@I")5C+F1$1O;FC,R-W$NL
MWH]O?A0D/41;>8C8>)CX?)A!X!$:P,,X\2$*?N@17O^1ZZ>:#_8DL#O K3I/
M7W@S^,ZS:#WN=&)<<,ZWC,Q)/.J4QYSS$Q?E.*-D9#[D9ZZ.LUI?A"C\DF3P
ME\3&KQ@ ?TT'_#(-X&5L\9L[$'[P\I\T> TQ"'8-]<P#,P[, # ][K\$\S$G
MQLAZD.=TR=H3?7=6ZRO.N1"S+L3^#!GT^ ![?$B"_!&)R%]IJQ_3^7U"7'R"
MP3_!<'\SJQ%<G7,0;L[Y$+,WQCR?UIQ):O;#F/,XS/-AS-FH9BW(##CJ?)C2
M$N%)V.,&?0G3^H*&\KDNASN>L)^P\ G.^RML]4.,\P%,^B]\:^0<4C,/8?:"
M_,0Y!_'?\P]F+L:<"6*>"YNE?\,QOU8C&)V4;?:B#%+V3,J>3[E+]&?[LU$V
MP)FW.9^-<A@S7*D_$*RO$CRO8,B78;._YI?F# ZS_^5G3FPS!_'#_Z'#O^2I
M?\#O_JY(?0S7_0B.^6=547Z+WH!OOZ8)U&-0OT6/7Z/'+V&1+\+ GH=E/HL>
M/X?W/P-+? J&_%."^2(HC_'N4;1\6-_8UW[\R#G_8=9?W'2)#O]VSD%\B&_>
MD86ZA.CWV.)E..9+*J'\6O1OH[2QV' "90]2]DS*GD?9BRE[)?5:K_MAP??"
M=2_0>=Q-0[Y3MX-E5H3\1C=3LY&S0,T3?<P9&*>=.M!CVA\W](XSK%X@+IY1
M %B1X"130BZZE],TZBF[G;+'4G8_I4^A_"$\/Y?Z#%/^"OCZ>KRP _2#="=7
MZ@R(I[#%E91X'(L>H[;F5%WSA"&S_L*<LON5<_[%;/EZT=FT'B4^[W>NP;A3
ML=0A'8P"RJ^ 03<0<>W482SE]U'^9,J?3B3.H?Q%E+V"B-A(=.Z"LQ_!(F95
MR.UT[X]J)Y[<061MUW?K+[;:Y^H<2ZU^[FR"#SB[GENPQ?7$Q=6TD=-*U$E\
M<@S>?U25Z-^ _FW:3WSL4R\8D\"8!L8<,(8I>Y6V\&\3&JSGEVNQQ1JLN(H&
MO8((6P[NI?+Z:)J\-W6G*5^@J[W5S='U7D5<G*"-'%$0]8D"*QF<;#"*P*@$
MH0&,-EI$E]:AQUH-:#5ZK$2/Y;279=Q9C%:+*&$AEIM/S>82I7/TMF;3TLR3
ML,V*+W-]B>[]<;JS']*5W,+U&H:=D^ASA*YNOSPHQ0][A6#=6$I- 2>'NA2#
M4:FEQ,=BM8+3!4XO.).(T"%PYE/^"GJ2S7AIOZ9BR4$B9S+^F(0_S"RG.8%H
MP"E/AV)_<P060\RU#+LG(\CM&'+VD)ILQ2[K7+RIFQ6\,+#BM$!IU"<7G&)P
MJL"I![45"W2!U4>43J'\692]F-:SCCM[T.Z$QKG<I!Z7!S5VU*_4[?:)ND?;
MOI7'S1Q,(D-8"KP7.<+K/=S;$D[J@5V66D9IOKNO9KL&:&A4A*:Y)FC0+5V3
MW?(T,+I$$T=7J=^]07WN;1KO/E;C/"9HK,=T=7O.5Z?G*HWQVJ%VKV-J\[Y!
M+=X/J-GG)37[?JPFB\TNS<A#=.6W9S D9S/4FS^_,-QN)P591UJVE+1H'C89
M\A^MR3X63? .4I]/E,;[)*K'-T/=OGGJ\BU5IZ5:8RR-:K>,4:MEO%K\IJC9
M;XX:_9:KWF^;ZOR/JM9Z7M76!U1E_:6J OZ&V.Q2C=R7X=A^>[;0L0QV;P%\
MS^R!(0592%HV$YM,QE_C SS5Y6]5AS54[=88M5J3U6+-4E- @1H#RM004*OZ
M@!;5!G:K)G"BJ@-GJC)HB2J"-JLL^)!*@Z]52<B]*@YY7D6A?U5QJ.U;N8?A
M_3PIZ*DRN#]#VTY2G_6\7\K]N=AD*G;J)PWH"G=3:[!%C<&!J@^.4%UPO&I"
MTE0=DJ.JD&)5A%:J/+119:$=*@WK4TG8=!6%+U)AQ ;E1QQ07N0URHV\H)RH
M7R ?*B?:IMPHA]QIUN* ?0).>Z :/R!KX=G#Z#$KS[$&9!QQTA8GU4=ZJSK"
MJLJ(4)5'Q*@T,DDED1DJCLQ74629"J-J51#5IKSH<<J-&51.S'QEQZY59NQE
MRHB[2NEQ=RLM_AFEQO^%Z[^5'F^SRVW4^QIPCY%^[FMPG,6Z&HJRT%"$$O*K
M?&A1EM2,'E7Q'BJ-]5-1;) *8R.4'QNOO-A4Y<;E*">N6-GQ5<J*;U9FPEAE
M)$Q26N)<I2:N5DK2'B4EG5%B\EU*2'Y*"2E_5F+*OWAO4Q)BTKVSX!^!S^XA
M_=S43"SP>C[WIO%9'SIV$",-Q&MYJJL*DGR5FQB@[,1092;&*",Q2>E)F4I+
M*E!J<H524AJ4G-*II-2)2DR=K82TE8I+VZ78]%.*2;]#41D_1=Y5=,8WBLFP
M<9\QC#J?!O,05& 7/'^C68?"ZWGH,@4]QN.C-F*E%I^5$*O9Z5Y*3_-76EJP
M4M(BE9R6H*3T-"6FYRHAHU3Q&76*RQRCV,Q^Q63-4!0$*3)[AR*R3RHLYS:%
MYCR!O,WKKQ6>8U,$<CWV/PGF03CUSF[BT:Q#,7^J1I=)S>8L$JFUAER/F"DB
M1C+SW)6<;5%"=J#BL\,5EQ.KV)P4Q>1D*SJW6%&YU8K,:U5XWGB%Y4]7:/X2
MA11L4U#!<046W*J PL>1/RFP\"ONV>QRSJ3_X.^'BFR'XZ^%6R^!6\\B]9N(
M'MVDHLW8J0J;%.";M%)7Q17Z*+K0JJC"$$441BF\,%%A11D*+2I02'&E@HN;
M%53<H\"2J0HH&9:U=(O\2Z^07^G-LI0]BOQ!EM(O>$_FB%P%SA7@[X.>;IWH
M7(<"SY_!^PG<[\(FC7RG'%USL5DR-HFN]%1HN9]"R@,57!ZNH(HX!5:D*J B
M5]:*,OE7-LBOLDN6JLG( OE &KVK#LFK^KP\JA]$?B//ZD_D567C/GD,]3U,
MZK\'3K]YT+$.90$<?SKO^]!E#':IY3O%V"H3GR7@G_!&5P76^\A:9Y5?70@2
M+4M]DGSKL^137RSO^EIY-73(HV&BW!OFRJUAK5P;#LBEX5J"&Y+0\!*O_XK\
M4Z/J;?:S@2\W^Y&F2QMF.-:AS$.F\7X\^K1 TRKY#NY5"G:)QB[!'?#_=D_Y
MM/G)LRU0'FT1<F^+U^CV=+FV%VA4.X'<CL+M?>:A-@@DOATRV0Y9:X<XM$$,
MVN#=;61P;38=H\[[P=P^FS%B+O$XC_YQGF,O3A?WZZ$E)>B2B9[QZ!.&;:P4
M[=/KH='C+7(9%T G1F<^+L;1F8VC@QU' (\CB,816..HS+AE"&2Y!^+80X8T
MEHQI+-E;-SITVQQGPH"Y9:%C'8IY-O%,Z&D?[UNA(Y7HDH=^R7PO<D@*I$C?
MJ9+[5#C=((G&% ;Y*20?4R(<$]N3&8 F%R$$\>0NQ\*>R<..11633D@#\*N!
MIPAXN/\$=)A@T^4+''N!-HZL0T&FK, &O*];2GODLW2*B($J!O-="WIY()I'
MDC./!&.NQ?QQ@<8<8A8Y(@PP<[#%'!K1;/PQ&\/--HM\-M+8(-4S(70SGJ 3
M?A?YFL"S:1]FVK;:L0YEJ5F'@O3RN@4IAQIF(?%\'HI+_1 /=-2(K" 17$$B
MN()D;'F 8TW*<@:XY6D(MEA&Y[(,?RS#J4LI9.E!&C[$<C%D=1@RN.A+!@6;
M=JUSG$D[L@YE8!MM :E&\K9+B5S#N.^/>" DD]^)>;\5/;:BQU;LL14]MJ+'
M5GCN5@:9+0Q^6]H1@FDS!MV\VW$^RD8RYPUDTNMA-.MLVF[.I(6"+B1D!J'E
MW81OG7DFSWYB  E'_!$/L_:$:I"TT[$[Y?(1P2^7>W(//0ZAQR'T.$Q"=IB!
M]S!Q<0A;'"*P+J>RET/T#Q*7!YZG,7R,V+0)W"5@3@=C'.4V'J$ON$)*A9Y'
M',?^WYZ#(L?ZD[/.^9#OBYD?N0:;7$.<GB,QOA8]KDMV_('H.CK;Z[#%M039
MM0"=NPF!R%_S9_N>G.748R:X?6 V@U-ZAOZ8,B,HT_\::?3WUZ#<ZIP+&1'[
MGASGW(@YK^1N%Q)4+^<9)22E]Q$;]^&3^QF([L,6]^' >ZG(O?15]_X&^41S
MJ.N$4W05X):#ET'(1-Y(_6^6W&YUEG^7<Z[E/B<)>E#?VXLCQQ^(1^9#S)J-
MISP@3NCQ"Y+V9QGXGR,^GV<@>(%&\#Q.?8["G\,6S_U)D\ ><QW] '7,IE[1
M8/KC+K>1N9>1_3B/Z;OU(#]SBID/&3F;Y,5+YD)&SDY]$]^\BQ[OT5;^S.#_
M/O'Y%]K(!\3%!U3\0X ^_,GWN+]9#V+V@)AGQ9@S2<U^&',>1Y/,6A#'7I1!
M6-(L?0G3^ +6\3FLYS,8T*>PR+_!QCZ&5WT$"_T ![Z/ =_#0._ I-^&<X^<
MP_&2<PW&H\XYB/^> S%S,8[U*/^"SWP%Q_Q<-93?2MD]E#T1]CQ5[Z+'V^CQ
M%GJ\"9-\'=;W!_3X/1SS%9CUR_:]*#=CGOM@F3_GW_OVN0^S^N4)YQR$>9+O
M'?]#AR\UFCKYZ:_PJK_ ==_%%F^JC/+K*7N,?JUQU&.B7D"/Y]#C%_"ZG\$O
MGT:/)]'C)S#2BS#4Q^!6C\+2'R)8'^#=?91PKWVGD&/^PZS!,,\A.7>)#F8.
M@-9JW]KTNGST6P6"%0U.*ACYE%])V8U8MD./H,>#Z/$ ?KE?,RE['F4OINR5
M,-N-H.ZDR5P.=S]-4[J))G6?KB-PKJ5F(V>!FK48YCR,*YPZF'- _G+)',0S
MQ,5%^8,5ALWBP<BD_"*\6T53;*+L,93<0]D3J,L4RA^B/G,I?Q@/K*3\343$
M'C".ZAAWCZ+581K-Y43$0:+)G"ACQ*R_,$]=_DR.Y4PO.T/=-*_[Y6)?@W$;
MMKC)?@Y&$AC9E%],S:KIKIHH?PSECZ7\/LJ?3+<YG?+G4/8PD;D*#;90_F5X
MYB3=^HV\NQ_-7L1;?_N/-1AK9+//__S2V>Q,D[_'V0U=ARW.$A<G:2-7P/L/
MXY.#\/[+5(+^U=J-7W:JC2CL!J,7C$E@3 =C+AA+M)9_J^R[4@YK&;980JT6
MX]%%M)2%1/L"L(TL1,PQ0S_U<)P!<H>[XV@HT_6>L \)WF!:J4\X./':3#O9
M".]?AQYK\,MJ-6#Y-BVGW2Y#CR7H,8Q?%A(?\[D[U[XRY#(B]Y1FV'<0/:)I
M>HUH_L+^%*A!I_R<8>8ANO<[&6JNYWJ*]T?0AR&$>HZF% N8@=0I$IP$ZI).
M7?*H0PDX5> T@-,*3A<XO6@P&9R9E+V(5VLT0"D3L&2_?17/_1J//\81_6;W
MW8@\'NQX'-J-9MDCJ= 1TK)]Z+,-7=9AEQ7RI&Y^X 7C[2A*3Z0^&>#D@5,"
M3A6U;Z"5M(+5#4X_FDRE[+E$B[&0V;5SB.@YIW8BNXV(;Z6O:*6W:Y5C-^"#
M40P[#/?G&&J/)SKVP&Q'GW6D1<NPRP*&P9ENWF!:P0L%*P:4)' RP<FG=92
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M[#@'=07ZS \GI\$N R95Q%]C7#W!M8 7 %8H6%'4*0&L5+"RP2H$JUQ%:%.
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M(4NIY)"IYF&2#R'_Q^?HD/)O'09_-YB;NAWK4!8A,^#Z W#K;HIHYO-J="G
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M#CO78(S,OQAL,P?Q@MV=+KC8!ZP <"+!2*3\+,HNINPJW80>-^"7ZV%ZU\+
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MC=S,D'*6].LP7?IN9&.HX[CX!6:)+':9Q- S7F[8TAM,/^H52,L,I4Y1X"2
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M$!SUA %G70Y&)#F(>>7 2Y %&62_H)46 TN@J78#^U#"X9G).(L#KSM- AE
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M+<Q>O&3ILIP5*_-6Y1>L7K-VW?JB#9N*-Y>4EFW=5EZQ8^>NW;_OW;>_NN;
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M)R>F\P.?"RP&VX7.+F: X]-^M*Q1:YD!<I5_ '@7,4E_-/-GXT4I3  UXX8
MYC !9 Q)1P'DN=JO&D,!SN29ENU#TY'971) 5W H0(L4YA3E!*D. :B29Y2?
M'UWN\Q,RKI-),;Z=*TZ>X6BFIZ6I:S*%63_87Y:'76VMEZ_>O#],.HO^^^C%
MM7KFOCV#'AU:-<=)1R)VF.3[I6$&//U6SWQZL&WAQ.\V._(W9NG/%U-^6#53
M'N63?[8+=W++HC^+&-)PC)D(4:TS!*!XD Q('=HV1<BS'*\-",V[B 2H)*0C
MLJ]E1P1DXNFWB>F(A@-^PP"D7NPB!@@FR3!>D7!<(8@$J-NZP,]8Z@<@G 0
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MTK'9!80,,2%*<8 HMKQP#@>@>B*@EP0HQ800Q $Y&$ +!R1C !<<$((!8G&
M)P98@P,F80"2&Z2+ 9[BO9@B!J#;8  )')"% 03PK;W- D0 .VEO'^X'D3:V
MG25ZE(B\&%P\9,J*1UB*R8+T];J&$V<N7N^X^_#YVV'7_ECT]]#'V\-LD7C6
MM'U9M/?$L3Q(C\FJ6WOAU/$_:VL+*7TY<4PB34"$8N:BATU K,72$0?F]%;@
M %P(DGN TC$92 "\DQJ' ZPQ@#T.T,0 <W" - 98@0.XL 7IO20IL=6BZR0
M7J'*.. H!O#& 7O^3,H2#' >[X,*,0#=#P,LP0$[^8F 5!Q CR8"R-,D'WP(
M %L2 "I$2</0TM$G<$[2_*4%FY@ 6/1WT.-+!XNS(UQ)4^) SZJRIYO*?]\C
MF49*/AT]?FA5X8,>/5N66-D\6,1:B%LD6D\$;",!L BDBP2PPF0@10?R&,"$
ME,5C(B"0!,!6,!:3 +5$P X2 )MH.4\"8!O67DCB@ RL&!8X( H#1." :1B
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MM(T(B"0!L-G@ A( B^UK20 LMO]C+ [P(@+H^-B.+#% "@[ O9S=V/P#DL0
MCVSQ+#  OF>&#&C#YXN_XH@*;2+@.@Z@K__187-+:]D&,MD]M".8EK5JTZ[Z
MEGNL8WW_1GITOK:R>&W>\D4+TN?2XJ+"J<3 O&&.O98,T>8HQ QP:T*(@PC
M]R8!$4]0Y)$!1!\%WV"-2(UW/ D0201,(P%<B8 E) #F:I&VBJ#11, U*1S
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MYY-:'C:/0EX"P=9 ^HQ) #VBE*1M&GCPCQ]5([6+8[)_ GA(#M8P59%667%
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M\T='K.I0ZRU871:\^,;ZLM#8@G1MZ2):EB%W4:%:[9/\CAGGTR>Q;W!O_'+
M%YU&$T7#> (*IT1OS>M='WGB=-HG^;RT+&O#K98'DD6*W$8>Z4@_H=S6LS\@
MIDU)X;X&9:-<;N#=M3:^>X*?5KE9?Z*\<WQ#G=1R\^5ZS7<^G3M*+*5%9_1-
M4@V_>R!7F)<S@8X>="OU14:QV]G.UO63FN7ZWK[ZMGSURA[ZS?\!4$L! A0#
M%     @ S(!W5I(.<@G)%   !M\  !$              ( !     &-B87DM
M,C R,C$R,S$N>'-D4$L! A0#%     @ S(!W5LJ7"F(I#   F:0  !4
M         ( !^!0  &-B87DM,C R,C$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M ,R =U8TE4C,?$0  /4=!  5              "  50A  !C8F%Y+3(P,C(Q
M,C,Q7V1E9BYX;6Q02P$"% ,4    " #,@'=69[_GQFAY  #^' < %0
M        @ $#9@  8V)A>2TR,#(R,3(S,5]L86(N>&UL4$L! A0#%     @
MS(!W5JG@0B<86@  @] % !4              ( !GM\  &-B87DM,C R,C$R
M,S%?<')E+GAM;%!+ 0(4 Q0    ( ,R =U9$]\>\:)<" (C,&@ /
M      "  >DY 0!D-#0V.3<U9#$P:RYH=&U02P$"% ,4    " #,@'=6LXOH
ML\LL 0 : @8 $@              @ %^T0, 9#0T-CDW-61E>#$P,3(N:'1M
M4$L! A0#%     @ S(!W5G/&8W*5 @  /0L  !$              ( !>?X$
M &0T-#8Y-S5D97@R,3$N:'1M4$L! A0#%     @ S(!W5L=< BBR P  # T
M !$              ( !/0$% &0T-#8Y-S5D97@R,S$N:'1M4$L! A0#%
M  @ S(!W5B&AX$J;!P  X2@  !$              ( !'@4% &0T-#8Y-S5D
M97@S,3$N:'1M4$L! A0#%     @ S(!W5MP>$AJQ!P  )BD  !$
M     ( !Z P% &0T-#8Y-S5D97@S,3(N:'1M4$L! A0#%     @ S(!W5NXV
M=A:2!0  %A0  !$              ( !R!0% &0T-#8Y-S5D97@S,C$N:'1M
M4$L! A0#%     @ S(!W5O7+OC[E^@4 ;_ ( !$              ( !B1H%
H &<T-#8Y-S5G,#!G,#$N:G!G4$L%!@     -  T 0@,  )T5"P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
